No,0-2
drug,,3-8
nutritional,9-20
supplement,,21-32
food,33-37
or,38-40
herb,41-45
interactions,46-58
have,59-63
yet,64-67
been,68-72
reported.,73-82

No,0-2
formal,3-9
drug/drug,10-19	DrugDDI.d512.s0.e0
interaction,20-31
studies,32-39
with,40-44
Plenaxis?,45-54
were,55-59
performed.,60-70

Cytochrome,0-10	DrugDDI.d512.s1.e0
P-450,11-16	DrugDDI.d512.s1.e0
is,17-19
not,20-23
known,24-29
to,30-32
be,33-35
involved,36-44
in,45-47
the,48-51
metabolism,52-62
of,63-65
Plenaxis?.,66-76

Plenaxis?,0-9
is,10-12
highly,13-19
bound,20-25
to,26-28
plasma,29-35	DrugDDI.d512.s2.e0
proteins,36-44	DrugDDI.d512.s2.e0
(96,45-48
to,49-51
99%).,52-57

Laboratory,0-10
Tests,11-16
Response,17-25
to,26-28
Plenaxis?,29-38
should,39-45
be,46-48
monitored,49-58
by,59-61
measuring,62-71
serum,72-77
total,78-83	DrugDDI.d512.s3.e0
testosterone,84-96	DrugDDI.d512.s3.e0
concentrations,97-111
just,112-116
prior,117-122
to,123-125
administration,126-140
on,141-143
Day,144-147
29,148-150
and,151-154
every,155-160
8,161-162
weeks,163-168
thereafter.,169-180

Serum,0-5
transaminase,6-18	DrugDDI.d512.s4.e0
levels,19-25
should,26-32
be,33-35
obtained,36-44
before,45-51
starting,52-60
treatment,61-70
with,71-75
Plenaxis?,76-85
and,86-89
periodically,90-102
during,103-109
treatment.,110-120

Formal,0-6
drug,7-11
interaction,12-23
studies,24-31
have,32-36
not,37-40
been,41-45
conducted,46-55
with,56-60
ORENCIA.,61-69	DrugDDI.d431.s0.e0

Population,0-10
pharmacokinetic,11-26
analyses,27-35
revealed,36-44
that,45-49
MTX,,50-54
NSAIDs,,55-62
corticosteroids,,63-79
and,80-83
TNF,84-87
blocking,88-96
agents,97-103
did,104-107
not,108-111
influence,112-121
abatacept,122-131	DrugDDI.d431.s1.e3
clearance.,132-142

The,0-3
majority,4-12
of,13-15
patients,16-24
in,25-27
RA,28-30
clinical,31-39
studies,40-47
received,48-56
one,57-60
or,61-63
more,64-68
of,69-71
the,72-75
following,76-85
concomitant,86-97
medications,98-109	DrugDDI.d431.s2.e0
with,110-114
ORENCIA:,115-123	DrugDDI.d431.s2.e1
MTX,,124-128
NSAIDs,,129-136
corticosteroids,,137-153
TNF,154-157
blocking,158-166
agents,,167-174
azathioprine,,175-188
chloroquine,,189-201
gold,,202-207
hydroxychloroquine,,208-227
leflunomide,,228-240
sulfasalazine,,241-255
and,256-259
anakinra.,260-269	DrugDDI.d431.s2.e11

Concurrent,0-10
administration,11-25
of,26-28
a,29-30
TNF,31-34	DrugDDI.d431.s3.e0
antagonist,35-45
with,46-50
ORENCIA,51-58	DrugDDI.d431.s3.e1
has,59-62
been,63-67
associated,68-78
with,79-83
an,84-86
increased,87-96
risk,97-101
of,102-104
serious,105-112
infections,113-123
and,124-127
no,128-130
significant,131-142
additional,143-153
efficacy,154-162
over,163-167
use,168-171
of,172-174
the,175-178
TNF,179-182
antagonists,183-194
alone.,195-201

Concurrent,0-10
therapy,11-18
with,19-23
ORENCIA,24-31	DrugDDI.d431.s4.e0
and,32-35
TNF,36-39	DrugDDI.d431.s4.e1
antagonists,40-51
is,52-54
not,55-58
recommended.,59-71

There,0-5
is,6-8
insufficient,9-21
experience,22-32
to,33-35
assess,36-42
the,43-46
safety,47-53
and,54-57
efficacy,58-66
of,67-69
ORENCIA,70-77	DrugDDI.d431.s5.e0
administered,78-90
concurrently,91-103
with,104-108
anakinra,,109-118
and,119-122
therefore,123-132
such,133-137
use,138-141
is,142-144
not,145-148
recommended.,149-161

Formal,0-6
drug,7-11
interaction,12-23
studies,24-31
with,32-36
Abciximab,37-46	DrugDDI.d453.s0.e0
have,47-51
not,52-55
been,56-60
conducted.,61-71

Abciximab,0-9	DrugDDI.d453.s1.e0
has,10-13
been,14-18
administered,19-31
to,32-34
patients,35-43
with,44-48
ischemic,49-57
heart,58-63
disease,64-71
treated,72-79
concomitantly,80-93
with,94-98
a,99-100
broad,101-106
range,107-112
of,113-115
medications,116-127	DrugDDI.d453.s1.e1
used,128-132
in,133-135
the,136-139
treatment,140-149
of,150-152
angina,153-159
myocardial,160-170
infarction,171-181
and,182-185
hypertension.,186-199

These,0-5
medications,6-17	DrugDDI.d453.s2.e0
have,18-22
included,23-31
heparin,32-39	DrugDDI.d453.s2.e1
warfarin,,40-49
beta-adrenergic,50-65	DrugDDI.d453.s2.e2
receptor,66-74	DrugDDI.d453.s2.e2
blockers,,75-84	DrugDDI.d453.s2.e2
calcium,85-92	DrugDDI.d453.s2.e3
channel,93-100	DrugDDI.d453.s2.e3
antagonists,,101-113
angiotensin,114-125	DrugDDI.d453.s2.e4
converting,126-136	DrugDDI.d453.s2.e4
enzyme,137-143	DrugDDI.d453.s2.e4
inhibitors,,144-155	DrugDDI.d453.s2.e4
intravenous,156-167
and,168-171
oral,172-176
nitrates,,177-186
ticlopidine,,187-199
and,200-203
aspirin.,204-212	DrugDDI.d453.s2.e7

Heparin,,0-8
other,9-14
anticoagulants,,15-30
thrombolytics,,31-45
and,46-49
anti,50-54	DrugDDI.d453.s3.e3
platelet,55-63	DrugDDI.d453.s3.e3
agents,64-70	DrugDDI.d453.s3.e3
are,71-74
associated,75-85
with,86-90
an,91-93
increase,94-102
in,103-105
bleeding.,106-115

Patients,0-8
with,9-13
HACA,14-18
titers,19-25
may,26-29
have,30-34
allergic,35-43
or,44-46
hypersensitivity,47-63
reactions,64-73
when,74-78
treated,79-86
with,87-91
other,92-97
diagnostic,98-108
or,109-111
therapeutic,112-123
monoclonal,124-134	DrugDDI.d453.s4.e0
antibodies.,135-146	DrugDDI.d453.s4.e0

The,0-3
concomitant,4-15
intake,16-22
of,23-25
alcohol,26-33	DrugDDI.d27.s0.e0
and,34-37
Acamprosate,38-49	DrugDDI.d27.s0.e1
does,50-54
not,55-58
affect,59-65
the,66-69
pharmacokinetics,70-86
of,87-89
either,90-96
alcohol,97-104	DrugDDI.d27.s0.e2
or,105-107
acamprosate.,108-120	DrugDDI.d27.s0.e3

Pharmacokinetic,0-15
studies,16-23
indicate,24-32
that,33-37
administration,38-52
of,53-55
disulfiram,56-66	DrugDDI.d27.s1.e0
or,67-69
diazepam,70-78	DrugDDI.d27.s1.e1
does,79-83
not,84-87
affect,88-94
the,95-98
pharmacokinetics,99-115
of,116-118
acamprosate.,119-131	DrugDDI.d27.s1.e2

Co-administration,0-17
of,18-20
naltrexone,21-31	DrugDDI.d27.s2.e0
with,32-36
Acamprosate,37-48	DrugDDI.d27.s2.e1
produced,49-57
a,58-59
25%,60-63
increase,64-72
in,73-75
AUC,76-79
and,80-83
a,84-85
33%,86-89
increase,90-98
in,99-101
the,102-105
Cmax,106-110
of,111-113
acamprosate.,114-126	DrugDDI.d27.s2.e2

The,0-3
pharmacokinetics,4-20
of,21-23
naltrexone,24-34	DrugDDI.d27.s4.e0
and,35-38
its,39-42
major,43-48
metabolite,49-59
6-beta-naltrexol,60-76
were,77-81
unaffected,82-92
following,93-102
co-administration,103-120
with,121-125
Acamprosate.,126-138	DrugDDI.d27.s4.e2

Other,0-5
concomitant,6-17
therapies:,18-28
In,29-31
clinical,32-40
trials,,41-48
the,49-52
safety,53-59
profile,60-67
in,68-70
subjects,71-79
treated,80-87
with,88-92
Acamprosate,93-104	DrugDDI.d27.s5.e0
concomitantly,105-118
with,119-123
anxiolytics,,124-136
hypnotics,137-146	DrugDDI.d27.s5.e2
and,147-150
sedatives,151-160	DrugDDI.d27.s5.e3
(including,161-171
benzodiazepines),,172-189
or,190-192
non-opioid,193-203	DrugDDI.d27.s5.e5
analgesics,204-214	DrugDDI.d27.s5.e5
was,215-218
similar,219-226
to,227-229
that,230-234
of,235-237
subjects,238-246
taking,247-253
placebo,254-261
with,262-266
these,267-272
concomitant,273-284
medications.,285-297	DrugDDI.d27.s5.e6

Patients,0-8
taking,9-15
Acamprosate,16-27	DrugDDI.d27.s6.e0
concomitantly,28-41
with,42-46
antidepressants,47-62	DrugDDI.d27.s6.e1
more,63-67
commonly,68-76
reported,77-85
both,86-90
weight,91-97
gain,98-102
and,103-106
weight,107-113
loss,,114-119
compared,120-128
with,129-133
patients,134-142
taking,143-149
either,150-156
medication,157-167	DrugDDI.d27.s6.e2
alone.,168-174

Certain,0-7
drugs,8-13	DrugDDI.d466.s0.e0
tend,14-18
to,19-21
produce,22-29
hyperglycemia,30-43
and,44-47
may,48-51
lead,52-56
to,57-59
loss,60-64
of,65-67
blood,68-73
glucose,74-81
control.,82-90

These,0-5
drugs,6-11	DrugDDI.d466.s1.e0
include,12-19
the,20-23
thiazides,24-33	DrugDDI.d466.s1.e1
and,34-37
other,38-43
diuretics,,44-54
corticosteroids,,55-71
phenothiazines,,72-87
thyroid,88-95	DrugDDI.d466.s1.e5
products,,96-105
estrogens,,106-116
oral,117-121	DrugDDI.d466.s1.e7
contraceptives,,122-137	DrugDDI.d466.s1.e7
phenytoin,,138-148
nicotinic,149-158	DrugDDI.d466.s1.e9
acid,,159-164	DrugDDI.d466.s1.e9
sympathomimetics,,165-182
calcium,183-190	DrugDDI.d466.s1.e11
channel-blocking,191-207	DrugDDI.d466.s1.e11
drugs,,208-214	DrugDDI.d466.s1.e11
and,215-218
isoniazid.,219-229	DrugDDI.d466.s1.e12

When,0-4
such,5-9
drugs,10-15	DrugDDI.d466.s2.e0
are,16-19
administered,20-32
to,33-35
a,36-37
patient,38-45
receiving,46-55
Acarbose,,56-65
the,66-69
patient,70-77
should,78-84
be,85-87
closely,88-95
observed,96-104
for,105-108
loss,109-113
of,114-116
blood,117-122
glucose,123-130
control.,131-139

When,0-4
such,5-9
drugs,10-15	DrugDDI.d466.s3.e0
are,16-19
withdrawn,20-29
from,30-34
patients,35-43
receiving,44-53
Acarbose,54-62	DrugDDI.d466.s3.e1
in,63-65
combination,66-77
with,78-82
sulfonylureas,83-96	DrugDDI.d466.s3.e2
or,97-99
insulin,,100-108
patients,109-117
should,118-124
be,125-127
observed,128-136
closely,137-144
for,145-148
any,149-152
evidence,153-161
of,162-164
hypoglycemia.,165-178

Intestinal,0-10
adsorbents,11-21	DrugDDI.d466.s4.e0
(e.,22-25
g.,,26-29
charcoal),30-39	DrugDDI.d466.s4.e1
and,40-43
digestive,44-53	DrugDDI.d466.s4.e2
enzyme,54-60	DrugDDI.d466.s4.e2
preparations,61-73	DrugDDI.d466.s4.e2
containing,74-84
carbohydrate-splitting,85-107
enzymes,108-115
(e.,116-119
g.,,120-123
amylase,,124-132
pancreatin),133-144	DrugDDI.d466.s4.e4
may,145-148
reduce,149-155
the,156-159
effect,160-166
of,167-169
Acarbose,170-178	DrugDDI.d466.s4.e5
and,179-182
should,183-189
not,190-193
be,194-196
taken,197-202
concomitantly.,203-217

Acarbose,0-8	DrugDDI.d466.s5.e0
has,9-12
been,13-17
shown,18-23
to,24-26
change,27-33
the,34-37
bioavailabillty,38-53
digoxin,54-61	DrugDDI.d466.s5.e1
when,62-66
they,67-71
are,72-75
co-administered,,76-92
which,93-98
may,99-102
require,103-110
digoxin,111-118
dose,119-123
adjustment.,124-135

Studies,0-7
in,8-10
healthy,11-18
volunteers,19-29
have,30-34
shown,35-40
that,41-45
Acarbose,46-54	DrugDDI.d466.s6.e0
has,55-58
no,59-61
effect,62-68
on,69-71
either,72-78
the,79-82
pharmacokinetics,83-99
or,100-102
pharmacodynamics,103-119
of,120-122
digoxin,,123-131
nifedipine,,132-143
propranolol,,144-156
or,157-159
ranitidine.,160-171	DrugDDI.d466.s6.e4

Acarbose,0-8	DrugDDI.d466.s7.e0
did,9-12
not,13-16
interfere,17-26
with,27-31
the,32-35
absorption,36-46
or,47-49
disposition,50-61
of,62-64
the,65-68
sulfonylurea,69-81	DrugDDI.d466.s7.e1
glyburide,82-91
in,92-94
diabetic,95-103
patients.,104-113

Acarbose,0-8	DrugDDI.d466.s8.e0
may,9-12
affect,13-19
digoxin,20-27	DrugDDI.d466.s8.e1
bioavailabillty,28-43
and,44-47
may,48-51
require,52-59
dose,60-64
adjustment,65-75
of,76-78
digoxin,79-86	DrugDDI.d466.s8.e2
by,87-89
16%,90-93
(90%,94-98
confidence,99-109
interval:,110-119
8-23%),,120-127
decrease,128-136
mean,137-141
C,142-143
max,144-147	DrugDDI.d466.s8.e3
digoxin,148-155
by,156-158
26%,159-162
(90%,163-167
confidence,168-178
interval:,179-188
16-34%),189-196
and,197-200
decrease,201-209
mean,210-214
trough,215-221
concentrations,222-236
of,237-239
digoxin,240-247	DrugDDI.d466.s8.e4
by,248-250
9%,251-253
(90%,254-258
confidence,259-269
limit:,270-276
19%,277-280
decrease,281-289
to,290-292
2%,293-295
increase).,296-306

The,0-3
amount,4-10
of,11-13
metformin,14-23	DrugDDI.d466.s9.e0
absorbed,24-32
while,33-38
taking,39-45
Acarbose,46-54	DrugDDI.d466.s9.e1
was,55-58
bioequivalent,59-72
to,73-75
the,76-79
amount,80-86
absorbed,87-95
when,96-100
taking,101-107
placebo,,108-116
as,117-119
indicated,120-129
by,130-132
the,133-136
plasma,137-143
AUC,144-147
values.,148-155

However,,0-8
the,9-12
peak,13-17
plasma,18-24
level,25-30
of,31-33
metformin,34-43	DrugDDI.d466.s10.e0
was,44-47
reduced,48-55
by,56-58
approximately,59-72
20%,73-76
when,77-81
taking,82-88
Acarbose,89-97	DrugDDI.d466.s10.e1
due,98-101
to,102-104
a,105-106
slight,107-113
delay,114-119
in,120-122
the,123-126
absorption,127-137
of,138-140
metformin.,141-151	DrugDDI.d466.s10.e2

There,0-5
is,6-8
little,9-15
if,16-18
any,19-22
clinically,23-33
significant,34-45
interaction,46-57
between,58-65
Acarbose,66-74	DrugDDI.d466.s11.e0
and,75-78
metformin.,79-89	DrugDDI.d466.s11.e1

Catecholamine-depleting,0-23
drugs,,24-30
such,31-35
as,36-38
reserpine,,39-49
may,50-53
have,54-58
an,59-61
additive,62-70
effect,71-77
when,78-82
given,83-88
with,89-93
beta-blocking,94-107	DrugDDI.d546.s0.e2
agents.,108-115	DrugDDI.d546.s0.e2

Patients,0-8
treated,9-16
with,17-21
acebutolol,22-32	DrugDDI.d546.s1.e0
plus,33-37
catecholamine,38-51
depletors,52-61
should,,62-69
therefore,,70-80
be,81-83
observed,84-92
closely,93-100
for,101-104
evidence,105-113
of,114-116
marked,117-123
bradycardia,124-135
or,136-138
hypotension,139-150
which,151-156
may,157-160
present,161-168
as,169-171
vertigo,,172-180
syncope/presyncope,,181-200
or,201-203
orthostatic,204-215
changes,216-223
in,224-226
blood,227-232
pressure,233-241
without,242-249
compensatory,250-262
tachycardia.,263-275

Exaggerated,0-11
hypertensive,12-24
responses,25-34
have,35-39
been,40-44
reported,45-53
from,54-58
the,59-62
combined,63-71
use,72-75
of,76-78
beta-adrenergic,79-94	DrugDDI.d546.s2.e0
antagonists,95-106	DrugDDI.d546.s2.e0
and,107-110
alpha-adrenergic,111-127
stimulants,,128-139
including,140-149
those,150-155
contained,156-165
in,166-168
proprietary,169-180
cold,181-185
remedies,186-194
and,195-198
vasoconstrictive,199-215
nasal,216-221
drops.,222-228

Patients,0-8
receiving,9-18
beta-blockers,19-32	DrugDDI.d546.s3.e0
should,33-39
be,40-42
warned,43-49
of,50-52
this,53-57
potential,58-67
hazard.,68-75

Blunting,0-8
of,9-11
the,12-15
antihypertensive,16-32	DrugDDI.d546.s4.e0
effect,33-39
of,40-42
beta-adrenoceptor,43-60	DrugDDI.d546.s4.e1
blocking,61-69	DrugDDI.d546.s4.e1
agents,70-76	DrugDDI.d546.s4.e1
by,77-79
nonsteroidal,80-92	DrugDDI.d546.s4.e2
anti-inflammatory,93-110	DrugDDI.d546.s4.e2
drugs,111-116	DrugDDI.d546.s4.e2
has,117-120
been,121-125
reported.,126-135

No,0-2
significant,3-14
interactions,15-27
with,28-32
digoxin,,33-41
hydrochlorothiazide,,42-62
hydralazine,,63-75
sulfinpyrazone,,76-91
oral,92-96	DrugDDI.d546.s5.e4
contraceptives,,97-112	DrugDDI.d546.s5.e4
tolbutamide,,113-125
or,126-128
warfarin,129-137	DrugDDI.d546.s5.e6
have,138-142
been,143-147
observed.,148-157

DIAMOX,0-6	DrugDDI.d228.s0.e0
modifies,7-15
phenytoin,16-25	DrugDDI.d228.s0.e1
metabolism,26-36
with,37-41
increased,42-51
serum,52-57
levels,58-64
of,65-67
phenytoin.,68-78	DrugDDI.d228.s0.e2

This,0-4
may,5-8
increase,9-17
or,18-20
enhance,21-28
the,29-32
occurrence,33-43
of,44-46
osteomalacia,47-59
in,60-62
some,63-67
patients,68-76
receiving,77-86
chronic,87-94
phenytoin,95-104	DrugDDI.d228.s1.e0
therapy.,105-113

By,0-2
decreasing,3-13
the,14-17
gastrointestinal,18-34
absorption,35-45
of,46-48
primidone,,49-59
DIAMOX,60-66	DrugDDI.d228.s3.e1
may,67-70
decrease,71-79
serum,80-85
concentrations,86-100
of,101-103
primidone,104-113	DrugDDI.d228.s3.e2
and,114-117
its,118-121
metabolites,,122-134
with,135-139
a,140-141
consequent,142-152
possible,153-161
decrease,162-170
in,171-173
anticonvulsant,174-188	DrugDDI.d228.s3.e4
effect.,189-196

Caution,0-7
is,8-10
advised,11-18
when,19-23
beginning,,24-34
discontinuing,,35-49
or,50-52
changing,53-61
the,62-65
dose,66-70
of,71-73
DIAMOX,74-80	DrugDDI.d228.s4.e0
in,81-83
patients,84-92
receiving,93-102
primidone.,103-113	DrugDDI.d228.s4.e1

Because,0-7
of,8-10
possible,11-19
additive,20-28
effects,29-36
with,37-41
other,42-47
carbonic,48-56	DrugDDI.d228.s5.e0
anhydrase,57-66	DrugDDI.d228.s5.e0
inhibitors,,67-78	DrugDDI.d228.s5.e0
concomitant,79-90
use,91-94
is,95-97
not,98-101
advisable.,102-112

Acetazolamide,0-13	DrugDDI.d228.s6.e0
may,14-17
increase,18-26
the,27-30
effects,31-38
of,39-41
other,42-47
folic,48-53	DrugDDI.d228.s6.e1
acid,54-58	DrugDDI.d228.s6.e1
antagonists.,59-71	DrugDDI.d228.s6.e1

Acetazolamide,0-13	DrugDDI.d228.s7.e0
may,14-17
increase,18-26
or,27-29
decrease,30-38
blood,39-44
glucose,45-52
levels.,53-60

Consideration,0-13
should,14-20
be,21-23
taken,24-29
in,30-32
patients,33-41
being,42-47
treated,48-55
with,56-60
antidiabetic,61-73	DrugDDI.d228.s8.e0
agents.,74-81	DrugDDI.d228.s8.e0

Acetazolamide,0-13	DrugDDI.d228.s9.e0
decreases,14-23
urinary,24-31
excretion,32-41
of,42-44
amphetamine,45-56	DrugDDI.d228.s9.e1
and,57-60
may,61-64
enhance,65-72
the,73-76
magnitude,77-86
and,87-90
duration,91-99
of,100-102
their,103-108
effect.,109-116

Acetazolamide,0-13	DrugDDI.d228.s10.e0
reduces,14-21
urinary,22-29
excretion,30-39
of,40-42
quinidine,43-52	DrugDDI.d228.s10.e1
and,53-56
may,57-60
enhance,61-68
its,69-72
effect.,73-80

Acetazolamide,0-13	DrugDDI.d228.s11.e0
may,14-17
prevent,18-25	DrugDDI.d228.s11.e1
the,26-29
urinary,30-37
antiseptic,38-48	DrugDDI.d228.s11.e2
effect,49-55
of,56-58
methenamine.,59-71	DrugDDI.d228.s11.e3

Acetazolamide,0-13	DrugDDI.d228.s12.e0
increases,14-23
lithium,24-31	DrugDDI.d228.s12.e1
excretion,32-41
and,42-45
the,46-49
lithium,50-57	DrugDDI.d228.s12.e2
may,58-61
be,62-64
decreased.,65-75

Acetazolamide,0-13	DrugDDI.d228.s13.e0
and,14-17
sodium,18-24	DrugDDI.d228.s13.e1
bicarbonate,25-36	DrugDDI.d228.s13.e1
used,37-41
concurrently,42-54
increases,55-64
the,65-68
risk,69-73
of,74-76
renal,77-82
calculus,83-91
formation.,92-102

Acetazolamide,0-13	DrugDDI.d228.s14.e0
may,14-17
elevate,18-25
cyclosporine,26-38	DrugDDI.d228.s14.e1
levels.,39-46

Concomitant,0-11
use,12-15
with,16-20
iron,21-25	DrugDDI.d327.s0.e0
supplements,26-37	DrugDDI.d327.s0.e0
may,38-41
result,42-48
in,49-51
the,52-55
reduced,56-63
absorption,64-74
of,75-77
iron.,78-83	DrugDDI.d327.s0.e1

Co-administration,0-17
of,18-20
probenecid,21-31	DrugDDI.d110.s0.e0
with,32-36
acyclovir,37-46	DrugDDI.d110.s0.e1
has,47-50
been,51-55
shown,56-61
to,62-64
increase,65-73
the,74-77
mean,78-82
half-life,83-92
and,93-96
the,97-100
area,101-105
under,106-111
the,112-115
concentration-time,116-134
curve.,135-141

Ethanol:Clinical,0-16	DrugDDI.d393.s0.e0
evidence,17-25
has,26-29
shown,30-35
that,36-40
etretinate,41-51	DrugDDI.d393.s0.e1
can,52-55
be,56-58
formed,59-65
with,66-70
concurrent,71-81
ingestion,82-91
of,92-94
acitretin,95-104	DrugDDI.d393.s0.e2
and,105-108
ethanol.,109-117	DrugDDI.d393.s0.e3

Glibenclamide:,0-14	DrugDDI.d393.s1.e0
In,15-17
a,18-19
study,20-25
of,26-28
7,29-30
healthy,31-38
male,39-43
volunteers,,44-55
acitretin,56-65	DrugDDI.d393.s1.e1
treatment,66-75
potentiated,76-87
the,88-91
blood,92-97
glucose,98-105
lowering,106-114
effect,115-121
of,122-124
glibenclamide,125-138	DrugDDI.d393.s1.e2
(a,139-141
sulfonylurea,142-154	DrugDDI.d393.s1.e3
similar,155-162
to,163-165
chlorpropamide),166-181	DrugDDI.d393.s1.e4
in,182-184
3,185-186
of,187-189
the,190-193
7,194-195
subjects.,196-205

Repeating,0-9
the,10-13
study,14-19
with,20-24
6,25-26
healthy,27-34
male,35-39
volunteers,40-50
in,51-53
the,54-57
absence,58-65
of,66-68
glibenclamide,69-82	DrugDDI.d393.s2.e0
did,83-86
not,87-90
detect,91-97
an,98-100
effect,101-107
of,108-110
acitretin,111-120	DrugDDI.d393.s2.e1
on,121-123
glucose,124-131
tolerance.,132-142

Careful,0-7
supervision,8-19
of,20-22
diabetic,23-31
patients,32-40
under,41-46
treatment,47-56
with,57-61
Soriatane,62-71	DrugDDI.d393.s3.e0
is,72-74
recommended.,75-87

Hormonal,0-8
Contraceptives:,9-24	DrugDDI.d393.s4.e0
It,25-27
has,28-31
not,32-35
been,36-40
established,41-52
if,53-55
there,56-61
is,62-64
a,65-66
pharmacokinetic,67-82
interaction,83-94
between,95-102
acitretin,103-112	DrugDDI.d393.s4.e1
and,113-116
combined,117-125	DrugDDI.d393.s4.e2
oral,126-130	DrugDDI.d393.s4.e2
contraceptives.,131-146	DrugDDI.d393.s4.e2

However,,0-8
it,9-11
has,12-15
been,16-20
established,21-32
that,33-37
acitretin,38-47	DrugDDI.d393.s5.e0
interferes,48-58
with,59-63
the,64-67
contraceptive,68-81	DrugDDI.d393.s5.e1
effect,82-88
of,89-91
microdosed,92-102	DrugDDI.d393.s5.e2
progestin,103-112	DrugDDI.d393.s5.e2
minipill,113-121	DrugDDI.d393.s5.e2
preparations.,122-135	DrugDDI.d393.s5.e2

Microdosed,0-10
minipill,11-19
progestin,20-29	DrugDDI.d393.s6.e0
preparations,30-42	DrugDDI.d393.s6.e0
are,43-46
not,47-50
recommended,51-62
for,63-66
use,67-70
with,71-75
Soriatane.,76-86	DrugDDI.d393.s6.e1

It,0-2
is,3-5
not,6-9
known,10-15
whether,16-23
other,24-29
progestational,30-44
contraceptives,,45-60
such,61-65
as,66-68
implants,69-77
and,78-81
injectables,,82-94
are,95-98
adequate,99-107
methods,108-115
of,116-118
contraception,119-132
during,133-139
acitretin,140-149	DrugDDI.d393.s7.e1
therapy.,150-158

Methotrexate:,0-13	DrugDDI.d393.s8.e0
An,14-16
increased,17-26
risk,27-31
of,32-34
hepatitis,35-44
has,45-48
been,49-53
reported,54-62
to,63-65
result,66-72
from,73-77
combined,78-86
use,87-90
of,91-93
methotrexate,94-106	DrugDDI.d393.s8.e1
and,107-110
etretinate.,111-122	DrugDDI.d393.s8.e2

Consequently,,0-13
the,14-17
combination,18-29
of,30-32
methotrexate,33-45	DrugDDI.d393.s9.e0
with,46-50
acitretin,51-60	DrugDDI.d393.s9.e1
is,61-63
also,64-68
contraindicated.,69-85

Phenytoin:,0-10	DrugDDI.d393.s10.e0
If,11-13
acitretin,14-23	DrugDDI.d393.s10.e1
is,24-26
given,27-32
concurrently,33-45
with,46-50
phenytoin,,51-61
the,62-65
protein,66-73
binding,74-81
of,82-84
phenytoin,85-94	DrugDDI.d393.s10.e3
may,95-98
be,99-101
reduced.,102-110

Tetracyclines:,0-14	DrugDDI.d393.s11.e0
Since,15-20
both,21-25
acitretin,26-35	DrugDDI.d393.s11.e1
and,36-39
tetracyclines,40-53	DrugDDI.d393.s11.e2
can,54-57
cause,58-63
increased,64-73
intracranial,74-86
pressure,,87-96
their,97-102
combined,103-111
use,112-115
is,116-118
contraindicated.,119-135

Vitamin,0-7	DrugDDI.d393.s12.e0
A,8-9	DrugDDI.d393.s12.e0
and,10-13
oral,14-18
retinoids:,19-29	DrugDDI.d393.s12.e1
Concomitant,30-41
administration,42-56
of,57-59
vitamin,60-67	DrugDDI.d393.s12.e2
A,68-69	DrugDDI.d393.s12.e2
and/or,70-76
other,77-82
oral,83-87
retinoids,88-97	DrugDDI.d393.s12.e3
with,98-102
acitretin,103-112	DrugDDI.d393.s12.e4
must,113-117
be,118-120
avoided,121-128
because,129-136
of,137-139
the,140-143
risk,144-148
of,149-151
hypervitaminosis,152-168
A.,169-171

Other:,0-6
There,7-12
appears,13-20
to,21-23
be,24-26
no,27-29
pharmacokinetic,30-45
interaction,46-57
between,58-65
acitretin,66-75	DrugDDI.d393.s13.e0
and,76-79
cimetidine,,80-91
digoxin,,92-100
or,101-103
glyburide.,104-114	DrugDDI.d393.s13.e3

Investigations,0-14
into,15-19
the,20-23
effect,24-30
of,31-33
acitretin,34-43	DrugDDI.d393.s14.e0
on,44-46
the,47-50
protein,51-58
binding,59-66
of,67-69
anticoagulants,70-84	DrugDDI.d393.s14.e1
of,85-87
the,88-91
coumarin,92-100	DrugDDI.d393.s14.e2
type,101-105
(warfarin),106-116
revealed,117-125
no,126-128
interaction.,129-141

Blood,0-5
Sugar:,6-12
Some,13-17
patients,18-26
receiving,27-36
retinoids,37-46	DrugDDI.d393.s16.e0
have,47-51
experienced,52-63
problems,64-72
with,73-77
blood,78-83
sugar,84-89
control.,90-98

In,0-2
addition,,3-12
new,13-16
cases,17-22
of,23-25
diabetes,26-34
have,35-39
been,40-44
diagnosed,45-54
during,55-61
retinoid,62-70	DrugDDI.d393.s17.e0
therapy,,71-79
including,80-89
diabetic,90-98
ketoacidosis.,99-112

It,0-2
is,3-5
recommended,6-17
that,18-22
these,23-28
tests,29-34
be,35-37
performed,38-47
weekly,48-54
or,55-57
every,58-63
other,64-69
week,70-74
until,75-80
the,81-84
lipid,85-90
response,91-99
to,100-102
Soriatane,103-112	DrugDDI.d393.s21.e0
has,113-116
stabilized.,117-128

Liver,0-5
Function,6-14
Tests:,15-21
Elevations,22-32
of,33-35
AST,36-39	DrugDDI.d393.s22.e0
(SGOT),,40-47
ALT,48-51
(SGPT),52-58
or,59-61
LDH,62-65	DrugDDI.d393.s22.e1
were,66-70
experienced,71-82
by,83-85
approximately,86-99
1,100-101
in,102-104
3,105-106
patients,107-115
treated,116-123
with,124-128
Soriatane.,129-139	DrugDDI.d393.s22.e2

It,0-2
is,3-5
recommended,6-17
that,18-22
these,23-28
tests,29-34
be,35-37
performed,38-47
prior,48-53
to,54-56
initiation,57-67
of,68-70
Soriatane,71-80	DrugDDI.d393.s23.e0
therapy,,81-89
at,90-92
1-,93-95
to,96-98
2-week,99-105
intervals,106-115
until,116-121
stable,122-128
and,129-132
thereafter,133-143
at,144-146
intervals,147-156
as,157-159
clinically,160-170
indicated.,171-181

Methotrexate,0-12	DrugDDI.d529.s0.e0
HUMIRA,13-19
has,20-23
been,24-28
studied,29-36
in,37-39
rheumatoid,40-50
arthritis,51-60
patients,61-69
taking,70-76
concomitant,77-88
MTX.,89-93	DrugDDI.d529.s0.e1

The,0-3
data,4-8
do,9-11
not,12-15
suggest,16-23
the,24-27
need,28-32
for,33-36
dose,37-41
adjustment,42-52
of,53-55
either,56-62
HUMIRA,63-69	DrugDDI.d529.s1.e0
or,70-72
MTX.,73-77	DrugDDI.d529.s1.e1

Anakinra,0-8	DrugDDI.d529.s2.e0
Concurrent,9-19
administration,20-34
of,35-37
anakinra,38-46	DrugDDI.d529.s2.e1
(an,47-50
interleukin-1,51-64	DrugDDI.d529.s2.e2
antagonist),65-76	DrugDDI.d529.s2.e2
and,77-80
another,81-88
TNF-blocking,89-101
agent,102-107
has,108-111
been,112-116
associated,117-127
with,128-132
an,133-135
increased,136-145
risk,146-150
of,151-153
serious,154-161
infections,,162-173
an,174-176
increased,177-186
risk,187-191
of,192-194
neutropenia,195-206
and,207-210
no,211-213
additional,214-224
benefit,225-232
compared,233-241
to,242-244
these,245-250
medicinal,251-260	DrugDDI.d529.s2.e3
products,261-269	DrugDDI.d529.s2.e3
alone.,270-276

The,0-3
safety,4-10
and,11-14
efficacy,15-23
of,24-26
anakinra,27-35	DrugDDI.d529.s3.e0
used,36-40
in,41-43
combination,44-55
with,56-60
HUMIRA,61-67	DrugDDI.d529.s3.e1
has,68-71
not,72-75
been,76-80
studied.,81-89

Therefore,0-9
the,,10-14
combination,15-26
of,27-29
anakinra,30-38	DrugDDI.d529.s4.e0
with,39-43
other,44-49
TNF-blocking,50-62
agents,,63-70
including,71-80
HUMIRA,,81-88
may,89-92
also,93-97
result,98-104
i,105-106
n,107-108
similar,109-116
toxicities.,117-128

As,0-2
DIFFERIN,3-11	DrugDDI.d268.s0.e0
Gel,12-15
has,16-19
the,20-23
potential,24-33
to,34-36
produce,37-44
local,45-50
irritation,51-61
in,62-64
some,65-69
patients,,70-79
concomitant,80-91
use,92-95
of,96-98
other,99-104
potentially,105-116
irritating,117-127
topical,128-135
products,136-144
(medicated,145-155
or,156-158
abrasive,159-167
soaps,168-173
and,174-177
cleansers,,178-188
soaps,189-194
and,195-198
cosmetics,199-208
that,209-213
have,214-218
a,219-220
strong,221-227
drying,228-234
effect,,235-242
and,243-246
products,247-255
with,256-260
high,261-265
concentrations,266-280
of,281-283
alcohol,,284-292
astringents,,293-305
spices,306-312
or,313-315
lime),316-321	DrugDDI.d268.s0.e3
should,322-328
be,329-331
approached,332-342
with,343-347
caution.,348-356

Particular,0-10
caution,11-18
should,19-25
be,26-28
exercised,29-38
in,39-41
using,42-47
preparations,48-60
containing,61-71
sulfur,,72-79
resorcinol,,80-91
or,92-94
salicylic,95-104	DrugDDI.d268.s1.e2
acid,105-109	DrugDDI.d268.s1.e2
in,110-112
combination,113-124
with,125-129
DIFFERIN,130-138	DrugDDI.d268.s1.e3
Gel.,139-143

If,0-2
these,3-8
preparations,9-21
have,22-26
been,27-31
used,32-36
it,37-39
is,40-42
advisable,43-52
not,53-56
to,57-59
start,60-65
therapy,66-73
with,74-78
DIFFERIN,79-87	DrugDDI.d268.s2.e0
Gel,88-91
until,92-97
the,98-101
effects,102-109
of,110-112
such,113-117
preparations,118-130
in,131-133
the,134-137
skin,138-142
have,143-147
subsided.,148-157

Before,0-6
using,7-12
this,13-17
medication,,18-29
tell,30-34
your,35-39
doctor,40-46
or,47-49
pharmacist,50-60
of,61-63
all,64-67
prescription,68-80
and,81-84
nonprescription,85-100
products,101-109
you,110-113
may,114-117
use,,118-122
especially,123-133
of:,134-137
aminoglycosides,138-153	DrugDDI.d181.s0.e1
(e.g.,,154-160
gentamicin,,161-172
amikacin),,173-183
amphotericin,184-196	DrugDDI.d181.s0.e4
B,,197-199	DrugDDI.d181.s0.e4
cyclosporine,,200-213
non-steroidal,214-227	DrugDDI.d181.s0.e6
anti-inflammatory,228-245	DrugDDI.d181.s0.e6
drugs,246-251	DrugDDI.d181.s0.e6
(e.g.,,252-258
ibuprofen),,259-270
tacrolimus,,271-282
vancomycin.,283-294	DrugDDI.d181.s0.e9

Do,0-2
not,3-6
start,7-12
or,13-15
stop,16-20
any,21-24
medicine,25-33	DrugDDI.d181.s1.e0
without,34-41
doctor,42-48
or,49-51
pharmacist,52-62
approval.,63-72

Intravenous,0-11
Adenocard,12-21	DrugDDI.d131.s0.e0
(adenosine),22-33
has,34-37
been,38-42
effectively,43-54
administered,55-67
in,68-70
the,71-74
presence,75-83
of,84-86
other,87-92
cardioactive,93-105	DrugDDI.d131.s0.e2
drugs,,106-112	DrugDDI.d131.s0.e2
such,113-117
as,118-120
quinidine,,121-131
beta-adrenergic,132-147	DrugDDI.d131.s0.e4
blocking,148-156	DrugDDI.d131.s0.e4
agents,,157-164	DrugDDI.d131.s0.e4
calcium,165-172	DrugDDI.d131.s0.e5
channel,173-180	DrugDDI.d131.s0.e5
blocking,181-189	DrugDDI.d131.s0.e5
agents,,190-197	DrugDDI.d131.s0.e5
and,198-201
angiotensin,202-213	DrugDDI.d131.s0.e6
converting,214-224	DrugDDI.d131.s0.e6
enzyme,225-231	DrugDDI.d131.s0.e6
inhibitors,,232-243	DrugDDI.d131.s0.e6
without,244-251
any,252-255
change,256-262
in,263-265
the,266-269
adverse,270-277
reaction,278-286
profile.,287-295

Digoxin,0-7	DrugDDI.d131.s1.e0
and,8-11
verapamil,12-21	DrugDDI.d131.s1.e1
use,22-25
may,26-29
be,30-32
rarely,33-39
associated,40-50
with,51-55
ventricular,56-67
fibrillation,68-80
when,81-85
combined,86-94
with,95-99
Adenocard.,100-110	DrugDDI.d131.s1.e2

Because,0-7
of,8-10
the,11-14
potential,15-24
for,25-28
additive,29-37
or,38-40
synergistic,41-52
depressant,53-63
effects,64-71
on,72-74
the,75-78
SA,79-81
and,82-85
AV,86-88
nodes,,89-95
however,,96-104
Adenocard,105-114	DrugDDI.d131.s2.e0
should,115-121
be,122-124
used,125-129
with,130-134
caution,135-142
in,143-145
the,146-149
presence,150-158
of,159-161
these,162-167
agents.,168-175

The,0-3
use,4-7
of,8-10
Adenocard,11-20	DrugDDI.d131.s3.e0
in,21-23
patients,24-32
receiving,33-42
digitalis,43-52	DrugDDI.d131.s3.e1
may,53-56
be,57-59
rarely,60-66
associated,67-77
with,78-82
ventricular,83-94
fibrillation.,95-108

The,0-3
effects,4-11
of,12-14
adenosine,15-24	DrugDDI.d131.s4.e0
are,25-28
antagonized,29-40
by,41-43
methylxanthines,44-59	DrugDDI.d131.s4.e1
such,60-64
as,65-67
caffeine,68-76	DrugDDI.d131.s4.e2
and,77-80
theophylline.,81-94	DrugDDI.d131.s4.e3

In,0-2
the,3-6
presence,7-15
of,16-18
these,19-24
methylxanthines,,25-41
larger,42-48
doses,49-54
of,55-57
adenosine,58-67	DrugDDI.d131.s5.e1
may,68-71
be,72-74
required,75-83
or,84-86
adenosine,87-96	DrugDDI.d131.s5.e2
may,97-100
not,101-104
be,105-107
effective.,108-118

Adenosine,0-9	DrugDDI.d131.s6.e0
effects,10-17
are,18-21
potentiated,22-33
by,34-36
dipyridamole.,37-50	DrugDDI.d131.s6.e1

Thus,,0-5
smaller,6-13
doses,14-19
of,20-22
adenosine,23-32	DrugDDI.d131.s7.e0
may,33-36
be,37-39
effective,40-49
in,50-52
the,53-56
presence,57-65
of,66-68
dipyridamole.,69-82	DrugDDI.d131.s7.e1

Carbamazepine,0-13	DrugDDI.d131.s8.e0
has,14-17
been,18-22
reported,23-31
to,32-34
increase,35-43
the,44-47
degree,48-54
of,55-57
heart,58-63
block,64-69
produced,70-78
by,79-81
other,82-87
agents.,88-95

As,0-2
the,3-6
primary,7-14
effect,15-21
of,22-24
adenosine,25-34	DrugDDI.d131.s9.e0
is,35-37
to,38-40
decrease,41-49
conduction,50-60
through,61-68
the,69-72
A-V,73-76
node,,77-82
higher,83-89
degrees,90-97
of,98-100
heart,101-106
block,107-112
may,113-116
be,117-119
produced,120-128
in,129-131
the,132-135
presence,136-144
of,145-147
carbamazepine.,148-162	DrugDDI.d131.s9.e1

Co-administration,0-17
with,18-22
antifungal,23-33	DrugDDI.d343.s0.e0
agents,34-40	DrugDDI.d343.s0.e0
such,41-45
as,46-48
ketoconazole,49-61	DrugDDI.d343.s0.e1
or,62-64
itraconazole,65-77	DrugDDI.d343.s0.e2
is,78-80
not,81-84
recommended.,85-97

Nafazodone,,0-11
fluvoxamine,,12-24
cimetidine,25-35	DrugDDI.d343.s1.e1
(consider,36-45
Xanax,46-51	DrugDDI.d343.s1.e2
dose,52-56
reduction).,57-68

Fluoxetine,,0-11
OCs,,12-16
sertraline,,17-28
diltiazem,,29-39
macrolide,40-49	DrugDDI.d343.s2.e3
antibiotics,50-61	DrugDDI.d343.s2.e3
(exercise,62-71
caution).,72-81

Dexamethasone:,0-14	DrugDDI.d516.s0.e0
Steady-state,15-27
trough,28-34
concentrations,35-49
of,50-52
albendazole,53-64	DrugDDI.d516.s0.e1
sulfoxide,65-74	DrugDDI.d516.s0.e1
were,75-79
about,80-85
56%,86-89
higher,90-96
when,97-101
8,102-103
mg,104-106
dexamethasone,107-120	DrugDDI.d516.s0.e2
was,121-124
coadministered,125-139
with,140-144
each,145-149
dose,150-154
of,155-157
albendazole,158-169	DrugDDI.d516.s0.e3
(15,170-173
mg/kg/day),174-184
in,185-187
eight,188-193
neurocysticercosis,194-212
patients.,213-222

Praziquantel:,0-13	DrugDDI.d516.s1.e0
In,14-16
the,17-20
fed,21-24
state,,25-31
praziquantel,32-44	DrugDDI.d516.s1.e1
(40,45-48
mg/kg),49-55
increased,56-65
mean,66-70
maximum,71-78
plasma,79-85
concentration,86-99
and,100-103
area,104-108
under,109-114
the,115-118
curve,119-124
of,125-127
albendazole,128-139	DrugDDI.d516.s1.e2
sulfoxide,140-149	DrugDDI.d516.s1.e2
by,150-152
about,153-158
50%,159-162
in,163-165
healthy,166-173
subjects,174-182
(n=10),183-189
compared,190-198
with,199-203
a,204-205
separate,206-214
group,215-220
of,221-223
subjects,224-232
(n=6),233-238
given,239-244
albendazole,245-256	DrugDDI.d516.s1.e3
alone.,257-263

Mean,0-4
T,5-6
max,7-10	DrugDDI.d516.s2.e0
and,11-14
mean,15-19
plasma,20-26
elimination,27-38
half-life,39-48
of,49-51
albendazole,52-63	DrugDDI.d516.s2.e1
sulfoxide,64-73	DrugDDI.d516.s2.e1
were,74-78
unchanged.,79-89

The,0-3
pharmacokinetics,4-20
of,21-23
praziquantel,24-36	DrugDDI.d516.s3.e0
were,37-41
unchanged,42-51
following,52-61
coadministration,62-78
with,79-83
albendazole,84-95	DrugDDI.d516.s3.e1
(400,96-100
mg).,101-105

Cimetidine:,0-11	DrugDDI.d516.s4.e0
Albendazole,12-23	DrugDDI.d516.s4.e1
sulfoxide,24-33	DrugDDI.d516.s4.e1
concentrations,34-48
in,49-51
bile,52-56
and,57-60
cystic,61-67
fluid,68-73
were,74-78
increased,79-88
(about,89-95
2-fold),96-103
in,104-106
hydatid,107-114
cyst,115-119
patients,120-128
treated,129-136
with,137-141
cimetidine,142-152	DrugDDI.d516.s4.e2
(10,153-156
mg/kg/day),157-167
(n=7),168-173
compared,174-182
with,183-187
albendazole,188-199	DrugDDI.d516.s4.e4
(20,200-203
mg/kg/day),204-214
alone,215-220
(n=12).,221-228

Albendazole,0-11	DrugDDI.d516.s5.e0
sulfoxide,12-21	DrugDDI.d516.s5.e0
plasma,22-28
concentrations,29-43
were,44-48
unchanged,49-58
4,59-60
hours,61-66
after,67-72
dosing.,73-80

Theophylline:,0-13	DrugDDI.d516.s6.e0
The,14-17
pharmacokinetics,18-34
of,35-37
theophylline,38-50	DrugDDI.d516.s6.e1
(aminophylline,51-65
5.8,66-69
mg/kg,70-75
infused,76-83
over,84-88
20,89-91
minutes),92-100
were,101-105
unchanged,106-115
following,116-125
a,126-127
single,128-134
oral,135-139
dose,140-144
of,145-147
albendazole,148-159	DrugDDI.d516.s6.e3
(400,160-164
mg),165-168
in,169-171
6,172-173
healthy,174-181
subjects.,182-191

PROLEUKIN,0-9	DrugDDI.d411.s0.e0
may,10-13
affect,14-20
central,21-28
nervous,29-36
function.,37-46

Therefore,,0-10
interactions,11-23
could,24-29
occur,30-35
following,36-45
concomitant,46-57
administration,58-72
of,73-75
psychotropic,76-88	DrugDDI.d411.s1.e0
drugs,89-94	DrugDDI.d411.s1.e0
(e.g.,,95-101
narcotics,,102-112
analgesics,,113-124
antiemetics,,125-137
sedatives,,138-148
tranquilizers).,149-164	DrugDDI.d411.s1.e5

Concurrent,0-10
administration,11-25
of,26-28
drugs,29-34	DrugDDI.d411.s2.e0
possessing,35-45
nephrotoxic,46-57
(e.g.,,58-64
aminoglycosides,,65-81
indomethacin),,82-96
myelotoxic,97-107
(e.g.,,108-114
cytotoxic,115-124
chemotherapy),,125-139
cardiotoxic,140-151
(e.g.,,152-158
doxorubicin),159-171	DrugDDI.d411.s2.e3
or,172-174
hepatotoxic,175-186
(e.g.,,187-193
methotrexate,,194-207
asparaginase),208-221	DrugDDI.d411.s2.e5
effects,222-229
with,230-234
PROLEUKIN,235-244	DrugDDI.d411.s2.e6
may,245-248
increase,249-257
toxicity,258-266
in,267-269
these,270-275
organ,276-281
systems.,282-290

The,0-3
safety,4-10
and,11-14
efficacy,15-23
of,24-26
PROLEUKIN,27-36	DrugDDI.d411.s3.e0
in,37-39
combination,40-51
with,52-56
any,57-60
antineoplastic,61-75	DrugDDI.d411.s3.e1
agents,76-82	DrugDDI.d411.s3.e1
have,83-87
not,88-91
been,92-96
established.,97-109

In,0-2
addition,,3-12
reduced,13-20
kidney,21-27
and,28-31
liver,32-37	DrugDDI.d411.s4.e0
function,38-46
secondary,47-56
to,57-59
PROLEUKIN,60-69	DrugDDI.d411.s4.e1
treatment,70-79
may,80-83
delay,84-89
elimination,90-101
of,102-104
concomitant,105-116
medications,117-128	DrugDDI.d411.s4.e2
and,129-132
increase,133-141
the,142-145
risk,146-150
of,151-153
adverse,154-161
events,162-168
from,169-173
those,174-179
drugs.,180-186	DrugDDI.d411.s4.e3

Hypersensitivity,0-16
reactions,17-26
have,27-31
been,32-36
reported,37-45
in,46-48
patients,49-57
receiving,58-67
combination,68-79
regimens,80-88
containing,89-99
sequential,100-110
high,111-115
dose,116-120
PROLEUKIN,121-130	DrugDDI.d411.s5.e0
and,131-134
antineoplastic,135-149	DrugDDI.d411.s5.e1
agents,,150-157	DrugDDI.d411.s5.e1
specifically,,158-171
dacarbazine,,172-184
cis-platinum,,185-198
tamoxifen,199-208	DrugDDI.d411.s5.e4
and,209-212
interferon-alfa.,213-229	DrugDDI.d411.s5.e5

Myocardial,0-10
injury,,11-18
including,19-28
myocardial,29-39
infarction,,40-51
myocarditis,,52-64
ventricular,65-76
hypokinesia,,77-89
and,90-93
severe,94-100
rhabdomyolysis,101-115
appear,116-122
to,123-125
be,126-128
increased,129-138
in,139-141
patients,142-150
receiving,151-160
PROLEUKIN,161-170	DrugDDI.d411.s8.e0
and,171-174
interferon-alfa,175-190	DrugDDI.d411.s8.e1
concurrently.,191-204

Exacerbation,0-12
or,13-15
the,16-19
initial,20-27
presentation,28-40
of,41-43
a,44-45
number,46-52
of,53-55
autoimmune,56-66
and,67-70
inflammatory,71-83
disorders,84-93
has,94-97
been,98-102
observed,103-111
following,112-121
concurrent,122-132
use,133-136
of,137-139
interferon-alfa,140-155	DrugDDI.d411.s9.e0
and,156-159
PROLEUKIN,,160-170
including,171-180
crescentic,181-191
IgA,192-195
glomerulonephritis,,196-215
oculo-bulbar,216-228
myasthenia,229-239
gravis,,240-247
inflammatory,248-260
arthritis,,261-271
thyroiditis,,272-284
bullous,285-292
pemphigoid,,293-304
and,305-308
Stevens-Johnson,309-324
syndrome.,325-334

Although,0-8
glucocorticoids,9-24	DrugDDI.d411.s10.e0
have,25-29
been,30-34
shown,35-40
to,41-43
reduce,44-50
PROLEUKIN-induced,51-68	DrugDDI.d411.s10.e1
side,69-73
effects,74-81
including,82-91
fever,,92-98
renal,99-104
insufficiency,,105-119
hyperbilirubinemia,,120-139
confusion,,140-150
and,151-154
dyspnea,,155-163
concomitant,164-175
administration,176-190
of,191-193
these,194-199
agents,200-206
with,207-211
PROLEUKIN,212-221	DrugDDI.d411.s10.e2
may,222-225
reduce,226-232
the,233-236
antitumor,237-246
effectiveness,247-260
of,261-263
PROLEUKIN,264-273	DrugDDI.d411.s10.e3
and,274-277
thus,278-282
should,283-289
be,290-292
avoided.,293-301
12,302-304	DrugDDI.d411.s10.e4
Beta-blockers,305-318	DrugDDI.d411.s10.e4
and,319-322
other,323-328	DrugDDI.d411.s10.e5
antihypertensives,329-346	DrugDDI.d411.s10.e5
may,347-350
potentiate,351-361
the,362-365
hypotension,366-377
seen,378-382
with,383-387
PROLEUKIN.,388-398	DrugDDI.d411.s10.e6

Delayed,0-7
Adverse,8-15
Reactions,16-25
to,26-28
Iodinated,29-38
Contrast,39-47
Media:,48-54
A,55-56
review,57-63
of,64-66
the,67-70
literature,71-81
revealed,82-90
that,91-95
12.6%,96-101
(range,102-108
11-28%),109-116
of,117-119
501,120-123
patients,124-132
treated,133-140
with,141-145
various,146-153
interleukin-2,154-167	DrugDDI.d411.s11.e0
containing,168-178
regimens,179-187
who,188-191
were,192-196
subsequently,197-209
administered,210-222
radiographic,223-235
iodinated,236-245
contrast,246-254
media,255-260
experienced,261-272
acute,,273-279
atypical,280-288
adverse,289-296
reactions.,297-307

Some,0-4
clinicians,5-15
have,16-20
noted,21-26
that,27-31
these,32-37
reactions,38-47
resemble,48-56
the,57-60
immediate,61-70
side,71-75
effects,76-83
caused,84-90
by,91-93
interleukin-2,94-107	DrugDDI.d411.s14.e0
administration,,108-123
however,124-131
the,132-135
cause,136-141
of,142-144
contrast,145-153
reactions,154-163
after,164-169
interleukin-2,170-183
therapy,184-191
is,192-194
unknown.,195-203

Most,0-4
events,5-11
were,12-16
reported,17-25
to,26-28
occur,29-34
when,35-39
contrast,40-48
media,49-54
was,55-58
given,59-64
within,65-71
4,72-73
weeks,74-79
after,80-85
the,86-89
last,90-94
dose,95-99
of,100-102
interleukin-2.,103-117	DrugDDI.d411.s15.e0

These,0-5
events,6-12
were,13-17
also,18-22
reported,23-31
to,32-34
occur,35-40
when,41-45
contrast,46-54
media,55-60
was,61-64
given,65-70
several,71-78
months,79-85
after,86-91
interleukin-2,92-105	DrugDDI.d411.s16.e0
treatment.,106-116

In,0-2
a,3-4
chronic,5-12
toxicity,13-21
study,,22-28
cynomolgus,29-39
monkeys,40-47
were,48-52
dosed,53-58
weekly,59-65
for,66-69
52,70-72
weeks,73-78
with,79-83
intravenous,84-95
alefacept,96-105	DrugDDI.d45.s3.e0
at,106-108
1,109-110
mg/kg/dose,111-121
or,122-124
20,125-127
mg/kg/dose.,128-139

In,0-2
a,3-4
separate,5-13
study,,14-20
baboons,21-28
given,29-34
3,35-36
doses,37-42
of,43-45
alefacept,46-55	DrugDDI.d45.s8.e0
at,56-58
1,59-60
mg/kg,61-66
every,67-72
8,73-74
weeks,75-80
were,81-85
found,86-91
to,92-94
have,95-99
centroblast,100-111
proliferation,112-125
in,126-128
B-cell,129-135
dependent,136-145
areas,146-151
in,152-154
the,155-158
germinal,159-167
centers,168-175
of,176-178
the,179-182
spleen,183-189
following,190-199
a,200-201
116-day,202-209
washout,210-217
period.,218-225

Since,0-5
the,6-9
effect,10-16
of,17-19
AMEVIVE?,20-28
on,29-31
pregnancy,32-41
and,42-45
fetal,46-51
development,,52-64
including,65-74
immune,75-81
system,82-88
development,,89-101
is,102-104
not,105-108
known,,109-115
health,116-122
care,123-127
providers,128-137
are,138-141
encouraged,142-152
to,153-155
enroll,156-162
patients,163-171
currently,172-181
taking,182-188
AMEVIVE?,189-197
who,198-201
become,202-208
pregnant,209-217
into,218-222
the,223-226
Biogen,227-233
Pregnancy,234-243
Registry,244-252
by,253-255
calling,256-263
1-866-AMEVIVE,264-277
(1-866-263-8483).,278-295

No,0-2
abortifacient,3-16	DrugDDI.d45.s18.e0
or,17-19
teratogenic,20-31
effects,32-39
were,40-44
observed,45-53
in,54-56
cynomolgus,57-67
monkeys,68-75
following,76-85
intravenous,86-97
bolus,98-103
injections,104-114
of,115-117
AMEVIVE?,118-126
administered,127-139
weekly,140-146
during,147-153
the,154-157
period,158-164
of,165-167
organogenesis,168-181
to,182-184
gestation.,185-195

If,0-2
pregnancy,3-12
occurs,13-19
while,20-25
taking,26-32
AMEVIVE?,,33-42
continued,43-52
use,53-56
of,57-59
the,60-63
drug,64-68	DrugDDI.d45.s24.e0
should,69-75
be,76-78
assessed.,79-88

Because,0-7
many,8-12
drugs,13-18	DrugDDI.d45.s27.e0
are,19-22
excreted,23-31
in,32-34
human,35-40
milk,,41-46
and,47-50
because,51-58
there,59-64
exists,65-71
the,72-75
potential,76-85
for,86-89
serious,90-97
adverse,98-105
reactions,106-115
in,116-118
nursing,119-126
infants,127-134
from,135-139
AMEVIVE?,,140-149
a,150-151
decision,152-160
should,161-167
be,168-170
made,171-175
whether,176-183
to,184-186
discontinue,187-198
nursing,199-206
while,207-212
taking,213-219
the,220-223
drug,224-228	DrugDDI.d45.s27.e1
or,229-231
to,232-234
discontinue,235-246
the,247-250
use,251-254
of,255-257
the,258-261
drug,,262-267
taking,268-274
into,275-279
account,280-287
the,288-291
importance,292-302
of,303-305
the,306-309
drug,310-314	DrugDDI.d45.s27.e3
to,315-317
the,318-321
mother.,322-329

Pediatric,0-9	DrugDDI.d45.s34.e0
Use,10-13

The,0-3
safety,4-10
and,11-14
efficacy,15-23
of,24-26
AMEVIVE?,27-35
in,36-38
pediatric,39-48	DrugDDI.d45.s35.e0
patients,49-57
have,58-62
not,63-66
been,67-71
studied.,72-80

AMEVIVE?,0-8
is,9-11
not,12-15
indicated,16-25
for,26-29
pediatric,30-39	DrugDDI.d45.s36.e0
patients.,40-49

Drug/Laboratory,0-15	DrugDDI.d75.s0.e0
Interactions,16-28
No,29-31
formal,32-38
drug,39-43
interaction,44-55
studies,56-63
have,64-68
been,69-73
performed,74-83
with,84-88
Campath.,89-97	DrugDDI.d75.s0.e1

An,0-2
immune,3-9
response,10-18
to,19-21
Campath,22-29	DrugDDI.d75.s1.e0
may,30-33
interfere,34-43
with,44-48
subsequent,49-59
diagnostic,60-70
serum,71-76
tests,77-82
that,83-87
utilize,88-95
antibodies,96-106	DrugDDI.d75.s1.e1

Intravenous,0-11
ranitidine,12-22	DrugDDI.d203.s0.e0
was,23-26
shown,27-32
to,33-35
double,36-42
the,43-46
bioavailability,47-62
of,63-65
oral,66-70
alendronate.,71-83	DrugDDI.d203.s0.e1

Products,0-8
containing,9-19
calcium,20-27	DrugDDI.d203.s3.e0
and,28-31
other,32-37
multivalent,38-49
cations,50-57	DrugDDI.d203.s3.e1
likely,58-64
will,65-69
interfere,70-79
with,80-84
absorption,85-95
of,96-98
alendronate.,99-111	DrugDDI.d203.s3.e2

Both,0-4
the,5-8
magnitude,9-18
and,19-22
duration,23-31
of,32-34
central,35-42
nervous,43-50
system,51-57
and,58-61
cardiovascular,62-76
effects,77-84
may,85-88
be,89-91
enhanced,92-100
when,101-105
ALFENTA,106-113	DrugDDI.d122.s0.e0
is,114-116
administered,117-129
in,130-132
combination,133-144
with,145-149
other,150-155
CNS,156-159	DrugDDI.d122.s0.e1
depressants,160-171	DrugDDI.d122.s0.e1
such,172-176
as,177-179
barbiturates,,180-193
tranquilizers,,194-208
opioids,,209-217
or,218-220
inhalation,221-231
general,232-239	DrugDDI.d122.s0.e5
anesthetics.,240-252	DrugDDI.d122.s0.e5

Limited,0-7
clinical,8-16
experience,17-27
indicates,28-37
that,38-42
requirements,43-55
for,56-59
volatile,60-68
inhalation,69-79
anesthetics,80-91	DrugDDI.d122.s3.e0
are,92-95
reduced,96-103
by,104-106
30,107-109
to,110-112
50%,113-116
for,117-120
the,121-124
first,125-130
sixty,131-136
(60),137-141
minutes,142-149
following,150-159
ALFENTA,160-167	DrugDDI.d122.s3.e1
induction,168-177
The,178-181
concomitant,182-193
use,194-197
of,198-200
erythromycin,201-213	DrugDDI.d122.s3.e2
with,214-218
ALFENTA,219-226	DrugDDI.d122.s3.e3
can,227-230
significantly,231-244
inhibit,245-252
ALFENTA,253-260	DrugDDI.d122.s3.e4
clearance,261-270
and,271-274
may,275-278
increase,279-287
the,288-291
risk,292-296
of,297-299
prolonged,300-309
or,310-312
delayed,313-320
respiratory,321-332
depression.,333-344

Cimetidine,0-10	DrugDDI.d122.s4.e0
reduces,11-18
the,19-22
clearance,23-32
of,33-35
ALFENTA.,36-44	DrugDDI.d122.s4.e1

Therefore,0-9
smaller,10-17
ALFENTA,18-25	DrugDDI.d122.s5.e0
doses,26-31
will,32-36
be,37-39
required,40-48
with,49-53
prolonged,54-63
administration,64-78
and,79-82
the,83-86
duration,87-95
of,96-98
action,99-105
of,106-108
ALFENTA,109-116	DrugDDI.d122.s5.e1
my,117-119
be,120-122
extended.,123-132

Perioperative,0-13
administration,14-28
of,29-31
drugs,32-37	DrugDDI.d122.s6.e0
affecting,38-47
hepatic,48-55
blood,56-61
flow,62-66
or,67-69
enzyme,70-76
function,77-85
may,86-89
reduce,90-96
plasma,97-103
clearance,104-113
and,114-117
prolong,118-125
recovery.,126-135

Drug-Drug,0-9
Interactions:,10-23
The,24-27
pharmacokinetic,28-43
and,44-47
pharmacodynamic,48-63
interactions,64-76
between,77-84
UROXATRAL,85-94	DrugDDI.d18.s0.e0
and,95-98
other,99-104
alpha-blockers,105-119	DrugDDI.d18.s0.e1
have,120-124
not,125-128
been,129-133
determined.,134-145

However,,0-8
interactions,9-21
may,22-25
be,26-28
expected,,29-38
and,39-42
UROXATRAL,43-52	DrugDDI.d18.s1.e0
should,53-59
NOT,60-63
be,64-66
used,67-71
in,72-74
combination,75-86
with,87-91
other,92-97
alpha-blockers.,98-113	DrugDDI.d18.s1.e1

Effects,0-7
of,8-10
Other,11-16
Drugs,17-22	DrugDDI.d225.s0.e0
on,23-25
Aliskiren,26-35	DrugDDI.d225.s0.e1
Based,36-41
on,42-44
in-vitro,45-53
studies,,54-62
aliskiren,63-72	DrugDDI.d225.s0.e2
is,73-75
metabolized,76-87
by,88-90
CYP,91-94	DrugDDI.d225.s0.e3
3A4.,95-99

Co-administration,0-17
of,18-20
lovastatin,,21-32
atenolol,,33-42
warfarin,,43-52
furosemide,,53-64
digoxin,,65-73
celecoxib,,74-84
hydrochlorothiazide,,85-105
ramapril,,106-115
valsartan,,116-126
metformin,127-136	DrugDDI.d225.s1.e8
and,137-140
amlodipine,141-151	DrugDDI.d225.s1.e9
did,152-155
not,156-159
result,160-166
in,167-169
clinically,170-180
significant,181-192
increases,193-202
in,203-205
aliskiren,206-215	DrugDDI.d225.s1.e10
exposure.,216-225

Co-administration,0-17
of,18-20
irbesartan,21-31	DrugDDI.d225.s2.e0
reduced,32-39
aliskiren,40-49	DrugDDI.d225.s2.e1
Cmax,50-54
up,55-57
to,58-60
50%,61-64
after,65-70
multiple,71-79
dosing.,80-87

Co-administration,0-17
of,18-20
atorvastatin,21-33	DrugDDI.d225.s3.e0
resulted,34-42
in,43-45
about,46-51
a,52-53
50%,54-57
increase,58-66
in,67-69
aliskiren,70-79	DrugDDI.d225.s3.e1
Cmax,80-84
and,85-88
AUC,89-92
after,93-98
multiple,99-107
dosing.,108-115

Ketoconazole,0-12	DrugDDI.d225.s4.e0
Co-administration,13-30
of,31-33
200,34-37
mg,38-40
twice-daily,41-52
ketoconazole,53-65	DrugDDI.d225.s4.e1
with,66-70
aliskiren,71-80	DrugDDI.d225.s4.e2
resulted,81-89
in,90-92
an,93-95
approximate,96-107
80%,108-111
increase,112-120
in,121-123
plasma,124-130
levels,131-137
of,138-140
aliskiren.,141-151	DrugDDI.d225.s4.e3

A,0-1
400,2-5
mg,6-8
once-daily,9-19
dose,20-24
was,25-28
not,29-32
studied,33-40
but,41-44
would,45-50
be,51-53
expected,54-62
to,63-65
increase,66-74
aliskiren,75-84	DrugDDI.d225.s5.e0
blood,85-90
levels,91-97
further.,98-106

Effects,0-7
of,8-10
Aliskiren,11-20	DrugDDI.d225.s6.e0
on,21-23
Other,24-29
Drugs,30-35	DrugDDI.d225.s6.e1
Aliskiren,36-45
does,46-50
not,51-54
inhibit,55-62
the,63-66
CYP450,67-73
isoenzymes,74-84	DrugDDI.d225.s6.e2
(CYP1A2,,85-93
2C8,,94-98
2C9,,99-103
2C19,,104-109
2D6,,110-114
2E1,,115-119
and,120-123
CYP,124-127	DrugDDI.d225.s6.e4
3A),128-131
or,132-134
induce,135-141
CYP,142-145	DrugDDI.d225.s6.e5
3A4.,146-150

Co-administration,0-17
of,18-20
aliskiren,21-30	DrugDDI.d225.s7.e0
did,31-34
not,35-38
significantly,39-52
affect,53-59
the,60-63
pharmacokinetics,64-80
of,81-83
lovastatin,,84-95
digoxin,,96-104
valsartan,,105-115
amlodipine,,116-127
metformin,,128-138
celecoxib,,139-149
atenolol,,150-159
atorvastatin,,160-173
ramipril,174-182	DrugDDI.d225.s7.e9
or,183-185
hydrochlorothiazide.,186-206	DrugDDI.d225.s7.e10

Warfarin,0-8	DrugDDI.d225.s8.e0
The,9-12
effects,13-20
of,21-23
aliskiren,24-33	DrugDDI.d225.s8.e1
on,34-36
warfarin,37-45	DrugDDI.d225.s8.e2
pharmacokinetics,46-62
have,63-67
not,68-71
been,72-76
evaluated,77-86
in,87-89
a,90-91
well-controlled,92-107
clinical,108-116
trial.,117-123

Furosemide,0-10	DrugDDI.d225.s9.e0
When,11-15
aliskiren,16-25	DrugDDI.d225.s9.e1
was,26-29
co-administered,30-45
with,46-50
furosemide,,51-62
the,63-66
AUC,67-70
and,71-74
Cmax,75-79
of,80-82
furosemide,83-93	DrugDDI.d225.s9.e3
were,94-98
reduced,99-106
by,107-109
about,110-115
30%,116-119
and,120-123
50%,,124-128
respectively.,129-142

Patients,0-8
who,9-12
are,13-16
applying,17-25
Panretin?,26-35
gel,36-39
should,40-46
not,47-50
concurrently,51-63
use,64-67
products,68-76
that,77-81
contain,82-89
DEET,90-94	DrugDDI.d447.s0.e0
(N,,95-98
N-diethyl-m-toluamide),,99-122
a,123-124
common,125-131
component,132-141
of,142-144
insect,145-151
repellent,152-161
products.,162-171

Animal,0-6
toxicology,7-17
studies,18-25
showed,26-32
increased,33-42
DEET,43-47	DrugDDI.d447.s1.e0
toxicity,48-56
when,57-61
DEET,62-66	DrugDDI.d447.s1.e1
was,67-70
included,71-79
as,80-82
proof,83-88
of,89-91
the,92-95
formulation.,96-108

Although,0-8
there,9-14
was,15-18
no,19-21
clinical,22-30
evidence,31-39
in,40-42
the,43-46
vehicle-controlled,47-65
studies,66-73
of,74-76
drug,77-81
interactions,82-94
with,95-99
systemic,100-108
antiretroviral,109-123	DrugDDI.d447.s2.e0
agents,,124-131	DrugDDI.d447.s2.e0
including,132-141
protease,142-150	DrugDDI.d447.s2.e1
inhibitors,,151-162	DrugDDI.d447.s2.e1
macrolide,163-172	DrugDDI.d447.s2.e2
antibiotics,,173-185	DrugDDI.d447.s2.e2
and,186-189
azole,190-195	DrugDDI.d447.s2.e3
antifungals,,196-208	DrugDDI.d447.s2.e3
the,209-212
effect,213-219
of,220-222
Panretin?,223-232
gel,233-236
on,237-239
the,240-243
steady-state,244-256
concentrations,257-271
of,272-274
these,275-280
drugs,281-286	DrugDDI.d447.s2.e4
is,287-289
not,290-293
known.,294-300

The,0-3
following,4-13
drug,14-18
interactions,19-31
were,32-36
observed,37-45
in,46-48
some,49-53
patients,54-62
undergoing,63-73
treatment,74-83
with,84-88
oral,89-93
allopurinol.,94-106	DrugDDI.d66.s0.e0

Although,0-8
the,9-12
pattern,13-20
of,21-23
use,24-27
for,28-31
oral,32-36
allopurinol,37-48	DrugDDI.d66.s1.e0
includes,49-57
longer,58-64
term,65-69
therapy,,70-78
particularly,79-91
for,92-95
gout,96-100
and,101-104
renal,105-110
calculi,,111-119
the,120-123
experience,124-134
gained,135-141
may,142-145
be,146-148
relevant.,149-158

Mercaptopurine/Azathioprine:,0-28	DrugDDI.d66.s2.e0
Allopurinol,29-40	DrugDDI.d66.s2.e2
inhibits,41-49
the,50-53
enzymatic,54-63
oxidation,64-73
of,74-76
mercaptopurine,77-91	DrugDDI.d66.s2.e3
and,92-95
azathioprine,96-108	DrugDDI.d66.s2.e4
to,109-111
6-thiouric,112-122
acid.,123-128

This,0-4
oxidation,,5-15
which,16-21
is,22-24
catalyzed,25-34
by,35-37
xanthine,38-46	DrugDDI.d66.s3.e0
oxidase,,47-55	DrugDDI.d66.s3.e0
inactivates,56-67
mercaptopurine.,68-83	DrugDDI.d66.s3.e1

In,0-2
patients,3-11
receiving,12-21
mercaptopurine,22-36	DrugDDI.d66.s4.e0
(Purinethol),37-49
or,50-52
azathioprine,53-65	DrugDDI.d66.s4.e2
(Imuran),,66-75
the,76-79
concomitant,80-91
administration,92-106
of,107-109
300-600,110-117
mg,118-120
of,121-123
allopurinol,124-135	DrugDDI.d66.s4.e4
per,136-139
day,140-143
will,144-148
require,149-156
a,157-158
reduction,159-168
in,169-171
dose,172-176
to,177-179
approximately,180-193
one-third,194-203
to,204-206
one-fourth,207-217
of,218-220
the,221-224
usual,225-230
dose,231-235
of,236-238
mercaptopurine,239-253	DrugDDI.d66.s4.e5
or,254-256
azathioprine.,257-270	DrugDDI.d66.s4.e6

Subsequent,0-10
adjustment,11-21
of,22-24
doses,25-30
of,31-33
mercaptopurine,34-48	DrugDDI.d66.s5.e0
or,49-51
azathioprine,52-64	DrugDDI.d66.s5.e1
should,65-71
be,72-74
made,75-79
on,80-82
the,83-86
basis,87-92
of,93-95
therapeutic,96-107
response,108-116
and,117-120
the,121-124
appearance,125-135
of,136-138
toxic,139-144
effects.,145-153

Dicumarol:,0-10	DrugDDI.d66.s6.e0
It,11-13
has,14-17
been,18-22
reported,23-31
that,32-36
allopurinol,37-48	DrugDDI.d66.s6.e1
prolongs,49-57
the,58-61
half-life,62-71
of,72-74
the,75-78
anticoagulant,,79-93
dicumarol.,94-104	DrugDDI.d66.s6.e3

The,0-3
clinical,4-12
basis,13-18
of,19-21
this,22-26
drug,27-31
interaction,32-43
has,44-47
not,48-51
been,52-56
established,57-68
but,69-72
should,73-79
be,80-82
noted,83-88
when,89-93
allopurinol,94-105	DrugDDI.d66.s7.e0
is,106-108
given,109-114
to,115-117
patients,118-126
already,127-134
on,135-137
dicumarol,138-147	DrugDDI.d66.s7.e1
therapy.,148-156

Consequently,,0-13
prothrombin,14-25
time,26-30
should,31-37
be,38-40
reassessed,41-51
periodically,52-64
in,65-67
patients,68-76
receiving,77-86
both,87-91
drugs.,92-98	DrugDDI.d66.s8.e0

Uricosuric,0-10	DrugDDI.d66.s9.e0
Agents:,11-18	DrugDDI.d66.s9.e0
Since,19-24
the,25-28
excretion,29-38
of,39-41
oxipurinol,42-52	DrugDDI.d66.s9.e1
is,53-55
similar,56-63
to,64-66
that,67-71
of,72-74
urate,,75-81
uricosuric,82-92	DrugDDI.d66.s9.e3
agents,,93-100	DrugDDI.d66.s9.e3
which,101-106
increase,107-115
the,116-119
excretion,120-129
of,130-132
urate,,133-139
are,140-143
also,144-148
likely,149-155
to,156-158
increase,159-167
the,168-171
excretion,172-181
of,182-184
oxipurinol,185-195	DrugDDI.d66.s9.e5
and,196-199
thus,200-204
lower,205-210
the,211-214
degree,215-221
of,222-224
inhibition,225-235
of,236-238
xanthine,239-247	DrugDDI.d66.s9.e6
oxidase.,248-256	DrugDDI.d66.s9.e6

The,0-3
concomitant,4-15
administration,16-30
of,31-33
uricosuric,34-44	DrugDDI.d66.s10.e0
agents,45-51	DrugDDI.d66.s10.e0
and,52-55
allopurinol,56-67	DrugDDI.d66.s10.e1
has,68-71
been,72-76
associated,77-87
with,88-92
a,93-94
decrease,95-103
in,104-106
the,107-110
excretion,111-120
of,121-123
oxypurines,124-134
(hypoxanthine,135-148
and,149-152
xanthine),153-162	DrugDDI.d66.s10.e3
and,163-166
an,167-169
increase,170-178
in,179-181
urinary,182-189
uric,190-194
acid,195-199
excretion,200-209
compared,210-218
with,219-223
that,224-228
observed,229-237
with,238-242
allopurinol,243-254	DrugDDI.d66.s10.e4
alone.,255-261

Although,0-8
clinical,9-17
evidence,18-26
to,27-29
date,30-34
has,35-38
not,39-42
demonstrated,43-55
renal,56-61
precipitation,62-75
of,76-78
oxypurines,79-89
in,90-92
patients,93-101
either,102-108
on,109-111
allopurinol,112-123	DrugDDI.d66.s11.e0
alone,124-129
or,130-132
in,133-135
combination,136-147
with,148-152
uricosuric,153-163	DrugDDI.d66.s11.e1
agents,,164-171	DrugDDI.d66.s11.e1
the,172-175
possibility,176-187
should,188-194
be,195-197
kept,198-202
in,203-205
mind.,206-211

Thiazide,0-8	DrugDDI.d66.s12.e0
Diuretics:,9-19	DrugDDI.d66.s12.e0
The,20-23
reports,24-31
that,32-36
the,37-40
concomitant,41-52
use,53-56
of,57-59
allopurinol,60-71	DrugDDI.d66.s12.e1
and,72-75
thiazide,76-84	DrugDDI.d66.s12.e2
diuretics,85-94	DrugDDI.d66.s12.e2
may,95-98
contribute,99-109
to,110-112
the,113-116
enhancement,117-128
of,129-131
allopurinol,132-143	DrugDDI.d66.s12.e3
toxicity,144-152
in,153-155
some,156-160
patients,161-169
have,170-174
been,175-179
reviewed,180-188
in,189-191
an,192-194
attempt,195-202
to,203-205
establish,206-215
a,216-217
cause-and-effect,218-234
relationship,235-247
and,248-251
a,252-253
mechanism,254-263
of,264-266
causation.,267-277

Review,0-6
of,7-9
these,10-15
case,16-20
reports,21-28
indicates,29-38
that,39-43
the,44-47
patients,48-56
were,57-61
mainly,62-68
receiving,69-78
thiazide,79-87	DrugDDI.d66.s13.e0
diuretics,88-97	DrugDDI.d66.s13.e0
for,98-101
hypertension,102-114
and,115-118
that,119-123
tests,124-129
to,130-132
rule,133-137
out,138-141
decreased,142-151
renal,152-157
function,158-166
secondary,167-176
to,177-179
hypertensive,180-192
nephropathy,193-204
were,205-209
not,210-213
often,214-219
performed.,220-230

In,0-2
those,3-8
patients,9-17
in,18-20
whom,21-25
renal,26-31
insufficiency,32-45
was,46-49
documented,,50-61
however,,62-70
the,71-74
recommendation,75-89
to,90-92
lower,93-98
the,99-102
dose,103-107
of,108-110
allopurinol,111-122	DrugDDI.d66.s14.e0
was,123-126
not,127-130
followed.,131-140

Although,0-8
a,9-10
causal,11-17
mechanism,18-27
and,28-31
a,32-33
cause-and-effect,34-50
relationship,51-63
have,64-68
not,69-72
been,73-77
established,,78-90
current,91-98
evidence,99-107
suggests,108-116
that,117-121
renal,122-127
function,128-136
should,137-143
be,144-146
monitored,147-156
in,157-159
patients,160-168
on,169-171
thiazide,172-180	DrugDDI.d66.s15.e0
diuretics,181-190	DrugDDI.d66.s15.e0
and,191-194
allopurinol,195-206	DrugDDI.d66.s15.e1
even,207-211
in,212-214
the,215-218
absence,219-226
of,227-229
renal,230-235
failure,,236-244
and,245-248
dosage,249-255
levels,256-262
should,263-269
be,270-272
even,273-277
more,278-282
conservatively,283-297
adjusted,298-306
in,307-309
those,310-315
patients,316-324
on,325-327
such,328-332
combined,333-341
therapy,342-349
if,350-352
diminished,353-363
renal,364-369
function,370-378
is,379-381
detected..,382-392

Ampicillin/Amoxicillin:,0-23	DrugDDI.d66.s16.e0
An,24-26
increase,27-35
in,36-38
the,39-42
frequency,43-52
of,53-55
skin,56-60
rash,61-65
has,66-69
been,70-74
reported,75-83
among,84-89
patients,90-98
receiving,99-108
ampicillin,109-119	DrugDDI.d66.s16.e2
or,120-122
amoxicillin,123-134	DrugDDI.d66.s16.e3
concurrently,135-147
with,148-152
allopurinol,153-164	DrugDDI.d66.s16.e4
compared,165-173
to,174-176
patients,177-185
who,186-189
are,190-193
not,194-197
receiving,198-207
both,208-212
drugs.,213-219	DrugDDI.d66.s16.e5

Cytotoxic,0-9	DrugDDI.d66.s18.e0
Agents:,10-17	DrugDDI.d66.s18.e0
Enhanced,18-26
bone,27-31
marrow,32-38
suppression,39-50
by,51-53
cyclophosphamide,54-70	DrugDDI.d66.s18.e1
and,71-74
other,75-80
cytotoxic,81-90	DrugDDI.d66.s18.e2
agents,91-97	DrugDDI.d66.s18.e2
has,98-101
been,102-106
reported,107-115
among,116-121
patients,122-130
with,131-135
neoplastic,136-146
disease,,147-155
except,156-162
leukemia,,163-172
in,173-175
the,176-179
presence,180-188
of,189-191
allopurinol.,192-204	DrugDDI.d66.s18.e3

However,,0-8
in,9-11
a,12-13
well-controlled,14-29
study,30-35
of,36-38
patients,39-47
with,48-52
lymphoma,53-61
on,62-64
combination,65-76
therapy,,77-85
allopurinol,86-97	DrugDDI.d66.s19.e0
did,98-101
not,102-105
increase,106-114
the,115-118
marrow,119-125
toxicity,126-134
of,135-137
patients,138-146
treated,147-154
with,155-159
cyclophosphamide,,160-177
doxorubicin,,178-190
bleomycin,,191-201
procarbazine,202-214	DrugDDI.d66.s19.e4
and/or,215-221
mechlorethamine.,222-238	DrugDDI.d66.s19.e5

Chlorpropamide:,0-15	DrugDDI.d66.s20.e0
Chlorpropamides,16-31	DrugDDI.d66.s20.e1
plasma,32-38
half-life,39-48
may,49-52
be,53-55
prolonged,56-65
by,66-68
allopurinol,,69-81
since,82-87
allopurinol,88-99	DrugDDI.d66.s20.e3
and,100-103
chlorpropamide,104-118	DrugDDI.d66.s20.e4
may,119-122
compete,123-130	DrugDDI.d66.s20.e5
for,131-134
excretion,135-144
in,145-147
the,148-151
renal,152-157
tubule.,158-165

The,0-3
risk,4-8
of,9-11
hypoglycemia,12-24
secondary,25-34
to,35-37
this,38-42
mechanism,43-52
may,53-56
be,57-59
increased,60-69
if,70-72
allopurinol,73-84	DrugDDI.d66.s21.e0
and,85-88
chlorpropamide,89-103	DrugDDI.d66.s21.e1
are,104-107
given,108-113
concomitantly,114-127
in,128-130
the,131-134
presence,135-143
of,144-146
renal,147-152
insufficiency.,153-167

Cyclosporin:,0-12	DrugDDI.d66.s22.e0
Reports,13-20
indicate,21-29
that,30-34
cyclosporine,35-47	DrugDDI.d66.s22.e1
levels,48-54
may,55-58
be,59-61
increased,62-71
during,72-78
concomitant,79-90
treatment,91-100
with,101-105
allopurinol,106-117	DrugDDI.d66.s22.e2
sodium,118-124	DrugDDI.d66.s22.e2
for,125-128
injection.,129-139

Monitoring,0-10
of,11-13
cyclosporine,14-26	DrugDDI.d66.s23.e0
levels,27-33
and,34-37
possible,38-46
adjustment,47-57
of,58-60
cyclosporine,61-73	DrugDDI.d66.s23.e1
dosage,74-80
should,81-87
be,88-90
considered,91-101
when,102-106
these,107-112
drugs,113-118	DrugDDI.d66.s23.e2
are,119-122
co-administered.,123-139

Tolbutamides,0-12	DrugDDI.d66.s24.e0
conversion,13-23
to,24-26
inactive,27-35
metabolites,36-47	DrugDDI.d66.s24.e1
has,48-51
been,52-56
shown,57-62
to,63-65
be,66-68
catalyzed,69-78
by,79-81
xanthine,82-90	DrugDDI.d66.s24.e2
oxidase,91-98	DrugDDI.d66.s24.e2
from,99-103
rat,104-107
liver.,108-114	DrugDDI.d66.s24.e3

Ergot-Containing,0-16	DrugDDI.d457.s0.e0
Drugs,17-22	DrugDDI.d457.s0.e0
These,23-28
drugs,29-34
have,35-39
been,40-44
reported,45-53
to,54-56
cause,57-62
prolonged,63-72
vasospastic,73-84
reactions.,85-95

Because,0-7
there,8-13
is,14-16
a,17-18
theoretical,19-30
basis,31-36
that,37-41
these,42-47
effects,48-55
may,56-59
be,60-62
additive,,63-72
use,73-76
of,77-79
ergotamine-containing,80-101	DrugDDI.d457.s1.e0
or,102-104
ergot-type,105-115
medications,116-127	DrugDDI.d457.s1.e1
(like,128-133
dihydroergotamine,134-151	DrugDDI.d457.s1.e2
or,152-154
methysergide),155-168	DrugDDI.d457.s1.e3
and,169-172
AXERT?,173-179	DrugDDI.d457.s1.e4
within,180-186
24,187-189
hours,190-195
of,196-198
each,199-203
other,204-209
should,210-216
be,217-219
avoided.,220-228

Monoamine,0-9	DrugDDI.d457.s2.e0
Oxidase,10-17	DrugDDI.d457.s2.e0
Inhibitors,18-28	DrugDDI.d457.s2.e0
Coadministration,29-45
of,46-48
moclobemide,49-60	DrugDDI.d457.s2.e1
resulted,61-69
in,70-72
a,73-74
27%,75-78
decrease,79-87
in,88-90
almotriptan,91-102	DrugDDI.d457.s2.e2
clearance,103-112
and,113-116
an,117-119
increase,120-128
in,129-131
Cmax,132-136
of,137-139
approximately,140-153
6%.,154-157

Other,0-5
5-HT1B/1D,6-15
Agonists,16-24
Concomitant,25-36
use,37-40
of,41-43
other,44-49
5-HT1B/1D,50-59
agonists,60-68	DrugDDI.d457.s4.e0
within,69-75
24,76-78
hours,79-84
of,85-87
treatment,88-97
with,98-102
AXERT?,103-109	DrugDDI.d457.s4.e1
is,110-112
contraindicated.,113-129

Propanolol,0-10	DrugDDI.d457.s5.e0
The,11-14
pharmacokinetics,15-31
of,32-34
almotriptan,35-46	DrugDDI.d457.s5.e1
were,47-51
not,52-55
affected,56-64
by,65-67
coadministration,68-84
of,85-87
propranolol.,88-100	DrugDDI.d457.s5.e2

Selective,0-9
Serotonin,10-19	DrugDDI.d457.s6.e0
Reuptake,20-28	DrugDDI.d457.s6.e0
Inhibitors,29-39	DrugDDI.d457.s6.e0
(SSRIs),40-47
SSRIs,48-53
(e.g.,,54-60
fluoxetine,,61-72
fluvoxamine,,73-85
paroxetine,,86-97
sertraline),98-109	DrugDDI.d457.s6.e4
have,110-114
been,115-119
rarely,120-126
reported,127-135
to,136-138
cause,139-144
weakness,,145-154
hyperreflexia,,155-169
and,170-173
incoordination,174-188
when,189-193
coadministered,194-208
with,209-213
5-HT1,214-219
agonists.,220-229	DrugDDI.d457.s6.e5

If,0-2
concomitant,3-14
treatment,15-24
with,25-29
AXERT?,30-36	DrugDDI.d457.s7.e0
and,37-40
an,41-43
SSRI,44-48
is,49-51
clinically,52-62
warranted,,63-73
appropriate,74-85
observation,86-97
of,98-100
the,101-104
patient,105-112
is,113-115
advised.,116-124

Verapamil,0-9	DrugDDI.d457.s8.e0
Coadministration,10-26
of,27-29
almotriptan,30-41	DrugDDI.d457.s8.e1
and,42-45
verapamil,46-55	DrugDDI.d457.s8.e2
resulted,56-64
in,65-67
a,68-69
24%,70-73
increase,74-82
in,83-85
plasma,86-92
concentrations,93-107
of,108-110
almotriptan.,111-123	DrugDDI.d457.s8.e3

Ketoconazole,0-12	DrugDDI.d457.s10.e0
and,13-16
Other,17-22
Potent,23-29
CYP3A4,30-36
Inhibitors,37-47
Coadministration,48-64
of,65-67
almotriptan,68-79	DrugDDI.d457.s10.e1
and,80-83
the,84-87
potent,88-94
CYP3A4,95-101
inhibitor,102-111
ketoconazole,112-124	DrugDDI.d457.s10.e2
(400,125-129
mg,130-132
q.d.,133-137
for,138-141
3,142-143
days),144-149
resulted,150-158
in,159-161
an,162-164
approximately,165-178
60%,179-182
increase,183-191
in,192-194
the,195-198
area,199-203
under,204-209
the,210-213
plasma,214-220
concentration-time,221-239
curve,240-245
and,246-249
maximal,250-257
plasma,258-264
concentrations,265-279
of,280-282
almotriptan.,283-295	DrugDDI.d457.s10.e3

Although,0-8
the,9-12
interaction,13-24
between,25-32
almotriptan,33-44	DrugDDI.d457.s11.e0
and,45-48
other,49-54
potent,55-61
CYP3A4,62-68	DrugDDI.d457.s11.e1
inhibitors,69-79
(e.g.,,80-86
itraconazole,,87-100
ritonavir,,101-111
and,112-115
erythromycin),116-129	DrugDDI.d457.s11.e4
has,130-133
not,134-137
been,138-142
studied,,143-151
increased,152-161
exposures,162-171
to,172-174
almotriptan,175-186	DrugDDI.d457.s11.e5
may,187-190
be,191-193
expected,194-202
when,203-207
almotriptan,208-219	DrugDDI.d457.s11.e6
is,220-222
used,223-227
concomitantly,228-241
with,242-246
these,247-252
medications.,253-265	DrugDDI.d457.s11.e7

Drug/Laboratory,0-15	DrugDDI.d457.s12.e0
Test,16-20
Interactions,21-33
AXERT?,34-40
is,41-43
not,44-47
known,48-53
to,54-56
interfere,57-66
with,67-71
commonly,72-80
employed,81-89
clinical,90-98
laboratory,99-109
tests.,110-116

Because,0-7
alosetron,8-17	DrugDDI.d6.s0.e0
is,18-20
metabolized,21-32
by,33-35
a,36-37
variety,38-45
of,46-48
hepatic,49-56
CYP,57-60
drug-metabolizing,61-78
enzymes,,79-87
inducers,88-96
or,97-99
inhibitors,100-110
of,111-113
these,114-119
enzymes,120-127
may,128-131
change,132-138
the,139-142
clearance,143-152
of,153-155
alosetron.,156-166	DrugDDI.d6.s0.e1

Fluvoxamine,0-11	DrugDDI.d6.s1.e0
is,12-14
a,15-16
known,17-22
strong,23-29
inhibitor,30-39
of,40-42
CYP1A2,43-49	DrugDDI.d6.s1.e1
and,50-53
also,54-58
inhibits,59-67
CYP3A4,,68-75
CYP2C9,,76-83
and,84-87
CYP2C19.,88-96	DrugDDI.d6.s1.e4

In,0-2
a,3-4
pharmacokinetic,5-20
study,,21-27
40,28-30
healthy,31-38
female,39-45
subjects,46-54
received,55-63
fluvoxamine,64-75	DrugDDI.d6.s2.e0
in,76-78
escalating,79-89
doses,90-95
from,96-100
50,101-103
to,104-106
200,107-110
mg,111-113
per,114-117
day,118-121
for,122-125
16,126-128
days,,129-134
with,135-139
coadministration,140-156
of,157-159
alosetron,160-169	DrugDDI.d6.s2.e1
1,170-171	DrugDDI.d6.s2.e1
mg,172-174	DrugDDI.d6.s2.e1
on,175-177
the,178-181
last,182-186
day.,187-191

Fluvoxamine,0-11	DrugDDI.d6.s3.e0
increased,12-21
mean,22-26
alosetron,27-36	DrugDDI.d6.s3.e1
plasma,37-43
concentrations,44-58
(AUC),59-64
approximately,65-78
6-fold,79-85
and,86-89
prolonged,90-99
the,100-103
half-life,104-113
by,114-116
approximately,117-130
3-fold.,131-138

Concomitant,0-11
administration,12-26
of,27-29
alosetron,30-39	DrugDDI.d6.s4.e0
and,40-43
fluvoxamine,44-55	DrugDDI.d6.s4.e1
is,56-58
contraindicated.,59-75

Concomitant,0-11
administration,12-26
of,27-29
alosetron,30-39	DrugDDI.d6.s5.e0
and,40-43
moderate,44-52
CYP1A2,53-59	DrugDDI.d6.s5.e1
inhibitors,,60-71
including,72-81
quinolone,82-91	DrugDDI.d6.s5.e2
antibiotics,92-103	DrugDDI.d6.s5.e2
and,104-107
cimetidine,,108-119
has,120-123
not,124-127
been,128-132
evaluated,,133-143
but,144-147
should,148-154
be,155-157
avoided,158-165
unless,166-172
clinically,173-183
necessary,184-193
because,194-201
of,202-204
similar,205-212
potential,213-222
drug,223-227
interactions.,228-241

Ketoconazole,0-12	DrugDDI.d6.s6.e0
is,13-15
a,16-17
known,18-23
strong,24-30
inhibitor,31-40
of,41-43
CYP3A4.,44-51	DrugDDI.d6.s6.e1

In,0-2
a,3-4
pharmacokinetic,5-20
study,,21-27
38,28-30
healthy,31-38
female,39-45
subjects,46-54
received,55-63
ketoconazole,64-76	DrugDDI.d6.s7.e0
200,77-80	DrugDDI.d6.s7.e0
mg,81-83	DrugDDI.d6.s7.e0
twice,84-89
daily,90-95
for,96-99
7,100-101
days,,102-107
with,108-112
coadministration,113-129
of,130-132
alosetron,133-142	DrugDDI.d6.s7.e1
1,143-144	DrugDDI.d6.s7.e1
mg,145-147	DrugDDI.d6.s7.e1
on,148-150
the,151-154
last,155-159
day.,160-164

Ketoconazole,0-12	DrugDDI.d6.s8.e0
increased,13-22
mean,23-27
alosetron,28-37	DrugDDI.d6.s8.e1
plasma,38-44
concentrations,45-59
(AUC),60-65
by,66-68
29%.,69-73

Caution,0-7
should,8-14
be,15-17
used,18-22
when,23-27
alosetron,28-37	DrugDDI.d6.s9.e0
and,38-41
ketoconazole,42-54	DrugDDI.d6.s9.e1
are,55-58
administered,59-71
concomitantly.,72-86

Coadministration,0-16
of,17-19
alosetron,20-29	DrugDDI.d6.s10.e0
and,30-33
strong,34-40
CYP3A4,41-47	DrugDDI.d6.s10.e1
inhibitors,,48-59
such,60-64
as,65-67
clarithromycin,,68-83
telithromycin,,84-98
protease,99-107	DrugDDI.d6.s10.e4
inhibitors,,108-119	DrugDDI.d6.s10.e4
voriconazole,,120-133
and,134-137
itraconazole,138-150	DrugDDI.d6.s10.e6
has,151-154
not,155-158
been,159-163
evaluated,164-173
but,174-177
should,178-184
be,185-187
undertaken,188-198
with,199-203
caution,204-211
because,212-219
of,220-222
similar,223-230
potential,231-240
drug,241-245
interactions.,246-259

The,0-3
effect,4-10
of,11-13
induction,14-23
or,24-26
inhibition,27-37
of,38-40
other,41-46
pathways,47-55
on,56-58
exposure,59-67
to,68-70
alosetron,71-80	DrugDDI.d6.s11.e0
and,81-84
its,85-88
metabolites,89-100	DrugDDI.d6.s11.e1
is,101-103
not,104-107
known.,108-114

In,0-2
vitro,3-8
human,9-14
liver,15-20
microsome,21-30
studies,31-38
and,39-42
an,43-45
in,46-48
vivo,49-53
metabolic,54-63
probe,64-69
study,70-75
demonstrated,76-88
that,89-93
alosetron,94-103	DrugDDI.d6.s12.e0
did,104-107
not,108-111
inhibit,112-119
CYP,120-123	DrugDDI.d6.s12.e1
enzymes,124-131	DrugDDI.d6.s12.e1
2D6,,132-136
3A4,,137-141
2C9,,142-146
or,147-149
2C19.,150-155

In,0-2
vitro,,3-9
at,10-12
total,13-18
drug,19-23
concentrations,24-38
27-fold,39-46
higher,47-53
than,54-58
peak,59-63
plasma,64-70
concentrations,71-85
observed,86-94
with,95-99
the,100-103
1-mg,104-108
dosage,,109-116
alosetron,117-126	DrugDDI.d6.s13.e0
inhibited,127-136
CYP,137-140	DrugDDI.d6.s13.e1
enzymes,141-148	DrugDDI.d6.s13.e1
1A2,149-152
(60%),153-158
and,159-162
2E1,163-166
(50%).,167-173

In,0-2
an,3-5
in,6-8
vivo,9-13
metabolic,14-23
probe,24-29
study,,30-36
alosetron,37-46	DrugDDI.d6.s14.e0
did,47-50
not,51-54
inhibit,55-62
CYP2E1,63-69	DrugDDI.d6.s14.e1
but,70-73
did,74-77
produce,78-85
30%,86-89
inhibition,90-100
of,101-103
both,104-108
CYP1A2,109-115	DrugDDI.d6.s14.e2
and,116-119
N-acetyltransferase.,120-140	DrugDDI.d6.s14.e3

Although,0-8
not,9-12
studied,13-20
with,21-25
alosetron,,26-36
inhibition,37-47
of,48-50
N-acetyltransferase,51-70
may,71-74
have,75-79
clinically,80-90
relevant,91-99
consequences,100-112
for,113-116
drugs,117-122	DrugDDI.d6.s15.e2
such,123-127
as,128-130
isoniazid,,131-141
procainamide,,142-155
and,156-159
hydralazine.,160-172	DrugDDI.d6.s15.e5

The,0-3
effect,4-10
on,11-13
CYP1A2,14-20	DrugDDI.d6.s16.e0
was,21-24
explored,25-33
further,34-41
in,42-44
a,45-46
clinical,47-55
interaction,56-67
study,68-73
with,74-78
theophylline,79-91	DrugDDI.d6.s16.e1
and,92-95
no,96-98
effect,99-105
on,106-108
metabolism,109-119
was,120-123
observed.,124-133

Another,0-7
study,8-13
showed,14-20
that,21-25
alosetron,26-35	DrugDDI.d6.s17.e0
had,36-39
no,40-42
clinically,43-53
significant,54-65
effect,66-72
on,73-75
plasma,76-82
concentrations,83-97
of,98-100
the,101-104
oral,105-109	DrugDDI.d6.s17.e1
contraceptive,110-123	DrugDDI.d6.s17.e1
agents,124-130	DrugDDI.d6.s17.e1
ethinyl,131-138
estradiol,139-148
and,149-152
levonorgestrel,153-167	DrugDDI.d6.s17.e2
(CYP3A4,168-175
substrates).,176-188

A,0-1
clinical,2-10
interaction,11-22
study,23-28
was,29-32
also,33-37
conducted,38-47
with,48-52
alosetron,53-62	DrugDDI.d6.s18.e0
and,63-66
the,67-70
CYP3A4,71-77
substrate,78-87
cisapride.,88-98	DrugDDI.d6.s18.e1

No,0-2
significant,3-14
effects,15-22
on,23-25
cisapride,26-35	DrugDDI.d6.s19.e0
metabolism,36-46
or,47-49
QT,50-52
interval,53-61
were,62-66
noted.,67-73

The,0-3
effect,4-10
of,11-13
alosetron,14-23	DrugDDI.d6.s20.e0
on,24-26
monoamine,27-36	DrugDDI.d6.s20.e1
oxidases,37-45	DrugDDI.d6.s20.e1
and,46-49
on,50-52
intestinal,53-63
first,64-69
pass,70-74
secondary,75-84
to,85-87
high,88-92
intraluminal,93-105
concentrations,106-120
have,121-125
not,126-129
been,130-134
examined.,135-144

Based,0-5
on,6-8
the,9-12
above,13-18
data,19-23
from,24-28
in,29-31
vitro,32-37
and,38-41
in,42-44
vivo,45-49
studies,,50-58
it,59-61
is,62-64
unlikely,65-73
that,74-78
alosetron,79-88	DrugDDI.d6.s21.e0
will,89-93
inhibit,94-101
the,102-105
hepatic,106-113
metabolic,114-123
clearance,124-133
of,134-136
drugs,137-142	DrugDDI.d6.s21.e1
metabolized,143-154
by,155-157
the,158-161
major,162-167
CYP,168-171	DrugDDI.d6.s21.e2
enzyme,172-178
3A4,,179-183
as,184-186
well,187-191
as,192-194
the,195-198
CYP,199-202	DrugDDI.d6.s21.e3
enzymes,203-210	DrugDDI.d6.s21.e3
2D6,,211-215
2C9,,216-220
2C19,,221-226
2E1,,227-231
or,232-234
1A2.,235-239

Alosetron,0-9	DrugDDI.d6.s22.e0
does,10-14
not,15-18
appear,19-25
to,26-28
induce,29-35
the,36-39
major,40-45
cytochrome,46-56	DrugDDI.d6.s22.e1
P450,57-61	DrugDDI.d6.s22.e1
(CYP),62-67
drug,68-72	DrugDDI.d6.s22.e3
metabolizing,73-85
enzyme,86-92
3A.,93-96

Alosetron,0-9	DrugDDI.d6.s23.e0
also,10-14
does,15-19
not,20-23
appear,24-30
to,31-33
induce,34-40
CYP,41-44	DrugDDI.d6.s23.e1
enzymes,45-52	DrugDDI.d6.s23.e1
2E1,53-56
or,57-59
2C19.,60-65

It,0-2
is,3-5
not,6-9
known,10-15
whether,16-23
alosetron,24-33	DrugDDI.d6.s24.e0
might,34-39
induce,40-46
other,47-52
enzymes.,53-61

The,0-3
benzodiazepines,,4-20
including,21-30
alprazolam,,31-42
produce,43-50
additive,51-59
CNS,60-63	DrugDDI.d463.s0.e2
depressant,64-74	DrugDDI.d463.s0.e2
effects,75-82
when,83-87
co-administered,88-103
with,104-108
other,109-114
psychotropic,115-127	DrugDDI.d463.s0.e3
medications,,128-140	DrugDDI.d463.s0.e3
anticonvulsants,,141-157
antihistaminics,,158-174
ethanol,,175-183
and,184-187
other,188-193
drugs,194-199	DrugDDI.d463.s0.e7
which,200-205
themselves,206-216
produce,217-224
CNS,225-228
depression.,229-240

The,0-3
steady,4-10
state,11-16
plasma,17-23
concentrations,24-38
of,39-41
imipramine,42-52	DrugDDI.d463.s1.e0
and,53-56
desipramine,57-68	DrugDDI.d463.s1.e1
have,69-73
been,74-78
reported,79-87
to,88-90
be,91-93
increased,94-103
an,104-106
average,107-114
of,115-117
31%,118-121
and,122-125
20%,,126-130
respectively,,131-144
by,145-147
the,148-151
concomitant,152-163
administration,164-178
of,179-181
alprazolam,182-192	DrugDDI.d463.s1.e2
tablets,193-200
in,201-203
doses,204-209
up,210-212
to,213-215
4,216-217
mg/day.,218-225

Drugs,0-5	DrugDDI.d463.s3.e0
That,6-10
Inhibit,11-18
Alprazolam,19-29	DrugDDI.d463.s3.e1
Metabolism,30-40
Via,41-44
Cytochrome,45-55	DrugDDI.d463.s3.e2
P450,56-60	DrugDDI.d463.s3.e2
3A:,61-64	DrugDDI.d463.s3.e2
The,65-68
initial,69-76
step,77-81
in,82-84
alprazolam,85-95	DrugDDI.d463.s3.e3
metabolism,96-106
is,107-109
hydroxylation,110-123
catalyzed,124-133
by,134-136
cytochrome,137-147	DrugDDI.d463.s3.e4
P450,148-152	DrugDDI.d463.s3.e4
3A,153-155	DrugDDI.d463.s3.e4
(CYP,156-160
3A).,161-165

Drugs,0-5	DrugDDI.d463.s4.e0
which,6-11
inhibit,12-19
this,20-24
metabolic,25-34
pathway,35-42
may,43-46
have,47-51
a,52-53
profound,54-62
effect,63-69
on,70-72
the,73-76
clearance,77-86
of,87-89
alprazolam,90-100	DrugDDI.d463.s4.e1
.,101-102

Drugs,0-5	DrugDDI.d463.s5.e0
Demonstrated,6-18
to,19-21
be,22-24
CYP,25-28	DrugDDI.d463.s5.e1
3A,29-31
Inhibitors,32-42
of,43-45
Possible,46-54
Clinical,55-63
Significance,64-76
on,77-79
the,80-83
Basis,84-89
of,90-92
Clinical,93-101
Studies,102-109
Involving,110-119
Alprazolam,120-130	DrugDDI.d463.s5.e2
(caution,131-139
is,140-142
recommended,143-154
during,155-161
coadministration,162-178
with,179-183
alprazolam):,184-196	DrugDDI.d463.s5.e3
Fluoxetine:,197-208	DrugDDI.d463.s5.e4
Coadministration,209-225
of,226-228
fluoxetine,229-239	DrugDDI.d463.s5.e5
with,240-244
alprazolam,245-255	DrugDDI.d463.s5.e6
increased,256-265
the,266-269
maximum,270-277
plasma,278-284
concentration,285-298
of,299-301
alprazolam,302-312	DrugDDI.d463.s5.e7
by,313-315
46%,,316-320
decreased,321-330
clearance,331-340
by,341-343
21%,,344-348
increased,349-358
half-life,359-368
by,369-371
17%,,372-376
and,377-380
decreased,381-390
measured,391-399
psychomotor,400-411
performance.,412-424

Propoxyphene:,0-13	DrugDDI.d463.s6.e0
Coadministration,14-30
of,31-33
propoxyphene,34-46	DrugDDI.d463.s6.e1
decreased,47-56
the,57-60
maximum,61-68
plasma,69-75
concentration,76-89
of,90-92
alprazolam,93-103	DrugDDI.d463.s6.e2
by,104-106
6%,,107-110
decreased,111-120
clearance,121-130
by,131-133
38%,,134-138
and,139-142
increased,143-152
half-life,153-162
by,163-165
58%.,166-170

Oral,0-4	DrugDDI.d463.s7.e0
Contraceptives:,5-20	DrugDDI.d463.s7.e0
Coadministration,21-37
of,38-40
oral,41-45	DrugDDI.d463.s7.e1
contraceptives,46-60	DrugDDI.d463.s7.e1
increased,61-70
the,71-74
maximum,75-82
plasma,83-89
concentration,90-103
of,104-106
alprazolam,107-117	DrugDDI.d463.s7.e2
by,118-120
18%,,121-125
decreased,126-135
clearance,136-145
by,146-148
22%,,149-153
and,154-157
increased,158-167
half-life,168-177
by,178-180
29%.,181-185

Drugs,0-5	DrugDDI.d463.s8.e0
and,6-9
other,10-15
substances,16-26
demonstrated,27-39
to,40-42
be,43-45
CYP,46-49	DrugDDI.d463.s8.e1
3A,50-52
inhibitors,53-63
on,64-66
the,67-70
basis,71-76
of,77-79
clinical,80-88
studies,89-96
involving,97-106
benzodiazepines,107-122	DrugDDI.d463.s8.e2
metabolized,123-134
similarly,135-144
to,145-147
alprazolam,148-158	DrugDDI.d463.s8.e3
or,159-161
on,162-164
the,165-168
basis,169-174
of,175-177
in,178-180
vitro,181-186
studies,187-194
with,195-199
alprazolam,200-210	DrugDDI.d463.s8.e4
or,211-213
other,214-219
benzodiazepines,220-235	DrugDDI.d463.s8.e5
(caution,236-244
is,245-247
recommended,248-259
during,260-266
coadministration,267-283
with,284-288
alprazolam):,289-301	DrugDDI.d463.s8.e6
Available,302-311
data,312-316
from,317-321
clinical,322-330
studies,331-338
of,339-341
benzodiazepines,342-357	DrugDDI.d463.s8.e7
other,358-363
than,364-368
alprazolam,369-379	DrugDDI.d463.s8.e8
suggest,380-387
a,388-389
possible,390-398
drug,399-403
interaction,404-415
with,416-420
alprazolam,421-431	DrugDDI.d463.s8.e9
for,432-435
the,436-439
following:,440-450
diltiazem,,451-461
isoniazid,,462-472
macrolide,473-482	DrugDDI.d463.s8.e12
antibiotics,483-494	DrugDDI.d463.s8.e12
such,495-499
as,500-502
erythromycin,503-515	DrugDDI.d463.s8.e13
and,516-519
clarithromycin,,520-535
and,536-539
grapefruit,540-550
juice.,551-557

Data,0-4
from,5-9
in,10-12
vitro,13-18
studies,19-26
of,27-29
alprazolam,30-40	DrugDDI.d463.s9.e0
suggest,41-48
a,49-50
possible,51-59
drug,60-64
interaction,65-76
with,77-81
alprazolam,82-92	DrugDDI.d463.s9.e1
for,93-96
the,97-100
following:,101-111
sertraline,112-122	DrugDDI.d463.s9.e2
and,123-126
paroxetine.,127-138	DrugDDI.d463.s9.e3

Data,0-4
from,5-9
in,10-12
vitro,13-18
studies,19-26
of,27-29
benzodiazepines,30-45	DrugDDI.d463.s10.e0
other,46-51
than,52-56
alprazolam,57-67	DrugDDI.d463.s10.e1
suggest,68-75
a,76-77
possible,78-86
drug,87-91
interaction,92-103
for,104-107
the,108-111
following:,112-122
ergotamine,,123-134
cyclosporine,,135-148
amiodarone,,149-160
nicardipine,,161-173
and,174-177
nifedipine.,178-189	DrugDDI.d463.s10.e6

Caution,0-7
is,8-10
recommended,11-22
during,23-29
the,30-33
coadministration,34-50
of,51-53
any,54-57
of,58-60
these,61-66
with,67-71
alprazolam.,72-83	DrugDDI.d463.s11.e0

Prostin,0-7	DrugDDI.d298.s0.e0
VR,8-10	DrugDDI.d298.s0.e0
Pediatric,11-20
Sterile,21-28
Solution,29-37
No,38-40
drug,41-45
interactions,46-58
have,59-63
been,64-68
reported,69-77
between,78-85
Prostin,86-93	DrugDDI.d298.s0.e1
VR,94-96	DrugDDI.d298.s0.e1
Pediatric,97-106
and,107-110
the,111-114
therapy,115-122
standard,123-131
in,132-134
neonates,135-143
with,144-148
restricted,149-159
pulmonary,160-169
or,170-172
systemic,173-181
blood,182-187
flow.,188-193

Standard,0-8
therapy,9-16
includes,17-25
antibiotics,,26-38
such,39-43
as,44-46
penicillin,47-57	DrugDDI.d298.s1.e1
and,58-61
gentamicin;,62-73	DrugDDI.d298.s1.e2

vasopressors,,0-13
such,14-18
as,19-21
dopamine,22-30	DrugDDI.d298.s2.e1
and,31-34
isoproterenol;,35-49	DrugDDI.d298.s2.e2

cardiac,0-7	DrugDDI.d298.s3.e0
glycosides;,8-19	DrugDDI.d298.s3.e0

and,0-3
diuretics,,4-14
such,15-19
as,20-22
furosemide.,23-34	DrugDDI.d298.s4.e1

Caverject,0-9	DrugDDI.d298.s5.e0
The,10-13
potential,14-23
for,24-27
pharmacokinetic,28-43
drug-drug,44-53
interactions,54-66
between,67-74
alprostadil,75-86	DrugDDI.d298.s5.e1
and,87-90
other,91-96
agents,97-103
has,104-107
not,108-111
been,112-116
formally,117-125
studied.,126-134

The,0-3
interaction,4-15
of,16-18
Activase,19-27	DrugDDI.d235.s0.e0
with,28-32
other,33-38
cardioactive,39-51
or,52-54
cerebroactive,55-68
drugs,69-74	DrugDDI.d235.s0.e1
has,75-78
not,79-82
been,83-87
studied.,88-96

In,0-2
addition,3-11
to,12-14
bleeding,15-23
associated,24-34
with,35-39
heparin,40-47	DrugDDI.d235.s1.e0
and,48-51
vitamin,52-59
K,60-61
antagonists,,62-74
drugs,75-80	DrugDDI.d235.s1.e1
that,81-85
alter,86-91
platelet,92-100
function,101-109
(such,110-115
as,116-118
acetylsalicylic,119-134	DrugDDI.d235.s1.e2
acid,,135-140	DrugDDI.d235.s1.e2
dipyridamole,141-153	DrugDDI.d235.s1.e3
and,154-157
Abciximab),158-168	DrugDDI.d235.s1.e4
may,169-172
increase,173-181
the,182-185
risk,186-190
of,191-193
bleeding,194-202
if,203-205
administered,206-218
prior,219-224
to,,225-228
during,,229-236
or,237-239
after,240-245
Activase,246-254	DrugDDI.d235.s1.e5
therapy.,255-263

Use,0-3
of,4-6
Antithrombotics,7-22
Aspirin,23-30	DrugDDI.d235.s2.e0
and,31-34
heparin,35-42	DrugDDI.d235.s2.e1
have,43-47
been,48-52
administered,53-65
concomitantly,66-79
with,80-84
and,85-88
following,89-98
infusions,99-108
of,109-111
Activase,112-120	DrugDDI.d235.s2.e2
in,121-123
the,124-127
management,128-138
of,139-141
acute,142-147
myocardial,148-158
infarction,159-169
or,170-172
pulmonary,173-182
embolism.,183-192

Because,0-7
heparin,,8-16
aspirin,,17-25
or,26-28
Activase,29-37	DrugDDI.d235.s3.e2
may,38-41
cause,42-47
bleeding,48-56
complications,,57-71
careful,72-79
monitoring,80-90
for,91-94
bleeding,95-103
is,104-106
advised,,107-115
especially,116-126
at,127-129
arterial,130-138
puncture,139-147
sites.,148-154

The,0-3
concomitant,4-15
use,16-19
of,20-22
heparin,23-30	DrugDDI.d235.s4.e0
or,31-33
aspirin,34-41	DrugDDI.d235.s4.e1
during,42-48
the,49-52
first,53-58
24,59-61
hours,62-67
following,68-77
symptom,78-85
onset,86-91
were,92-96
prohibited,97-107	DrugDDI.d235.s4.e2
in,108-110
The,111-114
NINDS,115-120
t-PA,121-125
Stroke,126-132
Trial.,133-139

The,0-3
safety,4-10
of,11-13
such,14-18
concomitant,19-30
use,31-34
with,35-39
Activase,40-48	DrugDDI.d235.s5.e0
for,49-52
the,53-56
management,57-67
of,68-70
acute,71-76
ischemic,77-85
stroke,86-92
is,93-95
unknown.,96-104

Concurrent,0-10
administration,11-25
of,26-28
HEXALEN,29-36	DrugDDI.d542.s0.e0
and,37-40
antidepressants,41-56	DrugDDI.d542.s0.e1
of,57-59
the,60-63
MAO,64-67	DrugDDI.d542.s0.e2
inhibitor,68-77	DrugDDI.d542.s0.e2
class,78-83
may,84-87
cause,88-93
severe,94-100
orthostatic,101-112
hypotension.Cimetidine,,113-136
an,137-139
inhibitor,140-149
of,150-152
microsomal,153-163
drug,164-168
metabolism,,169-180
increased,181-190
altretamines,191-203	DrugDDI.d542.s0.e4
half-life,204-213
and,214-217
toxicity,218-226
in,227-229
a,230-231
rat,232-235
model.,236-242

Data,0-4
from,5-9
a,10-11
randomized,12-22
trial,23-28
of,29-31
HEXALEN,32-39	DrugDDI.d542.s1.e0
and,40-43
cisplatin,44-53	DrugDDI.d542.s1.e1
plus,54-58
or,59-61
minus,62-67
pyridoxine,68-78	DrugDDI.d542.s1.e2
in,79-81
ovarian,82-89
cancer,90-96
indicated,97-106
that,107-111
pyridoxine,112-122	DrugDDI.d542.s1.e3
significantly,123-136
reduced,137-144
neurotoxicity;,145-159

however,,0-8
it,9-11
adversely,12-21
affected,22-30
response,31-39
duration,40-48
suggesting,49-59
that,60-64
pyridoxine,65-75	DrugDDI.d542.s2.e0
should,76-82
not,83-86
be,87-89
administered,90-102
with,103-107
HEXALEN,108-115	DrugDDI.d542.s2.e1
and/or,116-122
cisplatin.1,123-134	DrugDDI.d542.s2.e2

Careful,0-7
observation,8-19
is,20-22
required,23-31
when,32-36
amantadine,37-47	DrugDDI.d202.s0.e0
is,48-50
administered,51-63
concurrently,64-76
with,77-81
central,82-89	DrugDDI.d202.s0.e1
nervous,90-97	DrugDDI.d202.s0.e1
system,98-104	DrugDDI.d202.s0.e1
stimulants.,105-116	DrugDDI.d202.s0.e1

Coadministration,0-16
of,17-19
thioridazine,20-32	DrugDDI.d202.s1.e0
has,33-36
been,37-41
reported,42-50
to,51-53
worsen,54-60
the,61-64
tremor,65-71
in,72-74
elderly,75-82
patients,83-91
with,92-96
Parkinsons,97-107
disease;,108-116

however,,0-8
it,9-11
is,12-14
not,15-18
known,19-24
if,25-27
other,28-33
phenothiazines,34-48	DrugDDI.d202.s2.e0
produce,49-56
a,57-58
similar,59-66
response.,67-76

Coadministration,0-16
of,17-19
triamterene,20-31	DrugDDI.d202.s3.e0
and,32-35
hydrochlorothiazide,36-55	DrugDDI.d202.s3.e1
capsules,56-64
resulted,65-73
in,74-76
a,77-78
higher,79-85
plasma,86-92
amantadine,93-103	DrugDDI.d202.s3.e2
concentration,104-117
in,118-120
a,121-122
61,123-125
year,126-130
old,131-134
man,135-138
receiving,139-148
amantadine,149-159	DrugDDI.d202.s3.e3
(amantadine,160-171
hydrochloride),172-186
100,187-190
mg,191-193
TID,194-197
for,198-201
Parkinsons,202-212
disease.1,213-222
It,223-225
is,226-228
not,229-232
known,233-238
which,239-244
of,245-247
the,248-251
components,252-262
of,263-265
triamterene,266-277	DrugDDI.d202.s3.e5
and,278-281
hydrochlorothiazide,282-301	DrugDDI.d202.s3.e6
capsules,302-310
contributed,311-322
to,323-325
the,326-329
observation,330-341
or,342-344
if,345-347
related,348-355
drugs,356-361	DrugDDI.d202.s3.e7
produce,362-369
a,370-371
similar,372-379
response.,380-389

Interactions,0-12
can,13-16
occur,17-22
with,23-27
the,28-31
following,32-41
medications:,42-54	DrugDDI.d480.s0.e0
demecarium,55-65	DrugDDI.d480.s0.e1
(Humorsol),,66-77
echothiophate,78-91	DrugDDI.d480.s0.e3
(Phospholine,92-104
Iodide),,105-113
isoflurophate,114-127	DrugDDI.d480.s0.e5
(Floropryl),,128-140
malathion,141-150	DrugDDI.d480.s0.e7
(using,151-157
these,158-163
medicines,164-173	DrugDDI.d480.s0.e8
with,174-178
antimyasthenics,179-194
may,195-198
result,199-205
in,206-208
serious,209-216
side,217-221
effects),,222-231
guanadrel,232-241	DrugDDI.d480.s0.e9
(Hylorel),,242-252
guanethidine,253-265	DrugDDI.d480.s0.e11
(Ismelin),,266-276
mecamylamine,277-289	DrugDDI.d480.s0.e13
(Inversine),,290-302
procainamide,303-315	DrugDDI.d480.s0.e15
(Pronestyl),,316-328
and,329-332
trimethaphan,333-345	DrugDDI.d480.s0.e17
(the,346-350
effects,351-358
of,359-361
these,362-367
medicines,368-377	DrugDDI.d480.s0.e18
may,378-381
interfere,382-391
with,392-396
the,397-400
actions,401-408
of,409-411
the,412-415
antimyasthenics).,416-433

Special,0-7
consideration,8-21
should,22-28
be,29-31
given,32-37
to,38-40
the,41-44
administration,45-59
of,60-62
ETHYOL?,63-70
in,71-73
patients,74-82
receiving,83-92
antihypertensive,93-109	DrugDDI.d317.s0.e0
medications,110-121
or,122-124
other,125-130
drugs,131-136	DrugDDI.d317.s0.e1
that,137-141
could,142-147
cause,148-153
or,154-156
potentiate,157-167
hypotension.,168-180

When,0-4
amiloride,5-14	DrugDDI.d187.s0.e0
HCl,15-18	DrugDDI.d187.s0.e0
is,19-21
administered,22-34
concomitantly,35-48
with,49-53
an,54-56
angiotensin-converting,57-79	DrugDDI.d187.s0.e1
enzyme,80-86	DrugDDI.d187.s0.e1
inhibitor,,87-97	DrugDDI.d187.s0.e1
the,98-101
risk,102-106
of,107-109
hyperkalemia,110-122
may,123-126
be,127-129
increased.,130-140

Lithium,0-7	DrugDDI.d187.s2.e0
generally,8-17
should,18-24
not,25-28
be,29-31
given,32-37
with,38-42
diuretics,43-52	DrugDDI.d187.s2.e1
because,53-60
they,61-65
reduce,66-72
its,73-76
renal,77-82
clearance,83-92
and,93-96
add,97-100
a,101-102
high,103-107
risk,108-112
of,113-115
lithium,116-123
toxicity.,124-133

Read,0-4
circulars,5-14
for,15-18
lithium,19-26	DrugDDI.d187.s3.e0
preparations,27-39	DrugDDI.d187.s3.e0
before,40-46
use,47-50
of,51-53
such,54-58
concomitant,59-70
therapy.,71-79

In,0-2
some,3-7
patients,,8-17
the,18-21
administration,22-36
of,37-39
a,40-41
non-steroidal,42-55	DrugDDI.d187.s4.e0
anti-inflammatory,56-73	DrugDDI.d187.s4.e0
agent,74-79	DrugDDI.d187.s4.e0
can,80-83
reduce,84-90
the,91-94
diuretic,,95-104
natriuretic,,105-117
and,118-121
antihypertensive,122-138	DrugDDI.d187.s4.e2
effects,139-146
of,147-149
loop,,150-155
potassium-sparing,156-173	DrugDDI.d187.s4.e3
and,174-177
thiazide,178-186	DrugDDI.d187.s4.e4
diuretics.,187-197	DrugDDI.d187.s4.e4

Therefore,,0-10
when,11-15
MIDAMOR,16-23	DrugDDI.d187.s5.e0
and,24-27
non-steroidal,28-41	DrugDDI.d187.s5.e1
anti-inflammatory,42-59	DrugDDI.d187.s5.e1
agents,60-66	DrugDDI.d187.s5.e1
are,67-70
used,71-75
concomitantly,,76-90
the,91-94
patient,95-102
should,103-109
be,110-112
observed,113-121
closely,122-129
to,130-132
determine,133-142
if,143-145
the,146-149
desired,150-157
effect,158-164
of,165-167
the,168-171
diuretic,172-180	DrugDDI.d187.s5.e2
is,181-183
obtained.,184-193

Since,0-5
indomethacin,6-18	DrugDDI.d187.s6.e0
and,19-22
potassium-sparing,23-40	DrugDDI.d187.s6.e1
diuretics,,41-51	DrugDDI.d187.s6.e1
including,52-61
MIDAMOR,,62-70
may,71-74
each,75-79
be,80-82
associated,83-93
with,94-98
increased,99-108
serum,109-114
potassium,115-124
levels,,125-132
the,133-136
potential,137-146
effects,147-154
on,155-157
potassium,158-167	DrugDDI.d187.s6.e3
kinetics,168-176
and,177-180
renal,181-186
function,187-195
should,196-202
be,203-205
considered,206-216
when,217-221
these,222-227
agents,228-234
are,235-238
administered,239-251
concurrently.,252-265

Drug,0-4	DrugDDI.d282.s0.e0
Laboratory,5-15
Test,16-20
Interactions?,21-34
Prolongation,35-47
of,48-50
the,51-54
template,55-63
bleeding,64-72
time,73-77
has,78-81
been,82-86
reported,87-95
during,96-102
continuous,103-113
intravenous,114-125
infusion,126-134
of,135-137
AMICAR,138-144	DrugDDI.d282.s0.e1
at,145-147
dosages,148-155
exceeding,156-165
24,166-168
g/day.,169-175

However,,0-8
in,9-11
vitro,12-17
studies,18-25
have,26-30
shown,31-36
that,37-41
at,42-44
high,45-49
concentrations,50-64
(7.4,65-69
mMol/L,70-76
or,77-79
0.97,80-84
mg/mL,85-90
and,91-94
greater),95-103
EACA,104-108
inhibits,109-117
ADP,118-121
and,122-125
collagen-induced,126-142	DrugDDI.d282.s2.e0
platelet,143-151
aggregation,,152-164
the,165-168
release,169-176
of,177-179
ATP,180-183
and,184-187
serotonin,,188-198
and,199-202
the,203-206
binding,207-214
of,215-217
fibrinogen,218-228	DrugDDI.d282.s2.e1
to,229-231
the,232-235
platelets,236-245
in,246-248
a,249-250
concentration-response,251-273
manner.,274-281

Following,0-9
a,10-11
10,12-14
g,15-16
bolus,17-22
of,23-25
AMICAR,,26-33
transient,34-43
peak,44-48
plasma,49-55
concentrations,56-70
of,71-73
4.6,74-77
mMol/L,78-84
or,85-87
0.60,88-92
mg/mL,93-98
have,99-103
been,104-108
obtained.,109-118

The,0-3
concentration,4-17
of,18-20
AMICAR,21-27	DrugDDI.d282.s4.e0
necessary,28-37
to,38-40
maintain,41-49
inhibition,50-60
of,61-63
fibrinolysis,64-76
is,77-79
0.99,80-84
mMol/L,85-91
or,92-94
0.13,95-99
mg/mL.,100-106

However,,0-8
higher,9-15
plasma,16-22
concentrations,23-37
of,38-40
AMICAR,41-47	DrugDDI.d282.s7.e0
may,48-51
occur,52-57
in,58-60
patients,61-69
with,70-74
severe,75-81
renal,82-87
failure.?,88-97

Cytadren,0-8	DrugDDI.d556.s0.e0
accelerates,9-20
the,21-24
metabolism,25-35
of,36-38
dexamethasone;,39-53	DrugDDI.d556.s0.e1

therefore,,0-10
if,11-13
glucocorticoid,14-28
replacement,29-40
is,41-43
needed,,44-51
hydrocortisone,52-66	DrugDDI.d556.s1.e0
should,67-73
be,74-76
prescribed.,77-88

Aminoglutethimide,0-17	DrugDDI.d556.s2.e0
diminishes,18-28
the,29-32
effect,33-39
of,40-42
coumarin,43-51	DrugDDI.d556.s2.e1
and,52-55
warfarin.,56-65	DrugDDI.d556.s2.e2

Renal,0-5
clearance,6-15
measurements,16-28
of,29-31
PAH,32-35
cannot,36-42
be,43-45
made,46-50
with,51-55
any,56-59
significant,60-71
accuracy,72-80
in,81-83
patients,84-92
receiving,93-102
sulfonamides,,103-116
procaine,,117-126
or,127-129
thiazolesulfone.,130-146

Probenecid,0-10	DrugDDI.d141.s2.e0
depresses,11-20
tubular,21-28
secretion,29-38
of,39-41
certain,42-49
weak,50-54
acids,55-60
such,61-65
as,66-68
PAH.,69-73

Therefore,,0-10
patients,11-19
receiving,20-29
probenecid,30-40	DrugDDI.d141.s3.e0
will,41-45
have,46-50
erroneously,51-62
low,63-66
ERPF,67-71
and,72-75
Tm,76-78
PAH,79-82
values.,83-90

There,0-5
have,6-10
been,11-15
no,16-18
formal,19-25
studies,26-33
of,34-36
the,37-40
interaction,41-52
of,53-55
LEVULAN,56-63	DrugDDI.d360.s0.e0
KERASTICK,64-73	DrugDDI.d360.s0.e0
for,74-77
Topical,78-85
Solution,86-94
with,95-99
any,100-103
other,104-109
drugs,,110-116
and,117-120
no,121-123
drug-specific,124-137
interactions,138-150
were,151-155
noted,156-161
during,162-168
any,169-172
of,173-175
the,176-179
controlled,180-190
clinical,191-199
trials.,200-207

It,0-2
is,,3-6
however,,7-15
possible,16-24
that,25-29
concomitant,30-41
use,42-45
of,46-48
other,49-54
known,55-60
photosensitizing,61-77	DrugDDI.d360.s1.e0
agents,78-84	DrugDDI.d360.s1.e0
such,85-89
as,90-92
griseofulvin,,93-106
thiazide,107-115	DrugDDI.d360.s1.e2
diuretics,,116-126	DrugDDI.d360.s1.e2
sulfonylureas,,127-141
phenothiazines,,142-157
sulfonamides,158-170	DrugDDI.d360.s1.e5
and,171-174
tetracyclines,175-188	DrugDDI.d360.s1.e6
might,189-194
increase,195-203
the,204-207
photosensitivity,208-224
reaction,225-233
of,234-236
actinic,237-244
keratoses,245-254
treated,255-262
with,263-267
the,268-271
LEVULAN,272-279	DrugDDI.d360.s1.e7
KERASTICK,280-289	DrugDDI.d360.s1.e7
for,290-293
Topical,294-301
Solution.,302-311

Aminosalicylic,0-14	DrugDDI.d61.s0.e0
acid,15-19	DrugDDI.d61.s0.e0
may,20-23
decrease,24-32
the,33-36
amount,37-43
of,44-46
digoxin,47-54	DrugDDI.d61.s0.e1
(Lanoxin,,55-64
Lanoxicaps),65-76	DrugDDI.d61.s0.e3
that,77-81
gets,82-86	DrugDDI.d61.s0.e4
absorbed,87-95
into,96-100
your,101-105
body.,106-111

In,0-2
the,3-6
case,7-11
that,12-16
you,17-20
are,21-24
taking,25-31
digoxin,32-39	DrugDDI.d61.s1.e0
while,40-45
taking,46-52
aminosalicylic,53-67	DrugDDI.d61.s1.e1
acid,,68-73	DrugDDI.d61.s1.e1
higher,74-80
doses,81-86
of,87-89
digoxin,90-97	DrugDDI.d61.s1.e2
may,98-101
be,102-104
needed.,105-112

Aminosalicylic,0-14	DrugDDI.d61.s2.e0
acid,15-19	DrugDDI.d61.s2.e0
may,20-23
also,24-28
decrease,29-37
the,38-41
absorption,42-52
of,53-55
vitamin,56-63	DrugDDI.d61.s2.e1
B12,,64-68	DrugDDI.d61.s2.e1
which,69-74
can,75-78
lead,79-83
to,84-86
a,87-88
deficiency.,89-100

Therefore,0-9
you,10-13
may,14-17
need,18-22
to,23-25
take,26-30
a,31-32
vitamin,33-40
B12,41-44
supplement,45-55
while,56-61
taking,62-68
aminosalicylic,69-83	DrugDDI.d61.s3.e0
acid.,84-89	DrugDDI.d61.s3.e0

Amiodarone,0-10	DrugDDI.d273.s0.e0
is,11-13
metabolized,14-25
to,26-28
desethylamiodarone,29-47	DrugDDI.d273.s0.e1
by,48-50
the,51-54
cytochrome,55-65	DrugDDI.d273.s0.e2
P450,66-70	DrugDDI.d273.s0.e2
(CYP450),71-79
enzyme,80-86
group,,87-93
specifically,94-106
cytochromes,107-118	DrugDDI.d273.s0.e3
P450,119-123	DrugDDI.d273.s0.e3
3A4,124-127	DrugDDI.d273.s0.e3
(CYP3A4),128-136
and,137-140
CYP2C8.,141-148	DrugDDI.d273.s0.e5

The,0-3
CYP3A4,4-10	DrugDDI.d273.s1.e0
isoenzyme,11-20	DrugDDI.d273.s1.e0
is,21-23
present,24-31
in,32-34
both,35-39
the,40-43
liver,44-49	DrugDDI.d273.s1.e1
and,50-53
intestines.,54-65

Amiodarone,0-10	DrugDDI.d273.s2.e0
is,11-13
also,14-18
known,19-24
to,25-27
be,28-30
an,31-33
inhibitor,34-43
of,44-46
CYP3A4.,47-54	DrugDDI.d273.s2.e1

Therefore,,0-10
amiodarone,11-21	DrugDDI.d273.s3.e0
has,22-25
the,26-29
potential,30-39
for,40-43
interactions,44-56
with,57-61
drugs,62-67	DrugDDI.d273.s3.e1
or,68-70
substances,71-81
that,82-86
may,87-90
be,91-93
substrates,,94-105
inhibitors,106-116
or,117-119
inducers,120-128
of,129-131
CYP3A4.,132-139	DrugDDI.d273.s3.e2

While,0-5
only,6-10
a,11-12
limited,13-20
number,21-27
of,28-30
in,31-33
vivo,34-38
drug-drug,39-48
interactions,49-61
with,62-66
amiodarone,67-77	DrugDDI.d273.s4.e0
have,78-82
been,83-87
reported,,88-97
chiefly,98-105
with,106-110
the,111-114
oral,115-119
formulation,,120-132
the,133-136
potential,137-146
for,147-150
other,151-156
interactions,157-169
should,170-176
be,177-179
anticipated.,180-192

This,0-4
is,5-7
especially,8-18
important,19-28
for,29-32
drugs,33-38	DrugDDI.d273.s5.e0
associated,39-49
with,50-54
serious,55-62
toxicity,,63-72
such,73-77
as,78-80
other,81-86
antiarrhythmics.,87-103	DrugDDI.d273.s5.e1

If,0-2
such,3-7
drugs,8-13	DrugDDI.d273.s6.e0
are,14-17
needed,,18-25
their,26-31
dose,32-36
should,37-43
be,44-46
reassessed,47-57
and,,58-62
where,63-68
appropriate,,69-81
plasma,82-88
concentration,89-102
measured.,103-112

In,0-2
view,3-7
of,8-10
the,11-14
long,15-19
and,20-23
variable,24-32
half-life,33-42
of,43-45
amiodarone,,46-57
potential,58-67
for,68-71
drug,72-76
interactions,77-89
exists,90-96
not,97-100
only,101-105
with,106-110
concomitant,111-122
medication,123-133	DrugDDI.d273.s7.e1
but,134-137
also,138-142
with,143-147
drugs,148-153	DrugDDI.d273.s7.e2
administered,154-166
after,167-172
discontinuation,173-188
of,189-191
amiodarone.,192-203	DrugDDI.d273.s7.e3

Since,0-5
amiodarone,6-16	DrugDDI.d273.s8.e0
is,17-19
a,20-21
substrate,22-31
for,32-35
CYP3A4,36-42	DrugDDI.d273.s8.e1
and,43-46
CYP2C8,,47-54
drugs/substances,55-71	DrugDDI.d273.s8.e3
that,72-76
inhibit,77-84
these,85-90
isoenzymes,91-101	DrugDDI.d273.s8.e4
may,102-105
decrease,106-114
the,115-118
metabolism,119-129
and,130-133
increase,134-142
serum,143-148
concentration,149-162
of,163-165
amiodarone.,166-177	DrugDDI.d273.s8.e5

Reported,0-8
examples,9-17
include,18-25
the,26-29
following:,30-40
Protease,41-49	DrugDDI.d273.s9.e0
Inhibitors:,50-61	DrugDDI.d273.s9.e0
Protease,62-70	DrugDDI.d273.s9.e1
inhibitors,71-81	DrugDDI.d273.s9.e1
are,82-85
known,86-91
to,92-94
inhibit,95-102
CYP3A4,103-109	DrugDDI.d273.s9.e2
to,110-112
varying,113-120
degrees.,121-129

A,0-1
case,2-6
report,7-13
of,14-16
one,17-20
patient,21-28
taking,29-35
amiodarone,36-46	DrugDDI.d273.s10.e0
200,47-50	DrugDDI.d273.s10.e0
mg,51-53	DrugDDI.d273.s10.e0
and,54-57
indinavir,58-67	DrugDDI.d273.s10.e1
800,68-71
mg,72-74
three,75-80
times,81-86
a,87-88
day,89-92
resulted,93-101
in,102-104
increases,105-114
in,115-117
amiodarone,118-128	DrugDDI.d273.s10.e2
concentrations,129-143
from,144-148
0.9,149-152
mg/L,153-157
to,158-160
1.3,161-164
mg/L.,165-170

Monitoring,0-10
for,11-14
amiodarone,15-25	DrugDDI.d273.s13.e0
toxicity,26-34
and,35-38
serial,39-45
measurement,46-57
of,58-60
amiodarone,61-71	DrugDDI.d273.s13.e1
serum,72-77
concentration,78-91
during,92-98
concomitant,99-110
protease,111-119	DrugDDI.d273.s13.e2
inhibitor,120-129	DrugDDI.d273.s13.e2
therapy,130-137
should,138-144
be,145-147
considered.,148-159

Histamine,0-9	DrugDDI.d273.s14.e0
H2,10-12	DrugDDI.d273.s14.e0
antagonists:,13-25	DrugDDI.d273.s14.e0
Cimetidine,26-36	DrugDDI.d273.s14.e1
inhibits,37-45
CYP3A4,46-52	DrugDDI.d273.s14.e2
and,53-56
can,57-60
increase,61-69
serum,70-75
amiodarone,76-86
levels.,87-94

Other,0-5
substances:,6-17
Grapefruit,18-28
juice,29-34
given,35-40
to,41-43
healthy,44-51
volunteers,52-62
increased,63-72
amiodarone,73-83	DrugDDI.d273.s15.e0
AUC,84-87
by,88-90
50%,91-94
and,95-98
Cmax,99-103
by,104-106
84%,,107-111
resulting,112-121
in,122-124
increased,125-134
plasma,135-141
levels,142-148
of,149-151
amiodarone.,152-163	DrugDDI.d273.s15.e1

Grapefruit,0-10
juice,11-16
should,17-23
not,24-27
be,28-30
taken,31-36
during,37-43
treatment,44-53
with,54-58
oral,59-63
amiodarone.,64-75	DrugDDI.d273.s16.e0

This,0-4
information,5-16
should,17-23
be,24-26
considered,27-37
when,38-42
changing,43-51
from,52-56
intravenous,57-68
amiodarone,69-79	DrugDDI.d273.s17.e0
to,80-82
oral,83-87
amiodarone,88-98	DrugDDI.d273.s17.e1
.,99-100

Amiodarone,0-10	DrugDDI.d273.s18.e0
may,11-14
suppress,15-23
certain,24-31
CYP450,32-38
enzymes,,39-47
including,48-57
CYP1A2,,58-65
CYP2C9,,66-73
CYP2D6,,74-81
and,82-85
CYP3A4.,86-93	DrugDDI.d273.s18.e4

This,0-4
inhibition,5-15
can,16-19
result,20-26
in,27-29
unexpectedly,30-42
high,43-47
plasma,48-54
levels,55-61
of,62-64
other,65-70
drugs,71-76	DrugDDI.d273.s19.e0
which,77-82
are,83-86
metabolized,87-98
by,99-101
those,102-107
CYP450,108-114
enzymes.,115-123

Reported,0-8
examples,9-17
of,18-20
this,21-25
interaction,26-37
include,38-45
the,46-49
following:,50-60
Immunosuppressives:,61-80	DrugDDI.d273.s20.e0
Cyclosporine,81-93	DrugDDI.d273.s20.e1
(CYP3A4,94-101
substrate),102-112
administered,113-125
in,126-128
combination,129-140
with,141-145
oral,146-150
amiodarone,151-161	DrugDDI.d273.s20.e3
has,162-165
been,166-170
reported,171-179
to,180-182
produce,183-190
persistently,191-203
elevated,204-212
plasma,213-219
concentrations,220-234
of,235-237
cyclosporine,238-250	DrugDDI.d273.s20.e4
resulting,251-260
in,261-263
elevated,264-272
creatinine,,273-284
despite,285-292
reduction,293-302
in,303-305
dose,306-310
of,311-313
cyclosporine.,314-327	DrugDDI.d273.s20.e5

HMG-CoA,0-7	DrugDDI.d273.s21.e0
Reductase,8-17	DrugDDI.d273.s21.e0
Inhibitors:,18-29	DrugDDI.d273.s21.e0
Simvastatin,30-41	DrugDDI.d273.s21.e1
(CYP3A4,42-49
substrate),50-60
in,61-63
combination,64-75
with,76-80
amiodarone,81-91	DrugDDI.d273.s21.e3
has,92-95
been,96-100
associated,101-111
with,112-116
reports,117-124
of,125-127
myopathy/rhabdomyolysis.,128-152

Cardiovasculars:,0-16
Cardiac,17-24	DrugDDI.d273.s22.e0
glycosides:,25-36	DrugDDI.d273.s22.e0
In,37-39
patients,40-48
receiving,49-58
digoxin,59-66	DrugDDI.d273.s22.e1
therapy,,67-75
administration,76-90
of,91-93
oral,94-98
amiodarone,99-109	DrugDDI.d273.s22.e2
regularly,110-119
results,120-127
in,128-130
an,131-133
increase,134-142
in,143-145
serum,146-151
digoxin,152-159	DrugDDI.d273.s22.e3
concentration,160-173
that,174-178
may,179-182
reach,183-188
toxic,189-194
levels,195-201
with,202-206
resultant,207-216
clinical,217-225
toxicity.,226-235

Amiodarone,0-10	DrugDDI.d273.s23.e0
taken,11-16
concomitantly,17-30
with,31-35
digoxin,36-43	DrugDDI.d273.s23.e1
increases,44-53
the,54-57
serum,58-63
digoxin,64-71	DrugDDI.d273.s23.e2
concentration,72-85
by,86-88
70%,89-92
after,93-98
one,99-102
day.,103-107

On,0-2
administration,3-17
of,18-20
oral,21-25
amiodarone,,26-37
the,38-41
need,42-46
for,47-50
digitalis,51-60
therapy,61-68
should,69-75
be,76-78
reviewed,79-87
and,88-91
the,92-95
dose,96-100
reduced,101-108
by,109-111
approximately,112-125
50%,126-129
or,130-132
discontinued.,133-146

If,0-2
digitalis,3-12	DrugDDI.d273.s25.e0
treatment,13-22
is,23-25
continued,,26-36
serum,37-42
levels,43-49
should,50-56
be,57-59
closely,60-67
monitored,68-77
and,78-81
patients,82-90
observed,91-99
for,100-103
clinical,104-112
evidence,113-121
of,122-124
toxicity.,125-134

These,0-5
precautions,6-17
probably,18-26
should,27-33
apply,34-39
to,40-42
digitoxin,43-52	DrugDDI.d273.s26.e0
administration,53-67
as,68-70
well.,71-76

Antiarrhythmics:,0-16	DrugDDI.d273.s27.e0
Other,17-22
antiarrhythmic,23-37	DrugDDI.d273.s27.e1
drugs,,38-44	DrugDDI.d273.s27.e1
such,45-49
as,50-52
quinidine,,53-63
procainamide,,64-77
disopyramide,,78-91
and,92-95
phenytoin,,96-106
have,107-111
been,112-116
used,117-121
concurrently,122-134
with,135-139
amiodarone.,140-151	DrugDDI.d273.s27.e6

There,0-5
have,6-10
been,11-15
case,16-20
reports,21-28
of,29-31
increased,32-41
steady-state,42-54
levels,55-61
of,62-64
quinidine,,65-75
procainamide,,76-89
and,90-93
phenytoin,94-103	DrugDDI.d273.s28.e2
during,104-110
concomitant,111-122
therapy,123-130
with,131-135
amiodarone.,136-147	DrugDDI.d273.s28.e3

Phenytoin,0-9	DrugDDI.d273.s29.e0
decreases,10-19
serum,20-25
amiodarone,26-36
levels.,37-44

Amiodarone,0-10	DrugDDI.d273.s30.e0
taken,11-16
concomitantly,17-30
with,31-35
quinidine,36-45	DrugDDI.d273.s30.e1
increases,46-55
quinidine,56-65	DrugDDI.d273.s30.e2
serum,66-71
concentration,72-85
by,86-88
33%,89-92
after,93-98
two,99-102
days.,103-108

Amiodarone,0-10	DrugDDI.d273.s31.e0
taken,11-16
concomitantly,17-30
with,31-35
procainamide,36-48	DrugDDI.d273.s31.e1
for,49-52
less,53-57
than,58-62
seven,63-68
days,69-73
increases,74-83
plasma,84-90
concentrations,91-105
of,106-108
procainamide,109-121	DrugDDI.d273.s31.e2
and,122-125
n-acetyl,126-134
procainamide,135-147	DrugDDI.d273.s31.e3
by,148-150
55%,151-154
and,155-158
33%,,159-163
respectively.,164-177

Quinidine,0-9	DrugDDI.d273.s32.e0
and,10-13
procainamide,14-26
doses,27-32
should,33-39
be,40-42
reduced,43-50
by,51-53
one-third,54-63
when,64-68
either,69-75
is,76-78
administered,79-91
with,92-96
amiodarone.,97-108	DrugDDI.d273.s32.e1

Plasma,0-6
levels,7-13
of,14-16
flecainide,17-27	DrugDDI.d273.s33.e0
have,28-32
been,33-37
reported,38-46
to,47-49
increase,50-58
in,59-61
the,62-65
presence,66-74
of,75-77
oral,78-82
amiodarone;,83-94	DrugDDI.d273.s33.e1

because,0-7
of,8-10
this,,11-16
the,17-20
dosage,21-27
of,28-30
flecainide,31-41	DrugDDI.d273.s34.e0
should,42-48
be,49-51
adjusted,52-60
when,61-65
these,66-71
drugs,72-77	DrugDDI.d273.s34.e1
are,78-81
administered,82-94
concomitantly.,95-109

In,0-2
general,,3-11
any,12-15
added,16-21
antiarrhythmic,22-36	DrugDDI.d273.s35.e0
drug,37-41	DrugDDI.d273.s35.e0
should,42-48
be,49-51
initiated,52-61
at,62-64
a,65-66
lower,67-72
than,73-77
usual,78-83
dose,84-88
with,89-93
careful,94-101
monitoring.,102-113

Combination,0-11
of,12-14
amiodarone,15-25	DrugDDI.d273.s36.e0
with,26-30
other,31-36
antiarrhythmic,37-51	DrugDDI.d273.s36.e1
therapy,52-59
should,60-66
be,67-69
reserved,70-78
for,79-82
patients,83-91
with,92-96
life-threatening,97-113
ventricular,114-125
arrhythmias,126-137
who,138-141
are,142-145
incompletely,146-158
responsive,159-169
to,170-172
a,173-174
single,175-181
agent,182-187
or,188-190
incompletely,191-203
responsive,204-214
to,215-217
amiodarone.,218-229	DrugDDI.d273.s36.e2

During,0-6
transfer,7-15
to,16-18
oral,19-23
amiodarone,,24-35
the,36-39
dose,40-44
levels,45-51
of,52-54
previously,55-65
administered,66-78
agents,79-85
should,86-92
be,93-95
reduced,96-103
by,104-106
30,107-109
to,110-112
50%,113-116
several,117-124
days,125-129
after,130-135
the,136-139
addition,140-148
of,149-151
oral,152-156
amiodarone.,157-168	DrugDDI.d273.s37.e1

The,0-3
continued,4-13
need,14-18
for,19-22
the,23-26
other,27-32
antiarrhythmic,33-47	DrugDDI.d273.s38.e0
agent,48-53	DrugDDI.d273.s38.e0
should,54-60
be,61-63
reviewed,64-72
after,73-78
the,79-82
effects,83-90
of,91-93
amiodarone,94-104	DrugDDI.d273.s38.e1
have,105-109
been,110-114
established,,115-127
and,128-131
discontinuation,132-147
ordinarily,148-158
should,159-165
be,166-168
attempted.,169-179

If,0-2
the,3-6
treatment,7-16
is,17-19
continued,,20-30
these,31-36
patients,37-45
should,46-52
be,53-55
particularly,56-68
carefully,69-78
monitored,79-88
for,89-92
adverse,93-100
effects,,101-109
especially,110-120
conduction,121-131
disturbances,132-144
and,145-148
exacerbation,149-161
of,162-164
tachyarrhythmias,,165-182
as,183-185
amiodarone,186-196	DrugDDI.d273.s39.e0
is,197-199
continued.,200-210

In,0-2
amiodarone-treated,3-21	DrugDDI.d273.s40.e0
patients,22-30
who,31-34
require,35-42
additional,43-53
antiarrhythmic,54-68	DrugDDI.d273.s40.e1
therapy,,69-77
the,78-81
initial,82-89
dose,90-94
of,95-97
such,98-102
agents,103-109
should,110-116
be,117-119
approximately,120-133
half,134-138
of,139-141
the,142-145
usual,146-151
recommended,152-163
dose.,164-169

Antihypertensives:,0-18	DrugDDI.d273.s41.e0
Amiodarone,19-29	DrugDDI.d273.s41.e1
should,30-36
be,37-39
used,40-44
with,45-49
caution,50-57
in,58-60
patients,61-69
receiving,70-79
?-receptor,80-90
blocking,91-99
agents,100-106
(e.g.,,107-113
propranolol,,114-126
a,127-128
CYP3A4,129-135	DrugDDI.d273.s41.e4
inhibitor),136-146
or,147-149
calcium,150-157	DrugDDI.d273.s41.e5
channel,158-165	DrugDDI.d273.s41.e5
antagonists,166-177
(e.g.,,178-184
verapamil,,185-195
a,196-197
CYP3A4,198-204	DrugDDI.d273.s41.e7
substrate,,205-215
and,216-219
diltiazem,,220-230
a,231-232
CYP3A4,233-239	DrugDDI.d273.s41.e9
inhibitor),240-250
because,251-258
of,259-261
the,262-265
possible,266-274
potentiation,275-287
of,288-290
bradycardia,,291-303
sinus,304-309
arrest,,310-317
and,318-321
AV,322-324
block;,325-331

if,0-2
necessary,,3-13
amiodarone,14-24	DrugDDI.d273.s42.e0
can,25-28
continue,29-37
to,38-40
be,41-43
used,44-48
after,49-54
insertion,55-64
of,65-67
a,68-69
pacemaker,70-79
in,80-82
patients,83-91
with,92-96
severe,97-103
bradycardia,104-115
or,116-118
sinus,119-124
arrest.,125-132

Anticoagulants:,0-15	DrugDDI.d273.s43.e0
Potentiation,16-28
of,29-31
warfarin-type,32-45	DrugDDI.d273.s43.e1
(CYP2C9,46-53
and,54-57
CYP3A4,58-64	DrugDDI.d273.s43.e3
substrate),65-75
anticoagulant,76-89	DrugDDI.d273.s43.e4
response,90-98
is,99-101
almost,102-108
always,109-115
seen,116-120
in,121-123
patients,124-132
receiving,133-142
amiodarone,143-153	DrugDDI.d273.s43.e5
and,154-157
can,158-161
result,162-168
in,169-171
serious,172-179
or,180-182
fatal,183-188
bleeding.,189-198

Since,0-5
the,6-9
concomitant,10-21
administration,22-36
of,37-39
warfarin,40-48	DrugDDI.d273.s44.e0
with,49-53
amiodarone,54-64	DrugDDI.d273.s44.e1
increases,65-74
the,75-78
prothrombin,79-90
time,91-95
by,96-98
100%,99-103
after,104-109
3,110-111
to,112-114
4,115-116
days,,117-122
the,123-126
dose,127-131
of,132-134
the,135-138
anticoagulant,139-152	DrugDDI.d273.s44.e2
should,153-159
be,160-162
reduced,163-170
by,171-173
one-third,174-183
to,184-186
one-half,,187-196
and,197-200
prothrombin,201-212
times,213-218
should,219-225
be,226-228
monitored,229-238
closely.,239-247

Some,0-4
drugs/substances,5-21	DrugDDI.d273.s45.e0
are,22-25
known,26-31
to,32-34
accelerate,35-45
the,46-49
metabolism,50-60
of,61-63
amiodarone,64-74	DrugDDI.d273.s45.e1
by,75-77
stimulating,78-89
the,90-93
synthesis,94-103
of,104-106
CYP3A4,107-113	DrugDDI.d273.s45.e2
(enzyme,114-121
induction).,122-133

This,0-4
may,5-8
lead,9-13
to,14-16
low,17-20
amiodarone,21-31	DrugDDI.d273.s46.e0
serum,32-37
levels,38-44
and,45-48
potential,49-58
decrease,59-67
in,68-70
efficacy.,71-80

Reported,0-8
examples,9-17
of,18-20
this,21-25
interaction,26-37
include,38-45
the,46-49
following:,50-60
Antibiotics:,61-73	DrugDDI.d273.s47.e0
Rifampin,74-82	DrugDDI.d273.s47.e1
is,83-85
a,86-87
potent,88-94
inducer,95-102
of,103-105
CYP3A4.,106-113	DrugDDI.d273.s47.e2

Administration,0-14
of,15-17
rifampin,18-26	DrugDDI.d273.s48.e0
concomitantly,27-40
with,41-45
oral,46-50
amiodarone,51-61	DrugDDI.d273.s48.e1
has,62-65
been,66-70
shown,71-76
to,77-79
result,80-86
in,87-89
decreases,90-99
in,100-102
serum,103-108
concentrations,109-123
of,124-126
amiodarone,127-137	DrugDDI.d273.s48.e2
and,138-141
desethylamiodarone.,142-161	DrugDDI.d273.s48.e3

Other,0-5
substances,,6-17
including,18-27
herbal,28-34	DrugDDI.d273.s49.e0
preparations:,35-48	DrugDDI.d273.s49.e0
St.,49-52
John?s,53-59
Wort,60-64
(Hypericum,65-75
perforatum),76-87
induces,88-95
CYP3A4.,96-103	DrugDDI.d273.s49.e2

Since,0-5
amiodarone,6-16	DrugDDI.d273.s50.e0
is,17-19
a,20-21
substrate,22-31
for,32-35
CYP3A4,,36-43
there,44-49
is,50-52
the,53-56
potential,57-66
that,67-71
the,72-75
use,76-79
of,80-82
St.,83-86
John?s,87-93
Wort,94-98
in,99-101
patients,102-110
receiving,111-120
amiodarone,121-131	DrugDDI.d273.s50.e2
could,132-137
result,138-144
in,145-147
reduced,148-155
amiodarone,156-166	DrugDDI.d273.s50.e3
levels.,167-174

Other,0-5
reported,6-14
interactions,15-27
with,28-32
amiodarone:,33-44	DrugDDI.d273.s51.e0
Fentanyl,45-53	DrugDDI.d273.s51.e1
(CYP3A4,54-61
substrate),62-72
in,73-75
combination,76-87
with,88-92
amiodarone,93-103	DrugDDI.d273.s51.e3
may,104-107
cause,108-113
hypotension,,114-126
bradycardia,,127-139
and,140-143
decreased,144-153
cardiac,154-161
output.,162-169

Sinus,0-5
bradycardia,6-17
has,18-21
been,22-26
reported,27-35
with,36-40
oral,41-45
amiodarone,46-56	DrugDDI.d273.s52.e0
in,57-59
combination,60-71
with,72-76
lidocaine,77-86	DrugDDI.d273.s52.e1
(CYP3A4,87-94
substrate),95-105
given,106-111
for,112-115
local,116-121	DrugDDI.d273.s52.e3
anesthesia.,122-133	DrugDDI.d273.s52.e3

Seizure,,0-8
associated,9-19
with,20-24
increased,25-34
lidocaine,35-44	DrugDDI.d273.s53.e0
concentrations,,45-60
has,61-64
been,65-69
reported,70-78
with,79-83
concomitant,84-95
administration,96-110
of,111-113
intravenous,114-125
amiodarone.,126-137	DrugDDI.d273.s53.e1

Dextromethorphan,0-16	DrugDDI.d273.s54.e0
is,17-19
a,20-21
substrate,22-31
for,32-35
both,36-40
CYP2D6,41-47	DrugDDI.d273.s54.e1
and,48-51
CYP3A4.,52-59	DrugDDI.d273.s54.e2

Amiodarone,0-10	DrugDDI.d273.s55.e0
inhibits,11-19
CYP2D6.,20-27	DrugDDI.d273.s55.e1

Cholestyramine,0-14	DrugDDI.d273.s56.e0
increases,15-24
enterohepatic,25-38
elimination,39-50
of,51-53
amiodarone,54-64	DrugDDI.d273.s56.e1
and,65-68
may,69-72
reduce,73-79
its,80-83
serum,84-89
levels,90-96
and,97-100
t1/2.,101-106	DrugDDI.d273.s56.e2

Disopyramide,0-12	DrugDDI.d273.s57.e0
increases,13-22
QT,23-25
prolongation,26-38
which,39-44
could,45-50
cause,51-56
arrhythmia.,57-68

Fluoroquinolones,,0-17
macrolide,18-27	DrugDDI.d273.s58.e1
antibiotics,,28-40	DrugDDI.d273.s58.e1
and,41-44
azoles,45-51
are,52-55
known,56-61
to,62-64
cause,65-70
QTc,71-74
prolongation.,75-88

There,0-5
have,6-10
been,11-15
reports,16-23
of,24-26
QTc,27-30
prolongation,,31-44
with,45-49
or,50-52
without,53-60
TdP,,61-65
in,66-68
patients,69-77
taking,78-84
amiodarone,85-95	DrugDDI.d273.s59.e0
when,96-100
fluoroquinolones,,101-118
macrolide,119-128	DrugDDI.d273.s59.e2
antibiotics,,129-141	DrugDDI.d273.s59.e2
or,142-144
azoles,145-151
were,152-156
administered,157-169
concomitantly.,170-184

Hemodynamic,0-11
and,12-15
electrophysiologic,16-34
interactions,35-47
have,48-52
also,53-57
been,58-62
observed,63-71
after,72-77
concomitant,78-89
administration,90-104
with,105-109
propranolol,,110-122
diltiazem,,123-133
and,134-137
verapamil.,138-148	DrugDDI.d273.s60.e2

Volatile,0-8
Anesthetic,9-19	DrugDDI.d273.s61.e0
Agents:.,20-28	DrugDDI.d273.s61.e0

In,0-2
addition,3-11
to,12-14
the,15-18
interactions,19-31
noted,32-37
above,,38-44
chronic,45-52
(,53-54
,55-55
2,56-57
weeks),58-64
oral,65-69
Cordarone,70-79	DrugDDI.d273.s62.e0
administration,80-94
impairs,95-102
metabolism,103-113
of,114-116
phenytoin,,117-127
dextromethorphan,,128-145
and,146-149
methotrexate.,150-163	DrugDDI.d273.s62.e3

Electrolyte,0-11
Disturbances,12-24
Patients,25-33
with,34-38
hypokalemia,39-50
or,51-53
hypomagnesemia,54-68
should,69-75
have,76-80
the,81-84
condition,85-94
corrected,95-104
whenever,105-113
possible,114-122
before,123-129
being,130-135
treated,136-143
with,144-148
Cordarone,149-158	DrugDDI.d273.s63.e0
I.V.,,159-164	DrugDDI.d273.s63.e0
as,165-167
these,168-173
disorders,174-183
can,184-187
exaggerate,188-198
the,199-202
degree,203-209
of,210-212
QTc,213-216
prolongation,217-229
and,230-233
increase,234-242
the,243-246
potential,247-256
for,257-260
TdP.,261-265

Special,0-7
attention,8-17
should,18-24
be,25-27
given,28-33
to,34-36
electrolyte,37-48
and,49-52
acid-base,53-62
balance,63-70
in,71-73
patients,74-82
experiencing,83-95
severe,96-102
or,103-105
prolonged,106-115
diarrhea,116-124
or,125-127
in,128-130
patients,131-139
receiving,140-149
concomitant,150-161
diuretics.,162-172	DrugDDI.d273.s64.e0

Drugs,0-5	DrugDDI.d449.s0.e0
Metabolized,6-17
by,18-20
P450,21-25	DrugDDI.d449.s0.e1
2D6,26-29	DrugDDI.d449.s0.e1
-,30-31
The,32-35
biochemical,36-47
activity,48-56
of,57-59
the,60-63
drug,64-68	DrugDDI.d449.s0.e2
metabolizing,69-81
isozyme,82-89
cytochrome,90-100
P450,101-105
2D6,106-109
(debrisoquin,110-122
hydroxylase),123-135
is,136-138
reduced,139-146
in,147-149
a,150-151
subset,152-158
of,159-161
the,162-165
caucasian,166-175
population,176-186
(about,187-193
7-10%,194-199
of,200-202
caucasians,203-213
are,214-217
so,218-220
called,221-227
poor,228-232
metabolizers);,233-247

reliable,0-8
estimates,9-18
of,19-21
the,22-25
prevalence,26-36
of,37-39
reduced,40-47
P450,48-52	DrugDDI.d449.s1.e0
2D6,53-56	DrugDDI.d449.s1.e0
isozyme,57-64	DrugDDI.d449.s1.e0
activity,65-73
among,74-79
Asian,,80-86
African,87-94
and,95-98
other,99-104
populations,105-116
are,117-120
not,121-124
yet,125-128
available.,129-139

Poor,0-4
metabolizers,5-17
have,18-22
higher,23-29
than,30-34
expected,35-43
plasma,44-50
concentrations,51-65
of,66-68
tricyclic,69-78	DrugDDI.d449.s2.e0
antidepressants,79-94	DrugDDI.d449.s2.e0
(TCAs),95-101
when,102-106
given,107-112
usual,113-118
doses.,119-125

Depending,0-9
on,10-12
the,13-16
fraction,17-25
of,26-28
drug,29-33	DrugDDI.d449.s3.e0
metabolized,34-45
by,46-48
P450,49-53	DrugDDI.d449.s3.e1
2D6,,54-58	DrugDDI.d449.s3.e1
the,59-62
increase,63-71
in,72-74
plasma,75-81
concentration,82-95
may,96-99
be,100-102
small,,103-109
or,110-112
quite,113-118
large,119-124
(8-fold,125-132
increase,133-141
in,142-144
plasma,145-151
AUC,152-155
of,156-158
the,159-162
TCA).,163-168

In,0-2
addition,,3-12
certain,13-20
drugs,21-26	DrugDDI.d449.s4.e0
inhibit,27-34
the,35-38
activity,39-47
of,48-50
this,51-55
isozyme,56-63	DrugDDI.d449.s4.e1
and,64-67
make,68-72
normal,73-79
metabolizers,80-92
resemble,93-101
poor,102-106
metabolizers.,107-120

An,0-2
individual,3-13
who,14-17
is,18-20
stable,21-27
on,28-30
a,31-32
given,33-38
dose,39-43
of,44-46
TCA,47-50
may,51-54
become,55-61
abruptly,62-70
toxic,71-76
when,77-81
given,82-87
one,88-91
of,92-94
these,95-100
inhibiting,101-111
drugs,112-117	DrugDDI.d449.s5.e0
as,118-120
concomitant,121-132
therapy.,133-141

The,0-3
drugs,4-9	DrugDDI.d449.s6.e0
that,10-14
inhibit,15-22
cytochrome,23-33	DrugDDI.d449.s6.e1
P450,34-38	DrugDDI.d449.s6.e1
2D6,39-42	DrugDDI.d449.s6.e1
include,43-50
some,51-55
that,56-60
are,61-64
not,65-68
metabolized,69-80
by,81-83
the,84-87
enzyme,88-94
(quinidine;,95-106

cimetidine),0-11	DrugDDI.d449.s7.e0
and,12-15
many,16-20
that,21-25
are,26-29
substrates,30-40
for,41-44
P450,45-49	DrugDDI.d449.s7.e1
2D6,50-53	DrugDDI.d449.s7.e1
(many,54-59
other,60-65
antidepressants,,66-82
phenothiazines,,83-98
and,99-102
the,103-106
Type,107-111
1C,112-114
antiarrhythmics,115-130
propafenone,131-142	DrugDDI.d449.s7.e4
and,143-146
flecainide).,147-159	DrugDDI.d449.s7.e5

While,0-5
all,6-9
the,10-13
selective,14-23
serotonin,24-33	DrugDDI.d449.s8.e0
reuptake,34-42	DrugDDI.d449.s8.e0
inhibitors,43-53	DrugDDI.d449.s8.e0
(SSRIs),,54-62
e.g.,,63-68
fluoxetine,,69-80
sertraline,,81-92
and,93-96
paroxetine,,97-108
inhibit,109-116
P450,117-121	DrugDDI.d449.s8.e4
2D6,,122-126	DrugDDI.d449.s8.e4
they,127-131
may,132-135
vary,136-140
in,141-143
the,144-147
extent,148-154
of,155-157
inhibition.,158-169

Of,0-2
particular,3-13
importance,,14-25
sufficient,26-36
time,37-41
must,42-46
elapse,47-53
before,54-60
initiating,61-71
TCA,72-75
treatment,76-85
in,86-88
a,89-90
patient,91-98
being,99-104
withdrawn,105-114
from,115-119
fluoxetine,,120-131
given,132-137
the,138-141
long,142-146
half-life,147-156
of,157-159
the,160-163
parent,164-170
and,171-174
active,175-181	DrugDDI.d449.s11.e1
metabolite,182-192	DrugDDI.d449.s11.e1
(at,193-196
least,197-202
5,203-204
weeks,205-210
may,211-214
be,215-217
necessary).,218-229

Concomitant,0-11
use,12-15
of,16-18
tricyclic,19-28	DrugDDI.d449.s12.e0
antidepressants,29-44	DrugDDI.d449.s12.e0
with,45-49
drugs,50-55	DrugDDI.d449.s12.e1
that,56-60
can,61-64
inhibit,65-72
cytochrome,73-83	DrugDDI.d449.s12.e2
P450,84-88	DrugDDI.d449.s12.e2
2D6,89-92	DrugDDI.d449.s12.e2
may,93-96
require,97-104
lower,105-110
doses,111-116
than,117-121
usually,122-129
prescribed,130-140
for,141-144
either,145-151
the,152-155
tricyclic,156-165	DrugDDI.d449.s12.e3
antidepressant,166-180	DrugDDI.d449.s12.e3
or,181-183
the,184-187
other,188-193
drug.,194-199	DrugDDI.d449.s12.e4

Furthermore,,0-12
whenever,13-21
one,22-25
of,26-28
these,29-34
other,35-40
drugs,41-46	DrugDDI.d449.s13.e0
is,47-49
withdrawn,50-59
from,60-64
co-therapy,,65-76
an,77-79
increased,80-89
dose,90-94
of,95-97
tricyclic,98-107	DrugDDI.d449.s13.e1
antidepressant,108-122	DrugDDI.d449.s13.e1
may,123-126
be,127-129
required.,130-139

It,0-2
is,3-5
desirable,6-15
to,16-18
monitor,19-26
TCA,27-30
plasma,31-37
levels,38-44
whenever,45-53
a,54-55
TCA,56-59
is,60-62
going,63-68
to,69-71
be,72-74
coadministered,75-89
with,90-94
another,95-102
drug,103-107	DrugDDI.d449.s14.e0
known,108-113
to,114-116
be,117-119
an,120-122
inhibitor,123-132
of,133-135
P450,136-140	DrugDDI.d449.s14.e1
2D6.,141-145	DrugDDI.d449.s14.e1

Monoamine,0-9	DrugDDI.d449.s15.e0
Oxidase,10-17	DrugDDI.d449.s15.e0
Inhibitors:,18-29	DrugDDI.d449.s15.e0
Guanethidine,30-42	DrugDDI.d449.s15.e1
or,43-45
similarly,46-55
acting,56-62
compounds;,63-73

thyroid,0-7	DrugDDI.d449.s16.e0
medication;,8-19	DrugDDI.d449.s16.e0

alcohol,,0-8
barbiturates,9-21	DrugDDI.d449.s17.e1
and,22-25
other,26-31
CNS,32-35	DrugDDI.d449.s17.e2
depressants;,36-48	DrugDDI.d449.s17.e2

and,0-3
disulfiram,4-14	DrugDDI.d449.s18.e0
When,15-19
amitriptyline,20-33	DrugDDI.d449.s18.e1
HCl,34-37	DrugDDI.d449.s18.e1
is,38-40
given,41-46
with,47-51
anticholinergic,52-67	DrugDDI.d449.s18.e2
agents,68-74	DrugDDI.d449.s18.e2
or,75-77
sympathomimetic,78-93	DrugDDI.d449.s18.e3
drugs,,94-100	DrugDDI.d449.s18.e3
including,101-110
epinephrine,111-122	DrugDDI.d449.s18.e4
combined,123-131
with,132-136
local,137-142	DrugDDI.d449.s18.e5
anesthetics,,143-155	DrugDDI.d449.s18.e5
close,156-161
supervision,162-173
and,174-177
careful,178-185
adjustment,186-196
of,197-199
dosages,200-207
are,208-211
required.,212-221

Hyperpyrexia,0-12
has,13-16
been,17-21
reported,22-30
when,31-35
amitriptyline,36-49	DrugDDI.d449.s19.e0
HCl,50-53	DrugDDI.d449.s19.e0
is,54-56
administered,57-69
with,70-74
anticholinergic,75-90	DrugDDI.d449.s19.e1
agents,91-97	DrugDDI.d449.s19.e1
or,98-100
with,101-105
neuroleptic,106-117	DrugDDI.d449.s19.e2
drugs,,118-124	DrugDDI.d449.s19.e2
particularly,125-137
during,138-144
hot,145-148
weather.,149-157

Paralytic,0-9
ileus,10-15
may,16-19
occur,20-25
in,26-28
patients,29-37
taking,38-44
tricyclic,45-54	DrugDDI.d449.s20.e0
antidepressants,55-70	DrugDDI.d449.s20.e0
in,71-73
combination,74-85
with,86-90
anticholinergic-type,91-111	DrugDDI.d449.s20.e1
drugs.,112-118	DrugDDI.d449.s20.e1

Cimetidine,0-10	DrugDDI.d449.s21.e0
is,11-13
reported,14-22
to,23-25
reduce,26-32
hepatic,33-40
metabolism,41-51
of,52-54
certain,55-62
tricyclic,63-72	DrugDDI.d449.s21.e1
antidepressants,,73-89	DrugDDI.d449.s21.e1
thereby,90-97
delaying,98-106
elimination,107-118
and,119-122
increasing,123-133
steady-state,134-146
concentrations,147-161
of,162-164
these,165-170
drugs.,171-177	DrugDDI.d449.s21.e2

Clinically,0-10
significant,11-22
effects,23-30
have,31-35
been,36-40
reported,41-49
with,50-54
the,55-58
tricyclic,59-68	DrugDDI.d449.s22.e0
antidepressants,69-84	DrugDDI.d449.s22.e0
when,85-89
used,90-94
concomitantly,95-108
with,109-113
cimetidine.,114-125	DrugDDI.d449.s22.e1

Increases,0-9
in,10-12
plasma,13-19
levels,20-26
of,27-29
tricyclic,30-39	DrugDDI.d449.s23.e0
antidepressants,,40-56	DrugDDI.d449.s23.e0
and,57-60
in,61-63
the,64-67
frequency,68-77
and,78-81
severity,82-90
of,91-93
side,94-98
effects,,99-107
particularly,108-120
anticholinergic,,121-137
have,138-142
been,143-147
reported,148-156
when,157-161
cimetidine,162-172	DrugDDI.d449.s23.e2
was,173-176
added,177-182
to,183-185
the,186-189
drug,190-194	DrugDDI.d449.s23.e3
regimen.,195-203

Discontinuation,0-15
of,16-18
cimetidine,19-29	DrugDDI.d449.s24.e0
in,30-32
well-controlled,33-48
patients,49-57
receiving,58-67
tricyclic,68-77	DrugDDI.d449.s24.e1
antidepressants,78-93	DrugDDI.d449.s24.e1
and,94-97
cimetidine,98-108	DrugDDI.d449.s24.e2
may,109-112
decrease,113-121
the,122-125
plasma,126-132
levels,133-139
and,140-143
efficacy,144-152
of,153-155
the,156-159
antidepressants.,160-176	DrugDDI.d449.s24.e3

Caution,0-7
is,8-10
advised,11-18
if,19-21
patients,22-30
receive,31-38
large,39-44
doses,45-50
of,51-53
ethchlorvynol,54-67	DrugDDI.d449.s25.e0
concurrently.,68-81

Transient,0-9
delirium,10-18
has,19-22
been,23-27
reported,28-36
in,37-39
patients,40-48
who,49-52
were,53-57
treated,58-65
with,66-70
one,71-74
gram,75-79
of,80-82
ethchlorvynol,83-96	DrugDDI.d449.s26.e0
and,97-100
75,101-103
-,104-105
150,106-109
mg,110-112
of,113-115
amitriptyline,116-129	DrugDDI.d449.s26.e1
HCl.,130-134	DrugDDI.d449.s26.e1

In,0-2
vitro,3-8
data,9-13
indicate,14-22
that,23-27
NORVASC,28-35	DrugDDI.d114.s0.e0
has,36-39
no,40-42
effect,43-49
on,50-52
the,53-56
human,57-62	DrugDDI.d114.s0.e1
plasma,63-69	DrugDDI.d114.s0.e1
protein,70-77
binding,78-85
of,86-88
digoxin,,89-97
phenytoin,,98-108
warfarin,,109-118
and,119-122
indomethacin.,123-136	DrugDDI.d114.s0.e5

Effect,0-6
of,7-9
other,10-15
agents,16-22
on,23-25
NORVASC.,26-34	DrugDDI.d114.s1.e0

CIMETIDINE:,0-11	DrugDDI.d114.s2.e0
Co-administration,12-29
of,30-32
NORVASC,33-40	DrugDDI.d114.s2.e1
with,41-45
cimetidine,46-56	DrugDDI.d114.s2.e2
did,57-60
not,61-64
alter,65-70
the,71-74
pharmacokinetics,75-91
of,92-94
NORVASC.,95-103	DrugDDI.d114.s2.e3

GRAPEFRUIT,0-10
JUICE:,11-17
Co-administration,18-35
of,36-38
240,39-42
mL,43-45
of,46-48
grapefruit,49-59
juice,60-65
with,66-70
a,71-72
single,73-79
oral,80-84
dose,85-89
of,90-92
amlodipine,93-103	DrugDDI.d114.s3.e0
10,104-106	DrugDDI.d114.s3.e0
mg,107-109	DrugDDI.d114.s3.e0
in,110-112
20,113-115
healthy,116-123
volunteers,124-134
had,135-138
no,139-141
significant,142-153
effect,154-160
on,161-163
the,164-167
pharmacokinetics,168-184
of,185-187
amlodipine.,188-199	DrugDDI.d114.s3.e1

MAALOX,0-6	DrugDDI.d114.s4.e0
(antacid):,7-17
Co-administration,18-35
of,36-38
the,39-42
antacid,43-50
Maalox,51-57	DrugDDI.d114.s4.e2
with,58-62
a,63-64
single,65-71
dose,72-76
of,77-79
NORVASC,80-87	DrugDDI.d114.s4.e3
had,88-91
no,92-94
significant,95-106
effect,107-113
on,114-116
the,117-120
pharmacokinetics,121-137
of,138-140
NORVASC.,141-149	DrugDDI.d114.s4.e4

SILDENAFIL:,0-11	DrugDDI.d114.s5.e0
A,12-13
single,14-20
100,21-24
mg,25-27
dose,28-32
of,33-35
sildenafil,36-46	DrugDDI.d114.s5.e1
(Viagra?),47-56
in,57-59
subjects,60-68
with,69-73
essential,74-83
hypertension,84-96
had,97-100
no,101-103
effect,104-110
on,111-113
the,114-117
pharmacokinetic,118-133
parameters,134-144
of,145-147
NORVASC.,148-156	DrugDDI.d114.s5.e2

When,0-4
NORVASC,5-12	DrugDDI.d114.s6.e0
and,13-16
sildenafil,17-27	DrugDDI.d114.s6.e1
were,28-32
used,33-37
in,38-40
combination,,41-53
each,54-58
agent,59-64
independently,65-78
exerted,79-86
its,87-90
own,91-94
blood,95-100
pressure,101-109
lowering,110-118
effect.,119-126

Effect,0-6
of,7-9
NORVASC,10-17	DrugDDI.d114.s7.e0
on,18-20
other,21-26
agents.,27-34

ATORVASTATIN:,0-13	DrugDDI.d114.s8.e0
Co-administration,14-31
of,32-34
multiple,35-43
10,44-46
mg,47-49
doses,50-55
of,56-58
NORVASC,59-66	DrugDDI.d114.s8.e1
with,67-71
80,72-74
mg,75-77
of,78-80
atorvastatin,81-93	DrugDDI.d114.s8.e2
resulted,94-102
in,103-105
no,106-108
significant,109-120
change,121-127
in,128-130
the,131-134
steady,135-141
state,142-147
pharmacokinetic,148-163
parameters,164-174
of,175-177
atorvastatin.,178-191	DrugDDI.d114.s8.e3

DIGOXIN:,0-8	DrugDDI.d114.s9.e0
Co-administration,9-26
of,27-29
NORVASC,30-37	DrugDDI.d114.s9.e1
with,38-42
digoxin,43-50	DrugDDI.d114.s9.e2
did,51-54
not,55-58
change,59-65
serum,66-71
digoxin,72-79
levels,80-86
or,87-89
digoxin,90-97	DrugDDI.d114.s9.e3
renal,98-103
clearance,104-113
in,114-116
normal,117-123
volunteers.,124-135

ETHANOL,0-7	DrugDDI.d114.s10.e0
(alcohol):,8-18
Single,19-25
and,26-29
multiple,30-38
10,39-41
mg,42-44
doses,45-50
of,51-53
NORVASC,54-61	DrugDDI.d114.s10.e2
had,62-65
no,66-68
significant,69-80
effect,81-87
on,88-90
the,91-94
pharmacokinetics,95-111
of,112-114
ethanol.,115-123	DrugDDI.d114.s10.e3

WARFARIN:,0-9	DrugDDI.d114.s11.e0
Co-administration,10-27
of,28-30
NORVASC,31-38	DrugDDI.d114.s11.e1
with,39-43
warfarin,44-52	DrugDDI.d114.s11.e2
did,53-56
not,57-60
change,61-67
the,68-71
warfarin,72-80
prothrombin,81-92	DrugDDI.d114.s11.e3
response,93-101
time.,102-107

In,0-2
clinical,3-11
trials,,12-19
NORVASC,20-27	DrugDDI.d114.s12.e0
has,28-31
been,32-36
safely,37-43
administered,44-56
with,57-61
thiazide,62-70	DrugDDI.d114.s12.e1
diuretics,,71-81	DrugDDI.d114.s12.e1
beta-blockers,,82-96
angiotensin-converting,97-119	DrugDDI.d114.s12.e3
enzyme,120-126	DrugDDI.d114.s12.e3
inhibitors,,127-138	DrugDDI.d114.s12.e3
long-acting,139-150
nitrates,,151-160
sublingual,161-171
nitroglycerin,,172-186
digoxin,,187-195
warfarin,,196-205
non-steroidal,206-219	DrugDDI.d114.s12.e8
anti-inflammatory,220-237	DrugDDI.d114.s12.e8
drugs,,238-244	DrugDDI.d114.s12.e8
antibiotics,,245-257
and,258-261
oral,262-266	DrugDDI.d114.s12.e10
hypoglycemic,267-279	DrugDDI.d114.s12.e10
drugs.,280-286	DrugDDI.d114.s12.e10

Drug/Laboratory,0-15	DrugDDI.d114.s13.e0
Test,16-20
Interactions:,21-34
None,35-39
known.,40-46

Paralytic,0-9
ileus,10-15
may,16-19
occur,20-25
in,26-28
patients,29-37
taking,38-44
tricyclic,45-54	DrugDDI.d22.s0.e0
antidepressants,55-70	DrugDDI.d22.s0.e0
in,71-73
combination,74-85
with,86-90
anticholinergic,91-106	DrugDDI.d22.s0.e1
drugs.,107-113	DrugDDI.d22.s0.e1

Amoxapine,0-9	DrugDDI.d22.s1.e0
may,10-13
enhance,14-21
the,22-25
response,26-34
to,35-37
alcohol,38-45	DrugDDI.d22.s1.e1
and,46-49
the,50-53
effects,54-61
of,62-64
barbiturates,65-77	DrugDDI.d22.s1.e2
and,78-81
other,82-87
CNS,88-91	DrugDDI.d22.s1.e3
depressants.,92-104	DrugDDI.d22.s1.e3

Serum,0-5
levels,6-12
of,13-15
several,16-23
tricyclic,24-33	DrugDDI.d22.s2.e0
antidepressants,34-49	DrugDDI.d22.s2.e0
have,50-54
been,55-59
reported,60-68
to,69-71
be,72-74
significantly,75-88
increased,89-98
when,99-103
cimetidine,104-114	DrugDDI.d22.s2.e1
is,115-117
administered,118-130
concurrently,131-143
Although,144-152
such,153-157
an,158-160
interaction,161-172
has,173-176
not,177-180
been,181-185
reported,186-194
to,195-197
date,198-202
with,203-207
amoxapine,,208-218
specific,219-227
interaction,228-239
studies,240-247
have,248-252
not,253-256
been,257-261
done,,262-267
and,268-271
the,272-275
possibility,276-287
should,288-294
be,295-297
considered.,298-309

Drugs,0-5	DrugDDI.d22.s3.e0
Metabolized,6-17
by,18-20
P450,21-25	DrugDDI.d22.s3.e1
2D6,26-29	DrugDDI.d22.s3.e1

The,0-3
biochemical,4-15
activity,16-24
of,25-27
the,28-31
drug,32-36	DrugDDI.d22.s4.e0
metabolizing,37-49
isozyme,50-57
cytochrome,58-68
P450,69-73
2D6,74-77
(dehrisoquin,78-90
hydroxylase),91-103	DrugDDI.d22.s4.e1
is,104-106
reduced,107-114
in,115-117
a,118-119
subset,120-126
of,127-129
the,130-133
caucasian,134-143
population,144-154
(about,155-161
7,162-163
to,164-166
10%,167-170
of,171-173
caucasians,174-184
are,185-188
so,189-191
called,192-198
of,199-201
reduced,202-209
P450,210-214	DrugDDI.d22.s4.e2
2D6,215-218	DrugDDI.d22.s4.e2
isozyme,219-226	DrugDDI.d22.s4.e2
activity,227-235
among,236-241
p.o.,242-246
metabolizers);,247-261

Poor,0-4
metabolizers,5-17
have,18-22
higher,23-29
than,30-34
expected,35-43
plasma,44-50
concentrations,51-65
tricyclic,66-75	DrugDDI.d22.s6.e0
antidepressants,76-91	DrugDDI.d22.s6.e0
(TCAs),92-98
when,99-103
given,104-109
usual,110-115
doses.,116-122

Depending,0-9
on,10-12
the,13-16
fraction,17-25
of,26-28
drug,29-33	DrugDDI.d22.s7.e0
metabolized,34-45
by,46-48
P450,49-53	DrugDDI.d22.s7.e1
2D6,,54-58	DrugDDI.d22.s7.e1
the,59-62
increase,63-71
in,72-74
plasma,75-81
concentration,82-95
may,96-99
be,100-102
small,,103-109
or,110-112
quite,113-118
large,119-124
(8,125-127
fold,128-132
increase,133-141
in,142-144
plasma,145-151
AUC,152-155
of,156-158
the,159-162
TCA).,163-168

In,0-2
addition,3-11
certain,12-19
drugs,20-25	DrugDDI.d22.s8.e0
inhibit,26-33
the,34-37
activity,38-46
of,47-49
this,50-54
isozyme,55-62	DrugDDI.d22.s8.e1
and,63-66
make,67-71
normal,72-78
metabolizers,79-91
resemble,92-100
p.o.,101-105
metabolizers.,106-119

An,0-2
individual,3-13
who,14-17
is,18-20
stable,21-27
on,28-30
a,31-32
given,33-38
dose,39-43
of,44-46
TCA,47-50
may,51-54
become,55-61
abruptly,62-70
toxic,71-76
when,77-81
given,82-87
one,88-91
of,92-94
these,95-100
inhibiting,101-111
drugs,112-117	DrugDDI.d22.s9.e0
as,118-120
concomitant,121-132
therapy.,133-141

The,0-3
drugs,4-9	DrugDDI.d22.s10.e0
that,10-14
inhibit,15-22
cytochrome,23-33	DrugDDI.d22.s10.e1
P450,34-38	DrugDDI.d22.s10.e1
2D6,39-42	DrugDDI.d22.s10.e1
include,43-50
some,51-55
that,56-60
are,61-64
not,65-68
metabolized,69-80
by,81-83
the,84-87
enzymes,88-95
quinidine,,96-106
cimetidine,,107-118
and,119-122
many,123-127
that,128-132
are,133-136
substrates,137-147
for,148-151
P450,152-156	DrugDDI.d22.s10.e4
2D6,157-160	DrugDDI.d22.s10.e4
(many,161-166
other,167-172
antidepressants,,173-189
phenothiazines,,190-205
and,206-209
the,210-213
Type,214-218
1C,219-221
antiarrhythmics,222-237
propafenone,238-249	DrugDDI.d22.s10.e7
and,250-253
flecainide).,254-266	DrugDDI.d22.s10.e8

While,0-5
all,6-9
the,10-13
selective,14-23
serotonin,24-33	DrugDDI.d22.s11.e0
reuptake,34-42	DrugDDI.d22.s11.e0
inhibitors,43-53	DrugDDI.d22.s11.e0
(SSRls),,54-62
e.g.,63-67
fluoxetine,,68-79
sertraline,,80-91
and,92-95
paroxetine,96-106	DrugDDI.d22.s11.e3
inhibit,107-114
P450,115-119	DrugDDI.d22.s11.e4
2D6,,120-124	DrugDDI.d22.s11.e4
they,125-129
may,130-133
vary,134-138
in,139-141
the,142-145
extent,146-152
of,153-155
inhibition.,156-167

Sufficient,0-10
time,11-15
must,16-20
elapse,21-27
before,28-34
initiating,35-45
TCA,46-49
treatment,50-59
in,60-62
a,63-64
patient,65-72
being,73-78
withdrawn,79-88
from,89-93
fluoxetine,94-104	DrugDDI.d22.s14.e0
given.,105-111

The,0-3
long,4-8
half-life,9-18
of,19-21
the,22-25
parent,26-32
and,33-36
active,37-43	DrugDDI.d22.s15.e0
metabolite,44-54	DrugDDI.d22.s15.e0
(at,55-58
least,59-64
5,65-66
weeks,67-72
may,73-76
be,77-79
necessary).,80-91

Concomitant,0-11
use,12-15
of,16-18
tricyclic,19-28	DrugDDI.d22.s16.e0
antidepressants,29-44	DrugDDI.d22.s16.e0
with,45-49
drugs,50-55	DrugDDI.d22.s16.e1
that,56-60
can,61-64
inhibit,65-72
cytochrome,73-83	DrugDDI.d22.s16.e2
P450,84-88	DrugDDI.d22.s16.e2
2D6,89-92	DrugDDI.d22.s16.e2
may,93-96
require,97-104
lower,105-110
doses,111-116
than,117-121
usually,122-129
prescribed,130-140
for,141-144
either,145-151
the,152-155
tricyclic,156-165	DrugDDI.d22.s16.e3
antidepressant,166-180	DrugDDI.d22.s16.e3
or,181-183
the,184-187
other,188-193
drug.,194-199	DrugDDI.d22.s16.e4

Furthermore,,0-12
whenever,13-21
one,22-25
of,26-28
these,29-34
other,35-40
drugs,41-46	DrugDDI.d22.s17.e0
is,47-49
withdrawn,50-59
from,60-64
co-therapy,,65-76
an,77-79
increased,80-89
dose,90-94
of,95-97
tricyclic,98-107	DrugDDI.d22.s17.e1
antidepressant,108-122	DrugDDI.d22.s17.e1
may,123-126
be,127-129
required.,130-139

It,0-2
is,3-5
desirable,6-15
to,16-18
monitor,19-26
TCA,27-30
plasma,31-37
levels,38-44
whenever,45-53
a,54-55
TCA,56-59
is,60-62
going,63-68
to,69-71
be,72-74
co-administered,75-90
with,91-95
another,96-103
drug,104-108	DrugDDI.d22.s18.e0
known,109-114
to,115-117
be,118-120
an,121-123
inhibitor,124-133
of,134-136
P450,137-141	DrugDDI.d22.s18.e1
2D6.,142-146	DrugDDI.d22.s18.e1

Probenecid,0-10	DrugDDI.d342.s0.e0
decreases,11-20
the,21-24
renal,25-30
tubular,31-38
secretion,39-48
of,49-51
amoxicillin.,52-64	DrugDDI.d342.s0.e1

Concurrent,0-10
use,11-14
of,15-17
amoxicillin,18-29	DrugDDI.d342.s1.e0
and,30-33
probenecid,34-44	DrugDDI.d342.s1.e1
may,45-48
result,49-55
in,56-58
increased,59-68
and,69-72
prolonged,73-82
blood,83-88
levels,89-95
of,96-98
amoxicillin.,99-111	DrugDDI.d342.s1.e2

Chloramphenicol,,0-16
macrolides,,17-28
sulfonamides,,29-42
and,43-46
tetracy-clines,47-61
may,62-65
interfere,66-75
with,76-80
the,81-84
bactericidal,85-97
effects,98-105
of,106-108
penicillin.,109-120	DrugDDI.d342.s2.e3

Drug/Laboratory,0-15	DrugDDI.d342.s5.e0
Test,16-20
Interactions:,21-34
High,35-39
urine,40-45
concentrations,46-60
of,61-63
ampicillin,64-74	DrugDDI.d342.s5.e1
may,75-78
result,79-85
in,86-88
false-positive,89-103
reactions,104-113
when,114-118
testing,119-126
for,127-130
the,131-134
presence,135-143
of,144-146
glucose,147-154	DrugDDI.d342.s5.e2
in,155-157
urine,158-163
using,164-169
CLINITEST?,,170-181
Benedict?s,182-192
Solution,,193-202
or,203-205
Fehling?s,206-215
Solution.,216-225

Since,0-5
this,6-10
effect,11-17
may,18-21
also,22-26
occur,27-32
with,33-37
amoxicillin,,38-50
it,51-53
is,54-56
recommended,57-68
that,69-73
glucose,74-81
tests,82-87
based,88-93
on,94-96
enzymatic,97-106	DrugDDI.d342.s6.e1
glucose,107-114	DrugDDI.d342.s6.e1
oxi-dase,115-123	DrugDDI.d342.s6.e1
reactions,124-133
(such,134-139
as,140-142
CLINISTIX?),143-154
be,155-157
used.,158-163

Following,0-9
administration,10-24
of,25-27
ampicillin,28-38	DrugDDI.d342.s7.e0
to,39-41
pregnant,42-50
women,,51-57
a,58-59
transient,60-69
decrease,70-78
in,79-81
plasma,82-88
concentration,89-102
of,103-105
total,106-111
conjugated,112-122
estriol,,123-131
estriol-glucuronide,,132-152
conjugated,153-163
estrone,,164-172
and,173-176
estradiol,177-186	DrugDDI.d342.s7.e3
has,187-190
been,191-195
noted.,196-202

This,0-4
effect,5-11
may,12-15
also,16-20
occur,21-26
with,27-31
amoxicillin.,32-44	DrugDDI.d342.s8.e0

Studies,0-7
to,8-10
detect,11-17
mutagenic,18-27
potential,28-37
of,38-40
amoxicillin,41-52	DrugDDI.d342.s10.e0
alone,53-58
have,59-63
not,64-67
been,68-72
conducted;,73-83

however,,0-8
the,9-12
following,13-22
information,23-34
is,35-37
available,38-47
from,48-52
tests,53-58
on,59-61
a,62-63
4:1,64-67
mixture,68-75
of,76-78
amoxicillin,79-90	DrugDDI.d342.s11.e0
and,91-94
potassium,95-104	DrugDDI.d342.s11.e1
clavulanate,105-116	DrugDDI.d342.s11.e1
(AUGMENTIN).,117-129

AUGMENTIN,0-9	DrugDDI.d342.s12.e0
was,10-13
non-mutagenic,14-27
in,28-30
the,31-34
Ames,35-39	DrugDDI.d342.s12.e1
bacterial,40-49
mutation,50-58
assay,,59-65
and,66-69
the,70-73
yeast,74-79
gene,80-84
conversion,85-95
assay.,96-102

AUGMENTIN,0-9	DrugDDI.d342.s13.e0
was,10-13
weakly,14-20
positive,21-29
in,30-32
the,33-36
mouse,37-42
lymphoma,43-51
assay,,52-58
but,59-62
the,63-66
trend,67-72
toward,73-79
increased,80-89
mutation,90-98
frequencies,99-110
in,111-113
this,114-118
assay,119-124
occurred,125-133
at,134-136
doses,137-142
that,143-147
were,148-152
also,153-157
associated,158-168
with,169-173
decreased,174-183
cell,184-188
survival.,189-198

AUGMENTIN,0-9	DrugDDI.d342.s14.e0
was,10-13
negative,14-22
in,23-25
the,26-29
mouse,30-35
micronucleus,36-48
test,,49-54
and,55-58
in,59-61
the,62-65
dominant,66-74
lethal,75-81
assay,82-87
in,88-90
mice.,91-96

Potassium,0-9	DrugDDI.d342.s15.e0
clavulanate,10-21	DrugDDI.d342.s15.e0
alone,22-27
was,28-31
tested,32-38
in,39-41
the,42-45
Ames,46-50	DrugDDI.d342.s15.e1
bacterial,51-60
mutation,61-69
assay,70-75
and,76-79
in,80-82
the,83-86
mouse,87-92
micronucleus,93-105
test,,106-111
and,112-115
was,116-119
negative,120-128
in,129-131
each,132-136
of,137-139
these,140-145
assays.,146-153

Reproduction,0-12
studies,13-20
have,21-25
been,26-30
performed,31-40
in,41-43
mice,44-48
and,49-52
rats,53-57
at,58-60
doses,61-66
up,67-69
to,70-72
10,73-75
times,76-81
the,82-85
human,86-91
dose,92-96
and,97-100
have,101-105
revealed,106-114
no,115-117
evidence,118-126
of,127-129
impaired,130-138
fertility,139-148
or,149-151
harm,152-156
to,157-159
the,160-163
fetus,164-169
due,170-173
to,174-176
amoxicillin.,177-189	DrugDDI.d342.s18.e0

Because,0-7
animal,8-14
reproduction,15-27
studies,28-35
are,36-39
not,40-43
always,44-50
predictive,51-61
of,62-64
human,65-70
response,,71-80
this,81-85
drug,86-90	DrugDDI.d342.s20.e0
should,91-97
be,98-100
used,101-105
during,106-112
pregnancy,113-122
only,123-127
if,128-130
clearly,131-138
needed.,139-146

Labor,0-5
and,6-9
Delivery:,10-19
Oral,20-24	DrugDDI.d342.s21.e0
ampicillin-class,25-41	DrugDDI.d342.s21.e0
antibiotics,42-53
are,54-57
poorly,58-64
absorbed,65-73
during,74-80
labor.,81-87

Studies,0-7
in,8-10
guinea,11-17
pigs,18-22
showed,23-29
that,30-34
intravenous,35-46
administration,47-61
of,62-64
ampicillin,65-75	DrugDDI.d342.s22.e0
slightly,76-84
decreased,85-94
the,95-98
uterine,99-106
tone,107-111
and,112-115
frequency,116-125
of,126-128
contractions,129-141
but,142-145
moderately,146-156
increased,157-166
the,167-170
height,171-177
and,178-181
duration,182-190
of,191-193
contractions.,194-207

However,,0-8
it,9-11
is,12-14
not,15-18
known,19-24
whether,25-32
use,33-36
of,37-39
amoxicillin,40-51	DrugDDI.d342.s23.e0
in,52-54
humans,55-61
during,62-68
labor,69-74
or,75-77
delivery,78-86
has,87-90
immediate,91-100
or,101-103
delayed,104-111
adverse,112-119
effects,120-127
on,128-130
the,131-134
fetus,,135-141
prolongs,142-150
the,151-154
duration,155-163
of,164-166
labor,,167-173
or,174-176
increases,177-186
the,187-190
likelihood,191-201
that,202-206
forceps,207-214
delivery,215-223
or,224-226
other,227-232
obstetrical,233-244
intervention,245-257
or,258-260
resuscitation,261-274
of,275-277
the,278-281
newborn,282-289
will,290-294
be,295-297
necessary.,298-308

Nursing,0-7
Mothers:,8-16
Penicillins,17-28	DrugDDI.d342.s24.e0
have,29-33
been,34-38
shown,39-44
to,45-47
be,48-50
excreted,51-59
in,60-62
human,63-68
milk.,69-74

Amoxicillin,0-11	DrugDDI.d342.s25.e0
use,12-15
by,16-18
nursing,19-26
mothers,27-34
may,35-38
lead,39-43
to,44-46
sensitization,47-60
of,61-63
infants.,64-72

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
amoxicillin,33-44	DrugDDI.d342.s26.e0
is,45-47
administered,48-60
to,61-63
a,64-65
nursing,66-73
woman.,74-80

Pediatric,0-9	DrugDDI.d342.s27.e0
Use:,10-14
Because,15-22
of,23-25
incompletely,26-38
developed,39-48
renal,49-54
function,55-63
in,64-66
neonates,67-75
and,76-79
young,80-85
infants,,86-94
the,95-98
elimination,99-110
of,111-113
amoxicillin,114-125	DrugDDI.d342.s27.e1
may,126-129
be,130-132
delayed.,133-141

Dosing,0-6
of,7-9
AMOXIL,10-16	DrugDDI.d342.s28.e0
should,17-23
be,24-26
modified,27-35
in,36-38
pediatric,39-48	DrugDDI.d342.s28.e1
patients,49-57
12,58-60
weeks,61-66
or,67-69
younger,70-77
(?3,78-81
months).,82-90

Acidifying,0-10	DrugDDI.d183.s0.e0
agents,11-17	DrugDDI.d183.s0.e0
-,18-19
Gastrointestinal,20-36
acidifying,37-47
agents,48-54
(guanethidine,reserpine,,55-79
glutamic,80-88	DrugDDI.d183.s0.e3
acid,89-93	DrugDDI.d183.s0.e3
HCl,ascorbic,94-106	DrugDDI.d183.s0.e3
acid,,107-112
fruit,113-118
juices,,119-126
etc.),127-132
lower,133-138
absorption,139-149
of,150-152
amphetamines.,153-166	DrugDDI.d183.s0.e5

Urinary,0-7
acidifying,8-18	DrugDDI.d183.s1.e0
agents,19-25	DrugDDI.d183.s1.e0
-(ammonium,26-36
chloride,,37-46
sodium,47-53	DrugDDI.d183.s1.e2
acid,54-58	DrugDDI.d183.s1.e2
phosphate,,59-69	DrugDDI.d183.s1.e2
etc.),70-75

Increase,0-8
the,9-12
concentration,13-26
of,27-29
the,30-33
ionized,34-41
species,42-49
of,50-52
the,53-56
amphetamine.,57-69	DrugDDI.d183.s2.e0

Primary,0-7
excretion,8-17
-,18-19
Both,20-24
Groups,25-31
of,32-34
agents,35-41
lower,42-47
blood,48-53
levels,54-60
and,61-64
efficacy,65-73
of,74-76
amphetamines.,77-90	DrugDDI.d183.s3.e0

Adrenergic,0-10	DrugDDI.d183.s4.e0
blockers,11-19	DrugDDI.d183.s4.e0
-,20-21
Adrenergic,22-32
blockers,33-41
are,42-45
inhibited,46-55
by,56-58
amphetamines.,59-72	DrugDDI.d183.s4.e1

Alkalinizing,0-12	DrugDDI.d183.s5.e0
agents,13-19	DrugDDI.d183.s5.e0
-Gastrointestinal,20-37
alkalinizing,38-50
agents,51-57
(sodium,58-65
bicarbonate,,66-78
etc.)increase,79-92
absorption,93-103
of,104-106
amphetamines.,107-120	DrugDDI.d183.s5.e2

Urinary,0-7
alkalinizing,8-20	DrugDDI.d183.s6.e0
agents,21-27	DrugDDI.d183.s6.e0
(acetazolamide,,28-43
some,44-48
thiazides),49-59	DrugDDI.d183.s6.e2
increase,60-68
the,69-72
concentration,73-86
of,87-89
the,90-93
non-ionized,94-105
species,106-113
of,114-116
the,117-120
amphetamine,121-132	DrugDDI.d183.s6.e3
molecule,,133-142
thereby,143-150
decreasing,151-161
urinary,162-169
excretion.,170-180

Both,0-4
groups,5-11
of,12-14
agents,15-21
increase,22-30
blood,31-36
levels,37-43
and,44-47
therefore,48-57
potentate,58-67
the,68-71
actions,72-79
of,80-82
amphetamines.,83-96	DrugDDI.d183.s7.e0

Antidepressants,,0-16
tricyclic,17-26	DrugDDI.d183.s8.e1
-,27-28	DrugDDI.d183.s8.e1
Amphetamines,29-41	DrugDDI.d183.s8.e1
may,42-45
enhance,46-53
the,54-57
activity,58-66
of,67-69
tricyclic,70-79
or,80-82
sympathomimetic,83-98	DrugDDI.d183.s8.e2
agents;,99-106	DrugDDI.d183.s8.e2

d-amphetamine,0-13	DrugDDI.d183.s9.e0
with,14-18
desipramine,19-30	DrugDDI.d183.s9.e1
or,31-33
protriptyline,34-47	DrugDDI.d183.s9.e2
and,48-51
possibly,52-60
other,61-66
tricyclics,67-77	DrugDDI.d183.s9.e3
cause,78-83
striking,84-92
and,93-96
sustained,97-106
increases,107-116
in,117-119
the,120-123
concentration,124-137
of,138-140
d-amphetamine,141-154	DrugDDI.d183.s9.e4
in,155-157
the,158-161
brain;,162-168

MAO,0-3
inhibitors,4-14
-,15-16
MAO,17-20
antidepressants,,21-37
as,38-40
well,41-45
as,46-48
a,49-50
metabolite,51-61	DrugDDI.d183.s11.e1
of,62-64
furazolidone,,65-78
slow,79-83
amphetamine,84-95	DrugDDI.d183.s11.e3
metabolism.,96-107

This,0-4
slowing,5-12
potentiates,13-24
amphetamines,,25-38
increasing,39-49
their,50-55
effect,56-62
on,63-65
the,66-69
release,70-77
of,78-80
norepinephrine,81-95	DrugDDI.d183.s12.e1
and,96-99
other,100-105
monoamines,106-116
from,117-121
adrenergic,122-132
nerve,133-138
endings,,139-147
this,148-152
can,153-156
cause,157-162
headaches,163-172
and,173-176
other,177-182
signs,183-188
of,189-191
hypertensive,192-204
crisis.,205-212

Antihistamines,0-14	DrugDDI.d183.s14.e0
-,15-16
Amphetamines,17-29
may,30-33
counteract,34-44
the,45-48
sedative,49-57
effect,58-64
of,65-67
antihistamines.,68-83	DrugDDI.d183.s14.e1

Antihypertensives,0-17	DrugDDI.d183.s15.e0
-,18-19
Amphetamines,20-32
may,33-36
antagonize,37-47
the,48-51
hypotensive,52-63
effects,64-71
of,72-74
antihypertensives.,75-93	DrugDDI.d183.s15.e1

Chlorpromazine,0-14	DrugDDI.d183.s16.e0
-,15-16
Chlorpromazine,17-31
blocks,32-38
dopamine,39-47	DrugDDI.d183.s16.e1
and,48-51
norepinephrine,52-66	DrugDDI.d183.s16.e2
receptors,,67-77	DrugDDI.d183.s16.e2
thus,78-82
inhibiting,83-93
the,94-97
central,98-105	DrugDDI.d183.s16.e3
stimulant,106-115	DrugDDI.d183.s16.e3
effects,116-123
of,124-126
amphetamines,,127-140
and,141-144
can,145-148
be,149-151
used,152-156
to,157-159
treat,160-165
amphetamine,166-177
poisoning.,178-188

Ethosuximide,0-12	DrugDDI.d183.s17.e0
-,13-14
Amphetamines,15-27
may,28-31
delay,32-37
intestinal,38-48
absorption,49-59
of,60-62
ethosuximide.,63-76	DrugDDI.d183.s17.e1

Haloperidol,0-11	DrugDDI.d183.s18.e0
-,12-13
Haloperidol,14-25
blocks,26-32
dopamine,33-41	DrugDDI.d183.s18.e1
receptors,,42-52	DrugDDI.d183.s18.e1
thus,53-57
inhibiting,58-68
the,69-72
central,73-80	DrugDDI.d183.s18.e2
stimulant,81-90	DrugDDI.d183.s18.e2
effects,91-98
of,99-101
amphetamines.,102-115	DrugDDI.d183.s18.e3

Lithium,0-7	DrugDDI.d183.s19.e0
carbonate,8-17	DrugDDI.d183.s19.e0
-,18-19
The,20-23
anorectic,24-33
and,34-37
stimulatory,38-49
effects,50-57
of,58-60
amphetamines,61-73	DrugDDI.d183.s19.e1
may,74-77
be,78-80
inhibited,81-90
by,91-93
lithium,94-101	DrugDDI.d183.s19.e2
carbonate.,102-112	DrugDDI.d183.s19.e2

Meperidine,0-10	DrugDDI.d183.s20.e0
-,11-12
Amphetamines,13-25
pone,26-30
the,31-34
analgesic,35-44
effect,45-51
of,52-54
meperidine.,55-66	DrugDDI.d183.s20.e1

Methenamine,0-11	DrugDDI.d183.s21.e0
therapy,12-19
-,20-21
Urinary,22-29
excretion,30-39
of,40-42
amphetamines,43-55	DrugDDI.d183.s21.e1
is,56-58
increased,,59-69
and,70-73
efficacy,74-82
is,83-85
reduced,,86-94
by,95-97
acidifying,98-108	DrugDDI.d183.s21.e2
agents,109-115	DrugDDI.d183.s21.e2
used,116-120
in,121-123
methenamine,124-135	DrugDDI.d183.s21.e3
therapy.,136-144

Norepinephrine,0-14	DrugDDI.d183.s22.e0
-,15-16
Amphetamines,17-29
enhance,30-37
the,38-41
adrenergic,42-52
effect,53-59
of,60-62
norepinephrine.,63-78	DrugDDI.d183.s22.e1

Phenobarbital,0-13	DrugDDI.d183.s23.e0
-,14-15
Amphetamines,16-28
may,29-32
delay,33-38
intestinal,39-49
absorption,50-60
of,61-63
phenobarbital;,64-78	DrugDDI.d183.s23.e1

co-administration,0-17
of,18-20
phenobarbital,21-34	DrugDDI.d183.s24.e0
may,35-38
produce,39-46
a,47-48
synergistic,49-60
anticonvulsant,61-75	DrugDDI.d183.s24.e1
action.,76-83

Phenytoin,0-9	DrugDDI.d183.s25.e0
-,10-11	DrugDDI.d183.s25.e0
Amphetamines,12-24	DrugDDI.d183.s25.e0
may,25-28
delay,29-34
intestinal,35-45
absorption,46-56
of,57-59
phenytoin;,60-70	DrugDDI.d183.s25.e1

co-administration,0-17
of,18-20
phenytoin,21-30	DrugDDI.d183.s26.e0
may,31-34
produce,35-42
a,43-44
synergistic,45-56
anticonvulsant,57-71	DrugDDI.d183.s26.e1
action.,72-79

Propoxyphene,0-12	DrugDDI.d183.s27.e0
-,13-14
In,15-17
cases,18-23
of,24-26
propoxyphene,27-39	DrugDDI.d183.s27.e1
overdose,,40-49
amphetamine,50-61	DrugDDI.d183.s27.e2
CNS,62-65	DrugDDI.d183.s27.e2
stimulation,66-77
is,78-80
potentiated,81-92
and,93-96
fatal,97-102
convulsions,103-114
can,115-118
occur.,119-125

Veratrum,0-8	DrugDDI.d183.s28.e0
alkaloids,9-18	DrugDDI.d183.s28.e0
-,19-20
Amphetamines,21-33
inhibit,34-41
the,42-45
hypotensive,46-57
effect,58-64
of,65-67
veratrum,68-76	DrugDDI.d183.s28.e1
alkaloids.,77-87	DrugDDI.d183.s28.e1

Drug/Laboratory,0-15	DrugDDI.d183.s29.e0
Test,16-20
Interactions,21-33
Amphetamines,34-46	DrugDDI.d183.s29.e1
can,47-50
cause,51-56
a,57-58
significant,59-70
elevation,71-80
in,81-83
plasma,84-90
corticosteroid,91-105	DrugDDI.d183.s29.e2
levels.,106-113

Amphetamines,0-12	DrugDDI.d183.s31.e0
may,13-16
interfere,17-26
with,27-31
urinary,32-39
steroid,40-47
determinations.,48-63

When,0-4
administered,5-17
concurrently,,18-31
the,32-35
following,36-45
drugs,46-51	DrugDDI.d23.s0.e0
may,52-55
interact,56-64
with,65-69
amphotericin,70-82	DrugDDI.d23.s0.e1
B:,83-85	DrugDDI.d23.s0.e1
Antineoplastic,86-100	DrugDDI.d23.s0.e2
agents:,101-108	DrugDDI.d23.s0.e2
may,109-112
enhance,113-120
the,121-124
potential,125-134
for,135-138
renal,139-144
toxicity,,145-154
bronchospasm,155-167
and,168-171
hypotension.,172-184

Antineoplastic,0-14	DrugDDI.d23.s1.e0
agents,15-21	DrugDDI.d23.s1.e0
(e.,22-25
g.,,26-29
nitrogen,30-38	DrugDDI.d23.s1.e1
mustard,,39-47	DrugDDI.d23.s1.e1
etc.),48-53
should,54-60
be,61-63
given,64-69
concomitantly,70-83
only,84-88
with,89-93
great,94-99
caution.,100-108

Corticosteroids,0-15	DrugDDI.d23.s2.e0
and,16-19
Corticotropin,20-33	DrugDDI.d23.s2.e1
(ACTH):,34-41
may,42-45
potentiate,46-56
amphotericin,57-69	DrugDDI.d23.s2.e3
B-,70-72	DrugDDI.d23.s2.e3
induced,73-80
hypokalemia,81-92
which,93-98
may,99-102
predispose,103-113
the,114-117
patient,118-125
to,126-128
cardiac,129-136
dysfunction.,137-149

Avoid,0-5
concomitant,6-17
use,18-21
unless,22-28
necessary,29-38
to,39-41
control,42-49
side,50-54
effects,55-62
of,63-65
amphotericin,66-78	DrugDDI.d23.s3.e0
B.,79-81	DrugDDI.d23.s3.e0

Digitalis,0-9	DrugDDI.d23.s5.e0
glycosides:,10-21	DrugDDI.d23.s5.e0
amphotericin,22-34	DrugDDI.d23.s5.e1
B-induced,35-44	DrugDDI.d23.s5.e1
hypokalemia,45-56
may,57-60
potentiate,61-71
digitalis,72-81
toxicity.,82-91

Flucytosine:,0-12	DrugDDI.d23.s7.e0
while,13-18
a,19-20
synergistic,21-32
relationship,33-45
with,46-50
amphotericin,51-63	DrugDDI.d23.s7.e1
B,64-65	DrugDDI.d23.s7.e1
has,66-69
been,70-74
reported,,75-84
concomitant,85-96
use,97-100
may,101-104
increase,105-113
the,114-117
toxicity,118-126
of,127-129
flucytosine,130-141	DrugDDI.d23.s7.e2
by,142-144
possibly,145-153
increasing,154-164
its,165-168
cellular,169-177
uptake,178-184
and/or,185-191
impairing,192-201
its,202-205
renal,206-211
excretion.,212-222

Imidazoles,0-10	DrugDDI.d23.s8.e0
(e.,11-14
g.,,15-18
ketoconazole,,19-32
miconazole,,33-44
clotrimazole,,45-58
fluconazole,,59-71
etc.):,72-78
in,79-81
vitro,82-87
and,88-91
animal,92-98
studies,99-106
with,107-111
the,112-115
combination,116-127
of,128-130
amphotericin,131-143	DrugDDI.d23.s8.e5
B,144-145	DrugDDI.d23.s8.e5
and,146-149
imidazoles,150-160	DrugDDI.d23.s8.e6
suggest,161-168
that,169-173
imidazoles,174-184	DrugDDI.d23.s8.e7
may,185-188
induce,189-195
fungal,196-202
resistance,203-213
to,214-216
amphotericin,217-229	DrugDDI.d23.s8.e8
B.,230-232	DrugDDI.d23.s8.e8

Other,0-5
nephrotoxic,6-17	DrugDDI.d23.s10.e0
medications:,18-30	DrugDDI.d23.s10.e0
agents,31-37
such,38-42
as,43-45
aminoglycosides,,46-62
cyclosporine,,63-76
and,77-80
pentamidine,81-92	DrugDDI.d23.s10.e3
may,93-96
enhance,97-104
the,105-108
potential,109-118
for,119-122
drug-induced,123-135
renal,136-141
toxicity,,142-151
and,152-155
should,156-162
be,163-165
used,166-170
concomitantly,171-184
only,185-189
with,190-194
great,195-200
caution.,201-209

Intensive,0-9
monitoring,10-20
of,21-23
renal,24-29
function,30-38
is,39-41
recommended,42-53
in,54-56
patients,57-65
requiring,66-75
any,76-79
combination,80-91
of,92-94
nephrotoxic,95-106
medications,107-118	DrugDDI.d23.s11.e0
.,119-120

Skeletal,0-8	DrugDDI.d23.s12.e0
muscle,9-15	DrugDDI.d23.s12.e0
relaxants:,16-26	DrugDDI.d23.s12.e0
amphotericin,27-39	DrugDDI.d23.s12.e1
B-induced,40-49	DrugDDI.d23.s12.e1
hypokalemia,50-61
may,62-65
enhance,66-73
the,74-77
curariform,78-88	DrugDDI.d23.s12.e2
effect,89-95	DrugDDI.d23.s12.e2
of,96-98
skeletal,99-107	DrugDDI.d23.s12.e3
muscle,108-114	DrugDDI.d23.s12.e3
relaxants,115-124	DrugDDI.d23.s12.e3
(e.g.,,125-131
tubocurarine).,132-146	DrugDDI.d23.s12.e4

Leukocyte,0-9
transfusions:,10-23
acute,24-29
pulmonary,30-39
toxicity,40-48
has,49-52
been,53-57
reported,58-66
in,67-69
patients,70-78
receiving,79-88
intravenous,89-100
amphotericin,101-113	DrugDDI.d23.s14.e0
B,114-115	DrugDDI.d23.s14.e0
and,116-119
leukocyte,120-129
transfusions.,130-143

When,0-4
administered,5-17
concurrently,,18-31
the,32-35
following,36-45
drugs,46-51	DrugDDI.d76.s0.e0
may,52-55
interact,56-64
with,65-69
ampicillin.,70-81	DrugDDI.d76.s0.e1

Allopurinol:,0-12	DrugDDI.d76.s1.e0
Increased,13-22
possibility,23-34
of,35-37
skin,38-42
rash,,43-48
particularly,49-61
in,62-64
hyperuricemic,65-78
patients,79-87
may,88-91
occur.,92-98

Bacteriostatic,0-14	DrugDDI.d76.s2.e0
Antibiotics:,15-27
Chloramphenicol,,28-44
erythromycins,,45-59
sulfonamides,,60-73
or,74-76
tetracyclines,77-90	DrugDDI.d76.s2.e4
may,91-94
interfere,95-104
with,105-109
the,110-113
bactericidal,114-126
effect,127-133
of,134-136
penicillins.,137-149	DrugDDI.d76.s2.e5

Oral,0-4	DrugDDI.d76.s4.e0
Contraceptives:,5-20	DrugDDI.d76.s4.e0
May,21-24
be,25-27
less,28-32
effective,33-42
and,43-46
increased,47-56
breakthrough,57-69
bleeding,70-78
may,79-82
occur.,83-89

Probenecid:,0-11	DrugDDI.d76.s5.e0
May,12-15
decrease,16-24
renal,25-30
tubular,31-38
secretion,39-48
of,49-51
ampicillin,52-62	DrugDDI.d76.s5.e1
resulting,63-72
in,73-75
increased,76-85
blood,86-91
levels,92-98
and/or,99-105
ampicillin,106-116	DrugDDI.d76.s5.e2
toxicity.,117-126

Drug/Laboratory,0-15	DrugDDI.d76.s6.e0
Test,16-20
Interaction,21-32
After,33-38
treatment,39-48
with,49-53
ampicillin,,54-65
a,66-67
false-positive,68-82
reaction,83-91
for,92-95
glucose,96-103	DrugDDI.d76.s6.e2
in,104-106
the,107-110
urine,111-116
may,117-120
occur,121-126
with,127-131
copper,132-138	DrugDDI.d76.s6.e3
sulfate,139-146	DrugDDI.d76.s6.e3
tests,147-152
(Benedicts,153-163
solution,,164-173
Fehlings,174-182
solution,,183-192
or,193-195
Clinitest,196-205
tablets),206-214
but,215-218
not,219-222
with,223-227
enzyme,228-234
based,235-240
tests,241-246
such,247-251
as,252-254
Clinistix,255-264
and,265-268
Glucose,269-276	DrugDDI.d76.s6.e4
Enzymatic,277-286
Test,287-291
Strip,292-297
USP.,298-302

Amprenavir,0-10	DrugDDI.d86.s0.e0
is,11-13
metabolized,14-25
in,26-28
the,29-32
liver,33-38	DrugDDI.d86.s0.e1
by,39-41
the,42-45
cytochrome,46-56	DrugDDI.d86.s0.e2
P450,57-61	DrugDDI.d86.s0.e2
enzyme,62-68
system.,69-76

Amprenavir,0-10	DrugDDI.d86.s1.e0
inhibits,11-19
CYP3A4.,20-27	DrugDDI.d86.s1.e1

Caution,0-7
should,8-14
be,15-17
used,18-22
when,23-27
coadministering,28-43
medications,44-55	DrugDDI.d86.s2.e0
that,56-60
are,61-64
substrates,,65-76
inhibitors,,77-88
or,89-91
inducers,92-100
of,101-103
CYP3A4,,104-111
or,112-114
potentially,115-126
toxic,127-132
medications,133-144	DrugDDI.d86.s2.e2
that,145-149
are,150-153
metabolized,154-165
by,166-168
CYP3A4.,169-176	DrugDDI.d86.s2.e3

Amprenavir,0-10	DrugDDI.d86.s3.e0
does,11-15
not,16-19
inhibit,20-27
CYP2D6,,28-35
CYP1A2,,36-43
CYP2C9,,44-51
CYP2C19,,52-60
CYP2E1,,61-68
or,69-71
uridine,72-79	DrugDDI.d86.s3.e6
glucuronosyltransferase,80-103
(UDPGT).,104-112

HIV,0-3	DrugDDI.d86.s4.e0
Protease,4-12	DrugDDI.d86.s4.e0
Inhibitors:,13-24	DrugDDI.d86.s4.e0
The,25-28
effect,29-35
of,36-38
amprenavir,39-49	DrugDDI.d86.s4.e1
on,50-52
total,53-58
drug,59-63
concentrations,64-78
of,79-81
other,82-87
HIV,88-91	DrugDDI.d86.s4.e2
protease,92-100	DrugDDI.d86.s4.e2
inhibitors,101-111	DrugDDI.d86.s4.e2
in,112-114
subjects,115-123
receiving,124-133
both,134-138
agents,139-145
was,146-149
evaluated,150-159
using,160-165
comparisons,166-177
to,178-180
historical,181-191
data.,192-197

Indinavir,0-9	DrugDDI.d86.s5.e0
steady-state,10-22
Cmax,,23-28
A.C.,29-33
and,34-37
Cmin,38-42
were,43-47
decreased,48-57
by,58-60
22%,,61-65
38%,,66-70
and,71-74
27%,,75-79
respectively,,80-93
by,94-96
concomitant,97-108
amprenavir.,109-120	DrugDDI.d86.s5.e1

Saquinavir,0-10	DrugDDI.d86.s7.e0
steady-state,11-23
Cmax,,24-29
A.C.,30-34
and,35-38
Cmin,39-43
were,44-48
increased,49-58
21%,,59-63
decreased,64-73
19%,,74-78
and,79-82
decreased,83-92
48%,,93-97
respectively,,98-111
by,112-114
concomitant,115-126
amprenavir.,127-138	DrugDDI.d86.s7.e1

Nelfinavir,0-10	DrugDDI.d86.s8.e0
steady-state,11-23
Cmax,,24-29
A.C.,30-34
and,35-38
Cmin,39-43
were,44-48
increased,49-58
by,59-61
12%,,62-66
15%,,67-71
and,72-75
14%,,76-80
respectively,,81-94
by,95-97
concomitant,98-109
amprenavir.,110-121	DrugDDI.d86.s8.e1

Methadone:,0-10	DrugDDI.d86.s9.e0
Coadministration,11-27
of,28-30
amprenavir,31-41	DrugDDI.d86.s9.e1
and,42-45
methadone,46-55	DrugDDI.d86.s9.e2
can,56-59
decrease,60-68
plasma,69-75
levels,76-82
ofmethadone.,83-95

Coadministration,0-16
of,17-19
amprenavir,20-30	DrugDDI.d86.s10.e0
and,31-34
methadone,35-44	DrugDDI.d86.s10.e1
as,45-47
compared,48-56
to,57-59
a,60-61
non-matched,62-73
historicalcontrol,74-91
group,92-97
resulted,98-106
in,107-109
a,110-111
30%,,112-116
27%,,117-121
and,122-125
25%,126-129
decrease,130-138
in,139-141
serum,142-147
amprenavir,148-158	DrugDDI.d86.s10.e2
AUC,,159-163
Cmax,,164-169
andCmin,,170-178
respectively.,179-192

Amprenavir,0-10	DrugDDI.d86.s11.e0
is,11-13
an,14-16
inhibitor,17-26
of,27-29
cytochrome,30-40	DrugDDI.d86.s11.e1
P450,41-45	DrugDDI.d86.s11.e1
C.P.A.,46-52
metabolism,53-63
and,64-67
therefore,68-77
should,78-84
not,85-88
be,89-91
administered,92-104
concurrently,105-117
with,118-122
medications,123-134	DrugDDI.d86.s11.e2
with,135-139
narrow,140-146
therapeutic,147-158
windows,159-166
that,167-171
are,172-175
substrates,176-186
of,187-189
CYP3A4.,190-197	DrugDDI.d86.s11.e3

Laboratory,0-10
Tests:,11-17
The,18-21
combination,22-33
of,34-36
Amprenavir,37-47	DrugDDI.d86.s13.e0
and,48-51
low-dose,52-60
ritonavir,61-70	DrugDDI.d86.s13.e1
has,71-74
been,75-79
associated,80-90
with,91-95
elevations,96-106
of,107-109
cholesterol,110-121	DrugDDI.d86.s13.e2
and,122-125
triglycerides,,126-140
SGOT,141-145
(AST),,146-152
and,153-156
SGPT,157-161
(ALT),162-167
in,168-170
some,171-175
patients.,176-185

Appropriate,0-11
laboratory,12-22
testing,23-30
should,31-37
be,38-40
considered,41-51
prior,52-57
to,58-60
initiating,61-71
combination,72-83
therapy,84-91
with,92-96
Amprenavir,97-107	DrugDDI.d86.s14.e0
and,108-111
ritonavir,112-121	DrugDDI.d86.s14.e1
and,122-125
at,126-128
periodic,129-137
intervals,138-147
or,148-150
if,151-153
any,154-157
clinical,158-166
signs,167-172
or,173-175
symptoms,176-184
of,185-187
hyperlipidemia,188-202
or,203-205
elevated,206-214
liver,215-220
function,221-229
tests,230-235
occur,236-241
during,242-248
therapy.,249-257

For,0-3
comprehensive,4-17
information,18-29
concerning,30-40
laboratory,41-51
test,52-56
alterations,57-68
associated,69-79
with,80-84
ritonavir,,85-95
physicians,96-106
should,107-113
refer,114-119
to,120-122
the,123-126
complete,127-135
prescribing,136-147
information,148-159
for,160-163
NORVIR,164-170	DrugDDI.d86.s15.e1
(ritonavir).,171-183

Taking,0-6
amyl,7-11	DrugDDI.d73.s0.e0
nitrite,12-19	DrugDDI.d73.s0.e0
after,20-25
drinking,26-34	DrugDDI.d73.s0.e1
alcohol,35-42	DrugDDI.d73.s0.e1
may,43-46
worsen,47-53
side,54-58
effects,59-66
and,67-70
may,71-74
cause,75-80
severe,81-87
hypotension,88-99
and,100-103
cardiovascular,104-118
collapse.,119-128

Limited,0-7
PK,8-10	DrugDDI.d378.s0.e0
and/or,11-17
PD,18-20
studies,21-28
investigating,29-42
possible,43-51
interactions,52-64
between,65-72
anagrelide,73-83	DrugDDI.d378.s0.e1
and,84-87
other,88-93
medicinal,94-103	DrugDDI.d378.s0.e2
products,104-112	DrugDDI.d378.s0.e2
have,113-117
been,118-122
conducted.,123-133

In,0-2
vivo,3-7
interaction,8-19
studies,20-27
in,28-30
humans,31-37
have,38-42
demonstrated,43-55
that,56-60
digoxin,61-68	DrugDDI.d378.s1.e0
and,69-72
warfarin,73-81	DrugDDI.d378.s1.e1
do,82-84
not,85-88
affect,89-95
the,96-99
PK,100-102	DrugDDI.d378.s1.e2
properties,103-113
of,114-116
anagrelide,,117-128
nor,129-132
does,133-137
anagrelide,138-148	DrugDDI.d378.s1.e4
affect,149-155
the,156-159
PK,160-162	DrugDDI.d378.s1.e5
properties,163-173
of,174-176
digoxin,177-184	DrugDDI.d378.s1.e6
or,185-187
warfarin.,188-197	DrugDDI.d378.s1.e7

Although,0-8
additional,9-19
drug,20-24
interaction,25-36
studies,37-44
have,45-49
not,50-53
been,54-58
conducted,,59-69
the,70-73
most,74-78
common,79-85
medications,86-97	DrugDDI.d378.s2.e0
used,98-102
concomitantly,103-116
with,117-121
anagrelide,122-132	DrugDDI.d378.s2.e1
in,133-135
clinical,136-144
trials,145-151
were,152-156
aspirin,,157-165
acetaminophen,,166-180
furosemide,,181-192
iron,,193-198
ranitidine,,199-210
hydroxyurea,,211-223
and,224-227
allopurinol.,228-240	DrugDDI.d378.s2.e8

There,0-5
is,6-8
no,9-11
clinical,12-20
evidence,21-29
to,30-32
suggest,33-40
that,41-45
anagrelide,46-56	DrugDDI.d378.s3.e0
interacts,57-66
with,67-71
any,72-75
of,76-78
these,79-84
compounds.,85-95

An,0-2
in,3-5
vivo,6-10
interaction,11-22
study,23-28
in,29-31
humans,32-38
demonstrated,39-51
that,52-56
a,57-58
single,59-65
1mg,66-69
dose,70-74
of,75-77
anagrelide,78-88	DrugDDI.d378.s4.e0
administered,89-101
concomitantly,102-115
with,116-120
a,121-122
single,123-129
900,130-133
mg,134-136
dose,137-141
of,142-144
aspirin,145-152	DrugDDI.d378.s4.e1
was,153-156
generally,157-166
well,167-171
tolerated.,172-182

No,0-2
clinically,3-13
relevant,14-22
pharmacokinetic,23-38
interactions,39-51
between,52-59
anagrelide,60-70	DrugDDI.d378.s6.e0
and,71-74
acetylsalicylic,75-90	DrugDDI.d378.s6.e1
acid,91-95	DrugDDI.d378.s6.e1
were,96-100
observed.,101-110

In,0-2
that,3-7
same,8-12
study,,13-19
aspirin,20-27	DrugDDI.d378.s7.e0
alone,28-33
produced,34-42
a,43-44
marked,45-51
inhibition,52-62
in,63-65
platelet,66-74
aggregation,75-86
ex,87-89
vivo.,90-95

Anagrelide,0-10	DrugDDI.d378.s8.e0
alone,11-16
had,17-20
no,21-23
effect,24-30
on,31-33
platelet,34-42
aggregation,,43-55
but,56-59
did,60-63
slightly,64-72
enhance,73-80
the,81-84
inhibition,85-95
of,96-98
platelet,99-107
aggregation,108-119
by,120-122
aspirin.,123-131	DrugDDI.d378.s8.e1

Anagrelide,0-10	DrugDDI.d378.s9.e0
is,11-13
metabolized,14-25
at,26-28
least,29-34
in,35-37
part,38-42
by,43-45
CYP1A2.,46-53	DrugDDI.d378.s9.e1

It,0-2
is,3-5
known,6-11
that,12-16
CYP1A2,17-23	DrugDDI.d378.s10.e0
is,24-26
inhibited,27-36
by,37-39
several,40-47
medicinal,48-57	DrugDDI.d378.s10.e1
products,,58-67	DrugDDI.d378.s10.e1
including,68-77
fluvoxamine,,78-90
and,91-94
such,95-99
medicinal,100-109	DrugDDI.d378.s10.e3
products,110-118	DrugDDI.d378.s10.e3
could,119-124
theoretically,125-138
adversely,139-148
influence,149-158
the,159-162
clearance,163-172
of,173-175
anagrelide.,176-187	DrugDDI.d378.s10.e4

Anagrelide,0-10	DrugDDI.d378.s11.e0
demonstrates,11-23
some,24-28
limited,29-36
inhibitory,37-47
activity,48-56
towards,57-64
CYP1A2,65-71	DrugDDI.d378.s11.e1
which,72-77
may,78-81
present,82-89
a,90-91
theoretical,92-103
potential,104-113
for,114-117
interaction,118-129
with,130-134
other,135-140
coadministered,141-155
medicinal,156-165	DrugDDI.d378.s11.e2
products,166-174	DrugDDI.d378.s11.e2
sharing,175-182
that,183-187
clearance,188-197
mechanism,198-207
e.g.,208-212

theophylline.,0-13	DrugDDI.d378.s12.e0

Anagrelide,0-10	DrugDDI.d378.s13.e0
is,11-13
an,14-16
inhibitor,17-26
of,27-29
cyclic,30-36	DrugDDI.d378.s13.e1
AMP,37-40	DrugDDI.d378.s13.e1
PDE,41-44
III.,45-49

The,0-3
effects,4-11
of,12-14
medicinal,15-24	DrugDDI.d378.s14.e0
products,25-33	DrugDDI.d378.s14.e0
with,34-38
similar,39-46
properties,47-57
such,58-62
as,63-65
inotropes,66-75
milrinone,,76-86
enoximone,,87-97
amrinone,,98-107
olprinone,108-117	DrugDDI.d378.s14.e4
and,118-121
cilostazol,122-132	DrugDDI.d378.s14.e5
may,133-136
be,137-139
exacerbated,140-151
by,152-154
anagrelide.,155-166	DrugDDI.d378.s14.e6

There,0-5
is,6-8
a,9-10
single,11-17
case,18-22
report,,23-30
which,31-36
suggests,37-45
that,46-50
sucralfate,51-61	DrugDDI.d378.s15.e0
may,62-65
interfere,66-75
with,76-80
anagrelide,81-91	DrugDDI.d378.s15.e1
absorption.,92-103

Food,0-4
has,5-8
no,9-11
clinically,12-22
significant,23-34
effect,35-41
on,42-44
the,45-48
bioavailability,49-64
of,65-67
anagrelide.,68-79	DrugDDI.d378.s16.e0

Toxicologic,0-11
and,12-15
toxicokinetic,16-29
studies,30-37
in,38-40
rats,41-45
did,46-49
not,50-53
demonstrate,54-65
any,66-69
alterations,70-81
in,82-84
the,85-88
clearance,89-98
or,99-101
toxicologic,102-113
profile,114-121
of,122-124
either,125-131
methotrexate,132-144	DrugDDI.d132.s1.e0
or,145-147
Kineret?,148-156
when,157-161
the,162-165
two,166-169
agents,170-176
were,177-181
administered,182-194
together.,195-204

In,0-2
a,3-4
study,5-10
in,11-13
which,14-19
patients,20-28
with,29-33
active,34-40
RA,41-43
were,44-48
treated,49-56
for,57-60
up,61-63
to,64-66
24,67-69
weeks,70-75
with,76-80
concurrent,81-91
Kineret?,92-100
and,101-104
etanercept,105-115	DrugDDI.d132.s2.e0
therapy,,116-124
a,125-126
7%,127-129
rate,130-134
of,135-137
serious,138-145
infections,146-156
was,157-160
observed,,161-170
which,171-176
was,177-180
higher,181-187
than,188-192
that,193-197
observed,198-206
with,207-211
etanercept,212-222	DrugDDI.d132.s2.e1
alone,223-228
(0%).,229-234

Two,0-3
percent,4-11
of,12-14
patients,15-23
treated,24-31
concurrently,32-44
with,45-49
Kineret?,50-58
and,59-62
etanercept,63-73	DrugDDI.d132.s3.e0
developed,74-83
neutropenia,84-95
(ANC,96-100
,101-101
1,102-103
x,104-105
109/L).,106-113

Anastrozole,0-11	DrugDDI.d249.s0.e0
inhibited,12-21
in,22-24
vitro,25-30
metabolic,31-40
reactions,41-50
catalyzed,51-60
by,61-63
cytochromes,64-75	DrugDDI.d249.s0.e1
P450,76-80	DrugDDI.d249.s0.e1
1A2,,81-85	DrugDDI.d249.s0.e1
2C8/9,,86-92
and,93-96
3A4,97-100
but,101-104
only,105-109
at,110-112
relatively,113-123
high,124-128
concentrations.,129-144

Anastrozole,0-11	DrugDDI.d249.s1.e0
did,12-15
not,16-19
inhibit,20-27
P450,28-32	DrugDDI.d249.s1.e1
2A6,33-36
or,37-39
the,40-43
polymorphic,44-55	DrugDDI.d249.s1.e2
P450,56-60	DrugDDI.d249.s1.e2
2D6,61-64	DrugDDI.d249.s1.e2
in,65-67
human,68-73
liver,74-79
microsomes.,80-91

Anastrozole,0-11	DrugDDI.d249.s2.e0
did,12-15
not,16-19
alter,20-25
the,26-29
pharmacokinetics,30-46
of,47-49
antipyrine.,50-61	DrugDDI.d249.s2.e1

Although,0-8
there,9-14
have,15-19
been,20-24
no,25-27
formal,28-34
interaction,35-46
studies,47-54
other,55-60
than,61-65
with,66-70
antipyrine,,71-82
based,83-88
on,89-91
these,92-97
in,98-100
vivo,101-105
and,106-109
in,110-112
vitro,113-118
studies,,119-127
it,128-130
is,131-133
unlikely,134-142
that,143-147
co-administration,148-165
of,166-168
a,169-170
1,171-172
mg,173-175
dose,176-180
of,181-183
ARIMIDEX,184-192	DrugDDI.d249.s3.e1
with,193-197
other,198-203
drugs,204-209	DrugDDI.d249.s3.e2
will,210-214
result,215-221
in,222-224
clinically,225-235
significant,236-247
drug,248-252	DrugDDI.d249.s3.e3
inhibition,253-263
of,264-266
cytochrome,267-277	DrugDDI.d249.s3.e4
P450-mediated,278-291	DrugDDI.d249.s3.e4
metabolism,292-302
of,303-305
the,306-309
other,310-315
drugs.,316-322	DrugDDI.d249.s3.e5

An,0-2
interaction,3-14
study,15-20
with,21-25
warfarin,26-34	DrugDDI.d249.s4.e0
showed,35-41
no,42-44
clinically,45-55
significant,56-67
effect,68-74
of,75-77
anastrozole,78-89	DrugDDI.d249.s4.e1
on,90-92
warfarin,93-101	DrugDDI.d249.s4.e2
pharmacokinetics,102-118
or,119-121
anticoagulant,122-135
activity.,136-145

At,0-2
a,3-4
median,5-11
follow-up,12-21
of,22-24
33,25-27
months,,28-35
the,36-39
combination,40-51
of,52-54
ARIMIDEX,55-63	DrugDDI.d249.s5.e0
and,64-67
tamoxifen,68-77	DrugDDI.d249.s5.e1
did,78-81
not,82-85
demonstrate,86-97
any,98-101
efficacy,102-110
benefit,111-118
when,119-123
compared,124-132
with,133-137
tamoxifen,138-147	DrugDDI.d249.s5.e2
in,148-150
all,151-154
patients,155-163
as,164-166
well,167-171
as,172-174
in,175-177
the,178-181
hormone,182-189	DrugDDI.d249.s5.e3
receptor-positive,190-207	DrugDDI.d249.s5.e3
subpopulation.,208-222

Based,0-5
on,6-8
clinical,9-17
and,18-21
pharmacokinetic,22-37
results,38-45
from,46-50
the,51-54
ATAC,55-59
trial,,60-66
tamoxifen,67-76	DrugDDI.d249.s7.e0
should,77-83
not,84-87
be,88-90
administered,91-103
with,104-108
anastrozole,109-120	DrugDDI.d249.s7.e1
(see,121-125
CLINICAL,126-134
PHARMACOLOGY,135-147
?,148-149
Drug,150-154
Interactions,155-167
and,168-171
CLINICAL,172-180
PHARMACOLOGY,181-193
-,194-195
Clinical,196-204
Studies,205-212
-,213-214
Adjuvant,215-223
Treatment,224-233
of,234-236
Breast,237-243
Cancer,244-250
in,251-253
Postmenopausal,254-268
Women,269-274
subsections).,275-288

Co-administration,0-17
of,18-20
anastrozole,21-32	DrugDDI.d249.s8.e0
and,33-36
tamoxifen,37-46	DrugDDI.d249.s8.e1
resulted,47-55
in,56-58
a,59-60
reduction,61-70
of,71-73
anastrozole,74-85	DrugDDI.d249.s8.e2
plasma,86-92
levels,93-99
by,100-102
27%,103-106
compared,107-115
with,116-120
those,121-126
achieved,127-135
with,136-140
anastrozole,141-152	DrugDDI.d249.s8.e3
alone.,153-159

Estrogen-containing,0-19
therapies,20-29
should,30-36
not,37-40
be,41-43
used,44-48
with,49-53
ARIMIDEX,54-62	DrugDDI.d249.s9.e0
as,63-65
they,66-70
may,71-74
diminish,75-83
its,84-87
pharmacologic,88-101
action.,102-109

Drug/Laboratory,0-15	DrugDDI.d249.s10.e0
Test,16-20
Interactions,21-33
No,34-36
clinically,37-47
significant,48-59
changes,60-67
in,68-70
the,71-74
results,75-82
of,83-85
clinical,86-94
laboratory,95-105
tests,106-111
have,112-116
been,117-121
observed,122-130

No,0-2
clinically,3-13
relevant,14-22
drug-drug,23-32
interactions,33-45
have,46-50
been,51-55
observed,56-64
with,65-69
drugs,70-75	DrugDDI.d545.s0.e0
likely,76-82
to,83-85
be,86-88
co-administered,89-104
with,105-109
anidulafungin.,110-124	DrugDDI.d545.s0.e1

Caution,0-7
should,8-14
be,15-17
observed,18-26
when,27-31
anileridine,32-43	DrugDDI.d130.s0.e0
is,44-46
coadministered,47-61
with,62-66
other,67-72
opioids,,73-81
sedatives,,82-92
phenothiazines,,93-108
or,109-111
anesthetics,,112-124
as,125-127
these,128-133
agents,134-140
may,141-144
increase,145-153
respiratory,154-165
and,166-169
circulatory,170-181
depression.,182-193

Addition,0-8
or,9-11
deletion,12-20
of,21-23
any,24-27
drug,28-32	DrugDDI.d98.s0.e0
from,33-37
the,38-41
therapeutic,42-53
regimen,54-61
of,62-64
patients,65-73
receiving,74-83
oral,84-88	DrugDDI.d98.s0.e1
anticoagulants,89-103	DrugDDI.d98.s0.e1
may,104-107
affect,108-114
patient,115-122
response,123-131
to,132-134
the,135-138
anticoagulant.,139-153	DrugDDI.d98.s0.e2

Frequent,0-8
determination,9-22
of,23-25
prothrombin,26-37
time,38-42
and,43-46
close,47-52
monitoring,53-63
of,64-66
the,67-70
patient,71-78
is,79-81
essential,82-91
to,92-94
ascertain,95-104
when,105-109
adjustment,110-120
of,121-123
dosage,124-130
of,131-133
anticoagulant,134-147	DrugDDI.d98.s1.e0
may,148-151
be,152-154
needed.,155-162

Because,0-7
of,8-10
the,11-14
variability,15-26
of,27-29
individual,30-40
patient,41-48
response,,49-58
multiple,59-67
interacting,68-79
mechanisms,80-90
with,91-95
some,96-100
drugs,,101-107
the,108-111
dependency,112-122
of,123-125
the,126-129
extent,130-136
of,137-139
the,140-143
interaction,144-155
on,156-158
the,159-162
dosage,163-169
and,170-173
duration,174-182
of,183-185
therapy,,186-194
and,195-198
the,199-202
possible,203-211
administration,212-226
of,227-229
several,230-237
interacting,238-249
drugs,250-255	DrugDDI.d98.s2.e1
simultaneously,,256-271
it,272-274
is,275-277
difficult,278-287
to,288-290
predict,291-298
the,299-302
direction,303-312
and,313-316
degree,317-323
of,324-326
the,327-330
ultimate,331-339
effect,340-346
of,347-349
concomitant,350-361
medications,362-373	DrugDDI.d98.s2.e2
on,374-376
anticoagulant,377-390	DrugDDI.d98.s2.e3
response.,391-400

For,0-3
example,,4-12
since,13-18
cholestyramine,19-33	DrugDDI.d98.s3.e0
may,34-37
reduce,38-44
the,45-48
gastrointestinal,49-65
absorption,66-76
of,77-79
both,80-84
the,85-88
oral,89-93	DrugDDI.d98.s3.e1
anticoagulants,94-108	DrugDDI.d98.s3.e1
and,109-112
vitamin,113-120	DrugDDI.d98.s3.e2
K,,121-123	DrugDDI.d98.s3.e2
the,124-127
net,128-131	DrugDDI.d98.s3.e3
effects,132-139
are,140-143
unpredictable.,144-158

Chloral,0-7	DrugDDI.d98.s4.e0
hydrate,8-15	DrugDDI.d98.s4.e0
may,16-19
cause,20-25
an,26-28
increased,29-38
prothrombin,39-50	DrugDDI.d98.s4.e1
response,51-59
by,60-62
displacing,63-73
the,74-77
anticoagulant,78-91	DrugDDI.d98.s4.e2
from,92-96
protein,97-104	DrugDDI.d98.s4.e3
binding,105-112
sites,113-118
or,119-121
a,122-123
diminished,124-134
prothrombin,135-146	DrugDDI.d98.s4.e4
response,147-155
through,156-163
increased,164-173
metabolism,174-184
of,185-187
the,188-191
unbound,192-199
drug,200-204	DrugDDI.d98.s4.e5
by,205-207
hepatic,208-215
enzyme,216-222
induction,,223-233
thus,234-238
leading,239-246
to,247-249
inter-patient,250-263
variation,264-273
in,274-276
ultimate,277-285
prothrombin,286-297	DrugDDI.d98.s4.e6
effect.,298-305

An,0-2
interacting,3-14
drug,15-19	DrugDDI.d98.s5.e0
which,20-25
leads,26-31
to,32-34
a,35-36
decrease,37-45
in,46-48
prothrombin,49-60
time,61-65
necessitating,66-79
an,80-82
increased,83-92
dose,93-97
of,98-100
oral,101-105	DrugDDI.d98.s5.e1
anticoagulant,106-119	DrugDDI.d98.s5.e1
to,120-122
maintain,123-131
an,132-134
adequate,135-143
degree,144-150
of,151-153
anticoagulation,154-169
may,,170-174
if,175-177
abruptly,178-186
discontinued,,187-200
increase,201-209
the,210-213
risk,214-218
of,219-221
subsequent,222-232
bleeding.,233-242

Drugs,0-5	DrugDDI.d98.s6.e0
that,6-10
have,11-15
been,16-20
reported,21-29
to,30-32
diminish,33-41
oral,42-46	DrugDDI.d98.s6.e1
anticoagulant,47-60	DrugDDI.d98.s6.e1
response,,61-70
ie,,71-74
decreased,75-84
prothrom-bin,85-97
time,98-102
response,,103-112
in,113-115
man,116-119
significantly,120-133
include:,134-142
adrenocortical,143-157
steroids;,158-167

alcohol*;,0-9	DrugDDI.d98.s7.e0

antacids;,0-9	DrugDDI.d98.s8.e0

antihistamines;,0-15	DrugDDI.d98.s9.e0

barbiturates;,0-13	DrugDDI.d98.s10.e0

carbamazepine;,0-14	DrugDDI.d98.s11.e0

chloral,0-7	DrugDDI.d98.s12.e0
hydrate*;,8-17	DrugDDI.d98.s12.e0

chlordiazepoxide;,0-17	DrugDDI.d98.s13.e0

cholestyramine;,0-15	DrugDDI.d98.s14.e0

diet,0-4
high,5-9
in,10-12
vitamin,13-20	DrugDDI.d98.s15.e0
K;,21-23	DrugDDI.d98.s15.e0

diuretics*;,0-11	DrugDDI.d98.s16.e0

ethchlorvynol;,0-14	DrugDDI.d98.s17.e0

glu-tethimide;,0-14	DrugDDI.d98.s18.e0

griseofulvin;,0-13	DrugDDI.d98.s19.e0

haloperidol;,0-12	DrugDDI.d98.s20.e0

meprobamate;,0-12	DrugDDI.d98.s21.e0

oral,0-4	DrugDDI.d98.s22.e0
contraceptives;,5-20	DrugDDI.d98.s22.e0

paraldehyde;,0-12	DrugDDI.d98.s23.e0

primidone;,0-10	DrugDDI.d98.s24.e0

ranitidine*;,0-12	DrugDDI.d98.s25.e0

rifampin;,0-9	DrugDDI.d98.s26.e0

vitamin,0-7	DrugDDI.d98.s28.e0
C;,8-10	DrugDDI.d98.s28.e0

warfarin,0-8	DrugDDI.d98.s29.e0
sodium,9-15	DrugDDI.d98.s29.e0
under-dosage.,16-29

Drugs,0-5	DrugDDI.d98.s30.e0
that,6-10
reportedly,11-21
may,22-25
increase,26-34
oral,35-39	DrugDDI.d98.s30.e1
anticoagulant,40-53	DrugDDI.d98.s30.e1
response,,54-63
ie,,64-67
increased,68-77
prothrombin,78-89	DrugDDI.d98.s30.e2
response,,90-99
in,100-102
man,103-106
include:alcohol*;,107-124

allopurinol;,0-12	DrugDDI.d98.s31.e0

aminosalicylic,0-14	DrugDDI.d98.s32.e0
acid;,15-20	DrugDDI.d98.s32.e0

amiodarone;,0-11	DrugDDI.d98.s33.e0

anabolic,0-8	DrugDDI.d98.s34.e0
steroids;,9-18	DrugDDI.d98.s34.e0

antibiotics;,0-12	DrugDDI.d98.s35.e0

bromelains;,0-11	DrugDDI.d98.s36.e0

chloral,0-7	DrugDDI.d98.s37.e0
hydrate*;,8-17	DrugDDI.d98.s37.e0

chlorpro-pamide;,0-16	DrugDDI.d98.s38.e0

chymotrypsin;,0-13	DrugDDI.d98.s39.e0

cimetidine;,0-11	DrugDDI.d98.s40.e0

cinchophen;,0-11	DrugDDI.d98.s41.e0

clofibrate;,0-11	DrugDDI.d98.s42.e0

dextran;,0-8	DrugDDI.d98.s43.e0

dextrothyroxine;,0-16	DrugDDI.d98.s44.e0

diazoxide;,0-10	DrugDDI.d98.s45.e0

diflunisal;,0-11	DrugDDI.d98.s47.e0

diuretics*;,0-11	DrugDDI.d98.s48.e0

disulfiram;,0-11	DrugDDI.d98.s49.e0

drugs,0-5	DrugDDI.d98.s50.e0
affecting,6-15
blood,16-21
elements;,22-31

ethacrynic,0-10	DrugDDI.d98.s51.e0
acid;,11-16	DrugDDI.d98.s51.e0

fenoprofen;,0-11	DrugDDI.d98.s52.e0

glucagon;,0-9	DrugDDI.d98.s53.e0

hepatotoxic,0-11
drugs;,12-18	DrugDDI.d98.s54.e0

ibuprofen;,0-10	DrugDDI.d98.s55.e0

indomethacin;,0-13	DrugDDI.d98.s56.e0

influenza,0-9	DrugDDI.d98.s57.e0
virus,10-15	DrugDDI.d98.s57.e0
vaccine;,16-24	DrugDDI.d98.s57.e0

inhalation,0-10
anesthetics;,11-23	DrugDDI.d98.s58.e0

mefenamic,0-9	DrugDDI.d98.s59.e0
acid;,10-15	DrugDDI.d98.s59.e0

methyldopa;,0-11	DrugDDI.d98.s60.e0

methylphenidate;,0-16	DrugDDI.d98.s61.e0

metronidazole;,0-14	DrugDDI.d98.s62.e0

miconazole;,0-11	DrugDDI.d98.s63.e0

monoamine,0-9	DrugDDI.d98.s64.e0
oxidase,10-17	DrugDDI.d98.s64.e0
inhibitors;,18-29	DrugDDI.d98.s64.e0

nalidixic,0-9	DrugDDI.d98.s65.e0
acid;,10-15	DrugDDI.d98.s65.e0

naproxen;,0-9	DrugDDI.d98.s66.e0

oxolinic,0-8	DrugDDI.d98.s67.e0
acid;,9-14	DrugDDI.d98.s67.e0

oxyphenbutazone;,0-16	DrugDDI.d98.s68.e0

phenylbutazone;,0-15	DrugDDI.d98.s70.e0

phenyramidol;,0-13	DrugDDI.d98.s71.e0

prolonged,0-9
narcotics;,10-20	DrugDDI.d98.s74.e0

quinidine;,0-10	DrugDDI.d98.s76.e0

quinine;,0-8	DrugDDI.d98.s77.e0

ranitidine*;,0-12	DrugDDI.d98.s78.e0

sali-cylates;sulfinpyrazone;,0-28

sulfonamides,,0-13
long,14-18
acting;,19-26

sulindac;,0-9	DrugDDI.d98.s81.e0

thyroid,0-7	DrugDDI.d98.s82.e0
drugs;,8-14	DrugDDI.d98.s82.e0

tolbutamide;,0-12	DrugDDI.d98.s83.e0

triclofos,0-9	DrugDDI.d98.s84.e0
sodium;,10-17	DrugDDI.d98.s84.e0

trimethoprim/sulfamethoxazole;,0-30	DrugDDI.d98.s85.e0

warfarin,0-8
sodium,9-15	DrugDDI.d98.s87.e0
overdosage.,16-27

Oral,0-4	DrugDDI.d98.s88.e0
anticoagulants,5-19	DrugDDI.d98.s88.e0
may,20-23
potentiate,24-34
the,35-38
hypoglycemic,39-51	DrugDDI.d98.s88.e1
action,52-58	DrugDDI.d98.s88.e1
of,59-61
hypoglycemic,62-74	DrugDDI.d98.s88.e2
agents,,75-82	DrugDDI.d98.s88.e2
eg,,83-86
tolbut-amide,87-99
and,100-103
chlorpropamide,,104-119
by,120-122
inhibiting,123-133
their,134-139
metabolism,140-150
in,151-153
the,154-157
liver.,158-164	DrugDDI.d98.s88.e4

Because,0-7
oral,8-12	DrugDDI.d98.s89.e0
anticoagulants,13-27	DrugDDI.d98.s89.e0
may,28-31
interfere,32-41
with,42-46
the,47-50
hepatic,51-58
metabolism,59-69
of,70-72
phenytoin,,73-83
toxic,84-89
levels,90-96
of,97-99
the,100-103
anticonvulsant,104-118	DrugDDI.d98.s89.e2
may,119-122
occur,123-128
when,129-133
an,134-136
oral,137-141	DrugDDI.d98.s89.e3
anticoagulant,142-155	DrugDDI.d98.s89.e3
and,156-159
pheny-toin,160-170
are,171-174
administered,175-187
concurrently.,188-201

Drugs,0-5	DrugDDI.d98.s90.e0
that,6-10
reduce,11-17
the,18-21
number,22-28
of,29-31
blood,32-37
platelets,38-47
by,48-50
causing,51-58
bone,59-63
marrow,64-70
depression,71-81
(such,82-87
as,88-90
antineoplastic,91-105	DrugDDI.d98.s90.e1
agents),106-113	DrugDDI.d98.s90.e1
or,114-116
drugs,117-122	DrugDDI.d98.s90.e2
which,123-128
inhibit,129-136
platelet,137-145
function,146-154
(eg,,155-159
aspirin,160-167	DrugDDI.d98.s90.e3
and,168-171
other,172-177
non-steroidal,178-191	DrugDDI.d98.s90.e4
anti-inflammatory,192-209	DrugDDI.d98.s90.e4
drugs,,210-216	DrugDDI.d98.s90.e4
dipyridamole,,217-230
hydrochloroquine,,231-248
clofibrate,,249-260
dextran),261-269	DrugDDI.d98.s90.e7
may,270-273
increase,274-282
the,283-286
bleeding,287-295
tendency,296-304
produced,305-313
by,314-316
anticoagulants,317-331	DrugDDI.d98.s90.e8
without,332-339
altering,340-348
prothrombin,349-360
time,361-365
determinations.,366-381

The,0-3
beneficial,4-14
effects,15-22
on,23-25
arterial,26-34
thrombus,35-43
formation,44-53
from,54-58
combined,59-67
therapy,68-75
with,76-80
antiplatelet,81-93
and,94-97
anticoagulant,98-111	DrugDDI.d98.s91.e0
medication,112-122
must,123-127
be,128-130
weighed,131-138
against,139-146
an,147-149
increased,150-159
risk,160-164
of,165-167
inducing,168-176
hemorrhage.,177-188

Drug/Laboratory,0-15	DrugDDI.d98.s93.e0
Test,16-20
Interferences:,21-35
Dicu-marol,36-46
and,47-50
indanedione,51-62	DrugDDI.d98.s93.e1
anticoagulants,,63-78	DrugDDI.d98.s93.e1
including,79-88
anisindione,,89-101
or,102-104
their,105-110
metabolites,111-122	DrugDDI.d98.s93.e3
may,123-126
color,127-132
alkaline,133-141
urine,142-147
red-orange,,148-159
which,160-165
may,166-169
interfere,170-179
with,180-184
spectrophotometrically,185-207
determined,208-218
urinary,219-226
laboratory,227-237
tests.,238-244

5HT3,0-4
Antagonists,5-16
Based,17-22
on,23-25
reports,26-33
of,34-36
profound,37-45
hypotension,46-57
and,58-61
loss,62-66
of,67-69
consciousness,70-83
when,84-88
apomorphine,89-100	DrugDDI.d501.s0.e0
was,101-104
administered,105-117
with,118-122
ondansetron,,123-135
the,136-139
concomitant,140-151
use,152-155
of,156-158
apomorphine,159-170	DrugDDI.d501.s0.e2
with,171-175
drugs,176-181	DrugDDI.d501.s0.e3
of,182-184
the,185-188
5HT3,189-193
antagonist,194-204
class,205-210
(including,,211-222
for,223-226
example,,227-235
ondansetron,,236-248
granisetron,,249-261
dolasetron,,262-273
palonosetron,,274-287
and,288-291
alosetron),292-302	DrugDDI.d501.s0.e8
is,303-305
contraindicated,306-321
.,322-323

Antihypertensive,0-16	DrugDDI.d501.s1.e0
Medications,17-28
and,29-32
Vasodilators,33-45	DrugDDI.d501.s1.e1
The,46-49
following,50-59
adverse,60-67
events,68-74
were,75-79
experienced,80-91
more,92-96
commonly,97-105
in,106-108
patients,109-117
receiving,118-127
concomitant,128-139
antihypertensive,140-156	DrugDDI.d501.s1.e2
medications,157-168
or,169-171
vasodilators,172-184	DrugDDI.d501.s1.e3
(n,185-187
=,188-189
94),190-193
compared,194-202
to,203-205
patients,206-214
not,215-218
receiving,219-228
these,229-234
concomitant,235-246
drugs,247-252	DrugDDI.d501.s1.e4
(n,253-255
=,256-257
456):,258-263
hypotension,264-275
10%,276-279
vs,280-282
4%,,283-286
myocardial,287-297
infarction,298-308
3%,309-311
vs,312-314
1%,,315-318
serious,319-326
pneumonia,327-336
5%,337-339
vs,340-342
3%,,343-346
serious,347-354
falls,355-360
9%,361-363
vs,364-366
3%,,367-370
and,371-374
bone,375-379
and,380-383
joint,384-389
injuries,390-398
6%,399-401
vs,402-404
2%.,405-408

Dopamine,0-8	DrugDDI.d501.s3.e0
Antagonists,9-20	DrugDDI.d501.s3.e0
Since,21-26
apomorphine,27-38	DrugDDI.d501.s3.e1
is,39-41
a,42-43
dopamine,44-52	DrugDDI.d501.s3.e2
agonist,,53-61	DrugDDI.d501.s3.e2
it,62-64
is,65-67
possible,68-76
that,77-81
dopamine,82-90	DrugDDI.d501.s3.e3
antagonists,,91-103	DrugDDI.d501.s3.e3
such,104-108
as,109-111
the,112-115
neuroleptics,116-128	DrugDDI.d501.s3.e4
(phenoth-iazines,,129-146
butyrophenones,,147-162
thioxanthenes),163-177	DrugDDI.d501.s3.e6
or,178-180
metoclopramide,,181-196
may,197-200
diminish,201-209
the,210-213
effectiveness,214-227
of,228-230
APOKYN.,231-238	DrugDDI.d501.s3.e8

Patients,0-8
with,9-13
major,14-19
psychotic,20-29
disorders,,30-40
treated,41-48
with,49-53
neuroleptics,,54-67
should,68-74
be,75-77
treated,78-85
with,86-90
dopamine,91-99	DrugDDI.d501.s4.e1
agonists,100-108	DrugDDI.d501.s4.e1
only,109-113
if,114-116
the,117-120
potential,121-130
benefits,131-139
outweigh,140-148
the,149-152
risks.,153-159

Drugs,0-5	DrugDDI.d501.s5.e0
Prolonging,6-16
the,17-20
QT/QTc,21-27
Interval,28-36
Caution,37-44
should,45-51
be,52-54
exercised,55-64
when,65-69
prescribing,70-81
apomorphine,82-93	DrugDDI.d501.s5.e1
concomitantly,94-107
with,108-112
drugs,113-118	DrugDDI.d501.s5.e2
that,119-123
prolong,124-131
the,132-135
QT/QTc,136-142
interval.,143-152

Drug/Laboratory,0-15	DrugDDI.d501.s6.e0
Test,16-20
Interactions,21-33
There,34-39
are,40-43
no,44-46
known,47-52
interactions,53-65
between,66-73
APOKYN,74-80	DrugDDI.d501.s6.e1
and,81-84
laboratory,85-95
tests.,96-102

Apraclonidine,0-13	DrugDDI.d304.s0.e0
should,14-20
not,21-24
be,25-27
used,28-32
in,33-35
patients,36-44
receiving,45-54
MAO,55-58	DrugDDI.d304.s0.e1
inhibitors..,59-71	DrugDDI.d304.s0.e1

Although,0-8
no,9-11
specific,12-20
drug,21-25
interactions,26-38
with,39-43
topical,44-51
glaucoma,52-60
drugs,61-66	DrugDDI.d304.s1.e0
or,67-69
systemic,70-78
medications,79-90	DrugDDI.d304.s1.e1
were,91-95
identified,96-106
in,107-109
clinical,110-118
studies,119-126
of,127-129
IOPIDINE?,130-139
0.5%,140-144
Ophthalmic,145-155
Solution,,156-165
the,166-169
possibility,170-181
of,182-184
an,185-187
additive,188-196
or,197-199
potentiating,200-212
effect,213-219
with,220-224
CNS,225-228	DrugDDI.d304.s1.e2
depressants,229-240	DrugDDI.d304.s1.e2
(alcohol,,241-250
barbiturates,,251-264
opiates,,265-273
sedatives,,274-284
anesthetics),285-297	DrugDDI.d304.s1.e7
should,298-304
be,305-307
considered.,308-319

Tricyclic,0-9	DrugDDI.d304.s2.e0
antidepressants,10-25	DrugDDI.d304.s2.e0
have,26-30
been,31-35
reported,36-44
to,45-47
blunt,48-53
the,54-57
hypotensive,58-69
effect,70-76
of,77-79
systemic,80-88
clonidine.,89-99	DrugDDI.d304.s2.e1

It,0-2
is,3-5
not,6-9
known,10-15
whether,16-23
the,24-27
concurrent,28-38
use,39-42
of,43-45
these,46-51
agents,52-58
with,59-63
apraclonidine,64-77	DrugDDI.d304.s3.e0
can,78-81
lead,82-86
to,87-89
a,90-91
reduction,92-101
in,102-104
IOP,105-108
lowering,109-117
effect.,118-125

No,0-2
data,3-7
on,8-10
the,11-14
level,15-20
of,21-23
circulating,24-35
catecholamines,36-50
after,51-56
apraclonidine,57-70	DrugDDI.d304.s4.e0
withdrawal,71-81
are,82-85
available.,86-96

Caution,,0-8
however,,9-17
is,18-20
advised,21-28
in,29-31
patients,32-40
taking,41-47
tricyclic,48-57	DrugDDI.d304.s5.e0
antidepressants,58-73	DrugDDI.d304.s5.e0
which,74-79
can,80-83
affect,84-90
the,91-94
metabolism,95-105
and,106-109
uptake,110-116
of,117-119
circulating,120-131
amines.,132-139

An,0-2
additive,3-11
hypotensive,12-23
effect,24-30
has,31-34
been,35-39
reported,40-48
with,49-53
the,54-57
combination,58-69
of,70-72
systemic,73-81
clonidine,82-91	DrugDDI.d304.s6.e0
and,92-95
neuroleptic,96-107
therapy.,108-116

Systemic,0-8
clonidine,9-18	DrugDDI.d304.s7.e0
may,19-22
inhibit,23-30
the,31-34
production,35-45
of,46-48
catecholamines,49-63
in,64-66
response,67-75
to,76-78
insulin-induced,79-94
hypoglycemia,95-107
and,108-111
mask,112-116
the,117-120
signs,121-126
and,127-130
symptoms,131-139
of,140-142
hypoglycemia.,143-156

Since,0-5
apraclonidine,6-19	DrugDDI.d304.s8.e0
may,20-23
reduce,24-30
pulse,31-36
and,37-40
blood,41-46
pressure,,47-56
caution,57-64
in,65-67
using,68-73
drugs,74-79	DrugDDI.d304.s8.e1
such,80-84
as,85-87
beta-blockers,88-101	DrugDDI.d304.s8.e2
(ophthalmic,102-113
and,114-117
systemic),,118-128
antihypertensives,,129-147
and,148-151
cardiac,152-159	DrugDDI.d304.s8.e4
glycosides,160-170	DrugDDI.d304.s8.e4
is,171-173
advised.,174-182

Patients,0-8
using,9-14
cardiovascular,15-29	DrugDDI.d304.s9.e0
drugs,30-35	DrugDDI.d304.s9.e0
concurrently,36-48
with,49-53
IOPIDINE,54-62	DrugDDI.d304.s9.e1
0.5%,63-67	DrugDDI.d304.s9.e1
Ophthalmic,68-78
Solution,79-87
should,88-94
have,95-99
pulse,100-105
and,106-109
blood,110-115
pressures,116-125
frequently,126-136
monitored.,137-147

Caution,0-7
should,8-14
be,15-17
exercised,18-27
with,28-32
simultaneous,33-45
use,46-49
of,50-52
clonidine,53-62	DrugDDI.d304.s10.e0
and,63-66
other,67-72
similar,73-80
pharmacologic,81-94
agents,95-101

Aprepitant,0-10	DrugDDI.d422.s0.e0
is,11-13
a,14-15
substrate,,16-26
a,27-28
moderate,29-37
inhibitor,,38-48
and,49-52
an,53-55
inducer,56-63
of,64-66
CYP3A4.,67-74	DrugDDI.d422.s0.e1

Aprepitant,0-10	DrugDDI.d422.s1.e0
is,11-13
also,14-18
an,19-21
inducer,22-29
of,30-32
CYP2C9.,33-40	DrugDDI.d422.s1.e1

Effect,0-6
of,7-9
aprepitant,10-20	DrugDDI.d422.s2.e0
on,21-23
the,24-27
pharmacokinetics,28-44
of,45-47
other,48-53
agents,54-60

As,0-2
a,3-4
moderate,5-13
inhibitor,14-23
of,24-26
CYP3A4,,27-34
aprepitant,35-45	DrugDDI.d422.s3.e1
can,46-49
increase,50-58
plasma,59-65
concentrations,66-80
of,81-83
coadministered,84-98
medicinal,99-108	DrugDDI.d422.s3.e2
products,109-117	DrugDDI.d422.s3.e2
that,118-122
are,123-126
metabolized,127-138
through,139-146
CYP3A4.,147-154	DrugDDI.d422.s3.e3

Aprepitant,0-10	DrugDDI.d422.s4.e0
has,11-14
been,15-19
shown,20-25
to,26-28
induce,29-35
the,36-39
metabolism,40-50
of,51-53
S(-),54-58
warfarin,59-67	DrugDDI.d422.s4.e1
and,68-71
tolbutamide,,72-84
which,85-90
are,91-94
metabolized,95-106
through,107-114
CYP2C9.,115-122	DrugDDI.d422.s4.e3

Coadministration,0-16
of,17-19
Aprepitant,20-30	DrugDDI.d422.s5.e0
with,31-35
these,36-41
drugs,42-47	DrugDDI.d422.s5.e1
or,48-50
other,51-56
drugs,57-62	DrugDDI.d422.s5.e2
that,63-67
are,68-71
known,72-77
to,78-80
be,81-83
metabolized,84-95
by,96-98
CYP2C9,,99-106
such,107-111
as,112-114
phenytoin,,115-125
may,126-129
result,130-136
in,137-139
lower,140-145
plasma,146-152
concentrations,153-167
of,168-170
these,171-176
drugs.,177-183	DrugDDI.d422.s5.e5

Aprepitant,0-10	DrugDDI.d422.s6.e0
is,11-13
unlikely,14-22
to,23-25
interact,26-34
with,35-39
drugs,40-45	DrugDDI.d422.s6.e1
that,46-50
are,51-54
substrates,55-65
for,66-69
the,70-73
P-glycoprotein,74-88
transporter,,89-101
as,102-104
demonstrated,105-117
by,118-120
the,121-124
lack,125-129
of,130-132
interaction,133-144
of,145-147
Aprepitant,148-158	DrugDDI.d422.s6.e3
with,159-163
digoxin,164-171	DrugDDI.d422.s6.e4
in,172-174
a,175-176
clinical,177-185
drug,186-190
interaction,191-202
study.,203-209

5-HT3,0-5
antagonists:,6-18
In,19-21
clinical,22-30
drug,31-35
interaction,36-47
studies,,48-56
aprepitant,57-67	DrugDDI.d422.s7.e0
did,68-71
not,72-75
have,76-80
clinically,81-91
important,92-101
effects,102-109
on,110-112
the,113-116
pharmacokinetics,117-133
of,134-136
ondansetron,137-148	DrugDDI.d422.s7.e1
or,149-151
granisetron.,152-164	DrugDDI.d422.s7.e2

No,0-2
clinical,3-11
or,12-14
drug,15-19
interaction,20-31
study,32-37
was,38-41
conducted,42-51
with,52-56
dolasetron.,57-68	DrugDDI.d422.s8.e0

Corticosteroids:,0-16	DrugDDI.d422.s9.e0
Dexamethasone:,17-31	DrugDDI.d422.s9.e1
Aprepitant,,32-43
when,44-48
given,49-54
as,55-57
a,58-59
regimen,60-67
of,68-70
125mg,71-76
with,77-81
dexamethasone,82-95	DrugDDI.d422.s9.e3
coadministered,96-110
orally,111-117
as,118-120
20,121-123
mg,124-126
on,127-129
Day,130-133
1,,134-136
and,137-140
Aprepitant,141-151	DrugDDI.d422.s9.e4
when,152-156
given,157-162
as,163-165
80,166-168
mg/day,169-175
with,176-180
dexamethasone,181-194	DrugDDI.d422.s9.e5
coadministered,195-209
orally,210-216
as,217-219
8,220-221
mg,222-224
on,225-227
Days,228-232
2,233-234
through,235-242
5,,243-245
increased,246-255
the,256-259
AUC,260-263
of,264-266
dexamethasone,,267-281
a,282-283
CYP3A4,284-290	DrugDDI.d422.s9.e7
substrate,291-300
by,301-303
2.2-fold,,304-313
on,314-316
Days,317-321
1,322-323
and,324-327
5.,328-330

The,0-3
oral,4-8	DrugDDI.d422.s10.e0
dexamethasone,9-22	DrugDDI.d422.s10.e0
doses,23-28
should,29-35
be,36-38
reduced,39-46
by,47-49
approximately,50-63
50%,64-67
when,68-72
coadministered,73-87
with,88-92
Aprepitant,,93-104
to,105-107
achieve,108-115
exposures,116-125
of,126-128
dexamethasone,129-142	DrugDDI.d422.s10.e2
similar,143-150
to,151-153
those,154-159
obtained,160-168
when,169-173
it,174-176
is,177-179
given,180-185
without,186-193
Aprepitant.,194-205	DrugDDI.d422.s10.e3

The,0-3
daily,4-9
dose,10-14
of,15-17
dexamethasone,18-31	DrugDDI.d422.s11.e0
administered,32-44
in,45-47
clinical,48-56
studies,57-64
with,65-69
Aprepitant,70-80	DrugDDI.d422.s11.e1
reflects,81-89
an,90-92
approximate,93-104
50%,105-108
reduction,109-118
of,119-121
the,122-125
dose,126-130
of,131-133
dexamethasone.,134-148	DrugDDI.d422.s11.e2

Methylprednisolone,0-18	DrugDDI.d422.s12.e0

Aprepitant,,0-11
when,12-16
given,17-22
as,23-25
a,26-27
regimen,28-35
of,36-38
125,39-42
mg,43-45
on,46-48
Day,49-52
1,53-54
and,55-58
80,59-61
mg/day,62-68
on,69-71
Days,72-76
2,77-78
and,79-82
3,,83-85
increased,86-95
the,96-99
AUC,100-103
of,104-106
methylprednisolone,,107-126
a,127-128
CYP3A4,129-135	DrugDDI.d422.s13.e2
substrate,,136-146
by,147-149
1.34-fold,150-159
on,160-162
Day,163-166
1,167-168
and,169-172
by,173-175
2.5-fold,176-184
on,185-187
Day,188-191
3,,192-194
when,195-199
methylprednisolone,200-218	DrugDDI.d422.s13.e3
was,219-222
coadministered,223-237
intravenously,238-251
as,252-254
125,255-258
mg,259-261
on,262-264
Day,265-268
1,269-270
and,271-274
orally,275-281
as,282-284
40,285-287
mg,288-290
on,291-293
Days,294-298
2,299-300
and,301-304
3.,305-307

The,0-3
IV,4-6
methylprednisolone,7-25	DrugDDI.d422.s14.e0
dose,26-30
should,31-37
be,38-40
reduced,41-48
by,49-51
approximately,52-65
25%,,66-70
and,71-74
the,75-78
oral,79-83	DrugDDI.d422.s14.e1
methylprednisolone,84-102	DrugDDI.d422.s14.e1
dose,103-107
should,108-114
be,115-117
reduced,118-125
by,126-128
approximately,129-142
50%,143-146
when,147-151
coadministered,152-166
with,167-171
Aprepitant,172-182	DrugDDI.d422.s14.e2
to,183-185
achieve,186-193
exposures,194-203
of,204-206
methylprednisolone,207-225	DrugDDI.d422.s14.e3
similar,226-233
to,234-236
those,237-242
obtained,243-251
when,252-256
it,257-259
is,260-262
given,263-268
without,269-276
Aprepitant.,277-288	DrugDDI.d422.s14.e4

Warfarin:,0-9	DrugDDI.d422.s15.e0
A,10-11
single,12-18
125-mg,19-25
dose,26-30
of,31-33
Aprepitant,34-44	DrugDDI.d422.s15.e1
was,45-48
administered,49-61
on,62-64
Day,65-68
1,69-70
and,71-74
80,75-77
mg/day,78-84
on,85-87
Days,88-92
2,93-94
and,95-98
3,99-100
to,101-103
healthy,104-111
subjects,112-120
who,121-124
were,125-129
stabilized,130-140
on,141-143
chronic,144-151
warfarin,152-160	DrugDDI.d422.s15.e2
therapy.,161-169

Although,0-8
there,9-14
was,15-18
no,19-21
effect,22-28
of,29-31
Aprepitant,32-42	DrugDDI.d422.s16.e0
on,43-45
the,46-49
plasma,50-56
AUC,57-60
of,61-63
R(+),64-68
or,69-71
S(-),72-76
warfarin,77-85	DrugDDI.d422.s16.e1
determined,86-96
on,97-99
Day,100-103
3,,104-106
there,107-112
was,113-116
a,117-118
34%,119-122
decrease,123-131
in,132-134
S(-)warfarin,135-147
(a,148-150
CYP2C9,151-157	DrugDDI.d422.s16.e3
substrate),158-168
trough,169-175
concentration,176-189
accompanied,190-201
by,202-204
a,205-206
14%,207-210
decrease,211-219
in,220-222
the,223-226
prothrombin,227-238
time,239-243
(reported,244-253
as,254-256
International,257-270
Normalized,271-281
Ratio,282-287
or,288-290
INR),291-295
5,296-297
days,298-302
after,303-308
completion,309-319
of,320-322
dosing,323-329
with,330-334
Aprepitant.,335-346	DrugDDI.d422.s16.e4

In,0-2
patients,3-11
on,12-14
chronic,15-22
warfarin,23-31	DrugDDI.d422.s17.e0
therapy,,32-40
the,41-44
prothrombin,45-56
time,57-61
(INR),62-67
should,68-74
be,75-77
closely,78-85
monitored,86-95
in,96-98
the,99-102
2-week,103-109
period,,110-117
particularly,118-130
at,131-133
7,134-135
to,136-138
10,139-141
days,,142-147
following,148-157
initiation,158-168
of,169-171
the,172-175
3-day,176-181
regimen,182-189
of,190-192
Aprepitant,193-203	DrugDDI.d422.s17.e1
with,204-208
each,209-213
chemotherapy,214-226
cycle.,227-233

Tolbutamide:,0-12	DrugDDI.d422.s18.e0
Aprepitant,,13-24
when,25-29
given,30-35
as,36-38
125,39-42
mg,43-45
on,46-48
Day,49-52
1,53-54
and,55-58
80,59-61
mg/day,62-68
on,69-71
Days,72-76
2,77-78
and,79-82
3,,83-85
decreased,86-95
the,96-99
AUC,100-103
of,104-106
tolbutamide,107-118	DrugDDI.d422.s18.e2
(a,119-121
CYP2C9,122-128	DrugDDI.d422.s18.e3
substrate),129-139
by,140-142
23%,143-146
on,147-149
Day,150-153
4,,154-156
28%,157-160
on,161-163
Day,164-167
8,,168-170
and,171-174
15%,175-178
on,179-181
Day,182-185
15,,186-189
when,190-194
a,195-196
single,197-203
dose,204-208
of,209-211
tolbutamide,212-223	DrugDDI.d422.s18.e4
500,224-227	DrugDDI.d422.s18.e4
mg,228-230	DrugDDI.d422.s18.e4
was,231-234
admini,stered,235-248
orally,249-255
prior,256-261
to,262-264
the,265-268
administration,269-283
of,284-286
the,287-290
3-day,291-296
regimen,297-304
of,305-307
Aprepitant,308-318	DrugDDI.d422.s18.e5
and,319-322
on,323-325
Days,326-330
4,8,,331-335
and,336-339
15.,340-343

Oral,0-4	DrugDDI.d422.s19.e0
contraceptives:,5-20	DrugDDI.d422.s19.e0
Aprepitant,,21-32
when,33-37
given,38-43
once,44-48
daily,49-54
for,55-58
14,59-61
days,62-66
as,67-69
a,70-71
100-mg,72-78
capsule,79-86
with,87-91
an,92-94
oral,95-99	DrugDDI.d422.s19.e2
contraceptive,100-113	DrugDDI.d422.s19.e2
containing,114-124
35,125-127
mcg,128-131
of,132-134
ethinyl,135-142	DrugDDI.d422.s19.e3
estradiol,143-152	DrugDDI.d422.s19.e3
and,153-156
1,157-158
mg,159-161
of,162-164
norethindrone,,165-179
decreased,180-189
the,190-193
AUC,194-197
of,198-200
ethinyl,201-208	DrugDDI.d422.s19.e5
estradiol,209-218	DrugDDI.d422.s19.e5
by,219-221
43%,,222-226
and,227-230
decreased,231-240
the,241-244
AUC,245-248
of,249-251
norethindrone,252-265	DrugDDI.d422.s19.e6
by,266-268
8%;,269-272

therefore,,0-10
the,11-14
efficacy,15-23
of,24-26
oral,27-31	DrugDDI.d422.s20.e0
contraceptives,32-46	DrugDDI.d422.s20.e0
during,47-53
administration,54-68
of,69-71
Aprepitant,72-82	DrugDDI.d422.s20.e1
may,83-86
be,87-89
reduced.,90-98

Although,0-8
a,9-10
3-day,11-16
regimen,17-24
of,25-27
Aprepitant,28-38	DrugDDI.d422.s21.e0
given,39-44
concomitantly,45-58
with,59-63
oral,64-68	DrugDDI.d422.s21.e1
contraceptives,69-83	DrugDDI.d422.s21.e1
has,84-87
not,88-91
been,92-96
studied,,97-105
alternative,106-117
or,118-120
back-up,121-128
methods,129-136
of,137-139
contraception,140-153
should,154-160
be,161-163
used.,164-169

Midazolam:,0-10	DrugDDI.d422.s22.e0
Aprepitant,11-21	DrugDDI.d422.s22.e1
increased,22-31
the,32-35
AUC,36-39
of,40-42
midazolam,,43-53
a,54-55
sensitive,56-65
CYP3A4,66-72	DrugDDI.d422.s22.e3
substrate,,73-83
by,84-86
2.3-fold,87-95
on,96-98
Day,99-102
1,103-104
and,105-108
3.3-fold,109-117
on,118-120
Day,121-124
5,,125-127
when,128-132
a,133-134
single,135-141
oral,142-146
dose,147-151
of,152-154
midazolam,155-164	DrugDDI.d422.s22.e4
2,165-166
mg,167-169
was,170-173
coadministered,174-188
on,189-191
Day,192-195
1,196-197
and,198-201
Day,202-205
5,206-207
of,208-210
a,211-212
regimen,213-220
of,221-223
Aprepitant,224-234	DrugDDI.d422.s22.e5
125,235-238	DrugDDI.d422.s22.e5
mg,239-241	DrugDDI.d422.s22.e5
on,242-244
Day,245-248
1,249-250
and,251-254
80,255-257
mg/day,258-264
on,265-267
Days,268-272
2,273-274
through,275-282
5.,283-285

The,0-3
potential,4-13
effects,14-21
of,22-24
increased,25-34
plasma,35-41
concentrations,42-56
of,57-59
midazolam,60-69	DrugDDI.d422.s23.e0
or,70-72
other,73-78
benzodiazepines,79-94	DrugDDI.d422.s23.e1
metabolized,95-106
via,107-110
CYP3A4,111-117	DrugDDI.d422.s23.e2
(alprazolam,,118-130
triazolam),131-141	DrugDDI.d422.s23.e4
should,142-148
be,149-151
considered,152-162
when,163-167
coadministering,168-183
these,184-189
agents,190-196
with,197-201
Aprepitant.,202-213	DrugDDI.d422.s23.e5

In,0-2
another,3-10
study,11-16
with,17-21
intravenous,22-33
administration,34-48
of,49-51
midazolam,,52-62
Aprepitant,63-73	DrugDDI.d422.s24.e1
was,74-77
given,78-83
as,84-86
125,87-90
mg,91-93
on,94-96
Day,97-100
1,101-102
and,103-106
80,107-109
mg/day,110-116
on,117-119
Days,120-124
2,125-126
and,127-130
3,,131-133
and,134-137
midazolam,138-147	DrugDDI.d422.s24.e2
2,148-149
mg,150-152
IV,153-155
was,156-159
given,160-165
prior,166-171
to,172-174
the,175-178
administration,179-193
of,194-196
the,197-200
3-day,201-206
regimen,207-214
of,215-217
Aprepitant,218-228	DrugDDI.d422.s24.e3
and,229-232
on,233-235
Days,236-240
4,,241-243
8,,244-246
and,247-250
15.,251-254

Aprepitant,0-10	DrugDDI.d422.s25.e0
increased,11-20
the,21-24
AUC,25-28
of,29-31
midazolam,32-41	DrugDDI.d422.s25.e1
by,42-44
25%,45-48
on,49-51
Day,52-55
4,56-57
and,58-61
decreased,62-71
the,72-75
AUC,76-79
of,80-82
midazolam,83-92	DrugDDI.d422.s25.e2
by,93-95
19%,96-99
on,100-102
Day,103-106
8,107-108
relative,109-117
to,118-120
the,121-124
dosing,125-131
of,132-134
Aprepitant,135-145	DrugDDI.d422.s25.e3
on,146-148
Days,149-153
1,154-155
through,156-163
3.,164-166

The,0-3
AUC,4-7
of,8-10
midazolam,11-20	DrugDDI.d422.s27.e0
on,21-23
Day,24-27
15,28-30
was,31-34
similar,35-42
to,43-45
that,46-50
observed,51-59
at,60-62
baseline.,63-72

Effect,0-6
of,7-9
other,10-15
agents,16-22
on,23-25
the,26-29
pharmacokinefics,30-46
of,47-49
aprepitant,50-60	DrugDDI.d422.s28.e0

Aprepitant,0-10	DrugDDI.d422.s29.e0
is,11-13
a,14-15
substrate,16-25
for,26-29
CYP3A4;,30-37	DrugDDI.d422.s29.e1

therefore,,0-10
coadministration,11-27
of,28-30
Aprepitant,31-41	DrugDDI.d422.s30.e0
with,42-46
drugs,47-52	DrugDDI.d422.s30.e1
that,53-57
inhibit,58-65
CYP3A4,66-72	DrugDDI.d422.s30.e2
activity,73-81
may,82-85
result,86-92
in,93-95
increased,96-105
plasma,106-112
concentrations,113-127
of,128-130
aprepitant.,131-142	DrugDDI.d422.s30.e3

Consequently,,0-13
concomitant,14-25
administration,26-40
of,41-43
Aprepitant,44-54	DrugDDI.d422.s31.e0
with,55-59
strong,60-66
CYP3A4,67-73	DrugDDI.d422.s31.e1
inhibitors,74-84
(e.g.,,85-91
ketoconazole,,92-105
itraconazole,,106-119
nefazodone,,120-131
troleandomycin,,132-147
clarithromycin,,148-163
ritonavir,,164-174
nelfinavir),175-186	DrugDDI.d422.s31.e8
should,187-193
be,194-196
approached,197-207
with,208-212
caution.,213-221

Because,0-7
moderate,8-16
CYP3A4,17-23	DrugDDI.d422.s32.e0
inhibitors,24-34
(e.g.,,35-41
diltiazem),42-52	DrugDDI.d422.s32.e1
result,53-59
in,60-62
2-fold,63-69
increase,70-78
in,79-81
plasma,82-88
concentrations,89-103
of,104-106
aprepitant,,107-118
concomitant,119-130
administration,131-145
should,146-152
also,153-157
be,158-160
approached,161-171
with,172-176
caution.,177-185

Aprepitant,0-10	DrugDDI.d422.s33.e0
is,11-13
a,14-15
substrate,16-25
for,26-29
CYP3A4;,30-37	DrugDDI.d422.s33.e1

therefore,,0-10
coadministration,11-27
of,28-30
Aprepitant,31-41	DrugDDI.d422.s34.e0
with,42-46
drugs,47-52	DrugDDI.d422.s34.e1
that,53-57
strongly,58-66
induce,67-73
CYP3A4,74-80	DrugDDI.d422.s34.e2
activity,81-89
(e.g.,,90-96
rifampin,,97-106
carbamazepine,,107-121
phenytoin),122-132	DrugDDI.d422.s34.e5
may,133-136
result,137-143
in,144-146
reduced,147-154
plasma,155-161
concentrations,162-176
of,177-179
aprepitant,180-190	DrugDDI.d422.s34.e6
that,191-195
may,196-199
result,200-206
in,207-209
decreased,210-219
efficacy,220-228
of,229-231
Aprepitant.,232-243	DrugDDI.d422.s34.e7

Ketoconazole:,0-13	DrugDDI.d422.s35.e0
When,14-18
a,19-20
single,21-27
125-mg,28-34
dose,35-39
of,40-42
Aprepitant,43-53	DrugDDI.d422.s35.e1
was,54-57
administered,58-70
on,71-73
Day5,74-78
of,79-81
a,82-83

10-day,0-6
regimen,7-14
of,15-17
400,18-21
mg/day,22-28
of,29-31
ketoconazole,,32-45
a,46-47
strong,48-54
CYP3A4,55-61	DrugDDI.d422.s36.e1
inhibitor,,62-72
the,73-76
AUC,77-80
of,81-83
aprepitant,84-94	DrugDDI.d422.s36.e2
increased,95-104
approximately,105-118
5-fold,119-125
and,126-129
the,130-133
mean,134-138
terminal,139-147
half-life,148-157
of,158-160
aprepitant,161-171	DrugDDI.d422.s36.e3
increased,172-181
approximately,182-195
3-fold.,196-203

Concomitant,0-11
administration,12-26
of,27-29
Aprepitant,30-40	DrugDDI.d422.s37.e0
with,41-45
strong,46-52
CYP3A4,53-59	DrugDDI.d422.s37.e1
inhibitors,60-70
should,71-77
be,78-80
approached,81-91
cautiously.,92-103

Rifampin:,0-9	DrugDDI.d422.s38.e0
When,10-14
a,15-16
single,17-23
375-mg,24-30
dose,31-35
of,36-38
Aprepitant,39-49	DrugDDI.d422.s38.e1
was,50-53
administered,54-66
on,67-69
Day9,70-74
of,75-77
a,78-79
14-day,80-86
regimen,87-94
of,95-97
600,98-101
mg/day,102-108
of,109-111
rifampin,,112-121
a,122-123
strong,124-130
CYP3A4,131-137	DrugDDI.d422.s38.e3
inducer,,138-146
the,147-150
AUC,151-154
of,155-157
aprepitant,158-168	DrugDDI.d422.s38.e4
decreased,169-178
approximately,179-192
11-fold,193-200
and,201-204
the,205-208
mean,209-213
terminal,214-222
half-life,223-232
decreased,233-242
approximately,243-256
3-fold.,257-264

Coadministration,0-16
of,17-19
Aprepitant,20-30	DrugDDI.d422.s39.e0
with,31-35
drugs,36-41	DrugDDI.d422.s39.e1
that,42-46
induce,47-53
CYP3A4,54-60	DrugDDI.d422.s39.e2
activity,61-69
may,70-73
result,74-80
in,81-83
reduced,84-91
plasma,92-98
concentrations,99-113
and,114-117
decreased,118-127
efficacy,128-136
of,137-139
Aprepitant.,140-151	DrugDDI.d422.s39.e3

Diltiazem:,0-10	DrugDDI.d422.s41.e0
In,11-13
patients,14-22
with,23-27
mild,28-32
to,33-35
moderate,36-44
hypertension,,45-58
administration,59-73
of,74-76
aprepitant,77-87	DrugDDI.d422.s41.e1
once,88-92
daily,,93-99
as,100-102
a,103-104
tablet,105-111
formulation,112-123
comparable,124-134
to,135-137
230,138-141
mg,142-144
of,145-147
the,148-151
capsule,152-159
formulation,,160-172
with,173-177
diltiazem,178-187	DrugDDI.d422.s41.e2
120,188-191	DrugDDI.d422.s41.e2
mg,192-194	DrugDDI.d422.s41.e2
3,195-196
times,197-202
daily,203-208
for,209-212
5,213-214
days,,215-220
resulted,221-229
in,230-232
a,233-234
2-fold,235-241
increase,242-250
of,251-253
aprepitant,254-264	DrugDDI.d422.s41.e3
AUC,265-268
and,269-272
a,273-274
simultaneous,275-287
1.7-fold,288-296
increase,297-305
of,306-308
diltiazem,309-318	DrugDDI.d422.s41.e4
AUC.,319-323

These,0-5
pharmacokinetic,6-21
effects,22-29
did,30-33
not,34-37
result,38-44
in,45-47
clinically,48-58
meaningful,59-69
changes,70-77
in,78-80
ECG,,81-85
heart,86-91
rate,92-96
or,97-99
blood,100-105
pressure,106-114
beyond,115-121
those,122-127
changes,128-135
induced,136-143
by,144-146
diltiazem,147-156	DrugDDI.d422.s42.e0
alone.,157-163

Paroxetine:,0-11	DrugDDI.d422.s43.e0
Coadministration,12-28
of,29-31
once,32-36
daily,37-42
doses,43-48
of,49-51
aprepitant,,52-63
as,64-66
a,67-68
tablet,69-75
formulation,76-87
comparable,88-98
to,99-101
85,102-104
mg,105-107
or,108-110
170,111-114
mg,115-117
of,118-120
the,121-124
capsule,125-132
formulation,,133-145
with,146-150
paroxetine,151-161	DrugDDI.d422.s43.e2
20,162-164	DrugDDI.d422.s43.e2
mg,165-167	DrugDDI.d422.s43.e2
once,168-172
daily,,173-179
resulted,180-188
in,189-191
a,192-193
decrease,194-202
in,203-205
AUC,206-209
by,210-212
approximately,213-226
25%,227-230
and,231-234
Cmax,,235-240
by,241-243
approximately,244-257
20%,258-261
of,262-264
both,265-269
aprepitant,270-280	DrugDDI.d422.s43.e3
and,281-284
paroxetine.,285-296	DrugDDI.d422.s43.e4

Beta-adrenergic,0-15	DrugDDI.d297.s0.e0
blocking,16-24	DrugDDI.d297.s0.e0
agents:,25-32	DrugDDI.d297.s0.e0
concurrent,33-43
use,44-47
may,48-51
blunt,52-57
the,58-61
response,62-70
to,71-73
arbutamine.,74-85	DrugDDI.d297.s0.e1

Beta-adrenergic,0-15	DrugDDI.d297.s1.e0
blocking,16-24	DrugDDI.d297.s1.e0
agents,25-31	DrugDDI.d297.s1.e0
should,32-38
be,39-41
withdrawn,42-51
at,52-54
least,55-60
48,61-63
hours,64-69
before,70-76
conducting,77-87
an,88-90
arbutamine-mediated,91-110	DrugDDI.d297.s1.e1
stress,111-117
test.,118-123

Antiarrhythmic,0-14	DrugDDI.d297.s2.e0
agents,,15-22	DrugDDI.d297.s2.e0
class,23-28
I,29-30
(such,31-36
as,37-39
flecainide,,40-51
lidocaine,,52-62
or,63-65
quinidine):,66-77	DrugDDI.d297.s2.e3
concurrent,78-88
use,89-92
with,93-97
arbutamine,98-108	DrugDDI.d297.s2.e4
may,109-112
have,113-117
a,118-119
proarrhythmic,120-133
effect.,134-141

Antidepressants,0-15	DrugDDI.d297.s3.e0
(tricyclic),,16-28
atropine,29-37	DrugDDI.d297.s3.e1
or,38-40
other,41-46
anticholinergic,47-62	DrugDDI.d297.s3.e2
agents,,63-70	DrugDDI.d297.s3.e2
or,71-73
digitalis,74-83	DrugDDI.d297.s3.e3
glycosides:,84-95	DrugDDI.d297.s3.e3
concurrent,96-106
use,107-110
with,111-115
arbutamine,116-126	DrugDDI.d297.s3.e4
may,127-130
produce,131-138
additive,139-147
inotropic,148-157
and/or,158-164
chronotropic,165-177
effects.,178-186

Anticoagulants,0-14	DrugDDI.d399.s0.e0
including,15-24
coumarin,25-33	DrugDDI.d399.s0.e1
derivatives,,34-46
indandione,47-57
derivatives,,58-70
and,71-74
platelet,75-83	DrugDDI.d399.s0.e3
aggregation,84-95	DrugDDI.d399.s0.e3
inhibitors,96-106	DrugDDI.d399.s0.e3
such,107-111
as,112-114
nonsteroidal,115-127	DrugDDI.d399.s0.e4
anti-inflammatory,128-145	DrugDDI.d399.s0.e4
drugs,146-151	DrugDDI.d399.s0.e4
(NSAIDs),,152-161
and,162-165
aspirin,166-173	DrugDDI.d399.s0.e6
may,174-177
increase,178-186
the,187-190
risk,191-195
of,196-198
bleeding,199-207
when,208-212
administered,213-225
concomitantly,226-239
with,240-244
ardeparin.,245-255	DrugDDI.d399.s0.e7

If,0-2
additional,3-13
adrenergic,14-24	DrugDDI.d433.s0.e0
drugs,25-30	DrugDDI.d433.s0.e0
are,31-34
to,35-37
be,38-40
administered,41-53
by,54-56
any,57-60
route,,61-67
they,68-72
should,73-79
be,80-82
used,83-87
with,88-92
caution,93-100
because,101-108
the,109-112
pharmacologically,113-130
predictable,131-142
sympathetic,143-154
effects,155-162
of,163-165
BROVANA,166-173
may,174-177
be,178-180
potentiated.,181-193

When,0-4
paroxetine,,5-16
a,17-18
potent,19-25
inhibitor,26-35
of,36-38
CYP2D6,,39-46
was,47-50
co-administered,51-66
with,67-71
BROVANA,72-79
at,80-82
steady-state,,83-96
exposure,97-105
to,106-108
either,109-115
drug,116-120	DrugDDI.d433.s1.e2
was,121-124
not,125-128
altered.,129-137

Dosage,0-6
adjustments,7-18
of,19-21
BROVANA,22-29
are,30-33
not,34-37
necessary,38-47
when,48-52
the,53-56
drug,57-61	DrugDDI.d433.s2.e0
is,62-64
given,65-70
concomitantly,71-84
with,85-89
potent,90-96
CYP2D6,97-103	DrugDDI.d433.s2.e1
inhibitors.,104-115

Concomitant,0-11
treatment,12-21
with,22-26
methylxanthines,27-42	DrugDDI.d433.s3.e0
(aminophylline,,43-58
theophylline),,59-73
steroids,,74-83
or,84-86
diuretics,87-96	DrugDDI.d433.s3.e3
may,97-100
potentiate,101-111
any,112-115
hypokalemic,116-127
effect,128-134
of,135-137
adrenergic,138-148	DrugDDI.d433.s3.e4
agonists.,149-158	DrugDDI.d433.s3.e4

The,0-3
ECG,4-7
changes,8-15
and/or,16-22
hypokalemia,23-34
that,35-39
may,40-43
result,44-50
from,51-55
the,56-59
administration,60-74
of,75-77
non-potassium,78-91
sparing,92-99
diuretics,100-109
(such,110-115
as,116-118
loop,119-123
or,124-126
thiazide,127-135	DrugDDI.d433.s4.e1
diuretics),136-146	DrugDDI.d433.s4.e1
can,147-150
be,151-153
acutely,154-161
worsened,162-170
by,171-173
beta-agonists,,174-188
especially,189-199
when,200-204
the,205-208
recommended,209-220
dose,221-225
of,226-228
the,229-232
beta-agonist,233-245
is,246-248
exceeded.,249-258

Although,0-8
the,9-12
clinical,13-21
significance,22-34
of,35-37
these,38-43
effects,44-51
is,52-54
not,55-58
known,,59-65
caution,66-73
is,74-76
advised,77-84
in,85-87
the,88-91
co-administration,92-109
of,110-112
beta-agonists,113-126
with,127-131
non-potassium,132-145
sparing,146-153
diuretics.,154-164

BROVANA,,0-8
as,9-11
with,12-16
other,17-22
beta2-agonists,,23-38
should,39-45
be,46-48
administered,49-61
with,62-66
extreme,67-74
caution,75-82
to,83-85
patients,86-94
being,95-100
treated,101-108
with,109-113
monoamine,114-123	DrugDDI.d433.s6.e1
oxidase,124-131	DrugDDI.d433.s6.e1
inhibitors,,132-143	DrugDDI.d433.s6.e1
tricyclic,144-153	DrugDDI.d433.s6.e2
antidepressants,,154-170	DrugDDI.d433.s6.e2
or,171-173
drugs,174-179	DrugDDI.d433.s6.e3
known,180-185
to,186-188
prolong,189-196
the,197-200
QTc,201-204
interval,205-213
because,214-221
the,222-225
action,226-232
of,233-235
adrenergic,236-246	DrugDDI.d433.s6.e4
agonists,247-255	DrugDDI.d433.s6.e4
on,256-258
the,259-262
cardiovascular,263-277
system,278-284
may,285-288
be,289-291
potentiated,292-303
by,304-306
these,307-312
agents.,313-320

Drugs,0-5	DrugDDI.d433.s7.e0
that,6-10
are,11-14
known,15-20
to,21-23
prolong,24-31
the,32-35
QTc,36-39
interval,40-48
have,49-53
an,54-56
increased,57-66
risk,67-71
of,72-74
ventricular,75-86
arrhythmias.,87-99

The,0-3
concurrent,4-14
use,15-18
of,19-21
intravenously,22-35
or,36-38
orally,39-45
administered,46-58
methylxanthines,59-74	DrugDDI.d433.s8.e0
(e.g.,,75-81
aminophylline,,82-96
theophylline),97-110	DrugDDI.d433.s8.e2
by,111-113
patients,114-122
receiving,123-132
BROVANA,133-140
has,141-144
not,145-148
been,149-153
completely,154-164
evaluated.,165-175

In,0-2
two,3-6
combined,7-15
12-week,16-23
placebo,24-31
controlled,32-42
trials,43-49
that,50-54
included,55-63
BROVANA,64-71
doses,72-77
of,78-80
15,81-83
mcg,84-87
twice,88-93
daily,,94-100
25,101-103
mcg,104-107
twice,108-113
daily,,114-120
and,121-124
50,125-127
mcg,128-131
once,132-136
daily,,137-143
54,144-146
of,147-149
873,150-153
BROVANA,154-161
-treated,162-170
subjects,171-179
received,180-188
concomitant,189-200
theophylline,201-213	DrugDDI.d433.s9.e0
at,214-216
study,217-222
entry.,223-229

In,0-2
a,3-4
12-month,5-13
controlled,14-24
trial,25-30
that,31-35
included,36-44
a,45-46
50,47-49
mcg,50-53
once,54-58
daily,59-64
BROVANA,65-72
dose,,73-78
30,79-81
of,82-84
the,85-88
528,89-92
BROVANA,93-100
-treated,101-109
subjects,110-118
received,119-127
concomitant,128-139
theophylline,140-152	DrugDDI.d433.s10.e0
at,153-155
study,156-161
entry.,162-168

In,0-2
these,3-8
trials,,9-16
heart,17-22
rate,23-27
and,28-31
systolic,32-40
blood,41-46
pressure,47-55
were,56-60
approximately,61-74
2-3,75-78
bpm,79-82
and,83-86
6-8,87-90
mm,91-93
Hg,94-96
higher,,97-104
respectively,,105-118
in,119-121
subjects,122-130
on,131-133
concomitant,134-145
theophylline,146-158	DrugDDI.d433.s11.e0
compared,159-167
with,168-172
the,173-176
overall,177-184
population.,185-196

Beta-adrenergic,0-15	DrugDDI.d433.s12.e0
receptor,16-24	DrugDDI.d433.s12.e0
antagonists,25-36
(beta-blockers),37-52
and,53-56
BROVANA,57-64
may,65-68
interfere,69-78
with,79-83
the,84-87
effect,88-94
of,95-97
each,98-102
other,103-108
when,109-113
administered,114-126
concurrently.,127-140

Beta-blockers,0-13	DrugDDI.d433.s13.e0
not,14-17
only,18-22
block,23-28
the,29-32
therapeutic,33-44
effects,45-52
of,53-55
beta-agonists,,56-70
but,71-74
may,75-78
produce,79-86
severe,87-93
bronchospasm,94-106
in,107-109
COPD,110-114
patients.,115-124

Therefore,,0-10
patients,11-19
with,20-24
COPD,25-29
should,30-36
not,37-40
normally,41-49
be,50-52
treated,53-60
with,61-65
beta-blockers.,66-80	DrugDDI.d433.s14.e0

However,,0-8
under,9-14
certain,15-22
circumstances,,23-37
e.g.,,38-43
as,44-46
prophylaxis,47-58
after,59-64
myocardial,65-75
infarction,,76-87
there,88-93
may,94-97
be,98-100
no,101-103
acceptable,104-114
alternatives,115-127
to,128-130
the,131-134
use,135-138
of,139-141
beta-blockers,142-155	DrugDDI.d433.s15.e0
in,156-158
patients,159-167
with,168-172
COPD.,173-178

In,0-2
this,3-7
setting,,8-16
cardioselective,17-32	DrugDDI.d433.s16.e0
beta-blockers,33-46	DrugDDI.d433.s16.e0
could,47-52
be,53-55
considered,,56-67
although,68-76
they,77-81
should,82-88
be,89-91
administered,92-104
with,105-109
caution.,110-118

Heparin:,0-8	DrugDDI.d469.s0.e0
Since,9-14
heparin,15-22	DrugDDI.d469.s0.e1
is,23-25
contraindicated,26-41
in,42-44
patients,45-53
with,54-58
heparin-induced,59-74	DrugDDI.d469.s0.e2
thrombocytopenia,,75-92
the,93-96
co-administration,97-114
of,115-117
Argatroban,118-128	DrugDDI.d469.s0.e3
and,129-132
heparin,133-140	DrugDDI.d469.s0.e4
is,141-143
unlikely,144-152
for,153-156
this,157-161
indication.,162-173

However,,0-8
if,9-11
Argatroban,12-22	DrugDDI.d469.s1.e0
is,23-25
to,26-28
be,29-31
initiated,32-41
after,42-47
cessation,48-57
of,58-60
heparin,61-68
therapy,,69-77
allow,78-83
sufficient,84-94
time,95-99
for,100-103
heparins,104-112	DrugDDI.d469.s1.e1
effect,113-119
on,120-122
the,123-126
aPTT,127-131
to,132-134
decrease,135-143
prior,144-149
to,150-152
initiation,153-163
of,164-166
Argatroban,167-177	DrugDDI.d469.s1.e2
therapy.,178-186

Aspirin/Acetaminophen:,0-22	DrugDDI.d469.s2.e0
Pharmacokinetic,23-38
or,39-41
pharmacodynamic,42-57
drug-drug,58-67
interactions,68-80
have,81-85
not,86-89
been,90-94
demonstrated,95-107
between,108-115
Argatroban,116-126	DrugDDI.d469.s2.e2
and,127-130
concomitantly,131-144
administered,145-157
aspirin,158-165	DrugDDI.d469.s2.e3
(162.5,166-172
mg,173-175
orally,176-182
given,183-188
26,189-191
and,192-195
2,196-197
hours,198-203
prior,204-209
to,210-212
initiation,213-223
of,224-226
Argatroban,227-237	DrugDDI.d469.s2.e4
1,238-239
?g/kg/min.,240-250
over,251-255
4,256-257
hours),258-264
or,265-267
acetaminophen,268-281	DrugDDI.d469.s2.e5
(1000,282-287
mg,288-290
orally,291-297
given,298-303
12,,304-307
6,308-309
and,310-313
0,314-315
hours,316-321
prior,322-327
to,,328-331
and,332-335
6,336-337
and,338-341
12,342-344
hours,345-350
subsequent,351-361
to,,362-365
initiation,366-376
of,377-379
Argatroban,380-390	DrugDDI.d469.s2.e6
1.5,391-394
?g/kg/min.,395-405
over,406-410
18,411-413
hours).,414-421

Oral,0-4
anticoagulant,5-18	DrugDDI.d469.s3.e0
agents:,19-26	DrugDDI.d469.s3.e0
Pharmacokinetic,27-42
drug-drug,43-52
interactions,53-65
between,66-73
Argatroban,74-84	DrugDDI.d469.s3.e1
and,85-88
warfarin,89-97	DrugDDI.d469.s3.e2
(7.5,98-102
mg,103-105
single,106-112
oral,113-117
dose),118-123
have,124-128
not,129-132
been,133-137
demonstrated.,138-151

However,,0-8
the,9-12
concomitant,13-24
use,25-28
of,29-31
Argatroban,32-42	DrugDDI.d469.s4.e0
and,43-46
warfarin,47-55	DrugDDI.d469.s4.e1
(5-7.5,56-62
mg,63-65
initial,66-73
oral,74-78
dose,79-83
followed,84-92
by,93-95
2.5-6,96-101
mg/day,102-108
orally,109-115
for,116-119
6-10,120-124
days),125-130
results,131-138
in,139-141
prolongation,142-154
of,155-157
the,158-161
prothrombin,162-173
time,174-178
(PT),179-183
and,184-187
International,188-201
Normalized,202-212
Ratio,213-218
(INR).,219-225

Thrombolytic,0-12	DrugDDI.d469.s5.e0
agents:,13-20	DrugDDI.d469.s5.e0
The,21-24
safety,25-31
and,32-35
effectiveness,36-49
of,50-52
Argatroban,53-63	DrugDDI.d469.s5.e1
with,64-68
thrombolytic,69-81	DrugDDI.d469.s5.e2
agents,82-88	DrugDDI.d469.s5.e2
have,89-93
not,94-97
been,98-102
established.,103-115

Co-administration:,0-18
Concomitant,19-30
use,31-34
of,35-37
Argatroban,38-48	DrugDDI.d469.s6.e0
with,49-53
antiplatelet,54-66	DrugDDI.d469.s6.e1
agents,,67-74	DrugDDI.d469.s6.e1
thrombolytics,,75-89
and,90-93
other,94-99
anticoagulants,100-114	DrugDDI.d469.s6.e3
may,115-118
increase,119-127
the,128-131
risk,132-136
of,137-139
bleeding.,140-149

Drug-drug,0-9
interactions,10-22
have,23-27
not,28-31
been,32-36
observed,37-45
between,46-53
Argatroban,54-64	DrugDDI.d469.s7.e0
and,65-68
digoxin,69-76	DrugDDI.d469.s7.e1
or,77-79
erythromycin.,80-93	DrugDDI.d469.s7.e2

Drug-Drug,0-9
Interactions,10-22
Given,23-28
the,29-32
primary,33-40
CNS,41-44
effects,45-52
of,53-55
aripiprazole,,56-69
caution,70-77
should,78-84
be,85-87
used,88-92
when,93-97
ABILIFY,98-105	DrugDDI.d398.s0.e1
is,106-108
taken,109-114
in,115-117
combination,118-129
with,130-134
other,135-140
centrally,141-150	DrugDDI.d398.s0.e2
acting,151-157	DrugDDI.d398.s0.e2
drugs,158-163	DrugDDI.d398.s0.e2
and,164-167
alcohol.,168-176	DrugDDI.d398.s0.e3

1-,0-2	DrugDDI.d398.s2.e0
adrenergic,3-13	DrugDDI.d398.s2.e0
receptor,14-22	DrugDDI.d398.s2.e0
antagonism,,23-34	DrugDDI.d398.s2.e0
aripiprazole,35-47	DrugDDI.d398.s2.e1
has,48-51
the,52-55
potential,56-65
to,66-68
enhance,69-76
the,77-80
effect,81-87
of,88-90
certain,91-98
antihypertensive,99-115	DrugDDI.d398.s2.e2
agents.,116-123	DrugDDI.d398.s2.e2

Potential,0-9
for,10-13
Other,14-19
Drugs,20-25	DrugDDI.d398.s3.e0
to,26-28
Affect,29-35
ABILIFY,36-43	DrugDDI.d398.s3.e1
Aripiprazole,44-56
is,57-59
not,60-63
a,64-65
substrate,66-75
of,76-78
CYP1A1,,79-86
CYP1A2,,87-94
CYP2A6,,95-102
CYP2B6,,103-110
CYP2C8,,111-118
CYP2C9,,119-126
CYP2C19,,127-135
or,136-138
CYP2E1,139-145	DrugDDI.d398.s3.e9
enzymes.,146-154

Aripiprazole,0-12	DrugDDI.d398.s4.e0
also,13-17
does,18-22
not,23-26
undergo,27-34
direct,35-41
glucuronidation.,42-58

This,0-4
suggests,5-13
that,14-18
an,19-21
interaction,22-33
of,34-36
aripiprazole,37-49	DrugDDI.d398.s5.e0
with,50-54
inhibitors,55-65
or,66-68
inducers,69-77
of,78-80
these,81-86
enzymes,,87-95
or,96-98
other,99-104
factors,,105-113
like,114-118
smoking,,119-127
is,128-130
unlikely.,131-140

Both,0-4
CYP3A4,5-11	DrugDDI.d398.s6.e0
and,12-15
CYP2D6,16-22	DrugDDI.d398.s6.e1
are,23-26
responsible,27-38
for,39-42
aripiprazole,43-55	DrugDDI.d398.s6.e2
metabolism.,56-67

Agents,0-6
that,7-11
induce,12-18
CYP3A4,19-25	DrugDDI.d398.s7.e0
(eg,,26-30
carbamazepine),31-45	DrugDDI.d398.s7.e1
could,46-51
cause,52-57
an,58-60
increase,61-69
in,70-72
aripiprazole,73-85	DrugDDI.d398.s7.e2
clearance,86-95
and,96-99
lower,100-105
blood,106-111
levels.,112-119

Inhibitors,0-10
of,11-13
CYP3A4,14-20	DrugDDI.d398.s8.e0
(eg,,21-25
ketoconazole),26-39	DrugDDI.d398.s8.e1
or,40-42
CYP2D6,43-49	DrugDDI.d398.s8.e2
(eg,,50-54
quinidine,,55-65
fluoxetine,,66-77
or,78-80
paroxetine),81-92	DrugDDI.d398.s8.e5
can,93-96
inhibit,97-104
aripiprazole,105-117	DrugDDI.d398.s8.e6
elimination,118-129
and,130-133
cause,134-139
increased,140-149
blood,150-155
levels.,156-163

Ketoconazole:,0-13	DrugDDI.d398.s9.e0
Coadministration,14-30
of,31-33
ketoconazole,34-46	DrugDDI.d398.s9.e1
(200,47-51
mg/day,52-58
for,59-62
14,63-65
days),66-71
with,72-76
a,77-78
15-mg,79-84
single,85-91
dose,92-96
of,97-99
aripiprazole,100-112	DrugDDI.d398.s9.e2
increased,113-122
the,123-126
AUC,127-130
of,131-133
aripiprazole,134-146	DrugDDI.d398.s9.e3
and,147-150
its,151-154
active,155-161	DrugDDI.d398.s9.e4
metabolite,162-172	DrugDDI.d398.s9.e4
by,173-175
63%,176-179
and,180-183
77%,,184-188
respectively.,189-202

The,0-3
effect,4-10
of,11-13
a,14-15
higher,16-22
ketoconazole,23-35	DrugDDI.d398.s10.e0
dose,36-40
(400,41-45
mg/day),46-53
has,54-57
not,58-61
been,62-66
studied.,67-75

When,0-4
concomitant,5-16
administration,17-31
of,32-34
ketoconazole,35-47	DrugDDI.d398.s11.e0
with,48-52
aripiprazole,53-65	DrugDDI.d398.s11.e1
occurs,,66-73
aripiprazole,74-86	DrugDDI.d398.s11.e2
dose,87-91
should,92-98
be,99-101
reduced,102-109
to,110-112
one-half,113-121
of,122-124
its,125-128
normal,129-135
dose.,136-141

Other,0-5
strong,6-12
inhibitors,13-23
of,24-26
CYP3A4,27-33	DrugDDI.d398.s12.e0
(itraconazole),34-48
would,49-54
be,55-57
expected,58-66
to,67-69
have,70-74
similar,75-82
effects,83-90
and,91-94
need,95-99
similar,100-107
dose,108-112
reductions;,113-124

weaker,0-6
inhibitors,7-17
(erythromycin,,18-32
grapefruit,33-43
juice),44-50
have,51-55
not,56-59
been,60-64
studied.,65-73

When,0-4
the,5-8
CYP3A4,9-15	DrugDDI.d398.s14.e0
inhibitor,16-25
is,26-28
withdrawn,29-38
from,39-43
the,44-47
combination,48-59
therapy,,60-68
aripiprazole,69-81	DrugDDI.d398.s14.e1
dose,82-86
should,87-93
then,94-98
be,99-101
increased.,102-112

Quinidine:,0-10	DrugDDI.d398.s15.e0
Coadministration,11-27
of,28-30
a,31-32
10-mg,33-38
single,39-45
dose,46-50
of,51-53
aripiprazole,54-66	DrugDDI.d398.s15.e1
with,67-71
quinidine,72-81	DrugDDI.d398.s15.e2
(166,82-86
mg/day,87-93
for,94-97
13,98-100
days),,101-107
a,108-109
potent,110-116
inhibitor,117-126
of,127-129
CYP2D6,,130-137
increased,138-147
the,148-151
AUC,152-155
of,156-158
aripiprazole,159-171	DrugDDI.d398.s15.e4
by,172-174
112%,175-179
but,180-183
decreased,184-193
the,194-197
AUC,198-201
of,202-204
its,205-208
active,209-215	DrugDDI.d398.s15.e5
metabolite,,216-227	DrugDDI.d398.s15.e5
dehydroaripiprazole,,228-248
by,249-251
35%.,252-256

Aripiprazole,0-12	DrugDDI.d398.s16.e0
dose,13-17
should,18-24
be,25-27
reduced,28-35
to,36-38
one-half,39-47
of,48-50
its,51-54
normal,55-61
dose,62-66
when,67-71
concomitant,72-83
administration,84-98
of,99-101
quinidine,102-111	DrugDDI.d398.s16.e1
with,112-116
aripiprazole,117-129	DrugDDI.d398.s16.e2
occurs.,130-137

Other,0-5
significant,6-17
inhibitors,18-28
of,29-31
CYP2D6,,32-39
such,40-44
as,45-47
fluoxetine,48-58	DrugDDI.d398.s17.e1
or,59-61
paroxetine,,62-73
would,74-79
be,80-82
expected,83-91
to,92-94
have,95-99
similar,100-107
effects,108-115
and,,116-120
therefore,,121-131
should,132-138
be,139-141
accompanied,142-153
by,154-156
similar,157-164
dose,165-169
reductions.,170-181

When,0-4
the,5-8
CYP2D6,9-15	DrugDDI.d398.s18.e0
inhibitor,16-25
is,26-28
withdrawn,29-38
from,39-43
the,44-47
combination,48-59
therapy,,60-68
aripiprazole,69-81	DrugDDI.d398.s18.e1
dose,82-86
should,87-93
then,94-98
be,99-101
increased.,102-112

Carbamazepine:,0-14	DrugDDI.d398.s19.e0
Coadministration,15-31
of,32-34
carbamazepine,35-48	DrugDDI.d398.s19.e1
(200,49-53
mg,54-56
BID),,57-62
a,63-64
potent,65-71
CYP3A4,72-78	DrugDDI.d398.s19.e3
inducer,,79-87
with,88-92
aripiprazole,93-105	DrugDDI.d398.s19.e4
(30,106-109
mg,110-112
QD),113-116
resulted,117-125
in,126-128
an,129-131
approximate,132-143
70%,144-147
decrease,148-156
in,157-159
Cmax,160-164
and,165-168
AUC,169-172
values,173-179
of,180-182
both,183-187
aripiprazole,188-200	DrugDDI.d398.s19.e5
and,201-204
its,205-208
active,209-215	DrugDDI.d398.s19.e6
metabolite,,216-227	DrugDDI.d398.s19.e6
dehydro-aripiprazole.,228-249

When,0-4
carbamazepine,5-18	DrugDDI.d398.s20.e0
is,19-21
added,22-27
to,28-30
aripiprazole,31-43	DrugDDI.d398.s20.e1
therapy,,44-52
aripiprazole,53-65	DrugDDI.d398.s20.e2
dose,66-70
should,71-77
be,78-80
doubled.,81-89

When,0-4
carbamazepine,5-18	DrugDDI.d398.s22.e0
is,19-21
withdrawn,22-31
from,32-36
the,37-40
combination,41-52
therapy,,53-61
aripiprazole,62-74	DrugDDI.d398.s22.e1
dose,75-79
should,80-86
then,87-91
be,92-94
reduced.,95-103

No,0-2
clinically,3-13
significant,14-25
effect,26-32
of,33-35
famotidine,,36-47
valproate,,48-58
or,59-61
lithium,62-69	DrugDDI.d398.s23.e2
was,70-73
seen,74-78
on,79-81
the,82-85
pharmacokinetics,86-102
of,103-105
aripiprazole,106-118	DrugDDI.d398.s23.e3
(see,119-123
CLINICAL,124-132
PHARMACOLOGY:,133-146
Drug-,147-152
Drug,153-157
Interactions).,158-172

Potential,0-9
for,10-13
ABILIFY,14-21	DrugDDI.d398.s24.e0
to,22-24
Affect,25-31
Other,32-37
Drugs,38-43	DrugDDI.d398.s24.e1
Aripiprazole,44-56
is,57-59
unlikely,60-68
to,69-71
cause,72-77
clinically,78-88
important,89-98
pharmacokinetic,99-114
interactions,115-127
with,128-132
drugs,133-138	DrugDDI.d398.s24.e2
metabolized,139-150
by,151-153
cytochrome,154-164	DrugDDI.d398.s24.e3
P450,165-169	DrugDDI.d398.s24.e3
enzymes.,170-178

In,0-2
in,3-5
vivo,6-10
studies,,11-19
10-,20-23
to,24-26
30-mg/day,27-36
doses,37-42
of,43-45
aripiprazole,46-58	DrugDDI.d398.s25.e0
had,59-62
no,63-65
significant,66-77
effect,78-84
on,85-87
metabolism,88-98
by,99-101
CYP2D6,102-108	DrugDDI.d398.s25.e1
(dextromethorphan),,109-128
CYP2C9,129-135	DrugDDI.d398.s25.e3
(warfarin),,136-147
CYP2C19,148-155	DrugDDI.d398.s25.e5
(omeprazole,,156-168
warfarin),,169-179
and,180-183
CYP3A4,184-190	DrugDDI.d398.s25.e8
(dextromethorphan),191-209
substrates.,210-221

Additionally,,0-13
aripiprazole,14-26	DrugDDI.d398.s26.e0
and,27-30
dehydroaripiprazole,31-50
did,51-54
not,55-58
show,59-63
potential,64-73
for,74-77
altering,78-86
CYP1A2-mediated,87-102
metabolism,103-113
in,114-116
vitro.,117-123

Alcohol:,0-8	DrugDDI.d398.s27.e0
There,9-14
was,15-18
no,19-21
significant,22-33
difference,34-44
between,45-52
aripiprazole,53-65	DrugDDI.d398.s27.e1
coadministered,66-80
with,81-85
ethanol,86-93	DrugDDI.d398.s27.e2
and,94-97
placebo,98-105
coadministered,106-120
with,121-125
ethanol,126-133	DrugDDI.d398.s27.e3
on,134-136
performance,137-148
of,149-151
gross,152-157
motor,158-163
skills,164-170
or,171-173
stimulus,174-182
response,183-191
in,192-194
healthy,195-202
subjects.,203-212

As,0-2
with,3-7
most,8-12
psychoactive,13-25
medications,,26-38
patients,39-47
should,48-54
be,55-57
advised,58-65
to,66-68
avoid,69-74
alcohol,75-82	DrugDDI.d398.s28.e1
while,83-88
taking,89-95
ABILIFY,96-103	DrugDDI.d398.s28.e2

Caution,0-7
is,8-10
advised,11-18
when,19-23
TRISENOX?,24-33
is,34-36
coadministered,37-51
with,52-56
other,57-62
medications,63-74	DrugDDI.d81.s1.e0
that,75-79
can,80-83
prolong,84-91
the,92-95
QT,96-98
interval,99-107
(e.g.,108-113
certain,114-121
antiarrhythmics,122-137	DrugDDI.d81.s1.e1
or,138-140
thioridazine),141-154	DrugDDI.d81.s1.e2
or,155-157
lead,158-162
to,163-165
electrolyte,166-177
abnormalities,178-191
(such,192-197
as,198-200
diuretics,201-210	DrugDDI.d81.s1.e3
or,211-213
amphotericin,214-226	DrugDDI.d81.s1.e4
B).,227-230	DrugDDI.d81.s1.e4

Tissue,0-6
culture,7-14
and,15-18
animal,19-25
studies,26-33
indicate,34-42
that,43-47
ELSPAR,48-54	DrugDDI.d209.s0.e0
can,55-58
diminish,59-67
or,68-70
abolish,71-78
the,79-82
effect,83-89
of,90-92
methotrexate,93-105	DrugDDI.d209.s0.e1
on,106-108
malignant,109-118
cells.14,119-127
This,128-132
effect,133-139
on,140-142
methotrexate,143-155	DrugDDI.d209.s0.e2
activity,156-164
persists,165-173
as,174-176
long,177-181
as,182-184
plasma,185-191
asparagine,192-202
levels,203-209
are,210-213
suppressed.,214-225

These,0-5
results,6-13
would,14-19
seem,20-24
to,25-27
dictate,28-35
against,36-43
the,44-47
clinical,48-56
use,57-60
of,61-63
methotrexate,64-76	DrugDDI.d209.s1.e0
with,77-81
ELSPAR,,82-89
or,90-92
during,93-99
the,100-103
period,104-110
following,111-120
ELSPAR,121-127	DrugDDI.d209.s1.e2
therapy,128-135
when,136-140
plasma,141-147
asparagine,148-158
levels,159-165
are,166-169
below,170-175
normal.,176-183

Uricosuric,0-10	DrugDDI.d412.s0.e0
Agents:,11-18	DrugDDI.d412.s0.e0
Aspirin,19-26	DrugDDI.d412.s0.e1
may,27-30
decrease,31-39
the,40-43
effects,44-51
of,52-54
probenecid,,55-66
sulfinpyrazone,,67-82
and,83-86
phenylbutazone.,87-102	DrugDDI.d412.s0.e4

Alcohol:,0-8	DrugDDI.d412.s1.e0
Has,9-12
a,13-14
synergistic,15-26
effect,27-33
with,34-38
aspirin,39-46	DrugDDI.d412.s1.e1
in,47-49
causing,50-57
gastrointestinal,58-74
bleeding.,75-84

Corticosteroids:,0-16	DrugDDI.d412.s2.e0
Concomitant,17-28
administration,29-43
with,44-48
aspirin,49-56	DrugDDI.d412.s2.e1
may,57-60
increase,61-69
the,70-73
risk,74-78
of,79-81
gastrointestinal,82-98
ulceration,99-109
and,110-113
may,114-117
reduce,118-124
serum,125-130
salicylate,131-141
levels.,142-149

Pyrazolone,0-10	DrugDDI.d412.s3.e0
Derivatives,11-22
(phenylbutazone,,23-39
oxyphenbutazone,,40-56
and,57-60
possibly,61-69
dipyrone):,70-80	DrugDDI.d412.s3.e3
Concomitant,81-92
administration,93-107
with,108-112
aspirin,113-120	DrugDDI.d412.s3.e4
may,121-124
increase,125-133
the,134-137
risk,138-142
of,143-145
gastrointestinal,146-162
ulceration.,163-174

Nonsteroidal,0-12	DrugDDI.d412.s4.e0
Antiinflammatory,13-29	DrugDDI.d412.s4.e0
Agents:,30-37	DrugDDI.d412.s4.e0
Aspirin,38-45	DrugDDI.d412.s4.e1
is,46-48
contraindicated,49-64
in,65-67
patients,68-76
who,77-80
are,81-84
hypersensitive,85-99
to,100-102
nonsteroidal,103-115	DrugDDI.d412.s4.e2
anti-inflammatory,116-133	DrugDDI.d412.s4.e2
agents.,134-141	DrugDDI.d412.s4.e2

Urinary,0-7	DrugDDI.d412.s5.e0
Alkalinizers:,8-21
Decrease,22-30
aspirin,31-38	DrugDDI.d412.s5.e1
effectiveness,39-52
by,53-55
increasing,56-66
the,67-70
rate,71-75
of,76-78
salicylate,79-89	DrugDDI.d412.s5.e2
renal,90-95
excretion.,96-106

Phenobarbital:,0-14	DrugDDI.d412.s6.e0
Decreases,15-24
aspirin,25-32	DrugDDI.d412.s6.e1
effectiveness,33-46
by,47-49
enzyme,50-56
induction.,57-67

Phenytoin:,0-10	DrugDDI.d412.s7.e0
Serum,11-16	DrugDDI.d412.s7.e1
phenytoin,17-26	DrugDDI.d412.s7.e1
levels,27-33	DrugDDI.d412.s7.e1
may,34-37
be,38-40
increased,41-50
by,51-53
aspirin.,54-62	DrugDDI.d412.s7.e2

Propranolol:,0-12	DrugDDI.d412.s8.e0
May,13-16
decrease,17-25
aspirins,26-34	DrugDDI.d412.s8.e1
anti-inflammatory,35-52
action,53-59
by,60-62
competing,63-72
for,73-76
the,77-80
same,81-85
receptors.,86-96	DrugDDI.d412.s8.e2

Antacids:,0-9	DrugDDI.d412.s9.e0
Enteric,10-17
Coated,18-24	DrugDDI.d412.s9.e1
Aspirin,25-32	DrugDDI.d412.s9.e1
should,33-39
not,40-43
be,44-46
given,47-52
concurrently,53-65
with,66-70
antacids,,71-80
since,81-86
an,87-89
increase,90-98
in,99-101
the,102-105
pH,106-108
of,109-111
the,112-115
stomach,116-123
may,124-127
effect,128-134
the,135-138
enteric,139-146
coating,147-154
of,155-157
the,158-161
tablets.,162-170

Ketoconazole/Itraconazole,,0-26
Macrolides,,27-38
Including,39-48
Erythromycin,49-61	DrugDDI.d392.s0.e3

Catecholamine-depleting,0-23
drugs,24-29	DrugDDI.d205.s0.e0
(eg,,30-34
reserpine),35-45	DrugDDI.d205.s0.e1
may,46-49
have,50-54
an,55-57
additive,58-66
effect,67-73
when,74-78
given,79-84
with,85-89
beta-blocking,90-103	DrugDDI.d205.s0.e2
agents.,104-111	DrugDDI.d205.s0.e2

Patients,0-8
treated,9-16
with,17-21
TENORMIN,22-30	DrugDDI.d205.s1.e0
plus,31-35
a,36-37
catecholamine,38-51
depletor,52-60
should,61-67
therefore,68-77
be,78-80
closely,81-88
observed,89-97
for,98-101
evidence,102-110
of,111-113
hypotension,114-125
and/or,126-132
marked,133-139
bradycardia,140-151
which,152-157
may,158-161
produce,162-169
vertigo,,170-178
syncope,,179-187
or,188-190
postural,191-199
hypotension.,200-212

Calcium,0-7	DrugDDI.d205.s2.e0
channel,8-15	DrugDDI.d205.s2.e0
blockers,16-24	DrugDDI.d205.s2.e0
may,25-28
also,29-33
have,34-38
an,39-41
additive,42-50
effect,51-57
when,58-62
given,63-68
with,69-73
TENORMIN,74-82	DrugDDI.d205.s2.e1
.,83-84

Beta,0-4	DrugDDI.d205.s3.e0
blockers,5-13	DrugDDI.d205.s3.e0
may,14-17
exacerbate,18-28
the,29-32
rebound,33-40
hypertension,41-53
which,54-59
can,60-63
follow,64-70
the,71-74
withdrawal,75-85
of,86-88
clonidine.,89-99	DrugDDI.d205.s3.e1

If,0-2
the,3-6
two,7-10
drugs,11-16	DrugDDI.d205.s4.e0
are,17-20
coadministered,,21-36
the,37-40
beta,41-45	DrugDDI.d205.s4.e1
blocker,46-53	DrugDDI.d205.s4.e1
should,54-60
be,61-63
withdrawn,64-73
several,74-81
days,82-86
before,87-93
the,94-97
gradual,98-105
withdrawal,106-116
of,117-119
clonidine.,120-130	DrugDDI.d205.s4.e2

If,0-2
replacing,3-12
clonidine,13-22	DrugDDI.d205.s5.e0
by,23-25
beta-blocker,26-38	DrugDDI.d205.s5.e1
therapy,,39-47
the,48-51
introduction,52-64
of,65-67
beta,68-72	DrugDDI.d205.s5.e2
blockers,73-81	DrugDDI.d205.s5.e2
should,82-88
be,89-91
delayed,92-99
for,100-103
several,104-111
days,112-116
after,117-122
clonidine,123-132	DrugDDI.d205.s5.e3
administration,133-147
has,148-151
stopped.,152-160

Concomitant,0-11
use,12-15
of,16-18
prostaglandin,19-32	DrugDDI.d205.s6.e0
synthase,33-41	DrugDDI.d205.s6.e0
inhibiting,42-52
drugs,,53-59
eg,,60-63
indomethacin,,64-77
may,78-81
decrease,82-90
the,91-94
hypotensive,95-106
effects,107-114
of,115-117
beta,118-122	DrugDDI.d205.s6.e2
blockers.,123-132	DrugDDI.d205.s6.e2

Information,0-11
on,12-14
concurrent,15-25
usage,26-31
of,32-34
atenolol,35-43	DrugDDI.d205.s7.e0
and,44-47
aspirin,48-55	DrugDDI.d205.s7.e1
is,56-58
limited.,59-67

Data,0-4
from,5-9
several,10-17
studies,,18-26
ie,,27-30
TIMI-II,,31-39
ISIS-2,,40-47
currently,48-57
do,58-60
not,61-64
suggest,65-72
any,73-76
clinical,77-85
interaction,86-97
between,98-105
aspirin,106-113	DrugDDI.d205.s8.e0
and,114-117
beta,118-122	DrugDDI.d205.s8.e1
blockers,123-131	DrugDDI.d205.s8.e1
in,132-134
the,135-138
acute,139-144
myocardial,145-155
infarction,156-166
setting.,167-175

While,0-5
taking,6-12
beta,13-17	DrugDDI.d205.s9.e0
blockers,,18-27	DrugDDI.d205.s9.e0
patients,28-36
with,37-41
a,42-43
history,44-51
of,52-54
anaphylactic,55-67
reaction,68-76
to,77-79
a,80-81
variety,82-89
of,90-92
allergens,93-102
may,103-106
have,107-111
a,112-113
more,114-118
severe,119-125
reaction,126-134
on,135-137
repeated,138-146
challenge,,147-157
either,158-164
accidental,,165-176
diagnostic,177-187
or,188-190
therapeutic.,191-203

Such,0-4
patients,5-13
may,14-17
be,18-20
unresponsive,21-33
to,34-36
the,37-40
usual,41-46
doses,47-52
of,53-55
epinephrine,56-67	DrugDDI.d205.s10.e0
used,68-72
to,73-75
treat,76-81
the,82-85
allergic,86-94
reaction.,95-104

Drug-Drug,0-9
Interactions,10-22
Albuterol,23-32	DrugDDI.d568.s0.e0
-,33-34
STRATTERA,35-44
should,45-51
be,52-54
administered,55-67
with,68-72
caution,73-80
to,81-83
patients,84-92
being,93-98
treated,99-106
with,107-111
systemically-administered,112-137
(oral,138-143
or,144-146
intravenous),147-159
albuterol,160-169	DrugDDI.d568.s0.e1
(or,170-173
other,174-179
beta2,180-185
agonists),186-195	DrugDDI.d568.s0.e2
because,196-203
the,204-207
action,208-214
of,215-217
albuterol,218-227	DrugDDI.d568.s0.e3
on,228-230
the,231-234
cardiovascular,235-249
system,250-256
can,257-260
be,261-263
potentiated,264-275
resulting,276-285
in,286-288
increases,289-298
in,299-301
heart,302-307
rate,308-312
and,313-316
blood,317-322
pressure.,323-332

CYP2D6,0-6
inhibitors,7-17
-,18-19
Atomoxetine,20-31	DrugDDI.d568.s1.e0
is,32-34
primarily,35-44
metabolized,45-56
by,57-59
the,60-63
CYP2D6,64-70	DrugDDI.d568.s1.e1
pathway,71-78
to,79-81
4-hydroxyatomoxetine.,82-103

In,0-2
EMs,,3-7
selective,8-17
inhibitors,18-28
of,29-31
CYP2D6,32-38
increase,39-47
atomoxetine,48-59	DrugDDI.d568.s2.e0
steady-state,60-72
plasma,73-79
concentrations,80-94
to,95-97
exposures,98-107
similar,108-115
to,116-118
those,119-124
observed,125-133
in,134-136
PMs.,137-141

Dosage,0-6
adjustment,7-17
of,18-20
STRATTERA,21-30	DrugDDI.d568.s3.e0
may,31-34
be,35-37
necessary,38-47
when,48-52
coadministered,53-67
with,68-72
CYP2D6,73-79	DrugDDI.d568.s3.e1
inhibitors,,80-91
e.g.,,92-97
paroxetine,,98-109
fluoxetine,,110-121
and,122-125
quinidine.,126-136	DrugDDI.d568.s3.e4

In,0-2
EM,3-5
individuals,6-17
treated,18-25
with,26-30
paroxetine,31-41	DrugDDI.d568.s4.e0
or,42-44
fluoxetine,,45-56
the,57-60
AUC,61-64
of,65-67
atomoxetine,68-79	DrugDDI.d568.s4.e2
is,80-82
approximately,83-96
6-,97-99
to,100-102
8-fold,103-109
and,110-113
Css,max,114-121
is,122-124
about,125-130
3-,131-133
to,134-136
4-fold,137-143
greater,144-151
than,152-156
atomoxetine,157-168	DrugDDI.d568.s4.e3
alone.,169-175

In,0-2
vitro,3-8
studies,9-16
suggest,17-24
that,25-29
coadministration,30-46
of,47-49
cytochrome,50-60	DrugDDI.d568.s5.e0
P450,61-65	DrugDDI.d568.s5.e0
inhibitors,66-76
to,77-79
PMs,80-83
will,84-88
not,89-92
increase,93-101
the,102-105
plasma,106-112
concentrations,113-127
of,128-130
atomoxetine.,131-143	DrugDDI.d568.s5.e1

Pressor,0-7	DrugDDI.d568.s6.e0
agents,8-14	DrugDDI.d568.s6.e0
-,15-16
Because,17-24
of,25-27
possible,28-36
effects,37-44
on,45-47
blood,48-53
pressure,,54-63
STRATTERA,64-73	DrugDDI.d568.s6.e1
should,74-80
be,81-83
used,84-88
cautiously,89-99
with,100-104
pressor,105-112	DrugDDI.d568.s6.e2
agents.,113-120	DrugDDI.d568.s6.e2

The,0-3
risk,4-8
of,9-11
myopathy,12-20
during,21-27
treatment,28-37
with,38-42
drugs,43-48	DrugDDI.d109.s0.e0
of,49-51
this,52-56
class,57-62
is,63-65
increased,66-75
with,76-80
concurrent,81-91
administration,92-106
of,107-109
cyclosporine,,110-123
fibric,124-130
acid,131-135
derivatives,,136-148
niacin,149-155	DrugDDI.d109.s0.e3
(nicotinic,156-166
acid),,167-173
erythromycin,,174-187
azole,188-193	DrugDDI.d109.s0.e6
antifungals.,194-206	DrugDDI.d109.s0.e6

Antacid:,0-8	DrugDDI.d109.s1.e0
When,9-13
atorvastatin,14-26	DrugDDI.d109.s1.e1
and,27-30
Maalox?,31-38
TC,39-41
suspension,42-52
were,53-57
coadministered,,58-73
plasma,74-80
concentrations,81-95
of,96-98
atorvastatin,99-111	DrugDDI.d109.s1.e2
decreased,112-121
approximately,122-135
35%.,136-140

Antipyrine:,0-11	DrugDDI.d109.s3.e0
Because,12-19
atorvastatin,20-32	DrugDDI.d109.s3.e1
does,33-37
not,38-41
affect,42-48
the,49-52
pharmacokinetics,53-69
of,70-72
antipyrine,,73-84
interactions,85-97
with,98-102
other,103-108
drugs,109-114	DrugDDI.d109.s3.e3
metabolized,115-126
via,127-130
the,131-134
same,135-139
cytochrome,140-150
isozymes,151-159	DrugDDI.d109.s3.e4
are,160-163
not,164-167
expected.,168-177

Colestipol:,0-11	DrugDDI.d109.s4.e0
Plasma,12-18
concentrations,19-33
of,34-36
atorvastatin,37-49	DrugDDI.d109.s4.e1
decreased,50-59
approximately,60-73
25%,74-77
when,78-82
colestipol,83-93	DrugDDI.d109.s4.e2
and,94-97
atorvastatin,98-110	DrugDDI.d109.s4.e3
were,111-115
coadministered.,116-131

However,,0-8
LDL-C,9-14
reduction,15-24
was,25-28
greater,29-36
when,37-41
atorvastatin,42-54	DrugDDI.d109.s5.e0
and,55-58
colestipol,59-69	DrugDDI.d109.s5.e1
were,70-74
coadministered,75-89
than,90-94
when,95-99
either,100-106
drug,107-111	DrugDDI.d109.s5.e2
was,112-115
given,116-121
alone.,122-128

Cimetidine:,0-11	DrugDDI.d109.s6.e0
Atorvastatin,12-24	DrugDDI.d109.s6.e1
plasma,25-31
concentrations,32-46
and,47-50
LDL-C,51-56
reduction,57-66
were,67-71
not,72-75
altered,76-83
by,84-86
coadministration,87-103
of,104-106
cimetidine.,107-118	DrugDDI.d109.s6.e2

Digoxin:,0-8	DrugDDI.d109.s7.e0
When,9-13
multiple,14-22
doses,23-28
of,29-31
atorvastatin,32-44	DrugDDI.d109.s7.e1
and,45-48
digoxin,49-56	DrugDDI.d109.s7.e2
were,57-61
coadministered,,62-77
steady-state,78-90
plasma,91-97
digoxin,98-105	DrugDDI.d109.s7.e3
concentrations,106-120
increased,121-130
by,131-133
approximately,134-147
20%.,148-152

Patients,0-8
taking,9-15
digoxin,16-23	DrugDDI.d109.s8.e0
should,24-30
be,31-33
monitored,34-43
appropriately.,44-58

Erythromycin:,0-13	DrugDDI.d109.s9.e0
In,14-16
healthy,17-24
individuals,,25-37
plasma,38-44
concentrations,45-59
of,60-62
atorvastatin,63-75	DrugDDI.d109.s9.e1
increased,76-85
approximately,86-99
40%,100-103
with,104-108
coadministration,109-125
of,126-128
atorvastatin,129-141	DrugDDI.d109.s9.e2
and,142-145
erythromycin,,146-159
a,160-161
known,162-167
inhibitor,168-177
of,178-180
cytochrome,181-191	DrugDDI.d109.s9.e4
P450,192-196	DrugDDI.d109.s9.e4
3A4.,197-201	DrugDDI.d109.s9.e4

Oral,0-4	DrugDDI.d109.s10.e0
Contraceptives:,5-20	DrugDDI.d109.s10.e0
Coadministration,21-37
of,38-40
atorvastatin,41-53	DrugDDI.d109.s10.e1
and,54-57
an,58-60
oral,61-65	DrugDDI.d109.s10.e2
contraceptive,66-79	DrugDDI.d109.s10.e2
increased,80-89
AUC,90-93
values,94-100
for,101-104
norethindrone,105-118	DrugDDI.d109.s10.e3
and,119-122
ethinyl,123-130	DrugDDI.d109.s10.e4
estradiol,131-140	DrugDDI.d109.s10.e4
by,141-143
approximately,144-157
30%,158-161
and,162-165
20%.,166-170

These,0-5
increases,6-15
should,16-22
be,23-25
considered,26-36
when,37-41
selecting,42-51
an,52-54
oral,55-59	DrugDDI.d109.s11.e0
contraceptive,60-73	DrugDDI.d109.s11.e0
for,74-77
a,78-79
woman,80-85
taking,86-92
atorvastatin.,93-106	DrugDDI.d109.s11.e1

Warfarin:,0-9	DrugDDI.d109.s12.e0
Atorvastatin,10-22	DrugDDI.d109.s12.e1
had,23-26
no,27-29
clinically,30-40
significant,41-52
effect,53-59
on,60-62
prothrombin,63-74
time,75-79
when,80-84
administered,85-97
to,98-100
patients,101-109
receiving,110-119
chronic,120-127
warfarin,128-136
treatment.,137-147

Endocrine,0-9
Function,10-18
HMG-CoA,19-26	DrugDDI.d109.s13.e0
reductase,27-36	DrugDDI.d109.s13.e0
inhibitors,37-47	DrugDDI.d109.s13.e0
interfere,48-57
with,58-62
cholesterol,63-74	DrugDDI.d109.s13.e1
synthesis,75-84
and,85-88
theoretically,89-102
might,103-108
blunt,109-114
adrenal,115-122	DrugDDI.d109.s13.e2
and/or,123-129
gonadal,130-137
steroid,138-145
production.,146-157

Clinical,0-8
studies,9-16
have,17-21
shown,22-27
that,28-32
atorvastatin,33-45	DrugDDI.d109.s14.e0
does,46-50
not,51-54
reduce,55-61
basal,62-67
plasma,68-74
cortisol,75-83	DrugDDI.d109.s14.e1
concentration,84-97
or,98-100
impair,101-107
adrenal,108-115	DrugDDI.d109.s14.e2
reserve.,116-124

The,0-3
effects,4-11
of,12-14
HMG-CoA,15-22	DrugDDI.d109.s15.e0
reductase,23-32	DrugDDI.d109.s15.e0
inhibitors,33-43	DrugDDI.d109.s15.e0
on,44-46
male,47-51
fertility,52-61
have,62-66
not,67-70
been,71-75
studied,76-83
in,84-86
adequate,87-95
numbers,96-103
of,104-106
patients.,107-116

Caution,0-7
should,8-14
be,15-17
exercised,18-27
if,28-30
an,31-33
HMG-CoA,34-41	DrugDDI.d109.s17.e0
reductase,42-51	DrugDDI.d109.s17.e0
inhibitor,52-61	DrugDDI.d109.s17.e0
is,62-64
administered,65-77
concomitantly,78-91
with,92-96
drugs,97-102	DrugDDI.d109.s17.e1
that,103-107
may,108-111
decrease,112-120
the,121-124
levels,125-131
or,132-134
activity,135-143
of,144-146
endogenous,147-157
steroid,158-165
hormones,,166-175
such,176-180
as,181-183
ketoconazole,,184-197
spironolactone,,198-213
and,214-217
cimetidine.,218-229	DrugDDI.d109.s17.e4

The,0-3
120,4-7
mg/kg,8-13
dose,14-18
resulted,19-27
in,28-30
a,31-32
systemic,33-41
exposure,42-50
approximately,51-64
16,65-67
times,68-73
the,74-77
human,78-83	DrugDDI.d109.s20.e0
plasma,84-90	DrugDDI.d109.s20.e0
area-under-the-curve,91-111
(AUC,,112-117
0-24,118-122
hours),123-129
based,130-135
on,136-138
the,139-142
maximum,143-150
human,151-156
dose,157-161
of,162-164
80,165-167
mg/day.,168-175

A,0-1
chemically,2-12
similar,13-20
drug,21-25	DrugDDI.d109.s25.e0
in,26-28
this,29-33
class,34-39
produced,40-48
optic,49-54
nerve,55-60
degeneration,61-73
(Wallerian,74-84
degeneration,85-97
of,98-100
retinogeniculate,101-117
fibers),118-125
in,126-128
clinically,129-139
normal,140-146
dogs,147-151
in,152-154
a,155-156
dose-dependent,157-171
fashion,172-179
at,180-182
a,183-184
dose,185-189
that,190-194
produced,195-203
plasma,204-210
drug,211-215
levels,216-222
about,223-228
30,229-231
times,232-237
higher,238-244
than,245-249
the,250-253
mean,254-258
drug,259-263
level,264-269
in,270-272
humans,273-279
taking,280-286
the,287-290
highest,291-298
recommended,299-310
dose.,311-316

Atovaquone,0-10	DrugDDI.d349.s0.e0
is,11-13
highly,14-20
bound,21-26
to,27-29
plasma,30-36	DrugDDI.d349.s0.e1
protein,37-44	DrugDDI.d349.s0.e1
(99.9%).,45-53

Therefore,,0-10
caution,11-18
should,19-25
be,26-28
used,29-33
when,34-38
administering,39-52
MEPRON,53-59	DrugDDI.d349.s1.e0
concurrently,60-72
with,73-77
other,78-83
highly,84-90
plasma,91-97
protein-,98-106
bound,107-112
drugs,113-118
with,119-123
narrow,124-130
therapeutic,131-142
indices,,143-151
as,152-154
competition,155-166
for,167-170
binding,171-178
sites,179-184
may,185-188
occur.,189-195

The,0-3
extent,4-10
of,11-13
plasma,14-20	DrugDDI.d349.s2.e0
protein,21-28	DrugDDI.d349.s2.e0
binding,29-36
of,37-39
atovaquone,40-50	DrugDDI.d349.s2.e1
in,51-53
human,54-59	DrugDDI.d349.s2.e2
plasma,60-66	DrugDDI.d349.s2.e2
is,67-69
not,70-73
affected,74-82
by,83-85
the,86-89
presence,90-98
of,99-101
therapeutic,102-113
concentrations,114-128
of,129-131
phenytoin,132-141	DrugDDI.d349.s2.e3
(15,142-145
mcg/,146-150
mL),,151-155
nor,156-159
is,160-162
the,163-166
binding,167-174
of,175-177
phenytoin,178-187	DrugDDI.d349.s2.e4
affected,188-196
by,197-199
the,200-203
presence,204-212
of,213-215
atovaquone.,216-227	DrugDDI.d349.s2.e5

Rifampin:,0-9	DrugDDI.d349.s3.e0
Coadministration,10-26
of,27-29
rifampin,30-38	DrugDDI.d349.s3.e1
and,39-42
MEPRON,43-49	DrugDDI.d349.s3.e2
Suspension,50-60
results,61-68
in,69-71
a,72-73
significant,74-85
decrease,86-94
in,95-97
average,98-105
steady-,106-113
state,114-119
plasma,120-126
atovaquone,127-137	DrugDDI.d349.s3.e3
concentrations.,138-153

Alternatives,0-12
to,13-15
rifampin,16-24	DrugDDI.d349.s4.e0
should,25-31
be,32-34
considered,35-45
during,46-52
the,53-56
course,57-63
of,64-66
PCP,67-70
treatment,71-80
with,81-85
MEPRON.,86-93	DrugDDI.d349.s4.e1

Rifabutin,,0-10
another,11-18
rifamycin,,19-29
is,30-32
structurally,33-45
similar,46-53
to,54-56
rifampin,57-65	DrugDDI.d349.s5.e2
and,66-69
may,70-73
possibly,74-82
have,83-87
some,88-92
of,93-95
the,96-99
same,100-104
drug,105-109
interactions,110-122
as,123-125
rifampin.,126-135	DrugDDI.d349.s5.e3

No,0-2
interaction,3-14
trials,15-21
have,22-26
been,27-31
conducted,32-41
with,42-46
MEPRON,47-53	DrugDDI.d349.s6.e0
and,54-57
rifabutin.,58-68	DrugDDI.d349.s6.e1

Drug/,0-5	DrugDDI.d349.s7.e0
Laboratory,6-16
Test,17-21
Interactions:,22-35
It,36-38
is,39-41
not,42-45
known,46-51
if,52-54
MEPRON,55-61	DrugDDI.d349.s7.e1
interferes,62-72
with,73-77
clinical,78-86
laboratory,87-97
test,98-102
or,103-105
assay,106-111
results.,112-120

Drugs,0-5	DrugDDI.d574.s0.e0
which,6-11
may,12-15
enhance,16-23
the,24-27
neuromuscular,28-41
blocking,42-50
action,51-57
of,58-60
TRACRIUM,61-69	DrugDDI.d574.s0.e1
include:,70-78
enflurane;,79-89	DrugDDI.d574.s0.e2

isoflurane;,0-11	DrugDDI.d574.s1.e0

halothane;,0-10	DrugDDI.d574.s2.e0

certain,0-7
antibiotics,,8-20
especially,21-31
the,32-35
aminoglycosides,36-51	DrugDDI.d574.s3.e1
and,52-55
polymyxins;,56-67	DrugDDI.d574.s3.e2

lithium;,0-8	DrugDDI.d574.s4.e0

magnesium,0-9	DrugDDI.d574.s5.e0
salts;,10-16	DrugDDI.d574.s5.e0

procainamide;,0-13	DrugDDI.d574.s6.e0

and,0-3
quinidine.,4-14	DrugDDI.d574.s7.e0

If,0-2
other,3-8
muscle,9-15	DrugDDI.d574.s8.e0
relaxants,16-25	DrugDDI.d574.s8.e0
are,26-29
used,30-34
during,35-41
the,42-45
same,46-50
procedure,,51-61
the,62-65
possibility,66-77
of,78-80
a,81-82
synergistic,83-94
or,95-97
antagonist,98-108
effect,109-115
should,116-122
be,123-125
considered.,126-137

The,0-3
prior,4-9
administration,10-24
of,25-27
succinylcholine,28-43	DrugDDI.d574.s9.e0
does,44-48
not,49-52
enhance,53-60
the,61-64
duration,,65-74
but,75-78
quickens,79-87
the,88-91
onset,92-97
and,98-101
may,102-105
increase,106-114
the,115-118
depth,,119-125
of,126-128
neuromuscular,129-142
block,143-148
induced,149-156
by,157-159
TRACRIUM.,160-169	DrugDDI.d574.s9.e1

TRACRIUM,0-8	DrugDDI.d574.s10.e0
should,9-15
not,16-19
be,20-22
administered,23-35
until,36-41
a,42-43
patient,44-51
has,52-55
recovered,56-65
from,66-70
succinylcholine-induced,71-94	DrugDDI.d574.s10.e1
neuromuscular,95-108
block.,109-115

When,0-4
atropine,5-13	DrugDDI.d488.s0.e0
and,14-17
pralidoxime,18-29	DrugDDI.d488.s0.e1
are,30-33
used,34-38
together,,39-48
the,49-52
signs,53-58
of,59-61
atropinization,62-76
(flushing,,77-87
mydriasis,,88-98
tachycardia,,99-111
dryness,112-119
of,120-122
the,123-126
mouth,127-132
and,133-136
nose),137-142
may,143-146
occur,147-152
earlier,153-160
than,161-165
might,166-171
be,172-174
expected,175-183
than,184-188
when,189-193
atropine,194-202	DrugDDI.d488.s0.e2
is,203-205
used,206-210
alone,211-216
because,217-224
pralidoxime,225-236	DrugDDI.d488.s0.e3
may,237-240
potentiate,241-251
the,252-255
effect,256-262
of,263-265
atropine.,266-275	DrugDDI.d488.s0.e4

The,0-3
following,4-13
precautions,14-25
should,26-32
be,33-35
kept,36-40
in,41-43
mind,44-48
in,49-51
the,52-55
treatment,56-65
of,66-68
anticholinesterase,69-87
poisoning,88-97
although,98-106
they,107-111
do,112-114
not,115-118
bear,119-123
directly,124-132
on,133-135
the,136-139
use,140-143
of,144-146
atropine,147-155	DrugDDI.d488.s1.e0
and,156-159
pralidoxime.,160-172	DrugDDI.d488.s1.e1

Since,0-5
barbiturates,6-18	DrugDDI.d488.s2.e0
are,19-22
potentiated,23-34
by,35-37
the,38-41
anticholinesterases,,42-62
they,63-67
should,68-74
be,75-77
used,78-82
cautiously,83-93
in,94-96
the,97-100
treatment,101-110
of,111-113
convulsions.,114-126

Auranofin,0-9	DrugDDI.d321.s0.e0
should,10-16
be,17-19
avoided,20-27
by,28-30
patients,31-39
with,40-44
a,45-46
history,47-54
of,55-57
serious,58-65
reaction,66-74
to,75-77
any,78-81
gold,82-86
medication,,87-98
including,99-108
Solganal,109-117	DrugDDI.d321.s0.e2
and,118-121
Myochrysine.,122-134	DrugDDI.d321.s0.e3

Auranofin,0-9	DrugDDI.d321.s1.e0
should,10-16
not,17-20
be,21-23
used,24-28
together,29-37
with,38-42
penicillamine,43-56	DrugDDI.d321.s1.e1
(Depen,,57-64
Cuprimine),,65-76
another,77-84
arthritis,85-94	DrugDDI.d321.s1.e4
medication.,95-106	DrugDDI.d321.s1.e4

It,0-2
should,3-9
also,10-14
be,15-17
avoided,18-25
in,26-28
patients,29-37
with,38-42
blood,,43-49
liver,50-55	DrugDDI.d321.s2.e0
or,56-58
kidney,59-65
diseases,,66-75
recent,76-82
radiation,83-92
treatment,,93-103
or,104-106
uncontrolled,107-119
diabetes.,120-129

Patients,0-8
should,9-15
report,16-22
to,23-25
their,26-31
practitioners,32-45
any,46-49
new,50-53
rashes,,54-61
itching,,62-70
mouth,71-76
sores,,77-83
or,84-86
unusual,87-94
taste,95-100
while,101-106
taking,107-113
auranofin.,114-124	DrugDDI.d321.s3.e0

Gold,0-4	DrugDDI.d321.s4.e0
is,5-7
excreted,8-16
slowly,17-23
from,24-28
the,29-32
body.,33-38

No,0-2
formal,3-9
assessments,10-21
of,22-24
drug-drug,25-34
interactions,35-47
between,48-55
Vidaza,56-62	DrugDDI.d350.s0.e0
and,63-66
other,67-72
agents,73-79
have,80-84
been,85-89
conducted,90-99

MAO,0-3	DrugDDI.d105.s0.e0
inhibitors,4-14	DrugDDI.d105.s0.e0
prolong,15-22
and,23-26
intensify,27-36
the,37-40
effects,41-48
of,49-51
antihistamines.,52-67	DrugDDI.d105.s0.e1

Concomitant,0-11
use,12-15
of,16-18
antihistamines,19-33	DrugDDI.d105.s1.e0
with,34-38
alcohol,,39-47
tricyclic,48-57	DrugDDI.d105.s1.e2
antidepressants,,58-74	DrugDDI.d105.s1.e2
barbiturates,,75-88
or,89-91
other,92-97
central,98-105	DrugDDI.d105.s1.e4
nervous,106-113	DrugDDI.d105.s1.e4
system,114-120	DrugDDI.d105.s1.e4
depressants,121-132	DrugDDI.d105.s1.e4
may,133-136
have,137-141
an,142-144
additive,145-153
effect.,154-161

When,0-4
sympathomimetic,5-20	DrugDDI.d105.s2.e0
drugs,21-26	DrugDDI.d105.s2.e0
are,27-30
given,31-36
to,37-39
patients,40-48
receiving,49-58
monoamine,59-68	DrugDDI.d105.s2.e1
oxidase,69-76	DrugDDI.d105.s2.e1
inhibitors,,77-88	DrugDDI.d105.s2.e1
hypertensive,89-101
reactions,,102-112
including,113-122
hypertensive,123-135
crises,,136-143
may,144-147
occur.,148-154

The,0-3
antihypertensive,4-20	DrugDDI.d105.s3.e0
effects,21-28
of,29-31
methyldopa,,32-43
mecamylamine,,44-57
reserpine,,58-68
and,69-72
veratrum,73-81	DrugDDI.d105.s3.e4
alkaloids,82-91	DrugDDI.d105.s3.e4
may,92-95
be,96-98
reduced,99-106
by,107-109
sympathomimetics.,110-127	DrugDDI.d105.s3.e5

Beta-adrenergic,0-15	DrugDDI.d105.s4.e0
blocking,16-24	DrugDDI.d105.s4.e0
agents,25-31	DrugDDI.d105.s4.e0
may,32-35
also,36-40
interact,41-49
with,50-54
sympathomimetics.,55-72	DrugDDI.d105.s4.e1

Increased,0-9
ectopic,10-17
pacemaker,18-27
activity,28-36
can,37-40
occur,41-46
when,47-51
pseudoephedrine,52-67	DrugDDI.d105.s5.e0
is,68-70
used,71-75
concomitantly,76-89
with,90-94
digitalis.,95-105	DrugDDI.d105.s5.e1

Antacids,0-8	DrugDDI.d105.s6.e0
increase,9-17
the,18-21
rate,22-26
of,27-29
absorption,30-40
of,41-43
pseudoephedrine,,44-60
while,61-66
kaolin,67-73	DrugDDI.d105.s6.e2
decreases,74-83
it.,84-87

Use,0-3
with,4-8
Allopurinol:,9-21	DrugDDI.d92.s0.e0
The,22-25
principal,26-35
pathway,36-43
for,44-47
detoxification,48-62
of,63-65
azathioprine,66-78	DrugDDI.d92.s0.e1
is,79-81
inhibited,82-91
by,92-94
allopurinol.,95-107	DrugDDI.d92.s0.e2

Patients,0-8
receiving,9-18
azathioprine,19-31	DrugDDI.d92.s1.e0
and,32-35
allopurinol,36-47	DrugDDI.d92.s1.e1
concomitantly,48-61
should,62-68
have,69-73
a,74-75
dose,76-80
reduction,81-90
of,91-93
azathioprine,,94-107
to,108-110
approximately,111-124
1/3,125-128
to,129-131
1/4,132-135
the,136-139
usual,140-145
dose.,146-151

Use,0-3
with,4-8
Other,9-14
Agents,15-21
Affecting,22-31
Myelopoesis:,32-44
Drugs,45-50	DrugDDI.d92.s2.e0
which,51-56
may,57-60
affect,61-67
leukocyte,68-77
production,,78-89
including,90-99
co-trimoxazole,,100-115
may,116-119
lead,120-124
to,125-127
exaggerated,128-139
leukopenia,,140-151
especially,152-162
in,163-165
renal,166-171
transplant,172-182
recipients.,183-194

Use,0-3
with,4-8
Angiotensln,9-20
Converting,21-31
Enzyme,32-38	DrugDDI.d92.s3.e0
Inhibitors:,39-50	DrugDDI.d92.s3.e0
The,51-54
use,55-58
of,59-61
angiotensin,62-73	DrugDDI.d92.s3.e1
converting,74-84	DrugDDI.d92.s3.e1
enzyme,85-91	DrugDDI.d92.s3.e1
inhibitors,92-102
to,103-105
control,106-113
hypertension,114-126
in,127-129
patients,130-138
on,139-141
azathioprine,142-154	DrugDDI.d92.s3.e2
has,155-158
been,159-163
reported,164-172
to,173-175
induce,176-182
severe,183-189
leukopenia.,190-201

Co-administration,0-17
of,18-20
nelfinavir,21-31	DrugDDI.d526.s0.e0
at,32-34
steady-state,35-47
with,48-52
a,53-54
single,55-61
dose,62-66
of,67-69
azithromycin,70-82	DrugDDI.d526.s0.e1
(2,83-85
,86-86
span,87-91
class=,92-98
c94,99-102
??,103-105

600,0-3
mg,4-6
tablets),7-15
results,16-23
in,24-26
increased,27-36
azithromycin,37-49	DrugDDI.d526.s1.e0
serum,50-55
concentrations.,56-71

Although,0-8
a,9-10
dose,11-15
adjustment,16-26
of,27-29
azithromycin,30-42	DrugDDI.d526.s2.e0
is,43-45
not,46-49
recommended,50-61
when,62-66
administered,67-79
in,80-82
combination,83-94
with,95-99
nelfinavir,,100-111
close,112-117
monitoring,118-128
for,129-132
known,133-138
side,139-143
effects,144-151
of,152-154
azithromycin,,155-168
such,169-173
as,174-176
liver,177-182
enzyme,183-189
abnormalities,190-203
and,204-207
hearing,208-215
impairment,,216-227
is,228-230
warranted.,231-241

Azithromycin,0-12	DrugDDI.d526.s3.e0
did,13-16
not,17-20
affect,21-27
the,28-31
prothrombin,32-43
time,44-48
response,49-57
to,58-60
a,61-62
single,63-69
dose,70-74
of,75-77
warfarin.,78-87	DrugDDI.d526.s3.e1

However,,0-8
prudent,9-16
medical,17-24
practice,25-33
dictates,34-42
careful,43-50
monitoring,51-61
of,62-64
prothrombin,65-76
time,77-81
in,82-84
all,85-88
patients,89-97
treated,98-105
with,106-110
azithromycin,111-123	DrugDDI.d526.s4.e0
and,124-127
warfarin,128-136	DrugDDI.d526.s4.e1
concomitantly.,137-151

Concurrent,0-10
use,11-14
of,15-17
macrolides,18-28	DrugDDI.d526.s5.e0
and,29-32
warfarin,33-41	DrugDDI.d526.s5.e1
in,42-44
clinical,45-53
practice,54-62
has,63-66
been,67-71
associated,72-82
with,83-87
increased,88-97
anticoagulant,98-111
effects.,112-120

Drug,0-4
interaction,5-16
studies,17-24
were,25-29
performed,30-39
with,40-44
azithromycin,45-57	DrugDDI.d526.s6.e0
and,58-61
other,62-67
drugs,68-73	DrugDDI.d526.s6.e1
likely,74-80
to,81-83
be,84-86
co-administered.,87-103

When,0-4
used,5-9
in,10-12
therapeutic,13-24
doses,,25-31
azithromycin,32-44	DrugDDI.d526.s7.e0
had,45-48
a,49-50
modest,51-57
effect,58-64
on,65-67
the,68-71
pharmacokinetics,72-88
of,89-91
atorvastatin,,92-105
carbamazepine,,106-120
cetirizine,,121-132
didanosine,,133-144
efavirenz,,145-155
fluconazole,,156-168
indinavir,,169-179
midazolam,,180-190
rifabutin,,191-201
sildenafil,,202-213
theophylline,214-226	DrugDDI.d526.s7.e11
(intravenous,227-239
and,240-243
oral),,244-250
triazolam,,251-261
trimethoprim/sulfamethoxazole,262-291	DrugDDI.d526.s7.e13
or,292-294
zidovudine.,295-306	DrugDDI.d526.s7.e15

Co-administration,0-17
with,18-22
efavirenz,23-32	DrugDDI.d526.s8.e0
or,33-35
fluconazole,36-47	DrugDDI.d526.s8.e1
had,48-51
a,52-53
modest,54-60
effect,61-67
on,68-70
the,71-74
pharmacokinetics,75-91
of,92-94
azithromycin.,95-108	DrugDDI.d526.s8.e2

No,0-2
dosage,3-9
adjustment,10-20
of,21-23
either,24-30
drug,31-35	DrugDDI.d526.s9.e0
is,36-38
recommended,39-50
when,51-55
azithromycin,56-68	DrugDDI.d526.s9.e1
is,69-71
co,72-74
administered,75-87
with,88-92
any,93-96
of,97-99
the,100-103
above,104-109
agents.,110-117

Interactions,0-12
with,13-17
the,18-21
drugs,22-27	DrugDDI.d526.s10.e0
listed,28-34
below,35-40
have,41-45
not,46-49
been,50-54
reported,55-63
in,64-66
clinical,67-75
trials,76-82
with,83-87
azithromycin;,88-101	DrugDDI.d526.s10.e1

Nonetheless,,0-12
they,13-17
have,18-22
been,23-27
observed,28-36
with,37-41
macrolide,42-51	DrugDDI.d526.s12.e0
products.,52-61

Until,0-5
further,6-13
data,14-18
are,19-22
developed,23-32
regarding,33-42
drug,43-47
interactions,48-60
when,61-65
azithromycin,66-78	DrugDDI.d526.s13.e0
and,79-82
these,83-88
drugs,89-94	DrugDDI.d526.s13.e1
are,95-98
used,99-103
concomitantly,,104-118
careful,119-126
monitoring,127-137
of,138-140
patients,141-149
is,150-152
advised:,153-161
Digoxin?elevated,162-178	DrugDDI.d526.s13.e2
digoxin,179-186
concentrations.,187-202

Ergotamine,0-10	DrugDDI.d526.s14.e0
or,11-13
dihydroergotamine?acute,14-37
ergot,38-43
toxicity,44-52
characterized,53-66
by,67-69
severe,70-76
peripheral,77-87
vasospasm,88-97
and,98-101
dysesthesia.,102-114

Cyclosporine,,0-13
hexobarbital,14-26	DrugDDI.d526.s15.e1
and,27-30
phenytoin,31-40	DrugDDI.d526.s15.e2
concentrations.,41-56

Repeat,0-6
Treatment,7-16
Studies,17-24
evaluating,25-35
the,36-39
use,40-43
of,44-46
repeated,47-55
courses,56-63
of,64-66
Zmax,67-71	DrugDDI.d526.s17.e0
have,72-76
not,77-80
been,81-85
conducted.,86-96

Azlocillin,0-10	DrugDDI.d56.s0.e0
should,11-17
not,18-21
be,22-24
administered,25-37
concomitantly,38-51
with,52-56
amikacin,,57-66
ciprofloxacin,,67-81
gentamicin,,82-93
netilmicin,,94-105
or,106-108
tobramycin.,109-120	DrugDDI.d56.s0.e5

Injection,0-9
There,10-15
is,16-18
inadequate,19-29
systematic,30-40
experience,41-51
with,52-56
the,57-60
use,61-64
of,65-67
baclofen,68-76	DrugDDI.d363.s0.e0
injection,77-86
in,87-89
combination,90-101
with,102-106
other,107-112	DrugDDI.d363.s0.e1
medications,113-124	DrugDDI.d363.s0.e1
to,125-127
predict,128-135
specific,136-144
drug-drug,145-154
interactions.,155-168

Interactions,0-12
attributed,13-23
to,24-26
the,27-30
combined,31-39
use,40-43
of,44-46
baclofen,47-55	DrugDDI.d363.s1.e0
injection,56-65
and,66-69
epidural,70-78
morphine,79-87	DrugDDI.d363.s1.e1
include,88-95
hypotension,96-107
and,108-111
dyspnea.,112-120

SIDE,0-4
EFFECTS,5-12
(KEMSTRO),13-22
The,23-26
most,27-31
common,32-38
adverse,39-46
reaction,47-55
during,56-62
treatment,63-72
with,73-77
baclofen,78-86	DrugDDI.d363.s2.e0
is,87-89
transient,90-99
drowsiness,100-110
(10-63%).,111-120

In,0-2
one,3-6
controlled,7-17
study,18-23
of,24-26
175,27-30
patients,,31-40
transient,41-50
drowsiness,51-61
was,62-65
observed,66-74
in,75-77
63%,78-81
of,82-84
those,85-90
receiving,91-100
baclofen,101-109	DrugDDI.d363.s3.e0
tablets,110-117	DrugDDI.d363.s3.e0
compared,118-126
to,127-129
36%,130-133
of,134-136
those,137-142
in,143-145
the,146-149
placebo,150-157
group.,158-164

The,0-3
following,4-13
laboratory,14-24
tests,25-30
have,31-35
been,36-40
found,41-46
to,47-49
be,50-52
abnormal,53-61
in,62-64
a,65-66
few,67-70
patients,71-79
receiving,80-89
baclofen:,90-99	DrugDDI.d363.s15.e0
increased,100-109
SGOT,,110-115
elevated,116-124
alkaline,125-133	DrugDDI.d363.s15.e1
phosphatase,,134-146	DrugDDI.d363.s15.e1
and,147-150
elevation,151-160
of,161-163
blood,164-169
sugar.,170-176

The,0-3
adverse,4-11
experience,12-22
profile,23-30
seen,31-35
with,36-40
KEMSTROTM,41-50
was,51-54
similar,55-62
to,63-65
that,66-70
seen,71-75
with,76-80
baclofen,81-89	DrugDDI.d363.s16.e0
tablets.,90-98	DrugDDI.d363.s16.e0

No,0-2
drug,3-7
interaction,8-19
studies,20-27
have,28-32
been,33-37
conducted,38-47
for,48-51
COLAZAL,,52-60
however,61-68
the,69-72
use,73-76
of,77-79
orally,80-86
administered,87-99
antibiotics,100-111
could,,112-118
theoretically,,119-133
interfere,134-143
with,144-148
the,149-152
release,153-160
of,161-163
mesalamine,164-174	DrugDDI.d362.s0.e1
in,175-177
the,178-181
colon.,182-188

No,0-2
dose,3-7
adjustment,8-18
is,19-21
necessary,22-31
when,32-36
Simulect?,37-46
is,47-49
added,50-55
to,56-58
triple-immunosuppression,59-83
regimens,84-92
including,93-102
cyclosporine,,103-116
corticosteroids,,117-133
and,134-137
either,138-144
azathioprine,145-157	DrugDDI.d554.s0.e2
or,158-160
mycophenolate,161-174	DrugDDI.d554.s0.e3
mofetil.,175-183	DrugDDI.d554.s0.e3

Total,0-5
body,6-10
clearance,11-20
of,21-23
Simulect?,24-33
was,34-37
reduced,38-45
by,46-48
an,49-51
average,52-59
22%,60-63
and,64-67
51%,68-71
when,72-76
azathioprine,77-89	DrugDDI.d554.s3.e0
and,90-93
mycophenolate,94-107	DrugDDI.d554.s3.e1
mofetil,,108-116	DrugDDI.d554.s3.e1
respectively,,117-130
were,131-135
added,136-141
to,142-144
a,145-146
regimen,147-154
consisting,155-165
of,166-168
cyclosporine,,169-182
USP,183-186
(MODIFIED),187-197
and,198-201
corticosteroids.,202-218	DrugDDI.d554.s3.e3

Nonetheless,,0-12
the,13-16
range,17-22
of,23-25
individual,26-36
Simulect?,37-46
clearance,47-56
values,57-63
in,64-66
the,67-70
presence,71-79
of,80-82
azathioprine,83-95	DrugDDI.d554.s4.e0
(12-57,96-102
mL/h),103-108
or,109-111
mycophenolate,112-125	DrugDDI.d554.s4.e1
mofetil,126-133	DrugDDI.d554.s4.e1
(7-54,134-139
mL/h),140-145
did,146-149
not,150-153
extend,154-160
outside,161-168
the,169-172
range,173-178
observed,179-187
with,188-192
dual,193-197
therapy,198-205
(10-78,206-212
mL/h).,213-219

The,0-3
following,4-13
medications,14-25	DrugDDI.d554.s5.e0
have,26-30
been,31-35
administered,36-48
in,49-51
clinical,52-60
trials,61-67
with,68-72
Simulect?,73-82
with,83-87
no,88-90
increase,91-99
in,100-102
adverse,103-110
reactions:,111-121
ATG/ALG,,122-130
azathioprine,,131-144
corticosteroids,,145-161
cyclosporine,,162-175
mycophenolate,176-189	DrugDDI.d554.s5.e5
mofetil,,190-198	DrugDDI.d554.s5.e5
and,199-202
muromonab-CD3.,203-217	DrugDDI.d554.s5.e6

It,0-2
is,3-5
not,6-9
known,10-15
if,16-18
REGRANEX,19-27	DrugDDI.d284.s0.e0
Gel,28-31
interacts,32-41
with,42-46
other,47-52
topical,53-60
medications,61-72	DrugDDI.d284.s0.e1
applied,73-80
to,81-83
the,84-87
ulcer,88-93
site.,94-99

The,0-3
use,4-7
of,8-10
REGRANEX,11-19	DrugDDI.d284.s1.e0
Gel,20-23
with,24-28
other,29-34
topical,35-42
drugs,43-48	DrugDDI.d284.s1.e1
has,49-52
not,53-56
been,57-61
studied.,62-70

Albuterol,,0-10
Antihistamines,,11-26
antidiabetic,27-39	DrugDDI.d510.s0.e2
drugs,,40-46	DrugDDI.d510.s0.e2
diuretics,,47-57
digitalis.,58-68	DrugDDI.d510.s0.e4

Diuretics,0-9	DrugDDI.d420.s0.e0
Patients,10-18
on,19-21
diuretics,,22-32
especially,33-43
those,44-49
in,50-52
whom,53-57
diuretic,58-66
therapy,67-74
was,75-78
recently,79-87
instituted,,88-99
may,100-103
occasionally,104-116
experience,117-127
an,128-130
excessive,131-140
reduction,141-150
of,151-153
blood,154-159
pressure,160-168
after,169-174
initiation,175-185
of,186-188
therapy,189-196
with,197-201
Lotensin.,202-211	DrugDDI.d420.s0.e2

The,0-3
possibility,4-15
of,16-18
hypotensive,19-30
effects,31-38
with,39-43
Lotensin,44-52	DrugDDI.d420.s1.e0
can,53-56
be,57-59
minimized,60-69
by,70-72
either,73-79
discontinuing,80-93
the,94-97
diuretic,98-106	DrugDDI.d420.s1.e1
or,107-109
increasing,110-120
the,121-124
salt,125-129
intake,130-136
prior,137-142
to,143-145
initiation,146-156
of,157-159
treatment,160-169
with,170-174
Lotensin.,175-184	DrugDDI.d420.s1.e2

Potassium,0-9	DrugDDI.d420.s3.e0
Supplements,10-21	DrugDDI.d420.s3.e0
and,22-25
Potassium-Sparing,26-43	DrugDDI.d420.s3.e1
Diuretics,44-53	DrugDDI.d420.s3.e1
Lotensin,54-62
can,63-66
attenuate,67-76
potassium,77-86	DrugDDI.d420.s3.e2
loss,87-91
caused,92-98
by,99-101
thiazide,102-110	DrugDDI.d420.s3.e3
diuretics.,111-121	DrugDDI.d420.s3.e3

Potassium-sparing,0-17	DrugDDI.d420.s4.e0
diuretics,18-27	DrugDDI.d420.s4.e0
(spironolactone,,28-44
amiloride,,45-55
triamterene,,56-68
and,69-72
others),73-80
or,81-83
potassium,84-93	DrugDDI.d420.s4.e4
supplements,94-105	DrugDDI.d420.s4.e4
can,106-109
increase,110-118
the,119-122
risk,123-127
of,128-130
hyperkalemia.,131-144

Oral,0-4	DrugDDI.d420.s6.e0
Anticoagulants,5-19	DrugDDI.d420.s6.e0
Interaction,20-31
studies,32-39
with,40-44
warfarin,45-53	DrugDDI.d420.s6.e1
and,54-57
acenocoumarol,58-71	DrugDDI.d420.s6.e2
failed,72-78
to,79-81
identify,82-90
any,91-94
clinically,95-105
important,106-115
effects,116-123
on,124-126
the,127-130
serum,131-136
concentrations,137-151
or,152-154
clinical,155-163
effects,164-171
of,172-174
these,175-180
anticoagulants.,181-196	DrugDDI.d420.s6.e3

Lithium,0-7	DrugDDI.d420.s7.e0
Increased,8-17
serum,18-23
lithium,24-31
levels,32-38
and,39-42
symptoms,43-51
of,52-54
lithium,55-62
toxicity,63-71
have,72-76
been,77-81
reported,82-90
in,91-93
patients,94-102
receiving,103-112
ACE,113-116	DrugDDI.d420.s7.e1
inhibitors,117-127	DrugDDI.d420.s7.e1
during,128-134
therapy,135-142
with,143-147
lithium.,148-156	DrugDDI.d420.s7.e2

These,0-5
drugs,6-11	DrugDDI.d420.s8.e0
should,12-18
be,19-21
coadministered,22-36
with,37-41
caution,,42-50
and,51-54
frequent,55-63
monitoring,64-74
of,75-77
serum,78-83
lithium,84-91
levels,92-98
is,99-101
recommended.,102-114

If,0-2
a,3-4
diuretic,5-13	DrugDDI.d420.s9.e0
is,14-16
also,17-21
used,,22-27
the,28-31
risk,32-36
of,37-39
lithium,40-47
toxicity,48-56
may,57-60
be,61-63
increased.,64-74

Other,0-5
No,6-8
clinically,9-19
important,20-29
pharmacokinetic,30-45
interactions,46-58
occurred,59-67
when,68-72
Lotensin,73-81	DrugDDI.d420.s10.e0
was,82-85
administered,86-98
concomitantly,99-112
with,113-117
hydrochlorothiazide,,118-138
chlorthalidone,,139-154
furosemide,,155-166
digoxin,,167-175
propranolol,,176-188
atenolol,,189-198
naproxen,,199-208
or,209-211
cimetidine.,212-223	DrugDDI.d420.s10.e8

Lotensin,0-8	DrugDDI.d420.s11.e0
has,9-12
been,13-17
used,18-22
concomitantly,23-36
with,37-41
beta-adrenergic-blocking,42-66	DrugDDI.d420.s11.e1
agents,,67-74	DrugDDI.d420.s11.e1
calcium-channel-blocking,75-99	DrugDDI.d420.s11.e2
agents,,100-107	DrugDDI.d420.s11.e2
diuretics,,108-118
digoxin,,119-127
and,128-131
hydralazine,,132-144
without,145-152
evidence,153-161
of,162-164
clinically,165-175
important,176-185
adverse,186-193
interactions.,194-207

Benazepril,,0-11
like,12-16
other,17-22
ACE,23-26	DrugDDI.d420.s12.e1
inhibitors,,27-38	DrugDDI.d420.s12.e1
has,39-42
had,43-46
less,47-51
than,52-56
additive,57-65
effects,66-73
with,74-78
beta-adrenergic,79-94	DrugDDI.d420.s12.e2
blockers,,95-104	DrugDDI.d420.s12.e2
presumably,105-115
because,116-123
both,124-128
drugs,129-134	DrugDDI.d420.s12.e3
lower,135-140
blood,141-146
pressure,147-155
by,156-158
inhibiting,159-169
parts,170-175
of,176-178
the,179-182
renin-angiotensin,183-200
system,201-207

May,0-3
interact,4-12
with,13-17
the,18-21
following:,22-32
cholestyramine,,33-48
colestipol,49-59	DrugDDI.d370.s0.e1
(use,60-64
with,65-69
thiazide,70-78	DrugDDI.d370.s0.e2
diuretics,79-88	DrugDDI.d370.s0.e2
may,89-92
prevent,93-100	DrugDDI.d370.s0.e3
the,101-104
diuretic,105-113	DrugDDI.d370.s0.e4
from,114-118
working,119-126
properly;,127-136

take,0-4
the,5-8
diuretic,9-17	DrugDDI.d370.s1.e0
at,18-20
least,21-26
1,27-28
hour,29-33
before,34-40
or,41-43
4,44-45
hours,46-51
after,52-57
cholestyramine,58-72	DrugDDI.d370.s1.e1
or,73-75
colestipol),,76-88
digitalis,89-98	DrugDDI.d370.s1.e3
glycosides,99-109	DrugDDI.d370.s1.e3
(use,110-114
with,115-119
thiazide,120-128	DrugDDI.d370.s1.e4
diuretics,129-138	DrugDDI.d370.s1.e4
may,139-142
cause,143-148
high,149-153
blood,154-159
levels,160-166
of,167-169
digoxin,,170-178
which,179-184
may,185-188
increase,189-197
the,198-201
chance,202-208
of,209-211
side,212-216
effects),,217-226
and,227-230
lithium,231-238	DrugDDI.d370.s1.e6
(use,239-243
with,244-248
thiazide,249-257	DrugDDI.d370.s1.e7
diuretics,258-267	DrugDDI.d370.s1.e7
may,268-271
cause,272-277
high,278-282
blood,283-288
levels,289-295
of,296-298
lithium,,299-307
which,308-313
may,314-317
increase,318-326
the,327-330
chance,331-337
of,338-340
side,341-345
effects).,346-355

Bentiromide,0-11	DrugDDI.d389.s0.e0
may,12-15
interact,16-24
with,25-29
acetaminophen,30-43	DrugDDI.d389.s0.e1
(e.g.,,44-50
Tylenol),,51-60
chloramphenicol,61-76	DrugDDI.d389.s0.e3
(e.g.,,77-83
Chloromycetin),,84-99
local,100-105	DrugDDI.d389.s0.e5
anesthetics,106-117	DrugDDI.d389.s0.e5
(e.g.,,118-124
benzocaine,125-135	DrugDDI.d389.s0.e6
and,136-139
lidocaine),,140-151
para-aminobenzoic,152-169	DrugDDI.d389.s0.e8
acid,170-174	DrugDDI.d389.s0.e8
(PABA)-containing,175-192
preparations,193-205
(e.g.,,206-212
sunscreens,213-223	DrugDDI.d389.s0.e10
and,224-227
some,228-232
multivitamins),,233-248
procainamide,249-261	DrugDDI.d389.s0.e12
(e.g.,,262-268
Pronestyl),,269-280
sulfonamides,281-293	DrugDDI.d389.s0.e14
(sulfa,294-300
medicines),,301-312
thiazide,313-321	DrugDDI.d389.s0.e16
diuretics,322-331	DrugDDI.d389.s0.e16
(use,332-336
of,337-339
these,340-345
medicines,346-355	DrugDDI.d389.s0.e17
during,356-362
the,363-366
test,367-371
period,372-378
will,379-383
affect,384-390
the,391-394
test,395-399
results),,400-409
and,410-413
pancreatic,414-424
supplements,425-436
(use,437-441
of,442-444
pancreatic,445-455	DrugDDI.d389.s0.e18
supplements,456-467
may,468-471
give,472-476
false,477-482
test,483-487
results).,488-497

May,0-3
interact,4-12
with,13-17
other,18-23
creams,,24-31
lotions,,32-40
or,41-43
skin,44-48
medicines,49-58	DrugDDI.d549.s0.e0
when,59-63
placed,64-70
on,71-73
the,74-77
same,78-82
areas,83-88
of,89-91
your,92-96
skin,97-101
that,102-106
you,107-110
are,111-114
using,115-120
bentoquatam.,121-133	DrugDDI.d549.s0.e1

Hypertensive,0-12
crises,13-19
have,20-24
resulted,25-33
when,34-38
sympathomimetic,39-54	DrugDDI.d218.s0.e0
amines,55-61	DrugDDI.d218.s0.e0
have,62-66
been,67-71
used,72-76
concomitantly,77-90
within14,91-99
days,100-104
following,105-114
use,115-118
of,119-121
monoamine,122-131	DrugDDI.d218.s0.e1
oxidase,132-139	DrugDDI.d218.s0.e1
inhibitors.,140-151	DrugDDI.d218.s0.e1

DIDREX,0-6	DrugDDI.d218.s1.e0
should,7-13
not,14-17
be,18-20
used,21-25
concomitantly,26-39
with,40-44
other,45-50
CNS,51-54	DrugDDI.d218.s1.e1
stimulants.,55-66	DrugDDI.d218.s1.e1

Amphetamines,0-12	DrugDDI.d218.s2.e0
may,13-16
decrease,17-25
the,26-29
hypotensive,30-41
effect,42-48
of,49-51
antihypertensives.,52-70	DrugDDI.d218.s2.e1

Amphetamines,0-12	DrugDDI.d218.s3.e0
may,13-16
enhance,17-24
the,25-28
effects,29-36
of,37-39
tricyclic,40-49	DrugDDI.d218.s3.e1
antidepressants.,50-66	DrugDDI.d218.s3.e1

Urinary,0-7
alkalinizing,8-20	DrugDDI.d218.s4.e0
agents,21-27	DrugDDI.d218.s4.e0
increase,28-36
blood,37-42
levels,43-49
and,50-53
decrease,54-62
excretion,63-72
of,73-75
amphetamines.,76-89	DrugDDI.d218.s4.e1

Urinary,0-7
acidifying,8-18	DrugDDI.d218.s5.e0
agents,19-25	DrugDDI.d218.s5.e0
decrease,26-34
blood,35-40
levels,41-47
and,48-51
increase,52-60
excretion,61-70
of,71-73
amphetamines.,74-87	DrugDDI.d218.s5.e1

Benzthiazide,0-12	DrugDDI.d55.s0.e0
may,13-16
interact,17-25
with,26-30
alcohol,,31-39
blood,40-45	DrugDDI.d55.s0.e2
thinners,,46-55	DrugDDI.d55.s0.e2
decongestant,56-68	DrugDDI.d55.s0.e3
drugs,69-74	DrugDDI.d55.s0.e3
(allergy,,75-84
cold,,85-90
and,91-94
sinus,95-100
medicines),,101-112
diabetic,113-121
drugs,,122-128
lithium,,129-137
norepinephrine,,138-153
NSAIDs,154-160	DrugDDI.d55.s0.e8
like,161-165
Aleve,166-171	DrugDDI.d55.s0.e9
or,172-174
Ibuprofen,,175-185
and,186-189
high,190-194
blood,195-200
pressure,201-209
medications.,210-222	DrugDDI.d55.s0.e11

Antipsychotic,0-13	DrugDDI.d505.s0.e0
drugs,14-19	DrugDDI.d505.s0.e0
such,20-24
as,25-27
phenothiazines,28-42	DrugDDI.d505.s0.e1
or,43-45
haloperidol;,46-58	DrugDDI.d505.s0.e2

tricyclic,0-9	DrugDDI.d505.s1.e0
antidepressants.,10-26	DrugDDI.d505.s1.e0

Nitrates:,0-9	DrugDDI.d149.s0.e0
The,10-13
concomitant,14-25
use,26-29
of,30-32
Bepridil,33-41	DrugDDI.d149.s0.e1
with,42-46
long-,47-52
and,53-56
short-acting,57-69
nitrates,70-78	DrugDDI.d149.s0.e2
has,79-82
been,83-87
safely,88-94
tolerated,95-104
in,105-107
patients,108-116
with,117-121
stable,122-128
angina,129-135
pectoris.,136-145

Sublingual,0-10
nitroglycerin,11-24	DrugDDI.d149.s1.e0
may,25-28
be,29-31
taken,32-37
if,38-40
necessary,41-50
for,51-54
the,55-58
control,59-66
of,67-69
acute,70-75
angina,76-82
attacks,83-90
during,91-97
Bepridil,98-106	DrugDDI.d149.s1.e1
therapy.,107-115

Beta-blocking,0-13	DrugDDI.d149.s2.e0
Agents:,14-21	DrugDDI.d149.s2.e0
The,22-25
concomitant,26-37
use,38-41
of,42-44
Bepridil,45-53	DrugDDI.d149.s2.e1
and,54-57
beta-blocking,58-71	DrugDDI.d149.s2.e2
agents,72-78	DrugDDI.d149.s2.e2
has,79-82
been,83-87
well,88-92
tolerated,93-102
in,103-105
patients,106-114
with,115-119
stable,120-126
angina.,127-134

Available,0-9
data,10-14
are,15-18
not,19-22
sufficient,,23-34
however,,35-43
to,44-46
predict,47-54
the,55-58
effects,59-66
of,67-69
concomitant,70-81
medication,82-92	DrugDDI.d149.s3.e0
on,93-95
patients,96-104
with,105-109
impaired,110-118
ventricular,119-130
function,131-139
or,140-142
cardiac,143-150
conduction,151-161
abnormalities.,162-176

Digoxin:,0-8	DrugDDI.d149.s4.e0
In,9-11
controlled,12-22
studies,23-30
in,31-33
healthy,34-41
volunteers,,42-53
bepridil,54-62	DrugDDI.d149.s4.e1
hydrochloride,63-76	DrugDDI.d149.s4.e1
either,77-83
had,84-87
no,88-90
effect,91-97
(one,98-102
study),103-109
or,110-112
was,113-116
associated,117-127
with,128-132
modest,133-139
increases,,140-150
about,151-156
30%,157-160
(two,161-165
studies),166-174
in,175-177
steady-state,178-190
serum,191-196
digoxin,197-204	DrugDDI.d149.s4.e2
concentrations.,205-220

Limited,0-7
clinical,8-16
data,17-21
in,22-24
angina,25-31
patients,32-40
receiving,41-50
concomitant,51-62
bepridil,63-71	DrugDDI.d149.s5.e0
hydrochloride,72-85	DrugDDI.d149.s5.e0
and,86-89
digoxin,90-97	DrugDDI.d149.s5.e1
therapy,98-105
indicate,106-114
no,115-117
discernible,118-129
changes,130-137
in,138-140
serum,141-146
digoxin,147-154
levels.,155-162

Available,0-9
data,10-14
are,15-18
neither,19-26
sufficient,27-37
to,38-40
rule,41-45
out,46-49
possible,50-58
increases,59-68
in,69-71
serum,72-77
digoxin,78-85	DrugDDI.d149.s6.e0
with,86-90
concomitant,91-102
treatment,103-112
in,113-115
some,116-120
patients,,121-130
nor,131-134
other,135-140
possible,141-149
interactions,,150-163
particularly,164-176
in,177-179
patients,180-188
with,189-193
cardiac,194-201
conduction,202-212
abnormalities,213-226
(Also,227-232
see,233-236
WARNINGS,237-245
Congestive,246-256
Heart,257-262
Failure).,263-272

Oral,0-4	DrugDDI.d149.s7.e0
Hypoglycemics:,5-19	DrugDDI.d149.s7.e0
Bepridil,20-28	DrugDDI.d149.s7.e1
has,29-32
been,33-37
safely,38-44
used,45-49
in,50-52
diabetic,53-61
patients,62-70
without,71-78
significantly,79-92
lowering,93-101
their,102-107
blood,108-113
glucose,114-121
levels,122-128
or,129-131
altering,132-140
their,141-146
need,147-151
for,152-155
insulin,156-163	DrugDDI.d149.s7.e2
or,164-166
oral,167-171
hypoglycemic,172-184	DrugDDI.d149.s7.e3
agents.,185-192	DrugDDI.d149.s7.e3

General,0-7
Interactions:,8-21
Certain,22-29
drugs,30-35	DrugDDI.d149.s8.e0
could,36-41
increase,42-50
the,51-54
likelihood,55-65
of,66-68
potentially,69-80
serious,81-88
adverse,89-96
effects,97-104
with,105-109
bepridil,110-118	DrugDDI.d149.s8.e1
hydrochloride.,119-133	DrugDDI.d149.s8.e1

In,0-2
general,,3-11
these,12-17
are,18-21
drugs,22-27	DrugDDI.d149.s9.e0
that,28-32
have,33-37
one,38-41
or,42-44
more,45-49
pharmacologic,50-63
activities,64-74
similar,75-82
to,83-85
bepridil,86-94	DrugDDI.d149.s9.e1
hydrochloride,,95-109	DrugDDI.d149.s9.e1
including,110-119
anti-arrhythmic,120-135	DrugDDI.d149.s9.e2
agents,136-142	DrugDDI.d149.s9.e2
such,143-147
as,148-150
quinidine,151-160	DrugDDI.d149.s9.e3
and,161-164
procainamide,,165-178
cardiac,179-186	DrugDDI.d149.s9.e5
glycosides,187-197	DrugDDI.d149.s9.e5
and,198-201
tricyclic,202-211	DrugDDI.d149.s9.e6
anti-depressants.,212-229	DrugDDI.d149.s9.e6

Anti-arrhythmics,0-16	DrugDDI.d149.s10.e0
and,17-20
tricyclic,21-30	DrugDDI.d149.s10.e1
anti-depressants,31-47	DrugDDI.d149.s10.e1
could,48-53
exaggerate,54-64
the,65-68
prolongation,69-81
of,82-84
the,85-88
QT,89-91
interval,92-100
observed,101-109
with,110-114
bepridil,115-123	DrugDDI.d149.s10.e2
hydrochloride.,124-138	DrugDDI.d149.s10.e2

Cardiac,0-7	DrugDDI.d149.s11.e0
glycosides,8-18	DrugDDI.d149.s11.e0
could,19-24
exaggerate,25-35
the,36-39
depression,40-50
of,51-53
AV,54-56
nodal,57-62
conduction,63-73
observed,74-82
with,83-87
bepridil,88-96	DrugDDI.d149.s11.e1
hydrochloride.,97-111	DrugDDI.d149.s11.e1

The,0-3
following,4-13
drugs,14-19	DrugDDI.d582.s0.e0
have,20-24
been,25-29
coadministered,30-44
with,45-49
Kerlone,50-57	DrugDDI.d582.s0.e1
and,58-61
have,62-66
not,67-70
altered,71-78
its,79-82
pharmacokinetics:,83-100
cimetidine,,101-112
nifedipine,,113-124
chlorthalidone,,125-140
and,141-144
hydrochlorothiazide.,145-165	DrugDDI.d582.s0.e5

Concomitant,0-11
administration,12-26
of,27-29
Kerlone,30-37	DrugDDI.d582.s1.e0
with,38-42
the,43-46
oral,47-51	DrugDDI.d582.s1.e1
anticoagulant,52-65	DrugDDI.d582.s1.e1
warfarin,66-74	DrugDDI.d582.s1.e1
has,75-78
been,79-83
shown,84-89
not,90-93
to,94-96
potentiate,97-107
the,108-111
anticoagulant,112-125
effect,126-132
of,133-135
warfarin.,136-145	DrugDDI.d582.s1.e2

Catecholamine-depleting,0-23
drugs,24-29	DrugDDI.d582.s2.e0
(e.g.,,30-36
reserpine),37-47	DrugDDI.d582.s2.e1
may,48-51
have,52-56
an,57-59
additive,60-68
effect,69-75
when,76-80
given,81-86
with,87-91
beta-blocking,92-105	DrugDDI.d582.s2.e2
agents.,106-113	DrugDDI.d582.s2.e2

Patients,0-8
treated,9-16
with,17-21
a,22-23
beta-adrenergic,24-39	DrugDDI.d582.s3.e0
receptor,40-48	DrugDDI.d582.s3.e0
blocking,49-57	DrugDDI.d582.s3.e0
agent,58-63	DrugDDI.d582.s3.e0
plus,64-68
a,69-70
catecholamine,71-84
depletor,85-93
should,94-100
therefore,101-110
be,111-113
closely,114-121
observed,122-130
for,131-134
evidence,135-143
of,144-146
hypotension,147-158
or,159-161
marked,162-168
bradycardia,,169-181
which,182-187
may,188-191
produce,192-199
vertigo,,200-208
syncope,,209-217
or,218-220
postural,221-229
hypotension.,230-242

Should,0-6
it,7-9
be,10-12
decided,13-20
to,21-23
discontinue,24-35
therapy,36-43
in,44-46
patients,47-55
receiving,56-65
beta-blockers,66-79	DrugDDI.d582.s4.e0
and,80-83
clonidine,84-93	DrugDDI.d582.s4.e1
concurrently,,94-107
the,108-111
beta-blocker,112-124	DrugDDI.d582.s4.e2
should,125-131
be,132-134
discontinued,135-147
slowly,148-154
over,155-159
several,160-167
days,168-172
before,173-179
the,180-183
gradual,184-191
withdrawal,192-202
of,203-205
clonidine.,206-216	DrugDDI.d582.s4.e3

Literature,0-10
reports,11-18
suggest,19-26
that,27-31
oral,32-36
calcium,37-44	DrugDDI.d582.s5.e0
antagonists,45-56	DrugDDI.d582.s5.e0
may,57-60
be,61-63
used,64-68
in,69-71
combination,72-83
with,84-88
beta-adrenergic,89-104	DrugDDI.d582.s5.e1
blocking,105-113	DrugDDI.d582.s5.e1
agents,114-120	DrugDDI.d582.s5.e1
when,121-125
heart,126-131
function,132-140
is,141-143
normal,,144-151
but,152-155
should,156-162
be,163-165
avoided,166-173
in,174-176
patients,177-185
with,186-190
impaired,191-199
cardiac,200-207
function.,208-217

Hypotension,,0-12
AV,13-15
conduction,16-26
disturbances,,27-40
and,41-44
left,45-49
ventricular,50-61
failure,62-69
have,70-74
been,75-79
reported,80-88
in,89-91
some,92-96
patients,97-105
receiving,106-115
beta-adrenergic,116-131	DrugDDI.d582.s6.e0
blocking,132-140	DrugDDI.d582.s6.e0
agents,141-147	DrugDDI.d582.s6.e0
when,148-152
an,153-155
oral,156-160
calcium,161-168	DrugDDI.d582.s6.e1
antagonist,169-179	DrugDDI.d582.s6.e1
was,180-183
added,184-189
to,190-192
the,193-196
treatment,197-206
regimen.,207-215

Hypotension,0-11
was,12-15
more,16-20
likely,21-27
to,28-30
occur,31-36
if,37-39
the,40-43
calcium,44-51	DrugDDI.d582.s7.e0
antagonist,52-62	DrugDDI.d582.s7.e0
were,63-67
a,68-69
dihydropyridine,70-85	DrugDDI.d582.s7.e1
derivative,,86-97
e.g.,,98-103
nifedipine,,104-115
while,116-121
left,122-126
ventricular,127-138
failure,139-146
and,147-150
AV,151-153
conduction,154-164
disturbances,,165-178
including,179-188
complete,189-197
heart,198-203
block,,204-210
were,211-215
more,216-220
likely,221-227
to,228-230
occur,231-236
with,237-241
either,242-248
verapamil,249-258	DrugDDI.d582.s7.e3
or,259-261
diltiazem.,262-272	DrugDDI.d582.s7.e4

Risk,0-4
of,5-7
Anaphylactic,8-20
Reaction:,21-30
Although,31-39
it,40-42
is,43-45
known,46-51
that,52-56
patients,57-65
on,66-68
beta-blockers,69-82	DrugDDI.d582.s8.e0
may,83-86
be,87-89
refractory,90-100
to,101-103
epinephrine,104-115	DrugDDI.d582.s8.e1
in,116-118
the,119-122
treatment,123-132
of,133-135
anaphylactic,136-148
shock,,149-155
beta-blockers,156-169	DrugDDI.d582.s8.e2
can,,170-174
in,175-177
addition,,178-187
interfere,188-197
with,198-202
the,203-206
modulation,207-217
of,218-220
allergic,221-229
reaction,230-238
and,239-242
lead,243-247
to,248-250
an,251-253
increased,254-263
severity,264-272
and/or,273-279
frequency,280-289
of,290-292
attacks.,293-301

Severe,0-6
allergic,7-15
reactions,16-25
including,26-35
anaphylaxis,36-47
have,48-52
been,53-57
reported,58-66
in,67-69
patients,70-78
exposed,79-86
to,87-89
a,90-91
variety,92-99
of,100-102
allergens,103-112
either,113-119
by,120-122
repeated,123-131
challenge,,132-142
or,143-145
accidental,146-156
contact,,157-165
and,166-169
with,170-174
diagnostic,175-185
or,186-188
therapeutic,189-200	DrugDDI.d582.s9.e0
agents,201-207	DrugDDI.d582.s9.e0
while,208-213
receiving,214-223
beta-blockers.,224-238	DrugDDI.d582.s9.e1

Such,0-4
patients,5-13
may,14-17
be,18-20
unresponsive,21-33
to,34-36
the,37-40
usual,41-46
doses,47-52
of,53-55
epinephrine,56-67	DrugDDI.d582.s10.e0
used,68-72
to,73-75
treat,76-81
allergic,82-90
reaction.,91-100

Special,0-7
care,8-12
is,13-15
required,16-24
if,25-27
this,28-32
drug,33-37	DrugDDI.d464.s0.e0
is,38-40
given,41-46
to,47-49
patients,50-58
receiving,59-68
ganglion,69-77
blocking,78-86
compounds,87-96
because,97-104
a,105-106
critical,107-115
fall,116-120
in,121-123
blood,124-129
pressure,130-138
may,139-142
occur.,143-149

No,0-2
formal,3-9
drug,10-14
interaction,15-26
studies,27-34
with,35-39
anti-neoplastic,40-55	DrugDDI.d135.s0.e0
agents,56-62	DrugDDI.d135.s0.e0
have,63-67
been,68-72
conducted.,73-83

In,0-2
Study,3-8
1,,9-11
patients,12-20
with,21-25
colorectal,26-36
cancer,37-43
were,44-48
given,49-54
irinotecan/5-FU/leucovorin,55-81	DrugDDI.d135.s1.e0
(bolus-IFL),82-93
with,94-98
or,99-101
without,102-109
AVASTIN.,110-118	DrugDDI.d135.s1.e1

Irinotecan,0-10	DrugDDI.d135.s2.e0
concentrations,11-25
were,26-30
similar,31-38
in,39-41
patients,42-50
receiving,51-60
bolus-IFL,61-70
alone,71-76
and,77-80
in,81-83
combination,84-95
with,96-100
AVASTIN.,101-109	DrugDDI.d135.s2.e1

The,0-3
concentrations,4-18
of,19-21
SN38,,22-27
the,28-31
active,32-38	DrugDDI.d135.s3.e0
metabolite,39-49	DrugDDI.d135.s3.e0
of,50-52
irinotecan,,53-64
were,65-69
on,70-72
average,73-80
33%,81-84
higher,85-91
in,92-94
patients,95-103
receiving,104-113
bolus-IFL,114-123
in,124-126
combination,127-138
with,139-143
AVASTIN,144-151	DrugDDI.d135.s3.e2
when,152-156
compared,157-165
with,166-170
bolus-IFL,171-180
alone.,181-187

In,0-2
Study,3-8
1,,9-11
patients,12-20
receiving,21-30
bolus-IFL,31-40
plus,41-45
AVASTIN,46-53	DrugDDI.d135.s4.e0
had,54-57
a,58-59
higher,60-66
incidence,67-76
of,77-79
Grade,80-85
3-4,86-89
diarrhea,90-98
and,99-102
neutropenia.,103-115

Due,0-3
to,4-6
high,7-11
inter-patient,12-25
variability,26-37
and,38-41
limited,42-49
sampling,,50-59
the,60-63
extent,64-70
of,71-73
the,74-77
increase,78-86
in,87-89
SN38,90-94
levels,95-101
in,102-104
patients,105-113
receiving,114-123
concurrent,124-134
irinotecan,135-145	DrugDDI.d135.s5.e0
and,146-149
AVASTIN,150-157	DrugDDI.d135.s5.e1
is,158-160
uncertain.,161-171

No,0-2
formal,3-9
studies,10-17
to,18-20
evaluate,21-29
drug,30-34
interactions,35-47
with,48-52
bexarotene,53-63	DrugDDI.d133.s0.e0
have,64-68
been,69-73
conducted.,74-84

Bexarotene,0-10	DrugDDI.d133.s1.e0
oxidative,11-20
metabolites,21-32
appear,33-39
to,40-42
be,43-45
formed,46-52
by,53-55
cytochrome,56-66	DrugDDI.d133.s1.e1
P450,67-71	DrugDDI.d133.s1.e1
3A4.,72-76	DrugDDI.d133.s1.e1

On,0-2
the,3-6
basis,7-12
of,13-15
the,16-19
metabolism,20-30
of,31-33
bexarotene,34-44	DrugDDI.d133.s2.e0
by,45-47
cytochrome,48-58	DrugDDI.d133.s2.e1
P450,59-63	DrugDDI.d133.s2.e1
3A4,,64-68	DrugDDI.d133.s2.e1
ketoconazole,,69-82
itraconazole,,83-96
erythromycin,,97-110
gemfibrozil,,111-123
grapefruit,124-134
juice,,135-141
and,142-145
other,146-151
inhibitors,152-162
of,163-165
cytochrome,166-176	DrugDDI.d133.s2.e6
P450,177-181	DrugDDI.d133.s2.e6
3A4,182-185	DrugDDI.d133.s2.e6
would,186-191
be,192-194
expected,195-203
to,204-206
lead,207-211
to,212-214
an,215-217
increase,218-226
in,227-229
plasma,230-236
bexarotene,237-247	DrugDDI.d133.s2.e7
concentrations.,248-263

Furthermore,,0-12
rifampin,,13-22
phenytoin,,23-33
phenobarbital,,34-48
and,49-52
other,53-58
inducers,59-67
of,68-70
cytochrome,71-81	DrugDDI.d133.s3.e3
P450,82-86	DrugDDI.d133.s3.e3
3A4,87-90	DrugDDI.d133.s3.e3
may,91-94
cause,95-100
a,101-102
reduction,103-112
in,113-115
plasma,116-122
bexarotene,123-133	DrugDDI.d133.s3.e4
concentrations.,134-149

Concomitant,0-11
administration,12-26
of,27-29
Targretin,30-39	DrugDDI.d133.s4.e0
?,40-41
capsules,42-50
and,51-54
gemfibrozil,55-66	DrugDDI.d133.s4.e1
resulted,67-75
in,76-78
substantial,79-90
increases,91-100
in,101-103
plasma,104-110
concentrations,111-125
of,126-128
bexarotene,,129-140
probably,141-149
at,150-152
least,153-158
partially,159-168
related,169-176
to,177-179
cytochrome,180-190	DrugDDI.d133.s4.e3
P450,191-195	DrugDDI.d133.s4.e3
3A4,196-199	DrugDDI.d133.s4.e3
inhibition,200-210
by,211-213
gemfibrozil.,214-226	DrugDDI.d133.s4.e4

Under,0-5
similar,6-13
conditions,,14-25
bexarotene,26-36	DrugDDI.d133.s5.e0
concentrations,37-51
were,52-56
not,57-60
affected,61-69
by,70-72
concomitant,73-84
atorvastatin,85-97	DrugDDI.d133.s5.e1
administration.,98-113

Concomitant,0-11
administration,12-26
of,27-29
gemfibrozil,30-41	DrugDDI.d133.s6.e0
with,42-46
Targretin,47-56	DrugDDI.d133.s6.e1
?,57-58
capsules,59-67
is,68-70
not,71-74
recommended.,75-87

When,0-4
Bezalip,5-12	DrugDDI.d17.s0.e0
or,13-15
Bezalip,16-23	DrugDDI.d17.s0.e1
retard,24-30
is,31-33
used,34-38
at,39-41
the,42-45
same,46-50
time,51-55
as,56-58
other,59-64
medicines,65-74	DrugDDI.d17.s0.e2
or,75-77
substances,78-88
the,89-92
following,93-102
interactions,103-115
must,116-120
be,121-123
taken,124-129
into,130-134
account:,135-143
-,144-145
Bezalip,146-153	DrugDDI.d17.s0.e3
and,154-157
Bezalip,158-165	DrugDDI.d17.s0.e4
retard,166-172
may,173-176
enhance,177-184
the,185-188
action,189-195
of,196-198
anticoagulants,199-213	DrugDDI.d17.s0.e5
of,214-216
the,217-220
coumarin,221-229	DrugDDI.d17.s0.e6
type.,230-235

For,0-3
this,4-8
reason,,9-16
the,17-20
dose,21-25
of,26-28
the,29-32
anticoagulant,33-46	DrugDDI.d17.s1.e0
should,47-53
be,54-56
reduced,57-64
by,65-67
30,68-70
-,71-72
50%,73-76
at,77-79
the,80-83
start,84-89
of,90-92
treatment,93-102
with,103-107
Bezalip,108-115	DrugDDI.d17.s1.e1
or,116-118
Bezalip,119-126	DrugDDI.d17.s1.e2
retard,127-133
and,134-137
then,138-142
titrated,143-151
according,152-161
to,162-164
the,165-168
blood,169-174
clotting,175-183
parameters,184-194

-,0-1
The,2-5
action,6-12
of,13-15
sulphonylureas,16-30	DrugDDI.d17.s3.e0
and,31-34
insulin,35-42	DrugDDI.d17.s3.e1
may,43-46
be,47-49
enhanced,50-58
by,59-61
Bezalip,62-69	DrugDDI.d17.s3.e2
or,70-72
Bezalip,73-80	DrugDDI.d17.s3.e3
retard.,81-88

This,0-4
may,5-8
be,9-11
due,12-15
to,16-18
an,19-21
improved,22-30
glucose,31-38	DrugDDI.d17.s4.e0
utilization,39-50
with,51-55
simultaneous,56-68
reduction,69-78
in,79-81
insulin,82-89	DrugDDI.d17.s4.e1
requirement,90-101

-,0-1
In,2-4
isolated,5-13
cases,,14-20
a,21-22
pronounced,23-33
though,34-40
reversible,,41-52
impairment,53-63
of,64-66
renal,67-72
function,73-81
(accompanied,82-94
by,95-97
a,98-99
corresponding,100-113
increase,114-122
in,123-125
the,126-129
serum,130-135
creatinine,136-146
level),147-153
has,154-157
been,158-162
reported,163-171
in,172-174
organ,175-180
transplant,181-191
patients,192-200
receiving,201-210
immuno-suppressant,211-229
therapy,230-237
and,238-241
concomitant,242-253
bezafibrate.,254-266	DrugDDI.d17.s6.e0

Accordingly,,0-12
renal,13-18
function,19-27
should,28-34
be,35-37
closely,38-45
monitored,46-55
in,56-58
these,59-64
patients,65-73
and,,74-78
in,79-81
the,82-85
event,86-91
of,92-94
relevant,95-103
significant,104-115
changes,116-123
in,124-126
laboratory,127-137
parameters,,138-149
bezafibrate,150-161	DrugDDI.d17.s7.e0
should,,162-169
if,170-172
necessary,,173-183
be,184-186
discontinued,187-199

-,0-1
When,2-6
Bezalip,7-14	DrugDDI.d17.s9.e0
or,15-17
Bezalip,18-25	DrugDDI.d17.s9.e1
retard,26-32
is,33-35
used,36-40
concurrently,41-53
with,54-58
anion-exchange,59-73	DrugDDI.d17.s9.e2
resins,74-80	DrugDDI.d17.s9.e2
(e.g.,81-86
cholestryramine),,87-104
an,105-107
interval,108-116
of,117-119
at,120-122
least,123-128
2,129-130
hours,131-136
should,137-143
be,144-146
maintained,147-157
between,158-165
the,166-169
two,170-173
medicines,,174-184
since,185-190
the,191-194
absorption,195-205
of,206-208
Bezalip,209-216	DrugDDI.d17.s9.e4
or,217-219
Bezalip,220-227	DrugDDI.d17.s9.e5
retard,228-234
is,235-237
impaired,238-246

-,0-1
Perhexiline,2-13	DrugDDI.d17.s11.e0
hydrogen,14-22	DrugDDI.d17.s11.e0
maleate,23-30	DrugDDI.d17.s11.e0
or,31-33
MAO-inhibitors,34-48	DrugDDI.d17.s11.e1
(with,49-54
hepatotoxic,55-66
potential),67-77
must,78-82
not,83-86
be,87-89
administered,90-102
together,103-111
with,112-116
Bezalip,117-124	DrugDDI.d17.s11.e2
or,125-127
Bezalip,128-135	DrugDDI.d17.s11.e3
retard.,136-143

In,0-2
vitro,3-8
studies,9-16
have,17-21
shown,22-27
CASODEX,28-35	DrugDDI.d288.s0.e0
can,36-39
displace,40-48
coumarin,49-57	DrugDDI.d288.s0.e1
anticoagulants,,58-73	DrugDDI.d288.s0.e1
such,74-78
as,79-81
warfarin,,82-91
from,92-96
their,97-102
protein-binding,103-118	DrugDDI.d288.s0.e3
sites.,119-125

It,0-2
is,3-5
recommended,6-17
that,18-22
if,23-25
CASODEX,26-33	DrugDDI.d288.s1.e0
is,34-36
started,37-44
in,45-47
patients,48-56
already,57-64
receiving,65-74
coumarin,75-83	DrugDDI.d288.s1.e1
anticoagulants,,84-99	DrugDDI.d288.s1.e1
prothrombin,100-111
times,112-117
should,118-124
be,125-127
closely,128-135
monitored,136-145
and,146-149
adjustment,150-160
of,161-163
the,164-167
anticoagulant,168-181	DrugDDI.d288.s1.e2
dose,182-186
may,187-190
be,191-193
necessary.,194-204

Drug,0-4
Interactions:,5-18
The,19-22
central,23-30
anticholinergic,31-46
syndrome,47-55
can,56-59
occur,60-65
when,66-70
anticholinergic,71-86	DrugDDI.d557.s0.e0
agents,87-93	DrugDDI.d557.s0.e0
such,94-98
as,99-101
AKINETON,102-110	DrugDDI.d557.s0.e1
are,111-114
administered,115-127
concomitantly,128-141
with,142-146
drugs,147-152	DrugDDI.d557.s0.e2
that,153-157
have,158-162
secondary,163-172
anticholinergic,173-188	DrugDDI.d557.s0.e3
actions,,189-197
e.g.,,198-203
certain,204-211
narcotic,212-220	DrugDDI.d557.s0.e4
analgesics,221-231	DrugDDI.d557.s0.e4
such,232-236
as,237-239
meperidine,,240-251
the,252-255
phenothiazines,256-270	DrugDDI.d557.s0.e6
and,271-274
other,275-280
antipsychotics,,281-296
tricyclic,297-306	DrugDDI.d557.s0.e8
antidepressants,,307-323	DrugDDI.d557.s0.e8
certain,324-331
antiarrhythmics,332-347	DrugDDI.d557.s0.e9
such,348-352
as,353-355
the,356-359
quinidine,360-369	DrugDDI.d557.s0.e10
salts,,370-376
and,377-380
antihistamines.,381-396	DrugDDI.d557.s0.e11

ZEBETA,0-6	DrugDDI.d47.s0.e0
should,7-13
not,14-17
be,18-20
combined,21-29
with,30-34
other,35-40
beta-blocking,41-54	DrugDDI.d47.s0.e1
agents.,55-62	DrugDDI.d47.s0.e1

Patients,0-8
receiving,9-18
catecholamine-depleting,19-42
drugs,,43-49
such,50-54
as,55-57
reserpine,58-67	DrugDDI.d47.s1.e1
or,68-70
guanethidine,,71-84
should,85-91
be,92-94
closely,95-102
monitored,,103-113
because,114-121
the,122-125
added,126-131
beta-adrenergic,132-147
blocking,148-156
action,157-163
of,164-166
ZEBETA,167-173	DrugDDI.d47.s1.e3
may,174-177
produce,178-185
excessive,186-195
reduction,196-205
of,206-208
sympathetic,209-220
activity.,221-230

In,0-2
patients,3-11
receiving,12-21
concurrent,22-32
therapy,33-40
with,41-45
clonidine,,46-56
if,57-59
therapy,60-67
is,68-70
to,71-73
be,74-76
discontinued,,77-90
it,91-93
is,94-96
suggested,97-106
that,107-111
ZEBETA,112-118	DrugDDI.d47.s2.e1
be,119-121
discontinued,122-134
for,135-138
several,139-146
days,147-151
before,152-158
the,159-162
withdrawal,163-173
of,174-176
clonidine.,177-187	DrugDDI.d47.s2.e2

ZEBETA,0-6	DrugDDI.d47.s3.e0
should,7-13
be,14-16
used,17-21
with,22-26
care,27-31
when,32-36
myocardial,37-47	DrugDDI.d47.s3.e1
depressants,48-59	DrugDDI.d47.s3.e1
or,60-62
inhibitors,63-73
of,74-76
AV,77-79
conduction,,80-91
such,92-96
as,97-99
certain,100-107
calcium,108-115	DrugDDI.d47.s3.e2
antagonists,116-127	DrugDDI.d47.s3.e2
(particularly,128-141
of,142-144
the,145-148
phenylalkylamine,149-165
[verapamil],166-177
and,178-181
benzothiazepine,182-197
[diltiazem],198-209
classes),,210-219
or,220-222
antiarrhythmic,223-237	DrugDDI.d47.s3.e5
agents,,238-245	DrugDDI.d47.s3.e5
such,246-250
as,251-253
disopyramide,,254-267
are,268-271
used,272-276
concurrently.,277-290

Concurrent,0-10
use,11-14
of,15-17
rifampin,18-26	DrugDDI.d47.s4.e0
increases,27-36
the,37-40
metabolic,41-50
clearance,51-60
of,61-63
ZEBETA,,64-71
resulting,72-81
in,82-84
a,85-86
shortened,87-96
elimination,97-108
half-life,109-118
of,119-121
ZEBETA.,122-129	DrugDDI.d47.s4.e2

Pharmacokinetic,0-15
studies,16-23
document,24-32
no,33-35
clinically,36-46
relevant,47-55
interactions,56-68
with,69-73
other,74-79
agents,80-86
given,87-92
concomitantly,,93-107
including,108-117
thiazide,118-126	DrugDDI.d47.s6.e0
diuretics,,127-137	DrugDDI.d47.s6.e0
digoxin,,138-146
and,147-150
cimetidine.,151-162	DrugDDI.d47.s6.e2

There,0-5
was,6-9
no,10-12
effect,13-19
of,20-22
ZEBETA,23-29	DrugDDI.d47.s7.e0
on,30-32
prothrombin,33-44
time,45-49
in,50-52
patients,53-61
on,62-64
stable,65-71
doses,72-77
of,78-80
warfarin.,81-90	DrugDDI.d47.s7.e1

Risk,0-4
of,5-7
Anaphylactic,8-20
Reaction:,21-30
While,31-36
taking,37-43
beta-blockers,,44-58
patients,59-67
with,68-72
a,73-74
history,75-82
of,83-85
severe,86-92
anaphylactic,93-105
reaction,106-114
to,115-117
a,118-119
variety,120-127
of,128-130
allergens,131-140
may,141-144
be,145-147
more,148-152
reactive,153-161
to,162-164
repeated,165-173
challenge,,174-184
either,185-191
accidental,,192-203
diagnostic,,204-215
or,216-218
therapeutic.,219-231

Such,0-4
patients,5-13
may,14-17
be,18-20
unresponsive,21-33
to,34-36
the,37-40
usual,41-46
doses,47-52
of,53-55
epinephrine,56-67	DrugDDI.d47.s9.e0
used,68-72
to,73-75
treat,76-81
allergic,82-90
reactions.,91-101

Use,0-3
of,4-6
MAO,7-10	DrugDDI.d28.s0.e0
inhibitors,11-21	DrugDDI.d28.s0.e0
may,22-25
cause,26-31
an,32-34
excessive,35-44
increase,45-53
in,54-56
blood,57-62
pressure,63-71
and,72-75
heart,76-81
stimulation.,82-94

If,0-2
you,3-6
are,7-10
also,11-15
using,16-21
a,22-23
steroid,24-31
inhaler,,32-40
take,41-45
bitolterol,46-56	DrugDDI.d28.s1.e0
first,57-62
and,63-66
then,67-71
wait,72-76
about,77-82
15,83-85
minutes,86-93
before,94-100
using,101-106
the,107-110
steroid,111-118
inhaler.,119-127

This,0-4
allows,5-11
bitolterol,12-22	DrugDDI.d28.s2.e0
to,23-25
open,26-30
air,31-34
passages,,35-44
increasing,45-55
the,56-59
effectiveness,60-73
of,74-76
the,77-80
steroid.,81-89

Angiomax,0-8	DrugDDI.d508.s0.e0
does,9-13
not,14-17
exhibit,18-25
binding,26-33
to,34-36
plasma,37-43	DrugDDI.d508.s0.e1
proteins,44-52	DrugDDI.d508.s0.e1
(other,53-59
than,60-64
thrombin),65-74	DrugDDI.d508.s0.e2
or,75-77
red,78-81	DrugDDI.d508.s0.e3
blood,82-87	DrugDDI.d508.s0.e3
cells.,88-94	DrugDDI.d508.s0.e3

In,0-2
clinical,3-11
trials,12-18
in,19-21
patients,22-30
undergoing,31-41
PTCA/PCI,,42-51
co-administration,52-69
of,70-72
Angiomax,73-81	DrugDDI.d508.s1.e1
with,82-86
heparin,,87-95
warfarin,,96-105
thrombolytics,106-119	DrugDDI.d508.s1.e4
or,120-122
glycoprotein,123-135	DrugDDI.d508.s1.e5
IIb/IIIa,136-144
inhibitors,145-155
was,156-159
associated,160-170
with,171-175
increased,176-185
risks,186-191
of,192-194
major,195-200
bleeding,201-209
events,210-216
compared,217-225
to,226-228
patients,229-237
not,238-241
receiving,242-251
these,252-257
concomitant,258-269
medications.,270-282	DrugDDI.d508.s1.e6

There,0-5
is,6-8
no,9-11
experience,12-22
with,23-27
co-administration,28-45
of,46-48
Angiomax,49-57	DrugDDI.d508.s2.e0
and,58-61
plasma,62-68	DrugDDI.d508.s2.e1
expanders,69-78	DrugDDI.d508.s2.e1
such,79-83
as,84-86
dextran.,87-95	DrugDDI.d508.s2.e2

Angiomax,0-8	DrugDDI.d508.s3.e0
should,9-15
be,16-18
used,19-23
with,24-28
caution,29-36
in,37-39
patients,40-48
with,49-53
disease,54-61
states,62-68
associated,69-79
with,80-84
an,85-87
increased,88-97
risk,98-102
of,103-105
bleeding.,106-115

Immunogenicity/Re-exposure:,0-27
In,28-30
in,31-33
vitro,34-39
studies,,40-48
Angiomax,49-57	DrugDDI.d508.s4.e0
exhibited,58-67
no,68-70
platelet,71-79
aggregation,80-91
response,92-100
against,101-108
sera,109-113
from,114-118
patients,119-127
with,128-132
a,133-134
history,135-142
of,143-145
HIT/HITTS.,146-156

Among,0-5
494,6-9
subjects,10-18
who,19-22
received,23-31
Angiomax,32-40	DrugDDI.d508.s5.e0
in,41-43
clinical,44-52
trials,53-59
and,60-63
were,64-68
tested,69-75
for,76-79
antibodies,,80-91
2,92-93
subjects,94-102
had,103-106
treatment-emergent,107-125
positive,126-134
bivalirudin,135-146	DrugDDI.d508.s5.e2
antibody,147-155
tests.,156-162

Certain,0-7
antibiotic,,8-19
cisplatin,,20-30
cyclosporine,,31-44
diuretic,,45-54
foscarnet,,55-65
and,66-69
vaccines.,70-79	DrugDDI.d77.s0.e4

No,0-2
formal,3-9
drug,10-14
interaction,15-26
studies,27-34
have,35-39
been,40-44
conducted,45-54
with,55-59
VELCADE.,60-68	DrugDDI.d48.s0.e0

In,0-2
vitro,3-8
studies,9-16
with,17-21
human,22-27
liver,28-33
microsomes,34-44
indicate,45-53
that,54-58
bortezomib,59-69	DrugDDI.d48.s1.e0
is,70-72
primarily,73-82
a,83-84
substrate,85-94
for,95-98
cytochrome,99-109	DrugDDI.d48.s1.e1
P450,110-114	DrugDDI.d48.s1.e1
3A4,,115-119	DrugDDI.d48.s1.e1
2C19,,120-125
and,126-129
1A2.,130-134

Patients,0-8
who,9-12
are,13-16
concomitantly,17-30
receiving,31-40
VELCADE,41-48	DrugDDI.d48.s2.e0
and,49-52
drugs,53-58	DrugDDI.d48.s2.e1
that,59-63
are,64-67
inhibitors,68-78
or,79-81
inducers,82-90
of,91-93
cytochrome,94-104	DrugDDI.d48.s2.e2
P450,105-109	DrugDDI.d48.s2.e2
3A4,110-113	DrugDDI.d48.s2.e2
should,114-120
be,121-123
closely,124-131
monitored,132-141
for,142-145
either,146-152
toxicities,153-163
or,164-166
reduced,167-174
efficacy,175-183
.,184-185

During,0-6
clinical,7-15
trials,,16-23
hypoglycemia,24-36
and,37-40
hyperglycemia,41-54
were,55-59
reported,60-68
in,69-71
diabetic,72-80
patients,81-89
receiving,90-99
oral,100-104	DrugDDI.d48.s3.e0
hypoglycemics.,105-119	DrugDDI.d48.s3.e0

Patients,0-8
on,9-11
oral,12-16
antidiabetic,17-29	DrugDDI.d48.s4.e0
agents,30-36	DrugDDI.d48.s4.e0
receiving,37-46
VELCADE,47-54	DrugDDI.d48.s4.e1
treatment,55-64
may,65-68
require,69-76
close,77-82
monitoring,83-93
of,94-96
their,97-102
blood,103-108
glucose,109-116
levels,117-123
and,124-127
adjustment,128-138
of,139-141
the,142-145
dose,146-150
of,151-153
their,154-159
antidiabetic,160-172	DrugDDI.d48.s4.e2
medication.,173-184

Bosentan,0-8	DrugDDI.d375.s0.e0
is,9-11
metabolized,12-23
by,24-26
CYP2C9,27-33	DrugDDI.d375.s0.e1
and,34-37
CYP3A4.,38-45	DrugDDI.d375.s0.e2

Inhibition,0-10
of,11-13
these,14-19
isoenzymes,20-30	DrugDDI.d375.s1.e0
may,31-34
increase,35-43
the,44-47
plasma,48-54
concentration,55-68
of,69-71
bosentan.,72-81	DrugDDI.d375.s1.e1

Bosentan,0-8	DrugDDI.d375.s2.e0
is,9-11
an,12-14
inducer,15-22
of,23-25
CYP3A4,26-32	DrugDDI.d375.s2.e1
and,33-36
CYP2C9.,37-44	DrugDDI.d375.s2.e2

Consequently,,0-13
plasma,14-20
concentrations,21-35
of,36-38
drugs,39-44	DrugDDI.d375.s3.e0
metabolized,45-56
by,57-59
these,60-65
two,66-69
isoenzymes,70-80	DrugDDI.d375.s3.e1
will,81-85
be,86-88
decreased,89-98
when,99-103
TRACLEER?,104-113
is,114-116
co-administered.,117-133

Bosentan,0-8	DrugDDI.d375.s4.e0
had,9-12
no,13-15
relevant,16-24
inhibitory,25-35
effect,36-42
on,43-45
any,46-49
CYP,50-53
isoenzymes,54-64	DrugDDI.d375.s4.e1
tested,65-71
(CYP1A2,,72-80
CYP2C9,,81-88
CYP2C19,,89-97
CYP2D6,,98-105
CYP3A4).,106-114	DrugDDI.d375.s4.e6

Consequently,,0-13
TRACLEER?,14-23
is,24-26
not,27-30
expected,31-39
to,40-42
increase,43-51
the,52-55
plasma,56-62
concentrations,63-77
of,78-80
drugs,81-86	DrugDDI.d375.s5.e0
metabolized,87-98
by,99-101
these,102-107
enzymes.,108-116

Hormonal,0-8
Contraceptives,,9-24
Including,25-34
Oral,,35-40
Injectable,,41-52
Transdermal,,53-65
and,66-69
Implantable,70-81
Contraceptives:,82-97	DrugDDI.d375.s6.e1
An,98-100
interaction,101-112
study,113-118
demonstrated,119-131
that,132-136
co-administration,137-154
of,155-157
bosentan,158-166	DrugDDI.d375.s6.e2
and,167-170
the,171-174
oral,175-179	DrugDDI.d375.s6.e3
hormonal,180-188	DrugDDI.d375.s6.e3
contraceptive,189-202	DrugDDI.d375.s6.e3
Ortho-Novum?,203-215	DrugDDI.d375.s6.e3
produced,216-224
average,225-232
decreases,233-242
of,243-245
norethindrone,246-259	DrugDDI.d375.s6.e4
and,260-263
ethinyl,264-271	DrugDDI.d375.s6.e5
estradiol,272-281	DrugDDI.d375.s6.e5
levels,282-288
of,289-291
14%,292-295
and,296-299
31%,,300-304
respectively.,305-318

Therefore,,0-10
hormonal,11-19
contraceptives,,20-35
including,36-45
oral,,46-51
injectable,,52-63
transdermal,,64-76
and,77-80
implantable,81-92
forms,,93-99
may,100-103
not,104-107
be,108-110
reliable,111-119
when,120-124
TRACLEER?,125-134
is,135-137
co-administered.,138-154

Specific,0-8
interaction,9-20
studies,21-28
have,29-33
demonstrated,34-46
the,47-50
following:,51-61
Cyclosporine,62-74	DrugDDI.d375.s10.e0
A:,75-77	DrugDDI.d375.s10.e0
During,78-84
the,85-88
first,89-94
day,95-98
of,99-101
concomitant,102-113
administration,,114-129
trough,130-136
concentrations,137-151
of,152-154
bosentan,155-163	DrugDDI.d375.s10.e1
were,164-168
increased,169-178
by,179-181
about,182-187
30-fold.,188-196

Steady-state,0-12
bosentan,13-21	DrugDDI.d375.s11.e0
plasma,22-28
concentrations,29-43
were,44-48
3-,49-51
to,52-54
4-fold,55-61
higher,62-68
than,69-73
in,74-76
the,77-80
absence,81-88
of,89-91
cyclosporine,92-104	DrugDDI.d375.s11.e1
A.,105-107	DrugDDI.d375.s11.e1

The,0-3
concomitant,4-15
administration,16-30
of,31-33
bosentan,34-42	DrugDDI.d375.s12.e0
and,43-46
cyclosporine,47-59	DrugDDI.d375.s12.e1
A,60-61	DrugDDI.d375.s12.e1
is,62-64
contraindicated.,65-81

Co-administration,0-17
of,18-20
bosentan,21-29	DrugDDI.d375.s13.e0
decreased,30-39
the,40-43
plasma,44-50
concentrations,51-65
of,66-68
cyclosporine,69-81	DrugDDI.d375.s13.e1
A,82-83	DrugDDI.d375.s13.e1
(a,84-86
CYP3A4,87-93	DrugDDI.d375.s13.e2
substrate),94-104
by,105-107
approximately,108-121
50%.,122-126

Tacrolimus:,0-11	DrugDDI.d375.s14.e0
Co-administration,12-29
of,30-32
tacrolimus,33-43	DrugDDI.d375.s14.e1
and,44-47
bosentan,48-56	DrugDDI.d375.s14.e2
has,57-60
not,61-64
been,65-69
studied,70-77
in,78-80
man.,81-85

Co-administration,0-17
of,18-20
tacrolimus,21-31	DrugDDI.d375.s15.e0
and,32-35
bosentan,36-44	DrugDDI.d375.s15.e1
resulted,45-53
in,54-56
markedly,57-65
increased,66-75
plasma,76-82
concentrations,83-97
of,98-100
bosentan,101-109	DrugDDI.d375.s15.e2
in,110-112
animals.,113-121

Caution,0-7
should,8-14
be,15-17
exercised,18-27
if,28-30
tacrolimus,31-41	DrugDDI.d375.s16.e0
and,42-45
bosentan,46-54	DrugDDI.d375.s16.e1
are,55-58
used,59-63
together.,64-73

Glyburide:,0-10	DrugDDI.d375.s17.e0
An,11-13
increased,14-23
risk,24-28
of,29-31
elevated,32-40
liver,41-46
aminotransferases,47-64	DrugDDI.d375.s17.e1
was,65-68
observed,69-77
in,78-80
patients,81-89
receiving,90-99
concomitant,100-111
therapy,112-119
with,120-124
glyburide.,125-135	DrugDDI.d375.s17.e2

Therefore,,0-10
the,11-14
concomitant,15-26
administration,27-41
of,42-44
TRACLEER?,45-54
and,55-58
glyburide,59-68	DrugDDI.d375.s18.e0
is,69-71
contraindicated,,72-88
and,89-92
alternative,93-104
hypoglycemic,105-117	DrugDDI.d375.s18.e1
agents,118-124	DrugDDI.d375.s18.e1
should,125-131
be,132-134
considered.,135-146

Co-administration,0-17
of,18-20
bosentan,21-29	DrugDDI.d375.s19.e0
decreased,30-39
the,40-43
plasma,44-50
concentrations,51-65
of,66-68
glyburide,69-78	DrugDDI.d375.s19.e1
by,79-81
approximately,82-95
40%.,96-100

The,0-3
plasma,4-10
concentrations,11-25
of,26-28
bosentan,29-37	DrugDDI.d375.s20.e0
were,38-42
also,43-47
decreased,48-57
by,58-60
approximately,61-74
30%.,75-79

Bosentan,0-8	DrugDDI.d375.s21.e0
is,9-11
also,12-16
expected,17-25
to,26-28
reduce,29-35
plasma,36-42
concentrations,43-57
of,58-60
other,61-66
oral,67-71
hypoglycemic,72-84	DrugDDI.d375.s21.e1
agents,85-91	DrugDDI.d375.s21.e1
that,92-96
are,97-100
predominantly,101-114
metabolized,115-126
by,127-129
CYP2C9,130-136	DrugDDI.d375.s21.e2
or,137-139
CYP3A4.,140-147	DrugDDI.d375.s21.e3

Ketoconazole:,0-13	DrugDDI.d375.s23.e0
Co-administration,14-31
of,32-34
bosentan,35-43	DrugDDI.d375.s23.e1
125,44-47	DrugDDI.d375.s23.e1
mg,48-50	DrugDDI.d375.s23.e1
b.i.d.,51-57
and,58-61
ketoconazole,,62-75
a,76-77
potent,78-84
CYP3A4,85-91	DrugDDI.d375.s23.e3
inhibitor,,92-102
increased,103-112
the,113-116
plasma,117-123
concentrations,124-138
of,139-141
bosentan,142-150	DrugDDI.d375.s23.e4
by,151-153
approximately,154-167
2-fold.,168-175

No,0-2
dose,3-7
adjustment,8-18
of,19-21
bosentan,22-30	DrugDDI.d375.s24.e0
is,31-33
necessary,,34-44
but,45-48
increased,49-58
effects,59-66
of,67-69
bosentan,70-78	DrugDDI.d375.s24.e1
should,79-85
be,86-88
considered.,89-100

Simvastatin,0-11	DrugDDI.d375.s25.e0
and,12-15
Other,16-21
Statins:,22-30	DrugDDI.d375.s25.e1
Co-administration,31-48
of,49-51
bosentan,52-60	DrugDDI.d375.s25.e2
decreased,61-70
the,71-74
plasma,75-81
concentrations,82-96
of,97-99
simvastatin,100-111	DrugDDI.d375.s25.e3
(a,112-114
CYP3A4,115-121	DrugDDI.d375.s25.e4
substrate),,122-133
and,134-137
its,138-141
active,142-148
?-hydroxy,149-158
acid,159-163
metabolite,,164-175
by,176-178
approximately,179-192
50%.,193-197

The,0-3
plasma,4-10
concentrations,11-25
of,26-28
bosentan,29-37	DrugDDI.d375.s26.e0
were,38-42
not,43-46
affected.,47-56

Bosentan,0-8	DrugDDI.d375.s27.e0
is,9-11
also,12-16
expected,17-25
to,26-28
reduce,29-35
plasma,36-42
concentrations,43-57
of,58-60
other,61-66
statins,67-74	DrugDDI.d375.s27.e1
that,75-79
have,80-84
significant,85-96
metabolism,97-107
by,108-110
CYP3A4,,111-118
such,119-123
as,124-126
lovastatin,127-137	DrugDDI.d375.s27.e3
and,138-141
atorvastatin.,142-155	DrugDDI.d375.s27.e4

Patients,0-8
using,9-14
CYP3A4,15-21
metabolized,22-33
statins,34-41	DrugDDI.d375.s29.e0
should,42-48
have,49-53
cholesterol,54-65
levels,66-72
monitored,73-82
after,83-88
TRACLEER?,89-98
is,99-101
initiated,102-111
to,112-114
see,115-118
whether,119-126
the,127-130
statin,131-137
dose,138-142
needs,143-148
adjustment.,149-160

Warfarin:,0-9	DrugDDI.d375.s30.e0
Co-administration,10-27
of,28-30
bosentan,31-39	DrugDDI.d375.s30.e1
500,40-43
mg,44-46
b.i.d.,47-53
for,54-57
6,58-59
days,60-64
decreased,65-74
the,75-78
plasma,79-85
concentrations,86-100
of,101-103
both,104-108
S-warfarin,109-119
(a,120-122
CYP2C9,123-129	DrugDDI.d375.s30.e3
substrate),130-140
and,141-144
R-warfarin,145-155
(a,156-158
CYP3A4,159-165	DrugDDI.d375.s30.e5
substrate),166-176
by,177-179
29,180-182
and,183-186
38%,,187-191
respectively.,192-205

Clinical,0-8
experience,9-19
with,20-24
concomitant,25-36
administration,37-51
of,52-54
bosentan,55-63	DrugDDI.d375.s31.e0
and,64-67
warfarin,68-76	DrugDDI.d375.s31.e1
in,77-79
patients,80-88
with,89-93
pulmonary,94-103
arterial,104-112
hypertension,113-125
did,126-129
not,130-133
show,134-138
clinically,139-149
relevant,150-158
changes,159-166
in,167-169
INR,170-173
or,174-176
warfarin,177-185
dose,186-190
(baseline,191-200
vs.,201-204
end,205-208
of,209-211
the,212-215
clinical,216-224
studies),,225-234
and,235-238
the,239-242
need,243-247
to,248-250
change,251-257
the,258-261
warfarin,262-270
dose,271-275
during,276-282
the,283-286
trials,287-293
due,294-297
to,298-300
changes,301-308
in,309-311
INR,312-315
or,316-318
due,319-322
to,323-325
adverse,326-333
events,334-340
was,341-344
similar,345-352
among,353-358
bosentan-,359-368	DrugDDI.d375.s31.e2
and,369-372
placebo-treated,373-388
patients.,389-398

Digoxin,,0-8
Nimodipine,9-19	DrugDDI.d375.s32.e1
and,20-23
Losartan:,24-33	DrugDDI.d375.s32.e2
Bosentan,34-42	DrugDDI.d375.s32.e3
has,43-46
no,47-49
significant,50-61
pharmacokinetic,62-77
interactions,78-90
with,91-95
digoxin,96-103	DrugDDI.d375.s32.e4
and,104-107
nimodipine,,108-119
and,120-123
losartan,124-132	DrugDDI.d375.s32.e6
has,133-136
no,137-139
significant,140-151
effect,152-158
on,159-161
plasma,162-168
levels,169-175
of,176-178
bosentan.,179-188	DrugDDI.d375.s32.e7

Co-administration,0-17
of,18-20
BOTOX?,21-27
and,28-31
aminoglycosides,32-47	DrugDDI.d323.s0.e0
or,48-50
other,51-56
agents,57-63
interfering,64-75
with,76-80
neuromuscular,81-94
transmission,95-107
(e.g.,,108-114
curare-like,115-126	DrugDDI.d323.s0.e1
compounds),127-137
should,138-144
only,145-149
be,150-152
performed,153-162
with,163-167
caution,168-175
as,176-178
the,179-182
effect,183-189
of,190-192
the,193-196
toxin,197-202	DrugDDI.d323.s0.e2
may,203-206
be,207-209
potentiated.,210-222

The,0-3
effect,4-10
of,11-13
administering,14-27
different,28-37
botulinum,38-47	DrugDDI.d323.s1.e0
neurotoxin,48-58	DrugDDI.d323.s1.e0
serotypes,59-68
at,69-71
the,72-75
same,76-80
time,81-85
or,86-88
within,89-95
several,96-103
months,104-110
of,111-113
each,114-118
other,119-124
is,125-127
unknown.,128-136

Excessive,0-9
neuromuscular,10-23
weakness,24-32
may,33-36
be,37-39
exacerbated,40-51
by,52-54
administration,55-69
of,70-72
another,73-80
botulinum,81-90	DrugDDI.d323.s2.e0
toxin,91-96	DrugDDI.d323.s2.e0
prior,97-102
to,103-105
the,106-109
resolution,110-120
of,121-123
the,124-127
effects,128-135
of,136-138
a,139-140
previously,141-151
administered,152-164
botulinum,165-174	DrugDDI.d323.s2.e1
toxin.,175-181	DrugDDI.d323.s2.e1

Co-administration,0-17
of,18-20
MYOBLOC,21-28	DrugDDI.d322.s0.e0
and,29-32
aminoglycosides,33-48	DrugDDI.d322.s0.e1
or,49-51
other,52-57
agents,58-64
interfering,65-76
with,77-81
neuromuscular,82-95
transmission,96-108
(e.g.,,109-115
curare-like,116-127	DrugDDI.d322.s0.e2
compounds),128-138
should,139-145
only,146-150
be,151-153
performed,154-163
with,164-168
caution,169-176
as,177-179
the,180-183
effect,184-190
of,191-193
the,194-197
toxin,198-203	DrugDDI.d322.s0.e3
may,204-207
be,208-210
potentiated.,211-223

The,0-3
effect,4-10
of,11-13
administering,14-27
different,28-37
botulinum,38-47	DrugDDI.d322.s1.e0
neurotoxin,48-58	DrugDDI.d322.s1.e0
serotypes,59-68
at,69-71
the,72-75
same,76-80
time,81-85
or,86-88
within,89-95
less,96-100
than,101-105
4,106-107
months,108-114
of,115-117
each,118-122
other,123-128
is,129-131
unknown.,132-140

However,,0-8
neuromuscular,9-22
paralysis,23-32
may,33-36
be,37-39
potentiated,40-51
by,52-54
co-administration,55-72
or,73-75
overlapping,76-87
administration,88-102
of,103-105
different,106-115
botulinum,116-125	DrugDDI.d322.s2.e0
toxin,126-131	DrugDDI.d322.s2.e0
serotypes.,132-142	DrugDDI.d322.s2.e0

Digitalis,0-9
toxicity,10-18
may,19-22
be,23-25
aggravated,26-36
by,37-39
the,40-43
initial,44-51
release,52-59
of,60-62
norepinephrine,63-77	DrugDDI.d493.s0.e0
caused,78-84
by,85-87
Bretylium,88-97	DrugDDI.d493.s0.e1
Tosylate,98-106	DrugDDI.d493.s0.e1
Injection.,107-117	DrugDDI.d493.s0.e1

The,0-3
pressor,4-11	DrugDDI.d493.s1.e0
effects,12-19	DrugDDI.d493.s1.e0
of,20-22
catecholamines,23-37
such,38-42
as,43-45
dopamine,46-54	DrugDDI.d493.s1.e1
or,55-57
norepinephrine,58-72	DrugDDI.d493.s1.e2
are,73-76
enhanced,77-85
by,86-88
Bretylium,89-98	DrugDDI.d493.s1.e3
Tosylate.,99-108	DrugDDI.d493.s1.e3

Although,0-8
there,9-14
is,15-17
little,18-24
published,25-34
information,35-46
on,47-49
concomitant,50-61
administration,62-76
of,77-79
lidocaine,80-89	DrugDDI.d493.s3.e0
and,90-93
Bretylium,94-103	DrugDDI.d493.s3.e1
Tosylate,,104-113	DrugDDI.d493.s3.e1
these,114-119
drugs,120-125	DrugDDI.d493.s3.e2
are,126-129
often,130-135
administered,136-148
concurrently,149-161
without,162-169
any,170-173
evidence,174-182
of,183-185
interactions,186-198
resulting,199-208
in,209-211
adverse,212-219
effects,220-227
or,228-230
diminished,231-241
efficacy.,242-251

Although,0-8
specific,9-17
drug,18-22
interaction,23-34
studies,35-42
have,43-47
not,48-51
been,52-56
conducted,57-66
with,67-71
ALPHAGAN?,72-81
P,,82-84
the,85-88
possibility,89-100
of,101-103
an,104-106
additive,107-115
or,116-118
potentiating,119-131
effect,132-138
with,139-143
CNS,144-147	DrugDDI.d345.s0.e0
depressants,148-159	DrugDDI.d345.s0.e0
(alcohol,,160-169
barbiturates,,170-183
opiates,,184-192
sedatives,,193-203
or,204-206
anesthetics),207-219	DrugDDI.d345.s0.e5
should,220-226
be,227-229
considered.,230-241

Alpha-agonists,,0-15
as,16-18
a,19-20
class,,21-27
may,28-31
reduce,32-38
pulse,39-44
and,45-48
blood,49-54
pressure.,55-64

Caution,0-7
in,8-10
using,11-16
concomitant,17-28
drugs,29-34	DrugDDI.d345.s2.e0
such,35-39
as,40-42
beta-blockers,43-56	DrugDDI.d345.s2.e1
(ophthalmic,57-68
and,69-72
systemic),,73-83
anti-hypertensives,84-102	DrugDDI.d345.s2.e2
and/or,103-109
cardiac,110-117	DrugDDI.d345.s2.e3
glycosides,118-128	DrugDDI.d345.s2.e3
is,129-131
advised.,132-140

Tricyclic,0-9	DrugDDI.d345.s3.e0
antidepressants,10-25	DrugDDI.d345.s3.e0
have,26-30
been,31-35
reported,36-44
to,45-47
blunt,48-53
the,54-57
hypotensive,58-69
effect,70-76
of,77-79
systemic,80-88
clonidine.It,89-101	DrugDDI.d345.s3.e1
is,102-104
not,105-108
known,109-114
whether,115-122
the,123-126
concurrent,127-137
use,138-141
of,142-144
these,145-150
agents,151-157
with,158-162
ALPHAGAN?,163-172
P,173-174
in,175-177
humans,178-184
can,185-188
lead,189-193
to,194-196
resulting,197-206
interference,207-219
with,220-224
the,225-228
IOP,229-232
lowering,233-241
effect.,242-249

Caution,,0-8
however,,9-17
is,18-20
advised,21-28
in,29-31
patients,32-40
taking,41-47
tricyclic,48-57	DrugDDI.d345.s5.e0
antidepressants,58-73	DrugDDI.d345.s5.e0
which,74-79
can,80-83
affect,84-90
the,91-94
metabolism,95-105
and,106-109
uptake,110-116
of,117-119
circulating,120-131
amines.,132-139

AZOPT,0-5	DrugDDI.d158.s0.e0
(brinzolamide,6-19
ophthalmic,20-30
suspension),31-42
1%,43-45
contains,46-54
a,55-56
carbonic,57-65	DrugDDI.d158.s0.e2
anhydrase,66-75	DrugDDI.d158.s0.e2
inhibitor.,76-86	DrugDDI.d158.s0.e2

Acid-base,0-9
and,10-13
electrolyte,14-25
alterations,26-37
were,38-42
not,43-46
reported,47-55
in,56-58
the,59-62
clinical,63-71
trials,72-78
with,79-83
brinzolamide.,84-97	DrugDDI.d158.s1.e0

However,,0-8
in,9-11
patients,12-20
treated,21-28
with,29-33
oral,34-38
carbonic,39-47	DrugDDI.d158.s2.e0
anhydrase,48-57	DrugDDI.d158.s2.e0
inhibitors,,58-69	DrugDDI.d158.s2.e0
rare,70-74
instances,75-84
of,85-87
drug,88-92
interactions,93-105
have,106-110
occurred,111-119
with,120-124
high-dose,125-134
salicylate,135-145	DrugDDI.d158.s2.e1
therapy.,146-154

Therefore,,0-10
the,11-14
potential,15-24
for,25-28
such,29-33
drug,34-38
interaction,39-50
should,51-57
be,58-60
considered,61-71
in,72-74
patients,75-83
receiving,84-93
AZOPT,94-99	DrugDDI.d158.s3.e0
(brinzolamide,100-113
ophthalmic,114-124
suspension),125-136
1%.,137-140

The,0-3
risk,4-8
of,9-11
using,12-17
bromocriptine,18-31	DrugDDI.d499.s0.e0
mesylate,32-40	DrugDDI.d499.s0.e0
in,41-43
combination,44-55
with,56-60
other,61-66
drugs,67-72	DrugDDI.d499.s0.e1
has,73-76
not,77-80
been,81-85
systematically,86-100
evaluated,,101-111
but,112-115
alcohol,116-123	DrugDDI.d499.s0.e2
may,124-127
potentiate,128-138
the,139-142
side,143-147
effects,148-155
of,156-158
bromocriptine,159-172	DrugDDI.d499.s0.e3
mesylate.,173-182	DrugDDI.d499.s0.e3

Bromocriptine,0-13	DrugDDI.d499.s1.e0
mesylate,14-22	DrugDDI.d499.s1.e0
may,23-26
interact,27-35
with,36-40
dopamine,41-49	DrugDDI.d499.s1.e1
antagonists,,50-62	DrugDDI.d499.s1.e1
butyrophenones,,63-78
and,79-82
certain,83-90
other,91-96
agents.,97-104

Compounds,0-9
in,10-12
these,13-18
categories,19-29
result,30-36
in,37-39
a,40-41
decreased,42-51
efficacy,52-60
of,61-63
bromocriptine,64-77	DrugDDI.d499.s2.e0
mesylate:,78-87	DrugDDI.d499.s2.e0
phenothiazines,,88-103
haloperidol,,104-116
metoclopramide,,117-132
pimozide.,133-142	DrugDDI.d499.s2.e4

Concomitant,0-11
use,12-15
of,16-18
bromocriptine,19-32	DrugDDI.d499.s3.e0
mesylate,33-41	DrugDDI.d499.s3.e0
with,42-46
other,47-52
ergot,53-58	DrugDDI.d499.s3.e1
alkaloids,59-68	DrugDDI.d499.s3.e1
is,69-71
not,72-75
recommended.,76-88

Dexbrompheniramine,0-18	DrugDDI.d330.s0.e0
can,19-22
interact,23-31
with,32-36
alcohol,37-44	DrugDDI.d330.s0.e1
or,45-47
other,48-53
CNS,54-57	DrugDDI.d330.s0.e2
depressants,58-69	DrugDDI.d330.s0.e2
(may,70-74
potentiate,75-85
the,86-89
CNS,90-93	DrugDDI.d330.s0.e3
depressant,94-104	DrugDDI.d330.s0.e3
effects,105-112
of,113-115
either,116-122
these,123-128
medications,129-140	DrugDDI.d330.s0.e4
or,141-143
antihistamines),,144-160
anticholinergics,161-177	DrugDDI.d330.s0.e6
or,178-180
other,181-186	DrugDDI.d330.s0.e7
medications,187-198	DrugDDI.d330.s0.e7
with,199-203
anticholinergic,204-219	DrugDDI.d330.s0.e8
activity,220-228
(anticholinergic,229-245
effects,246-253
may,254-257
be,258-260
potentiated,261-272
when,273-277
these,278-283
medications,284-295	DrugDDI.d330.s0.e10
are,296-299
used,300-304
concurrently,305-317
with,318-322
antihistamines),,323-339
and,340-343
monoamine,344-353	DrugDDI.d330.s0.e12
oxidase,354-361	DrugDDI.d330.s0.e12
(MAO),362-367
inhibitors,368-378
(concurrent,379-390
use,391-394
with,395-399
antihistamines,400-414	DrugDDI.d330.s0.e13
may,415-418
prolong,419-426
and,427-430
intensify,431-440
the,441-444
anticholinergic,445-460	DrugDDI.d330.s0.e14
and,461-464
CNS,465-468	DrugDDI.d330.s0.e15
depressant,469-479	DrugDDI.d330.s0.e15
effects,480-487
of,488-490
antihistamines).,491-507	DrugDDI.d330.s0.e16

This,0-4
drug,5-9	DrugDDI.d368.s0.e0
may,10-13
interact,14-22
with,23-27
alcohol,28-35	DrugDDI.d368.s0.e1
or,36-38
other,39-44
CNS,45-48	DrugDDI.d368.s0.e2
depressants,49-60	DrugDDI.d368.s0.e2
(may,61-65
potentiate,66-76
the,77-80
CNS,81-84	DrugDDI.d368.s0.e3
depressant,85-95	DrugDDI.d368.s0.e3
effects,96-103
of,104-106
either,107-113
these,114-119
medications,120-131	DrugDDI.d368.s0.e4
or,132-134
antihistamines),,135-151
anticholinergics,152-168	DrugDDI.d368.s0.e6
or,169-171
other,172-177	DrugDDI.d368.s0.e7
medications,178-189	DrugDDI.d368.s0.e7
with,190-194
anticholinergic,195-210	DrugDDI.d368.s0.e8
activity,211-219
(anticholinergic,220-236
effects,237-244
may,245-248
be,249-251
potentiated,252-263
when,264-268
these,269-274
medications,275-286	DrugDDI.d368.s0.e10
are,287-290
used,291-295
concurrently,296-308
with,309-313
antihistamines),,314-330
and,331-334
monoamine,335-344	DrugDDI.d368.s0.e12
oxidase,345-352	DrugDDI.d368.s0.e12
(MAO),353-358
inhibitors,359-369
(concurrent,370-381
use,382-385
with,386-390
antihistamines,391-405	DrugDDI.d368.s0.e14
may,406-409
prolong,410-417
and,418-421
intensify,422-431
the,432-435
anticholinergic,436-451	DrugDDI.d368.s0.e15
and,452-455
CNS,456-459	DrugDDI.d368.s0.e16
depressant,460-470	DrugDDI.d368.s0.e16
effects,471-478
of,479-481
antihistamines).,482-498	DrugDDI.d368.s0.e17

Concomitant,0-11
oral,12-16
administration,17-31
of,32-34
ketoconazole,35-47	DrugDDI.d334.s0.e0
(a,48-50
known,51-56
inhibitor,57-66
of,67-69
CYP3A4,70-76	DrugDDI.d334.s0.e1
activity,77-85
in,86-88
the,89-92
liver,93-98	DrugDDI.d334.s0.e2
and,99-102
in,103-105
the,106-109
intestinal,110-120
mucosa),121-128
caused,129-135
an,136-138
eight-fold,139-149
increase,150-158
of,159-161
the,162-165
systemic,166-174
exposure,175-183
to,184-186
oral,187-191	DrugDDI.d334.s0.e3
budesonide.,192-203	DrugDDI.d334.s0.e3

If,0-2
treatment,3-12
with,13-17
inhibitors,18-28
of,29-31
CYP3A4,32-38	DrugDDI.d334.s1.e0
activity,39-47
(such,48-53
as,54-56
ketoconazole,,57-70
intraconazole,,71-85
ritonavir,,86-96
indinavir,,97-107
saquinavir,,108-119
erythromycin,,120-133
etc.),134-139
is,140-142
indicated,,143-153
reduction,154-163
of,164-166
the,167-170
budesonide,171-181	DrugDDI.d334.s1.e6
dose,182-186
should,187-193
be,194-196
considered.,197-208

After,0-5
extensive,6-15
intake,16-22
of,23-25
grapefruit,26-36
juice,37-42
(which,43-49
inhibits,50-58
CYP3A4,59-65	DrugDDI.d334.s2.e0
activity,66-74
predominantly,75-88
in,89-91
the,92-95
intestinal,96-106
mucosa),,107-115
the,116-119
systemic,120-128
exposure,129-137
for,138-141
oral,142-146	DrugDDI.d334.s2.e1
budesonide,147-157	DrugDDI.d334.s2.e1
increased,158-167
about,168-173
two,174-177
times.,178-184

As,0-2
with,3-7
other,8-13
drugs,14-19	DrugDDI.d334.s3.e0
primarily,20-29
being,30-35
metabolized,36-47
through,48-55
CYP3A4,,56-63
ingestion,64-73
of,74-76
grapefruit,77-87	DrugDDI.d334.s3.e2
or,88-90
grapefruit,91-101
juice,102-107
should,108-114
be,115-117
avoided,118-125
in,126-128
connection,129-139
with,140-144
budesonide,145-155	DrugDDI.d334.s3.e3
administration.,156-171

-,0-1
Drugs,2-7	DrugDDI.d566.s0.e0
with,8-12
ototoxic,13-21
potential:,22-32
Especially,33-43
in,44-46
the,47-50
presence,51-59
of,60-62
impaired,63-71
renal,72-77
function,,78-87
the,88-91
use,92-95
of,96-98
parenterally,99-111
administered,112-124
bumetanide,125-135	DrugDDI.d566.s0.e1
in,136-138
patients,139-147
to,148-150
whom,151-155
aminoglycoside,156-170	DrugDDI.d566.s0.e2
antibiotics,171-182	DrugDDI.d566.s0.e2
are,183-186
also,187-191
being,192-197
given,198-203
should,204-210
be,211-213
avoided,,214-222
except,223-229
in,230-232
life-threatening,233-249
conditions.,250-261

-,0-1
Drugs,2-7	DrugDDI.d566.s1.e0
with,8-12
nephrotoxic,13-24
potential:,25-35
There,36-41
has,42-45
been,46-50
no,51-53
experience,54-64
on,65-67
the,68-71
concurrent,72-82
use,83-86
of,87-89
bumetanide,90-100	DrugDDI.d566.s1.e1
with,101-105
drugs,106-111	DrugDDI.d566.s1.e2
known,112-117
to,118-120
have,121-125
a,126-127
nephrotoxic,128-139
potential.,140-150

Therefore,,0-10
the,11-14
simultaneous,15-27
administration,28-42
of,43-45
these,46-51
drugs,52-57	DrugDDI.d566.s2.e0
should,58-64
be,65-67
avoided.,68-76

-,0-1
Lithium:,2-10	DrugDDI.d566.s3.e0
Lithium,11-18	DrugDDI.d566.s3.e1
should,19-25
generally,26-35
not,36-39
be,40-42
given,43-48
with,49-53
diuretics,54-63	DrugDDI.d566.s3.e2
(such,64-69
as,70-72
bumetanide),73-84	DrugDDI.d566.s3.e3
because,85-92
they,93-97
reduce,98-104
its,105-108
renal,109-114
clearance,115-124
and,125-128
add,129-132
a,133-134
high,135-139
risk,140-144
of,145-147
lithium,148-155
toxicity.,156-165

-,0-1
Probenecid:,2-13	DrugDDI.d566.s4.e0
Pretreatment,14-26
with,27-31
probenecid,32-42	DrugDDI.d566.s4.e1
reduces,43-50
both,51-55
the,56-59
natriuresis,60-71
and,72-75
hyperreninemia,76-90
produced,91-99
by,100-102
bumetanide.,103-114	DrugDDI.d566.s4.e2

This,0-4
antagonistic,5-17
effect,18-24
of,25-27
probenecid,28-38	DrugDDI.d566.s5.e0
on,39-41
bu-metanide,42-53
natriuresis,54-65
is,66-68
not,69-72
due,73-76
to,77-79
a,80-81
direct,82-88
action,89-95
on,96-98
sodium,99-105	DrugDDI.d566.s5.e1
excretion,106-115
but,116-119
is,120-122
probably,123-131
secondary,132-141
to,142-144
its,145-148
inhibitory,149-159
effect,160-166
on,167-169
renal,170-175
tubular,176-183
secretion,184-193
of,194-196
bumetanide.,197-208	DrugDDI.d566.s5.e2

Thus,,0-5
probenecid,6-16	DrugDDI.d566.s6.e0
should,17-23
not,24-27
be,28-30
administered,31-43
concurrently,44-56
with,57-61
bumetanide.,62-73	DrugDDI.d566.s6.e1

-,0-1
Indomethacin:,2-15	DrugDDI.d566.s7.e0
Indomethacin,16-28	DrugDDI.d566.s7.e1
blunts,29-35
the,36-39
increases,40-49
in,50-52
urine,53-58
volume,59-65
and,66-69
sodium,70-76	DrugDDI.d566.s7.e2
excretion,77-86
seen,87-91
during,92-98
bumetanide,99-109
treatment,110-119
and,120-123
inhibits,124-132
the,133-136
bumetanide-induced,137-155	DrugDDI.d566.s7.e3
increase,156-164
in,165-167
plasma,168-174
renin,175-180
activity.,181-190

Concurrent,0-10
therapy,11-18
with,19-23
bumetanide,24-34	DrugDDI.d566.s8.e0
is,35-37
thus,38-42
not,43-46
recommended.,47-59

-,0-1
Antihypertensives:,2-20	DrugDDI.d566.s9.e0
Bumetanide,21-31	DrugDDI.d566.s9.e1
may,32-35
potentiate,36-46
the,47-50
effect,51-57
of,58-60
various,61-68
antihypertensive,69-85	DrugDDI.d566.s9.e2
drugs,,86-92	DrugDDI.d566.s9.e2
necessitating,93-106
a,107-108
reduction,109-118
in,119-121
the,122-125
dosage,126-132
of,133-135
these,136-141
drugs.,142-148	DrugDDI.d566.s9.e3

-,0-1
Digoxin:,2-10	DrugDDI.d566.s10.e0
Interaction,11-22
studies,23-30
in,31-33
humans,34-40
have,41-45
shown,46-51
no,52-54
effect,55-61
on,62-64
digoxin,65-72
blood,73-78
levels.,79-86

-,0-1
Anticoagulants:,2-17	DrugDDI.d566.s11.e0
Interaction,18-29
studies,30-37
in,38-40
humans,41-47
have,48-52
shown,53-58
bumetanide,59-69	DrugDDI.d566.s11.e1
to,70-72
have,73-77
no,78-80
effect,81-87
on,88-90
warfarin,91-99	DrugDDI.d566.s11.e2
metabolism,100-110
or,111-113
on,114-116
plasma,117-123
prothrombin,124-135
activity.,136-145

The,0-3
administration,4-18
of,19-21
local,22-27	DrugDDI.d414.s0.e0
anesthetic,28-38	DrugDDI.d414.s0.e0
solutions,39-48
containing,49-59
epinephrine,60-71	DrugDDI.d414.s0.e1
or,72-74
norepinephrine,75-89	DrugDDI.d414.s0.e2
to,90-92
patients,93-101
receiving,102-111
monoamine,112-121	DrugDDI.d414.s0.e3
oxidase,122-129	DrugDDI.d414.s0.e3
inhibitors,130-140	DrugDDI.d414.s0.e3
or,141-143
tricyclic,144-153	DrugDDI.d414.s0.e4
antidepressants,154-169	DrugDDI.d414.s0.e4
may,170-173
produce,174-181
severe,,182-189
prolonged,190-199
hypertension.,200-213

Concurrent,0-10
administration,11-25
of,26-28
vasopressor,29-40	DrugDDI.d414.s3.e0
drugs,41-46	DrugDDI.d414.s3.e0
and,47-50
of,51-53
ergot-type,54-64
oxytocic,65-73	DrugDDI.d414.s3.e1
drugs,74-79	DrugDDI.d414.s3.e1
may,80-83
cause,84-89
severe,,90-97
persistent,98-108
hypertension,109-121
or,122-124
cerebrovascular,125-140
accidents.,141-151

Phenothiazines,0-14	DrugDDI.d414.s4.e0
and,15-18
butyrophenones,19-33	DrugDDI.d414.s4.e1
may,34-37
reduce,38-44
or,45-47
reverse,48-55
the,56-59
pressor,60-67	DrugDDI.d414.s4.e2
effect,68-74	DrugDDI.d414.s4.e2
of,75-77
epinephrine.,78-90	DrugDDI.d414.s4.e3

Buprenorphine,0-13	DrugDDI.d128.s0.e0
is,14-16
metabolized,17-28
to,29-31
norbuprenorphine,32-48
by,49-51
cytochrome,52-62	DrugDDI.d128.s0.e1
CYP,63-66
3A4.,67-71

Because,0-7
CYP,8-11	DrugDDI.d128.s1.e0
3A4,12-15
inhibitors,16-26
may,27-30
increase,31-39
plasma,40-46
concentrations,47-61
of,62-64
buprenorphine,,65-79
patients,80-88
already,89-96
on,97-99
CYP,100-103	DrugDDI.d128.s1.e2
3A4,104-107
inhibitors,108-118
such,119-123
as,124-126
azole,127-132	DrugDDI.d128.s1.e3
antifungals,133-144	DrugDDI.d128.s1.e3
(e.g.,145-150

ketoconazole),,0-14
macrolide,15-24	DrugDDI.d128.s2.e1
antibiotics,25-36	DrugDDI.d128.s2.e1
(e.g.,37-42
erythromycin),,43-57
and,58-61
HIV,62-65	DrugDDI.d128.s2.e3
protease,66-74	DrugDDI.d128.s2.e3
inhibitors,75-85	DrugDDI.d128.s2.e3
(e.g.,86-91
ritonavir,,92-102
indi-navir,103-113
and,114-117
saquinavir),118-129	DrugDDI.d128.s2.e5
should,130-136
have,137-141
their,142-147
dose,148-152
of,153-155
SUBUTEX,156-163	DrugDDI.d128.s2.e6
or,164-166
SUBOXONE,167-175	DrugDDI.d128.s2.e7
adjusted.,176-185

Based,0-5
on,6-8
anecdotal,9-18
reports,,19-27
there,28-33
may,34-37
be,38-40
an,41-43
interaction,44-55
between,56-63
buprenorphine,64-77	DrugDDI.d128.s3.e0
and,78-81
benzodiazepines.,82-98	DrugDDI.d128.s3.e1

There,0-5
have,6-10
been,11-15
a,16-17
number,18-24
of,25-27
reports,28-35
in,36-38
the,39-42
post-marketing,43-57
experience,58-68
of,69-71
coma,72-76
and,77-80
death,81-86
associated,87-97
with,98-102
the,103-106
concomitant,107-118
intravenous,119-130
misuse,131-137
of,138-140
buprenorphine,141-154	DrugDDI.d128.s4.e0
and,155-158
benzodiazepines,159-174	DrugDDI.d128.s4.e1
by,175-177
addicts.,178-186

In,0-2
many,3-7
of,8-10
these,11-16
cases,,17-23
buprenorphine,24-37	DrugDDI.d128.s5.e0
was,38-41
misused,42-49
by,50-52
self-injection,53-67
of,68-70
crushed,71-78
SUBUTEX,79-86	DrugDDI.d128.s5.e1
tablets.,87-95

SUBUTEX,0-7	DrugDDI.d128.s6.e0
and,8-11
SUBOXONE,12-20	DrugDDI.d128.s6.e1
should,21-27
be,28-30
prescribed,31-41
with,42-46
caution,47-54
to,55-57
patients,58-66
on,67-69
benzodiazepines,70-85	DrugDDI.d128.s6.e2
or,86-88
other,89-94
drugs,95-100	DrugDDI.d128.s6.e3
that,101-105
act,106-109
on,110-112
the,113-116
central,117-124
nervous,125-132
system,,133-140
regardless,141-151
of,152-154
whether,155-162
these,163-168
drugs,169-174	DrugDDI.d128.s6.e4
are,175-178
taken,179-184
on,185-187
the,188-191
advice,192-198
of,199-201
a,202-203
physician,204-213
or,214-216
are,217-220
taken,221-226
as,227-229
drugs,230-235	DrugDDI.d128.s6.e5
of,236-238
abuse.,239-245

Patients,0-8
should,9-15
be,16-18
warned,19-25
of,26-28
the,29-32
potential,33-42
danger,43-49
of,50-52
the,53-56
intravenous,57-68
self-administration,69-88
of,89-91
benzodiazepines,92-107	DrugDDI.d128.s7.e0
while,108-113
under,114-119
treatment,120-129
with,130-134
SUBOXONE,135-143	DrugDDI.d128.s7.e1
or,144-146
SUBUTEX.,147-155	DrugDDI.d128.s7.e2

Few,0-3
systemic,4-12
data,13-17
have,18-22
been,23-27
collected,28-37
on,38-40
the,41-44
metabolism,45-55
of,56-58
WELLBUTRIN,59-69	DrugDDI.d258.s0.e0
following,70-79
concomitant,80-91
administration,92-106
with,107-111
other,112-117
drugs,118-123	DrugDDI.d258.s0.e1
or,,124-127
alternatively,,128-142
the,143-146
effect,147-153
of,154-156
concomitant,157-168
administration,169-183
of,184-186
WELLBUTRIN,187-197	DrugDDI.d258.s0.e2
on,198-200
the,201-204
metabolism,205-215
of,216-218
other,219-224
drugs.,225-231	DrugDDI.d258.s0.e3

Because,0-7
bupropion,8-17	DrugDDI.d258.s1.e0
is,18-20
extensively,21-32
metabolized,,33-45
the,46-49
coadministration,50-66
of,67-69
other,70-75
drugs,76-81	DrugDDI.d258.s1.e1
may,82-85
affect,86-92
its,93-96
clinical,97-105
activity.,106-115

In,0-2
vitro,3-8
studies,9-16
indicate,17-25
that,26-30
bupropion,31-40	DrugDDI.d258.s2.e0
is,41-43
primarily,44-53
metabolized,54-65
to,66-68
hydroxybupropion,69-85	DrugDDI.d258.s2.e1
by,86-88
the,89-92
CYP2B6,93-99	DrugDDI.d258.s2.e2
isoenzyme.,100-110	DrugDDI.d258.s2.e2

Therefore,,0-10
the,11-14
potential,15-24
exists,25-31
for,32-35
a,36-37
drug,38-42
interaction,43-54
between,55-62
WELLBUTRIN,63-73	DrugDDI.d258.s3.e0
and,74-77
drugs,78-83	DrugDDI.d258.s3.e1
that,84-88
affect,89-95
the,96-99
CYP2B6,100-106	DrugDDI.d258.s3.e2
isoenzyme,107-116	DrugDDI.d258.s3.e2
(e.g.,,117-123
orphenadrine,124-136	DrugDDI.d258.s3.e3
and,137-140
cyclophosphamide).,141-159	DrugDDI.d258.s3.e4

The,0-3
threohydrobupropion,4-23	DrugDDI.d258.s4.e0
metabolite,24-34	DrugDDI.d258.s4.e0
of,35-37
bupropion,38-47	DrugDDI.d258.s4.e1
does,48-52
not,53-56
appear,57-63
to,64-66
be,67-69
produced,70-78
by,79-81
the,82-85
cytochrome,86-96	DrugDDI.d258.s4.e2
P450,97-101	DrugDDI.d258.s4.e2
isoenzymes.,102-113

The,0-3
effects,4-11
of,12-14
concomitant,15-26
administration,27-41
of,42-44
cimetidine,45-55	DrugDDI.d258.s5.e0
on,56-58
the,59-62
pharmacokinetics,63-79
of,80-82
bupropion,83-92	DrugDDI.d258.s5.e1
and,93-96
its,97-100
active,101-107
metabolites,108-119	DrugDDI.d258.s5.e2
were,120-124
studied,125-132
in,133-135
24,136-138
healthy,139-146
young,147-152
male,153-157
volunteers.,158-169

Following,0-9
oral,10-14
administration,15-29
of,30-32
two,33-36
150-mg,37-43
sustained-release,44-61
tablets,62-69
with,70-74
and,75-78
without,79-86
800,87-90
mg,91-93
of,94-96
cimetidine,,97-108
the,109-112
pharmacokinetics,113-129
of,130-132
bupropion,133-142	DrugDDI.d258.s6.e1
and,143-146
hydroxybupropion,147-163	DrugDDI.d258.s6.e2
were,164-168
unaffected.,169-180

While,0-5
not,6-9
systematically,10-24
studied,,25-33
certain,34-41
drugs,42-47	DrugDDI.d258.s8.e0
may,48-51
induce,52-58
the,59-62
metabolism,63-73
of,74-76
bupropion,77-86	DrugDDI.d258.s8.e1
(e.g.,,87-93
carbamazepine,,94-108
phenobarbital,,109-123
phenytoin).,124-135	DrugDDI.d258.s8.e4

Animal,0-6
data,7-11
indicated,12-21
that,22-26
bupropion,27-36	DrugDDI.d258.s9.e0
may,37-40
be,41-43
an,44-46
inducer,47-54
of,55-57
drug-metabolizing,58-75	DrugDDI.d258.s9.e1
enzymes,76-83
in,84-86
humans.,87-94

In,0-2
one,3-6
study,,7-13
following,14-23
chronic,24-31
administration,32-46
of,47-49
bupropion,,50-60
100,61-64
mg,65-67
3,68-69
times,70-75
daily,76-81
to,82-84
8,85-86
healthy,87-94
male,95-99
volunteers,100-110
for,111-114
14,115-117
days,,118-123
there,124-129
was,130-133
no,134-136
evidence,137-145
of,146-148
induction,149-158
of,159-161
its,162-165
own,166-169
metabolism.,170-181

Nevertheless,,0-13
there,14-19
may,20-23
be,24-26
the,27-30
potential,31-40
for,41-44
clinically,45-55
important,56-65
alterations,66-77
of,78-80
blood,81-86
levels,87-93
of,94-96
coadministered,97-111
drugs.,112-118	DrugDDI.d258.s11.e0

Drugs,0-5	DrugDDI.d258.s12.e0
Metabolized,6-17
by,18-20
Cytochrome,21-31	DrugDDI.d258.s12.e1
P450IID6,32-40
(CYP2D6):,41-50
Many,51-55
drugs,,56-62
including,63-72
most,73-77
antidepressants,78-93	DrugDDI.d258.s12.e4
(SSRIs,,94-101
many,102-106
tricyclics),,107-119
beta-blockers,,120-134
antiarrhythmics,,135-151
and,152-155
antipsychotics,156-170	DrugDDI.d258.s12.e8
are,171-174
metabolized,175-186
by,187-189
the,190-193
CYP2D6,194-200	DrugDDI.d258.s12.e9
isoenzyme.,201-211	DrugDDI.d258.s12.e9

Although,0-8
bupropion,9-18	DrugDDI.d258.s13.e0
is,19-21
not,22-25
metabolized,26-37
by,38-40
this,41-45
isoenzyme,,46-56
bupropion,57-66	DrugDDI.d258.s13.e2
and,67-70
hydroxybupropion,71-87	DrugDDI.d258.s13.e3
are,88-91
inhibitors,92-102
of,103-105
the,106-109
CYP2D6,110-116	DrugDDI.d258.s13.e4
isoenzyme,117-126	DrugDDI.d258.s13.e4
in,127-129
vitro.,130-136

In,0-2
a,3-4
study,5-10
of,11-13
15,14-16
male,17-21
subjects,22-30
(ages,31-36
19,37-39
to,40-42
35,43-45
years),46-52
who,53-56
were,57-61
extensive,62-71
metabolizers,72-84
of,85-87
the,88-91
CYP2D6,92-98	DrugDDI.d258.s14.e0
isoenzyme,,99-109	DrugDDI.d258.s14.e0
daily,110-115
doses,116-121
of,122-124
bupropion,125-134	DrugDDI.d258.s14.e1
given,135-140
as,141-143
150,144-147
mg,148-150
twice,151-156
daily,157-162
followed,163-171
by,172-174
a,175-176
single,177-183
dose,184-188
of,189-191
50,192-194
mg,195-197
desipramine,198-209	DrugDDI.d258.s14.e2
increased,210-219
the,220-223
Cmax,,224-229
AUC,,230-234
and,235-238
t1/2,239-243	DrugDDI.d258.s14.e3
of,244-246
desipramine,247-258	DrugDDI.d258.s14.e4
by,259-261
an,262-264
average,265-272
of,273-275
approximately,276-289
2-,,290-293
5-,294-296
and,297-300
2-fold,,301-308
respectively.,309-322

The,0-3
effect,4-10
was,11-14
present,15-22
for,23-26
at,27-29
least,30-35
7,36-37
days,38-42
after,43-48
the,49-52
last,53-57
dose,58-62
of,63-65
bupropion.,66-76	DrugDDI.d258.s15.e0

Concomitant,0-11
use,12-15
of,16-18
bupropion,19-28	DrugDDI.d258.s16.e0
with,29-33
other,34-39
drugs,40-45	DrugDDI.d258.s16.e1
metabolized,46-57
by,58-60
CYP2D6,61-67	DrugDDI.d258.s16.e2
has,68-71
not,72-75
been,76-80
formally,81-89
studied.,90-98

Therefore,,0-10
co-administration,11-28
of,29-31
bupropion,32-41	DrugDDI.d258.s17.e0
with,42-46
drugs,47-52	DrugDDI.d258.s17.e1
that,53-57
are,58-61
metabolized,62-73
by,74-76
CYP2D6,77-83	DrugDDI.d258.s17.e2
isoenzyme,84-93	DrugDDI.d258.s17.e2
including,94-103
certain,104-111
antidepressants,112-127	DrugDDI.d258.s17.e3
(e.g.,,128-134
nortriptyline,,135-149
imipramine,,150-161
desipramine,,162-174
paroxetine,,175-186
fluoxetine,,187-198
sertraline),,199-211
antipsychotics,212-226	DrugDDI.d258.s17.e10
(e.g.,,227-233
haloperidol,,234-246
risperidone,,247-259
thioridazine),,260-274
beta-blockers,275-288	DrugDDI.d258.s17.e14
(e.g.,,289-295
metoprolol),,296-308
and,309-312
Type,313-317
1C,318-320
antiarrhythmics,321-336	DrugDDI.d258.s17.e16
(e.g.,,337-343
propafenone,,344-356
flecainide),,357-369
should,370-376
be,377-379
approached,380-390
with,391-395
caution,396-403
and,404-407
should,408-414
be,415-417
initiated,418-427
at,428-430
the,431-434
lower,435-440
end,441-444
of,445-447
the,448-451
dose,452-456
range,457-462
of,463-465
the,466-469
concomitant,470-481
medication.,482-493	DrugDDI.d258.s17.e19

If,0-2
bupropion,3-12	DrugDDI.d258.s18.e0
is,13-15
added,16-21
to,22-24
the,25-28
treatment,29-38
regimen,39-46
of,47-49
a,50-51
patient,52-59
already,60-67
receiving,68-77
a,78-79
drug,80-84	DrugDDI.d258.s18.e1
metabolized,85-96
by,97-99
CYP2D6,,100-107
the,108-111
need,112-116
to,117-119
decrease,120-128
the,129-132
dose,133-137
of,138-140
the,141-144
original,145-153
medication,154-164	DrugDDI.d258.s18.e3
should,165-171
be,172-174
considered,,175-186
particularly,187-199
for,200-203
those,204-209
concomitant,210-221
medications,222-233	DrugDDI.d258.s18.e4
with,234-238
a,239-240
narrow,241-247
therapeutic,248-259
index.,260-266

MAO,0-3	DrugDDI.d258.s19.e0
Inhibitors:,4-15	DrugDDI.d258.s19.e0
Studies,16-23
in,24-26
animals,27-34
demonstrate,35-46
that,47-51
the,52-55
acute,56-61
toxicity,62-70
of,71-73
bupropion,74-83	DrugDDI.d258.s19.e1
is,84-86
enhanced,87-95
by,96-98
the,99-102
MAO,103-106	DrugDDI.d258.s19.e2
inhibitor,107-116	DrugDDI.d258.s19.e2
phenelzine,117-127
.,128-129

Levodopa,0-8	DrugDDI.d258.s20.e0
and,9-12
Amantadine:,13-24	DrugDDI.d258.s20.e1
Limited,25-32
clinical,33-41
data,42-46
suggest,47-54
a,55-56
higher,57-63
incidence,64-73
of,74-76
adverse,77-84
experiences,85-96
in,97-99
patients,100-108
receiving,109-118
bupropion,119-128	DrugDDI.d258.s20.e2
concurrently,129-141
with,142-146
either,147-153
levodopa,154-162	DrugDDI.d258.s20.e3
or,163-165
amantadine.,166-177	DrugDDI.d258.s20.e4

Administration,0-14
of,15-17
WELLBUTRIN,18-28	DrugDDI.d258.s21.e0
Tablets,29-36	DrugDDI.d258.s21.e0
to,37-39
patients,40-48
receiving,49-58
either,59-65
levodopa,66-74	DrugDDI.d258.s21.e1
or,75-77
amantadine,78-88	DrugDDI.d258.s21.e2
concurrently,89-101
should,102-108
be,109-111
undertaken,112-122
with,123-127
caution,,128-136
using,137-142
small,143-148
initial,149-156
doses,157-162
and,163-166
small,167-172
gradual,173-180
dose,181-185
increases.,186-196

Drugs,0-5	DrugDDI.d258.s22.e0
that,6-10
Lower,11-16
Seizure,17-24
Threshold:,25-35
Concurrent,36-46
administration,47-61
of,62-64
WELLBUTRIN,65-75	DrugDDI.d258.s22.e1
and,76-79
agents,80-86
(e.g.,,87-93
antipsychotics,,94-109
other,110-115
antidepressants,,116-132
theophylline,,133-146
systemic,147-155	DrugDDI.d258.s22.e5
steroids,,156-165
etc.),166-171
that,172-176
lower,177-182
seizure,183-190
threshold,191-200
should,201-207
be,208-210
undertaken,211-221
only,222-226
with,227-231
extreme,232-239
caution.,240-248

Nicotine,0-8	DrugDDI.d258.s24.e0
Transdermal,9-20
System:,21-28
.,29-30

Alcohol:,0-8	DrugDDI.d258.s25.e0
In,9-11
post-marketing,12-26
experience,,27-38
there,39-44
have,45-49
been,50-54
rare,55-59
reports,60-67
of,68-70
adverse,71-78
neuropsychiatric,79-95
events,96-102
or,103-105
reduced,106-113
alcohol,114-121
tolerance,122-131
in,132-134
patients,135-143
who,144-147
were,148-152
drinking,153-161	DrugDDI.d258.s25.e1
alcohol,162-169	DrugDDI.d258.s25.e1
during,170-176
treatment,177-186
with,187-191
WELLBUTRIN.,192-203	DrugDDI.d258.s25.e2

The,0-3
consumption,4-15
of,16-18
alcohol,19-26	DrugDDI.d258.s26.e0
during,27-33
treatment,34-43
with,44-48
WELLBUTRIN,49-59	DrugDDI.d258.s26.e1
should,60-66
be,67-69
minimized,70-79
or,80-82
avoided,83-90
(also,91-96
see,97-100
,101-101
a,102-103
href=,104-109
bupropz_od.htm#CI,110-127
CONTRAINDICATIONS),128-146

It,0-2
is,3-5
recommended,6-17
that,18-22
buspirone,23-32	DrugDDI.d34.s0.e0
hydrochloride,33-46	DrugDDI.d34.s0.e0
not,47-50
be,51-53
used,54-58
concomitantly,59-72
with,73-77
MAO,78-81	DrugDDI.d34.s0.e1
inhibitors,82-92	DrugDDI.d34.s0.e1
Because,93-100
the,101-104
effects,105-112
of,113-115
concomitant,116-127
administration,128-142
of,143-145
buspirone,146-155	DrugDDI.d34.s0.e2
HCl,156-159	DrugDDI.d34.s0.e2
with,160-164
most,165-169
other,170-175
psychotropic,176-188	DrugDDI.d34.s0.e3
drugs,189-194	DrugDDI.d34.s0.e3
have,195-199
not,200-203
been,204-208
studied,,209-217
the,218-221
concomitant,222-233
use,234-237
of,238-240
buspirone,241-250	DrugDDI.d34.s0.e4
HCl,251-254	DrugDDI.d34.s0.e4
with,255-259
other,260-265
CNS-active,266-276	DrugDDI.d34.s0.e5
drugs,277-282	DrugDDI.d34.s0.e5
should,283-289
be,290-292
approached,293-303
with,304-308
caution.,309-317

There,0-5
is,6-8
one,9-12
report,13-19
suggesting,20-30
that,31-35
the,36-39
concomitant,40-51
use,52-55
of,56-58
trazodone,59-68	DrugDDI.d34.s1.e0
hydrochloride,69-82	DrugDDI.d34.s1.e0
(Desyrel),83-92
and,93-96
buspirone,97-106	DrugDDI.d34.s1.e2
HCl,107-110	DrugDDI.d34.s1.e2
may,111-114
have,115-119
caused,120-126
3-,127-129
to,130-132
6-fold,133-139
elevations,140-150
on,151-153
SGPT,154-158
(ALT),159-164
in,165-167
a,168-169
few,170-173
patients.,174-183

In,0-2
a,3-4
similar,5-12
study,,13-19
attempting,20-30
to,31-33
replicate,34-43
this,44-48
finding,,49-57
no,58-60
interactive,61-72
effect,73-79
on,80-82
hepatic,83-90
transaminases,91-104	DrugDDI.d34.s2.e0
was,105-108
identified.,109-120

In,0-2
a,3-4
study,5-10
in,11-13
normal,14-20
volunteers,,21-32
concomitant,33-44
administration,45-59
of,60-62
buspirone,63-72	DrugDDI.d34.s3.e0
HCl,73-76	DrugDDI.d34.s3.e0
and,77-80
haloperidol,81-92	DrugDDI.d34.s3.e1
resulted,93-101
in,102-104
increased,105-114
serum,115-120
haloperidol,121-132	DrugDDI.d34.s3.e2
concentrations.,133-148

In,0-2
vitro,,3-9
buspirone,10-19	DrugDDI.d34.s5.e0
does,20-24
not,25-28
displace,29-37
tightly,38-45
bound,46-51
drugs,52-57
like,58-62
phenytoin,,63-73
propranolol,,74-86
and,87-90
warfarin,91-99	DrugDDI.d34.s5.e3
from,100-104
serum,105-110	DrugDDI.d34.s5.e4
proteins.,111-120	DrugDDI.d34.s5.e4

However,,0-8
there,9-14
has,15-18
been,19-23
one,24-27
report,28-34
of,35-37
prolonged,38-47
prothrombin,48-59
time,60-64
when,65-69
buspirone,70-79	DrugDDI.d34.s6.e0
was,80-83
added,84-89
to,90-92
the,93-96
regimen,97-104
of,105-107
a,108-109
patient,110-117
treated,118-125
with,126-130
warfarin.,131-140	DrugDDI.d34.s6.e1

The,0-3
patient,4-11
was,12-15
also,16-20
chronically,21-32
receiving,33-42
phenytoin,,43-53
phenobarbital,,54-68
digoxin,,69-77
and,78-81
levothyroxine,82-95	DrugDDI.d34.s7.e3
sodium.,96-103	DrugDDI.d34.s7.e3

In,0-2
vitro,,3-9
buspirone,10-19	DrugDDI.d34.s8.e0
may,20-23
displace,24-32
less,33-37
firmly,38-44
bound,45-50
drugs,51-56
like,57-61
digoxin.,62-70	DrugDDI.d34.s8.e1

Itraconazole,0-12	DrugDDI.d355.s0.e0
decreases,13-22
busulfan,23-31	DrugDDI.d355.s0.e1
clearance,32-41
by,42-44
up,45-47
to,48-50
25%,,51-55
and,56-59
may,60-63
produce,64-71
AUCs,72-76
,77-77
,78-78
1500,79-83
?M?min,84-90
in,91-93
some,94-98
patients.,99-108

Fluconazole,,0-12
and,13-16
the,17-20
5-HT3,21-26
antiemetics,27-38	DrugDDI.d355.s1.e1
odansetron,39-49
(Zofran),50-58
and,59-62
granisetron,63-74	DrugDDI.d355.s1.e3
(Kytril),75-83
have,84-88
all,89-92
been,93-97
used,98-102
with,103-107
BUSULFEX.,108-117	DrugDDI.d355.s1.e5

Phenytoin,0-9	DrugDDI.d355.s2.e0
increases,10-19
the,20-23
clearance,24-33
of,34-36
busulfan,37-45	DrugDDI.d355.s2.e1
by,46-48
15%,49-52
or,53-55
more,,56-61
possibly,62-70
due,71-74
to,75-77
the,78-81
induction,82-91
of,92-94
glutathione-S-transferase.,95-121	DrugDDI.d355.s2.e2

Since,0-5
the,6-9
pharmacokinetics,10-26
of,27-29
BUSULFEX,30-38	DrugDDI.d355.s3.e0
were,39-43
studied,44-51
in,52-54
patients,55-63
treated,64-71
with,72-76
phenytoin,,77-87
the,88-91
clearance,92-101
of,102-104
BUSULFEX,105-113	DrugDDI.d355.s3.e2
at,114-116
the,117-120
recommended,121-132
dose,133-137
may,138-141
be,142-144
lower,145-150
and,151-154
exposure,155-163
(AUC),164-169
higher,170-176
in,177-179
patients,180-188
not,189-192
treated,193-200
with,201-205
phenytoin.,206-216	DrugDDI.d355.s3.e3

Because,0-7
busulfan,8-16	DrugDDI.d355.s4.e0
is,17-19
eliminated,20-30
from,31-35
the,36-39
body,40-44
via,45-48
conjugation,49-60
with,61-65
glutathione,,66-78
use,79-82
of,83-85
acetaminophen,86-99	DrugDDI.d355.s4.e2
prior,100-105
to,106-108
(,109-110
72,111-113
hours),114-120
or,121-123
concurrent,124-134
with,135-139
BUSULFEX,140-148	DrugDDI.d355.s4.e3
may,149-152
result,153-159
in,160-162
reduced,163-170
busulfan,171-179	DrugDDI.d355.s4.e4
clearance,180-189
based,190-195
upon,196-200
the,201-204
known,205-210
property,211-219
of,220-222
acetaminophen,223-236	DrugDDI.d355.s4.e5
to,237-239
decrease,240-248
glutathione,249-260	DrugDDI.d355.s4.e6
levels,261-267
in,268-270
the,271-274
blood,275-280
and,281-284
tissues.,285-293

Interactions,0-12
may,13-16
occur,17-22
with,23-27
the,28-31
following:,32-42
adrenocorticoids,43-59
(cortisone-like,60-75
medicine),,76-86
anticoagulants,87-101	DrugDDI.d544.s0.e2
(blood,102-108
thinners),,109-119
carbamazepine,,120-134
corticotropin,135-148	DrugDDI.d544.s0.e5
(barbiturates,149-162
may,163-166
decrease,167-175
the,176-179
effects,180-187
of,188-190
these,191-196
medicines),,197-208
central,209-216
nervous,217-224
system,225-231
(CNS),232-237
depressants,238-249
(using,250-256
these,257-262
medicines,263-272	DrugDDI.d544.s0.e8
with,273-277
barbiturates,278-290	DrugDDI.d544.s0.e9
may,291-294
result,295-301
in,302-304
increased,305-314
CNS,315-318	DrugDDI.d544.s0.e10
depressant,319-329	DrugDDI.d544.s0.e10
effects),,330-339
divalproex,340-350	DrugDDI.d544.s0.e11
sodium,,351-358	DrugDDI.d544.s0.e11
valproic,359-367	DrugDDI.d544.s0.e12
acid,368-372	DrugDDI.d544.s0.e12
(using,373-379
these,380-385
medicines,386-395	DrugDDI.d544.s0.e13
with,396-400
barbiturates,401-413	DrugDDI.d544.s0.e14
may,414-417
change,418-424
the,425-428
amount,429-435
of,436-438
either,439-445
medicine,446-454	DrugDDI.d544.s0.e15
that,455-459
you,460-463
need,464-468
to,469-471
take),,472-478
and,479-482
oral,483-487	DrugDDI.d544.s0.e16
contraceptives,488-502	DrugDDI.d544.s0.e16
containing,503-513
estrogens,514-523	DrugDDI.d544.s0.e17
(barbiturates,524-537
may,538-541
decrease,542-550
the,551-554
effectiveness,555-568
of,569-571
these,572-577
oral,578-582	DrugDDI.d544.s0.e19
contraceptives,,583-598	DrugDDI.d544.s0.e19
and,599-602
you,603-606
may,607-610
need,611-615
to,616-618
change,619-625
to,626-628
a,629-630
different,631-640
type,641-645
of,646-648
birth,649-654	DrugDDI.d544.s0.e20
control).,655-664	DrugDDI.d544.s0.e20

The,0-3
CNS,4-7
effects,8-15
of,16-18
butalbital,19-29	DrugDDI.d387.s0.e0
may,30-33
be,34-36
enhanced,37-45
by,46-48
monoamine,49-58	DrugDDI.d387.s0.e1
oxidase,59-66	DrugDDI.d387.s0.e1
(MAO),67-72
inhibitors.,73-84

Butalbital,,0-11
acetaminophen,12-25
and,26-29
caffeine,30-38	DrugDDI.d387.s1.e1
may,39-42
enhance,43-50
the,51-54
effects,55-62
of:,63-66
other,67-72	DrugDDI.d387.s1.e2
narcotic,73-81	DrugDDI.d387.s1.e2
analgesics,,82-93	DrugDDI.d387.s1.e2
alcohol,,94-102
general,103-110	DrugDDI.d387.s1.e4
anesthetics,,111-123	DrugDDI.d387.s1.e4
tranquilizers,124-137	DrugDDI.d387.s1.e5
such,138-142
as,143-145
chlordiazepoxide,,146-163
sedative-hypnotics,,164-183
or,184-186
other,187-192
CNS,193-196	DrugDDI.d387.s1.e8
depressants,,197-209	DrugDDI.d387.s1.e8
causing,210-217
increased,218-227
CNS,228-231
depression.,232-243

Drug/Laboratory,0-15	DrugDDI.d387.s2.e0
Test,16-20
Interactions,21-33
Acetaminophen,34-47	DrugDDI.d387.s2.e1
may,48-51
produce,52-59
false-positive,60-74
test,75-79
results,80-87
for,88-91
urinary,92-99	DrugDDI.d387.s2.e2
5-hydroxyindoleacetic,100-121	DrugDDI.d387.s2.e2
acid.,122-127	DrugDDI.d387.s2.e2

Potential,0-9
drug,10-14
interactions,15-27
between,28-35
Mentax?,36-43
(butenafine,44-55
HCl,56-59
cream),60-66
Cream,,67-73
1%,,74-77
and,78-81
other,82-87
drugs,88-93	DrugDDI.d356.s0.e1
have,94-98
not,99-102
been,103-107
systematically,108-122
evaluated.,123-133

Interactions,0-12
may,13-16
occur,17-22
with,23-27
the,28-31
following:,32-42
adrenocorticoids,43-59
(cortisone-like,60-75
medicine),,76-86
anticoagulants,87-101	DrugDDI.d407.s0.e2
(blood,102-108
thinners),,109-119
carbamazepine,,120-134
corticotropin,135-148	DrugDDI.d407.s0.e5
(barbiturates,149-162
may,163-166
decrease,167-175
the,176-179
effects,180-187
of,188-190
these,191-196
medicines),,197-208
central,209-216
nervous,217-224
system,225-231
(CNS),232-237
depressants,238-249
(using,250-256
these,257-262
medicines,263-272	DrugDDI.d407.s0.e8
with,273-277
barbiturates,278-290	DrugDDI.d407.s0.e9
may,291-294
result,295-301
in,302-304
increased,305-314
CNS,315-318	DrugDDI.d407.s0.e10
depressant,319-329	DrugDDI.d407.s0.e10
effects),,330-339
divalproex,340-350	DrugDDI.d407.s0.e11
sodium,,351-358	DrugDDI.d407.s0.e11
valproic,359-367	DrugDDI.d407.s0.e12
acid,368-372	DrugDDI.d407.s0.e12
(using,373-379
these,380-385
medicines,386-395	DrugDDI.d407.s0.e13
with,396-400
barbiturates,401-413	DrugDDI.d407.s0.e14
may,414-417
change,418-424
the,425-428
amount,429-435
of,436-438
either,439-445
medicine,446-454	DrugDDI.d407.s0.e15
that,455-459
you,460-463
need,464-468
to,469-471
take),,472-478
and,479-482
oral,483-487	DrugDDI.d407.s0.e16
contraceptives,488-502	DrugDDI.d407.s0.e16
containing,503-513
estrogens,514-523	DrugDDI.d407.s0.e17
(barbiturates,524-537
may,538-541
decrease,542-550
the,551-554
effectiveness,555-568
of,569-571
these,572-577
oral,578-582	DrugDDI.d407.s0.e19
contraceptives,,583-598	DrugDDI.d407.s0.e19
and,599-602
you,603-606
may,607-610
need,611-615
to,616-618
change,619-625
to,626-628
a,629-630
different,631-640
type,641-645
of,646-648
birth,649-654	DrugDDI.d407.s0.e20
control).,655-664	DrugDDI.d407.s0.e20

Concurrent,0-10
use,11-14
of,15-17
butorphanol,18-29	DrugDDI.d487.s0.e0
with,30-34
central,35-42	DrugDDI.d487.s0.e1
nervous,43-50	DrugDDI.d487.s0.e1
system,51-57	DrugDDI.d487.s0.e1
depressants,58-69	DrugDDI.d487.s0.e1
(e.g.,,70-76
alcohol,,77-85
barbiturates,,86-99
tranquilizers,,100-114
and,115-118
antihistamines),119-134	DrugDDI.d487.s0.e5
may,135-138
result,139-145
in,146-148
increased,149-158
central,159-166	DrugDDI.d487.s0.e6
nervous,167-174	DrugDDI.d487.s0.e6
system,175-181	DrugDDI.d487.s0.e6
depressant,182-192	DrugDDI.d487.s0.e6
effects.,193-201

When,0-4
used,5-9
concurrently,10-22
with,23-27
such,28-32
drugs,,33-39
the,40-43
dose,44-48
of,49-51
butorphanol,52-63	DrugDDI.d487.s1.e1
should,64-70
be,71-73
the,74-77
smallest,78-86
effective,87-96
dose,97-101
and,102-105
the,106-109
frequency,110-119
of,120-122
dosing,123-129
reduced,130-137
as,138-140
much,141-145
as,146-148
possible,149-157
when,158-162
administered,163-175
concomitantly,176-189
with,190-194
drugs,195-200	DrugDDI.d487.s1.e2
that,201-205
potentiate,206-216
the,217-220
action,221-227
of,228-230
opioids.,231-239	DrugDDI.d487.s1.e3

In,0-2
healthy,3-10
volunteers,,11-22
the,23-26
pharmacokinetics,27-43
of,44-46
a,47-48
1-mg,49-53
dose,54-58
of,59-61
butorphanol,62-73	DrugDDI.d487.s2.e0
administered,74-86
as,87-89
STADOL,90-96	DrugDDI.d487.s2.e1
NS,97-99	DrugDDI.d487.s2.e1
were,100-104
not,105-108
affected,109-117
by,118-120
the,121-124
coadministration,125-141
of,142-144
a,145-146
single,147-153
6-mg,154-158
subcutaneous,159-171
dose,172-176
of,177-179
sumatriptan.,180-192	DrugDDI.d487.s2.e2

However,,0-8
in,9-11
another,12-19
study,20-25
in,26-28
healthy,29-36
volunteers,,37-48
the,49-52
pharmacokinetics,53-69
of,70-72
butorphanol,73-84	DrugDDI.d487.s3.e0
were,85-89
significantly,90-103
altered,104-111
(29%,112-116
decrease,117-125
in,126-128
AUC,129-132
and,133-136
38%,137-140
decrease,141-149
in,150-152
Cmax),153-158
when,159-163
a,164-165
1-mg,166-170
dose,171-175
of,176-178
STADOL,179-185	DrugDDI.d487.s3.e1
NS,186-188	DrugDDI.d487.s3.e1
was,189-192
administered,193-205
1,206-207
minute,208-214
after,215-220
a,221-222
20-mg,223-228
dose,229-233
of,234-236
sumatriptan,237-248	DrugDDI.d487.s3.e2
nasal,249-254	DrugDDI.d487.s3.e2
spray.,255-261	DrugDDI.d487.s3.e2

(The,0-4
two,5-8
drugs,9-14	DrugDDI.d487.s4.e0
were,15-19
administered,20-32
in,33-35
opposite,36-44
nostrils.),45-55

When,0-4
the,5-8
STADOL,9-15	DrugDDI.d487.s5.e0
NS,16-18	DrugDDI.d487.s5.e0
was,19-22
administered,23-35
30,36-38
minutes,39-46
after,47-52
the,53-56
sumatriptan,57-68	DrugDDI.d487.s5.e1
nasal,69-74	DrugDDI.d487.s5.e1
spray,,75-81	DrugDDI.d487.s5.e1
the,82-85
AUC,86-89
of,90-92
butorphanol,93-104	DrugDDI.d487.s5.e2
increased,105-114
11%,115-118
and,119-122
Cmax,123-127
decreased,128-137
18%.,138-142

In,0-2
neither,3-10
case,11-15
were,16-20
the,21-24
pharmacokinetics,25-41
of,42-44
sumatriptan,45-56	DrugDDI.d487.s6.e0
affected,57-65
by,66-68
coadministration,69-85
with,86-90
STADOL,91-97	DrugDDI.d487.s6.e1
NS.,98-101	DrugDDI.d487.s6.e1

These,0-5
results,6-13
suggest,14-21
that,22-26
the,27-30
analgesic,31-40
effect,41-47
of,48-50
STADOL,51-57	DrugDDI.d487.s7.e0
NS,58-60	DrugDDI.d487.s7.e0
may,61-64
be,65-67
diminished,68-78
when,79-83
it,84-86
is,87-89
administered,90-102
shortly,103-110
after,111-116
sumatriptan,117-128	DrugDDI.d487.s7.e1
nasal,129-134	DrugDDI.d487.s7.e1
spray,,135-141	DrugDDI.d487.s7.e1
but,142-145
by,146-148
30,149-151
minutes,152-159
any,160-163
such,164-168
reduction,169-178
in,179-181
effect,182-188
should,189-195
be,196-198
minimal.,199-207

The,0-3
safety,4-10
of,11-13
using,14-19
STADOL,20-26	DrugDDI.d487.s8.e0
NS,27-29	DrugDDI.d487.s8.e0
and,30-33
IMITREX?,34-42
(sumatriptan),43-56
Nasal,57-62
Spray,63-68
during,69-75
the,76-79
same,80-84
episode,85-92
of,93-95
migraine,96-104
has,105-108
not,109-112
been,113-117
established.,118-130

The,0-3
pharmacokinetics,4-20
of,21-23
a,24-25
1-mg,26-30
dose,31-35
of,36-38
butorphanol,39-50	DrugDDI.d487.s10.e0
administered,51-63
as,64-66
STADOL,67-73	DrugDDI.d487.s10.e1
NS,74-76	DrugDDI.d487.s10.e1
were,77-81
not,82-85
affected,86-94
by,95-97
the,98-101
coadministration,102-118
of,119-121
cimetidine,122-132	DrugDDI.d487.s10.e2
(300,133-137
mg,138-140
QID).,141-146

Conversely,,0-11
the,12-15
administration,16-30
of,31-33
STADOL,34-40	DrugDDI.d487.s11.e0
NS,41-43	DrugDDI.d487.s11.e0
(1,44-46
mg,47-49
butorphanol,50-61	DrugDDI.d487.s11.e1
QID),62-66
did,67-70
not,71-74
alter,75-80
the,81-84
pharmacokinetics,85-101
of,102-104
a,105-106
300-mg,107-113
dose,114-118
of,119-121
cimetidine.,122-133	DrugDDI.d487.s11.e2

It,0-2
is,3-5
not,6-9
known,10-15
if,16-18
the,19-22
effects,23-30
of,31-33
butorphanol,34-45	DrugDDI.d487.s12.e0
are,46-49
altered,50-57
by,58-60
concomitant,61-72
medications,73-84	DrugDDI.d487.s12.e1
that,85-89
affect,90-96
hepatic,97-104
metabolism,105-115
of,116-118
drugs,119-124	DrugDDI.d487.s12.e2
(erythromycin,,125-139
etc.),,140-146
but,147-150
physicians,151-161
should,162-168
be,169-171
alert,172-177
to,178-180
the,181-184
possibility,185-196
that,197-201
a,202-203
smaller,204-211
initial,212-219
dose,220-224
and,225-228
longer,229-235
intervals,236-245
between,246-253
doses,254-259
may,260-263
be,264-266
needed.,267-274

The,0-3
fraction,4-12
of,13-15
STADOL,16-22	DrugDDI.d487.s13.e0
NS,23-25	DrugDDI.d487.s13.e0
absorbed,26-34
is,35-37
unaffected,38-48
by,49-51
the,52-55
concomitant,56-67
administration,68-82
of,83-85
a,86-87
nasal,88-93	DrugDDI.d487.s13.e1
vasoconstrictor,94-109	DrugDDI.d487.s13.e1
(oxymetazoline),,110-126
but,127-130
the,131-134
rate,135-139
of,140-142
absorption,143-153
is,154-156
decreased.,157-167

Therefore,,0-10
a,11-12
slower,13-19
onset,20-25
can,26-29
be,30-32
anticipated,33-44
if,45-47
STADOL,48-54	DrugDDI.d487.s14.e0
NS,55-57	DrugDDI.d487.s14.e0
is,58-60
administered,61-73
concomitantly,74-87
with,,88-93
or,94-96
immediately,97-108
following,,109-119
a,120-121
nasal,122-127	DrugDDI.d487.s14.e1
vasoconstrictor.,128-144	DrugDDI.d487.s14.e1

No,0-2
information,3-14
is,15-17
available,18-27
about,28-33
the,34-37
use,38-41
of,42-44
butorphanol,45-56	DrugDDI.d487.s15.e0
concurrently,57-69
with,70-74
MAO,75-78	DrugDDI.d487.s15.e1
inhibitors.,79-90	DrugDDI.d487.s15.e1

DOSTINEX,0-8	DrugDDI.d303.s0.e0
should,9-15
not,16-19
be,20-22
administered,23-35
concurrently,36-48
with,49-53
D2-antagonists,,54-69
such,70-74
as,75-77
phenothiazines,,78-93
butyrophenones,,94-109
thioxanthines,,110-124
or,125-127
metoclopramide.,128-143	DrugDDI.d303.s0.e3

Cytochrome,0-10	DrugDDI.d175.s0.e0
P450,11-15	DrugDDI.d175.s0.e0
1A2,16-19	DrugDDI.d175.s0.e0
(CYP1A2),20-28
is,29-31
known,32-37
to,38-40
be,41-43
the,44-47
major,48-53
enzyme,54-60
involved,61-69
in,70-72
the,73-76
metabolism,77-87
of,88-90
caffeine.,91-100	DrugDDI.d175.s0.e2

Therefore,,0-10
caffeine,11-19	DrugDDI.d175.s1.e0
has,20-23
the,24-27
potential,28-37
to,38-40
interact,41-49
with,50-54
drugs,55-60	DrugDDI.d175.s1.e1
that,61-65
are,66-69
substrates,70-80
for,81-84
CYP1A2,,85-92
inhibit,93-100
CYP1A2,,101-108
or,109-111
induce,112-118
CYP1A2.,119-126	DrugDDI.d175.s1.e4

Few,0-3
data,4-8
exist,9-14
on,15-17
drug,18-22
interactions,23-35
with,36-40
caffeine,41-49	DrugDDI.d175.s2.e0
in,50-52
preterm,53-60
neonates.,61-70

Based,0-5
on,6-8
adult,9-14
data,,15-20
lower,21-26
doses,27-32
of,33-35
caffeine,36-44	DrugDDI.d175.s3.e0
may,45-48
be,49-51
needed,52-58
following,59-68
coadministration,69-85
of,86-88
drugs,89-94	DrugDDI.d175.s3.e1
which,95-100
are,101-104
reported,105-113
to,114-116
decrease,117-125
caffeine,126-134	DrugDDI.d175.s3.e2
elimination,135-146
(e.g.,,147-153
cimetidine,154-164	DrugDDI.d175.s3.e3
and,165-168
ketoconazole),169-182	DrugDDI.d175.s3.e4
and,183-186
higher,187-193
caffeine,194-202	DrugDDI.d175.s3.e5
doses,203-208
may,209-212
be,213-215
needed,216-222
following,223-232
coadministration,233-249
of,250-252
drugs,253-258	DrugDDI.d175.s3.e6
that,259-263
increase,264-272
caffeine,273-281	DrugDDI.d175.s3.e7
elimination,282-293
(e.g.,,294-300
phenobarbital,301-314	DrugDDI.d175.s3.e8
and,315-318
phenytoin).,319-330	DrugDDI.d175.s3.e9

Caffeine,0-8	DrugDDI.d175.s4.e0
administered,9-21
concurrently,22-34
with,35-39
ketoprofen,40-50	DrugDDI.d175.s4.e1
reduced,51-58
the,59-62
urine,63-68
volume,69-75
in,76-78
4,79-80
healthy,81-88
volunteers.,89-100

Interconversion,0-15
between,16-23
caffeine,24-32	DrugDDI.d175.s6.e0
and,33-36
theophylline,37-49	DrugDDI.d175.s6.e1
has,50-53
been,54-58
reported,59-67
in,68-70
preterm,71-78
neonates.,79-88

The,0-3
concurrent,4-14
use,15-18
of,19-21
these,22-27
drugs,28-33	DrugDDI.d175.s7.e0
is,34-36
not,37-40
recommended.,41-53

Interactions,0-12
for,13-16
vitamin,17-24
D,25-26
analogues,27-36
(Vitamin,37-45
D2,,46-49
Vitamin,50-57	DrugDDI.d127.s0.e1
D3,,58-61	DrugDDI.d127.s0.e1
Calcitriol,,62-73
and,74-77
Calcidiol):,78-89	DrugDDI.d127.s0.e3
Cholestyramine:,90-105	DrugDDI.d127.s0.e4
Cholestyramine,106-120	DrugDDI.d127.s0.e5
has,121-124
been,125-129
reported,130-138
to,139-141
reduce,142-148
intestinal,149-159
absorption,160-170
of,171-173
fat,174-177
soluble,178-185
vitamins;,186-195

as,0-2
such,3-7
it,8-10
may,11-14
impair,15-21
intestinal,22-32
absorption,33-43
of,44-46
any,47-50
of,51-53
vitamin,54-61	DrugDDI.d127.s1.e0
D.,62-64	DrugDDI.d127.s1.e0

Phenytoin/Phenobarbital:,0-24	DrugDDI.d127.s2.e0
The,25-28
coadministration,29-45
of,46-48
phenytoin,49-58	DrugDDI.d127.s2.e2
or,59-61
phenobarbital,62-75	DrugDDI.d127.s2.e3
will,76-80
not,81-84
affect,85-91
plasma,92-98
concentrations,99-113
of,114-116
vitamin,117-124	DrugDDI.d127.s2.e4
D,,125-127	DrugDDI.d127.s2.e4
but,128-131
may,132-135
reduce,136-142
endogenous,143-153
plasma,154-160
levels,161-167
of,168-170
calcitriol/ergocalcitriol,171-196	DrugDDI.d127.s2.e5
by,197-199
accelerating,200-212
metabolism.,213-224

Since,0-5
blood,6-11
level,12-17
of,18-20
calcitriol/ergocalcitriol,21-46	DrugDDI.d127.s3.e0
will,47-51
be,52-54
reduced,,55-63
higher,64-70
doses,71-76
of,77-79
Rocaltrol,80-89	DrugDDI.d127.s3.e1
may,90-93
be,94-96
necessary,97-106
if,107-109
these,110-115
drugs,116-121	DrugDDI.d127.s3.e2
are,122-125
administered,126-138
simultaneously.,139-154

Thiazides:,0-10	DrugDDI.d127.s4.e0
Thiazides,11-20	DrugDDI.d127.s4.e1
are,21-24
known,25-30
to,31-33
induce,34-40
hypercalcemia,41-54
by,55-57
the,58-61
reduction,62-71
of,72-74
calcium,75-82	DrugDDI.d127.s4.e2
excretion,83-92
in,93-95
urine.,96-102

Some,0-4
reports,5-12
have,13-17
shown,18-23
that,24-28
the,29-32
concomitant,33-44
administration,45-59
of,60-62
thiazides,63-72	DrugDDI.d127.s5.e0
with,73-77
vitamin,78-85	DrugDDI.d127.s5.e1
D,86-87	DrugDDI.d127.s5.e1
causes,88-94
hypercalcemia.,95-109

Digitalis:,0-10	DrugDDI.d127.s7.e0
Vitamin,11-18	DrugDDI.d127.s7.e1
D,19-20	DrugDDI.d127.s7.e1
dosage,21-27
must,28-32
be,33-35
determined,36-46
with,47-51
care,52-56
in,57-59
patients,60-68
undergoing,69-79
treatment,80-89
with,90-94
digitalis,,95-105
as,106-108
hypercalcemia,109-122
in,123-125
such,126-130
patients,131-139
may,140-143
precipitate,144-155
cardiac,156-163
arrhythmias.,164-176

Ketoconazole:,0-13	DrugDDI.d127.s8.e0
Ketoconazole,14-26	DrugDDI.d127.s8.e1
may,27-30
inhibit,31-38
both,39-43
synthetic,44-53
and,54-57
catabolic,58-67
enzymes,68-75
of,76-78
vitamin,79-86	DrugDDI.d127.s8.e2
D.,87-89	DrugDDI.d127.s8.e2

Reductions,0-10
in,11-13
serum,14-19
endogenous,20-30
vitamin,31-38
D,39-40
concentrations,41-55
have,56-60
been,61-65
observed,66-74
following,75-84
the,85-88
administration,89-103
of,104-106
300,107-110
mg/day,111-117
to,118-120
1200,121-125
mg/day,126-132
ketoconazole,133-145	DrugDDI.d127.s9.e0
for,146-149
a,150-151
week,152-156
to,157-159
healthy,160-167
men.,168-172

However,,0-8
in,9-11
vivo,12-16
drug,17-21
interaction,22-33
studies,34-41
of,42-44
ketoconazole,45-57	DrugDDI.d127.s10.e0
with,58-62
vitamin,63-70	DrugDDI.d127.s10.e1
D,71-72	DrugDDI.d127.s10.e1
have,73-77
not,78-81
been,82-86
investigated.,87-100

Corticosteroids:,0-16	DrugDDI.d127.s11.e0
A,17-18
relationship,19-31
of,32-34
functional,35-45
antagonism,46-56
exists,57-63
between,64-71
vitamin,72-79
D,80-81
analogues,,82-92
which,93-98
promote,99-106
calcium,107-114	DrugDDI.d127.s11.e1
absorption,,115-126
and,127-130
corticosteroids,,131-147
which,148-153
inhibit,154-161
calcium,162-169	DrugDDI.d127.s11.e3
absorption.,170-181

Phosphate-Binding,0-17	DrugDDI.d127.s12.e0
Agents:,18-25	DrugDDI.d127.s12.e0
Since,26-31
vitamin,32-39	DrugDDI.d127.s12.e1
D,40-41	DrugDDI.d127.s12.e1
also,42-46
has,47-50
an,51-53
effect,54-60
on,61-63
phosphate,64-73
transport,74-83
in,84-86
the,87-90
intestine,,91-101
kidneys,102-109
and,110-113
bones,,114-120
the,121-124
dosage,125-131
of,132-134
phosphate-binding,135-152	DrugDDI.d127.s12.e2
agents,153-159	DrugDDI.d127.s12.e2
must,160-164
be,165-167
adjusted,168-176
in,177-179
accordance,180-190
with,191-195
the,196-199
serum,200-205
phosphate,206-215
concentration.,216-230

Vitamin,0-7	DrugDDI.d127.s13.e0
D:,8-10	DrugDDI.d127.s13.e0
The,11-14
coadministration,15-31
of,32-34
any,35-38
of,39-41
the,42-45
vitamin,46-53
D,54-55
analogues,56-65
should,66-72
be,73-75
avoided,76-83
as,84-86
this,87-91
could,92-97
create,98-104
possible,105-113
additive,114-122
effects,123-130
and,131-134
hypercalcemia.,135-149

Calcium,0-7	DrugDDI.d127.s14.e0
Supplements:,8-20
Uncontrolled,21-33
intake,34-40
of,41-43
additional,44-54
calcium-containing,55-73	DrugDDI.d127.s14.e1
preparations,74-86	DrugDDI.d127.s14.e1
should,87-93
be,94-96
avoided.,97-105

Magnesium:,0-10	DrugDDI.d127.s15.e0
Magnesium-containing,11-31	DrugDDI.d127.s15.e1
preparations,32-44	DrugDDI.d127.s15.e1
(eg,,45-49
antacids),50-59	DrugDDI.d127.s15.e2
may,60-63
cause,64-69
hypermagnesemia,70-85
and,86-89
should,90-96
therefore,97-106
not,107-110
be,111-113
taken,114-119
during,120-126
therapy,127-134
with,135-139
vitamin,140-147	DrugDDI.d127.s15.e3
D,148-149	DrugDDI.d127.s15.e3
by,150-152
patients,153-161
on,162-164
chronic,165-172
renal,173-178
dialysis.,179-188

Interactions,0-12
for,13-16
vitamin,17-24
D,25-26
analogues,27-36
(Vitamin,37-45
D2,,46-49
Vitamin,50-57	DrugDDI.d93.s0.e1
D3,,58-61	DrugDDI.d93.s0.e1
Calcitriol,,62-73
and,74-77
Calcidiol):,78-89	DrugDDI.d93.s0.e3
Cholestyramine:,90-105	DrugDDI.d93.s0.e4
Cholestyramine,106-120	DrugDDI.d93.s0.e5
has,121-124
been,125-129
reported,130-138
to,139-141
reduce,142-148
intestinal,149-159
absorption,160-170
of,171-173
fat,174-177
soluble,178-185
vitamins;,186-195

as,0-2
such,3-7
it,8-10
may,11-14
impair,15-21
intestinal,22-32
absorption,33-43
of,44-46
any,47-50
of,51-53
vitamin,54-61	DrugDDI.d93.s1.e0
D.,62-64	DrugDDI.d93.s1.e0

Phenytoin/Phenobarbital:,0-24	DrugDDI.d93.s2.e0
The,25-28
coadministration,29-45
of,46-48
phenytoin,49-58	DrugDDI.d93.s2.e2
or,59-61
phenobarbital,62-75	DrugDDI.d93.s2.e3
will,76-80
not,81-84
affect,85-91
plasma,92-98
concentrations,99-113
of,114-116
vitamin,117-124	DrugDDI.d93.s2.e4
D,,125-127	DrugDDI.d93.s2.e4
but,128-131
may,132-135
reduce,136-142
endogenous,143-153
plasma,154-160
levels,161-167
of,168-170
calcitriol/ergocalcitriol,171-196	DrugDDI.d93.s2.e5
by,197-199
accelerating,200-212
metabolism.,213-224

Since,0-5
blood,6-11
level,12-17
of,18-20
calcitriol/ergocalcitriol,21-46	DrugDDI.d93.s3.e0
will,47-51
be,52-54
reduced,,55-63
higher,64-70
doses,71-76
of,77-79
Rocaltrol,80-89	DrugDDI.d93.s3.e1
may,90-93
be,94-96
necessary,97-106
if,107-109
these,110-115
drugs,116-121	DrugDDI.d93.s3.e2
are,122-125
administered,126-138
simultaneously.,139-154

Thiazides:,0-10	DrugDDI.d93.s4.e0
Thiazides,11-20	DrugDDI.d93.s4.e1
are,21-24
known,25-30
to,31-33
induce,34-40
hypercalcemia,41-54
by,55-57
the,58-61
reduction,62-71
of,72-74
calcium,75-82	DrugDDI.d93.s4.e2
excretion,83-92
in,93-95
urine.,96-102

Some,0-4
reports,5-12
have,13-17
shown,18-23
that,24-28
the,29-32
concomitant,33-44
administration,45-59
of,60-62
thiazides,63-72	DrugDDI.d93.s5.e0
with,73-77
vitamin,78-85	DrugDDI.d93.s5.e1
D,86-87	DrugDDI.d93.s5.e1
causes,88-94
hypercalcemia.,95-109

Digitalis:,0-10	DrugDDI.d93.s7.e0
Vitamin,11-18	DrugDDI.d93.s7.e1
D,19-20	DrugDDI.d93.s7.e1
dosage,21-27
must,28-32
be,33-35
determined,36-46
with,47-51
care,52-56
in,57-59
patients,60-68
undergoing,69-79
treatment,80-89
with,90-94
digitalis,,95-105
as,106-108
hypercalcemia,109-122
in,123-125
such,126-130
patients,131-139
may,140-143
precipitate,144-155
cardiac,156-163
arrhythmias.,164-176

Ketoconazole:,0-13	DrugDDI.d93.s8.e0
Ketoconazole,14-26	DrugDDI.d93.s8.e1
may,27-30
inhibit,31-38
both,39-43
synthetic,44-53
and,54-57
catabolic,58-67
enzymes,68-75
of,76-78
vitamin,79-86	DrugDDI.d93.s8.e2
D.,87-89	DrugDDI.d93.s8.e2

Reductions,0-10
in,11-13
serum,14-19
endogenous,20-30
vitamin,31-38
D,39-40
concentrations,41-55
have,56-60
been,61-65
observed,66-74
following,75-84
the,85-88
administration,89-103
of,104-106
300,107-110
mg/day,111-117
to,118-120
1200,121-125
mg/day,126-132
ketoconazole,133-145	DrugDDI.d93.s9.e0
for,146-149
a,150-151
week,152-156
to,157-159
healthy,160-167
men.,168-172

However,,0-8
in,9-11
vivo,12-16
drug,17-21
interaction,22-33
studies,34-41
of,42-44
ketoconazole,45-57	DrugDDI.d93.s10.e0
with,58-62
vitamin,63-70	DrugDDI.d93.s10.e1
D,71-72	DrugDDI.d93.s10.e1
have,73-77
not,78-81
been,82-86
investigated.,87-100

Corticosteroids:,0-16	DrugDDI.d93.s11.e0
A,17-18
relationship,19-31
of,32-34
functional,35-45
antagonism,46-56
exists,57-63
between,64-71
vitamin,72-79
D,80-81
analogues,,82-92
which,93-98
promote,99-106
calcium,107-114	DrugDDI.d93.s11.e1
absorption,,115-126
and,127-130
corticosteroids,,131-147
which,148-153
inhibit,154-161
calcium,162-169	DrugDDI.d93.s11.e3
absorption.,170-181

Phosphate-Binding,0-17	DrugDDI.d93.s12.e0
Agents:,18-25	DrugDDI.d93.s12.e0
Since,26-31
vitamin,32-39	DrugDDI.d93.s12.e1
D,40-41	DrugDDI.d93.s12.e1
also,42-46
has,47-50
an,51-53
effect,54-60
on,61-63
phosphate,64-73
transport,74-83
in,84-86
the,87-90
intestine,,91-101
kidneys,102-109
and,110-113
bones,,114-120
the,121-124
dosage,125-131
of,132-134
phosphate-binding,135-152	DrugDDI.d93.s12.e2
agents,153-159	DrugDDI.d93.s12.e2
must,160-164
be,165-167
adjusted,168-176
in,177-179
accordance,180-190
with,191-195
the,196-199
serum,200-205
phosphate,206-215
concentration.,216-230

Vitamin,0-7	DrugDDI.d93.s13.e0
D:,8-10	DrugDDI.d93.s13.e0
The,11-14
coadministration,15-31
of,32-34
any,35-38
of,39-41
the,42-45
vitamin,46-53
D,54-55
analogues,56-65
should,66-72
be,73-75
avoided,76-83
as,84-86
this,87-91
could,92-97
create,98-104
possible,105-113
additive,114-122
effects,123-130
and,131-134
hypercalcemia.,135-149

Calcium,0-7	DrugDDI.d93.s14.e0
Supplements:,8-20
Uncontrolled,21-33
intake,34-40
of,41-43
additional,44-54
calcium-containing,55-73	DrugDDI.d93.s14.e1
preparations,74-86	DrugDDI.d93.s14.e1
should,87-93
be,94-96
avoided.,97-105

Magnesium:,0-10	DrugDDI.d93.s15.e0
Magnesium-containing,11-31	DrugDDI.d93.s15.e1
preparations,32-44	DrugDDI.d93.s15.e1
(eg,,45-49
antacids),50-59	DrugDDI.d93.s15.e2
may,60-63
cause,64-69
hypermagnesemia,70-85
and,86-89
should,90-96
therefore,97-106
not,107-110
be,111-113
taken,114-119
during,120-126
therapy,127-134
with,135-139
vitamin,140-147	DrugDDI.d93.s15.e3
D,148-149	DrugDDI.d93.s15.e3
by,150-152
patients,153-161
on,162-164
chronic,165-172
renal,173-178
dialysis.,179-188

Concomitant,0-11
use,12-15
with,16-20
other,21-26
calcium-containing,27-45	DrugDDI.d562.s0.e0
medicines,46-55
(including,56-66
antacids),67-76	DrugDDI.d562.s0.e1
may,77-80
cause,81-86
too,87-90
much,91-95
calcium,96-103	DrugDDI.d562.s0.e2
in,104-106
the,107-110
blood,111-116
or,117-119
urine,,120-126
which,127-132
may,133-136
increase,137-145
the,146-149
chance,150-156
of,157-159
side,160-164
effects.,165-173

Using,0-5
calcium,6-13	DrugDDI.d562.s1.e0
acetate,14-21	DrugDDI.d562.s1.e0
with,22-26
digitalis,27-36	DrugDDI.d562.s1.e1
glycosides,37-47	DrugDDI.d562.s1.e1
(heart,48-54
medicine),55-64
may,65-68
cause,69-74
hypercalcemia,75-88
(too,89-93
much,94-98
calcium,99-106	DrugDDI.d562.s1.e3
in,107-109
the,110-113
blood),,114-121
which,122-127
could,128-133
increase,134-142
the,143-146
chance,147-153
of,154-156
developing,157-167
an,168-170
irregular,171-180
heartbeat.,181-191

May,0-3
interact,4-12
with,13-17
cefamandole,18-29	DrugDDI.d148.s0.e0
naftate,,30-38	DrugDDI.d148.s0.e0
cephalothin,39-50	DrugDDI.d148.s0.e1
sodium,,51-58	DrugDDI.d148.s0.e1
magnesium,59-68	DrugDDI.d148.s0.e2
sulfate,,69-77	DrugDDI.d148.s0.e2
prednisolone,78-90	DrugDDI.d148.s0.e3
sodium,91-97
succi?nate,,98-109
and,110-113
prochlorperazine,114-130	DrugDDI.d148.s0.e4
edisylate.,131-141	DrugDDI.d148.s0.e4

No,0-2
significant,3-14
drug,15-19
interactions,20-32
have,33-37
been,38-42
reported,43-51
in,52-54
studies,55-62
of,63-65
candesartan,66-77	DrugDDI.d112.s0.e0
cilexetil,78-87	DrugDDI.d112.s0.e0
given,88-93
with,94-98
other,99-104
drugs,105-110	DrugDDI.d112.s0.e1
such,111-115
as,116-118
glyburide,,119-129
nifedipine,,130-141
digoxin,,142-150
warfarin,,151-160
hydrochlorothiazide,,161-181
and,182-185
oral,186-190	DrugDDI.d112.s0.e7
contraceptives,191-205	DrugDDI.d112.s0.e7
in,206-208
healthy,209-216
volunteers,,217-228
or,229-231
given,232-237
with,238-242
enalapril,243-252	DrugDDI.d112.s0.e8
to,253-255
patients,256-264
with,265-269
heart,270-275
failure,276-283
(NYHA,284-289
class,290-295
II,296-298
and,299-302
III).,303-308

Because,0-7
candesartan,8-19	DrugDDI.d112.s1.e0
is,20-22
not,23-26
significantly,27-40
metabolized,41-52
by,53-55
the,56-59
cytochrome,60-70	DrugDDI.d112.s1.e1
P450,71-75	DrugDDI.d112.s1.e1
system,76-82
and,83-86
at,87-89
therapeutic,90-101
concentrations,102-116
has,117-120
no,121-123
effects,124-131
on,132-134
P450,135-139	DrugDDI.d112.s1.e2
enzymes,,140-148
interactions,149-161
with,162-166
drugs,167-172	DrugDDI.d112.s1.e3
that,173-177
inhibit,178-185
or,186-188
are,189-192
metabolized,193-204
by,205-207
those,208-213
enzymes,214-221
would,222-227
not,228-231
be,232-234
expected.,235-244

Lithium?,0-8
Reversible,9-19
increases,20-29
in,30-32
serum,33-38
lithium,39-46	DrugDDI.d112.s2.e0
concentrations,47-61
and,62-65
toxicity,66-74
have,75-79
been,80-84
reported,85-93
during,94-100
concomitant,101-112
administration,113-127
of,128-130
lithium,131-138	DrugDDI.d112.s2.e1
with,139-143
ACE,144-147	DrugDDI.d112.s2.e2
inhibitors,,148-159	DrugDDI.d112.s2.e2
and,160-163
with,164-168
some,169-173
angiotensin,174-185	DrugDDI.d112.s2.e3
II,186-188	DrugDDI.d112.s2.e3
receptor,189-197	DrugDDI.d112.s2.e3
antagonists.,198-210	DrugDDI.d112.s2.e3

An,0-2
increase,3-11
in,12-14
serum,15-20
lithium,21-28	DrugDDI.d112.s3.e0
concentration,29-42
has,43-46
been,47-51
reported,52-60
during,61-67
concomitant,68-79
administration,80-94
of,95-97
lithium,98-105	DrugDDI.d112.s3.e1
with,106-110
ATACAND,,111-119
so,120-122
careful,123-130
monitoring,131-141
of,142-144
serum,145-150
lithium,151-158
levels,159-165
is,166-168
recommended,169-180
during,181-187
concomitant,188-199
use.,200-204

Antacid,0-7
The,8-11
effect,12-18
of,19-21
an,22-24
aluminum,25-33	DrugDDI.d236.s0.e0
hydroxide-,34-44	DrugDDI.d236.s0.e0
and,45-48
magnesium,49-58	DrugDDI.d236.s0.e1
hydroxide-containing,59-79	DrugDDI.d236.s0.e1
antacid,80-87	DrugDDI.d236.s0.e1
(Maalox)*,88-97
on,98-100
the,101-104
pharmacokinetics,105-121
of,122-124
capecitabine,125-137	DrugDDI.d236.s0.e3
was,138-141
investigated,142-154
in,155-157
12,158-160
cancer,161-167
patients.,168-177

There,0-5
was,6-9
a,10-11
small,12-17
increase,18-26
in,27-29
plasma,30-36
concentrations,37-51
of,52-54
capecitabine,55-67	DrugDDI.d236.s1.e0
and,68-71
one,72-75
metabolite,76-86	DrugDDI.d236.s1.e1
(5-DFCR);,87-96

there,0-5
was,6-9
no,10-12
effect,13-19
on,20-22
the,23-26
3,27-28
major,29-34
metabolites,35-46	DrugDDI.d236.s2.e0
(5-DFUR,,47-55
5-FU,56-60	DrugDDI.d236.s2.e1
and,61-64
FBAL).,65-71	DrugDDI.d236.s2.e2

Coumarin,0-8	DrugDDI.d236.s3.e0
Anticoagulants,9-23	DrugDDI.d236.s3.e0
Altered,24-31
coagulation,32-43
parameters,44-54
and/or,55-61
bleeding,62-70
have,71-75
been,76-80
reported,81-89
in,90-92
patients,93-101
taking,102-108
capecitabine,109-121	DrugDDI.d236.s3.e1
concomitantly,122-135
with,136-140
coumarin-derivative,141-160	DrugDDI.d236.s3.e2
anticoagulants,161-175	DrugDDI.d236.s3.e2
such,176-180
as,181-183
warfarin,184-192	DrugDDI.d236.s3.e3
and,193-196
phenprocoumon.,197-211	DrugDDI.d236.s3.e4

Patients,0-8
taking,9-15
coumarin-derivative,16-35	DrugDDI.d236.s4.e0
anticoagulants,36-50	DrugDDI.d236.s4.e0
concomitantly,51-64
with,65-69
capecitabine,70-82	DrugDDI.d236.s4.e1
should,83-89
be,90-92
monitored,93-102
regularly,103-112
for,113-116
alterations,117-128
in,129-131
their,132-137
coagulation,138-149
parameters,150-160
(PT,161-164
or,165-167
INR).,168-173

Leucovorin,0-10	DrugDDI.d236.s5.e0
The,11-14
concentration,15-28
of,29-31
5-fluorouracil,32-46
is,47-49
increased,50-59
and,60-63
its,64-67
toxicity,68-76
may,77-80
be,81-83
enhanced,84-92
by,93-95
leucovorin.,96-107	DrugDDI.d236.s5.e2

Deaths,0-6
from,7-11
severe,12-18
enterocolitis,,19-33
diarrhea,,34-43
and,44-47
dehydration,48-59
have,60-64
been,65-69
reported,70-78
in,79-81
elderly,82-89
patients,90-98
receiving,99-108
weekly,109-115
leucovorin,116-126	DrugDDI.d236.s6.e0
and,127-130
fluorouracil.,131-144	DrugDDI.d236.s6.e1

Hypotension,0-11
?,12-13
Patients,14-22
on,23-25
Diuretic,26-34
Therapy:,35-43
Patients,44-52
on,53-55
diuretics,56-65	DrugDDI.d279.s0.e0
and,66-69
especially,70-80
those,81-86
in,87-89
whom,90-94
diuretic,95-103
therapy,104-111
was,112-115
recently,116-124
instituted,,125-136
as,137-139
well,140-144
as,145-147
those,148-153
on,154-156
severe,157-163
dietary,164-171
salt,172-176	DrugDDI.d279.s0.e1
restriction,177-188
or,189-191
dialysis,,192-201
may,202-205
occasionally,206-218
experience,219-229
a,230-231
precipitous,232-243
reduction,244-253
of,254-256
blood,257-262
pressure,263-271
usually,272-279
within,280-286
the,287-290
first,291-296
hour,297-301
after,302-307
receiving,308-317
the,318-321
initial,322-329
dose,330-334
of,335-337
captopril.,338-348	DrugDDI.d279.s0.e2

The,0-3
possibility,4-15
of,16-18
hypotensive,19-30
effects,31-38
with,39-43
captopril,44-53	DrugDDI.d279.s1.e0
can,54-57
be,58-60
minimized,61-70
by,71-73
either,74-80
discontinuing,81-94
the,95-98
diuretic,99-107	DrugDDI.d279.s1.e1
or,108-110
increasing,111-121
the,122-125
salt,126-130
intake,131-137
approximately,138-151
one,152-155
week,156-160
prior,161-166
to,167-169
initiation,170-180
of,181-183
treatment,184-193
with,194-198
captopril,199-208	DrugDDI.d279.s1.e2
(captopril,209-219
tablets,,220-228
USP),229-233
or,234-236
initiating,237-247
therapy,248-255
with,256-260
small,261-266
doses,267-272
(6.25,273-278
or,279-281
12.5,282-286
mg).,287-291

If,0-2
hypotension,3-14
occurs,,15-22
the,23-26
patient,27-34
should,35-41
be,42-44
placed,45-51
in,52-54
a,55-56
supine,57-63
position,64-72
and,,73-77
if,78-80
necessary,,81-91
receive,92-99
an,100-102
intravenous,103-114
infusion,115-123
of,124-126
normal,127-133	DrugDDI.d279.s3.e0
saline.,134-141	DrugDDI.d279.s3.e0

Agents,0-6
Having,7-13
Vasodilator,14-25	DrugDDI.d279.s5.e0
Activity:,26-35
Data,36-40
on,41-43
the,44-47
effect,48-54
of,55-57
concomitant,58-69
use,70-73
of,74-76
other,77-82
vasodilators,83-95	DrugDDI.d279.s5.e1
in,96-98
patients,99-107
receiving,108-117
captopril,118-127	DrugDDI.d279.s5.e2
for,128-131
heart,132-137
failure,138-145
are,146-149
not,150-153
available;,154-164

therefore,,0-10
nitroglycerin,11-24	DrugDDI.d279.s6.e0
or,25-27
other,28-33
nitrates,34-42	DrugDDI.d279.s6.e1
(as,43-46
used,47-51
for,52-55
management,56-66
of,67-69
angina),70-77
or,78-80
other,81-86
drugs,87-92	DrugDDI.d279.s6.e2
having,93-99
vasodilator,100-111	DrugDDI.d279.s6.e3
activity,112-120
should,,121-128
if,129-131
possible,,132-141
be,142-144
discontinued,145-157
before,158-164
starting,165-173
captopril.,174-184	DrugDDI.d279.s6.e4

If,0-2
resumed,3-10
during,11-17
captopril,18-27	DrugDDI.d279.s7.e0
therapy,,28-36
such,37-41
agents,42-48
should,49-55
be,56-58
administered,59-71
cautiously,,72-83
and,84-87
perhaps,88-95
at,96-98
lower,99-104
dosage.,105-112

Agents,0-6
Causing,7-14
Renin,15-20
Release,21-28
Captopril?s,29-40
effect,41-47
will,48-52
be,53-55
augmented,56-65
by,66-68
antihypertensive,69-85	DrugDDI.d279.s8.e1
agents,86-92	DrugDDI.d279.s8.e1
that,93-97
cause,98-103
renin,104-109	DrugDDI.d279.s8.e2
release.,110-118

For,0-3
example,,4-12
diuretics,13-22	DrugDDI.d279.s9.e0
(e.g.,,23-29
thiazides),30-40	DrugDDI.d279.s9.e1
may,41-44
activate,45-53
the,54-57
renin-angiotensin-aldosterone,58-87
system.,88-95

Agents,0-6
Affecting,7-16
Sympathetic,17-28
Activity,29-37
The,38-41
sympathetic,42-53
nervous,54-61
system,62-68
may,69-72
be,73-75
especially,76-86
important,87-96
in,97-99
supporting,100-110
blood,111-116
pressure,117-125
in,126-128
patients,129-137
receiving,138-147
captopril,148-157	DrugDDI.d279.s10.e0
alone,158-163
or,164-166
with,167-171
diuretics.,172-182	DrugDDI.d279.s10.e1

Therefore,,0-10
agents,11-17
affecting,18-27
sympathetic,28-39
activity,40-48
(e.g.,,49-55
ganglionic,56-66	DrugDDI.d279.s11.e0
blocking,67-75	DrugDDI.d279.s11.e0
agents,76-82	DrugDDI.d279.s11.e0
or,83-85
adrenergic,86-96	DrugDDI.d279.s11.e1
neuron,97-103	DrugDDI.d279.s11.e1
blocking,104-112	DrugDDI.d279.s11.e1
agents),113-120	DrugDDI.d279.s11.e1
should,121-127
be,128-130
used,131-135
with,136-140
caution.,141-149

Beta-adrenergic,0-15
blocking,16-24
drugs,25-30
add,31-34
some,35-39
further,40-47
antihypertensive,48-64	DrugDDI.d279.s12.e1
effect,65-71
to,72-74
captopril,,75-85
but,86-89
the,90-93
overall,94-101
response,102-110
is,111-113
less,114-118
than,119-123
additive.,124-133

Agents,0-6
Increasing,7-17
Serum,18-23
Potassium,24-33
Since,34-39
captopril,40-49	DrugDDI.d279.s13.e0
decreases,50-59
aldosterone,60-71	DrugDDI.d279.s13.e1
production,,72-83
elevation,84-93
of,94-96
serum,97-102
potassium,103-112
may,113-116
occur.,117-123

Potassium-sparing,0-17	DrugDDI.d279.s14.e0
diuretics,18-27	DrugDDI.d279.s14.e0
such,28-32
as,33-35
spironolactone,,36-51
triamterene,,52-64
or,65-67
amiloride,,68-78
or,79-81
potassium,82-91	DrugDDI.d279.s14.e4
supplements,92-103	DrugDDI.d279.s14.e4
should,104-110
be,111-113
given,114-119
only,120-124
for,125-128
documented,129-139
hypokalemia,,140-152
and,153-156
then,157-161
with,162-166
caution,,167-175
since,176-181
they,182-186
may,187-190
lead,191-195
to,196-198
a,199-200
significant,201-212
increase,213-221
of,222-224
serum,225-230
potassium.,231-241

Salt,0-4	DrugDDI.d279.s15.e0
substitutes,5-16
containing,17-27
potassium,28-37	DrugDDI.d279.s15.e1
should,38-44
also,45-49
be,50-52
used,53-57
with,58-62
caution.,63-71

Inhibitors,0-10
Of,11-13
Endogenous,14-24
Prostaglandin,25-38	DrugDDI.d279.s16.e0
Synthesis,39-48
It,49-51
has,52-55
been,56-60
reported,61-69
that,70-74
indomethacin,75-87	DrugDDI.d279.s16.e1
may,88-91
reduce,92-98
the,99-102
antihypertensive,103-119	DrugDDI.d279.s16.e2
effect,120-126
of,127-129
captopril,,130-140
especially,141-151
in,152-154
cases,155-160
of,161-163
low,164-167
renin,168-173
hypertension.,174-187

Other,0-5
nonsteroidal,6-18	DrugDDI.d279.s17.e0
anti-inflammatory,19-36	DrugDDI.d279.s17.e0
agents,37-43	DrugDDI.d279.s17.e0
(e.g.,,44-50
aspirin),51-59	DrugDDI.d279.s17.e1
may,60-63
also,64-68
have,69-73
this,74-78
effect.,79-86

Lithium,0-7	DrugDDI.d279.s18.e0
Increased,8-17
serum,18-23
lithium,24-31
levels,32-38
and,39-42
symptoms,43-51
of,52-54
lithium,55-62
toxicity,63-71
have,72-76
been,77-81
reported,82-90
in,91-93
patients,94-102
receiving,103-112
concomitant,113-124
lithium,125-132	DrugDDI.d279.s18.e1
and,133-136
ACE,137-140	DrugDDI.d279.s18.e2
inhibitor,141-150	DrugDDI.d279.s18.e2
therapy.,151-159

These,0-5
drugs,6-11	DrugDDI.d279.s19.e0
should,12-18
be,19-21
coad-ministered,22-37
with,38-42
caution,43-50
and,51-54
frequent,55-63
monitoring,64-74
of,75-77
serum,78-83
lithium,84-91
levels,92-98
is,99-101
recommended.,102-114

If,0-2
a,3-4
diuretic,5-13	DrugDDI.d279.s20.e0
is,14-16
also,17-21
used,,22-27
it,28-30
may,31-34
increase,35-43
the,44-47
risk,48-52
of,53-55
lithium,56-63
toxicity.,64-73

Cardiac,0-7	DrugDDI.d279.s21.e0
Glycosides,8-18	DrugDDI.d279.s21.e0
In,19-21
a,22-23
study,24-29
of,30-32
young,33-38
healthy,39-46
male,47-51
subjects,52-60
no,61-63
evidence,64-72
of,73-75
a,76-77
direct,78-84
pharmacokinetic,85-100
captopril-digoxin,101-118	DrugDDI.d279.s21.e1
interaction,119-130
could,131-136
be,137-139
found.,140-146

Loop,0-4	DrugDDI.d279.s22.e0
Diuretics:,5-15	DrugDDI.d279.s22.e0
Furosemide,16-26	DrugDDI.d279.s22.e1
administered,27-39
concurrently,40-52
with,53-57
cap-topril,58-68
does,69-73
not,74-77
alter,78-83
the,84-87
pharmacokinetics,88-104
of,105-107
captopril,108-117	DrugDDI.d279.s22.e2
in,118-120
renally,121-128
impaired,129-137
hypertensive,138-150
patients.,151-160

Allopurinol,0-11	DrugDDI.d279.s23.e0
In,12-14
a,15-16
study,17-22
of,23-25
healthy,26-33
male,34-38
volunteers,39-49
no,50-52
significant,53-64
pharmacokinetic,65-80
interaction,81-92
occurred,93-101
when,102-106
captopril,107-116	DrugDDI.d279.s23.e1
and,117-120
allop-urinol,121-133
were,134-138
administered,139-151
concomitantly,152-165
for,166-169
6,170-171
days.,172-177

Drug/Laboratory,0-15	DrugDDI.d279.s24.e0
Test,16-20
Interaction,21-32
Captopril,33-42	DrugDDI.d279.s24.e1
may,43-46
cause,47-52
a,53-54
false-positive,55-69
urine,70-75
test,76-80
for,81-84
acetone.,85-93	DrugDDI.d279.s24.e2

Clinically,0-10
meaningful,11-21
drug,22-26
interactions,27-39
have,40-44
occurred,45-53
with,54-58
concomitant,59-70
medications,71-82	DrugDDI.d338.s0.e0
and,83-86
include,,87-95
but,96-99
are,100-103
not,104-107
limited,108-115
to,116-118
the,119-122
following:,123-133
Agents,134-140
Highly,141-147
Bound,148-153
to,154-156
Plasma,157-163	DrugDDI.d338.s0.e1
Protein,164-171	DrugDDI.d338.s0.e1
Carbamazepine,172-185
is,186-188
not,189-192
highly,193-199
bound,200-205
to,206-208
plasma,209-215	DrugDDI.d338.s0.e2
proteins;,216-225	DrugDDI.d338.s0.e2

therefore,,0-10
administration,11-25
of,26-28
EQUETROTM,29-38	DrugDDI.d338.s1.e0
to,39-41
a,42-43
patient,44-51
taking,52-58
another,59-66
drug,67-71	DrugDDI.d338.s1.e1
that,72-76
is,77-79
highly,80-86
protein,87-94	DrugDDI.d338.s1.e2
bound,95-100
should,101-107
not,108-111
cause,112-117
increased,118-127
free,128-132
concentrations,133-147
of,148-150
the,151-154
other,155-160
drug.,161-166	DrugDDI.d338.s1.e3

Agents,0-6
that,7-11
Inhibit,12-19
Cytochrome,20-30	DrugDDI.d338.s2.e0
P450,31-35	DrugDDI.d338.s2.e0
Isoenzymes,36-46
and/or,47-53
Epoxide,54-61	DrugDDI.d338.s2.e1
Hydrolase,62-71	DrugDDI.d338.s2.e1
Carbamazepine,72-85
is,86-88
metabolized,89-100
mainly,101-107
by,108-110
cytochrome,111-121	DrugDDI.d338.s2.e2
P450,122-126	DrugDDI.d338.s2.e2
(CYP),127-132
3A4,133-136
to,137-139
the,140-143
active,144-150
carbamazepine,151-164	DrugDDI.d338.s2.e4
10,11-epoxide,,165-179	DrugDDI.d338.s2.e4
which,180-185
is,186-188
further,189-196
metabolized,197-208
to,209-211
the,212-215
trans-diol,216-226
by,227-229
epoxide,230-237	DrugDDI.d338.s2.e5
hydrolase.,238-248	DrugDDI.d338.s2.e5

Therefore,,0-10
the,11-14
potential,15-24
exists,25-31
for,32-35
interaction,36-47
between,48-55
carbamazepine,56-69	DrugDDI.d338.s3.e0
and,70-73
any,74-77
agent,78-83
that,84-88
inhibits,89-97
CYP3A4,98-104	DrugDDI.d338.s3.e1
and/or,105-111
epoxide,112-119	DrugDDI.d338.s3.e2
hydrolase.,120-130	DrugDDI.d338.s3.e2

Agents,0-6
that,7-11
are,12-15
CYP3A4,16-22	DrugDDI.d338.s4.e0
inhibitors,23-33
that,34-38
have,39-43
been,44-48
found,,49-55
or,56-58
are,59-62
expected,,63-72
to,73-75
increase,76-84
plasma,85-91
levels,92-98
of,99-101
EQUETROTM,102-111	DrugDDI.d338.s4.e1
are,112-115
the,116-119
following:,120-130
Acetazolamide,,131-145
azole,146-151	DrugDDI.d338.s4.e3
antifungals,,152-164	DrugDDI.d338.s4.e3
cimetidine,,165-176
clarithromycin(1),,177-195
dalfopristin,,196-209
danazol,,210-218
delavirdine,,219-231
diltiazem,,232-242
erythromycin(1),,243-259
fluoxetine,,260-271
fluvoxamine,,272-284
grapefruit,285-295
juice,,296-302
isoniazid,,303-313
itraconazole,,314-327
ketoconazole,,328-341
loratadine,,342-353
nefazodone,,354-365
niacinamide,,366-378
nicotinamide,,379-392
protease,393-401	DrugDDI.d338.s4.e20
inhibitors,,402-413	DrugDDI.d338.s4.e20
propoxyphene,,414-427
quinine,,428-436
quinupristin,,437-450
troleandomycin,,451-466
valproate(1),,467-480
verapamil,,481-491
zileuton.,492-501	DrugDDI.d338.s4.e27

Thus,,0-5
if,6-8
a,9-10
patient,11-18
has,19-22
been,23-27
titrated,28-36
to,37-39
a,40-41
stable,42-48
dosage,49-55
of,56-58
EQUETROTM,,59-69
and,70-73
then,74-78
begins,79-85
a,86-87
course,88-94
of,95-97
treatment,98-107
with,108-112
one,113-116
of,117-119
these,120-125
CYP3A4,126-132	DrugDDI.d338.s5.e1
or,133-135
epoxide,136-143	DrugDDI.d338.s5.e2
hydrolase,144-153	DrugDDI.d338.s5.e2
inhibitors,,154-165
it,166-168
is,169-171
reasonable,172-182
to,183-185
expect,186-192
that,193-197
a,198-199
dose,200-204
reduction,205-214
for,215-218
EQUETROTM,219-228	DrugDDI.d338.s5.e3
may,229-232
be,233-235
necessary.,236-246

Agents,0-6
that,7-11
Induce,12-18
Cytochrome,19-29	DrugDDI.d338.s6.e0
P450,30-34	DrugDDI.d338.s6.e0
Isoenzymes,35-45
Carbamazepine,46-59
is,60-62
metabolized,63-74
by,75-77
CYP3A4.,78-85	DrugDDI.d338.s6.e1

Therefore,,0-10
the,11-14
potential,15-24
exists,25-31
for,32-35
interaction,36-47
between,48-55
carbamazepine,56-69	DrugDDI.d338.s7.e0
and,70-73
any,74-77
agent,78-83
that,84-88
induces,89-96
CYP3A4.,97-104	DrugDDI.d338.s7.e1

Agents,0-6
that,7-11
are,12-15
CYP,16-19	DrugDDI.d338.s8.e0
inducers,20-28
that,29-33
have,34-38
been,39-43
found,,44-50
or,51-53
are,54-57
expected,,58-67
to,68-70
decrease,71-79
plasma,80-86
levels,87-93
of,94-96
EQUETROTM,97-106	DrugDDI.d338.s8.e1
are,107-110
the,111-114
following:,115-125
Cisplatin,,126-136
doxorubicin,137-148	DrugDDI.d338.s8.e3
HCL,,149-153	DrugDDI.d338.s8.e3
felbamate,,154-164
rifampin,,165-174
phenobarbital,,175-189
Phenytoin(2),,190-203
primidone,,204-214
methsuximide,,215-228
and,229-232
theophylline,233-245	DrugDDI.d338.s8.e10
Thus,,246-251
if,252-254
a,255-256
patient,257-264
has,265-268
been,269-273
titrated,274-282
to,283-285
a,286-287
stable,288-294
dosage,295-301
on,302-304
EQUETROTM,,305-315
and,316-319
then,320-324
begins,325-331
a,332-333
course,334-340
of,341-343
treatment,344-353
with,354-358
one,359-362
of,363-365
these,366-371
CYP3A4,372-378	DrugDDI.d338.s8.e12
inducers,,379-388
it,389-391
is,392-394
reasonable,395-405
to,406-408
expect,409-415
that,416-420
a,421-422
dose,423-427
increase,428-436
for,437-440
EQUETROTM,441-450	DrugDDI.d338.s8.e13
may,451-454
be,455-457
necessary.,458-468

Agents,0-6
with,7-11
Decreased,12-21
Levels,22-28
in,29-31
the,32-35
Presence,36-44
of,45-47
Carbamazepine,48-61	DrugDDI.d338.s9.e0
due,62-65
to,66-68
Induction,69-78
of,79-81
Cytochrome,82-92	DrugDDI.d338.s9.e1
P450,93-97	DrugDDI.d338.s9.e1
Enzymes,98-105
Carbamazepine,106-119
is,120-122
known,123-128
to,129-131
induce,132-138
CYP1A2,139-145	DrugDDI.d338.s9.e2
and,146-149
CYP3A4.,150-157	DrugDDI.d338.s9.e3

Therefore,,0-10
the,11-14
potential,15-24
exists,25-31
for,32-35
interaction,36-47
between,48-55
carbamazepine,56-69	DrugDDI.d338.s10.e0
and,70-73
any,74-77
agent,78-83
metabolized,84-95
by,96-98
one,99-102
(or,103-106
more),107-112
of,113-115
these,116-121
enzymes.,122-130

Agents,0-6
that,7-11
have,12-16
been,17-21
found,,22-28
or,29-31
are,32-35
expected,36-44
to,45-47
have,48-52
decreased,53-62
plasma,63-69
levels,70-76
in,77-79
the,80-83
presence,84-92
of,93-95
EQUETROTM,96-105	DrugDDI.d338.s11.e0
due,106-109
to,110-112
induction,113-122
of,123-125
CYP,126-129	DrugDDI.d338.s11.e1
enzymes,130-137
are,138-141
the,142-145
following:,146-156
Acetaminophen,,157-171
alprazolam,,172-183
amitriptyline,,184-198
bupropion,,199-209
buspirone,,210-220
citalopram,,221-232
clobazam,,233-242
clonazepam,,243-254
clozapine,,255-265
cyclosporin,,266-278
delavirdine,,279-291
desipramine,,292-304
diazepam,,305-314
dicumarol,,315-325
doxycycline,,326-338
ethosuximide,,339-352
felbamate,,353-363
felodipine,,364-375
glucocorticoids,,376-392
haloperidol,,393-405
itraconazole,,406-419
lamotrigine,,420-432
levothyroxine,,433-447
lorazepam,,448-458
methadone,,459-469
midazolam,,470-480
mirtazapine,,481-493
nortriptyline,,494-508
olanzapine,,509-520
oral,521-525	DrugDDI.d338.s11.e30
contraceptives(3),,526-544	DrugDDI.d338.s11.e30
oxcarbazepine,,545-559
Phenytoin(4),,560-573
praziquantel,,574-587
protease,588-596	DrugDDI.d338.s11.e34
inhibitors,,597-608	DrugDDI.d338.s11.e34
quetiapine,,609-620
risperidone,,621-633
theophylline,,634-647
topiramate,,648-659
tiagabine,,660-670
tramadol,,671-680
triazolam,,681-691
valproate,,692-702
warfarin(5),703-714	DrugDDI.d338.s11.e43
,,715-716
ziprasidone,,717-729
and,730-733
zonisamide.,734-745	DrugDDI.d338.s11.e45

Thus,,0-5
if,6-8
a,9-10
patient,11-18
has,19-22
been,23-27
titrated,28-36
to,37-39
a,40-41
stable,42-48
dosage,49-55
on,56-58
one,59-62
of,63-65
the,66-69
agents,70-76
in,77-79
this,80-84
category,,85-94
and,95-98
then,99-103
begins,104-110
a,111-112
course,113-119
of,120-122
treatment,123-132
with,133-137
EQUETROTM,,138-148
it,149-151
is,152-154
reasonable,155-165
to,166-168
expect,169-175
that,176-180
a,181-182
dose,183-187
increase,188-196
for,197-200
the,201-204
concomitant,205-216
agent,217-222
may,223-226
be,227-229
necessary.,230-240

Agents,0-6
with,7-11
Increased,12-21
Levels,22-28
in,29-31
the,32-35
Presence,36-44
of,45-47
Carbamazepine:,48-62	DrugDDI.d338.s13.e0
EQUETROTM,63-72	DrugDDI.d338.s13.e1
increases,73-82
the,83-86
plasma,87-93
levels,94-100
of,101-103
the,104-107
following,108-117
agents:,118-125
Clomipramine,126-138	DrugDDI.d338.s13.e2
HCl,,139-143
Phenytoin(6),,144-157
and,158-161
primidone,162-171	DrugDDI.d338.s13.e4
Thus,,172-177
if,178-180
a,181-182
patient,183-190
has,191-194
been,195-199
titrated,200-208
to,209-211
a,212-213
stable,214-220
dosage,221-227
on,228-230
one,231-234
of,235-237
the,238-241
agents,242-248
in,249-251
this,252-256
category,,257-266
and,267-270
then,271-275
begins,276-282
a,283-284
course,285-291
of,292-294
the,295-298
treatment,299-308
with,309-313
EQUETROTM,,314-324
it,325-327
is,328-330
reasonable,331-341
to,342-344
expect,345-351
that,352-356
a,357-358
dose,359-363
decrease,364-372
for,373-376
the,377-380
concomitant,381-392
agent,393-398
may,399-402
be,403-405
necessary.,406-416

Pharmacological/Pharmacodynamic,0-31
Interactions,32-44
with,45-49
Carbamazepine,50-63	DrugDDI.d338.s14.e0
Concomitant,64-75
administration,76-90
of,91-93
carbamazepine,94-107	DrugDDI.d338.s14.e1
and,108-111
lithium,112-119	DrugDDI.d338.s14.e2
may,120-123
increase,124-132
the,133-136
risk,137-141
of,142-144
neurotoxic,145-155
side,156-160
effects.,161-169

Given,0-5
the,6-9
anticonvulsant,10-24	DrugDDI.d338.s15.e0
properties,25-35
of,36-38
carbamazepine,,39-53
EQUETROTM,54-63	DrugDDI.d338.s15.e2
may,64-67
reduce,68-74
the,75-78
thyroid,79-86
function,87-95
as,96-98
has,99-102
been,103-107
reported,108-116
with,117-121
other,122-127
anticonvulsants.,128-144	DrugDDI.d338.s15.e3

Additionally,,0-13
anti-malarial,14-27	DrugDDI.d338.s16.e0
drugs,,28-34	DrugDDI.d338.s16.e0
such,35-39
as,40-42
chloroquine,43-54	DrugDDI.d338.s16.e1
and,55-58
mefloquine,,59-70
may,71-74
antagonize,75-85
the,86-89
activity,90-98
of,99-101
carbamazepine.,102-116	DrugDDI.d338.s16.e3

Thus,0-4
if,5-7
a,8-9
patient,10-17
has,18-21
been,22-26
titrated,27-35
to,36-38
a,39-40
stable,41-47
dosage,48-54
on,55-57
one,58-61
of,62-64
the,65-68
agents,69-75
in,76-78
this,79-83
category,,84-93
and,94-97
then,98-102
begins,103-109
a,110-111
course,112-118
of,119-121
treatment,122-131
with,132-136
EQUETROTM,,137-147
it,148-150
is,151-153
reasonable,154-164
to,165-167
expect,168-174
that,175-179
a,180-181
dose,182-186
adjustment,187-197
may,198-201
be,202-204
necessary.,205-215

Because,0-7
of,8-10
its,11-14
primary,15-22
CNS,23-26
effect,,27-34
caution,35-42
should,43-49
be,50-52
used,53-57
when,58-62
EQUETROTM,63-72	DrugDDI.d338.s18.e0
is,73-75
taken,76-81
with,82-86
other,87-92
centrally,93-102	DrugDDI.d338.s18.e1
acting,103-109	DrugDDI.d338.s18.e1
drugs,110-115	DrugDDI.d338.s18.e1
and,116-119
alcohol.,120-128	DrugDDI.d338.s18.e2

Geocillin,0-9	DrugDDI.d373.s0.e0
(carbenicillin,10-24
indanyl,25-32
sodium),33-40
blood,41-46
levels,47-53
may,54-57
be,58-60
increased,61-70
and,71-74
prolonged,75-84
by,85-87
concurrent,88-98
administration,99-113
of,114-116
probenecid.,117-128	DrugDDI.d373.s0.e2

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
the,33-36
following,37-46
drugs,47-52	DrugDDI.d180.s0.e0
are,53-56
administered,57-69
concomitantly,70-83
with,84-88
LODOSYN,89-96	DrugDDI.d180.s0.e1
(Carbidopa),97-108
given,109-114
with,115-119
levodopa,120-128	DrugDDI.d180.s0.e3
or,129-131
carbidopa-levodopa,132-150	DrugDDI.d180.s0.e4
combination,151-162
products.,163-172

Symptomatic,0-11
postural,12-20
hypotension,21-32
has,33-36
occurred,37-45
when,46-50
LODOSYN,,51-59
given,60-65
with,66-70
levodopa,71-79	DrugDDI.d180.s1.e1
or,80-82
carbidopa-levodopa,83-101	DrugDDI.d180.s1.e2
combination,102-113
products,,114-123
was,124-127
added,128-133
to,134-136
the,137-140
treatment,141-150
of,151-153
a,154-155
patient,156-163
receiving,164-173
antihypertensive,174-190	DrugDDI.d180.s1.e3
drugs.,191-197	DrugDDI.d180.s1.e3

Therefore,,0-10
when,11-15
therapy,16-23
with,24-28
LODOSYN,,29-37
given,38-43
with,44-48
or,49-51
without,52-59
levodopa,60-68	DrugDDI.d180.s2.e1
or,69-71
carbidopa-levodopa,72-90	DrugDDI.d180.s2.e2
combination,91-102
products,,103-112
is,113-115
started,,116-124
dosage,125-131
adjustment,132-142
of,143-145
the,146-149
antihypertensive,150-166	DrugDDI.d180.s2.e3
drug,167-171	DrugDDI.d180.s2.e3
may,172-175
be,176-178
required.,179-188

For,0-3
patients,4-12
receiving,13-22
monoamine,23-32	DrugDDI.d180.s3.e0
oxidase,33-40	DrugDDI.d180.s3.e0
inhibitors,,41-52	DrugDDI.d180.s3.e0
see,53-56
CONTRAINDICATIONS.,57-75

Concomitant,0-11
therapy,12-19
with,20-24
selegiline,25-35	DrugDDI.d180.s4.e0
and,36-39
carbidopa-levodopa,40-58	DrugDDI.d180.s4.e1
may,59-62
be,63-65
associated,66-76
with,77-81
severe,82-88
orthostatic,89-100
hypotension,101-112
not,113-116
attributable,117-129
to,130-132
carbidopa-levodopa,133-151	DrugDDI.d180.s4.e2
alone.,152-158

There,0-5
have,6-10
been,11-15
rare,16-20
reports,21-28
of,29-31
adverse,32-39
reactions,,40-50
including,51-60
hypertension,61-73
and,74-77
dyskinesia,,78-89
resulting,90-99
from,100-104
the,105-108
concomitant,109-120
use,121-124
of,125-127
tricyclic,128-137	DrugDDI.d180.s5.e0
antidepressants,138-153	DrugDDI.d180.s5.e0
and,154-157
carbidopa-levodopa,158-176	DrugDDI.d180.s5.e1
preparations.,177-190	DrugDDI.d180.s5.e1

Dopamine,0-8	DrugDDI.d180.s6.e0
D2,9-11	DrugDDI.d180.s6.e0
receptor,12-20	DrugDDI.d180.s6.e0
antagonists,21-32	DrugDDI.d180.s6.e0
(e.g.,,33-39
phenothiazines,,40-55
butyrophenones,,56-71
risperidone),72-84	DrugDDI.d180.s6.e3
and,85-88
isoniazid,89-98	DrugDDI.d180.s6.e4
may,99-102
reduce,103-109
the,110-113
therapeutic,114-125
effects,126-133
of,134-136
levodopa.,137-146	DrugDDI.d180.s6.e5

In,0-2
addition,,3-12
the,13-16
beneficial,17-27
effects,28-35
of,36-38
levodopa,39-47	DrugDDI.d180.s7.e0
in,48-50
Parkinsons,51-61
disease,62-69
have,70-74
been,75-79
reported,80-88
to,89-91
be,92-94
reversed,95-103
by,104-106
phenytoin,107-116	DrugDDI.d180.s7.e1
and,117-120
papaverine.,121-132	DrugDDI.d180.s7.e2

Patients,0-8
taking,9-15
these,16-21
drugs,22-27	DrugDDI.d180.s8.e0
with,28-32
LODOSYN,33-40	DrugDDI.d180.s8.e1
and,41-44
levodopa,45-53	DrugDDI.d180.s8.e2
or,54-56
carbidopa-levodopa,57-75	DrugDDI.d180.s8.e3
combination,76-87
products,88-96
should,97-103
be,104-106
carefully,107-116
observed,117-125
for,126-129
loss,130-134
of,135-137
therapeutic,138-149
response.,150-159

Iron,0-4
salts,5-10
may,11-14
reduce,15-21
the,22-25
bioavailability,26-41
of,42-44
carbidopa,45-54	DrugDDI.d180.s9.e0
and,55-58
levodopa.,59-68	DrugDDI.d180.s9.e1

Although,0-8
metoclopramide,9-23	DrugDDI.d180.s11.e0
may,24-27
increase,28-36
the,37-40
bioavailability,41-56
of,57-59
levodopa,60-68	DrugDDI.d180.s11.e1
by,69-71
increasing,72-82
gastric,83-90
emptying,,91-100
metoclopramide,101-115	DrugDDI.d180.s11.e2
may,116-119
also,120-124
adversely,125-134
affect,135-141
disease,142-149
control,150-157
by,158-160
its,161-164
dopamine,165-173	DrugDDI.d180.s11.e3
receptor,174-182	DrugDDI.d180.s11.e3
antagonistic,183-195	DrugDDI.d180.s11.e3
properties.,196-207

Iodine,0-6	DrugDDI.d305.s0.e0
or,7-9
iodine,10-16	DrugDDI.d305.s0.e1
excess,17-23
may,24-27
decrease,28-36
the,37-40
effect,41-47
of,48-50
Carbimazole,,51-63
and,64-67
an,68-70
iodine,71-77
deficiency,78-88
can,89-92
increase,93-101
the,102-105
effect,106-112
of,113-115
Carbimazole.,116-128	DrugDDI.d305.s0.e3

Serum,0-5
concentration,6-19
of,20-22
digoxin,23-30	DrugDDI.d305.s1.e0
and,31-34
digitoxin,35-44	DrugDDI.d305.s1.e1
may,45-48
increase,49-57
when,58-62
patients,63-71
take,72-76
antithyroid,77-88	DrugDDI.d305.s1.e2
agents.,89-96	DrugDDI.d305.s1.e2

Antithyroid,0-11	DrugDDI.d305.s3.e0
agents,12-18	DrugDDI.d305.s3.e0
may,19-22
decrease,23-31
thyroidal,32-41	DrugDDI.d305.s3.e1
uptake,42-48
of,49-51
sodium,52-58	DrugDDI.d305.s3.e2
iodide,59-65	DrugDDI.d305.s3.e2
I131,,66-71	DrugDDI.d305.s3.e2
a,72-73
rebound,74-81
in,82-84
uptake,85-91
may,92-95
occur,96-101
up,102-104
to,105-107
5,108-109
days,110-114
after,115-120
sudden,121-127
withdrawal,128-138
of,139-141
Carbimazole.,142-154	DrugDDI.d305.s3.e3

Patients,0-8
response,9-17
to,18-20
oral,21-25	DrugDDI.d305.s4.e0
anticoagulants,26-40	DrugDDI.d305.s4.e0
may,41-44
be,45-47
affected,48-56
by,57-59
his/her,60-67
thyroid,68-75	DrugDDI.d305.s4.e1
and,76-79
metabolic,80-89
status.,90-97

An,0-2
evaluation,3-13
of,14-16
prothrombin,17-28
time,29-33
and,34-37
an,38-40
adjustment,41-51
of,52-54
anticoagulant,55-68	DrugDDI.d305.s5.e0
dosage,69-75
are,76-79
recommended,80-91

Antihistamines,0-14	DrugDDI.d2.s0.e0
may,15-18
enhance,19-26
the,27-30
effects,31-38
of,39-41
tricyclic,42-51	DrugDDI.d2.s0.e1
antidepressants,,52-68	DrugDDI.d2.s0.e1
barbiturates,,69-82
alcohol,,83-91
and,92-95
other,96-101
CNS,102-105	DrugDDI.d2.s0.e4
depressants.,106-118	DrugDDI.d2.s0.e4

MAO,0-3	DrugDDI.d2.s1.e0
inhibitors,4-14	DrugDDI.d2.s1.e0
prolong,15-22
and,23-26
intensify,27-36
the,37-40
anticholinergic,41-56	DrugDDI.d2.s1.e1
effects,57-64
of,65-67
antihistamines.,68-83	DrugDDI.d2.s1.e2

Sympathomimetic,0-15	DrugDDI.d2.s2.e0
amines,16-22	DrugDDI.d2.s2.e0
may,23-26
reduce,27-33
the,34-37
antihypertensive,38-54	DrugDDI.d2.s2.e1
effects,55-62
of,63-65
reserpine,,66-76
veratrum,77-85	DrugDDI.d2.s2.e3
alkaloids,,86-96	DrugDDI.d2.s2.e3
methyldopa,97-107	DrugDDI.d2.s2.e4
and,108-111
mecamylamine.,112-125	DrugDDI.d2.s2.e5

Effects,0-7
of,8-10
sympathomimetics,11-27	DrugDDI.d2.s3.e0
are,28-31
increased,32-41
with,42-46
MAO,47-50	DrugDDI.d2.s3.e1
inhibitors,51-61	DrugDDI.d2.s3.e1
and,62-65
beta,66-70	DrugDDI.d2.s3.e2
adrenergic,71-81	DrugDDI.d2.s3.e2
blockers.,82-91	DrugDDI.d2.s3.e2

The,0-3
renal,4-9
effects,10-17
of,18-20
nephrotoxic,21-32
compounds,33-42
may,43-46
be,47-49
potentiated,50-61
by,62-64
Carboplatin.,65-77	DrugDDI.d427.s0.e0

HEMABATE,0-8	DrugDDI.d250.s0.e0
may,9-12
augment,13-20
the,21-24
activity,25-33
of,34-36
other,37-42
oxytocic,43-51	DrugDDI.d250.s0.e1
agents.,52-59	DrugDDI.d250.s0.e1

Concomitant,0-11
use,12-15
with,16-20
other,21-26
oxytocic,27-35	DrugDDI.d250.s1.e0
agents,36-42	DrugDDI.d250.s1.e0
is,43-45
not,46-49
recommended,50-61

Ocupress,0-8	DrugDDI.d456.s0.e0
should,9-15
be,16-18
used,19-23
with,24-28
caution,29-36
in,37-39
patients,40-48
who,49-52
are,53-56
receiving,57-66
a,67-68
beta-adrenergic,69-84	DrugDDI.d456.s0.e1
blocking,85-93	DrugDDI.d456.s0.e1
agent,94-99	DrugDDI.d456.s0.e1
orally,100-106
because,107-114
of,115-117
the,118-121
potential,122-131
for,132-135
additive,136-144
effects,145-152
on,153-155
systemic,156-164
beta-blockade.,165-179

Close,0-5
observation,6-17
of,18-20
the,21-24
patient,25-32
is,33-35
recommended,36-47
when,48-52
a,53-54
beta-blocker,55-67	DrugDDI.d456.s1.e0
is,68-70
administered,71-83
to,84-86
patients,87-95
receiving,96-105
catecholamine-depleting,106-129
drugs,130-135	DrugDDI.d456.s1.e1
such,136-140
as,141-143
reserpine,,144-154
because,155-162
of,163-165
possible,166-174
additive,175-183
effects,184-191
and,192-195
the,196-199
production,200-210
of,211-213
hypotension,214-225
and/or,226-232
marked,233-239
bradycardia,,240-252
which,253-258
may,259-262
produce,263-270
vertigo,,271-279
syncope,,280-288
or,289-291
postural,292-300
hypotension.,301-313

Inhibitors,0-10
of,11-13
CYP2D6;,14-21	DrugDDI.d547.s0.e0

poor,0-4
metabolizers,5-17
of,18-20
debrisoquin:,21-33	DrugDDI.d547.s1.e0
Interactions,34-46
of,47-49
carvedilol,50-60	DrugDDI.d547.s1.e1
with,61-65
strong,66-72
inhibitors,73-83
of,84-86
CYP2D6,87-93	DrugDDI.d547.s1.e2
(such,94-99
as,100-102
quinidine,,103-113
fluoxetine,,114-125
paroxetine,,126-137
and,138-141
propafenone),142-154	DrugDDI.d547.s1.e6
have,155-159
not,160-163
been,164-168
studied,,169-177
but,178-181
these,182-187
drugs,188-193	DrugDDI.d547.s1.e7
would,194-199
be,200-202
expected,203-211
to,212-214
increase,215-223
blood,224-229
levels,230-236
of,237-239
the,240-243
R(+),244-248
enantiomer,249-259	DrugDDI.d547.s1.e8
of,260-262
carvedilol,263-273	DrugDDI.d547.s1.e9
.,274-275

Retrospective,0-13
analysis,14-22
of,23-25
side,26-30
effects,31-38
in,39-41
clinical,42-50
trials,51-57
showed,58-64
that,65-69
poor,70-74
2D6,75-78
metabolizers,79-91
had,92-95
a,96-97
higher,98-104
rate,105-109
of,110-112
dizziness,113-122
during,123-129
up-titration,,130-143
presumably,144-154
resulting,155-164
from,165-169
vasodilating,170-182
effects,183-190
of,191-193
the,194-197
higher,198-204
concentrations,205-219
of,220-222
the,223-226
a-blocking,227-237
R(+),238-242
enantiomer.,243-254	DrugDDI.d547.s2.e0

Catecholamine-depleting,0-23
Agents:,24-31
Patients,32-40
taking,41-47
both,48-52
agents,53-59
with,60-64
b-blocking,65-75
properties,76-86
and,87-90
a,91-92
drug,93-97	DrugDDI.d547.s3.e0
that,98-102
can,103-106
deplete,107-114
catecholamines,115-129
(e.g.,,130-136
reserpine,137-146	DrugDDI.d547.s3.e1
and,147-150
monoamine,151-160	DrugDDI.d547.s3.e2
oxidase,161-168	DrugDDI.d547.s3.e2
inhibitors),169-180	DrugDDI.d547.s3.e2
should,181-187
be,188-190
observed,191-199
closely,200-207
for,208-211
signs,212-217
of,218-220
hypotension,221-232
and/or,233-239
severe,240-246
bradycardia.,247-259

Clonidine:,0-10	DrugDDI.d547.s4.e0
Concomitant,11-22
administration,23-37
of,38-40
clonidine,41-50	DrugDDI.d547.s4.e1
with,51-55
agents,56-62
with,63-67
b-blocking,68-78
properties,79-89
may,90-93
potentiate,94-104
blood-pressure-,105-120
and,121-124
heart-rate-lowering,125-144
effects.,145-153

When,0-4
concomitant,5-16
treatment,17-26
with,27-31
agents,32-38
with,39-43
b-blocking,44-54
properties,55-65
and,66-69
clonidine,70-79	DrugDDI.d547.s5.e0
is,80-82
to,83-85
be,86-88
terminated,,89-100
the,101-104
b-blocking,105-115
agent,116-121
should,122-128
be,129-131
discontinued,132-144
first.,145-151

Clonidine,0-9	DrugDDI.d547.s6.e0
therapy,10-17
can,18-21
then,22-26
be,27-29
discontinued,30-42
several,43-50
days,51-55
later,56-61
by,62-64
gradually,65-74
decreasing,75-85
the,86-89
dosage.,90-97

Cyclosporine:,0-13	DrugDDI.d547.s7.e0
Modest,14-20
increases,21-30
in,31-33
mean,34-38
trough,39-45
cyclosporine,46-58	DrugDDI.d547.s7.e1
concentrations,59-73
were,74-78
observed,79-87
following,88-97
initiation,98-108
of,109-111
carvedilol,112-122	DrugDDI.d547.s7.e2
treatment,123-132
in,133-135
21,136-138
renal,139-144
transplant,145-155
patients,156-164
suffering,165-174
from,175-179
chronic,180-187
vascular,188-196
rejection.,197-207

In,0-2
about,3-8
30%,9-12
of,13-15
patients,,16-25
the,26-29
dose,30-34
of,35-37
cyclosporine,38-50	DrugDDI.d547.s8.e0
had,51-54
to,55-57
be,58-60
reduced,61-68
in,69-71
order,72-77
to,78-80
maintain,81-89
cyclosporine,90-102	DrugDDI.d547.s8.e1
concentrations,103-117
within,118-124
the,125-128
therapeutic,129-140
range,,141-147
while,148-153
in,154-156
the,157-160
remainder,161-170
no,171-173
adjustment,174-184
was,185-188
needed.,189-196

On,0-2
the,3-6
average,7-14
for,15-18
the,19-22
group,,23-29
the,30-33
dose,34-38
of,39-41
cyclosporine,42-54	DrugDDI.d547.s9.e0
was,55-58
reduced,59-66
about,67-72
20%,73-76
in,77-79
these,80-85
patients.,86-95

Due,0-3
to,4-6
wide,7-11
interindividual,12-27
variability,28-39
in,40-42
the,43-46
dose,47-51
adjustment,52-62
required,,63-72
it,73-75
is,76-78
recommended,79-90
that,91-95
cyclosporine,96-108	DrugDDI.d547.s10.e0
concentrations,109-123
be,124-126
monitored,127-136
closely,137-144
after,145-150
initiation,151-161
of,162-164
carvedilol,165-175	DrugDDI.d547.s10.e1
therapy,176-183
and,184-187
that,188-192
the,193-196
dose,197-201
of,202-204
cyclosporine,205-217	DrugDDI.d547.s10.e2
be,218-220
adjusted,221-229
as,230-232
appropriate.,233-245

Digoxin:,0-8	DrugDDI.d547.s11.e0
Digoxin,9-16	DrugDDI.d547.s11.e1
concentrations,17-31
are,32-35
increased,36-45
by,46-48
about,49-54
15%,55-58
when,59-63
digoxin,64-71	DrugDDI.d547.s11.e2
and,72-75
carvedilol,76-86	DrugDDI.d547.s11.e3
are,87-90
administered,91-103
concomitantly.,104-118

Both,0-4
digoxin,5-12	DrugDDI.d547.s12.e0
and,13-16
COREG,17-22	DrugDDI.d547.s12.e1
slow,23-27
AV,28-30
conduction.,31-42

Therefore,,0-10
increased,11-20
monitoring,21-31
of,32-34
digoxin,35-42	DrugDDI.d547.s13.e0
is,43-45
recommended,46-57
when,58-62
initiating,,63-74
adjusting,,75-85
or,86-88
discontinuing,89-102
COREG.,103-109	DrugDDI.d547.s13.e1

Inducers,0-8
and,9-12
Inhibitors,13-23
of,24-26
Hepatic,27-34
Metabolism:,35-46
Rifampin,47-55	DrugDDI.d547.s14.e0
reduced,56-63
plasma,64-70
concentrations,71-85
of,86-88
carvedilol,89-99	DrugDDI.d547.s14.e1
by,100-102
about,103-108
70%.,109-113

Cimetidine,0-10	DrugDDI.d547.s15.e0
increased,11-20
AUC,21-24
by,25-27
about,28-33
30%,34-37
but,38-41
caused,42-48
no,49-51
change,52-58
in,59-61
Cmax.,62-67

Calcium,0-7	DrugDDI.d547.s16.e0
Channel,8-15	DrugDDI.d547.s16.e0
Blockers:,16-25	DrugDDI.d547.s16.e0
Isolated,26-34
cases,35-40
of,41-43
conduction,44-54
disturbance,55-66
(rarely,67-74
with,75-79
hemodynamic,80-91
compromise),92-103
have,104-108
been,109-113
observed,114-122
when,123-127
COREG,128-133	DrugDDI.d547.s16.e1
is,134-136
co-administered,137-152
with,153-157
diltiazem.,158-168	DrugDDI.d547.s16.e2

As,0-2
with,3-7
other,8-13
agents,14-20
with,21-25
b-blocking,26-36
properties,,37-48
if,49-51
COREG,52-57	DrugDDI.d547.s17.e0
is,58-60
to,61-63
be,64-66
administered,67-79
orally,80-86
with,87-91
calcium,92-99	DrugDDI.d547.s17.e1
channel,100-107	DrugDDI.d547.s17.e1
blockers,108-116	DrugDDI.d547.s17.e1
of,117-119
the,120-123
verapamil,124-133	DrugDDI.d547.s17.e2
or,134-136
diltiazem,137-146	DrugDDI.d547.s17.e3
type,,147-152
it,153-155
is,156-158
recommended,159-170
that,171-175
ECG,176-179
and,180-183
blood,184-189
pressure,190-198
be,199-201
monitored.,202-212

Insulin,0-7	DrugDDI.d547.s18.e0
or,8-10
Oral,11-15	DrugDDI.d547.s18.e1
Hypoglycemics:,16-30	DrugDDI.d547.s18.e1
Agents,31-37
with,38-42
b-blocking,43-53
properties,54-64
may,65-68
enhance,69-76
the,77-80
blood-sugar-reducing,81-101
effect,102-108
of,109-111
insulin,112-119	DrugDDI.d547.s18.e2
and,120-123
oral,124-128	DrugDDI.d547.s18.e3
hypoglycemics.,129-143	DrugDDI.d547.s18.e3

Therefore,,0-10
in,11-13
patients,14-22
taking,23-29
insulin,30-37	DrugDDI.d547.s19.e0
or,38-40
oral,41-45	DrugDDI.d547.s19.e1
hypoglycemics,,46-60	DrugDDI.d547.s19.e1
regular,61-68
monitoring,69-79
of,80-82
blood,83-88
glucose,89-96
is,97-99
recommended.,100-112

Studies,0-7
in,8-10
vitro,11-16
show,17-21
that,22-26
caspofungin,27-38	DrugDDI.d534.s0.e0
acetate,39-46	DrugDDI.d534.s0.e0
is,47-49
not,50-53
an,54-56
inhibitor,57-66
of,67-69
any,70-73
enzyme,74-80
in,81-83
the,84-87
cytochrome,88-98	DrugDDI.d534.s0.e1
P450,99-103	DrugDDI.d534.s0.e1
(CYP),104-109
system.,110-117

In,0-2
clinical,3-11
studies,,12-20
caspofungin,21-32	DrugDDI.d534.s1.e0
did,33-36
not,37-40
induce,41-47
the,48-51
CYP3A4,52-58	DrugDDI.d534.s1.e1
metabolism,59-69
of,70-72
other,73-78
drugs.,79-85	DrugDDI.d534.s1.e2

Caspofungin,0-11	DrugDDI.d534.s2.e0
is,12-14
not,15-18
a,19-20
substrate,21-30
for,31-34
P-glycoprotein,35-49
and,50-53
is,54-56
a,57-58
poor,59-63
substrate,64-73
for,74-77
cytochrome,78-88	DrugDDI.d534.s2.e2
P450,89-93	DrugDDI.d534.s2.e2
enzymes.,94-102

Clinical,0-8
studies,9-16
in,17-19
healthy,20-27
volunteers,28-38
show,39-43
that,44-48
the,49-52
pharmacokinetics,53-69
of,70-72
CANCIDAS,73-81	DrugDDI.d534.s3.e0
are,82-85
not,86-89
altered,90-97
by,98-100
itraconazole,,101-114
amphotericin,115-127	DrugDDI.d534.s3.e2
B,,128-130	DrugDDI.d534.s3.e2
mycophenolate,,131-145
nelfinavir,,146-157
or,158-160
tacrolimus.,161-172	DrugDDI.d534.s3.e5

CANCIDAS,0-8	DrugDDI.d534.s4.e0
has,9-12
no,13-15
effect,16-22
on,23-25
the,26-29
pharmacokinetics,30-46
of,47-49
itraconazole,,50-63
amphotericin,64-76	DrugDDI.d534.s4.e2
B,,77-79	DrugDDI.d534.s4.e2
or,80-82
the,83-86
active,87-93	DrugDDI.d534.s4.e3
metabolite,94-104	DrugDDI.d534.s4.e3
of,105-107
mycophenolate.,108-122	DrugDDI.d534.s4.e4

CANCIDAS,0-8	DrugDDI.d534.s5.e0
reduced,9-16
the,17-20
blood,21-26
AUC0-12,27-34
of,35-37
tacrolimus,38-48	DrugDDI.d534.s5.e1
(FK-506,,49-57
Prograf,58-65
span,66-70
class=,71-77
c4,78-80	DrugDDI.d534.s5.e3
?3),81-84
by,85-87
approximately,88-101
20%,,102-106
peak,107-111
blood,112-117
concentration,118-131
(Cmax),132-138
by,139-141
16%,,142-146
and,147-150
12-hour,151-158
blood,159-164
concentration,165-178
(C12hr),179-186
by,187-189
26%,190-193
in,194-196
healthy,197-204
subjects,205-213
when,214-218
tacrolimus,219-229	DrugDDI.d534.s5.e4
(2,230-232
doses,233-238
of,239-241
0.1,242-245
mg/kg,246-251
12,252-254
hours,255-260
apart),261-267
was,268-271
administered,272-284
on,285-287
the,288-291
10th,292-296
day,297-300
of,301-303
CANCIDAS,304-312	DrugDDI.d534.s5.e5
70,313-315
mg,316-318
daily,,319-325
as,326-328
compared,329-337
to,338-340
results,341-348
from,349-353
a,354-355
control,356-363
period,364-370
in,371-373
which,374-379
tacrolimus,380-390	DrugDDI.d534.s5.e6
was,391-394
administered,395-407
alone.,408-414

For,0-3
patients,4-12
receiving,13-22
both,23-27
therapies,,28-38
standard,39-47
monitoring,48-58
of,59-61
tacrolimus,62-72	DrugDDI.d534.s6.e0
blood,73-78
concentrations,79-93
and,94-97
appropriate,98-109
tacrolimus,110-120	DrugDDI.d534.s6.e1
dosage,121-127
adjustments,128-139
are,140-143
recommended.,144-156

In,0-2
two,3-6
clinical,7-15
studies,,16-24
cyclosporine,25-37	DrugDDI.d534.s7.e0
(one,38-42
4,43-44
mg/kg,45-50
dose,51-55
or,56-58
two,59-62
3,63-64
mg/kg,65-70
doses),71-77
increased,78-87
the,88-91
AUC,92-95
of,96-98
caspofungin,99-110	DrugDDI.d534.s7.e1
by,111-113
approximately,114-127
35%.,128-132

CANCIDAS,0-8	DrugDDI.d534.s8.e0
did,9-12
not,13-16
increase,17-25
the,26-29
plasma,30-36
levels,37-43
of,44-46
cyclosporine.,47-60	DrugDDI.d534.s8.e1

There,0-5
were,6-10
transient,11-20
increases,21-30
in,31-33
liver,34-39	DrugDDI.d534.s9.e0
ALT,40-43
and,44-47
AST,48-51	DrugDDI.d534.s9.e1
when,52-56
CANCIDAS,57-65	DrugDDI.d534.s9.e2
and,66-69
cyclosporine,70-82	DrugDDI.d534.s9.e3
were,83-87
co-administered.,88-104

A,0-1
drug-drug,2-11
interaction,12-23
study,24-29
with,30-34
rifampin,35-43	DrugDDI.d534.s10.e0
in,44-46
healthy,47-54
volunteers,55-65
has,66-69
shown,70-75
a,76-77
30%,78-81
decrease,82-90
in,91-93
caspofungin,94-105	DrugDDI.d534.s10.e1
trough,106-112
concentrations.,113-128

Patients,0-8
on,9-11
rifampin,12-20	DrugDDI.d534.s11.e0
should,21-27
receive,28-35
70,36-38
mg,39-41
of,42-44
CANCIDAS,45-53	DrugDDI.d534.s11.e1
daily.,54-60

In,0-2
addition,,3-12
results,13-20
from,21-25
regression,26-36
analyses,37-45
of,46-48
patient,49-56
pharmacokinetic,57-72
data,73-77
suggest,78-85
that,86-90
co-administration,91-108
of,109-111
other,112-117
inducers,118-126
of,127-129
drug,130-134
clearance,135-144
(efavirenz,,145-156
nevirapine,,157-168
phenytoin,,169-179
dexamethasone,,180-194
or,195-197
carbamazepine),198-212	DrugDDI.d534.s12.e4
with,213-217
CANCIDAS,218-226	DrugDDI.d534.s12.e5
may,227-230
result,231-237
in,238-240
clinically,241-251
meaningful,252-262
reductions,263-273
in,274-276
caspofungin,277-288	DrugDDI.d534.s12.e6
concentrations.,289-304

It,0-2
is,3-5
not,6-9
known,10-15
which,16-21
drug,22-26
clearance,27-36
mechanism,37-46
involved,47-55
in,56-58
caspofungin,59-70	DrugDDI.d534.s13.e0
disposition,71-82
may,83-86
be,87-89
inducible.,90-100

When,0-4
CANCIDAS,5-13	DrugDDI.d534.s14.e0
is,14-16
co-administered,17-32
with,33-37
inducers,38-46
of,47-49
drug,50-54
clearance,,55-65
such,66-70
as,71-73
efavirenz,,74-84
nevirapine,,85-96
phenytoin,,97-107
dexamethasone,,108-122
or,123-125
carbamazepine,,126-140
use,141-144
of,145-147
a,148-149
daily,150-155
dose,156-160
of,161-163
70,164-166
mg,167-169
of,170-172
CANCIDAS,173-181	DrugDDI.d534.s14.e6
should,182-188
be,189-191
considered,192-202

Drug/Laboratory,0-15	DrugDDI.d265.s0.e0
Test,16-20
Interactions,21-33
Positive,34-42
direct,43-49
Coombs?,50-57
tests,58-63
have,64-68
been,69-73
reported,74-82
during,83-89
treatment,90-99
with,100-104
the,105-108
cephalosporin,109-122	DrugDDI.d265.s0.e1
antibiotics.,123-135	DrugDDI.d265.s0.e1

In,0-2
hematologic,3-14
studies,15-22
or,23-25
in,26-28
transfusion,29-40
cross-matching,41-55
procedures,56-66
when,67-71
anti-globulin,72-85
tests,86-91
are,92-95
performed,96-105
on,106-108
the,109-112
minor,113-118
side,119-123
or,124-126
in,127-129
Coombs?,130-137
testing,138-145
of,146-148
newborns,149-157
whose,158-163
mothers,164-171
have,172-176
received,177-185
cephalosporin,186-199	DrugDDI.d265.s1.e0
antibiotics,200-211	DrugDDI.d265.s1.e0
before,212-218
parturition,,219-231
it,232-234
should,235-241
be,242-244
recognized,245-255
that,256-260
a,261-262
positive,263-271
Coombs?,272-279
test,280-284
may,285-288
be,289-291
due,292-295
to,296-298
the,299-302
drug.,303-308	DrugDDI.d265.s1.e1

Probenecid,0-10	DrugDDI.d5.s0.e0
may,11-14
decrease,15-23
renal,24-29
tubular,30-37
secretion,38-47
of,48-50
cephalosporins,51-65	DrugDDI.d5.s0.e1
when,66-70
used,71-75
concurrently,,76-89
resulting,90-99
in,100-102
increased,103-112
and,113-116
more,117-121
prolonged,122-131
cephalosporin,132-145	DrugDDI.d5.s0.e2
blood,146-151
levels.,152-159

Drug/Laboratory,0-15	DrugDDI.d5.s1.e0
Test,16-20
Interactions,21-33
A,34-35
false,36-41
positive,42-50
reaction,51-59
for,60-63
glucose,64-71	DrugDDI.d5.s1.e1
in,72-74
the,75-78
urine,79-84
may,85-88
occur,89-94
with,95-99
Benedicts,100-109
solution,,110-119
Fehlings,120-128
solution,129-137
or,138-140
with,141-145
CLINITEST?,146-156
tablets,,157-165
but,166-169
not,170-173
with,174-178
enzyme-based,179-191
tests,192-197
such,198-202
as,203-205
CLINISTIX?.,206-217

Positive,0-8
direct,9-15
and,16-19
indirect,20-28
antiglobulin,29-41	DrugDDI.d5.s2.e0
(Coombs),42-50
tests,51-56
have,57-61
occurred;,62-71

these,0-5
may,6-9
also,10-14
occur,15-20
in,21-23
neonates,24-32
whose,33-38
mothers,39-46
received,47-55
cephalosporins,56-70	DrugDDI.d5.s3.e0
before,71-77
delivery.,78-87

Antacids,0-8	DrugDDI.d137.s0.e0
(aluminum-,9-19
or,20-22
magnesium-containing),23-44	DrugDDI.d137.s0.e1
Concomitant,45-56
administration,57-71
of,72-74
300-mg,75-81
cefdinir,82-90	DrugDDI.d137.s0.e2
capsules,91-99
with,100-104
30,105-107
mL,108-110
Maalox?,111-118
TC,119-121
suspension,122-132
reduces,133-140
the,141-144
rate,145-149
(Cmax),150-156
and,157-160
extent,161-167
(AUC),168-173
of,174-176
absorption,177-187
by,188-190
approximately,191-204
40%.,205-209

There,0-5
are,6-9
no,10-12
significant,13-24
effects,25-32
on,33-35
cefdinir,36-44	DrugDDI.d137.s2.e0
pharmacokinetics,45-61
if,62-64
the,65-68
antacid,69-76	DrugDDI.d137.s2.e1
is,77-79
administered,80-92
2,93-94
hours,95-100
before,101-107
or,108-110
2,111-112
hours,113-118
after,119-124
cefdinir.,125-134	DrugDDI.d137.s2.e2

If,0-2
antacids,3-11	DrugDDI.d137.s3.e0
are,12-15
required,16-24
during,25-31
OMNICEF,32-39	DrugDDI.d137.s3.e1
therapy,,40-48
OMNICEF,49-56	DrugDDI.d137.s3.e2
should,57-63
be,64-66
taken,67-72
at,73-75
least,76-81
2,82-83
hours,84-89
before,90-96
or,97-99
after,100-105
the,106-109
antacid.,110-118	DrugDDI.d137.s3.e3

Probenecid,0-10	DrugDDI.d137.s4.e0
As,11-13
with,14-18
other,19-24
b,25-26
span,27-31
class=,32-38
c233,39-43	DrugDDI.d137.s4.e1
-lactam,44-51	DrugDDI.d137.s4.e1
antibiotics,,52-64	DrugDDI.d137.s4.e1
probenecid,65-75	DrugDDI.d137.s4.e2
inhibits,76-84
the,85-88
renal,89-94
excretion,95-104
of,105-107
cefdinir,,108-117
resulting,118-127
in,128-130
an,131-133
approximate,134-145
doubling,146-154
in,155-157
A.C.,158-162
a,163-164
54%,165-168
increase,169-177
in,178-180
peak,181-185
cefdinir,186-194	DrugDDI.d137.s4.e4
plasma,195-201
levels,,202-209
and,210-213
a,214-215
50%,216-219
prolongation,220-232
in,233-235
the,236-239
apparent,240-248
elimination,249-260
half-life.,261-271

Iron,0-4	DrugDDI.d137.s5.e0
Supplements,5-16	DrugDDI.d137.s5.e0
and,17-20
Foods,21-26
Fortified,27-36
With,37-41
Iron,42-46	DrugDDI.d137.s5.e1
Concomitant,47-58
administration,59-73
of,74-76
cefdinir,77-85	DrugDDI.d137.s5.e2
with,86-90
a,91-92
therapeutic,93-104
iron,105-109	DrugDDI.d137.s5.e3
supplement,110-120	DrugDDI.d137.s5.e3
containing,121-131
60,132-134
mg,135-137
of,138-140
elemental,141-150	DrugDDI.d137.s5.e4
iron,151-155	DrugDDI.d137.s5.e4
(as,156-159
FeSO4),160-166
or,167-169
vitamins,170-178	DrugDDI.d137.s5.e5
supplemented,179-191
with,192-196
10,197-199
mg,200-202
of,203-205
elemental,206-215	DrugDDI.d137.s5.e6
iron,216-220	DrugDDI.d137.s5.e6
reduced,221-228
extent,229-235
of,236-238
absorption,239-249
by,250-252
80%,253-256
and,257-260
31%,,261-265
respectively.,266-279

If,0-2
iron,3-7	DrugDDI.d137.s6.e0
supplements,8-19	DrugDDI.d137.s6.e0
are,20-23
required,24-32
during,33-39
OMNICEF,40-47	DrugDDI.d137.s6.e1
therapy,,48-56
OMNICEF,57-64	DrugDDI.d137.s6.e2
should,65-71
be,72-74
taken,75-80
at,81-83
least,84-89
2,90-91
hours,92-97
before,98-104
or,105-107
after,108-113
the,114-117
supplement.,118-129

The,0-3
effect,4-10
of,11-13
foods,14-19
highly,20-26
fortified,27-36
with,37-41
elemental,42-51	DrugDDI.d137.s7.e0
iron,52-56	DrugDDI.d137.s7.e0
(primarily,57-67
iron-fortified,68-82	DrugDDI.d137.s7.e1
breakfast,83-92
cereals),93-101
on,102-104
cefdinir,105-113	DrugDDI.d137.s7.e2
absorption,114-124
has,125-128
not,129-132
been,133-137
studied.,138-146

Concomitantly,0-13
administered,14-26
iron-fortified,27-41
infant,42-48
formula,49-56
(2.2,57-61
mg,62-64
elemental,65-74	DrugDDI.d137.s8.e0
iron/6,75-81	DrugDDI.d137.s8.e0
oz),82-85
has,86-89
no,90-92
significant,93-104
effect,105-111
on,112-114
cefdinir,115-123	DrugDDI.d137.s8.e1
pharmacokinetics.,124-141

Therefore,,0-10
OMNICEF,11-18	DrugDDI.d137.s9.e0
for,19-22
Oral,23-27
Suspension,28-38
can,39-42
be,43-45
administered,46-58
with,59-63
iron-fortified,64-78	DrugDDI.d137.s9.e1
infant,79-85
formula.,86-94

There,0-5
have,6-10
been,11-15
rare,16-20
reports,21-28
of,29-31
reddish,32-39
stools,40-46
in,47-49
patients,50-58
who,59-62
have,63-67
received,68-76
cefdinir,77-85	DrugDDI.d137.s10.e0
in,86-88
Japan.,89-95

The,0-3
reddish,4-11
color,12-17
is,18-20
due,21-24
to,25-27
the,28-31
formation,32-41
of,42-44
a,45-46
nonabsorbable,47-60
complex,61-68
between,69-76
cefdinir,77-85	DrugDDI.d137.s11.e0
or,86-88
its,89-92
breakdown,93-102
products,103-111
and,112-115
iron,116-120	DrugDDI.d137.s11.e1
in,121-123
the,124-127
gastrointestinal,128-144
tract.,145-151

Drug/Laboratory,0-15	DrugDDI.d137.s12.e0
Test,16-20
Interactions,21-33
A,34-35
false-positive,36-50
reaction,51-59
for,60-63
ketones,64-71
in,72-74
the,75-78
urine,79-84
may,85-88
occur,89-94
with,95-99
tests,100-105
using,106-111
nitroprusside,,112-126
but,127-130
not,131-134
with,135-139
those,140-145
using,146-151
nitroferricyanide.,152-170	DrugDDI.d137.s12.e2

The,0-3
administration,4-18
of,19-21
cefdinir,22-30	DrugDDI.d137.s13.e0
may,31-34
result,35-41
in,42-44
a,45-46
false-positive,47-61
reaction,62-70
for,71-74
glucose,75-82	DrugDDI.d137.s13.e1
in,83-85
urine,86-91
using,92-97
Clinitest?,,98-109
Benedict?s,110-120
solution,,121-130
or,131-133
Fehlings,134-142
solution.,143-152

It,0-2
is,3-5
recommended,6-17
that,18-22
glucose,23-30
tests,31-36
based,37-42
on,43-45
enzymatic,46-55
glucose,56-63	DrugDDI.d137.s14.e0
oxidase,64-71	DrugDDI.d137.s14.e0
reactions,72-81
(such,82-87
as,88-90
Clinistix?,91-101
or,102-104
Tes-Tape?),105-115
be,116-118
used.,119-124

Cephalosporins,0-14	DrugDDI.d137.s15.e0
are,15-18
known,19-24
to,25-27
occasionally,28-40
induce,41-47
a,48-49
positive,50-58
direct,59-65
Coombs?,66-73
test.,74-79

Oral,0-4	DrugDDI.d379.s0.e0
Contraceptives,5-19	DrugDDI.d379.s0.e0
Multiple,20-28
doses,29-34
of,35-37
cefditoren,38-48	DrugDDI.d379.s0.e1
pivoxil,49-56	DrugDDI.d379.s0.e1
had,57-60
no,61-63
effect,64-70
on,71-73
the,74-77
pharmacokinetics,78-94
of,95-97
ethinyl,98-105	DrugDDI.d379.s0.e2
estradiol,,106-116	DrugDDI.d379.s0.e2
the,117-120
estrogenic,121-131	DrugDDI.d379.s0.e3
component,132-141
in,142-144
most,145-149
oral,150-154	DrugDDI.d379.s0.e4
contraceptives.,155-170	DrugDDI.d379.s0.e4

Antacids,0-8	DrugDDI.d379.s1.e0
Co-administration,9-26
of,27-29
a,30-31
single,32-38
dose,39-43
of,44-46
an,47-49
antacid,50-57	DrugDDI.d379.s1.e1
which,58-63
contained,64-73
both,74-78
magnesium,79-88	DrugDDI.d379.s1.e2
(800,89-93
mg),94-97
and,98-101
aluminum,102-110
(900,111-115
mg),116-119
hydroxides,120-130
reduced,131-138
the,139-142
oral,143-147
absorption,148-158
of,159-161
a,162-163
single,164-170
400,171-174
mg,175-177
dose,178-182
of,183-185
cefditoren,186-196	DrugDDI.d379.s1.e3
pivoxil,197-204	DrugDDI.d379.s1.e3
administered,205-217
following,218-227
a,228-229
meal,,230-235
as,236-238
evidenced,239-248
by,249-251
a,252-253
14%,254-257
decrease,258-266
in,267-269
mean,270-274
Cmax,275-279
and,280-283
an,284-286
11%,287-290
decrease,291-299
in,300-302
mean,303-307
AUC.,308-312

Although,0-8
the,9-12
clinical,13-21
significance,22-34
is,35-37
not,38-41
known,,42-48
it,49-51
is,52-54
not,55-58
recommended,59-70
that,71-75
cefditoren,76-86	DrugDDI.d379.s2.e0
pivoxil,87-94	DrugDDI.d379.s2.e0
be,95-97
taken,98-103
concomitantly,104-117
with,118-122
antacids.,123-132	DrugDDI.d379.s2.e1

H2-Receptor,0-11	DrugDDI.d379.s3.e0
Antagonists,12-23	DrugDDI.d379.s3.e0
Co-administration,24-41
of,42-44
a,45-46
single,47-53
dose,54-58
of,59-61
intravenously,62-75
administered,76-88
famotidine,89-99	DrugDDI.d379.s3.e1
(20,100-103
mg),104-107
reduced,108-115
the,116-119
oral,120-124
absorption,125-135
of,136-138
a,139-140
single,141-147
400,148-151
mg,152-154
dose,155-159
of,160-162
cefditoren,163-173	DrugDDI.d379.s3.e2
pivoxil,174-181	DrugDDI.d379.s3.e2
administered,182-194
following,195-204
a,205-206
meal,,207-212
as,213-215
evidenced,216-225
by,226-228
a,229-230
27%,231-234
decrease,235-243
in,244-246
mean,247-251
Cmax,252-256
and,257-260
a,261-262
22%,263-266
decrease,267-275
in,276-278
mean,279-283
AUC.,284-288

Although,0-8
the,9-12
clinical,13-21
significance,22-34
is,35-37
not,38-41
known,,42-48
it,49-51
is,52-54
not,55-58
recommended,59-70
that,71-75
cefditoren,76-86	DrugDDI.d379.s4.e0
pivoxil,87-94	DrugDDI.d379.s4.e0
be,95-97
taken,98-103
concomitantly,104-117
with,118-122
H2,123-125	DrugDDI.d379.s4.e1
receptor,126-134	DrugDDI.d379.s4.e1
antagonists.,135-147

Probenecid,0-10	DrugDDI.d379.s5.e0
As,11-13
with,14-18
other,19-24
b-lactam,25-33	DrugDDI.d379.s5.e1
antibiotics,,34-46	DrugDDI.d379.s5.e1
co-administration,47-64
of,65-67
probenecid,68-78	DrugDDI.d379.s5.e2
with,79-83
cefditoren,84-94	DrugDDI.d379.s5.e3
pivoxil,95-102	DrugDDI.d379.s5.e3
resulted,103-111
in,112-114
an,115-117
increase,118-126
in,127-129
the,130-133
plasma,134-140
exposure,141-149
of,150-152
cefditoren,,153-164
with,165-169
a,170-171
49%,172-175
increase,176-184
in,185-187
mean,188-192
Cmax,,193-198
a,199-200
122%,201-205
increase,206-214
in,215-217
mean,218-222
AUC,,223-227
and,228-231
a,232-233
53%,234-237
increase,238-246
in,247-249
half-life.,250-260

Drug/Laboratory,0-15	DrugDDI.d379.s6.e0
Test,16-20
Interactions,21-33
Cephalosporins,34-48	DrugDDI.d379.s6.e1
are,49-52
known,53-58
to,59-61
occasionally,62-74
induce,75-81
a,82-83
positive,84-92
direct,93-99
Coombs,100-106
test.,107-112

A,0-1
false-positive,2-16
reaction,17-25
for,26-29
glucose,30-37	DrugDDI.d379.s7.e0
in,38-40
the,41-44
urine,45-50
may,51-54
occur,55-60
with,61-65
copper,66-72
reduction,73-82
tests,83-88
(Benedicts,89-99
or,100-102
Fehlings,103-111
solution,112-120
or,121-123
with,124-128
CLINITEST,129-138
tablets),,139-148
but,149-152
not,153-156
with,157-161
enzyme-based,162-174
tests,175-180
for,181-184
glycosuria,185-195
(e.g.,,196-202
CLINISTIX,,203-213
TES-TAPE).,214-224

As,0-2
a,3-4
false-negative,5-19
result,20-26
may,27-30
occur,31-36
in,37-39
the,40-43
ferricyanide,44-56
test,,57-62
it,63-65
is,66-68
recommended,69-80
that,81-85
either,86-92
the,93-96
glucose,97-104	DrugDDI.d379.s8.e0
oxidase,105-112	DrugDDI.d379.s8.e0
or,113-115
hexokinase,116-126	DrugDDI.d379.s8.e1
method,127-133
be,134-136
used,137-141
to,142-144
determine,145-154
blood/plasma,155-167
glucose,168-175
levels,176-182
in,183-185
patients,186-194
receiving,195-204
cefditoren,205-215	DrugDDI.d379.s8.e2
pivoxil.,216-224	DrugDDI.d379.s8.e2

Renal,0-5
function,6-14
should,15-21
be,22-24
monitored,25-34
carefully,35-44
if,45-47
high,48-52
doses,53-58
of,59-61
aminoglycosides,62-77	DrugDDI.d256.s0.e0
are,78-81
to,82-84
be,85-87
administered,88-100
with,101-105
MAXIPIME,106-114	DrugDDI.d256.s0.e1
because,115-122
of,123-125
the,126-129
increased,130-139
potential,140-149
of,150-152
nephrotoxicity,153-167
and,168-171
ototoxicity,172-183
of,184-186
aminoglycoside,187-201	DrugDDI.d256.s0.e2
antibiotics.,202-214	DrugDDI.d256.s0.e2

Nephrotoxicity,0-14
has,15-18
been,19-23
reported,24-32
following,33-42
concomitant,43-54
administration,55-69
of,70-72
other,73-78
cephalosporins,79-93	DrugDDI.d256.s1.e0
with,94-98
potent,99-105
diuretics,106-115	DrugDDI.d256.s1.e1
such,116-120
as,121-123
furosemide.,124-135	DrugDDI.d256.s1.e2

Drug/Laboratory,0-15	DrugDDI.d256.s2.e0
Test,16-20
Interactions,21-33
The,34-37
administration,38-52
of,53-55
cefepime,56-64	DrugDDI.d256.s2.e1
may,65-68
result,69-75
in,76-78
a,79-80
false-positive,81-95
reaction,96-104
for,105-108
glucose,109-116	DrugDDI.d256.s2.e2
in,117-119
the,120-123
urine,124-129
when,130-134
using,135-140
Clinitest?,141-151
tablets.,152-160

It,0-2
is,3-5
recommended,6-17
that,18-22
glucose,23-30
tests,31-36
based,37-42
on,43-45
enzymatic,46-55
glucose,56-63	DrugDDI.d256.s3.e0
oxidase,64-71	DrugDDI.d256.s3.e0
reactions,72-81
(such,82-87
as,88-90
Clinistix?,91-101
or,102-104
Tes-Tape?,105-114
),115-116
be,117-119
used.,120-125

Carbamazepine:,0-14	DrugDDI.d479.s0.e0
Elevated,15-23
carbamazepine,24-37
levels,38-44
have,45-49
been,50-54
reported,55-63
in,64-66
postmarketing,67-80
experience,81-91
when,92-96
SUPRAX,97-103	DrugDDI.d479.s0.e1
is,104-106
administered,107-119
concomitantly.,120-134

Drug,0-4
monitoring,5-15
may,16-19
be,20-22
of,23-25
assistance,26-36
in,37-39
detecting,40-49
alterations,50-61
in,62-64
carbamazepine,65-78	DrugDDI.d479.s1.e0
plasma,79-85
concentrations.,86-101

Warfarin,0-8	DrugDDI.d479.s2.e0
and,9-12
Anticoagulants:,13-28	DrugDDI.d479.s2.e1
Increased,29-38
prothrombin,39-50
time,,51-56
with,57-61
or,62-64
without,65-72
clinical,73-81
bleeding,,82-91
has,92-95
been,96-100
reported,101-109
when,110-114
cefixime,115-123	DrugDDI.d479.s2.e2
is,124-126
administered,127-139
concomitantly.,140-154

Drug/Laboratory,0-15	DrugDDI.d479.s3.e0
Test,16-20
Interactions,21-33
A,34-35
false-positive,36-50
reaction,51-59
for,60-63
ketones,64-71
in,72-74
the,75-78
urine,79-84
may,85-88
occur,89-94
with,95-99
tests,100-105
using,106-111
nitroprusside,112-125	DrugDDI.d479.s3.e1
but,126-129
not,130-133
with,134-138
those,139-144
using,145-150
nitroferricyanide.,151-169	DrugDDI.d479.s3.e2

The,0-3
administration,4-18
of,19-21
SUPRAX,22-28	DrugDDI.d479.s4.e0
may,29-32
result,33-39
in,40-42
a,43-44
false-positive,45-59
reaction,60-68
for,69-72
glucose,73-80	DrugDDI.d479.s4.e1
in,81-83
the,84-87
urine,88-93
using,94-99
Clinitest?**,,100-113
Benedict?s,114-124
solution,,125-134
or,135-137
Fehling?s,138-147
solution.,148-157

It,0-2
is,3-5
recommended,6-17
that,18-22
glucose,23-30
tests,31-36
based,37-42
on,43-45
enzymatic,46-55
glucose,56-63	DrugDDI.d479.s5.e0
oxidase,64-71	DrugDDI.d479.s5.e0
reactions,72-81
(such,82-87
as,88-90
Clinistix?**,91-103
or,104-106
Tes-Tape?**),107-119
be,120-122
used.,123-128

A,0-1
false-positive,2-16
direct,17-23
Coombs,24-30
test,31-35
has,36-39
been,40-44
reported,45-53
during,54-60
treatment,61-70
with,71-75
other,76-81
cephalosporin,82-95	DrugDDI.d479.s6.e0
antibiotics;,96-108	DrugDDI.d479.s6.e0

therefore,,0-10
it,11-13
should,14-20
be,21-23
recognized,24-34
that,35-39
a,40-41
positive,42-50
Coombs,51-57
test,58-62
may,63-66
be,67-69
due,70-73
to,74-76
the,77-80
drug.,81-86	DrugDDI.d479.s7.e0

Increased,0-9
nephrotoxicity,10-24
has,25-28
been,29-33
reported,34-42
following,43-52
concomitant,53-64
administration,65-79
of,80-82
cephalosporins,83-97	DrugDDI.d391.s0.e0
and,98-101
aminoglycoside,102-116	DrugDDI.d391.s0.e1
antibiotics.,117-129	DrugDDI.d391.s0.e1

Drug/Laboratory,0-15	DrugDDI.d391.s1.e0
Test,16-20
Interactions,21-33
Cephalosporins,,34-49
including,50-59
cefotaxime,60-70	DrugDDI.d391.s1.e2
sodium,,71-78	DrugDDI.d391.s1.e2
are,79-82
known,83-88
to,89-91
occasionally,92-104
induce,105-111
a,112-113
positive,114-122
direct,123-129
Coombs,130-136
test.,137-142

Increases,0-9
in,10-12
serum,13-18
creatinine,19-29
have,30-34
occurred,35-43
when,44-48
CEFOTAN,49-56	DrugDDI.d138.s0.e0
was,57-60
given,61-66
alone.,67-73

If,0-2
CEFOTAN,3-10	DrugDDI.d138.s1.e0
and,11-14
an,15-17
aminoglycoside,18-32	DrugDDI.d138.s1.e1
are,33-36
used,37-41
concomitantly,,42-56
renal,57-62
function,63-71
should,72-78
be,79-81
carefully,82-91
monitored,,92-102
because,103-110
nephrotoxicity,111-125
may,126-129
be,130-132
potentiated.,133-145

Drug/Laboratory,0-15	DrugDDI.d138.s2.e0
Test,16-20
Interactions:,21-34
The,35-38
administration,39-53
of,54-56
CEFOTAN,57-64	DrugDDI.d138.s2.e1
may,65-68
result,69-75
in,76-78
a,79-80
false,81-86
positive,87-95
reaction,96-104
for,105-108
glucose,109-116	DrugDDI.d138.s2.e2
in,117-119
the,120-123
urine,124-129
using,130-135
Clinitest??,,136-148
Benedicts,149-158
solution,,159-168
or,169-171
Fehlings,172-180
solution.,181-190

It,0-2
is,3-5
recommended,6-17
that,18-22
glucose,23-30
tests,31-36
based,37-42
on,43-45
enzymatic,46-55
glucose,56-63	DrugDDI.d138.s3.e0
oxidase,64-71	DrugDDI.d138.s3.e0
be,72-74
used.,75-80

As,0-2
with,3-7
other,8-13
cephalosporins,,14-29
high,30-34
concentrations,35-49
of,50-52
cefotetan,53-62	DrugDDI.d138.s4.e1
may,63-66
interfere,67-76
with,77-81
measurement,82-93
of,94-96
serum,97-102
and,103-106
urine,107-112
creatinine,113-123
levels,124-130
by,131-133
Jaffe?,134-140
reaction,141-149
and,150-153
produce,154-161
false,162-167
increases,168-177
in,178-180
the,181-184
levels,185-191
of,192-194
creatinine,195-205	DrugDDI.d138.s4.e2
reported.,206-215

Increased,0-9
nephrotoxicity,10-24
has,25-28
been,29-33
reported,34-42
following,43-52
concomitant,53-64
administration,65-79
of,80-82
cephalosporins,83-97	DrugDDI.d220.s0.e0
and,98-101
aminoglycoside,102-116	DrugDDI.d220.s0.e1
antibiotics.,117-129	DrugDDI.d220.s0.e1

Drug/Laboratory,0-15	DrugDDI.d220.s1.e0
Test,16-20
Interactions,21-33
As,34-36
with,37-41
cephalothin,,42-54
high,55-59
concentrations,60-74
of,75-77
cefoxitin,78-87	DrugDDI.d220.s1.e2
(,88-89
100,90-93
micrograms/mL),94-108
may,109-112
interfere,113-122
with,123-127
measurement,128-139
of,140-142
serum,143-148
and,149-152
urine,153-158
creatinine,159-169
levels,170-176
by,177-179
the,180-183
Jaff?,184-189
reaction,,190-199
and,200-203
produce,204-211
false,212-217
increases,218-227
of,228-230
modest,231-237
degree,238-244
in,245-247
the,248-251
levels,252-258
of,259-261
creatinine,262-272	DrugDDI.d220.s1.e3
reported.,273-282

Serum,0-5
samples,6-13
from,14-18
patients,19-27
treated,28-35
with,36-40
cefoxitin,41-50	DrugDDI.d220.s2.e0
should,51-57
not,58-61
be,62-64
analyzed,65-73
for,74-77
creatinine,78-88	DrugDDI.d220.s2.e1
if,89-91
withdrawn,92-101
within,102-108
2,109-110
hours,111-116
of,117-119
drug,120-124
administration.,125-140

High,0-4
concentrations,5-19
of,20-22
cefoxitin,23-32	DrugDDI.d220.s3.e0
in,33-35
the,36-39
urine,40-45
may,46-49
interfere,50-59
with,60-64
measurement,65-76
of,77-79
urinary,80-87
17-hydroxy-corticosteroids,88-114
by,115-117
the,118-121
Porter-Silber,122-135
reaction,,136-145
and,146-149
produce,150-157
false,158-163
increases,164-173
of,174-176
modest,177-183
degree,184-190
in,191-193
the,194-197
levels,198-204
reported.,205-214

A,0-1
false-positive,2-16
reaction,17-25
for,26-29
glucose,30-37	DrugDDI.d220.s4.e0
in,38-40
the,41-44
urine,45-50
may,51-54
occur.,55-61

?,0-1
Registered,2-12
trademark,13-22
of,23-25
Ames,26-30	DrugDDI.d220.s7.e0
Company,,31-39
Division,40-48
of,49-51
Miles,52-57
Laboratories,,58-71
Inc.,72-76

Nephrotoxicity,0-14
has,15-18
been,19-23
reported,24-32
following,33-42
concomitant,43-54
administration,55-69
of,70-72
aminoglycoside,73-87	DrugDDI.d31.s0.e0
antibiotics,88-99	DrugDDI.d31.s0.e0
and,100-103
cephalosporin,104-117	DrugDDI.d31.s0.e1
antibiotics.,118-130	DrugDDI.d31.s0.e1

Concomitant,0-11
administration,12-26
of,27-29
probenecid,30-40	DrugDDI.d31.s1.e0
doubled,41-48
the,49-52
AUC,53-56
for,57-60
cefprozil.,61-71	DrugDDI.d31.s1.e1

The,0-3
bioavailability,4-19
of,20-22
the,23-26
capsule,27-34
formulation,35-46
of,47-49
cefprozil,50-59	DrugDDI.d31.s2.e0
was,60-63
not,64-67
affected,68-76
when,77-81
administered,82-94
5,95-96
minutes,97-104
following,105-114
an,115-117
antacid.,118-126	DrugDDI.d31.s2.e1

Nephrotoxicity,0-14
has,15-18
been,19-23
reported,24-32
following,33-42
concomitant,43-54
administration,55-69
of,70-72
cephalosporins,73-87	DrugDDI.d366.s0.e0
with,88-92
aminoglycoside,93-107	DrugDDI.d366.s0.e1
antibiotics,108-119	DrugDDI.d366.s0.e1
or,120-122
potent,123-129
diuretics,130-139	DrugDDI.d366.s0.e2
such,140-144
as,145-147
furosemide.,148-159	DrugDDI.d366.s0.e3

Renal,0-5
function,6-14
should,15-21
be,22-24
carefully,25-34
monitored,,35-45
especially,46-56
if,57-59
higher,60-66
dosages,67-74
of,75-77
the,78-81
aminoglycosides,82-97	DrugDDI.d366.s1.e0
are,98-101
to,102-104
be,105-107
administered,108-120
or,121-123
if,124-126
therapy,127-134
is,135-137
prolonged,,138-148
because,149-156
of,157-159
the,160-163
potential,164-173
nephrotoxicity,174-188
and,189-192
ototoxicity,193-204
of,205-207
aminoglycosidic,208-223
antibiotics.,224-236	DrugDDI.d366.s1.e1

Nephrotoxicity,0-14
and,15-18
ototoxicity,19-30
were,31-35
not,36-39
noted,40-45
when,46-50
ceftazidime,51-62	DrugDDI.d366.s2.e0
was,63-66
given,67-72
alone,73-78
in,79-81
clinical,82-90
trials.,91-98

Chloramphenicol,0-15	DrugDDI.d366.s3.e0
has,16-19
been,20-24
shown,25-30
to,31-33
be,34-36
antagonistic,37-49
to,50-52
beta-lactam,53-64	DrugDDI.d366.s3.e1
antibiotics,,65-77	DrugDDI.d366.s3.e1
including,78-87
ceftazidime,,88-100
based,101-106
on,107-109
in,110-112
vitro,113-118
studies,119-126
and,127-130
time,131-135
kill,136-140
curves,141-147
with,148-152
enteric,153-160
gram-negative,161-174
bacilli.,175-183

Due,0-3
to,4-6
the,7-10
possibility,11-22
of,23-25
antagonism,26-36
in,37-39
vivo,,40-45
particularly,46-58
when,59-63
bactericidal,64-76
activity,77-85
is,86-88
desired,,89-97
this,98-102
drug,103-107	DrugDDI.d366.s4.e0
combination,108-119
should,120-126
be,127-129
avoided.,130-138

Drug/Laboratory,0-15	DrugDDI.d366.s5.e0
Test,16-20
Interactions,21-33
The,34-37
administration,38-52
of,53-55
ceftazidime,56-67	DrugDDI.d366.s5.e1
may,68-71
result,72-78
in,79-81
a,82-83
false-positive,84-98
reaction,99-107
for,108-111
glucose,112-119	DrugDDI.d366.s5.e2
in,120-122
the,123-126
urine,127-132
when,133-137
using,138-143
CLINITEST?,144-154
tablets,,155-163
Benedicts,164-173
solution,,174-183
or,184-186
Fehlings,187-195
solution.,196-205

It,0-2
is,3-5
recommended,6-17
that,18-22
glucose,23-30
tests,31-36
based,37-42
on,43-45
enzymatic,46-55
glucose,56-63	DrugDDI.d366.s6.e0
oxidase,64-71	DrugDDI.d366.s6.e0
reactions,72-81
(such,82-87
as,88-90
CLINISTIX?,91-101
or,102-104
TES-TAPE?),105-115
be,116-118
used.,119-124

Theophylline:,0-13	DrugDDI.d509.s0.e0
Twelve,14-20
healthy,21-28
male,29-33
volunteers,34-44
were,45-49
administered,50-62
one,63-66
200-mg,67-73
ceftibuten,74-84
capsule,85-92
twice,93-98
daily,99-104
for,105-108
6,109-110
days.,111-116

With,0-4
the,5-8
morning,9-16
dose,17-21
of,22-24
ceftibuten,25-35	DrugDDI.d509.s1.e0
on,36-38
day,39-42
6,,43-45
each,46-50
volunteer,51-60
received,61-69
a,70-71
single,72-78
intravenous,79-90
infusion,91-99
of,100-102
theophylline,103-115	DrugDDI.d509.s1.e1
(4,116-118
mg/kg).,119-126

The,0-3
pharmacokinetics,4-20
of,21-23
theophylline,24-36	DrugDDI.d509.s2.e0
were,37-41
not,42-45
altered.,46-54

The,0-3
effect,4-10
of,11-13
ceftibuten,14-24	DrugDDI.d509.s3.e0
on,25-27
the,28-31
pharmacokinetics,32-48
of,49-51
theophylline,52-64	DrugDDI.d509.s3.e1
administered,65-77
orally,78-84
has,85-88
not,89-92
been,93-97
investigated.,98-111

Antacids,0-8	DrugDDI.d509.s4.e0
or,9-11
H,12-13	DrugDDI.d509.s4.e1
2,14-15	DrugDDI.d509.s4.e1
-receptor,16-25	DrugDDI.d509.s4.e1
antagonists:,26-38	DrugDDI.d509.s4.e1
The,39-42
effect,43-49
of,50-52
increased,53-62
gastric,63-70
pH,71-73
on,74-76
the,77-80
bioavailability,81-96
of,97-99
ceftibuten,100-110	DrugDDI.d509.s4.e2
was,111-114
evaluated,115-124
in,125-127
18,128-130
healthy,131-138
adult,139-144
volunteers.,145-156

A,0-1
single,2-8
dose,9-13
of,14-16
liquid,17-23
antacid,24-31	DrugDDI.d509.s6.e0
did,32-35
not,36-39
affect,40-46
the,47-50
C,51-52
max,53-56	DrugDDI.d509.s6.e1
or,57-59
AUC,60-63
of,64-66
ceftibuten;,67-78	DrugDDI.d509.s6.e2

however,,0-8
150,9-12
mg,13-15
of,16-18
ranitidine,19-29	DrugDDI.d509.s7.e0
q12h,30-34
for,35-38
3,39-40
days,41-45
increased,46-55
the,56-59
ceftibuten,60-70	DrugDDI.d509.s7.e1
C,71-72
max,73-76
by,77-79
23%,80-83
and,84-87
ceftibuten,88-98	DrugDDI.d509.s7.e2
AUC,99-102
by,103-105
16%.,106-110

Drug/Laboratory,0-15	DrugDDI.d509.s9.e0
Test,16-20
Interactions:,21-34
There,35-40
have,41-45
been,46-50
no,51-53
chemical,54-62
or,63-65
laboratory,66-76
test,77-81
interactions,82-94
with,95-99
ceftibuten,100-110	DrugDDI.d509.s9.e1
noted,111-116
to,117-119
date.,120-125

False-positive,0-14
direct,15-21
Coombs,22-28
tests,29-34
have,35-39
been,40-44
reported,45-53
during,54-60
treatment,61-70
with,71-75
other,76-81
cephalosporins.,82-97	DrugDDI.d509.s10.e0

Therefore,,0-10
it,11-13
should,14-20
be,21-23
recognized,24-34
that,35-39
a,40-41
positive,42-50
Coombs,51-57
test,58-62
could,63-68
be,69-71
due,72-75
to,76-78
the,79-82
drug.,83-88	DrugDDI.d509.s11.e0

The,0-3
results,4-11
of,12-14
assays,15-21
using,22-27
red,28-31
cells,32-37
from,38-42
healthy,43-50
subjects,51-59
to,60-62
determine,63-72
whether,73-80
ceftibuten,81-91	DrugDDI.d509.s12.e0
would,92-97
cause,98-103
direct,104-110
Coombs,111-117
reactions,118-127
in,128-130
vitro,131-136
showed,137-143
no,144-146
positive,147-155
reaction,156-164
at,165-167
ceftibuten,168-178	DrugDDI.d509.s12.e1
concentrations,179-193
as,194-196
high,197-201
as,202-204
40,205-207
?g/mL.,208-214

Although,0-8
the,9-12
occurrence,13-23
has,24-27
not,28-31
been,32-36
reported,37-45
with,46-50
Cefizox,,51-59
nephrotoxicity,60-74
has,75-78
been,79-83
reported,84-92
following,93-102
concomitant,103-114
administration,115-129
of,130-132
other,133-138
cephalosporins,139-153	DrugDDI.d234.s0.e1
and,154-157
aminoglycosides.,158-174	DrugDDI.d234.s0.e2

Drug/Laboratory,0-15	DrugDDI.d30.s0.e0
Test,16-20
Interactions:,21-34
A,35-36
false-positive,37-51
reaction,52-60
for,61-64
glucose,65-72	DrugDDI.d30.s0.e1
in,73-75
the,76-79
urine,80-85
may,86-89
occur,90-95
with,96-100
copper,101-107
reduction,108-117
tests,118-123
(Benedict?s,124-135
or,136-138
Fehling?s,139-148
solution,149-157
or,158-160
with,161-165
Clinitest?,166-176
tablets),177-185
but,186-189
not,190-193
with,194-198
enzyme-based,199-211
tests,212-217
for,218-221
glycosuria.,222-233

As,0-2
a,3-4
false-negative,5-19
result,20-26
may,27-30
occur,31-36
in,37-39
the,40-43
ferricyanide,44-56
test,,57-62
it,63-65
is,66-68
recommended,69-80
that,81-85
either,86-92
the,93-96
glucose,97-104	DrugDDI.d30.s1.e0
oxidase,105-112	DrugDDI.d30.s1.e0
or,113-115
hexokinase,116-126	DrugDDI.d30.s1.e1
method,127-133
be,134-136
used,137-141
to,142-144
determine,145-154
blood,155-160
plasma,161-167
glucose,168-175
levels,176-182
in,183-185
patients,186-194
receiving,195-204
cefuroxime.,205-216	DrugDDI.d30.s1.e2

Cefuroxime,0-10	DrugDDI.d30.s2.e0
does,11-15
not,16-19
interfere,20-29
with,30-34
the,35-38
assay,39-44
of,45-47
serum,48-53
and,54-57
urine,58-63
creatinine,64-74
by,75-77
the,78-81
alkaline,82-90
picrate,91-98
method.,99-106

General:,0-8
Significant,9-20
interactions,21-33
may,34-37
occur,38-43
when,44-48
celecoxib,49-58	DrugDDI.d523.s0.e0
is,59-61
administered,62-74
together,75-83
with,84-88
drugs,89-94	DrugDDI.d523.s0.e1
that,95-99
inhibit,100-107
P450,108-112	DrugDDI.d523.s0.e2
2C9.,113-117

Celecoxib,0-9	DrugDDI.d523.s1.e0
metabolism,10-20
is,21-23
predominantly,24-37
mediated,38-46
via,47-50
cytochrome,51-61	DrugDDI.d523.s1.e1
P450,62-66	DrugDDI.d523.s1.e1
2C9,67-70	DrugDDI.d523.s1.e1
in,71-73
the,74-77
liver.,78-84	DrugDDI.d523.s1.e2

Co-administration,0-17
of,18-20
celecoxib,21-30	DrugDDI.d523.s2.e0
with,31-35
drugs,36-41	DrugDDI.d523.s2.e1
that,42-46
are,47-50
known,51-56
to,57-59
inhibit,60-67
2C9,68-71
should,72-78
be,79-81
done,82-86
with,87-91
caution.,92-100

In,0-2
vitro,3-8
studies,9-16
indicate,17-25
that,26-30
celecoxib,31-40	DrugDDI.d523.s3.e0
is,41-43
not,44-47
an,48-50
inhibitor,51-60
of,61-63
cytochrome,64-74	DrugDDI.d523.s3.e1
P450,75-79	DrugDDI.d523.s3.e1
2C9,,80-84	DrugDDI.d523.s3.e1
2C19,85-89
or,90-92
3A4.,93-97

In,0-2
vitro,3-8
studies,9-16
also,17-21
indicate,22-30
that,31-35
celecoxib,,36-46
although,47-55
not,56-59
a,60-61
substrate,,62-72
is,73-75
an,76-78
inhibitor,79-88
of,89-91
cytochrome,92-102	DrugDDI.d523.s4.e1
P450,103-107	DrugDDI.d523.s4.e1
2D6.,108-112	DrugDDI.d523.s4.e1

Therefore,,0-10
there,11-16
is,17-19
a,20-21
potential,22-31
for,32-35
an,36-38
in,39-41
vivo,42-46
drug,47-51
interaction,52-63
with,64-68
drugs,69-74	DrugDDI.d523.s5.e0
that,75-79
are,80-83
metabolized,84-95
by,96-98
P450,99-103	DrugDDI.d523.s5.e1
2D6.,104-108	DrugDDI.d523.s5.e1

Clinical,0-8
studies,9-16
with,17-21
celecoxib,22-31	DrugDDI.d523.s6.e0
have,32-36
identified,37-47
potentially,48-59
significant,60-71
interactions,72-84
with,85-89
fluconazole,90-101	DrugDDI.d523.s6.e1
and,102-105
lithium.,106-114	DrugDDI.d523.s6.e2

Experience,0-10
with,11-15
nonsteroidal,16-28	DrugDDI.d523.s7.e0
anti-inflammatory,29-46	DrugDDI.d523.s7.e0
drugs,47-52	DrugDDI.d523.s7.e0
(NSAIDs),53-61
suggests,62-70
the,71-74
potential,75-84
for,85-88
interactions,89-101
with,102-106
furosemide,107-117	DrugDDI.d523.s7.e2
and,118-121
ACE,122-125	DrugDDI.d523.s7.e3
inhibitors.,126-137	DrugDDI.d523.s7.e3

The,0-3
effects,4-11
celecoxib,12-21	DrugDDI.d523.s8.e0
on,22-24
the,25-28
pharmacokinetics,29-45
and/or,46-52
pharmacodynamics,53-69
of,70-72
glyburide,,73-83
ketoconazole,,84-97
methotrexate,,98-111
phenytoin,,112-122
tolbutamide,,123-135
and,136-139
warfarin,140-148	DrugDDI.d523.s8.e6
have,149-153
been,154-158
studied,159-166
in,167-169
vivo,170-174
and,175-178
clinically,179-189
important,190-199
interactions,200-212
have,213-217
not,218-221
been,222-226
found.,227-233

ACE,0-3	DrugDDI.d523.s9.e0
inhibitors:,4-15	DrugDDI.d523.s9.e0
Reports,16-23
suggest,24-31
that,32-36
NSAIDs,37-43	DrugDDI.d523.s9.e1
may,44-47
diminish,48-56
the,57-60
antihypertensive,61-77	DrugDDI.d523.s9.e2
effect,78-84
of,85-87
Angiotensin,88-99	DrugDDI.d523.s9.e3
Converting,100-110	DrugDDI.d523.s9.e3
Enzyme,111-117	DrugDDI.d523.s9.e3
(ACE),118-123
inhibitors.,124-135

This,0-4
interaction,5-16
should,17-23
be,24-26
given,27-32
consideration,33-46
in,47-49
patients,50-58
taking,59-65
CELEBREX,66-74	DrugDDI.d523.s10.e0
concomitantly,75-88
with,89-93
ACE-inhibitors.,94-109	DrugDDI.d523.s10.e1

Furosemide:,0-11	DrugDDI.d523.s11.e0
Clinical,12-20
studies,,21-29
as,30-32
well,33-37
as,38-40
post,41-45
marketing,46-55
observations,,56-69
have,70-74
shown,75-80
that,81-85
NSAIDs,86-92	DrugDDI.d523.s11.e1
can,93-96
reduce,97-103
the,104-107
natriuretic,108-119	DrugDDI.d523.s11.e2
effect,120-126
of,127-129
furosemide,130-140	DrugDDI.d523.s11.e3
and,141-144
thiazides,145-154	DrugDDI.d523.s11.e4
in,155-157
some,158-162
patients.,163-172

This,0-4
response,5-13
has,14-17
been,18-22
attributed,23-33
to,34-36
inhibition,37-47
of,48-50
renal,51-56
prostaglandin,57-70	DrugDDI.d523.s12.e0
synthesis.,71-81

Aspirin:,0-8	DrugDDI.d523.s13.e0
CELEBREX,9-17	DrugDDI.d523.s13.e1
can,18-21
be,22-24
used,25-29
with,30-34
low,35-38
dose,39-43
aspirin.,44-52	DrugDDI.d523.s13.e2

However,,0-8
concomitant,9-20
administration,21-35
of,36-38
aspirin,39-46	DrugDDI.d523.s14.e0
with,47-51
CELEBREX,52-60	DrugDDI.d523.s14.e1
may,61-64
result,65-71
in,72-74
an,75-77
increased,78-87
rate,88-92
of,93-95
GI,96-98
ulceration,99-109
or,110-112
other,113-118
complications,,119-133
compared,134-142
to,143-145
use,146-149
of,150-152
CELEBREX,153-161	DrugDDI.d523.s14.e2
alone.,162-168

Because,0-7
of,8-10
its,11-14
lack,15-19
of,20-22
platelet,23-31
effects,,32-40
CELEBREX,41-49	DrugDDI.d523.s15.e0
is,50-52
not,53-56
a,57-58
substitute,59-69
for,70-73
aspirin,74-81	DrugDDI.d523.s15.e1
for,82-85
cardiovascular,86-100
prophylaxis.,101-113

Fluconazole:,0-12	DrugDDI.d523.s16.e0
Concomitant,13-24
administration,25-39
of,40-42
fluconazole,43-54	DrugDDI.d523.s16.e1
at,55-57
200,58-61
mg,62-64
QD,65-67
resulted,68-76
in,77-79
a,80-81
two-fold,82-90
increase,91-99
in,100-102
celecoxib,103-112	DrugDDI.d523.s16.e2
plasma,113-119
concentration.,120-134

This,0-4
increase,5-13
is,14-16
due,17-20
to,21-23
the,24-27
inhibition,28-38
of,39-41
celecoxib,42-51	DrugDDI.d523.s17.e0
metabolism,52-62
via,63-66
P450,67-71	DrugDDI.d523.s17.e1
2C9,72-75
by,76-78
fluconazole,79-90	DrugDDI.d523.s17.e2
(see,91-95
CLINICAL,96-104
PHARMACOLOGY,105-117
-,118-119
Pharmacokinetics:,120-137
Metabolism).,138-150

CELEBREX,0-8	DrugDDI.d523.s18.e0
should,9-15
be,16-18
introduced,19-29
at,30-32
the,33-36
lowest,37-43
recommended,44-55
dose,56-60
in,61-63
patients,64-72
receiving,73-82
fluconazole.,83-95	DrugDDI.d523.s18.e1

Lithium:,0-8	DrugDDI.d523.s19.e0
In,9-11
a,12-13
study,14-19
conducted,20-29
in,30-32
healthy,33-40
subjects,,41-50
mean,51-55
steady-state,56-68
lithium,69-76
plasma,77-83
levels,84-90
increased,91-100
approximately,101-114
17%,115-118
in,119-121
subjects,122-130
receiving,131-140
lithium,141-148	DrugDDI.d523.s19.e1
450,149-152
mg,153-155
BID,156-159
with,160-164
CELEBREX,165-173	DrugDDI.d523.s19.e2
200,174-177
mg,178-180
BID,181-184
as,185-187
compared,188-196
to,197-199
subjects,200-208
receiving,209-218
lithium,219-226	DrugDDI.d523.s19.e3
alone.,227-233

Patients,0-8
on,9-11
lithium,12-19	DrugDDI.d523.s20.e0
treatment,20-29
should,30-36
be,37-39
closely,40-47
monitored,48-57
when,58-62
CELEBREX,63-71	DrugDDI.d523.s20.e1
is,72-74
introduced,75-85
or,86-88
withdrawn.,89-99

Methotrexate:,0-13	DrugDDI.d523.s21.e0
In,14-16
an,17-19
interaction,20-31
study,32-37
of,38-40
rheumatoid,41-51
arthritis,52-61
patients,62-70
taking,71-77
methotrexate,,78-91
CELEBREX,92-100	DrugDDI.d523.s21.e2
did,101-104
not,105-108
have,109-113
a,114-115
significant,116-127
effect,128-134
on,135-137
the,138-141
pharmacokinetics,142-158
of,159-161
methotrexate.,162-175	DrugDDI.d523.s21.e3

Warfarin:,0-9	DrugDDI.d523.s22.e0
The,10-13
effect,14-20
of,21-23
celecoxib,24-33	DrugDDI.d523.s22.e1
on,34-36
the,37-40
anti-coagulant,41-55
effect,56-62
of,63-65
warfarin,66-74	DrugDDI.d523.s22.e2
was,75-78
studied,79-86
in,87-89
a,90-91
group,92-97
of,98-100
healthy,101-108
subjects,109-117
receiving,118-127
daily,128-133
doses,134-139
of,140-142
2-5,143-146
mg,147-149
of,150-152
warfarin.,153-162	DrugDDI.d523.s22.e3

In,0-2
these,3-8
subjects,,9-18
celecoxib,19-28	DrugDDI.d523.s23.e0
did,29-32
not,33-36
alter,37-42
the,43-46
anticoagulant,47-60
effect,61-67
of,68-70
warfarin,71-79	DrugDDI.d523.s23.e1
as,80-82
determined,83-93
by,94-96
prothrombin,97-108
time.,109-114

However,,0-8
caution,9-16
should,17-23
be,24-26
used,27-31
when,32-36
administering,37-50
CELEBREX,51-59	DrugDDI.d523.s24.e0
with,60-64
warfarin,65-73	DrugDDI.d523.s24.e1
since,74-79
these,80-85
patients,86-94
are,95-98
at,99-101
increased,102-111
risk,112-116
of,117-119
bleeding,120-128
complications.,129-143

Metformin,0-9	DrugDDI.d309.s0.e0
In,10-12
healthy,13-20
subjects,21-29
given,30-35
single,36-42
500,43-46
mg,47-49
doses,50-55
of,56-58
cephalexin,59-69	DrugDDI.d309.s0.e1
and,70-73
metformin,,74-84
plasma,85-91
metformin,92-101	DrugDDI.d309.s0.e3
mean,102-106
cmax,107-111
and,112-115
AUC,116-119
increased,120-129
by,130-132
an,133-135
average,136-143
of,144-146
34%,147-150
and,151-154
24%,,155-159
respectively,,160-173
and,174-177
metformin,178-187	DrugDDI.d309.s0.e4
mean,188-192
renal,193-198
clearance,199-208
decreased,209-218
by,219-221
14%.,222-226

No,0-2
information,3-14
is,15-17
available,18-27
about,28-33
the,34-37
interaction,38-49
of,50-52
cephalexin,53-63	DrugDDI.d309.s1.e0
and,64-67
metformin,68-77	DrugDDI.d309.s1.e1
following,78-87
multiple,88-96
doses,97-102
of,103-105
either,106-112
drug.,113-118	DrugDDI.d309.s1.e2

Although,0-8
not,9-12
observed,13-21
in,22-24
this,25-29
study,,30-36
adverse,37-44
effects,45-52
could,53-58
potentially,59-70
arise,71-76
from,77-81
co-administration,82-99
of,100-102
cephalexin,103-113	DrugDDI.d309.s2.e0
and,114-117
metformin,118-127	DrugDDI.d309.s2.e1
by,128-130
inhibition,131-141
of,142-144
tubular,145-152
secretion,153-162
via,163-166
organic,167-174	DrugDDI.d309.s2.e2
cationic,175-183	DrugDDI.d309.s2.e2
transporter,184-195
systems.,196-204

Accordingly,,0-12
careful,13-20
patient,21-28
monitoring,29-39
and,40-43
dose,44-48
adjustment,49-59
of,60-62
metformin,63-72	DrugDDI.d309.s3.e0
is,73-75
recommended,76-87
in,88-90
patients,91-99
concomitantly,100-113
taking,114-120
cephalexin,121-131	DrugDDI.d309.s3.e1
and,132-135
metformin.,136-146	DrugDDI.d309.s3.e2

Probenecid,0-10	DrugDDI.d309.s4.e0
As,11-13
with,14-18
other,19-24
b-lactams,,25-35
the,36-39
renal,40-45
excretion,46-55
of,56-58
cephalexin,59-69	DrugDDI.d309.s4.e2
is,70-72
inhibited,73-82
by,83-85
probenecid.,86-97	DrugDDI.d309.s4.e3

Drug,0-4	DrugDDI.d309.s5.e0
/,5-6
Laboratory,7-17
Test,18-22
Interactions,23-35
As,36-38
a,39-40
result,41-47
of,48-50
administration,51-65
of,66-68
Keflex,,69-76
a,77-78
false-positive,79-93
reaction,94-102
for,103-106
glucose,107-114	DrugDDI.d309.s5.e2
in,115-117
the,118-121
urine,122-127
may,128-131
occur.,132-138

Immunosuppressive,0-17	DrugDDI.d300.s0.e0
Drugs,,18-24
Fibric,25-31
Acid,32-36
Derivatives,,37-49
Niacin,50-56	DrugDDI.d300.s0.e2
(Nicotinic,57-67
Acid,,68-73
Erythromycin,,74-87
Azole,88-93	DrugDDI.d300.s0.e5
Antifungals:,94-106	DrugDDI.d300.s0.e5
Skeletal,107-115
Muscle.,116-123

ANTACID,0-7	DrugDDI.d300.s1.e0
(Magnesium-Aluminum,8-27
Hydroxide):,28-39
Cerivastatin,40-52	DrugDDI.d300.s1.e2
plasma,53-59
concentrations,60-74
were,75-79
not,80-83
affected,84-92
by,93-95
co-administration,96-113
of,114-116
antacid.,117-125	DrugDDI.d300.s1.e3

CIMETlDINE:,0-11
Cerivastatin,12-24	DrugDDI.d300.s2.e0
plasma,25-31
concentrations,32-46
were,47-51
not,52-55
affected,56-64
by,65-67
co-administration,68-85
of,86-88
cimetidine.,89-100	DrugDDI.d300.s2.e1

CHOLESTYRAMINE:,0-15	DrugDDI.d300.s3.e0
The,16-19
influence,20-29
of,30-32
the,33-36
bile-acidsequestering,37-58	DrugDDI.d300.s3.e1
agent,59-64	DrugDDI.d300.s3.e1
cholestyramine,65-79
on,80-82
the,83-86
pharmacokinetits,87-103
of,104-106
cerivastatin,107-119	DrugDDI.d300.s3.e2
sodium,120-126	DrugDDI.d300.s3.e2
was,127-130
evaluated,131-140
in,141-143
12,144-146
healthy,147-154
males,155-160
in,161-163
2,164-165
separate,166-174
randomized,175-185
crossover,186-195
studies.,196-204

In,0-2
the,3-6
first,7-12
study,,13-19
concomitant,20-31
administration,32-46
of,47-49
0.2,50-53
mg,54-56
cerivastatin,57-69	DrugDDI.d300.s4.e0
sodium,70-76	DrugDDI.d300.s4.e0
and,77-80
12,81-83
g,84-85
cholestyramine,86-100	DrugDDI.d300.s4.e1
resulted,101-109
in,110-112
decreases,113-122
of,123-125
more,126-130
than,131-135
22%,136-139
for,140-143
AUC,144-147
and,148-151
40%,152-155
for,156-159
Cmax,160-164
when,165-169
compared,170-178
to,179-181
dosing,182-188
cerivastatin,189-201	DrugDDI.d300.s4.e2
sodium,202-208	DrugDDI.d300.s4.e2
alone.,209-215

However,,0-8
in,9-11
the,12-15
second,16-22
study,,23-29
administration,30-44
of,45-47
12,48-50
g,51-52
cholestyramine,53-67	DrugDDI.d300.s5.e0
1,68-69
hour,70-74
before,75-81
the,82-85
evening,86-93
meal,94-98
and,99-102
0.3,103-106
mg,107-109
cerivastatin,110-122	DrugDDI.d300.s5.e1
sodium,123-129	DrugDDI.d300.s5.e1
approximately,130-143
4,144-145
hours,146-151
after,152-157
the,158-161
same,162-166
evening,167-174
meal,175-179
resulted,180-188
in,189-191
a,192-193
decrease,194-202
in,203-205
the,206-209
cerivastatin,210-222	DrugDDI.d300.s5.e2
AUC,223-226
of,227-229
less,230-234
than,235-239
8%,,240-243
and,244-247
a,248-249
decrease,250-258
in,259-261
Cmax,262-266
of,267-269
about,270-275
30%,276-279
when,280-284
compared,285-293
to,294-296
dosing,297-303
cerivastatin,304-316	DrugDDI.d300.s5.e3
sodium,317-323	DrugDDI.d300.s5.e3
alone.,324-330

Therefore,,0-10
it,11-13
would,14-19
be,20-22
expected,23-31
that,32-36
a,37-38
dosing,39-45
schedule,46-54
of,55-57
cerivastatin,58-70	DrugDDI.d300.s6.e0
sodium,71-77	DrugDDI.d300.s6.e0
given,78-83
at,84-86
bedtime,87-94
and,95-98
cholestyramine,99-113	DrugDDI.d300.s6.e1
given,114-119
before,120-126
the,127-130
evening,131-138
meal,139-143
would,144-149
not,150-153
result,154-160
in,161-163
a,164-165
significant,166-177
decrease,178-186
in,187-189
the,190-193
clinical,194-202
effect,203-209
of,210-212
cerivastatin,213-225	DrugDDI.d300.s6.e2
sodium.,226-233	DrugDDI.d300.s6.e2

DIGOXIN:,0-8	DrugDDI.d300.s7.e0
Plasma,9-15
digoxin,16-23
levels,24-30
and,31-34
digoxin,35-42	DrugDDI.d300.s7.e1
clearance,43-52
at,53-55
steady-state,56-68
were,69-73
not,74-77
affected,78-86
by,87-89
co-administration,90-107
of,108-110
0.2,111-114
mg,115-117
cerivastatin,118-130	DrugDDI.d300.s7.e2
sodium.,131-138	DrugDDI.d300.s7.e2

Cerivastatin,0-12	DrugDDI.d300.s8.e0
plasma,13-19
concentrations,20-34
were,35-39
also,40-44
not,45-48
affected,49-57
by,58-60
co-administration,61-78
of,79-81
digoxin.,82-90	DrugDDI.d300.s8.e1

WARFARIN:,0-9	DrugDDI.d300.s9.e0
Co-,10-13
administration,14-28
of,29-31
warfarin,32-40	DrugDDI.d300.s9.e1
and,41-44
cerivastatin,45-57	DrugDDI.d300.s9.e2
to,58-60
healthy,61-68
volunteers,69-79
did,80-83
not,84-87
result,88-94
in,95-97
any,98-101
changes,102-109
in,110-112
prothrombin,113-124
time,125-129
or,130-132
clotting,133-141
factor,142-148	DrugDDI.d300.s9.e3
VII,149-152	DrugDDI.d300.s9.e3
when,153-157
compared,158-166
to,167-169
co-administration,170-187
of,188-190
warfarin,191-199	DrugDDI.d300.s9.e4
and,200-203
placebo.,204-212

The,0-3
AUC,4-7
and,8-11
Cmax,12-16
of,17-19
both,20-24
the,25-28
(R),29-32
and,33-36
(S),37-40
isomers,41-48
of,49-51
warfarin,52-60	DrugDDI.d300.s10.e0
were,61-65
unaffected,66-76
by,77-79
concurrent,80-90
dosing,91-97
of,98-100
0.3,101-104
mg,105-107
cerivastatin,108-120	DrugDDI.d300.s10.e1
sodium.,121-128	DrugDDI.d300.s10.e1

Co-administration,0-17
of,18-20
warfarin,21-29	DrugDDI.d300.s11.e0
and,30-33
cerivastatin,34-46	DrugDDI.d300.s11.e1
did,47-50
not,51-54
alter,55-60
the,61-64
pharmacokinetics,65-81
of,82-84
cerivastatin,85-97	DrugDDI.d300.s11.e2
sodium.,98-105	DrugDDI.d300.s11.e2

ERYTHROMYCIN:,0-13	DrugDDI.d300.s12.e0
In,14-16
hypercholesterolemic,17-37
patients,,38-47
steady-state,48-60
cerivastatin,61-73	DrugDDI.d300.s12.e1
AUC,74-77
and,78-81
Cmax,82-86
increased,87-96
approximately,97-110
50%,111-114
and,115-118
24%,119-122
respectively,123-135
after,136-141
10,142-144
days,145-149
with,150-154
co-administration,155-172
of,173-175
erythromycin,,176-189
a,190-191
known,192-197
inhibitor,198-207
of,208-210
cytochrome,211-221	DrugDDI.d300.s12.e3
P450,222-226	DrugDDI.d300.s12.e3
3A4.,227-231	DrugDDI.d300.s12.e3

OTHER,0-5
CONCOMITANT,6-17
THERAPY:,18-26
Although,27-35
specific,36-44
interaction,45-56
studies,57-64
were,65-69
not,70-73
performed,,74-84
in,85-87
clinical,88-96
studies,,97-105
cerivastatin,106-118	DrugDDI.d300.s13.e0
sodium,119-125	DrugDDI.d300.s13.e0
was,126-129
used,130-134
concomitantly,135-148
with,149-153
angiotensin-,154-166	DrugDDI.d300.s13.e1
converting,167-177	DrugDDI.d300.s13.e1
enzyme,178-184	DrugDDI.d300.s13.e1
(ACE),185-190
inhibitors,,191-202
betablockers,,203-216
calcium-channel,217-232	DrugDDI.d300.s13.e2
blockers,,233-242	DrugDDI.d300.s13.e2
diuretics,,243-253
and,254-257
nonsteroidal,258-270	DrugDDI.d300.s13.e4
anti-inflammatory,271-288	DrugDDI.d300.s13.e4
drugs,289-294	DrugDDI.d300.s13.e4
(NSAIDs),295-303
without,304-311
evidence,312-320
of,321-323
clinically,324-334
significant,335-346
adverse,347-354
interactions.,355-368

Pharmacokinetic,0-15
interaction,16-27
studies,28-35
with,36-40
cetirizine,41-51	DrugDDI.d89.s0.e0
in,52-54
adults,55-61
were,62-66
conducted,67-76
with,77-81
pseudoephedrine,,82-98
antipyrine,,99-110
ketoconazole,,111-124
erythromycin,125-137	DrugDDI.d89.s0.e4
and,138-141
azithromycin.,142-155	DrugDDI.d89.s0.e5

In,0-2
a,3-4
multiple,5-13
dose,14-18
study,19-24
of,25-27
theophylline,28-40	DrugDDI.d89.s2.e0
(400,41-45
mg,46-48
once,49-53
daily,54-59
for,60-63
3,64-65
days),66-71
and,72-75
cetirizine,76-86	DrugDDI.d89.s2.e1
(20,87-90
mg,91-93
once,94-98
daily,99-104
for,105-108
3,109-110
days),,111-117
a,118-119
16%,120-123
decrease,124-132
in,133-135
the,136-139
clearance,140-149
of,150-152
cetirizine,153-163	DrugDDI.d89.s2.e2
was,164-167
observed.,168-177

The,0-3
disposition,4-15
of,16-18
theophylline,19-31	DrugDDI.d89.s3.e0
was,32-35
not,36-39
altered,40-47
by,48-50
concomitant,51-62
cetirizine,63-73	DrugDDI.d89.s3.e1
administration.,74-89

Drug-Drug,0-9
Interactions:,10-23
No,24-26
clinically,27-37
significant,38-49
drug,50-54
interactions,55-67
have,68-72
been,73-77
found,78-83
with,84-88
theophylline,89-101	DrugDDI.d89.s4.e0
at,102-104
a,105-106
low,107-110
dose,,111-116
azithromycin,,117-130
pseudoephedrine,,131-147
ketoconazole,,148-161
or,162-164
erythromycin.,165-178	DrugDDI.d89.s4.e4

There,0-5
was,6-9
a,10-11
small,12-17
decrease,18-26
in,27-29
the,30-33
clearance,34-43
of,44-46
cetirizine,47-57	DrugDDI.d89.s5.e0
caused,58-64
by,65-67
a,68-69
400-mg,70-76
dose,77-81
of,82-84
theophylline;,85-98	DrugDDI.d89.s5.e1

A,0-1
drug,2-6
interaction,7-18
study,19-24
was,25-28
performed,29-38
in,39-41
which,42-47
ERBITUX,48-55	DrugDDI.d174.s0.e0
was,56-59
administered,60-72
in,73-75
combination,76-87
with,88-92
irinotecan.,93-104	DrugDDI.d174.s0.e1

There,0-5
was,6-9
no,10-12
evidence,13-21
of,22-24
any,25-28
pharmacokinetic,29-44
interactions,45-57
between,58-65
ERBITUX,66-73	DrugDDI.d174.s1.e0
and,74-77
irinotecan.,78-89	DrugDDI.d174.s1.e1

Cevimeline,0-10	DrugDDI.d85.s0.e0
should,11-17
be,18-20
administered,21-33
with,34-38
caution,39-46
to,47-49
patients,50-58
taking,59-65
beta,66-70	DrugDDI.d85.s0.e1
adrenergic,71-81	DrugDDI.d85.s0.e1
antagonists,,82-94	DrugDDI.d85.s0.e1
because,95-102
of,103-105
the,106-109
possibility,110-121
of,122-124
conduction,125-135
disturbances.,136-149

Drugs,0-5	DrugDDI.d85.s1.e0
with,6-10
parasympathomimetic,11-30	DrugDDI.d85.s1.e1
effects,31-38
administered,39-51
concurrently,52-64
with,65-69
cevimeline,70-80	DrugDDI.d85.s1.e2
can,81-84
be,85-87
expected,88-96
to,97-99
have,100-104
additive,105-113
effects.,114-122

Cevimeline,0-10	DrugDDI.d85.s2.e0
might,11-16
interfere,17-26
with,27-31
desirable,32-41
antimuscarinic,42-56	DrugDDI.d85.s2.e1
effects,57-64
of,65-67
drugs,68-73	DrugDDI.d85.s2.e2
used,74-78
concomitantly.,79-93

Drugs,0-5	DrugDDI.d85.s3.e0
which,6-11
inhibit,12-19
CYP2D6,20-26	DrugDDI.d85.s3.e1
and,27-30
CYP3A3/4,31-39
also,40-44
inhibit,45-52
the,53-56
metabolism,57-67
of,68-70
cevimeline.,71-82	DrugDDI.d85.s3.e2

Cevimeline,0-10	DrugDDI.d85.s4.e0
should,11-17
be,18-20
used,21-25
with,26-30
caution,31-38
in,39-41
individuals,42-53
known,54-59
or,60-62
suspected,63-72
to,73-75
be,76-78
deficient,79-88
in,89-91
CYP2D6,92-98	DrugDDI.d85.s4.e1
activity,,99-108
based,109-114
on,115-117
previous,118-126
experience,,127-138
as,139-141
they,142-146
may,147-150
be,151-153
at,154-156
a,157-158
higher,159-165
risk,166-170
of,171-173
adverse,174-181
events.,182-189

In,0-2
an,3-5
in,6-8
vitro,9-14
study,,15-21
cytochrome,22-32	DrugDDI.d85.s5.e0
P450,33-37	DrugDDI.d85.s5.e0
isozymes,38-46	DrugDDI.d85.s5.e0
1A2,,47-51	DrugDDI.d85.s5.e0
2A6,,52-56
2C9,,57-61
2C19,,62-67
2D6,,68-72
2E1,,73-77
and,78-81
3A4,82-85
were,86-90
not,91-94
inhibited,95-104
by,105-107
exposure,108-116
to,117-119
cevimeline.,120-131	DrugDDI.d85.s5.e1

There,0-5
are,6-9
no,10-12
known,13-18
drug/drug,19-28	DrugDDI.d324.s0.e0
interactions,29-41
with,42-46
chlorambucil.,47-60	DrugDDI.d324.s0.e1

Although,0-8
clinical,9-17
studies,18-25
have,26-30
not,31-34
established,35-46
a,47-48
cause,49-54
and,55-58
effect,59-65
relationship,,66-79
physicians,80-90
should,91-97
be,98-100
aware,101-106
that,107-111
variable,112-120
effects,121-128
an,129-131
blood,132-137
coagulation,138-149
have,150-154
been,155-159
reported,160-168
very,169-173
rarely,174-180
in,181-183
patients,184-192
receiving,193-202
oral,203-207	DrugDDI.d454.s0.e0
anticoagulants,208-222	DrugDDI.d454.s0.e0
and,223-226
chlordiazepoxide.,227-244	DrugDDI.d454.s0.e1

The,0-3
concomitant,4-15
use,16-19
of,20-22
alcohol,23-30	DrugDDI.d454.s1.e0
or,31-33
other,34-39
central,40-47	DrugDDI.d454.s1.e1
nervous,48-55	DrugDDI.d454.s1.e1
system,56-62	DrugDDI.d454.s1.e1
depressants,63-74	DrugDDI.d454.s1.e1
may,75-78
have,79-83
an,84-86
additive,87-95
effect.,96-103

The,0-3
administration,4-18
of,19-21
local,22-27	DrugDDI.d351.s0.e0
anesthetic,28-38	DrugDDI.d351.s0.e0
solutions,39-48
containing,49-59
epinephrine,60-71	DrugDDI.d351.s0.e1
or,72-74
norepinephrine,75-89	DrugDDI.d351.s0.e2
to,90-92
patients,93-101
receiving,102-111
monoamine,112-121	DrugDDI.d351.s0.e3
oxidase,122-129	DrugDDI.d351.s0.e3
inhibitors,,130-141	DrugDDI.d351.s0.e3
tricyclic,142-151	DrugDDI.d351.s0.e4
antidepressants,152-167	DrugDDI.d351.s0.e4
or,168-170
phenothiazines,171-185	DrugDDI.d351.s0.e5
may,186-189
produce,190-197
severe,,198-205
prolonged,206-215
hypotension,216-227
or,228-230
hypertension.,231-244

Concurrent,0-10
administration,11-25
of,26-28
vasopressor,29-40	DrugDDI.d351.s3.e0
drugs,41-46	DrugDDI.d351.s3.e0
(for,47-51
the,52-55
treatment,56-65
of,66-68
hypotension,69-80
related,81-88
to,89-91
obstetric,92-101
blocks),102-109
and,110-113
ergot-type,114-124
oxytocic,125-133	DrugDDI.d351.s3.e1
drugs,134-139	DrugDDI.d351.s3.e1
may,140-143
cause,144-149
severe,,150-157
persistent,158-168
hypertension,169-181
or,182-184
cerebrovascular,185-200
accidents.,201-211

The,0-3
para-aminobenzoic,4-21	DrugDDI.d351.s4.e0
acid,22-26	DrugDDI.d351.s4.e0
metabolite,27-37
of,38-40
chloroprocaine,41-55	DrugDDI.d351.s4.e1
inhibits,56-64
the,65-68
action,69-75
of,76-78
sulfonamides.,79-92	DrugDDI.d351.s4.e2

Therefore,,0-10
chloroprocaine,11-25	DrugDDI.d351.s5.e0
should,26-32
not,33-36
be,37-39
used,40-44
in,45-47
any,48-51
condition,52-61
in,62-64
which,65-70
a,71-72
sulfonamide,73-84	DrugDDI.d351.s5.e1
drug,85-89
is,90-92
being,93-98
employed.,99-108

Antacids,0-8	DrugDDI.d11.s0.e0
and,9-12
kaolin:,13-20	DrugDDI.d11.s0.e1
Antacids,21-29	DrugDDI.d11.s0.e2
and,30-33
kaolin,34-40	DrugDDI.d11.s0.e3
can,41-44
reduce,45-51
absorption,52-62
of,63-65
chloroquine;,66-78	DrugDDI.d11.s0.e4

an,0-2
interval,3-11
of,12-14
at,15-17
least,18-23
4,24-25
hours,26-31
between,32-39
intake,40-46
of,47-49
these,50-55
agents,56-62
and,63-66
chloroquine,67-78	DrugDDI.d11.s1.e0
should,79-85
be,86-88
observed.,89-98

Cimetidine:,0-11	DrugDDI.d11.s2.e0
Cimetidine,12-22	DrugDDI.d11.s2.e1
can,23-26
inhibit,27-34
the,35-38
metabolism,39-49
of,50-52
chloroquine,,53-65
increasing,66-76
its,77-80
plasma,81-87
level.,88-94

Concomitant,0-11
use,12-15
of,16-18
cimetidine,19-29	DrugDDI.d11.s3.e0
should,30-36
be,37-39
avoided.,40-48

Ampicillin:,0-11	DrugDDI.d11.s4.e0
In,12-14
a,15-16
study,17-22
of,23-25
healthy,26-33
volunteers,,34-45
chloroquine,46-57	DrugDDI.d11.s4.e1
significantly,58-71
reduced,72-79
the,80-83
bioavailability,84-99
of,100-102
ampicillin.,103-114	DrugDDI.d11.s4.e2

An,0-2
interval,3-11
of,12-14
at,15-17
least,18-23
two,24-27
hours,28-33
between,34-41
intake,42-48
of,49-51
this,52-56
agent,57-62
and,63-66
chloroquine,67-78	DrugDDI.d11.s5.e0
should,79-85
be,86-88
observed.,89-98

Cyclosporin:,0-12	DrugDDI.d11.s6.e0
After,13-18
introduction,19-31
of,32-34
chloroquine,35-46	DrugDDI.d11.s6.e1
(oral,47-52
form),,53-59
a,60-61
sudden,62-68
increase,69-77
in,78-80
serum,81-86
cyclosporin,87-98
level,99-104
has,105-108
been,109-113
reported.,114-123

Therefore,,0-10
close,11-16
monitoring,17-27
of,28-30
serum,31-36
cyclosporin,37-48
level,49-54
is,55-57
recommended,58-69
and,,70-74
if,75-77
necessary,,78-88
chloroquine,89-100	DrugDDI.d11.s7.e0
should,101-107
be,108-110
discontinued.,111-124

When,0-4
given,5-10
concurrently,11-23
the,24-27
following,28-37
drugs,38-43	DrugDDI.d558.s0.e0
may,44-47
interact,48-56
with,57-61
thiazide,62-70	DrugDDI.d558.s0.e1
diuretics.,71-81	DrugDDI.d558.s0.e1

-,0-1
Alcohol,,2-10
barbiturates,,11-24
or,25-27
narcotics:,28-38	DrugDDI.d558.s1.e2
Potentiation,39-51
of,52-54
otthostatic,55-66
hypotension,67-78
may,79-82
occur,83-88

-,0-1
Antidiabetic,2-14	DrugDDI.d558.s3.e0
drugs:,15-21	DrugDDI.d558.s3.e0
(Oral,22-27
agents,28-34
and,35-38
insulin),39-47	DrugDDI.d558.s3.e1
Dosage,48-54
adjustment,55-65
of,66-68
the,69-72
antidiabetic,73-85	DrugDDI.d558.s3.e2
drug,86-90	DrugDDI.d558.s3.e2
may,91-94
be,95-97
required,98-106

-,0-1
Other,2-7
antihypertensive,8-24	DrugDDI.d558.s5.e0
drugs:,25-31	DrugDDI.d558.s5.e0
Additive,32-40
effect,41-47
or,48-50
potentiation,51-63

-,0-1
Cholestyramine,2-16	DrugDDI.d558.s7.e0
and,17-20
colestipol,21-31	DrugDDI.d558.s7.e1
resins:,32-39
Cholestytamine,40-54
and,55-58
colestipol,59-69	DrugDDI.d558.s7.e2
resins,70-76
have,77-81
the,82-85
potential,86-95
of,96-98
binding,99-106
thiazide,107-115	DrugDDI.d558.s7.e3
diuretics,116-125	DrugDDI.d558.s7.e3
and,126-129
reducing,130-138
diuretic,139-147	DrugDDI.d558.s7.e4
absorption,148-158
from,159-163
the,164-167
gastrointestinal,168-184
tract,185-190

-,0-1
Corticosteroids,,2-18
ACTH:,19-24	DrugDDI.d558.s9.e1
Intensified,25-36
electrolyte,37-48
depletion,,49-59
particularly,60-72
hypokalemia,73-84

-,0-1
Pressor,2-9	DrugDDI.d558.s11.e0
amines,10-16	DrugDDI.d558.s11.e0
(e.g.,,17-23
norepinephrine):,24-40	DrugDDI.d558.s11.e1
Possible,41-49
decreased,50-59
response,60-68
to,69-71
pressor,72-79	DrugDDI.d558.s11.e2
amines,80-86	DrugDDI.d558.s11.e2
but,87-90
not,91-94
sufficient,95-105
to,106-108
preclude,109-117
their,118-123
use,124-127

-,0-1
Skeletal,2-10	DrugDDI.d558.s13.e0
muscle,11-17	DrugDDI.d558.s13.e0
relaxants,,18-28	DrugDDI.d558.s13.e0
nondepolarizing,29-44
(e.g.,,45-51
tubocurarine):,52-66	DrugDDI.d558.s13.e1
Possible,67-75
increased,76-85
responsiveness,86-100
to,101-103
the,104-107
muscle,108-114	DrugDDI.d558.s13.e2
relaxant,115-123	DrugDDI.d558.s13.e2

-,0-1
Lithium:,2-10	DrugDDI.d558.s15.e0
Generally,11-20
should,21-27
not,28-31
be,32-34
given,35-40
with,41-45
diuretics.,46-56	DrugDDI.d558.s15.e1

Diuretic,0-8	DrugDDI.d558.s16.e0
agents,9-15
reduce,16-22
the,23-26
renal,27-32
clearance,33-42
of,43-45
lithium,46-53	DrugDDI.d558.s16.e1
and,54-57
add,58-61
a,62-63
high,64-68
risk,69-73
of,74-76
lithium,77-84
toxicity.,85-94

Refer,0-5
to,6-8
the,9-12
package,13-20
insert,21-27
for,28-31
lithium,32-39	DrugDDI.d558.s17.e0
preparations,40-52	DrugDDI.d558.s17.e0
before,53-59
use,60-63
of,64-66
such,67-71
preparations,72-84
with,85-89
chlorothiazide,90-104	DrugDDI.d558.s17.e1

-,0-1
Non-steroidal,2-15	DrugDDI.d558.s19.e0
Anti-inflammatory,16-33	DrugDDI.d558.s19.e0
Drugs:,34-40	DrugDDI.d558.s19.e0
In,41-43
some,44-48
patients,,49-58
the,59-62
administration,63-77
of,78-80
a,81-82
non-steroidal,83-96	DrugDDI.d558.s19.e1
anti-inflammatory,97-114	DrugDDI.d558.s19.e1
agent,115-120	DrugDDI.d558.s19.e1
can,121-124
reduce,125-131
the,132-135
diuretic,,136-145
natriuretic,,146-158
and,159-162
antihypertensive,163-179	DrugDDI.d558.s19.e3
effects,180-187
of,188-190
loop,,191-196
potassium-sparing,197-214	DrugDDI.d558.s19.e4
and,215-218
thiazide,219-227	DrugDDI.d558.s19.e5
diuretics.,228-238	DrugDDI.d558.s19.e5

Therefore,,0-10
when,11-15
chlorothiazide,16-30	DrugDDI.d558.s20.e0
and,31-34
non-steroidal,35-48	DrugDDI.d558.s20.e1
anti-inflammatory,49-66	DrugDDI.d558.s20.e1
agents,67-73	DrugDDI.d558.s20.e1
are,74-77
used,78-82
concomitantly,,83-97
the,98-101
patient,102-109
should,110-116
be,117-119
observed,120-128
closely,129-136
to,137-139
determine,140-149
if,150-152
the,153-156
desired,157-164
effect,165-171
of,172-174
the,175-178
diuretic,179-187	DrugDDI.d558.s20.e2
is,188-190
obtained,191-199

-,0-1
Drug/Laboratory,2-17	DrugDDI.d558.s22.e0
Test,18-22
Interactions:,23-36
Thiazides,37-46	DrugDDI.d558.s22.e1
should,47-53
be,54-56
discontinued,57-69
before,70-76
carrying,77-85
out,86-89
tests,90-95
for,96-99
parathyroid,100-111	DrugDDI.d558.s22.e2
function.,112-121

Chlorotrianisene,0-16	DrugDDI.d382.s0.e0
may,17-20
interact,21-29
with,30-34
antidepressants,,35-51
aspirin,,52-60
barbiturates,,61-74
bromocriptine,,75-89
calcium,90-97	DrugDDI.d382.s0.e5
supplements,,98-110
corticosteroids,,111-127
corticotropin,,128-142
cyclosporine,,143-156
dantrolene,,157-168
nicotine,,169-178
somatropin,,179-190
tamoxifen,,191-201
and,202-205
warfarin.,206-215	DrugDDI.d382.s0.e13

Substrate,0-9
of,10-12
CYP2D6,13-19	DrugDDI.d67.s0.e0
(minor),,20-28
3A4,29-32
(major);,33-41

Inhibits,0-8
CYP2D6,9-15	DrugDDI.d67.s1.e0
(weak).,16-23

Increased,0-9
toxicity,10-18
(CNS,19-23
depression):,24-36
CNS,37-40	DrugDDI.d67.s2.e0
depressants,,41-53	DrugDDI.d67.s2.e0
MAO,54-57	DrugDDI.d67.s2.e1
inhibitors,,58-69	DrugDDI.d67.s2.e1
tricyclic,70-79	DrugDDI.d67.s2.e2
antidepressants,,80-96	DrugDDI.d67.s2.e2
phenothiazines.,97-112	DrugDDI.d67.s2.e3

CYP3A4,0-6	DrugDDI.d67.s3.e0
inhibitors:,7-18
May,19-22
increase,23-31
the,32-35
levels/effects,36-50
of,51-53
chlorpheniramine.,54-71	DrugDDI.d67.s3.e1

Example,0-7
inhibitors,8-18
include,19-26
azole,27-32	DrugDDI.d67.s4.e0
antifungals,,33-45	DrugDDI.d67.s4.e0
ciprofloxacin,,46-60
clarithromycin,,61-76
diclofenac,,77-88
doxycycline,,89-101
erythromycin,,102-115
imatinib,,116-125
isoniazid,,126-136
nefazodone,,137-148
nicardipine,,149-161
propofol,,162-171
protease,172-180	DrugDDI.d67.s4.e11
inhibitors,,181-192	DrugDDI.d67.s4.e11
quinidine,,193-203
and,204-207
verapamil.,208-218	DrugDDI.d67.s4.e13

The,0-3
concurrent,4-14
use,15-18
of,19-21
two,22-25
or,26-28
more,29-33
drugs,34-39	DrugDDI.d316.s0.e0
with,40-44
anticholinergic,45-60	DrugDDI.d316.s0.e1
activity--such,61-75
as,76-78
an,79-81
antipsychotic,82-95	DrugDDI.d316.s0.e2
drug,96-100	DrugDDI.d316.s0.e2
(eg,,101-105
chlorpromazine),,106-122
an,123-125
antiparkinsonian,126-142	DrugDDI.d316.s0.e4
drug,143-147	DrugDDI.d316.s0.e4
(eg,,148-152
trihexyphenidyl),,153-170
and/or,171-177
a,178-179
tricyclic,180-189	DrugDDI.d316.s0.e6
antidepressant,190-204	DrugDDI.d316.s0.e6
(eg,,205-209
amitriptyline)--commonly,210-234	DrugDDI.d316.s0.e7
results,235-242
in,243-245
excessive,246-255
anticholinergic,256-271	DrugDDI.d316.s0.e8
effects,,272-280
including,281-290
dry,291-294
mouth,295-300
and,301-304
associated,305-315
dental,316-322
complications,,323-337
blurred,338-345
vision,,346-353
and,,354-358
in,359-361
patients,362-370
exposed,371-378
to,379-381
high,382-386
temperature,387-398
and,399-402
humidity,,403-412
hyperpyrexia.,413-426

Interactions,0-12
may,13-16
also,17-21
occur,22-27
with,28-32
the,33-36
following:,37-47
anti-depressants/anti-anxiety,48-77	DrugDDI.d316.s1.e0
drugs,,78-84
drugs,85-90	DrugDDI.d316.s1.e2
used,91-95
to,96-98
treat,99-104
an,105-107
overactive,108-118
thyroid,,119-127
beta-blockers,128-141	DrugDDI.d316.s1.e3
(e.g.,,142-148
propranolol),,149-162
sparfloxacin,,163-176
grepafloxacin,,177-191
guanethidine,,192-205
guanadrel,,206-216
metrizamide,,217-229
cabergoline,,230-242
lithium,,243-251
narcotic,252-260	DrugDDI.d316.s1.e12
pain,261-265
medication,266-276
(e.g.,,277-283
codeine),,284-293
drugs,294-299	DrugDDI.d316.s1.e14
used,300-304
to,305-307
aid,308-311
sleep,,312-318
drowsiness-causing,319-337
antihistamines,338-352	DrugDDI.d316.s1.e15
(e.g.,,353-359
diphenhydramine),,360-377
any,378-381
other,382-387
drugs,388-393	DrugDDI.d316.s1.e17
that,394-398
may,399-402
make,403-407
you,408-411
drowsy.,412-419

The,0-3
hypoglycemic,4-16	DrugDDI.d221.s0.e0
action,17-23	DrugDDI.d221.s0.e0
of,24-26
sulfonylurea,27-39	DrugDDI.d221.s0.e1
may,40-43
be,44-46
potentiated,47-58
by,59-61
certain,62-69
drugs,70-75	DrugDDI.d221.s0.e2
including,76-85
nonsteroidal,86-98	DrugDDI.d221.s0.e3
anti-inflammatory,99-116	DrugDDI.d221.s0.e3
agents,117-123	DrugDDI.d221.s0.e3
and,124-127
other,128-133
drugs,134-139	DrugDDI.d221.s0.e4
that,140-144
are,145-148
highly,149-155
protein,156-163	DrugDDI.d221.s0.e5
bound,,164-170
salicylates,,171-183
sulfonamides,,184-197
chloramphenicol,,198-214
probenecid,,215-226
coumarins,,227-237
monoamine,238-247	DrugDDI.d221.s0.e11
oxidase,248-255	DrugDDI.d221.s0.e11
inhibitors,,256-267	DrugDDI.d221.s0.e11
and,268-271
beta,272-276	DrugDDI.d221.s0.e12
adrenergic,277-287	DrugDDI.d221.s0.e12
blocking,288-296	DrugDDI.d221.s0.e12
agents.,297-304	DrugDDI.d221.s0.e12

When,0-4
such,5-9
drugs,10-15	DrugDDI.d221.s1.e0
are,16-19
administered,20-32
to,33-35
a,36-37
patient,38-45
receiving,46-55
DIABINESE,,56-66
the,67-70
patient,71-78
should,79-85
be,86-88
observed,89-97
closely,98-105
for,106-109
hypoglycemia.,110-123

When,0-4
such,5-9
drugs,10-15	DrugDDI.d221.s2.e0
are,16-19
withdrawn,20-29
from,30-34
a,35-36
patient,37-44
receiving,45-54
DIABINESE,,55-65
the,66-69
patient,70-77
should,78-84
be,85-87
observed,88-96
closely,97-104
for,105-108
loss,109-113
of,114-116
control.,117-125

Certain,0-7
drugs,8-13	DrugDDI.d221.s3.e0
tend,14-18
to,19-21
produce,22-29
hyperglycemia,30-43
and,44-47
may,48-51
lead,52-56
to,57-59
loss,60-64
of,65-67
control.,68-76

These,0-5
drugs,6-11	DrugDDI.d221.s4.e0
include,12-19
the,20-23
thiazides,24-33	DrugDDI.d221.s4.e1
and,34-37
other,38-43
diuretics,,44-54
corticosteroids,,55-71
phenothiazines,,72-87
thyroid,88-95	DrugDDI.d221.s4.e5
products,,96-105
estrogens,,106-116
oral,117-121	DrugDDI.d221.s4.e7
contraceptives,,122-137	DrugDDI.d221.s4.e7
phenytoin,,138-148
nicotinic,149-158	DrugDDI.d221.s4.e9
acid,,159-164	DrugDDI.d221.s4.e9
sympathomimetics,,165-182
calcium,183-190	DrugDDI.d221.s4.e11
channel,191-198	DrugDDI.d221.s4.e11
blocking,199-207	DrugDDI.d221.s4.e11
drugs,,208-214	DrugDDI.d221.s4.e11
and,215-218
isoniazid.,219-229	DrugDDI.d221.s4.e12

When,0-4
such,5-9
drugs,10-15	DrugDDI.d221.s5.e0
are,16-19
administered,20-32
to,33-35
a,36-37
patient,38-45
receiving,46-55
DIABINESE,,56-66
the,67-70
patient,71-78
should,79-85
be,86-88
closely,89-96
observed,97-105
for,106-109
loss,110-114
of,115-117
control.,118-126

When,0-4
such,5-9
drugs,10-15	DrugDDI.d221.s6.e0
are,16-19
withdrawn,20-29
from,30-34
a,35-36
patient,37-44
receiving,45-54
DIABINESE,,55-65
the,66-69
patient,70-77
should,78-84
be,85-87
observed,88-96
closely,97-104
for,105-108
hypoglycemia.,109-122

Since,0-5
animal,6-12
studies,13-20
suggest,21-28
that,29-33
the,34-37
action,38-44
of,45-47
barbiturates,48-60	DrugDDI.d221.s7.e0
may,61-64
be,65-67
prolonged,68-77
by,78-80
therapy,81-88
with,89-93
chlorpropamide,,94-109
barbiturates,110-122	DrugDDI.d221.s7.e2
should,123-129
be,130-132
employed,133-141
with,142-146
caution.,147-155

In,0-2
some,3-7
patients,,8-17
a,18-19
disulfiram-like,20-35	DrugDDI.d221.s8.e0
reaction,36-44
may,45-48
be,49-51
produced,52-60
by,61-63
the,64-67
ingestion,68-77
of,78-80
alcohol.,81-89	DrugDDI.d221.s8.e1

A,0-1
potential,2-11
interaction,12-23
between,24-31
oral,32-36	DrugDDI.d221.s9.e0
miconazole,37-47	DrugDDI.d221.s9.e0
and,48-51
oral,52-56
hypoglycemic,57-69	DrugDDI.d221.s9.e1
agents,70-76	DrugDDI.d221.s9.e1
leading,77-84
to,85-87
severe,88-94
hypoglycemia,95-107
has,108-111
been,112-116
reported.,117-126

Whether,0-7
this,8-12
interaction,13-24
also,25-29
occurs,30-36
with,37-41
the,42-45
intravenous,,46-58
topical,,59-67
or,68-70
vaginal,71-78
preparations,79-91
of,92-94
miconazole,95-105	DrugDDI.d221.s10.e0
is,106-108
not,109-112
known.,113-119

Chlorprothixene,0-15	DrugDDI.d157.s0.e0
may,16-19
increase,20-28
the,29-32
plasma-level,33-45
of,46-48
concomitantly,49-62
given,63-68
lithium.,69-77	DrugDDI.d157.s0.e1

If,0-2
chlorprothixene,3-18	DrugDDI.d157.s2.e0
is,19-21
given,22-27
concomitantly,28-41
with,42-46
opioids,,47-55
the,56-59
opioid,60-66	DrugDDI.d157.s2.e2
dose,67-71
should,72-78
be,79-81
reduced,82-89
(by,90-93
approx.,94-101
50%),,102-107
because,108-115
chlorprothixene,116-131	DrugDDI.d157.s2.e3
amplifies,132-141
the,142-145
therapeutic,146-157
actions,158-165
and,166-169
side-effects,170-182
of,183-185
opioids,186-193	DrugDDI.d157.s2.e4
massively.,194-204

Avoid,0-5
the,6-9
concomitant,10-21
use,22-25
of,26-28
chlorprothixene,29-44	DrugDDI.d157.s3.e0
and,45-48
tramadol,49-57	DrugDDI.d157.s3.e1
(Ultram).,58-67

Consider,0-8
additive,9-17
sedative,18-26	DrugDDI.d157.s5.e0
effects,27-34
and,35-38
confusional,39-50
states,51-57
to,58-60
emerge,,61-68
if,69-71
chlorprothixene,72-87	DrugDDI.d157.s5.e1
is,88-90
given,91-96
with,97-101
benzodiazepines,102-117	DrugDDI.d157.s5.e2
or,118-120
barbituates.,121-133

Choose,0-6
particular,7-17
low,18-21
doses,22-27
of,28-30
these,31-36
drugs.,37-43	DrugDDI.d157.s6.e0

Exert,0-5
particular,6-16
caution,17-24
in,25-27
combining,28-37
chlorprothixene,38-53	DrugDDI.d157.s7.e0
with,54-58
other,59-64
anticholinergic,65-80	DrugDDI.d157.s7.e1
drugs,81-86	DrugDDI.d157.s7.e1
(tricyclic,87-97
antidepressants,98-113
and,114-117
antiparkinsonian,118-134	DrugDDI.d157.s7.e3
agents):,135-143	DrugDDI.d157.s7.e3
Particularly,144-156
the,157-160
elderly,161-168
may,169-172
develop,173-180
delirium,,181-190
high,191-195
fever,,196-202
severe,203-209
obstipation,,210-222
even,223-227
ileus,228-233
and,234-237
glaucoma.,238-247

Chlorthalidone,0-14	DrugDDI.d71.s0.e0
may,15-18
add,19-22
to,23-25
or,26-28
potentiate,29-39
the,40-43
action,44-50
of,51-53
other,54-59
antihypertensive,60-76	DrugDDI.d71.s0.e1
drugs.,77-83	DrugDDI.d71.s0.e1

Potentiation,0-12
occurs,13-19
with,20-24
ganglionic,25-35
peripheral,36-46	DrugDDI.d71.s1.e0
adrenergic,47-57	DrugDDI.d71.s1.e0
blocking,58-66	DrugDDI.d71.s1.e0
drugs.,67-73	DrugDDI.d71.s1.e0

Medication,0-10	DrugDDI.d71.s2.e0
such,11-15
as,16-18
digitalis,19-28	DrugDDI.d71.s2.e1
may,29-32
also,33-37
influence,38-47
serum,48-53
electrolytes.,54-67

Insulin,0-7	DrugDDI.d71.s4.e0
requirements,8-20
in,21-23
diabetic,24-32
patients,33-41
may,42-45
be,46-48
increased,,49-59
decreased,,60-70
or,71-73
unchanged.,74-84

Higher,0-6
dosage,7-13
of,14-16
oral,17-21
hypoglycemic,22-34	DrugDDI.d71.s5.e0
agents,35-41	DrugDDI.d71.s5.e0
may,42-45
be,46-48
required.,49-58

Latent,0-6
diabetes,7-15
mellitus,16-24
may,25-28
become,29-35
manifest,36-44
during,45-51
chlorthalidone,52-66	DrugDDI.d71.s6.e0
administration.,67-82

Chlorthalidone,0-14	DrugDDI.d71.s7.e0
and,15-18
related,19-26
drugs,27-32	DrugDDI.d71.s7.e1
may,33-36
increase,37-45
the,46-49
responsiveness,50-64
to,65-67
tubocurarine.,68-81	DrugDDI.d71.s7.e2

Chlorthalidone,0-14	DrugDDI.d71.s8.e0
and,15-18
related,19-26
drugs,27-32	DrugDDI.d71.s8.e1
may,33-36
decrease,37-45
arterial,46-54
responsiveness,55-69
to,70-72
norepinephrine.,73-88	DrugDDI.d71.s8.e2

This,0-4
diminution,5-15
is,16-18
not,19-22
sufficient,23-33
to,34-36
preclude,37-45
effectiveness,46-59
of,60-62
the,63-66
pressor,67-74	DrugDDI.d71.s9.e0
agent,75-80	DrugDDI.d71.s9.e0
for,81-84
therapeutic,85-96
use.,97-101

The,0-3
concomitant,4-15
use,16-19
of,20-22
alcohol,23-30	DrugDDI.d170.s0.e0
or,31-33
other,34-39
central,40-47	DrugDDI.d170.s0.e1
nervous,48-55	DrugDDI.d170.s0.e1
system,56-62	DrugDDI.d170.s0.e1
depressants,63-74	DrugDDI.d170.s0.e1
may,75-78
have,79-83
an,84-86
additive,87-95
effect.,96-103

Interactions,0-12
for,13-16
vitamin,17-24
D,25-26
analogues,27-36
(Vitamin,37-45
D2,,46-49
Vitamin,50-57	DrugDDI.d482.s0.e1
D3,,58-61	DrugDDI.d482.s0.e1
Calcitriol,,62-73
and,74-77
Calcidiol):,78-89	DrugDDI.d482.s0.e3
Cholestyramine:,90-105	DrugDDI.d482.s0.e4
Cholestyramine,106-120	DrugDDI.d482.s0.e5
has,121-124
been,125-129
reported,130-138
to,139-141
reduce,142-148
intestinal,149-159
absorption,160-170
of,171-173
fat,174-177
soluble,178-185
vitamins;,186-195

as,0-2
such,3-7
it,8-10
may,11-14
impair,15-21
intestinal,22-32
absorption,33-43
of,44-46
any,47-50
of,51-53
vitamin,54-61	DrugDDI.d482.s1.e0
D.,62-64	DrugDDI.d482.s1.e0

Phenytoin/Phenobarbital:,0-24	DrugDDI.d482.s2.e0
The,25-28
coadministration,29-45
of,46-48
phenytoin,49-58	DrugDDI.d482.s2.e2
or,59-61
phenobarbital,62-75	DrugDDI.d482.s2.e3
will,76-80
not,81-84
affect,85-91
plasma,92-98
concentrations,99-113
of,114-116
vitamin,117-124	DrugDDI.d482.s2.e4
D,,125-127	DrugDDI.d482.s2.e4
but,128-131
may,132-135
reduce,136-142
endogenous,143-153
plasma,154-160
levels,161-167
of,168-170
calcitriol/ergocalcitriol,171-196	DrugDDI.d482.s2.e5
by,197-199
accelerating,200-212
metabolism.,213-224

Since,0-5
blood,6-11
level,12-17
of,18-20
calcitriol/ergocalcitriol,21-46	DrugDDI.d482.s3.e0
will,47-51
be,52-54
reduced,,55-63
higher,64-70
doses,71-76
of,77-79
Rocaltrol,80-89	DrugDDI.d482.s3.e1
may,90-93
be,94-96
necessary,97-106
if,107-109
these,110-115
drugs,116-121	DrugDDI.d482.s3.e2
are,122-125
administered,126-138
simultaneously.,139-154

Thiazides:,0-10	DrugDDI.d482.s4.e0
Thiazides,11-20	DrugDDI.d482.s4.e1
are,21-24
known,25-30
to,31-33
induce,34-40
hypercalcemia,41-54
by,55-57
the,58-61
reduction,62-71
of,72-74
calcium,75-82	DrugDDI.d482.s4.e2
excretion,83-92
in,93-95
urine.,96-102

Some,0-4
reports,5-12
have,13-17
shown,18-23
that,24-28
the,29-32
concomitant,33-44
administration,45-59
of,60-62
thiazides,63-72	DrugDDI.d482.s5.e0
with,73-77
vitamin,78-85	DrugDDI.d482.s5.e1
D,86-87	DrugDDI.d482.s5.e1
causes,88-94
hypercalcemia.,95-109

Digitalis:,0-10	DrugDDI.d482.s7.e0
Vitamin,11-18	DrugDDI.d482.s7.e1
D,19-20	DrugDDI.d482.s7.e1
dosage,21-27
must,28-32
be,33-35
determined,36-46
with,47-51
care,52-56
in,57-59
patients,60-68
undergoing,69-79
treatment,80-89
with,90-94
digitalis,,95-105
as,106-108
hypercalcemia,109-122
in,123-125
such,126-130
patients,131-139
may,140-143
precipitate,144-155
cardiac,156-163
arrhythmias.,164-176

Ketoconazole:,0-13	DrugDDI.d482.s8.e0
Ketoconazole,14-26	DrugDDI.d482.s8.e1
may,27-30
inhibit,31-38
both,39-43
synthetic,44-53
and,54-57
catabolic,58-67
enzymes,68-75
of,76-78
vitamin,79-86	DrugDDI.d482.s8.e2
D.,87-89	DrugDDI.d482.s8.e2

Reductions,0-10
in,11-13
serum,14-19
endogenous,20-30
vitamin,31-38
D,39-40
concentrations,41-55
have,56-60
been,61-65
observed,66-74
following,75-84
the,85-88
administration,89-103
of,104-106
300,107-110
mg/day,111-117
to,118-120
1200,121-125
mg/day,126-132
ketoconazole,133-145	DrugDDI.d482.s9.e0
for,146-149
a,150-151
week,152-156
to,157-159
healthy,160-167
men.,168-172

However,,0-8
in,9-11
vivo,12-16
drug,17-21
interaction,22-33
studies,34-41
of,42-44
ketoconazole,45-57	DrugDDI.d482.s10.e0
with,58-62
vitamin,63-70	DrugDDI.d482.s10.e1
D,71-72	DrugDDI.d482.s10.e1
have,73-77
not,78-81
been,82-86
investigated.,87-100

Corticosteroids:,0-16	DrugDDI.d482.s11.e0
A,17-18
relationship,19-31
of,32-34
functional,35-45
antagonism,46-56
exists,57-63
between,64-71
vitamin,72-79
D,80-81
analogues,,82-92
which,93-98
promote,99-106
calcium,107-114	DrugDDI.d482.s11.e1
absorption,,115-126
and,127-130
corticosteroids,,131-147
which,148-153
inhibit,154-161
calcium,162-169	DrugDDI.d482.s11.e3
absorption.,170-181

Phosphate-Binding,0-17	DrugDDI.d482.s12.e0
Agents:,18-25	DrugDDI.d482.s12.e0
Since,26-31
vitamin,32-39	DrugDDI.d482.s12.e1
D,40-41	DrugDDI.d482.s12.e1
also,42-46
has,47-50
an,51-53
effect,54-60
on,61-63
phosphate,64-73
transport,74-83
in,84-86
the,87-90
intestine,,91-101
kidneys,102-109
and,110-113
bones,,114-120
the,121-124
dosage,125-131
of,132-134
phosphate-binding,135-152	DrugDDI.d482.s12.e2
agents,153-159	DrugDDI.d482.s12.e2
must,160-164
be,165-167
adjusted,168-176
in,177-179
accordance,180-190
with,191-195
the,196-199
serum,200-205
phosphate,206-215
concentration.,216-230

Vitamin,0-7	DrugDDI.d482.s13.e0
D:,8-10	DrugDDI.d482.s13.e0
The,11-14
coadministration,15-31
of,32-34
any,35-38
of,39-41
the,42-45
vitamin,46-53
D,54-55
analogues,56-65
should,66-72
be,73-75
avoided,76-83
as,84-86
this,87-91
could,92-97
create,98-104
possible,105-113
additive,114-122
effects,123-130
and,131-134
hypercalcemia.,135-149

Calcium,0-7	DrugDDI.d482.s14.e0
Supplements:,8-20
Uncontrolled,21-33
intake,34-40
of,41-43
additional,44-54
calcium-containing,55-73	DrugDDI.d482.s14.e1
preparations,74-86	DrugDDI.d482.s14.e1
should,87-93
be,94-96
avoided.,97-105

Magnesium:,0-10	DrugDDI.d482.s15.e0
Magnesium-containing,11-31	DrugDDI.d482.s15.e1
preparations,32-44	DrugDDI.d482.s15.e1
(eg,,45-49
antacids),50-59	DrugDDI.d482.s15.e2
may,60-63
cause,64-69
hypermagnesemia,70-85
and,86-89
should,90-96
therefore,97-106
not,107-110
be,111-113
taken,114-119
during,120-126
therapy,127-134
with,135-139
vitamin,140-147	DrugDDI.d482.s15.e3
D,148-149	DrugDDI.d482.s15.e3
by,150-152
patients,153-161
on,162-164
chronic,165-172
renal,173-178
dialysis.,179-188

Cholestyramine,0-14	DrugDDI.d155.s0.e0
resin,15-20	DrugDDI.d155.s0.e1
may,21-24
delay,25-30
or,31-33
reduce,34-40
the,41-44
absorption,45-55
of,56-58
concomitant,59-70
oral,71-75
medication,76-86
such,87-91
as,92-94
phenylbutazone,,95-110
warfarin,,111-120
thiazide,121-129	DrugDDI.d155.s0.e4
diuretics,130-139	DrugDDI.d155.s0.e4
(acidic),140-148
or,149-151
propranolol,152-163	DrugDDI.d155.s0.e5
(basic),,164-172
as,173-175
well,176-180
as,181-183
tetracycline,184-196	DrugDDI.d155.s0.e6
penicillin,197-207
G,,208-210
phenobarbital,,211-225
thyroid,226-233	DrugDDI.d155.s0.e8
and,234-237
thyroxine,238-247	DrugDDI.d155.s0.e9
preparations,,248-261	DrugDDI.d155.s0.e9
estrogens,262-271	DrugDDI.d155.s0.e10
and,272-275
progestins,,276-287
and,288-291
digitalis.,292-302	DrugDDI.d155.s0.e12

Interference,0-12
with,13-17
the,18-21
absorption,22-32
of,33-35
oral,36-40	DrugDDI.d155.s1.e0
phosphate,41-50	DrugDDI.d155.s1.e0
supplements,51-62	DrugDDI.d155.s1.e0
has,63-66
been,67-71
observed,72-80
with,81-85
another,86-93
positively-charged,94-112	DrugDDI.d155.s1.e1
bile,113-117	DrugDDI.d155.s1.e1
acid,118-122	DrugDDI.d155.s1.e1
sequestrant.,123-135	DrugDDI.d155.s1.e1

Cholestyramine,0-14	DrugDDI.d155.s2.e0
resin,15-20
may,21-24
interfere,25-34
with,35-39
the,40-43
pharmacokinetics,44-60
of,61-63
drugs,64-69	DrugDDI.d155.s2.e1
that,70-74
undergo,75-82
enterohepatic,83-96
circulation,,97-109
The,110-113
discontinuance,114-128
of,129-131
cholestyramine,132-146	DrugDDI.d155.s2.e2
resin,147-152
could,153-158
pose,159-163
a,164-165
hazard,166-172
to,173-175
health,176-182
if,183-185
a,186-187
potentially,188-199
toxic,200-205
drug,206-210	DrugDDI.d155.s2.e3
such,211-215
as,216-218
digitalis,219-228	DrugDDI.d155.s2.e4
has,229-232
been,233-237
filtrated,238-247
to,248-250
a,251-252
maintenance,253-264
level,265-270
while,271-276
the,277-280
patient,281-288
was,289-292
taking,293-299
cholestyramine,300-314	DrugDDI.d155.s2.e5
resin.,315-321	DrugDDI.d155.s2.e6

Because,0-7
cholestyramine,8-22	DrugDDI.d155.s3.e0
binds,23-28
bile,29-33	DrugDDI.d155.s3.e1
acids,,34-40	DrugDDI.d155.s3.e1
cholestyramine,41-55	DrugDDI.d155.s3.e2
resin,56-61
may,62-65
interfere,66-75
with,76-80
normal,81-87
fat,88-91
digestion,92-101
and,102-105
absorption,106-116
and,117-120
thus,121-125
may,126-129
prevent,130-137	DrugDDI.d155.s3.e3
absorption,138-148
of,149-151
fat,152-155
soluble,156-163
vitamins,164-172
such,173-177
as,178-180
A,,181-183
D,,184-186
E,,187-189
and,190-193
K.,194-196

When,0-4
cholestyramine,5-19	DrugDDI.d155.s4.e0
resin,20-25	DrugDDI.d155.s4.e1
is,26-28
given,29-34
for,35-38
long,39-43
periods,44-51
of,52-54
time,,55-60
concomitant,61-72
supplementation,73-88
with,89-93
water-miscible,94-108	DrugDDI.d155.s4.e2
(or,109-112
parenteral),113-124
forms,125-130
of,131-133
fat-soluble,134-145
vitamins,146-154
should,155-161
be,162-164
considered.,165-176

SINCE,0-5
CHOLESTYRAMINE,6-20	DrugDDI.d155.s5.e0
RESIN,21-26	DrugDDI.d155.s5.e0
MAY,27-30
BIND,31-35
OTHER,36-41
DRUGS,42-47	DrugDDI.d155.s5.e1
GIVEN,48-53
CONCURRENTLY,,54-67
IT,68-70
IS,71-73
RECOMMENDED,74-85
THAT,86-90
PATIENTS,91-99
TAKE,100-104
OTHER,105-110
DRUGS,111-116	DrugDDI.d155.s5.e2
AT,117-119
LEAST,120-125
1,126-127
HOUR,128-132
BEFORE,133-139
OR,140-142
4,143-144
TO,145-147
6,148-149
HOURS,150-155
AFTER,156-161
CHOLESTYRAMINE,162-176	DrugDDI.d155.s5.e3
RESIN,177-182	DrugDDI.d155.s5.e3
(OR,183-186
AT,187-189
AS,190-192
GREAT,193-198
AN,199-201
INTERVAL,202-210
AS,211-213
POSSIBLE),214-223
TO,224-226
AVOID,227-232
IMPEDING,233-241
THEIR,242-247
ABSORPTION.,248-259

Based,0-5
on,6-8
in,9-11
vitro,12-17
studies,18-25
in,26-28
human,29-34
liver,35-40
microsomes,,41-52
des-ciclesonide,53-68	DrugDDI.d227.s0.e0
appears,69-76
to,77-79
have,80-84
no,85-87
inhibitory,88-98
or,99-101
induction,102-111
potential,112-121
on,122-124
the,125-128
metabolism,129-139
of,140-142
other,143-148
drugs,149-154	DrugDDI.d227.s0.e1
metabolized,155-166
by,167-169
CYP,170-173	DrugDDI.d227.s0.e2
450,174-177
enzymes.,178-186

The,0-3
inhibitory,4-14
potential,15-24
of,25-27
ciclesonide,28-39	DrugDDI.d227.s1.e0
on,40-42
CYP450,43-49
isoenzymes,50-60	DrugDDI.d227.s1.e1
has,61-64
not,65-68
been,69-73
studied.,74-82

In,0-2
vitro,3-8
studies,9-16
demonstrated,17-29
that,30-34
the,35-38
plasma,39-45	DrugDDI.d227.s2.e0
protein,46-53	DrugDDI.d227.s2.e0
binding,54-61
of,62-64
des-ciclesonide,65-80	DrugDDI.d227.s2.e1
was,81-84
not,85-88
affected,89-97
by,98-100
warfarin,101-109	DrugDDI.d227.s2.e2
or,110-112
salicylic,113-122	DrugDDI.d227.s2.e3
acid,,123-128	DrugDDI.d227.s2.e3
indicating,129-139
no,140-142
potential,143-152
for,153-156
protein,157-164
binding-based,165-178
drug,179-183
interactions.,184-197

In,0-2
a,3-4
drug,5-9
interaction,10-21
study,,22-28
co-administration,29-46
of,47-49
orally,50-56
inhaled,57-64
ciclesonide,65-76	DrugDDI.d227.s3.e0
and,77-80
oral,81-85
erythromycin,,86-99
an,100-102
inhibitor,103-112
of,113-115
cytochrome,116-126	DrugDDI.d227.s3.e1
P450,127-131	DrugDDI.d227.s3.e1
3A4,,132-136	DrugDDI.d227.s3.e1
had,137-140
no,141-143
effect,144-150
on,151-153
the,154-157
pharmacokinetics,158-174
of,175-177
either,178-184
des-ciclesonide,185-200	DrugDDI.d227.s3.e2
or,201-203
erythromycin.,204-217	DrugDDI.d227.s3.e3

In,0-2
another,3-10
drug,11-15
interaction,16-27
study,,28-34
co-administration,35-52
of,53-55
orally,56-62
inhaled,63-70
ciclesonide,71-82	DrugDDI.d227.s4.e0
and,83-86
oral,87-91
ketoconazole,,92-105
a,106-107
potent,108-114
inhibitor,115-124
of,125-127
cytochrome,128-138	DrugDDI.d227.s4.e2
P450,139-143	DrugDDI.d227.s4.e2
3A4,,144-148	DrugDDI.d227.s4.e2
increased,149-158
the,159-162
exposure,163-171
(AUC),172-177
of,178-180
des-ciclesonide,181-196	DrugDDI.d227.s4.e3
by,197-199
approximately,200-213
3.6-fold,214-222
at,223-225
steady,226-232
state,,233-239
while,240-245
levels,246-252
of,253-255
ciclesonide,256-267	DrugDDI.d227.s4.e4
remained,268-276
unchanged.,277-287

Therefore,,0-10
ketoconazole,11-23	DrugDDI.d227.s5.e0
should,24-30
be,31-33
administered,34-46
with,47-51
caution,52-59
with,60-64
intranasal,65-75
ciclesonide.,76-88	DrugDDI.d227.s5.e1

Probenecid,0-10	DrugDDI.d266.s0.e0
:,11-12
Probenecid,13-23	DrugDDI.d266.s0.e1
is,24-26
known,27-32
to,33-35
interact,36-44
with,45-49
the,50-53
metabolism,54-64
or,65-67
renal,68-73
tubular,74-81
excretion,82-91
of,92-94
many,95-99
drugs,100-105	DrugDDI.d266.s0.e2
(e.g.,,106-112
acetaminophen,,113-127
acyclovir,,128-138
angiotensin-converting,139-161	DrugDDI.d266.s0.e5
enzyme,162-168	DrugDDI.d266.s0.e5
inhibitors,,169-180	DrugDDI.d266.s0.e5
aminosalicylic,181-195	DrugDDI.d266.s0.e6
acid,,196-201	DrugDDI.d266.s0.e6
barbiturates,,202-215
benzodiazepines,,216-232
bumetanide,,233-244
clofibrate,,245-256
methotrexate,,257-270
famotidine,,271-282
furosemide,,283-294
nonsteroidal,295-307	DrugDDI.d266.s0.e14
anti-inflammatory,308-325	DrugDDI.d266.s0.e14
agents,,326-333	DrugDDI.d266.s0.e14
theophylline,,334-347
and,348-351
zidovudine).,352-364	DrugDDI.d266.s0.e16

Concomitant,0-11
medications,12-23	DrugDDI.d266.s1.e0
should,24-30
be,31-33
carefully,34-43
assessed.,44-53

Zidovudine,0-10	DrugDDI.d266.s2.e0
should,11-17
either,18-24
be,25-27
temporarily,28-39
discontinued,40-52
or,53-55
decreased,56-65
by,66-68
50%,69-72
when,73-77
coadministered,78-92
with,93-97
probenecid,98-108	DrugDDI.d266.s2.e1
on,109-111
the,112-115
day,116-119
of,120-122
VISTIDE,123-130	DrugDDI.d266.s2.e2
infusion.,131-140

Nephrotoxic,0-11
agents,12-18
:,19-20
Concomitant,21-32
administration,33-47
of,48-50
VISTIDE,51-58	DrugDDI.d266.s3.e0
and,59-62
agents,63-69
with,70-74
nephrotoxic,75-86
potential,87-96
[e.g.,,97-103
intravenous,104-115
aminoglycosides,116-131	DrugDDI.d266.s3.e1
(e.g.,,132-138
tobramycin,,139-150
gentamicin,,151-162
and,163-166
amikacin),,167-177
amphotericin,178-190	DrugDDI.d266.s3.e5
B,,191-193	DrugDDI.d266.s3.e5
foscarnet,,194-204
intravenous,205-216
pentamidine,,217-229
vancomycin,,230-241
and,242-245
non-steroidal,246-259	DrugDDI.d266.s3.e9
anti-inflammatory,260-277	DrugDDI.d266.s3.e9
agents],278-285	DrugDDI.d266.s3.e9
is,286-288
contraindicated.,289-305

Such,0-4
agents,5-11
must,12-16
be,17-19
discontinued,20-32
at,33-35
least,36-41
seven,42-47
days,48-52
prior,53-58
to,59-61
starting,62-70
therapy,71-78
with,79-83
VISTIDE.,84-92	DrugDDI.d266.s4.e0

Since,0-5
PLETAL,6-12	DrugDDI.d452.s0.e0
is,13-15
extensively,16-27
metabolized,28-39
by,40-42
cytochrome,43-53	DrugDDI.d452.s0.e1
P-450,54-59	DrugDDI.d452.s0.e1
isoenzymes,,60-71
caution,72-79
should,80-86
be,87-89
exercised,90-99
when,100-104
PLETAL,105-111	DrugDDI.d452.s0.e2
is,112-114
coadministered,115-129
with,130-134
inhibitors,135-145
of,146-148
C.P.A.,149-155
such,156-160
as,161-163
ketoconazole,164-176	DrugDDI.d452.s0.e3
and,177-180
erythromycin,181-193	DrugDDI.d452.s0.e4
or,194-196
inhibitors,197-207
of,208-210
CYP2C19,211-218	DrugDDI.d452.s0.e5
such,219-223
as,224-226
omeprazole.,227-238	DrugDDI.d452.s0.e6

Pharmacokinetic,0-15
studies,16-23
have,24-28
demonstrated,29-41
that,42-46
omeprazole,47-57	DrugDDI.d452.s1.e0
and,58-61
erythromycin,62-74	DrugDDI.d452.s1.e1
significantly,75-88
increased,89-98
the,99-102
systemic,103-111
exposure,112-120
of,121-123
cilostazol,124-134	DrugDDI.d452.s1.e2
and/or,135-141
its,142-145
major,146-151
metabolites.,152-164	DrugDDI.d452.s1.e3

Population,0-10
pharmacokinetic,11-26
studies,27-34
showed,35-41
higher,42-48
concentrations,49-63
of,64-66
cilostazol,67-77	DrugDDI.d452.s2.e0
among,78-83
patients,84-92
concurrently,93-105
treated,106-113
with,114-118
diltiazem,,119-129
an,130-132
inhibitor,133-142
of,143-145
C.P.A..,146-153

Pletal,0-6	DrugDDI.d452.s3.e0
does,7-11
not,,12-16
however,,17-25
appear,26-32
to,33-35
cause,36-41
increased,42-51
blood,52-57
levels,58-64
of,65-67
drugs,68-73	DrugDDI.d452.s3.e1
metabolized,74-85
by,86-88
CYP3A4,,89-96
as,97-99
it,100-102
had,103-106
no,107-109
effect,110-116
on,117-119
lovastatin,,120-131
a,132-133
drug,134-138	DrugDDI.d452.s3.e4
with,139-143
metabolism,144-154
very,155-159
sensitive,160-169
to,170-172
C.P.A.,173-179
inhibition.,180-191

Tagamet,,0-8
apparently,9-19
through,20-27
an,28-30
effect,31-37
on,38-40
certain,41-48
microsomal,49-59	DrugDDI.d293.s0.e1
enzyme,60-66	DrugDDI.d293.s0.e1
systems,,67-75
has,76-79
been,80-84
reported,85-93
to,94-96
reduce,97-103
the,104-107
hepatic,108-115
metabolism,116-126
of,127-129
warfarin-type,130-143
anticoagulants,,144-159
phenytoin,,160-170
propranolol,,171-183
nifedipine,,184-195
chlordiazepoxide,,196-213
diazepam,,214-223
certain,224-231
tricyclic,232-241	DrugDDI.d293.s0.e8
antidepressants,,242-258	DrugDDI.d293.s0.e8
lidocaine,,259-269
theophylline,270-282	DrugDDI.d293.s0.e10
and,283-286
metronidazole,,287-301
thereby,302-309
delaying,310-318
elimination,319-330
and,331-334
increasing,335-345
blood,346-351
levels,352-358
of,359-361
these,362-367
drugs.,368-374	DrugDDI.d293.s0.e12

Clinically,0-10
significant,11-22
effects,23-30
have,31-35
been,36-40
reported,41-49
with,50-54
the,55-58
warfarin,59-67
anticoagulants;,68-83	DrugDDI.d293.s1.e0

therefore,,0-10
close,11-16
monitoring,17-27
of,28-30
prothrombin,31-42
time,43-47
is,48-50
recommended,,51-63
and,64-67
adjustment,68-78
of,79-81
the,82-85
anticoagulant,86-99	DrugDDI.d293.s2.e0
dose,100-104
may,105-108
be,109-111
necessary,112-121
when,122-126
Tagamet,127-134	DrugDDI.d293.s2.e1
is,135-137
administered,138-150
concomitantly.,151-165

Interaction,0-11
with,12-16
phenytoin,,17-27
lidocaine,28-37	DrugDDI.d293.s3.e1
and,38-41
theophylline,42-54	DrugDDI.d293.s3.e2
has,55-58
also,59-63
been,64-68
reported,69-77
to,78-80
produce,81-88
adverse,89-96
clinical,97-105
effects.,106-114

However,,0-8
a,9-10
crossover,11-20
study,21-26
in,27-29
healthy,30-37
subjects,38-46
receiving,47-56
either,57-63
Tagamet,64-71	DrugDDI.d293.s4.e0
300,72-75	DrugDDI.d293.s4.e0
mg,76-78
q.i.d.,79-85
or,86-88
800,89-92
mg,93-95
h.s.,96-100
concomitantly,101-114
with,115-119
a,120-121
300,122-125
mg,126-128
b.i.d.,129-135
dosage,136-142
of,143-145
theophylline,146-158	DrugDDI.d293.s4.e1
(Theo-Dur?,,159-170
Key,171-174
Pharmaceuticals,,175-191
Inc.),192-197
demonstrated,198-210
less,211-215
alteration,216-226
in,227-229
steady-state,230-242
theophylline,243-255	DrugDDI.d293.s4.e2
peak,256-260
serum,261-266
levels,267-273
with,274-278
the,279-282
800,283-286
mg,287-289
h.s.,290-294
regimen,,295-303
particularly,304-316
in,317-319
subjects,320-328
aged,329-333
54,334-336
years,337-342
and,343-346
older.,347-353

(Note:,0-6
All,7-10
patients,11-19
receiving,20-29
theophylline,30-42	DrugDDI.d293.s6.e0
should,43-49
be,50-52
monitored,53-62
appropriately,,63-77
regardless,78-88
of,89-91
concomitant,92-103
drug,104-108
therapy.),109-118

Dosage,0-6
of,7-9
the,10-13
drugs,14-19	DrugDDI.d293.s7.e0
mentioned,20-29
above,30-35
and,36-39
other,40-45
similarly,46-55
metabolized,56-67
drugs,,68-74
particularly,75-87
those,88-93
of,94-96
low,97-100
therapeutic,101-112
ratio,113-118
or,119-121
in,122-124
patients,125-133
with,134-138
renal,139-144
and/or,145-151
hepatic,152-159
impairment,,160-171
may,172-175
require,176-183
adjustment,184-194
when,195-199
starting,200-208
or,209-211
stopping,212-220
concomitantly,221-234
administered,235-247
Tagamet,248-255	DrugDDI.d293.s7.e2
to,256-258
maintain,259-267
optimum,268-275
therapeutic,276-287
blood,288-293
levels.,294-301

Alteration,0-10
of,11-13
pH,14-16
may,17-20
affect,21-27
absorption,28-38
of,39-41
certain,42-49
drugs,50-55	DrugDDI.d293.s8.e0
(e.g.,,56-62
ketoconazole).,63-77	DrugDDI.d293.s8.e1

If,0-2
these,3-8
products,9-17
are,18-21
needed,,22-29
they,30-34
should,35-41
be,42-44
given,45-50
at,51-53
least,54-59
2,60-61
hours,62-67
before,68-74
cimetidine,75-85	DrugDDI.d293.s9.e0
administration.,86-101

Additional,0-10
clinical,11-19
experience,20-30
may,31-34
reveal,35-41
other,42-47
drugs,48-53	DrugDDI.d293.s10.e0
affected,54-62
by,63-65
the,66-69
concomitant,70-81
administration,82-96
of,97-99
Tagamet.,100-108	DrugDDI.d293.s10.e1

and/or,0-6
Drug/Laboratory,7-22	DrugDDI.d80.s0.e0
Test,23-27
Interactions,28-40
See,41-44
CLINICAL,45-53
PHARMACOLOGY,,54-67
Pharmacokinetics,68-84
and,85-88
Drug,89-93
Interactions.,94-107

Effect,0-6
of,7-9
Sensipar,10-18	DrugDDI.d80.s1.e0
on,19-21
other,22-27
drugs:,28-34	DrugDDI.d80.s1.e1
Drugs,35-40	DrugDDI.d80.s1.e2
metabolized,41-52
by,53-55
cytochrome,56-66	DrugDDI.d80.s1.e3
P450,67-71	DrugDDI.d80.s1.e3
2D6,72-75	DrugDDI.d80.s1.e3
(CYP2D6):,76-85
Sensipar?,86-95
is,96-98
a,99-100
strong,101-107
in,108-110
vitro,111-116
inhibitor,117-126
of,127-129
CYP2D6.,130-137	DrugDDI.d80.s1.e5

Therefore,,0-10
dose,11-15
adjustments,16-27
of,28-30
concomitant,31-42
medications,43-54	DrugDDI.d80.s2.e0
that,55-59
are,60-63
predominantly,64-77
metabolized,78-89
by,90-92
CYP2D6,93-99	DrugDDI.d80.s2.e1
and,100-103
have,104-108
a,109-110
narrow,111-117
therapeutic,118-129
index,130-135
(e.g.,,136-142
flecainide,,143-154
vinblastine,,155-167
thioridazine,168-180	DrugDDI.d80.s2.e4
and,181-184
most,185-189
tricyclic,190-199	DrugDDI.d80.s2.e5
antidepressants),200-216	DrugDDI.d80.s2.e5
may,217-220
be,221-223
required.,224-233

Amitriptyline:,0-14	DrugDDI.d80.s3.e0
Concurrent,15-25
administration,26-40
of,41-43
25,44-46
mg,47-49
or,50-52
100,53-56
mg,57-59
cinacalcet,60-70	DrugDDI.d80.s3.e1
with,71-75
50,76-78
mg,79-81
amitriptyline,82-95	DrugDDI.d80.s3.e2
increased,96-105
amitriptyline,106-119	DrugDDI.d80.s3.e3
exposure,120-128
and,129-132
nortriptyline,133-146	DrugDDI.d80.s3.e4
(active,147-154
metabolite),155-166
exposure,167-175
by,176-178
approximately,179-192
20%,193-196
in,197-199
CYP2D6,200-206	DrugDDI.d80.s3.e6
extensive,207-216
metabolizers.,217-230

Effect,0-6
of,7-9
other,10-15
drugs,16-21	DrugDDI.d80.s4.e0
on,22-24
Sensipar,25-33	DrugDDI.d80.s4.e1
:,34-35
Sensipar?,36-45
is,46-48
metabolized,49-60
by,61-63
multiple,64-72
cytochrome,73-83	DrugDDI.d80.s4.e2
P450,84-88	DrugDDI.d80.s4.e2
enzymes,,89-97
primarily,98-107
CYP3A4,,108-115
CYP2D6,,116-123
and,124-127
CYP1A2.,128-135	DrugDDI.d80.s4.e5

Ketoconazole:,0-13	DrugDDI.d80.s5.e0
Sensipar,14-22	DrugDDI.d80.s5.e1
is,23-25
metabolized,26-37
in,38-40
part,41-45
by,46-48
CYP3A4.,49-56	DrugDDI.d80.s5.e2

Co-administration,0-17
of,18-20
ketoconazole,,21-34
a,35-36
strong,37-43
inhibitor,44-53
of,54-56
CYP3A4,,57-64
increased,65-74
cinacalcet,75-85	DrugDDI.d80.s6.e2
exposure,86-94
following,95-104
a,105-106
single,107-113
90,114-116
mg,117-119
dose,120-124
of,125-127
Sensipar,128-136	DrugDDI.d80.s6.e3
by,137-139
2.3,140-143
fold.,144-149

Dose,0-4
adjustment,5-15
of,16-18
Sensipar,19-27	DrugDDI.d80.s7.e0
may,28-31
be,32-34
required,35-43
and,44-47
PTH,48-51	DrugDDI.d80.s7.e1
and,52-55
serum,56-61
calcium,62-69
concentrations,70-84
should,85-91
be,92-94
closely,95-102
monitored,103-112
if,113-115
a,116-117
patient,118-125
initiates,126-135
or,136-138
discontinues,139-151
therapy,152-159
with,160-164
a,165-166
strong,167-173
CYP3A4,174-180	DrugDDI.d80.s7.e2
inhibitor,181-190
(e.g.,,191-197
ketoconazole,,198-211
erythromycin,,212-225
itraconazole;,226-239	DrugDDI.d80.s7.e5

Elevated,0-8
plasma,9-15
levels,16-22
of,23-25
theophylline,26-38	DrugDDI.d52.s0.e0
have,39-43
been,44-48
reported,49-57
with,58-62
concomitant,63-74
use,75-78
of,79-81
some,82-86
quinolones.,87-98	DrugDDI.d52.s0.e1

There,0-5
have,6-10
been,11-15
reports,16-23
of,24-26
theophylline-related,27-47	DrugDDI.d52.s1.e0
side-effects,48-60
in,61-63
patients,64-72
on,73-75
concomitant,76-87
theophylline-quinolone,88-110	DrugDDI.d52.s1.e1
therapy.,111-119

Therefore,,0-10
monitoring,11-21
of,22-24
theophylline,25-37	DrugDDI.d52.s2.e0
plasma,38-44
levels,45-51
should,52-58
be,59-61
considered,62-72
and,73-76
dosage,77-83
of,84-86
theophylline,87-99
adjusted,100-108
as,109-111
required.,112-121

Quinolones,0-10	DrugDDI.d52.s3.e0
have,11-15
also,16-20
been,21-25
shown,26-31
to,32-34
interfere,35-44
with,45-49
the,50-53
metabolism,54-64
of,65-67
caffeine.,68-77	DrugDDI.d52.s3.e1

This,0-4
may,5-8
lead,9-13
to,14-16
reduced,17-24
clearance,25-34
of,35-37
caffeine,38-46	DrugDDI.d52.s4.e0
and,47-50
a,51-52
prolongation,53-65
of,66-68
its,69-72
plasma,73-79
half-life.,80-90

Although,0-8
this,9-13
interaction,14-25
has,26-29
not,30-33
been,34-38
reported,39-47
with,48-52
cinoxacin,,53-63
caution,64-71
should,72-78
be,79-81
exercised,82-91
when,92-96
cinoxacin,97-106	DrugDDI.d52.s5.e1
is,107-109
given,110-115
concomitantly,116-129
with,130-134
caffeine-containing,135-154	DrugDDI.d52.s5.e2
products.,155-164

Antacids,0-8	DrugDDI.d52.s6.e0
or,9-11
sucralfate,12-22	DrugDDI.d52.s6.e1
substantially,23-36
interfere,37-46
with,47-51
the,52-55
absorption,56-66
of,67-69
some,70-74
quinolones,,75-86
resulting,87-96
in,97-99
low,100-103
urine,104-109
levels.,110-117

Also,,0-5
concomitant,6-17
administration,18-32
of,33-35
quinolones,36-46	DrugDDI.d52.s7.e0
with,47-51
products,52-60
containing,61-71
iron,,72-77
multivitamins,78-91	DrugDDI.d52.s7.e2
containing,92-102
zinc,,103-108
or,109-111
Videx,112-117	DrugDDI.d52.s7.e4
(didanosine),118-130
chewable/buffered,131-148
tablets,149-156
or,157-159
the,160-163
pediatric,164-173	DrugDDI.d52.s7.e7
powder,174-180
for,181-184
oral,185-189
solution,190-198
may,199-202
result,203-209
in,210-212
low,213-216
urine,217-222
levels.,223-230

Quinolones,,0-11
including,12-21
cinoxacin,,22-32
may,33-36
enhance,37-44
the,45-48
effects,49-56
of,57-59
oral,60-64	DrugDDI.d52.s8.e2
anticoagulants,,65-80	DrugDDI.d52.s8.e2
such,81-85
as,86-88
warfarin,89-97	DrugDDI.d52.s8.e3
or,98-100
its,101-104
derivatives.,105-117	DrugDDI.d52.s8.e4

Seizures,0-8
have,9-13
been,14-18
reported,19-27
in,28-30
patients,31-39
taking,40-46
another,47-54
quinolone,55-64	DrugDDI.d52.s10.e0
class,65-70	DrugDDI.d52.s10.e0
antimicrobial,71-84	DrugDDI.d52.s10.e0
and,85-88
the,89-92
nonsteroidal,93-105	DrugDDI.d52.s10.e1
anti-inflammatory,106-123	DrugDDI.d52.s10.e1
drug,124-128	DrugDDI.d52.s10.e1
fenbufen,129-137
concurrently.,138-151

Animal,0-6
studies,7-14
also,15-19
suggest,20-27
an,28-30
increased,31-40
potential,41-50
for,51-54
seizures,55-63
when,64-68
these,69-74
2,75-76
drugs,77-82	DrugDDI.d52.s11.e0
are,83-86
given,87-92
concomitantly.,93-107

Fenbufen,0-8	DrugDDI.d52.s12.e0
is,9-11
not,12-15
approved,16-24
in,25-27
the,28-31
United,32-38
States,39-45
at,46-48
this,49-53
time.,54-59

Physicians,0-10
are,11-14
provided,15-23
this,24-28
information,29-40
to,41-43
increase,44-52
awareness,53-62
of,63-65
the,66-69
potential,70-79
for,80-83
serious,84-91
interactions,92-104
when,105-109
cinoxacin,110-119	DrugDDI.d52.s13.e0
and,120-123
certain,124-131
nonsteroidal,132-144	DrugDDI.d52.s13.e1
anti-inflammatory,145-162	DrugDDI.d52.s13.e1
agents,163-169	DrugDDI.d52.s13.e1
are,170-173
administered,174-186
concomitantly.,187-201

Elevated,0-8
cyclosporine,9-21	DrugDDI.d52.s14.e0
serum,22-27
levels,28-34
have,35-39
been,40-44
reported,45-53
with,54-58
the,59-62
concomitant,63-74
use,75-78
of,79-81
quinolones,82-92	DrugDDI.d52.s14.e1
and,93-96
cyclosporine.,97-110	DrugDDI.d52.s14.e2

Some,0-4
quinolones,,5-16
including,17-26
ciprofloxacin,,27-41
have,42-46
also,47-51
been,52-56
shown,57-62
to,63-65
interfere,66-75
with,76-80
the,81-84
metabolism,85-95
of,96-98
caffeine.,99-108	DrugDDI.d444.s0.e2

This,0-4
may,5-8
lead,9-13
to,14-16
reduced,17-24
clearance,25-34
of,35-37
caffeine,38-46	DrugDDI.d444.s1.e0
and,47-50
a,51-52
prolongation,53-65
of,66-68
its,69-72
serum,73-78
half-life.,79-89

Some,0-4
quinolones,,5-16
including,17-26
ciprofloxacin,,27-41
have,42-46
been,47-51
associated,52-62
with,63-67
transient,68-77
elevations,78-88
in,89-91
serum,92-97
creatinine,98-108
in,109-111
patients,112-120
receiving,121-130
cyclosporine,131-143	DrugDDI.d444.s2.e2
concomitantly.,144-158

Glyburide,0-9	DrugDDI.d444.s3.e0
The,10-13
concomitant,14-25
administration,26-40
of,41-43
ciprofloxacin,44-57	DrugDDI.d444.s3.e1
with,58-62
the,63-66
sulfonylurea,67-79	DrugDDI.d444.s3.e2
glyburide,80-89
has,,90-94
on,95-97
rare,98-102
occasions,,103-113
resulted,114-122
in,123-125
severe,126-132
hypoglycemia.,133-146

Histamine,0-9	DrugDDI.d444.s4.e0
H2-receptor,10-21	DrugDDI.d444.s4.e0
antagonists,22-33	DrugDDI.d444.s4.e0
Histamine,34-43
H2-receptor,44-55
antagonists,56-67
appear,68-74
to,75-77
have,78-82
no,83-85
significant,86-97
effect,98-104
on,105-107
the,108-111
bioavailability,112-127
of,128-130
ciprofloxacin.,131-145	DrugDDI.d444.s4.e1

Methotrexate,0-12	DrugDDI.d444.s5.e0
Renal,13-18
tubular,19-26
transport,27-36
of,37-39
methotrexate,40-52	DrugDDI.d444.s5.e1
may,53-56
be,57-59
inhibited,60-69
by,70-72
concomitant,73-84
administration,85-99
of,100-102
ciprofloxacin,,103-117
potentially,118-129
leading,130-137
to,138-140
increased,141-150
plasma,151-157
levels,158-164
of,165-167
methotrexate.,168-181	DrugDDI.d444.s5.e3

This,0-4
might,5-10
increase,11-19
the,20-23
risk,24-28
of,29-31
methotrexate,32-44	DrugDDI.d444.s6.e0
toxic,45-50
reactions.,51-61

Therefore,,0-10
patients,11-19
under,20-25
methotrexate,26-38	DrugDDI.d444.s7.e0
therapy,39-46
should,47-53
be,54-56
carefully,57-66
monitored,67-76
when,77-81
concomitant,82-93
ciprofloxacin,94-107	DrugDDI.d444.s7.e1
therapy,108-115
is,116-118
indicated.,119-129

Multivalent,0-11
Cation-Containing,12-29	DrugDDI.d444.s8.e0
Products,30-38
Concurrent,39-49
administration,50-64
of,65-67
a,68-69
quinolone,,70-80
including,81-90
ciprofloxacin,,91-105
with,106-110
multivalent,111-122
cation-containing,123-140	DrugDDI.d444.s8.e3
products,141-149
such,150-154
as,155-157
magnesium,158-167	DrugDDI.d444.s8.e4
or,168-170
aluminum,171-179	DrugDDI.d444.s8.e5
antacids,,180-189	DrugDDI.d444.s8.e5
sucralfate,,190-201
VIDEX,202-207	DrugDDI.d444.s8.e7
chewable/buffered,208-225
tablets,226-233
or,234-236
pediatric,237-246	DrugDDI.d444.s8.e9
powder,,247-254
or,255-257
products,258-266
containing,267-277
calcium,,278-286
iron,,287-292
or,293-295
zinc,296-300	DrugDDI.d444.s8.e12
may,301-304
substantially,305-318
decrease,319-327
the,328-331
absorption,332-342
of,343-345
ciprofloxacin,,346-360
resulting,361-370
in,371-373
serum,374-379
and,380-383
urine,384-389
levels,390-396
considerably,397-409
lower,410-415
than,416-420
desired.,421-429

This,0-4
time,5-9
window,10-16
is,17-19
different,20-29
than,30-34
for,35-38
other,39-44
oral,45-49
formulations,50-62
of,63-65
ciprofloxacin,,66-80
which,81-86
are,87-90
usually,91-98
administered,99-111
2,112-113
hours,114-119
before,120-126
or,127-129
6,130-131
hours,132-137
after,138-143
antacids.,144-153	DrugDDI.d444.s10.e1

Non-steroidal,0-13	DrugDDI.d444.s11.e0
anti-inflammatory,14-31	DrugDDI.d444.s11.e0
drugs,32-37	DrugDDI.d444.s11.e0
(but,38-42
not,43-46
aspirin),47-55	DrugDDI.d444.s11.e1
These,56-61
drugs,62-67	DrugDDI.d444.s11.e2
in,68-70
combination,71-82
with,83-87
very,88-92
high,93-97
doses,98-103
of,104-106
quinolones,107-117	DrugDDI.d444.s11.e3
have,118-122
been,123-127
shown,128-133
to,134-136
provoke,137-144
convulsions,145-156
in,157-159
pre-clinical,160-172
studies.,173-181

Omeprazole,0-10	DrugDDI.d444.s12.e0
The,11-14
rate,15-19
and,20-23
extent,24-30
of,31-33
absorption,34-44
of,45-47
ciprofloxacin,48-61	DrugDDI.d444.s12.e1
was,62-65
bioequivalent,66-79
when,80-84
Proquin,85-92
XR,93-95
was,96-99
given,100-105
alone,106-111
or,112-114
when,115-119
Proquin,120-127
XR,128-130
was,131-134
given,135-140
2,141-142
hours,143-148
after,149-154
omeprazole,155-165	DrugDDI.d444.s12.e2
at,166-168
the,169-172
dose,173-177
that,178-182
maximally,183-192
suppresses,193-203
gastric,204-211
acid,212-216
secretion.,217-227

Omeprazole,0-10	DrugDDI.d444.s13.e0
should,11-17
be,18-20
taken,21-26
as,27-29
directed,30-38
and,39-42
Proquin,43-50
XR,51-53
should,54-60
be,61-63
taken,64-69
with,70-74
a,75-76
main,77-81
meal,82-86
of,87-89
the,90-93
day,,94-98
preferably,99-109
the,110-113
evening,114-121
meal..,122-128

Phenytoin,0-9	DrugDDI.d444.s14.e0
Altered,10-17
serum,18-23
levels,24-30
of,31-33
phenytoin,34-43	DrugDDI.d444.s14.e1
(increased,44-54
and,55-58
decreased),59-69
have,70-74
been,75-79
reported,80-88
in,89-91
patients,92-100
receiving,101-110
concomitant,111-122
ciprofloxacin.,123-137	DrugDDI.d444.s14.e2

Probenecid,0-10	DrugDDI.d444.s15.e0
Probenecid,11-21
interferes,22-32
with,33-37
renal,38-43
tubular,44-51
secretion,52-61
of,62-64
ciprofloxacin,65-78	DrugDDI.d444.s15.e1
and,79-82
produces,83-91
an,92-94
increase,95-103
in,104-106
the,107-110
level,111-116
of,117-119
ciprofloxacin,120-133	DrugDDI.d444.s15.e2
in,134-136
serum.,137-143

Theophylline,0-12	DrugDDI.d444.s16.e0
As,13-15
with,16-20
some,21-25
other,26-31
quinolones,,32-43
concurrent,44-54
administration,55-69
of,70-72
ciprofloxacin,73-86	DrugDDI.d444.s16.e2
with,87-91
theophylline,92-104	DrugDDI.d444.s16.e3
may,105-108
lead,109-113
to,114-116
elevated,117-125
serum,126-131
concentrations,132-146
of,147-149
theophylline,150-162	DrugDDI.d444.s16.e4
and,163-166
prolongation,167-179
of,180-182
its,183-186
elimination,187-198
half-life.,199-209

If,0-2
concomitant,3-14
use,15-18
cannot,19-25
be,26-28
avoided,,29-37
serum,38-43
levels,44-50
of,51-53
theophylline,54-66	DrugDDI.d444.s18.e0
should,67-73
be,74-76
monitored,77-86
and,87-90
dosage,91-97
adjustments,98-109
made,110-114
as,115-117
appropriate.,118-130

Warfarin,0-8
Quinolones,9-19	DrugDDI.d444.s19.e0
have,20-24
been,25-29
reported,30-38
to,39-41
enhance,42-49
the,50-53
effects,54-61
of,62-64
the,65-68
oral,69-73	DrugDDI.d444.s19.e1
anticoagulant,74-87	DrugDDI.d444.s19.e1
warfarin,88-96	DrugDDI.d444.s19.e1
or,97-99
its,100-103
derivatives.,104-116	DrugDDI.d444.s19.e2

Cisapride,0-9	DrugDDI.d397.s0.e0
is,10-12
metabolized,13-24
mainly,25-31
via,32-35
the,36-39
cytochrome,40-50	DrugDDI.d397.s0.e1
P450,51-55	DrugDDI.d397.s0.e1
3A4,56-59	DrugDDI.d397.s0.e1
enzyme.,60-67

In,0-2
some,3-7
cases,8-13
where,14-19
serious,20-27
ventricular,28-39
arrhythmias,,40-52
QT,53-55
prolongation,,56-69
and,70-73
torsades,74-82
de,83-85
pointes,86-93
have,94-98
occurred,99-107
when,108-112
cisapride,113-122	DrugDDI.d397.s1.e0
was,123-126
taken,127-132
in,133-135
conjunction,136-147
with,148-152
one,153-156
of,157-159
the,160-163
cytochrome,164-174	DrugDDI.d397.s1.e1
P450,175-179	DrugDDI.d397.s1.e1
3A4,180-183	DrugDDI.d397.s1.e1
inhibitors,,184-195
elevated,196-204
blood,205-210
cisapride,211-220	DrugDDI.d397.s1.e2
levels,221-227
were,228-232
noted,233-238
at,239-241
the,242-245
time,246-250
of,251-253
the,254-257
QT,258-260
prolongation.,261-274

Antibiotics:,0-12	DrugDDI.d397.s2.e0
In,13-15
vitro,16-21
and/or,22-28
in,29-31
vivo,32-36
data,37-41
show,42-46
that,47-51
clarithromycin,,52-67
erythromycin,,68-81
and,82-85
troleandomycin,86-100	DrugDDI.d397.s2.e3
markedly,101-109
inhibit,110-117
the,118-121
metabolism,122-132
of,133-135
cisapride,,136-146
which,147-152
can,153-156
result,157-163
in,164-166
an,167-169
increase,170-178
in,179-181
plasma,182-188
cisapride,189-198	DrugDDI.d397.s2.e5
levels,199-205
and,206-209
prolongation,210-222
of,223-225
the,226-229
QT,230-232
interval,233-241
on,242-244
the,245-248
ECG.,249-253

Anticholinergics:,0-17	DrugDDI.d397.s3.e0
Concurrent,18-28
administration,29-43
of,44-46
certain,47-54
anticholinergic,55-70	DrugDDI.d397.s3.e1
compounds,,71-81
such,82-86
as,87-89
belladonna,90-100	DrugDDI.d397.s3.e2
alkaloids,101-110	DrugDDI.d397.s3.e2
and,111-114
dicyclomine,,115-127
would,128-133
be,134-136
expected,137-145
to,146-148
compromise,149-159
the,160-163
beneficial,164-174
effects,175-182
of,183-185
cisapride.,186-196	DrugDDI.d397.s3.e4

Anticoagulants,0-14	DrugDDI.d397.s4.e0
(Oral):,15-22
In,23-25
patients,26-34
receiving,35-44
oral,45-49	DrugDDI.d397.s4.e1
anticoagulants,,50-65	DrugDDI.d397.s4.e1
the,66-69
coagulation,70-81
times,82-87
were,88-92
increased,93-102
in,103-105
some,106-110
cases.,111-117

It,0-2
is,3-5
advisable,6-15
to,16-18
check,19-24
coagulation,25-36
time,37-41
within,42-48
the,49-52
first,53-58
few,59-62
days,63-67
after,68-73
the,74-77
start,78-83
and,84-87
discontinuation,88-103
of,104-106
cisapride,107-116	DrugDDI.d397.s5.e0
therapy,,117-125
with,126-130
an,131-133
appropriate,134-145
adjustment,146-156
of,157-159
the,160-163
anticoagulant,164-177	DrugDDI.d397.s5.e1
dose,,178-183
if,184-186
necessary.,187-197

Antidepressants:,0-16	DrugDDI.d397.s6.e0
In,17-19
vitro,20-25
data,26-30
indicate,31-39
that,40-44
nefazodone,45-55	DrugDDI.d397.s6.e1
inhibits,56-64
the,65-68
metabolism,69-79
of,80-82
cisapride,,83-93
which,94-99
can,100-103
result,104-110
in,111-113
an,114-116
increase,117-125
in,126-128
plasma,129-135
cisapride,136-145	DrugDDI.d397.s6.e3
levels,146-152
and,153-156
prolongation,157-169
of,170-172
the,173-176
QT,177-179
interval,180-188
on,189-191
the,192-195
ECG.,196-200

Antifungals:,0-12	DrugDDI.d397.s7.e0
In,13-15
vitro,16-21
and/or,22-28
in,29-31
vivo,32-36
data,37-41
indicate,42-50
that,51-55
fluconazole,,56-68
itraconazole,,69-82
and,83-86
oral,87-91
ketoconazole,92-104	DrugDDI.d397.s7.e3
markedly,105-113
inhibit,114-121
the,122-125
metabolism,126-136
of,137-139
cisapride,,140-150
which,151-156
can,157-160
result,161-167
in,168-170
an,171-173
increase,174-182
in,183-185
plasma,186-192
cisapride,193-202	DrugDDI.d397.s7.e5
levels,203-209
and,210-213
prolongation,214-226
of,227-229
the,230-233
QT,234-236
interval,237-245
on,246-248
the,249-252
ECG.,253-257

Human,0-5
pharmacokinetic,6-21
data,22-26
indicate,27-35
that,36-40
oral,41-45
ketoconazole,46-58	DrugDDI.d397.s8.e0
markedly,59-67
inhibits,68-76
the,77-80
metabolism,81-91
of,92-94
cisapride,,95-105
resulting,106-115
in,116-118
a,119-120
mean,121-125
eight-fold,126-136
increase,137-145
in,146-148
AUC,149-152
of,153-155
cisapride.,156-166	DrugDDI.d397.s8.e2

A,0-1
study,2-7
in,8-10
14,11-13
normal,14-20
male,21-25
and,26-29
female,30-36
volunteers,37-47
suggests,48-56
that,57-61
coadministration,62-78
of,79-81
cisapride,82-91	DrugDDI.d397.s9.e0
and,92-95
ketoconazole,96-108	DrugDDI.d397.s9.e1
can,109-112
result,113-119
in,120-122
prolongation,123-135
of,136-138
the,139-142
QT,143-145
interval,146-154
on,155-157
the,158-161
ECG.,162-166

H2,0-2	DrugDDI.d397.s10.e0
Receptor,3-11	DrugDDI.d397.s10.e0
Antagonists:,12-24
Cimetidine,25-35	DrugDDI.d397.s10.e1
coadministration,36-52
leads,53-58
to,59-61
an,62-64
increased,65-74
peak,75-79
plasma,80-86
concentration,87-100
and,101-104
AUC,105-108
of,109-111
cisapride,,112-122
there,123-128
is,129-131
no,132-134
effect,135-141
on,142-144
cisapride,145-154	DrugDDI.d397.s10.e3
absorption,155-165
when,166-170
it,171-173
is,174-176
coadministered,177-191
with,192-196
ranitidine.,197-208	DrugDDI.d397.s10.e4

The,0-3
gastrointestinal,4-20
absorption,21-31
of,32-34
cimetidine,35-45	DrugDDI.d397.s11.e0
and,46-49
ranitidine,50-60	DrugDDI.d397.s11.e1
is,61-63
accelerated,64-75
when,76-80
they,81-85
are,86-89
coadministered,90-104
with,105-109
cisapride.,110-120	DrugDDI.d397.s11.e2

Protease,0-8	DrugDDI.d397.s12.e0
Inhibitors:,9-20	DrugDDI.d397.s12.e0
In,21-23
vitro,24-29
data,30-34
indicate,35-43
that,44-48
indinavir,49-58	DrugDDI.d397.s12.e1
and,59-62
ritonavir,63-72	DrugDDI.d397.s12.e2
markedly,73-81
inhibit,82-89
the,90-93
metabolism,94-104
of,105-107
cisapride,108-117	DrugDDI.d397.s12.e3
which,118-123
can,124-127
result,128-134
in,135-137
an,138-140
increase,141-149
in,150-152
plasma,153-159
cisapride,160-169	DrugDDI.d397.s12.e4
levels,170-176
and,177-180
prolongation,181-193
of,194-196
the,197-200
QT,201-203
interval,204-212
on,213-215
the,216-219
ECG.,220-224

Other:,0-6
Coadministration,7-23
of,24-26
grapefruit,27-37
juice,38-43
with,44-48
cisapride,49-58	DrugDDI.d397.s13.e0
increases,59-68
the,69-72
bioavailability,73-88
of,89-91
cisapride,92-101	DrugDDI.d397.s13.e1
and,102-105
concomitant,106-117
use,118-121
should,122-128
be,129-131
avoided.,132-140

Cisapride,0-9	DrugDDI.d397.s14.e0
should,10-16
not,17-20
be,21-23
used,24-28
concomitantly,29-42
with,43-47
other,48-53
drugs,54-59	DrugDDI.d397.s14.e1
known,60-65
to,66-68
prolong,69-76
the,77-80
QT,81-83
interval:,84-93
certain,94-101
antiarrhythmics,,102-118
including,119-128
those,129-134
of,135-137
Class,138-143
IA,144-146
(such,147-152
as,153-155
quinidine,156-165	DrugDDI.d397.s14.e3
and,166-169
procainamide),170-183	DrugDDI.d397.s14.e4
and,184-187
Class,188-193
III,194-197
(such,198-203
as,204-206
sotalol);,207-216	DrugDDI.d397.s14.e5

tricyclic,0-9	DrugDDI.d397.s15.e0
antidepressants,10-25	DrugDDI.d397.s15.e0
(such,26-31
as,32-34
amitriptyline);,35-50	DrugDDI.d397.s15.e1

certain,0-7
tetracyclic,8-19	DrugDDI.d397.s16.e0
antidepressants,20-35	DrugDDI.d397.s16.e0
(such,36-41
as,42-44
maprotiline);,45-58	DrugDDI.d397.s16.e1

certain,0-7
antipsychotic,8-21
medications,22-33
(such,34-39
as,40-42
sertindole);,43-55	DrugDDI.d397.s17.e0

astemizole,,0-11
bepridil,,12-21
sparfloxacin,,22-35
and,36-39
terodiline.,40-51	DrugDDI.d397.s18.e3

The,0-3
preceding,4-13
lists,14-19
of,20-22
drugs,23-28	DrugDDI.d397.s19.e0
are,29-32
not,33-36
comprehensive.,37-51

The,0-3
acceleration,4-16
of,17-19
gastric,20-27
emptying,28-36
by,37-39
cisapride,40-49	DrugDDI.d397.s20.e0
could,50-55
affect,56-62
the,63-66
rate,67-71
of,72-74
absorption,75-85
of,86-88
other,89-94
drugs.,95-101	DrugDDI.d397.s20.e1

Patients,0-8
receiving,9-18
narrow,19-25
therapeutic,26-37
ratio,38-43
drugs,44-49	DrugDDI.d397.s21.e0
or,50-52
other,53-58
drugs,59-64	DrugDDI.d397.s21.e1
that,65-69
require,70-77
careful,78-85
titration,86-95
should,96-102
be,103-105
followed,106-114
closely;,115-123

NIMBEX,0-6	DrugDDI.d553.s0.e0
has,7-10
been,11-15
used,16-20
safely,21-27
following,28-37
varying,38-45
degrees,46-53
of,54-56
recovery,57-65
from,66-70
succinylcholine-induced,71-94	DrugDDI.d553.s0.e1
neuromuscular,95-108
block.,109-115

Administration,0-14
of,15-17
0.1-mg/kg,18-27
(2,28-30
x,31-32
ED95),33-38
NIMBEX,39-45	DrugDDI.d553.s1.e0
at,46-48
10%,49-52
or,53-55
95%,56-59
recovery,60-68
following,69-78
an,79-81
intubating,82-92
dose,93-97
of,98-100
succinylcholine,101-116	DrugDDI.d553.s1.e1
(1,117-119
mg/kg),120-126
produced,127-135
?95%,136-140
neuromuscular,141-154
block.,155-161

The,0-3
time,4-8
to,9-11
onset,12-17
of,18-20
maximum,21-28
block,29-34
following,35-44
NIMBEX,45-51	DrugDDI.d553.s2.e0
is,52-54
approximately,55-68
2,69-70
minutes,71-78
faster,79-85
with,86-90
prior,91-96
administration,97-111
of,112-114
succinylcholine.,115-131	DrugDDI.d553.s2.e1

Prior,0-5
administration,6-20
of,21-23
succinylcholine,24-39	DrugDDI.d553.s3.e0
had,40-43
no,44-46
effect,47-53
on,54-56
the,57-60
duration,61-69
of,70-72
neuromuscular,73-86
block,87-92
following,93-102
initial,103-110
or,111-113
maintenance,114-125
bolus,126-131
doses,132-137
of,138-140
NIMBEX.,141-148	DrugDDI.d553.s3.e1

Infusion,0-8
requirements,9-21
of,22-24
NIMBEX,25-31	DrugDDI.d553.s4.e0
in,32-34
patients,35-43
administered,44-56
succinylcholine,57-72	DrugDDI.d553.s4.e1
prior,73-78
to,79-81
infusions,82-91
of,92-94
NIMBEX,95-101	DrugDDI.d553.s4.e2
were,102-106
comparable,107-117
to,118-120
or,121-123
slightly,124-132
greater,133-140
than,141-145
when,146-150
succinylcholine,151-166	DrugDDI.d553.s4.e3
was,167-170
not,171-174
administered.,175-188

The,0-3
use,4-7
of,8-10
NIMBEX,11-17	DrugDDI.d553.s5.e0
before,18-24
succinylcholine,25-40	DrugDDI.d553.s5.e1
to,41-43
attenuate,44-53
some,54-58
of,59-61
the,62-65
side,66-70
effects,71-78
of,79-81
succinylcholine,82-97	DrugDDI.d553.s5.e2
has,98-101
not,102-105
been,106-110
studied.,111-119

Although,0-8
not,9-12
studied,13-20
systematically,21-35
in,36-38
clinical,39-47
trials,,48-55
no,56-58
drug,59-63
interactions,64-76
were,77-81
observed,82-90
when,91-95
vecuronium,,96-107
pancuronium,,108-120
or,121-123
atracurium,124-134	DrugDDI.d553.s6.e2
were,135-139
administered,140-152
following,153-162
varying,163-170
degrees,171-178
of,179-181
recovery,182-190
from,191-195
single,196-202
doses,203-208
or,209-211
infusions,212-221
of,222-224
NIMBEX.,225-232	DrugDDI.d553.s6.e3

Isoflurane,0-10	DrugDDI.d553.s7.e0
or,11-13
enflurane,14-23	DrugDDI.d553.s7.e1
administered,24-36
with,37-41
nitrous,42-49	DrugDDI.d553.s7.e2
oxide/oxygen,50-62	DrugDDI.d553.s7.e2
to,63-65
achieve,66-73
1.25,74-78
MAC,79-82
[Minimum,83-91
Alveolar,92-100
Concentration],101-115
may,116-119
prolong,120-127
the,128-131
clinically,132-142
effective,143-152
duration,153-161
of,162-164
action,165-171
of,172-174
initial,175-182
and,183-186
maintenance,187-198
doses,199-204
of,205-207
NIMBEX,208-214	DrugDDI.d553.s7.e4
and,215-218
decrease,219-227
the,228-231
required,232-240
infusion,241-249
rate,250-254
of,255-257
NIMBEX.,258-265	DrugDDI.d553.s7.e5

Fifteen,0-7
to,8-10
30,11-13
minutes,14-21
of,22-24
exposure,25-33
to,34-36
1.25,37-41
MAC,42-45
isoflurane,46-56	DrugDDI.d553.s9.e0
or,57-59
enflurane,60-69	DrugDDI.d553.s9.e1
had,70-73
minimal,74-81
effects,82-89
on,90-92
the,93-96
duration,97-105
of,106-108
action,109-115
of,116-118
initial,119-126
doses,127-132
of,133-135
NIMBEX,136-142	DrugDDI.d553.s9.e2
and,143-146
therefore,,147-157
no,158-160
adjustment,161-171
to,172-174
the,175-178
initial,179-186
dose,187-191
should,192-198
be,199-201
necessary,202-211
when,212-216
NIMBEX,217-223	DrugDDI.d553.s9.e3
is,224-226
administered,227-239
shortly,240-247
after,248-253
initiation,254-264
of,265-267
volatile,268-276
agents.,277-284

In,0-2
long,3-7
surgical,8-16
procedures,17-27
during,28-34
enflurane,35-44	DrugDDI.d553.s10.e0
or,45-47
isoflurane,48-58	DrugDDI.d553.s10.e1
anesthesia,,59-70
less,71-75
frequent,76-84
maintenance,85-96
dosing,,97-104
lower,105-110
maintenance,111-122
doses,,123-129
or,130-132
reduced,133-140
infusion,141-149
rates,150-155
of,156-158
NIMBEX,159-165	DrugDDI.d553.s10.e2
may,166-169
be,170-172
necessary.,173-183

In,0-2
clinical,3-11
studies,12-19
propofol,20-28	DrugDDI.d553.s12.e0
had,29-32
no,33-35
effect,36-42
on,43-45
the,46-49
duration,50-58
of,59-61
action,62-68
or,69-71
dosing,72-78
requirements,79-91
for,92-95
NIMBEX.,96-103	DrugDDI.d553.s12.e1

Other,0-5
drugs,6-11	DrugDDI.d553.s13.e0
which,12-17
may,18-21
enhance,22-29
the,30-33
neuromuscular,34-47
blocking,48-56
action,57-63
of,64-66
nondepolarizing,67-82	DrugDDI.d553.s13.e1
agents,83-89	DrugDDI.d553.s13.e1
such,90-94
as,95-97
NIMBEX,98-104	DrugDDI.d553.s13.e2
include,105-112
certain,113-120
antibiotics,121-132	DrugDDI.d553.s13.e3
(e.,133-136
g.,,137-140
aminoglycosides,,141-157
tetracyclines,,158-172
bacitracin,,173-184
polymyxins,,185-196
lincomycin,,197-208
clindamycin,,209-221
colistin,,222-231
and,232-235
sodium,236-242	DrugDDI.d553.s13.e11
colistemethate),,243-259
magnesium,260-269	DrugDDI.d553.s13.e12
salts,,270-276	DrugDDI.d553.s13.e12
lithium,,277-285
local,286-291	DrugDDI.d553.s13.e14
anesthetics,,292-304	DrugDDI.d553.s13.e14
procainamide,,305-318
and,319-322
quinidine.,323-333	DrugDDI.d553.s13.e16

Resistance,0-10
to,11-13
the,14-17
neuromuscular,18-31
blocking,32-40
action,41-47
of,48-50
nondepolarizing,51-66
neuromuscular,67-80	DrugDDI.d553.s14.e0
blocking,81-89	DrugDDI.d553.s14.e0
agents,90-96	DrugDDI.d553.s14.e0
has,97-100
been,101-105
demonstrated,106-118
in,119-121
patients,122-130
chronically,131-142
administered,143-155
phenytoin,156-165	DrugDDI.d553.s14.e1
or,166-168
carbamazepine.,169-183	DrugDDI.d553.s14.e2

While,0-5
the,6-9
effects,10-17
of,18-20
chronic,21-28
phenytoin,29-38	DrugDDI.d553.s15.e0
or,39-41
carbamazepine,42-55	DrugDDI.d553.s15.e1
therapy,56-63
on,64-66
the,67-70
action,71-77
of,78-80
NIMBEX,81-87	DrugDDI.d553.s15.e2
are,88-91
unknown,,92-100
slightly,101-109
shorter,110-117
durations,118-127
of,128-130
neuromuscular,131-144
block,145-150
may,151-154
be,155-157
anticipated,158-169
and,170-173
infusion,174-182
rate,183-187
requirements,188-200
may,201-204
be,205-207
higher.,208-215

Drug/Laboratory,0-15	DrugDDI.d553.s16.e0
Test,16-20
Interactions,21-33
None,34-38
known.,39-45

Plasma,0-6
levels,7-13
of,14-16
anticonvulsant,17-31	DrugDDI.d468.s0.e0
agents,32-38	DrugDDI.d468.s0.e0
may,39-42
become,43-49
subtherapeutic,50-64
during,65-71
cisplatin,72-81	DrugDDI.d468.s0.e1
therapy.,82-90

In,0-2
a,3-4
randomized,5-15
trial,16-21
in,22-24
advanced,25-33
ovarian,34-41
cancer,,42-49
response,50-58
duration,59-67
was,68-71
adversely,72-81
affected,82-90
when,91-95
pyridoxine,96-106	DrugDDI.d468.s1.e0
was,107-110
used,111-115
in,116-118
combination,119-130
with,131-135
altretamine,136-147	DrugDDI.d468.s1.e1
(hexamethylmelamine),148-168
and,169-172
cisplatin.1,173-184	DrugDDI.d468.s1.e3

Central,0-7	DrugDDI.d302.s0.e0
nervous,8-15	DrugDDI.d302.s0.e0
system,16-22	DrugDDI.d302.s0.e0
depressant,23-33	DrugDDI.d302.s0.e0
(CNS),34-39
drugs,40-45	DrugDDI.d302.s0.e1
including,46-55
alcohol,,56-64
antidepressants,,65-81
antihistamines,,82-97
antipsychotics,,98-113
blood,114-119
pressure,120-128
medications,129-140	DrugDDI.d302.s0.e6
(reserpine,,141-152
methyldopa,,153-164
beta-blockers),,165-180
motion,181-187
sickness,188-196
medications,,197-209
muscle,210-216	DrugDDI.d302.s0.e11
relaxants,,217-227	DrugDDI.d302.s0.e11
narcotics,,228-238
sedatives,,239-249
sleeping,250-258
pills,259-264
and,265-268
tranquilizers,269-282	DrugDDI.d302.s0.e14

There,0-5
are,6-9
no,10-12
known,13-18
drug,19-23
interactions,24-36
with,37-41
LEUSTATIN,42-51	DrugDDI.d44.s0.e0
Injection.,52-62

Caution,0-7
should,8-14
be,15-17
exercised,18-27
if,28-30
LEUSTATIN,31-40	DrugDDI.d44.s1.e0
Injection,41-50
is,51-53
administered,54-66
before,,67-74
after,,75-81
or,82-84
in,85-87
conjunction,88-99
with,100-104
other,105-110
drugs,111-116	DrugDDI.d44.s1.e1
known,117-122
to,123-125
cause,126-131
immunosuppression,132-149
or,150-152
myelosuppression.,153-170

The,0-3
concurrent,4-14
administration,15-29
of,30-32
allopurinol,33-44	DrugDDI.d35.s0.e0
and,45-48
ampicillin,49-59	DrugDDI.d35.s0.e1
increases,60-69
substantially,70-83
the,84-87
incidence,88-97
of,98-100
rashes,101-107
in,108-110
patients,111-119
receiving,120-129
both,130-134
drugs,135-140	DrugDDI.d35.s0.e2
as,141-143
compared,144-152
to,153-155
patients,156-164
receiving,165-174
ampicillin,175-185	DrugDDI.d35.s0.e3
alone.,186-192

It,0-2
is,3-5
not,6-9
known,10-15
whether,16-23
this,24-28
potentiation,29-41
of,42-44
ampicillin,45-55	DrugDDI.d35.s1.e0
rashes,56-62
is,63-65
due,66-69
to,70-72
allopurinol,73-84	DrugDDI.d35.s1.e1
or,85-87
the,88-91
hyperuricemia,92-105
present,106-113
in,114-116
these,117-122
patients.,123-132

In,0-2
controlled,3-13
clinical,14-22
trials,23-29
of,30-32
AUGMENTIN,33-42	DrugDDI.d35.s2.e0
XR,,43-46	DrugDDI.d35.s2.e0
22,47-49
patients,50-58
received,59-67
concomitant,68-79
allopurinol,80-91	DrugDDI.d35.s2.e1
and,92-95
AUGMENTIN,96-105	DrugDDI.d35.s2.e2
XR.,106-109	DrugDDI.d35.s2.e2

However,,0-8
this,9-13
sample,14-20
size,21-25
is,26-28
too,29-32
small,33-38
to,39-41
allow,42-47
for,48-51
any,52-55
conclusions,56-67
to,68-70
be,71-73
drawn,74-79
regarding,80-89
the,90-93
risk,94-98
of,99-101
rashes,102-108
with,109-113
concomitant,114-125
AUGMENTIN,126-135	DrugDDI.d35.s4.e0
XR,136-138	DrugDDI.d35.s4.e0
and,139-142
allopurinol,143-154	DrugDDI.d35.s4.e1
use.,155-159

In,0-2
common,3-9
with,10-14
other,15-20
broad-spectrum,21-35
antibiotics,,36-48
AUGMENTIN,49-58	DrugDDI.d35.s5.e1
XR,59-61	DrugDDI.d35.s5.e1
may,62-65
reduce,66-72
the,73-76
efficacy,77-85
of,86-88
oral,89-93	DrugDDI.d35.s5.e2
contraceptives,94-108	DrugDDI.d35.s5.e2

Additive,0-8
CNS,9-12
depression,13-23
may,24-27
occur,28-33
when,34-38
antihistamines,39-53	DrugDDI.d357.s0.e0
are,54-57
administered,58-70
concomitantly,71-84
with,85-89
other,90-95
CNS,96-99	DrugDDI.d357.s0.e1
depressants,100-111	DrugDDI.d357.s0.e1
including,112-121
barbiturates,,122-135
tranquilizers,,136-150
and,151-154
alcohol.,155-163	DrugDDI.d357.s0.e4

Patients,0-8
receiving,9-18
antihistamines,19-33	DrugDDI.d357.s1.e0
should,34-40
be,41-43
advised,44-51
against,52-59
the,60-63
concurrent,64-74
use,75-78
of,79-81
other,82-87
CNS,88-91	DrugDDI.d357.s1.e1
depressant,92-102	DrugDDI.d357.s1.e1
drugs.,103-109	DrugDDI.d357.s1.e1

Monoamine,0-9	DrugDDI.d357.s2.e0
oxidase,10-17	DrugDDI.d357.s2.e0
(MAO),18-23
inhibitors,24-34
prolong,35-42
and,43-46
intensify,47-56
the,57-60
anticholinergic,61-76	DrugDDI.d357.s2.e1
effects,77-84
of,85-87
antihistamines.,88-103	DrugDDI.d357.s2.e2

Amantadine,,0-11
tricyclic,12-21	DrugDDI.d40.s0.e1
antidepressants,,22-38	DrugDDI.d40.s0.e1
and,39-42
MAOIs,43-48
may,49-52
increase,53-61
anticholinergic,62-77	DrugDDI.d40.s0.e2
effect,78-84
of,85-87
clidinium.,88-98	DrugDDI.d40.s0.e3

Clidinium,0-9	DrugDDI.d40.s1.e0
may,10-13
decrease,14-22
the,23-26
effect,27-33
of,34-36
phenothiazines,,37-52
levodopa,,53-62
and,63-66
ketoconazole.,67-80	DrugDDI.d40.s1.e3

Clindamycin,0-11	DrugDDI.d274.s0.e0
has,12-15
been,16-20
shown,21-26
to,27-29
have,30-34
neuromuscular,35-48
blocking,49-57
properties,58-68
that,69-73
may,74-77
enhance,78-85
the,86-89
action,90-96
of,97-99
other,100-105
neuromuscular,106-119	DrugDDI.d274.s0.e1
blocking,120-128	DrugDDI.d274.s0.e1
agents.,129-136	DrugDDI.d274.s0.e1

Antagonism,0-10
has,11-14
been,15-19
demonstrated,20-32
between,33-40
clindamycin,41-52	DrugDDI.d274.s2.e0
and,53-56
erythromycin,57-69	DrugDDI.d274.s2.e1
in,70-72
vitro.,73-79

Because,0-7
of,8-10
possible,11-19
clinical,20-28
significance,,29-42
these,43-48
two,49-52
drugs,53-58	DrugDDI.d274.s3.e0
should,59-65
not,66-69
be,70-72
administered,73-85
concurrently.,86-99

Alcohol,0-7	DrugDDI.d477.s0.e0
(increases,8-18
bioavailability,19-34
by,35-37
50%),,38-43
cimetidine,,44-55
and,56-59
valproates.,60-71

Although,0-8
no,9-11
clinical,12-20
drug-drug,21-30
interaction,31-42
studies,43-50
have,51-55
been,56-60
conducted,61-70
to,71-73
date,,74-79
on,80-82
the,83-86
basis,87-92
of,93-95
the,96-99
in,100-102
vitro,103-108
studies,,109-117
cytochrome,118-128	DrugDDI.d520.s0.e0
p450,129-133	DrugDDI.d520.s0.e0
inhibitors,134-144
and,145-148
inducers,149-157
are,158-161
unlikely,162-170
to,171-173
affect,174-180
the,181-184
metabolism,185-195
of,196-198
clofarabine.,199-211	DrugDDI.d520.s0.e1

The,0-3
effect,4-10
of,11-13
clofarabine,14-25	DrugDDI.d520.s1.e0
on,26-28
the,29-32
metabolism,33-43
of,44-46
cytochrome,47-57	DrugDDI.d520.s1.e1
p450,58-62	DrugDDI.d520.s1.e1
substrates,63-73
has,74-77
not,78-81
been,82-86
studied.,87-95

Drug/Laboratory,0-15	DrugDDI.d520.s2.e0
Tests,16-21
Interactions,22-34
There,35-40
are,41-44
no,45-47
known,48-53
clinically,54-64
significant,65-76
interactions,77-89
of,90-92
CLOLAR?,93-100
with,101-105
other,106-111
medications,112-123	DrugDDI.d520.s2.e1
or,124-126
laboratory,127-137
tests.,138-144

No,0-2
formal,3-9
drug/laboratory,10-25	DrugDDI.d520.s3.e0
test,26-30
interaction,31-42
studies,43-50
have,51-55
been,56-60
conducted,61-70
with,71-75
CLOLAR?,76-83
.,84-85

Preliminary,0-11
data,12-16
which,17-22
suggest,23-30
that,31-35
dapsone,36-43	DrugDDI.d296.s0.e0
may,44-47
inhibit,48-55
the,56-59
anti-inflammatory,60-77
activity,78-86
of,87-89
Lamprene,90-98	DrugDDI.d296.s0.e1
have,99-103
not,104-107
been,108-112
confirmed.,113-123

If,0-2
leprosy-associated,3-21	DrugDDI.d296.s1.e0
inflammatory,22-34
reactions,35-44
develop,45-52
in,53-55
patients,56-64
being,65-70
treated,71-78
with,79-83
dapsone,84-91	DrugDDI.d296.s1.e1
and,92-95
clofazimine,,96-108
it,109-111
is,112-114
still,115-120
advisable,121-130
to,131-133
continue,134-142
treatment,143-152
with,153-157
both,158-162
drugs.,163-169	DrugDDI.d296.s1.e3

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
anticoagulants,33-47	DrugDDI.d219.s0.e0
are,48-51
given,52-57
in,58-60
conjunction,61-72
with,73-77
Atromid-S.,78-88	DrugDDI.d219.s0.e1

Usually,,0-8
the,9-12
dosage,13-19
of,20-22
the,23-26
anticoagulant,27-40	DrugDDI.d219.s1.e0
should,41-47
be,48-50
reduced,51-58
by,59-61
one-half,62-70
(depending,71-81
on,82-84
the,85-88
individual,89-99
case),100-105
to,106-108
maintain,109-117
the,118-121
prothrombin,122-133
time,134-138
at,139-141
the,142-145
desired,146-153
level,154-159
to,160-162
prevent,163-170	DrugDDI.d219.s1.e1
bleeding,171-179
complications.,180-194

Frequent,0-8
prothrombin,9-20	DrugDDI.d219.s2.e0
determinations,21-35
are,36-39
advisable,40-49
until,50-55
it,56-58
has,59-62
been,63-67
determined,68-78
definitely,79-89
that,90-94
the,95-98
prothrombin,99-110
level,111-116
has,117-120
been,121-125
stabilized.,126-137

Atromid-S,0-9	DrugDDI.d219.s3.e0
may,10-13
displace,14-22
acidic,23-29
drugs,30-35	DrugDDI.d219.s3.e1
such,36-40
as,41-43
phenytoin,44-53	DrugDDI.d219.s3.e2
or,54-56
tolbutamide,57-68	DrugDDI.d219.s3.e3
from,69-73
their,74-79
binding,80-87
sites.,88-94

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
treating,33-41
patients,42-50
with,51-55
either,56-62
of,63-65
these,66-71
drugs,72-77	DrugDDI.d219.s4.e0
or,78-80
other,81-86
highly,87-93
protein-bound,94-107
drugs,108-113
and,114-117
Atromid-S.,118-128	DrugDDI.d219.s4.e1

The,0-3
hypoglycemic,4-16	DrugDDI.d219.s5.e0
effect,17-23	DrugDDI.d219.s5.e0
of,24-26
tolbutamide,27-38	DrugDDI.d219.s5.e1
has,39-42
been,43-47
reported,48-56
to,57-59
increase,60-68
when,69-73
Atromid-S,74-83	DrugDDI.d219.s5.e2
is,84-86
given,87-92
concurrently.,93-106

Fulminant,0-9
rhabdomyolysis,10-24
has,25-28
been,29-33
seen,34-38
as,39-41
early,42-47
as,48-50
three,51-56
weeks,57-62
after,63-68
initiation,69-79
of,80-82
combined,83-91
therapy,92-99
with,100-104
another,105-112
fibrate,113-120	DrugDDI.d219.s6.e0
and,121-124
lovastatin,125-135	DrugDDI.d219.s6.e1
but,136-139
may,140-143
be,144-146
seen,147-151
after,152-157
several,158-165
months.,166-173

For,0-3
these,4-9
reasons,,10-18
it,19-21
is,22-24
felt,25-29
that,,30-35
in,36-38
most,39-43
subjects,44-52
who,53-56
have,57-61
had,62-65
an,66-68
unsatisfactory,69-83
lipid,84-89
response,90-98
to,99-101
either,102-108
drug,109-113	DrugDDI.d219.s7.e0
alone,,114-120
the,121-124
possible,125-133
benefits,134-142
of,143-145
combined,146-154
therapy,155-162
with,163-167
lovastatin,168-178	DrugDDI.d219.s7.e1
and,179-182
a,183-184
fibrate,185-192	DrugDDI.d219.s7.e2
do,193-195
not,196-199
outweigh,200-208
the,209-212
risks,213-218
of,219-221
severe,222-228
myopathy,,229-238
rhabdomyolysis,,239-254
and,255-258
acute,259-264
renal,265-270
failure.,271-279

While,0-5
it,6-8
is,9-11
not,12-15
known,16-21
whether,22-29
this,30-34
interaction,35-46
occurs,47-53
with,54-58
fibrates,59-67	DrugDDI.d219.s8.e0
other,68-73
than,74-78
gemfibrozil,,79-91
myopathy,92-100
and,101-104
rhabdomyolysis,105-119
have,120-124
occasionally,125-137
been,138-142
associated,143-153
with,154-158
the,159-162
use,163-166
of,167-169
fibrates,170-178	DrugDDI.d219.s8.e2
alone,,179-185
including,186-195
clofibrate.,196-207	DrugDDI.d219.s8.e3

Therefore,,0-10
the,11-14
combined,15-23
use,24-27
of,28-30
lovastatin,31-41	DrugDDI.d219.s9.e0
with,42-46
fibrates,47-55	DrugDDI.d219.s9.e1
should,56-62
generally,63-72
be,73-75
avoided.,76-84

Drug,0-4
interactions,5-17
with,18-22
clomiphene,23-33	DrugDDI.d103.s0.e0
citrate,34-41	DrugDDI.d103.s0.e0
tablets,42-49	DrugDDI.d103.s0.e0
USP,50-53
have,54-58
not,59-62
been,63-67
documented.,68-79

The,0-3
risks,4-9
of,10-12
using,13-18
Anafranil,19-28	DrugDDI.d91.s0.e0
in,29-31
combination,32-43
with,44-48
other,49-54
drugs,55-60	DrugDDI.d91.s0.e1
have,61-65
not,66-69
been,70-74
systematically,75-89
evaluated.,90-100

Given,0-5
the,6-9
primary,10-17
CNS,18-21
effects,22-29
of,30-32
Anafranil,,33-43
caution,44-51
is,52-54
advised,55-62
in,63-65
using,66-71
it,72-74
concomitantly,75-88
with,89-93
other,94-99
CNS-active,100-110	DrugDDI.d91.s1.e1
drugs.,111-117	DrugDDI.d91.s1.e1

Anafranil,0-9	DrugDDI.d91.s2.e0
should,10-16
not,17-20
be,21-23
used,24-28
with,29-33
MAO,34-37	DrugDDI.d91.s2.e1
inhibitors.,38-49	DrugDDI.d91.s2.e1

Close,0-5
supervision,6-17
and,18-21
careful,22-29
adjustment,30-40
of,41-43
dosage,44-50
are,51-54
required,55-63
when,64-68
Anafranil,69-78	DrugDDI.d91.s3.e0
is,79-81
administered,82-94
with,95-99
anticholinergic,100-115	DrugDDI.d91.s3.e1
or,116-118
sympathomimetic,119-134	DrugDDI.d91.s3.e2
drugs.,135-141	DrugDDI.d91.s3.e2

Several,0-7
tricyclic,8-17	DrugDDI.d91.s4.e0
antidepressants,18-33	DrugDDI.d91.s4.e0
have,34-38
been,39-43
reported,44-52
to,53-55
block,56-61
the,62-65
pharmacologic,66-79
effects,80-87
of,88-90
guanethidine,,91-104
clonidine,,105-115
or,116-118
similar,119-126
agents,,127-134
and,135-138
such,139-143
an,144-146
effect,147-153
may,154-157
be,158-160
anticipated,161-172
with,173-177
CMI,178-181
because,182-189
of,190-192
its,193-196
structural,197-207
similarity,208-218
to,219-221
other,222-227
tricyclic,228-237	DrugDDI.d91.s4.e3
antidepressants.,238-254	DrugDDI.d91.s4.e3

The,0-3
plasma,4-10
concentration,11-24
of,25-27
CMI,28-31
has,32-35
been,36-40
reported,41-49
to,50-52
be,53-55
increased,56-65
by,66-68
the,69-72
concomitant,73-84
administration,85-99
of,100-102
haloperidol;,103-115	DrugDDI.d91.s5.e0

plasma,0-6
levels,7-13
of,14-16
several,17-24
closely,25-32
related,33-40
tricyclic,41-50	DrugDDI.d91.s6.e0
antidepressants,51-66	DrugDDI.d91.s6.e0
have,67-71
been,72-76
reported,77-85
to,86-88
be,89-91
increased,92-101
by,102-104
the,105-108
concomitant,109-120
administration,121-135
of,136-138
methylphenidate,139-154	DrugDDI.d91.s6.e1
or,155-157
hepatic,158-165
enzyme,166-172	DrugDDI.d91.s6.e2
inhibitors,173-183	DrugDDI.d91.s6.e2
(e.g.,,184-190
cimetidine,,191-202
fluoxetine),203-214	DrugDDI.d91.s6.e4
and,215-218
decreased,219-228
by,229-231
the,232-235
concomitant,236-247
administration,248-262
of,263-265
hepatic,266-273
enzyme,274-280
inducers,281-289
(e.g.,,290-296
barbiturates,,297-310
phenytoin),,311-322
and,323-326
such,327-331
an,332-334
effect,335-341
may,342-345
be,346-348
anticipated,349-360
with,361-365
CMI,366-369
as,370-372
well.,373-378

Administration,0-14
of,15-17
CMI,18-21
has,22-25
been,26-30
reported,31-39
to,40-42
increase,43-51
the,52-55
plasma,56-62
levels,63-69
of,70-72
phenobarbital,,73-87
if,88-90
given,91-96
concomitantly.,97-111

Drugs,0-5	DrugDDI.d91.s8.e0
Metabolized,6-17
by,18-20
P450,21-25	DrugDDI.d91.s8.e1
2D6:,26-30	DrugDDI.d91.s8.e1
The,31-34
biochemical,35-46
activity,47-55
of,56-58
the,59-62
drug,63-67	DrugDDI.d91.s8.e2
metabolizing,68-80
isozyme,81-88
cytochrome,89-99
P450,100-104
2D6,105-108
(debrisoquin,109-121
hydroxylase),122-134
is,135-137
reduced,138-145
in,146-148
a,149-150
subset,151-157
of,158-160
the,161-164
aucasian,165-173
population,174-184
(about,185-191
7%-10%,192-198
of,199-201
Caucasians,202-212
are,213-216
so-called,217-226
poor,227-231
metabolizers);,232-246

reliable,0-8
estimates,9-18
of,19-21
the,22-25
prevalence,26-36
of,37-39
reduced,40-47
P450,48-52	DrugDDI.d91.s9.e0
2D6,53-56	DrugDDI.d91.s9.e0
isozyme,57-64	DrugDDI.d91.s9.e0
activity,65-73
among,74-79
Asian,,80-86
African,87-94
and,95-98
other,99-104
populations,105-116
are,117-120
not,121-124
yet,125-128
available.,129-139

Poor,0-4
metabolizers,5-17
have,18-22
higher,23-29
than,30-34
expected,35-43
lasma,44-49	DrugDDI.d91.s10.e0
concentrations,50-64
of,65-67
tricyclic,68-77	DrugDDI.d91.s10.e1
antidepressants,78-93	DrugDDI.d91.s10.e1
(TCAs),94-100
when,101-105
given,106-111
usual,112-117
doses.,118-124

Depending,0-9
on,10-12
the,13-16
fraction,17-25
of,26-28
drug,29-33	DrugDDI.d91.s11.e0
metabolized,34-45
by,46-48
P450,49-53	DrugDDI.d91.s11.e1
2D6,,54-58	DrugDDI.d91.s11.e1
the,59-62
increase,63-71
in,72-74
plasma,75-81
concentration,82-95
may,96-99
be,100-102
small,,103-109
or,110-112
quite,113-118
large,119-124
(8,125-127
fold,128-132
increase,133-141
in,142-144
plasma,145-151
AUC,152-155
of,156-158
the,159-162
TCA).,163-168

In,0-2
addition,,3-12
certain,13-20
drugs,21-26	DrugDDI.d91.s12.e0
inhibit,27-34
the,35-38
activity,39-47
of,48-50
this,51-55
isozyme,56-63	DrugDDI.d91.s12.e1
and,64-67
make,68-72
normal,73-79
metabolizers,80-92
resemble,93-101
poor,102-106
metabolizers.,107-120

An,0-2
individual,3-13
who,14-17
is,18-20
stable,21-27
on,28-30
a,31-32
given,33-38
dose,39-43
of,44-46
TCAmay,47-53
become,54-60
abruptly,61-69
toxic,70-75
when,76-80
given,81-86
one,87-90
of,91-93
these,94-99
inhibiting,100-110
drugs,111-116	DrugDDI.d91.s13.e0
as,117-119
concomitant,120-131
therapy.,132-140

The,0-3
drugs,4-9	DrugDDI.d91.s14.e0
that,10-14
inhibit,15-22
cytochrome,23-33	DrugDDI.d91.s14.e1
P450,34-38	DrugDDI.d91.s14.e1
2D6,39-42	DrugDDI.d91.s14.e1
include,43-50
some,51-55
that,56-60
are,61-64
not,65-68
metabolized,69-80
by,81-83
the,84-87
enzyme,88-94
(quinidine;,95-106

cimetidine),0-11	DrugDDI.d91.s15.e0
and,12-15
many,16-20
that,21-25
are,26-29
substrates,30-40
for,41-44
P450,45-49	DrugDDI.d91.s15.e1
2D6,50-53	DrugDDI.d91.s15.e1
(many,54-59
other,60-65
antidepressants,,66-82
phenothiazines,,83-98
and,99-102
the,103-106
Type,107-111
1C,112-114
antiarrhythmics,115-130
propafenone,131-142	DrugDDI.d91.s15.e4
and,143-146
flecainide).,147-159	DrugDDI.d91.s15.e5

While,0-5
all,6-9
the,10-13
selective,14-23
serotonin,24-33	DrugDDI.d91.s16.e0
reuptake,34-42	DrugDDI.d91.s16.e0
inhibitors,43-53	DrugDDI.d91.s16.e0
(SSRIs),,54-62
e.g.,,63-68
fluoxetine,,69-80
sertraline,,81-92
paroxetine,,93-104
and,105-108
fluvoxamine,,109-121
inhibit,122-129
P450,130-134	DrugDDI.d91.s16.e5
2D6,,135-139	DrugDDI.d91.s16.e5
they,140-144
may,145-148
vary,149-153
in,154-156
the,157-160
extent,161-167
of,168-170
inhibition.,171-182

Fluvoxamine,0-11	DrugDDI.d91.s17.e0
has,12-15
also,16-20
been,21-25
shown,26-31
to,32-34
inhibit,35-42
P450,43-47	DrugDDI.d91.s17.e1
1A2,,48-52
an,53-55
isoform,56-63	DrugDDI.d91.s17.e2
also,64-68
involved,69-77
in,78-80
TCAmetabolism.,81-95

Of,0-2
particular,3-13
importance,,14-25
sufficient,26-36
time,37-41
must,42-46
elapse,47-53
before,54-60
initiating,61-71
TCAtreatment,72-84
in,85-87
a,88-89
patient,90-97
being,98-103
withdrawn,104-113
from,114-118
fluoxetine,,119-130
given,131-136
the,137-140
long,141-145
half-life,146-155
of,156-158
the,159-162
parent,163-169
and,170-173
active,174-180	DrugDDI.d91.s20.e1
metabolite,181-191	DrugDDI.d91.s20.e1
(at,192-195
least,196-201
5,202-203
weeks,204-209
may,210-213
be,214-216
necessary).,217-228

Concomitant,0-11
use,12-15
of,16-18
agents,19-25
in,26-28
the,29-32
tricyclic,33-42	DrugDDI.d91.s21.e0
antidepressant,43-57	DrugDDI.d91.s21.e0
class,58-63
(which,64-70
includes,71-79
Anafranil),80-90	DrugDDI.d91.s21.e1
with,91-95
drugs,96-101	DrugDDI.d91.s21.e2
that,102-106
can,107-110
inhibit,111-118
cytochrome,119-129	DrugDDI.d91.s21.e3
P450,130-134	DrugDDI.d91.s21.e3
2D6,135-138	DrugDDI.d91.s21.e3
may,139-142
require,143-150
lower,151-156
doses,157-162
than,163-167
usually,168-175
prescribed,176-186
for,187-190
either,191-197
the,198-201
tricyclic,202-211	DrugDDI.d91.s21.e4
antidepressant,212-226	DrugDDI.d91.s21.e4
agent,227-232
or,233-235
the,236-239
other,240-245
drug.,246-251	DrugDDI.d91.s21.e5

Furthermore,,0-12
whenever,13-21
one,22-25
of,26-28
these,29-34
drugs,35-40	DrugDDI.d91.s22.e0
is,41-43
withdrawn,44-53
from,54-58
co-therapy,,59-70
an,71-73
increased,74-83
dose,84-88
of,89-91
tricyclic,92-101	DrugDDI.d91.s22.e1
antidepressant,102-116	DrugDDI.d91.s22.e1
agent,117-122
may,123-126
be,127-129
required.,130-139

It,0-2
is,3-5
desirable,6-15
to,16-18
monitor,19-26
TCAplasma,27-36
levels,37-43
whenever,44-52
an,53-55
agent,56-61
of,62-64
the,65-68
tricyclic,69-78	DrugDDI.d91.s23.e0
antidepressant,79-93	DrugDDI.d91.s23.e0
class,94-99
including,100-109
Anafranil,110-119	DrugDDI.d91.s23.e1
is,120-122
going,123-128
to,129-131
be,132-134
co-administered,135-150
with,151-155
another,156-163
drug,164-168	DrugDDI.d91.s23.e2
known,169-174
to,175-177
be,178-180
an,181-183
inhibitor,184-193
of,194-196
P450,197-201	DrugDDI.d91.s23.e3
2D6,202-205	DrugDDI.d91.s23.e3
(and/or,206-213
P450,214-218	DrugDDI.d91.s23.e4
1A2).,219-224

Because,0-7
Anafranil,8-17	DrugDDI.d91.s24.e0
is,18-20
highly,21-27
bound,28-33
to,34-36
serum,37-42
protein,,43-51
the,52-55
administration,56-70
of,71-73
Anafranil,74-83	DrugDDI.d91.s24.e2
to,84-86
patients,87-95
taking,96-102
other,103-108
drugs,109-114	DrugDDI.d91.s24.e3
that,115-119
are,120-123
highly,124-130
bound,131-136
to,137-139
protein,140-147	DrugDDI.d91.s24.e4
(e.g.,,148-154
warfarin,,155-164
digoxin),165-173	DrugDDI.d91.s24.e6
may,174-177
cause,178-183
an,184-186
increase,187-195
in,196-198
plasma,199-205
concentrations,206-220
of,221-223
these,224-229
drugs,,230-236
potentially,237-248
resulting,249-258
in,259-261
adverse,262-269
effects.,270-278

Conversely,,0-11
adverse,12-19
effects,20-27
may,28-31
result,32-38
from,39-43
displacement,44-56
of,57-59
protein-bound,60-73
Anafranil,74-83	DrugDDI.d91.s25.e0
by,84-86
other,87-92
highly,93-99
bound,100-105
drugs.,106-112

Effect,0-6
of,7-9
Clonazepam,10-20	DrugDDI.d87.s0.e0
on,21-23
the,24-27
Pharmacokinetics,28-44
of,45-47
Other,48-53
Drugs:,54-60	DrugDDI.d87.s0.e1
Clonazepam,61-71	DrugDDI.d87.s0.e2
does,72-76
not,77-80
appear,81-87
to,88-90
alter,91-96
the,97-100
pharmacokinetics,101-117
of,118-120
phenytoin,,121-131
carbamazepine,,132-146
or,147-149
phenobarbital.,150-164	DrugDDI.d87.s0.e5

The,0-3
effect,4-10
of,11-13
clonazepam,14-24	DrugDDI.d87.s1.e0
on,25-27
the,28-31
metabolism,32-42
of,43-45
other,46-51
drugs,52-57	DrugDDI.d87.s1.e1
has,58-61
not,62-65
been,66-70
investigated.,71-84

Effect,0-6
of,7-9
Other,10-15
Drugs,16-21	DrugDDI.d87.s2.e0
on,22-24
the,25-28
Pharmacokinetics,29-45
of,46-48
Clonazepam:,49-60	DrugDDI.d87.s2.e1
Literature,61-71
reports,72-79
suggest,80-87
that,88-92
ranitidine,,93-104
an,105-107
agent,108-113
that,114-118
decreases,119-128
stomach,129-136
acidity,,137-145
does,146-150
not,151-154
greatly,155-162
alter,163-168
clonazepam,169-179	DrugDDI.d87.s2.e3
pharmacokinetics.,180-197

In,0-2
a,3-4
study,5-10
in,11-13
which,14-19
the,20-23
2,24-25
mg,26-28
clonazepam,29-39	DrugDDI.d87.s3.e0
orally,40-46
disintegrating,47-61
tablet,62-68
was,69-72
administered,73-85
with,86-90
and,91-94
without,95-102
propantheline,103-116	DrugDDI.d87.s3.e1
(an,117-120
anticholinergic,121-136	DrugDDI.d87.s3.e2
agent,137-142	DrugDDI.d87.s3.e2
with,143-147
multiple,148-156
effects,157-164
on,165-167
the,168-171
GI,172-174
tract),175-181
to,182-184
healthy,185-192
volunteers,,193-204
the,205-208
AUC,209-212
of,213-215
clonazepam,216-226	DrugDDI.d87.s3.e3
was,227-230
10%,231-234
lower,235-240
and,241-244
the,245-248
Cmax,249-253
of,254-256
clonazepam,257-267	DrugDDI.d87.s3.e4
was,268-271
20%,272-275
lower,276-281
when,282-286
the,287-290
orally,291-297
disintegrating,298-312
tablet,313-319
was,320-323
given,324-329
with,330-334
propantheline,335-348	DrugDDI.d87.s3.e5
compared,349-357
to,358-360
when,361-365
it,366-368
was,369-372
given,373-378
alone.,379-385

Fluoxetine,0-10	DrugDDI.d87.s4.e0
does,11-15
not,16-19
affect,20-26
the,27-30
pharmacokinetics,31-47
of,48-50
clonazepam.,51-62	DrugDDI.d87.s4.e1

Cytochrome,0-10	DrugDDI.d87.s5.e0
P-450,11-16	DrugDDI.d87.s5.e0
inducers,,17-26
such,27-31
as,32-34
phenytoin,,35-45
carbamazepine,46-59	DrugDDI.d87.s5.e2
and,60-63
phenobarbital,,64-78
induce,79-85
clonazepam,86-96	DrugDDI.d87.s5.e4
metabolism,,97-108
causing,109-116
an,117-119
approximately,120-133
30%,134-137
decrease,138-146
in,147-149
plasma,150-156
clonazepam,157-167
levels.,168-175

Although,0-8
clinical,9-17
studies,18-25
have,26-30
not,31-34
been,35-39
performed,,40-50
based,51-56
on,57-59
the,60-63
involvement,64-75
of,76-78
the,79-82
cytochrome,83-93	DrugDDI.d87.s6.e0
P-450,94-99	DrugDDI.d87.s6.e0
3A,100-102
family,103-109
in,110-112
clonazepam,113-123	DrugDDI.d87.s6.e1
metabolism,,124-135
inhibitors,136-146
of,147-149
this,150-154
enzyme,155-161
system,,162-169
notably,170-177
oral,178-182
antifungal,183-193	DrugDDI.d87.s6.e2
agents,,194-201	DrugDDI.d87.s6.e2
should,202-208
be,209-211
used,212-216
cautiously,217-227
in,228-230
patients,231-239
receiving,240-249
clonazepam.,250-261	DrugDDI.d87.s6.e3

Pharmacodynamic,0-15
Interactions:,16-29
The,30-33
CNS-depressant,34-48	DrugDDI.d87.s7.e0
action,49-55	DrugDDI.d87.s7.e0
of,56-58
the,59-62
benzodiazepine,63-77	DrugDDI.d87.s7.e1
class,78-83
of,84-86
drugs,87-92	DrugDDI.d87.s7.e2
may,93-96
be,97-99
potentiated,100-111
by,112-114
alcohol,,115-123
narcotics,,124-134
barbiturates,,135-148
nonbarbiturate,149-163
hypnotics,,164-174
antianxiety,175-186	DrugDDI.d87.s7.e7
agents,,187-194	DrugDDI.d87.s7.e7
the,195-198
phenothiazines,,199-214
thioxanthene,215-227	DrugDDI.d87.s7.e9
and,228-231
butyrophenone,232-245	DrugDDI.d87.s7.e10
classes,246-253
of,254-256
antipsychotic,257-270	DrugDDI.d87.s7.e11
agents,,271-278	DrugDDI.d87.s7.e11
monoamine,279-288	DrugDDI.d87.s7.e12
oxidase,289-296	DrugDDI.d87.s7.e12
inhibitors,297-307	DrugDDI.d87.s7.e12
and,308-311
the,312-315
tricyclic,316-325	DrugDDI.d87.s7.e13
antidepressants,,326-342	DrugDDI.d87.s7.e13
and,343-346
by,347-349
other,350-355
anticonvulsant,356-370	DrugDDI.d87.s7.e14
drugs.,371-377	DrugDDI.d87.s7.e14

Tablet,0-6
If,7-9
a,10-11
patient,12-19
receiving,20-29
clonidine,30-39	DrugDDI.d337.s0.e0
hydrochloride,40-53	DrugDDI.d337.s0.e0
is,54-56
also,57-61
taking,62-68
tricyclic,69-78	DrugDDI.d337.s0.e1
antidepressants,,79-95	DrugDDI.d337.s0.e1
the,96-99
effect,100-106
of,107-109
clonidine,110-119	DrugDDI.d337.s0.e2
may,120-123
be,124-126
reduced,,127-135
thus,136-140
necessitating,141-154
an,155-157
increase,158-166
in,167-169
dosage.,170-177

Clonidine,0-9	DrugDDI.d337.s1.e0
hydrochloride,10-23	DrugDDI.d337.s1.e0
may,24-27
enhance,28-35
the,36-39
CNS-depressive,40-54
effects,55-62
of,63-65
alcohol,,66-74
barbiturates,75-87	DrugDDI.d337.s1.e2
or,88-90
other,91-96
sedatives.,97-107	DrugDDI.d337.s1.e3

Amitriptyline,0-13	DrugDDI.d337.s2.e0
in,14-16
combination,17-28
with,29-33
clonidine,34-43	DrugDDI.d337.s2.e1
enhances,44-52
the,53-56
manifestation,57-70
of,71-73
corneal,74-81
lesions,82-89
in,90-92
rats,93-97
Epidural,98-106
Injection,107-116
Clonidine,117-126	DrugDDI.d337.s2.e2
may,127-130
potentiate,131-141
the,142-145
CNS-depressive,146-160
effect,161-167
of,168-170
alcohol,,171-179
barbiturates,180-192	DrugDDI.d337.s2.e4
or,193-195
other,196-201
sedating,202-210
drugs.,211-217	DrugDDI.d337.s2.e5

Narcotic,0-8	DrugDDI.d337.s3.e0
analgesics,9-19	DrugDDI.d337.s3.e0
may,20-23
potentiate,24-34
the,35-38
hypotensive,39-50
effects,51-58
of,59-61
clonidine.,62-72	DrugDDI.d337.s3.e1

Tricyclic,0-9	DrugDDI.d337.s4.e0
antidepressants,10-25	DrugDDI.d337.s4.e0
may,26-29
antagonize,30-40
the,41-44
hypotensive,45-56
effects,57-64
of,65-67
clonidine.,68-78	DrugDDI.d337.s4.e1

The,0-3
effects,4-11
of,12-14
tricyclic,15-24	DrugDDI.d337.s5.e0
antidepressants,25-40	DrugDDI.d337.s5.e0
on,41-43
clonidines,44-54	DrugDDI.d337.s5.e1
analgesic,55-64	DrugDDI.d337.s5.e2
actions,65-72
are,73-76
not,77-80
known.,81-87

Beta,0-4	DrugDDI.d337.s6.e0
blockers,5-13	DrugDDI.d337.s6.e0
may,14-17
exacerbate,18-28
the,29-32
hypertensive,33-45
response,46-54
seen,55-59
with,60-64
clonidine,65-74	DrugDDI.d337.s6.e1
withdrawl.,75-85

Also,,0-5
due,6-9
to,10-12
the,13-16
potential,17-26
for,27-30
additive,31-39
effects,40-47
such,48-52
as,53-55
bradycardia,56-67
and,68-71
AV,72-74
block,,75-81
caution,82-89
is,90-92
warranted,93-102
in,103-105
patients,106-114
receiving,115-124
clonidine,125-134	DrugDDI.d337.s7.e0
with,135-139
agents,140-146
known,147-152
to,153-155
affect,156-162
sinus,163-168
node,169-173
function,174-182
or,183-185
AV,186-188
nodal,189-194
conduction,195-205
(e.g.,,206-212
digitalis,,213-223
calcium,224-231	DrugDDI.d337.s7.e2
channel,232-239	DrugDDI.d337.s7.e2
blockers,,240-249	DrugDDI.d337.s7.e2
and,250-253
beta-blockers.),254-269	DrugDDI.d337.s7.e3

There,0-5
is,6-8
one,9-12
reported,13-21
case,22-26
of,27-29
a,30-31
patient,32-39
with,40-44
acute,45-50
delirium,51-59
associated,60-70
with,71-75
the,76-79
simultaneous,80-92
use,93-96
of,97-99
fluphenazine,100-112	DrugDDI.d337.s8.e0
and,113-116
oral,117-121
clonidine.,122-132	DrugDDI.d337.s8.e1

Symptoms,0-8
resolved,9-17
when,18-22
clonidine,23-32	DrugDDI.d337.s9.e0
was,33-36
withdrawn,37-46
and,47-50
recurred,51-59
when,60-64
the,65-68
patient,69-76
was,77-80
rechallenged,81-93
with,94-98
clonidine.,99-109	DrugDDI.d337.s9.e1

Epidural,0-8
clonidine,9-18	DrugDDI.d337.s10.e0
may,19-22
prolong,23-30
the,31-34
duration,35-43
of,44-46
pharmacologic,47-60
effects,61-68
of,69-71
epidural,72-80
local,81-86	DrugDDI.d337.s10.e1
anesthetics,,87-99	DrugDDI.d337.s10.e1
including,100-109
both,110-114
sensory,115-122
and,123-126
motor,127-132
blockade.,133-142

Aspirin,,0-8
warfarin,,9-18
heparin,,19-27
NSAIDs,28-34	DrugDDI.d151.s0.e3

If,0-2
TRANXENE,3-11	DrugDDI.d96.s0.e0
is,12-14
to,15-17
be,18-20
combined,21-29
with,30-34
other,35-40
drugs,41-46	DrugDDI.d96.s0.e1
acting,47-53
on,54-56
the,57-60
central,61-68
nervous,69-76
system,,77-84
careful,85-92
consideration,93-106
should,107-113
be,114-116
given,117-122
to,123-125
the,126-129
pharmacology,130-142
of,143-145
the,146-149
agents,150-156
to,157-159
be,160-162
employed.,163-172

Animal,0-6
experience,7-17
indicates,18-27
that,28-32
clorazepate,33-44	DrugDDI.d96.s1.e0
dipotassium,45-56	DrugDDI.d96.s1.e0
prolongs,57-65
the,66-69
sleeping,70-78
time,79-83
after,84-89
hexobarbital,90-102	DrugDDI.d96.s1.e1
or,103-105
after,106-111
ethyl,112-117	DrugDDI.d96.s1.e2
alcohol,,118-126	DrugDDI.d96.s1.e2
increases,127-136
the,137-140
inhibitory,141-151
effects,152-159
of,160-162
chlorpromazine,,163-178
but,179-182
does,183-187
not,188-191
exhibit,192-199
monoamine,200-209	DrugDDI.d96.s1.e4
oxidase,210-217	DrugDDI.d96.s1.e4
inhibition.,218-229

Clinical,0-8
studies,9-16
have,17-21
shown,22-27
increased,28-37
sedation,38-46
with,47-51
concurrent,52-62
hypnotic,63-71	DrugDDI.d96.s2.e0
medications.,72-84

The,0-3
actions,4-11
of,12-14
the,15-18
benzodiazepines,19-34	DrugDDI.d96.s3.e0
may,35-38
be,39-41
potentiated,42-53
by,54-56
barbiturates,,57-70
narcotics,,71-81
phenothiazines,,82-97
monoamine,98-107	DrugDDI.d96.s3.e4
oxidase,108-115	DrugDDI.d96.s3.e4
inhibitors,116-126	DrugDDI.d96.s3.e4
or,127-129
other,130-135
antidepressants.,136-152	DrugDDI.d96.s3.e5

If,0-2
TRANXENE,3-11	DrugDDI.d96.s4.e0
tablets,12-19
are,20-23
used,24-28
to,29-31
treat,32-37
anxiety,38-45
associated,46-56
with,57-61
somatic,62-69
disease,70-77
states,,78-85
careful,86-93
attention,94-103
must,104-108
be,109-111
paid,112-116
to,117-119
possible,120-128
drug,129-133
interaction,134-145
with,146-150
concomitant,151-162
medication.,163-174	DrugDDI.d96.s4.e1

In,0-2
bioavailability,3-18
studies,19-26
with,27-31
normal,32-38
subjects,,39-48
the,49-52
concurrent,53-63
administration,64-78
of,79-81
antacids,82-90	DrugDDI.d96.s5.e0
at,91-93
therapeutic,94-105
levels,106-112
did,113-116
not,117-120
significantly,121-134
influence,135-144
the,145-148
bioavailability,149-164
of,165-167
TRANXENE,168-176	DrugDDI.d96.s5.e1
tablets.,177-185

The,0-3
risks,4-9
of,10-12
using,13-18
Clozapine,19-28	DrugDDI.d58.s0.e0
in,29-31
combination,32-43
with,44-48
other,49-54
drugs,55-60	DrugDDI.d58.s0.e1
have,61-65
not,66-69
been,70-74
systematically,75-89
evaluated.,90-100

Pharmacodynamic-related,0-23
Interactions:,24-37
The,38-41
mechanism,42-51
of,52-54
Clozapine,55-64	DrugDDI.d58.s1.e0
induced,65-72
agranulocytosis,73-88
is,89-91
unknown;,92-100

Therefore,,0-10
Clozapine,11-20	DrugDDI.d58.s3.e0
should,21-27
not,28-31
be,32-34
used,35-39
with,40-44
other,45-50
agents,51-57
having,58-64
a,65-66
well-known,67-77
potential,78-87
to,88-90
suppress,91-99
bone,100-104
marrow,105-111
function.,112-121

Given,0-5
the,6-9
primary,10-17
CNS,18-21
effects,22-29
of,30-32
Clozapine,,33-43
caution,44-51
is,52-54
advised,55-62
in,63-65
using,66-71
it,72-74
concomitantly,75-88
with,89-93
other,94-99
CNS-active,100-110	DrugDDI.d58.s4.e1
drugs,111-116	DrugDDI.d58.s4.e1
or,117-119
alcohol.,120-128	DrugDDI.d58.s4.e2

Orthostatic,0-11
hypotension,12-23
in,24-26
patients,27-35
taking,36-42
clozapine,43-52	DrugDDI.d58.s5.e0
can,,53-57
in,58-60
rare,61-65
cases,66-71
(approximately,72-86
1,87-88
case,89-93
per,94-97
3,000,98-103
patients),,104-114
be,115-117
accompanied,118-129
by,130-132
profound,133-141
collapse,142-150
and,151-154
respiratory,155-166
and/or,167-173
cardiac,174-181
arrest.,182-189

Some,0-4
of,5-7
the,8-11
cases,12-17
of,18-20
collapse/respiratory,21-41
arrest/cardiac,42-56
arrest,57-63
during,64-70
initial,71-78
treatment,79-88
occurred,89-97
in,98-100
patients,101-109
who,110-113
were,114-118
being,119-124
administered,125-137
benzodiazepines;,138-154	DrugDDI.d58.s6.e0

similar,0-7
events,8-14
have,15-19
been,20-24
reported,25-33
in,34-36
patients,37-45
taking,46-52
other,53-58
psychotropic,59-71	DrugDDI.d58.s7.e0
drugs,72-77	DrugDDI.d58.s7.e0
or,78-80
even,81-85
Clozapine,86-95	DrugDDI.d58.s7.e1
by,96-98
itself.,99-106

Although,0-8
it,9-11
has,12-15
not,16-19
been,20-24
established,25-36
that,37-41
there,42-47
is,48-50
an,51-53
interaction,54-65
between,66-73
Clozapine,74-83	DrugDDI.d58.s8.e0
and,84-87
benzodiazepines,88-103	DrugDDI.d58.s8.e1
or,104-106
other,107-112
psychotropics,,113-127
caution,128-135
is,136-138
advised,139-146
when,147-151
clozapine,152-161	DrugDDI.d58.s8.e2
is,162-164
initiated,165-174
in,175-177
patients,178-186
taking,187-193
a,194-195
benzodiazepine,196-210	DrugDDI.d58.s8.e3
or,211-213
any,214-217
other,218-223
psychotropic,224-236	DrugDDI.d58.s8.e4
drug.,237-242	DrugDDI.d58.s8.e4

Clozapine,0-9	DrugDDI.d58.s9.e0
may,10-13
potentiate,14-24
the,25-28
hypotensive,29-40
effects,41-48
of,49-51
antihypertensive,52-68	DrugDDI.d58.s9.e1
drugs,69-74	DrugDDI.d58.s9.e1
and,75-78
the,79-82
anticholinergic,83-98	DrugDDI.d58.s9.e2
effects,99-106
of,107-109
atropine-type,110-123	DrugDDI.d58.s9.e3
drugs.,124-130

The,0-3
administration,4-18
of,19-21
epinephrine,22-33	DrugDDI.d58.s10.e0
should,34-40
be,41-43
avoided,44-51
in,52-54
the,55-58
treatment,59-68
of,69-71
drug,72-76
induced,77-84
hypotension,85-96
because,97-104
of,105-107
a,108-109
possible,110-118
reverse,119-126
epinephrine,127-138
effect.,139-146

Pharmacokinetic-related,0-23
Interactions:,24-37
Clozapine,38-47	DrugDDI.d58.s11.e0
is,48-50
a,51-52
substrate,53-62
for,63-66
many,67-71
CYP,72-75
450,76-79
isozymes,,80-89
in,90-92
particular,93-103
1A2,,104-108
2D6,,109-113
and,114-117
3A4.,118-122

The,0-3
risk,4-8
of,9-11
metabolic,12-21
interactions,22-34
caused,35-41
by,42-44
an,45-47
effect,48-54
on,55-57
an,58-60
individual,61-71
isoform,72-79	DrugDDI.d58.s12.e0
is,80-82
therefore,83-92
minimized.,93-103

Nevertheless,,0-13
caution,14-21
should,22-28
be,29-31
used,32-36
in,37-39
patients,40-48
receiving,49-58
concomitant,59-70
treatment,71-80
with,81-85
other,86-91
drugs,92-97	DrugDDI.d58.s13.e0
that,98-102
are,103-106
either,107-113
inhibitors,114-124
or,125-127
inducers,128-136
of,137-139
these,140-145
enzymes.,146-154

Concomitant,0-11
administration,12-26
of,27-29
drugs,30-35	DrugDDI.d58.s14.e0
known,36-41
to,42-44
induce,45-51
cytochrome,52-62	DrugDDI.d58.s14.e1
P450,63-67	DrugDDI.d58.s14.e1
enzymes,68-75
may,76-79
decrease,80-88
the,89-92
plasma,93-99
levels,100-106
of,107-109
clozapine.,110-120	DrugDDI.d58.s14.e2

Phenytoin,,0-10
nicotine,,11-20
and,21-24
rifampin,25-33	DrugDDI.d58.s15.e2
may,34-37
decrease,38-46
Clozapine,47-56
plasma,57-63
levels,,64-71
resulting,72-81
in,82-84
a,85-86
decrease,87-95
in,96-98
effectiveness,99-112
of,113-115
a,116-117
previously,118-128
effective,129-138
Clozapine,139-148
dose.,149-154

Concomitant,0-11
administration,12-26
of,27-29
drugs,30-35	DrugDDI.d58.s16.e0
known,36-41
to,42-44
inhibit,45-52
the,53-56
activity,57-65
of,66-68
cytochrome,69-79	DrugDDI.d58.s16.e1
P450,80-84	DrugDDI.d58.s16.e1
isozymes,85-93
may,94-97
increase,98-106
the,107-110
plasma,111-117
levels,118-124
of,125-127
clozapine.,128-138	DrugDDI.d58.s16.e2

Cimetidine,,0-11
caffeine,,12-21
and,22-25
erythromycin,26-38	DrugDDI.d58.s17.e2
may,39-42
increase,43-51
plasma,52-58
levels,59-65
of,66-68
Clozapine,,69-79
potentially,80-91
resulting,92-101
in,102-104
adverse,105-112
effects.,113-121

Although,0-8
concomitant,9-20
use,21-24
of,25-27
Clozapine,28-37	DrugDDI.d58.s18.e0
and,38-41
carbamazepine,42-55	DrugDDI.d58.s18.e1
is,56-58
not,59-62
recommended,,63-75
it,76-78
should,79-85
be,86-88
noted,89-94
that,95-99
discontinuation,100-115
of,116-118
concomitant,119-130
carbamazepine,131-144	DrugDDI.d58.s18.e2
administration,145-159
may,160-163
result,164-170
in,171-173
an,174-176
increase,177-185
in,186-188
Clozapine,189-198
plasma,199-205
levels.,206-213

In,0-2
a,3-4
study,5-10
of,11-13
schizophrenic,14-27
patients,28-36
who,37-40
received,41-49
clozapine,50-59	DrugDDI.d58.s19.e0
under,60-65
steady,66-72
state,73-78
conditions,,79-90
fluvoxamine,91-102	DrugDDI.d58.s19.e1
or,103-105
paroxetine,106-116	DrugDDI.d58.s19.e2
was,117-120
added,121-126
in,127-129
16,130-132
and,133-136
14,137-139
patients,,140-149
respectively.,150-163

After,0-5
14,6-8
days,9-13
of,14-16
co-administration,,17-35
mean,36-40
trough,41-47
concentrations,48-62
of,63-65
clozapine,66-75	DrugDDI.d58.s20.e0
and,76-79
its,80-83
metabolites,,84-96
N-desmethylclozapine,97-117	DrugDDI.d58.s20.e2
and,118-121
clozapine,122-131
N-oxide,,132-140
were,141-145
elevated,146-154
with,155-159
fluvoxamine,160-171	DrugDDI.d58.s20.e3
by,172-174
about,175-180
three-fold,181-191
compared,192-200
to,201-203
baseline,204-212
concentrations.,213-228

Paroxetine,0-10	DrugDDI.d58.s21.e0
produced,11-19
only,20-24
minor,25-30
changes,31-38
in,39-41
the,42-45
levels,46-52
of,53-55
clozapine,56-65	DrugDDI.d58.s21.e1
and,66-69
its,70-73
metabolites.,74-86	DrugDDI.d58.s21.e2

However,,0-8
other,9-14
published,15-24
reports,25-32
describe,33-41
modest,42-48
elevations,49-59
(less,60-65
than,66-70
two-fold),71-80
of,81-83
clozapine,84-93	DrugDDI.d58.s22.e0
and,94-97
metabolite,98-108	DrugDDI.d58.s22.e1
concentrations,109-123
when,124-128
clozapine,129-138	DrugDDI.d58.s22.e2
was,139-142
taken,143-148
with,149-153
paroxetine,,154-165
fluoxetine,,166-177
and,178-181
sertraline.,182-193	DrugDDI.d58.s22.e5

Therefore,,0-10
such,11-15
combined,16-24
treatment,25-34
should,35-41
be,42-44
approached,45-55
with,56-60
caution,61-68
and,69-72
patients,73-81
should,82-88
be,89-91
monitored,92-101
closely,102-109
when,110-114
Clozapine,115-124	DrugDDI.d58.s23.e0
is,125-127
combined,128-136
with,137-141
these,142-147
drugs,,148-154
particularly,155-167
with,168-172
fluvoxamine.,173-185	DrugDDI.d58.s23.e2

A,0-1
subset,2-8
(3%-10%),9-17
of,18-20
the,21-24
population,25-35
has,36-39
reduced,40-47
activity,48-56
of,57-59
certain,60-67
drug,68-72
metabolizing,73-85
enzymes,86-93
such,94-98
as,99-101
the,102-105
cytochrome,106-116	DrugDDI.d58.s25.e0
P450,117-121	DrugDDI.d58.s25.e0
isozyme,122-129	DrugDDI.d58.s25.e0
P450,130-134	DrugDDI.d58.s25.e0
2D6.,135-139	DrugDDI.d58.s25.e0

Such,0-4
individuals,5-16
are,17-20
referred,21-29
to,30-32
as,33-35
poor,36-40
metabolizers,41-53
of,54-56
drugs,57-62	DrugDDI.d58.s26.e0
such,63-67
as,68-70
debrisoquin,,71-83
dextromethorphan,,84-101
the,102-105
tricyclic,106-115	DrugDDI.d58.s26.e3
antidepressants,,116-132	DrugDDI.d58.s26.e3
and,133-136
clozapine.,137-147	DrugDDI.d58.s26.e4

These,0-5
individuals,6-17
may,18-21
develop,22-29
higher,30-36
than,37-41
expected,42-50
plasma,51-57
concentrations,58-72
of,73-75
clozapine,76-85	DrugDDI.d58.s27.e0
when,86-90
given,91-96
usual,97-102
doses.,103-109

In,0-2
addition,,3-12
certain,13-20
drugs,21-26	DrugDDI.d58.s28.e0
that,27-31
are,32-35
metabolized,36-47
by,48-50
this,51-55
isozyme,,56-64
including,65-74
many,75-79
antidepressants,80-95	DrugDDI.d58.s28.e2
(clozapine,,96-107
selective,108-117
serotonin,118-127	DrugDDI.d58.s28.e4
reuptake,128-136	DrugDDI.d58.s28.e4
inhibitors,,137-148	DrugDDI.d58.s28.e4
and,149-152
others),,153-161
may,162-165
inhibit,166-173
the,174-177
activity,178-186
of,187-189
this,190-194
isozyme,,195-203
and,204-207
thus,208-212
may,213-216
make,217-221
normal,222-228
metabolizers,229-241
resemble,242-250
poor,251-255
metabolizers,256-268
with,269-273
regard,274-280
to,281-283
concomitant,284-295
therapy,296-303
with,304-308
other,309-314
drugs,315-320	DrugDDI.d58.s28.e6
metabolized,321-332
by,333-335
this,336-340
enzyme,341-347
system,,348-355
leading,356-363
to,364-366
drug,367-371
interaction.,372-384

Concomitant,0-11
use,12-15
of,16-18
clozapine,19-28	DrugDDI.d58.s29.e0
with,29-33
other,34-39
drugs,40-45	DrugDDI.d58.s29.e1
metabolized,46-57
by,58-60
cytochrome,61-71	DrugDDI.d58.s29.e2
P450,72-76	DrugDDI.d58.s29.e2
2D6,77-80	DrugDDI.d58.s29.e2
may,81-84
require,85-92
lower,93-98
doses,99-104
than,105-109
usually,110-117
prescribed,118-128
for,129-132
either,133-139
clozapine,140-149	DrugDDI.d58.s29.e3
or,150-152
the,153-156
other,157-162
drug.,163-168	DrugDDI.d58.s29.e4

Therefore,,0-10
co-administration,11-28
of,29-31
clozapine,32-41	DrugDDI.d58.s30.e0
with,42-46
other,47-52
drugs,53-58	DrugDDI.d58.s30.e1
that,59-63
are,64-67
metabolized,68-79
by,80-82
this,83-87
isozyme,,88-96
including,97-106
antidepressants,,107-123
phenothiazines,,124-139
carbamazepine,,140-154
and,155-158
Type,159-163
1C,164-166
antiarrhythmics,167-182	DrugDDI.d58.s30.e6
(e.g.,,183-189
propafenone,,190-202
flecainide,203-213	DrugDDI.d58.s30.e8
and,214-217
encainide),,218-229
or,230-232
that,233-237
inhibit,238-245
this,246-250
enzyme,251-257
(e.g.,,258-264
quinidine),,265-276
should,277-283
be,284-286
approached,287-297
with,298-302
caution.,303-311

The,0-3
risk,4-8
of,9-11
a,12-13
potential,14-23
interaction,24-35
between,36-43
NovoSeven,44-53	DrugDDI.d374.s0.e0
and,54-57
coagulation,58-69	DrugDDI.d374.s0.e1
factor,70-76	DrugDDI.d374.s0.e1
concentrates,77-89
has,90-93
not,94-97
been,98-102
adequately,103-113
evaluated,114-123
in,124-126
preclinical,127-138
or,139-141
clinical,142-150
studies.,151-159

Simultaneous,0-12
use,13-16
of,17-19
activated,20-29	DrugDDI.d374.s1.e0
prothrombin,30-41	DrugDDI.d374.s1.e0
complex,42-49	DrugDDI.d374.s1.e0
concentrates,50-62	DrugDDI.d374.s1.e0
or,63-65
prothrombin,66-77	DrugDDI.d374.s1.e1
complex,78-85	DrugDDI.d374.s1.e1
concentrates,86-98	DrugDDI.d374.s1.e1
should,99-105
be,106-108
avoided.,109-117

Although,0-8
the,9-12
specific,13-21
drug,22-26
interaction,27-38
was,39-42
not,43-46
studied,47-54
in,55-57
a,58-59
clinical,60-68
trial,,69-75
there,76-81
have,82-86
been,87-91
more,92-96
than,97-101
50,102-104
episodes,105-113
of,114-116
concomitant,117-128
use,129-132
of,133-135
antifibrinolytic,136-152
therapies,153-162
(i.e.,,163-169
tranexamic,170-180	DrugDDI.d374.s2.e0
acid,,181-186	DrugDDI.d374.s2.e0
aminocaproic,187-199	DrugDDI.d374.s2.e1
acid),200-205	DrugDDI.d374.s2.e1
and,206-209
NovoSeven.,210-220	DrugDDI.d374.s2.e2

NovoSeven,0-9	DrugDDI.d374.s3.e0
should,10-16
not,17-20
be,21-23
mixed,24-29
with,30-34
infusion,35-43
solutions,44-53
until,54-59
clinical,60-68
data,69-73
are,74-77
available,78-87
to,88-90
direct,91-97
this,98-102
use.,103-107

Codeine,0-7	DrugDDI.d241.s0.e0
in,8-10
combination,11-22
with,23-27
other,28-33	DrugDDI.d241.s0.e1
narcotic,34-42	DrugDDI.d241.s0.e1
analgesics,,43-54	DrugDDI.d241.s0.e1
general,55-62	DrugDDI.d241.s0.e2
anesthetics,,63-75	DrugDDI.d241.s0.e2
phenothiazines,,76-91
tranquilizers,,92-106
sedative-hypnotics,,107-126
or,127-129
other,130-135
CNS,136-139	DrugDDI.d241.s0.e6
depressants,140-151	DrugDDI.d241.s0.e6
(including,152-162
alcohol),163-171	DrugDDI.d241.s0.e7
has,172-175
additive,176-184
depressant,185-195
effects.,196-204

Colchicine,0-10	DrugDDI.d421.s0.e0
is,11-13
inhibited,14-23
by,24-26
acidifying,27-37	DrugDDI.d421.s0.e1
agents.,38-45	DrugDDI.d421.s0.e1

The,0-3
action,4-10
of,11-13
colchicine,14-24	DrugDDI.d421.s1.e0
is,25-27
potentiated,28-39
by,40-42
alkalinizing,43-55	DrugDDI.d421.s1.e1
agents.,56-63	DrugDDI.d421.s1.e1

Colchicine,0-10	DrugDDI.d421.s2.e0
may,11-14
increase,15-23
sensitivity,24-35
to,36-38
the,39-42
CNS,43-46	DrugDDI.d421.s2.e1
depressants.,47-59	DrugDDI.d421.s2.e1

Response,0-8
to,9-11
sympathomimetic,12-27	DrugDDI.d421.s3.e0
agents,28-34	DrugDDI.d421.s3.e0
may,35-38
be,39-41
enhanced,42-50
by,51-53
colchicine.,54-65	DrugDDI.d421.s3.e1

WelChol?,0-8
has,9-12
been,13-17
studied,18-25
in,26-28
several,29-36
human,37-42
drug,43-47
interaction,48-59
studies,60-67
in,68-70
which,71-76
it,77-79
was,80-83
administered,84-96
with,97-101
a,102-103
meal,104-108
and,109-112
the,113-116
test,117-121
drug.,122-127	DrugDDI.d46.s0.e0

WelChol?,0-8
was,9-12
found,13-18
to,19-21
have,22-26
no,27-29
significant,30-41
effect,42-48
on,49-51
the,52-55
bioavailability,56-71
of,72-74
digoxin,,75-83
lovastatin,,84-95
metoprolol,,96-107
quinidine,,108-118
valproic,119-127	DrugDDI.d46.s1.e4
acid,,128-133	DrugDDI.d46.s1.e4
and,134-137
warfarin.,138-147	DrugDDI.d46.s1.e5

WelChol?,0-8
decreased,9-18
the,19-22
Cmax,23-27
and,28-31
AUC,32-35
of,36-38
sustained-release,39-56
verapamil,57-66	DrugDDI.d46.s2.e0
(Calan,67-73
SR?),74-78
by,79-81
approximately,82-95
31%,96-99
and,100-103
11%,,104-108
respectively.,109-122

Since,0-5
there,6-11
is,12-14
a,15-16
high,17-21
degree,22-28
of,29-31
variability,32-43
in,44-46
the,47-50
bioavailability,51-66
of,67-69
verapamil,,70-80
the,81-84
clinical,85-93
significance,94-106
of,107-109
this,110-114
finding,115-122
is,123-125
unclear.,126-134

In,0-2
clinical,3-11
studies,,12-20
coadministration,21-37
of,38-40
WelChol?,41-49
with,50-54
atorvastatin,,55-68
lovastatin,,69-80
or,81-83
simvastatin,84-95	DrugDDI.d46.s4.e2
did,96-99
not,100-103
interfere,104-113
with,114-118
the,119-122
lipid-lowering,123-137
activity,138-146
of,147-149
the,150-153
HMG-CoA,154-161	DrugDDI.d46.s4.e3
reductase,162-171	DrugDDI.d46.s4.e3
inhibitor.,172-182	DrugDDI.d46.s4.e3

Other,0-5
drugs,6-11	DrugDDI.d46.s5.e0
have,12-16
not,17-20
been,21-25
studied.,26-34

When,0-4
administering,5-18
other,19-24
drugs,25-30	DrugDDI.d46.s6.e0
for,31-34
which,35-40
alterations,41-52
in,53-55
blood,56-61
levels,62-68
could,69-74
have,75-79
a,80-81
clinically,82-92
significant,93-104
effect,105-111
on,112-114
safety,115-121
or,122-124
efficacy,,125-134
physicians,135-145
should,146-152
consider,153-161
monitoring,162-172
drug,173-177
levels,178-184
or,185-187
effects.,188-196

Since,0-5
colestipol,6-16	DrugDDI.d575.s0.e0
hydrochloride,17-30	DrugDDI.d575.s0.e0
is,31-33
an,34-36
anion,37-42	DrugDDI.d575.s0.e1
exchange,43-51	DrugDDI.d575.s0.e1
resin,,52-58	DrugDDI.d575.s0.e1
it,59-61
may,62-65
have,66-70
a,71-72
strong,73-79
affinity,80-88
for,89-92
anions,93-99
other,100-105
than,106-110
the,111-114
bile,115-119	DrugDDI.d575.s0.e2
acids.,120-126	DrugDDI.d575.s0.e2

In,0-2
vitro,3-8
studies,9-16
have,17-21
indicated,22-31
that,32-36
colestipol,37-47	DrugDDI.d575.s1.e0
hydrochloride,48-61	DrugDDI.d575.s1.e0
binds,62-67
a,68-69
number,70-76
of,77-79
drugs.,80-86	DrugDDI.d575.s1.e1

The,0-3
interval,4-12
between,13-20
the,21-24
administration,25-39
of,40-42
COLESTID,43-51	DrugDDI.d575.s3.e0
Tablets,52-59
and,60-63
any,64-67
other,68-73
medication,74-84	DrugDDI.d575.s3.e1
should,85-91
be,92-94
as,95-97
long,98-102
as,103-105
possible.,106-115

Patients,0-8
should,9-15
take,16-20
other,21-26
drugs,27-32	DrugDDI.d575.s4.e0
at,33-35
least,36-41
one,42-45
hour,46-50
before,51-57
or,58-60
four,61-65
hours,66-71
after,72-77
COLESTID,78-86	DrugDDI.d575.s4.e1
Tablets,87-94
to,95-97
avoid,98-103
impeding,104-112
their,113-118
absorption.,119-130

Repeated,0-8
doses,9-14
of,15-17
colestipol,18-28	DrugDDI.d575.s5.e0
hydrochloride,29-42	DrugDDI.d575.s5.e0
given,43-48
prior,49-54
to,55-57
a,58-59
single,60-66
dose,67-71
of,72-74
propranolol,75-86	DrugDDI.d575.s5.e1
in,87-89
human,90-95
trials,96-102
have,103-107
been,108-112
reported,113-121
to,122-124
decrease,125-133
propranolol,134-145	DrugDDI.d575.s5.e2
absorption.,146-157

However,,0-8
in,9-11
a,12-13
follow-up,14-23
study,24-29
in,30-32
normal,33-39
subjects,,40-49
single-dose,50-61
administration,62-76
of,77-79
colestipol,80-90	DrugDDI.d575.s6.e0
hydrochloride,91-104	DrugDDI.d575.s6.e0
and,105-108
propranolol,109-120	DrugDDI.d575.s6.e1
and,121-124
twice-a-day,125-136
administration,137-151
for,152-155
5,156-157
days,158-162
of,163-165
both,166-170
agents,171-177
did,178-181
not,182-185
affect,186-192
the,193-196
extent,197-203
of,204-206
propranolol,207-218	DrugDDI.d575.s6.e2
absorption,,219-230
but,231-234
had,235-238
a,239-240
small,241-246
yet,247-250
statistically,251-264
significant,265-276
effect,277-283
on,284-286
its,287-290
rate,291-295
of,296-298
absorption;,299-310

Effects,0-7
on,8-10
the,11-14
absorption,15-25
of,26-28
other,29-34
beta-blockers,35-48	DrugDDI.d575.s8.e0
have,49-53
not,54-57
been,58-62
determined.,63-74

Therefore,,0-10
patients,11-19
on,20-22
propranolol,23-34	DrugDDI.d575.s9.e0
should,35-41
be,42-44
observed,45-53
when,54-58
COLESTID,59-67	DrugDDI.d575.s9.e1
Tablets,68-75
are,76-79
either,80-86
added,87-92
or,93-95
deleted,96-103
from,104-108
a,109-110
therapeutic,111-122
regimen.,123-131

Studies,0-7
in,8-10
humans,11-17
show,18-22
that,23-27
the,28-31
absorption,32-42
of,43-45
chlorothiazide,46-60	DrugDDI.d575.s10.e0
as,61-63
reflected,64-73
in,74-76
urinary,77-84
excretion,85-94
is,95-97
markedly,98-106
decreased,107-116
even,117-121
when,122-126
administered,127-139
one,140-143
hour,144-148
before,149-155
colestipol,156-166	DrugDDI.d575.s10.e1
hydrochloride.,167-181	DrugDDI.d575.s10.e1

The,0-3
absorption,4-14
of,15-17
tetracycline,,18-31
furosemide,,32-43
penicillin,44-54	DrugDDI.d575.s11.e2
G,,55-57	DrugDDI.d575.s11.e2
hydrochlorothiazide,,58-78
and,79-82
gemfibrozil,83-94	DrugDDI.d575.s11.e4
was,95-98
significantly,99-112
decreased,113-122
when,123-127
given,128-133
simultaneously,134-148
with,149-153
colestipol,154-164	DrugDDI.d575.s11.e5
hydrochloride;,165-179	DrugDDI.d575.s11.e5

these,0-5
drugs,6-11	DrugDDI.d575.s12.e0
were,12-16
not,17-20
tested,21-27
to,28-30
determine,31-40
the,41-44
effect,45-51
of,52-54
administration,55-69
one,70-73
hour,74-78
before,79-85
colestipol,86-96	DrugDDI.d575.s12.e1
hydrochloride.,97-111	DrugDDI.d575.s12.e1

No,0-2
depressant,3-13
effect,14-20
on,21-23
blood,24-29
levels,30-36
in,37-39
humans,40-46
was,47-50
noted,51-56
when,57-61
colestipol,62-72	DrugDDI.d575.s13.e0
hydrochloride,73-86	DrugDDI.d575.s13.e0
was,87-90
administered,91-103
with,104-108
any,109-112
of,113-115
the,116-119
following,120-129
drugs:,130-136	DrugDDI.d575.s13.e1
aspirin,,137-145
clindamycin,,146-158
clofibrate,,159-170
methyldopa,,171-182
nicotinic,183-192	DrugDDI.d575.s13.e6
acid,193-197	DrugDDI.d575.s13.e6
(niacin),,198-207
tolbutamide,,208-220
phenytoin,221-230	DrugDDI.d575.s13.e9
or,231-233
warfarin.,234-243	DrugDDI.d575.s13.e10

Particular,0-10
caution,11-18
should,19-25
be,26-28
observed,29-37
with,38-42
digitalis,43-52	DrugDDI.d575.s14.e0
preparations,53-65	DrugDDI.d575.s14.e0
since,66-71
there,72-77
are,78-81
conflicting,82-93
results,94-101
for,102-105
the,106-109
effect,110-116
of,117-119
colestipol,120-130	DrugDDI.d575.s14.e1
hydrochloride,131-144	DrugDDI.d575.s14.e1
on,145-147
the,148-151
availability,152-164
of,165-167
digoxin,168-175	DrugDDI.d575.s14.e2
and,176-179
digitoxin.,180-190	DrugDDI.d575.s14.e3

The,0-3
potential,4-13
for,14-17
binding,18-25
of,26-28
these,29-34
drugs,35-40	DrugDDI.d575.s15.e0
if,41-43
given,44-49
concomitantly,50-63
is,64-66
present.,67-75

Discontinuing,0-13
colestipol,14-24	DrugDDI.d575.s16.e0
hydrochloride,25-38	DrugDDI.d575.s16.e0
could,39-44
pose,45-49
a,50-51
hazard,52-58
to,59-61
health,62-68
if,69-71
a,72-73
potentially,74-85
toxic,86-91
drug,92-96	DrugDDI.d575.s16.e1
that,97-101
is,102-104
significantly,105-118
bound,119-124
to,125-127
the,128-131
resin,132-137	DrugDDI.d575.s16.e2
has,138-141
been,142-146
titrated,147-155
to,156-158
a,159-160
maintenance,161-172
level,173-178
while,179-184
the,185-188
patient,189-196
was,197-200
taking,201-207
colestipol,208-218	DrugDDI.d575.s16.e3
hydrochloride.,219-233	DrugDDI.d575.s16.e3

Bile,0-4	DrugDDI.d575.s17.e0
acid,5-9	DrugDDI.d575.s17.e0
binding,10-17
resins,18-24
may,25-28
also,29-33
interfere,34-43
with,44-48
the,49-52
absorption,53-63
of,64-66
oral,67-71	DrugDDI.d575.s17.e1
phosphate,72-81	DrugDDI.d575.s17.e1
supplements,82-93	DrugDDI.d575.s17.e1
and,94-97
hydrocortisone.,98-113	DrugDDI.d575.s17.e2

Certain,0-7
other,8-13	DrugDDI.d119.s0.e0
antibiotics,14-25	DrugDDI.d119.s0.e0
(aminoglycosides,26-42
and,43-46
polymyxin),47-57	DrugDDI.d119.s0.e2
have,58-62
also,63-67
been,68-72
reported,73-81
to,82-84
interfere,85-94
with,95-99
the,100-103
nerve,104-109
transmission,110-122
at,123-125
the,126-129
neuromuscular,130-143
junction.,144-153

Based,0-5
on,6-8
this,9-13
reported,14-22
activity,,23-32
they,33-37
should,38-44
not,45-48
be,49-51
given,52-57
concomitantly,58-71
with,72-76
Coly-Mycin,77-87	DrugDDI.d119.s1.e0
M,88-89	DrugDDI.d119.s1.e0
Parenteral,90-100	DrugDDI.d119.s1.e0
except,101-107
with,108-112
the,113-116
greatest,117-125
caution.,126-134

Curariform,0-10	DrugDDI.d119.s2.e0
muscle,11-17	DrugDDI.d119.s2.e0
relaxants,18-27	DrugDDI.d119.s2.e0
(eg,,28-32
tubocurarine),33-46	DrugDDI.d119.s2.e1
and,47-50
other,51-56
drugs,,57-63
including,64-73
ether,,74-80
succinylcholine,,81-97
gallamine,,98-108
decamethonium,109-122	DrugDDI.d119.s2.e6
and,123-126
sodium,127-133	DrugDDI.d119.s2.e7
citrate,,134-142	DrugDDI.d119.s2.e7
potentiate,143-153
the,154-157
neuromuscular,158-171
blocking,172-180
effect,181-187
and,188-191
should,192-198
be,199-201
used,202-206
with,207-211
extreme,212-219
caution,220-227
in,228-230
patients,231-239
being,240-245
treated,246-253
with,254-258
Coly-Mycin,259-269	DrugDDI.d119.s2.e8
M,270-271	DrugDDI.d119.s2.e8
Parenteral.,272-283	DrugDDI.d119.s2.e8

Sodium,0-6	DrugDDI.d119.s3.e0
cephalothin,7-18	DrugDDI.d119.s3.e0
may,19-22
enhance,23-30
the,31-34
nephrotoxicity,35-49
of,50-52
Coly-Mycin,53-63	DrugDDI.d119.s3.e1
M,64-65	DrugDDI.d119.s3.e1
Parenteral.,66-77	DrugDDI.d119.s3.e1

The,0-3
concomitant,4-15
use,16-19
of,20-22
sodium,23-29	DrugDDI.d119.s4.e0
cephalothin,30-41	DrugDDI.d119.s4.e0
and,42-45
Coly-Mycin,46-56	DrugDDI.d119.s4.e1
M,57-58	DrugDDI.d119.s4.e1
Parenteral,59-69	DrugDDI.d119.s4.e1
should,70-76
be,77-79
avoided.,80-88

Digoxin,0-7	DrugDDI.d65.s0.e0
Coadministration,8-24
of,25-27
digoxin,,28-36
a,37-38
P-glycoprotein,39-53
substrate,,54-64
with,65-69
oral,70-74
conivaptan,75-85	DrugDDI.d65.s0.e3
resulted,86-94
in,95-97
a,98-99
reduction,100-109
in,110-112
clearance,113-122
and,123-126
an,127-129
increase,130-138
in,139-141
digoxin,142-149	DrugDDI.d65.s0.e4
Cmax,150-154
and,155-158
AUC,159-162
values.,163-170

Therefore,,0-10
if,11-13
digoxin,14-21	DrugDDI.d65.s1.e0
is,22-24
administered,25-37
with,38-42
VAPRISOL,,43-52
the,53-56
clinician,57-66
should,67-73
be,74-76
alert,77-82
to,83-85
the,86-89
possibility,90-101
of,102-104
increases,105-114
in,115-117
digoxin,118-125
levels.,126-133

DRUG/LABORATORY,0-15	DrugDDI.d361.s0.e0
TEST,16-20
INTERACTIONS,21-33
1.,34-36

increased,0-9
factors,10-17	DrugDDI.d361.s3.e0
II,,18-21	DrugDDI.d361.s3.e0
VII,22-25
antigen,,26-34
VIII,35-39
antigen,,40-48
VIII,49-53	DrugDDI.d361.s3.e3
coagulant,54-63	DrugDDI.d361.s3.e3
activity,,64-73
IX,,74-77
X,,78-80
XII,,81-85
VII-X,86-91
complex,,92-100
II-VII-X,101-109
complex,,110-118
and,119-122
beta-thromboglobulin;,123-144	DrugDDI.d361.s3.e4

decreased,0-9
levels,10-16
of,17-19
anti-factor,20-31	DrugDDI.d361.s4.e0
Xa,32-34	DrugDDI.d361.s4.e0
and,35-38
antithrombin,39-51	DrugDDI.d361.s4.e1
III,,52-56	DrugDDI.d361.s4.e1
decreased,57-66
antithrombin,67-79	DrugDDI.d361.s4.e2
III,80-83	DrugDDI.d361.s4.e2
activity;,84-93

increased,0-9
levels,10-16
of,17-19
fibrinogen,20-30	DrugDDI.d361.s5.e0
and,31-34
fibrinogen,35-45
activity;,46-55

Increased,0-9
thyroid-binding,10-25
globulin,26-34
(TBG),35-40
levels,41-47
leading,48-55
to,56-58
increased,59-68
circulating,69-80
total,81-86
thyroid,87-94
hormone,95-102
levels,103-109
as,110-112
measured,113-121
by,122-124
protein-bound,125-138	DrugDDI.d361.s8.e0
iodine,139-145	DrugDDI.d361.s8.e0
(PBI),,146-152
T4,153-155
levels,156-162
(by,163-166
column,167-173
or,174-176
by,177-179
radioimmunoassay),180-197
or,198-200
T3,201-203
levels,204-210
by,211-213
radioimmunoassay.,214-231

Patients,0-8
on,9-11
thyroid,12-19	DrugDDI.d361.s11.e0
replacement,20-31
therapy,32-39
may,40-43
require,44-51
higher,52-58
doses,59-64
of,65-67
thyroid,68-75	DrugDDI.d361.s11.e1
hormone.,76-84	DrugDDI.d361.s11.e1

Other,0-5
binding,6-13	DrugDDI.d361.s13.e0
proteins,14-22	DrugDDI.d361.s13.e0
may,23-26
be,27-29
elevated,30-38
in,39-41
serum,,42-48
(i.e.,,49-55
corticosteroid,56-70	DrugDDI.d361.s13.e1
binding,71-78	DrugDDI.d361.s13.e1
globulin,79-87	DrugDDI.d361.s13.e1
(CBG),,88-94
sex,95-98
hormone,99-106
binding,107-114	DrugDDI.d361.s13.e3
globulin,115-123	DrugDDI.d361.s13.e3
(SHBG)),124-131
leading,132-139
to,140-142
increased,143-152
total,153-158
circulating,159-170
corticosteroids,171-186	DrugDDI.d361.s13.e4
and,187-190
sex,191-194
steroids,,195-204
respectively.,205-218

Other,0-5
plasma,6-12	DrugDDI.d361.s15.e0
proteins,13-21	DrugDDI.d361.s15.e0
may,22-25
be,26-28
increased,29-38
(angiotensinogen/renin,39-61
substrate,,62-72
alpha-1-antitrypsin,,73-93
ceruloplasmin).,94-109	DrugDDI.d361.s15.e4

Increased,0-9
plasma,10-16
HDL,17-20
and,21-24
HDL2,25-29
cholesterol,30-41	DrugDDI.d361.s17.e0
subfraction,42-53
concentrations,,54-69
reduced,70-77
LDL,78-81	DrugDDI.d361.s17.e1
cholesterol,82-93	DrugDDI.d361.s17.e1
concentration,,94-108
increased,109-118
triglyceride,119-131
levels.,132-139

Corticotropin,0-13	DrugDDI.d167.s0.e0
may,14-17
accentuate,18-28
the,29-32
electrolyte,33-44
loss,45-49
associated,50-60
with,61-65
diuretic,66-74
therapy.,75-83

Drugs,0-5	DrugDDI.d470.s1.e0
that,6-10
induce,11-17
hepatic,18-25
enzymes,26-33
such,34-38
as,39-41
phenobarbital,,42-56
phenytoin,57-66	DrugDDI.d470.s1.e2
and,67-70
rifampin,71-79	DrugDDI.d470.s1.e3
may,80-83
increase,84-92
the,93-96
clearance,97-106
of,107-109
corticosteroids,110-125	DrugDDI.d470.s1.e4
and,126-129
may,130-133
require,134-141
increases,142-151
in,152-154
corticosteroid,155-169	DrugDDI.d470.s1.e5
dose,170-174
to,175-177
achieve,178-185
the,186-189
desired,190-197
response.,198-207

Drugs,0-5	DrugDDI.d470.s2.e0
such,6-10
as,11-13
troleandomycin,14-28	DrugDDI.d470.s2.e1
and,29-32
ketoconazole,33-45	DrugDDI.d470.s2.e2
may,46-49
inhibit,50-57
the,58-61
metabolism,62-72
of,73-75
corticosteroids,76-91	DrugDDI.d470.s2.e3
and,92-95
thus,96-100
decrease,101-109
their,110-115
clearance.,116-126

Therefore,,0-10
the,11-14
dose,15-19
of,20-22
corticosteroid,23-37	DrugDDI.d470.s3.e0
should,38-44
be,45-47
titrated,48-56
to,57-59
avoid,60-65
steroid,66-73
toxicity.,74-83

Corticosteroids,0-15	DrugDDI.d470.s4.e0
may,16-19
increase,20-28
the,29-32
clearance,33-42
of,43-45
chronic,46-53
high,54-58
dose,59-63
aspirin.,64-72	DrugDDI.d470.s4.e1

This,0-4
could,5-10
lead,11-15
to,16-18
decreased,19-28
salicylate,29-39
serum,40-45
levels,46-52
or,53-55
increase,56-64
the,65-68
risk,69-73
of,74-76
salicylate,77-87
toxicity,88-96
when,97-101
corticosteroid,102-116	DrugDDI.d470.s5.e0
is,117-119
withdrawn.,120-130

Aspirin,0-7	DrugDDI.d470.s6.e0
should,8-14
be,15-17
used,18-22
cautiously,23-33
in,34-36
conjunction,37-48
with,49-53
cortico-steroids,54-70	DrugDDI.d470.s6.e1
in,71-73
patients,74-82
suffering,83-92
from,93-97
hypopro-thrombinemia.,98-119

The,0-3
effect,4-10
of,11-13
corticosteroids,14-29	DrugDDI.d470.s7.e0
on,30-32
oral,33-37	DrugDDI.d470.s7.e1
anticoagulants,38-52	DrugDDI.d470.s7.e1
is,53-55
variable.,56-65

There,0-5
are,6-9
reports,10-17
of,18-20
enhanced,21-29
as,30-32
well,33-37
as,38-40
diminished,41-51
effects,52-59
of,60-62
anticoagulants,63-77	DrugDDI.d470.s8.e0
when,78-82
given,83-88
concurrently,89-101
with,102-106
corticosteroids.,107-123	DrugDDI.d470.s8.e1

Corticotropin,0-13	DrugDDI.d312.s0.e0
may,14-17
accentuate,18-28
the,29-32
electrolyte,33-44
loss,45-49
associated,50-60
with,61-65
diuretic,66-74
therapy.,75-83

Drug,0-4
Interaction,5-16
During,17-23
Pregnancy:,24-34
Cromolyn,35-43	DrugDDI.d514.s0.e0
sodium,44-50	DrugDDI.d514.s0.e0
and,51-54
isoproterenol,55-68	DrugDDI.d514.s0.e1
were,69-73
studied,74-81
following,82-91
subcutaneous,92-104
injections,105-115
in,116-118
pregnant,119-127
mice.,128-133

Cromolyn,0-8	DrugDDI.d514.s1.e0
sodium,9-15	DrugDDI.d514.s1.e0
alone,16-21
in,22-24
doses,25-30
up,31-33
to,34-36
540,37-40
mg/kg/day,41-50
(approximately,51-65
340,66-69
times,70-75
the,76-79
maximum,80-87
recommended,88-99
daily,100-105
inhalation,106-116
dose,117-121
in,122-124
adults,125-131
on,132-134
a,135-136
mg/m2,137-142
basis),143-149
did,150-153
not,154-157
cause,158-163
significant,164-175
increases,176-185
in,186-188
resorptions,189-200
or,201-203
major,204-209
malformations.,210-224

Isoproterenol,0-13	DrugDDI.d514.s2.e0
alone,14-19
at,20-22
a,23-24
dose,25-29
of,30-32
2.7,33-36
mg/kg/day,37-46
(approximately,47-61
7,62-63
times,64-69
the,70-73
maximum,74-81
recommended,82-93
daily,94-99
inhalation,100-110
dose,111-115
in,116-118
adults,119-125
on,126-128
a,129-130
mg/m2,131-136
basis),137-143
increased,144-153
both,154-158
resorptions,159-170
and,171-174
malformations.,175-189

The,0-3
addition,4-12
of,13-15
540,16-19
mg/kg/day,20-29
of,30-32
cromolyn,33-41	DrugDDI.d514.s3.e0
sodium,42-48	DrugDDI.d514.s3.e0
(approximately,49-63
340,64-67
times,68-73
the,74-77
maximum,78-85
recommended,86-97
daily,98-103
inhalation,104-114
dose,115-119
in,120-122
adults,123-129
on,130-132
a,133-134
mg/m2,135-140
basis),141-147
to,148-150
2.7,151-154
mg/kg/day,155-164
of,165-167
isoproterenol,168-181	DrugDDI.d514.s3.e1
(approximately,182-196
7,197-198
times,199-204
the,205-208
maximum,209-216
recommended,217-228
daily,229-234
inhalation,235-245
dose,246-250
in,251-253
adults,254-260
on,261-263
a,264-265
mg/m2,266-271
basis),272-278
appears,279-286
to,287-289
have,290-294
increased,295-304
the,305-308
incidence,309-318
of,319-321
both,322-326
resorptions,327-338
and,339-342
malformations.,343-357

Persons,0-7
taking,8-14
most,15-19
antibiotics,,20-32
methotrexate,33-45	DrugDDI.d507.s0.e1
and,46-49
pyrimethamine,50-63	DrugDDI.d507.s0.e2
invalidate,64-74
folic,75-80	DrugDDI.d507.s0.e3
acid,81-85	DrugDDI.d507.s0.e3
and,86-89
vitamin,90-97	DrugDDI.d507.s0.e4
B12,98-101	DrugDDI.d507.s0.e4
diagnostic,102-112
blood,113-118
assays.,119-126

Colchicine,0-10	DrugDDI.d507.s1.e0
para-aminosalicylic,11-30
acid,31-35
and,36-39
heavy,40-45
alcohol,46-53
intake,54-60
for,61-64
longer,65-71
than,72-76
2,77-78
weeks,79-84
may,85-88
produce,89-96
malabsorption,97-110
of,111-113
vitamin,114-121	DrugDDI.d507.s1.e1
B12.,122-126	DrugDDI.d507.s1.e1

Persons,0-7
taking,8-14
most,15-19
antibiotics,,20-32
methotrexate,33-45	DrugDDI.d572.s0.e1
and,46-49
pyrimethamine,50-63	DrugDDI.d572.s0.e2
invalidate,64-74
folic,75-80	DrugDDI.d572.s0.e3
acid,81-85	DrugDDI.d572.s0.e3
and,86-89
vitamin,90-97	DrugDDI.d572.s0.e4
B12,98-101	DrugDDI.d572.s0.e4
diagnostic,102-112
blood,113-118
assays.,119-126

Colchicine,0-10	DrugDDI.d572.s1.e0
para-aminosalicylic,11-30
acid,31-35
and,36-39
heavy,40-45
alcohol,46-53
intake,54-60
for,61-64
longer,65-71
than,72-76
2,77-78
weeks,79-84
may,85-88
produce,89-96
malabsorption,97-110
of,111-113
vitamin,114-121	DrugDDI.d572.s1.e1
B12.,122-126	DrugDDI.d572.s1.e1

FLEXERIL,0-8	DrugDDI.d117.s0.e0
may,9-12
have,13-17
life-threatening,18-34
interactions,35-47
with,48-52
MAO,53-56	DrugDDI.d117.s0.e1
inhibitors.,57-68	DrugDDI.d117.s0.e1

FLEXERIL,0-8	DrugDDI.d117.s1.e0
may,9-12
enhance,13-20
the,21-24
effects,25-32
of,33-35
alcohol,,36-44
barbiturates,,45-58
and,59-62
other,63-68
CNS,69-72	DrugDDI.d117.s1.e3
depressants.,73-85	DrugDDI.d117.s1.e3

Tricyclic,0-9	DrugDDI.d117.s2.e0
antidepressants,10-25	DrugDDI.d117.s2.e0
may,26-29
block,30-35
the,36-39
antihypertensive,40-56	DrugDDI.d117.s2.e1
action,57-63
of,64-66
guanethidine,67-79	DrugDDI.d117.s2.e2
and,80-83
similarly,84-93
acting,94-100
compounds.,101-111

Tricyclic,0-9	DrugDDI.d117.s3.e0
antidepressants,10-25	DrugDDI.d117.s3.e0
may,26-29
enhance,30-37
the,38-41
seizure,42-49
risk,50-54
in,55-57
patients,58-66
taking,67-73
tramadol,74-82	DrugDDI.d117.s3.e1

Cyclopentolate,0-14	DrugDDI.d198.s0.e0
may,15-18
interfere,19-28
with,29-33
the,34-37
anti-glaucoma,38-51
action,52-58
of,59-61
carbachol,62-71	DrugDDI.d198.s0.e1
or,72-74
pilocarpine;,75-87	DrugDDI.d198.s0.e2

also,,0-5
concurrent,6-16
use,17-20
of,21-23
this,24-28
medication,29-39	DrugDDI.d198.s1.e0
may,40-43
antagonise,44-54
the,55-58
anti-glaucoma,59-72
and,73-76
miotic,77-83	DrugDDI.d198.s1.e1
actions,84-91
of,92-94
ophthalmic,95-105
cholinesterase,106-120	DrugDDI.d198.s1.e2
inhibitors.,121-132	DrugDDI.d198.s1.e2

The,0-3
rate,4-8
of,9-11
metabolism,12-22
and,23-26
the,27-30
leukopenic,31-41
activity,42-50
of,51-53
cyclophosphamide,54-70	DrugDDI.d489.s0.e0
reportedly,71-81
are,82-85
increased,86-95
by,96-98
chronic,99-106
administration,107-121
of,122-124
high,125-129
doses,130-135
of,136-138
phenobarbital.,139-153	DrugDDI.d489.s0.e1

The,0-3
physician,4-13
should,14-20
be,21-23
alert,24-29
for,30-33
possible,34-42
combined,43-51
drug,52-56
actions,,57-65
desirable,66-75
or,76-78
undesirable,,79-91
involving,92-101
cyclophosphamide,102-118	DrugDDI.d489.s1.e0
even,119-123
though,124-130
cyclophosphamide,131-147	DrugDDI.d489.s1.e1
has,148-151
been,152-156
used,157-161
successfully,162-174
concurrently,175-187
with,188-192
other,193-198
drugs,,199-205
including,206-215
other,216-221	DrugDDI.d489.s1.e3
cytotoxic,222-231	DrugDDI.d489.s1.e3
drugs.,232-238	DrugDDI.d489.s1.e3

Cyclophosphamide,0-16
treatment,,17-27
which,28-33
causes,34-40
a,41-42
marked,43-49
and,50-53
persistent,54-64
inhibition,65-75
of,76-78
cholinesterase,79-93
activity,,94-103
potentiates,104-115
the,116-119
effect,120-126
of,127-129
succinylcholine,130-145	DrugDDI.d489.s2.e0
chloride.,146-155	DrugDDI.d489.s2.e0

If,0-2
a,3-4
patient,5-12
has,13-16
been,17-21
treated,22-29
with,30-34
cyclophosphamide,35-51	DrugDDI.d489.s3.e0
within,52-58
10,59-61
days,62-66
of,67-69
general,70-77
anesthesia,,78-89
the,90-93
anesthesiologist,94-110
should,111-117
be,118-120
alerted.,121-129

May,0-3
interact,4-12
with,13-17
wthionamide,18-29
(Trecator-SC),30-43
and,44-47
isoniazid,48-57	DrugDDI.d111.s0.e1
(Nydrazid).,58-69

MAO,0-3	DrugDDI.d171.s0.e0
inhibitors,4-14	DrugDDI.d171.s0.e0
prolong,15-22
and,23-26
intensify,27-36
the,37-40
anticholinergic,41-56	DrugDDI.d171.s0.e1
effects,57-64
of,65-67
antihistamines.,68-83	DrugDDI.d171.s0.e2

Antihistamines,0-14	DrugDDI.d171.s1.e0
may,15-18
have,19-23
additive,24-32
effects,33-40
with,41-45
alcohol,46-53	DrugDDI.d171.s1.e1
and,54-57
other,58-63
CNS,64-67	DrugDDI.d171.s1.e2
depressants,,68-80	DrugDDI.d171.s1.e2
e.g.,,81-86
hypnotics,,87-97
sedatives,,98-108
tranquilizers,,109-123
antianxiety,124-135	DrugDDI.d171.s1.e6
agents.,136-143	DrugDDI.d171.s1.e6

Reversible,0-10
decreases,11-20
in,21-23
steady-state,24-36
plasma,37-43
digoxin,44-51	DrugDDI.d140.s0.e0
concentrations,52-66
and,67-70
renal,71-76
glycoside,77-86	DrugDDI.d140.s0.e1
excretion,87-96
were,97-101
observed,102-110
in,111-113
patients,114-122
receiving,123-132
beta-acetyl,133-144
digoxin,145-152	DrugDDI.d140.s0.e2
and,153-156
chemotherapy,157-169
regimens,170-178
containing,179-189
cyclophosphamide,,190-207
vincristine,,208-220
and,221-224
prednisone,225-235	DrugDDI.d140.s0.e5
with,236-240
or,241-243
without,244-251
cytarabine,252-262	DrugDDI.d140.s0.e6
or,263-265
procarbazine.,266-279	DrugDDI.d140.s0.e7

Steady,0-6
state,7-12
plasma,13-19
digitoxin,20-29	DrugDDI.d140.s1.e0
concentrations,30-44
did,45-48
not,49-52
appear,53-59
to,60-62
change.,63-70

The,0-3
utilization,4-15
of,16-18
digitoxin,19-28	DrugDDI.d140.s3.e0
for,29-32
such,33-37
patients,38-46
may,47-50
be,51-53
considered,54-64
as,65-67
an,68-70
alternative.,71-83

Also,0-4
flucytosine.,5-17	DrugDDI.d140.s4.e0

Drug/LaboratoryTest,0-19	DrugDDI.d443.s0.e0
Interactions,20-32
Dactinomycin,33-45	DrugDDI.d443.s0.e1
may,46-49
interfere,50-59
with,60-64
bioassay,65-73
procedures,74-84
for,85-88
the,89-92
determination,93-106
of,107-109
antibacterial,110-123	DrugDDI.d443.s0.e2
drug,124-128	DrugDDI.d443.s0.e2
levels.,129-136

Dantrium,0-8	DrugDDI.d163.s0.e0
is,9-11
metabolized,12-23
by,24-26
the,27-30
liver,,31-37
and,38-41
it,42-44
is,45-47
theoretically,48-61
possible,62-70
that,71-75
its,76-79
metabolism,80-90
may,91-94
be,95-97
enhanced,98-106
by,107-109
drugs,110-115	DrugDDI.d163.s0.e2
known,116-121
to,122-124
induce,125-131
hepatic,132-139
microsomal,140-150	DrugDDI.d163.s0.e3
enzymes.,151-159	DrugDDI.d163.s0.e3

However,,0-8
neither,9-16
phenobarbital,17-30	DrugDDI.d163.s1.e0
nor,31-34
diazepam,35-43	DrugDDI.d163.s1.e1
appears,44-51
to,52-54
affect,55-61
Dantrium,62-70	DrugDDI.d163.s1.e2
metabolism.,71-82

Binding,0-7
to,8-10
plasma,11-17	DrugDDI.d163.s2.e0
protein,18-25	DrugDDI.d163.s2.e0
is,26-28
not,29-32
significantly,33-46
altered,47-54
by,55-57
diazepam,,58-67
diphenylhydantoin,,68-86
or,87-89
phenylbutazone.,90-105	DrugDDI.d163.s2.e3

Binding,0-7
to,8-10
plasma,11-17	DrugDDI.d163.s3.e0
proteins,18-26	DrugDDI.d163.s3.e0
is,27-29
reduced,30-37
by,38-40
warfarin,41-49	DrugDDI.d163.s3.e1
and,50-53
clotibrate,54-64
and,65-68
increased,69-78
by,79-81
tolbutamide.,82-94	DrugDDI.d163.s3.e2

Cardiovascular,0-14
collapse,15-23
in,24-26
patients,27-35
treated,36-43
simultaneously,44-58
with,59-63
varapamil,64-73
and,74-77
dantrolene,78-88	DrugDDI.d163.s4.e0
sodium,89-95	DrugDDI.d163.s4.e0
is,96-98
rare.,99-104

The,0-3
combination,4-15
of,16-18
therapeutic,19-30
doses,31-36
of,37-39
intravenous,40-51
dantrolene,52-62	DrugDDI.d163.s5.e0
sodium,63-69	DrugDDI.d163.s5.e0
and,70-73
verapamil,74-83	DrugDDI.d163.s5.e1
in,84-86
halothane/,87-97	DrugDDI.d163.s5.e2
span,98-102
class=,103-109
c35,110-113
a-chloralose,114-126
anesthetized,127-139
swine,140-145
has,146-149
resulted,150-158
in,159-161
ventricular,162-173
fibrillation,174-186
and,187-190
cardiovascular,191-205
collapse,206-214
in,215-217
association,218-229
with,230-234
marked,235-241
hyperkalemia.,242-255

It,0-2
is,3-5
recommended,6-17
that,18-22
the,23-26
combination,27-38
of,39-41
intravenous,42-53
dantrolene,54-64	DrugDDI.d163.s6.e0
sodium,65-71	DrugDDI.d163.s6.e0
and,72-75
calcium,76-83	DrugDDI.d163.s6.e1
channel,84-91	DrugDDI.d163.s6.e1
blockers,,92-101	DrugDDI.d163.s6.e1
such,102-106
as,107-109
verapamil,,110-120
not,121-124
be,125-127
used,128-132
together,133-141
during,142-148
the,149-152
management,153-163
of,164-166
malignant,167-176
hyperthermia,177-189
crisis,190-196
until,197-202
the,203-206
relevance,207-216
of,217-219
these,220-225
findings,226-234
to,235-237
humans,238-244
is,245-247
established.,248-260

Administration,0-14
of,15-17
dantrolene,18-28	DrugDDI.d163.s7.e0
may,29-32
potentiate,33-43
vecuronium-induced,44-62	DrugDDI.d163.s7.e1
neuromuscular,63-76
block.,77-83

A,0-1
drug-drug,2-11
interaction,12-23
study,24-29
evaluated,30-39
the,40-43
effect,44-50
of,51-53
the,54-57
use,58-61
of,62-64
ACZONE,65-71
Gel,,72-76
5%,,77-80
in,81-83
combination,84-95
with,96-100
double,101-107
strength,108-116
(160,117-121
mg/800,122-128
mg),129-132
trimethoprim/sulfamethoxazole,133-162	DrugDDI.d13.s0.e0
(TMP/SMX).,163-173

During,0-6
co-administration,,7-25
systemic,26-34
levels,35-41
of,42-44
TMP,45-48	DrugDDI.d13.s1.e0
and,49-52
SMX,53-56
were,57-61
essentially,62-73
unchanged.,74-84

However,,0-8
levels,9-15
of,16-18
dapsone,19-26	DrugDDI.d13.s2.e0
and,27-30
its,31-34
metabolites,35-46	DrugDDI.d13.s2.e1
increased,47-56
in,57-59
the,60-63
presence,64-72
of,73-75
TMP/SMX.,76-84	DrugDDI.d13.s2.e2

Systemic,0-8
exposure,9-17
(AUC0-12),18-27
of,28-30
dapsone,31-38	DrugDDI.d13.s3.e0
and,39-42
N-acetyl-dapsone,43-59
(NAD),60-65
were,66-70
increased,71-80
by,81-83
about,84-89
40%,90-93
and,94-97
20%,98-101
respectively,102-114
in,115-117
presence,118-126
of,127-129
TMP/SMX.,130-138	DrugDDI.d13.s3.e3

Notably,,0-8
systemic,9-17
exposure,18-26
(AUC0-12),27-36
of,37-39
dapsone,40-47	DrugDDI.d13.s4.e0
hydroxylamine,48-61	DrugDDI.d13.s4.e0
(DHA),62-67
was,68-71
more,72-76
than,77-81
doubled,82-89
in,90-92
the,93-96
presence,97-105
of,106-108
TMP/SMX.,109-117	DrugDDI.d13.s4.e1

Exposure,0-8
from,9-13
the,14-17
proposed,18-26
topical,27-34
dose,35-39
is,40-42
about,43-48
1%,49-51
of,52-54
that,55-59
from,60-64
the,65-68
100,69-72
mg,73-75
oral,76-80
dose,,81-86
even,87-91
when,92-96
co-administered,97-112
with,113-117
TMP/SMX.,118-126	DrugDDI.d13.s5.e0

Certain,0-7
concomitant,8-19
medications,20-31	DrugDDI.d13.s6.e0
(such,32-37
as,38-40
rifampin,,41-50
anticonvulsants,,51-67
St.,68-71

John?s,0-6
wort),7-12
may,13-16
increase,17-25
the,26-29
formation,30-39
of,40-42
dapsone,43-50
hydroxylamine,,51-65
a,66-67
metabolite,68-78	DrugDDI.d13.s7.e0
of,79-81
dapsone,82-89	DrugDDI.d13.s7.e1
associated,90-100
with,101-105
hemolysis.,106-116

With,0-4
oral,5-9
dapsone,10-17	DrugDDI.d13.s8.e0
treatment,,18-28
folic,29-34	DrugDDI.d13.s8.e1
acid,35-39	DrugDDI.d13.s8.e1
antagonists,40-51	DrugDDI.d13.s8.e1
such,52-56
as,57-59
pyrimethamine,60-73	DrugDDI.d13.s8.e2
have,74-78
been,79-83
noted,84-89
to,90-92
possibly,93-101
increase,102-110
the,111-114
likelihood,115-125
of,126-128
hematologic,129-140
reactions,141-150

Warfarin,0-8	DrugDDI.d12.s0.e0
Concomitant,9-20
administration,21-35
of,36-38
daptomycin,39-49	DrugDDI.d12.s0.e1
(6,50-52
mg/kg,53-58
once,59-63
every,64-69
24,70-72
hours,73-78
for,79-82
5,83-84
days),85-90
and,91-94
warfarin,95-103	DrugDDI.d12.s0.e2
(25,104-107
mg,108-110
single,111-117
oral,118-122
dose),123-128
had,129-132
no,133-135
significant,136-147
effect,148-154
on,155-157
the,158-161
pharmacokinetics,162-178
of,179-181
either,182-188
drug,,189-194
and,195-198
the,199-202
INR,203-206
was,207-210
not,211-214
significantly,215-228
altered.,229-237

As,0-2
experience,3-13
with,14-18
the,19-22
concomitant,23-34
administration,35-49
of,50-52
daptomycin,53-63	DrugDDI.d12.s1.e0
and,64-67
warfarin,68-76	DrugDDI.d12.s1.e1
is,77-79
limited,80-87
to,88-90
volunteer,91-100
studies,,101-109
anticoagulant,110-123
activity,124-132
in,133-135
patients,136-144
receiving,145-154
daptomycin,155-165	DrugDDI.d12.s1.e2
and,166-169
warfarin,170-178	DrugDDI.d12.s1.e3
should,179-185
be,186-188
monitored,189-198
for,199-202
the,203-206
first,207-212
several,213-220
days,221-225
after,226-231
initiating,232-242
therapy,243-250
with,251-255
Fentanyl.,256-265	DrugDDI.d12.s1.e4

HMG-CoA,0-7	DrugDDI.d12.s2.e0
Reductase,8-17	DrugDDI.d12.s2.e0
Inhibitors,18-28	DrugDDI.d12.s2.e0
Inhibitors,29-39
of,40-42
HMG-CoA,43-50	DrugDDI.d12.s2.e1
reductase,51-60	DrugDDI.d12.s2.e1
may,61-64
cause,65-70
myopathy,,71-80
which,81-86
is,87-89
manifested,90-100
as,101-103
muscle,104-110
pain,111-115
or,116-118
weakness,119-127
associated,128-138
with,139-143
elevated,144-152
levels,153-159
of,160-162
CPK.,163-167

There,0-5
were,6-10
no,11-13
reports,14-21
of,22-24
skeletal,25-33
myopathy,34-42
in,43-45
a,46-47
placebo-controlled,48-66
Phase,67-72
I,73-74
trial,75-80
in,81-83
which,84-89
10,90-92
healthy,93-100
subjects,101-109
on,110-112
stable,113-119
simvastatin,120-131	DrugDDI.d12.s3.e0
therapy,132-139
were,140-144
treated,145-152
concurrently,153-165
with,166-170
daptomycin,171-181	DrugDDI.d12.s3.e1
(4,182-184
mg/kg,185-190
once,191-195
every,196-201
24,202-204
hours),205-211
for,212-215
14,216-218
days.,219-224

Experience,0-10
with,11-15
co-administration,16-33
of,34-36
HMG-CoA,37-44	DrugDDI.d12.s4.e0
reduc-tase,45-55
inhibitors,56-66
and,67-70
Fentanyl,71-79	DrugDDI.d12.s4.e1
in,80-82
patients,83-91
is,92-94
limited,therefore,consideration,95-126
should,127-133
be,134-136
given,137-142
to,143-145
temporarily,146-157
suspending,158-168
use,169-172
of,173-175
HMG-CoA,176-183	DrugDDI.d12.s4.e2
reductase,184-193	DrugDDI.d12.s4.e2
inhibitors,194-204	DrugDDI.d12.s4.e2
in,205-207
patients,208-216
receiving,217-226
Fentanyl.,227-236	DrugDDI.d12.s4.e3

The,0-3
daily,4-9
dose,10-14
of,15-17
ENABLEX,18-25	DrugDDI.d136.s0.e0
should,26-32
not,33-36
exceed,37-43
7.5,44-47
mg,48-50
when,51-55
coadministered,56-70
with,71-75
potent,76-82
CYP3A4,83-89	DrugDDI.d136.s0.e1
inhibitors,90-100
(e.g.,,101-107
ketoconazole,,108-121
itraconazole,,122-135
ritonavir,,136-146
nelfinavir,,147-158
clarithromycin,159-173	DrugDDI.d136.s0.e6
and,174-177
nefazadone),178-189
.,190-191

Caution,0-7
should,8-14
be,15-17
taken,18-23
when,24-28
ENABLEX,29-36	DrugDDI.d136.s1.e0
is,37-39
used,40-44
concomitantly,45-58
with,59-63
medications,64-75	DrugDDI.d136.s1.e1
that,76-80
are,81-84
predominantly,85-98
metabolized,99-110
by,111-113
CYP2D6,114-120	DrugDDI.d136.s1.e2
and,121-124
which,125-130
have,131-135
a,136-137
narrow,138-144
therapeutic,145-156
window,,157-164
such,165-169
as,170-172
flecainide,,173-184
thioridazine,185-197	DrugDDI.d136.s1.e4
and,198-201
tricyclic,202-211	DrugDDI.d136.s1.e5
antidepressants,212-227	DrugDDI.d136.s1.e5
(see,228-232
CLINICAL,233-241
PHARMACOLOGY).,242-256

The,0-3
concomitant,4-15
use,16-19
of,20-22
ENABLEX,23-30	DrugDDI.d136.s2.e0
with,31-35
other,36-41
anticholinergic,42-57	DrugDDI.d136.s2.e1
agents,58-64	DrugDDI.d136.s2.e1
may,65-68
increase,69-77
the,78-81
frequency,82-91
and/or,92-98
severity,99-107
of,108-110
dry,111-114
mouth,,115-121
constipation,,122-135
blurred,136-143
vision,144-150
and,151-154
other,155-160
anticholinergic,161-176	DrugDDI.d136.s2.e2
pharmacological,177-192
effects.,193-201

Anticholinergic,0-15	DrugDDI.d136.s3.e0
agents,16-22	DrugDDI.d136.s3.e0
may,23-26
potentially,27-38
alter,39-44
the,45-48
absorption,49-59
of,60-62
some,63-67
concomitantly,68-81
administered,82-94
drugs,95-100	DrugDDI.d136.s3.e1
due,101-104
to,105-107
effects,108-115
on,116-118
gastrointestinal,119-135
motility.,136-145

Drug,0-4
Laboratory,5-15
Test,16-20
Interactions,21-33
Interactions,34-46
between,47-54
darifenacin,55-66	DrugDDI.d136.s4.e0
and,67-70
laboratory,71-81
tests,82-87
have,88-92
not,93-96
been,97-101
studied.,102-110

Drugs,0-5	DrugDDI.d445.s0.e0
that,6-10
may,11-14
increase,15-23
dasatinib,24-33
plasma,34-40
concentrations,41-55
CYP3A4,56-62	DrugDDI.d445.s0.e1
Inhibitors:,63-74
Dasatinib,75-84
is,85-87
a,88-89
CYP3A4,90-96	DrugDDI.d445.s0.e2
substrate.,97-107

Concomitant,0-11
use,12-15
of,16-18
SPRYCEL,19-26
and,27-30
drugs,31-36	DrugDDI.d445.s1.e0
that,37-41
inhibit,42-49
CYP3A4,50-56	DrugDDI.d445.s1.e1
(eg,,57-61
ketoconazole,,62-75
itraconazole,,76-89
erythromycin,,90-103
clarithromycin,,104-119
ritonavir,,120-130
atazanavir,,131-142
indinavir,,143-153
nefazodone,,154-165
nelfinavir,,166-177
saquinavir,,178-189
telithromycin),190-204	DrugDDI.d445.s1.e12
may,205-208
increase,209-217
exposure,218-226
to,227-229
dasatinib,230-239
and,240-243
should,244-250
be,251-253
avoided.,254-262

In,0-2
patients,3-11
receiving,12-21
treatment,22-31
with,32-36
SPRYCEL,,37-45
close,46-51
monitoring,52-62
for,63-66
toxicity,67-75
and,76-79
a,80-81
SPRYCEL,82-89
dose,90-94
reduction,95-104
should,105-111
be,112-114
considered,115-125
if,126-128
systemic,129-137
administration,138-152
of,153-155
a,156-157
potent,158-164
CYP3A4,165-171	DrugDDI.d445.s2.e0
inhibitor,172-181
cannot,182-188
be,189-191
avoided.,192-200

Drugs,0-5	DrugDDI.d445.s3.e0
that,6-10
may,11-14
decrease,15-23
dasatinib,24-33
plasma,34-40
concentrations,41-55
CYP3A4,56-62	DrugDDI.d445.s3.e1
Inducers:,63-72
Drugs,73-78	DrugDDI.d445.s3.e2
that,79-83
induce,84-90
CYP3A4,91-97	DrugDDI.d445.s3.e3
activity,98-106
may,107-110
decrease,111-119
dasatinib,120-129
plasma,130-136
concentrations.,137-152

In,0-2
patients,3-11
in,12-14
whom,15-19
CYP3A4,20-26	DrugDDI.d445.s4.e0
inducers,27-35
(eg,,36-40
dexamethasone,,41-55
phenytoin,,56-66
carbamazepine,,67-81
rifampicin,,82-93
phenobarbital),94-108	DrugDDI.d445.s4.e5
are,109-112
indicated,,113-123
alternative,124-135
agents,136-142
with,143-147
less,148-152
enzyme,153-159
induction,160-169
potential,170-179
should,180-186
be,187-189
used.,190-195

If,0-2
SPRYCEL,3-10
must,11-15
be,16-18
administered,19-31
with,32-36
a,37-38
CYP3A4,39-45	DrugDDI.d445.s5.e0
inducer,,46-54
a,55-56
dose,57-61
increase,62-70
in,71-73
SPRYCEL,74-81
should,82-88
be,89-91
considered.,92-103

St.,0-3	DrugDDI.d445.s6.e0
Johns,4-9	DrugDDI.d445.s6.e0
wort,10-14	DrugDDI.d445.s6.e0
(Hypericum,15-25
perforatum),26-37
may,38-41
decrease,42-50
SPRYCEL,51-58
plasma,59-65
concentrations,66-80
unpredictably.,81-95

Patients,0-8
receiving,9-18
SPRYCEL,19-26
should,27-33
not,34-37
take,38-42
St.,43-46	DrugDDI.d445.s7.e0
Johns,47-52	DrugDDI.d445.s7.e0
wort.,53-58	DrugDDI.d445.s7.e0

Antacids:,0-9	DrugDDI.d445.s8.e0
Nonclinical,10-21
data,22-26
demonstrate,27-38
that,39-43
the,44-47
solubility,48-58
of,59-61
dasatinib,62-71
is,72-74
pH,75-77
dependent.,78-88

Simultaneous,0-12
administration,13-27
of,28-30
SPRYCEL,31-38
with,39-43
antacids,44-52	DrugDDI.d445.s9.e0
should,53-59
be,60-62
avoided.,63-71

If,0-2
antacid,3-10
therapy,11-18
is,19-21
needed,,22-29
the,30-33
antacid,34-41	DrugDDI.d445.s10.e0
dose,42-46
should,47-53
be,54-56
administered,57-69
at,70-72
least,73-78
2,79-80
hours,81-86
prior,87-92
to,93-95
or,96-98
2,99-100
hours,101-106
after,107-112
the,113-116
dose,117-121
of,122-124
SPRYCEL.,125-133

H2,0-2	DrugDDI.d445.s11.e0
Blockers/Proton,3-18	DrugDDI.d445.s11.e0
Pump,19-23
Inhibitors:,24-35
Long-term,36-45
suppression,46-57
of,58-60
gastric,61-68
acid,69-73
secretion,74-83
by,84-86
H2,87-89	DrugDDI.d445.s11.e2
blockers,90-98	DrugDDI.d445.s11.e2
or,99-101
proton,102-108	DrugDDI.d445.s11.e3
pump,109-113	DrugDDI.d445.s11.e3
inhibitors,114-124	DrugDDI.d445.s11.e3
(eg,,125-129
famotidine,130-140	DrugDDI.d445.s11.e4
and,141-144
omeprazole),145-156	DrugDDI.d445.s11.e5
is,157-159
likely,160-166
to,167-169
reduce,170-176
dasatinib,177-186
exposure.,187-196

The,0-3
concomitant,4-15
use,16-19
of,20-22
H2,23-25	DrugDDI.d445.s12.e0
blockers,26-34	DrugDDI.d445.s12.e0
or,35-37
proton,38-44	DrugDDI.d445.s12.e1
pump,45-49	DrugDDI.d445.s12.e1
inhibitors,50-60	DrugDDI.d445.s12.e1
with,61-65
SPRYCEL,66-73
is,74-76
not,77-80
recommended.,81-93

The,0-3
use,4-7
of,8-10
antacids,11-19	DrugDDI.d445.s13.e0
should,20-26
be,27-29
considered,30-40
in,41-43
place,44-49
of,50-52
H2,53-55	DrugDDI.d445.s13.e1
blockers,56-64	DrugDDI.d445.s13.e1
or,65-67
proton,68-74	DrugDDI.d445.s13.e2
pump,75-79	DrugDDI.d445.s13.e2
inhibitors,80-90	DrugDDI.d445.s13.e2
in,91-93
patients,94-102
receiving,103-112
SPRYCEL,113-120
therapy.,121-129

Drugs,0-5	DrugDDI.d445.s14.e0
that,6-10
may,11-14
have,15-19
their,20-25
plasma,26-32
concentration,33-46
altered,47-54
by,55-57
dasatinib,58-67
CYP3A4,68-74	DrugDDI.d445.s14.e1
Substrates:,75-86
Dasatinib,87-96
is,97-99
a,100-101
time-dependent,102-116
inhibitor,117-126
of,127-129
CYP3A4.,130-137	DrugDDI.d445.s14.e2

Therefore,,0-10
CYP3A4,11-17	DrugDDI.d445.s15.e0
substrates,18-28
known,29-34
to,35-37
have,38-42
a,43-44
narrow,45-51
therapeutic,52-63
index,64-69
such,70-74
as,75-77
alfentanil,,78-89
astemizole,,90-101
terfenadine,,102-114
cisapride,,115-125
cyclosporine,,126-139
fentanyl,,140-149
pimozide,,150-159
quinidine,,160-170
sirolimus,,171-181
tacrolimus,,182-193
or,194-196
ergot,197-202	DrugDDI.d445.s15.e11
alkaloids,203-212	DrugDDI.d445.s15.e11
(ergotamine,,213-225
dihydroergotamine),226-244	DrugDDI.d445.s15.e13
should,245-251
be,252-254
administered,255-267
with,268-272
caution,273-280
in,281-283
patients,284-292
receiving,293-302
SPRYCEL.,303-311

Hepatic,0-7
Impairment,8-18
There,19-24
are,25-28
currently,29-38
no,39-41
clinical,42-50
studies,51-58
with,59-63
SPRYCEL,64-71
in,72-74
patients,75-83
with,84-88
impaired,89-97
liver,98-103
function,104-112
(clinical,113-122
studies,123-130
have,131-135
excluded,136-144
patients,145-153
with,154-158
ALT,159-162
and/or,163-169
AST,170-173	DrugDDI.d445.s16.e0
,174-174
2.5,175-178
times,179-184
the,185-188
upper,189-194
limit,195-200
of,201-203
the,204-207
normal,208-214
range,215-220
and/or,221-227
total,228-233	DrugDDI.d445.s16.e1
bilirubin,234-243	DrugDDI.d445.s16.e1
,244-244
2,245-246
times,247-252
the,253-256
upper,257-262
limit,263-268
of,269-271
the,272-275
normal,276-282
range).,283-290

Renal,0-5
Impairment,6-16
There,17-22
are,23-26
currently,27-36
no,37-39
clinical,40-48
studies,49-56
with,57-61
SPRYCEL,62-69
in,70-72
patients,73-81
with,82-86
impaired,87-95
renal,96-101
function,102-110
(clinical,111-120
studies,121-128
have,129-133
excluded,134-142
patients,143-151
with,152-156
serum,157-162
creatinine,163-173	DrugDDI.d445.s19.e0
concentration,174-187
,188-188
1.5,189-192
times,193-198
the,199-202
upper,203-208
limit,209-214
of,215-217
the,218-221
normal,222-228
range).,229-236

Dasatinib,0-9
and,10-13
its,14-17
metabolites,18-29	DrugDDI.d445.s20.e0
are,30-33
minimally,34-43
excreted,44-52
via,53-56
the,57-60
kidney.,61-68

Since,0-5
the,6-9
renal,10-15
excretion,16-25
of,26-28
unchanged,29-38
dasatinib,39-48
and,49-52
its,53-56
metabolites,57-68	DrugDDI.d445.s21.e0
is,69-71
,72-72
4%,,73-76
a,77-78
decrease,79-87
in,88-90
total,91-96
body,97-101
clearance,102-111
is,112-114
not,115-118
expected,119-127
in,128-130
patients,131-139
with,140-144
renal,145-150
insufficiency.,151-165

Use,0-3
of,4-6
Cerubidine,7-17	DrugDDI.d386.s0.e0
in,18-20
a,21-22
patient,23-30
who,31-34
has,35-38
previously,39-49
received,50-58
doxorubicin,59-70	DrugDDI.d386.s0.e1
increases,71-80
the,81-84
risk,85-89
of,90-92
cardiotoxicity.,93-108

Cerubidine,0-10	DrugDDI.d386.s1.e0
should,11-17
not,18-21
be,22-24
used,25-29
in,30-32
patients,33-41
who,42-45
have,46-50
previously,51-61
received,62-70
the,71-74
recommended,75-86
maximum,87-94
cumulative,95-105
doses,106-111
of,112-114
doxorubicin,115-126	DrugDDI.d386.s1.e1
or,127-129
Cerubidine.,130-141	DrugDDI.d386.s1.e2

Cyclophosphamide,0-16	DrugDDI.d386.s2.e0
used,17-21
concurrently,22-34
with,35-39
Cerubidine,40-50	DrugDDI.d386.s2.e1
may,51-54
also,55-59
result,60-66
in,67-69
increased,70-79
cardiotoxicity.,80-95

Dosage,0-6
reduction,7-16
of,17-19
Cerubidine,20-30	DrugDDI.d386.s3.e0
may,31-34
be,35-37
required,38-46
when,47-51
used,52-56
concurrently,57-69
with,70-74
other,75-80
myelosuppressive,81-97
agents.,98-105

Hepatotoxic,0-11
medications,,12-24
such,25-29
as,30-32
high-dose,33-42
methotrexate,,43-56
may,57-60
impair,61-67
liver,68-73
function,74-82
and,83-86
increase,87-95
the,96-99
risk,100-104
of,105-107
toxicity.,108-117

Potentially,0-11
fatal,12-17
drug,18-22
interactions,23-35
may,36-39
occur,40-45
when,46-50
coadministered,51-65
with,66-70
digoxin,,71-79
as,80-82
this,83-87
may,88-91
enhance,92-99
cardiovascular,100-114
depression,115-125
and,126-129
bradyarrhythmias,130-146
may,147-150
occur.,151-157

Anticholinesterases,0-19	DrugDDI.d189.s1.e0
(neostgmine,,20-32
physostigmine),,33-48
lignocaine,,49-60
quinine,,61-69
procainamide,70-82	DrugDDI.d189.s1.e4
can,83-86
enhance,87-94
toxicity,95-103
and,104-107
cause,108-113
cardio,114-120
respiratory,121-132
depression.,133-144

In,0-2
addition,,3-12
neuromuscular,13-26
blocking,27-35
action,36-42
is,43-45
enhanced,46-54
by,55-57
general,58-65	DrugDDI.d189.s2.e0
anesthetics,,66-78	DrugDDI.d189.s2.e0
local,79-84	DrugDDI.d189.s2.e1
anesthetics,85-96	DrugDDI.d189.s2.e1
like,97-101
lidocaine,,102-112
procaine,,113-122
beta-blockers,,123-137
metaclopramide,,138-153
lithium,154-161	DrugDDI.d189.s2.e6
carbonate,,162-172	DrugDDI.d189.s2.e6
and,173-176
terbutaline.,177-189	DrugDDI.d189.s2.e7

Drug,0-4
interaction,5-16
studies,17-24
with,25-29
decitabine,30-40	DrugDDI.d563.s0.e0
have,41-45
not,46-49
been,50-54
conducted.,55-65

In,0-2
vitro,3-8
studies,9-16
in,17-19
human,20-25
liver,26-31
microsomes,32-42
suggest,43-50
that,51-55
decitabine,56-66	DrugDDI.d563.s1.e0
is,67-69
unlikely,70-78
to,79-81
inhibit,82-89
or,90-92
induce,93-99
cytochrome,100-110	DrugDDI.d563.s1.e1
P450,111-115	DrugDDI.d563.s1.e1
enzymes.,116-124

In,0-2
vitro,3-8
metabolism,9-19
studies,20-27
have,28-32
suggested,33-42
that,43-47
decitabine,48-58	DrugDDI.d563.s2.e0
is,59-61
not,62-65
a,66-67
substrate,68-77
for,78-81
the,82-85
human,86-91
liver,92-97
cytochrome,98-108	DrugDDI.d563.s2.e1
P450,109-113	DrugDDI.d563.s2.e1
enzymes.,114-122	DrugDDI.d563.s2.e1

As,0-2
plasma,3-9	DrugDDI.d563.s3.e0
protein,10-17	DrugDDI.d563.s3.e0
binding,18-25
of,26-28
decitabine,29-39	DrugDDI.d563.s3.e1
is,40-42
negligible,43-53
(,54-55
1%),,56-60
interactions,61-73
due,74-77
to,78-80
displacement,81-93
of,94-96
more,97-101
highly,102-108
protein,109-116
bound,117-122
drugs,123-128
from,129-133
plasma,134-140	DrugDDI.d563.s3.e2
proteins,141-149	DrugDDI.d563.s3.e2
are,150-153
not,154-157
expected.,158-167

The,0-3
concomitant,4-15
administration,16-30
of,31-33
Exjade,34-40	DrugDDI.d580.s0.e0
and,41-44
aluminum-containing,45-64	DrugDDI.d580.s0.e1
antacid,65-72	DrugDDI.d580.s0.e1
preparations,73-85	DrugDDI.d580.s0.e1
has,86-89
not,90-93
been,94-98
formally,99-107
studied.,108-116

Although,0-8
deferasirox,9-20	DrugDDI.d580.s1.e0
has,21-24
a,25-26
lower,27-32
affinity,33-41
for,42-45
aluminum,46-54
than,55-59
for,60-63
iron,,64-69
Exjade,70-76	DrugDDI.d580.s1.e2
should,77-83
not,84-87
be,88-90
taken,91-96
with,97-101
aluminum-containing,102-121	DrugDDI.d580.s1.e3
antacid,122-129	DrugDDI.d580.s1.e3
preparations.,130-143	DrugDDI.d580.s1.e3

In,0-2
healthy,3-10
volunteers,,11-22
Exjade,23-29	DrugDDI.d580.s2.e0
had,30-33
no,34-36
effect,37-43
on,44-46
the,47-50
pharmacokinetics,51-67
of,68-70
digoxin.,71-79	DrugDDI.d580.s2.e1

The,0-3
effect,4-10
of,11-13
digoxin,14-21	DrugDDI.d580.s3.e0
on,22-24
Exjade,25-31	DrugDDI.d580.s3.e1
pharmacokinetics,32-48
has,49-52
not,53-56
been,57-61
studied.,62-70

The,0-3
concomitant,4-15
administration,16-30
of,31-33
Exjade,34-40	DrugDDI.d580.s4.e0
and,41-44
vitamin,45-52	DrugDDI.d580.s4.e1
C,53-54	DrugDDI.d580.s4.e1
has,55-58
not,59-62
been,63-67
formally,68-76
studied.,77-85

Doses,0-5
of,6-8
vitamin,9-16	DrugDDI.d580.s5.e0
C,17-18	DrugDDI.d580.s5.e0
up,19-21
to,22-24
200,25-28
mg,29-31
were,32-36
allowed,37-44
in,45-47
clinical,48-56
studies,57-64
without,65-72
negative,73-81
consequences.,82-95

The,0-3
interaction,4-15
of,16-18
Exjade,19-25	DrugDDI.d580.s6.e0
with,26-30
hydroxyurea,31-42	DrugDDI.d580.s6.e1
has,43-46
not,47-50
been,51-55
formally,56-64
studied.,65-73

No,0-2
inhibition,3-13
of,14-16
deferasirox,17-28	DrugDDI.d580.s7.e0
metabolism,29-39
by,40-42
hydroxyurea,43-54	DrugDDI.d580.s7.e1
is,55-57
expected,58-66
based,67-72
on,73-75
the,76-79
results,80-87
of,88-90
an,91-93
in,94-96
vitro,97-102
study.,103-109

Exjade,0-6	DrugDDI.d580.s8.e0
should,7-13
not,14-17
be,18-20
combined,21-29
with,30-34
other,35-40
iron,41-45	DrugDDI.d580.s8.e1
chelator,46-54	DrugDDI.d580.s8.e1
therapies,,55-65	DrugDDI.d580.s8.e1
as,66-68
safety,69-75
of,76-78
such,79-83
combinations,84-96
has,97-100
not,101-104
been,105-109
established.,110-122

Drug/Food,0-9	DrugDDI.d580.s9.e0
Interactions,10-22
The,23-26
bioavailability,27-42
(AUC),43-48
of,49-51
deferasirox,52-63	DrugDDI.d580.s9.e1
was,64-67
variably,68-76
increased,77-86
when,87-91
taken,92-97
with,98-102
a,103-104
meal.,105-110

Deferasirox,0-11	DrugDDI.d580.s10.e0
should,12-18
be,19-21
taken,22-27
on,28-30
an,31-33
empty,34-39
stomach,40-47
30,48-50
minutes,51-58
before,59-65
eating.,66-73

Exjade,0-6	DrugDDI.d580.s11.e0
tablets,7-14
for,15-18
oral,19-23
suspension,24-34
can,35-38
be,39-41
dispersed,42-51
in,52-54
water,,55-61
orange,62-68
juice,,69-75
or,76-78
apple,79-84
juice.,85-91

Antiacid,,0-9
clarithromycin,,10-25
Didanosine,,26-37
Fluconazole,,38-50
Fluoxetine,,51-62
Indanavir,,63-73
Ketoconazole,,74-87
Phenytoin,,88-98
Phenobarbitol,,99-113
carbamazepine,,114-128
Rifabutin,,129-139
Rifampin,,140-149
Ritanovir,,150-160
Saquinavir.,161-172	DrugDDI.d50.s0.e9

Possible,0-8
drug,9-13
interactions,14-26
of,27-29
HUMORSOL,30-38	DrugDDI.d145.s0.e0
with,39-43
succinylcholine,44-59	DrugDDI.d145.s0.e1
or,60-62
with,63-67
other,68-73
anticholinesterase,74-92	DrugDDI.d145.s0.e2
agents.,93-100	DrugDDI.d145.s0.e2

Because,0-7
the,8-11
tetracyclines,12-25	DrugDDI.d263.s0.e0
have,26-30
been,31-35
shown,36-41
to,42-44
depress,45-52
plasma,53-59
prothrombin,60-71
activity,,72-81
patients,82-90
who,91-94
are,95-98
on,99-101
anticoagulant,102-115
therapy,116-123
may,124-127
require,128-135
downward,136-144
adjustment,145-155
of,156-158
their,159-164
anticoagulant,165-178	DrugDDI.d263.s0.e1
dosage.,179-186

Since,0-5
bacteriostatic,6-20	DrugDDI.d263.s1.e0
drugs,,21-27
such,28-32
as,33-35
the,36-39
tetracycline,40-52	DrugDDI.d263.s1.e1
class,53-58
of,59-61
antibiotics,,62-74
may,75-78
interfere,79-88
with,89-93
the,94-97
bactericidal,98-110
action,111-117
of,118-120
penicillins,,121-133
it,134-136
is,137-139
not,140-143
advisable,144-153
to,154-156
administer,157-167
these,168-173
drugs,174-179	DrugDDI.d263.s1.e4
concomitantly.,180-194

Concurrent,0-10
use,11-14
of,15-17
tetracyclines,18-31	DrugDDI.d263.s2.e0
with,32-36
oral,37-41	DrugDDI.d263.s2.e1
contraceptives,42-56	DrugDDI.d263.s2.e1
may,57-60
render,61-67
oral,68-72	DrugDDI.d263.s2.e2
contraceptives,73-87	DrugDDI.d263.s2.e2
less,88-92	DrugDDI.d263.s2.e2
effective.,93-103	DrugDDI.d263.s2.e2

However,,0-8
in,9-11
a,12-13
single,14-20
in,21-23
vivo,24-28
rodent,29-35
study,36-41
denileukin,42-52	DrugDDI.d213.s1.e0
diftitox,53-61	DrugDDI.d213.s1.e0
had,62-65
no,66-68
effect,69-75
on,76-78
P450,79-83	DrugDDI.d213.s1.e1
levels.,84-91

Taking,0-6
a,7-8
rauwolfia,9-18	DrugDDI.d153.s0.e0
alkaloid,19-27	DrugDDI.d153.s0.e0
while,28-33
you,34-37
are,38-41
taking,42-48
or,49-51
within,52-58
2,59-60
weeks,61-66
of,67-69
taking,70-76
MAO,77-80	DrugDDI.d153.s0.e1
inhibitors,81-91	DrugDDI.d153.s0.e1
may,92-95
increase,96-104
the,105-108
risk,109-113
of,114-116
central,117-124
nervous,125-132
system,133-139
depression,140-150
or,151-153
may,154-157
cause,158-163
a,164-165
severe,166-172
high,173-177
blood,178-183
pressure,184-192
reaction.,193-202

No,0-2
clinically,3-13
significant,14-25
adverse,26-33
interactions,34-46
with,47-51
commonly,52-60
used,61-65
preanesthetic,66-79
drugs,,80-86
or,87-89
drugs,90-95	DrugDDI.d60.s0.e1
used,96-100
during,101-107
anesthesia,108-118
(muscle,119-126
relaxants,,127-137
intravenous,138-149
agents,,150-157
and,158-161
local,162-167
anesthetic,168-178	DrugDDI.d60.s0.e3
agents),179-186	DrugDDI.d60.s0.e3
were,187-191
reported,192-200
in,201-203
clinical,204-212
trials.,213-220

The,0-3
effect,4-10
of,11-13
desflurane,14-24	DrugDDI.d60.s1.e0
on,25-27
the,28-31
disposition,32-43
of,44-46
other,47-52
drugs,53-58	DrugDDI.d60.s1.e1
has,59-62
not,63-66
been,67-71
determined.,72-83

Like,0-4
isoflurane,,5-16
desflurane,17-27	DrugDDI.d60.s2.e1
does,28-32
not,33-36
predispose,37-47
to,48-50
premature,51-60
ventricular,61-72
arrhythmias,73-84
in,85-87
the,88-91
presence,92-100
of,101-103
exogenously,104-115
infused,116-123
epinephrine,124-135	DrugDDI.d60.s2.e2
in,136-138
swine.,139-145

Drugs,0-5	DrugDDI.d409.s1.e0
Metabolized,6-17
by,18-20
P450,21-25	DrugDDI.d409.s1.e1
2D6:,26-30	DrugDDI.d409.s1.e1
The,31-34
biochemical,35-46
activity,47-55
of,56-58
the,59-62
drug,63-67	DrugDDI.d409.s1.e2
metabolizing,68-80
isozyme,81-88
cytochrome,89-99
P450,100-104
2D6,105-108
(debrisoquin,109-121
hydroxylase),122-134
is,135-137
reduced,138-145
in,146-148
a,149-150
subset,151-157
of,158-160
the,161-164
caucasian,165-174
population,175-185
(about,186-192
7,193-194
to,195-197
10%,198-201
of,202-204
caucasians,205-215
are,216-219
so,220-222
called,223-229
poor,230-234
metabolizers);,235-249

reliable,0-8
estimates,9-18
of,19-21
the,22-25
prevalence,26-36
of,37-39
reduced,40-47
P450,48-52	DrugDDI.d409.s2.e0
2D6,53-56	DrugDDI.d409.s2.e0
isozyme,57-64	DrugDDI.d409.s2.e0
activity,65-73
among,74-79
Asian,,80-86
African,87-94
and,95-98
other,99-104
populations,105-116
are,117-120
not,121-124
yet,125-128
available.,129-139

Poor,0-4
metabolizers,5-17
have,18-22
higher,23-29
than,30-34
expected,35-43
plasma,44-50
concentrations,51-65
of,66-68
tricyclic,69-78	DrugDDI.d409.s3.e0
antidepressants,79-94	DrugDDI.d409.s3.e0
(TCAs),95-101
when,102-106
given,107-112
usual,113-118
doses.,119-125

Depending,0-9
on,10-12
the,13-16
traction,17-25
of,26-28
drug,29-33	DrugDDI.d409.s4.e0
metabolized,34-45
by,46-48
P450,49-53	DrugDDI.d409.s4.e1
2D6,,54-58	DrugDDI.d409.s4.e1
the,59-62
increase,63-71
in,72-74
plasma,75-81
concentration,82-95
may,96-99
be,100-102
small,,103-109
or,110-112
quite,113-118
large,119-124
(8,125-127
fold,128-132
increase,133-141
in,142-144
plasma,145-151
AUC,152-155
of,156-158
the,159-162
TCA).,163-168

In,0-2
addition,,3-12
certain,13-20
drugs,21-26	DrugDDI.d409.s5.e0
inhibit,27-34
the,35-38
activity,39-47
of,48-50
this,51-55
isozyme,56-63	DrugDDI.d409.s5.e1
and,64-67
make,68-72
normal,73-79
metabolizers,80-92
resemble,93-101
p.o.,102-106

An,0-2
individual,3-13
who,14-17
is,18-20
stable,21-27
on,28-30
a,31-32
given,33-38
dose,39-43
of,44-46
TCA,47-50
may,51-54
become,55-61
abruptly,62-70
toxic,71-76
when,77-81
given,82-87
one,88-91
of,92-94
these,95-100
inhibiting,101-111
drugs,112-117	DrugDDI.d409.s7.e0
as,118-120
concomitant,121-132
therapy.,133-141

The,0-3
drugs,4-9	DrugDDI.d409.s8.e0
that,10-14
inhibit,15-22
cytochrome,23-33	DrugDDI.d409.s8.e1
P450,34-38	DrugDDI.d409.s8.e1
2D6,39-42	DrugDDI.d409.s8.e1
include,43-50
some,51-55
that,56-60
are,61-64
not,65-68
metabolized,69-80
by,81-83
the,84-87
enzyme,88-94
(quinidine;,95-106

cimetidine),0-11	DrugDDI.d409.s9.e0
and,12-15
many,16-20
that,21-25
are,26-29
substrates,30-40
for,41-44
P450,45-49	DrugDDI.d409.s9.e1
2D6,50-53	DrugDDI.d409.s9.e1
(many,54-59
other,60-65
antidepressants,,66-82
phenothiazines,,83-98
and,99-102
the,103-106
Type,107-111
1C,112-114
antiarrhythrnics,115-131
propatenone,132-143
and,144-147
flecainide).,148-160	DrugDDI.d409.s9.e4

While,0-5
all,6-9
the,10-13
selective,14-23
serotonin,24-33	DrugDDI.d409.s10.e0
reuptake,34-42	DrugDDI.d409.s10.e0
inhibitors,43-53	DrugDDI.d409.s10.e0
(SSRIs),,54-62
e.g.,,63-68
fluoxetine,,69-80
seriraline,,81-92
and,93-96
paroxetine,,97-108
inhibit,109-116
P450,117-121	DrugDDI.d409.s10.e3
2D6,,122-126	DrugDDI.d409.s10.e3
they,127-131
may,132-135
vary,136-140
in,141-143
the,144-147
extent,148-154
of,155-157
inhibition.,158-169

Nevertheless,,0-13
caution,14-21
is,22-24
indicated,25-34
in,35-37
the,38-41
co-administration,42-59
of,60-62
T.A.,63-67	DrugDDI.d409.s12.e0
with,68-72
any,73-76
of,77-79
the,80-83
SSRIs,84-89
and,90-93
also,94-98
in,99-101
switching,102-111
from,112-116
one,117-120
class,121-126
to,127-129
the,130-133
other.,134-140

Of,0-2
particular,3-13
importance,,14-25
sufficient,26-36
time,37-41
must,42-46
elapse,47-53
before,54-60
initiating,61-71
TCA,72-75
treatment,76-85
in,86-88
a,89-90
patient,91-98
being,99-104
withdrawn,105-114
from,115-119
fluoxetine,,120-131
given,132-137
the,138-141
long,142-146
half-life,147-156
of,157-159
the,160-163
parent,164-170
and,171-174
active,175-181	DrugDDI.d409.s13.e1
metabolite,182-192	DrugDDI.d409.s13.e1
(at,193-196
least,197-202
5,203-204
weeks,205-210
may,211-214
be,215-217
necessary).,218-229

Concomitant,0-11
use,12-15
of,16-18
tricyclic,19-28	DrugDDI.d409.s14.e0
antidepressants,29-44	DrugDDI.d409.s14.e0
with,45-49
drugs,50-55	DrugDDI.d409.s14.e1
that,56-60
can,61-64
inhibit,65-72
cytochrome,73-83	DrugDDI.d409.s14.e2
P450,84-88	DrugDDI.d409.s14.e2
2D6,89-92	DrugDDI.d409.s14.e2
may,93-96
require,97-104
lower,105-110
doses,111-116
than,117-121
usually,122-129
prescribed,130-140
for,141-144
either,145-151
the,152-155
tricyclic,156-165	DrugDDI.d409.s14.e3
antidepressant,166-180	DrugDDI.d409.s14.e3
or,181-183
the,184-187
other,188-193
drug.,194-199	DrugDDI.d409.s14.e4

Furthermore,,0-12
whenever,13-21
one,22-25
of,26-28
these,29-34
other,35-40
drugs,41-46	DrugDDI.d409.s15.e0
is,47-49
withdrawn,50-59
from,60-64
co-therapy,,65-76
an,77-79
increased,80-89
dose,90-94
of,95-97
tricyclic,98-107	DrugDDI.d409.s15.e1
antidepressant,108-122	DrugDDI.d409.s15.e1
may,123-126
be,127-129
required.,130-139

It,0-2
is,3-5
desirable,6-15
to,16-18
monitor,19-26
TCA,27-30
plasma,31-37
levels,38-44
whenever,45-53
a,54-55
TCA,56-59
is,60-62
going,63-68
to,69-71
be,72-74
co-administered,75-90
with,91-95
another,96-103
drug,104-108	DrugDDI.d409.s16.e0
known,109-114
to,115-117
be,118-120
an,121-123
inhibitor,124-133
of,134-136
P450,137-141	DrugDDI.d409.s16.e1
2D6.,142-146	DrugDDI.d409.s16.e1

Close,0-5
supervision,6-17
and,18-21
careful,22-29
adjustment,30-40
of,41-43
dosage,44-50
are,51-54
required,55-63
when,64-68
this,69-73
drug,74-78	DrugDDI.d409.s18.e0
is,79-81
given,82-87
concomitantly,88-101
with,102-106
anticholinergic,107-122	DrugDDI.d409.s18.e1
or,123-125
sympathomimetic,126-141	DrugDDI.d409.s18.e2
drugs.,142-148	DrugDDI.d409.s18.e2

Clinical,0-8
experience,9-19
in,20-22
the,23-26
concurrent,27-37
administration,38-52
of,53-55
ECT,56-59
and,60-63
antidepressant,64-78	DrugDDI.d409.s20.e0
drugs,79-84	DrugDDI.d409.s20.e0
is,85-87
limited.,88-96

If,0-2
desipramine,3-14	DrugDDI.d409.s23.e0
hydrochloride,15-28	DrugDDI.d409.s23.e0
is,29-31
to,32-34
be,35-37
combined,38-46
with,47-51
other,52-57
psychotropic,58-70	DrugDDI.d409.s23.e1
agents,71-77	DrugDDI.d409.s23.e1
such,78-82
as,83-85
tranquilizers,86-99	DrugDDI.d409.s23.e2
or,100-102
sedative/hypnotics,,103-122
careful,123-130
consideration,131-144
should,145-151
be,152-154
given,155-160
to,161-163
the,164-167
pharmacology,168-180
of,181-183
the,184-187
agents,188-194
employed,195-203
since,204-209
the,210-213
sedative,214-222	DrugDDI.d409.s23.e5
effects,223-230
of,231-233
desipramine,234-245	DrugDDI.d409.s23.e6
and,246-249
benzodiazepines,250-265	DrugDDI.d409.s23.e7
(e.g.,,266-272
chlordiazepoxide,273-289	DrugDDI.d409.s23.e8
or,290-292
diazepam),293-302	DrugDDI.d409.s23.e9
are,303-306
additive.,307-316

Both,0-4
the,5-8
sedative,9-17	DrugDDI.d409.s24.e0
and,18-21
anticholinergic,22-37	DrugDDI.d409.s24.e1
effects,38-45
of,46-48
the,49-52
major,53-58	DrugDDI.d409.s24.e2
tranquilizers,59-72	DrugDDI.d409.s24.e2
are,73-76
also,77-81
additive,82-90
to,91-93
those,94-99
of,100-102
desipramine.,103-115	DrugDDI.d409.s24.e3

Concurrent,0-10
administration,11-25
of,26-28
cimetidine,29-39	DrugDDI.d409.s26.e0
and,40-43
tricyclic,44-53	DrugDDI.d409.s26.e1
antidepressants,54-69	DrugDDI.d409.s26.e1
can,70-73
produce,74-81
clinically,82-92
significant,93-104
increases,105-114
in,115-117
the,118-121
plasma,122-128
levels,129-135
of,136-138
the,139-142
tricyclic,143-152	DrugDDI.d409.s26.e2
antidepressants.,153-169	DrugDDI.d409.s26.e2

Conversely,,0-11
decreases,12-21
in,22-24
plasma,25-31
levels,32-38
of,39-41
the,42-45
tricyclic,46-55	DrugDDI.d409.s27.e0
antidepressants,56-71	DrugDDI.d409.s27.e0
have,72-76
been,77-81
reported,82-90
upon,91-95
discontinuation,96-111
of,112-114
cimetidine,115-125	DrugDDI.d409.s27.e1
which,126-131
may,132-135
result,136-142
in,143-145
the,146-149
loss,150-154
of,155-157
the,158-161
therapeutic,162-173
efficacy,174-182
of,183-185
the,186-189
tricyclic,190-199	DrugDDI.d409.s27.e2
antidepressant,200-214	DrugDDI.d409.s27.e2
6.,215-217

There,0-5
have,6-10
been,11-15
greater,16-23
than,24-28
two-fold,29-37
increases,38-47
of,48-50
previously,51-61
stable,62-68
plasma,69-75
levels,76-82
of,83-85
tricyclic,86-95	DrugDDI.d409.s28.e0
antidepressants,96-111	DrugDDI.d409.s28.e0
when,112-116
fluoxetine,117-127	DrugDDI.d409.s28.e1
has,128-131
been,132-136
administered,137-149
in,150-152
combination,153-164
with,165-169
these,170-175
agents.,176-183

In,0-2
two,3-6
controlled,7-17
crossover,18-27
clinical,28-36
pharmacology,37-49
studies,50-57
in,58-60
healthy,61-68
male,69-73
(n=12,74-79
in,80-82
each,83-87
study),88-94
a,95-96
nd,97-99	DrugDDI.d340.s0.e0
female,100-106	DrugDDI.d340.s0.e0
(n=12,107-112
in,113-115
each,116-120
study),121-127
volunteers,,128-139
desloratadine,140-153	DrugDDI.d340.s0.e1
7.5,154-157	DrugDDI.d340.s0.e1
mg,158-160
(1.5,161-165
times,166-171
the,172-175
daily,176-181
dose),182-187
once,188-192
daily,193-198
was,199-202
coadministered,203-217
with,218-222
erythromycin,223-235	DrugDDI.d340.s0.e2
500,236-239	DrugDDI.d340.s0.e2
mg,240-242	DrugDDI.d340.s0.e2
every,243-248
8,249-250
hours,251-256
or,257-259
ketoconazole,260-272	DrugDDI.d340.s0.e3
200,273-276	DrugDDI.d340.s0.e3
mg,277-279	DrugDDI.d340.s0.e3
every,280-285
12,286-288
hours,289-294
for,295-298
10,299-301
days.,302-307

In,0-2
three,3-8
separate,9-17
controlled,,18-29
parallel,30-38
group,39-44
clinical,45-53
pharmacology,54-66
studies,,67-75
desloratadine,76-89	DrugDDI.d340.s1.e0
at,90-92
the,93-96
clinical,97-105
dose,106-110
of,111-113
5,114-115
mg,116-118
has,119-122
been,123-127
coadministered,128-142
with,143-147
azithromycin,148-160	DrugDDI.d340.s1.e1
500,161-164	DrugDDI.d340.s1.e1
mg,165-167	DrugDDI.d340.s1.e1
followed,168-176
by,177-179
250,180-183
mg,184-186
once,187-191
daily,192-197
for,198-201
4,202-203
days,204-208
(n=18),209-215
or,216-218
with,219-223
fluoxetine,224-234	DrugDDI.d340.s1.e2
20,235-237	DrugDDI.d340.s1.e2
mg,238-240	DrugDDI.d340.s1.e2
once,241-245
daily,246-251
for,252-255
7,256-257
days,258-262
after,263-268
a,269-270
23,271-273
day,274-277
pretreatment,278-290
period,291-297
with,298-302
fluoxetine,303-313	DrugDDI.d340.s1.e3
(n=18),314-320
or,321-323
with,324-328
cimetidine,329-339	DrugDDI.d340.s1.e4
600,340-343	DrugDDI.d340.s1.e4
mg,344-346	DrugDDI.d340.s1.e4
every,347-352
12,353-355
hours,356-361
for,362-365
14,366-368
days,369-373
(n=18),374-380
under,381-386
steady,387-393
state,394-399
conditions,400-410
to,411-413
normal,414-420
healthy,421-428
male,429-433
and,434-437
female,438-444
volunteers.,445-456

Although,0-8
increased,9-18
plasma,19-25
concentrations,26-40
(C,41-43
max,44-47	DrugDDI.d340.s2.e0
and,48-51
AUC,52-55
0-24,56-60
hrs),61-65
of,66-68
desloratadine,69-82	DrugDDI.d340.s2.e1
and,83-86
3-hydroxydesloratadine,87-109
were,110-114
observed,115-123
,,124-125
there,126-131
were,132-136
no,137-139
clinically,140-150
relevant,151-159
changes,160-167
in,168-170
the,171-174
safety,175-181
profile,182-189
of,190-192
desloratadine,,193-207
as,208-210
assessed,211-219
by,220-222
electrocardiographic,223-243
parameters,244-254
(including,255-265
the,266-269
corrected,270-279
QT,280-282
interval),,283-293
clinical,294-302
laboratory,303-313
tests,,314-320
vital,321-326
signs,,327-333
and,334-337
adverse,338-345
events.,346-353

Table,0-5
1,6-7
Changes,8-15
in,16-18
Desloratadine,19-32	DrugDDI.d340.s3.e0
and,33-36
3-Hydroxydesloratadine,37-59
Pharmacokinetics,60-76
in,77-79
Healthy,80-87
Male,88-92
and,93-96
Female,97-103
Volunteers,104-114

Desloratadine,0-13	DrugDDI.d340.s5.e0
3-Hydroxydesloratadine,14-36

Erythromycin,0-12	DrugDDI.d340.s8.e0

Ketoconazole,0-12	DrugDDI.d340.s11.e0

Azithromycin,0-12	DrugDDI.d340.s14.e0

(500,0-4
mg,5-7
day,8-11
1,,12-14
250,15-18	DrugDDI.d340.s15.e0
mg,19-21
QD,22-24
?,25-26
4,27-28
days),29-34

Fluoxetine,0-10	DrugDDI.d340.s17.e0

Cimetidine,0-10	DrugDDI.d340.s20.e0

Although,0-8
the,9-12
pressor,13-20	DrugDDI.d560.s0.e0
activity,21-29
of,30-32
Desmopressin,33-45	DrugDDI.d560.s0.e1
is,46-48
very,49-53
low,54-57
compared,58-66
to,67-69
its,70-73
antidiuretic,74-86	DrugDDI.d560.s0.e2
activity,,87-96
large,97-102
doses,103-108
of,109-111
Desmopressin,112-124	DrugDDI.d560.s0.e3
Tablets,125-132
should,133-139
be,140-142
used,143-147
with,148-152
other,153-158
pressor,159-166	DrugDDI.d560.s0.e4
agents,167-173	DrugDDI.d560.s0.e4
only,174-178
with,179-183
careful,184-191
patient,192-199
monitoring.,200-211

Reduced,0-7
efficacy,8-16
and,17-20
increased,21-30
incidence,31-40
of,41-43
breakthrough,44-56
bleeding,57-65
and,66-69
menstrual,70-79
irregularities,80-94
have,95-99
been,100-104
associated,105-115
with,116-120
concomitant,121-132
use,133-136
of,137-139
rifampin.,140-149	DrugDDI.d552.s0.e0

A,0-1
similar,2-9
association,,10-22
though,23-29
less,30-34
marked,,35-42
has,43-46
been,47-51
suggested,52-61
with,62-66
barbiturates,,67-80
phenyl-butazone,,81-97
phenytoin,98-107	DrugDDI.d552.s1.e2
sodium,,108-115	DrugDDI.d552.s1.e2
carbamazepine,116-129	DrugDDI.d552.s1.e3
and,130-133
possibly,134-142
with,143-147
griseofulvin,,148-161
ampicillin,,162-173
and,174-177
tetracyclines,178-191	DrugDDI.d552.s1.e6
(72),192-196

Aminoglutethimide:,0-18	DrugDDI.d413.s0.e0
Aminoglutethimide,19-36	DrugDDI.d413.s0.e1
may,37-40
diminish,41-49
adrenal,50-57
suppression,58-69
by,70-72
corticosteroids.,73-89	DrugDDI.d413.s0.e2

Amphotericin,0-12	DrugDDI.d413.s1.e0
B,13-14	DrugDDI.d413.s1.e0
injection,15-24
and,25-28
potassium-depleting,29-48	DrugDDI.d413.s1.e1
agents:,49-56
When,57-61
corticosteroids,62-77	DrugDDI.d413.s1.e2
are,78-81
administered,82-94
concomitantly,95-108
with,109-113
potassium-depleting,114-133	DrugDDI.d413.s1.e3
agents,134-140
(e.g.,,141-147
amphotericin,148-160	DrugDDI.d413.s1.e4
B,,161-163	DrugDDI.d413.s1.e4
diuretics),,164-175
patients,176-184
should,185-191
be,192-194
observed,195-203
closely,204-211
for,212-215
development,216-227
of,228-230
hypokalemia.,231-243

In,0-2
addition,,3-12
there,13-18
have,19-23
been,24-28
cases,29-34
reported,35-43
in,44-46
which,47-52
concomitant,53-64
use,65-68
of,69-71
amphotericin,72-84	DrugDDI.d413.s2.e0
B,85-86	DrugDDI.d413.s2.e0
and,87-90
hydrocortisone,91-105	DrugDDI.d413.s2.e1
was,106-109
followed,110-118
by,119-121
cardiac,122-129
enlargement,130-141
and,142-145
congestive,146-156
heart,157-162
failure.,163-171

Antibiotics:,0-12	DrugDDI.d413.s3.e0
Macrolide,13-22	DrugDDI.d413.s3.e1
antibiotics,23-34	DrugDDI.d413.s3.e1
have,35-39
been,40-44
reported,45-53
to,54-56
cause,57-62
a,63-64
significant,65-76
decrease,77-85
in,86-88
corticosteroid,89-103	DrugDDI.d413.s3.e2
clearance.,104-114

Anticholinesterases:,0-20	DrugDDI.d413.s4.e0
Concomitant,21-32
use,33-36
of,37-39
anticholinesterase,40-58	DrugDDI.d413.s4.e1
agents,59-65	DrugDDI.d413.s4.e1
and,66-69
corticosteroids,70-85	DrugDDI.d413.s4.e2
may,86-89
produce,90-97
severe,98-104
weakness,105-113
in,114-116
patients,117-125
with,126-130
myasthenia,131-141
gravis.,142-149

If,0-2
possible,,3-12
anticholinesterase,13-31	DrugDDI.d413.s5.e0
agents,32-38	DrugDDI.d413.s5.e0
should,39-45
be,46-48
withdrawn,49-58
at,59-61
least,62-67
24,68-70
hours,71-76
before,77-83
initiating,84-94
corticosteroid,95-109
therapy.,110-118

Anticoagulants,,0-15
oral:,16-21
Co-administration,22-39
of,40-42
corticosteroids,43-58	DrugDDI.d413.s6.e1
and,59-62
warfarin,63-71	DrugDDI.d413.s6.e2
usually,72-79
results,80-87
in,88-90
inhibition,91-101
of,102-104
response,105-113
to,114-116
warfarin,,117-126
although,127-135
there,136-141
have,142-146
been,147-151
some,152-156
conflicting,157-168
reports.,169-177

Antidiabetics:,0-14	DrugDDI.d413.s8.e0
Because,15-22
corticosteroids,23-38	DrugDDI.d413.s8.e1
may,39-42
increase,43-51
blood,52-57
glucose,58-65
concentrations,,66-81
dosage,82-88
adjustments,89-100
of,101-103
antidiabetic,104-116	DrugDDI.d413.s8.e2
agents,117-123	DrugDDI.d413.s8.e2
may,124-127
be,128-130
required.,131-140

Antitubercular,0-14	DrugDDI.d413.s9.e0
drugs:,15-21	DrugDDI.d413.s9.e0
Serum,22-27
concentrations,28-42
of,43-45
isoniazid,46-55	DrugDDI.d413.s9.e1
may,56-59
be,60-62
decreased.,63-73

Cholestyramine:,0-15	DrugDDI.d413.s10.e0
Cholestyramine,16-30	DrugDDI.d413.s10.e1
may,31-34
increase,35-43
the,44-47
clearance,48-57
of,58-60
corticosteroids.,61-77	DrugDDI.d413.s10.e2

Cyclosporine:,0-13	DrugDDI.d413.s11.e0
Increased,14-23
activity,24-32
of,33-35
both,36-40
cyclosporine,41-53	DrugDDI.d413.s11.e1
and,54-57
corticosteroids,58-73	DrugDDI.d413.s11.e2
may,74-77
occur,78-83
when,84-88
the,89-92
two,93-96
are,97-100
used,101-105
concurrently.,106-119

Dexamethasone,0-13
suppression,14-25
test,26-30
(DST):,31-37
False-negative,38-52
results,53-60
in,61-63
the,64-67
dexamethasone,68-81
suppression,82-93
test,94-98
(DST),99-104
in,105-107
patients,108-116
being,117-122
treated,123-130
with,131-135
indomethacin,136-148	DrugDDI.d413.s13.e0
have,149-153
been,154-158
reported.,159-168

Digitalis,0-9	DrugDDI.d413.s15.e0
glycosides:,10-21	DrugDDI.d413.s15.e0
Patients,22-30
on,31-33
digitalis,34-43	DrugDDI.d413.s15.e1
glycosides,44-54	DrugDDI.d413.s15.e1
may,55-58
be,59-61
at,62-64
increased,65-74
risk,75-79
of,80-82
arrhythmias,83-94
due,95-98
to,99-101
hypokalemia.,102-114

Ephedrine:,0-10	DrugDDI.d413.s16.e0
Ephedrine,11-20	DrugDDI.d413.s16.e1
may,21-24
enhance,25-32
the,33-36
metabolic,37-46
clearance,47-56
of,57-59
corticosteroids,,60-76
resulting,77-86
in,87-89
decreased,90-99
blood,100-105
levels,106-112
and,113-116
lessened,117-125
physiologic,126-137
activity,,138-147
thus,148-152
requiring,153-162
an,163-165
increase,166-174
in,175-177
corticosteroid,178-192	DrugDDI.d413.s16.e3
dosage.,193-200

Estrogens,,0-10
including,11-20
oral,21-25	DrugDDI.d413.s17.e1
contraceptives:,26-41	DrugDDI.d413.s17.e1
Estrogens,42-51	DrugDDI.d413.s17.e2
may,52-55
decrease,56-64
the,65-68
hepatic,69-76
metabolism,77-87
of,88-90
certain,91-98
corticosteroids,,99-115
thereby,116-123
increasing,124-134
their,135-140
effect.,141-148

Hepatic,0-7
Enzyme,8-14
Inducers,,15-24
Inhibitors,25-35
and,36-39
Substrates:,40-51
Drugs,52-57	DrugDDI.d413.s18.e0
which,58-63
induce,64-70
cytochrome,71-81	DrugDDI.d413.s18.e1
P450,82-86	DrugDDI.d413.s18.e1
3A4,87-90	DrugDDI.d413.s18.e1
(CYP,91-95
3A4),96-100
enzyme,101-107
activity,108-116
(e.g.,,117-123
barbiturates,,124-137
phenytoin,,138-148
carbamazepine,,149-163
rifampin),164-173	DrugDDI.d413.s18.e6
may,174-177
enhance,178-185
the,186-189
metabolism,190-200
of,201-203
corticosteroids,204-219	DrugDDI.d413.s18.e7
and,220-223
require,224-231
that,232-236
the,237-240
dosage,241-247
of,248-250
the,251-254
corticosteroid,255-269	DrugDDI.d413.s18.e8
be,270-272
increased.,273-283

Drugs,0-5	DrugDDI.d413.s19.e0
which,6-11
inhibit,12-19
CYP,20-23	DrugDDI.d413.s19.e1
3A4,24-27
(e.g.,,28-34
ketoconazole,,35-48
macrolide,49-58	DrugDDI.d413.s19.e3
antibiotics,59-70	DrugDDI.d413.s19.e3
such,71-75
as,76-78
erythromycin),79-92	DrugDDI.d413.s19.e4
have,93-97
the,98-101
potential,102-111
to,112-114
result,115-121
in,122-124
increased,125-134
plasma,135-141
concentrations,142-156
of,157-159
corticosteroids.,160-176	DrugDDI.d413.s19.e5

Dexamethasone,0-13	DrugDDI.d413.s20.e0
is,14-16
a,17-18
moderate,19-27
inducer,28-35
of,36-38
CYP,39-42	DrugDDI.d413.s20.e1
3A4.,43-47

Co-administration,0-17
with,18-22
other,23-28
drugs,29-34	DrugDDI.d413.s21.e0
that,35-39
are,40-43
metabolized,44-55
by,56-58
CYP,59-62	DrugDDI.d413.s21.e1
3A4,63-66
(e.g.,,67-73
indinavir,,74-84
erythromycin),85-98	DrugDDI.d413.s21.e3
may,99-102
increase,103-111
their,112-117
clearance,,118-128
resulting,129-138
in,139-141
decreased,142-151
plasma,152-158
concentration.,159-173

Ketoconazole:,0-13	DrugDDI.d413.s22.e0
Ketoconazole,14-26	DrugDDI.d413.s22.e1
has,27-30
been,31-35
reported,36-44
to,45-47
decrease,48-56
the,57-60
metabolism,61-71
of,72-74
certain,75-82
corticosteroids,83-98	DrugDDI.d413.s22.e2
by,99-101
up,102-104
to,105-107
60%,,108-112
leading,113-120
to,121-123
increased,124-133
risk,134-138
of,139-141
corticosteroid,142-156	DrugDDI.d413.s22.e3
side,157-161
effects.,162-170

In,0-2
addition,,3-12
ketoconazole,13-25	DrugDDI.d413.s23.e0
alone,26-31
can,32-35
inhibit,36-43
adrenal,44-51
corticosteroid,52-66	DrugDDI.d413.s23.e1
synthesis,67-76
and,77-80
may,81-84
cause,85-90
adrenal,91-98
insufficiency,99-112
during,113-119
corticosteroid,120-134	DrugDDI.d413.s23.e2
withdrawal.,135-146

Nonsteroidal,0-12	DrugDDI.d413.s24.e0
anti-inflammatory,13-30	DrugDDI.d413.s24.e0
agents,31-37	DrugDDI.d413.s24.e0
(NSAIDS):,38-47
Concomitant,48-59
use,60-63
of,64-66
aspirin,67-74	DrugDDI.d413.s24.e2
(or,75-78
other,79-84
nonsteroidal,85-97	DrugDDI.d413.s24.e3
antiinflammatory,98-114	DrugDDI.d413.s24.e3
agents),115-122	DrugDDI.d413.s24.e3
and,123-126
corticosteroids,127-142	DrugDDI.d413.s24.e4
increases,143-152
the,153-156
risk,157-161
of,162-164
gastrointestinal,165-181
side,182-186
effects.,187-195

Aspirin,0-7	DrugDDI.d413.s25.e0
should,8-14
be,15-17
used,18-22
cautiously,23-33
in,34-36
conjunction,37-48
with,49-53
corticosteroids,54-69	DrugDDI.d413.s25.e1
in,70-72
hypoprothrombinemia.,73-93

The,0-3
clearance,4-13
of,14-16
salicylates,17-28	DrugDDI.d413.s26.e0
may,29-32
be,33-35
increased,36-45
with,46-50
concurrent,51-61
use,62-65
of,66-68
corticosteroids.,69-85	DrugDDI.d413.s26.e1

Phenytoin:,0-10	DrugDDI.d413.s27.e0
In,11-13
post-marketing,14-28
experience,,29-40
there,41-46
have,47-51
been,52-56
reports,57-64
of,65-67
both,68-72
increases,73-82
and,83-86
decreases,87-96
in,97-99
phenytoin,100-109
levels,110-116
with,117-121
dexamethasone,122-135	DrugDDI.d413.s27.e1
co-administration,,136-154
leading,155-162
to,163-165
alterations,166-177
in,178-180
seizure,181-188
control.,189-197

Skin,0-4
tests:,5-11
Corticosteroids,12-27	DrugDDI.d413.s28.e0
may,28-31
suppress,32-40
reactions,41-50
to,51-53
skin,54-58
tests.,59-65

Thalidomide:,0-12	DrugDDI.d413.s29.e0
Co-administration,13-30
with,31-35
thalidomide,36-47	DrugDDI.d413.s29.e1
should,48-54
be,55-57
employed,58-66
cautiously,,67-78
as,79-81
toxic,82-87
epidermal,88-97
necrolysis,98-108
has,109-112
been,113-117
reported,118-126
with,127-131
concomitant,132-143
use.,144-148

Vaccines:,0-9	DrugDDI.d413.s30.e0
Patients,10-18
on,19-21
corticosteroid,22-36
therapy,37-44
may,45-48
exhibit,49-56
a,57-58
diminished,59-69
response,70-78
to,79-81
toxoids,82-89	DrugDDI.d413.s30.e1
and,90-93
live,94-98
or,99-101
inactivated,102-113	DrugDDI.d413.s30.e2
vaccines,114-122	DrugDDI.d413.s30.e2
due,123-126
to,127-129
inhibition,130-140
of,141-143
antibody,144-152
response.,153-162

Corticosteroids,0-15	DrugDDI.d413.s31.e0
may,16-19
also,20-24
potentiate,25-35
the,36-39
replication,40-51
of,52-54
some,55-59
organisms,60-69
contained,70-79
in,80-82
live,83-87	DrugDDI.d413.s31.e1
attenuated,88-98	DrugDDI.d413.s31.e1
vaccines.,99-108	DrugDDI.d413.s31.e1

Routine,0-7
administration,8-22
of,23-25
vaccines,26-34	DrugDDI.d413.s32.e0
or,35-37
toxoids,38-45	DrugDDI.d413.s32.e1
should,46-52
be,53-55
deferred,56-64
until,65-70
corticosteroid,71-85
therapy,86-93
is,94-96
discontinued,97-109
if,110-112
possible.,113-122

Dexbrompheniramine,0-18	DrugDDI.d335.s0.e0
can,19-22
interact,23-31
with,32-36
alcohol,37-44	DrugDDI.d335.s0.e1
or,45-47
other,48-53
CNS,54-57	DrugDDI.d335.s0.e2
depressants,58-69	DrugDDI.d335.s0.e2
(may,70-74
potentiate,75-85
the,86-89
CNS,90-93	DrugDDI.d335.s0.e3
depressant,94-104	DrugDDI.d335.s0.e3
effects,105-112
of,113-115
either,116-122
these,123-128
medications,129-140	DrugDDI.d335.s0.e4
or,141-143
antihistamines),,144-160
anticholinergics,161-177	DrugDDI.d335.s0.e6
or,178-180
other,181-186	DrugDDI.d335.s0.e7
medications,187-198	DrugDDI.d335.s0.e7
with,199-203
anticholinergic,204-219	DrugDDI.d335.s0.e8
activity,220-228
(anticholinergic,229-245
effects,246-253
may,254-257
be,258-260
potentiated,261-272
when,273-277
these,278-283
medications,284-295	DrugDDI.d335.s0.e10
are,296-299
used,300-304
concurrently,305-317
with,318-322
antihistamines),,323-339
and,340-343
monoamine,344-353	DrugDDI.d335.s0.e12
oxidase,354-361	DrugDDI.d335.s0.e12
(MAO),362-367
inhibitors,368-378
(concurrent,379-390
use,391-394
with,395-399
antihistamines,400-414	DrugDDI.d335.s0.e13
may,415-418
prolong,419-426
and,427-430
intensify,431-440
the,441-444
anticholinergic,445-460	DrugDDI.d335.s0.e14
and,461-464
CNS,465-468	DrugDDI.d335.s0.e15
depressant,469-479	DrugDDI.d335.s0.e15
effects,480-487
of,488-490
antihistamines).,491-507	DrugDDI.d335.s0.e16

In,0-2
patients,3-11
receiving,12-21
nonselective,22-34
monoamine,35-44	DrugDDI.d39.s0.e0
oxidase,45-52	DrugDDI.d39.s0.e0
inhibitors,53-63	DrugDDI.d39.s0.e0
(MAOIs),64-71
(e.g.,,72-78
selegiline,79-89	DrugDDI.d39.s0.e1
hydrochloride),90-104	DrugDDI.d39.s0.e1
in,105-107
combination,108-119
with,120-124
serotoninergic,125-139
agents,140-146
(e.g.,,147-153
fluoxetine,,154-165
fluvoxamine,,166-178
paroxetine,,179-190
sertraline,,191-202
venlafaxine),,203-216
there,217-222
have,223-227
been,228-232
reports,233-240
of,241-243
serious,,244-252
sometimes,253-262
fatal,,263-269
reactions.,270-280

Because,0-7
dexfenfluramine,8-23	DrugDDI.d39.s1.e0
is,24-26
a,27-28
serotonin,29-38
releaser,39-47
and,48-51
reuptake,52-60	DrugDDI.d39.s1.e1
inhibitor,,61-71	DrugDDI.d39.s1.e1
dexfenfluramine,72-87	DrugDDI.d39.s1.e2
should,88-94
not,95-98
be,99-101
used,102-106
concomitantly,107-120
with,121-125
a,126-127
MAO,128-131	DrugDDI.d39.s1.e3
inhibitor.,132-142	DrugDDI.d39.s1.e3

At,0-2
least,3-8
14,9-11
days,12-16
should,17-23
elapse,24-30
between,31-38
discontinuation,39-54
of,55-57
a,58-59
MAO,60-63	DrugDDI.d39.s2.e0
inhibitor,64-73	DrugDDI.d39.s2.e0
and,74-77
initiation,78-88
of,89-91
treatment,92-101
with,102-106
dexfenfluramine.,107-123	DrugDDI.d39.s2.e1

At,0-2
least,3-8
3,9-10
weeks,11-16
should,17-23
elapse,24-30
between,31-38
discontinuation,39-54
of,55-57
dexfenfluramine,58-73	DrugDDI.d39.s3.e0
and,74-77
initiation,78-88
of,89-91
treatment,92-101
with,102-106
a,107-108
MAO,109-112	DrugDDI.d39.s3.e1
inhibitor.,113-123	DrugDDI.d39.s3.e1

A,0-1
rare,,2-7
but,8-11
serious,,12-20
constellation,21-34
of,35-37
symptoms,,38-47
termed,48-54
serotonin,55-64
syndrome,,65-74
has,75-78
been,79-83
reported,84-92
with,93-97
the,98-101
concomitant,102-113
use,114-117
of,118-120
selective,121-130
serotonin,131-140	DrugDDI.d39.s4.e0
reuptake,141-149	DrugDDI.d39.s4.e0
inhibitors,150-160	DrugDDI.d39.s4.e0
(SSRIs),161-168
and,169-172
agents,173-179
for,180-183
migraine,184-192
therapy,,193-201
such,202-206
as,207-209
Imitrex,210-217	DrugDDI.d39.s4.e1
(sumatriptan,218-230
succinate),231-241
and,242-245
dihydroergotamine.,246-264	DrugDDI.d39.s4.e3

Dexfenfluramine,0-15	DrugDDI.d39.s6.e0
should,16-22
not,23-26
be,27-29
administered,30-42
with,43-47
other,48-53
serotoninergic,54-68
agents.,69-76

The,0-3
appropriate,4-15
interval,16-24
between,25-32
administration,33-47
of,48-50
these,51-56
agents,57-63
and,64-67
dexfenfluramine,68-83	DrugDDI.d39.s7.e0
has,84-87
not,88-91
been,92-96
established.,97-109

The,0-3
use,4-7
of,8-10
dexfenfluramine,11-26	DrugDDI.d39.s8.e0
with,27-31
other,32-37
CNS-active,38-48	DrugDDI.d39.s8.e1
drugs,49-54	DrugDDI.d39.s8.e1
has,55-58
not,59-62
been,63-67
systematically,68-82
evaluated;,83-93

consequently,,0-13
caution,14-21
is,22-24
advised,25-32
if,33-35
dexfenfluramine,36-51	DrugDDI.d39.s9.e0
and,52-55
such,56-60
drugs,61-66	DrugDDI.d39.s9.e1
are,67-70
prescribed,71-81
concurrently.,82-95

General,0-7
In,8-10
vitro,11-16
studies,17-24
in,25-27
human,28-33
liver,34-39
microsomes,40-50
demonstrated,51-63
no,64-66
evidence,67-75
of,76-78
cytochrome,79-89	DrugDDI.d429.s0.e0
P450-mediated,90-103
drug,104-108
interactions,109-121
that,122-126
are,127-130
likely,131-137
to,138-140
be,141-143
of,144-146
clinical,147-155
relevance.,156-166

Anesthetics/Sedatives/Hypnotics/Opioids,0-39	DrugDDI.d429.s1.e0
Co-administration,40-57
of,58-60
PRECEDEX,61-69	DrugDDI.d429.s1.e4
with,70-74
anesthetics,,75-87
sedatives,,88-98
hypnotics,,99-109
and,110-113
opioids,114-121	DrugDDI.d429.s1.e8
is,122-124
likely,125-131
to,132-134
lead,135-139
to,140-142
an,143-145
enhancement,146-157
of,158-160
effects.,161-169

Specific,0-8
studies,9-16
have,17-21
confirmed,22-31
these,32-37
effects,38-45
with,46-50
sevoflurane,,51-63
isoflurane,,64-75
propofol,,76-85
alfentanil,,86-97
and,98-101
midazolam.,102-112	DrugDDI.d429.s2.e4

No,0-2
pharmacokinetic,3-18
interactions,19-31
between,32-39
dexmedetomidine,40-55	DrugDDI.d429.s3.e0
and,56-59
isoflurane,,60-71
propofol,,72-81
alfentanil,,82-93
and,94-97
midazolam,98-107	DrugDDI.d429.s3.e4
have,108-112
been,113-117
demonstrated.,118-131

However,,0-8
due,9-12
to,13-15
possible,16-24
pharmacodynamic,25-40
interactions,,41-54
when,55-59
co-administered,60-75
with,76-80
PRECEDEX,,81-90
a,91-92
reduction,93-102
in,103-105
dosage,106-112
of,113-115
PRECEDEX,116-124	DrugDDI.d429.s4.e1
on,125-127
the,128-131
concomitant,132-143
anesthetic,,144-155
sedative,,156-165
hypnotic,166-174	DrugDDI.d429.s4.e3
or,175-177
opioid,178-184	DrugDDI.d429.s4.e4
may,185-188
be,189-191
required.,192-201

Neuromuscular,0-13	DrugDDI.d429.s5.e0
Blockers,14-22	DrugDDI.d429.s5.e0
In,23-25
one,26-29
study,30-35
of,36-38
10,39-41
healthy,42-49
volunteers,,50-61
administration,62-76
of,77-79
PRECEDEX,80-88	DrugDDI.d429.s5.e1
for,89-92
45,93-95
minutes,96-103
at,104-106
a,107-108
plasma,109-115
concentration,116-129
of,130-132
1,133-134
(one),135-140
ng/mL,141-146
resulted,147-155
in,156-158
no,159-161
clinically,162-172
meaningful,173-183
increases,184-193
in,194-196
the,197-200
magnitude,201-210
or,211-213
neuromuscular,214-227
blockade,228-236
associated,237-247
with,248-252
rocuronium,253-263	DrugDDI.d429.s5.e2
administration.,264-279

ZINECARD,0-8	DrugDDI.d72.s0.e0
does,9-13
not,14-17
influence,18-27
the,28-31
pharmacokinetics,32-48
of,49-51
doxorubicin.,52-64	DrugDDI.d72.s0.e1

Carcinogenesis,,0-15
Mutagenesis,,16-28
Impairment,29-39
of,40-42
Fertility,43-52
No,53-55
long-term,56-65
carcinogenicity,66-81
studies,82-89
have,90-94
been,95-99
carried,100-107
out,108-111
with,112-116
dexrazoxane,117-128	DrugDDI.d72.s1.e0
in,129-131
animals.,132-140

Dexrazoxane,0-11	DrugDDI.d72.s2.e0
was,12-15
not,16-19
mutagenic,20-29
in,30-32
the,33-36
Ames,37-41	DrugDDI.d72.s2.e1
test,42-46
but,47-50
was,51-54
found,55-60
to,61-63
be,64-66
clastogenic,67-78
to,79-81
human,82-87
lymphocytes,88-99
in,100-102
vitro,103-108
and,109-112
to,113-115
mouse,116-121
bone,122-126
marrow,127-133
erythrocytes,134-146
in,147-149
vivo,150-154
(micronucleus,155-168
test).,169-175

The,0-3
possible,4-12
adverse,13-20
effects,21-28
of,29-31
ZINECARD,32-40	DrugDDI.d72.s3.e0
on,41-43
the,44-47
fertility,48-57
of,58-60
humans,61-67
and,68-71
experimental,72-84
animals,,85-93
male,94-98
or,99-101
female,,102-109
have,110-114
not,115-118
been,119-123
adequately,124-134
studied.,135-143

Testicular,0-10
atrophy,11-18
was,19-22
seen,23-27
with,28-32
dexrazoxane,33-44	DrugDDI.d72.s4.e0
administration,45-59
at,60-62
doses,63-68
as,69-71
low,72-75
as,76-78
30,79-81
mg/kg,82-87
weekly,88-94
for,95-98
6,99-100
weeks,101-106
in,107-109
rats,110-114
(1/3,115-119
the,120-123
human,124-129
dose,130-134
on,135-137
a,138-139
mg/m,140-144
2,145-146
basis),147-153
and,154-157
as,158-160
low,161-164
as,165-167
20,168-170
mg/kg,171-176
weekly,177-183
for,184-187
13,188-190
weeks,191-196
in,197-199
dogs,200-204
(approximately,205-219
equal,220-225
to,226-228
the,229-232
human,233-238
dose,239-243
on,244-246
a,247-248
mg/m,249-253
2,254-255
basis).,256-263

Acidifying,0-10	DrugDDI.d377.s0.e0
agents:,11-18	DrugDDI.d377.s0.e0
Gastrointestinal,19-35	DrugDDI.d377.s0.e1
acidifying,36-46	DrugDDI.d377.s0.e1
agents,47-53	DrugDDI.d377.s0.e1
(guanethidine,,54-68
reserpine,,69-79
glutamic,80-88	DrugDDI.d377.s0.e4
acid,89-93	DrugDDI.d377.s0.e4
HCl,,94-98	DrugDDI.d377.s0.e4
ascorbic,99-107	DrugDDI.d377.s0.e5
acid,,108-113	DrugDDI.d377.s0.e5
fruit,114-119
juices,,120-127
etc.),128-133
lower,134-139
absorption,140-150
of,151-153
amphetamines.,154-167	DrugDDI.d377.s0.e6

Urinary,0-7
acidifying,8-18	DrugDDI.d377.s1.e0
agents,19-25	DrugDDI.d377.s1.e0
(ammonium,26-35
chloride,,36-45
sodium,46-52	DrugDDI.d377.s1.e2
acid,53-57	DrugDDI.d377.s1.e2
phosphate,,58-68	DrugDDI.d377.s1.e2
etc.),69-74
increase,75-83
the,84-87
concentration,88-101
of,102-104
the,105-108
ionized,109-116
species,117-124
of,125-127
the,128-131
amphetamine,132-143	DrugDDI.d377.s1.e3
molecule,,144-153
thereby,154-161
increasing,162-172
urinary,173-180
excretion.,181-191

Both,0-4
groups,5-11
of,12-14
agents,15-21
lower,22-27
blood,28-33
levels,34-40
and,41-44
efficacy,45-53
of,54-56
amphetamines.,57-70	DrugDDI.d377.s2.e0

Adrenergic,0-10	DrugDDI.d377.s3.e0
blockers:,11-20	DrugDDI.d377.s3.e0
Adrenergic,21-31	DrugDDI.d377.s3.e1
blockers,32-40	DrugDDI.d377.s3.e1
are,41-44
inhibited,45-54
by,55-57
amphetamines.,58-71	DrugDDI.d377.s3.e2

Alkalinizing,0-12	DrugDDI.d377.s4.e0
agents:,13-20	DrugDDI.d377.s4.e0
Gastrointestinal,21-37	DrugDDI.d377.s4.e1
alkalinizing,38-50	DrugDDI.d377.s4.e1
agents,51-57	DrugDDI.d377.s4.e1
(sodium,58-65
bicarbonate,,66-78
etc.),79-84
increase,85-93
absorption,94-104
of,105-107
amphetamines.,108-121	DrugDDI.d377.s4.e3

Urinary,0-7
alkalinizing,8-20	DrugDDI.d377.s5.e0
agents,21-27	DrugDDI.d377.s5.e0
(acetazolamide,,28-43
some,44-48
thiazides),49-59	DrugDDI.d377.s5.e2
increase,60-68
the,69-72
concentration,73-86
of,87-89
the,90-93
non-ionized,94-105
species,106-113
of,114-116
the,117-120
amphetamine,121-132	DrugDDI.d377.s5.e3
molecule,,133-142
thereby,143-150
decreasing,151-161
urinary,162-169
excretion.,170-180

Both,0-4
groups,5-11
of,12-14
agents,15-21
increase,22-30
blood,31-36
levels,37-43
and,44-47
therefore,48-57
potentiate,58-68
the,69-72
actions,73-80
of,81-83
amphetamines.,84-97	DrugDDI.d377.s6.e0

Antidepressants,,0-16
tricyclic:,17-27
Amphetamines,28-40	DrugDDI.d377.s7.e1
may,41-44
enhance,45-52
the,53-56
activity,57-65
of,66-68
tricyclic,69-78
or,79-81
sympathomimetic,82-97	DrugDDI.d377.s7.e2
agents;,98-105	DrugDDI.d377.s7.e2

d-amphetamine,0-13	DrugDDI.d377.s8.e0
with,14-18
desipramine,19-30	DrugDDI.d377.s8.e1
or,31-33
protriptyline,34-47	DrugDDI.d377.s8.e2
and,48-51
possibly,52-60
other,61-66
tricyclics,67-77	DrugDDI.d377.s8.e3
cause,78-83
striking,84-92
and,93-96
sustained,97-106
increases,107-116
in,117-119
the,120-123
concentration,124-137
of,138-140
d-amphetamine,141-154	DrugDDI.d377.s8.e4
in,155-157
the,158-161
brain;,162-168

MAO,0-3	DrugDDI.d377.s10.e0
inhibitors:,4-15	DrugDDI.d377.s10.e0
MAOI,16-20
antidepressants,,21-37
as,38-40
well,41-45
as,46-48
a,49-50
metabolite,51-61	DrugDDI.d377.s10.e2
of,62-64
furazolidone,,65-78
slow,79-83
amphetamine,84-95	DrugDDI.d377.s10.e4
metabolism.,96-107

This,0-4
slowing,5-12
potentiates,13-24
amphetamines,,25-38
increasing,39-49
their,50-55
effect,56-62
on,63-65
the,66-69
release,70-77
of,78-80
norepinephrine,81-95	DrugDDI.d377.s11.e1
and,96-99
other,100-105
monoamines,106-116
from,117-121
adrenergic,122-132
nerve,133-138
endings;,139-147

Antihistamines:,0-15	DrugDDI.d377.s14.e0
Amphetamines,16-28	DrugDDI.d377.s14.e1
may,29-32
counteract,33-43
the,44-47
sedative,48-56	DrugDDI.d377.s14.e2
effect,57-63
of,64-66
antihistamines.,67-82	DrugDDI.d377.s14.e3

Antihypertensives:,0-18	DrugDDI.d377.s15.e0
Amphetamines,19-31	DrugDDI.d377.s15.e1
may,32-35
antagonize,36-46
the,47-50
hypotensive,51-62
effects,63-70
of,71-73
antihypertensives.,74-92	DrugDDI.d377.s15.e2

Chlorpromazine:,0-15	DrugDDI.d377.s16.e0
Chlorpromazine,16-30	DrugDDI.d377.s16.e1
blocks,31-37
dopamine,38-46	DrugDDI.d377.s16.e2
and,47-50
norepinephrine,51-65	DrugDDI.d377.s16.e3
reuptake,,66-75
thus,76-80
inhibiting,81-91
the,92-95
central,96-103	DrugDDI.d377.s16.e4
stimulant,104-113	DrugDDI.d377.s16.e4
effects,114-121
of,122-124
amphetamines,,125-138
and,139-142
can,143-146
be,147-149
used,150-154
to,155-157
treat,158-163
amphetamine,164-175
poisoning.,176-186

Ethosuximide:,0-13	DrugDDI.d377.s17.e0
Amphetamines,14-26	DrugDDI.d377.s17.e1
may,27-30
delay,31-36
intestinal,37-47
absorption,48-58
of,59-61
ethosuximide.,62-75	DrugDDI.d377.s17.e2

Haloperidol:,0-12	DrugDDI.d377.s18.e0
Haloperidol,13-24	DrugDDI.d377.s18.e1
blocks,25-31
dopamine,32-40	DrugDDI.d377.s18.e2
and,41-44
norepinephrine,45-59	DrugDDI.d377.s18.e3
reuptake,,60-69
thus,70-74
inhibiting,75-85
the,86-89
central,90-97	DrugDDI.d377.s18.e4
stimulant,98-107	DrugDDI.d377.s18.e4
effects,108-115
of,116-118
amphetamines.,119-132	DrugDDI.d377.s18.e5

Lithium,0-7	DrugDDI.d377.s19.e0
carbonate:,8-18	DrugDDI.d377.s19.e0
The,19-22
stimulatory,23-34
effects,35-42
of,43-45
amphetamines,46-58	DrugDDI.d377.s19.e1
may,59-62
be,63-65
inhibited,66-75
by,76-78
lithium,79-86	DrugDDI.d377.s19.e2
carbonate.,87-97	DrugDDI.d377.s19.e2

Meperidine:,0-11	DrugDDI.d377.s20.e0
Amphetamines,12-24	DrugDDI.d377.s20.e1
potentiate,25-35
the,36-39
analgesic,40-49
effect,50-56
of,57-59
meperidine.,60-71	DrugDDI.d377.s20.e2

Methenamine,0-11	DrugDDI.d377.s21.e0
therapy:,12-20
Urinary,21-28
excretion,29-38
of,39-41
amphetamines,42-54	DrugDDI.d377.s21.e1
is,55-57
increased,,58-68
and,69-72
efficacy,73-81
is,82-84
reduced,,85-93
by,94-96
acidifying,97-107	DrugDDI.d377.s21.e2
agents,108-114	DrugDDI.d377.s21.e2
used,115-119
in,120-122
methenamine,123-134	DrugDDI.d377.s21.e3
therapy.,135-143

Norepinephrine:,0-15	DrugDDI.d377.s22.e0
Amphetamines,16-28	DrugDDI.d377.s22.e1
enhance,29-36
the,37-40
adrenergic,41-51
effect,52-58
of,59-61
norepinephrine.,62-77	DrugDDI.d377.s22.e2

Phenobarbital:,0-14	DrugDDI.d377.s23.e0
Amphetamines,15-27	DrugDDI.d377.s23.e1
may,28-31
delay,32-37
intestinal,38-48
absorption,49-59
of,60-62
phenobarbital;,63-77	DrugDDI.d377.s23.e2

co-administration,0-17
of,18-20
phenobarbital,21-34	DrugDDI.d377.s24.e0
may,35-38
produce,39-46
a,47-48
synergistic,49-60
anticonvulsant,61-75	DrugDDI.d377.s24.e1
action.,76-83

Phenytoin:,0-10	DrugDDI.d377.s25.e0
Amphetamines,11-23	DrugDDI.d377.s25.e1
may,24-27
delay,28-33
intestinal,34-44
absorption,45-55
of,56-58
phenytoin;,59-69	DrugDDI.d377.s25.e2

co-administration,0-17
of,18-20
phenytoin,21-30	DrugDDI.d377.s26.e0
may,31-34
produce,35-42
a,43-44
synergistic,45-56
anticonvulsant,57-71	DrugDDI.d377.s26.e1
action.,72-79

Propoxyphene:,0-13	DrugDDI.d377.s27.e0
In,14-16
cases,17-22
of,23-25
propoxyphene,26-38	DrugDDI.d377.s27.e1
overdosage,,39-50
amphetamine,51-62	DrugDDI.d377.s27.e2
CNS,63-66	DrugDDI.d377.s27.e2
stimulation,67-78
is,79-81
potentiated,82-93
and,94-97
fatal,98-103
convulsions,104-115
can,116-119
occur.,120-126

Veratrum,0-8	DrugDDI.d377.s28.e0
alkaloids:,9-19	DrugDDI.d377.s28.e0
Amphetamines,20-32	DrugDDI.d377.s28.e1
inhibit,33-40
the,41-44
hypotensive,45-56
effect,57-63
of,64-66
veratrum,67-75	DrugDDI.d377.s28.e2
alkaloids.,76-86	DrugDDI.d377.s28.e2

Drug/Laboratory,0-15	DrugDDI.d377.s29.e0
Test,16-20
Interactions:,21-34
Amphetamines,35-47	DrugDDI.d377.s29.e1
can,48-51
cause,52-57
a,58-59
significant,60-71
elevation,72-81
in,82-84
plasma,85-91
corticosteroid,92-106	DrugDDI.d377.s29.e2
levels.,107-114

Amphetamines,0-12	DrugDDI.d377.s31.e0
may,13-16
interfere,17-26
with,27-31
urinary,32-39
steroid,40-47
determinations.,48-63

Additive,0-8
depressant,9-19
effect,20-26
when,27-31
used,32-36
with,37-41
general,42-49	DrugDDI.d352.s0.e0
anesthetics,,50-62	DrugDDI.d352.s0.e0
sedatives,,63-73
antianxiety,74-85	DrugDDI.d352.s0.e2
drugs,,86-92	DrugDDI.d352.s0.e2
hypnotics,,93-103
alcohol,,104-112
and,113-116
other,117-122
opiate,123-129	DrugDDI.d352.s0.e5
analgesics.,130-141

May,0-3
interact,4-12
with,13-17
thyroid,18-25	DrugDDI.d152.s0.e0
medication,26-36	DrugDDI.d152.s0.e0
(e.g.,,37-43
levothyroxine),,44-59
iodine-containing,60-77	DrugDDI.d152.s0.e2
products,,78-87
antacids,,88-97
H2-antagonists,98-112
(e.g.,,113-119
famotidine,,120-131
ranitidine),,132-144
and,145-148
proton,149-155	DrugDDI.d152.s0.e6
pump,156-160	DrugDDI.d152.s0.e6
inhibitors,161-171	DrugDDI.d152.s0.e6
(e.g.,,172-178
lansoprazole,,179-192
omeprazole).,193-205	DrugDDI.d152.s0.e8

Caution,0-7
is,8-10
advised,11-18
in,19-21
patients,22-30
receiving,31-40
concomitant,41-52
high-dose,53-62
aspirin,63-70	DrugDDI.d519.s0.e0
and,71-74
carbonic,75-83	DrugDDI.d519.s0.e1
anhydrase,84-93	DrugDDI.d519.s0.e1
inhibitors,,94-105	DrugDDI.d519.s0.e1
as,106-108
anorexia,,109-118
tachypnea,,119-129
lethargy,130-138
and,139-142
coma,143-147
have,148-152
been,153-157
rarely,158-164
reported,165-173
due,174-177
to,178-180
a,181-182
possible,183-191
drug,192-196
interaction.,197-209

Aspirin:,0-8	DrugDDI.d186.s0.e0
Concomitant,9-20
administration,21-35
of,36-38
diclofenac,39-49	DrugDDI.d186.s0.e1
and,50-53
aspirin,54-61	DrugDDI.d186.s0.e2
is,62-64
not,65-68
recommended,69-80
because,81-88
diclofenac,89-99	DrugDDI.d186.s0.e3
is,100-102
displaced,103-112
from,113-117
its,118-121
binding,122-129
sites,130-135
during,136-142
the,143-146
concomitant,147-158
administration,159-173
of,174-176
aspirin,,177-185
resulting,186-195
in,196-198
lower,199-204
plasma,205-211
concentrations,,212-227
peak,228-232
plasma,233-239
levels,,240-247
and,248-251
AUC,252-255
values.,256-263

Anticoagulants:,0-15	DrugDDI.d186.s1.e0
While,16-21
studies,22-29
have,30-34
not,35-38
shown,39-44
diclofenac,45-55	DrugDDI.d186.s1.e1
to,56-58
interact,59-67
with,68-72
anticoagulants,73-87	DrugDDI.d186.s1.e2
of,88-90
the,91-94
warfarin,95-103	DrugDDI.d186.s1.e3
type,,104-109
caution,110-117
should,118-124
be,125-127
exercised,,128-138
nonetheless,,139-151
since,152-157
interactions,158-170
have,171-175
been,176-180
seen,181-185
with,186-190
other,191-196
NSAIDs.,197-204	DrugDDI.d186.s1.e4

Because,0-7
prostaglandins,8-22	DrugDDI.d186.s2.e0
play,23-27
an,28-30
important,31-40
role,41-45
in,46-48
hemostasis,,49-60
and,61-64
NSAIDs,65-71	DrugDDI.d186.s2.e1
affect,72-78
platelet,79-87
function,88-96
as,97-99
well,,100-105
concurrent,106-116
therapy,117-124
with,125-129
all,130-133
NSAIDs,,134-141
including,142-151
diclofenac,,152-163
and,164-167
warfarin,168-176	DrugDDI.d186.s2.e4
requires,177-185
close,186-191
monitoring,192-202
of,203-205
patients,206-214
to,215-217
be,218-220
certain,221-228
that,229-233
no,234-236
change,237-243
in,244-246
their,247-252
anticoagulant,253-266	DrugDDI.d186.s2.e5
dosage,267-273
is,274-276
required.,277-286

Digoxin,,0-8
Methotrexate,,9-22
Cyclosporine:,23-36	DrugDDI.d186.s3.e2
Diclofenac,,37-48
like,49-53
other,54-59
NSAIDs,,60-67
may,68-71
affect,72-78
renal,79-84
prostaglandins,85-99	DrugDDI.d186.s3.e5
and,100-103
increase,104-112
the,113-116
toxicity,117-125
of,126-128
certain,129-136
drugs.,137-143	DrugDDI.d186.s3.e6

Ingestion,0-9
of,10-12
diclofenac,13-23	DrugDDI.d186.s4.e0
may,24-27
increase,28-36
serum,37-42
concentrations,43-57
of,58-60
digoxin,61-68	DrugDDI.d186.s4.e1
and,69-72
methotrexate,73-85	DrugDDI.d186.s4.e2
and,86-89
increase,90-98
cyclosporine?s,99-113
nephrotoxicity.,114-129

Patients,0-8
who,9-12
begin,13-18
taking,19-25
diclofenac,26-36	DrugDDI.d186.s5.e0
or,37-39
who,40-43
increase,44-52
their,53-58
diclofenac,59-69	DrugDDI.d186.s5.e1
dose,70-74
or,75-77
any,78-81
other,82-87
NSAID,88-93	DrugDDI.d186.s5.e2
while,94-99
taking,100-106
digoxin,,107-115
methotrexate,,116-129
or,130-132
cyclosporine,133-145	DrugDDI.d186.s5.e5
may,146-149
develop,150-157
toxicity,158-166
characteristics,167-182
for,183-186
these,187-192
drugs.,193-199	DrugDDI.d186.s5.e6

In,0-2
the,3-6
case,7-11
of,12-14
digoxin,,15-23
serum,24-29
levels,30-36
should,37-43
be,44-46
monitored.,47-57

Lithium:,0-8	DrugDDI.d186.s8.e0
Diclofenac,9-19	DrugDDI.d186.s8.e1
decreases,20-29
lithium,30-37
renal,38-43
clearance,44-53
and,54-57
increases,58-67
lithium,68-75
plasma,76-82
levels.,83-90

In,0-2
patients,3-11
taking,12-18
diclofenac,19-29	DrugDDI.d186.s9.e0
and,30-33
lithium,34-41	DrugDDI.d186.s9.e1
concomitantly,,42-56
lithium,57-64
toxicity,65-73
may,74-77
develop.,78-86

Oral,0-4	DrugDDI.d186.s10.e0
Hypoglycemics:,5-19	DrugDDI.d186.s10.e0
Diclofenac,20-30	DrugDDI.d186.s10.e1
does,31-35
not,36-39
alter,40-45
glucose,46-53
metabolism,54-64
in,65-67
normal,68-74
subjects,75-83
nor,84-87
does,88-92
it,93-95
alter,96-101
the,102-105
effects,106-113
of,114-116
oral,117-121
hypoglycemic,122-134	DrugDDI.d186.s10.e2
agents.,135-142	DrugDDI.d186.s10.e2

There,0-5
are,6-9
rare,10-14
reports,,15-23
however,,24-32
from,33-37
marketing,38-47
experiences,,48-60
of,61-63
changes,64-71
in,72-74
effects,75-82
of,83-85
insulin,86-93	DrugDDI.d186.s11.e0
or,94-96
oral,97-101
hypoglycemic,102-114	DrugDDI.d186.s11.e1
agents,115-121	DrugDDI.d186.s11.e1
in,122-124
the,125-128
presence,129-137
of,138-140
diclofenac,141-151	DrugDDI.d186.s11.e2
that,152-156
necessitated,157-169
changes,170-177
in,178-180
the,181-184
doses,185-190
of,191-193
such,194-198
agents.,199-206

A,0-1
direct,2-8
causal,9-15
relationship,16-28
has,29-32
not,33-36
been,37-41
established,,42-54
but,55-58
physicians,59-69
should,70-76
consider,77-85
the,86-89
possibility,90-101
that,102-106
diclofenac,107-117	DrugDDI.d186.s13.e0
may,118-121
alter,122-127
a,128-129
diabetic,130-138
patient?s,139-148
response,149-157
to,158-160
insulin,161-168	DrugDDI.d186.s13.e1
or,169-171
oral,172-176
hypoglycemic,177-189	DrugDDI.d186.s13.e2
agents.,190-197	DrugDDI.d186.s13.e2

Diuretics:,0-10	DrugDDI.d186.s14.e0
Diclofenac,11-21	DrugDDI.d186.s14.e1
and,22-25
other,26-31
NSAIDs,32-38	DrugDDI.d186.s14.e2
can,39-42
inhibit,43-50
the,51-54
activity,55-63
of,64-66
diuretics.,67-77	DrugDDI.d186.s14.e3

Concomitant,0-11
treatment,12-21
with,22-26
potassium-sparing,27-44	DrugDDI.d186.s15.e0
diuretics,45-54	DrugDDI.d186.s15.e0
may,55-58
be,59-61
associated,62-72
with,73-77
increased,78-87
serum,88-93
potassium,94-103
levels.,104-111

Other,0-5
Drugs:,6-12	DrugDDI.d186.s16.e0
In,13-15
small,16-21
groups,22-28
of,29-31
patients,32-40
(7-10/interaction,41-58
study),,59-66
the,67-70
concomitant,71-82
administration,83-97
of,98-100
azathioprine,,101-114
gold,,115-120
chloroquine,,121-133
D-penicillamine,,134-150
prednisolone,,151-164
doxycycline,,165-177
or,178-180
digitoxin,181-190	DrugDDI.d186.s16.e7
did,191-194
not,195-198
significantly,199-212
affect,213-219
the,220-223
peak,224-228
levels,229-235
and,236-239
AUC,240-243
values,244-250
of,251-253
diclofenac.,254-265	DrugDDI.d186.s16.e8

Phenobarbital,0-13
toxicity,14-22
has,23-26
been,27-31
reported,32-40
to,41-43
have,44-48
occurred,49-57
in,58-60
a,61-62
patient,63-70
on,71-73
chronic,74-81
phenobarbital,82-95
treatment,96-105
following,106-115
the,116-119
initiation,120-130
of,131-133
diclofenac,134-144	DrugDDI.d186.s17.e0
therapy.,145-153

Protein,0-7
Binding,8-15
In,16-18
vitro,,19-25
diclofenac,26-36	DrugDDI.d186.s18.e0
interferes,37-47
minimally,48-57
or,58-60
not,61-64
at,65-67
all,68-71
with,72-76
the,77-80
protein,81-88
binding,89-96
of,97-99
salicylic,100-109	DrugDDI.d186.s18.e1
acid,110-114	DrugDDI.d186.s18.e1
(20%,115-119
decrease,120-128
in,129-131
binding),,132-141
tolbutamide,,142-154
prednisolone,155-167	DrugDDI.d186.s18.e3
(10%,168-172
decrease,173-181
in,182-184
binding),,185-194
or,195-197
warfarin.,198-207	DrugDDI.d186.s18.e4

Benzylpenicillin,,0-17
ampicillin,,18-29
oxacillin,,30-40
chlortetracycline,,41-59
doxycycline,,60-72
cephalothin,,73-85
erythromycin,,86-99
and,100-103
sulfamethoxazole,104-120	DrugDDI.d186.s19.e7
have,121-125
no,126-128
influence,129-138
in,139-141
vitro,142-147
on,148-150
the,151-154
protein,155-162
binding,163-170
of,171-173
diclofenac,174-184	DrugDDI.d186.s19.e8
in,185-187
human,188-193
serum.,194-200

Drug/Laboratory,0-15	DrugDDI.d186.s20.e0
Test,16-20
Interactions,21-33
Effect,34-40
on,41-43
Blood,44-49
Coagulation:,50-62
Diclofenac,63-73	DrugDDI.d186.s20.e1
increases,74-83
platelet,84-92
aggregation,93-104
time,105-109
but,110-113
does,114-118
not,119-122
affect,123-129
bleeding,130-138
time,,139-144
plasma,145-151
thrombin,152-160
clotting,161-169
time,,170-175
plasma,176-182
fibrinogen,,183-194
or,195-197
factors,198-205	DrugDDI.d186.s20.e2
V,206-207	DrugDDI.d186.s20.e2
and,208-211
VII,212-215
to,216-218
XII.,219-223

Statistically,0-13
significant,14-25
changes,26-33
in,34-36
prothrombin,37-48	DrugDDI.d186.s21.e0
and,49-52
partial,53-60
thromboplastin,61-75
times,76-81
have,82-86
been,87-91
reported,92-100
in,101-103
normal,104-110
volunteers.,111-122

Diclofenac,0-10	DrugDDI.d186.s23.e0
is,11-13
a,14-15
prostaglandin,16-29	DrugDDI.d186.s23.e1
synthetase,30-40	DrugDDI.d186.s23.e1
inhibitor,,41-51	DrugDDI.d186.s23.e1
however,,52-60
and,61-64
all,65-68
drugs,69-74	DrugDDI.d186.s23.e2
that,75-79
inhibit,80-87
prostaglandin,88-101	DrugDDI.d186.s23.e3
synthesis,102-111
interfere,112-121
with,122-126
platelet,127-135
function,136-144
to,145-147
some,148-152
degree;,153-160

Tetracycline,,0-13
a,14-15
bacteriostatic,16-30	DrugDDI.d548.s0.e1
antibiotic,,31-42
may,43-46
antagonize,47-57
the,58-61
bactercidal,62-73
effect,74-80
of,81-83
penicillin,84-94	DrugDDI.d548.s0.e2
and,95-98
concurrent,99-109
use,110-113
of,114-116
these,117-122
drugs,123-128	DrugDDI.d548.s0.e3
should,129-135
be,136-138
avoided.,139-147

The,0-3
following,4-13
agents,14-20
may,21-24
increase,25-33
certain,34-41
actions,42-49
or,50-52
side,53-57
effects,58-65
of,66-68
anticholinergic,69-84	DrugDDI.d503.s0.e0
drugs.,85-91	DrugDDI.d503.s0.e0
amantadine,92-102	DrugDDI.d503.s0.e1
antiarrhythmic,103-117
agents,118-124
of,125-127
class,128-133
(e.g.,134-139
quinidine),,140-151
antihistamines,152-166	DrugDDI.d503.s0.e3
antipsychotic,167-180	DrugDDI.d503.s0.e4
agents,181-187	DrugDDI.d503.s0.e4
(e.g.,188-193
phenothiazines),,194-210
benzodiazepines.,211-227	DrugDDI.d503.s0.e6

MAO,0-3	DrugDDI.d503.s1.e0
inhibitors,,4-15	DrugDDI.d503.s1.e0
narcotic,16-24	DrugDDI.d503.s1.e1
analgesics,25-35	DrugDDI.d503.s1.e1
(e.g.,,36-42
meperidine),,43-55
nitrates,56-64	DrugDDI.d503.s1.e3
and,65-68
nitrites,,69-78
sympathomimetic,79-94	DrugDDI.d503.s1.e5
agents,,95-102	DrugDDI.d503.s1.e5
tricyclic,103-112	DrugDDI.d503.s1.e6
antidepressants,,113-129	DrugDDI.d503.s1.e6
and,130-133
other,134-139
drugs,140-145	DrugDDI.d503.s1.e7
having,146-152
anticholinergic,153-168	DrugDDI.d503.s1.e8
activity.,169-178

Anticholinergics,0-16	DrugDDI.d503.s2.e0
antagonize,17-27
the,28-31
effects,32-39
of,40-42
antiglaucoma,43-55
agents.,56-63

Anticholinergic,0-15	DrugDDI.d503.s3.e0
drugs,16-21	DrugDDI.d503.s3.e0
in,22-24
the,25-28
presence,29-37
of,38-40
increased,41-50
intraocular,51-62
pressure,63-71
may,72-75
be,76-78
hazardous,79-88
when,89-93
taken,94-99
concurrently,100-112
with,113-117
agents,118-124
such,125-129
as,130-132
corti,133-138
costeroids..,139-151

Anticholinergic,0-15	DrugDDI.d503.s4.e0
agents,16-22	DrugDDI.d503.s4.e0
may,23-26
affect,27-33
gastrointestinal,34-50
absorption,51-61
of,62-64
various,65-72
drugs,,73-79
such,80-84
as,85-87
slowly,88-94
dissolving,95-105
dosage,106-112
forms,113-118
of,119-121
digoxin;,122-130	DrugDDI.d503.s4.e2

increased,0-9
serum,10-15
digoxin,16-23	DrugDDI.d503.s5.e0
concentrations,24-38
may,39-42
result.,43-50

Anticholinergic,0-15	DrugDDI.d503.s6.e0
drugs,16-21	DrugDDI.d503.s6.e0
may,22-25
antagonize,26-36
the,37-40
effects,41-48
of,49-51
the,52-55
drugs,56-61	DrugDDI.d503.s6.e1
that,62-66
alter,67-72
gastrointestinal,73-89
motility,,90-99
such,100-104
as,105-107
metoclopramide.,108-123	DrugDDI.d503.s6.e2

Because,0-7
antacids,8-16	DrugDDI.d503.s7.e0
may,17-20
interfere,21-30
with,31-35
the,36-39
absorption,40-50
of,51-53
anticholinergic,54-69	DrugDDI.d503.s7.e1
agents,,70-77	DrugDDI.d503.s7.e1
simultaneous,78-90
use,91-94
of,95-97
these,98-103
drugs,104-109	DrugDDI.d503.s7.e2
should,110-116
be,117-119
avoided.,120-128

The,0-3
inhibiting,4-14
effects,15-22
of,23-25
anticholinergic,26-41	DrugDDI.d503.s8.e0
drugs,42-47	DrugDDI.d503.s8.e0
on,48-50
gastric,51-58
hydrochloric,59-71
acid,72-76
secretion,77-86
are,87-90
antagonized,91-102
by,103-105
agents,106-112
used,113-117
to,118-120
treat,121-126
achlorhydria,127-139
and,140-143
those,144-149
used,150-154
to,155-157
test,158-162
gastric,163-170
secretion.,171-181

Coadministration,0-16
of,17-19
VIDEX,20-25	DrugDDI.d496.s0.e0
with,26-30
drugs,31-36	DrugDDI.d496.s0.e1
that,37-41
are,42-45
known,46-51
to,52-54
cause,55-60
pancreatitis,61-73
may,74-77
increase,78-86
the,87-90
risk,91-95
of,96-98
this,99-103
toxicity,104-112
(see,113-117
WARNINGS),118-127
and,128-131
should,132-138
be,139-141
done,142-146
with,147-151
extreme,152-159
caution,,160-168
only,169-173
if,174-176
other,177-182
alternatives,183-195
are,196-199
not,200-203
available,,204-214
and,215-218
only,219-223
if,224-226
clearly,227-234
indicated.,235-245

Neuropathy,0-10
has,11-14
occurred,15-23
more,24-28
frequently,29-39
in,40-42
patients,43-51
with,52-56
a,57-58
history,59-66
of,67-69
neuropathy,70-80
or,81-83
neurotoxic,84-94
drug,95-99
therapy,,100-108
including,109-118
stavudine,,119-129
and,130-133
these,134-139
patients,140-148
may,149-152
be,153-155
at,156-158
increased,159-168
risk,169-173
of,174-176
neuropathy,177-187
during,188-194
VIDEX,195-200	DrugDDI.d496.s1.e1
therapy,201-208
(see,209-213
ADVERSE,214-221
REACTIONS).,222-233

Allopurinol:,0-12	DrugDDI.d496.s2.e0
The,13-16
AUC,17-20
of,21-23
didanosine,24-34	DrugDDI.d496.s2.e1
was,35-38
increased,39-48
about,49-54
4-fold,55-61
when,62-66
allopurinol,67-78	DrugDDI.d496.s2.e2
at,79-81
300,82-85
mg/day,86-92
was,93-96
coadministered,97-111
with,112-116
a,117-118
single,119-125
200-mg,126-132
dose,133-137
of,138-140
VIDEX,141-146	DrugDDI.d496.s2.e3
to,147-149
two,150-153
patients,154-162
with,163-167
renal,168-173
impairment,174-184
(CLcr=15,185-193
and,194-197
18,198-200
mL/min).,201-209

The,0-3
effects,4-11
of,12-14
allopurinol,15-26	DrugDDI.d496.s3.e0
on,27-29
didanosine,30-40	DrugDDI.d496.s3.e1
pharmacokinetics,41-57
in,58-60
subjects,61-69
with,70-74
normal,75-81
renal,82-87
function,88-96
are,97-100
not,101-104
known.,105-111

Antacids:,0-9	DrugDDI.d496.s4.e0
Concomitant,10-21
administration,22-36
of,37-39
antacids,40-48	DrugDDI.d496.s4.e1
containing,49-59
magnesium,60-69	DrugDDI.d496.s4.e2
or,70-72
aluminum,73-81
with,82-86
VIDEX,87-92	DrugDDI.d496.s4.e3
Chewable/Dispersible,93-113
Buffered,114-122
Tablets,123-130
or,131-133
Pediatric,134-143	DrugDDI.d496.s4.e5
Powder,144-150
for,151-154
Oral,155-159
Solution,160-168
may,169-172
potentiate,173-183
adverse,184-191
events,192-198
associated,199-209
with,210-214
the,215-218
antacid,219-226	DrugDDI.d496.s4.e6
components.,227-238

Drugs,0-5	DrugDDI.d496.s5.e0
Whose,6-11
Absorption,12-22
Can,23-26
Be,27-29
Affected,30-38
by,39-41
the,42-45
Level,46-51
of,52-54
Acidity,55-62
in,63-65
the,66-69
Stomach:,70-78
Drugs,79-84	DrugDDI.d496.s5.e1
such,85-89
as,90-92
ketoconazole,93-105	DrugDDI.d496.s5.e2
and,106-109
itraconazole,110-122	DrugDDI.d496.s5.e3
should,123-129
be,130-132
administered,133-145
at,146-148
least,149-154
2,155-156
hours,157-162
prior,163-168
to,169-171
dosing,172-178
with,179-183
VIDEX.,184-190	DrugDDI.d496.s5.e4

Ganciclovir:,0-12	DrugDDI.d496.s6.e0
Administration,13-27
of,28-30
VIDEX,31-36	DrugDDI.d496.s6.e1
2,37-38
hours,39-44
prior,45-50
to,51-53
or,54-56
concurrent,57-67
with,68-72
oral,73-77
ganciclovir,78-89	DrugDDI.d496.s6.e2
was,90-93
associated,94-104
with,105-109
a,110-111
111,112-115
(114)%,116-122
increase,123-131
in,132-134
the,135-138
steady-state,139-151
AUC,152-155
of,156-158
didanosine,159-169	DrugDDI.d496.s6.e3
(n,170-172
=,173-174
12).,175-179

A,0-1
21,2-4
(17)%,5-10
decrease,11-19
in,20-22
the,23-26
steady-state,27-39
AUC,40-43
of,44-46
ganciclovir,47-58	DrugDDI.d496.s7.e0
was,59-62
observed,63-71
when,72-76
VIDEX,77-82	DrugDDI.d496.s7.e1
was,83-86
administered,87-99
2,100-101
hours,102-107
prior,108-113
to,114-116
ganciclovir,,117-129
but,130-133
not,134-137
when,138-142
the,143-146
two,147-150
drugs,151-156	DrugDDI.d496.s7.e3
were,157-161
administered,162-174
simultaneously,175-189
(n,190-192
=,193-194
12).,195-199

Quinolone,0-9	DrugDDI.d496.s8.e0
Antibiotics:,10-22	DrugDDI.d496.s8.e0
VIDEX,23-28	DrugDDI.d496.s8.e1
should,29-35
be,36-38
administered,39-51
at,52-54
least,55-60
2,61-62
hours,63-68
after,69-74
or,75-77
6,78-79
hours,80-85
before,86-92
dosing,93-99
with,100-104
ciprofloxacin,105-118	DrugDDI.d496.s8.e2
because,119-126
plasma,127-133
concentrations,134-148
of,149-151
ciprofloxacin,152-165	DrugDDI.d496.s8.e3
are,166-169
decreased,170-179
when,180-184
administered,185-197
with,198-202
antacids,203-211	DrugDDI.d496.s8.e4
containing,212-222
magnesium,,223-233
calcium,,234-242
or,243-245
aluminum.,246-255

In,0-2
eight,3-8
HIV-infected,9-21
patients,,22-31
the,32-35
steady-state,36-48
AUC,49-52
of,53-55
ciprofloxacin,56-69	DrugDDI.d496.s9.e0
was,70-73
decreased,74-83
an,84-86
average,87-94
of,95-97
26%,98-101
(95%,102-106
CI,107-109
=,110-111
14%,,112-116
37%),117-121
when,122-126
ciprofloxacin,127-140	DrugDDI.d496.s9.e1
was,141-144
administered,145-157
2,158-159
hours,160-165
prior,166-171
to,172-174
a,175-176
marketed,177-185
chewable/dispersible,186-206
tablet,207-213
formulation,214-225
of,226-228
VIDEX.,229-235	DrugDDI.d496.s9.e3

The,0-3
AUC,4-7
of,8-10
ciprofloxacin,11-24	DrugDDI.d496.s10.e0
was,25-28
decreased,29-38
an,39-41
average,42-49
of,50-52
15-fold,53-60
in,61-63
12,64-66
healthy,67-74
subjects,75-83
given,84-89
ciprofloxacin,90-103	DrugDDI.d496.s10.e1
and,104-107
didanosine-placebo,108-126	DrugDDI.d496.s10.e2
tablets,127-134
concurrently.,135-148

In,0-2
a,3-4
single,5-11
subject,12-19
given,20-25
one,26-29
dose,30-34
of,35-37
ciprofloxacin,38-51	DrugDDI.d496.s11.e0
2,52-53
hours,54-59
after,60-65
a,66-67
dose,68-72
of,73-75
didanosine-placebo,76-94	DrugDDI.d496.s11.e1
tablets,,95-103
a,104-105
greater,106-113
than,114-118
50%,119-122
reduction,123-132
in,133-135
the,136-139
AUC,140-143
of,144-146
ciprofloxacin,147-160	DrugDDI.d496.s11.e2
was,161-164
observed.,165-174

Plasma,0-6
concentrations,7-21
of,22-24
quinolone,25-34	DrugDDI.d496.s12.e0
antibiotics,35-46	DrugDDI.d496.s12.e0
are,47-50
decreased,51-60
when,61-65
administered,66-78
with,79-83
antacids,84-92	DrugDDI.d496.s12.e1
containing,93-103
magnesium,,104-114
calcium,,115-123
or,124-126
aluminum.,127-136

The,0-3
optimal,4-11
dosing,12-18
interval,19-27
for,28-31
coadministration,32-48
with,49-53
VIDEX,54-59	DrugDDI.d496.s13.e0
should,60-66
be,67-69
determined,70-80
by,81-83
consulting,84-94
the,95-98
appropriate,99-110
quinolone,111-120	DrugDDI.d496.s13.e1
package,121-128
insert.,129-136

Interactions,0-12
with,13-17
Other,18-23
Antiretroviral,24-38
Drugs:,39-45	DrugDDI.d496.s14.e0
Significant,46-57
decreases,58-67
in,68-70
the,71-74
AUC,75-78
of,79-81
delavirdine,82-93	DrugDDI.d496.s14.e1
(20%),94-99
and,100-103
indinavir,104-113	DrugDDI.d496.s14.e2
(84%),114-119
occurred,120-128
following,129-138
simultaneous,139-151
administration,152-166
of,167-169
these,170-175
agents,176-182
with,183-187
VIDEX.,188-194	DrugDDI.d496.s14.e3

To,0-2
avoid,3-8
this,9-13
interaction,,14-26
delavirdine,27-38	DrugDDI.d496.s15.e0
or,39-41
indinavir,42-51	DrugDDI.d496.s15.e1
should,52-58
be,59-61
given,62-67
1,68-69
hour,70-74
prior,75-80
to,81-83
dosing,84-90
with,91-95
VIDEX.,96-102	DrugDDI.d496.s15.e2

The,0-3
pharmacokinetics,4-20
of,21-23
nelfinavir,24-34	DrugDDI.d496.s16.e0
are,35-38
not,39-42
altered,43-50
to,51-53
a,54-55
clinically,56-66
significant,67-78
degree,79-85
when,86-90
it,91-93
is,94-96
administered,97-109
with,110-114
a,115-116
light,117-122
meal,123-127
1,128-129
hour,130-134
after,135-140
VIDEX.,141-147	DrugDDI.d496.s16.e1

Drug/,0-5	DrugDDI.d223.s0.e0
Laboratory,6-16
Test,17-21
Interactions,22-34
Certain,35-42
endocrine,43-52
and,53-56
liver,57-62
function,63-71
tests,72-77
may,78-81
be,82-84
affected,85-93
by,94-96
estrogen-containing,97-116	DrugDDI.d223.s0.e1
oral,117-121	DrugDDI.d223.s0.e2
contraceptives.,122-137	DrugDDI.d223.s0.e2

The,0-3
following,4-13
similar,14-21
changes,22-29
may,30-33
be,34-36
expected,37-45
with,46-50
larger,51-57
doses,58-63
of,64-66
estrogen:,67-76	DrugDDI.d223.s1.e0
-,77-78
Increased,79-88
sulfobromophthalein,89-108
retention,109-118

-,0-1
Increased,2-11
prothrombin,12-23	DrugDDI.d223.s3.e0
and,24-27
factors,28-35	DrugDDI.d223.s3.e1
VII,,36-40	DrugDDI.d223.s3.e1
VIII,,41-46
IX,,47-50
and,51-54
X;,55-57

decreased,0-9
antithrombin,10-22	DrugDDI.d223.s4.e0
3;,23-25

increased,0-9
norepinephrine-induced,10-32	DrugDDI.d223.s5.e0
platelet,33-41
aggregability,42-55

-,0-1
Increased,2-11
thyroid-binding,12-27
globulin,28-36
(TBG),37-42
leading,43-50
to,51-53
in-creased,54-64
circulating,65-76
total,77-82
thyroid,83-90	DrugDDI.d223.s7.e0
hormone;,91-99	DrugDDI.d223.s7.e0

as,0-2
measured,3-11
by,12-14
PBI,,15-19
T4,20-22	DrugDDI.d223.s8.e0
by,23-25
column,,26-33
or,34-36
T4,37-39	DrugDDI.d223.s8.e1
by,40-42
radioimmunoassay.,43-60

-,0-1
Increased,2-11
serum,12-17
triglyceride,18-30
and,31-34
phospholipid,35-47	DrugDDI.d223.s20.e0
concentration.,48-62

Antidiabetic,0-12	DrugDDI.d320.s0.e0
drug,13-17	DrugDDI.d320.s0.e0
requirements,18-30
(i.e.,,31-37
insulin),38-46	DrugDDI.d320.s0.e1
may,47-50
be,51-53
altered.,54-62

Concurrent,0-10
use,11-14
with,15-19
general,20-27	DrugDDI.d320.s1.e0
anesthetics,28-39	DrugDDI.d320.s1.e0
may,40-43
result,44-50
in,51-53
arrhythmias.,54-66

The,0-3
pressor,4-11	DrugDDI.d320.s2.e0
effects,12-19	DrugDDI.d320.s2.e0
of,20-22
diethylpropion,23-37	DrugDDI.d320.s2.e1
and,38-41
those,42-47
of,48-50
other,51-56
drugs,57-62	DrugDDI.d320.s2.e2
may,63-66
be,67-69
additive,70-78
when,79-83
the,84-87
drugs,88-93	DrugDDI.d320.s2.e3
are,94-97
used,98-102
concomitantly;,103-117

conversely,,0-11
diethylpropion,12-26	DrugDDI.d320.s3.e0
may,27-30
interfere,31-40
with,41-45
antihypertensive,46-62	DrugDDI.d320.s3.e1
drugs,63-68	DrugDDI.d320.s3.e1
(i.e.,,69-75
guanethidine,,76-89
a-methyldopa).,90-104

Concurrent,0-10
use,11-14
of,15-17
phenothiazines,18-32	DrugDDI.d320.s4.e0
may,33-36
antagonize,37-47
the,48-51
anorectic,52-61
effect,62-68
of,69-71
diethylpropion.,72-87	DrugDDI.d320.s4.e1

May,0-3
interact,4-12
anticoagulants,13-27	DrugDDI.d108.s0.e0
(altered,28-36
hypo-prothrombinemic,37-57
effect),,58-66
barbiturates,,67-80
rifampin,81-89	DrugDDI.d108.s0.e2
and,90-93
other,94-99
inducers,100-108
of,109-111
hepatic,112-119
microsomal,120-130	DrugDDI.d108.s0.e3
enzyme,131-137	DrugDDI.d108.s0.e3
oxidation,138-147
system,148-154
(decreased,155-165
effect,166-172
of,173-175
diethylstilbestrol),,176-196
corticosteroids,197-212	DrugDDI.d108.s0.e5
(increased,213-223
effect,224-230
of,231-233
corticosteroids).,234-251	DrugDDI.d108.s0.e6

Oral,0-4	DrugDDI.d384.s0.e0
Anticoagulants:,5-20	DrugDDI.d384.s0.e0
In,21-23
some,24-28
normal,29-35
volunteers,,36-47
the,48-51
concomitant,52-63
administration,64-78
of,79-81
diflunisal,82-92	DrugDDI.d384.s0.e1
and,93-96
warfarin,,97-106
acenocoumarol,,107-121
or,122-124
phenprocoumon,125-138	DrugDDI.d384.s0.e4
resulted,139-147
in,148-150
prolongation,151-163
of,164-166
prothrombin,167-178
time.,179-184

This,0-4
may,5-8
occur,9-14
because,15-22
diflunisal,23-33	DrugDDI.d384.s1.e0
competitively,34-47
displaces,48-57
coumarins,58-67	DrugDDI.d384.s1.e1
from,68-72
protein,73-80	DrugDDI.d384.s1.e2
binding,81-88
sites.,89-95

Accordingly,,0-12
when,13-17
diflunisal,18-28	DrugDDI.d384.s2.e0
is,29-31
administered,32-44
with,45-49
oral,50-54	DrugDDI.d384.s2.e1
anticoagulants,,55-70	DrugDDI.d384.s2.e1
the,71-74
prothrombin,75-86
time,87-91
should,92-98
be,99-101
closely,102-109
monitored,110-119
during,120-126
and,127-130
for,131-134
several,135-142
days,143-147
after,148-153
concomitant,154-165
drug,166-170
administration.,171-186

Adjustment,0-10
of,11-13
dosage,14-20
of,21-23
oral,24-28	DrugDDI.d384.s3.e0
anticoagulants,29-43	DrugDDI.d384.s3.e0
may,44-47
be,48-50
required.,51-60

Tolbutamide:,0-12	DrugDDI.d384.s4.e0
In,13-15
diabetic,16-24
patients,25-33
receiving,34-43
diflunisal,44-54	DrugDDI.d384.s4.e1
and,55-58
tolbutamide,,59-71
no,72-74
significant,75-86
effects,87-94
were,95-99
seen,100-104
on,105-107
tolbutamide,108-119	DrugDDI.d384.s4.e3
plasma,120-126
levels,127-133
or,134-136
fasting,137-144
blood,145-150
glucose.,151-159

Hydrochlorothiazide:,0-20	DrugDDI.d384.s5.e0
In,21-23
normal,24-30
volunteers,,31-42
concomitant,43-54
administration,55-69
of,70-72
diflunisal,73-83	DrugDDI.d384.s5.e1
and,84-87
hydrochlorothiazide,88-107	DrugDDI.d384.s5.e2
resulted,108-116
in,117-119
significantly,120-133
increased,134-143
plasma,144-150
levels,151-157
of,158-160
hydrochlorothiazide.,161-181	DrugDDI.d384.s5.e3

Diflunisal,0-10	DrugDDI.d384.s6.e0
decreased,11-20
the,21-24
hyperuricemic,25-38
effect,39-45
of,46-48
hydrochlorothiazide.,49-69	DrugDDI.d384.s6.e1

Furosemide:,0-11	DrugDDI.d384.s7.e0
In,12-14
normal,15-21
volunteers,,22-33
the,34-37
concomitant,38-49
administration,50-64
of,65-67
diflunisal,68-78	DrugDDI.d384.s7.e1
and,79-82
furosemide,83-93	DrugDDI.d384.s7.e2
had,94-97
no,98-100
effect,101-107
on,108-110
the,111-114
diuretic,115-123	DrugDDI.d384.s7.e3
activity,124-132
of,133-135
furosemide.,136-147	DrugDDI.d384.s7.e4

Diflunisal,0-10	DrugDDI.d384.s8.e0
decreased,11-20
the,21-24
hyperuricemic,25-38
effect,39-45
of,46-48
furosemide.,49-60	DrugDDI.d384.s8.e1

Antacids:,0-9	DrugDDI.d384.s9.e0
Concomitant,10-21
administration,22-36
of,37-39
antacids,40-48	DrugDDI.d384.s9.e1
may,49-52
reduce,53-59
plasma,60-66
levels,67-73
of,74-76
diflunisal.,77-88	DrugDDI.d384.s9.e2

This,0-4
effect,5-11
is,12-14
small,15-20
with,21-25
occasional,26-36
doses,37-42
of,43-45
antacids,,46-55
but,56-59
may,60-63
be,64-66
clinically,67-77
significant,78-89
when,90-94
antacids,95-103	DrugDDI.d384.s10.e1
are,104-107
used,108-112
on,113-115
a,116-117
continuous,118-128
schedule.,129-138

Acetaminophen:,0-14	DrugDDI.d384.s11.e0
In,15-17
normal,18-24
volunteers,,25-36
concomitant,37-48
administration,49-63
of,64-66
diflunisal,67-77	DrugDDI.d384.s11.e1
and,78-81
acetaminophen,82-95	DrugDDI.d384.s11.e2
resulted,96-104
in,105-107
an,108-110
approximate,111-122
50%,123-126
increase,127-135
in,136-138
plasma,139-145
levels,146-152
of,153-155
acetaminophen.,156-170	DrugDDI.d384.s11.e3

Acetaminophen,0-13	DrugDDI.d384.s12.e0
had,14-17
no,18-20
effect,21-27
on,28-30
plasma,31-37
levels,38-44
of,45-47
diflunisal.,48-59	DrugDDI.d384.s12.e1

Since,0-5
acetaminophen,6-19	DrugDDI.d384.s13.e0
in,20-22
high,23-27
doses,28-33
has,34-37
been,38-42
associated,43-53
with,54-58
hepatotoxicity,,59-74
concomitant,75-86
administration,87-101
of,102-104
diflunisal,105-115	DrugDDI.d384.s13.e1
and,116-119
acetaminophen,120-133	DrugDDI.d384.s13.e2
should,134-140
be,141-143
used,144-148
cautiously,,149-160
with,161-165
careful,166-173
monitoring,174-184
of,185-187
patients.,188-197

Concomitant,0-11
administration,12-26
of,27-29
diflunisal,30-40	DrugDDI.d384.s14.e0
and,41-44
acetaminophen,45-58	DrugDDI.d384.s14.e1
in,59-61
dogs,,62-67
but,68-71
not,72-75
in,76-78
rats,,79-84
at,85-87
approximately,88-101
2,102-103
times,104-109
the,110-113
recommended,114-125
maximum,126-133
human,134-139
therapeutic,140-151
dose,152-156
of,157-159
each,160-164
(40,165-168
to,169-171
52,172-174
mg/kg/day,175-184
of,185-187
diflunisal/acetaminophen),188-213	DrugDDI.d384.s14.e2
resulted,214-222
in,223-225
greater,226-233
gastrointestinal,234-250
toxicity,251-259
than,260-264
when,265-269
either,270-276
drug,277-281	DrugDDI.d384.s14.e4
was,282-285
administered,286-298
alone.,299-305

Methotrexate:,0-13	DrugDDI.d384.s16.e0
Caution,14-21
should,22-28
be,29-31
used,32-36
if,37-39
diflunisal,40-50	DrugDDI.d384.s16.e1
is,51-53
administered,54-66
concomitantly,67-80
with,81-85
methotrexate.,86-99	DrugDDI.d384.s16.e2

Nonsteroidal,0-12	DrugDDI.d384.s17.e0
anti-inflammatory,13-30	DrugDDI.d384.s17.e0
drugs,31-36	DrugDDI.d384.s17.e0
have,37-41
been,42-46
reported,47-55
to,56-58
decrease,59-67
the,68-71
tubular,72-79
secretion,80-89
of,90-92
methotrexate,93-105	DrugDDI.d384.s17.e1
and,106-109
to,110-112
potentiate,113-123
its,124-127
toxicity.,128-137

Cyclosporine:,0-13	DrugDDI.d384.s18.e0
Administration,14-28
of,29-31
nonsteroial,32-43	DrugDDI.d384.s18.e1
anti-inflammatory,44-61	DrugDDI.d384.s18.e1
drugs,62-67	DrugDDI.d384.s18.e1
concomitantly,68-81
with,82-86
cyclosporine,87-99	DrugDDI.d384.s18.e2
has,100-103
been,104-108
associated,109-119
with,120-124
an,125-127
increase,128-136
in,137-139
cyclosporine-induced,140-160
toxicity,,161-170
possibly,171-179
due,180-183
to,184-186
decreased,187-196
synthesis,197-206
of,207-209
renal,210-215
prostacyclin.,216-229	DrugDDI.d384.s18.e3

NSAIDs,0-6	DrugDDI.d384.s19.e0
should,7-13
be,14-16
used,17-21
with,22-26
caution,27-34
in,35-37
patients,38-46
taking,47-53
cyclosporine,,54-67
and,68-71
renal,72-77
function,78-86
should,87-93
be,94-96
carefully,97-106
monitored.,107-117

Nonsteroidal,0-12	DrugDDI.d384.s20.e0
Anti-Inflammatory,13-30	DrugDDI.d384.s20.e0
Drugs,31-36	DrugDDI.d384.s20.e0
The,37-40
administration,41-55
of,56-58
diflunisal,59-69	DrugDDI.d384.s20.e1
to,70-72
normal,73-79
volunteers,80-90
receiving,91-100
indomethacin,101-113	DrugDDI.d384.s20.e2
decreased,114-123
the,124-127
renal,128-133
clearance,134-143
and,144-147
significantly,148-161
increased,162-171
the,172-175
plasma,176-182
levels,183-189
of,190-192
indomethacin.,193-206	DrugDDI.d384.s20.e3

In,0-2
some,3-7
patients,8-16
the,17-20
combined,21-29
use,30-33
of,34-36
indomethacin,37-49	DrugDDI.d384.s21.e0
and,50-53
diflunisal,54-64	DrugDDI.d384.s21.e1
has,65-68
been,69-73
associated,74-84
with,85-89
fatal,90-95
gastrointestinal,96-112
hemorrhage.,113-124

Therefore,,0-10
indomethacin,11-23	DrugDDI.d384.s22.e0
and,24-27
diflunisal,28-38	DrugDDI.d384.s22.e1
should,39-45
not,46-49
be,50-52
used,53-57
concomitantly.,58-72

The,0-3
concomitant,4-15
use,16-19
of,20-22
diflunisal,23-33	DrugDDI.d384.s23.e0
tablets,34-41
and,42-45
other,46-51
NSAIDs,52-58	DrugDDI.d384.s23.e1
is,59-61
not,62-65
recommended,66-77
due,78-81
to,82-84
the,85-88
increased,89-98
possibility,99-110
of,111-113
gastrointestinal,114-130
toxicity,,131-140
with,141-145
little,146-152
or,153-155
no,156-158
increase,159-167
in,168-170
efficacy.,171-180

Aspirin:,0-8	DrugDDI.d384.s25.e0
In,9-11
normal,12-18
volunteers,,19-30
a,31-32
small,33-38
decrease,39-47
in,48-50
diflunisal,51-61	DrugDDI.d384.s25.e1
levels,62-68
was,69-72
observed,73-81
when,82-86
multiple,87-95
doses,96-101
of,102-104
diflunisal,105-115	DrugDDI.d384.s25.e2
and,116-119
aspirin,120-127	DrugDDI.d384.s25.e3
were,128-132
administered,133-145
concomitantly.,146-160

Sulindac:,0-9	DrugDDI.d384.s26.e0
The,10-13
concomitant,14-25
administration,26-40
of,41-43
diflunisal,44-54	DrugDDI.d384.s26.e1
and,55-58
sulindac,59-67	DrugDDI.d384.s26.e2
in,68-70
normal,71-77
volunteers,78-88
resulted,89-97
in,98-100
lowering,101-109
of,110-112
the,113-116
plasma,117-123
levels,124-130
of,131-133
the,134-137
active,138-144
sulindac,145-153	DrugDDI.d384.s26.e3
sulfide,154-161	DrugDDI.d384.s26.e3
metabolite,162-172	DrugDDI.d384.s26.e3
by,173-175
approximately,176-189
one-third.,190-200

Naproxen:,0-9	DrugDDI.d384.s27.e0
The,10-13
concomitant,14-25
administration,26-40
of,41-43
diflunisal,44-54	DrugDDI.d384.s27.e1
and,55-58
naproxen,59-67	DrugDDI.d384.s27.e2
in,68-70
normal,71-77
volunteers,78-88
had,89-92
no,93-95
effect,96-102
on,103-105
the,106-109
plasma,110-116
levels,117-123
of,124-126
naproxen,,127-136
but,137-140
significantly,141-154
decreased,155-164
the,165-168
urinary,169-176
excretion,177-186
of,187-189
naproxen,190-198	DrugDDI.d384.s27.e4
and,199-202
its,203-206
glucuronide,207-218	DrugDDI.d384.s27.e5
metabolite.,219-230	DrugDDI.d384.s27.e5

Naproxen,0-8	DrugDDI.d384.s28.e0
had,9-12
no,13-15
effect,16-22
on,23-25
plasma,26-32
levels,33-39
of,40-42
diflunisal.,43-54	DrugDDI.d384.s28.e1

Drug,0-4
laboratory,5-15
Test,16-20
Interactions,21-33
Serum,34-39
Salicylate,40-50	DrugDDI.d384.s29.e0
Assays:,51-58
Caution,59-66
should,67-73
be,74-76
used,77-81
in,82-84
interpreting,85-97
the,98-101
results,102-109
of,110-112
serum,113-118
salicylate,119-129	DrugDDI.d384.s29.e1
assays,130-136
when,137-141
diflunisal,142-152	DrugDDI.d384.s29.e2
is,153-155
present.,156-164

Potassium-depleting,0-19	DrugDDI.d147.s0.e0
diuretics,20-29	DrugDDI.d147.s0.e0
are,30-33
a,34-35
major,36-41
contributing,42-54
factor,55-61
to,62-64
digitalis,65-74
toxicity.,75-84

Calcium,,0-8
particularly,9-21
if,22-24
administered,25-37
rapidly,38-45
by,46-48
the,49-52
intravenous,53-64
route,,65-71
may,72-75
produce,76-83
serious,84-91
arrhythmias,92-103
in,104-106
digitalized,107-118
patients.,119-128

Quinidine,,0-10
verapamil,,11-21
amiodarone,,22-33
propafenone,,34-46
indomethacin,,47-60
itraconazole,,61-74
alprazolam,,75-86
and,87-90
spironolactone,91-105	DrugDDI.d147.s2.e7
raise,106-111
the,112-115
serum,116-121
digoxin,122-129	DrugDDI.d147.s2.e8
concentration,130-143
due,144-147
to,148-150
a,151-152
reduction,153-162
in,163-165
clearance,166-175
and/or,176-182
in,183-185
volume,186-192
of,193-195
distribution,196-208
of,209-211
the,212-215
drug,,216-221
with,222-226
the,227-230
implication,231-242
that,243-247
digitalis,248-257
intoxication,258-270
may,271-274
result.,275-282

Erythromycin,0-12	DrugDDI.d147.s3.e0
and,13-16
clarithromycin,17-31	DrugDDI.d147.s3.e1
(and,32-36
possibly,37-45
other,46-51
macrolide,52-61	DrugDDI.d147.s3.e2
antibiotics),62-74	DrugDDI.d147.s3.e2
and,75-78
tetracycline,79-91	DrugDDI.d147.s3.e3
may,92-95
increase,96-104
digoxin,105-112	DrugDDI.d147.s3.e4
absorption,113-123
in,124-126
patients,127-135
who,136-139
inactivate,140-150
digoxin,151-158	DrugDDI.d147.s3.e5
by,159-161
bacterial,162-171
metabolism,172-182
in,183-185
the,186-189
lower,190-195
intestine,,196-206
so,207-209
that,210-214
digitalis,215-224
intoxication,225-237
may,238-241
result.,242-249

The,0-3
risk,4-8
of,9-11
this,12-16
interaction,17-28
may,29-32
be,33-35
reduced,36-43
if,44-46
digoxin,47-54	DrugDDI.d147.s4.e0
is,55-57
given,58-63
as,64-66
capsules.,67-76

Propantheline,0-13	DrugDDI.d147.s5.e0
and,14-17
diphenoxylate,,18-32
by,33-35
decreasing,36-46
gut,47-50
motility,,51-60
may,61-64
increase,65-73
digoxin,74-81	DrugDDI.d147.s5.e2
absorption.,82-93

Antacids,,0-9
kaolin-pectin,,10-24
sulfasalazine,,25-39
neomycin,,40-49
cholestyramine,,50-65
certain,66-73
anticancer,74-84
drugs,,85-91
and,92-95
metoclopramide,96-110	DrugDDI.d147.s6.e5
may,111-114
interfere,115-124
with,125-129
intestinal,130-140
digoxin,141-148	DrugDDI.d147.s6.e6
absorption,,149-160
resulting,161-170
in,171-173
unexpectedly,174-186
low,187-190
serum,191-196
concentrations.,197-212

Rifampin,0-8	DrugDDI.d147.s7.e0
may,9-12
decrease,13-21
serum,22-27
digoxin,28-35	DrugDDI.d147.s7.e1
concentration,,36-50
especially,51-61
in,62-64
patients,65-73
with,74-78
renal,79-84
dysfunction,,85-97
by,98-100
increasing,101-111
the,112-115
non-renal,116-125
clearance,126-135
of,136-138
digoxin.,139-147	DrugDDI.d147.s7.e2

There,0-5
have,6-10
been,11-15
inconsistent,16-28
reports,29-36
regarding,37-46
the,47-50
effects,51-58
of,59-61
other,62-67
drugs,68-73	DrugDDI.d147.s8.e0
(e.g.,,74-80
quinine,,81-89
penicillamine),90-104	DrugDDI.d147.s8.e2
on,105-107
serum,108-113
digoxin,114-121	DrugDDI.d147.s8.e3
concentration.,122-136

Thyroid,0-7	DrugDDI.d147.s9.e0
administration,8-22
to,23-25
a,26-27
digitalized,,28-40
hypothyroid,41-52
patient,53-60
may,61-64
increase,65-73
the,74-77
dose,78-82
requirement,83-94
of,95-97
digoxin.,98-106	DrugDDI.d147.s9.e1

Concomitant,0-11
use,12-15
of,16-18
digoxin,19-26	DrugDDI.d147.s10.e0
and,27-30
sympathomimetics,31-47	DrugDDI.d147.s10.e1
increases,48-57
the,58-61
risk,62-66
of,67-69
cardiac,70-77
arrhythmias.,78-90

Succinylcholine,0-15	DrugDDI.d147.s11.e0
may,16-19
cause,20-25
a,26-27
sudden,28-34
extrusion,35-44
of,45-47
potassium,48-57	DrugDDI.d147.s11.e1
from,58-62
muscle,63-69
cells,,70-76
and,77-80
may,81-84
thereby,85-92
cause,93-98
arrhythmias,99-110
in,111-113
digitalized,114-125
patients.,126-135

Although,0-8
beta-adrenergic,9-24	DrugDDI.d147.s12.e0
blockers,25-33	DrugDDI.d147.s12.e0
or,34-36
calcium,37-44	DrugDDI.d147.s12.e1
channel,45-52	DrugDDI.d147.s12.e1
blockers,53-61	DrugDDI.d147.s12.e1
and,62-65
digoxin,66-73	DrugDDI.d147.s12.e2
may,74-77
be,78-80
useful,81-87
in,88-90
combination,91-102
to,103-105
control,106-113
atrial,114-120
fibrillation,,121-134
their,135-140
additive,141-149
effects,150-157
on,158-160
AV,161-163
node,164-168
conduction,169-179
can,180-183
result,184-190
in,191-193
advanced,194-202
or,203-205
complete,206-214
heart,215-220
block.,221-227

Due,0-3
to,4-6
the,7-10
considerable,11-23
variability,24-35
of,36-38
these,39-44
interactions,,45-58
the,59-62
dosage,63-69
of,70-72
digoxin,73-80	DrugDDI.d147.s13.e0
should,81-87
be,88-90
individualized,91-105
when,106-110
patients,111-119
receive,120-127
these,128-133
medications,134-145	DrugDDI.d147.s13.e1
concurrently.,146-159

Furthermore,,0-12
caution,13-20
should,21-27
be,28-30
exercised,31-40
when,41-45
combining,46-55
digoxin,56-63	DrugDDI.d147.s14.e0
with,64-68
any,69-72
drug,73-77	DrugDDI.d147.s14.e1
that,78-82
may,83-86
cause,87-92
a,93-94
significant,95-106
deterioration,107-120
in,121-123
renal,124-129
function,,130-139
since,140-145
a,146-147
decline,148-155
in,156-158
glomerular,159-169
filtration,170-180
or,181-183
tubular,184-191
secretion,192-201
may,202-205
impair,206-212
the,213-216
excretion,217-226
of,227-229
digoxin.,230-238	DrugDDI.d147.s14.e2

Vasoconstrictors:,0-17	DrugDDI.d204.s0.e0
D.H.E.,18-24
45?,25-28
(dihydroergotamine,29-47
mesylate),48-57
Injection,,58-68
USP,69-72
should,73-79
not,80-83
be,84-86
used,87-91
with,92-96
peripheral,97-107
vasoconstrictors,108-124	DrugDDI.d204.s0.e2
because,125-132
the,133-136
combination,137-148
may,149-152
cause,153-158
synergistic,159-170
elevation,171-180
of,181-183
blood,184-189
pressure.,190-199

Sumatriptan:,0-12	DrugDDI.d204.s1.e0
Sumatriptan,13-24	DrugDDI.d204.s1.e1
has,25-28
been,29-33
reported,34-42
to,43-45
cause,46-51
coronary,52-60
artery,61-67
vasospasm,,68-78
and,79-82
its,83-86
effect,87-93
could,94-99
be,100-102
additive,103-111
with,112-116
D.H.E.,117-123
45?,124-127
(dihydroergotamine,128-146
mesylate),147-156
Injection,,157-167
USP.,168-172

Sumatriptan,0-11	DrugDDI.d204.s2.e0
and,12-15
D.H.E.,16-22
45?,23-26
(dihydroergotamine,27-45
mesylate),46-55
Injection,,56-66
USP,67-70
should,71-77
not,78-81
be,82-84
taken,85-90
within,91-97
24,98-100
hours,101-106
of,107-109
each,110-114
other..,115-122

Beta,0-4	DrugDDI.d204.s3.e0
Blockers:,5-14	DrugDDI.d204.s3.e0
Although,15-23
the,24-27
results,28-35
of,36-38
a,39-40
clinical,41-49
study,50-55
did,56-59
not,60-63
indicate,64-72
a,73-74
safe,75-79
problem,80-87
associated,88-98
with,99-103
the,104-107
administration,108-122
of,123-125
D.H.E.,126-132
45?,133-136
(dihydroergotamine,137-155
mesylate),156-165
Injection,,166-176
USP,177-180
to,181-183
subjects,184-192
already,193-200
receiving,201-210
propranolol,,211-223
there,224-229
have,230-234
been,235-239
reports,240-247
that,248-252
propranolol,253-264	DrugDDI.d204.s3.e3
may,265-268
potentiate,269-279
the,280-283
vasoconstrictive,284-300
action,301-307
of,308-310
ergotamine,311-321	DrugDDI.d204.s3.e4
by,322-324
blocking,325-333
the,334-337
vasodilating,338-350
property,351-359
of,360-362
epinephrine.,363-375	DrugDDI.d204.s3.e5

Nicotine:,0-9	DrugDDI.d204.s4.e0
Nicotine,10-18	DrugDDI.d204.s4.e1
may,19-22
provoke,23-30
vasoconstriction,31-47
in,48-50
some,51-55
patients,,56-65
predisposing,66-78
to,79-81
a,82-83
greater,84-91
ischemic,92-100
response,101-109
to,110-112
ergot,113-118	DrugDDI.d204.s4.e2
therapy.,119-127

Macrolide,0-9	DrugDDI.d204.s5.e0
Antibiotics,10-21	DrugDDI.d204.s5.e0
(e.,22-25
g.,26-28
erythromycin,29-41	DrugDDI.d204.s5.e1
and,42-45
troleandomycin):,46-62	DrugDDI.d204.s5.e2
Agents,63-69
of,70-72
the,73-76
ergot,77-82	DrugDDI.d204.s5.e3
alkaloid,83-91	DrugDDI.d204.s5.e3
class,,92-98
of,99-101
which,102-107
D.H.E.,108-114
45?,115-118
(dihydroergotamine,119-137
mesylate),138-147
Injection,,148-158
USP,159-162
is,163-165
a,166-167
member,,168-175
have,176-180
been,181-185
shown,186-191
to,192-194
interact,195-203
with,204-208
antibiotics,209-220	DrugDDI.d204.s5.e5
of,221-223
the,224-227
macrolide,228-237	DrugDDI.d204.s5.e6
class,,238-244
resulting,245-254
in,255-257
increased,258-267
plasma,268-274
levels,275-281
of,282-284
unchanged,285-294
alkaloids,295-304
and,305-308
peripheral,309-319
vasoconstriction.,320-337

Vasospastic,0-11
reactions,12-21
have,22-26
been,27-31
reported,32-40
with,41-45
therapeutic,46-57
doses,58-63
of,64-66
ergotamine-containing,67-88	DrugDDI.d204.s6.e0
drugs,89-94
when,95-99
co-administered,100-115
with,116-120
these,121-126
antibiotics.,127-139	DrugDDI.d204.s6.e1

SSRIs:,0-6
Weakness,7-15
hyperreflexia,,16-30
and,31-34
incoordination,35-49
have,50-54
been,55-59
reported,60-68
rarely,69-75
when,76-80
5-HT1,81-86	DrugDDI.d204.s7.e0
agonists,87-95	DrugDDI.d204.s7.e0
have,96-100
been,101-105
co-administered,106-121
with,122-126
SSRIs,127-132
(e.,133-136
g.,137-139

fluoxetine,,0-11
fluvoxamine,,12-24
paroxetine,,25-36
sertraline).,37-49	DrugDDI.d204.s8.e3

There,0-5
have,6-10
been,11-15
no,16-18
reported,19-27
cases,28-33
from,34-38
spontaneous,39-50
reports,51-58
of,59-61
drug,62-66
interaction,67-78
between,79-86
SSRIs,87-92
and,93-96
D.H.E.,97-103
45?,104-107
(dihydroergotamine,108-126
mesylate),127-136
Injection,,137-147
USP.,148-152

Oral,0-4	DrugDDI.d204.s10.e0
Contraceptives:,5-20	DrugDDI.d204.s10.e0
The,21-24
effect,25-31
of,32-34
oral,35-39	DrugDDI.d204.s10.e1
contraceptives,40-54	DrugDDI.d204.s10.e1
on,55-57
the,58-61
pharmacokinetics,62-78
of,79-81
D.H.E.,82-88
45?,89-92
(dihydroergotamine,93-111
mesylate),112-121
Injection,,122-132
USP,133-136
has,137-140
not,141-144
been,145-149
studied.,150-158

Administration,0-14
of,15-17
thiazide,18-26	DrugDDI.d311.s0.e0
diuretics,27-36	DrugDDI.d311.s0.e0
to,37-39
hypoparathyroid,40-55
patients,56-64
who,65-68
are,69-72
concurrently,73-85
being,86-91
treated,92-99
with,100-104
dihydrotachysterol,105-123	DrugDDI.d311.s0.e1
may,124-127
cause,128-133
hypercalcemia.,134-148

Due,0-3
to,4-6
the,7-10
potential,11-20
for,21-24
additive,25-33
effects,,34-42
caution,43-50
and,51-54
careful,55-62
titration,63-72
are,73-76
warranted,77-86
in,87-89
patients,90-98
receiving,99-108
diltiazem,109-118	DrugDDI.d82.s0.e0
hydrochloride,119-132	DrugDDI.d82.s0.e0
concomitantly,133-146
with,147-151
other,152-157
agents,158-164
known,165-170
to,171-173
affect,174-180
cardiac,181-188
contractility,189-202
and/or,203-209
conduction.,210-221

Pharmacologic,0-13
studies,14-21
indicate,22-30
that,31-35
there,36-41
may,42-45
be,46-48
additive,49-57
effects,58-65
in,66-68
prolonging,69-79
AV,80-82
conduction,83-93
when,94-98
using,99-104
beta-blockers,105-118	DrugDDI.d82.s1.e0
or,119-121
digitalis,122-131	DrugDDI.d82.s1.e1
concomitantly,132-145
with,146-150
Tiazac.,151-158	DrugDDI.d82.s1.e2

As,0-2
with,3-7
all,8-11
drugs,,12-18
care,19-23
should,24-30
be,31-33
exercised,34-43
when,44-48
treating,49-57
patients,58-66
with,67-71
multiple,72-80
medications.,81-93	DrugDDI.d82.s2.e1

Diltiazem,0-9	DrugDDI.d82.s3.e0
is,10-12
both,13-17
a,18-19
substrate,20-29
and,30-33
an,34-36
inhibitor,37-46
of,47-49
the,50-53
cytochrome,54-64	DrugDDI.d82.s3.e1
P-450,65-70	DrugDDI.d82.s3.e1
3A4,71-74	DrugDDI.d82.s3.e1
enzyme,75-81
system.,82-89

Other,0-5
drugs,6-11	DrugDDI.d82.s4.e0
that,12-16
are,17-20
specific,21-29
substrates,,30-41
inhibitors,,42-53
or,54-56
inducers,57-65
of,66-68
the,69-72
enzyme,73-79
system,80-86
may,87-90
have,91-95
a,96-97
significant,98-109
impact,110-116
on,117-119
the,120-123
efficacy,124-132
and,133-136
side,137-141
effect,142-148
profile,149-156
of,157-159
diltiazem.,160-170	DrugDDI.d82.s4.e1

Patients,0-8
taking,9-15
other,16-21
drugs,22-27	DrugDDI.d82.s5.e0
that,28-32
are,33-36
substrates,37-47
of,48-50
CYP450,51-57
3A4,,58-62
especially,63-73
patients,74-82
with,83-87
renal,88-93
and/or,94-100
hepatic,101-108
impairment,,109-120
may,121-124
require,125-132
dosage,133-139
adjustment,140-150
when,151-155
starting,156-164
or,165-167
stopping,168-176
concomitantly,177-190
administered,191-203
diltiazem,204-213	DrugDDI.d82.s5.e1
in,214-216
order,217-222
to,223-225
maintain,226-234
optimum,235-242
therapeutic,243-254
blood,255-260
levels.,261-268

Beta,0-4	DrugDDI.d82.s6.e0
Blockers,5-13	DrugDDI.d82.s6.e0

Controlled,0-10
and,11-14
uncontrolled,15-27
domestic,28-36
studies,37-44
suggest,45-52
that,53-57
concomitant,58-69
use,70-73
of,74-76
diltiazem,77-86	DrugDDI.d82.s7.e0
hydrochloride,87-100	DrugDDI.d82.s7.e0
and,101-104
beta-blockers,105-118	DrugDDI.d82.s7.e1
is,119-121
usually,122-129
well,130-134
tolerated,,135-145
but,146-149
available,150-159
data,160-164
are,165-168
not,169-172
sufficient,173-183
to,184-186
predict,187-194
the,195-198
effects,199-206
of,207-209
concomitant,210-221
treatment,222-231
in,232-234
patients,235-243
with,244-248
left,249-253
ventricular,254-265
dysfunction,266-277
or,278-280
cardiac,281-288
conduction,289-299
abnormalities.,300-314

Administration,0-14
of,15-17
diltiazem,18-27	DrugDDI.d82.s8.e0
hydrochloride,28-41	DrugDDI.d82.s8.e0
concomitantly,42-55
with,56-60
propranolol,61-72	DrugDDI.d82.s8.e1
in,73-75
five,76-80
normal,81-87
volunteers,88-98
resulted,99-107
in,108-110
increased,111-120
propranolol,121-132	DrugDDI.d82.s8.e2
levels,133-139
in,140-142
all,143-146
subjects,147-155
and,156-159
bioavailability,160-175
of,176-178
propranolol,179-190	DrugDDI.d82.s8.e3
was,191-194
increased,195-204
approximately,205-218
50%.,219-223

In,0-2
vitro,,3-9
propranolol,10-21	DrugDDI.d82.s9.e0
appears,22-29
to,30-32
be,33-35
displaced,36-45
from,46-50
its,51-54
binding,55-62
sites,63-68
by,69-71
diltiazem.,72-82	DrugDDI.d82.s9.e1

If,0-2
combination,3-14
therapy,15-22
is,23-25
initiated,26-35
or,36-38
withdrawn,39-48
in,49-51
conjunction,52-63
with,64-68
propranolol,,69-81
an,82-84
adjustment,85-95
in,96-98
the,99-102
propranolol,103-114
dose,115-119
may,120-123
be,124-126
warranted.,127-137

Cimetidine,0-10	DrugDDI.d82.s11.e0

A,0-1
study,2-7
in,8-10
six,11-14
healthy,15-22
volunteers,23-33
has,34-37
shown,38-43
a,44-45
significant,46-57
increase,58-66
in,67-69
peak,70-74
diltiazem,75-84	DrugDDI.d82.s12.e0
plasma,85-91
levels,92-98
(58%),99-104
and,105-108
AUC,109-112
(53%),113-118
after,119-124
a,125-126
1-week,127-133
course,134-140
of,141-143
cimetidine,144-154	DrugDDI.d82.s12.e1
1200,155-159
mg/day,160-166
and,167-170
a,171-172
single,173-179
dose,180-184
of,185-187
diltiazem,188-197	DrugDDI.d82.s12.e2
60mg.,198-203

Ranitidine,0-10	DrugDDI.d82.s13.e0
produced,11-19
smaller,,20-28
nonsignificant,29-43
increases.,44-54

The,0-3
effect,4-10
may,11-14
be,15-17
mediated,18-26
by,27-29
cimetidines,30-41	DrugDDI.d82.s14.e0
known,42-47
inhibition,48-58
of,59-61
hepatic,62-69
cytochrome,70-80	DrugDDI.d82.s14.e1
P-450,,81-87	DrugDDI.d82.s14.e1
the,88-91
enzyme,92-98
system,99-105
responsible,106-117
for,118-121
the,122-125
first-pass,126-136
metabolism,137-147
of,148-150
diltiazem.,151-161	DrugDDI.d82.s14.e2

Patients,0-8
currently,9-18
receiving,19-28
diltiazem,29-38	DrugDDI.d82.s15.e0
therapy,39-46
should,47-53
be,54-56
carefully,57-66
monitored,67-76
for,77-80
a,81-82
change,83-89
in,90-92
pharmacological,93-108
effect,109-115
when,116-120
initiating,121-131
and,132-135
discontinuing,136-149
therapy,150-157
with,158-162
cimetidine.,163-174	DrugDDI.d82.s15.e1

An,0-2
adjustment,3-13
in,14-16
the,17-20
diltiazem,21-30	DrugDDI.d82.s16.e0
dose,31-35
may,36-39
be,40-42
warranted.,43-53

Digitalis,0-9	DrugDDI.d82.s17.e0

Administration,0-14
of,15-17
diltiazem,18-27	DrugDDI.d82.s18.e0
hydrochloride,28-41	DrugDDI.d82.s18.e0
with,42-46
digoxin,47-54	DrugDDI.d82.s18.e1
in,55-57
24,58-60
healthy,61-68
male,69-73
subjects,74-82
increased,83-92
plasma,93-99
digoxin,100-107	DrugDDI.d82.s18.e2
concentrations,108-122
approximately,123-136
20%.,137-141

Since,0-5
there,6-11
have,12-16
been,17-21
conflicting,22-33
results,34-41
regarding,42-51
the,52-55
effect,56-62
of,63-65
digoxin,66-73
levels,,74-81
it,82-84
is,85-87
recommended,88-99
that,100-104
digoxin,105-112
levels,113-119
be,120-122
monitored,123-132
when,133-137
initiating,,138-149
adjusting,,150-160
and,161-164
discontinuing,165-178
diltiazem,179-188	DrugDDI.d82.s20.e0
hydrochloride,189-202	DrugDDI.d82.s20.e0
therapy,203-210
to,211-213
avoid,214-219
possible,220-228
over-,229-234
or,235-237
under-digitalization.,238-259

Anesthetics,0-11	DrugDDI.d82.s21.e0

The,0-3
depression,4-14
of,15-17
cardiac,18-25
contractility,,26-40
conductivity,,41-54
and,55-58
automaticity,59-71
as,72-74
well,75-79
as,80-82
the,83-86
vascular,87-95
dilation,96-104
associated,105-115
with,116-120
anesthetics,121-132	DrugDDI.d82.s22.e0
may,133-136
be,137-139
potentiated,140-151
by,152-154
calcium,155-162	DrugDDI.d82.s22.e1
channel,163-170	DrugDDI.d82.s22.e1
blockers.,171-180	DrugDDI.d82.s22.e1

When,0-4
used,5-9
concomitantly,,10-24
anesthetics,25-36	DrugDDI.d82.s23.e0
and,37-40
calcium,41-48	DrugDDI.d82.s23.e1
channel,49-56	DrugDDI.d82.s23.e1
blockers,57-65	DrugDDI.d82.s23.e1
should,66-72
be,73-75
titrated,76-84
carefully.,85-95

Cyclosporine,0-12	DrugDDI.d82.s24.e0

A,0-1
pharmacokinetic,2-17
interaction,18-29
between,30-37
diltiazem,38-47	DrugDDI.d82.s25.e0
and,48-51
cyclosporine,52-64	DrugDDI.d82.s25.e1
has,65-68
been,69-73
observed,74-82
during,83-89
studies,90-97
involving,98-107
renal,108-113
and,114-117
cardiac,118-125
transplant,126-136
patients.,137-146

In,0-2
renal,3-8
and,9-12
cardiac,13-20
transplant,21-31
recipients,,32-43
a,44-45
reduction,46-55
of,56-58
cyclosporine,59-71	DrugDDI.d82.s26.e0
dose,72-76
ranging,77-84
from,85-89
15%,90-93
to,94-96
48%,97-100
was,101-104
necessary,105-114
to,115-117
maintain,118-126
cyclosporine,127-139	DrugDDI.d82.s26.e1
trough,140-146
concentrations,147-161
similar,162-169
to,170-172
those,173-178
seen,179-183
prior,184-189
to,190-192
the,193-196
addition,197-205
of,206-208
diltiazem.,209-219	DrugDDI.d82.s26.e2

If,0-2
these,3-8
agents,9-15
are,16-19
to,20-22
be,23-25
administered,26-38
concurrently,,39-52
cyclosporine,53-65	DrugDDI.d82.s27.e0
concentrations,66-80
should,81-87
be,88-90
monitored,,91-101
especially,102-112
when,113-117
diltiazem,118-127	DrugDDI.d82.s27.e1
therapy,128-135
is,136-138
initiated,,139-149
adjusted,,150-159
or,160-162
discontinued.,163-176

The,0-3
effect,4-10
of,11-13
cyclosporine,14-26	DrugDDI.d82.s28.e0
on,27-29
diltiazem,30-39	DrugDDI.d82.s28.e1
plasma,40-46
concentrations,47-61
has,62-65
not,66-69
been,70-74
evaluated.,75-85

Carbamazepine,0-13	DrugDDI.d82.s29.e0

Concomitant,0-11
administration,12-26
of,27-29
diltiazem,30-39	DrugDDI.d82.s30.e0
with,40-44
carbamazepine,45-58	DrugDDI.d82.s30.e1
has,59-62
been,63-67
reported,68-76
to,77-79
result,80-86
in,87-89
elevated,90-98
serum,99-104
levels,105-111
of,112-114
carbamazepine,115-128	DrugDDI.d82.s30.e2
(40%,129-133
to,134-136
72%,137-140
increase),,141-151
resulting,152-161
in,162-164
toxicity,165-173
in,174-176
some,177-181
cases.,182-188

Patients,0-8
receiving,9-18
these,19-24
drugs,25-30	DrugDDI.d82.s31.e0
concurrently,31-43
should,44-50
be,51-53
monitored,54-63
for,64-67
a,68-69
potential,70-79
drug,80-84
interaction.,85-97

Benzodiazepines,0-15	DrugDDI.d82.s32.e0

Studies,0-7
showed,8-14
that,15-19
diltiazem,20-29	DrugDDI.d82.s33.e0
increased,30-39
the,40-43
AUC,44-47
of,48-50
midazolam,51-60	DrugDDI.d82.s33.e1
and,61-64
triazolam,65-74	DrugDDI.d82.s33.e2
by,75-77
3-4,78-81
fold,82-86
and,87-90
the,91-94
Cmax,95-99
by,100-102
2-fold,,103-110
compared,111-119
to,120-122
placebo.,123-131

The,0-3
elimination,4-15
half,16-20
life,21-25
of,26-28
midazolam,29-38	DrugDDI.d82.s34.e0
and,39-42
triazolam,43-52	DrugDDI.d82.s34.e1
also,53-57
increased,58-67
(1.5-2.5,68-76
fold),77-82
during,83-89
coadministration,90-106
with,107-111
diltiazem.,112-122	DrugDDI.d82.s34.e2

These,0-5
pharmacokinetic,6-21
effects,22-29
seen,30-34
during,35-41
diltiazem,42-51	DrugDDI.d82.s35.e0
coadministration,52-68
can,69-72
result,73-79
in,80-82
increased,83-92
clinical,93-101
effects,102-109
(e.g.,,110-116
prolonged,117-126
sodation)of,127-138
both,139-143
midazolam,144-153	DrugDDI.d82.s35.e1
and,154-157
triazolam.,158-168	DrugDDI.d82.s35.e2

Lovastatin,0-10	DrugDDI.d82.s36.e0

In,0-2
a,3-4
ten-subject,5-16
study,,17-23
coadministration,24-40
of,41-43
diltiazem,44-53	DrugDDI.d82.s37.e0
(120,54-58
mg,59-61
bid),62-66	DrugDDI.d82.s37.e1
with,67-71
lovastatin,72-82	DrugDDI.d82.s37.e2
resulted,83-91
in,92-94
a,95-96
3-4,97-100
times,101-106
increase,107-115
in,116-118
mean,119-123
lovastatin,124-134	DrugDDI.d82.s37.e3
AUC,135-138
and,139-142
Cmax,143-147
vs.,148-151
lovastatin,152-162	DrugDDI.d82.s37.e4
alone;,163-169

no,0-2
change,3-9
in,10-12
pravastatin,13-24	DrugDDI.d82.s38.e0
AUC,25-28
and,29-32
Cmax,33-37
was,38-41
observed,42-50
during,51-57
diltiazem,58-67	DrugDDI.d82.s38.e1
coadministration.,68-85

Diltiazem,0-9	DrugDDI.d82.s39.e0
plasma,10-16
levels,17-23
were,24-28
not,29-32
significantly,33-46
affected,47-55
by,56-58
lovastatin,59-69	DrugDDI.d82.s39.e1
or,70-72
pravastatin.,73-85	DrugDDI.d82.s39.e2

Rifampin,0-8	DrugDDI.d82.s40.e0

Coadministration,0-16
of,17-19
rifampin,20-28	DrugDDI.d82.s41.e0
with,29-33
diltiazem,34-43	DrugDDI.d82.s41.e1
lowered,44-51
the,52-55
diltiazem,56-65	DrugDDI.d82.s41.e2
plasma,66-72
concentrations,73-87
to,88-90
undetectable,91-103
levels.,104-111

Coadministration,0-16
of,17-19
diltiazem,20-29	DrugDDI.d82.s42.e0
with,30-34
rifampin,35-43	DrugDDI.d82.s42.e1
or,44-46
any,47-50
known,51-56
CYP3A4,57-63	DrugDDI.d82.s42.e2
inducer,64-71
should,72-78
be,79-81
avoided,82-89
when,90-94
possible,,95-104
and,105-108
alternative,109-120
therapy,121-128
considered.,129-140

Dimenhydrinate,0-14	DrugDDI.d294.s0.e0
may,15-18
decrease,19-27
emetic,28-34	DrugDDI.d294.s0.e1
response,35-43
to,44-46
apomorphine.,47-59	DrugDDI.d294.s0.e2

Oxytocin,0-8	DrugDDI.d178.s0.e0
or,9-11
other,12-17
oxytocics,18-27	DrugDDI.d178.s0.e1
(concurrent,28-39
use,40-43
with,44-48
dinoprost,49-58	DrugDDI.d178.s0.e2
may,59-62
result,63-69
in,70-72
uterine,73-80
hypertonus,,81-92
possibly,93-101
causing,102-109
uterine,110-117
rupture,118-125
or,126-128
cervical,129-137
laceration,,138-149
especially,150-160
in,161-163
the,164-167
absence,168-175
of,176-178
adequate,179-187
cervical,188-196
dilatation;,197-208

PROSTIN,0-7	DrugDDI.d451.s0.e0
E2,8-10	DrugDDI.d451.s0.e0
may,11-14
augment,15-22
the,23-26
activity,27-35
of,36-38
other,39-44
oxytocic,45-53	DrugDDI.d451.s0.e1
drugs.,54-60	DrugDDI.d451.s0.e1

Concomitant,0-11
use,12-15
with,16-20
other,21-26
oxytocic,27-35	DrugDDI.d451.s1.e0
agents,36-42	DrugDDI.d451.s1.e0
is,43-45
not,46-49
recommended.,50-62

Diphenhydramine,0-15	DrugDDI.d314.s0.e0
hydrochloride,16-29	DrugDDI.d314.s0.e0
has,30-33
additive,34-42
effects,43-50
with,51-55
alcohol,56-63	DrugDDI.d314.s0.e1
and,64-67
other,68-73
CNS,74-77	DrugDDI.d314.s0.e2
depressants,78-89	DrugDDI.d314.s0.e2
(hypnotics,,90-101
sedatives,,102-112
tranquilizers,,113-127
etc).,128-133

MAO,0-3	DrugDDI.d314.s1.e0
inhibitors,4-14	DrugDDI.d314.s1.e0
prolong,15-22
and,23-26
intensify,27-36
the,37-40
anticholinergic,41-56	DrugDDI.d314.s1.e1
(drying),57-65
effects,66-73
of,74-76
antihistamines.,77-92	DrugDDI.d314.s1.e2

CNS,0-3
depression?producing,4-24
medications,25-36
-,37-38
concurrent,39-49
use,50-53
may,54-57
potentiate,58-68
the,69-72
effects,73-80
of,81-83
either,84-90
these,91-96
medications,97-108	DrugDDI.d33.s0.e0
or,109-111
diphenidol;,112-123	DrugDDI.d33.s0.e1

anticholinergics,0-16	DrugDDI.d33.s1.e0
or,17-19
other,20-25	DrugDDI.d33.s1.e1
medications,26-37	DrugDDI.d33.s1.e1
with,38-42
anticholinergic,43-58	DrugDDI.d33.s1.e2
activity,59-67
-,68-69
anticholinergic,70-85
effects,86-93
may,94-97
be,98-100
potentiated,101-112
when,113-117
these,118-123
medications,124-135	DrugDDI.d33.s1.e3
are,136-139
used,140-144
concurrently,145-157
with,158-162
diphenidol;,163-174	DrugDDI.d33.s1.e4

apomorphine,0-11	DrugDDI.d33.s2.e0
-,12-13
prior,14-19
ingestion,20-29
of,30-32
diphenidol,33-43	DrugDDI.d33.s2.e1
may,44-47
decrease,48-56
the,57-60
emetic,61-67	DrugDDI.d33.s2.e2
response,68-76
to,77-79
apomorphine,80-91	DrugDDI.d33.s2.e3
in,92-94
the,95-98
treatment,99-108
of,109-111
poisoning.,112-122

Known,0-5
drug,6-10
interactions,11-23
include,24-31
barbiturates,,32-45
tranquilizers,,46-60
and,61-64
alcohol.,65-73	DrugDDI.d101.s0.e2

Diphenoxylate,0-13	DrugDDI.d101.s1.e0
HCl,14-17	DrugDDI.d101.s1.e0
and,18-21
atropine,22-30	DrugDDI.d101.s1.e1
sulfate,31-38	DrugDDI.d101.s1.e1
may,39-42
interact,43-51
with,52-56
MAO,57-60	DrugDDI.d101.s1.e2
inhibitors,61-71	DrugDDI.d101.s1.e2
In,72-74
studies,75-82
with,83-87
male,88-92
rats,,93-98
diphenoxylate,99-112	DrugDDI.d101.s1.e3
hydrochloride,113-126	DrugDDI.d101.s1.e3
was,127-130
found,131-136
to,137-139
inhibit,140-147
the,148-151
hepatic,152-159
microsomal,160-170	DrugDDI.d101.s1.e4
enzyme,171-177	DrugDDI.d101.s1.e4
system,178-184
at,185-187
a,188-189
dose,190-194
of,195-197
2,198-199
mg/kg/day.,200-210

Therefore,,0-10
diphenoxylate,11-24	DrugDDI.d101.s2.e0
has,25-28
the,29-32
potential,33-42
to,43-45
prolong,46-53
the,54-57
biological,58-68
half-lives,69-79
of,80-82
drugs,83-88	DrugDDI.d101.s2.e1
for,89-92
which,93-98
the,99-102
rate,103-107
of,108-110
elimination,111-122
is,123-125
dependent,126-135
on,136-138
the,139-142
microsomal,143-153	DrugDDI.d101.s2.e2
drug,154-158	DrugDDI.d101.s2.e2
metabolizing,159-171
enzyme,172-178
system.,179-186

This,0-4
drug,5-9	DrugDDI.d435.s0.e0
may,10-13
interact,14-22
with,23-27
alcohol,28-35	DrugDDI.d435.s0.e1
or,36-38
other,39-44
CNS,45-48	DrugDDI.d435.s0.e2
depressants,49-60	DrugDDI.d435.s0.e2
(may,61-65
potentiate,66-76
the,77-80
CNS,81-84	DrugDDI.d435.s0.e3
depressant,85-95	DrugDDI.d435.s0.e3
effects,96-103
of,104-106
either,107-113
these,114-119
medications,120-131	DrugDDI.d435.s0.e4
or,132-134
antihistamines),,135-151
anticholinergics,152-168	DrugDDI.d435.s0.e6
or,169-171
other,172-177	DrugDDI.d435.s0.e7
medications,178-189	DrugDDI.d435.s0.e7
with,190-194
anticholinergic,195-210	DrugDDI.d435.s0.e8
activity,211-219
(anticholinergic,220-236
effects,237-244
may,245-248
be,249-251
potentiated,252-263
when,264-268
these,269-274
medications,275-286	DrugDDI.d435.s0.e10
are,287-290
used,291-295
concurrently,296-308
with,309-313
antihistamines),,314-330
and,331-334
monoamine,335-344	DrugDDI.d435.s0.e12
oxidase,345-352	DrugDDI.d435.s0.e12
(MAO),353-358
inhibitors,359-369
(concurrent,370-381
use,382-385
with,386-390
antihistamines,391-405	DrugDDI.d435.s0.e13
may,406-409
prolong,410-417
and,418-421
intensify,422-431
the,432-435
anticholinergic,436-451	DrugDDI.d435.s0.e14
and,452-455
CNS,456-459	DrugDDI.d435.s0.e15
depressant,460-470	DrugDDI.d435.s0.e15
effects,471-478
of,479-481
antihistamines).,482-498	DrugDDI.d435.s0.e16

No,0-2
pharmacokinetic,3-18
drug-drug,19-28
interaction,29-40
studies,41-48
were,49-53
conducted,54-63
with,64-68
PERSANTINE?,69-80
(dipyridamole,81-94
USP),95-99
Tablets.,100-108

Adenosine:,0-10	DrugDDI.d26.s2.e0
Dipyridamole,11-23	DrugDDI.d26.s2.e1
has,24-27
been,28-32
reported,33-41
to,42-44
increase,45-53
the,54-57
plasma,58-64
levels,65-71
and,72-75
cardiovascular,76-90
effects,91-98
of,99-101
adenosine.,102-112	DrugDDI.d26.s2.e2

Adjustment,0-10
of,11-13
adenosine,14-23	DrugDDI.d26.s3.e0
dosage,24-30
may,31-34
be,35-37
necessary.,38-48

Cholinesterase,0-14	DrugDDI.d26.s4.e0
Inhibitors:,15-26	DrugDDI.d26.s4.e0
Dipyridamole,27-39	DrugDDI.d26.s4.e1
may,40-43
counteract,44-54
the,55-58
anticholinesterase,59-77	DrugDDI.d26.s4.e2
effect,78-84
of,85-87
cholinesterase,88-102	DrugDDI.d26.s4.e3
inhibitors,,103-114	DrugDDI.d26.s4.e3
thereby,115-122
potentially,123-134
aggravating,135-146
myasthenia,147-157
gravis.,158-165

Terfenadine,0-11	DrugDDI.d29.s0.e0
In,12-14
a,15-16
prospective,17-28
study,29-34
involving,35-44
six-healthy-male,45-61
volunteers,,62-73
dirithromycin,74-87	DrugDDI.d29.s0.e1
did,88-91
not,92-95
affect,96-102
the,103-106
metabolism,107-117
of,118-120
terfenadine.,121-133	DrugDDI.d29.s0.e2

These,0-5
six,6-9
volunteers,10-20
received,21-29
terfenadine,30-41	DrugDDI.d29.s1.e0
alone,42-47
(60,48-51
mg,52-54
twice,55-60
daily),61-67
for,68-71
8,72-73
days,,74-79
followed,80-88
by,89-91
terfenadine,92-103	DrugDDI.d29.s1.e1
in,104-106
combination,107-118
with,119-123
dirithromycin,124-137	DrugDDI.d29.s1.e2
(500,138-142
mg,143-145
once,146-150
daily),151-157
for,158-161
10,162-164
days.,165-170

(Both,0-5
drugs,6-11	DrugDDI.d29.s2.e0
were,12-16
thus,17-21
dosed,22-27
to,28-30
steady,31-37
state.),38-45

The,0-3
pharmacokinetics,4-20
of,21-23
terfenadine,24-35	DrugDDI.d29.s3.e0
and,36-39
its,40-43
acid,44-48	DrugDDI.d29.s3.e1
metabolite,49-59	DrugDDI.d29.s3.e1
and,60-63
the,64-67
electrocardiographic,68-88
QT,89-91
c,92-93
interval,94-102
were,103-107
measured,108-116
during,117-123
both,124-128
periods:,129-137
with,138-142
terfenadine,143-154	DrugDDI.d29.s3.e2
alone,,155-161
and,162-165
with,166-170
terfenadine,171-182	DrugDDI.d29.s3.e3
plus,183-187
dirithromycin.,188-202	DrugDDI.d29.s3.e4

In,0-2
five,3-7
men,,8-12
terfenadine,13-24	DrugDDI.d29.s4.e0
levels,25-31
were,32-36
undetectable,37-49
(,50-51
5,52-53
ng/mL),54-60
throughout,61-71
the,72-75
study;,76-82

in,0-2
one,3-6
man,,7-11
the,12-15
C,16-17
max,18-21	DrugDDI.d29.s5.e0
of,22-24
terfenadine,25-36	DrugDDI.d29.s5.e1
was,37-40
8.1,41-44
ng/mL,45-50
with,51-55
terfenadine,56-67	DrugDDI.d29.s5.e2
alone,68-73
and,74-77
7.2,78-81
ng/mL,82-87
with,88-92
terfenadine,93-104	DrugDDI.d29.s5.e3
plus,105-109
dirithromycin.,110-124	DrugDDI.d29.s5.e4

The,0-3
mean,4-8
C,9-10
max,11-14	DrugDDI.d29.s6.e0
,,15-16
T,17-18
max,19-22	DrugDDI.d29.s6.e1
,,23-24
and,25-28
AUC,29-32
of,33-35
the,36-39
acid,40-44	DrugDDI.d29.s6.e2
metabolite,45-55	DrugDDI.d29.s6.e2
of,56-58
terfenadine,59-70	DrugDDI.d29.s6.e3
were,71-75
not,76-79
significantly,80-93
changed.,94-102

The,0-3
mean,4-8
QT,9-11
c,12-13
interval,14-22
(msec),23-29
was,30-33
369,34-37
with,38-42
terfenadine,43-54	DrugDDI.d29.s7.e0
alone,55-60
and,61-64
367,65-68
with,69-73
terfenadine,74-85	DrugDDI.d29.s7.e1
plus,86-90
dirithromycin.,91-105	DrugDDI.d29.s7.e2

Also,,0-5
in,6-8
vitro,9-14
experiments,15-26
demonstrated,27-39
a,40-41
lack,42-46
of,47-49
interaction,50-61
between,62-69
dirithromycin,70-83	DrugDDI.d29.s8.e0
and,84-87
terfenadine.,88-100	DrugDDI.d29.s8.e1

Thus,,0-5
the,6-9
interaction,10-21
observed,22-30
between,31-38
erythromycin,39-51	DrugDDI.d29.s9.e0
and,52-55
terfenadine,56-67	DrugDDI.d29.s9.e1
is,68-70
not,71-74
expected,75-83
for,84-87
dirithromycin.,88-102	DrugDDI.d29.s9.e2

Serious,0-7
cardiac,8-15
dysrhythmias,,16-29
some,30-34
resulting,35-44
in,45-47
death,,48-54
have,55-59
occurred,60-68
in,69-71
patients,72-80
receiving,81-90
terfenadine,91-102	DrugDDI.d29.s10.e0
concomitantly,103-116
with,117-121
other,122-127
macrolide,128-137	DrugDDI.d29.s10.e1
antibiotics.,138-150	DrugDDI.d29.s10.e1

In,0-2
addition,,3-12
most,13-17
macrolides,18-28	DrugDDI.d29.s11.e0
are,29-32
contraindicated,33-48
in,49-51
patients,52-60
receiving,61-70
terfenadine,71-82	DrugDDI.d29.s11.e1
therapy,83-90
who,91-94
have,95-99
pre-existing,100-112
cardiac,113-120
abnormalities,121-134
(arrhythmia,,135-147
bradycardia,,148-160
QT,161-163
c,164-165
interval,166-174
prolongation,,175-188
ischemic,189-197
heart,198-203
disease,,204-212
congestive,213-223
heart,224-229
failure,,230-238
etc.),239-244
or,245-247
electrolyte,248-259
disturbances.,260-273

Theophylline,0-12	DrugDDI.d29.s12.e0
Following,13-22
co-administration,23-40
of,41-43
two,44-47
250-mg,48-54
dirithromycin,55-68
tablets,69-76
administered,77-89
once,90-94
daily,95-100
with,101-105
200-mg,106-112
theophylline,113-125	DrugDDI.d29.s12.e1
tablets,126-133
administered,134-146
twice,147-152
daily,153-158
for,159-162
10,163-165
days,166-170
to,171-173
14,174-176
healthy,177-184
subjects,,185-194
the,195-198
steady-state,199-211
plasma,212-218
concentration,219-232
of,233-235
theophylline,236-248	DrugDDI.d29.s12.e2
was,249-252
not,253-256
significantly,257-270
altered.,271-279

In,0-2
general,,3-11
most,12-16
patients,17-25
treated,26-33
with,34-38
dirithromycin,39-52	DrugDDI.d29.s13.e0
who,53-56
are,57-60
receiving,61-70
concomitant,71-82
theophylline,83-95	DrugDDI.d29.s13.e1
therapy,96-103
may,104-107
not,108-111
require,112-119
empiric,120-127
adjustment,128-138
of,139-141
theophylline,142-154	DrugDDI.d29.s13.e2
dosage,155-161
or,162-164
monitoring,165-175
of,176-178
theophylline,179-191	DrugDDI.d29.s13.e3
plasma,192-198
concentrations.,199-214

However,,0-8
theophylline,9-21	DrugDDI.d29.s14.e0
plasma,22-28
concentrations,29-43
should,44-50
be,51-53
monitored,,54-64
with,65-69
dosage,70-76
adjustment,77-87
as,88-90
appropriate,,91-103
in,104-106
patients,107-115
whose,116-121
pulmonary,122-131
disease,132-139
requires,140-148
maintaining,149-160
a,161-162
given,163-168
theophylline,169-181
plasma,182-188
concentration,189-202
for,203-206
optimal,207-214
pulmonary,215-224
function,225-233
or,234-236
in,237-239
patients,240-248
with,249-253
theophylline,254-266	DrugDDI.d29.s14.e1
concentrations,267-281
at,282-284
the,285-288
higher,289-295
end,296-299
of,300-302
the,303-306
therapeutic,307-318
range.,319-325

Antacids,0-8	DrugDDI.d29.s15.e0
or,9-11
H,12-13	DrugDDI.d29.s15.e1
2,14-15	DrugDDI.d29.s15.e1
receptor,16-24	DrugDDI.d29.s15.e1
antagonists,25-36	DrugDDI.d29.s15.e1
When,37-41
dirithromycin,42-55	DrugDDI.d29.s15.e2
is,56-58
administered,59-71
immediately,72-83
following,84-93
antacids,94-102	DrugDDI.d29.s15.e3
or,103-105
H,106-107	DrugDDI.d29.s15.e4
2,108-109	DrugDDI.d29.s15.e4
-receptor,110-119	DrugDDI.d29.s15.e4
antagonists,,120-132	DrugDDI.d29.s15.e4
the,133-136
absorption,137-147
of,148-150
dirithromycin,151-164	DrugDDI.d29.s15.e5
is,165-167
slightly,168-176
enhanced.,177-186

The,0-3
following,4-13
drug,14-18
interactions,19-31
have,32-36
been,37-41
reported,42-50
with,51-55
erythromycin,56-68	DrugDDI.d29.s16.e0
products.,69-78	DrugDDI.d29.s16.e0

It,0-2
is,3-5
presently,6-15
not,16-19
known,20-25
whether,26-33
these,34-39
same,40-44
drug,45-49
interactions,50-62
occur,63-68
with,69-73
dirithromycin.,74-88	DrugDDI.d29.s17.e0

Until,0-5
further,6-13
data,14-18
are,19-22
available,23-32
regarding,33-42
the,43-46
potential,47-56
interaction,57-68
of,69-71
dirithromycin,72-85	DrugDDI.d29.s18.e0
with,86-90
these,91-96
compounds,,97-107
caution,108-115
should,116-122
be,123-125
used,126-130
during,131-137
coadministration.,138-155

Triazolam,0-9	DrugDDI.d29.s19.e0
Erythromycin,10-22
has,23-26
been,27-31
reported,32-40
to,41-43
decrease,44-52
the,53-56
clearance,57-66
of,67-69
triazolam,70-79	DrugDDI.d29.s19.e1
and,,80-84
thus,,85-90
may,91-94
increase,95-103
the,104-107
pharmacologic,108-121
effect,122-128
of,129-131
triazolam.,132-142	DrugDDI.d29.s19.e2

Digoxin,0-7	DrugDDI.d29.s20.e0
Concomitant,8-19
administration,20-34
of,35-37
erythromycin,38-50	DrugDDI.d29.s20.e1
and,51-54
digoxin,55-62	DrugDDI.d29.s20.e2
has,63-66
been,67-71
reported,72-80
to,81-83
result,84-90
in,91-93
elevated,94-102
digoxin,103-110
serum,111-116
levels.,117-124

Anticoagulants,0-14	DrugDDI.d29.s21.e0
There,15-20
have,21-25
been,26-30
reports,31-38
of,39-41
increased,42-51
anticoagulant,52-65
effects,66-73
when,74-78
erythromycin,79-91	DrugDDI.d29.s21.e1
and,92-95
oral,96-100	DrugDDI.d29.s21.e2
anticoagulants,101-115	DrugDDI.d29.s21.e2
were,116-120
used,121-125
concomitantly.,126-140

Increased,0-9
anticoagulation,10-25
effects,26-33
due,34-37
to,38-40
a,41-42
drug,43-47
interaction,48-59
with,60-64
erythromycin,65-77	DrugDDI.d29.s22.e0
may,78-81
be,82-84
more,85-89
pronounced,90-100
in,101-103
the,104-107
elderly.,108-116

Ergotamine,0-10	DrugDDI.d29.s23.e0
Concurrent,11-21
use,22-25
of,26-28
erythromycin,29-41	DrugDDI.d29.s23.e1
and,42-45
ergotamine,46-56	DrugDDI.d29.s23.e2
or,57-59
dihydroergotamine,60-77	DrugDDI.d29.s23.e3
has,78-81
been,82-86
associated,87-97
in,98-100
some,101-105
patients,106-114
with,115-119
acute,120-125
ergot,126-131	DrugDDI.d29.s23.e4
toxicity,132-140
characterized,141-154
by,155-157
severe,158-164
peripheral,165-175
vasospasm,176-185
and,186-189
dysesthesia.,190-202

Other,0-5
drugs,6-11
Drug,12-16
interactions,17-29
have,30-34
been,35-39
reported,40-48
with,49-53
concomitant,54-65
administration,66-80
of,81-83
erythromycin,84-96	DrugDDI.d29.s24.e0
and,97-100
other,101-106	DrugDDI.d29.s24.e1
medications,,107-119	DrugDDI.d29.s24.e1
including,120-129
cyclosporine,,130-143
hexobarbital,,144-157
carbamazepine,,158-172
alfentanil,,173-184
disopyramide,,185-198
phenytoin,,199-209
bromocriptine,,210-224
valproate,,225-235
astemizole,,236-247
and,248-251
lovastatin.,252-263	DrugDDI.d29.s24.e11

If,0-2
phenytoin,3-12	DrugDDI.d551.s0.e0
or,13-15
other,16-21
hepatic,22-29
enzyme,30-36
inducers,37-45
are,46-49
taken,50-55
concurrently,56-68
with,69-73
Norpace,74-81	DrugDDI.d551.s0.e1
or,82-84
Norpace,85-92	DrugDDI.d551.s0.e2
CR,,93-96	DrugDDI.d551.s0.e2
lower,97-102
plasma,103-109
levels,110-116
of,117-119
disopyramide,120-132	DrugDDI.d551.s0.e3
may,133-136
occur.,137-143

Monitoring,0-10
of,11-13
disopyramide,14-26	DrugDDI.d551.s1.e0
plasma,27-33
levels,34-40
is,41-43
recommended,44-55
in,56-58
such,59-63
concurrent,64-74
use,75-78
to,79-81
avoid,82-87
ineffective,88-99
therapy.,100-108

Other,0-5
antiarrhythmic,6-20	DrugDDI.d551.s2.e0
drugs,21-26	DrugDDI.d551.s2.e0
(eg,,27-31
quinidine,,32-42
procainamide,,43-56
lidocaine,,57-67
propranolol),68-80	DrugDDI.d551.s2.e4
have,81-85
occasionally,86-98
been,99-103
used,104-108
concurrently,109-121
with,122-126
Norpace.,127-135	DrugDDI.d551.s2.e5

In,0-2
healthy,3-10
subjects,,11-20
no,21-23
significant,24-35
drug-drug,36-45
interaction,46-57
was,58-61
observed,62-70
when,71-75
Norpace,76-83	DrugDDI.d551.s4.e0
was,84-87
coadministered,88-102
with,103-107
either,108-114
propranolol,115-126	DrugDDI.d551.s4.e1
or,127-129
diazepam.,130-139	DrugDDI.d551.s4.e2

Concomitant,0-11
administration,12-26
of,27-29
Norpace,30-37	DrugDDI.d551.s5.e0
and,38-41
quinidine,42-51	DrugDDI.d551.s5.e1
resulted,52-60
in,61-63
slight,64-70
increases,71-80
in,81-83
plasma,84-90
disopyramide,91-103	DrugDDI.d551.s5.e2
levels,104-110
and,111-114
slight,115-121
decreases,122-131
in,132-134
plasma,135-141
quinidine,142-151	DrugDDI.d551.s5.e3
levels.,152-159

Norpace,0-7	DrugDDI.d551.s6.e0
does,8-12
not,13-16
increase,17-25
serum,26-31
digoxin,32-39
levels.,40-47

Patients,0-8
taking,9-15
disopyramide,16-28	DrugDDI.d551.s7.e0
phosphate,29-38	DrugDDI.d551.s7.e0
and,39-42
erythromycin,43-55	DrugDDI.d551.s7.e1
concomitantly,56-69
may,70-73
develop,74-81
increased,82-91
serum,92-97
concentrations,98-112
of,113-115
disopyramide,116-128	DrugDDI.d551.s7.e2
resulting,129-138
in,139-141
excessive,142-151
widening,152-160
of,161-163
the,164-167
QRS,168-171
complex,172-179
and/or,180-186
prolongation,187-199
of,200-202
the,203-206
Q-T,207-210
interval.,211-220

Patients,0-8
taking,9-15
disopyramide,16-28	DrugDDI.d551.s8.e0
phosphate,29-38	DrugDDI.d551.s8.e0
and,39-42
hepatic,43-50
enzyme,51-57	DrugDDI.d551.s8.e1
inhibitors,58-68	DrugDDI.d551.s8.e1
concomitantly,69-82
should,83-89
be,90-92
closely,93-100
monitored.,101-111

Until,0-5
data,6-10
on,11-13
possible,14-22
interactions,23-35
between,36-43
verapamil,44-53	DrugDDI.d551.s9.e0
and,54-57
disopyramide,58-70	DrugDDI.d551.s9.e1
phosphate,71-80	DrugDDI.d551.s9.e1
are,81-84
obtained,,85-94
disopyramide,95-107	DrugDDI.d551.s9.e2
should,108-114
not,115-118
be,119-121
administered,122-134
within,135-141
48,142-144
hours,145-150
before,151-157
or,158-160
24,161-163
hours,164-169
after,170-175
verapamil,176-185	DrugDDI.d551.s9.e3
administration.,186-201

Disulfiram,0-10	DrugDDI.d458.s0.e0
appears,11-18
to,19-21
decrease,22-30
the,31-34
rate,35-39
at,40-42
which,43-48
certain,49-56
drugs,57-62	DrugDDI.d458.s0.e1
are,63-66
metabolized,67-78
and,79-82
therefore,83-92
may,93-96
increase,97-105
the,106-109
blood,110-115
levels,116-122
and,123-126
the,127-130
possibility,131-142
of,143-145
clinical,146-154
toxicity,155-163
of,164-166
drugs,167-172	DrugDDI.d458.s0.e2
given,173-178
concomitantly.,179-193

DISULFIRAM,0-10	DrugDDI.d458.s1.e0
SHOULD,11-17
BE,18-20
USED,21-25
WITH,26-30
CAUTION,31-38
IN,39-41
THOSE,42-47
PATIENTS,48-56
REVEIVING,57-66
PHENYTOIN,67-76	DrugDDI.d458.s1.e1
AND,77-80
ITS,81-84
CONGENERS.,85-95	DrugDDI.d458.s1.e2

SINCE,0-5
THE,6-9
CONCOMITANT,10-21
ADMINISTRATION,22-36
OF,37-39
THESE,40-45
TWO,46-49
DRUGS,50-55	DrugDDI.d458.s2.e0
CAN,56-59
LEAD,60-64
TO,65-67
PHENYTOIN,68-77
INTOXICATION,,78-91
PRIOR,92-97
TO,98-100
ADMINISTERING,101-114
DISULFIRAM,115-125	DrugDDI.d458.s2.e1
TO,126-128
A,129-130
PATIENT,131-138
ON,139-141
PHENYTOIN,142-151	DrugDDI.d458.s2.e2
THERAPY,,152-160
A,161-162
BASELINE,163-171
PHENYTOIN,172-181
SERUM,182-187
LEVEL,188-193
SHOULD,194-200
BE,201-203
OBTAINED.,204-213

SERUM,0-5
LEVELS,6-12
OF,13-15
PHENYTOIN,16-25	DrugDDI.d458.s4.e0
SHOULD,26-32
BE,33-35
DETERMINED,36-46
ON,47-49
DIFFERENT,50-59
DAYS,60-64
FOR,65-68
EVIDENCE,69-77
OF,78-80
AN,81-83
INCREASE,84-92
OR,93-95
FOR,96-99
A,100-101
CONTINUING,102-112
RISE,113-117
IN,118-120
LEVELS.,121-128

It,0-2
may,3-6
be,7-9
necessary,10-19
to,20-22
adjust,23-29
the,30-33
dosage,34-40
of,41-43
oral,44-48	DrugDDI.d458.s6.e0
anticoagulants,49-63	DrugDDI.d458.s6.e0
upon,64-68
beginning,69-78
or,79-81
stopping,82-90
disulfiram.,91-102	DrugDDI.d458.s6.e1
since,103-108
disulfiram,109-119	DrugDDI.d458.s6.e2
may,120-123
prolong,124-131
prothrombin,132-143
time.,144-149

Patients,0-8
taking,9-15
isoniazid,16-25	DrugDDI.d458.s7.e0
when,26-30
disulfiram,31-41	DrugDDI.d458.s7.e1
is,42-44
given,45-50
should,51-57
be,58-60
observed,61-69
for,70-73
the,74-77
appearance,78-88
of,89-91
unsteady,92-100
gait,101-105
or,106-108
marked,109-115
changes,116-123
in,124-126
mental,127-133
status;,134-141

the,0-3
disulfiram,4-14	DrugDDI.d458.s8.e0
should,15-21
be,22-24
discontinued,25-37
if,38-40
such,41-45
signs,46-51
appear.,52-59

In,0-2
rats,,3-8
simultaneous,9-21
ingestion,22-31
of,32-34
disulfiram,35-45	DrugDDI.d458.s9.e0
and,46-49
nitrite,50-57	DrugDDI.d458.s9.e1
in,58-60
the,61-64
diet,65-69
for,70-73
78,74-76
weeks,77-82
has,83-86
been,87-91
reported,92-100
to,101-103
cause,104-109
tumors,,110-117
and,118-121
it,122-124
has,125-128
been,129-133
suggested,134-143
that,144-148
disulfiram,149-159	DrugDDI.d458.s9.e2
may,160-163
react,164-169
with,170-174
nitrites,175-183	DrugDDI.d458.s9.e3
in,184-186
the,187-190
rat,191-194
stomach,195-202
to,203-205
form,206-210
a,211-212
nitrosamine,,213-225
which,226-231
is,232-234
tumorigenic.,235-247

Disulfiram,0-10	DrugDDI.d458.s10.e0
alone,11-16
in,17-19
the,20-23
rat?s,24-29
diet,30-34
did,35-38
not,39-42
lead,43-47
to,48-50
such,51-55
tumors.,56-63

Animal,0-6
studies,7-14
indicate,15-23
that,24-28
dobutamine,29-39	DrugDDI.d410.s0.e0
may,40-43
be,44-46
ineffective,47-58
if,59-61
the,62-65
patient,66-73
has,74-77
recently,78-86
received,87-95
a,96-97
,98-98
span,99-103
class=,104-110
c65,111-114
b-blocking,115-125
drug.,126-131

Preliminary,0-11
studies,12-19
indicate,20-28
that,29-33
the,34-37
concomitant,38-49
use,50-53
of,54-56
dobutamine,57-67	DrugDDI.d410.s2.e0
and,68-71
nitroprusside,72-85	DrugDDI.d410.s2.e1
results,86-93
in,94-96
a,97-98
higher,99-105
cardiac,106-113
output,114-120
and,,121-125
usually,,126-134
a,135-136
lower,137-142
pulmonary,143-152
wedge,153-158
pressure,159-167
than,168-172
when,173-177
either,178-184
drug,185-189	DrugDDI.d410.s2.e2
is,190-192
used,193-197
alone.,198-204

There,0-5
was,6-9
no,10-12
evidence,13-21
of,22-24
drug,25-29
interactions,30-42
in,43-45
clinical,46-54
studies,55-62
in,63-65
which,66-71
dobutamine,72-82	DrugDDI.d410.s3.e0
was,83-86
administered,87-99
concurrently,100-112
with,113-117
other,118-123
drugs,,124-130
including,131-140
digitalis,141-150	DrugDDI.d410.s3.e2
preparations,,151-164	DrugDDI.d410.s3.e2
furosemide,,165-176
spironolactone,,177-192
lidocaine,,193-203
glyceryl,204-212	DrugDDI.d410.s3.e6
trinitrate,,213-224	DrugDDI.d410.s3.e6
isosorbide,225-235	DrugDDI.d410.s3.e7
dinitrate,,236-246	DrugDDI.d410.s3.e7
morphine,,247-256
atropine,,257-266
heparin,,267-275
protamine,,276-286
potassium,287-296	DrugDDI.d410.s3.e12
chloride,,297-306	DrugDDI.d410.s3.e12
folic,307-312	DrugDDI.d410.s3.e13
acid,,313-318	DrugDDI.d410.s3.e13
and,319-322
acetaminophen.,323-337	DrugDDI.d410.s3.e14

There,0-5
have,6-10
been,11-15
no,16-18
formal,19-25
clinical,26-34
studies,35-42
to,43-45
evaluate,46-54
the,55-58
drug,59-63
interactions,64-76
of,77-79
TAXOTERE,80-88	DrugDDI.d115.s0.e0
with,89-93
other,94-99	DrugDDI.d115.s0.e1
medications.,100-112	DrugDDI.d115.s0.e1

In,0-2
vitro,3-8
studies,9-16
have,17-21
shown,22-27
that,28-32
the,33-36
metabolism,37-47
of,48-50
docetaxel,51-60	DrugDDI.d115.s1.e0
may,61-64
be,65-67
modified,68-76
by,77-79
the,80-83
concomitant,84-95
administration,96-110
of,111-113
compounds,114-123
that,124-128
induce,,129-136
inhibit,,137-145
or,146-148
are,149-152
metabolized,153-164
by,165-167
cytochrome,168-178	DrugDDI.d115.s1.e1
P450,179-183	DrugDDI.d115.s1.e1
3A4,,184-188	DrugDDI.d115.s1.e1
such,189-193
as,194-196
cyclosporine,,197-210
terfenadine,,211-223
ketoconazole,,224-237
erythromycin,,238-251
and,252-255
troleandomycin.,256-271	DrugDDI.d115.s1.e6

Caution,0-7
should,8-14
be,15-17
exercised,18-27
with,28-32
these,33-38
drugs,39-44	DrugDDI.d115.s2.e0
when,45-49
treating,50-58
patients,59-67
receiving,68-77
TAXOTERE,78-86	DrugDDI.d115.s2.e1
as,87-89
there,90-95
is,96-98
a,99-100
potential,101-110
for,111-114
a,115-116
significant,117-128
interaction.,129-141

Drug/Laboratory,0-15	DrugDDI.d42.s0.e0
Test,16-20
Interactions,21-33
None,34-38
known.,39-45

Drug-Drug,0-9
Interactions,10-22
Cimetidine:,23-34	DrugDDI.d42.s1.e0
Concomitant,35-46
use,47-50
of,51-53
cimetidine,54-64	DrugDDI.d42.s1.e1
is,65-67
contraindicated.,68-84

Cimetidine,0-10	DrugDDI.d42.s2.e0
at,11-13
400,14-17
mg,18-20
BID,21-24	DrugDDI.d42.s2.e1
(the,25-29
usual,30-35
prescription,36-48
dose),49-54
co-administered,55-70
with,71-75
TIKOSYN,76-83	DrugDDI.d42.s2.e2
(500,84-88
mcg,89-92
BID),93-97	DrugDDI.d42.s2.e3
for,98-101
7,102-103
days,104-108
has,109-112
been,113-117
shown,118-123
to,124-126
increase,127-135
dofetilide,136-146	DrugDDI.d42.s2.e4
plasma,147-153
levels,154-160
by,161-163
58%.,164-168

Cimetidine,0-10	DrugDDI.d42.s3.e0
at,11-13
doses,14-19
of,20-22
100,23-26
mg,27-29
BID,30-33	DrugDDI.d42.s3.e1
(OTC,34-38
dose),39-44
resulted,45-53
in,54-56
a,57-58
13%,59-62
increase,63-71
in,72-74
dofetilide,75-85	DrugDDI.d42.s3.e2
plasma,86-92
levels,93-99
(500,100-104
mcg,105-108
single,109-115
dose).,116-122

No,0-2
studies,3-10
have,11-15
been,16-20
conducted,21-30
at,31-33
intermediate,34-46
doses,47-52
of,53-55
cimetidine.,56-67	DrugDDI.d42.s4.e0

If,0-2
a,3-4
patient,5-12
requires,13-21
TIKOSYN,22-29	DrugDDI.d42.s5.e0
and,30-33
anti-ulcer,34-44
therapy,,45-53
it,54-56
is,57-59
suggested,60-69
that,70-74
omeprazole,,75-86
ranitidine,,87-98
or,99-101
antacids,102-110	DrugDDI.d42.s5.e3
(aluminum,111-120
and,121-124
magnesium,125-134	DrugDDI.d42.s5.e4
hydroxides),135-146	DrugDDI.d42.s5.e4
be,147-149
used,150-154
as,155-157
alternatives,158-170
to,171-173
cimetidine,,174-185
as,186-188
these,189-194
agents,195-201
have,202-206
no,207-209
effect,210-216
on,217-219
the,220-223
pharmacokinetic,224-239
profile,240-247
of,248-250
TIKOSYN.,251-259	DrugDDI.d42.s5.e6

Verapamil:,0-10	DrugDDI.d42.s6.e0
Concomitant,11-22
use,23-26
of,27-29
verapamil,30-39	DrugDDI.d42.s6.e1
is,40-42
contraindicated.,43-59

Co-administration,0-17
of,18-20
TIKOSYN,21-28	DrugDDI.d42.s7.e0
with,29-33
verapamil,34-43	DrugDDI.d42.s7.e1
resulted,44-52
in,53-55
increases,56-65
in,66-68
dofetilide,69-79	DrugDDI.d42.s7.e2
peak,80-84
plasma,85-91
levels,92-98
of,99-101
42%,,102-106
although,107-115
overall,116-123
exposure,124-132
to,133-135
dofetilide,136-146	DrugDDI.d42.s7.e3
was,147-150
not,151-154
significantly,155-168
increased.,169-179

In,0-2
an,3-5
analysis,6-14
of,15-17
the,18-21
supraventricular,22-38
arrhythmia,39-49
and,50-53
DIAMOND,54-61
patient,62-69
populations,,70-82
the,83-86
concomitant,87-98
administration,99-113
of,114-116
verapamil,117-126	DrugDDI.d42.s8.e0
with,127-131
dofetilide,132-142	DrugDDI.d42.s8.e1
was,143-146
associated,147-157
with,158-162
a,163-164
higher,165-171
occurrence,172-182
of,183-185
torsade,186-193
de,194-196
pointes.,197-205

Ketoconazole:,0-13	DrugDDI.d42.s9.e0
Concomitant,14-25
use,26-29
of,30-32
ketoconazole,33-45	DrugDDI.d42.s9.e1
is,46-48
contraindicated.,49-65

Ketoconazole,0-12	DrugDDI.d42.s10.e0
at,13-15
400,16-19
mg,20-22
daily,23-28
(the,29-33
maximum,34-41
approved,42-50
prescription,51-63
dose),64-69
co-administered,70-85
with,86-90
TIKOSYN,91-98	DrugDDI.d42.s10.e1
(500,99-103
mcg,104-107
BID),108-112	DrugDDI.d42.s10.e2
for,113-116
7,117-118
days,119-123
has,124-127
been,128-132
shown,133-138
to,139-141
increase,142-150
dofetilide,151-161	DrugDDI.d42.s10.e3
Cmax,162-166
by,167-169
53%,170-173
in,174-176
males,177-182
and,183-186
97%,187-190
in,191-193
females,,194-202
and,203-206
AUC,207-210
by,211-213
41%,214-217
in,218-220
males,221-226
and,227-230
69%,231-234
in,235-237
females.,238-246

Trimethoprim,0-12	DrugDDI.d42.s11.e0
Alone,13-18
or,19-21
in,22-24
Combination,25-36
with,37-41
Sulfamethoxazole:,42-59	DrugDDI.d42.s11.e1
Concomitant,60-71
use,72-75
of,76-78
trimethoprim,79-91	DrugDDI.d42.s11.e2
alone,92-97
or,98-100
in,101-103
combination,104-115
with,116-120
sulfamethoxazole,121-137	DrugDDI.d42.s11.e3
is,138-140
contraindicated.,141-157

Trimethoprim,0-12	DrugDDI.d42.s12.e0
160,13-16	DrugDDI.d42.s12.e0
mg,17-19	DrugDDI.d42.s12.e0
in,20-22
combination,23-34
with,35-39
800,40-43
mg,44-46
sulfamethoxazole,47-63	DrugDDI.d42.s12.e1
co-administered,64-79
BID,80-83	DrugDDI.d42.s12.e2
with,84-88
TIKOSYN,89-96	DrugDDI.d42.s12.e3
(500,97-101
mcg,102-105
BID),106-110	DrugDDI.d42.s12.e4
for,111-114
4,115-116
days,117-121
has,122-125
been,126-130
shown,131-136
to,137-139
increase,140-148
dofetilide,149-159	DrugDDI.d42.s12.e5
AUC,160-163
by,164-166
103%,167-171
and,172-175
Cmax,176-180
by,181-183
93%.,184-188

Hydrochlorothiazide,0-19	DrugDDI.d42.s13.e0
(HCTZ),20-26
Alone,27-32
or,33-35
in,36-38
Combination,39-50
with,51-55
Triamterene:,56-68	DrugDDI.d42.s13.e2
Concomitant,69-80
use,81-84
of,85-87
HCTZ,88-92	DrugDDI.d42.s13.e3
alone,93-98
or,99-101
in,102-104
combination,105-116
with,117-121
triamterene,122-133	DrugDDI.d42.s13.e4
is,134-136
contraindicated.,137-153

HCTZ,0-4	DrugDDI.d42.s14.e0
50,5-7
mg,8-10
QD,11-13
or,14-16
HCTZ/triamterene,17-33	DrugDDI.d42.s14.e1
50/100,34-40
mg,41-43
QD,44-46
was,47-50
co-administered,51-66
with,67-71
TIKOSYN,72-79	DrugDDI.d42.s14.e3
(500,80-84
mcg,85-88
BID),89-93	DrugDDI.d42.s14.e4
for,94-97
5,98-99
days,100-104
(following,105-115
2,116-117
days,118-122
of,123-125
diuretic,126-134	DrugDDI.d42.s14.e5
use,135-138
at,139-141
half,142-146
dose).,147-153

In,0-2
patients,3-11
receiving,12-21
HCTZ,22-26	DrugDDI.d42.s15.e0
alone,,27-33
dofetilide,34-44
AUC,45-48
increased,49-58
by,59-61
27%,62-65
and,66-69
Cmax,70-74
by,75-77
21%.,78-82

In,0-2
patients,3-11
receiving,12-21
HCTZ,22-26	DrugDDI.d42.s17.e0
in,27-29
combination,30-41
with,42-46
triamterene,,47-59
dofetilide,60-70	DrugDDI.d42.s17.e2
AUC,71-74
increased,75-84
by,85-87
30%,88-91
and,92-95
Cmax,96-100
by,101-103
16%.,104-108

The,0-3
pharmacodynamic,4-19
effects,20-27
can,28-31
be,32-34
explained,35-44
by,45-47
a,48-49
combination,50-61
of,62-64
the,65-68
increase,69-77
in,78-80
dofetilide,81-91	DrugDDI.d42.s19.e0
exposure,92-100
and,101-104
the,105-108
reductions,109-119
in,120-122
serum,123-128
potassium.,129-139

In,0-2
the,3-6
DIAMOND,7-14
trials,,15-22
1252,23-27
patients,28-36
were,37-41
treated,42-49
with,50-54
TIKOSYN,55-62	DrugDDI.d42.s20.e0
and,63-66
diuretics,67-76	DrugDDI.d42.s20.e1
concomitantly,77-90
of,91-93
whom,94-98
493,99-102
died,103-107
compared,108-116
to,117-119
508,120-123
deaths,124-130
among,131-136
the,137-140
1248,141-145
patients,146-154
receiving,155-164
placebo,165-172
and,173-176
diuretics.,177-187	DrugDDI.d42.s20.e2

Of,0-2
the,3-6
229,7-10
patients,11-19
who,20-23
had,24-27
potassium,28-37	DrugDDI.d42.s21.e0
depleting,38-47	DrugDDI.d42.s21.e0
diuretics,48-57	DrugDDI.d42.s21.e0
added,58-63
to,64-66
their,67-72
concomitant,73-84
medications,85-96	DrugDDI.d42.s21.e1
in,97-99
the,100-103
DIAMOND,104-111
trials,,112-119
the,120-123
patients,124-132
on,133-135
TIKOSYN,136-143	DrugDDI.d42.s21.e2
had,144-147
a,148-149
non-significantly,150-167
reduced,168-175
relative,176-184
risk,185-189
for,190-193
death,194-199
of,200-202
0.68,203-207
(95%,208-212
CI,213-215
0.376,,216-222
1.230).,223-230

Potential,0-9
Drug,10-14
Interactions,15-27
Dofetilide,28-38	DrugDDI.d42.s22.e0
is,39-41
eliminated,42-52
in,53-55
the,56-59
kidney,60-66
by,67-69
cationic,70-78	DrugDDI.d42.s22.e1
secretion.,79-89

Inhibitors,0-10
of,11-13
renal,14-19
cationic,20-28	DrugDDI.d42.s23.e0
secretion,29-38
are,39-42
contraindicated,43-58
with,59-63
TIKOSYN.,64-72	DrugDDI.d42.s23.e1

In,0-2
addition,,3-12
drugs,13-18	DrugDDI.d42.s24.e0
that,19-23
are,24-27
actively,28-36
secreted,37-45
via,46-49
this,50-54
route,55-60
(e.g.,,61-67
triamterene,,68-80
metformin,81-90	DrugDDI.d42.s24.e2
and,91-94
amiloride),95-105	DrugDDI.d42.s24.e3
should,106-112
be,113-115
co-administered,116-131
with,132-136
care,137-141
as,142-144
they,145-149
might,150-155
increase,156-164
dofetilide,165-175	DrugDDI.d42.s24.e4
levels.,176-183

Dofetilide,0-10	DrugDDI.d42.s25.e0
is,11-13
metabolized,14-25
to,26-28
a,29-30
small,31-36
extent,37-43
by,44-46
the,47-50
CYP3A4,51-57	DrugDDI.d42.s25.e1
isoenzyme,58-67	DrugDDI.d42.s25.e1
of,68-70
the,71-74
cytochrome,75-85	DrugDDI.d42.s25.e2
P450,86-90	DrugDDI.d42.s25.e2
system.,91-98

Inhibitors,0-10
of,11-13
the,14-17
CYP3A4,18-24	DrugDDI.d42.s26.e0
isoenzyme,25-34	DrugDDI.d42.s26.e0
could,35-40
increase,41-49
systemic,50-58
dofetilide,59-69	DrugDDI.d42.s26.e1
exposure.,70-79

Inhibitors,0-10
of,11-13
this,14-18
isoenzyme,19-28	DrugDDI.d42.s27.e0
(e.g.,,29-35
macrolide,36-45	DrugDDI.d42.s27.e1
antibiotics,,46-58	DrugDDI.d42.s27.e1
azole,59-64
antifungal,65-75	DrugDDI.d42.s27.e2
agents,,76-83	DrugDDI.d42.s27.e2
protease,84-92	DrugDDI.d42.s27.e3
inhibitors,,93-104	DrugDDI.d42.s27.e3
serotonin,105-114	DrugDDI.d42.s27.e4
reuptake,115-123	DrugDDI.d42.s27.e4
inhibitors,,124-135	DrugDDI.d42.s27.e4
amiodarone,,136-147
cannabinoids,,148-161
diltiazem,,162-172
grapefruit,173-183
juice,,184-190
nefazadone,,191-202
norfloxacin,,203-215
quinine,,216-224
zafirlukast),225-237	DrugDDI.d42.s27.e9
should,238-244
be,245-247
cautiously,248-258
coadministered,259-273
with,274-278
TIKOSYN,279-286	DrugDDI.d42.s27.e10
as,287-289
they,290-294
can,295-298
potentially,299-310
increase,311-319
dofetilide,320-330	DrugDDI.d42.s27.e11
levels.,331-338

Dofetilide,0-10	DrugDDI.d42.s28.e0
is,11-13
not,14-17
an,18-20
inhibitor,21-30
of,31-33
CYP3A4,34-40	DrugDDI.d42.s28.e1
nor,41-44
of,45-47
other,48-53
cytochrome,54-64	DrugDDI.d42.s28.e2
P450,65-69	DrugDDI.d42.s28.e2
isoenzymes,70-80
(e.g.,,81-87
CYP2C9,,88-95
CYP2D6),96-103	DrugDDI.d42.s28.e4
and,104-107
is,108-110
not,111-114
expected,115-123
to,124-126
increase,127-135
levels,136-142
of,143-145
drugs,146-151	DrugDDI.d42.s28.e5
metabolized,152-163
by,164-166
CYP3A4.,167-174	DrugDDI.d42.s28.e6

Other,0-5
Drug,6-10
Interaction,11-22
Information,23-34
Digoxin:,35-43	DrugDDI.d42.s29.e0
Studies,44-51
in,52-54
healthy,55-62
volunteers,63-73
have,74-78
shown,79-84
that,85-89
TIKOSYN,90-97	DrugDDI.d42.s29.e1
does,98-102
not,103-106
affect,107-113
the,114-117
pharmacokinetics,118-134
of,135-137
digoxin.,138-146	DrugDDI.d42.s29.e2

In,0-2
patients,,3-12
the,13-16
concomitant,17-28
administration,29-43
of,44-46
digoxin,47-54	DrugDDI.d42.s30.e0
with,55-59
dofetilide,60-70	DrugDDI.d42.s30.e1
was,71-74
associated,75-85
with,86-90
a,91-92
higher,93-99
occurrence,100-110
of,111-113
torsade,114-121
de,122-124
pointes.,125-133

It,0-2
is,3-5
not,6-9
clear,10-15
whether,16-23
this,24-28
represents,29-39
an,40-42
interaction,43-54
with,55-59
TIKOSYN,60-67	DrugDDI.d42.s31.e0
or,68-70
the,71-74
presence,75-83
of,84-86
more,87-91
severe,92-98
structural,99-109
heart,110-115
disease,116-123
in,124-126
patients,127-135
on,136-138
digoxin;,139-147	DrugDDI.d42.s31.e1

No,0-2
increase,3-11
in,12-14
mortality,15-24
was,25-28
observed,29-37
in,38-40
patients,41-49
taking,50-56
digoxin,57-64	DrugDDI.d42.s33.e0
as,65-67
concomitant,68-79
medication.,80-91	DrugDDI.d42.s33.e1

Other,0-5
Drugs:,6-12	DrugDDI.d42.s34.e0
In,13-15
healthy,16-23
volunteers,,24-35
amlodipine,,36-47
phenytoin,,48-58
glyburide,,59-69
ranitidine,,70-81
omeprazole,,82-93
hormone,94-101
replacement,102-113
therapy,114-121
(a,122-124
combination,125-136
of,137-139
conjugated,140-150
estrogens,151-160	DrugDDI.d42.s34.e6
and,161-164
medroxyprogesterone),,165-186
antacid,187-194	DrugDDI.d42.s34.e8
(aluminum,195-204
and,205-208
magnesium,209-218	DrugDDI.d42.s34.e9
hydroxides),219-230	DrugDDI.d42.s34.e9
and,231-234
theophylline,235-247	DrugDDI.d42.s34.e10
did,248-251
not,252-255
affect,256-262
the,263-266
pharmacokinetics,267-283
of,284-286
TIKOSYN.,287-295	DrugDDI.d42.s34.e11

In,0-2
addition,,3-12
studies,13-20
in,21-23
healthy,24-31
volunteers,32-42
have,43-47
shown,48-53
that,54-58
TIKOSYN,59-66	DrugDDI.d42.s35.e0
does,67-71
not,72-75
affect,76-82
the,83-86
pharmacokinetics,87-103
or,104-106
pharmacodynamics,107-123
of,124-126
warfarin,,127-136
or,137-139
the,140-143
pharmacokinetics,144-160
of,161-163
propranolol,164-175	DrugDDI.d42.s35.e2
(40,176-179
mg,180-182
twice,183-188
daily),,189-196
phenytoin,,197-207
theophylline,,208-221
or,222-224
oral,225-229	DrugDDI.d42.s35.e5
contraceptives.,230-245	DrugDDI.d42.s35.e5

Population,0-10
pharmacokinetic,11-26
analyses,27-35
were,36-40
conducted,41-50
on,51-53
plasma,54-60
concentration,61-74
data,75-79
from,80-84
1445,85-89
patients,90-98
in,99-101
clinical,102-110
trials,111-117
to,118-120
examine,121-128
the,129-132
effects,133-140
of,141-143
concomitant,144-155
medications,156-167	DrugDDI.d42.s36.e0
on,168-170
clearance,171-180
or,181-183
volume,184-190
of,191-193
distribution,194-206
of,207-209
dofetilide.,210-221	DrugDDI.d42.s36.e1

Concomitant,0-11
medications,12-23	DrugDDI.d42.s37.e0
were,24-28
grouped,29-36
as,37-39
ACE,40-43	DrugDDI.d42.s37.e1
inhibitors,,44-55	DrugDDI.d42.s37.e1
oral,56-60	DrugDDI.d42.s37.e2
anticoagulants,,61-76	DrugDDI.d42.s37.e2
calcium,77-84	DrugDDI.d42.s37.e3
channel,85-92	DrugDDI.d42.s37.e3
blockers,,93-102	DrugDDI.d42.s37.e3
beta,103-107	DrugDDI.d42.s37.e4
blockers,,108-117	DrugDDI.d42.s37.e4
cardiac,118-125	DrugDDI.d42.s37.e5
glycosides,,126-137	DrugDDI.d42.s37.e5
inducers,138-146
of,147-149
CYP3A4,,150-157
substrates,158-168
and,169-172
inhibitors,173-183
of,184-186
CYP3A4,,187-194
substrates,195-205
and,206-209
inhibitors,210-220
of,221-223
P-glycoprotein,,224-239
nitrates,,240-249
sulphonylureas,,250-265
loop,266-270	DrugDDI.d42.s37.e11
diuretics,,271-281	DrugDDI.d42.s37.e11
potassium,282-291	DrugDDI.d42.s37.e12
sparing,292-299	DrugDDI.d42.s37.e12
diuretics,,300-310	DrugDDI.d42.s37.e12
thiazide,311-319	DrugDDI.d42.s37.e13
diuretics,,320-330	DrugDDI.d42.s37.e13
substrates,331-341
and,342-345
inhibitors,346-356
of,357-359
tubular,360-367
organic,368-375
cation,376-382
transport,,383-393
and,394-397
QTc-prolonging,398-412
drugs.,413-419	DrugDDI.d42.s37.e14

Differences,0-11
in,12-14
clearance,15-24
between,25-32
patients,33-41
on,42-44
these,45-50
medications,51-62	DrugDDI.d42.s38.e0
(at,63-66
any,67-70
occasion,71-79
in,80-82
the,83-86
study),87-93
and,94-97
those,98-103
off,104-107
medications,108-119	DrugDDI.d42.s38.e1
varied,120-126
between,127-134
-16%,135-139
and,140-143
+3%.,144-148

The,0-3
mean,4-8
clearances,9-19
of,20-22
dofetilide,23-33	DrugDDI.d42.s39.e0
were,34-38
16%,39-42
and,43-46
15%,47-50
lower,51-56
in,57-59
patients,60-68
on,69-71
thiazide,72-80	DrugDDI.d42.s39.e1
diuretics,81-90	DrugDDI.d42.s39.e1
and,91-94
inhibitors,95-105
of,106-108
tubular,109-116
organic,117-124
cation,125-131
transport,,132-142
respectively.,143-156

The,0-3
potential,4-13
for,14-17
clinically,18-28
significant,29-40
drug-drug,41-50
interactions,51-63
posed,64-69
by,70-72
dolasetron,73-83	DrugDDI.d426.s0.e0
and,84-87
hydrodolasetron,88-103
appears,104-111
to,112-114
be,115-117
low,118-121
for,122-125
drugs,126-131	DrugDDI.d426.s0.e1
commonly,132-140
used,141-145
in,146-148
chemotherapy,149-161
or,162-164
surgery,,165-173
because,174-181
hydrodolasetron,182-197
is,198-200
eliminated,201-211
by,212-214
multiple,215-223
routes.,224-231

Blood,0-5
levels,6-12
of,13-15
hydrodolasetron,16-31
increased,32-41
24%,42-45
when,46-50
dolasetron,51-61
was,62-65
coadministered,66-80
with,81-85
cimetidine,86-96	DrugDDI.d426.s1.e1
(nonselective,97-110
inhibitor,111-120
of,121-123
cytochrome,124-134	DrugDDI.d426.s1.e2
P-450),135-141	DrugDDI.d426.s1.e2
for,142-145
7,146-147
days,,148-153
and,154-157
decreased,158-167
28%,168-171
with,172-176
coadministration,177-193
of,194-196
rifampin,197-205	DrugDDI.d426.s1.e3
(potent,206-213
inducer,214-221
of,222-224
cytochrome,225-235	DrugDDI.d426.s1.e4
P-450),236-242	DrugDDI.d426.s1.e4
for,243-246
7,247-248
days.,249-254

Dolasetron,0-10	DrugDDI.d426.s2.e0
has,11-14
been,15-19
safely,20-26
coadministered,27-41
with,42-46
drugs,47-52	DrugDDI.d426.s2.e1
used,53-57
in,58-60
chemotherapy,61-73
and,74-77
surgery.,78-86

As,0-2
with,3-7
other,8-13
agents,14-20
which,21-26
prolong,27-34
ECG,35-38
intervals,,39-49
caution,50-57
should,58-64
be,65-67
exercised,68-77
in,78-80
patients,81-89
taking,90-96
drugs,97-102	DrugDDI.d426.s3.e0
which,103-108
prolong,109-116
ECG,117-120
intervals,,121-131
particularly,132-144
QTc.,145-149

In,0-2
patients,3-11
taking,12-18
furosemide,,19-30
nifedipine,,31-42
diltiazem,,43-53
ACE,54-57	DrugDDI.d426.s4.e3
inhibitors,,58-69	DrugDDI.d426.s4.e3
verapamil,,70-80
glyburide,,81-91
propranolol,,92-104
and,105-108
various,109-116
chemotherapy,117-129	DrugDDI.d426.s4.e7
agents,,130-137	DrugDDI.d426.s4.e7
no,138-140
effect,141-147
was,148-151
shown,152-157
on,158-160
the,161-164
clearance,165-174
of,175-177
hydrodolasetron.,178-194

Clearance,0-9
of,10-12
hydrodolasetron,13-28
decreased,29-38
by,39-41
about,42-47
27%,48-51
when,52-56
dolasetron,57-67	DrugDDI.d426.s5.e0
mesylate,68-76	DrugDDI.d426.s5.e0
was,77-80
administered,81-93
intravenously,94-107
concomitantly,108-121
with,122-126
atenolol.,127-136	DrugDDI.d426.s5.e1

Dolasetron,0-10	DrugDDI.d426.s6.e0
does,11-15
not,16-19
influence,20-29
anesthesia,30-40
recovery,41-49
time,50-54
in,55-57
patients.,58-67

Dolasetron,0-10	DrugDDI.d426.s7.e0
mesylate,11-19	DrugDDI.d426.s7.e0
did,20-23
not,24-27
inhibit,28-35
the,36-39
antitumor,40-49
activity,50-58
of,59-61
four,62-66
chemotherapeutic,67-83	DrugDDI.d426.s7.e1
agents,84-90	DrugDDI.d426.s7.e1
(cisplatin,,91-102
5-fluorouracil,,103-118
doxorubicin,,119-131
cyclophosphamide),132-149	DrugDDI.d426.s7.e5
in,150-152
four,153-157
murine,158-164
models.,165-172

Drugs,0-5	DrugDDI.d229.s0.e0
that,6-10
inhibit,11-18
or,19-21
Induce,22-28
CYP,29-32	DrugDDI.d229.s0.e1
2D6,33-36	DrugDDI.d229.s0.e1
and,37-40
CYP,41-44	DrugDDI.d229.s0.e2
3A4,45-48
may,49-52
affect,53-59
the,60-63
concentration,64-77
on,78-80
Aricept.,81-89	DrugDDI.d229.s0.e3

Because,0-7
dopamine,8-16	DrugDDI.d307.s0.e0
is,17-19
metabolized,20-31
by,32-34
monoamine,35-44	DrugDDI.d307.s0.e1
oxidase,45-52	DrugDDI.d307.s0.e1
(MAO),,53-59
inhibition,60-70
of,71-73
this,74-78
enzyme,79-85
prolongs,86-94
and,95-98
potentiates,99-110
the,111-114
effect,115-121
of,122-124
dopamine.,125-134	DrugDDI.d307.s0.e2

Patients,0-8
who,9-12
have,13-17
been,18-22
treated,23-30
with,31-35
MAO,36-39	DrugDDI.d307.s1.e0
inhibitors,40-50	DrugDDI.d307.s1.e0
within,51-57
two,58-61
to,62-64
three,65-70
weeks,71-76
prior,77-82
to,83-85
the,86-89
administration,90-104
of,105-107
dopamine,108-116	DrugDDI.d307.s1.e1
HCl,117-120	DrugDDI.d307.s1.e1
should,121-127
receive,128-135
initial,136-143
doses,144-149
of,150-152
dopamine,153-161	DrugDDI.d307.s1.e2
HCl,162-165	DrugDDI.d307.s1.e2
no,166-168
greater,169-176
than,177-181
one-tenth,182-191
(1/10),192-198
of,199-201
the,202-205
usual,206-211
dose.,212-217

Concurrent,0-10
administration,11-25
of,26-28
low-dose,29-37
dopamine,38-46	DrugDDI.d307.s2.e0
HCl,47-50	DrugDDI.d307.s2.e0
and,51-54
diuretic,55-63	DrugDDI.d307.s2.e1
agents,64-70
may,71-74
produce,75-82
an,83-85
additive,86-94
or,95-97
potentiating,98-110
effect,111-117
on,118-120
urine,121-126
flow.,127-132

Tricyclic,0-9	DrugDDI.d307.s3.e0
antidepressants,10-25	DrugDDI.d307.s3.e0
may,26-29
potentiate,30-40
the,41-44
cardiovascular,45-59
effects,60-67
of,68-70
adreneric,71-80
agents.,81-88

Cardiac,0-7
effects,8-15
of,16-18
dopamine,19-27	DrugDDI.d307.s4.e0
are,28-31
antagonized,32-43
by,44-46
beta-adrenergic,47-62	DrugDDI.d307.s4.e1
blocking,63-71	DrugDDI.d307.s4.e1
agents,,72-79	DrugDDI.d307.s4.e1
such,80-84
as,85-87
propranolol,88-99	DrugDDI.d307.s4.e2
and,100-103
metoprolol.,104-115	DrugDDI.d307.s4.e3

The,0-3
peripheral,4-14
vasoconstriction,15-31
caused,32-38
by,39-41
high,42-46
doses,47-52
of,53-55
dopamine,56-64	DrugDDI.d307.s5.e0
HCl,65-68	DrugDDI.d307.s5.e0
is,69-71
antagonized,72-83
by,84-86
alpha-adrenergic,87-103	DrugDDI.d307.s5.e1
blocking,104-112	DrugDDI.d307.s5.e1
agents.,113-120	DrugDDI.d307.s5.e1

Dopamine-induced,0-16	DrugDDI.d307.s6.e0
renal,17-22
and,23-26
mesenteric,27-37
vasodilation,38-50
is,51-53
not,54-57
antagonized,58-69
by,70-72
either,73-79
alpha-or,80-88
beta-adrenergic,89-104	DrugDDI.d307.s6.e1
blocking,105-113	DrugDDI.d307.s6.e1
agents.,114-121	DrugDDI.d307.s6.e1

Butyrophenones,0-14	DrugDDI.d307.s7.e0
(such,15-20
as,21-23
haloperidol),24-36	DrugDDI.d307.s7.e1
and,37-40
phenothiazines,41-55	DrugDDI.d307.s7.e2
can,56-59
suppress,60-68
the,69-72
dopaminergic,73-85
renal,86-91
and,92-95
mesenteric,96-106
vasodilation,107-119
induced,120-127
with,128-132
low,133-136
dose,137-141
dopamine,142-150	DrugDDI.d307.s7.e3
infusion.,151-160

Cyclopropane,0-12	DrugDDI.d307.s8.e0
or,13-15
halogenated,16-27	DrugDDI.d307.s8.e1
hydrocarbon,28-39	DrugDDI.d307.s8.e1
anesthetics,40-51	DrugDDI.d307.s8.e1
increase,52-60
cardiac,61-68
autonomic,69-78
irritability,79-91
and,92-95
may,96-99
sensitize,100-109
the,110-113
myocardium,114-124
to,125-127
the,128-131
action,132-138
of,139-141
certain,142-149
intravenously,150-163
administered,164-176
catecholamines,,177-192
such,193-197
as,198-200
dopamine.,201-210	DrugDDI.d307.s8.e2

This,0-4
interaction,5-16
appears,17-24
to,25-27
be,28-30
related,31-38
both,39-43
to,44-46
pressor,47-54	DrugDDI.d307.s9.e0
activity,55-63
and,64-67
to,68-70
beta-adrenergic,71-86
stimulating,87-98
properties,99-109
of,110-112
these,113-118
catecholamines,119-133
and,134-137
may,138-141
produce,142-149
ventricular,150-161
arrhythmias,162-173
and,174-177
hypertension.,178-191

Therefore,,0-10
EXTREME,11-18
CAUTION,19-26
should,27-33
be,34-36
exercised,37-46
when,47-51
administering,52-65
dopamine,66-74	DrugDDI.d307.s10.e0
HCl,75-78	DrugDDI.d307.s10.e0
to,79-81
patients,82-90
receiving,91-100
cyclopropane,101-113	DrugDDI.d307.s10.e1
or,114-116
halogenated,117-128	DrugDDI.d307.s10.e2
hydrocarbon,129-140	DrugDDI.d307.s10.e2
anesthetics.,141-153	DrugDDI.d307.s10.e2

It,0-2
has,3-6
been,7-11
reported,12-20
that,21-25
results,26-33
of,34-36
studies,37-44
in,45-47
animals,48-55
indicate,56-64
that,65-69
dopamine-induced,70-86	DrugDDI.d307.s11.e0
ventricular,87-98
arrhythmias,99-110
during,111-117
anesthesia,118-128
can,129-132
be,133-135
reversed,136-144
by,145-147
propranolol.,148-160	DrugDDI.d307.s11.e1

The,0-3
concomitant,4-15
use,16-19
of,20-22
vasopressors,,23-36
vasoconstricting,37-53
agents,54-60
(such,61-66
as,67-69
ergonovine),70-81	DrugDDI.d307.s12.e1
and,82-85
some,86-90
oxytocic,91-99	DrugDDI.d307.s12.e2
drugs,100-105	DrugDDI.d307.s12.e2
may,106-109
result,110-116
in,117-119
severe,120-126
hypertension.,127-140

Administration,0-14
of,15-17
phenytoin,18-27	DrugDDI.d307.s13.e0
to,28-30
patients,31-39
receiving,40-49
dopamine,50-58	DrugDDI.d307.s13.e1
HCl,59-62	DrugDDI.d307.s13.e1
has,63-66
been,67-71
reported,72-80
to,81-83
lead,84-88
to,89-91
hypotension,92-103
and,104-107
bradycardia.,108-120

It,0-2
is,3-5
suggested,6-15
that,16-20
in,21-23
patients,24-32
receiving,33-42
dopamine,43-51	DrugDDI.d307.s14.e0
HCl,,52-56	DrugDDI.d307.s14.e0
alternatives,57-69
to,70-72
phenytoin,73-82	DrugDDI.d307.s14.e1
should,83-89
be,90-92
used,93-97
if,98-100
anticonvulsant,101-115
therapy,116-123
is,124-126
needed.,127-134

Clinical,0-8
trials,9-15
have,16-20
indicated,21-30
that,31-35
Pulmozyme,36-45	DrugDDI.d194.s0.e0
can,46-49
be,50-52
effectively,53-64
and,65-68
safely,69-75
used,76-80
in,81-83
conjunction,84-95
with,96-100
standard,101-109
cystic,110-116
fibrosis,117-125
therapies,126-135
including,136-145
oral,,146-151
inhaled,152-159
and/or,160-166
parenteral,167-177
antibiotics,,178-190
bronchodilators,,191-207
enzyme,208-214
supplements,,215-227
vitamins,,228-237
oral,238-242
or,243-245
inhaled,246-253
corticosteroids,,254-270
and,271-274
analgesics.,275-286	DrugDDI.d194.s0.e5

Although,0-8
acid-base,9-18
and,19-22
electrolyte,23-34
disturbances,35-47
were,48-52
not,53-56
reported,57-65
in,66-68
the,69-72
clinical,73-81
trials,82-88
with,89-93
dorzolamide,,94-106
these,107-112
disturbances,113-125
have,126-130
been,131-135
reported,136-144
with,145-149
oral,150-154
carbonic,155-163	DrugDDI.d290.s0.e1
anhydrase,164-173	DrugDDI.d290.s0.e1
inhibitors,174-184	DrugDDI.d290.s0.e1
and,185-188
have,,189-194
in,195-197
some,198-202
instances,,203-213
resulted,214-222
in,223-225
drug,226-230
interactions,231-243
(e.g.,,244-250
toxicity,251-259
associated,260-270
with,271-275
high-dose,276-285
salicylate,286-296	DrugDDI.d290.s0.e2
therapy).,297-306

Therefore,,0-10
the,11-14
potential,15-24
for,25-28
such,29-33
drug,34-38
interactions,39-51
should,52-58
be,59-61
considered,62-72
in,73-75
patients,76-84
receiving,85-94
dorzolamide.,95-107	DrugDDI.d290.s1.e0

Prior,0-5
administration,6-20
of,21-23
succinylcholine,24-39	DrugDDI.d200.s0.e0
has,40-43
no,44-46
clinically,47-57
important,58-67
effect,68-74
on,75-77
the,78-81
neuromuscular,82-95
blocking,96-104
action,105-111
of,112-114
NUROMAX.,115-123	DrugDDI.d200.s0.e1

The,0-3
use,4-7
of,8-10
NUROMAX,11-18	DrugDDI.d200.s1.e0
before,19-25
succinylcholine,26-41	DrugDDI.d200.s1.e1
to,42-44
attenuate,45-54
some,55-59
of,60-62
the,63-66
side,67-71
effects,72-79
of,80-82
succinylcholine,83-98	DrugDDI.d200.s1.e2
has,99-102
not,103-106
been,107-111
studied.,112-120

There,0-5
are,6-9
no,10-12
clinical,13-21
data,22-26
on,27-29
concomitant,30-41
use,42-45
of,46-48
NUROMAX,49-56	DrugDDI.d200.s2.e0
and,57-60
other,61-66
nondepolarizing,67-82
neuromuscular,83-96	DrugDDI.d200.s2.e1
blocking,97-105	DrugDDI.d200.s2.e1
agents.,106-113	DrugDDI.d200.s2.e1

Isoflurane,,0-11
enflurane,,12-22
and,23-26
halothane,27-36	DrugDDI.d200.s3.e2
decrease,37-45
the,46-49
ED50,50-54
of,55-57
NUROMAX,58-65	DrugDDI.d200.s3.e3
by,66-68
30%,69-72
to,73-75
45%.,76-80

Other,0-5
drugs,6-11	DrugDDI.d200.s5.e0
which,12-17
may,18-21
enhance,22-29
the,30-33
neuromuscular,34-47
blocking,48-56
action,57-63
of,64-66
nondepolarizing,67-82	DrugDDI.d200.s5.e1
agents,83-89	DrugDDI.d200.s5.e1
such,90-94
as,95-97
NUROMAX,98-105	DrugDDI.d200.s5.e2
include,106-113
certain,114-121
antibiotics,122-133	DrugDDI.d200.s5.e3
(e.,134-137
g.,,138-141
aminoglycosides,,142-158
tetracyclines,,159-173
bacitracin,,174-185
polymyxins,,186-197
lincomycin,,198-209
clindamycin,,210-222
colistin,,223-232
and,233-236
sodium,237-243	DrugDDI.d200.s5.e11
colistimethate),,244-260
magnesium,261-270	DrugDDI.d200.s5.e12
salts,,271-277	DrugDDI.d200.s5.e12
lithium,,278-286
local,287-292	DrugDDI.d200.s5.e14
anesthetics,,293-305	DrugDDI.d200.s5.e14
procainamide,,306-319
and,320-323
quinidine.,324-334	DrugDDI.d200.s5.e16

As,0-2
with,3-7
some,8-12
other,13-18
nondepolarizing,19-34
neuromuscular,35-48	DrugDDI.d200.s6.e0
blocking,49-57	DrugDDI.d200.s6.e0
agents,,58-65	DrugDDI.d200.s6.e0
the,66-69
time,70-74
of,75-77
onset,78-83
of,84-86
neuromuscular,87-100
block,101-106
induced,107-114
by,115-117
NUROMAX,118-125	DrugDDI.d200.s6.e1
is,126-128
lengthened,129-139
and,140-143
the,144-147
duration,148-156
of,157-159
block,160-165
is,166-168
shortened,169-178
in,179-181
patients,182-190
receiving,191-200
phenytoin,201-210	DrugDDI.d200.s6.e2
or,211-213
carbamazepine.,214-228	DrugDDI.d200.s6.e3

Administration,0-14
of,15-17
doxapram,18-26	DrugDDI.d313.s0.e0
to,27-29
patients,30-38
who,39-42
are,43-46
receiving,47-56
sympathomimetic,57-72	DrugDDI.d313.s0.e1
or,73-75
monoamine,76-85	DrugDDI.d313.s0.e2
oxidase,86-93	DrugDDI.d313.s0.e2
inhibiting,94-104
drugs,105-110
may,111-114
result,115-121
in,122-124
an,125-127
additive,128-136	DrugDDI.d313.s0.e3
pressor,137-144	DrugDDI.d313.s0.e3
effect,145-151	DrugDDI.d313.s0.e3
.,152-153

In,0-2
patients,3-11
who,12-15
have,16-20
received,21-29
muscle,30-36	DrugDDI.d313.s1.e0
relaxants,,37-47	DrugDDI.d313.s1.e0
doxapram,48-56	DrugDDI.d313.s1.e1
may,57-60
temporarily,61-72
mask,73-77
the,78-81
residual,82-90
effects,91-98
of,99-101
muscle,102-108
relaxant,109-117
drugs.,118-124	DrugDDI.d313.s1.e2

In,0-2
patients,3-11
who,12-15
have,16-20
received,21-29
general,30-37
anesthesia,38-48
utilizing,49-58
a,59-60
volatile,61-69
agent,70-75
known,76-81
to,82-84
sensitize,85-94
the,95-98
myocardium,99-109
to,110-112
catecholamines,,113-128
administration,129-143
of,144-146
doxapram,147-155	DrugDDI.d313.s2.e0
should,156-162
be,163-165
delayed,166-173
until,174-179
the,180-183
volatile,184-192
agent,193-198
has,199-202
been,203-207
excreted,208-216
in,217-219
order,220-225
to,226-228
lessen,229-235
the,236-239
potential,240-249
for,250-253
arrhythmias,,254-266
including,267-276
ventricular,277-288
tachycardia,289-300
and,301-304
ventricular,305-316
fibrillation.,317-330

Most,0-4
(98%),5-10
of,11-13
plasma,14-20
doxazosin,21-30	DrugDDI.d483.s0.e0
is,31-33
protein,34-41	DrugDDI.d483.s0.e1
bound.,42-48

In,0-2
vitro,3-8
data,9-13
in,14-16
human,17-22	DrugDDI.d483.s1.e0
plasma,23-29	DrugDDI.d483.s1.e0
indicate,30-38
that,39-43
doxazosin,44-53	DrugDDI.d483.s1.e1
mesylate,54-62	DrugDDI.d483.s1.e1
has,63-66
no,67-69
effect,70-76
on,77-79
protein,80-87
binding,88-95
of,96-98
digoxin,,99-107
warfarin,,108-117
phenytoin,118-127	DrugDDI.d483.s1.e4
or,128-130
indomethacin.,131-144	DrugDDI.d483.s1.e5

There,0-5
is,6-8
no,9-11
information,12-23
on,24-26
the,27-30
effect,31-37
of,38-40
other,41-46
highly,47-53
plasma,54-60
protein,61-68
bound,69-74
drugs,75-80
on,81-83
doxazosin,84-93	DrugDDI.d483.s2.e0
binding.,94-102

Doxazosin,0-9	DrugDDI.d483.s3.e0
mesylate,10-18	DrugDDI.d483.s3.e0
has,19-22
been,23-27
administered,28-40
without,41-48
any,49-52
evidence,53-61
of,62-64
an,65-67
adverse,68-75
drug,76-80
interaction,81-92
to,93-95
patients,96-104
receiving,105-114
thiazide,115-123	DrugDDI.d483.s3.e1
diuretics,,124-134	DrugDDI.d483.s3.e1
beta-blocking,135-148	DrugDDI.d483.s3.e2
agents,,149-156	DrugDDI.d483.s3.e2
and,157-160
nonsteroidal,161-173	DrugDDI.d483.s3.e3
anti-inflammatory,174-191	DrugDDI.d483.s3.e3
drugs.,192-198	DrugDDI.d483.s3.e3

In,0-2
a,3-4
placebo-controlled,5-23
trial,24-29
in,30-32
normal,33-39
volunteers,,40-51
the,52-55
administration,56-70
of,71-73
a,74-75
single,76-82
1,83-84
mg,85-87
dose,88-92
of,93-95
doxazosin,96-105	DrugDDI.d483.s4.e0
on,106-108
day,109-112
1,113-114
of,115-117
a,118-119
four-day,120-128
regimen,129-136
of,137-139
oral,140-144	DrugDDI.d483.s4.e1
cimetidine,145-155	DrugDDI.d483.s4.e1
(400,156-160
mg,161-163
twice,164-169
daily),170-176
resulted,177-185
in,186-188
a,189-190
10%,191-194
increase,195-203
in,204-206
mean,207-211
AUC,212-215
of,216-218
doxazosin,219-228	DrugDDI.d483.s4.e2
(p=0.006),,229-239
and,240-243
a,244-245
slight,246-252
but,253-256
not,257-260
statistically,261-274
significant,275-286
increase,287-295
in,296-298
mean,299-303
Cmax,304-308
and,309-312
mean,313-317
half-life,318-327
of,328-330
doxazosin.,331-341	DrugDDI.d483.s4.e3

The,0-3
clinical,4-12
significance,13-25
of,26-28
this,29-33
increase,34-42
in,43-45
doxazosin,46-55	DrugDDI.d483.s5.e0
AUC,56-59
is,60-62
unknown.,63-71

In,0-2
clinical,3-11
trials,,12-19
doxazosin,20-29	DrugDDI.d483.s6.e0
mesylate,30-38	DrugDDI.d483.s6.e0
tablets,39-46
have,47-51
been,52-56
administered,57-69
to,70-72
patients,73-81
on,82-84
a,85-86
variety,87-94
of,95-97
concomitant,98-109
medications;,110-122	DrugDDI.d483.s6.e1

Doxazosin,0-9	DrugDDI.d483.s8.e0
mesylate,10-18	DrugDDI.d483.s8.e0
tablets,19-26
have,27-31
been,32-36
used,37-41
with,42-46
the,47-50
following,51-60
drugs,61-66	DrugDDI.d483.s8.e1
or,67-69
drug,70-74	DrugDDI.d483.s8.e2
classes:,75-83
1.,84-86

Analgesic/anti-inflammatory,0-27	DrugDDI.d483.s9.e0
(e.g.,,28-34
acetaminophen,,35-49
aspirin,,50-58
codeine,59-66	DrugDDI.d483.s9.e3
and,67-70
codeine,71-78	DrugDDI.d483.s9.e4
combinations,,79-92
ibuprofen,,93-103
indomethacin).,104-118	DrugDDI.d483.s9.e6

Antibiotics,0-11	DrugDDI.d483.s11.e0
(e.g.,,12-18
erythromycin,,19-32
trimethoprim,33-45	DrugDDI.d483.s11.e2
and,46-49
sulfamethoxazole,,50-67
amoxicillin).,68-81	DrugDDI.d483.s11.e4

Antihistamines,0-14	DrugDDI.d483.s13.e0
(e.g.,,15-21
chlorpheniramine).,22-40	DrugDDI.d483.s13.e1

Cardiovascular,0-14	DrugDDI.d483.s15.e0
agents,15-21	DrugDDI.d483.s15.e0
(e.g.,,22-28
atenolol,,29-38
hydrochlorothiazide,,39-59
propranolol).,60-73	DrugDDI.d483.s15.e3

Corticosteroids.,0-16	DrugDDI.d483.s17.e0

Gastrointestinal,0-16	DrugDDI.d483.s19.e0
agents,17-23	DrugDDI.d483.s19.e0
(e.g.,,24-30
antacids).,31-41	DrugDDI.d483.s19.e1

Hypoglycemics,0-13	DrugDDI.d483.s21.e0
and,14-17
endocrine,18-27	DrugDDI.d483.s21.e1
drugs.,28-34	DrugDDI.d483.s21.e1

Sedatives,0-9	DrugDDI.d483.s23.e0
and,10-13
tranquilizers,14-27	DrugDDI.d483.s23.e1
(e.g.,,28-34
diazepam).,35-45	DrugDDI.d483.s23.e2

Cold,0-4
and,5-8
flu,9-12
remedies.,13-22	DrugDDI.d483.s25.e0

Drugs,0-5	DrugDDI.d372.s0.e0
Metabolized,6-17
by,18-20
P450,21-25	DrugDDI.d372.s0.e1
2D6:,26-30	DrugDDI.d372.s0.e1
The,31-34
biochemical,35-46
activity,47-55
of,56-58
the,59-62
drug,63-67	DrugDDI.d372.s0.e2
metabolizing,68-80
isozyme,81-88
cytochrome,89-99
P450,100-104
2D6,105-108
(debrisoquin,109-121
hydroxylase),122-134
is,135-137
reduced,138-145
in,146-148
a,149-150
subset,151-157
of,158-160
the,161-164
Caucasian,165-174
population,175-185
(about,186-192
7-10%,193-198
of,199-201
Caucasians,202-212
are,213-216
so-called,217-226
poor,227-231
metabolizers);,232-246

reliable,0-8
estimates,9-18
of,19-21
the,22-25
prevalence,26-36
of,37-39
reduced,40-47
P450,48-52	DrugDDI.d372.s1.e0
2D6,53-56	DrugDDI.d372.s1.e0
isozyme,57-64	DrugDDI.d372.s1.e0
activity,65-73
among,74-79
Asian,,80-86
African,87-94
and,95-98
other,99-104
populations,105-116
are,117-120
not,121-124
yet,125-128
available.,129-139

Poor,0-4
metabolizers,5-17
have,18-22
higher,23-29
than,30-34
expected,35-43
plasma,44-50
concentrations,51-65
of,66-68
tricyclic,69-78	DrugDDI.d372.s2.e0
antidepressants,79-94	DrugDDI.d372.s2.e0
(TCAs),95-101
when,102-106
given,107-112
usual,113-118
doses.,119-125

Depending,0-9
on,10-12
the,13-16
fraction,17-25
of,26-28
drug,29-33	DrugDDI.d372.s3.e0
metabolized,34-45
by,46-48
P450,49-53	DrugDDI.d372.s3.e1
2D6,,54-58	DrugDDI.d372.s3.e1
the,59-62
increase,63-71
in,72-74
plasma,75-81
concentration,82-95
may,96-99
be,100-102
small,,103-109
or,110-112
quite,113-118
large,119-124
(8-fold,125-132
increase,133-141
in,142-144
plasma,145-151
AUC,152-155
of,156-158
the,159-162
TCA).,163-168

In,0-2
addition,,3-12
certain,13-20
drugs,21-26	DrugDDI.d372.s4.e0
inhibit,27-34
the,35-38
activity,39-47
of,48-50
this,51-55
isozyme,56-63	DrugDDI.d372.s4.e1
and,64-67
make,68-72
normal,73-79
metabolizers,80-92
resemble,93-101
poor,102-106
metabolizers.,107-120

An,0-2
individual,3-13
who,14-17
is,18-20
stable,21-27
on,28-30
a,31-32
given,33-38
dose,39-43
of,44-46
TCA,47-50
may,51-54
become,55-61
abruptly,62-70
toxic,71-76
when,77-81
given,82-87
one,88-91
of,92-94
these,95-100
inhibiting,101-111
drugs,112-117	DrugDDI.d372.s5.e0
as,118-120
concomitant,121-132
therapy.,133-141

The,0-3
drugs,4-9	DrugDDI.d372.s6.e0
that,10-14
inhibit,15-22
cytochrome,23-33	DrugDDI.d372.s6.e1
P450,34-38	DrugDDI.d372.s6.e1
2D6,39-42	DrugDDI.d372.s6.e1
include,43-50
some,51-55
that,56-60
are,61-64
not,65-68
metabolized,69-80
by,81-83
the,84-87
enzyme,88-94
(quinidine;,95-106

cimetidine),0-11	DrugDDI.d372.s7.e0
and,12-15
many,16-20
that,21-25
are,26-29
substrates,30-40
for,41-44
P450,45-49	DrugDDI.d372.s7.e1
2D6,50-53	DrugDDI.d372.s7.e1
(many,54-59
other,60-65
antidepressants,,66-82
phenothiazines,,83-98
and,99-102
the,103-106
Type,107-111
1C,112-114
antiarrhythmics,115-130
propafenone,131-142	DrugDDI.d372.s7.e4
and,143-146
flecainide).,147-159	DrugDDI.d372.s7.e5

While,0-5
all,6-9
the,10-13
selective,14-23
serotonin,24-33	DrugDDI.d372.s8.e0
reuptake,34-42	DrugDDI.d372.s8.e0
inhibitors,43-53	DrugDDI.d372.s8.e0
(SSRIs),,54-62
e.g.,,63-68
citalopram,,69-80
escitalopram,,81-94
fluoxetine,,95-106
sertraline,,107-118
and,119-122
paroxetine,,123-134
inhibit,135-142
P450,143-147	DrugDDI.d372.s8.e6
2D6,,148-152	DrugDDI.d372.s8.e6
they,153-157
may,158-161
vary,162-166
in,167-169
the,170-173
extent,174-180
of,181-183
inhibition.,184-195

Of,0-2
particular,3-13
importance,,14-25
sufficient,26-36
time,37-41
must,42-46
elapse,47-53
before,54-60
initiating,61-71
TCA,72-75
treatment,76-85
in,86-88
a,89-90
patient,91-98
being,99-104
withdrawn,105-114
from,115-119
fluoxetine,,120-131
given,132-137
the,138-141
long,142-146
half-life,147-156
of,157-159
the,160-163
parent,164-170
and,171-174
active,175-181	DrugDDI.d372.s11.e1
metabolite,182-192	DrugDDI.d372.s11.e1
(at,193-196
least,197-202
5,203-204
weeks,205-210
may,211-214
be,215-217
necessary).,218-229

Concomitant,0-11
use,12-15
of,16-18
tricyclic,19-28	DrugDDI.d372.s12.e0
antidepressants,29-44	DrugDDI.d372.s12.e0
with,45-49
drugs,50-55	DrugDDI.d372.s12.e1
that,56-60
can,61-64
inhibit,65-72
cytochrome,73-83	DrugDDI.d372.s12.e2
P450,84-88	DrugDDI.d372.s12.e2
2D6,89-92	DrugDDI.d372.s12.e2
may,93-96
require,97-104
lower,105-110
doses,111-116
than,117-121
usually,122-129
prescribed,130-140
for,141-144
either,145-151
the,152-155
tricyclic,156-165	DrugDDI.d372.s12.e3
antidepressant,166-180	DrugDDI.d372.s12.e3
or,181-183
the,184-187
other,188-193
drug.,194-199	DrugDDI.d372.s12.e4

Furthermore,,0-12
whenever,13-21
one,22-25
of,26-28
these,29-34
other,35-40
drugs,41-46	DrugDDI.d372.s13.e0
is,47-49
withdrawn,50-59
from,60-64
co-therapy,,65-76
an,77-79
increased,80-89
dose,90-94
of,95-97
tricyclic,98-107	DrugDDI.d372.s13.e1
antidepressant,108-122	DrugDDI.d372.s13.e1
may,123-126
be,127-129
required.,130-139

It,0-2
is,3-5
desirable,6-15
to,16-18
monitor,19-26
TCA,27-30
plasma,31-37
levels,38-44
whenever,45-53
a,54-55
TCA,56-59
is,60-62
going,63-68
to,69-71
be,72-74
co-administered,75-90
with,91-95
another,96-103
drug,104-108	DrugDDI.d372.s14.e0
known,109-114
to,115-117
be,118-120
an,121-123
inhibitor,124-133
of,134-136
P450,137-141	DrugDDI.d372.s14.e1
2D6.,142-146	DrugDDI.d372.s14.e1

Doxepin,0-7	DrugDDI.d372.s15.e0
is,8-10
primarily,11-20
metabolized,21-32
by,33-35
CYP2D6,36-42	DrugDDI.d372.s15.e1
(with,43-48
CYP1A2,49-55
,56-56
and,57-60
,61-61
CYP3A4,62-68	DrugDDI.d372.s15.e2
as,69-71
minor,72-77
pathways).,78-88

Inhibitors,0-10
or,11-13
substrates,14-24
of,25-27
CYP2D6,28-34	DrugDDI.d372.s16.e0
(i.e.,,35-41
quinidine,,42-52
selective,53-62
serotonin,63-72	DrugDDI.d372.s16.e2
reuptake,73-81	DrugDDI.d372.s16.e2
inhibitors,82-92	DrugDDI.d372.s16.e2
[SSRIs]),93-101
may,102-105
increase,106-114
the,115-118
plasma,119-125
concentration,126-139
of,140-142
doxepin,143-150	DrugDDI.d372.s16.e3
when,151-155
administered,156-168
concomitantly.,169-183

The,0-3
extent,4-10
of,11-13
interaction,14-25
depends,26-33
on,34-36
the,37-40
variability,41-52
of,53-55
effect,56-62
on,63-65
CYP2D6.,66-73	DrugDDI.d372.s17.e0

The,0-3
clinical,4-12
significance,13-25
of,26-28
this,29-33
interaction,34-45
with,46-50
doxepin,51-58	DrugDDI.d372.s18.e0
has,59-62
not,63-66
been,67-71
systematically,72-86
evaluated.,87-97

MAO,0-3	DrugDDI.d372.s19.e0
Inhibitors:,4-15	DrugDDI.d372.s19.e0
Serious,16-23
side,24-28
effects,29-36
and,37-40
even,41-45
death,46-51
have,52-56
been,57-61
reported,62-70
following,71-80
the,81-84
concomitant,85-96
use,97-100
of,101-103
certain,104-111
drugs,112-117	DrugDDI.d372.s19.e1
with,118-122
MAO,123-126	DrugDDI.d372.s19.e2
inhibitors.,127-138	DrugDDI.d372.s19.e2

Therefore,,0-10
MAO,11-14	DrugDDI.d372.s20.e0
inhibitors,15-25	DrugDDI.d372.s20.e0
should,26-32
be,33-35
discontinued,36-48
at,49-51
least,52-57
two,58-61
weeks,62-67
prior,68-73
to,74-76
the,77-80
cautious,81-89
initiation,90-100
of,101-103
therapy,104-111
with,112-116
SINEQUAN.,117-126	DrugDDI.d372.s20.e1

The,0-3
exact,4-9
length,10-16
of,17-19
time,20-24
may,25-28
vary,29-33
and,34-37
is,38-40
dependent,41-50
upon,51-55
the,56-59
particular,60-70
MAO,71-74	DrugDDI.d372.s21.e0
inhibitor,75-84	DrugDDI.d372.s21.e0
being,85-90
used,,91-96
the,97-100
length,101-107
of,108-110
time,111-115
it,116-118
has,119-122
been,123-127
administered,,128-141
and,142-145
the,146-149
dosage,150-156
involved.,157-166

Cimetidine:,0-11	DrugDDI.d372.s22.e0
Cimetidine,12-22	DrugDDI.d372.s22.e1
has,23-26
been,27-31
reported,32-40
to,41-43
produce,44-51
clinically,52-62
significant,63-74
fluctuations,75-87
in,88-90
steady-state,91-103
serum,104-109
concentrations,110-124
of,125-127
various,128-135
tricyclic,136-145	DrugDDI.d372.s22.e2
antidepressants.,146-162	DrugDDI.d372.s22.e2

Serious,0-7
anticholinergic,8-23	DrugDDI.d372.s23.e0
symptoms,24-32
(i.e.,,33-39
severe,40-46
dry,47-50
mouth,,51-57
urinary,58-65
retention,66-75
and,76-79
blurred,80-87
vision),88-95
have,96-100
been,101-105
associated,106-116
with,117-121
elevations,122-132
in,133-135
the,136-139
serum,140-145
levels,146-152
of,153-155
tricyclic,156-165	DrugDDI.d372.s23.e1
antidepressant,166-180	DrugDDI.d372.s23.e1
when,181-185
cimetidine,186-196	DrugDDI.d372.s23.e2
therapy,197-204
is,205-207
initiated.,208-218

Additionally,,0-13
higher,14-20
than,21-25
expected,26-34
tricyclic,35-44
antidepressant,45-59
levels,60-66
have,67-71
been,72-76
observed,77-85
when,86-90
they,91-95
are,96-99
begun,100-105
in,106-108
patients,109-117
already,118-125
taking,126-132
cimetidine.,133-144	DrugDDI.d372.s24.e0

In,0-2
patients,3-11
who,12-15
have,16-20
been,21-25
reported,26-34
to,35-37
be,38-40
well,41-45
controlled,46-56
on,57-59
tricyclic,60-69	DrugDDI.d372.s25.e0
antidepressants,70-85	DrugDDI.d372.s25.e0
receiving,86-95
concurrent,96-106
cimetidine,107-117	DrugDDI.d372.s25.e1
therapy,,118-126
discontinuation,127-142
of,143-145
cimetidine,146-156	DrugDDI.d372.s25.e2
has,157-160
been,161-165
reported,166-174
to,175-177
decrease,178-186
established,187-198
steady-state,199-211
serum,212-217
tricyclic,218-227
antidepressant,228-242
levels,243-249
and,250-253
compromise,254-264
their,265-270
therapeutic,271-282
effects.,283-291

Alcohol:,0-8	DrugDDI.d372.s26.e0
It,9-11
should,12-18
be,19-21
borne,22-27
in,28-30
mind,31-35
that,36-40
alcohol,41-48
ingestion,49-58
may,59-62
increase,63-71
the,72-75
danger,76-82
inherent,83-91
in,92-94
any,95-98
intentional,99-110
or,111-113
unintentional,114-127
SINEQUAN,128-136	DrugDDI.d372.s26.e1
overdosage.,137-148

This,0-4
is,5-7
especially,8-18
important,19-28
in,29-31
patients,32-40
who,41-44
may,45-48
use,49-52
alcohol,53-60	DrugDDI.d372.s27.e0
excessively.,61-73

Tolazamide:,0-11	DrugDDI.d372.s28.e0
A,12-13
case,14-18
of,19-21
severe,22-28
hypoglycemia,29-41
has,42-45
been,46-50
reported,51-59
in,60-62
a,63-64
type,65-69
II,70-72
diabetic,73-81
patient,82-89
maintained,90-100
on,101-103
tolazamide,104-114	DrugDDI.d372.s28.e1
(1,115-117
gm/day),118-125
11,126-128
days,129-133
after,134-139
the,140-143
addition,144-152
of,153-155
doxepin,156-163	DrugDDI.d372.s28.e2
(75,164-167
mg/day).,168-176

Until,0-5
specific,6-14
compatibility,15-28
data,29-33
are,34-37
available,,38-48
it,49-51
is,52-54
not,55-58
recommended,59-70
that,71-75
DOXIL?,76-82
be,83-85
mixed,86-91
with,92-96
other,97-102
drugs.,103-109	DrugDDI.d161.s1.e0

DOXIL?,0-6
may,7-10
interact,11-19
with,20-24
drugs,25-30	DrugDDI.d161.s2.e0
known,31-36
to,37-39
interact,40-48
with,49-53
the,54-57
conventional,58-70
formulation,71-82
of,83-85
doxorubicin,86-97	DrugDDI.d161.s2.e1
HCl.,98-102	DrugDDI.d161.s2.e1

Because,0-7
tetracyclines,8-21	DrugDDI.d260.s0.e0
have,22-26
been,27-31
shown,32-37
to,38-40
depress,41-48
plasma,49-55
prothrombin,56-67
activity,,68-77
patients,78-86
who,87-90
are,91-94
on,95-97
anticoagulant,98-111
therapy,112-119
may,120-123
require,124-131
downward,132-140
adjustment,141-151
of,152-154
their,155-160
anticoagulant,161-174	DrugDDI.d260.s0.e1
dosage.,175-182

Since,0-5
bacteriostatic,6-20	DrugDDI.d260.s1.e0
drugs,21-26
may,27-30
interfere,31-40
with,41-45
the,46-49
bactericidal,50-62
action,63-69
of,70-72
penicillin,,73-84
it,85-87
is,88-90
advisable,91-100
to,101-103
avoid,104-109
giving,110-116
tetracyclines,117-130	DrugDDI.d260.s1.e2
in,131-133
conjunction,134-145
with,146-150
penicillin.,151-162	DrugDDI.d260.s1.e3

Absorption,0-10
of,11-13
tetracyclines,14-27	DrugDDI.d260.s2.e0
is,28-30
impaired,31-39
by,40-42
antacids,43-51	DrugDDI.d260.s2.e1
containing,52-62
aluminum,,63-72
calcium,,73-81
or,82-84
magnesium,,85-95
and,96-99
iron-containing,100-115	DrugDDI.d260.s2.e4
preparations.,116-129	DrugDDI.d260.s2.e4

Absorption,0-10
of,11-13
tetracycline,14-26	DrugDDI.d260.s3.e0
is,27-29
impaired,30-38
by,39-41
bismuth,42-49	DrugDDI.d260.s3.e1
subsalicylate.,50-64	DrugDDI.d260.s3.e1

Barbiturates,,0-13
carbamazepine,,14-28
and,29-32
phenytoin,33-42	DrugDDI.d260.s4.e2
decrease,43-51
the,52-55
half-life,56-65
of,66-68
doxycycline.,69-81	DrugDDI.d260.s4.e3

The,0-3
concurrent,4-14
use,15-18
of,19-21
tetracycline,22-34	DrugDDI.d260.s5.e0
and,35-38
Penthrane,39-48	DrugDDI.d260.s5.e1
(methoxyflurane),49-65
has,66-69
been,70-74
reported,75-83
to,84-86
result,87-93
in,94-96
fatal,97-102
renal,103-108
toxicity.,109-118

Concurrent,0-10
use,11-14
of,15-17
tetracycline,18-30	DrugDDI.d260.s6.e0
may,31-34
render,35-41
oral,42-46	DrugDDI.d260.s6.e1
contraceptives,47-61	DrugDDI.d260.s6.e1
less,62-66	DrugDDI.d260.s6.e1
effective.,67-77	DrugDDI.d260.s6.e1

Drug/Laboratory,0-15	DrugDDI.d260.s7.e0
Test,16-20
Interactions,21-33
False,34-39
elevations,40-50
of,51-53
urinary,54-61
catecholamine,62-75
levels,76-82
may,83-86
occur,87-92
due,93-96
to,97-99
interference,100-112
with,113-117
the,118-121
fluorescence,122-134
test.,135-140

Potential,0-9
drug,10-14
interactions,15-27
for,28-31
doxylamine,32-42	DrugDDI.d156.s0.e0
include,,43-51
increased,52-61
seda?tion,62-71
if,72-74
doxylamine,75-85	DrugDDI.d156.s0.e1
is,86-88
combined,89-97
with,98-102
other,103-108
CNS,109-112	DrugDDI.d156.s0.e2
depressant,113-123	DrugDDI.d156.s0.e2
drugs.,124-130	DrugDDI.d156.s0.e2

Antihistamines,0-14	DrugDDI.d156.s1.e0
may,15-18
partially,19-28
counteract,29-39
the,40-43
anticoagulation,44-59
effects,60-67
of,68-70
heparin,71-78	DrugDDI.d156.s1.e1
or,79-81
warfarin.,82-91	DrugDDI.d156.s1.e2

Doxylamine,0-10	DrugDDI.d156.s2.e0
may,11-14
enhance,15-22
the,23-26
effects,27-34
of,35-37
epinephrine.,38-50	DrugDDI.d156.s2.e1

Androgens,0-9	DrugDDI.d53.s0.e0
may,10-13
increase,14-22
sensitivity,23-34
to,35-37
oral,38-42
anticoagulahts.,43-58

Dosage,0-6
of,7-9
the,10-13
anticoagulant,14-27	DrugDDI.d53.s1.e0
may,28-31
require,32-39
reduction,40-49
in,50-52
order,53-58
to,59-61
maintain,62-70
satisfactory,71-83
therapeutic,84-95
hypoprothrombinemia.,96-116

Concurrent,0-10
administration,11-25
of,26-28
oxyphenbutazone,29-44	DrugDDI.d53.s2.e0
and,45-48
androgens,49-58	DrugDDI.d53.s2.e1
may,59-62
result,63-69
in,70-72
elevated,73-81
serum,82-87
levels,88-94
of,95-97
oxyphenbutazone.,98-114	DrugDDI.d53.s2.e2

In,0-2
diabetic,3-11
patients,,12-21
the,22-25
metabolic,26-35
effects,36-43
of,44-46
androgens,47-56	DrugDDI.d53.s3.e0
may,57-60
decrease,61-69
blood,70-75
glucose,76-83
and,84-87
therefore,,88-98
insulin,99-106	DrugDDI.d53.s3.e1
requirements.,107-120

Other,0-5
CNS,6-9	DrugDDI.d95.s0.e0
depressant,10-20	DrugDDI.d95.s0.e0
drugs,21-26	DrugDDI.d95.s0.e0
(e.g.,27-32
barbiturates,,33-46
tranquilizers,,47-61
opioids,62-69	DrugDDI.d95.s0.e3
and,70-73
general,74-81	DrugDDI.d95.s0.e4
anesthetics),82-94	DrugDDI.d95.s0.e4
have,95-99
additive,100-108
or,109-111
potentiating,112-124
effects,125-132
with,133-137
INAPSINE.,138-147	DrugDDI.d95.s0.e5

When,0-4
patients,5-13
have,14-18
received,19-27
such,28-32
drugs,,33-39
the,40-43
dose,44-48
of,49-51
INAPSINE,52-60	DrugDDI.d95.s1.e1
required,61-69
will,70-74
be,75-77
less,78-82
than,83-87
usual.,88-94

Following,0-9
the,10-13
administration,14-28
of,29-31
INAPSINE,,32-41
the,42-45
dose,46-50
of,51-53
other,54-59
CNS,60-63	DrugDDI.d95.s2.e1
depressant,64-74	DrugDDI.d95.s2.e1
drugs,75-80	DrugDDI.d95.s2.e1
should,81-87
be,88-90
reduced.,91-99

Drug,0-4
interaction,5-16
studies,17-24
with,25-29
Xigris,30-36	DrugDDI.d471.s0.e0
have,37-41
not,42-45
been,46-50
performed,51-60
in,61-63
patients,64-72
with,73-77
severe,78-84
sepsis.,85-92

However,,0-8
since,9-14
there,15-20
is,21-23
an,24-26
increased,27-36
risk,37-41
of,42-44
bleeding,45-53
with,54-58
Xigris,,59-66
caution,67-74
should,75-81
be,82-84
employed,85-93
when,94-98
Xigris,99-105	DrugDDI.d471.s1.e1
is,106-108
used,109-113
with,114-118
other,119-124
drugs,125-130	DrugDDI.d471.s1.e2
that,131-135
affect,136-142
hemostasis.,143-154

Approximately,0-13
2/3,14-17
of,18-20
the,21-24
patients,25-33
in,34-36
the,37-40
Phase,41-46
3,47-48
study,49-54
received,55-63
either,64-70
prophylactic,71-83
low,84-87
dose,88-92
heparin,93-100	DrugDDI.d471.s2.e0
(unfractionated,101-116
heparin,117-124
up,125-127
to,128-130
15,000,131-137
units/day),138-148
or,149-151
prophylactic,152-164	DrugDDI.d471.s2.e2
doses,165-170
of,171-173
low,174-177	DrugDDI.d471.s2.e3
molecular,178-187	DrugDDI.d471.s2.e3
weight,188-194	DrugDDI.d471.s2.e3
heparins,195-203	DrugDDI.d471.s2.e3
as,204-206
indicated,207-216
in,217-219
the,220-223
prescribing,224-235
information,236-247
for,248-251
the,252-255
specific,256-264
products.,265-274

Concomitant,0-11
use,12-15
of,16-18
prophylactic,19-31
low,32-35
dose,36-40
heparin,41-48	DrugDDI.d471.s3.e0
did,49-52
not,53-56
appear,57-63
to,64-66
affect,67-73
safety,,74-81
however,,82-90
its,91-94
effects,95-102
on,103-105
the,106-109
efficacy,110-118
of,119-121
Xigris,122-128	DrugDDI.d471.s3.e1
have,129-133
not,134-137
been,138-142
evaluated,143-152
in,153-155
an,156-158
adequate,159-167
and,168-171
well-controlled,172-187
clinical,188-196
trial.,197-203

Drug/Laboratory,0-15	DrugDDI.d471.s4.e0
Test,16-20
Interaction,21-32
Because,33-40
Xigris,41-47	DrugDDI.d471.s4.e1
may,48-51
affect,52-58
the,59-62
APTT,63-67
assay,,68-74
Xigris,75-81	DrugDDI.d471.s4.e2
present,82-89
in,90-92
plasma,93-99
samples,100-107
may,108-111
interfere,112-121
with,122-126
one-stage,127-136
coagulation,137-148
assays,149-155
based,156-161
on,162-164
the,165-168
APTT,169-173
(such,174-179
as,180-182
factor,183-189	DrugDDI.d471.s4.e3
VIII,,190-195	DrugDDI.d471.s4.e3
IX,,196-199
and,200-203
XI,204-206
assays).,207-215

Xigris,0-6	DrugDDI.d471.s6.e0
present,7-14
in,15-17
plasma,18-24
samples,25-32
does,33-37
not,38-41
interfere,42-51
with,52-56
one-stage,57-66
factor,67-73
assays,74-80
based,81-86
on,87-89
the,90-93
PT,94-96
(such,97-102
as,103-105
factor,106-112	DrugDDI.d471.s6.e1
II,,113-116	DrugDDI.d471.s6.e1
V,,117-119
VII,,120-124
and,125-128
X,129-130
assays).,131-139

Potential,0-9
for,10-13
Other,14-19
Drugs,20-25	DrugDDI.d64.s0.e0
to,26-28
Affect,29-35
Duloxetine:,36-47	DrugDDI.d64.s0.e1
Both,48-52
CYP1A2,53-59	DrugDDI.d64.s0.e2
and,60-63
CYP2D6,64-70	DrugDDI.d64.s0.e3
are,71-74
responsible,75-86
for,87-90
duloxetine,91-101	DrugDDI.d64.s0.e4
metabolism.,102-113

Inhibitors,0-10
of,11-13
CYP1A2:,14-21	DrugDDI.d64.s1.e0
Concomitant,22-33
use,34-37
of,38-40
duloxetine,41-51	DrugDDI.d64.s1.e1
with,52-56
fluvoxamine,,57-69
an,70-72
inhibitor,73-82
of,83-85
CYP1A2,,86-93
results,94-101
in,102-104
approximately,105-118
a,119-120
6-fold,121-127
increase,128-136
in,137-139
AUC,140-143
and,144-147
about,148-153
a,154-155
2.5-fold,156-164
increase,165-173
in,174-176
Cmax,177-181
of,182-184
duloxetine.,185-196	DrugDDI.d64.s1.e4

Some,0-4
quinolone,5-14	DrugDDI.d64.s2.e0
antibiotics,15-26	DrugDDI.d64.s2.e0
would,27-32
be,33-35
expected,36-44
to,45-47
have,48-52
similar,53-60
effects,61-68
and,69-72
these,73-78
combinations,79-91
should,92-98
be,99-101
avoided.,102-110

Inhibitors,0-10
of,11-13
CYP2D6:,14-21	DrugDDI.d64.s3.e0
Because,22-29
CYP2D6,30-36	DrugDDI.d64.s3.e1
is,37-39
involved,40-48
in,49-51
duloxetine,52-62	DrugDDI.d64.s3.e2
metabolism,,63-74
concomitant,75-86
use,87-90
of,91-93
duloxetine,94-104	DrugDDI.d64.s3.e3
with,105-109
potent,110-116
inhibitors,117-127
of,128-130
CYP2D6,131-137	DrugDDI.d64.s3.e4
may,138-141
result,142-148
in,149-151
higher,152-158
concentrations,159-173
of,174-176
duloxetine.,177-188	DrugDDI.d64.s3.e5

Paroxetine,0-10	DrugDDI.d64.s4.e0
(20,11-14
mg,15-17
QD),18-21
increased,22-31
the,32-35
concentration,36-49
of,50-52
duloxetine,53-63	DrugDDI.d64.s4.e1
(40,64-67
mg,68-70
QD),71-74
by,75-77
about,78-83
60%,,84-88
and,89-92
greater,93-100
degrees,101-108
of,109-111
inhibition,112-122
are,123-126
expected,127-135
with,136-140
higher,141-147
doses,148-153
of,154-156
paroxetine.,157-168	DrugDDI.d64.s4.e2

Similar,0-7
effects,8-15
would,16-21
be,22-24
expected,25-33
with,34-38
other,39-44
potent,45-51
CYP2D6,52-58	DrugDDI.d64.s5.e0
inhibitors,59-69
(e.g.,,70-76
fluoxetine,,77-88
quinidine).,89-100	DrugDDI.d64.s5.e2

Potential,0-9
for,10-13
Duloxetine,14-24	DrugDDI.d64.s6.e0
to,25-27
Affect,28-34
Other,35-40
Drugs:,41-47	DrugDDI.d64.s6.e1
Drugs,48-53	DrugDDI.d64.s6.e2
Metabolized,54-65
by,66-68
CYP1A2:,69-76	DrugDDI.d64.s6.e3
In,77-79
vitro,80-85
drug,86-90
interaction,91-102
studies,103-110
demonstrate,111-122
that,123-127
duloxetine,128-138	DrugDDI.d64.s6.e4
does,139-143
not,144-147
induce,148-154
CYP1A2,155-161	DrugDDI.d64.s6.e5
activity,,162-171
and,172-175
it,176-178
is,179-181
unlikely,182-190
to,191-193
have,194-198
a,199-200
clinically,201-211
significant,212-223
effect,224-230
on,231-233
the,234-237
metabolism,238-248
of,249-251
CYP1A2,252-258	DrugDDI.d64.s6.e6
substrates.,259-270

Drugs,0-5	DrugDDI.d64.s7.e0
Metabolized,6-17
by,18-20
CYP2D6:,21-28	DrugDDI.d64.s7.e1
Duloxetine,29-39	DrugDDI.d64.s7.e2
is,40-42
a,43-44
moderate,45-53
inhibitor,54-63
of,64-66
CYP2D6.,67-74	DrugDDI.d64.s7.e3

When,0-4
duloxetine,5-15	DrugDDI.d64.s8.e0
was,16-19
administered,20-32
(at,33-36
a,37-38
dose,39-43
of,44-46
60,47-49
mg,50-52
BID),53-57	DrugDDI.d64.s8.e1
in,58-60
conjunction,61-72
with,73-77
a,78-79
single,80-86
50-mg,87-92
dose,93-97
of,98-100
desipramine,,101-113
a,114-115
CYP2D6,116-122	DrugDDI.d64.s8.e3
substrate,,123-133
the,134-137
AUC,138-141
of,142-144
desipramine,145-156	DrugDDI.d64.s8.e4
increased,157-166
3-fold.,167-174

Therefore,,0-10
co-administration,11-28
of,29-31
Duloxetine,32-42	DrugDDI.d64.s9.e0
with,43-47
other,48-53
drugs,54-59	DrugDDI.d64.s9.e1
that,60-64
are,65-68
extensively,69-80
metabolized,81-92
by,93-95
this,96-100
isozyme,101-108	DrugDDI.d64.s9.e2
and,109-112
which,113-118
have,119-123
a,124-125
narrow,126-132
therapeutic,133-144
index,,145-151
including,152-161
certain,162-169
antidepressants,170-185	DrugDDI.d64.s9.e3
(tricyclic,186-196
antidepressants,197-212
[TCAs],,213-220
such,221-225
as,226-228
nortriptyline,,229-243
amitriptyline,,244-258
and,259-262
imipramine),,263-275
phenothiazines,276-290	DrugDDI.d64.s9.e8
and,291-294
Type,295-299
1C,300-302
antiarrhythmics,303-318	DrugDDI.d64.s9.e9
(e.g.,,319-325
propafenone,,326-338
flecainide),,339-351
should,352-358
be,359-361
approached,362-372
with,373-377
caution.,378-386

Plasma,0-6
TCA,7-10
concentrations,11-25
may,26-29
need,30-34
to,35-37
be,38-40
monitored,41-50
and,51-54
the,55-58
dose,59-63
of,64-66
the,67-70
TCA,71-74
may,75-78
need,79-83
to,84-86
be,87-89
reduced,90-97
if,98-100
a,101-102
TCA,103-106
is,107-109
co-administered,110-125
with,126-130
Duloxetine.,131-142	DrugDDI.d64.s10.e0

Because,0-7
of,8-10
the,11-14
risk,15-19
of,20-22
serious,23-30
ventricular,31-42
arrhythmias,43-54
and,55-58
sudden,59-65
death,66-71
potentially,72-83
associated,84-94
with,95-99
elevated,100-108
plasma,109-115
levels,116-122
of,123-125
thioridazine,,126-139
Duloxetine,140-150	DrugDDI.d64.s11.e1
and,151-154
thioridazine,155-167	DrugDDI.d64.s11.e2
should,168-174
not,175-178
be,179-181
co-administered.,182-198

Drugs,0-5	DrugDDI.d64.s12.e0
Metabolized,6-17
by,18-20
CYP3A:,21-27	DrugDDI.d64.s12.e1
Results,28-35
of,36-38
in,39-41
vitro,42-47
studies,48-55
demonstrate,56-67
that,68-72
duloxetine,73-83	DrugDDI.d64.s12.e2
does,84-88
not,89-92
inhibit,93-100
or,101-103
induce,104-110
CYP3A,111-116	DrugDDI.d64.s12.e3
activity.,117-126

Duloxetine,0-10	DrugDDI.d64.s13.e0
May,11-14
Have,15-19
a,20-21
Clinically,22-32
Important,33-42
Interaction,43-54
with,55-59
the,60-63
Following,64-73
Other,74-79
Drugs:,80-86	DrugDDI.d64.s13.e1
Alcohol:,87-95	DrugDDI.d64.s13.e2
When,96-100
Duloxetine,101-111	DrugDDI.d64.s13.e3
and,112-115
ethanol,116-123	DrugDDI.d64.s13.e4
were,124-128
administered,129-141
several,142-149
hours,150-155
apart,156-161
so,162-164
that,165-169
peak,170-174
concentrations,175-189
of,190-192
each,193-197
would,198-203
coincide,,204-213
Duloxetine,214-224	DrugDDI.d64.s13.e5
did,225-228
not,229-232
increase,233-241
the,242-245
impairment,246-256
of,257-259
mental,260-266
and,267-270
motor,271-276
skills,277-283
caused,284-290
by,291-293
alcohol.,294-302	DrugDDI.d64.s13.e6

In,0-2
the,3-6
Duloxetine,7-17	DrugDDI.d64.s14.e0
clinical,18-26
trials,27-33
database,,34-43
three,44-49
Duloxetine-treated,50-68	DrugDDI.d64.s14.e1
patients,69-77
had,78-81
liver,82-87
injury,88-94
as,95-97
manifested,98-108
by,109-111
ALT,112-115
and,116-119
total,120-125	DrugDDI.d64.s14.e2
bilirubin,126-135	DrugDDI.d64.s14.e2
elevations,,136-147
with,148-152
evidence,153-161
of,162-164
obstruction.,165-177

Substantial,0-11
intercurrent,12-24
ethanol,25-32	DrugDDI.d64.s15.e0
use,33-36
was,37-40
present,41-48
in,49-51
each,52-56
of,57-59
these,60-65
cases,,66-72
and,73-76
this,77-81
may,82-85
have,86-90
contributed,91-102
to,103-105
the,106-109
abnormalities,110-123
seen.,124-129

CNS,0-3	DrugDDI.d64.s16.e0
Acting,4-10	DrugDDI.d64.s16.e0
Drugs:,11-17	DrugDDI.d64.s16.e0
Given,18-23
the,24-27
primary,28-35
CNS,36-39
effects,40-47
of,48-50
Duloxetine,,51-62
it,63-65
should,66-72
be,73-75
used,76-80
with,81-85
caution,86-93
when,94-98
it,99-101
is,102-104
taken,105-110
in,111-113
combination,114-125
with,126-130
or,131-133
substituted,134-145
for,146-149
other,150-155
centrally,156-165	DrugDDI.d64.s16.e2
acting,166-172	DrugDDI.d64.s16.e2
drugs,,173-179	DrugDDI.d64.s16.e2
including,180-189
those,190-195
with,196-200
a,201-202
similar,203-210
mechanism,211-220
of,221-223
action.,224-231

Potential,0-9
for,10-13
Interaction,14-25
with,26-30
Drugs,31-36	DrugDDI.d64.s17.e0
that,37-41
Affect,42-48
Gastric,49-56
Acidity:,57-65
Duloxetine,66-76	DrugDDI.d64.s17.e1
has,77-80
an,81-83
enteric,84-91
coating,92-99
that,100-104
resists,105-112
dissolution,113-124
until,125-130
reaching,131-139
a,140-141
segment,142-149
of,150-152
the,153-156
gastrointestinal,157-173
tract,174-179
where,180-185
the,186-189
pH,190-192
exceeds,193-200
5.5.,201-205

In,0-2
extremely,3-12
acidic,13-19
conditions,,20-31
Duloxetine,,32-43
unprotected,44-55
by,56-58
the,59-62
enteric,63-70
coating,,71-79
may,80-83
undergo,84-91
hydrolysis,92-102
to,103-105
form,106-110
naphthol.,111-120

Caution,0-7
is,8-10
advised,11-18
in,19-21
using,22-27
Duloxetine,28-38	DrugDDI.d64.s19.e0
in,39-41
patients,42-50
with,51-55
conditions,56-66
that,67-71
may,72-75
slow,76-80
gastric,81-88
emptying,89-97
(e.g.,,98-104
some,105-109
diabetics).,110-121

Drugs,0-5	DrugDDI.d64.s20.e0
that,6-10
raise,11-16
the,17-20
gastrointestinal,21-37
pH,38-40
may,41-44
lead,45-49
to,50-52
an,53-55
earlier,56-63
release,64-71
of,72-74
duloxetine.,75-86	DrugDDI.d64.s20.e1

However,,0-8
co-administration,9-26
of,27-29
Duloxetine,30-40	DrugDDI.d64.s21.e0
with,41-45
aluminum-,46-55
and,56-59
magnesium-containing,60-80	DrugDDI.d64.s21.e1
antacids,81-89	DrugDDI.d64.s21.e1
(51,90-93
mEq),94-98
or,99-101
Duloxetine,102-112	DrugDDI.d64.s21.e2
with,113-117
famotidine,,118-129
had,130-133
no,134-136
significant,137-148
effect,149-155
on,156-158
the,159-162
rate,163-167
or,168-170
extent,171-177
of,178-180
duloxetine,181-191	DrugDDI.d64.s21.e4
absorption,192-202
after,203-208
administration,209-223
of,224-226
a,227-228
40-mg,229-234
oral,235-239
dose.,240-245

It,0-2
is,3-5
unknown,6-13
whether,14-21
the,22-25
concomitant,26-37
administration,38-52
of,53-55
proton,56-62	DrugDDI.d64.s22.e0
pump,63-67	DrugDDI.d64.s22.e0
inhibitors,68-78	DrugDDI.d64.s22.e0
affects,79-86
duloxetine,87-97	DrugDDI.d64.s22.e1
absorption.,98-109

Synergism,0-9
between,10-17
xanthine,18-26	DrugDDI.d329.s0.e0
bronchodilators,27-42	DrugDDI.d329.s0.e0
(e.g.,,43-49
theophylline),,50-64
ephedrine,,65-75
and,76-79
other,80-85
sympathomimetic,86-101	DrugDDI.d329.s0.e3
bronchodilators,102-117	DrugDDI.d329.s0.e3
has,118-121
been,122-126
reported.,127-136

Concurrent,0-10
administration,11-25
of,26-28
dyphylline,29-39	DrugDDI.d329.s2.e0
and,40-43
probenecid,,44-55
which,56-61
competes,62-70	DrugDDI.d329.s2.e2
for,71-74
tubular,75-82
secretion,,83-93
has,94-97
been,98-102
shown,103-108
to,109-111
increase,112-120
the,121-124
plasma,125-131
half-life,132-141
of,142-144
dyphylline,145-155	DrugDDI.d329.s2.e3
.,156-157

Phospholine,0-11	DrugDDI.d191.s0.e0
Iodide,12-18	DrugDDI.d191.s0.e0
potentiates,19-30
other,31-36
cholinesterase,37-51	DrugDDI.d191.s0.e1
inhibitors,52-62	DrugDDI.d191.s0.e1
such,63-67
as,68-70
succinylcholine,71-86	DrugDDI.d191.s0.e2
or,87-89
organophosphate,90-105	DrugDDI.d191.s0.e3
and,106-109
carbamate,110-119	DrugDDI.d191.s0.e4
insecticides.,120-133	DrugDDI.d191.s0.e4

Patients,0-8
undergoing,9-19
systemic,20-28
anticholinesterase,29-47
treatment,48-57
should,58-64
be,65-67
warned,68-74
of,75-77
the,78-81
possible,82-90
additive,91-99
effects,100-107
of,108-110
Phospholine,111-122	DrugDDI.d191.s1.e0
Iodide.,123-130	DrugDDI.d191.s1.e0

Steroids,0-8
enhance,9-16
the,17-20
renal,21-26
toxicity,27-35
of,36-38
edetate,39-46	DrugDDI.d467.s1.e0
calcium,47-54	DrugDDI.d467.s1.e0
disodium,55-63	DrugDDI.d467.s1.e0
in,64-66
animals.,67-75
7,76-77
Edetate,78-85	DrugDDI.d467.s1.e1
calcium,86-93	DrugDDI.d467.s1.e1
disodium,94-102	DrugDDI.d467.s1.e1
interferes,103-113
with,114-118
the,119-122
action,123-129
of,130-132
zinc,133-137	DrugDDI.d467.s1.e2
insulin,138-145
preparations,146-158
by,159-161
chelating,162-171
the,172-175
zinc.,176-181	DrugDDI.d467.s1.e3
7,182-183

Care,0-4
should,5-11
be,12-14
given,15-20
when,21-25
administering,26-39
this,40-44
drug,45-49	DrugDDI.d4.s0.e0
to,50-52
patients,53-61
with,62-66
symptoms,67-75
of,76-78
myasthenic,79-89
weakness,90-98
who,99-102
are,103-106
also,107-111
on,112-114
anticholinesterase,115-133	DrugDDI.d4.s0.e1
drugs.,134-140	DrugDDI.d4.s0.e1

Since,0-5
symptoms,6-14
of,15-17
anticholinesterase,18-36
overdose,37-45
(cholinergic,46-58
crisis),59-66
may,67-70
mimic,71-76
underdosage,77-88
(myasthenic,89-100
weakness),,101-111
their,112-117
condition,118-127
may,128-131
be,132-134
worsened,135-143
by,144-146
the,147-150
use,151-154
of,155-157
this,158-162
drug.,163-168	DrugDDI.d4.s1.e0

No,0-2
formal,3-9
drug,10-14
interaction,15-26
studies,27-34
have,35-39
been,40-44
performed,45-54
with,55-59
RAPTIVA.,60-68	DrugDDI.d199.s0.e0

RAPTIVA,0-7	DrugDDI.d199.s1.e0
should,8-14
not,15-18
be,19-21
used,22-26
with,27-31
other,32-37
immunosuppressive,38-55	DrugDDI.d199.s1.e1
drugs.,56-62

Acellular,,0-10
live,11-15
and,16-19
live-attenuated,20-35	DrugDDI.d199.s2.e0
vaccines,36-44	DrugDDI.d199.s2.e0
should,45-51
not,52-55
be,56-58
administered,59-71
during,72-78
RAPTIVA,79-86	DrugDDI.d199.s2.e1
treatment.,87-97

Drug/Laboratory,0-15	DrugDDI.d199.s3.e0
Test,16-20
Interactions,21-33
Increases,34-43
in,44-46
lymphocyte,47-57
counts,58-64
related,65-72
to,73-75
the,76-79
pharmacologic,80-93
mechanism,94-103
of,104-106
action,107-113
are,114-117
frequently,118-128
observed,129-137
during,138-144
RAPTIVA,145-152	DrugDDI.d199.s3.e1
treatment.,153-163

Efavirenz,0-9	DrugDDI.d270.s0.e0
has,10-13
been,14-18
shown,19-24
in,25-27
vivo,28-32
to,33-35
induce,36-42
CYP3A4.,43-50	DrugDDI.d270.s0.e1

Other,0-5
compounds,6-15
that,16-20
are,21-24
substrates,25-35
of,36-38
CYP3A4,39-45	DrugDDI.d270.s1.e0
may,46-49
have,50-54
decreased,55-64
plasma,65-71
concentrations,72-86
when,87-91
coadministered,92-106
with,107-111
SUSTIVA,112-119	DrugDDI.d270.s1.e1
(efavirenz).,120-132

In,0-2
vitro,3-8
studies,9-16
have,17-21
demonstrated,22-34
that,35-39
efavirenz,40-49	DrugDDI.d270.s2.e0
inhibits,50-58
2C9,,59-63
2C19,,64-69
and,70-73
3A4,74-77
isozymes,78-86	DrugDDI.d270.s2.e1
in,87-89
the,90-93
range,94-99
of,100-102
observed,103-111
efavirenz,112-121	DrugDDI.d270.s2.e2
plasma,122-128
concentrations.,129-144

Coadministration,0-16
of,17-19
efavirenz,20-29	DrugDDI.d270.s3.e0
with,30-34
drugs,35-40	DrugDDI.d270.s3.e1
primarily,41-50
metabolized,51-62
by,63-65
these,66-71
isozymes,72-80	DrugDDI.d270.s3.e2
may,81-84
result,85-91
in,92-94
altered,95-102
plasma,103-109
concentrations,110-124
of,125-127
the,128-131
coadministered,132-146
drug.,147-152	DrugDDI.d270.s3.e3

Therefore,,0-10
appropriate,11-22
dose,23-27
adjustments,28-39
may,40-43
be,44-46
necessary,47-56
for,57-60
these,61-66
drugs.,67-73	DrugDDI.d270.s4.e0

Drugs,0-5	DrugDDI.d270.s5.e0
which,6-11
induce,12-18
CYP3A4,19-25	DrugDDI.d270.s5.e1
activity,26-34
(eg,,35-39
phenobarbital,,40-54
rifampin,,55-64
rifabutin),65-75	DrugDDI.d270.s5.e4
would,76-81
be,82-84
expected,85-93
to,94-96
increase,97-105
the,106-109
clearance,110-119
of,120-122
efavirenz,123-132	DrugDDI.d270.s5.e5
resulting,133-142
in,143-145
lowered,146-153
plasma,154-160
concentrations.,161-176

Drug,0-4
interactions,5-17
with,18-22
SUSTIVA,23-30	DrugDDI.d270.s6.e0
are,31-34
summarized,35-45
in,46-48
Table,49-54
5.,55-57

Table,0-5
5a:,6-9
Drugs,10-15	DrugDDI.d270.s7.e0
That,16-20
Should,21-27
Not,28-31
Be,32-34
Coadministered,35-49
With,50-54
SUSTIVA,55-62	DrugDDI.d270.s7.e1

Drug,0-4	DrugDDI.d270.s8.e0
Class,5-10

Drugs,0-5	DrugDDI.d270.s9.e0
Within,6-12
Class,13-18
Not,19-22
To,23-25
Be,26-28
Coadministered,29-43
With,44-48
SUSTIVA,49-56	DrugDDI.d270.s9.e1

Antihistamines,0-14	DrugDDI.d270.s10.e0
Benzodiazepines,15-30
GI,31-33
Motility,34-42
Agents,43-49
Anti-Migraine,50-63
Antifungal,64-74

astemizole,0-10	DrugDDI.d270.s11.e0
midazolam,,11-21
triazolam,22-31	DrugDDI.d270.s11.e1
cisapride,32-41
ergot,42-47
derivatives,48-59
voriconazole,60-72	DrugDDI.d270.s11.e2

Drug,0-4	DrugDDI.d270.s14.e0
Name,5-9

Atazanavir,0-10	DrugDDI.d270.s17.e0

When,0-4
coadministered,5-19
with,20-24
SUSTIVA,25-32	DrugDDI.d270.s19.e0
in,33-35
treatment-naive,36-51
patients,,52-61
the,62-65
recommended,66-77
dose,78-82
of,83-85
atazanavir,86-96	DrugDDI.d270.s19.e1
is,97-99
300,100-103
mg,104-106
with,107-111
ritonavir,112-121	DrugDDI.d270.s19.e2
100,122-125	DrugDDI.d270.s19.e2
mg,126-128	DrugDDI.d270.s19.e2
and,129-132
SUSTIVA,133-140	DrugDDI.d270.s19.e3
600,141-144
mg,145-147
(all,148-152
once,153-157
daily).,158-165

Dosing,0-6
recommendations,7-22
for,23-26
SUSTIVA,27-34	DrugDDI.d270.s20.e0
and,35-38
atazanavir,39-49	DrugDDI.d270.s20.e1
in,50-52
treatment-experienced,53-74
patients,75-83
have,84-88
not,89-92
been,93-97
established.,98-110

Drug,0-4	DrugDDI.d270.s22.e0
Name,5-9

Clarithromycin,0-14	DrugDDI.d270.s25.e0

??clarithromycin,0-16
concentration,17-30

Plasma,0-6
concentrations,7-21
decreased,22-31
by,32-34
SUSTIVA;,35-43	DrugDDI.d270.s27.e0

In,0-2
uninfected,3-13
volunteers,,14-25
46%,26-29
developed,30-39
rash,40-44
while,45-50
receiving,51-60
SUSTIVA,61-68	DrugDDI.d270.s29.e0
and,69-72
clarithromycin.,73-88	DrugDDI.d270.s29.e1

No,0-2
dose,3-7
adjustment,8-18
of,19-21
SUSTIVA,22-29	DrugDDI.d270.s30.e0
is,30-32
recommended,33-44
when,45-49
given,50-55
with,56-60
clarithromycin.,61-76	DrugDDI.d270.s30.e1

Alternatives,0-12
to,13-15
clarithromycin,,16-31
such,32-36
as,37-39
azithromycin,,40-53
should,54-60
be,61-63
considered.,64-75

Other,0-5
macrolide,6-15	DrugDDI.d270.s32.e0
antibiotics,,16-28	DrugDDI.d270.s32.e0
such,29-33
as,34-36
erythromycin,,37-50
have,51-55
not,56-59
been,60-64
studied,65-72
in,73-75
combination,76-87
with,88-92
SUSTIVA.,93-101	DrugDDI.d270.s32.e2

Indinavir,0-9	DrugDDI.d270.s35.e0

??indinavir,0-11
concentration,12-25

The,0-3
optimal,4-11
dose,12-16
of,17-19
indinavir,,20-30
when,31-35
given,36-41
in,42-44
combination,45-56
with,57-61
SUSTIVA,,62-70
is,71-73
not,74-77
known.,78-84

Increasing,0-10
the,11-14
indinavir,15-24	DrugDDI.d270.s38.e0
dose,25-29
to,30-32
1000,33-37
mg,38-40
every,41-46
8,47-48
hours,49-54
does,55-59
not,60-63
compensate,64-74
for,75-78
the,79-82
increased,83-92
indinavir,93-102	DrugDDI.d270.s38.e1
metabolism,103-113
due,114-117
to,118-120
SUSTIVA.,121-129	DrugDDI.d270.s38.e2

When,0-4
indinavir,5-14	DrugDDI.d270.s39.e0
at,15-17
an,18-20
increased,21-30
dose,31-35
(1000,36-41
mg,42-44
every,45-50
8,51-52
hours),53-59
was,60-63
given,64-69
with,70-74
SUSTIVA,75-82	DrugDDI.d270.s39.e1
(600,83-87
mg,88-90
once,91-95
daily),,96-103
the,104-107
indinavir,108-117	DrugDDI.d270.s39.e2
AUC,118-121
and,122-125
Cmin,126-130
were,131-135
decreased,136-145
on,146-148
average,149-156
by,157-159
33-46%,160-166
and,167-170
39-57%,,171-178
respectively,,179-192
compared,193-201
to,202-204
when,205-209
indinavir,210-219	DrugDDI.d270.s39.e3
(800,220-224
mg,225-227
every,228-233
8,234-235
hours),236-242
was,243-246
given,247-252
alone.,253-259

Lopinavir/ritonavir,0-19	DrugDDI.d270.s40.e0

??lopinavir,0-11
concentration,12-25

A,0-1
dose,2-6
increase,7-15
of,16-18
lopinavir/ritonavir,19-38	DrugDDI.d270.s42.e0
to,39-41
533/133,42-49
mg,50-52
(4,53-55
capsules,56-64
or,65-67
6.5,68-71
mL),72-75
twice,76-81
daily,82-87
taken,88-93
with,94-98
food,99-103
is,104-106
recommended,107-118
when,119-123
used,124-128
in,129-131
combination,132-143
with,144-148
SUSTIVA.,149-157	DrugDDI.d270.s42.e2

Methadone,0-9	DrugDDI.d270.s43.e0

??methadone,0-11
concentration,12-25

Coadministration,0-16
in,17-19
HIV-infected,20-32
individuals,33-44
with,45-49
a,50-51
history,52-59
of,60-62
injection,63-72
drug,73-77
use,78-81
resulted,82-90
in,91-93
decreased,94-103
plasma,104-110
levels,111-117
of,118-120
methadone,121-130	DrugDDI.d270.s45.e0
and,131-134
signs,135-140
of,141-143
opiate,144-150	DrugDDI.d270.s45.e1
withdrawal.,151-162

Ethinyl,0-7	DrugDDI.d270.s48.e0
estradiol,8-17	DrugDDI.d270.s48.e0

??ethinyl,0-9
estradiol,10-19
concentration,20-33

Plasma,0-6
concentrations,7-21
increased,22-31
by,32-34
SUSTIVA,35-42	DrugDDI.d270.s50.e0
(efavirenz);,43-55

Because,0-7
the,8-11
potential,12-21
interaction,22-33
of,34-36
efavirenz,37-46	DrugDDI.d270.s52.e0
with,47-51
oral,52-56	DrugDDI.d270.s52.e1
contraceptives,57-71	DrugDDI.d270.s52.e1
has,72-75
not,76-79
been,80-84
fully,85-90
characterized,,91-105
a,106-107
reliable,108-116
method,117-123
of,124-126
barrier,127-134
contraception,135-148
should,149-155
be,156-158
used,159-163
in,164-166
addition,167-175
to,176-178
oral,179-183	DrugDDI.d270.s52.e2
contraceptives.,184-199	DrugDDI.d270.s52.e2

Rifabutin,0-9	DrugDDI.d270.s53.e0

??rifabutin,0-11
concentration,12-25

Increase,0-8
daily,9-14
dose,15-19
of,20-22
rifabutin,23-32	DrugDDI.d270.s55.e0
by,33-35
50%.,36-40

Consider,0-8
doubling,9-17
the,18-21
rifabutin,22-31	DrugDDI.d270.s56.e0
dose,32-36
in,37-39
regimens,40-48
where,49-54
rifabutin,55-64	DrugDDI.d270.s56.e1
is,65-67
given,68-73
2,74-75
or,76-78
3,79-80
times,81-86
a,87-88
week.,89-94

Rifampin,0-8	DrugDDI.d270.s57.e0

??efavirenz,0-11
concentration,12-25

Clinical,0-8
significance,9-21
of,22-24
reduced,25-32
efavirenz,33-42	DrugDDI.d270.s59.e0
concentrations,43-57
unknown.,58-66

Ritonavir,0-9	DrugDDI.d270.s60.e0

??ritonavir,0-11
concentration,12-25

Monitoring,0-10
of,11-13
liver,14-19	DrugDDI.d270.s63.e0
enzymes,20-27	DrugDDI.d270.s63.e0
is,28-30
recommended,31-42
when,43-47
SUSTIVA,48-55	DrugDDI.d270.s63.e1
is,56-58
used,59-63
in,64-66
combination,67-78
with,79-83
ritonavir.,84-94	DrugDDI.d270.s63.e2

??efavirenz,0-11
concentration,12-25

Saquinavir,0-10	DrugDDI.d270.s65.e0

??saquinavir,0-12
concentration,13-26

Should,0-6
not,7-10
be,11-13
used,14-18
as,19-21
sole,22-26
protease,27-35	DrugDDI.d270.s67.e0
inhibitor,36-45	DrugDDI.d270.s67.e0
in,46-48
combination,49-60
with,61-65
SUSTIVA.,66-74	DrugDDI.d270.s67.e1

Sertraline,0-10	DrugDDI.d270.s68.e0

??sertraline,0-12
concentration,13-26

Other,0-5
Potentially,6-17
Clinically,18-28
Significant,29-40
Drug,41-45	DrugDDI.d270.s71.e0
or,46-48
Herbal,49-55
Product,56-63
Interactions,64-76
With,77-81
SUSTIVAb,82-90

Anticoagulants:,0-15	DrugDDI.d270.s72.e0
Warfarin,16-24	DrugDDI.d270.s72.e1

Plasma,0-6
concentrations,7-21
and,22-25
effects,26-33
potentially,34-45
increased,46-55
or,56-58
decreased,59-68
by,69-71
SUSTIVA.,72-80	DrugDDI.d270.s73.e0

Anticonvulsants:,0-16	DrugDDI.d270.s74.e0
Phenytoin,17-26
Phenobarbital,27-40	DrugDDI.d270.s74.e1
Carbamazepine,41-54

Potential,0-9
for,10-13
reduction,14-23
in,24-26
anticonvulsant,27-41	DrugDDI.d270.s75.e0
and/or,42-48
efavirenz,49-58	DrugDDI.d270.s75.e1
plasma,59-65
levels;,66-73

periodic,0-8
monitoring,9-19
of,20-22
anticonvulsant,23-37	DrugDDI.d270.s76.e0
plasma,38-44
levels,45-51
should,52-58
be,59-61
conducted.,62-72

Antifungals:,0-12	DrugDDI.d270.s77.e0
Itraconazole,13-25	DrugDDI.d270.s77.e1
Ketoconazole,26-38

Drug,0-4
interaction,5-16
studies,17-24
with,25-29
SUSTIVA,30-37	DrugDDI.d270.s78.e0
and,38-41
these,42-47
imidazole,48-57	DrugDDI.d270.s78.e1
and,58-61
triazole,62-70	DrugDDI.d270.s78.e2
antifungals,71-82	DrugDDI.d270.s78.e2
have,83-87
not,88-91
been,92-96
conducted.,97-107

SUSTIVA,0-7	DrugDDI.d270.s79.e0
has,8-11
the,12-15
potential,16-25
to,26-28
decrease,29-37
plasma,38-44
concentrations,45-59
of,60-62
itraconazole,63-75	DrugDDI.d270.s79.e1
and,76-79
ketoconazole.,80-93	DrugDDI.d270.s79.e2

Anti-HIV,0-8	DrugDDI.d270.s80.e0
protease,9-17	DrugDDI.d270.s80.e0
inhibitors:,18-29	DrugDDI.d270.s80.e0
Saquinavir/ritonavir,30-50	DrugDDI.d270.s80.e1
combination,51-62

Amprenavir,0-10	DrugDDI.d270.s82.e0

SUSTIVAhas,0-10
the,11-14
potential,15-24
to,25-27
decrease,28-36
serum,37-42
concentrations,43-57
of,58-60
amprenavir.,61-72	DrugDDI.d270.s83.e0

Non-nucleoside,0-14	DrugDDI.d270.s84.e0
reverse,15-22	DrugDDI.d270.s84.e0
transcriptase,23-36	DrugDDI.d270.s84.e0
inhibitors,37-47	DrugDDI.d270.s84.e0

St.,0-3
John?s,4-10
wort,11-15
(Hypericum,16-26
perforatum),27-38

Expected,0-8
to,9-11
substantially,12-25
decrease,26-34
plasma,35-41
levels,42-48
of,49-51
efavirenz;has,52-65	DrugDDI.d270.s87.e0
not,66-69
been,70-74
studied,75-82
in,83-85
combination,86-97
with,98-102
SUSTIVA.,103-111	DrugDDI.d270.s87.e1

Other,0-5
Drugs:,6-12	DrugDDI.d270.s90.e0
Based,13-18
on,19-21
the,22-25
results,26-33
of,34-36
drug,37-41
interaction,42-53
studies,,54-62
no,63-65
dosage,66-72
adjustment,73-83
is,84-86
recommended,87-98
when,99-103
SUSTIVA,104-111	DrugDDI.d270.s90.e1
(efavirenz),112-123
is,124-126
given,127-132
with,133-137
the,138-141
following:,142-152
aluminum/magnesium,153-171
hydroxide,172-181
antacids,,182-191
azithromycin,,192-205
cetirizine,,206-217
famotidine,,218-229
fluconazole,,230-242
lamivudine,,243-254
lorazepam,,255-265
nelfinavir,,266-277
paroxetine,,278-289
and,290-293
zidovudine.,294-305	DrugDDI.d270.s90.e12

Specific,0-8
drug,9-13
interaction,14-25
studies,26-33
have,34-38
not,39-42
been,43-47
performed,48-57
with,58-62
SUSTIVA,63-70	DrugDDI.d270.s91.e0
and,71-74
NRTIs,75-80
other,81-86
than,87-91
lamivudine,92-102	DrugDDI.d270.s91.e1
and,103-106
zidovudine.,107-118	DrugDDI.d270.s91.e2

Clinically,0-10
significant,11-22
interactions,23-35
would,36-41
not,42-45
be,46-48
expected,49-57
since,58-63
the,64-67
NRTIs,68-73
are,74-77
metabolized,78-89
via,90-93
a,94-95
different,96-105
route,106-111
than,112-116
efavirenz,117-126	DrugDDI.d270.s92.e0
and,127-130
would,131-136
be,137-139
unlikely,140-148
to,149-151
compete,152-159	DrugDDI.d270.s92.e1
for,160-163
the,164-167
same,168-172
metabolic,173-182
enzymes,183-190
and,191-194
elimination,195-206
pathways.,207-216

The,0-3
potential,4-13
for,14-17
drug,18-22
interactions,23-35
with,36-40
EMTRIVA,41-48	DrugDDI.d43.s0.e0
has,49-52
been,53-57
studied,58-65
in,66-68
combination,69-80
with,81-85
indinavir,,86-96
stavudine,,97-107
famciclovir,,108-120
and,121-124
tenofovir,125-134	DrugDDI.d43.s0.e4
disoproxil,135-145	DrugDDI.d43.s0.e4
fumarate.,146-155	DrugDDI.d43.s0.e4

There,0-5
were,6-10
no,11-13
clinically,14-24
significant,25-36
drug,37-41
interactions,42-54
for,55-58
any,59-62
of,63-65
these,66-71
drugs,72-77	DrugDDI.d43.s1.e0

Hypotension:,0-12
Patients,13-21
on,22-24
Diuretic,25-33
Therapy:,34-42
Patients,43-51
on,52-54
diuretics,55-64	DrugDDI.d173.s0.e0
and,65-68
especially,69-79
those,80-85
in,86-88
whom,89-93
diuretic,94-102
therapy,103-110
was,111-114
recently,115-123
instituted,,124-135
may,136-139
occasionally,140-152
experience,153-163
an,164-166
excessive,167-176
reduction,177-186
of,187-189
blood,190-195
pressure,196-204
after,205-210
initiation,211-221
of,222-224
therapy,225-232
with,233-237
enalapril,238-247	DrugDDI.d173.s0.e1
or,248-250
enalaprilat.,251-263	DrugDDI.d173.s0.e2

The,0-3
possibility,4-15
of,16-18
hypotensive,19-30
effects,31-38
with,39-43
enalapril,44-53	DrugDDI.d173.s1.e0
or,54-56
enalaprilat,57-68	DrugDDI.d173.s1.e1
can,69-72
be,73-75
minimized,76-85
by,86-88
either,89-95
discontinuing,96-109
the,110-113
diuretic,114-122	DrugDDI.d173.s1.e2
or,123-125
increasing,126-136
the,137-140
salt,141-145
intake,146-152
prior,153-158
to,159-161
initiation,162-172
of,173-175
treatment,176-185
with,186-190
enalapril,191-200	DrugDDI.d173.s1.e3
or,201-203
enalaprilat.,204-216	DrugDDI.d173.s1.e4

If,0-2
it,3-5
is,6-8
necessary,9-18
to,19-21
continue,22-30
the,31-34
diuretic,,35-44
provide,45-52
close,53-58
medical,59-66
supervision,67-78
after,79-84
the,85-88
initial,89-96
dose,97-101
for,102-105
at,106-108
least,109-114
two,115-118
hours,119-124
and,125-128
until,129-134
blood,135-140
pressure,141-149
has,150-153
stabilized,154-164
for,165-168
at,169-171
least,172-177
an,178-180
additional,181-191
hour..,192-198

Agents,0-6
Causing,7-14
Renin,15-20	DrugDDI.d173.s3.e0
Release:,21-29
The,30-33
antihypertensive,34-50	DrugDDI.d173.s3.e1
effect,51-57
of,58-60
enalapril,61-70	DrugDDI.d173.s3.e2
and,71-74
enalapril,75-84	DrugDDI.d173.s3.e3
IV,85-87
is,88-90
augmented,91-100
by,101-103
antihypertensive,104-120	DrugDDI.d173.s3.e4
agents,121-127	DrugDDI.d173.s3.e4
that,128-132
cause,133-138
renin,139-144	DrugDDI.d173.s3.e5
release,145-152
(e.g.,,153-159
diuretics).,160-171	DrugDDI.d173.s3.e6

Non-steroidal,0-13	DrugDDI.d173.s4.e0
Anti-inflammatory,14-31	DrugDDI.d173.s4.e0
Agents:,32-39	DrugDDI.d173.s4.e0
In,40-42
some,43-47
patients,48-56
with,57-61
compromised,62-73
renal,74-79
function,80-88
who,89-92
are,93-96
being,97-102
treated,103-110
with,111-115
nonsteroidal,116-128	DrugDDI.d173.s4.e1
anti-inflammatory,129-146	DrugDDI.d173.s4.e1
drugs,,147-153	DrugDDI.d173.s4.e1
the,154-157
co-administration,158-175
of,176-178
enalapril,179-188	DrugDDI.d173.s4.e2
may,189-192
result,193-199
in,200-202
a,203-204
further,205-212
deterioration,213-226
of,227-229
renal,230-235
function.,236-245

In,0-2
a,3-4
clinical,5-13
pharmacology,14-26
study,,27-33
indomethacin,34-46	DrugDDI.d173.s6.e0
or,47-49
sulindac,50-58	DrugDDI.d173.s6.e1
was,59-62
administered,63-75
to,76-78
hypertensive,79-91
patients,92-100
receiving,101-110
VASOTEC.,111-119	DrugDDI.d173.s6.e2

In,0-2
this,3-7
study,8-13
there,14-19
was,20-23
no,24-26
evidence,27-35
of,36-38
a,39-40
blunting,41-49
of,50-52
the,53-56
antihypertensive,57-73	DrugDDI.d173.s7.e0
action,74-80
of,81-83
VASOTEC.,84-92	DrugDDI.d173.s7.e1

However,,0-8
reports,9-16
suggest,17-24
that,25-29
NSAIDs,30-36	DrugDDI.d173.s8.e0
may,37-40
diminish,41-49
the,50-53
antihypertensive,54-70	DrugDDI.d173.s8.e1
effect,71-77
of,78-80
ACE,81-84	DrugDDI.d173.s8.e2
inhibitors.,85-96	DrugDDI.d173.s8.e2

This,0-4
interaction,5-16
should,17-23
be,24-26
given,27-32
consideration,33-46
in,47-49
patients,50-58
taking,59-65
NSAIDs,66-72	DrugDDI.d173.s9.e0
concomitantly,73-86
with,87-91
ACE,92-95	DrugDDI.d173.s9.e1
inhibitors.,96-107	DrugDDI.d173.s9.e1

Other,0-5
Cardiovascular,6-20	DrugDDI.d173.s10.e0
Agents:,21-28	DrugDDI.d173.s10.e0
Enalapril,29-38	DrugDDI.d173.s10.e1
and,39-42
enalapril,43-52	DrugDDI.d173.s10.e2
IV,53-55
have,56-60
been,61-65
used,66-70
concomitantly,71-84
with,85-89
beta,90-94	DrugDDI.d173.s10.e3
adrenergic-blocking,95-114	DrugDDI.d173.s10.e3
agents,,115-122	DrugDDI.d173.s10.e3
methyldopa,,123-134
nitrates,,135-144
calcium-blocking,145-161	DrugDDI.d173.s10.e6
agents,,162-169
hydralazine,,170-182
prazosin,183-191	DrugDDI.d173.s10.e8
and,192-195
digoxin,196-203	DrugDDI.d173.s10.e9
without,204-211
evidence,212-220
of,221-223
clinically,224-234
significant,235-246
adverse,247-254
interactions.,255-268

Enalapril,0-9	DrugDDI.d173.s11.e0
IV,10-12
has,13-16
been,17-21
used,22-26
concomitantly,27-40
with,41-45
digitalis,46-55	DrugDDI.d173.s11.e1
without,56-63
evidence,64-72
of,73-75
clinically,76-86
significant,87-98
adverse,99-106
reactions.,107-117

Agents,0-6
Increasing,7-17
Serum,18-23
Potassium:,24-34
Enalapril,35-44	DrugDDI.d173.s12.e0
and,45-48
enalapril,49-58	DrugDDI.d173.s12.e1
IV,59-61
attenuate,62-71
potassium,72-81	DrugDDI.d173.s12.e2
loss,82-86
caused,87-93
by,94-96
thiazide-type,97-110	DrugDDI.d173.s12.e3
diuretics.,111-121	DrugDDI.d173.s12.e3

Potassium-sparing,0-17	DrugDDI.d173.s13.e0
diuretics,18-27	DrugDDI.d173.s13.e0
(e.g.,,28-34
spironolactone,,35-50
triamterene,,51-63
or,64-66
amiloride),,67-78
potassium,79-88	DrugDDI.d173.s13.e4
supplements,,89-101	DrugDDI.d173.s13.e4
or,102-104
potassium-containing,105-125	DrugDDI.d173.s13.e5
salt,126-130	DrugDDI.d173.s13.e5
substitutes,131-142	DrugDDI.d173.s13.e5
may,143-146
lead,147-151
to,152-154
significant,155-166
increases,167-176
in,177-179
serum,180-185
potassium.,186-196

Potassium,0-9	DrugDDI.d173.s15.e0
sparing,10-17
agents,18-24
should,25-31
generally,32-41
not,42-45
be,46-48
used,49-53
in,54-56
patients,57-65
with,66-70
heart,71-76
failure,77-84
receiving,85-94
enalapril.,95-105	DrugDDI.d173.s15.e1

Lithium:,0-8	DrugDDI.d173.s16.e0
Lithium,9-16
toxicity,17-25
has,26-29
been,30-34
reported,35-43
in,44-46
patients,47-55
receiving,56-65
lithium,66-73	DrugDDI.d173.s16.e1
concomitantly,74-87
with,88-92
drugs,93-98	DrugDDI.d173.s16.e2
which,99-104
cause,105-110
elimination,111-122
of,123-125
sodium,,126-133
including,134-143
ACE,144-147	DrugDDI.d173.s16.e4
inhibitors.,148-159	DrugDDI.d173.s16.e4

A,0-1
few,2-5
cases,6-11
of,12-14
lithium,15-22
toxicity,23-31
have,32-36
been,37-41
reported,42-50
in,51-53
patients,54-62
receiving,63-72
concomitant,73-84
enalapril/enalapril,85-104	DrugDDI.d173.s17.e0
IV,105-107
and,108-111
lithium,112-119	DrugDDI.d173.s17.e2
and,120-123
were,124-128
reversible,129-139
upon,140-144
discontinuation,145-160
of,161-163
both,164-168
drugs.,169-175	DrugDDI.d173.s17.e3

It,0-2
is,3-5
recommended,6-17
that,18-22
serum,23-28
lithium,29-36
levels,37-43
be,44-46
monitored,47-56
frequently,57-67
if,68-70
enalapril,71-80	DrugDDI.d173.s18.e0
is,81-83
administered,84-96
concomitantly,97-110
with,111-115
lithium.,116-124	DrugDDI.d173.s18.e1

The,0-3
action,4-10
of,11-13
nondepolarizing,14-29
relaxants,30-39
is,40-42
augmented,43-52
by,53-55
Enflurane.,56-66	DrugDDI.d359.s0.e0

Less,0-4
than,5-9
the,10-13
usual,14-19
amounts,20-27
of,28-30
these,31-36
medicines,37-46	DrugDDI.d359.s1.e0
should,47-53
be,54-56
used.,57-62

If,0-2
the,3-6
usual,7-12
amounts,13-20
of,21-23
nondepolarizing,24-39
relaxants,40-49
are,50-53
given,,54-60
the,61-64
time,65-69
for,70-73
recovery,74-82
from,83-87
neuromuscular,88-101
blockade,102-110
will,111-115
be,116-118
longer,119-125
in,126-128
the,129-132
presence,133-141
of,142-144
Enflurane,145-154	DrugDDI.d359.s2.e0
than,155-159
when,160-164
halothane,165-174	DrugDDI.d359.s2.e1
or,175-177
nitrous,178-185	DrugDDI.d359.s2.e2
oxide,186-191	DrugDDI.d359.s2.e2
with,192-196
a,197-198
balanced,199-207
technique,208-217
are,218-221
used.,222-227

CYP450,0-6
Metabolized,7-18
Drugs,19-24	DrugDDI.d446.s0.e0
Results,25-32
from,33-37
in,38-40
vitro,41-46
and,47-50
in,51-53
vivo,54-58
studies,59-66
suggest,67-74
that,75-79
enfuvirtide,80-91	DrugDDI.d446.s0.e1
is,92-94
unlikely,95-103
to,104-106
have,107-111
significant,112-123
drug,124-128
interactions,129-141
with,142-146
concomitantly,147-160
administered,161-173
drugs,174-179	DrugDDI.d446.s0.e2
metabolized,180-191
by,192-194
CYP450,195-201
enzymes.,202-210

Antiretroviral,0-14	DrugDDI.d446.s1.e0
Agents,15-21	DrugDDI.d446.s1.e0
No,22-24
drug,25-29
interactions,30-42
with,43-47
other,48-53
antiretroviral,54-68	DrugDDI.d446.s1.e1
medications,69-80	DrugDDI.d446.s1.e1
have,81-85
been,86-90
identified,91-101
that,102-106
would,107-112
warrant,113-120
alteration,121-131
of,132-134
either,135-141
the,142-145
enfuvirtide,146-157	DrugDDI.d446.s1.e2
dose,158-162
or,163-165
the,166-169
dose,170-174
of,175-177
the,178-181
other,182-187
antiretroviral,188-202	DrugDDI.d446.s1.e3
medication.,203-214	DrugDDI.d446.s1.e3

Bismuth:,0-8
Bismuth,9-16	DrugDDI.d535.s0.e0
subsalicylate,,17-31	DrugDDI.d535.s0.e0
given,32-37
concomitantly,38-51
with,52-56
enoxacin,57-65	DrugDDI.d535.s0.e1
or,66-68
60,69-71
minutes,72-79
following,80-89
enoxacin,90-98	DrugDDI.d535.s0.e2
administration,,99-114
decreased,115-124
enoxacin,125-133	DrugDDI.d535.s0.e3
bioavailability,134-149
by,150-152
approximately,153-166
25%.,167-171

Thus,,0-5
concomitant,6-17
administration,18-32
of,33-35
enoxacin,36-44	DrugDDI.d535.s1.e0
and,45-48
bismuth,49-56	DrugDDI.d535.s1.e1
subsalicylate,57-70	DrugDDI.d535.s1.e1
should,71-77
be,78-80
avoided.,81-89

Caffeine:,0-9	DrugDDI.d535.s2.e0
Enoxacin,10-18	DrugDDI.d535.s2.e1
is,19-21
a,22-23
potent,24-30
inhibitor,31-40
of,41-43
the,44-47
cytochrome,48-58	DrugDDI.d535.s2.e2
P-450,59-64	DrugDDI.d535.s2.e2
isozymes,65-73
responsible,74-85
for,86-89
the,90-93
metabolism,94-104
of,105-107
methylxanthines.,108-124	DrugDDI.d535.s2.e3

In,0-2
a,3-4
multiple-dose,5-18
study,,19-25
enoxacin,26-34	DrugDDI.d535.s3.e0
caused,35-41
a,42-43
dose-related,44-56
increase,57-65
in,66-68
the,69-72
mean,73-77
elimination,78-89
half-life,90-99
of,100-102
caffeine,,103-112
thereby,113-120
decreasing,121-131
the,132-135
clearance,136-145
of,146-148
caffeine,149-157	DrugDDI.d535.s3.e2
by,158-160
up,161-163
to,164-166
80%,167-170
and,171-174
leading,175-182
to,183-185
a,186-187
five-fold,188-197
increase,198-206
in,207-209
the,210-213
AUC,214-217
and,218-221
the,222-225
half-life,226-235
of,236-238
caffeine.,239-248	DrugDDI.d535.s3.e3

Trough,0-6
plasma,7-13
enoxacin,14-22	DrugDDI.d535.s4.e0
levels,23-29
were,30-34
also,35-39
20%,40-43
higher,44-50
when,51-55
caffeine,56-64	DrugDDI.d535.s4.e1
and,65-68
enoxacin,69-77	DrugDDI.d535.s4.e2
were,78-82
administered,83-95
concomitantly.,96-110

Caffeine-related,0-16	DrugDDI.d535.s5.e0
adverse,17-24
effects,25-32
have,33-37
occurred,38-46
in,47-49
patients,50-58
consuming,59-68
caffeine,69-77	DrugDDI.d535.s5.e1
while,78-83
on,84-86
therapy,87-94
with,95-99
enoxacin.,100-109	DrugDDI.d535.s5.e2

Cyclosporine:,0-13	DrugDDI.d535.s6.e0
Elevated,14-22
serum,23-28
levels,29-35
of,36-38
cyclosporine,39-51	DrugDDI.d535.s6.e1
have,52-56
been,57-61
reported,62-70
with,71-75
concomitant,76-87
use,88-91
of,92-94
cyclosporine,95-107	DrugDDI.d535.s6.e2
with,108-112
other,113-118
members,119-126
of,127-129
the,130-133
quinolone,134-143	DrugDDI.d535.s6.e3
class.,144-150	DrugDDI.d535.s6.e3

Digoxin:,0-8	DrugDDI.d535.s7.e0
Enoxacin,9-17	DrugDDI.d535.s7.e1
may,18-21
raise,22-27
serum,28-33
digoxin,34-41
levels,42-48
in,49-51
some,52-56
individuals.,57-69

If,0-2
signs,3-8
and,9-12
symptoms,13-21
suggestive,22-32
of,33-35
digoxin,36-43
toxicity,44-52
occur,53-58
when,59-63
enoxacin,64-72	DrugDDI.d535.s8.e0
and,73-76
digoxin,77-84	DrugDDI.d535.s8.e1
are,85-88
given,89-94
concomitantly,,95-109
physicians,110-120
are,121-124
advised,125-132
to,133-135
obtain,136-142
serum,143-148
digoxin,149-156
levels,157-163
and,164-167
adjust,168-174
digoxin,175-182
doses,183-188
appropriately.,189-203

Non-steroidal,0-13	DrugDDI.d535.s9.e0
anti-inflammatory,14-31	DrugDDI.d535.s9.e0
agents:,32-39	DrugDDI.d535.s9.e0
Seizures,40-48
have,49-53
been,54-58
reported,59-67
in,68-70
patients,71-79
taking,80-86
enoxacin,87-95	DrugDDI.d535.s9.e1
concomitantly,96-109
with,110-114
the,115-118
nonsteroidal,119-131	DrugDDI.d535.s9.e2
anti-inflammatory,132-149	DrugDDI.d535.s9.e2
drug,150-154	DrugDDI.d535.s9.e2
fenbufen.,155-164

Animal,0-6
studies,7-14
also,15-19
suggest,20-27
an,28-30
increased,31-40
potential,41-50
for,51-54
seizures,55-63
when,64-68
these,69-74
two,75-78
drugs,79-84	DrugDDI.d535.s10.e0
are,85-88
given,89-94
concomitantly.,95-109

Fenbufen,0-8	DrugDDI.d535.s11.e0
is,9-11
not,12-15
approved,16-24
in,25-27
the,28-31
United,32-38
States,39-45
at,46-48
this,49-53
time.,54-59

Sucralfate,0-10	DrugDDI.d535.s12.e0
and,11-14
antacids:,15-24	DrugDDI.d535.s12.e1
Quinolones,25-35	DrugDDI.d535.s12.e2
form,36-40
chelates,41-49
with,50-54
metal,55-60
cations.,61-69	DrugDDI.d535.s12.e3

Therefore,,0-10
administration,11-25
of,26-28
quinolones,29-39	DrugDDI.d535.s13.e0
with,40-44
antacids,45-53	DrugDDI.d535.s13.e1
containing,54-64
calcium,,65-73
magnesium,,74-84
or,85-87
aluminum;,88-97

with,0-4
sucralfate;,5-16	DrugDDI.d535.s14.e0

with,0-4
divalent,5-13
or,14-16
trivalent,17-26
cations,27-34	DrugDDI.d535.s15.e0
such,35-39
as,40-42
iron;,43-48	DrugDDI.d535.s15.e1

or,0-2
with,3-7
multivitamins,8-21	DrugDDI.d535.s16.e0
containing,22-32
zinc,33-37	DrugDDI.d535.s16.e1
may,38-41
substantially,42-55
interfere,56-65
with,66-70
drug,71-75
absorption,76-86
and,87-90
result,91-97
in,98-100
insufficient,101-113
plasma,114-120
and,121-124
tissue,125-131	DrugDDI.d535.s16.e2
quinolone,132-141	DrugDDI.d535.s16.e2
concentrations.,142-157

Antacids,0-8	DrugDDI.d535.s17.e0
containing,9-19
aluminum,20-28	DrugDDI.d535.s17.e1
hydroxide,29-38	DrugDDI.d535.s17.e1
and,39-42
magnesium,43-52	DrugDDI.d535.s17.e2
hydroxide,53-62	DrugDDI.d535.s17.e2
reduce,63-69
the,70-73
oral,74-78
absorption,79-89
of,90-92
enoxacin,93-101	DrugDDI.d535.s17.e3
by,102-104
75%.,105-109

The,0-3
oral,4-8
bioavailability,9-24
of,25-27
enoxacin,28-36	DrugDDI.d535.s18.e0
is,37-39
reduced,40-47
by,48-50
60%,51-54
with,55-59
coadministration,60-76
of,77-79
ranitidine.,80-91	DrugDDI.d535.s18.e1

These,0-5
agents,6-12
should,13-19
not,20-23
be,24-26
taken,27-32
for,33-36
8,37-38
hours,39-44
before,45-51
or,52-54
for,55-58
2,59-60
hours,61-66
after,67-72
enoxacin,73-81	DrugDDI.d535.s19.e0
administration.,82-97

Theophylline:,0-13	DrugDDI.d535.s20.e0
Enoxacin,14-22	DrugDDI.d535.s20.e1
is,23-25
a,26-27
potent,28-34
inhibitor,35-44
of,45-47
the,48-51
cytochrome,52-62	DrugDDI.d535.s20.e2
P-450,63-68	DrugDDI.d535.s20.e2
isozymes,69-77
responsible,78-89
for,90-93
the,94-97
metabolism,98-108
of,109-111
methylxanthines.,112-128	DrugDDI.d535.s20.e3

Enoxacin,0-8	DrugDDI.d535.s21.e0
interferes,9-19
with,20-24
the,25-28
metabolism,29-39
of,40-42
theophylline,43-55	DrugDDI.d535.s21.e1
resulting,56-65
in,66-68
a,69-70
42%,71-74
to,75-77
74%,78-81
dose-related,82-94
decrease,95-103
in,104-106
theophylline,107-119	DrugDDI.d535.s21.e2
clearance,120-129
and,130-133
a,134-135
subsequent,136-146
260%,147-151
to,152-154
350%,155-159
increase,160-168
in,169-171
serum,172-177
theophylline,178-190
levels.,191-198

Theophylline-related,0-20	DrugDDI.d535.s22.e0
adverse,21-28
effects,29-36
have,37-41
occurred,42-50
in,51-53
patients,54-62
when,63-67
theophylline,68-80	DrugDDI.d535.s22.e1
and,81-84
enoxacin,85-93	DrugDDI.d535.s22.e2
were,94-98
coadministered.,99-114

Warfarin:,0-9	DrugDDI.d535.s23.e0
Quinolones,,10-21
including,22-31
enoxacin,,32-41
decrease,42-50
the,51-54
clearance,55-64
of,65-67
R-warfarin,,68-79
the,80-83
less,84-88
active,89-95
isomer,96-102
of,103-105
racemic,106-113
warfarin.,114-123	DrugDDI.d535.s23.e4

Enoxacin,0-8	DrugDDI.d535.s24.e0
does,9-13
not,14-17
affect,18-24
the,25-28
clearance,29-38
of,39-41
the,42-45
active,46-52
S-isomer,,53-62
and,63-66
changes,67-74
in,75-77
clotting,78-86
time,87-91
have,92-96
not,97-100
been,101-105
observed,106-114
when,115-119
enoxacin,120-128	DrugDDI.d535.s24.e1
and,129-132
warfarin,133-141	DrugDDI.d535.s24.e2
were,142-146
coadministered.,147-162

Nevertheless,,0-13
the,14-17
prothrombin,18-29
time,30-34
or,35-37
other,38-43
suitable,44-52
coagulation,53-64
test,65-69
should,70-76
be,77-79
monitored,80-89
when,90-94
warfarin,95-103	DrugDDI.d535.s25.e0
or,104-106
its,107-110
derivatives,111-122	DrugDDI.d535.s25.e1
and,123-126
enoxacin,127-135	DrugDDI.d535.s25.e2
are,136-139
given,140-145
concomitantly.,146-160

Unless,0-6
really,7-13
needed,,14-21
agents,22-28
which,29-34
may,35-38
enhance,39-46
the,47-50
risk,51-55
of,56-58
hemorrhage,59-69
should,70-76
be,77-79
discontinued,80-92
prior,93-98
to,99-101
initiation,102-112
of,113-115
Lovenox,116-123	DrugDDI.d396.s0.e0
Injection,124-133
therapy.,134-142

These,0-5
agents,6-12
include,13-20
medications,21-32	DrugDDI.d396.s1.e0
such,33-37
as:,38-41
anticoagulants,,42-57
platelet,58-66	DrugDDI.d396.s1.e2
inhibitors,67-77	DrugDDI.d396.s1.e2
including,78-87
acetylsalicylic,88-103	DrugDDI.d396.s1.e3
acid,,104-109	DrugDDI.d396.s1.e3
sali-cylates,,110-123
NSAIDs,124-130	DrugDDI.d396.s1.e5
(including,131-141
ketorolac,142-151	DrugDDI.d396.s1.e6
tromethamine),,152-166	DrugDDI.d396.s1.e6
dipyridamole,,167-180
or,181-183
sulfinpyrazone.,184-199	DrugDDI.d396.s1.e8

In,0-2
vitro,3-8
studies,9-16
of,17-19
human,20-25
CYP,26-29	DrugDDI.d319.s0.e0
enzymes,30-37
showed,38-44
that,45-49
entacapone,50-60	DrugDDI.d319.s0.e1
inhibited,61-70
the,71-74
CYP,75-78	DrugDDI.d319.s0.e2
enzymes,79-86	DrugDDI.d319.s0.e2
1A2,,87-91
2A6,,92-96
2C9,,97-101
2C19,,102-107
2D6,,108-112
2E1,113-116
and,117-120
3A,121-123
only,124-128
at,129-131
very,132-136
high,137-141
concentrations,142-156
(IC50,157-162
from,163-167
200,168-171
to,172-174
over,175-179
1000,180-184
uM;,185-188

Protein,0-7
Binding:,8-16
Entacapone,17-27	DrugDDI.d319.s3.e0
is,28-30
highly,31-37
protein,38-45	DrugDDI.d319.s3.e1
bound,46-51
(98%).,52-58

In,0-2
vitro,3-8
studies,9-16
have,17-21
shown,22-27
no,28-30
binding,31-38
displacement,39-51
between,52-59
entacapone,60-70	DrugDDI.d319.s4.e0
and,71-74
other,75-80
highly,81-87
bound,88-93
drugs,,94-100
such,101-105
as,106-108
warfarin,,109-118
salicylic,119-128	DrugDDI.d319.s4.e2
acid,,129-134	DrugDDI.d319.s4.e2
phenylbutazone,,135-150
and,151-154
diazepam.,155-164	DrugDDI.d319.s4.e4

Drugs,0-5	DrugDDI.d319.s5.e0
Metabolized,6-17
by,18-20
Catechol-O-methyltransferase,21-49	DrugDDI.d319.s5.e1
(COMT):,50-57
Hormone,58-65
levels:,66-73
Levodopa,74-82	DrugDDI.d319.s5.e2
is,83-85
known,86-91
to,92-94
depress,95-102
prolactin,103-112	DrugDDI.d319.s5.e3
secretion,113-122
and,123-126
increase,127-135
growth,136-142
hormone,143-150
levels.,151-158

Treatment,0-9
with,10-14
entacapone,15-25	DrugDDI.d319.s6.e0
coadministered,26-40
with,41-45
levodopa/dopa,46-59	DrugDDI.d319.s6.e1
decarboxylase,60-73
inhibitor,74-83
does,84-88
not,89-92
change,93-99
these,100-105
effects.,106-114

No,0-2
interaction,3-14
was,15-18
noted,19-24
with,25-29
the,30-33
MAO-B,34-39	DrugDDI.d319.s7.e0
inhibitor,40-49	DrugDDI.d319.s7.e0
selegiline,50-60
in,61-63
two,64-67
multiple-dose,68-81
interaction,82-93
studies,94-101
when,102-106
entacapone,107-117	DrugDDI.d319.s7.e1
was,118-121
coadministered,122-136
with,137-141
a,142-143
levodopa/dopa,144-157	DrugDDI.d319.s7.e2
decarboxylase,158-171
inhibitor,172-181
(n=29).,182-189

More,0-4
than,5-9
600,10-13
Parkinsons,14-24
disease,25-32
patients,33-41
in,42-44
clinical,45-53
trials,54-60
have,61-65
used,66-70
selegiline,71-81	DrugDDI.d319.s8.e0
in,82-84
combination,85-96
with,97-101
entacapone,102-112	DrugDDI.d319.s8.e1
and,113-116
levodopa/dopa,117-130	DrugDDI.d319.s8.e2
decarboxylase,131-144
inhibitor.,145-155

As,0-2
most,3-7
entacapone,8-18	DrugDDI.d319.s9.e0
excretion,19-28
is,29-31
via,32-35
the,36-39
bile,,40-45
caution,46-53
should,54-60
be,61-63
exercised,64-73
when,74-78
drugs,79-84	DrugDDI.d319.s9.e1
known,85-90
to,91-93
interfere,94-103
with,104-108
biliary,109-116
excretion,,117-127
glucuronidation,,128-144
and,145-148
intestinal,149-159
beta-glucuronidase,160-178	DrugDDI.d319.s9.e2
are,179-182
given,183-188
concurrently,189-201
with,202-206
entacapone.,207-218	DrugDDI.d319.s9.e3

These,0-5
include,6-13
probenecid,,14-25
cholestyramine,,26-41
and,42-45
some,46-50
antibiotics,51-62	DrugDDI.d319.s10.e2
(e.g.,63-68
erythromycin,,69-82
rifamipicin,,83-95
ampicillin,96-106	DrugDDI.d319.s10.e4
and,107-110
chloramphenicol).,111-128	DrugDDI.d319.s10.e5

No,0-2
interaction,3-14
with,15-19
the,20-23
tricyclic,24-33	DrugDDI.d319.s11.e0
antidepressant,34-48	DrugDDI.d319.s11.e0
imipramine,49-59
was,60-63
shown,64-69
in,70-72
a,73-74
single-dose,75-86
study,87-92
with,93-97
entacapone,98-108	DrugDDI.d319.s11.e1
without,109-116
coadministered,117-131
levodopa/dopa-decarboxylase,132-159	DrugDDI.d319.s11.e2
inhibitor.,160-170

Since,0-5
entecavir,6-15	DrugDDI.d440.s0.e0
is,16-18
primarily,19-28
eliminated,29-39
by,40-42
the,43-46
kidneys,,47-55
coadministration,56-72
of,73-75
BARACLUDE,76-85	DrugDDI.d440.s0.e1
with,86-90
drugs,91-96	DrugDDI.d440.s0.e2
that,97-101
reduce,102-108
renal,109-114
function,115-123
or,124-126
compete,127-134	DrugDDI.d440.s0.e3
for,135-138
active,139-145
tubular,146-153
secretion,154-163
may,164-167
increase,168-176
serum,177-182
concentrations,183-197
of,198-200
either,201-207
entecavir,208-217	DrugDDI.d440.s0.e4
or,218-220
the,221-224
coadministered,225-239
drug.,240-245	DrugDDI.d440.s0.e5

Coadministration,0-16
of,17-19
entecavir,20-29	DrugDDI.d440.s1.e0
with,30-34
lamivudine,,35-46
adefovir,47-55	DrugDDI.d440.s1.e2
dipivoxil,or,56-68	DrugDDI.d440.s1.e2
tenofovir,69-78	DrugDDI.d440.s1.e3
disoproxil,79-89	DrugDDI.d440.s1.e3
fumarate,90-98	DrugDDI.d440.s1.e3
did,99-102
not,103-106
result,107-113
in,114-116
significant,117-128
drug,129-133
interactions.,134-147

The,0-3
effects,4-11
of,12-14
coadministration,15-31
of,32-34
BARACLUDE,35-44	DrugDDI.d440.s2.e0
with,45-49
other,50-55
drugs,56-61	DrugDDI.d440.s2.e1
that,62-66
are,67-70
renally,71-78
eliminated,79-89
or,90-92
are,93-96
known,97-102
to,103-105
affect,106-112
renal,113-118
function,119-127
have,128-132
not,133-136
been,137-141
evaluated,,142-152
and,153-156
patients,157-165
should,166-172
be,173-175
monitored,176-185
closely,186-193
for,194-197
adverse,198-205
events,206-212
when,213-217
BARACLUDE,218-227	DrugDDI.d440.s2.e2
is,228-230
coadministered,231-245
with,246-250
such,251-255
drugs.,256-262	DrugDDI.d440.s2.e3

Epinephrine,0-11	DrugDDI.d230.s0.e0
should,12-18
be,19-21
used,22-26
cautiously,27-37
in,38-40
patients,41-49
with,50-54
hyperthyroidism,,55-71
hypertension,72-84
and,85-88
cardiac,89-96
arrhythmias.,97-109

All,0-3
vasopressors,4-16	DrugDDI.d230.s1.e0
should,17-23
be,24-26
used,27-31
cautiously,32-42
in,43-45
patients,46-54
taking,55-61
monoamine,62-71	DrugDDI.d230.s1.e1
oxidase,72-79	DrugDDI.d230.s1.e1
(MAO),80-85
inhibitors.,86-97

Epinephrine,0-11	DrugDDI.d230.s2.e0
should,12-18
not,19-22
be,23-25
administered,26-38
concomitantly,39-52
with,53-57
other,58-63
sympathomimetic,64-79	DrugDDI.d230.s2.e1
drugs,80-85	DrugDDI.d230.s2.e1
(such,86-91
as,92-94
isoproterenol),95-109	DrugDDI.d230.s2.e2
because,110-117
of,118-120
possible,121-129
additive,130-138
effects,139-146
and,147-150
increased,151-160
toxicity.,161-170

They,0-4
may,5-8
be,9-11
administered,12-24
alternately,25-36
when,37-41
the,42-45
preceding,46-55
effect,56-62
of,63-65
other,66-71
such,72-76
drug,77-81	DrugDDI.d230.s4.e0
has,82-85
subsided.,86-95

Administration,0-14
of,15-17
epinephrine,18-29	DrugDDI.d230.s5.e0
to,30-32
patients,33-41
receiving,42-51
cyclopropane,52-64	DrugDDI.d230.s5.e1
or,65-67
halogenated,68-79	DrugDDI.d230.s5.e2
hydrocarbon,80-91	DrugDDI.d230.s5.e2
general,92-99	DrugDDI.d230.s5.e2
anesthetics,100-111	DrugDDI.d230.s5.e2
such,112-116
as,117-119
halothane,120-129	DrugDDI.d230.s5.e3
which,130-135
sensitize,136-145
the,146-149
myocardium,,150-161
may,162-165
induce,166-172
cardiac,173-180
arrhythmia..,181-193

When,0-4
encountered,,5-17
such,18-22
arrhythmias,23-34
may,35-38
respond,39-46
to,47-49
administration,50-64
of,65-67
a,68-69
beta-adrenergic,70-85	DrugDDI.d230.s6.e0
blocking,86-94	DrugDDI.d230.s6.e0
drug.,95-100	DrugDDI.d230.s6.e0

Epinephrine,0-11	DrugDDI.d230.s7.e0
also,12-16
should,17-23
be,24-26
used,27-31
cautiously,32-42
with,43-47
other,48-53
drugs,54-59	DrugDDI.d230.s7.e1
(e.g.,,60-66
digitalis,,67-77
glycosides),78-89
that,90-94
sensitize,95-104
the,105-108
myocardium,109-119
to,120-122
the,123-126
actions,127-134
of,135-137
sympathomimetic,138-153	DrugDDI.d230.s7.e3
drugs.,154-160	DrugDDI.d230.s7.e3

Diuretic,0-8	DrugDDI.d230.s8.e0
agents,9-15
may,16-19
decrease,20-28
vascular,29-37
response,38-46
to,47-49
pressor,50-57	DrugDDI.d230.s8.e1
drugs,58-63	DrugDDI.d230.s8.e1
such,64-68
as,69-71
epinephrine.,72-84	DrugDDI.d230.s8.e2

Epinephrine,0-11	DrugDDI.d230.s9.e0
may,12-15
antagonize,16-26
the,27-30
neuron,31-37
blockade,38-46
produced,47-55
by,56-58
guanethidine,59-71	DrugDDI.d230.s9.e1
resulting,72-81
in,82-84
decreased,85-94
antihypertensive,95-111	DrugDDI.d230.s9.e2
effect,112-118
and,119-122
requiring,123-132
increased,133-142
dosage,143-149
of,150-152
the,153-156
latter.,157-164

ELLENCE,0-7	DrugDDI.d428.s0.e0
when,8-12
used,13-17
in,18-20
combination,21-32
with,33-37
other,38-43	DrugDDI.d428.s0.e1
cytotoxic,44-53	DrugDDI.d428.s0.e1
drugs,54-59	DrugDDI.d428.s0.e1
may,60-63
show,64-68
on-treatment,69-81
additive,82-90
toxicity,,91-100
especially,101-111
hematologic,112-123
and,124-127
gastrointestinal,128-144
effects.,145-153

Concomitant,0-11
use,12-15
of,16-18
ELLENCE,19-26	DrugDDI.d428.s1.e0
with,27-31
other,32-37
cardioactive,38-50
compounds,51-60
that,61-65
could,66-71
cause,72-77
heart,78-83
failure,84-91
(e.g.,,92-98
calcium,99-106	DrugDDI.d428.s1.e1
channel,107-114	DrugDDI.d428.s1.e1
blockers),,115-125	DrugDDI.d428.s1.e1
requires,126-134
close,135-140
monitoring,141-151
of,152-154
cardiac,155-162
function,163-171
throughout,172-182
treatment.,183-193

There,0-5
are,6-9
few,10-13
data,14-18
regarding,19-28
the,29-32
coadministration,33-49
of,50-52
radiation,53-62
therapy,63-70
and,71-74
epirubicin.,75-86	DrugDDI.d428.s2.e0

In,0-2
adjuvant,3-11
trials,12-18
of,19-21
epirubicin-containing,22-43	DrugDDI.d428.s3.e0
CEF-120,44-51
or,52-54
FEC-100,55-62
chemotherapies,,63-78
breast,79-85
irradiation,86-97
was,98-101
delayed,102-109
until,110-115
after,116-121
chemotherapy,122-134
was,135-138
completed.,139-149

A,0-1
small,2-7
number,8-14
of,15-17
patients,18-26
received,27-35
epirubicin-based,36-52	DrugDDI.d428.s5.e0
chemotherapy,53-65
concomitantly,66-79
with,80-84
radiation,85-94
therapy,95-102
but,103-106
had,107-110
chemotherapy,111-123
interrupted,124-135
in,136-138
order,139-144
to,145-147
avoid,148-153
potential,154-163
overlapping,164-175
toxicities.,176-187

It,0-2
is,3-5
likely,6-12
that,13-17
use,18-21
of,22-24
epirubicin,25-35	DrugDDI.d428.s6.e0
with,36-40
radiotherapy,41-53
may,54-57
sensitize,58-67
tissues,68-75
to,76-78
the,79-82
cytotoxic,83-92
actions,93-100
of,101-103
irradiation.,104-116

Administration,0-14
of,15-17
ELLENCE,18-25	DrugDDI.d428.s7.e0
after,26-31
previous,32-40
radiation,41-50
therapy,51-58
may,59-62
induce,63-69
an,70-72
inflammatory,73-85
recall,86-92
reaction,93-101
at,102-104
the,105-108
site,109-113
of,114-116
the,117-120
irradiation.,121-133

Epirubicin,0-10	DrugDDI.d428.s8.e0
is,11-13
extensively,14-25
metabolized,26-37
by,38-40
the,41-44
liver.,45-51	DrugDDI.d428.s8.e1

Changes,0-7
in,8-10
hepatic,11-18
function,19-27
induced,28-35
by,36-38
concomitant,39-50
therapies,51-60
may,61-64
affect,65-71
epirubicin,72-82	DrugDDI.d428.s9.e0
metabolism,,83-94
pharmacokinetics,,95-112
therapeutic,113-124
efficacy,,125-134
and/or,135-141
toxicity.,142-151

Cimetidine,0-10	DrugDDI.d428.s10.e0
increased,11-20
the,21-24
AUC,25-28
of,29-31
epirubicin,32-42	DrugDDI.d428.s10.e1
by,43-45
50%.,46-50

Cimetidine,0-10	DrugDDI.d428.s11.e0
treatment,11-20
should,21-27
be,28-30
stopped,31-38
during,39-45
treatment,46-55
with,56-60
ELLENCE.,61-69	DrugDDI.d428.s11.e1

Drug-Laboratory,0-15
Test,16-20
Interactions,21-33
There,34-39
are,40-43
no,44-46
known,47-52
interactions,53-65
between,66-73
ELLENCE,74-81	DrugDDI.d428.s12.e0
and,82-85
laboratory,86-96
tests.,97-103

Inhibitors,0-10
of,11-13
CYP3A4-Eplerenone,14-31	DrugDDI.d79.s0.e0
metabolism,32-42
is,43-45
predominantly,46-59
mediated,60-68
via,69-72
CYP3A4.,73-80	DrugDDI.d79.s0.e1

A,0-1
pharmacokinetic,2-17
study,18-23
evaluating,24-34
the,35-38
administration,39-53
of,54-56
a,57-58
single,59-65
dose,66-70
of,71-73
INSPRA,74-80	DrugDDI.d79.s1.e0
100,81-84
mg,85-87
with,88-92
ketoconazole,93-105	DrugDDI.d79.s1.e1
200,106-109	DrugDDI.d79.s1.e1
mg,110-112	DrugDDI.d79.s1.e1
BID,,113-117
a,118-119
potent,120-126
inhibitor,127-136
of,137-139
the,140-143
CYP3A4,144-150	DrugDDI.d79.s1.e2
pathway,,151-159
showed,160-166
a,167-168
1.7-fold,169-177
increase,178-186
in,187-189
Cmax,190-194
of,195-197
eplerenone,198-208	DrugDDI.d79.s1.e3
and,209-212
a,213-214
5.4-fold,215-223
increase,224-232
in,233-235
AUC,236-239
of,240-242
eplerenone.,243-254	DrugDDI.d79.s1.e4

INSPRA,0-6	DrugDDI.d79.s2.e0
should,7-13
not,14-17
be,18-20
used,21-25
with,26-30
drugs,31-36	DrugDDI.d79.s2.e1
described,37-46
as,47-49
strong,50-56
inhibitors,57-67
of,68-70
CYP3A4,71-77	DrugDDI.d79.s2.e2
in,78-80
their,81-86
labeling.,87-96

Administration,0-14
of,15-17
eplerenone,18-28	DrugDDI.d79.s3.e0
with,29-33
other,34-39
CYP3A4,40-46	DrugDDI.d79.s3.e1
inhibitors,47-57
(e.g.,,58-64
erythromycin,65-77	DrugDDI.d79.s3.e2
500,78-81	DrugDDI.d79.s3.e2
mg,82-84	DrugDDI.d79.s3.e2
BID,,85-89
verapamil,90-99	DrugDDI.d79.s3.e3
240,100-103	DrugDDI.d79.s3.e3
mg,104-106	DrugDDI.d79.s3.e3
QD,,107-110
saquinavir,111-121	DrugDDI.d79.s3.e4
1200,122-126
mg,127-129
TID,,130-134
fluconazole,135-146	DrugDDI.d79.s3.e5
200,147-150	DrugDDI.d79.s3.e5
mg,151-153	DrugDDI.d79.s3.e5
QD),154-157
resulted,158-166
in,167-169
increases,170-179
in,180-182
Cmax,183-187
of,188-190
eplerenone,191-201	DrugDDI.d79.s3.e6
ranging,202-209
from,210-214
1.4-,215-219
to,220-222
1.6-,223-227
fold,228-232
and,233-236
AUC,237-240
from,241-245
2.0-,246-250
to,251-253
2.9-,254-258
fold.,259-264

ACE,0-3	DrugDDI.d79.s4.e0
Inhibitors,4-14	DrugDDI.d79.s4.e0
and,15-18
Angiotensin,19-30	DrugDDI.d79.s4.e1
II,31-33	DrugDDI.d79.s4.e1
Receptor,34-42	DrugDDI.d79.s4.e1
Antagonists,43-54	DrugDDI.d79.s4.e1
(Congestive,55-66
Heart,67-72
Failure,73-80
Post-Myocardial,81-96
Infarction)-,97-109
In,110-112
EPHESUS,,113-121
3020,122-126
(91%),127-132
patients,133-141
receiving,142-151
INSPRA,152-158	DrugDDI.d79.s4.e2
25,159-161
to,162-164
50,165-167
mg,168-170
also,171-175
received,176-184
ACE,185-188	DrugDDI.d79.s4.e3
inhibitors,189-199	DrugDDI.d79.s4.e3
or,200-202
angiotensin,203-214	DrugDDI.d79.s4.e4
II,215-217	DrugDDI.d79.s4.e4
receptor,218-226	DrugDDI.d79.s4.e4
antagonists,227-238	DrugDDI.d79.s4.e4
(ACEI/ARB).,239-250

ACE,0-3	DrugDDI.d79.s6.e0
Inhibitors,4-14	DrugDDI.d79.s6.e0
and,15-18
Angiotensin,19-30	DrugDDI.d79.s6.e1
II,31-33	DrugDDI.d79.s6.e1
Receptor,34-42	DrugDDI.d79.s6.e1
Antagonists,43-54	DrugDDI.d79.s6.e1
(Hypertension)-,55-70
In,71-73
clinical,74-82
studies,83-90
of,91-93
patients,94-102
with,103-107
hypertension,,108-121
the,122-125
addition,126-134
of,135-137
INSPRA,138-144	DrugDDI.d79.s6.e2
50,145-147
to,148-150
100,151-154
mg,155-157
to,158-160
ACE,161-164	DrugDDI.d79.s6.e3
inhibitors,165-175	DrugDDI.d79.s6.e3
and,176-179
angiotensin,180-191	DrugDDI.d79.s6.e4
II,192-194	DrugDDI.d79.s6.e4
receptor,195-203	DrugDDI.d79.s6.e4
antagonists,204-215	DrugDDI.d79.s6.e4
increased,216-225
mean,226-230
serum,231-236
potassium,237-246
slightly,247-255
(about,256-262
0.09-0.13,263-272
mEq/L).,273-280

In,0-2
a,3-4
study,5-10
in,11-13
diabetics,14-23
with,24-28
microalbuminuria,29-45
INSPRA,46-52	DrugDDI.d79.s7.e0
200,53-56
mg,57-59
combined,60-68
with,69-73
the,74-77
ACE,78-81
inhibitor,82-91
enalapril,92-101	DrugDDI.d79.s7.e1
10,102-104	DrugDDI.d79.s7.e1
mg,105-107	DrugDDI.d79.s7.e1
increased,108-117
the,118-121
frequency,122-131
of,132-134
hyperkalemia,135-147
(serum,148-154
potassium,155-164
,165-165
5.5,166-169
mEq/L),170-176
from,177-181
17%,182-185
on,186-188
enalapril,189-198	DrugDDI.d79.s7.e2
alone,199-204
to,205-207
38%.,208-212

Lithium-A,0-9	DrugDDI.d79.s8.e0
drug,10-14
interaction,15-26
study,27-32
of,33-35
eplerenone,36-46	DrugDDI.d79.s8.e1
with,47-51
lithium,52-59	DrugDDI.d79.s8.e2
has,60-63
not,64-67
been,68-72
conducted.,73-83

Lithium,0-7
toxicity,8-16
has,17-20
been,21-25
reported,26-34
in,35-37
patients,38-46
receiving,47-56
lithium,57-64	DrugDDI.d79.s9.e0
concomitantly,65-78
with,79-83
diuretics,84-93	DrugDDI.d79.s9.e1
and,94-97
ACE,98-101	DrugDDI.d79.s9.e2
inhibitors.,102-113	DrugDDI.d79.s9.e2

Serum,0-5
lithium,6-13
levels,14-20
should,21-27
be,28-30
monitored,31-40
frequently,41-51
if,52-54
INSPRA,55-61	DrugDDI.d79.s10.e0
is,62-64
administered,65-77
concomitantly,78-91
with,92-96
lithium.,97-105	DrugDDI.d79.s10.e1

Nonsteroidal,0-12	DrugDDI.d79.s11.e0
Anti-Inflammatory,13-30	DrugDDI.d79.s11.e0
Drugs,31-36	DrugDDI.d79.s11.e0
(NSAIDs)-A,37-47
drug,48-52
interaction,53-64
study,65-70
of,71-73
eplerenone,74-84	DrugDDI.d79.s11.e2
with,85-89
an,90-92
NSAID,93-98	DrugDDI.d79.s11.e3
has,99-102
not,103-106
been,107-111
conducted.,112-122

The,0-3
administration,4-18
of,19-21
other,22-27
potassium-sparing,28-45	DrugDDI.d79.s12.e0
antihypertensives,46-63	DrugDDI.d79.s12.e0
with,64-68
NSAIDs,69-75	DrugDDI.d79.s12.e1
has,76-79
been,80-84
shown,85-90
to,91-93
reduce,94-100
the,101-104
antihypertensive,105-121
effect,122-128
in,129-131
some,132-136
patients,137-145
and,146-149
result,150-156
in,157-159
severe,160-166
hyperkalemia,167-179
in,180-182
patients,183-191
with,192-196
impaired,197-205
renal,206-211
function.,212-221

Therefore,,0-10
when,11-15
INSPRA,16-22	DrugDDI.d79.s13.e0
and,23-26
NSAIDs,27-33	DrugDDI.d79.s13.e1
are,34-37
used,38-42
concomitantly,,43-57
patients,58-66
should,67-73
be,74-76
observed,77-85
to,86-88
determine,89-98
whether,99-106
the,107-110
desired,111-118
effect,119-125
on,126-128
blood,129-134
pressure,135-143
is,144-146
obtained.,147-156

No,0-2
evidence,3-11
of,12-14
interaction,15-26
of,27-29
PROCRIT,30-37	DrugDDI.d310.s0.e0
with,38-42
other,43-48
drugs,49-54	DrugDDI.d310.s0.e1
was,55-58
observed,59-67
in,68-70
the,71-74
course,75-81
of,82-84
clinical,85-93
trials.,94-101
?,102-103

Additional,0-10
reductions,11-21
in,22-24
blood,25-30
pressure,31-39
may,40-43
occur,44-49
when,50-54
FLOLAN,55-61	DrugDDI.d262.s0.e0
is,62-64
administered,65-77
with,78-82
diuretics,,83-93
antihypertensive,94-110	DrugDDI.d262.s0.e2
agents,,111-118	DrugDDI.d262.s0.e2
or,119-121
other,122-127
vasodilators.,128-141	DrugDDI.d262.s0.e3

When,0-4
other,5-10
antiplatelet,11-23	DrugDDI.d262.s1.e0
agents,24-30	DrugDDI.d262.s1.e0
or,31-33
anticoagulants,34-48	DrugDDI.d262.s1.e1
are,49-52
used,53-57
concomitantly,,58-72
there,73-78
is,79-81
the,82-85
potential,86-95
for,96-99
FLOLAN,100-106	DrugDDI.d262.s1.e2
to,107-109
increase,110-118
the,119-122
risk,123-127
of,128-130
bleeding.,131-140

However,,0-8
patients,9-17
receiving,18-27
infusions,28-37
of,38-40
FLOLAN,41-47	DrugDDI.d262.s2.e0
in,48-50
clinical,51-59
trials,60-66
were,67-71
maintained,72-82
on,83-85
anticoagulants,86-100	DrugDDI.d262.s2.e1
without,101-108
evidence,109-117
of,118-120
increased,121-130
bleeding.,131-140

In,0-2
clinical,3-11
trials,,12-19
FLOLAN,20-26	DrugDDI.d262.s3.e0
was,27-30
used,31-35
with,36-40
digoxin,,41-49
diuretics,,50-60
anticoagulants,,61-76
oral,77-81
vasodilators,,82-95
and,96-99
supplemental,100-112
oxygen.In,113-122	DrugDDI.d262.s3.e5
a,123-124
pharmacokinetic,125-140
substudy,141-149
in,150-152
patients,153-161
with,162-166
congestive,167-177
heart,178-183
failure,184-191
receiving,192-201
furosemide,202-212	DrugDDI.d262.s3.e6
or,213-215
digoxin,216-223	DrugDDI.d262.s3.e7
in,224-226
whom,227-231
therapy,232-239
with,240-244
FLOLAN,245-251	DrugDDI.d262.s3.e8
was,252-255
initiated,,256-266
apparent,267-275
oral,276-280
clearance,281-290
values,291-297
for,298-301
furosemide,302-312	DrugDDI.d262.s3.e9
(n,313-315
=,316-317
23),318-321
and,322-325
digoxin,326-333	DrugDDI.d262.s3.e10
(n,334-336
=,337-338
30),339-342
were,343-347
decreased,348-357
by,358-360
13%,361-364
and,365-368
15%,,369-373
respectively,,374-387
on,388-390
the,391-394
second,395-401
day,402-405
of,406-408
therapy,409-416
and,417-420
had,421-424
returned,425-433
to,434-436
baseline,437-445
values,446-452
by,453-455
day,456-459
87.,460-463

The,0-3
change,4-10
in,11-13
furosemide,14-24	DrugDDI.d262.s4.e0
clearance,25-34
value,35-40
is,41-43
not,44-47
likely,48-54
to,55-57
be,58-60
clinically,61-71
significant.,72-84

However,,0-8
patients,9-17
on,18-20
digoxin,21-28	DrugDDI.d262.s5.e0
may,29-32
show,33-37
elevations,38-48
of,49-51
digoxin,52-59	DrugDDI.d262.s5.e1
concentrations,60-74
after,75-80
initiation,81-91
of,92-94
therapy,95-102
with,103-107
FLOLAN,,108-115
which,116-121
may,122-125
be,126-128
clinically,129-139
significant,140-151
in,152-154
patients,155-163
prone,164-169
to,170-172
digoxin,173-180
toxicity.,181-190

Eprosartan,0-10	DrugDDI.d121.s0.e0
has,11-14
been,15-19
shown,20-25
to,26-28
have,29-33
no,34-36
effect,37-43
on,44-46
the,47-50
pharmacokinetics,51-67
of,68-70
digoxin,71-78	DrugDDI.d121.s0.e1
and,79-82
the,83-86
pharmacodynamics,87-103
of,104-106
warfarin,107-115	DrugDDI.d121.s0.e2
and,116-119
glyburide.,120-130	DrugDDI.d121.s0.e3

Because,0-7
eprosartan,8-18	DrugDDI.d121.s2.e0
is,19-21
not,22-25
metabolized,26-37
by,38-40
the,41-44
cytochrome,45-55	DrugDDI.d121.s2.e1
P450,56-60	DrugDDI.d121.s2.e1
system,,61-68
inhibitors,69-79
of,80-82
CYP450,83-89
enzyme,90-96
would,97-102
not,103-106
be,107-109
expected,110-118
to,119-121
affect,122-128
its,129-132
metabolism,,133-144
and,145-148
ketoconazole,149-161	DrugDDI.d121.s2.e2
and,162-165
fluconazole,,166-178
potent,179-185
inhibitors,186-196
of,197-199
CYP3A,200-205	DrugDDI.d121.s2.e4
and,206-209
2C9,,210-214
respectively,,215-228
have,229-233
been,234-238
shown,239-244
to,245-247
have,248-252
no,253-255
effect,256-262
on,263-265
eprosartan,266-276	DrugDDI.d121.s2.e5
pharmacokinetics.,277-294

Ranitidine,0-10	DrugDDI.d121.s3.e0
also,11-15
has,16-19
no,20-22
effect,23-29
on,30-32
eprosartan,33-43	DrugDDI.d121.s3.e1
pharmacokinetics.,44-61

Eprosartan,0-10	DrugDDI.d121.s4.e0
(up,11-14
to,15-17
400,18-21
mg,22-24
b.i.d.,25-31
or,32-34
800,35-38
mg,39-41
q.d.),42-47
doses,48-53
have,54-58
been,59-63
safely,64-70
used,71-75
concomitantly,76-89
with,90-94
a,95-96
thiazide,97-105	DrugDDI.d121.s4.e1
diuretic,106-114	DrugDDI.d121.s4.e1
(hydrochlorothiazide).,115-137

Eprosartan,0-10	DrugDDI.d121.s5.e0
doses,11-16
of,17-19
up,20-22
to,23-25
300,26-29
mg,30-32
b.i.d.,33-39
have,40-44
been,45-49
safely,50-56
used,57-61
concomitantly,62-75
with,76-80
sustained-release,81-98
calcium,99-106	DrugDDI.d121.s5.e1
channel,107-114	DrugDDI.d121.s5.e1
blockers,115-123	DrugDDI.d121.s5.e1
(sustained-release,124-142
nifedipine),143-154	DrugDDI.d121.s5.e2
with,155-159
no,160-162
clinically,163-173
significant,174-185
adverse,186-193
interactions.,194-207

Enoxaparin,0-10	DrugDDI.d113.s0.e0
dosed,11-16
as,17-19
a,20-21
1.0,22-25
mg/kg,26-31
subcutaneous,32-44
injection,45-54
q12h,55-59
for,60-63
four,64-68
doses,69-74
did,75-78
not,79-82
alter,83-88
the,89-92
pharmacokinetics,93-109
of,110-112
eptifibatide,113-125	DrugDDI.d113.s0.e1
or,126-128
the,129-132
level,133-138
of,139-141
platelet,142-150
aggregation,151-162
in,163-165
healthy,166-173
adults.,174-181

Mineral,0-7	DrugDDI.d416.s0.e0
oil,8-11	DrugDDI.d416.s0.e0
interferes,12-22
with,23-27
the,28-31
absorption,32-42
of,43-45
fat-soluble,46-57
vitamins,,58-67
including,68-77
vitamin,78-85	DrugDDI.d416.s0.e1
D,86-87	DrugDDI.d416.s0.e1
preparations.,88-101	DrugDDI.d416.s0.e1

Administration,0-14
of,15-17
thiazide,18-26	DrugDDI.d416.s1.e0
diuretics,27-36	DrugDDI.d416.s1.e0
to,37-39
hypoparathyroid,40-55
patients,56-64
who,65-68
are,69-72
concurrently,73-85
being,86-91
treated,92-99
with,100-104
ergocalciferol,105-119	DrugDDI.d416.s1.e1
may,120-123
cause,124-129
hypercalcemia.,130-144

The,0-3
effects,4-11
of,12-14
ERGOMAR,15-22	DrugDDI.d287.s0.e0
may,23-26
be,27-29
potentiated,30-41
by,42-44
triacetyloleandomycin,45-66	DrugDDI.d287.s0.e1
which,67-72
inhibits,73-81
the,82-85
metabolism,86-96
of,97-99
ergotamine.,100-111	DrugDDI.d287.s0.e2

The,0-3
pressor,4-11	DrugDDI.d287.s1.e0
effects,12-19	DrugDDI.d287.s1.e0
of,20-22
ERGOMAR,23-30	DrugDDI.d287.s1.e1
and,31-34
other,35-40
vasoconstrictor,41-56	DrugDDI.d287.s1.e2
drugs,57-62	DrugDDI.d287.s1.e2
can,63-66
combine,67-74
to,75-77
cause,78-83
dangerous,84-93
hypertension.,94-107

Co-treatment,0-12
with,13-17
the,18-21
potent,22-28
CYP3A4,29-35
inhibitor,36-45
ketoconazole,46-58	DrugDDI.d318.s0.e0
increases,59-68
erlotinib,69-78	DrugDDI.d318.s0.e1
AUC,79-82
by,83-85
2/3.,86-90

Caution,0-7
should,8-14
be,15-17
used,18-22
when,23-27
administering,28-41
or,42-44
taking,45-51
TARCEVA,52-59	DrugDDI.d318.s1.e0
with,60-64
ketoconazole,65-77	DrugDDI.d318.s1.e1
and,78-81
other,82-87
strong,88-94
CYP3A4,95-101	DrugDDI.d318.s1.e2
inhibitors,102-112
such,113-117
as,,118-121
but,122-125
not,126-129
limited,130-137
to,,138-141
atazanavir,,142-153
clarithromycin,,154-169
indinavir,,170-180
itraconazole,,181-194
nefazodone,,195-206
nelfinavir,,207-218
ritonavir,,219-229
saquinavir,,230-241
telithromycin,,242-256
troleandomycin,257-271	DrugDDI.d318.s1.e12
(TAO),,272-278
and,279-282
voriconazole,283-295	DrugDDI.d318.s1.e14
.,296-297

Pre-treatment,0-13
with,14-18
the,19-22
CYP3A4,23-29
inducer,30-37
rifampicin,38-48	DrugDDI.d318.s2.e0
decreased,49-58
erlotinib,59-68	DrugDDI.d318.s2.e1
AUC,69-72
by,73-75
about,76-81
2/3.,82-86

Alternate,0-9
treatments,10-20
lacking,21-28
CYP3A4,29-35	DrugDDI.d318.s3.e0
inducing,36-44
activity,45-53
should,54-60
be,61-63
considered.,64-75

If,0-2
an,3-5
alternative,6-17
treatment,18-27
is,28-30
unavailable,,31-43
a,44-45
TARCEVA,46-53	DrugDDI.d318.s4.e0
dose,54-58
greater,59-66
than,67-71
150,72-75
mg,76-78
should,79-85
be,86-88
considered,89-99
for,100-103
NSCLC,104-109
patients,,110-119
and,120-123
greater,124-131
than,132-136
100,137-140
mg,141-143
considered,144-154
for,155-158
pancreatic,159-169
cancer,170-176
patients.,177-186

If,0-2
the,3-6
TARCEVA,7-14	DrugDDI.d318.s5.e0
dose,15-19
is,20-22
adjusted,23-31
upward,,32-39
the,40-43
dose,44-48
will,49-53
need,54-58
to,59-61
be,62-64
reduced,65-72
upon,73-77
discontinuation,78-93
of,94-96
rifampicin,97-107	DrugDDI.d318.s5.e1
or,108-110
other,111-116
inducers.,117-126

Other,0-5
CYP3A4,6-12	DrugDDI.d318.s6.e0
inducers,13-21
include,,22-30
but,31-34
are,35-38
not,39-42
limited,43-50
to,,51-54
rifabutin,,55-65
rifapentine,,66-78
phenytoin,,79-89
carbamazepine,,90-104
phenobarbital,105-118	DrugDDI.d318.s6.e5
and,119-122
St.,123-126	DrugDDI.d318.s6.e6
Johns,127-132	DrugDDI.d318.s6.e6
Wort.,133-138	DrugDDI.d318.s6.e6

Hepatotoxicity,0-14
Asymptomatic,15-27
increases,28-37
in,38-40
liver,41-46
transaminases,47-60	DrugDDI.d318.s7.e0
have,61-65
been,66-70
observed,71-79
in,80-82
TARCEVA,83-90	DrugDDI.d318.s7.e1
treated,91-98
patients;,99-108

therefore,,0-10
periodic,11-19
liver,20-25
function,26-34
testing,35-42
(transaminases,,43-58
bilirubin,,59-69
and,70-73
alkaline,74-82	DrugDDI.d318.s8.e2
phosphatase),83-95	DrugDDI.d318.s8.e2
should,96-102
be,103-105
considered.,106-117

Dose,0-4
reduction,5-14
or,15-17
interruption,18-30
of,31-33
TARCEVA,34-41	DrugDDI.d318.s9.e0
should,42-48
be,49-51
considered,52-62
if,63-65
changes,66-73
in,74-76
liver,77-82
function,83-91
are,92-95
severe.,96-103

Patients,0-8
with,9-13
Hepatic,14-21
Impairment,22-32
In,33-35
vitro,36-41
and,42-45
in,46-48
vivo,49-53
evidence,54-62
suggest,63-70
that,71-75
erlotinib,76-85	DrugDDI.d318.s10.e0
is,86-88
cleared,89-96
primarily,97-106
by,107-109
the,110-113
liver.,114-120	DrugDDI.d318.s10.e1

Therefore,,0-10
erlotinib,11-20	DrugDDI.d318.s11.e0
exposure,21-29
may,30-33
be,34-36
increased,37-46
in,47-49
patients,50-58
with,59-63
hepatic,64-71
dysfunction.,72-84

Elevated,0-8
International,9-22
Normalized,23-33
Ratio,34-39
and,40-43
Potential,44-53
Bleeding,54-62
International,63-76
Normalized,77-87
Ratio,88-93
(INR),94-99
elevations,100-110
and,111-114
infrequent,115-125
reports,126-133
of,134-136
bleeding,137-145
events,146-152
including,153-162
gastrointestinal,163-179
and,180-183
non-gastrointestinal,184-204
bleedings,205-214
have,215-219
been,220-224
reported,225-233
in,234-236
clinical,237-245
studies,,246-254
some,255-259
associated,260-270
with,271-275
concomitant,276-287
warfarin,288-296	DrugDDI.d318.s12.e0
administration.,297-312

Patients,0-8
taking,9-15
warfarin,16-24	DrugDDI.d318.s13.e0
or,25-27
other,28-33
coumarin-derivative,34-53	DrugDDI.d318.s13.e1
anticoagulants,54-68	DrugDDI.d318.s13.e1
should,69-75
be,76-78
monitored,79-88
regularly,89-98
for,99-102
changes,103-110
in,111-113
prothrombin,114-125
time,126-130
or,131-133
INR,134-137

When,0-4
ertapenem,5-14	DrugDDI.d532.s0.e0
is,15-17
co-administered,18-33
with,34-38
probenecid,39-49	DrugDDI.d532.s0.e1
(500,50-54
mg,55-57
p.o.,58-62
every,63-68
6,69-70
hours),,71-78
probenecid,79-89	DrugDDI.d532.s0.e3
competes,90-98
for,99-102
active,103-109
tubular,110-117
secretion,118-127
and,128-131
reduces,132-139
the,140-143
renal,144-149
clearance,150-159
of,160-162
ertapenem.,163-173	DrugDDI.d532.s0.e4

Based,0-5
on,6-8
total,9-14
ertapenem,15-24	DrugDDI.d532.s1.e0
concentrations,,25-40
probenecid,41-51	DrugDDI.d532.s1.e1
increased,52-61
the,62-65
AUC,66-69
by,70-72
25%,73-76
and,77-80
reduced,81-88
the,89-92
plasma,93-99
and,100-103
renal,104-109
clearances,110-120
by,121-123
20%,124-127
and,128-131
35%,,132-136
respectively.,137-150

Because,0-7
of,8-10
the,11-14
small,15-20
effect,21-27
on,28-30
half-life,,31-41
the,42-45
coadministration,46-62
with,63-67
probenecid,68-78	DrugDDI.d532.s3.e0
to,79-81
extend,82-88
the,89-92
half-life,93-102
of,103-105
ertapenem,106-115	DrugDDI.d532.s3.e1
is,116-118
not,119-122
recommended.,123-135

In,0-2
vitro,3-8
studies,9-16
indicate,17-25
that,26-30
ertapenem,31-40	DrugDDI.d532.s4.e0
does,41-45
not,46-49
inhibit,50-57
P-glycoprotein-mediated,58-81
transport,82-91
of,92-94
digoxin,95-102	DrugDDI.d532.s4.e2
or,103-105
vinblastine,106-117	DrugDDI.d532.s4.e3
and,118-121
that,122-126
ertapenem,127-136	DrugDDI.d532.s4.e4
is,137-139
not,140-143
a,144-145
substrate,146-155
for,156-159
P-glycoprotein-mediated,160-183
transport.,184-194

In,0-2
vitro,3-8
studies,9-16
in,17-19
human,20-25
liver,26-31
microsomes,32-42
indicate,43-51
that,52-56
ertapenem,57-66	DrugDDI.d532.s5.e0
does,67-71
not,72-75
inhibit,76-83
metabolism,84-94
mediated,95-103
by,104-106
any,107-110
of,111-113
the,114-117
following,118-127
six,128-131
cytochrome,132-142	DrugDDI.d532.s5.e1
p450,143-147	DrugDDI.d532.s5.e1
(CYP),148-153
isoforms:,154-163	DrugDDI.d532.s5.e3
1A2,,164-168
2C9,,169-173
2C19,,174-179
2D6,,180-184
2E1,185-188
and,189-192
3A4.,193-197

Drug,0-4
interactions,5-17
caused,18-24
by,25-27
inhibition,28-38
of,39-41
P-glycoprotein-mediated,42-65
drug,66-70
clearance,71-80
or,81-83
CYP-mediated,84-96	DrugDDI.d532.s6.e1
drug,97-101
clearance,102-111
with,112-116
the,117-120
listed,121-127
isoforms,128-136	DrugDDI.d532.s6.e2
are,137-140
unlikely.,141-150

Other,0-5
than,6-10
with,11-15
probenecid,,16-27
no,28-30
specific,31-39
clinical,40-48
drug,49-53
interaction,54-65
studies,66-73
have,74-78
been,79-83
conducted,84-93

Erythromycin,0-12	DrugDDI.d277.s0.e0
use,13-16
in,17-19
patients,20-28
who,29-32
are,33-36
receiving,37-46
high,47-51
doses,52-57
of,58-60
theophylline,61-73	DrugDDI.d277.s0.e1
may,74-77
be,78-80
associated,81-91
with,92-96
an,97-99
increase,100-108
in,109-111
serum,112-117
theophylline,118-130
levels,131-137
and,138-141
potential,142-151
theophylline,152-164
toxicity.,165-174

In,0-2
case,3-7
of,8-10
theophylline,11-23	DrugDDI.d277.s1.e0
toxicity,24-32
and/or,33-39
elevated,40-48
serum,49-54
theophylline,55-67
levels,,68-75
the,76-79
dose,80-84
of,85-87
theophylline,88-100
should,101-107
be,108-110
reduced,111-118
while,119-124
the,125-128
patient,129-136
is,137-139
receiving,140-149
concomitant,150-161
erythromycin,162-174	DrugDDI.d277.s1.e1
therapy.,175-183

Concomitant,0-11
administration,12-26
of,27-29
erythromycin,30-42	DrugDDI.d277.s2.e0
and,43-46
digoxin,47-54	DrugDDI.d277.s2.e1
has,55-58
been,59-63
reported,64-72
to,73-75
result,76-82
in,83-85
elevated,86-94
digoxin,95-102
serum,103-108
levels.,109-116

There,0-5
have,6-10
been,11-15
reports,16-23
of,24-26
increased,27-36
anticoagulant,37-50
effects,51-58
when,59-63
erythromycin,64-76	DrugDDI.d277.s3.e0
and,77-80
oral,81-85	DrugDDI.d277.s3.e1
anticoagulants,86-100	DrugDDI.d277.s3.e1
were,101-105
used,106-110
concomitantly.,111-125

Increased,0-9
anticoagulation,10-25
effects,26-33
due,34-37
to,38-40
interactions,41-53
of,54-56
erythromycin,57-69	DrugDDI.d277.s4.e0
with,70-74
various,75-82
oral,83-87
anticoagulents,88-102
may,103-106
be,107-109
more,110-114
pronounced,115-125
in,126-128
the,129-132
elderly.,133-141

Concurrent,0-10
use,11-14
of,15-17
erythromycin,18-30	DrugDDI.d277.s5.e0
and,31-34
ergotamine,35-45	DrugDDI.d277.s5.e1
or,46-48
dihydroergotamine,49-66	DrugDDI.d277.s5.e2
has,67-70
been,71-75
associated,76-86
in,87-89
some,90-94
patients,95-103
with,104-108
acute,109-114
ergot,115-120	DrugDDI.d277.s5.e3
toxicity,121-129
characterized,130-143
by,144-146
severe,147-153
peripheral,154-164
vasospasm,165-174
and,175-178
dysesthesia.,179-191

Erythromycin,0-12	DrugDDI.d277.s6.e0
has,13-16
been,17-21
reported,22-30
to,31-33
decrease,34-42
the,43-46
clearance,47-56
of,57-59
triazolam,60-69	DrugDDI.d277.s6.e1
and,70-73
midazolam,74-83	DrugDDI.d277.s6.e2
and,84-87
thus,88-92
may,93-96
increase,97-105
the,106-109
pharmacologic,110-123
effect,124-130
of,131-133
these,134-139
benzodiazepines.,140-156	DrugDDI.d277.s6.e3

The,0-3
use,4-7
of,8-10
erythromycin,11-23	DrugDDI.d277.s7.e0
in,24-26
patients,27-35
concurrently,36-48
taking,49-55
drugs,56-61	DrugDDI.d277.s7.e1
metabolized,62-73
by,74-76
the,77-80
cytochrome,81-91	DrugDDI.d277.s7.e2
P450,92-96	DrugDDI.d277.s7.e2
system,97-103
may,104-107
be,108-110
associated,111-121
with,122-126
elevations,127-137
in,138-140
serum,141-146
levels,147-153
of,154-156
these,157-162
other,163-168
drugs.,169-175	DrugDDI.d277.s7.e3

There,0-5
have,6-10
been,11-15
reports,16-23
of,24-26
interactions,27-39
of,40-42
erythromycin,43-55	DrugDDI.d277.s8.e0
with,56-60
carbamazepine,,61-75
cyclosporine,,76-89
tacrolimus,,90-101
hexobarbital,,102-115
phenytoin,,116-126
alfentanil,,127-138
cisapride,,139-149
disopyramide,,150-163
lovastatin,,164-175
bromocriptine,,176-190
valproate,,191-201
terfenadine,,202-214
and,215-218
astemizole.,219-230	DrugDDI.d277.s8.e13

Serum,0-5
concentrations,6-20
of,21-23
drugs,24-29	DrugDDI.d277.s9.e0
metabolized,30-41
by,42-44
the,45-48
cytochrome,49-59	DrugDDI.d277.s9.e1
P450,60-64	DrugDDI.d277.s9.e1
system,65-71
should,72-78
be,79-81
monitored,82-91
closely,92-99
in,100-102
patients,103-111
concurrently,112-124
receiving,125-134
erythromycin.,135-148	DrugDDI.d277.s9.e2

Erythromycin,0-12	DrugDDI.d277.s10.e0
has,13-16
been,17-21
reported,22-30
to,31-33
significantly,34-47
alter,48-53
the,54-57
metabolism,58-68
of,69-71
nonsedating,72-83
antihistamines,84-98	DrugDDI.d277.s10.e1
terfenadine,99-110
and,111-114
astemizole,115-125	DrugDDI.d277.s10.e2
when,126-130
taken,131-136
concomitantly.,137-151

In,0-2
addition,,3-12
deaths,13-19
have,20-24
been,25-29
reported,30-38
rarely,39-45
with,46-50
concomitant,51-62
administration,63-77
of,78-80
terfenadine,81-92	DrugDDI.d277.s12.e0
and,93-96
erythromycin.,97-110	DrugDDI.d277.s12.e1

There,0-5
have,6-10
been,11-15
postmarketing,16-29
reports,30-37
of,38-40
drug,41-45
interactions,46-58
when,59-63
erythromycin,64-76	DrugDDI.d277.s13.e0
is,77-79
coadministered,80-94
with,95-99
cisapride,,100-110
resulting,111-120
in,121-123
QT,124-126
prolongation,,127-140
cardiac,141-148
arrythmias,,149-160
ventricular,161-172
tachycardia,,173-185
ventricular,186-197
fibrulation,,198-210
and,211-214
torsades,215-223
de,224-226
pointes,,227-235
most,236-240
like,241-245
due,246-249
to,250-252
inhibition,253-263
of,264-266
hepatic,267-274
metabolism,275-285
of,286-288
cisapride,289-298	DrugDDI.d277.s13.e2
by,299-301
erythromycin.,302-315	DrugDDI.d277.s13.e3

Patients,0-8
receiving,9-18
concomitant,19-30
lovastatin,31-41	DrugDDI.d277.s15.e0
and,42-45
erythromycin,46-58	DrugDDI.d277.s15.e1
should,59-65
be,66-68
carefully,69-78
monitored;,79-89

CNS,0-3	DrugDDI.d245.s0.e0
Drugs,4-9	DrugDDI.d245.s0.e0
-,10-11
Given,12-17
the,18-21
primary,22-29
CNS,30-33
effects,34-41
of,42-44
escitalopram,,45-58
caution,59-66
should,67-73
be,74-76
used,77-81
when,82-86
it,87-89
is,90-92
taken,93-98
in,99-101
combination,102-113
with,114-118
other,119-124
centrally,125-134	DrugDDI.d245.s0.e2
acting,135-141	DrugDDI.d245.s0.e2
drugs.,142-148	DrugDDI.d245.s0.e2

Alcohol,0-7	DrugDDI.d245.s1.e0
-,8-9
Although,10-18
LEXAPRO,19-26	DrugDDI.d245.s1.e1
did,27-30
not,31-34
potentiate,35-45
the,46-49
cognitive,50-59
and,60-63
motor,64-69
effects,70-77
of,78-80
alcohol,81-88	DrugDDI.d245.s1.e2
in,89-91
a,92-93
clinical,94-102
trial,,103-109
as,110-112
with,113-117
other,118-123
psychotropic,124-136	DrugDDI.d245.s1.e3
medications,,137-149	DrugDDI.d245.s1.e3
the,150-153
use,154-157
of,158-160
alcohol,161-168	DrugDDI.d245.s1.e4
by,169-171
patients,172-180
taking,181-187
LEXAPRO,188-195	DrugDDI.d245.s1.e5
is,196-198
not,199-202
recommended.,203-215

Monoamine,0-9	DrugDDI.d245.s2.e0
Oxidase,10-17	DrugDDI.d245.s2.e0
Inhibitors,18-28	DrugDDI.d245.s2.e0
(MAOIs),29-36
-,37-38
See,39-42
Contraindications,43-60
and,61-64
,65-65
a,66-67
href=,68-73
lexapro_wcp.htm#W,74-91	DrugDDI.d245.s2.e1
Warnings.,92-101

Drugs,0-5	DrugDDI.d245.s3.e0
That,6-10
Interfere,11-20
With,21-25
Hemostasis,26-36
(NSAIDs,,37-45
Aspirin,,46-54
Warfarin,,55-64
etc.),65-70

Epidemiological,0-15
studies,16-23
of,24-26
the,27-30
case-control,31-43
and,44-47
cohort,48-54
design,55-61
that,62-66
have,67-71
demonstrated,72-84
an,85-87
association,88-99
between,100-107
use,108-111
of,112-114
psychotropic,115-127	DrugDDI.d245.s5.e0
drugs,128-133	DrugDDI.d245.s5.e0
that,134-138
interfere,139-148
with,149-153
serotonin,154-163
reuptake,164-172
and,173-176
the,177-180
occurrence,181-191
of,192-194
upper,195-200
gastrointestinal,201-217
bleeding,218-226
have,227-231
also,232-236
shown,237-242
that,243-247
concurrent,248-258
use,259-262
of,263-265
an,266-268
NSAID,269-274	DrugDDI.d245.s5.e1
or,275-277
aspirin,278-285	DrugDDI.d245.s5.e2
potentiated,286-297
the,298-301
risk,302-306
of,307-309
bleeding.,310-319

Thus,,0-5
patients,6-14
should,15-21
be,22-24
cautioned,25-34
about,35-40
the,41-44
use,45-48
of,49-51
such,52-56
drugs,57-62	DrugDDI.d245.s6.e0
concurrently,63-75
with,76-80
LEXAPRO.,81-89	DrugDDI.d245.s6.e1

Cimetidine,0-10	DrugDDI.d245.s7.e0
-,11-12
In,13-15
subjects,16-24
who,25-28
had,29-32
received,33-41
21,42-44
days,45-49
of,50-52
40,53-55
mg/day,56-62
racemic,63-70
citalopram,,71-82
combined,83-91
administration,92-106
of,107-109
400,110-113
mg/day,114-120
cimetidine,121-131	DrugDDI.d245.s7.e2
for,132-135
8,136-137
days,138-142
resulted,143-151
in,152-154
an,155-157
increase,158-166
in,167-169
citalopram,170-180	DrugDDI.d245.s7.e3
AUC,181-184
and,185-188
Cmax,189-193
of,194-196
43%,197-200
and,201-204
39%,,205-209
respectively.,210-223

Digoxin,0-7	DrugDDI.d245.s9.e0
-,8-9
In,10-12
subjects,13-21
who,22-25
had,26-29
received,30-38
21,39-41
days,42-46
of,47-49
40,50-52
mg/day,53-59
racemic,60-67
citalopram,,68-79
combined,80-88
administration,89-103
of,104-106
citalopram,107-117	DrugDDI.d245.s9.e2
and,118-121
digoxin,122-129	DrugDDI.d245.s9.e3
(single,130-137
dose,138-142
of,143-145
1,146-147
mg),148-151
did,152-155
not,156-159
significantly,160-173
affect,174-180
the,181-184
pharmacokinetics,185-201
of,202-204
either,205-211
citalopram,212-222	DrugDDI.d245.s9.e4
or,223-225
digoxin.,226-234	DrugDDI.d245.s9.e5

Lithium,0-7	DrugDDI.d245.s10.e0
-,8-9
Coadministration,10-26
of,27-29
racemic,30-37
citalopram,38-48	DrugDDI.d245.s10.e1
(40,49-52
mg/day,53-59
for,60-63
10,64-66
days),67-72
and,73-76
lithium,77-84	DrugDDI.d245.s10.e2
(30,85-88
mmol/day,89-97
for,98-101
5,102-103
days),104-109
had,110-113
no,114-116
significant,117-128
effect,129-135
on,136-138
the,139-142
pharmacokinetics,143-159
of,160-162
citalopram,163-173	DrugDDI.d245.s10.e3
or,174-176
lithium.,177-185	DrugDDI.d245.s10.e4

Because,0-7
lithium,8-15	DrugDDI.d245.s12.e0
may,16-19
enhance,20-27
the,28-31
serotonergic,32-44
effects,45-52
of,53-55
escitalopram,,56-69
caution,70-77
should,78-84
be,85-87
exercised,88-97
when,98-102
LEXAPRO,103-110	DrugDDI.d245.s12.e2
and,111-114
lithium,115-122	DrugDDI.d245.s12.e3
are,123-126
coadministered.,127-142

Pimozide,0-8	DrugDDI.d245.s13.e0
and,9-12
Celexa,13-19	DrugDDI.d245.s13.e1
-,20-21
In,22-24
a,25-26
controlled,27-37
study,,38-44
a,45-46
single,47-53
dose,54-58
of,59-61
pimozide,62-70	DrugDDI.d245.s13.e2
2,71-72	DrugDDI.d245.s13.e2
mg,73-75	DrugDDI.d245.s13.e2
co-administered,76-91
with,92-96
racemic,97-104
citalopram,105-115	DrugDDI.d245.s13.e3
40,116-118	DrugDDI.d245.s13.e3
mg,119-121	DrugDDI.d245.s13.e3
given,122-127
once,128-132
daily,133-138
for,139-142
11,143-145
days,146-150
was,151-154
associated,155-165
with,166-170
a,171-172
mean,173-177
increase,178-186
in,187-189
QTc,190-193
values,194-200
of,201-203
approximately,204-217
10,218-220
msec,221-225
compared,226-234
to,235-237
pimozide,238-246	DrugDDI.d245.s13.e4
given,247-252
alone.,253-259

Racemic,0-7
citalopram,8-18	DrugDDI.d245.s14.e0
did,19-22
not,23-26
alter,27-32
the,33-36
mean,37-41
AUC,42-45
or,46-48
Cmax,49-53
of,54-56
pimozide.,57-66	DrugDDI.d245.s14.e1

Sumatriptan,0-11	DrugDDI.d245.s16.e0
-,12-13
There,14-19
have,20-24
been,25-29
rare,30-34
postmarketing,35-48
reports,49-56
describing,57-67
patients,68-76
with,77-81
weakness,,82-91
hyperreflexia,,92-106
and,107-110
incoordination,111-125
following,126-135
the,136-139
use,140-143
of,144-146
a,147-148
selective,149-158
serotonin,159-168	DrugDDI.d245.s16.e1
reuptake,169-177	DrugDDI.d245.s16.e1
inhibitor,178-187	DrugDDI.d245.s16.e1
(SSRI),188-194
and,195-198
sumatriptan.,199-211	DrugDDI.d245.s16.e2

If,0-2
concomitant,3-14
treatment,15-24
with,25-29
sumatriptan,30-41	DrugDDI.d245.s17.e0
and,42-45
an,46-48
SSRI,49-53
(e.g.,,54-60
fluoxetine,,61-72
fluvoxamine,,73-85
paroxetine,,86-97
sertraline,,98-109
citalopram,,110-121
escitalopram),122-135	DrugDDI.d245.s17.e6
is,136-138
clinically,139-149
warranted,,150-160
appropriate,161-172
observation,173-184
of,185-187
the,188-191
patient,192-199
is,200-202
advised.,203-211

Theophylline,0-12	DrugDDI.d245.s18.e0
-,13-14
Combined,15-23
administration,24-38
of,39-41
racemic,42-49
citalopram,50-60	DrugDDI.d245.s18.e1
(40,61-64
mg/day,65-71
for,72-75
21,76-78
days),79-84
and,85-88
the,89-92
CYP1A2,93-99
substrate,100-109
theophylline,110-122	DrugDDI.d245.s18.e2
(single,123-130
dose,131-135
of,136-138
300,139-142
mg),143-146
did,147-150
not,151-154
affect,155-161
the,162-165
pharmacokinetics,166-182
of,183-185
theophylline.,186-199	DrugDDI.d245.s18.e3

The,0-3
effect,4-10
of,11-13
theophylline,14-26	DrugDDI.d245.s19.e0
on,27-29
the,30-33
pharmacokinetics,34-50
of,51-53
citalopram,54-64	DrugDDI.d245.s19.e1
was,65-68
not,69-72
evaluated.,73-83

Warfarin,0-8	DrugDDI.d245.s20.e0
-,9-10
Administration,11-25
of,26-28
40,29-31
mg/day,32-38
racemic,39-46
citalopram,47-57	DrugDDI.d245.s20.e1
for,58-61
21,62-64
days,65-69
did,70-73
not,74-77
affect,78-84
the,85-88
pharmacokinetics,89-105
of,106-108
warfarin,,109-118
a,119-120
CYP3A4,121-127	DrugDDI.d245.s20.e3
substrate.,128-138

Carbamazepine,0-13	DrugDDI.d245.s22.e0
-,14-15
Combined,16-24
administration,25-39
of,40-42
racemic,43-50
citalopram,51-61	DrugDDI.d245.s22.e1
(40,62-65
mg/day,66-72
for,73-76
14,77-79
days),80-85
and,86-89
carbamazepine,90-103	DrugDDI.d245.s22.e2
(titrated,104-113
to,114-116
400,117-120
mg/day,121-127
for,128-131
35,132-134
days),135-140
did,141-144
not,145-148
significantly,149-162
affect,163-169
the,170-173
pharmacokinetics,174-190
of,191-193
carbamazepine,,194-208
a,209-210
CYP3A4,211-217	DrugDDI.d245.s22.e4
substrate.,218-228

Although,0-8
trough,9-15
citalopram,16-26	DrugDDI.d245.s23.e0
plasma,27-33
levels,34-40
were,41-45
unaffected,,46-57
given,58-63
the,64-67
enzyme-inducing,68-83
properties,84-94
of,95-97
carbamazepine,,98-112
the,113-116
possibility,117-128
that,129-133
carbamazepine,134-147	DrugDDI.d245.s23.e2
might,148-153
increase,154-162
the,163-166
clearance,167-176
of,177-179
escitalopram,180-192	DrugDDI.d245.s23.e3
should,193-199
be,200-202
considered,203-213
if,214-216
the,217-220
two,221-224
drugs,225-230	DrugDDI.d245.s23.e4
are,231-234
coadministered.,235-250

Triazolam,0-9	DrugDDI.d245.s24.e0
-,10-11
Combined,12-20
administration,21-35
of,36-38
racemic,39-46
citalopram,47-57	DrugDDI.d245.s24.e1
(titrated,58-67
to,68-70
40,71-73
mg/day,74-80
for,81-84
28,85-87
days),88-93
and,94-97
the,98-101
CYP3A4,102-108
substrate,109-118
triazolam,119-128	DrugDDI.d245.s24.e2
(single,129-136
dose,137-141
of,142-144
0.25,145-149
mg),150-153
did,154-157
not,158-161
significantly,162-175
affect,176-182
the,183-186
pharmacokinetics,187-203
of,204-206
either,207-213
citalopram,214-224	DrugDDI.d245.s24.e3
or,225-227
triazolam.,228-238	DrugDDI.d245.s24.e4

Ketoconazole,0-12	DrugDDI.d245.s25.e0
-,13-14
Combined,15-23
administration,24-38
of,39-41
racemic,42-49
citalopram,50-60	DrugDDI.d245.s25.e1
(40,61-64
mg),65-68
and,69-72
ketoconazole,73-85	DrugDDI.d245.s25.e2
(200,86-90
mg),91-94
decreased,95-104
the,105-108
Cmax,109-113
and,114-117
AUC,118-121
of,122-124
ketoconazole,125-137	DrugDDI.d245.s25.e3
by,138-140
21%,141-144
and,145-148
10%,,149-153
respectively,,154-167
and,168-171
did,172-175
not,176-179
significantly,180-193
affect,194-200
the,201-204
pharmacokinetics,205-221
of,222-224
citalopram.,225-236	DrugDDI.d245.s25.e4

Ritonavir,0-9	DrugDDI.d245.s26.e0
-,10-11
Combined,12-20
administration,21-35
of,36-38
a,39-40
single,41-47
dose,48-52
of,53-55
ritonavir,56-65	DrugDDI.d245.s26.e1
(600,66-70
mg),,71-75
both,76-80
a,81-82
CYP3A4,83-89	DrugDDI.d245.s26.e2
substrate,90-99
and,100-103
a,104-105
potent,106-112
inhibitor,113-122
of,123-125
CYP3A4,,126-133
and,134-137
escitalopram,138-150	DrugDDI.d245.s26.e4
(20,151-154
mg),155-158
did,159-162
not,163-166
affect,167-173
the,174-177
pharmacokinetics,178-194
of,195-197
either,198-204
ritonavir,205-214	DrugDDI.d245.s26.e5
or,215-217
escitalopram.,218-231	DrugDDI.d245.s26.e6

CYP3A4,0-6	DrugDDI.d245.s27.e0
and,7-10
-2C19,11-16
Inhibitors,17-27
-,28-29
In,30-32
vitro,33-38
studies,39-46
indicated,47-56
that,57-61
CYP3A4,62-68	DrugDDI.d245.s27.e1
and,69-72
-2C19,73-78
are,79-82
the,83-86
primary,87-94
enzymes,95-102
involved,103-111
in,112-114
the,115-118
metabolism,119-129
of,130-132
escitalopram.,133-146	DrugDDI.d245.s27.e2

However,,0-8
coadministration,9-25
of,26-28
escitalopram,29-41	DrugDDI.d245.s28.e0
(20,42-45
mg),46-49
and,50-53
ritonavir,54-63	DrugDDI.d245.s28.e1
(600,64-68
mg),,69-73
a,74-75
potent,76-82
inhibitor,83-92
of,93-95
CYP3A4,,96-103
did,104-107
not,108-111
significantly,112-125
affect,126-132
the,133-136
pharmacokinetics,137-153
of,154-156
escitalopram.,157-170	DrugDDI.d245.s28.e3

Because,0-7
escitalopram,8-20	DrugDDI.d245.s29.e0
is,21-23
metabolized,24-35
by,36-38
multiple,39-47
enzyme,48-54
systems,,55-63
inhibition,64-74
of,75-77
a,78-79
single,80-86
enzyme,87-93
may,94-97
not,98-101
appreciably,102-113
decrease,114-122
escitalopram,123-135	DrugDDI.d245.s29.e1
clearance.,136-146

Drugs,0-5	DrugDDI.d245.s30.e0
Metabolized,6-17
by,18-20
Cytochrome,21-31	DrugDDI.d245.s30.e1
P4502D6,32-39
-,40-41
In,42-44
vitro,45-50
studies,51-58
did,59-62
not,63-66
reveal,67-73
an,74-76
inhibitory,77-87
effect,88-94
of,95-97
escitalopram,98-110	DrugDDI.d245.s30.e2
on,111-113
CYP2D6.,114-121	DrugDDI.d245.s30.e3

In,0-2
addition,,3-12
steady,13-19
state,20-25
levels,26-32
of,33-35
racemic,36-43
citalopram,44-54	DrugDDI.d245.s31.e0
were,55-59
not,60-63
significantly,64-77
different,78-87
in,88-90
poor,91-95
metabolizers,96-108
and,109-112
extensive,113-122
CYP2D6,123-129	DrugDDI.d245.s31.e1
metabolizers,130-142
after,143-148
multiple-dose,149-162
administration,163-177
of,178-180
citalopram,,181-192
suggesting,193-203
that,204-208
coadministration,,209-226
with,227-231
escitalopram,,232-245
of,246-248
a,249-250
drug,251-255	DrugDDI.d245.s31.e4
that,256-260
inhibits,261-269
CYP2D6,,270-277
is,278-280
unlikely,281-289
to,290-292
have,293-297
clinically,298-308
significant,309-320
effects,321-328
on,329-331
escitalopram,332-344	DrugDDI.d245.s31.e6
metabolism.,345-356

However,,0-8
there,9-14
are,15-18
limited,19-26
in,27-29
vivo,30-34
data,35-39
suggesting,40-50
a,51-52
modest,53-59
CYP2D6,60-66	DrugDDI.d245.s32.e0
inhibitory,67-77
effect,78-84
for,85-88
escitalopram,,89-102
i.e.,,103-108
coadministration,109-125
of,126-128
escitalopram,129-141	DrugDDI.d245.s32.e2
(20,142-145
mg/day,146-152
for,153-156
21,157-159
days),160-165
with,166-170
the,171-174
tricyclic,175-184	DrugDDI.d245.s32.e3
antidepressant,185-199	DrugDDI.d245.s32.e3
desipramine,200-211
(single,212-219
dose,220-224
of,225-227
50,228-230
mg),,231-235
a,236-237
substrate,238-247
for,248-251
CYP2D6,,252-259
resulted,260-268
in,269-271
a,272-273
40%,274-277
increase,278-286
in,287-289
Cmax,290-294
and,295-298
a,299-300
100%,301-305
increase,306-314
in,315-317
AUC,318-321
of,322-324
desipramine.,325-337	DrugDDI.d245.s32.e5

Nevertheless,,0-13
caution,14-21
is,22-24
indicated,25-34
in,35-37
the,38-41
coadministration,42-58
of,59-61
escitalopram,62-74	DrugDDI.d245.s34.e0
and,75-78
drugs,79-84	DrugDDI.d245.s34.e1
metabolized,85-96
by,97-99
CYP2D6.,100-107	DrugDDI.d245.s34.e2

Metoprolol,0-10	DrugDDI.d245.s35.e0
-,11-12
Administration,13-27
of,28-30
20,31-33
mg/day,34-40
LEXAPRO,41-48	DrugDDI.d245.s35.e1
for,49-52
21,53-55
days,56-60
in,61-63
healthy,64-71
volunteers,72-82
resulted,83-91
in,92-94
a,95-96
50%,97-100
increase,101-109
in,110-112
Cmax,113-117
and,118-121
82%,122-125
increase,126-134
in,135-137
AUC,138-141
of,142-144
the,145-148
beta-adrenergic,149-164	DrugDDI.d245.s35.e2
blocker,165-172	DrugDDI.d245.s35.e2
metoprolol,173-183	DrugDDI.d245.s35.e2
(given,184-190
in,191-193
a,194-195
single,196-202
dose,203-207
of,208-210
100,211-214
mg).,215-219

Increased,0-9
metoprolol,10-20	DrugDDI.d245.s36.e0
plasma,21-27
levels,28-34
have,35-39
been,40-44
associated,45-55
with,56-60
decreased,61-70
cardioselectivity.,71-89

Coadministration,0-16
of,17-19
LEXAPRO,20-27	DrugDDI.d245.s37.e0
and,28-31
metoprolol,32-42	DrugDDI.d245.s37.e1
had,43-46
no,47-49
clinically,50-60
significant,61-72
effects,73-80
on,81-83
blood,84-89
pressure,90-98
or,99-101
heart,102-107
rate.,108-113

Electroconvulsive,0-17
Therapy,18-25
(ECT),26-31
-,32-33
There,34-39
are,40-43
no,44-46
clinical,47-55
studies,56-63
of,64-66
the,67-70
combined,71-79
use,80-83
of,84-86
ECT,87-90
and,91-94
escitalopram.,95-108	DrugDDI.d245.s38.e0

Concomitant,0-11
Administration,12-26
with,27-31
Racemic,32-39
Citalopram,40-50	DrugDDI.d245.s39.e0
Citalopram,51-61
-,62-63
Since,64-69
escitalopram,70-82	DrugDDI.d245.s39.e1
is,83-85
the,86-89
active,90-96
isomer,97-103
of,104-106
racemic,107-114
citalopram,115-125	DrugDDI.d245.s39.e2
(Celexa),,126-135
the,136-139
two,140-143
agents,144-150
should,151-157
not,158-161
be,162-164
coadministered.,165-180

Catecholamine-depleting,0-23
drugs,,24-30
e.g.,,31-36
reserpine,,37-47
may,48-51
have,52-56
an,57-59
additive,60-68
effect,69-75
when,76-80
given,81-86
with,87-91
beta,92-96	DrugDDI.d192.s0.e2
blocking,97-105	DrugDDI.d192.s0.e2
agents.,106-113	DrugDDI.d192.s0.e2

Patients,0-8
treated,9-16
concurrently,17-29
with,30-34
BREVIBLOC,35-44	DrugDDI.d192.s1.e0
(esmolol,45-53
HCl),54-58
and,59-62
a,63-64
catecholamine,65-78
depletor,79-87
should,88-94
therefore,95-104
be,105-107
closely,108-115
observed,116-124
for,125-128
evidence,129-137
of,138-140
hypotension,141-152
or,153-155
marked,156-162
bradycardia,,163-175
which,176-181
may,182-185
result,186-192
in,193-195
vertigo,,196-204
syncope,,205-213
or,214-216
postural,217-225
hypotension.,226-238

A,0-1
study,2-7
of,8-10
interaction,11-22
between,23-30
BREVIBLOC,31-40	DrugDDI.d192.s2.e0
and,41-44
warfarin,45-53	DrugDDI.d192.s2.e1
showed,54-60
that,61-65
concomitant,66-77
administration,78-92
of,93-95
BREVIBLOC,96-105	DrugDDI.d192.s2.e2
and,106-109
warfarin,110-118	DrugDDI.d192.s2.e3
does,119-123
not,124-127
alter,128-133
warfarin,134-142	DrugDDI.d192.s2.e4
plasma,143-149
levels.,150-157

BREVIBLOC,0-9	DrugDDI.d192.s3.e0
concentrations,10-24
were,25-29
equivocally,30-41
higher,42-48
when,49-53
given,54-59
with,60-64
warfarin,,65-74
but,75-78
this,79-83
is,84-86
not,87-90
likely,91-97
to,98-100
be,101-103
clinically,104-114
important.,115-125

When,0-4
digoxin,5-12	DrugDDI.d192.s4.e0
and,13-16
BREVIBLOC,17-26	DrugDDI.d192.s4.e1
were,27-31
concomitantly,32-45
administered,46-58
intravenously,59-72
to,73-75
normal,76-82
volunteers,,83-94
there,95-100
was,101-104
a,105-106
10-20%,107-113
increase,114-122
in,123-125
digoxin,126-133
blood,134-139
levels,140-146
at,147-149
some,150-154
time,155-159
points.,160-167

Digoxin,0-7	DrugDDI.d192.s5.e0
did,8-11
not,12-15
affect,16-22
BREVIBLOC,23-32	DrugDDI.d192.s5.e1
pharmacokinetics.,33-50

When,0-4
intravenous,5-16
morphine,17-25	DrugDDI.d192.s6.e0
and,26-29
BREVIBLOC,30-39	DrugDDI.d192.s6.e1
were,40-44
concomitantly,45-58
administered,59-71
in,72-74
normal,75-81
subjects,,82-91
no,92-94
effect,95-101
on,102-104
morphine,105-113	DrugDDI.d192.s6.e2
blood,114-119
levels,120-126
was,127-130
seen,,131-136
but,137-140
BREVIBLOC,141-150	DrugDDI.d192.s6.e3
steady-state,151-163
blood,164-169
levels,170-176
were,177-181
increased,182-191
by,192-194
46%,195-198
in,199-201
the,202-205
presence,206-214
of,215-217
morphine.,218-227	DrugDDI.d192.s6.e4

The,0-3
effect,4-10
of,11-13
BREVIBLOC,14-23	DrugDDI.d192.s8.e0
on,24-26
the,27-30
duration,31-39
of,40-42
succinylcholine-induced,43-66	DrugDDI.d192.s8.e1
neuromuscular,67-80
blockade,81-89
was,90-93
studied,94-101
in,102-104
patients,105-113
undergoing,114-124
surgery.,125-133

The,0-3
onset,4-9
of,10-12
neuromuscular,13-26
blockade,27-35
by,36-38
succinylcholine,39-54	DrugDDI.d192.s9.e0
was,55-58
unaffected,59-69
by,70-72
BREVIBLOC,,73-83
but,84-87
the,88-91
duration,92-100
of,101-103
neuromuscular,104-117
blockade,118-126
was,127-130
prolonged,131-140
from,141-145
5,146-147
minutes,148-155
to,156-158
8,159-160
minutes.,161-169

Although,0-8
the,9-12
interactions,13-25
observed,26-34
in,35-37
these,38-43
studies,44-51
do,52-54
not,55-58
appear,59-65
to,66-68
be,69-71
of,72-74
major,75-80
clinical,81-89
importance,,90-101
BREVIBLOC,102-111	DrugDDI.d192.s10.e0
should,112-118
be,119-121
titrated,122-130
with,131-135
caution,136-143
in,144-146
patients,147-155
being,156-161
treated,162-169
concurrently,170-182
with,183-187
digoxin,,188-196
morphine,,197-206
succinylcholine,207-222	DrugDDI.d192.s10.e3
or,223-225
warfarin.,226-235	DrugDDI.d192.s10.e4

While,0-5
taking,6-12
beta,13-17	DrugDDI.d192.s11.e0
blockers,,18-27	DrugDDI.d192.s11.e0
patients,28-36
with,37-41
a,42-43
history,44-51
of,52-54
severe,55-61
anaphylactic,62-74
reaction,75-83
to,84-86
a,87-88
variety,89-96
of,97-99
allergens,100-109
may,110-113
be,114-116
more,117-121
reactive,122-130
to,131-133
repeated,134-142
challenge,,143-153
either,154-160
accidental,,161-172
diagnostic,,173-184
or,185-187
therapeutic.,188-200

Such,0-4
patients,5-13
may,14-17
be,18-20
unresponsive,21-33
to,34-36
the,37-40
usual,41-46
doses,47-52
of,53-55
epinephrine,56-67	DrugDDI.d192.s12.e0
used,68-72
to,73-75
treat,76-81
allergic,82-90
reaction.,91-100

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
considering,33-44
the,45-48
use,49-52
of,53-55
BREVIBLOC,56-65	DrugDDI.d192.s13.e0
and,66-69
verapamil,70-79	DrugDDI.d192.s13.e1
in,80-82
patients,83-91
with,92-96
depressed,97-106
myocardial,107-117
function.,118-127

Fatal,0-5
cardiac,6-13
arrests,14-21
have,22-26
occurred,27-35
in,36-38
patients,39-47
receiving,48-57
both,58-62
drugs.,63-69	DrugDDI.d192.s14.e0

Additionally,,0-13
BREVIBLOC,14-23	DrugDDI.d192.s15.e0
should,24-30
not,31-34
be,35-37
used,38-42
to,43-45
control,46-53
supraventricular,54-70
tachycardia,71-82
in,83-85
the,86-89
presence,90-98
of,99-101
agents,102-108
which,109-114
are,115-118
vasoconstrictive,119-135
and,136-139
inotropic,140-149
such,150-154
as,155-157
dopamine,,158-167
epinephrine,,168-180
and,181-184
norepinephrine,185-199	DrugDDI.d192.s15.e3
because,200-207
of,208-210
the,211-214
danger,215-221
of,222-224
blocking,225-233
cardiac,234-241
contractility,242-255
when,256-260
systemic,261-269
vascular,270-278
resistance,279-289
is,290-292
high.,293-298

Esomeprazole,0-12	DrugDDI.d418.s0.e0
is,13-15
extensively,16-27
metabolized,28-39
in,40-42
the,43-46
liver,47-52	DrugDDI.d418.s0.e1
by,53-55
CYP2C19,56-63	DrugDDI.d418.s0.e2
and,64-67
CYP3A4.,68-75	DrugDDI.d418.s0.e3

In,0-2
vitro,3-8
and,9-12
in,13-15
vivo,16-20
studies,21-28
have,29-33
shown,34-39
that,40-44
esomeprazole,45-57	DrugDDI.d418.s1.e0
is,58-60
not,61-64
likely,65-71
to,72-74
inhibit,75-82
CYPs,83-87	DrugDDI.d418.s1.e1
1A2,,88-92	DrugDDI.d418.s1.e1
2A6,,93-97
2C9,,98-102
2D6,,103-107
2E1,108-111
and,112-115
3A4.,116-120

No,0-2
clinically,3-13
relevant,14-22
interactions,23-35
with,36-40
drugs,41-46	DrugDDI.d418.s2.e0
metabolized,47-58
by,59-61
these,62-67
CYP,68-71	DrugDDI.d418.s2.e1
enzymes,72-79
would,80-85
be,86-88
expected.,89-98

Drug,0-4
interaction,5-16
studies,17-24
have,25-29
shown,30-35
that,36-40
esomeprazole,41-53	DrugDDI.d418.s3.e0
does,54-58
not,59-62
have,63-67
any,68-71
clinically,72-82
significant,83-94
interactions,95-107
with,108-112
phenytoin,,113-123
warfarin,,124-133
quinidine,,134-144
clarithromycin,145-159	DrugDDI.d418.s3.e4
or,160-162
amoxicillin.,163-175	DrugDDI.d418.s3.e5

Post-marketing,0-14
reports,15-22
of,23-25
changes,26-33
in,34-36
prothrombin,37-48	DrugDDI.d418.s4.e0
measures,49-57
have,58-62
been,63-67
received,68-76
among,77-82
patients,83-91
on,92-94
concomitant,95-106
warfarin,107-115	DrugDDI.d418.s4.e1
and,116-119
esomeprazole,120-132	DrugDDI.d418.s4.e2
therapy.,133-141

Patients,0-8
treated,9-16
with,17-21
proton,22-28	DrugDDI.d418.s6.e0
pump,29-33	DrugDDI.d418.s6.e0
inhibitors,34-44	DrugDDI.d418.s6.e0
and,45-48
warfarin,49-57	DrugDDI.d418.s6.e1
concomitantly,58-71
may,72-75
need,76-80
to,81-83
be,84-86
monitored,87-96
for,97-100
increases,101-110
in,111-113
INR,114-117
and,118-121
prothrombin,122-133
time.,134-139

Esomeprazole,0-12	DrugDDI.d418.s7.e0
may,13-16
potentially,17-28
interfere,29-38
with,39-43
CYP2C19,,44-52
the,53-56
major,57-62
esomeprazole,63-75
metabolizing,76-88
enzyme.,89-96

Coadministration,0-16
of,17-19
esomeprazole,20-32	DrugDDI.d418.s8.e0
30,33-35
mg,36-38
and,39-42
diazepam,,43-52
a,53-54
CYP2C19,55-62	DrugDDI.d418.s8.e2
substrate,,63-73
resulted,74-82
in,83-85
a,86-87
45%,88-91
decrease,92-100
in,101-103
clearance,104-113
of,114-116
diazepam.,117-126	DrugDDI.d418.s8.e3

Increased,0-9
plasma,10-16
levels,17-23
of,24-26
diazepam,27-35	DrugDDI.d418.s9.e0
were,36-40
observed,41-49
12,50-52
hours,53-58
after,59-64
dosing,65-71
and,72-75
onwards.,76-84

However,,0-8
at,9-11
that,12-16
time,,17-22
the,23-26
plasma,27-33
levels,34-40
of,41-43
diazepam,44-52	DrugDDI.d418.s10.e0
were,53-57
below,58-63
the,64-67
therapeutic,68-79
interval,,80-89
and,90-93
thus,94-98
this,99-103
interaction,104-115
is,116-118
unlikely,119-127
to,128-130
be,131-133
of,134-136
clinical,137-145
relevance.,146-156

Esomeprazole,0-12	DrugDDI.d418.s11.e0
inhibits,13-21
gastric,22-29
acid,30-34
secretion.,35-45

Therefore,,0-10
esomeprazole,11-23	DrugDDI.d418.s12.e0
may,24-27
interfere,28-37
with,38-42
the,43-46
absorption,47-57
of,58-60
drugs,61-66	DrugDDI.d418.s12.e1
where,67-72
gastric,73-80
pH,81-83
is,84-86
an,87-89
important,90-99
determinant,100-111
of,112-114
bioavailability,115-130
(eg,,131-135
ketoconazole,,136-149
iron,150-154
salts,155-160
and,161-164
digoxin).,165-174	DrugDDI.d418.s12.e3

Coadministration,0-16
of,17-19
oral,20-24	DrugDDI.d418.s13.e0
contraceptives,,25-40	DrugDDI.d418.s13.e0
diazepam,,41-50
phenytoin,,51-61
or,62-64
quinidine,65-74	DrugDDI.d418.s13.e3
did,75-78
not,79-82
seem,83-87
to,88-90
change,91-97
the,98-101
pharmacokinetic,102-117
profile,118-125
of,126-128
esomeprazole.,129-142	DrugDDI.d418.s13.e4

Combination,0-11
Therapy,12-19
with,20-24
Clarithromycin,25-39	DrugDDI.d418.s14.e0
Co-administration,40-57
of,58-60
esomeprazole,,61-74
clarithromycin,,75-90
and,91-94
amoxicillin,95-106	DrugDDI.d418.s14.e3
has,107-110
resulted,111-119
in,120-122
increases,123-132
in,133-135
the,136-139
plasma,140-146
levels,147-153
of,154-156
esomeprazole,157-169	DrugDDI.d418.s14.e4
and,170-173
14-hydroxyclarithromycin.,174-199	DrugDDI.d418.s14.e5

Concomitant,0-11
administration,12-26
of,27-29
clarithromycin,30-44	DrugDDI.d418.s15.e0
with,45-49
pimozide,50-58	DrugDDI.d418.s15.e1
is,59-61
contraindicated.,62-78

If,0-2
ProSom,3-9	DrugDDI.d68.s0.e0
is,10-12
given,13-18
concomitantly,19-32
with,33-37
other,38-43
drugs,44-49	DrugDDI.d68.s0.e1
acting,50-56
on,57-59
the,60-63
central,64-71
nervous,72-79
system,,80-87
careful,88-95
consideration,96-109
should,110-116
be,117-119
given,120-125
to,126-128
the,129-132
pharmacology,133-145
of,146-148
all,149-152
agents.,153-160

The,0-3
action,4-10
of,11-13
the,14-17
benzodiazepines,18-33	DrugDDI.d68.s1.e0
may,34-37
be,38-40
potentiated,41-52
by,53-55
anticonvulsants,,56-72
antihistamines,,73-88
alcohol,,89-97
barbiturates,,98-111
monoamine,112-121	DrugDDI.d68.s1.e5
oxidase,122-129	DrugDDI.d68.s1.e5
inhibitors,,130-141	DrugDDI.d68.s1.e5
narcotics,,142-152
phenothiazines,,153-168
psychotropic,169-181
medications,,182-194
or,195-197
other,198-203
drugs,204-209	DrugDDI.d68.s1.e9
that,210-214
produce,215-222
CNS,223-226
depression.,227-238

Smokers,0-7
have,8-12
an,13-15
increased,16-25
clearance,26-35
of,36-38
benzodiazepines,39-54	DrugDDI.d68.s2.e0
as,55-57
compared,58-66
to,67-69
nonsmokers;,70-81

this,0-4
was,5-8
seen,9-13
in,14-16
studies,17-24
with,25-29
estazolam.,30-40	DrugDDI.d68.s3.e0

While,0-5
no,6-8
in,9-11
vivo,12-16
drug-drug,17-26
interaction,27-38
studies,39-46
were,47-51
conducted,52-61
between,62-69
estazolam,70-79	DrugDDI.d68.s4.e0
and,80-83
inducers,84-92
of,93-95
CYP3A,,96-102
compounds,103-112
that,113-117
are,118-121
potent,122-128
CYP3A,129-134	DrugDDI.d68.s4.e2
inducers,135-143
(such,144-149
as,150-152
carbamazepine,,153-167
phenytoin,,168-178
rifampin,,179-188
and,189-192
barbiturates),193-206	DrugDDI.d68.s4.e6
would,207-212
be,213-215
expected,216-224
to,225-227
decrease,228-236
estazolam,237-246	DrugDDI.d68.s4.e7
concentrations.,247-262

Estazolam,0-9	DrugDDI.d68.s5.e0
Interaction,10-21
with,22-26
Drugs,27-32	DrugDDI.d68.s5.e1
that,33-37
Inhibit,38-45
Metabolism,46-56
via,57-60
Cytochrome,61-71	DrugDDI.d68.s5.e2
P450,72-76	DrugDDI.d68.s5.e2
3A,77-79	DrugDDI.d68.s5.e2
(CYP3A):,80-88
The,89-92
metabolism,93-103
of,104-106
estazolam,107-116	DrugDDI.d68.s5.e4
to,117-119
the,120-123
major,124-129
circulating,130-141
metabolite,142-152
4-hydroxy-estazolam,153-172
and,173-176
the,177-180
metabolism,181-191
of,192-194
other,195-200
triazolobenzodiazepines,201-224
is,225-227
catalyzed,228-237
by,238-240
CYP3A.,241-247	DrugDDI.d68.s5.e6

Consequently,,0-13
estazolam,14-23	DrugDDI.d68.s6.e0
should,24-30
be,31-33
avoided,34-41
in,42-44
patients,45-53
receiving,54-63
ketoconazole,64-76	DrugDDI.d68.s6.e1
and,77-80
itraconazole,,81-94
which,95-100
are,101-104
very,105-109
potent,110-116
inhibitors,117-127
of,128-130
CYP3A.,131-137	DrugDDI.d68.s6.e3

With,0-4
drugs,5-10	DrugDDI.d68.s7.e0
inhibiting,11-21
CYP3A,22-27	DrugDDI.d68.s7.e1
to,28-30
a,31-32
lesser,,33-40
but,41-44
still,45-50
significant,51-62
degree,,63-70
estazolam,71-80	DrugDDI.d68.s7.e2
should,81-87
be,88-90
used,91-95
only,96-100
with,101-105
caution,106-113
and,114-117
consideration,118-131
of,132-134
appropriate,135-146
dosage,147-153
reduction.,154-164

The,0-3
following,4-13
are,14-17
examples,18-26
of,27-29
drugs,30-35	DrugDDI.d68.s8.e0
known,36-41
to,42-44
inhibit,45-52
the,53-56
metabolism,57-67
of,68-70
other,71-76
related,77-84
benzodiazepines,,85-101
presumably,102-112
through,113-120
inhibition,121-131
of,132-134
CYP3A:,135-141	DrugDDI.d68.s8.e2
nefazodone,,142-153
fluvoxamine,,154-166
cimetidine,,167-178
diltiazem,,179-189
isoniazide,,190-201
and,202-205
some,206-210
macrolide,211-220	DrugDDI.d68.s8.e8
antibiotics.,221-233	DrugDDI.d68.s8.e8

Drug,0-4
Interaction,5-16
with,17-21
Fluoxetine:,22-33	DrugDDI.d68.s9.e0
A,34-35
multiple-dose,36-49
study,50-55
was,56-59
conducted,60-69
to,70-72
assess,73-79
the,80-83
effect,84-90
of,91-93
fluoxetine,94-104	DrugDDI.d68.s9.e1
20,105-107	DrugDDI.d68.s9.e1
mg,108-110	DrugDDI.d68.s9.e1
BID,111-114
on,115-117
the,118-121
pharmacokinetics,122-138
of,139-141
estazolam,142-151	DrugDDI.d68.s9.e2
2,152-153	DrugDDI.d68.s9.e2
mg,154-156	DrugDDI.d68.s9.e2
QHS,157-160
after,161-166
seven,167-172
days.,173-178

The,0-3
pharmacokinetics,4-20
of,21-23
estazolam,24-33	DrugDDI.d68.s10.e0
(Cmax,34-39
and,40-43
AUC),44-48
were,49-53
not,54-57
affected,58-66
during,67-73
multiple-dose,74-87
fluoxetine,,88-99
suggesting,100-110
no,111-113
clinically,114-124
significant,125-136
pharmacokinetic,137-152
interaction.,153-165

Estazolam,0-9	DrugDDI.d68.s11.e0
Interaction,10-21
with,22-26
Other,27-32
Drugs,33-38	DrugDDI.d68.s11.e1
that,39-43
are,44-47
Metabolized,48-59
by,60-62
Cytochrome,63-73	DrugDDI.d68.s11.e2
P450,74-78	DrugDDI.d68.s11.e2
(CYP):,79-85
At,86-88
clinically,89-99
relevant,100-108
concentrations,,109-124
in,125-127
vitro,128-133
studies,134-141
indicate,142-150
that,151-155
estazolam,156-165	DrugDDI.d68.s11.e4
(0.6?M),166-173
was,174-177
not,178-181
inhibitory,182-192
towards,193-200
the,201-204
major,205-210
cytochrome,211-221	DrugDDI.d68.s11.e5
P450,222-226	DrugDDI.d68.s11.e5
isoforms,227-235
CYP1A2,,236-243
CYP2A6,,244-251
CYP2C9,,252-259
CYP2C19,,260-268
CYP2D6,,269-276
CYP2E1,,277-284
and,285-288
CYP3A.,289-295	DrugDDI.d68.s11.e11

Therefore,,0-10
based,11-16
on,17-19
these,20-25
in,26-28
vitro,29-34
data,,35-40
estazolam,41-50	DrugDDI.d68.s12.e0
is,51-53
very,54-58
unlikely,59-67
to,68-70
inhibit,71-78
the,79-82
biotransformation,83-100
of,101-103
other,104-109
drugs,110-115	DrugDDI.d68.s12.e1
metabolized,116-127
by,128-130
these,131-136
CYP,137-140
isoforms,141-149	DrugDDI.d68.s12.e2

Drug,0-4	DrugDDI.d190.s1.e0
and,5-8
Laboratory,9-19
Test,20-24
Interactions,25-37
1.,38-40

increased,0-9
factors,10-17	DrugDDI.d190.s4.e0
II,,18-21	DrugDDI.d190.s4.e0
VII,22-25
antigen,,26-34
VIII,35-39
antigen,,40-48
VIII,49-53	DrugDDI.d190.s4.e3
coagulant,54-63	DrugDDI.d190.s4.e3
activity,,64-73
IX,,74-77
X,,78-80
XII,,81-85
VII-X,86-91
complex,,92-100
II-VII-X,101-109
complex,,110-118
and,119-122
beta-thromboglobulin;,123-144	DrugDDI.d190.s4.e4

decreased,0-9
levels,10-16
of,17-19
anti-factor,20-31	DrugDDI.d190.s5.e0
Xa,32-34	DrugDDI.d190.s5.e0
and,35-38
antithrombin,39-51	DrugDDI.d190.s5.e1
III,,52-56	DrugDDI.d190.s5.e1
decreased,57-66
antithrombin,67-79	DrugDDI.d190.s5.e2
III,80-83	DrugDDI.d190.s5.e2
activity;,84-93

increased,0-9
levels,10-16
of,17-19
fibrinogen,20-30	DrugDDI.d190.s6.e0
and,31-34
fibrinogen,35-45
activity;,46-55

Increased,0-9
thyroid-binding,10-25
globulin,26-34
(TBG),35-40
leading,41-48
to,49-51
increased,52-61
circulating,62-73
total,74-79
thyroid,80-87
hormone,88-95
levels,,96-103
as,104-106
measured,107-115
by,116-118
protein-bound,119-132	DrugDDI.d190.s9.e0
iodine,133-139	DrugDDI.d190.s9.e0
(PBI),,140-146
T4,147-149
levels,150-156
(by,157-160
column,161-167
or,168-170
by,171-173
radioimmunoassay),174-191
or,192-194
T3,195-197
levels,198-204
by,205-207
radioimmunoassay.,208-225

Free,0-4
T4,5-7
and,8-11
T3,12-14	DrugDDI.d190.s11.e0
concentrations,15-29
are,30-33
unaltered.,34-44

Patients,0-8
on,9-11
thyroid,12-19	DrugDDI.d190.s12.e0
replacement,20-31
therapy,32-39
may,40-43
require,44-51
higher,52-58
doses,59-64
of,65-67
thyroid,68-75	DrugDDI.d190.s12.e1
hormone.,76-84	DrugDDI.d190.s12.e1

Other,0-5
binding,6-13	DrugDDI.d190.s14.e0
proteins,14-22	DrugDDI.d190.s14.e0
may,23-26
be,27-29
elevated,30-38
in,39-41
serum,,42-48
i.e.,,49-54
corticosteroid,55-69	DrugDDI.d190.s14.e1
binding,70-77	DrugDDI.d190.s14.e1
globulin,78-86	DrugDDI.d190.s14.e1
(CBG),,87-93
sex,94-97	DrugDDI.d190.s14.e3
hormone-binding,98-113	DrugDDI.d190.s14.e3
globulin,114-122	DrugDDI.d190.s14.e3
(SHBG),,123-130
leading,131-138
to,139-141
increased,142-151
total,152-157
circulating,158-169
corticosteroids,170-185	DrugDDI.d190.s14.e4
and,186-189
sex,190-193
steroids,,194-203
respectively.,204-217

Other,0-5
plasma,6-12	DrugDDI.d190.s16.e0
proteins,13-21	DrugDDI.d190.s16.e0
may,22-25
be,26-28
increased,29-38
(angiotensinogen/renin,39-61
substrate,,62-72
alpha-1-antitrypsin,,73-93
ceruloplasmin).,94-109	DrugDDI.d190.s16.e4

Increased,0-9
plasma,10-16
HDL,17-20
and,21-24
HDL2,25-29
cholesterol,30-41	DrugDDI.d190.s18.e0
subfraction,42-53
concentrations,,54-69
reduced,70-77
LDL,78-81	DrugDDI.d190.s18.e1
cholesterol,82-93	DrugDDI.d190.s18.e1
concentration,,94-108
increased,109-118
triglyceride,119-131
levels.,132-139

Milk,,0-5
milk,6-10
products,,11-20
and,21-24
calcium-rich,25-37	DrugDDI.d160.s0.e0
foods,38-43
or,44-46
drugs,47-52	DrugDDI.d160.s0.e1
may,53-56
impair,57-63
the,64-67
absorption,68-78
of,79-81
EMCYT.,82-88	DrugDDI.d160.s0.e2

CNS-Active,0-10	DrugDDI.d506.s0.e0
Drugs,11-16	DrugDDI.d506.s0.e0
Ethanol,17-24
An,25-27
additive,28-36
effect,37-43
on,44-46
psychomotor,47-58
performance,59-70
was,71-74
seen,75-79
with,80-84
coadministration,85-101
of,102-104
eszopiclone,105-116	DrugDDI.d506.s0.e1
and,117-120
ethanol,121-128	DrugDDI.d506.s0.e2
0.70,129-133
g/kg,134-138
for,139-142
up,143-145
to,146-148
4,149-150
hours,151-156
after,157-162
ethanol,163-170	DrugDDI.d506.s0.e3
administration.,171-186

Paroxetine,0-10	DrugDDI.d506.s1.e0
Coadministration,11-27
of,28-30
single,31-37
doses,38-43
of,44-46
eszopiclone,47-58	DrugDDI.d506.s1.e1
3,59-60	DrugDDI.d506.s1.e1
mg,61-63	DrugDDI.d506.s1.e1
and,64-67
paroxetine,68-78	DrugDDI.d506.s1.e2
20,79-81	DrugDDI.d506.s1.e2
mg,82-84	DrugDDI.d506.s1.e2
daily,85-90
for,91-94
7,95-96
days,97-101
produced,102-110
no,111-113
pharmacokinetic,114-129
or,130-132
pharmacodynamic,133-148
interaction.,149-161

Lorazepam,0-9	DrugDDI.d506.s2.e0
Coadministration,10-26
of,27-29
single,30-36
doses,37-42
of,43-45
eszopiclone,46-57	DrugDDI.d506.s2.e1
3,58-59	DrugDDI.d506.s2.e1
mg,60-62	DrugDDI.d506.s2.e1
and,63-66
lorazepam,67-76	DrugDDI.d506.s2.e2
2,77-78	DrugDDI.d506.s2.e2
mg,79-81	DrugDDI.d506.s2.e2
did,82-85
not,86-89
have,90-94
clinically,95-105
relevant,106-114
effects,115-122
on,123-125
the,126-129
pharmacodynamics,130-146
or,147-149
pharmacokinetics,150-166
of,167-169
either,170-176
drug.,177-182	DrugDDI.d506.s2.e3

Olanzapine,0-10	DrugDDI.d506.s3.e0
Coadministration,11-27
of,28-30
eszopiclone,31-42	DrugDDI.d506.s3.e1
3,43-44	DrugDDI.d506.s3.e1
mg,45-47	DrugDDI.d506.s3.e1
and,48-51
olanzapine,52-62	DrugDDI.d506.s3.e2
10,63-65	DrugDDI.d506.s3.e2
mg,66-68	DrugDDI.d506.s3.e2
produced,69-77
a,78-79
decrease,80-88
in,89-91
DSST,92-96
scores.,97-104

there,0-5
was,6-9
no,10-12
alteration,13-23
in,24-26
the,27-30
pharmacokinetics,31-47
of,48-50
either,51-57
drug.,58-63	DrugDDI.d506.s5.e0

Drugs,0-5	DrugDDI.d506.s6.e0
That,6-10
Inhibit,11-18
CYP3A4,19-25	DrugDDI.d506.s6.e1
(Ketoconazole),26-40
CYP3A4,41-47	DrugDDI.d506.s6.e3
is,48-50
a,51-52
major,53-58
metabolic,59-68
pathway,69-76
for,77-80
elimination,81-92
of,93-95
eszopiclone.,96-108	DrugDDI.d506.s6.e4

The,0-3
AUC,4-7
of,8-10
eszopiclone,11-22	DrugDDI.d506.s7.e0
was,23-26
increased,27-36
2.2-fold,37-45
by,46-48
coadministration,49-65
of,66-68
ketoconazole,,69-82
a,83-84
potent,85-91
inhibitor,92-101
of,102-104
CYP3A4,,105-112
400,113-116
mg,117-119
daily,120-125
for,126-129
5,130-131
days.,132-137

Cmax,0-4
and,5-8
t1/2,9-13	DrugDDI.d506.s8.e0
were,14-18
increased,19-28
1.4-fold,29-37
and,38-41
1.3-fold,,42-51
respectively.,52-65

Other,0-5
strong,6-12
inhibitors,13-23
of,24-26
CYP3A4,27-33	DrugDDI.d506.s9.e0
(e.g.,,34-40
itraconazole,,41-54
clarithromycin,,55-70
nefazodone,,71-82
troleandomycin,,83-98
ritonavir,,99-109
nelfinavir),110-121	DrugDDI.d506.s9.e6
would,122-127
be,128-130
expected,131-139
to,140-142
behave,143-149
similarly.,150-160

Drugs,0-5	DrugDDI.d506.s10.e0
That,6-10
Induce,11-17
CYP3A4,18-24	DrugDDI.d506.s10.e1
(Rifampicin),25-37
Racemic,38-45
zopiclone,46-55	DrugDDI.d506.s10.e3
exposure,56-64
was,65-68
decreased,69-78
80%,79-82
by,83-85
concomitant,86-97
useof,98-103
rifampicin,,104-115
a,116-117
potent,118-124
inducer,125-132
of,133-135
CYP3A4.,136-143	DrugDDI.d506.s10.e5

A,0-1
similar,2-9
effect,10-16
would,17-22
be,23-25
expected,26-34
with,35-39
eszopiclone.,40-52	DrugDDI.d506.s11.e0

Drugs,0-5	DrugDDI.d506.s12.e0
Highly,6-12
Bound,13-18
To,19-21
Plasma,22-28	DrugDDI.d506.s12.e1
Protein,29-36	DrugDDI.d506.s12.e1
Eszopiclone,37-48
is,49-51
not,52-55
highly,56-62
bound,63-68
to,69-71
plasma,72-78	DrugDDI.d506.s12.e2
proteins,79-87	DrugDDI.d506.s12.e2
(52-59%,88-95
bound);,96-103

therefore,,0-10
the,11-14
disposition,15-26
of,27-29
eszopiclone,30-41	DrugDDI.d506.s13.e0
is,42-44
not,45-48
expected,49-57
to,58-60
be,61-63
sensitive,64-73
to,74-76
alterations,77-88
in,89-91
protein,92-99
binding.,100-108

Administration,0-14
of,15-17
eszopiclone,18-29	DrugDDI.d506.s14.e0
3,30-31	DrugDDI.d506.s14.e0
mg,32-34	DrugDDI.d506.s14.e0
to,35-37
a,38-39
patient,40-47
taking,48-54
another,55-62
drug,63-67	DrugDDI.d506.s14.e1
that,68-72
is,73-75
highly,76-82
protein-bound,83-96	DrugDDI.d506.s14.e2
would,97-102
not,103-106
be,107-109
expected,110-118
to,119-121
cause,122-127
an,128-130
alteration,131-141
in,142-144
the,145-148
free,149-153
concentration,154-167
of,168-170
either,171-177
drug.,178-183	DrugDDI.d506.s14.e3

Drugs,0-5	DrugDDI.d506.s15.e0
With,6-10
A,11-12
Narrow,13-19
Therapeutic,20-31
Index,32-37
Digoxin,38-45
A,46-47
single,48-54
dose,55-59
of,60-62
eszopiclone,63-74	DrugDDI.d506.s15.e1
3,75-76	DrugDDI.d506.s15.e1
mg,77-79	DrugDDI.d506.s15.e1
did,80-83
not,84-87
affect,88-94
the,95-98
pharmacokinetics,99-115
of,116-118
digoxin,119-126	DrugDDI.d506.s15.e2
measured,127-135
at,136-138
steady,139-145
state,146-151
following,152-161
dosing,162-168
of,169-171
0.5,172-175
mg,176-178
twice,179-184
daily,185-190
for,191-194
one,195-198
day,199-202
and,203-206
0.25,207-211
mg,212-214
daily,215-220
for,221-224
the,225-228
next,229-233
6,234-235
days.,236-241

Warfarin,0-8	DrugDDI.d506.s16.e0
Eszopiclone,9-20	DrugDDI.d506.s16.e0
3,21-22	DrugDDI.d506.s16.e0
mg,23-25
administered,26-38
daily,39-44
for,45-48
5,49-50
days,51-55
did,56-59
not,60-63
affect,64-70
the,71-74
pharmacokinetics,75-91
of,92-94
(R)-,95-99
or,100-102
(S)-warfarin,,103-116
nor,117-120
were,121-125
there,126-131
any,132-135
changes,136-143
in,144-146
the,147-150
pharmacodynamic,151-166
profile,167-174
(prothrombin,175-187
time),188-193
following,194-203
a,204-205
single,206-212
25,213-215
mg,216-218
oral,219-223
dose,224-228
of,229-231
warfarin,232-240	DrugDDI.d506.s16.e2

However,,0-8
it,9-11
was,12-15
observed,16-24
that,25-29
the,30-33
pharmacokinetics,34-50
of,51-53
ENBREL?,54-61
was,62-65
unaltered,66-75
by,76-78
concomitant,79-90
methotrexate,91-103	DrugDDI.d353.s1.e0
in,104-106
rheumatoid,107-117
arthritis,118-127
patients.,128-137

In,0-2
a,3-4
study,5-10
in,11-13
which,14-19
patients,20-28
with,29-33
active,34-40
RA,41-43
were,44-48
treated,49-56
for,57-60
up,61-63
to,64-66
24,67-69
weeks,70-75
with,76-80
concurrent,81-91
ENBREL?,92-99
and,100-103
anakinra,104-112	DrugDDI.d353.s2.e0
therapy,,113-121
a,122-123
7%,124-126
rate,127-131
of,132-134
serious,135-142
infections,143-153
was,154-157
observed,,158-167
which,168-173
was,174-177
higher,178-184
than,185-189
that,190-194
observed,195-203
with,204-208
ENBREL?,209-216
alone,217-222
(0%).,223-228

Two,0-3
percent,4-11
of,12-14
patients,15-23
treated,24-31
concurrently,32-44
with,45-49
ENBREL?,50-57
and,58-61
anakinra,62-70	DrugDDI.d353.s3.e0
developed,71-80
neutropenia,81-92
(ANC,93-97
,98-98
,99-99
1,100-101
x,102-103
109/L).,104-111

Patients,0-8
in,9-11
a,12-13
clinical,14-22
study,23-28
who,29-32
were,33-37
on,38-40
established,41-52
therapy,53-60
with,61-65
sulfasalazine,,66-80
to,81-83
which,84-89
ENBREL,90-96	DrugDDI.d353.s4.e1
was,97-100
added,,101-107
were,108-112
noted,113-118
to,119-121
develop,122-129
a,130-131
mild,132-136
decrease,137-145
in,146-148
mean,149-153
neutrophil,154-164
counts,165-171
in,172-174
comparison,175-185
to,186-188
groups,189-195
treated,196-203
with,204-208
either,209-215
ENBREL,216-222	DrugDDI.d353.s4.e2
CI,223-225
or,226-228
sulfasalazine,229-242	DrugDDI.d353.s4.e3
alone.,243-249

Lithium,0-7	DrugDDI.d166.s0.e0
generally,8-17
should,18-24
not,25-28
be,29-31
given,32-37
with,38-42
diuretics,43-52	DrugDDI.d166.s0.e1
because,53-60
they,61-65
reduce,66-72
its,73-76
renal,77-82
clearance,83-92
and,93-96
add,97-100
a,101-102
high,103-107
risk,108-112
of,113-115
lithium,116-123
toxicity.,124-133

Read,0-4
circulars,5-14
for,15-18
lithium,19-26	DrugDDI.d166.s1.e0
preparations,27-39	DrugDDI.d166.s1.e0
before,40-46
use,47-50
of,51-53
such,54-58
concomitant,59-70
therapy.,71-79

EDECRIN,0-7	DrugDDI.d166.s2.e0
may,8-11
increase,12-20
the,21-24
ototoxic,25-33
potential,34-43
of,44-46
other,47-52
drugs,53-58	DrugDDI.d166.s2.e1
such,59-63
as,64-66
aminoglycoside,67-81	DrugDDI.d166.s2.e2
and,82-85
some,86-90
cephalosporin,91-104	DrugDDI.d166.s2.e3
antibiotics.,105-117	DrugDDI.d166.s2.e3

A,0-1
number,2-8
of,9-11
drugs,,12-18
including,19-28
ethacrynic,29-39	DrugDDI.d166.s4.e1
acid,,40-45	DrugDDI.d166.s4.e1
have,46-50
been,51-55
shown,56-61
to,62-64
displace,65-73
warfarin,74-82	DrugDDI.d166.s4.e2
from,83-87
plasma,88-94	DrugDDI.d166.s4.e3
protein;,95-103	DrugDDI.d166.s4.e3

a,0-1
reduction,2-11
in,12-14
the,15-18
usual,19-24
anticoagulant,25-38	DrugDDI.d166.s5.e0
dosage,39-45
may,46-49
be,50-52
required,53-61
in,62-64
patients,65-73
receiving,74-83
both,84-88
drugs.,89-95	DrugDDI.d166.s5.e1

In,0-2
some,3-7
patients,,8-17
the,18-21
administration,22-36
of,37-39
a,40-41
non-,42-46	DrugDDI.d166.s6.e0
steroidal,47-56	DrugDDI.d166.s6.e0
antiinflammatory,57-73	DrugDDI.d166.s6.e0
agent,74-79	DrugDDI.d166.s6.e0
can,80-83
reduce,84-90
the,91-94
diuretic,,95-104
natriuretic,,105-117
and,118-121
antihypertensive,122-138	DrugDDI.d166.s6.e2
effects,139-146
of,147-149
loop,,150-155
potassium-,156-166	DrugDDI.d166.s6.e3
sparing,167-174
and,175-178
thiazide,179-187	DrugDDI.d166.s6.e4
diuretics.,188-198	DrugDDI.d166.s6.e4

Therefore,,0-10
when,11-15
EDECRIN,16-23	DrugDDI.d166.s7.e0
and,24-27
non-,28-32
steroidal,33-42	DrugDDI.d166.s7.e1
anti-,43-48	DrugDDI.d166.s7.e1
inflammatory,49-61	DrugDDI.d166.s7.e1
agents,62-68	DrugDDI.d166.s7.e1
are,69-72
used,73-77
concomitantly,,78-92
the,93-96
patient,97-104
should,105-111
be,112-114
observed,115-123
closely,124-131
to,132-134
determine,135-144
if,145-147
the,148-151
desired,152-159
effect,160-166
of,167-169
the,170-173
diuretic,174-182	DrugDDI.d166.s7.e2
is,183-185
obtained.,186-195

The,0-3
results,4-11
of,12-14
a,15-16
study,17-22
of,23-25
coadministration,26-42
of,43-45
ethambutol,46-56	DrugDDI.d336.s0.e0
(50,57-60
mg/kg),61-67
with,68-72
an,73-75
aluminum,76-84	DrugDDI.d336.s0.e1
hydroxide,85-94	DrugDDI.d336.s0.e1
containing,95-105	DrugDDI.d336.s0.e1
antacid,106-113	DrugDDI.d336.s0.e1
to,114-116
13,117-119
patients,120-128
with,129-133
tuberculosis,134-146
showed,147-153
a,154-155
reduction,156-165
of,166-168
mean,169-173
serum,174-179
concentrations,180-194
and,195-198
urinary,199-206
excretion,207-216
of,217-219
ethambutol,220-230	DrugDDI.d336.s0.e2
of,231-233
approximately,234-247
20%,248-251
and,252-255
13%,,256-260
respectively,,261-274
suggesting,275-285
that,286-290
the,291-294
oral,295-299
absorption,300-310
of,311-313
ethambutol,314-324	DrugDDI.d336.s0.e3
may,325-328
be,329-331
reduced,332-339
by,340-342
these,343-348
antacid,349-356	DrugDDI.d336.s0.e4
products.,357-366

It,0-2
is,3-5
recommended,6-17
to,18-20
avoid,21-26
concurrent,27-37
administration,38-52
of,53-55
ethambutol,56-66	DrugDDI.d336.s1.e0
with,67-71
aluminum,72-80	DrugDDI.d336.s1.e1
hydroxide,81-90	DrugDDI.d336.s1.e1
containing,91-101	DrugDDI.d336.s1.e1
antacids,102-110	DrugDDI.d336.s1.e1
for,111-114
at,115-117
least,118-123
4,124-125
hours,126-131
following,132-141
ethambutol,142-152	DrugDDI.d336.s1.e2
administration.,153-168

Dicumarol,0-9	DrugDDI.d106.s0.e0
and,10-13
warfarin,14-22	DrugDDI.d106.s0.e1
may,23-26
decrease,27-35
hypoprothrombinemic,36-55
effect.,56-63

Other,0-5
depressasnts,6-18
such,19-23
as,24-26
alcohol,,27-35
barbiturates,,36-49
and,50-53
MAOIs,54-59
may,60-63
enhance,64-71
CNS,72-75
depression,76-86
when,87-91
administered,92-104
with,105-109
ethchlorvynol.,110-124	DrugDDI.d106.s1.e2

May,0-3
interact,4-12
with,13-17
addictive,18-27
medications,,28-40
especially,41-51
central,52-59
nervous,60-67
system,68-74
(CNS),75-80
depressants,81-92
with,93-97
habituating,98-109
potential,110-119
(prolonged,120-130
concurrent,131-141
use,142-145
may,146-149
increase,150-158
the,159-162
risk,163-167
of,168-170
habituation),,171-184
alcohol,185-192	DrugDDI.d83.s0.e1
or,193-195
CNS,196-199
depression?producing,200-220
medications,221-232	DrugDDI.d83.s0.e2
(concurrent,233-244
use,245-248
may,249-252
increase,253-261
the,262-265
CNS,266-269	DrugDDI.d83.s0.e3
depressant,270-280	DrugDDI.d83.s0.e3
effects,281-288
of,289-291
either,292-298
these,299-304
medications,305-316	DrugDDI.d83.s0.e4
or,317-319
ethinamate).,320-332	DrugDDI.d83.s0.e5

Certain,0-7
endocrine,8-17
and,18-21
liver,22-27
function,28-36
tests,37-42
may,43-46
be,47-49
affected,50-58
by,59-61
estrogen-containing,62-81	DrugDDI.d306.s0.e0
oral,82-86	DrugDDI.d306.s0.e1
contraceptives.,87-102	DrugDDI.d306.s0.e1

The,0-3
following,4-13
similar,14-21
changes,22-29
may,30-33
be,34-36
expected,37-45
with,46-50
larger,51-57
doses,58-63
of,64-66
estrogen:,67-76	DrugDDI.d306.s1.e0
Increased,77-86
sulfobromophthalein,87-106
retention;,107-117

increased,0-9
prothrombin,10-21	DrugDDI.d306.s2.e0
and,22-25
factors,26-33	DrugDDI.d306.s2.e1
VII,,34-38	DrugDDI.d306.s2.e1
VIII,,39-44
IX,,45-48
and,49-52
X;,53-55

decreased,0-9
antithrombin,10-22	DrugDDI.d306.s3.e0
3;,23-25

increased,0-9
norepinephrine-induced,10-32	DrugDDI.d306.s4.e0
platel,33-39
et,40-42
aggregation;,43-55

increased,0-9
thyroid,10-17
binding,18-25
globulin,26-34
(TBG),35-40
leading,41-48
to,49-51
increased,52-61
circulating,62-73
total,74-79
thyroid,80-87	DrugDDI.d306.s5.e0
hormone,,88-96	DrugDDI.d306.s5.e0
as,97-99
measured,100-108
by,109-111
PBI,,112-116
T4,117-119	DrugDDI.d306.s5.e1
by,120-122
column,,123-130
or,131-133
T4,134-136	DrugDDI.d306.s5.e2
by,137-139
radioimmunoassay.,140-157

increased,0-9
serum,10-15
triglyceride,16-28
and,29-32
phospholipid,33-45	DrugDDI.d306.s11.e0
concentration.,46-60

Trecator,0-8	DrugDDI.d257.s0.e0
has,9-12
been,13-17
found,18-23
to,24-26
temporarily,27-38
raise,39-44
serum,45-50
concentrations,51-65
of,66-68
isoniazid.,69-79	DrugDDI.d257.s0.e1

Trecator,0-8	DrugDDI.d257.s1.e0
may,9-12
potentiate,13-23
the,24-27
adverse,28-35
effects,36-43
of,44-46
other,47-52
antituberculous,53-68	DrugDDI.d257.s1.e1
drugs,69-74	DrugDDI.d257.s1.e1
administered,75-87
concomitantly.,88-102

In,0-2
particular,,3-14
convulsions,15-26
have,27-31
been,32-36
reported,37-45
when,46-50
ethionamide,51-62	DrugDDI.d257.s2.e0
is,63-65
administered,66-78
with,79-83
cycloserine,84-95	DrugDDI.d257.s2.e1
and,96-99
special,100-107
care,108-112
should,113-119
be,120-122
taken,123-128
when,129-133
the,134-137
treatment,138-147
regimen,148-155
includes,156-164
both,165-169
of,170-172
these,173-178
drugs.,179-185	DrugDDI.d257.s2.e2

Excessive,0-9
ethanol,10-17	DrugDDI.d257.s3.e0
ingestion,18-27
should,28-34
be,35-37
avoided,38-45
because,46-53
a,54-55
psychotic,56-65
reaction,66-74
has,75-78
been,79-83
reported.,84-93

Ethopropazine,0-13	DrugDDI.d494.s0.e0
may,14-17
interact,18-26
with,27-31
alcohol,32-39	DrugDDI.d494.s0.e1
or,40-42
other,43-48
CNS,49-52	DrugDDI.d494.s0.e2
depressants,,53-65	DrugDDI.d494.s0.e2
causing,66-73
increased,74-83
sedative,84-92	DrugDDI.d494.s0.e3
effects.,93-101

It,0-2
may,3-6
also,7-11
interact,12-20
with,21-25
amantadine,26-36	DrugDDI.d494.s1.e0
or,37-39
other,40-45
anticholinergic,46-61	DrugDDI.d494.s1.e1
drugs,62-67	DrugDDI.d494.s1.e1
or,68-70
MAOIs,,71-77
which,78-83
may,84-87
intensify,88-97
the,98-101
anticholinergic,102-117	DrugDDI.d494.s1.e2
action.,118-125

Ethopropazine,0-13	DrugDDI.d494.s2.e0
can,14-17
interact,18-26
with,27-31
chlorpromazine,,32-47
increasing,48-58
the,59-62
metabolism,63-73
of,74-76
chlorpromazine.,77-92	DrugDDI.d494.s2.e2

Since,0-5
Zarontin,6-14	DrugDDI.d242.s0.e0
(ethosuximide),15-29
may,30-33
interact,34-42
with,43-47
concurrently,48-60
administered,61-73
antiepileptic,74-87	DrugDDI.d242.s0.e2
drugs,,88-94	DrugDDI.d242.s0.e2
periodic,95-103
serum,104-109
level,110-115
determinations,116-130
of,131-133
these,134-139
drugs,140-145	DrugDDI.d242.s0.e3
may,146-149
be,150-152
necessary,153-162
(eg,,163-167
ethosuximide,168-180	DrugDDI.d242.s0.e4
may,181-184
elevate,185-192
phenytoin,193-202
serum,203-208
levels,209-215
and,216-219
valproic,220-228	DrugDDI.d242.s0.e5
acid,229-233	DrugDDI.d242.s0.e5
has,234-237
been,238-242
reported,243-251
to,252-254
both,255-259
increase,260-268
and,269-272
decrease,273-281
ethosuximide,282-294
levels).,295-303

PEGANONE,0-8	DrugDDI.d206.s0.e0
used,9-13
in,14-16
combination,17-28
with,29-33
other,34-39
drugs,40-45	DrugDDI.d206.s0.e1
known,46-51
to,52-54
adversely,55-64
affect,65-71
the,72-75
hematopoietic,76-89
system,90-96
should,97-103
be,104-106
avoided,107-114
if,115-117
possible.,118-127

Considerable,0-12
caution,13-20
should,21-27
be,28-30
exercised,31-40
if,41-43
PEGANONE,44-52	DrugDDI.d206.s1.e0
is,53-55
administered,56-68
concurrently,69-81
with,82-86
Phenurone,87-96	DrugDDI.d206.s1.e1
(phenacemide),97-110
since,111-116
paranoid,117-125
symptoms,126-134
have,135-139
been,140-144
reported,145-153
during,154-160
therapy,161-168
with,169-173
this,174-178
combination.,179-191

A,0-1
two-way,2-9
interaction,10-21
between,22-29
the,30-33
hydantoin,34-43	DrugDDI.d206.s2.e0
antiepileptic,,44-58	DrugDDI.d206.s2.e0
phenytoin,,59-69
and,70-73
the,74-77
coumarin,78-86	DrugDDI.d206.s2.e1
anticoagulants,87-101	DrugDDI.d206.s2.e1
has,102-105
been,106-110
suggested.,111-121

Presumably,,0-11
phenytoin,12-21	DrugDDI.d206.s3.e0
acts,22-26
as,27-29
a,30-31
stimulator,32-42
of,43-45
coumarin,46-54
metabolism,55-65
and,66-69
has,70-73
been,74-78
reported,79-87
to,88-90
cause,91-96
decreased,97-106
serum,107-112
levels,113-119
of,120-122
the,123-126
coumarin,127-135	DrugDDI.d206.s3.e1
anticoagulants,136-150	DrugDDI.d206.s3.e1
and,151-154
increased,155-164
prothrombin-proconvertin,165-189	DrugDDI.d206.s3.e2
concentrations.,190-205

Conversely,,0-11
the,12-15
coumarin,16-24	DrugDDI.d206.s4.e0
anticoagulants,25-39	DrugDDI.d206.s4.e0
have,40-44
been,45-49
reported,50-58
to,59-61
increase,62-70
the,71-74
serum,75-80
levels,81-87
and,88-91
prolong,92-99
the,100-103
serum,104-109
half-life,110-119
of,120-122
phenytoin,123-132	DrugDDI.d206.s4.e1
by,133-135
inhibiting,136-146
its,147-150
metabolism.,151-162

Although,0-8
there,9-14
is,15-17
no,18-20
documentation,21-34
of,35-37
such,,38-43
a,44-45
similar,46-53
interaction,54-65
between,66-73
ethotoin,74-82	DrugDDI.d206.s5.e0
and,83-86
the,87-90
coumarin,91-99	DrugDDI.d206.s5.e1
anticoagulants,100-114	DrugDDI.d206.s5.e1
may,115-118
occur.,119-125

Caution,0-7
is,8-10
therefore,11-20
advised,21-28
when,29-33
administering,34-47
PEGANONE,48-56	DrugDDI.d206.s6.e0
to,57-59
patients,60-68
receiving,69-78
coumarin,79-87	DrugDDI.d206.s6.e1
anticoagulants.,88-103	DrugDDI.d206.s6.e1

Ethoxzolamide,0-13	DrugDDI.d326.s0.e0
may,14-17
increase,18-26
the,27-30
action,31-37
of,38-40
tricyclics,,41-52
amphetamines,,53-66
procainamide,,67-80
and,81-84
quinidine.,85-95	DrugDDI.d326.s0.e4

It,0-2
may,3-6
increase,7-15
excretion,16-25
of,26-28
barbiturates,,29-42
lithium,,43-51
and,52-55
ASA,56-59
and,60-63
may,64-67
also,68-72
increase,73-81
the,82-85
toxicity,86-94
of,95-97
salicylates.,98-110	DrugDDI.d326.s1.e2

Coadministration,0-16
of,17-19
ethoxzolamide,20-33	DrugDDI.d326.s2.e0
with,34-38
other,39-44
diuretics,,45-55
amphotericin,56-68	DrugDDI.d326.s2.e2
B,,69-71	DrugDDI.d326.s2.e2
and,72-75
corticosteroids,76-91	DrugDDI.d326.s2.e3
may,92-95
cause,96-101
hypokalemia.,102-114

Ethinyl,0-7	DrugDDI.d59.s0.e0
estradiol:,8-18	DrugDDI.d59.s0.e0
Substrate,19-28
of,29-31
CYP3A4,32-38	DrugDDI.d59.s0.e1
(major),,39-47
3A5-7,48-53
(minor);,54-62

Inhibits,0-8
CYP1A2,9-15	DrugDDI.d59.s1.e0
(weak),,16-23
2B6,24-27
(weak),,28-35
2C19,36-40
(weak),,41-48
3A4,49-52
(weak).,53-60

Acetaminophen:,0-14	DrugDDI.d59.s2.e0
May,15-18
increase,19-27
plasma,28-34
concentration,35-48
of,49-51
synthetic,52-61	DrugDDI.d59.s2.e1
estrogens,,62-72	DrugDDI.d59.s2.e1
possibly,73-81
by,82-84
inhibiting,85-95
conjugation.,96-108

Combination,0-11
hormonal,12-20
contraceptives,21-35	DrugDDI.d59.s3.e0
may,36-39
also,40-44
decrease,45-53
the,54-57
plasma,58-64
concentration,65-78
of,79-81
acetaminophen.,82-96	DrugDDI.d59.s3.e1

Acitretin:,0-10	DrugDDI.d59.s4.e0
Interferes,11-21
with,22-26
the,27-30
contraceptive,31-44	DrugDDI.d59.s4.e1
effect,45-51
of,52-54
microdosed,55-65
progestin-containing,66-86	DrugDDI.d59.s4.e2
minipill,87-95
preparations.,96-109

The,0-3
effect,4-10
on,11-13
other,14-19
progestational,20-34
contraceptives,35-49	DrugDDI.d59.s5.e0
(eg,,50-54
implants,,55-64
injectables),65-77
is,78-80
unknown.,81-89

Aminoglutethimide:,0-18	DrugDDI.d59.s6.e0
May,19-22
increase,23-31
CYP,32-35	DrugDDI.d59.s6.e1
metabolism,36-46
of,47-49
progestins,50-60	DrugDDI.d59.s6.e2
leading,61-68
to,69-71
possible,72-80
decrease,81-89
in,90-92
contraceptive,93-106	DrugDDI.d59.s6.e3
effectiveness.,107-121

Use,0-3
of,4-6
a,7-8
nonhormonal,9-20
contraceptive,21-34	DrugDDI.d59.s7.e0
product,35-42
is,43-45
recommended.,46-58

Antibiotics,0-11	DrugDDI.d59.s8.e0
(ampicillin,,12-24
tetracycline):,25-39	DrugDDI.d59.s8.e2
Pregnancy,40-49
has,50-53
been,54-58
reported,59-67
following,68-77
concomitant,78-89
use,,90-94
however,,95-103
pharmacokinetic,104-119
studies,120-127
have,128-132
not,133-136
shown,137-142
consistent,143-153
effects,154-161
with,162-166
these,167-172
antibiotics,173-184	DrugDDI.d59.s8.e3
on,185-187
plasma,188-194
concentrations,195-209
of,210-212
synthetic,213-222
steroids.,223-232

Use,0-3
of,4-6
a,7-8
nonhormonal,9-20
contraceptive,21-34	DrugDDI.d59.s9.e0
product,35-42
is,43-45
recommended.,46-58

Anticoagulants:,0-15	DrugDDI.d59.s10.e0
Combination,16-27
hormonal,28-36
contraceptives,37-51	DrugDDI.d59.s10.e1
may,52-55
increase,56-64
or,65-67
decrease,68-76
the,77-80
effects,81-88
of,89-91
coumarin,92-100	DrugDDI.d59.s10.e2
derivatives.,101-113

Combination,0-11
hormonal,12-20
contraceptives,21-35	DrugDDI.d59.s11.e0
may,36-39
also,40-44
increase,45-53
risk,54-58
of,59-61
thromboembolic,62-76
disorders.,77-87

Anticonvulsants,0-15	DrugDDI.d59.s12.e0
(carbamazepine,,16-31
felbamate,,32-42
phenobarbital,,43-57
phenytoin,,58-68
topiramate):,69-81	DrugDDI.d59.s12.e5
Increase,82-90
the,91-94
metabolism,95-105
of,106-108
ethinyl,109-116	DrugDDI.d59.s12.e6
estradiol,117-126	DrugDDI.d59.s12.e6
and/or,127-133
some,134-138
progestins,,139-150
leading,151-158
to,159-161
possible,162-170
decrease,171-179
in,180-182
contraceptive,183-196	DrugDDI.d59.s12.e8
effectiveness.,197-211

Use,0-3
of,4-6
a,7-8
nonhormonal,9-20
contraceptive,21-34	DrugDDI.d59.s13.e0
product,35-42
is,43-45
recommended.,46-58

Ascorbic,0-8	DrugDDI.d59.s14.e0
acid:,9-14	DrugDDI.d59.s14.e0
Doses,15-20
of,21-23
ascorbic,24-32	DrugDDI.d59.s14.e1
acid,33-37	DrugDDI.d59.s14.e1
(vitamin,38-46
C),47-49
1,50-51
g/day,52-57
have,58-62
been,63-67
reported,68-76
to,77-79
increase,80-88
plasma,89-95
concentration,96-109
of,110-112
synthetic,113-122	DrugDDI.d59.s14.e3
estrogens,123-132	DrugDDI.d59.s14.e3
by,133-135
~47%,,136-141
possibly,142-150
by,151-153
inhibiting,154-164
conjugation;,165-177

Atorvastatin:,0-13	DrugDDI.d59.s16.e0
Atorvastatin,14-26	DrugDDI.d59.s16.e1
increases,27-36
the,37-40
AUC,41-44
for,45-48
norethindrone,49-62	DrugDDI.d59.s16.e2
and,63-66
ethinyl,67-74	DrugDDI.d59.s16.e3
estradiol.,75-85	DrugDDI.d59.s16.e3

Benzodiazepines:,0-16	DrugDDI.d59.s17.e0
Combination,17-28
hormonal,29-37
contraceptives,38-52	DrugDDI.d59.s17.e1
may,53-56
decrease,57-65
the,66-69
clearance,70-79
of,80-82
some,83-87
benzodiazepines,88-103	DrugDDI.d59.s17.e2
(alprazolam,,104-116
chlordiazepoxide,,117-134
diazepam),135-144	DrugDDI.d59.s17.e5
and,145-148
increase,149-157
the,158-161
clearance,162-171
of,172-174
others,175-181
(lorazepam,,182-193
oxazepam,,194-203
temazepam).,204-215	DrugDDI.d59.s17.e8

Clofibric,0-9	DrugDDI.d59.s18.e0
acid:,10-15	DrugDDI.d59.s18.e0
Combination,16-27
hormonal,28-36
contraceptives,37-51	DrugDDI.d59.s18.e1
may,52-55
increase,56-64
the,65-68
clearance,69-78
of,79-81
clofibric,82-91	DrugDDI.d59.s18.e2
acid.,92-97	DrugDDI.d59.s18.e2

Cyclosporine:,0-13	DrugDDI.d59.s19.e0
Combination,14-25
hormonal,26-34
contraceptives,35-49	DrugDDI.d59.s19.e1
may,50-53
inhibit,54-61
the,62-65
metabolism,66-76
of,77-79
cyclosporine,,80-93
leading,94-101
to,102-104
increased,105-114
plasma,115-121
concentrations;,122-137

monitor,0-7
cyclosporine,8-20	DrugDDI.d59.s20.e0
levels.,21-28

CYP3A4,0-6	DrugDDI.d59.s21.e0
inducers:,7-16
CYP3A4,17-23	DrugDDI.d59.s21.e1
inducers,24-32
may,33-36
decrease,37-45
the,46-49
levels/effects,50-64
of,65-67
ethinyl,68-75	DrugDDI.d59.s21.e2
estradiol.,76-86	DrugDDI.d59.s21.e2

Example,0-7
inducers,8-16
include,17-24
aminoglutethimide,,25-43
carbamazepine,,44-58
nafcillin,,59-69
nevirapine,,70-81
phenobarbital,,82-96
phenytoin,,97-107
and,108-111
rifamycins.,112-123	DrugDDI.d59.s22.e6

Griseofulvin:,0-13	DrugDDI.d59.s23.e0
Griseofulvin,14-26	DrugDDI.d59.s23.e1
may,27-30
induce,31-37
the,38-41
metabolism,42-52
of,53-55
combination,56-67
hormonal,68-76
contraceptives,77-91	DrugDDI.d59.s23.e2
causing,92-99
menstrual,100-109
changes;,110-118

Use,0-3
of,4-6
barrier,7-14
form,15-19
of,20-22
contraception,23-36
is,37-39
suggested,40-49
while,50-55
on,56-58
griseofulvin,59-71	DrugDDI.d59.s25.e0
therapy.,72-80

Morphine:,0-9	DrugDDI.d59.s26.e0
Combination,10-21
hormonal,22-30
contraceptives,31-45	DrugDDI.d59.s26.e1
may,46-49
increase,50-58
the,59-62
clearance,63-72
of,73-75
morphine.,76-85	DrugDDI.d59.s26.e2

Non-nucleoside,0-14	DrugDDI.d59.s27.e0
reverse,15-22	DrugDDI.d59.s27.e0
transcriptase,23-36	DrugDDI.d59.s27.e0
inhibitors,37-47	DrugDDI.d59.s27.e0
(NNRTIs):,48-57
Nevirapine,58-68	DrugDDI.d59.s27.e1
may,69-72
decrease,73-81
plasma,82-88
levels,89-95
of,96-98
combination,99-110
hormonal,111-119
contraceptives;,120-135	DrugDDI.d59.s27.e2

use,0-3
of,4-6
a,7-8
nonhormonal,9-20
contraceptive,21-34	DrugDDI.d59.s28.e0
product,35-42
is,43-45
recommended.,46-58

No,0-2
data,3-7
for,8-11
delavirdine;,12-24	DrugDDI.d59.s29.e0

incomplete,0-10
data,11-15
for,16-19
efavirenz.,20-30	DrugDDI.d59.s30.e0

Prednisolone:,0-13	DrugDDI.d59.s31.e0
Ethinyl,14-21	DrugDDI.d59.s31.e1
estradiol,22-31	DrugDDI.d59.s31.e1
may,32-35
inhibit,36-43
the,44-47
metabolism,48-58
of,59-61
prednisolone,,62-75
leading,76-83
to,84-86
increased,87-96
plasma,97-103
concentrations.,104-119

Protease,0-8	DrugDDI.d59.s32.e0
inhibitors:,9-20	DrugDDI.d59.s32.e0
Amprenavir,,21-32
lopinavir,,33-43
nelfinavir,,44-55
and,56-59
ritonavir,60-69	DrugDDI.d59.s32.e4
have,70-74
been,75-79
shown,80-85
to,86-88
decrease,89-97
plasma,98-104
levels,105-111
of,112-114
combination,115-126
hormonal,127-135
contraceptives;,136-151	DrugDDI.d59.s32.e5

use,0-3
of,4-6
a,7-8
nonhormonal,9-20
contraceptive,21-34	DrugDDI.d59.s33.e0
product,35-42
is,43-45
recommended.,46-58

Indinavir,0-9	DrugDDI.d59.s34.e0
has,10-13
been,14-18
shown,19-24
to,25-27
increase,28-36
plasma,37-43
levels,44-50
of,51-53
combination,54-65
hormonal,66-74
contraceptives.,75-90	DrugDDI.d59.s34.e1

No,0-2
data,3-7
for,8-11
saquinavir.,12-23	DrugDDI.d59.s35.e0

Rifampin:,0-9	DrugDDI.d59.s36.e0
Rifampin,10-18	DrugDDI.d59.s36.e1
increases,19-28
the,29-32
metabolism,33-43
of,44-46
ethinyl,47-54	DrugDDI.d59.s36.e2
estradiol,55-64	DrugDDI.d59.s36.e2
and,65-68
some,69-73
progestins,74-84	DrugDDI.d59.s36.e3
(norethindrone),85-100
resulting,101-110
in,111-113
decreased,114-123
contraceptive,124-137	DrugDDI.d59.s36.e5
effectiveness,138-151
and,152-155
increased,156-165
menstrual,166-175
irregularities.,176-191

Use,0-3
of,4-6
a,7-8
nonhormonal,9-20
contraceptive,21-34	DrugDDI.d59.s37.e0
product,35-42
is,43-45
recommended.,46-58

Salicylic,0-9	DrugDDI.d59.s38.e0
acid:,10-15	DrugDDI.d59.s38.e0
Combination,16-27
hormonal,28-36
contraceptives,37-51	DrugDDI.d59.s38.e1
may,52-55
increase,56-64
the,65-68
clearance,69-78
of,79-81
salicylic,82-91	DrugDDI.d59.s38.e2
acid.,92-97	DrugDDI.d59.s38.e2

Selegiline:,0-11	DrugDDI.d59.s39.e0
Combination,12-23
hormonal,24-32
contraceptives,33-47	DrugDDI.d59.s39.e1
may,48-51
increase,52-60
the,61-64
serum,65-70
concentration,71-84
of,85-87
selegiline.,88-99	DrugDDI.d59.s39.e2

Theophylline:,0-13	DrugDDI.d59.s40.e0
Ethinyl,14-21	DrugDDI.d59.s40.e1
estradiol,22-31	DrugDDI.d59.s40.e1
may,32-35
inhibit,36-43
the,44-47
metabolism,48-58
of,59-61
theophylline,,62-75
leading,76-83
to,84-86
increased,87-96
plasma,97-103
concentrations.,104-119

Tricyclic,0-9	DrugDDI.d59.s41.e0
antidepressants,10-25	DrugDDI.d59.s41.e0
(amitriptyline,,26-41
imipramine,,42-53
nortriptyline):,54-69	DrugDDI.d59.s41.e3
Metabolism,70-80
may,81-84
be,85-87
inhibited,88-97
by,98-100
combination,101-112
hormonal,113-121
contraceptives,,122-137
increasing,138-148
plasma,149-155
levels,156-162
of,163-165
antidepressant;,166-181	DrugDDI.d59.s41.e5

ETHANOL,0-7	DrugDDI.d59.s43.e0
/,8-9
NUTRITION,10-19
/,20-21
HERB,22-26
INTERACTIONS:,27-40
Food:,41-46
CNS,47-50
effects,51-58
of,59-61
caffeine,62-70	DrugDDI.d59.s43.e1
may,71-74
be,75-77
enhanced,78-86
if,87-89
combination,90-101
hormonal,102-110
contraceptives,111-125	DrugDDI.d59.s43.e2
are,126-129
used,130-134
concurrently,135-147
with,148-152
caffeine.,153-162	DrugDDI.d59.s43.e3

Grapefruit,0-10
juice,11-16
increases,17-26
ethinyl,27-34	DrugDDI.d59.s44.e0
estradiol,35-44	DrugDDI.d59.s44.e0
concentrations,45-59
and,60-63
would,64-69
be,70-72
expected,73-81
to,82-84
increase,85-93
progesterone,94-106
serum,107-112
levels,113-119
as,120-122
well;,123-128

Herb/Nutraceutical:,0-19
St,20-22
Johns,23-28
wort,29-33
may,34-37
decrease,38-46
the,47-50
effectiveness,51-64
of,65-67
combination,68-79
hormonal,80-88
contraceptives,89-103	DrugDDI.d59.s46.e0
by,104-106
inducing,107-115
hepatic,116-123
enzymes.,124-132

Avoid,0-5
dong,6-10	DrugDDI.d59.s47.e0
quai,11-15	DrugDDI.d59.s47.e0
and,16-19
black,20-25	DrugDDI.d59.s47.e1
cohosh,26-32	DrugDDI.d59.s47.e1
(have,33-38
estrogen,39-47	DrugDDI.d59.s47.e2
activity).,48-58

Avoid,0-5
saw,6-9	DrugDDI.d59.s48.e0
palmetto,,10-19	DrugDDI.d59.s48.e0
red,20-23	DrugDDI.d59.s48.e1
clover,,24-31	DrugDDI.d59.s48.e1
ginseng.,32-40	DrugDDI.d59.s48.e2

There,0-5
have,6-10
been,11-15
isolated,16-24
reports,25-32
of,33-35
patients,36-44
experiencing,45-57
increases,58-67
in,68-70
their,71-76
prothrombin,77-88
times,89-94
when,95-99
etidronate,100-110	DrugDDI.d63.s0.e0
was,111-114
added,115-120
to,121-123
warfarin,124-132	DrugDDI.d63.s0.e1
therapy.,133-141

Although,0-8
the,9-12
relevance,13-22
of,23-25
these,26-31
reports,32-39
and,40-43
any,44-47
mechanism,48-57
of,58-60
coagulation,61-72
alterations,73-84
is,85-87
unclear,,88-96
patients,97-105
on,106-108
warfarin,109-117	DrugDDI.d63.s2.e0
should,118-124
have,125-129
their,130-135
prothrombin,136-147
time,148-152
monitored.,153-163

ACE-inhibitors,0-14	DrugDDI.d533.s0.e0
Reports,15-22
suggest,23-30
that,31-35
NSAIDs,36-42	DrugDDI.d533.s0.e1
may,43-46
diminish,47-55
the,56-59
antihypertensive,60-76	DrugDDI.d533.s0.e2
effect,77-83
of,84-86
ACE-inhibitors.,87-102	DrugDDI.d533.s0.e3

This,0-4
interaction,5-16
should,17-23
be,24-26
given,27-32
consideration,33-46
in,47-49
patients,50-58
taking,59-65
NSAIDs,66-72	DrugDDI.d533.s1.e0
concomitantly,73-86
with,87-91
ACE-inhibitors.,92-107	DrugDDI.d533.s1.e1

Antacids,0-8	DrugDDI.d533.s2.e0
The,9-12
concomitant,13-24
administration,25-39
of,40-42
antacids,43-51	DrugDDI.d533.s2.e1
has,52-55
no,56-58
apparent,59-67
effect,68-74
on,75-77
the,78-81
extent,82-88
of,89-91
absorption,92-102
of,103-105
Lodine.,106-113	DrugDDI.d533.s2.e2

However,,0-8
antacids,9-17	DrugDDI.d533.s3.e0
can,18-21
decrease,22-30
the,31-34
peak,35-39
concentration,40-53
reached,54-61
by,62-64
15%,65-68
to,69-71
20%,72-75
but,76-79
have,80-84
no,85-87
detectable,88-98
effect,99-105
on,106-108
the,109-112
time-to-peak.,113-126

Aspirin,0-7	DrugDDI.d533.s4.e0
When,8-12
Lodine,13-19	DrugDDI.d533.s4.e1
is,20-22
administered,23-35
with,36-40
aspirin,,41-49
its,50-53
protein,54-61
binding,62-69
is,70-72
reduced,,73-81
although,82-90
the,91-94
clearance,95-104
of,105-107
free,108-112
etodolac,113-121	DrugDDI.d533.s4.e3
is,122-124
not,125-128
altered.,129-137

however,,0-8
as,9-11
with,12-16
other,17-22
NSAIDs,,23-30
concomitant,31-42
administration,43-57
of,58-60
Lodine,61-67	DrugDDI.d533.s6.e1
and,68-71
aspirin,72-79	DrugDDI.d533.s6.e2
is,80-82
not,83-86
generally,87-96
recommended,97-108
because,109-116
of,117-119
the,120-123
potential,124-133
of,134-136
increased,137-146
adverse,147-154
effects.,155-163

Cyclosporine,,0-13
Digoxin,,14-22
Methotrexate,23-35	DrugDDI.d533.s7.e2
Lodine,,36-43
like,44-48
other,49-54
NSAIDs,,55-62
through,63-70
effects,71-78
on,79-81
renal,82-87
prostaglandins,,88-103
may,104-107
cause,108-113
changes,114-121
in,122-124
the,125-128
elimination,129-140
of,141-143
these,144-149
drugs,150-155	DrugDDI.d533.s7.e5
leading,156-163
to,164-166
elevated,167-175
serum,176-181
levels,182-188
of,189-191
cyclosporine,,192-205
digoxin,,206-214
methotrexate,,215-228
and,229-232
increased,233-242
toxicity.,243-252

Nephrotoxicity,0-14
associated,15-25
with,26-30
cyclosporine,31-43	DrugDDI.d533.s8.e0
may,44-47
also,48-52
be,53-55
enhanced.,56-65

Patients,0-8
receiving,9-18
these,19-24
drugs,25-30	DrugDDI.d533.s9.e0
who,31-34
are,35-38
given,39-44
Lodine,,45-52
or,53-55
any,56-59
other,60-65
NSAID,,66-72
and,73-76
particularly,77-89
those,90-95
patients,96-104
with,105-109
altered,110-117
renal,118-123
function,,124-133
should,134-140
be,141-143
observed,144-152
for,153-156
the,157-160
development,161-172
of,173-175
the,176-179
specific,180-188
toxicities,189-199
of,200-202
these,203-208
drugs.,209-215	DrugDDI.d533.s9.e3

Diuretics,0-9	DrugDDI.d533.s10.e0
Etodolac,10-18
has,19-22
no,23-25
apparent,26-34
pharmacokinetic,35-50
interaction,51-62
when,63-67
administered,68-80
with,81-85
furosemide,86-96	DrugDDI.d533.s10.e1
or,97-99
hydrochlorothiazide.,100-120	DrugDDI.d533.s10.e2

Nevertheless,,0-13
clinical,14-22
studies,,23-31
as,32-34
well,35-39
as,40-42
postmarketing,43-56
observations,57-69
have,70-74
shown,75-80
that,81-85
Lodine,86-92	DrugDDI.d533.s11.e0
can,93-96
reduce,97-103
the,104-107
natriuretic,108-119	DrugDDI.d533.s11.e1
effect,120-126
of,127-129
furosemide,130-140	DrugDDI.d533.s11.e2
and,141-144
thiazides,145-154	DrugDDI.d533.s11.e3
in,155-157
some,158-162
patients.,163-172

This,0-4
response,5-13
has,14-17
been,18-22
attributed,23-33
to,34-36
inhibition,37-47
of,48-50
renal,51-56
prostaglandin,57-70	DrugDDI.d533.s12.e0
synthesis.,71-81

During,0-6
concomitant,7-18
therapy,19-26
with,27-31
NSAIDs,,32-39
the,40-43
patient,44-51
should,52-58
be,59-61
observed,62-70
closely,71-78
for,79-82
signs,83-88
of,89-91
renal,92-97
failure,,98-106
as,107-109
well,110-114
as,115-117
to,118-120
assure,121-127
diuretic,128-136	DrugDDI.d533.s13.e1
efficacy.,137-146

Glyburide,0-9	DrugDDI.d533.s14.e0
Etodolac,10-18
has,19-22
no,23-25
apparent,26-34
pharmacokinetic,35-50
interaction,51-62
when,63-67
administered,68-80
with,81-85
glyburide.,86-96	DrugDDI.d533.s14.e1

Lithium,0-7	DrugDDI.d533.s15.e0
NSAIDs,8-14
have,15-19
produced,20-28
an,29-31
elevation,32-41
of,42-44
plasma,45-51
lithium,52-59
levels,60-66
and,67-70
a,71-72
reduction,73-82
in,83-85
renal,86-91
lithium,92-99	DrugDDI.d533.s15.e1
clearance.,100-110

The,0-3
mean,4-8
minimum,9-16
lithium,17-24	DrugDDI.d533.s16.e0
concentration,25-38
increased,39-48
15%,49-52
and,53-56
the,57-60
renal,61-66
clearance,67-76
was,77-80
decreased,81-90
by,91-93
approximately,94-107
20%.,108-112

These,0-5
effects,6-13
have,14-18
been,19-23
attributed,24-34
to,35-37
inhibition,38-48
of,49-51
renal,52-57
prostaglandin,58-71	DrugDDI.d533.s17.e0
synthesis,72-81
by,82-84
the,85-88
NSAID.,89-95	DrugDDI.d533.s17.e1

Thus,,0-5
when,6-10
NSAIDs,11-17	DrugDDI.d533.s18.e0
and,18-21
lithium,22-29	DrugDDI.d533.s18.e1
are,30-33
administered,34-46
concurrently,,47-60
subjects,61-69
should,70-76
be,77-79
observed,80-88
carefully,89-98
for,99-102
signs,103-108
of,109-111
lithium,112-119
toxicity.,120-129

Phenylbutazone,0-14	DrugDDI.d533.s19.e0
Phenylbutazone,15-29
causes,30-36
increase,37-45
(by,46-49
about,50-55
80%),56-60
in,61-63
the,64-67
free,68-72
fraction,73-81
of,82-84
etodolac.,85-94	DrugDDI.d533.s19.e1

Although,0-8
in,9-11
vivo,12-16
studies,17-24
have,25-29
not,30-33
been,34-38
done,39-43
to,44-46
see,47-50
if,51-53
etodolac,54-62	DrugDDI.d533.s20.e0
clearance,63-72
is,73-75
changed,76-83
by,84-86
coadministration,87-103
of,104-106
phenylbutazone,,107-122
it,123-125
is,126-128
not,129-132
recommended,133-144
that,145-149
they,150-154
be,155-157
coadministered.,158-173

Phenytoin,0-9
Etodolac,10-18	DrugDDI.d533.s21.e0
has,19-22
no,23-25
apparent,26-34
pharmacokinetic,35-50
interaction,51-62
when,63-67
administered,68-80
with,81-85
phenytoin.,86-96	DrugDDI.d533.s21.e1

Warfarin,0-8	DrugDDI.d533.s22.e0
The,9-12
effects,13-20
of,21-23
warfarin,24-32	DrugDDI.d533.s22.e1
and,33-36
NSAIDs,37-43	DrugDDI.d533.s22.e2
on,44-46
GI,47-49
bleeding,50-58
are,59-62
synergistic,,63-75
such,76-80
that,81-85
users,86-91
of,92-94
both,95-99
drugs,100-105	DrugDDI.d533.s22.e3
together,106-114
have,115-119
a,120-121
risk,122-126
of,127-129
serious,130-137
GI,138-140
bleeding,141-149
higher,150-156
than,157-161
that,162-166
of,167-169
users,170-175
of,176-178
either,179-185
drug,186-190	DrugDDI.d533.s22.e4
alone.,191-197

Short-term,0-10
pharmacokinetic,11-26
studies,27-34
have,35-39
demonstrated,40-52
that,53-57
concomitant,58-69
administration,70-84
of,85-87
warfarin,88-96	DrugDDI.d533.s23.e0
and,97-100
Lodine?,101-108
(etodolac,109-118
capsules,119-127
and,128-131
tablets),132-140
results,141-148
in,149-151
reduced,152-159
protein,160-167
binding,168-175
of,176-178
warfarin,,179-188
but,189-192
there,193-198
was,199-202
no,203-205
change,206-212
in,213-215
the,216-219
clearance,220-229
of,230-232
free,233-237
warfarin.,238-247	DrugDDI.d533.s23.e3

There,0-5
was,6-9
no,10-12
significant,13-24
difference,25-35
in,36-38
the,39-42
pharmacodynamic,43-58
effect,59-65
of,66-68
warfarin,69-77	DrugDDI.d533.s24.e0
administered,78-90
alone,91-96
and,97-100
warfarin,101-109	DrugDDI.d533.s24.e1
administered,110-122
with,123-127
Lodine,128-134	DrugDDI.d533.s24.e2
as,135-137
measured,138-146
by,147-149
prothrombin,150-161
time.,162-167

Thus,,0-5
concomitant,6-17
therapy,18-25
with,26-30
warfarin,31-39	DrugDDI.d533.s25.e0
and,40-43
Lodine,44-50	DrugDDI.d533.s25.e1
should,51-57
not,58-61
require,62-69
dosage,70-76
adjustment,77-87
of,88-90
either,91-97
drug.,98-103	DrugDDI.d533.s25.e2

However,,0-8
caution,9-16
should,17-23
be,24-26
exercised,27-36
because,37-44
there,45-50
have,51-55
been,56-60
a,61-62
few,63-66
spontaneous,67-78
reports,79-86
of,87-89
prolonged,90-99
prothrombin,100-111
times,,112-118
with,119-123
or,124-126
without,127-134
bleeding,,135-144
in,145-147
etodolac-treated,148-164	DrugDDI.d533.s26.e0
patients,165-173
receiving,174-183
concomitant,184-195
warfarin,196-204	DrugDDI.d533.s26.e1
therapy.,205-213

Drug/Laboratory,0-15	DrugDDI.d533.s27.e0
Test,16-20
Interactions,21-33
The,34-37
urine,38-43
of,44-46
patients,47-55
who,56-59
take,60-64
Lodine,65-71	DrugDDI.d533.s27.e1
can,72-75
give,76-80
a,81-82
false-positive,83-97
reaction,98-106
for,107-110
urinary,111-118
bilirubin,119-128
(urobilin),129-139
due,140-143
to,144-146
the,147-150
presence,151-159
of,160-162
phenolic,163-171	DrugDDI.d533.s27.e3
metabolites,172-183	DrugDDI.d533.s27.e3
of,184-186
etodolac.,187-196	DrugDDI.d533.s27.e4

Diagnostic,0-10
dip-stick,11-20
methodology,,21-33
used,34-38
to,39-41
detect,42-48
ketone,49-55	DrugDDI.d533.s28.e0
bodies,56-62	DrugDDI.d533.s28.e0
in,63-65
urine,,66-72
has,73-76
resulted,77-85
in,86-88
false-positive,89-103
findings,104-112
in,113-115
some,116-120
patients,121-129
treated,130-137
with,138-142
Lodine.,143-150	DrugDDI.d533.s28.e1

Lodine,0-6	DrugDDI.d533.s31.e0
treatment,7-16
is,17-19
associated,20-30
with,31-35
a,36-37
small,38-43
decrease,44-52
in,53-55
serum,56-61
uric,62-66
acid,67-71
levels.,72-79

In,0-2
clinical,3-11
trials,,12-19
mean,20-24
decreases,25-34
of,35-37
1,38-39
to,40-42
2,43-44
mg/dL,45-50
were,51-55
observed,56-64
in,65-67
arthritic,68-77
patients,78-86
receiving,87-96
etodolac,97-105	DrugDDI.d533.s32.e0
(600,106-110
mg,111-113
to,114-116
1000,117-121
mg/day),122-129
after,130-135
4,136-137
weeks,138-143
of,144-146
therapy.,147-155

The,0-3
following,4-13
drug,14-18
interactions,19-31
have,32-36
been,37-41
reported,42-50
with,51-55
etomidate.,56-66	DrugDDI.d8.s0.e0

???Opioid,0-9
analgesics,10-20	DrugDDI.d8.s5.e0
???Decreased,21-33
antinociceptive,34-49
action,50-56

Etonogestrel,0-12	DrugDDI.d299.s0.e0
may,13-16
interact,17-25
with,26-30
the,31-34
following,35-44
medications:,45-57	DrugDDI.d299.s0.e1
acetaminophen,58-71	DrugDDI.d299.s0.e2
(Tylenol),,72-82
antibiotics,83-94	DrugDDI.d299.s0.e4
such,95-99
as,100-102
ampicillin,103-113	DrugDDI.d299.s0.e5
and,114-117
tetracycline,,118-131
anticonvulsants,132-147	DrugDDI.d299.s0.e7
(Dilantin,,148-158
Phenobarbital,,159-173
Tegretol,,174-183
Trileptal,,184-194
Topamax,,195-203
Felbatol),,204-214
antifungals,215-226	DrugDDI.d299.s0.e14
(Gris-PEG,,227-237
Nizoral,,238-246
Sporanox),,247-257
atorvastatin,258-270	DrugDDI.d299.s0.e18
(Lipitor),,271-281
clofibrate,282-292	DrugDDI.d299.s0.e20
(Atromid-S),,293-305
cyclosporine,306-318	DrugDDI.d299.s0.e22
(Neoral,,319-327
Sandimmune),,328-340
HIV,341-344
drugs,345-350	DrugDDI.d299.s0.e25
classified,351-361
as,362-364
protease,365-373	DrugDDI.d299.s0.e26
inhibitors,374-384	DrugDDI.d299.s0.e26
(Agenerase,,385-396
Crixivan,,397-406
Fortovase,,407-417
Invirase,,418-427
Kaletra,,428-436
Norvir,,437-444
Viracept),,445-455
morphine,456-464	DrugDDI.d299.s0.e34
(Astramorph,,465-477
Kadian,,478-485
MS,486-488	DrugDDI.d299.s0.e37
Contin),,489-497	DrugDDI.d299.s0.e37
phenylbutazone,,498-513
prednisolone,514-526	DrugDDI.d299.s0.e39
(Prelone),,527-537
rifadin,538-545	DrugDDI.d299.s0.e41
(rifampin),,546-557
St.,558-561	DrugDDI.d299.s0.e43
Johns,562-567	DrugDDI.d299.s0.e43
wort,,568-573	DrugDDI.d299.s0.e43
temazepam,,574-584
theophylline,585-597	DrugDDI.d299.s0.e45
(Theo-Dur),,598-609
and,610-613
vitamin,614-621	DrugDDI.d299.s0.e47
C.,622-624	DrugDDI.d299.s0.e47

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
administering,33-46
ETOPOPHOS,47-56	DrugDDI.d576.s0.e0
with,57-61
drugs,62-67	DrugDDI.d576.s0.e1
that,68-72
are,73-76
known,77-82
to,83-85
inhibit,86-93
phosphatase,94-105
activities,106-116
(e.g.,,117-123
levamisole,124-134	DrugDDI.d576.s0.e2
hydrochloride).,135-150	DrugDDI.d576.s0.e2

High-dose,0-9
cyclosporin,10-21	DrugDDI.d576.s1.e0
A,22-23	DrugDDI.d576.s1.e0
resulting,24-33
in,34-36
concentrations,37-51
above,52-57
2000,58-62
ng/mL,63-68
administered,69-81
with,82-86
oral,87-91
etoposide,92-101	DrugDDI.d576.s1.e1
has,102-105
led,106-109
to,110-112
an,113-115
80%,116-119
increase,120-128
in,129-131
etoposide,132-141	DrugDDI.d576.s1.e2
exposure,142-150
with,151-155
a,156-157
38%,158-161
decrease,162-170
in,171-173
total,174-179
body,180-184
clearance,185-194
of,195-197
etoposide,198-207	DrugDDI.d576.s1.e3
compared,208-216
to,217-219
etoposide,220-229	DrugDDI.d576.s1.e4
alone.,230-236

Exemestane,0-10	DrugDDI.d7.s0.e0
is,11-13
extensively,14-25
metabolized,26-37
by,38-40
CYP,41-44	DrugDDI.d7.s0.e1
3A4,,45-49
but,50-53
coadministration,54-70
of,71-73
ketoconazole,,74-87
a,88-89
potent,90-96
inhibitor,97-106
of,107-109
CYP,110-113	DrugDDI.d7.s0.e3
3A4,,114-118
has,119-122
no,123-125
significant,126-137
effect,138-144
on,145-147
exemestane,148-158	DrugDDI.d7.s0.e4
pharmacokinetics.,159-176

Significant,0-11
pharmacokinetic,12-27
interactions,28-40
mediated,41-49
by,50-52
inhibition,53-63
of,64-66
CYP,67-70
isoenzymes,71-81	DrugDDI.d7.s1.e0
therefore,82-91
appear,92-98
unlikely.,99-108

Co-medications,0-14
that,15-19
induce,20-26
CYP,27-30	DrugDDI.d7.s2.e1
3A4,31-34
(e.g.,,35-41
rifampicin,,42-53
phenytoin,,54-64
carbamazepine,,65-79
phenobarbital,,80-94
or,95-97
St.,98-101
John?s,102-108
wort),109-114
may,115-118
significantly,119-132
decrease,133-141
exposure,142-150
to,151-153
exemestane.,154-165	DrugDDI.d7.s2.e6

Dose,0-4
modification,5-17
is,18-20
recommended,21-32
for,33-36
patients,37-45
who,46-49
are,50-53
also,54-58
receiving,59-68
a,69-70
potent,71-77
CYP,78-81	DrugDDI.d7.s3.e0
3A4,82-85
inducer.,86-94

Drug/Laboratory,0-15	DrugDDI.d7.s4.e0
Tests,16-21
Interactions,22-34
No,35-37
clinically,38-48
relevant,49-57
changes,58-65
in,66-68
the,69-72
results,73-80
of,81-83
clinical,84-92
laboratory,93-103
tests,104-109
have,110-114
been,115-119
observed.,120-129

Concurrent,0-10
use,11-14
with,15-19
probenecid,20-30	DrugDDI.d417.s0.e0
or,31-33
other,34-39
drugs,40-45	DrugDDI.d417.s0.e1
significantly,46-59
eliminated,60-70
by,71-73
active,74-80
renal,81-86
tubular,87-94
secretion,95-104
may,105-108
result,109-115
in,116-118
increased,119-128
plasma,129-135
concentrations,136-150
of,151-153
penciclovir.,154-166	DrugDDI.d417.s0.e2

The,0-3
conversion,4-14
of,15-17
6-deoxy,18-25
penciclovir,26-37	DrugDDI.d417.s1.e0
to,38-40
penciclovir,41-52	DrugDDI.d417.s1.e1
is,53-55
catalyzed,56-65
by,66-68
aldehyde,69-77	DrugDDI.d417.s1.e2
oxidase.,78-86	DrugDDI.d417.s1.e2

Interactions,0-12
with,13-17
other,18-23
drugs,24-29	DrugDDI.d417.s2.e0
metabolized,30-41
by,42-44
this,45-49
enzyme,50-56
could,57-62
potentially,63-74
occur.,75-81

Studies,0-7
with,8-12
famotidine,13-23	DrugDDI.d104.s1.e0
in,24-26
man,,27-31
in,32-34
animal,35-41
models,,42-49
and,50-53
in,54-56
vitro,57-62
have,63-67
shown,68-73
no,74-76
significant,77-88
interference,89-101
with,102-106
the,107-110
disposition,111-122
of,123-125
compounds,126-135
metabolized,136-147
by,148-150
the,151-154
hepatic,155-162
microsomal,163-173	DrugDDI.d104.s1.e1
enzymes,,174-182	DrugDDI.d104.s1.e1
e.g.,,183-188
cytochrome,189-199	DrugDDI.d104.s1.e2
P450,200-204	DrugDDI.d104.s1.e2
system.,205-212

Compounds,0-9
tested,10-16
in,17-19
man,20-23
include,24-31
warfarin,,32-41
theophylline,,42-55
phenytoin,,56-66
diazepam,,67-76
aminopyrine,77-88	DrugDDI.d104.s2.e4
and,89-92
antipyrine.,93-104	DrugDDI.d104.s2.e5

Use,0-3
in,4-6
Conjunction,7-18
with,19-23
Other,24-29
Antiepileptic,30-43	DrugDDI.d438.s1.e0
Drugs:,44-50	DrugDDI.d438.s1.e0
The,51-54
addition,55-63
of,64-66
Felbatol?,67-76
to,77-79
antiepileptic,80-93	DrugDDI.d438.s1.e1
drugs,94-99	DrugDDI.d438.s1.e1
(AEDs),100-106
affects,107-114
the,115-118
steady-state,119-131
plasma,132-138
concentrations,139-153
of,154-156
AEDs.,157-162

Phenytoin,0-9	DrugDDI.d438.s4.e0
?,10-11
?,12-13

Valproate,0-9	DrugDDI.d438.s5.e0
?,10-11
?**,12-15

Carbamazepine,0-13	DrugDDI.d438.s6.e0
(CBZ),14-19
?,20-21
?,22-23

Phenobarbital,0-13	DrugDDI.d438.s8.e0
?,14-15
?,16-17

*Not,0-4
administered,,5-18
but,19-22
an,23-25
active,26-32	DrugDDI.d438.s9.e0
metabolite,33-43	DrugDDI.d438.s9.e0
of,44-46
carbamazepine.,47-61	DrugDDI.d438.s9.e1

Specific,0-8
Effects,9-16
of,17-19
Felbatol?,20-29
on,30-32
Other,33-38
Antiepileptic,39-52	DrugDDI.d438.s11.e0
Drugs,53-58	DrugDDI.d438.s11.e0
Phenytoin:,59-69
Felbatol?,70-79
causes,80-86
an,87-89
increase,90-98
in,99-101
steady-state,102-114
phenytoin,115-124	DrugDDI.d438.s11.e1
plasma,125-131
concentrations.,132-147

In,0-2
10,3-5
otherwise,6-15
healthy,16-23
subjects,24-32
with,33-37
epilepsy,38-46
ingesting,47-56
phenytoin,,57-67
the,68-71
steadystate,72-83
trough,84-90
(Cmin),91-97
phenytoin,98-107	DrugDDI.d438.s12.e1
plasma,108-114
concentration,115-128
was,129-132
17?5,133-137
micrograms/mL.,138-152

The,0-3
steady-state,4-16
Cmin,17-21
increased,22-31
to,32-34
21?5,35-39
micrograms/mL,40-53
when,54-58
1200,59-63
mg/day,64-70
of,71-73
felbamate,74-83	DrugDDI.d438.s13.e0
was,84-87
coadministered.,88-103

Increasing,0-10
the,11-14
felbamate,15-24
dose,25-29
to,30-32
1800,33-37
mg/day,38-44
in,45-47
six,48-51
of,52-54
these,55-60
subjects,61-69
increased,70-79
the,80-83
steady-state,84-96
phenytoin,97-106	DrugDDI.d438.s14.e0
Cmin,107-111
to,112-114
25?7,115-119
micrograms/mL.,120-134

Carbamazepine:,0-14	DrugDDI.d438.s17.e0
Felbatol?,15-24
causes,25-31
a,32-33
decrease,34-42
in,43-45
the,46-49
steady-state,50-62
carbamazepine,63-76	DrugDDI.d438.s17.e1
plasma,77-83
concentrations,84-98
and,99-102
an,103-105
increase,106-114
in,115-117
the,118-121
steady-state,122-134
carbamazepine,135-148	DrugDDI.d438.s17.e2
epoxide,149-156	DrugDDI.d438.s17.e2
plasma,157-163
concentration.,164-178

In,0-2
nine,3-7
otherwise,8-17
healthy,18-25
subjects,26-34
with,35-39
epilepsy,40-48
ingesting,49-58
carbamazepine,,59-73
the,74-77
steady-state,78-90
trough,91-97
(Cmin),98-104
carbamazepine,105-118	DrugDDI.d438.s18.e1
concentration,119-132
was,133-136
8?2,137-140
micrograms/mL.,141-155

The,0-3
carbamazepine,4-17	DrugDDI.d438.s19.e0
steady-state,18-30
Cmin,31-35
decreased,36-45
31%,46-49
to,50-52
5?1,53-56
micrograms/mL,57-70
when,71-75
felbamate,76-85	DrugDDI.d438.s19.e1
(3000,86-91
mg/day,,92-99
divided,100-107
into,108-112
three,113-118
doses),119-125
was,126-129
coadministered.,130-145

Carbamazepine,0-13	DrugDDI.d438.s20.e0
epoxide,14-21	DrugDDI.d438.s20.e0
steady-state,22-34
Cmin,35-39
concentrations,40-54
increased,55-64
57%,65-68
from,69-73
1.0?0.3,74-81
to,82-84
1.6?0.4,85-92
micrograms/mL,93-106
with,107-111
the,112-115
addition,116-124
of,125-127
felbamate.,128-138	DrugDDI.d438.s20.e1

In,0-2
clinical,3-11
trials,,12-19
similar,20-27
changes,28-35
in,36-38
carbamazepine,39-52	DrugDDI.d438.s21.e0
and,53-56
carbamazepine,57-70	DrugDDI.d438.s21.e1
epoxide,71-78	DrugDDI.d438.s21.e1
were,79-83
seen.,84-89

Valproate:,0-10	DrugDDI.d438.s22.e0
Felbatol?,11-20
causes,21-27
an,28-30
increase,31-39
in,40-42
steady-state,43-55
valproate,56-65	DrugDDI.d438.s22.e1
concentrations.,66-81

In,0-2
four,3-7
subjects,8-16
with,17-21
epilepsy,22-30
ingesting,31-40
valproate,,41-51
the,52-55
steady-state,56-68
trough,69-75
(Cmin),76-82
valproate,83-92	DrugDDI.d438.s23.e1
plasma,93-99
concentration,100-113
was,114-117
63?16,118-123
micrograms/mL.,124-138

The,0-3
steady-state,4-16
Cmin,17-21
increased,22-31
to,32-34
78?14,35-40
micrograms/mL,41-54
when,55-59
1200,60-64
mg/day,65-71
of,72-74
felbamate,75-84	DrugDDI.d438.s24.e0
was,85-88
coadministered.,89-104

Increasing,0-10
the,11-14
felbamate,15-24
dose,25-29
to,30-32
2400,33-37
mg/day,38-44
increased,45-54
the,55-58
steadystate,59-70
valproate,71-80	DrugDDI.d438.s25.e0
Cmin,81-85
to,86-88
96?25,89-94
micrograms/mL.,95-109

The,0-3
ratios,4-10
of,11-13
the,14-17
AUCs,18-22
of,23-25
unbound,26-33
valproate,34-43	DrugDDI.d438.s27.e0
to,44-46
the,47-50
AUCs,51-55
of,56-58
the,59-62
total,63-68
valproate,69-78	DrugDDI.d438.s27.e1
were,79-83
11.1,84-88
%,,89-91
13.0%,,92-98
and,99-102
11.5%,,103-109
with,110-114
coadministration,115-131
of,132-134
0,,135-137
1200,,138-143
and,144-147
2400,148-152
mg/day,153-159
of,160-162
Felbatol?,,163-173
respectively.,174-187

This,0-4
indicates,5-14
that,15-19
the,20-23
protein,24-31
binding,32-39
of,40-42
valproate,43-52	DrugDDI.d438.s28.e0
did,53-56
not,57-60
change,61-67
appreciably,68-79
with,80-84
increasing,85-95
doses,96-101
of,102-104
Felbatol?,105-114
Phenobarbital:,115-129	DrugDDI.d438.s28.e1
Coadministration,130-146
of,147-149
felbamate,150-159	DrugDDI.d438.s28.e2
with,160-164
phenobarbital,165-178	DrugDDI.d438.s28.e3
causes,179-185
an,186-188
increase,189-197
in,198-200
phenobarbital,201-214	DrugDDI.d438.s28.e4
plasma,215-221
concentrations,,222-237
In,238-240
12,241-243
otherwise,244-253
healthy,254-261
male,262-266
volunteers,267-277
ingesting,278-287
phenobarbital,,288-302
the,303-306
steady-state,307-319
trough,320-326
(Cmin),327-333
phenobarbital,334-347	DrugDDI.d438.s28.e6
concentration,348-361
was,362-365
14.2,366-370
micrograms/mL.,371-385

The,0-3
steady-state,4-16
Cmin,17-21
concentration,22-35
increased,36-45
to,46-48
17.8,49-53
micrograms/mL,54-67
when,68-72
2400,73-77
mg/day,78-84
of,85-87
felbamate,88-97	DrugDDI.d438.s29.e0
was,98-101
coadministered,102-116
for,117-120
one,121-124
week.,125-130

Effects,0-7
of,8-10
Other,11-16
Antiepileptic,17-30	DrugDDI.d438.s30.e0
Drugs,31-36	DrugDDI.d438.s30.e0
on,37-39
Felbatol?,40-49
Phenytoin:,50-60	DrugDDI.d438.s30.e1
Phenytoin,61-70	DrugDDI.d438.s30.e2
causes,71-77
an,78-80
approximate,81-92
doubling,93-101
of,102-104
the,105-108
clearance,109-118
of,119-121
Felbatol?,122-131
(felbamate),132-143
at,144-146
steady,147-153
state,154-159
and,,160-164
therefore,,165-175
the,176-179
addition,180-188
of,189-191
phenytoin,192-201	DrugDDI.d438.s30.e4
causes,202-208
an,209-211
approximate,212-223
45%,224-227
decrease,228-236
in,237-239
the,240-243
steady-state,244-256
trough,257-263
concentrations,264-278
of,279-281
Felbatol?,282-291
as,292-294
compared,295-303
to,304-306
the,307-310
same,311-315
dose,316-320
of,321-323
Felbatol?,324-333
given,334-339
as,340-342
monotherapy.,343-355

Carbamazepine:,0-14	DrugDDI.d438.s31.e0
Carbamazepine,15-28	DrugDDI.d438.s31.e1
causes,29-35
an,36-38
approximate,39-50
50%,51-54
increase,55-63
in,64-66
the,67-70
clearance,71-80
of,81-83
Felbatol?,84-93
at,94-96
steady,97-103
state,104-109
and,,110-114
therefore,,115-125
the,126-129
addition,130-138
of,139-141
carbamazepine,142-155	DrugDDI.d438.s31.e2
results,156-163
in,164-166
an,167-169
approximate,170-181
40%,182-185
decrease,186-194
in,195-197
the,198-201
steady-state,202-214
trough,215-221
concentrations,222-236
of,237-239
Felbatol?,240-249
as,250-252
compared,253-261
to,262-264
the,265-268
same,269-273
dose,274-278
of,279-281
Felbatol?,282-291
given,292-297
as,298-300
monotherapy.,301-313

Valproate:,0-10	DrugDDI.d438.s32.e0
Available,11-20
data,21-25
suggest,26-33
that,34-38
there,39-44
is,45-47
no,48-50
significant,51-62
effect,63-69
of,70-72
valproate,73-82	DrugDDI.d438.s32.e1
on,83-85
the,86-89
clearance,90-99
of,100-102
Felbatol?,103-112
at,113-115
steady,116-122
state,,123-129
Therefore,,130-140
the,141-144
addition,145-153
of,154-156
valproate,157-166	DrugDDI.d438.s32.e2
is,167-169
not,170-173
expected,174-182
to,183-185
cause,186-191
a,192-193
clinically,194-204
important,205-214
effect,215-221
on,222-224
Felbatol?,225-234
(felbamate),235-246
plasma,247-253
concentrations.,254-269

Phenobarbital:,0-14	DrugDDI.d438.s33.e0
It,15-17
appears,18-25
that,26-30
phenobarbital,31-44	DrugDDI.d438.s33.e1
may,45-48
reduce,49-55
plasma,56-62
felbamate,63-72	DrugDDI.d438.s33.e2
concentrations.,73-88

Steady-state,0-12
plasma,13-19
felbamate,20-29	DrugDDI.d438.s34.e0
concentrations,30-44
were,45-49
found,50-55
to,56-58
be,59-61
29%,62-65
lower,66-71
than,72-76
the,77-80
mean,81-85
concentrations,86-100
of,101-103
a,104-105
group,106-111
of,112-114
newly,115-120
diagnosed,121-130
subjects,131-139
with,140-144
epilepsy,145-153
also,154-158
receiving,159-168
2400,169-173
mg,174-176
of,177-179
felbamate,180-189	DrugDDI.d438.s34.e1
a,190-191
day.,192-196

Effects,0-7
of,8-10
Antacids,11-19	DrugDDI.d438.s35.e0
on,20-22
Felbatol?,23-32
The,33-36
rate,37-41
and,42-45
extent,46-52
of,53-55
absorption,56-66
of,67-69
a,70-71
2400,72-76
mg,77-79
dose,80-84
of,85-87
Felbatol?,88-97
as,98-100
monotherapy,101-112
given,113-118
as,119-121
tablets,122-129
was,130-133
not,134-137
affected,138-146
when,147-151
coadministered,152-166
with,167-171
antacids.,172-181	DrugDDI.d438.s35.e1

Effects,0-7
of,8-10
Erythromycin,11-23	DrugDDI.d438.s36.e0
on,24-26
Felbatol?,27-36
The,37-40
coadministration,41-57
of,58-60
erythromycin,61-73	DrugDDI.d438.s36.e1
(1000,74-79
mg/day),80-87
for,88-91
10,92-94
days,95-99
did,100-103
not,104-107
alter,108-113
the,114-117
pharmacokinetic,118-133
parameters,134-144
of,145-147
Cmax,,148-153
Cmin,,154-159
AUC,,160-164
CI/kg,165-170
or,171-173
tmax,174-178
at,179-181
felbamate,182-191
daily,192-197
doses,198-203
of,204-206
3000,207-211
or,212-214
3600,215-219
mg/day,220-226
in,227-229
10,230-232
otherwise,233-242
healthy,243-250
subjects,251-259
with,260-264
epilepsy.,265-274

Effects,0-7
of,8-10
Felbatol?,11-20
on,21-23
Low-Dose,24-32	DrugDDI.d438.s37.e0
Combination,33-44	DrugDDI.d438.s37.e0
Oral,45-49	DrugDDI.d438.s37.e0
Contraceptives,50-64	DrugDDI.d438.s37.e0
A,65-66
group,67-72
of,73-75
24,76-78
nonsmoking,,79-90
healthy,91-98
white,99-104
female,105-111
volunteers,112-122
established,123-134
on,135-137
an,138-140
oral,141-145	DrugDDI.d438.s37.e1
contraceptive,146-159	DrugDDI.d438.s37.e1
regimen,160-167
containing,168-178
30,179-181
mg,182-184
ethinyl,185-192	DrugDDI.d438.s37.e2
estradiol,193-202	DrugDDI.d438.s37.e2
and,203-206
75,207-209
mg,210-212
gestodene,213-222	DrugDDI.d438.s37.e3
for,223-226
at,227-229
least,230-235
3,236-237
months,238-244
received,245-253
2400,254-258
mg/day,259-265
of,266-268
felbamate,269-278	DrugDDI.d438.s37.e4
from,279-283
midcycle,284-292
(day,293-297
15),298-301
to,302-304
midcycle,305-313
(day,314-318
14),319-322
of,323-325
two,326-329
consecutive,330-341
oral,342-346	DrugDDI.d438.s37.e5
contraceptive,347-360	DrugDDI.d438.s37.e5
cycles.,361-368

Felbamate,0-9	DrugDDI.d438.s38.e0
treatment,10-19
resulted,20-28
in,29-31
a,32-33
42%,34-37
decrease,38-46
in,47-49
the,50-53
gestodene,54-63	DrugDDI.d438.s38.e1
AUC,64-67
0-24,,68-73
but,74-77
no,78-80
clinically,81-91
relevant,92-100
effect,101-107
was,108-111
observed,112-120
on,121-123
the,124-127
pharmacokinetic,128-143
parameters,144-154
of,155-157
ethinyl,158-165	DrugDDI.d438.s38.e2
estradiol.,166-176	DrugDDI.d438.s38.e2

No,0-2
volunteer,3-12
showed,13-19
hormonal,20-28
evidence,29-37
of,38-40
ovulation,,41-51
but,52-55
one,56-59
volunteer,60-69
reported,70-78
intermenstrual,79-93
bleeding,94-102
during,103-109
felbamate,110-119	DrugDDI.d438.s39.e0
treatment.,120-130

CYP3A4,0-6	DrugDDI.d216.s0.e0
Inhibitors?Felodipine,7-28
is,29-31
metabolized,32-43
by,44-46
CYP3A4.,47-54	DrugDDI.d216.s0.e1

Co-administration,0-17
of,18-20
CYP3A4,21-27	DrugDDI.d216.s1.e0
inhibitors,28-38
(eg,,39-43
ketoconazole,,44-57
itraconazole,,58-71
erythromycin,,72-85
grapefruit,86-96
juice,,97-103
cimetidine),104-115	DrugDDI.d216.s1.e4
with,116-120
felodipine,121-131	DrugDDI.d216.s1.e5
may,132-135
lead,136-140
to,141-143
several-,144-152
fold,153-157
increases,158-167
in,168-170
the,171-174
plasma,175-181
levels,182-188
of,189-191
felodipine,,192-203
either,204-210
due,211-214
to,215-217
an,218-220
increase,221-229
in,230-232
bioavailability,233-248
or,249-251
due,252-255
to,256-258
a,259-260
decrease,261-269
in,270-272
metabolism.,273-284

These,0-5
effects,6-13
have,14-18
been,19-23
observed,24-32
with,33-37
co-administration,38-55
of,56-58
itraconazole,59-71	DrugDDI.d216.s3.e0
(a,72-74
potent,75-81
CYP3A4,82-88	DrugDDI.d216.s3.e1
inhibitor).,89-100

Caution,0-7
should,8-14
be,15-17
used,18-22
when,23-27
CYP3A4,28-34	DrugDDI.d216.s4.e0
inhibitors,35-45
are,46-49
co-administered,50-65
with,66-70
felodipine.,71-82	DrugDDI.d216.s4.e1

A,0-1
conservative,2-14
approach,15-23
to,24-26
dosing,27-33
felodipine,34-44	DrugDDI.d216.s5.e0
should,45-51
be,52-54
taken.,55-61

The,0-3
following,4-13
specific,14-22
interactions,23-35
have,36-40
been,41-45
reported:,46-55
Itraconazole?Co-administration,56-86
of,87-89
another,90-97
extended,98-106
release,107-114
formulation,115-126
of,127-129
felodipine,130-140	DrugDDI.d216.s6.e0
with,141-145
itraconazole,146-158	DrugDDI.d216.s6.e1
resulted,159-167
in,168-170
approximately,171-184
8-fold,185-191
increase,192-200
in,201-203
the,204-207
AUC,,208-212
more,213-217
than,218-222
6-,223-225
fold,226-230
increase,231-239
in,240-242
the,243-246
Cmax,,247-252
and,253-256
2-fold,257-263
prolongation,264-276
in,277-279
the,280-283
half-,284-289
life,290-294
of,295-297
felodipine.,298-309	DrugDDI.d216.s6.e2

Erythromycin?Co-administration,0-30
of,31-33
felodipine,34-44	DrugDDI.d216.s7.e0
(PLENDIL),45-54
with,55-59
erythromycin,60-72	DrugDDI.d216.s7.e2
resulted,73-81
in,82-84
approximately,85-98
2.5-,99-103
fold,104-108
increase,109-117
in,118-120
the,121-124
AUC,125-128
and,129-132
Cmax,,133-138
and,139-142
about,143-148
2-,149-151
fold,152-156
prolongation,157-169
in,170-172
the,173-176
half-,177-182
life,183-187
of,188-190
felodipine.,191-202	DrugDDI.d216.s7.e3

Grapefruit,0-10	DrugDDI.d216.s8.e0
juice?Co-administration,11-34
of,35-37
felodipine,38-48	DrugDDI.d216.s8.e1
with,49-53
grapefruit,54-64
juice,65-70
resulted,71-79
in,80-82
more,83-87
than,88-92
2-fold,93-99
increase,100-108
in,109-111
the,112-115
AUC,116-119
and,120-123
Cmax,,124-129
but,130-133
no,134-136
prolongation,137-149
in,150-152
the,153-156
half-,157-162
life,163-167
of,168-170
felodipine.,171-182	DrugDDI.d216.s8.e2

Cimetidine?Co-administration,0-28
of,29-31
felodipine,32-42	DrugDDI.d216.s9.e0
with,43-47
cimetidine,48-58	DrugDDI.d216.s9.e1
(a,59-61
non-specific,62-74
CYP-450,75-82
inhibitor),83-93
resulted,94-102
in,103-105
an,106-108
increase,109-117
of,118-120
approximately,121-134
50%,135-138
in,139-141
the,142-145
AUC,146-149
and,150-153
the,154-157
Cmax,,158-163
of,164-166
felodipine.,167-178	DrugDDI.d216.s9.e2

Beta-Blocking,0-13
Agents?,14-21
A,22-23
pharmacokinetic,24-39
study,40-45
of,46-48
felodipine,49-59	DrugDDI.d216.s10.e0
in,60-62
conjunction,63-74
with,75-79
metoprolol,80-90	DrugDDI.d216.s10.e1
demonstrated,91-103
no,104-106
significant,107-118
effects,119-126
on,127-129
the,130-133
pharmacokinetics,134-150
of,151-153
felodipine.,154-165	DrugDDI.d216.s10.e2

The,0-3
AUC,4-7
and,8-11
Cmax,12-16
of,17-19
metoprolol,,20-31
however,,32-40
were,41-45
increased,46-55
approximately,56-69
31,70-72
and,73-76
38%,,77-81
respectively.,82-95

In,0-2
controlled,3-13
clinical,14-22
trials,,23-30
however,,31-39
beta,40-44	DrugDDI.d216.s12.e0
blockers,45-53	DrugDDI.d216.s12.e0
including,54-63
metoprolol,64-74	DrugDDI.d216.s12.e1
were,75-79
concurrently,80-92
administered,93-105
with,106-110
felodipine,111-121	DrugDDI.d216.s12.e2
and,122-125
were,126-130
well,131-135
tolerated.,136-146

Digoxin?,0-8
When,9-13
given,14-19
concomitantly,20-33
with,34-38
PLENDIL,39-46	DrugDDI.d216.s13.e0
the,47-50
pharmacokinetics,51-67
of,68-70
digoxin,71-78	DrugDDI.d216.s13.e1
in,79-81
patients,82-90
with,91-95
heart,96-101
failure,102-109
were,110-114
not,115-118
significantly,119-132
altered.,133-141

Anticonvulsants?,0-16
In,17-19
a,20-21
pharmacokinetic,22-37
study,,38-44
maximum,45-52
plasma,53-59
concentrations,60-74
of,75-77
felodipine,78-88	DrugDDI.d216.s14.e0
were,89-93
considerably,94-106
lower,107-112
in,113-115
epileptic,116-125
patients,126-134
on,135-137
long-term,138-147
anticonvulsant,148-162
therapy,163-170
(eg,,171-175
phenytoin,,176-186
carbamazepine,,187-201
or,202-204
phenobarbital),205-219	DrugDDI.d216.s14.e3
than,220-224
in,225-227
healthy,228-235
volunteers.,236-247

In,0-2
such,3-7
patients,,8-17
the,18-21
mean,22-26
area,27-31
under,32-37
the,38-41
felodipine,42-52	DrugDDI.d216.s15.e0
plasma,53-59
concentration-time,60-78
curve,79-84
was,85-88
also,89-93
reduced,94-101
to,102-104
approximately,105-118
6%,119-121
of,122-124
that,125-129
observed,130-138
in,139-141
healthy,142-149
volunteers.,150-161

Since,0-5
a,6-7
clinically,8-18
significant,19-30
interaction,31-42
may,43-46
be,47-49
anticipated,,50-62
alternative,63-74
antihypertensive,75-91	DrugDDI.d216.s16.e0
therapy,92-99
should,100-106
be,107-109
considered,110-120
in,121-123
these,124-129
patients.,130-139

Tacrolimus?,0-11
Felodipine,12-22	DrugDDI.d216.s17.e0
may,23-26
increase,27-35
the,36-39
blood,40-45
concentration,46-59
of,60-62
tacrolimus.,63-74	DrugDDI.d216.s17.e1

When,0-4
given,5-10
concomitantly,11-24
with,25-29
felodipine,,30-41
the,42-45
tacrolimus,46-56	DrugDDI.d216.s18.e1
blood,57-62
concentration,63-76
should,77-83
be,84-86
followed,87-95
and,96-99
the,100-103
tacrolimus,104-114
dose,115-119
may,120-123
need,124-128
to,129-131
be,132-134
adjusted.,135-144

Other,0-5
Concomitant,6-17
Therapy?,18-26
In,27-29
healthy,30-37
subjects,38-46
there,47-52
were,53-57
no,58-60
clinically,61-71
significant,72-83
interactions,84-96
when,97-101
felodipine,102-112	DrugDDI.d216.s19.e0
was,113-116
given,117-122
concomitantly,123-136
with,137-141
indomethacin,142-154	DrugDDI.d216.s19.e1
or,155-157
spironolactone.,158-173	DrugDDI.d216.s19.e2

Fenfluramine,0-12	DrugDDI.d530.s0.e0
may,13-16
increase,17-25
slightly,26-34
the,35-38
effect,39-45
of,46-48
antihypertensive,49-65	DrugDDI.d530.s0.e1
drugs,,66-72	DrugDDI.d530.s0.e1
e.g.,,73-78
guanethidine,,79-92
methyldopa,,93-104
reserpine.,105-115	DrugDDI.d530.s0.e4

Other,0-5
CNS,6-9	DrugDDI.d530.s1.e0
depressant,10-20	DrugDDI.d530.s1.e0
drugs,21-26	DrugDDI.d530.s1.e0
should,27-33
be,34-36
used,37-41
with,42-46
caution,47-54
in,55-57
patients,58-66
taking,67-73
fenfluramine,,74-87
since,88-93
the,94-97
effects,98-105
may,106-109
be,110-112
additive.,113-122

Oral,0-4	DrugDDI.d143.s0.e0
Anticoagulants,5-19	DrugDDI.d143.s0.e0
CAUTION,20-27
SHOULD,28-34
BE,35-37
EXERCISED,38-47
WHEN,48-52
COUMARIN,53-61	DrugDDI.d143.s0.e1
ANTICOAGULANTS,62-76	DrugDDI.d143.s0.e1
ARE,77-80
GIVEN,81-86
IN,87-89
CONJUNCTION,90-101
WITH,102-106
TRICOR.,107-114	DrugDDI.d143.s0.e2

THE,0-3
DOSAGE,4-10
OF,11-13
THE,14-17
ANTICOAGULANTS,18-32	DrugDDI.d143.s1.e0
SHOULD,33-39
BE,40-42
REDUCED,43-50
TO,51-53
MAINTAIN,54-62
THE,63-66
PROTHROMBIN,67-78
TIME/INR,79-87
AT,88-90
THE,91-94
DESIRED,95-102
LEVEL,103-108
TO,109-111
PREVENT,112-119	DrugDDI.d143.s1.e1
BLEEDING,120-128
COMPLICATIONS.,129-143

HMG-CoA,0-7	DrugDDI.d143.s3.e0
reductase,8-17	DrugDDI.d143.s3.e0
inhibitors,18-28	DrugDDI.d143.s3.e0
The,29-32
combined,33-41
use,42-45
of,46-48
TRICOR,49-55	DrugDDI.d143.s3.e1
and,56-59
HMG-CoA,60-67	DrugDDI.d143.s3.e2
reductase,68-77	DrugDDI.d143.s3.e2
inhibitors,78-88	DrugDDI.d143.s3.e2
should,89-95
be,96-98
avoided,99-106
unless,107-113
the,114-117
benefit,118-125
of,126-128
further,129-136
alterations,137-148
in,149-151
lipid,152-157
levels,158-164
is,165-167
likely,168-174
to,175-177
outweigh,178-186
the,187-190
increased,191-200
risk,201-205
of,206-208
this,209-213
drug,214-218	DrugDDI.d143.s3.e3
combination.,219-231

Resins,0-6	DrugDDI.d143.s4.e0
Since,7-12
bile,13-17	DrugDDI.d143.s4.e1
acid,18-22	DrugDDI.d143.s4.e1
sequestrants,23-35	DrugDDI.d143.s4.e1
may,36-39
bind,40-44
other,45-50
drugs,51-56	DrugDDI.d143.s4.e2
given,57-62
concurrently,,63-76
patients,77-85
should,86-92
take,93-97
TRICOR,98-104	DrugDDI.d143.s4.e3
at,105-107
least,108-113
1,114-115
hour,116-120
before,121-127
or,128-130
4-6,131-134
hours,135-140
after,141-146
a,147-148
bile,149-153	DrugDDI.d143.s4.e4
acid,154-158	DrugDDI.d143.s4.e4
binding,159-166
resin,167-172
to,173-175
avoid,176-181
impeding,182-190
its,191-194
absorption.,195-206

Cyclosporine,0-12	DrugDDI.d143.s5.e0
Because,13-20
cyclosporine,21-33	DrugDDI.d143.s5.e1
can,34-37
produce,38-45
nephrotoxicity,46-60
with,61-65
decreases,66-75
in,76-78
creatinine,79-89
clearance,90-99
and,100-103
rises,104-109	DrugDDI.d143.s5.e2
in,110-112
serum,113-118
creatinine,,119-130
and,131-134
because,135-142
renal,143-148
excretion,149-158
is,159-161
the,162-165
primary,166-173
elimination,174-185
route,186-191
of,192-194
fibrate,195-202	DrugDDI.d143.s5.e3
drugs,203-208	DrugDDI.d143.s5.e3
including,209-218
TRICOR,,219-226
there,227-232
is,233-235
a,236-237
risk,238-242
that,243-247
an,248-250
interaction,251-262
will,263-267
lead,268-272
to,273-275
deterioration.,276-290

The,0-3
benefits,4-12
and,13-16
risks,17-22
of,23-25
using,26-31
TRICOR,32-38	DrugDDI.d143.s6.e0
with,39-43
immunosuppressants,44-62	DrugDDI.d143.s6.e1
and,63-66
other,67-72
potentially,73-84
nephrotoxic,85-96
agents,97-103
should,104-110
be,111-113
carefully,114-123
considered,,124-135
and,136-139
the,140-143
lowest,144-150
effective,151-160
dose,161-165
employed,166-174

?,0-1
Drug-drug,2-11
interactions,12-24
In,25-27
vitro,28-33
studies,34-41
using,42-47
human,48-53
liver,54-59
microsomes,60-70
indicate,71-79
that,80-84
fenofibrate,85-96	DrugDDI.d143.s8.e0
and,97-100
fenofibric,101-111	DrugDDI.d143.s8.e1
acid,112-116	DrugDDI.d143.s8.e1
are,117-120
not,121-124
inhibitors,125-135
of,136-138
cytochrome,139-149	DrugDDI.d143.s8.e2
(CYP),150-155
P450,156-160	DrugDDI.d143.s8.e4
isoforms,161-169
CYP3A4,,170-177
CYP2D6,,178-185
CYP2E1,,186-193
or,194-196
CYP1A2.,197-204	DrugDDI.d143.s8.e7

They,0-4
are,5-8
weak,9-13
inhibitors,14-24
of,25-27
CYP2C19,28-35	DrugDDI.d143.s9.e0
and,36-39
CYP2A6,,40-47
and,48-51
mild-to-moderate,52-68
inhibitors,69-79
of,80-82
CYP2C9,83-89	DrugDDI.d143.s9.e2
at,90-92
therapeutic,93-104
concentrations.,105-120

Potentiation,0-12
of,13-15
coumarin-type,16-29	DrugDDI.d143.s10.e0
anticoagulants,30-44	DrugDDI.d143.s10.e0
has,45-48
been,49-53
observed,54-62
with,63-67
prolongation,68-80
of,81-83
the,84-87
prothrombin,88-99
time/INR.,100-109

Bile,0-4	DrugDDI.d143.s11.e0
acid,5-9	DrugDDI.d143.s11.e0
sequestrants,10-22	DrugDDI.d143.s11.e0
have,23-27
been,28-32
shown,33-38
to,39-41
bind,42-46
other,47-52
drugs,53-58	DrugDDI.d143.s11.e1
given,59-64
concurrently.,65-78

Therefore,,0-10
fenofibrate,11-22	DrugDDI.d143.s12.e0
should,23-29
be,30-32
taken,33-38
at,39-41
least,42-47
1,48-49
hour,50-54
before,55-61
or,62-64
4-6,65-68
hours,69-74
after,75-80
a,81-82
bile,83-87	DrugDDI.d143.s12.e1
acid,88-92	DrugDDI.d143.s12.e1
binding,93-100
resin,101-106
to,107-109
avoid,110-115
impeding,116-124
its,125-128
absorption,129-139
.,140-141

Concomitant,0-11
administration,12-26
of,27-29
fenofibrate,30-41	DrugDDI.d143.s13.e0
(equivalent,42-53
to,54-56
145mg,57-62
TRICOR),63-70	DrugDDI.d143.s13.e1
with,71-75
pravastatin,76-87	DrugDDI.d143.s13.e2
(40,88-91
mg),92-95
once,96-100
daily,101-106
for,107-110
10,111-113
days,114-118
has,119-122
been,123-127
shown,128-133
to,134-136
increase,137-145
the,146-149
mean,150-154
Cmax,155-159
and,160-163
AUC,164-167
values,168-174
for,175-178
pravastatin,179-190	DrugDDI.d143.s13.e3
by,191-193
36%,194-197
(range,198-204
from,205-209
69%,210-213
decrease,214-222
to,223-225
321%,226-230
increase),231-240
and,241-244
28%,245-248
(range,249-255
from,256-260
54%,261-264
decrease,265-273
to,274-276
128%,277-281
increase),,282-292
respectively,,293-306
and,307-310
for,311-314
3?-hydroxy-iso-pravastatin,315-341
by,342-344
55%,345-348
(range,349-355
from,356-360
32%,361-364
decrease,365-373
to,374-376
314%,377-381
increase),382-391
and,392-395
39%,396-399
(range,400-406
from,407-411
24%,412-415
decrease,416-424
to,425-427
261%,428-432
increase),,433-443
respectively,444-456
in,457-459
23,460-462
healthy,463-470
adults.,471-478

A,0-1
single,2-8
dose,9-13
of,14-16
pravastatin,17-28	DrugDDI.d143.s14.e0
had,29-32
no,33-35
clinically,36-46
important,47-56
effect,57-63
on,64-66
the,67-70
pharmacokinetics,71-87
of,88-90
fenofibric,91-101	DrugDDI.d143.s14.e1
acid.,102-107	DrugDDI.d143.s14.e1

Concomitant,0-11
administration,12-26
of,27-29
fenofibrate,30-41	DrugDDI.d143.s15.e0
(equivalent,42-53
to,54-56
145,57-60
mg,61-63
TRICOR),64-71	DrugDDI.d143.s15.e1
with,72-76
atorvastatin,77-89	DrugDDI.d143.s15.e2
(20,90-93
mg),94-97
once,98-102
daily,103-108
for,109-112
10,113-115
days,116-120
resulted,121-129
in,130-132
approximately,133-146
17%,147-150
decrease,151-159
(range,160-166
from,167-171
67%,172-175
decrease,176-184
to,185-187
44%,188-191
increase),192-201
in,202-204
atorvastatin,205-217	DrugDDI.d143.s15.e3
AUC,218-221
values,222-228
in,229-231
22,232-234
healthy,235-242
males.,243-249

The,0-3
atorvastatin,4-16	DrugDDI.d143.s16.e0
Cmax,17-21
values,22-28
were,29-33
not,34-37
significantly,38-51
affected,52-60
by,61-63
fenofibrate.,64-76	DrugDDI.d143.s16.e1

The,0-3
pharmacokinetics,4-20
of,21-23
fenofibric,24-34	DrugDDI.d143.s17.e0
acid,35-39	DrugDDI.d143.s17.e0
were,40-44
not,45-48
significantly,49-62
affected,63-71
by,72-74
atorvastatin,75-87	DrugDDI.d143.s17.e1

Drug,0-4
Interactions,5-17
with,18-22
Beta-Blockers:,23-37	DrugDDI.d150.s0.e0
Concomitant,38-49
use,50-53
of,54-56
fenoldopam,57-67	DrugDDI.d150.s0.e1
with,68-72
beta-blockers,73-86	DrugDDI.d150.s0.e2
should,87-93
be,94-96
avoided.,97-105

If,0-2
the,3-6
drugs,7-12	DrugDDI.d150.s1.e0
are,13-16
used,17-21
together,,22-31
caution,32-39
should,40-46
be,47-49
exercised,50-59
because,60-67
unexpected,68-78
hypotension,79-90
could,91-96
result,97-103
from,104-108
beta-blocker,109-121	DrugDDI.d150.s1.e1
inhibition,122-132
of,133-135
the,136-139
sympathetic,140-151
reflex,152-158
response,159-167
to,168-170
fenoldopam.,171-182	DrugDDI.d150.s1.e2

Drug,0-4
Interactions,,5-18
General:,19-27
Although,28-36
there,37-42
have,43-47
been,48-52
no,53-55
formal,56-62
interaction,63-74
studies,,75-83
intravenous,84-95
fenoldopam,96-106	DrugDDI.d150.s2.e0
has,107-110
been,111-115
administered,116-128
safely,129-135
with,136-140
drugs,141-146	DrugDDI.d150.s2.e1
such,147-151
as,152-154
digitalis,155-164	DrugDDI.d150.s2.e2
and,165-168
sublingual,169-179
nitroglycerin.,180-194	DrugDDI.d150.s2.e3

There,0-5
is,6-8
limited,9-16
experience,17-27
with,28-32
concomitant,33-44
antihypertensive,45-61	DrugDDI.d150.s3.e0
agents,62-68	DrugDDI.d150.s3.e0
such,69-73
as,74-76
alpha-blockers,,77-92
calcium,93-100	DrugDDI.d150.s3.e1
channel-blockers,,101-118	DrugDDI.d150.s3.e1
ACE,119-122	DrugDDI.d150.s3.e2
inhibitors,,123-134	DrugDDI.d150.s3.e2
and,135-138
diuretics,139-148	DrugDDI.d150.s3.e3
(both,149-154
thiazide-like,155-168	DrugDDI.d150.s3.e4
and,169-172
loop).,173-179

The,0-3
coadministration,4-20
of,21-23
aspirin,24-31	DrugDDI.d172.s0.e0
decreases,32-41
the,42-45
biologic,46-54
half-life,55-64
of,65-67
fenoprofen,68-78	DrugDDI.d172.s0.e1
because,79-86
of,87-89
an,90-92
increase,93-101
in,102-104
metabolic,105-114
clearance,115-124
that,125-129
results,130-137
in,138-140
a,141-142
greater,143-150
amount,151-157
of,158-160
hydroxylated,161-173
fenoprofen,174-184	DrugDDI.d172.s0.e2
in,185-187
the,188-191
urine.,192-198

Although,0-8
the,9-12
mechanism,13-22
of,23-25
interaction,26-37
between,38-45
fenoprofen,46-56	DrugDDI.d172.s1.e0
and,57-60
aspirin,61-68	DrugDDI.d172.s1.e1
is,69-71
not,72-75
totally,76-83
known,,84-90
enzyme,91-97
induction,98-107
and,108-111
displacement,112-124
of,125-127
fenoprofen,128-138	DrugDDI.d172.s1.e2
from,139-143
plasma,144-150	DrugDDI.d172.s1.e3
albumin,151-158	DrugDDI.d172.s1.e3
binding,159-166
sites,167-172
are,173-176
possibilities.,177-191

Because,0-7
Nalfon,8-14	DrugDDI.d172.s2.e0
has,15-18
not,19-22
been,23-27
shown,28-33
to,34-36
produce,37-44
any,45-48
additional,49-59
effect,60-66
beyond,67-73
that,74-78
obtained,79-87
with,88-92
aspirin,93-100	DrugDDI.d172.s2.e1
alone,101-106
and,107-110
because,111-118
aspirin,119-126	DrugDDI.d172.s2.e2
increases,127-136
the,137-140
rate,141-145
of,146-148
excretion,149-158
of,159-161
Nalfon,,162-169
the,170-173
concomitant,174-185
use,186-189
of,190-192
Nalfon,193-199	DrugDDI.d172.s2.e4
and,200-203
salicylates,204-215	DrugDDI.d172.s2.e5
is,216-218
not,219-222
recommended.,223-235

Chronic,0-7
administration,8-22
of,23-25
phenobarbital,,26-40
a,41-42
known,43-48
enzyme,49-55
inducer,,56-64
may,65-68
be,69-71
associated,72-82
with,83-87
a,88-89
decrease,90-98
in,99-101
the,102-105
plasma,106-112
half-life,113-122
of,123-125
fenoprofen.,126-137	DrugDDI.d172.s3.e1

When,0-4
phenobarbital,5-18	DrugDDI.d172.s4.e0
is,19-21
added,22-27
to,28-30
or,31-33
withdrawn,34-43
from,44-48
treatment,,49-59
dosage,60-66
adjustment,67-77
of,78-80
Nalfon,81-87	DrugDDI.d172.s4.e1
may,88-91
be,92-94
required.,95-104

In,0-2
vitro,3-8
studies,9-16
have,17-21
shown,22-27
that,28-32
fenoprofen,,33-44
because,45-52
of,53-55
its,56-59
affinity,60-68
for,69-72
albumin,,73-81
may,82-85
displace,86-94
from,95-99
their,100-105
binding,106-113
sites,114-119
other,120-125
drugs,126-131	DrugDDI.d172.s5.e2
that,132-136
are,137-140
also,141-145
albumin,146-153	DrugDDI.d172.s5.e3
bound,,154-160
and,161-164
this,165-169
may,170-173
lead,174-178
to,179-181
drug,182-186
interaction.,187-199

Theoretically,,0-14
fenoprofen,15-25	DrugDDI.d172.s6.e0
could,26-31
likewise,32-40
be,41-43
displaced.,44-54

Patients,0-8
receiving,9-18
hydantoins,,19-30
sulfonamides,,31-44
or,45-47
sulfonylureas,48-61	DrugDDI.d172.s7.e2
should,62-68
be,69-71
observed,72-80
for,81-84
increased,85-94
activity,95-103
of,104-106
these,107-112
drugs,113-118	DrugDDI.d172.s7.e3
and,,119-123
therefore,,124-134
signs,135-140
of,141-143
toxicity,144-152
from,153-157
these,158-163
drugs.,164-170	DrugDDI.d172.s7.e4

In,0-2
patients,3-11
receiving,12-21
coumarin-type,22-35	DrugDDI.d172.s8.e0
anticoagulants,,36-51	DrugDDI.d172.s8.e0
the,52-55
addition,56-64
of,65-67
Nalfon,68-74	DrugDDI.d172.s8.e1
to,75-77
therapy,78-85
could,86-91
prolong,92-99
the,100-103
prothrombin,104-115
time.,116-121

Patients,0-8
receiving,9-18
both,19-23
drugs,24-29	DrugDDI.d172.s9.e0
should,30-36
be,37-39
under,40-45
careful,46-53
observation.,54-66

Patients,0-8
treated,9-16
with,17-21
Nalfon,22-28	DrugDDI.d172.s10.e0
may,29-32
be,33-35
resistant,36-45
to,46-48
the,49-52
effects,53-60
of,61-63
loop,64-68	DrugDDI.d172.s10.e1
diuretics.,69-79	DrugDDI.d172.s10.e1

In,0-2
patients,3-11
receiving,12-21
Nalfon,22-28	DrugDDI.d172.s11.e0
and,29-32
a,33-34
steroid,35-42
concomitantly,,43-57
any,58-61
reduction,62-71
in,72-74
steroid,75-82
dosage,83-89
should,90-96
be,97-99
gradual,100-107
in,108-110
order,111-116
to,117-119
avoid,120-125
the,126-129
possible,130-138
complications,139-152
of,153-155
sudden,156-162
steroid,163-170
withdrawal.,171-182

Agents,0-6
Affecting,7-16
Cytochrome,17-27	DrugDDI.d331.s0.e0
P450,28-32	DrugDDI.d331.s0.e0
3A4,33-36	DrugDDI.d331.s0.e0
Isoenzyme,37-46
System,47-53
Fentanyl,54-62
is,63-65
metabolized,66-77
mainly,78-84
via,85-88
the,89-92
human,93-98
cytochrome,99-109	DrugDDI.d331.s0.e1
P450,110-114	DrugDDI.d331.s0.e1
3A4,115-118	DrugDDI.d331.s0.e1
isoenzyme,119-128
system,129-135
(CYP3A4),,136-145
therefore,146-155
potential,156-165
interactions,166-178
may,179-182
occur,183-188
when,189-193
DURAGESIC?,194-204
is,205-207
given,208-213
concurrently,214-226
with,227-231
agents,232-238
that,239-243
affect,244-250
CYP3A4,251-257	DrugDDI.d331.s0.e3
activity.,258-267

The,0-3
concomitant,4-15
use,16-19
of,20-22
transdermal,23-34
fentanyl,35-43	DrugDDI.d331.s2.e0
with,44-48
ritonavir,49-58	DrugDDI.d331.s2.e1
or,59-61
other,62-67
potent,68-74
3A4,75-78
inhibitors,79-89
such,90-94
as,95-97
ketoconazole,,98-111
itraconazole,,112-125
troleandomycin,,126-141
clarithromycin,,142-157
nelfinavir,,158-169
and,170-173
nefazadone,174-184
may,185-188
result,189-195
in,196-198
an,199-201
increase,202-210
in,211-213
fentanyl,214-222	DrugDDI.d331.s2.e7
plasma,223-229
concentrations.,230-245

The,0-3
concomitant,4-15
use,16-19
of,20-22
other,23-28
CYP3A4,29-35	DrugDDI.d331.s3.e0
inhibitors,36-46
such,47-51
as,52-54
diltiazem,55-64	DrugDDI.d331.s3.e1
and,65-68
erythromycin,69-81	DrugDDI.d331.s3.e2
with,82-86
transdermal,87-98
fentanyl,99-107	DrugDDI.d331.s3.e3
may,108-111
also,112-116
result,117-123
in,124-126
an,127-129
increase,130-138
in,139-141
fentanyl,142-150	DrugDDI.d331.s3.e4
plasma,151-157
concentrations,,158-173
which,174-179
could,180-185
increase,186-194
or,195-197
prolong,198-205
adverse,206-213
drug,214-218
effects,219-226
and,227-230
may,231-234
cause,235-240
serious,241-248
respiratory,249-260
depression.,261-272

Central,0-7	DrugDDI.d331.s5.e0
Nervous,8-15	DrugDDI.d331.s5.e0
System,16-22	DrugDDI.d331.s5.e0
Depressants,23-34	DrugDDI.d331.s5.e0
The,35-38
concomitant,39-50
use,51-54
of,55-57
DURAGESIC?,58-68
(fentanyl,69-78
transdermal,79-90
system),91-98
with,99-103
other,104-109
central,110-117	DrugDDI.d331.s5.e2
nervous,118-125	DrugDDI.d331.s5.e2
system,126-132	DrugDDI.d331.s5.e2
depressants,,133-145	DrugDDI.d331.s5.e2
including,146-155
but,156-159
not,160-163
limited,164-171
to,172-174
other,175-180
opioids,,181-189
sedatives,,190-200
hypnotics,,201-211
tranquilizers,212-225	DrugDDI.d331.s5.e6
(e.g.,,226-232
benzodiazepines),,233-250
general,251-258	DrugDDI.d331.s5.e8
anesthetics,,259-271	DrugDDI.d331.s5.e8
phenothiazines,,272-287
skeletal,288-296	DrugDDI.d331.s5.e10
muscle,297-303	DrugDDI.d331.s5.e10
relaxants,,304-314	DrugDDI.d331.s5.e10
and,315-318
alcohol,,319-327
may,328-331
cause,332-337
respiratory,338-349
depression,,350-361
hypotension,,362-374
and,375-378
profound,379-387
sedation,,388-397
or,398-400
potentially,401-412
result,413-419
in,420-422
coma,423-427
or,428-430
death.,431-437

MAO,0-3	DrugDDI.d331.s7.e0
Inhibitors,4-14	DrugDDI.d331.s7.e0
DURAGESIC?,15-25
is,26-28
not,29-32
recommended,33-44
for,45-48
use,49-52
in,53-55
patients,56-64
who,65-68
have,69-73
received,74-82
MAOI,83-87
within,88-94
14,95-97
days,98-102
because,103-110
severe,111-117
and,118-121
unpredictable,122-135
potentiation,136-148
by,149-151
MAO,152-155	DrugDDI.d331.s7.e1
inhibitors,156-166	DrugDDI.d331.s7.e1
has,167-170
been,171-175
reported,176-184
with,185-189
opioid,190-196	DrugDDI.d331.s7.e2
analgesics,197-207	DrugDDI.d331.s7.e2

Drug,0-4
Interaction,5-16
with,17-21
Erythromycin,22-34	DrugDDI.d528.s0.e0
and,35-38
Ketoconazole,39-51	DrugDDI.d528.s0.e1
Fexofenadine,52-64
has,65-68
been,69-73
shown,74-79
to,80-82
exhibit,83-90
minimal,91-98
(ca.,99-103
5%),104-107
metabolism.,108-119

However,,0-8
co?,9-12
administration,13-27
of,28-30
fexofenadine,31-43	DrugDDI.d528.s1.e0
hydrochloride,44-57	DrugDDI.d528.s1.e0
with,58-62
either,63-69
ketoconazole,70-82	DrugDDI.d528.s1.e1
or,83-85
erythromycin,86-98	DrugDDI.d528.s1.e2
led,99-102
to,103-105
increased,106-115
plasma,116-122
concentrations,123-137
of,138-140
fexofenadine.,141-154	DrugDDI.d528.s1.e3

Fexofenadine,0-12	DrugDDI.d528.s2.e0
had,13-16
no,17-19
effect,20-26
on,27-29
the,30-33
pharmacokinetics,34-50
of,51-53
either,54-60
erythromycin,61-73	DrugDDI.d528.s2.e1
or,74-76
ketoconazole.,77-90	DrugDDI.d528.s2.e2

In,0-2
2,3-4
separate,5-13
studies,,14-22
fexofenadine,23-35	DrugDDI.d528.s3.e0
hydrochloride,36-49	DrugDDI.d528.s3.e0
120,50-53	DrugDDI.d528.s3.e0
mg,54-56
twice,57-62
daily,63-68
(240,69-73
mg,74-76
total,77-82
daily,83-88
dose),89-94
was,95-98
co-administered,99-114
with,115-119
either,120-126
erythromycin,127-139	DrugDDI.d528.s3.e1
500,140-143	DrugDDI.d528.s3.e1
mg,144-146	DrugDDI.d528.s3.e1
every,147-152
8,153-154
hours,155-160
or,161-163
ketoconazole,164-176	DrugDDI.d528.s3.e2
400,177-180	DrugDDI.d528.s3.e2
mg,181-183	DrugDDI.d528.s3.e2
once,184-188
daily,189-194
under,195-200
steady-state,201-213
conditions,214-224
to,225-227
healthy,228-235
volunteers,236-246
(n=24,,247-253
each,254-258
study).,259-266

No,0-2
differences,3-14
in,15-17
adverse,18-25
events,26-32
or,33-35
QTc,36-39
interval,40-48
were,49-53
observed,54-62
when,63-67
subjects,68-76
were,77-81
administered,82-94
fexofenadine,95-107	DrugDDI.d528.s4.e0
hydrochloride,108-121	DrugDDI.d528.s4.e0
alone,122-127
or,128-130
in,131-133
combination,134-145
with,146-150
either,151-157
erythromycin,158-170	DrugDDI.d528.s4.e1
or,171-173
ketoconazole.,174-187	DrugDDI.d528.s4.e2

The,0-3
findings,4-12
of,13-15
these,16-21
studies,22-29
are,30-33
summarized,34-44
in,45-47
the,48-51
following,52-61
table:,62-68
Effects,69-76
on,77-79
steady-state,80-92
fexofenadine,93-105	DrugDDI.d528.s5.e0
pharmacokinetics,106-122
after,123-128
7,129-130
days,131-135
of,136-138
co-administration,139-156
with,157-161
fexofenadine,162-174	DrugDDI.d528.s5.e1
hydrochloride,175-188	DrugDDI.d528.s5.e1
120,189-192	DrugDDI.d528.s5.e1
mg,193-195
every,196-201
12,202-204
hours,205-210
(two,211-215
times,216-221
the,222-225
recommended,226-237
twice,238-243
daily,244-249
dose),250-255
in,256-258
healthy,259-266
volunteers,267-277
(n=24),278-284

Concomitant,0-11
Drug,12-16	DrugDDI.d528.s6.e0

Erythromycin,0-12	DrugDDI.d528.s9.e0
(500,13-17
mg,18-20
every,21-26
8,27-28
hrs),29-33

Ketoconazole,0-12	DrugDDI.d528.s12.e0
(400,13-17
mg,18-20
once,21-25
daily),26-32

These,0-5
studies,6-13
indicate,14-22
that,23-27
ketoconazole,28-40	DrugDDI.d528.s17.e0
or,41-43
erythromycin,44-56	DrugDDI.d528.s17.e1
co-administration,57-74
enhances,75-83
fexofenadine,84-96	DrugDDI.d528.s17.e2
gastrointestinal,97-113
absorption.,114-125

This,0-4
observed,5-13
increase,14-22
in,23-25
the,26-29
bioavailability,30-45
of,46-48
fexofenadine,49-61	DrugDDI.d528.s18.e0
may,62-65
be,66-68
due,69-72
to,73-75
transport-related,76-93
effects,,94-102
such,103-107
as,108-110
p-glycoprotein.,111-126
in,127-129
vivo,130-134
animal,135-141
studies,142-149
also,150-154
suggest,155-162
that,163-167
in,168-170
addition,171-179
to,180-182
enhancing,183-192
absorption,,193-204
ketoconazole,205-217	DrugDDI.d528.s18.e2
decreases,218-227
fexofenadine,228-240	DrugDDI.d528.s18.e3
gastrointestinal,241-257
secretion,,258-268
while,269-274
erythromycin,275-287	DrugDDI.d528.s18.e4
may,288-291
also,292-296
decrease,297-305
biliary,306-313
excretion.,314-324

Drug,0-4
Interactions,5-17
with,18-22
Antacids,23-31	DrugDDI.d528.s19.e0
Administration,32-46
of,47-49
120,50-53
mg,54-56
of,57-59
fexofenadine,60-72	DrugDDI.d528.s19.e1
hydrochloride,73-86	DrugDDI.d528.s19.e1
(2,87-89
x,90-91
60,92-94
mg,95-97
capsule),98-106
within,107-113
15,114-116
minutes,117-124
of,125-127
an,128-130
aluminum,131-139
and,140-143
magnesium,144-153	DrugDDI.d528.s19.e2
containing,154-164	DrugDDI.d528.s19.e2
antacid,165-172	DrugDDI.d528.s19.e2
(Maalox?),173-182
decreased,183-192
fexofenadine,193-205	DrugDDI.d528.s19.e3
AUC,206-209
by,210-212
41%,213-216
and,217-220
cmax,221-225
by,226-228
43%.,229-233

ALLEGRA,0-7	DrugDDI.d528.s20.e0
should,8-14
not,15-18
be,19-21
taken,22-27
closely,28-35
in,36-38
time,39-43
with,44-48
aluminum,49-57
and,58-61
magnesium,62-71	DrugDDI.d528.s20.e1
containing,72-82	DrugDDI.d528.s20.e1
antacids.,83-92	DrugDDI.d528.s20.e1

Interactions,0-12
with,13-17
Fruit,18-23
Juices,24-30
Fruit,31-36
juices,37-43
such,44-48
as,49-51
grapefruit,,52-63
orange,64-70
and,71-74
apple,75-80
may,81-84
reduce,85-91
the,92-95
bioavailability,96-111
and,112-115
exposure,116-124
of,125-127
fexofenadine.,128-141	DrugDDI.d528.s21.e1

The,0-3
size,4-8
of,9-11
wheal,12-17
and,18-21
flare,22-27
were,28-32
significantly,33-46
larger,47-53
when,54-58
fexofenadine,59-71	DrugDDI.d528.s23.e0
hydrochloride,72-85	DrugDDI.d528.s23.e0
was,86-89
administered,90-102
with,103-107
either,108-114
grapefruit,115-125	DrugDDI.d528.s23.e1
or,126-128
orange,129-135
juices,136-142
compared,143-151
to,152-154
water.,155-161	DrugDDI.d528.s23.e2

In,0-2
addition,,3-12
based,13-18
on,19-21
the,22-25
population,26-36
pharmacokinetics,37-53
analysis,54-62
of,63-65
the,66-69
combined,70-78
data,79-83
from,84-88
grapefruit,89-99	DrugDDI.d528.s26.e0
and,100-103
orange,104-110
juices,111-117
studies,118-125
with,126-130
the,131-134
data,135-139
from,140-144
a,145-146
bioequivalence,147-161
study,,162-168
the,169-172
bioavailability,173-188
of,189-191
fexofenadine,192-204	DrugDDI.d528.s26.e1
was,205-208
reduced,209-216
by,217-219
36%.,220-224

Therefore,,0-10
to,11-13
maximize,14-22
the,23-26
effects,27-34
of,35-37
fexofenadine,,38-51
it,52-54
is,55-57
recommended,58-69
that,70-74
ALLEGRA,75-82	DrugDDI.d528.s27.e1
should,83-89
be,90-92
taken,93-98
with,99-103
water,104-109	DrugDDI.d528.s27.e2

Drug,0-4
interactions,5-17
between,18-25
NEUPOGEN?,26-35
and,36-39
other,40-45
drugs,46-51	DrugDDI.d450.s0.e0
have,52-56
not,57-60
been,61-65
fully,66-71
evaluated.,72-82

Drugs,0-5	DrugDDI.d450.s1.e0
which,6-11
may,12-15
potentiate,16-26
the,27-30
release,31-38
of,39-41
neutrophils,,42-54
such,55-59
as,60-62
lithium,,63-71
should,72-78
be,79-81
used,82-86
with,87-91
caution.,92-100

Finasteride,0-11	DrugDDI.d408.s1.e0
does,12-16
not,17-20
appear,21-27
to,28-30
affect,31-37
the,38-41
cytochrome,42-52	DrugDDI.d408.s1.e1
P450-linked,53-64	DrugDDI.d408.s1.e1
drug-metabolizing,65-82
enzyme,83-89
system.,90-97

Compounds,0-9
that,10-14
have,15-19
been,20-24
tested,25-31
in,32-34
man,35-38
include,39-46
antipyrine,,47-58
digoxin,,59-67
propranolol,,68-80
theophylline,,81-94
and,95-98
warfarin,99-107	DrugDDI.d408.s2.e4
and,108-111
no,112-114
clinically,115-125
meaningful,126-136
interactions,137-149
were,150-154
found.,155-161

Other,0-5
concomitant,6-17
therapy,18-25
Although,26-34
specific,35-43
interaction,44-55
studies,56-63
were,64-68
not,69-72
performed,,73-83
finasteride,84-95	DrugDDI.d408.s3.e0
doses,96-101
of,102-104
1,105-106
mg,107-109
or,110-112
more,113-117
were,118-122
concomitantly,123-136
used,137-141
in,142-144
clinical,145-153
studies,154-161
with,162-166
acetaminophen,,167-181
acetylsalicylic,182-197	DrugDDI.d408.s3.e2
acid,,198-203	DrugDDI.d408.s3.e2
a-blockers,,204-215
analgesics,,216-227
angiotensin-converting,228-250	DrugDDI.d408.s3.e4
enzyme,251-257	DrugDDI.d408.s3.e4
(ACE),258-263
inhibitors,,264-275
anticonvulsants,,276-292
benzodiazepines,,293-309
beta,310-314	DrugDDI.d408.s3.e7
blockers,,315-324	DrugDDI.d408.s3.e7
calcium-channel,325-340	DrugDDI.d408.s3.e8
blockers,,341-350	DrugDDI.d408.s3.e8
cardiac,351-358
nitrates,,359-368
diuretics,,369-379
H2,380-382
antagonists,,383-395
HMG-CoA,396-403	DrugDDI.d408.s3.e11
reductase,404-413	DrugDDI.d408.s3.e11
inhibitors,,414-425	DrugDDI.d408.s3.e11
prostaglandin,426-439	DrugDDI.d408.s3.e12
synthetase,440-450	DrugDDI.d408.s3.e12
inhibitors,451-461	DrugDDI.d408.s3.e12
(also,462-467
referred,468-476
to,477-479
as,480-482
NSAIDs),,483-491
and,492-495
quinolone,496-505	DrugDDI.d408.s3.e14
anti-infectives,506-521	DrugDDI.d408.s3.e14
without,522-529
evidence,530-538
of,539-541
clinically,542-552
significant,553-564
adverse,565-572
interactions.,573-586

Drug/Laboratory,0-15	DrugDDI.d408.s4.e0
Test,16-20
Interactions,21-33
Finasteride,34-45	DrugDDI.d408.s4.e1
had,46-49
no,50-52
effect,53-59
on,60-62
circulating,63-74
levels,75-81
of,82-84
cortisol,,85-94
thyroid-stimulating,95-114	DrugDDI.d408.s4.e3
hormone,,115-123	DrugDDI.d408.s4.e3
or,124-126
thyroxine,,127-137
nor,138-141
did,142-145
it,146-148
affect,149-155
the,156-159
plasma,160-166
lipid,167-172
profile,173-180
(e.g.,,181-187
total,188-193
cholesterol,,194-206
low-density,207-218	DrugDDI.d408.s4.e5
lipoproteins,,219-232	DrugDDI.d408.s4.e5
high-density,233-245	DrugDDI.d408.s4.e6
lipoproteins,246-258	DrugDDI.d408.s4.e6
and,259-262
triglycerides),263-277	DrugDDI.d408.s4.e7
or,278-280
bone,281-285
mineral,286-293
density.,294-302

In,0-2
studies,3-10
with,11-15
finasteride,,16-28
no,29-31
clinically,32-42
meaningful,43-53
changes,54-61
in,62-64
luteinizing,65-76	DrugDDI.d408.s5.e1
hormone,77-84
(LH),,85-90
follicle-stimulating,91-111	DrugDDI.d408.s5.e2
hormone,112-119
(FSH),120-125
or,126-128
prolactin,129-138	DrugDDI.d408.s5.e4
were,139-143
detected.,144-153

In,0-2
healthy,3-10
volunteers,,11-22
treatment,23-32
with,33-37
finasteride,38-49	DrugDDI.d408.s6.e0
did,50-53
not,54-57
alter,58-63
the,64-67
response,68-76
of,77-79
LH,80-82
and,83-86
FSH,87-90	DrugDDI.d408.s6.e1
to,91-93
gonadotropin-releasing,94-116	DrugDDI.d408.s6.e2
hormone,117-124
indicating,125-135
that,136-140
the,141-144
hypothalamic-pituitary-testicular,145-178
axis,179-183
was,184-187
not,188-191
affected.,192-201

In,0-2
clinical,3-11
studies,12-19
with,20-24
PROPECIA,25-33	DrugDDI.d408.s7.e0
(finasteride,,34-47
1,48-49
mg),50-53
in,54-56
men,57-60
18-41,61-66
years,67-72
of,73-75
age,,76-80
the,81-84
mean,85-89
value,90-95
of,96-98
serum,99-104
prostate-specific,105-122
antigen,123-130
(PSA),131-136
decreased,137-146
from,147-151
0.7,152-155
ng/mL,156-161
at,162-164
baseline,165-173
to,174-176
0.5,177-180
ng/mL,181-186
at,187-189
Month,190-195
12.,196-199

Further,,0-8
in,9-11
clinical,12-20
studies,21-28
with,29-33
PROSCAR,34-41	DrugDDI.d408.s8.e0
(finasteride,,42-55
5,56-57
mg),58-61
when,62-66
used,67-71
in,72-74
older,75-80
men,81-84
who,85-88
have,89-93
benign,94-100
prostatic,101-110
hyperplasia,111-122
(BPH),,123-129
PSA,130-133
levels,134-140
are,141-144
decreased,145-154
by,155-157
approximately,158-171
50%.,172-176

These,0-5
findings,6-14
should,15-21
be,22-24
taken,25-30
into,31-35
account,36-43
for,44-47
proper,48-54
interpretation,55-69
of,70-72
serum,73-78
PSA,79-82
when,83-87
evaluating,88-98
men,99-102
treated,103-110
with,111-115
finasteride.,116-128	DrugDDI.d408.s9.e0

TAMBOCOR,0-8	DrugDDI.d476.s1.e0
has,9-12
been,13-17
administered,18-30
to,31-33
patients,34-42
receiving,43-52
digitalis,53-62	DrugDDI.d476.s1.e1
preparations,63-75	DrugDDI.d476.s1.e1
or,76-78
beta-adrenergic,79-94	DrugDDI.d476.s1.e2
blocking,95-103	DrugDDI.d476.s1.e2
agents,104-110	DrugDDI.d476.s1.e2
without,111-118
adverse,119-126
effects.,127-135

During,0-6
administration,7-21
of,22-24
multiple,25-33
oral,34-38
doses,39-44
of,45-47
TAMBOCOR,48-56	DrugDDI.d476.s2.e0
to,57-59
healthy,60-67
subjects,68-76
stabilized,77-87
on,88-90
a,91-92
maintenance,93-104
dose,105-109
of,110-112
digoxin,,113-121
a,122-123
13%-19%,124-131
increase,132-140
in,141-143
plasma,144-150
digoxin,151-158
levels,159-165
occurred,166-174
at,175-177
six,178-181
hours,182-187
postdose.,188-197

In,0-2
a,3-4
study,5-10
involving,11-20
healthy,21-28
subjects,29-37
receiving,38-47
TAMBOCOR,48-56	DrugDDI.d476.s3.e0
and,57-60
propranolol,61-72	DrugDDI.d476.s3.e1
concurrently,,73-86
plasma,87-93
flecainide,94-104	DrugDDI.d476.s3.e2
levels,105-111
were,112-116
increased,117-126
about,127-132
20%,133-136
and,137-140
propranolol,141-152	DrugDDI.d476.s3.e3
levels,153-159
were,160-164
increased,165-174
about,175-180
30%,181-184
compared,185-193
to,194-196
control,197-204
values.,205-212

In,0-2
this,3-7
formal,8-14
interaction,15-26
study,,27-33
TAMBOCOR,34-42	DrugDDI.d476.s4.e0
and,43-46
propranolol,47-58	DrugDDI.d476.s4.e1
were,59-63
each,64-68
found,69-74
to,75-77
have,78-82
negative,83-91
inotropic,92-101
effects;,102-110

when,0-4
the,5-8
drugs,9-14	DrugDDI.d476.s5.e0
were,15-19
administered,20-32
together,,33-42
the,43-46
effects,47-54
were,55-59
additive.,60-69

The,0-3
effects,4-11
of,12-14
concomitant,15-26
administration,27-41
of,42-44
TAMBOCOR,45-53	DrugDDI.d476.s6.e0
and,54-57
propranolol,58-69	DrugDDI.d476.s6.e1
on,70-72
the,73-76
PR,77-79
interval,80-88
were,89-93
less,94-98
than,99-103
additive.,104-113

In,0-2
TAMBOCOR,3-11	DrugDDI.d476.s7.e0
clinical,12-20
trials,,21-28
patients,29-37
who,38-41
were,42-46
receiving,47-56
beta,57-61	DrugDDI.d476.s7.e1
blockers,62-70	DrugDDI.d476.s7.e1
concurrently,71-83
did,84-87
not,88-91
experience,92-102
an,103-105
increased,106-115
incidence,116-125
of,126-128
side,129-133
effects.,134-142

Nevertheless,,0-13
the,14-17
possibility,18-29
of,30-32
additive,33-41
negative,42-50
inotropic,51-60
effects,61-68
of,69-71
beta,72-76	DrugDDI.d476.s8.e0
blockers,77-85	DrugDDI.d476.s8.e0
and,86-89
flecainide,90-100	DrugDDI.d476.s8.e1
should,101-107
be,108-110
recognized.,111-122

Flecainide,0-10	DrugDDI.d476.s9.e0
is,11-13
not,14-17
extensively,18-29
bound,30-35
to,36-38
plasma,39-45	DrugDDI.d476.s9.e1
proteins.,46-55	DrugDDI.d476.s9.e1

In,0-2
vitro,3-8
studies,9-16
with,17-21
several,22-29
drugs,30-35	DrugDDI.d476.s10.e0
which,36-41
may,42-45
be,46-48
administered,49-61
concomitantly,62-75
showed,76-82
that,83-87
the,88-91
extent,92-98
of,99-101
flecainide,102-112	DrugDDI.d476.s10.e1
binding,113-120
to,121-123
human,124-129
plasma,130-136	DrugDDI.d476.s10.e2
proteins,137-145	DrugDDI.d476.s10.e2
is,146-148
either,149-155
unchanged,156-165
or,166-168
only,169-173
slightly,174-182
less.,183-188

Consequently,,0-13
interactions,14-26
with,27-31
other,32-37
drugs,38-43	DrugDDI.d476.s11.e0
which,44-49
are,50-53
highly,54-60
protein,61-68	DrugDDI.d476.s11.e1
bound,69-74
(e.g.,,75-81
anticoagulants,82-96	DrugDDI.d476.s11.e2
),97-98
would,99-104
not,105-108
be,109-111
expected.,112-121

TAMBOCOR,0-8	DrugDDI.d476.s12.e0
has,9-12
been,13-17
used,18-22
in,23-25
a,26-27
large,28-33
number,34-40
of,41-43
patients,44-52
receiving,53-62
diuretics,63-72	DrugDDI.d476.s12.e1
without,73-80
apparent,81-89
interaction.,90-102

Limited,0-7
data,8-12
in,13-15
patients,16-24
receiving,25-34
known,35-40
enzyme,41-47
inducers,48-56
(,57-58
phenytoin,,59-69
phenobarbital,,70-84
carbamazepine,85-98	DrugDDI.d476.s13.e2
),99-100
indicate,101-109
only,110-114
a,115-116
30%,117-120
increase,121-129
in,130-132
the,133-136
rate,137-141
of,142-144
flecainide,145-155	DrugDDI.d476.s13.e3
elimination.,156-168

In,0-2
healthy,3-10
subjects,11-19
receiving,20-29
cimetidine,30-40	DrugDDI.d476.s14.e0
(1,41-43
gm,44-46
daily),47-53
for,54-57
one,58-61
week,,62-67
plasma,68-74
flecainide,75-85	DrugDDI.d476.s14.e1
levels,86-92
increased,93-102
by,103-105
about,106-111
30%,112-115
and,116-119
half-life,120-129
increased,130-139
by,140-142
about,143-148
10%.,149-153

When,0-4
amiodarone,5-15	DrugDDI.d476.s15.e0
is,16-18
added,19-24
to,25-27
flecainide,28-38	DrugDDI.d476.s15.e1
therapy,,39-47
plasma,48-54
flecainide,55-65	DrugDDI.d476.s15.e2
levels,66-72
may,73-76
increase,77-85
two-fold,86-94
or,95-97
more,98-102
in,103-105
some,106-110
patients,,111-120
if,121-123
flecainide,124-134	DrugDDI.d476.s15.e3
dosage,135-141
is,142-144
not,145-148
reduced.,149-157

Drugs,0-5	DrugDDI.d476.s16.e0
that,6-10
inhibit,11-18
cytochrome,19-29	DrugDDI.d476.s16.e1
P450IID6,,30-39
such,40-44
as,45-47
quinidine,48-57	DrugDDI.d476.s16.e2
,,58-59
might,60-65
increase,66-74
the,75-78
plasma,79-85
concentrations,86-100
of,101-103
flecainide,104-114	DrugDDI.d476.s16.e3
in,115-117
patients,118-126
that,127-131
are,132-135
on,136-138
chronic,139-146
flecainide,147-157	DrugDDI.d476.s16.e4
therapy;,158-166

There,0-5
has,6-9
been,10-14
little,15-21
experience,22-32
with,33-37
the,38-41
coadministration,42-58
of,59-61
TAMBOCOR,62-70	DrugDDI.d476.s18.e0
and,71-74
either,75-81
disopyramide,82-94	DrugDDI.d476.s18.e1
or,95-97
verapamil.,98-108	DrugDDI.d476.s18.e2

Because,0-7
both,8-12
of,13-15
these,16-21
drugs,22-27	DrugDDI.d476.s19.e0
have,28-32
negative,33-41
inotropic,42-51
properties,52-62
and,63-66
the,67-70
effects,71-78
of,79-81
coadministration,82-98
with,99-103
TAMBOCOR,104-112	DrugDDI.d476.s19.e1
are,113-116
unknown,,117-125
neither,126-133
disopyramide,134-146	DrugDDI.d476.s19.e2
nor,147-150
verapamil,151-160	DrugDDI.d476.s19.e3
should,161-167
be,168-170
administered,171-183
concurrently,184-196
with,197-201
TAMBOCOR,202-210	DrugDDI.d476.s19.e4
unless,,211-218
in,219-221
the,222-225
judgment,226-234
of,235-237
the,238-241
physician,,242-252
the,253-256
benefits,257-265
of,266-268
this,269-273
combination,274-285
outweigh,286-294
the,295-298
risks.,299-305

There,0-5
has,6-9
been,10-14
too,15-18
little,19-25
experience,26-36
with,37-41
the,42-45
coadministration,46-62
of,63-65
TAMBOCOR,66-74	DrugDDI.d476.s20.e0
with,75-79
nifedipine,80-90	DrugDDI.d476.s20.e1
or,91-93
diltiazem,94-103	DrugDDI.d476.s20.e2
to,104-106
recommend,107-116
concomitant,117-128
use.,129-133

Combination,0-11
Therapy:,12-20
Any,21-24
form,25-29
of,30-32
therapy,33-40
which,41-46
adds,47-51
to,52-54
the,55-58
stress,59-65	DrugDDI.d497.s0.e0
of,66-68
the,69-72
patient,,73-81
interferes,82-92
with,93-97
nutrition,98-107
or,108-110
depresses,111-120
bone,121-125
marrow,126-132
function,133-141
will,142-146
increase,147-155
the,156-159
toxicity,160-168
of,169-171
Floxuridine.,172-184	DrugDDI.d497.s0.e1

Cytosine,0-8	DrugDDI.d465.s0.e0
arabinoside,,9-21	DrugDDI.d465.s0.e0
a,22-23
cytostatic,24-34	DrugDDI.d465.s0.e1
agent,,35-41	DrugDDI.d465.s0.e1
has,42-45
been,46-50
reported,51-59
to,60-62
inactivate,63-73
the,74-77
antifungal,78-88	DrugDDI.d465.s0.e2
activity,89-97
of,98-100
flucytosine,101-112	DrugDDI.d465.s0.e3
by,113-115
competitive,116-127
inhibition.,128-139

Drugs,0-5	DrugDDI.d465.s1.e0
which,6-11
impair,12-18
glomerular,19-29
filtration,30-40
may,41-44
prolong,45-52
the,53-56
biological,57-67
half-life,68-77
of,78-80
flucytosine.,81-93	DrugDDI.d465.s1.e1

Drug/Laboratory,0-15	DrugDDI.d465.s2.e0
Test,16-20
Interactions:,21-34
Measurement,35-46
of,47-49
serum,50-55
creatinine,56-66
levels,67-73
should,74-80
be,81-83
determined,84-94
by,95-97
the,98-101
Jaffe,102-107
reaction,,108-117
since,118-123
Ancobon,124-131	DrugDDI.d465.s2.e1
does,132-136
not,137-140
interfere,141-150
with,151-155
the,156-159
determination,160-173
of,174-176
creatinine,177-187	DrugDDI.d465.s2.e2
values,188-194
by,195-197
this,198-202
method.,203-210

Most,0-4
automated,5-14
equipment,15-24
for,25-28
measurement,29-40
of,41-43
creatinine,44-54	DrugDDI.d465.s3.e0
makes,55-60
use,61-64
of,65-67
the,68-71
Jaffe,72-77
reaction.,78-87

The,0-3
use,4-7
of,8-10
FLUDARA,11-18	DrugDDI.d233.s0.e0
FOR,19-22
INJECTION,23-32
in,33-35
combination,36-47
with,48-52
pentostatin,53-64	DrugDDI.d233.s0.e1
is,65-67
not,68-71
recommended,72-83
due,84-87
to,88-90
the,91-94
risk,95-99
of,100-102
severe,103-109
pulmonary,110-119
toxicity.,120-129

When,0-4
administered,5-17
concurrently,,18-31
the,32-35
following,36-45
drugs,46-51	DrugDDI.d395.s0.e0
may,52-55
interact,56-64
with,65-69
adrenal,70-77
corticosteroids.,78-94	DrugDDI.d395.s0.e1

Amphotericin,0-12	DrugDDI.d395.s1.e0
B,13-14	DrugDDI.d395.s1.e0
or,15-17
potassium-depleting,18-37	DrugDDI.d395.s1.e1
diuretics,38-47	DrugDDI.d395.s1.e1
(benzothiadiazines,48-66
and,67-70
related,71-78
drugs,,79-85
ethacrynic,86-96	DrugDDI.d395.s1.e3
acid,97-101	DrugDDI.d395.s1.e3
and,102-105
furosemide)?enhanced,106-126	DrugDDI.d395.s1.e4
hypokalemia.,127-139

use,0-3
potassium,4-13	DrugDDI.d395.s3.e0
supplements,14-25
if,26-28
necessary,29-38
.,39-40

Digitalis,0-9	DrugDDI.d395.s4.e0
glycosides?enhanced,10-29
possibility,30-41
of,42-44
arrhythmias,45-56
or,57-59
digitalis,60-69
toxicity,70-78
associated,79-89
with,90-94
hypokalemia.,95-107

use,0-3
potassium,4-13	DrugDDI.d395.s6.e0
supplements,14-25
if,26-28
necessary.,29-39

Monitor,0-7
prothrombin,8-19
levels,20-26
and,27-30
adjust,31-37
anticoagulant,38-51	DrugDDI.d395.s8.e0
dosage,52-58
accordingly.,59-71

Antidiabetic,0-12	DrugDDI.d395.s9.e0
drugs,13-18	DrugDDI.d395.s9.e0
(oral,19-24
agents,25-31
and,32-35
insulin)?diminished,36-55	DrugDDI.d395.s9.e1
antidiabetic,56-68	DrugDDI.d395.s9.e2
effect.,69-76

adjust,0-6
dosage,7-13
of,14-16
antidiabetic,17-29	DrugDDI.d395.s11.e0
drug,30-34	DrugDDI.d395.s11.e0
upward,35-41
if,42-44
necessary.,45-55

decreased,0-9
pharmacologic,10-23
effect,24-30
of,31-33
aspirin.,34-42	DrugDDI.d395.s13.e0

Rarely,0-6
salicylate,7-17
toxicity,18-26
may,27-30
occur,31-36
in,37-39
patients,40-48
who,49-52
discontinue,53-64
steroids,65-73
after,74-79
concurrent,80-90
high-dose,91-100
aspirin,101-108	DrugDDI.d395.s14.e0
therapy.,109-117

Monitor,0-7
salicylate,8-18
levels,19-25
or,26-28
the,29-32
therapeutic,33-44
effect,45-51
for,52-55
which,56-61
aspirin,62-69	DrugDDI.d395.s15.e0
is,70-72
given;,73-79

adjust,0-6
salicylate,7-17	DrugDDI.d395.s16.e0
dosage,18-24
accordingly,25-36
if,37-39
effect,40-46
is,47-49
altered.,50-58

Barbiturates,,0-13
phenytoin,,14-24
or,25-27
rifampin?increased,28-46
metabolic,47-56
clearance,57-66
of,67-69
fludrocortisone,70-85	DrugDDI.d395.s17.e2
acetate,86-93	DrugDDI.d395.s17.e2
because,94-101
of,102-104
the,105-108
induction,109-118
of,119-121
hepatic,122-129
enzymes.,130-138

Anabolic,0-8	DrugDDI.d395.s19.e0
steroids,9-17	DrugDDI.d395.s19.e0
(particularly,18-31
C-17,32-36
alkylated,37-46
androgens,47-56	DrugDDI.d395.s19.e1
such,57-61
as,62-64
oxymetholone,,65-78
methandrostenolone,,79-98
norethandrolone,,99-115
and,116-119
similar,120-127
compounds)?enhanced,128-147
tendency,148-156
toward,157-163
edema.,164-170

Use,0-3
caution,4-11
when,12-16
giving,17-23
these,24-29
drugs,30-35	DrugDDI.d395.s20.e0
together,,36-45
especially,46-56
in,57-59
patients,60-68
with,69-73
hepatic,74-81
or,82-84
cardiac,85-92
disease.,93-101

Estrogen?increased,0-18
levels,19-25
of,26-28
corticosteroid-binding,29-51	DrugDDI.d395.s22.e0
globulin,,52-61	DrugDDI.d395.s22.e0
thereby,62-69
increasing,70-80
the,81-84
bound,85-90
(inactive),91-101
fraction;,102-111

this,0-4
effect,5-11
is,12-14
at,15-17
least,18-23
balanced,24-32
by,33-35
decreased,36-45
metabolism,46-56
of,57-59
corticosteroids.,60-76	DrugDDI.d395.s23.e0

When,0-4
estrogen,5-13
therapy,14-21
is,22-24
initiated,,25-35
a,36-37
reduction,38-47
in,48-50
corticosteroid,51-65	DrugDDI.d395.s24.e0
dosage,66-72
may,73-76
be,77-79
required,,80-89
and,90-93
increased,94-103
amounts,104-111
may,112-115
be,116-118
required,119-127
when,128-132
estrogen,133-141	DrugDDI.d395.s24.e1
is,142-144
terminated.,145-156

Drug/Laboratory,0-15	DrugDDI.d395.s25.e0
Test,16-20
Interactions,21-33
Corticosteroids,34-49	DrugDDI.d395.s25.e1
may,50-53
affect,54-60
the,61-64
nitrobluetetrazolium,65-85
test,86-90
for,91-94
bacterial,95-104
infection,105-114
and,115-118
produce,119-126
false-negative,127-141
results,142-149

Interaction,0-11
with,12-16
central,17-24	DrugDDI.d564.s0.e0
nervous,25-32	DrugDDI.d564.s0.e0
system,33-39	DrugDDI.d564.s0.e0
depressants,40-51	DrugDDI.d564.s0.e0
other,52-57
than,58-62
benzodiazepines,63-78	DrugDDI.d564.s0.e1
has,79-82
not,83-86
been,87-91
specifically,92-104
studied;,105-113

however,,0-8
no,9-11
deleterious,12-23
interactions,24-36
were,37-41
seen,42-46
when,47-51
ROMAZICON,52-61	DrugDDI.d564.s1.e0
was,62-65
administered,66-78
after,79-84
narcotics,,85-95
inhalational,96-108	DrugDDI.d564.s1.e2
anesthetics,,109-121	DrugDDI.d564.s1.e2
muscle,122-128	DrugDDI.d564.s1.e3
relaxants,129-138	DrugDDI.d564.s1.e3
and,139-142
muscle,143-149	DrugDDI.d564.s1.e4
relaxant,150-158	DrugDDI.d564.s1.e4
antagonists,159-170
administered,171-183
in,184-186
conjunction,187-198
with,199-203
sedation,204-212
or,213-215
anesthesia.,216-227

Particular,0-10
caution,11-18
is,19-21
necessary,22-31
when,32-36
using,37-42
ROMAZICON,43-52	DrugDDI.d564.s2.e0
in,53-55
cases,56-61
of,62-64
mixed,65-70
drug,71-75	DrugDDI.d564.s2.e1
overdosage,76-86
since,87-92
the,93-96
toxic,97-102
effects,103-110
(such,111-116
as,117-119
convulsions,120-131
and,132-135
cardiac,136-143
dysrhythmias),144-157
of,158-160
other,161-166
drugs,167-172	DrugDDI.d564.s2.e2
taken,173-178
in,179-181
overdose,182-190
(especially,191-202
cyclic,203-209
antidepressants),210-226	DrugDDI.d564.s2.e3
may,227-230
emerge,231-237
with,238-242
the,243-246
reversal,247-255
of,256-258
the,259-262
benzodiazepine,263-277	DrugDDI.d564.s2.e4
effect,278-284
by,285-287
flumazenil.,288-299	DrugDDI.d564.s2.e5

The,0-3
use,4-7
of,8-10
ROMAZICON,11-20	DrugDDI.d564.s3.e0
is,21-23
not,24-27
recommended,28-39
in,40-42
epileptic,43-52
patients,53-61
who,62-65
have,66-70
been,71-75
receiving,76-85
benzodiazepine,86-100	DrugDDI.d564.s3.e1
treatment,101-110
for,111-114
a,115-116
prolonged,117-126
period.,127-134

Although,0-8
ROMAZICON,9-18	DrugDDI.d564.s4.e0
exerts,19-25
a,26-27
slight,28-34
intrinsic,35-44
anticonvulsant,45-59	DrugDDI.d564.s4.e1
effect,,60-67
its,68-71
abrupt,72-78
suppression,79-90
of,91-93
the,94-97
protective,98-108
effect,109-115
of,116-118
a,119-120
benzodiazepine,121-135	DrugDDI.d564.s4.e2
agonist,136-143
can,144-147
give,148-152
rise,153-157
to,158-160
convulsions,161-172
in,173-175
epileptic,176-185
patients.,186-195

ROMAZICON,0-9	DrugDDI.d564.s5.e0
blocks,10-16
the,17-20
central,21-28
effects,29-36
of,37-39
benzodiazepines,40-55	DrugDDI.d564.s5.e1
by,56-58
competitive,59-70
interaction,71-82
at,83-85
the,86-89
receptor,90-98	DrugDDI.d564.s5.e2
level.,99-105

The,0-3
effects,4-11
of,12-14
nonbenzodiazepine,15-32
agonists,33-41	DrugDDI.d564.s6.e0
at,42-44
benzodiazepine,45-59	DrugDDI.d564.s6.e1
receptors,,60-70	DrugDDI.d564.s6.e1
such,71-75
as,76-78
zopiclone,,79-89
triazolopyridazines,90-109
and,110-113
others,,114-121
are,122-125
also,126-130
blocked,131-138
by,139-141
ROMAZICON.,142-152	DrugDDI.d564.s6.e3

The,0-3
pharmacokinetics,4-20
of,21-23
benzodiazepines,24-39	DrugDDI.d564.s7.e0
are,40-43
unaltered,44-53
in,54-56
the,57-60
presence,61-69
of,70-72
flumazenil,73-83	DrugDDI.d564.s7.e1
and,84-87
vice,88-92
versa.,93-99

There,0-5
is,6-8
no,9-11
pharmacokinetic,12-27
interaction,28-39
between,40-47
ethanol,48-55	DrugDDI.d564.s8.e0
and,56-59
flumazenil.,60-71	DrugDDI.d564.s8.e1

Use,0-3
in,4-6
Ambulatory,7-17
Patients,18-26
The,27-30
effects,31-38
of,39-41
ROMAZICON,42-51	DrugDDI.d564.s9.e0
may,52-55
wear,56-60
off,61-64
before,65-71
a,72-73
long-acting,74-85	DrugDDI.d564.s9.e1
benzodiazepine,86-100	DrugDDI.d564.s9.e1
is,101-103
completely,104-114
cleared,115-122
from,123-127
the,128-131
body.,132-137

In,0-2
general,,3-11
if,12-14
a,15-16
patient,17-24
shows,25-30
no,31-33
signs,34-39
of,40-42
sedation,43-51
within,52-58
2,59-60
hours,61-66
after,67-72
a,73-74
1-mg,75-79
dose,80-84
of,85-87
flumazenil,,88-99
serious,100-107
resedation,108-118
at,119-121
a,122-123
later,124-129
time,130-134
is,135-137
unlikely.,138-147

An,0-2
adequate,3-11
period,12-18
of,19-21
observation,22-33
must,34-38
be,39-41
provided,42-50
for,51-54
any,55-58
patient,59-66
in,67-69
whom,70-74
either,75-81
long-acting,82-93	DrugDDI.d564.s11.e0
benzodiazepines,94-109	DrugDDI.d564.s11.e0
(such,110-115
as,116-118
diazepam),119-128	DrugDDI.d564.s11.e1
or,129-131
large,132-137
doses,138-143
of,144-146
short-acting,147-159	DrugDDI.d564.s11.e2
benzodiazepines,160-175	DrugDDI.d564.s11.e2
(such,176-181
as,182-184
,185-185
10,186-188
mg,189-191
of,192-194
midazolam),195-205	DrugDDI.d564.s11.e3
have,206-210
been,211-215
used.,216-221

Because,0-7
of,8-10
the,11-14
increased,15-24
risk,25-29
of,30-32
adverse,33-40
reactions,41-50
in,51-53
patients,54-62
who,63-66
have,67-71
been,72-76
taking,77-83
benzodiazepines,84-99	DrugDDI.d564.s12.e0
on,100-102
a,103-104
regular,105-112
basis,,113-119
it,120-122
is,123-125
particularly,126-138
important,139-148
that,149-153
physicians,154-164
query,165-170
patients,171-179
or,180-182
their,183-188
guardians,189-198
carefully,199-208
about,209-214
benzodiazepine,,215-230
alcohol,231-238	DrugDDI.d564.s12.e2
and,239-242
sedative,243-251	DrugDDI.d564.s12.e3
use,252-255
as,256-258
part,259-263
of,264-266
the,267-270
history,271-278
prior,279-284
to,285-287
any,288-291
procedure,292-301
in,302-304
which,305-310
the,311-314
use,315-318
of,319-321
ROMAZICON,322-331	DrugDDI.d564.s12.e4
is,332-334
planned.,335-343

Do,0-2
not,3-6
take,7-11
this,12-16
medicine,17-25	DrugDDI.d539.s0.e0
with,26-30
thioridizine,,31-44
or,45-47
within,48-54
5,55-56
weeks,57-62
of,63-65
taking,66-72
fluoxetine.,73-84	DrugDDI.d539.s0.e1

Talk,0-4
to,5-7
your,8-12
doctor,13-19
if,20-22
you,23-26
are,27-30
taking,31-37
certain,38-45
antibiotics,46-57	DrugDDI.d539.s1.e0
such,58-62
as,63-65
erythromycin,,66-79
clarithromycin,80-94	DrugDDI.d539.s1.e2
or,95-97
azithromycin.,98-111	DrugDDI.d539.s1.e3

This,0-4
medicine,5-13	DrugDDI.d539.s2.e0
should,14-20
not,21-24
be,25-27
taken,28-33
with,34-38
MAO,39-42	DrugDDI.d539.s2.e1
inhibitors.,43-54	DrugDDI.d539.s2.e1

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
taking,33-39
this,40-44
medicine,45-53
certain,54-61
antibiotics,,62-74
such,75-79
as,80-82
erythromycin,,83-96
clarithromycin,,97-112
or,113-115
azithromycin.,116-129	DrugDDI.d539.s3.e3

This,0-4
medicine,5-13	DrugDDI.d539.s4.e0
should,14-20
not,21-24
be,25-27
taken,28-33
with,34-38
MAO,39-42	DrugDDI.d539.s4.e1
inhibitors.,43-54	DrugDDI.d539.s4.e1

If,0-2
you,3-6
think,7-12
you,13-16
are,17-20
taking,21-27
an,28-30
MAO,31-34	DrugDDI.d539.s5.e0
inhibitor,35-44	DrugDDI.d539.s5.e0
talk,45-49
to,50-52
your,53-57
doctor,58-64
or,65-67
pharmacist.,68-79

Do,0-2
not,3-6
take,7-11
this,12-16
medicine,17-25	DrugDDI.d539.s6.e0
with,26-30
St.,31-34	DrugDDI.d539.s6.e1
Johns,35-40	DrugDDI.d539.s6.e1
Wort,41-45	DrugDDI.d539.s6.e1
because,46-53
of,54-56
the,57-60
additive,61-69
effects,70-77
of,78-80
sertonin.,81-90

This,0-4
medication,5-15	DrugDDI.d539.s7.e0
should,16-22
not,23-26
be,27-29
taken,30-35
with,36-40
MAO,41-44	DrugDDI.d539.s7.e1
inhibitors.,45-56	DrugDDI.d539.s7.e1

Your,0-4
doctor,5-11
or,12-14
pharmacist,15-25
can,26-29
give,30-34
you,35-38
more,39-43
information,44-55
on,56-58
MAO,59-62	DrugDDI.d539.s8.e0
inhibitors.,63-74	DrugDDI.d539.s8.e0

Wait,0-4
5,5-6
weeks,7-12
after,13-18
stopping,19-27
escitalopram,28-40	DrugDDI.d539.s9.e0
before,41-47
starting,48-56
a,57-58
non-selective,59-72
MAO,73-76	DrugDDI.d539.s9.e1
inhibitor.,77-87	DrugDDI.d539.s9.e1

Wait,0-4
2,5-6
weeks,7-12
after,13-18
stopping,19-27
an,28-30
MAO,31-34	DrugDDI.d539.s10.e0
inhibitor,35-44	DrugDDI.d539.s10.e0
before,45-51
starting,52-60
escitalopram.,61-74	DrugDDI.d539.s10.e1

If,0-2
you,3-6
are,7-10
taking,11-17
medications,18-29
for,30-33
migraines,34-43
such,44-48
as,49-51
Imitrex,,52-60
talk,61-65
to,66-68
your,69-73
doctor,74-80
before,81-87
starting,88-96
this,97-101
medicine.,102-111	DrugDDI.d539.s11.e1

If,0-2
you,3-6
are,7-10
taking,11-17
a,18-19
tricyclic,20-29	DrugDDI.d539.s12.e0
antidepressant,,30-45	DrugDDI.d539.s12.e0
talk,46-50
to,51-53
your,54-58
doctor,59-65
before,66-72
taking,73-79
this,80-84
medicine.,85-94	DrugDDI.d539.s12.e1

St.,0-3
John??s,4-11
Wort,12-16
should,17-23
be,24-26
avoided,27-34
while,35-40
taking,41-47
this,48-52
medicine,53-61	DrugDDI.d539.s13.e0
due,62-65
to,66-68
the,69-72
additive,73-81
effects,82-89
of,90-92
serotonin.,93-103

Tell,0-4
your,5-9
doctor,10-16
if,17-19
you,20-23
are,24-27
taking,28-34
any,35-38
of,39-41
the,42-45
following,46-55
drugs:,56-62	DrugDDI.d539.s14.e0
blood,63-68	DrugDDI.d539.s14.e1
thinners,69-77	DrugDDI.d539.s14.e1
(Coumadin),78-88
other,89-94
antidepressants,95-110	DrugDDI.d539.s14.e3
metoprolol,111-121
antihistamines,122-136	DrugDDI.d539.s14.e4
carbamazepine,137-150	DrugDDI.d539.s14.e5
(Tegretol),151-161
cimetidine,162-172	DrugDDI.d539.s14.e7
(Tagamet),173-182
estrogens,183-192	DrugDDI.d539.s14.e9
fluoxetine,193-203
(Prozac),204-212
intraconazole,213-226
(Sporanox),227-237
ketoconazole,238-250	DrugDDI.d539.s14.e12
(Nizoral),251-260
levodopa,261-269	DrugDDI.d539.s14.e14
lithium,270-277
muscle,278-284
relaxants,285-294
birth,295-300
control,301-308
pills,309-314
sleeping,315-323
pills,324-329
thyroid,330-337
medications,338-349

Androgens,0-9	DrugDDI.d424.s0.e0
may,10-13
increase,14-22
sensitivity,23-34
to,35-37
oral,38-42
anticoagulahts.,43-58

Dosage,0-6
of,7-9
the,10-13
anticoagulant,14-27	DrugDDI.d424.s1.e0
may,28-31
require,32-39
reduction,40-49
in,50-52
order,53-58
to,59-61
maintain,62-70
satisfactory,71-83
therapeutic,84-95
hypoprothrombinemia.,96-116

Concurrent,0-10
administration,11-25
of,26-28
oxyphenbutazone,29-44	DrugDDI.d424.s2.e0
and,45-48
androgens,49-58	DrugDDI.d424.s2.e1
may,59-62
result,63-69
in,70-72
elevated,73-81
serum,82-87
levels,88-94
of,95-97
oxyphenbutazone.,98-114	DrugDDI.d424.s2.e2

In,0-2
diabetic,3-11
patients,,12-21
the,22-25
metabolic,26-35
effects,36-43
of,44-46
androgens,47-56	DrugDDI.d424.s3.e0
may,57-60
decrease,61-69
blood,70-75
glucose,76-83
and,84-87
therefore,,88-98
insulin,99-106	DrugDDI.d424.s3.e1
requirements.,107-120

Drug,0-4
Interactions:,5-18
Flupenthixol,19-31	DrugDDI.d371.s0.e0
may,32-35
interact,36-44
with,45-49
some,50-54
drugs,,55-61
like:,62-67
-,68-69
Monoamine,70-79	DrugDDI.d371.s0.e2
oxidase,80-87	DrugDDI.d371.s0.e2
inhibitors,88-98	DrugDDI.d371.s0.e2
(MAOI):,99-106
MAOI,107-111	DrugDDI.d371.s0.e4
could,112-117
theoretically,118-131
affect,132-138
flupenthixol,139-151	DrugDDI.d371.s0.e5
pharmacodynamics,152-168
-,169-170
Arecoline,171-180
-,181-182
Eproxindine,183-194
-,195-196
Ethanol:,197-205
Flupenthixol,206-218	DrugDDI.d371.s0.e6
and,219-222
Ethanol,223-230	DrugDDI.d371.s0.e7
cause,231-236
additive,237-245
CNS,246-249
depression,250-260
-,261-262
Tricyclic,263-272
antidepressants:,273-289
Flupenthixol,290-302	DrugDDI.d371.s0.e8
increases,303-312
the,313-316
effect,317-323
of,324-326
Tricyclic,327-336	DrugDDI.d371.s0.e9
antidepressants,337-352	DrugDDI.d371.s0.e9

Antacids:,0-9	DrugDDI.d185.s0.e0
Administration,10-24
of,25-27
flurbiprofen,28-40	DrugDDI.d185.s0.e1
to,41-43
volunteers,44-54
under,55-60
fasting,61-68
conditions,,69-80
or,81-83
with,84-88
antacid,89-96	DrugDDI.d185.s0.e2
suspension,97-107	DrugDDI.d185.s0.e2
yielded,108-115
similar,116-123
serum,124-129
flurbiprofen,130-142	DrugDDI.d185.s0.e3
time,143-147
profiles,148-156
in,157-159
young,160-165
subjects,166-174
(n=12).,175-182

In,0-2
geriatric,3-12
subjects,13-21
(n=7),22-27
there,28-33
was,34-37
a,38-39
reduction,40-49
in,50-52
the,53-56
rate,57-61
but,62-65
not,66-69
the,70-73
extent,74-80
of,81-83
flurbiprofen,84-96	DrugDDI.d185.s1.e1
absorption.,97-108

Anticoagulants:,0-15	DrugDDI.d185.s2.e0
Flurbiprofen,16-28	DrugDDI.d185.s2.e1
like,29-33
other,34-39
nonsteroidal,40-52	DrugDDI.d185.s2.e2
anti-inflammatory,53-70	DrugDDI.d185.s2.e2
drugs,,71-77	DrugDDI.d185.s2.e2
has,78-81
been,82-86
shown,87-92
to,93-95
affect,96-102
bleeding,103-111
parameters,112-122
in,123-125
patients,126-134
receiving,135-144
anti-coagulants,,145-161
and,162-165
serious,166-173
clinical,174-182
bleeding,183-191
has,192-195
been,196-200
reported.,201-210

The,0-3
physician,4-13
should,14-20
be,21-23
cautious,24-32
when,33-37
administering,38-51
flurbiprofen,52-64	DrugDDI.d185.s3.e0
to,65-67
patients,68-76
taking,77-83
anticoagulants.,84-99	DrugDDI.d185.s3.e1

Aspirin:,0-8	DrugDDI.d185.s4.e0
Concurrent,9-19
administration,20-34
of,35-37
aspirin,38-45	DrugDDI.d185.s4.e1
and,46-49
flurbiprofen,50-62	DrugDDI.d185.s4.e2
resulted,63-71
in,72-74
50%,75-78
lower,79-84
serum,85-90
flurbiprofen,91-103	DrugDDI.d185.s4.e3
concentrations.,104-119

This,0-4
effect,5-11
of,12-14
aspirin,15-22	DrugDDI.d185.s5.e0
(which,23-29
also,30-34
lowers,35-41
serum,42-47
concentrations,48-62
of,63-65
other,66-71
nonsteroidal,72-84	DrugDDI.d185.s5.e1
anti-inflammatory,85-102	DrugDDI.d185.s5.e1
drugs,103-108	DrugDDI.d185.s5.e1
given,109-114
with,115-119
it),120-123
has,124-127
been,128-132
demonstrated,133-145
in,146-148
patients,149-157
with,158-162
rheumatoid,163-173
arthritis,174-183
(n=,184-187
15),188-191
as,192-194
well,195-199
as,200-202
normal,203-209
volunteers,210-220
(n=,221-224
16).,225-229

Concurrent,0-10
use,11-14
of,15-17
flurbiprofen,18-30	DrugDDI.d185.s6.e0
and,31-34
aspirin,35-42	DrugDDI.d185.s6.e1
is,43-45
therefore,46-55
not,56-59
recommended.,60-72

Beta-adrenergic,0-15	DrugDDI.d185.s7.e0
Blocking,16-24	DrugDDI.d185.s7.e0
Agents:,25-32	DrugDDI.d185.s7.e0
The,33-36
effect,37-43
of,44-46
flurbiprofen,47-59	DrugDDI.d185.s7.e1
on,60-62
blood,63-68
pressure,69-77
response,78-86
to,87-89
propranolol,90-101	DrugDDI.d185.s7.e2
and,102-105
atenolol,106-114	DrugDDI.d185.s7.e3
was,115-118
evaluated,119-128
in,129-131
men,132-135
with,136-140
mild,141-145
uncomplicated,146-159
hypertension,160-172
(n,173-175
=,176-177
10).,178-182

Flurbiprofen,0-12	DrugDDI.d185.s8.e0
pretreatment,13-25
attenuated,26-36
the,37-40
hypotensive,41-52
effect,53-59
of,60-62
a,63-64
single,65-71
dose,72-76
of,77-79
propranolol,80-91	DrugDDI.d185.s8.e1
but,92-95
not,96-99
atenolol.,100-109	DrugDDI.d185.s8.e2

Flurbiprofen,0-12	DrugDDI.d185.s9.e0
did,13-16
not,17-20
appear,21-27
to,28-30
affect,31-37
the,38-41
beta-blocker-mediated,42-63	DrugDDI.d185.s9.e1
reduction,64-73
in,74-76
heart,77-82
rate.,83-88

Flurbiprofen,0-12	DrugDDI.d185.s10.e0
did,13-16
not,17-20
affect,21-27
the,28-31
pharmacokinetic,32-47
profile,48-55
of,56-58
either,59-65
drug,,66-71
and,72-75
the,76-79
mechanism,80-89
under,90-95
lying,96-101
the,102-105
interference,106-118
with,119-123
propranolols,124-136	DrugDDI.d185.s10.e2
hypotensive,137-148
effect,149-155
is,156-158
unknown.,159-167

Patients,0-8
taking,9-15
both,16-20
flurbiprofen,21-33	DrugDDI.d185.s11.e0
and,34-37
a,38-39
beta-blocker,40-52	DrugDDI.d185.s11.e1
should,53-59
be,60-62
monitored,63-72
to,73-75
ensure,76-82
that,83-87
a,88-89
satisfactory,90-102
hypotensive,103-114
effect,115-121
is,122-124
achieved.,125-134

Cimetidine,,0-11
Ranitidine:,12-23	DrugDDI.d185.s12.e1
In,24-26
normal,27-33
volunteers,34-44
(n=9),,45-51
pretreatment,52-64
with,65-69
cimetidine,70-80	DrugDDI.d185.s12.e3
or,81-83
ranitidine,84-94	DrugDDI.d185.s12.e4
did,95-98
not,99-102
affect,103-109
flurbiprofen,110-122	DrugDDI.d185.s12.e5
pharmacokinetics,123-139
except,140-146
that,147-151
a,152-153
small,154-159
(13,160-163
%),164-166
but,167-170
statistically,171-184
significant,185-196
increase,197-205
in,206-208
the,209-212
area,213-217
under,218-223
the,224-227
serum,228-233
concentration,234-247
curve,248-253
of,254-256
flurbiprofen,257-269	DrugDDI.d185.s12.e6
resulted,270-278
with,279-283
cimetidine.,284-295	DrugDDI.d185.s12.e7

Digoxin:,0-8	DrugDDI.d185.s13.e0
Studies,9-16
of,17-19
concomitant,20-31
administration,32-46
of,47-49
flurbiprofen,50-62	DrugDDI.d185.s13.e1
and,63-66
digoxin,67-74	DrugDDI.d185.s13.e2
to,75-77
healthy,78-85
men,86-89
(n=,90-93
14),94-97
did,98-101
not,102-105
show,106-110
a,111-112
change,113-119
in,120-122
the,123-126
steady,127-133
state,134-139
serum,140-145
levels,146-152
of,153-155
either,156-162
drug.,163-168	DrugDDI.d185.s13.e3

Diuretics:,0-10	DrugDDI.d185.s14.e0
Studies,11-18
in,19-21
normal,22-28
volunteers,29-39
have,40-44
shown,45-50
that,51-55
flurbiprofen,56-68	DrugDDI.d185.s14.e1
like,69-73
other,74-79
nonsteroidal,80-92	DrugDDI.d185.s14.e2
anti-inflammatory,93-110	DrugDDI.d185.s14.e2
drugs,,111-117	DrugDDI.d185.s14.e2
can,118-121
interfere,122-131
with,132-136
the,137-140
effects,141-148
of,149-151
furosemide.,152-163	DrugDDI.d185.s14.e3

Although,0-8
results,9-16
have,17-21
varied,22-28
from,29-33
study,34-39
to,40-42
study,,43-49
effects,50-57
have,58-62
been,63-67
shown,68-73
on,74-76
furosemide-stimulated,77-98	DrugDDI.d185.s15.e0
diuresis,,99-108	DrugDDI.d185.s15.e0
natriuresis,,109-121
and,122-125
kaliuresis.,126-137

Other,0-5
nonsteroidal,6-18	DrugDDI.d185.s16.e0
anti-inflammatory,19-36	DrugDDI.d185.s16.e0
drugs,37-42	DrugDDI.d185.s16.e0
that,43-47
inhibit,48-55
prostaglandin,56-69	DrugDDI.d185.s16.e1
synthesis,70-79
have,80-84
been,85-89
shown,90-95
to,96-98
interfere,99-108
with,109-113
thiazide,114-122	DrugDDI.d185.s16.e2
diuretics,123-132	DrugDDI.d185.s16.e2
in,133-135
some,136-140
studies,141-148
and,149-152
with,153-157
potassium-sparing,158-175	DrugDDI.d185.s16.e3
diuretics.,176-186	DrugDDI.d185.s16.e3

Patients,0-8
receiving,9-18
flurbiprofen,19-31	DrugDDI.d185.s17.e0
and,32-35
furosemide,36-46	DrugDDI.d185.s17.e1
or,47-49
other,50-55
diuretics,56-65	DrugDDI.d185.s17.e2
should,66-72
be,73-75
observed,76-84
closely,85-92
to,93-95
determine,96-105
if,106-108
the,109-112
desired,113-120
effect,121-127
is,128-130
obtained.,131-140

Oral,0-4
Hypoglycemic,5-17	DrugDDI.d185.s18.e0
Agents:,18-25	DrugDDI.d185.s18.e0
In,26-28
one,29-32
study,,33-39
flurbiprofen,40-52	DrugDDI.d185.s18.e1
was,53-56
given,57-62
to,63-65
adult,66-71
diabetics,72-81
who,82-85
were,86-90
already,91-98
receiving,99-108
glyburide,109-118	DrugDDI.d185.s18.e2
(n=4),,119-125
metformin,126-135	DrugDDI.d185.s18.e3
(n=2),136-141
chlorpropamide,142-156	DrugDDI.d185.s18.e4
with,157-161
phenformin,162-172	DrugDDI.d185.s18.e5
(n=,173-176
3),177-179
or,180-182
glyburide,183-192	DrugDDI.d185.s18.e7
with,193-197
phenformin,198-208	DrugDDI.d185.s18.e8
(n=6).,209-215

Although,0-8
there,9-14
was,15-18
a,19-20
slight,21-27
reduction,28-37
in,38-40
blood,41-46
sugar,47-52
concentrations,53-67
during,68-74
concomitant,75-86
administration,87-101
of,102-104
flurbiprofen,105-117	DrugDDI.d185.s19.e0
and,118-121
hypoglycemic,122-134	DrugDDI.d185.s19.e1
agents,,135-142	DrugDDI.d185.s19.e1
there,143-148
were,149-153
no,154-156
signs,157-162
or,163-165
symptoms,166-174
of,175-177
hypoglycemia.,178-191

Increases,0-9
in,10-12
prothrombin,13-24
time,25-29
have,30-34
been,35-39
noted,40-45
in,46-48
patients,49-57
receiving,58-67
long-,68-73
term,74-78
warfarin,79-87	DrugDDI.d472.s0.e0
therapy,88-95
after,96-101
flutamide,102-111	DrugDDI.d472.s0.e1
was,112-115
initiated.,116-126

Therefore,,0-10
close,11-16
monitoring,17-27
of,28-30
prothrombin,31-42
time,43-47
is,48-50
recommended,51-62
and,63-66
adjustment,67-77
of,78-80
the,81-84
anticoagulant,85-98	DrugDDI.d472.s1.e0
dose,99-103
may,104-107
be,108-110
necessary,111-120
when,121-125
EULEXIN,126-133	DrugDDI.d472.s1.e1
Capsules,134-142	DrugDDI.d472.s1.e1
are,143-146
administered,147-159
concomitantly,160-173
with,174-178
warfarin.,179-188	DrugDDI.d472.s1.e2

Potential,0-9
for,10-13
Interaction,14-25
with,26-30
Monoamine,31-40	DrugDDI.d559.s0.e0
Oxidase,41-48	DrugDDI.d559.s0.e0
Inhibitors,49-59	DrugDDI.d559.s0.e0

In,0-2
patients,3-11
receiving,12-21
another,22-29
serotonin,30-39	DrugDDI.d559.s1.e0
reuptake,40-48	DrugDDI.d559.s1.e0
inhibitor,49-58	DrugDDI.d559.s1.e0
drug,59-63
in,64-66
combination,67-78
with,79-83
monoamine,84-93	DrugDDI.d559.s1.e1
oxidase,94-101	DrugDDI.d559.s1.e1
inhibitors,102-112	DrugDDI.d559.s1.e1
(MAOI),,113-120
there,121-126
have,127-131
been,132-136
reports,137-144
of,145-147
serious,,148-156
sometimes,157-166
fatal,,167-173
reactions,174-183
including,184-193
hyperthermia,,194-207
rigidity,,208-217
myoclonus,,218-228
autonomic,229-238
instability,239-250
with,251-255
possible,256-264
rapid,265-270
fluctuations,271-283
of,284-286
vital,287-292
signs,,293-299
and,300-303
mental,304-310
status,311-317
changes,318-325
that,326-330
include,331-338
extreme,339-346
agitation,347-356
progressing,357-368
to,369-371
delirium,372-380
and,381-384
coma.,385-390

These,0-5
reactions,6-15
have,16-20
also,21-25
been,26-30
reported,31-39
in,40-42
patients,43-51
who,52-55
have,56-60
discontinued,61-73
that,74-78
drug,79-83	DrugDDI.d559.s2.e0
and,84-87
have,88-92
been,93-97
started,98-105
on,106-108
a,109-110
MAOI.,111-116

Therefore,,0-10
it,11-13
is,14-16
recommended,17-28
that,29-33
Fluvoxamine,34-45	DrugDDI.d559.s4.e0
Tablets,46-53
not,54-57
be,58-60
used,61-65
in,66-68
combination,69-80
with,81-85
MAOIs,,86-92
or,93-95
within,96-102
14,103-105
days,106-110
of,111-113
discontinuing,114-127
treatment,128-137
with,138-142
a,143-144
MAOI.,145-150

After,0-5
stopping,6-14
Fluvoxamine,15-26	DrugDDI.d559.s5.e0
Tablets,,27-35
at,36-38
least,39-44
2,45-46
weeks,47-52
should,53-59
be,60-62
allowed,63-70
before,71-77
starting,78-86
a,87-88
MAOI.,89-94

Potential,0-9
Terfenadine,,10-22
Astemizole,,23-34
and,35-38
Cisapride,39-48	DrugDDI.d559.s6.e2
Interactions,49-61

Terfenadine,,0-12
astemizole,13-23	DrugDDI.d559.s7.e1
and,24-27
cisapride,28-37	DrugDDI.d559.s7.e2
are,38-41
all,42-45
metabolized,46-57
by,58-60
the,61-64
cytochrome,65-75
P450IIIA4,76-85
isozyme,,86-94
and,95-98
it,99-101
has,102-105
been,106-110
demonstrated,111-123
that,124-128
ketoconazole,,129-142
a,143-144
potent,145-151
inhibitor,152-161
of,162-164
IIIA4,,165-171
blocks,172-178
the,179-182
metabolism,183-193
of,194-196
these,197-202
drugs,,203-209
resulting,210-219
in,220-222
increased,223-232
plasma,233-239
concentrations,240-254
of,255-257
parent,258-264
drug.,265-270	DrugDDI.d559.s7.e6

Increased,0-9
plasma,10-16
concentrations,17-31
of,32-34
terfenadine,,35-47
astemizole,,48-59
and,60-63
cisapride,64-73	DrugDDI.d559.s8.e2
cause,74-79
QT,80-82
prolongation,83-95
and,96-99
have,100-104
been,105-109
associated,110-120
with,121-125
torsades,126-134
de,135-137
pointes-type,138-150
ventricular,151-162
tachycardia,,163-175
sometimes,176-185
fatal.,186-192

As,0-2
noted,3-8
below,,9-15
a,16-17
sub-,18-22
for,23-26
fluvoxamine,27-38	DrugDDI.d559.s9.e0
in,39-41
combination,42-53
with,54-58
alprazolam,,59-70
a,71-72
drug,73-77	DrugDDI.d559.s9.e2
that,78-82
is,83-85
known,86-91
to,92-94
be,95-97
metabolized,98-109
by,110-112
the,113-116
IIIA4,117-122
isozyme.,123-131	DrugDDI.d559.s9.e3

Although,0-8
it,9-11
has,12-15
not,16-19
been,20-24
definitively,25-37
demonstrated,38-50
that,51-55
fluvoxamine,56-67	DrugDDI.d559.s10.e0
is,68-70
a,71-72
potent,73-79
IIIA4,80-85
inhibitor,,86-96
it,97-99
is,100-102
likely,103-109
to,110-112
be,,113-116
given,117-122
the,123-126
substantial,127-138
interaction,139-150
of,151-153
fluvoxamine,154-165	DrugDDI.d559.s10.e1
with,166-170
alprazolam.,171-182	DrugDDI.d559.s10.e2

Consequently,,0-13
it,14-16
is,17-19
recommended,20-31
that,32-36
fluvoxamine,37-48	DrugDDI.d559.s11.e0
not,49-52
be,53-55
used,56-60
in,61-63
combination,64-75
with,76-80
either,81-87
terbinafine,,88-100
astemizole,,101-112
or,113-115
cisapride.,116-126	DrugDDI.d559.s11.e3

Other,0-5
Potentially,6-17
Important,18-27
Drug,28-32
Interactions:,33-46
Benzodiazepines:,47-63	DrugDDI.d559.s12.e0
Benzodiazepines,64-79	DrugDDI.d559.s12.e1
metabolized,80-91
by,92-94
hepatic,95-102
oxidation,103-112
(e.g.,,113-119
alprazolam,,120-131
midazolam,,132-142
triazolam,143-152	DrugDDI.d559.s12.e4
elc.),153-158
should,159-165
be,166-168
used,169-173
with,174-178
caution,179-186
because,187-194
the,195-198
clearance,199-208
of,209-211
these,212-217
drugs,218-223	DrugDDI.d559.s12.e5
is,224-226
likely,227-233
to,234-236
be,237-239
reduced,240-247
by,248-250
fluvoxamine.,251-263	DrugDDI.d559.s12.e6

The,0-3
clearance,4-13
of,14-16
benzodiazepines,17-32	DrugDDI.d559.s13.e0
metabolized,33-44
by,45-47
glucuronidation,48-63
(e.,64-67
g.,,68-71
lorazepam,,72-82
oxazepam,,83-92
temazepam),93-103	DrugDDI.d559.s13.e3
is,104-106
unlikely,107-115
to,116-118
be,119-121
affected,122-130
by,131-133
fluvoxamine.,134-146	DrugDDI.d559.s13.e4

Alprazolam:,0-11	DrugDDI.d559.s14.e0
When,12-16
fluvoxamine,17-28	DrugDDI.d559.s14.e1
maleate,29-36
(100,37-41
mg,42-44
qd),45-48
and,49-52
alprazolam,53-63	DrugDDI.d559.s14.e2
(1,64-66
mg,67-69
q.d.,70-74
were,75-79
co-administered,80-95
to,96-98
steady,99-105
state,,106-112
plasma,113-119
concentration,120-133
and,134-137
other,138-143
pharmacokinetics,144-160
parameters,161-171
(AUC,,172-177
Cmax,,178-183
T1/2,),184-190
of,191-193
alprazolam,194-204	DrugDDI.d559.s14.e4
were,205-209
approximately,210-223
twice,224-229
those,230-235
observed,236-244
when,245-249
alprazolam,250-260	DrugDDI.d559.s14.e5
was,261-264
administered,265-277
alone;,278-284

The,0-3
elevated,4-12
plasma,13-19
alprazolam,20-30	DrugDDI.d559.s16.e0
concentrations,31-45
resulted,46-54
in,55-57
decreased,58-67
psychomotor,68-79
performance,80-91
and,92-95
memory.,96-103

This,0-4
interaction,,5-17
which,18-23
has,24-27
not,28-31
been,32-36
investigated,37-49
using,50-55
higher,56-62
doses,63-68
of,69-71
fluvoxamine,,72-84
may,85-88
be,89-91
more,92-96
pronounced,97-107
if,108-110
a,111-112
300,113-116
mg,117-119
daily,120-125
dose,126-130
is,131-133
co-administered,,134-150
particularly,151-163
since,164-169
fluvoxamine,170-181	DrugDDI.d559.s17.e1
exhibits,182-190
non-linear,191-201
pharmacokinetics,202-218
over,219-223
the,224-227
dosage,228-234
range,235-240
100-300,241-248
mg.,249-252
If,253-255
alprazolam,256-266	DrugDDI.d559.s17.e2
is,267-269
co-administered,270-285
with,286-290
Fluvoxamine,291-302	DrugDDI.d559.s17.e3
Tablets,,303-311
the,312-315
initial,316-323
alprazolam,324-334	DrugDDI.d559.s17.e4
dosage,335-341
should,342-348
be,349-351
at,352-354
least,355-360
halved,361-367
and,368-371
titration,372-381
to,382-384
the,385-388
lowest,389-395
effective,396-405
dose,406-410
is,411-413
recommended.,414-426

No,0-2
dosage,3-9
adjustment,10-20
is,21-23
required,24-32
for,33-36
Fluvoxamine,37-48	DrugDDI.d559.s18.e0
Tablets.,49-57

Diazepam:,0-9	DrugDDI.d559.s19.e0
The,10-13
co-administration,14-31
of,32-34
Fluvoxamine,35-46	DrugDDI.d559.s19.e1
Tablets,47-54
and,55-58
diazepam,59-67	DrugDDI.d559.s19.e2
is,68-70
generally,71-80
not,81-84
advisable.,85-95

Because,0-7
fluvoxamine,8-19	DrugDDI.d559.s20.e0
reduces,20-27
the,28-31
clearance,32-41
of,42-44
both,45-49
diazepam,50-58	DrugDDI.d559.s20.e1
and,59-62
its,63-66
active,67-73	DrugDDI.d559.s20.e2
metabolite,,74-85	DrugDDI.d559.s20.e2
N-desmethyldiazepam,,86-106
there,107-112
is,113-115
a,116-117
strong,118-124
likelihood,125-135
of,136-138
substantial,139-150
accumulation,151-163
of,164-166
both,167-171
species,172-179
during,180-186
chronic,187-194
co-administration.,195-213

Evidence,0-8
supporting,9-19
the,20-23
conclusion,24-34
that,35-39
it,40-42
is,43-45
inadvisable,46-57
to,58-60
co-administer,61-74
fluvoxamine,75-86	DrugDDI.d559.s21.e0
and,87-90
diazepam,91-99	DrugDDI.d559.s21.e1
is,100-102
derived,103-110
from,111-115
a,116-117
study,118-123
in,124-126
which,127-132
healthy,133-140
volunteers,141-151
taking,152-158
150,159-162
mg/day,163-169
of,170-172
fluvoxamine,173-184	DrugDDI.d559.s21.e2
were,185-189
administered,190-202
a,203-204
single,205-211
oral,212-216
dose,217-221
of,222-224
10,225-227
mg,228-230
of,231-233
diazepam.,234-243	DrugDDI.d559.s21.e3

In,0-2
these,3-8
subjects,9-17
(R=,18-21
B),,22-25
the,26-29
clearance,30-39
of,40-42
diazepam,43-51	DrugDDI.d559.s22.e0
was,52-55
reduced,56-63
by,64-66
65%,67-70
and,71-74
that,75-79
of,80-82
N-desmethyldiazepam,83-102
to,103-105
a,106-107
level,108-113
that,114-118
was,119-122
too,123-126
low,127-130
to,131-133
measure,134-141
over,142-146
the,147-150
course,151-157
of,158-160
the,161-164
2,165-166
week,167-171
long,172-176
study.,177-183

It,0-2
is,3-5
likely,6-12
that,13-17
experience,18-28
significantly,29-42
underestimates,43-57
the,58-61
degree,62-68
of,69-71
accumulation,72-84
that,85-89
might,90-95
occur,96-101
with,102-106
repealed,107-115
diazepam,116-124	DrugDDI.d559.s23.e0
administration.,125-140

Moreover,,0-9
as,10-12
noted,13-18
with,19-23
alprazolam,,24-35
the,36-39
effect,40-46
of,47-49
fluvoxamine,50-61	DrugDDI.d559.s24.e1
may,62-65
even,66-70
be,71-73
more,74-78
pronounced,79-89
when,90-94
it,95-97
is,98-100
administered,101-113
at,114-116
higher,117-123
doses.,124-130

Accordingly,,0-12
diazepam,13-21	DrugDDI.d559.s25.e0
and,22-25
fluvoxamine,26-37	DrugDDI.d559.s25.e1
should,38-44
not,45-48
ordinarily,49-59
be,60-62
co-administered.,63-79

Theophylline:,0-13	DrugDDI.d559.s26.e0
The,14-17
effect,18-24
of,25-27
steady-state,28-40
fluvoxamine,41-52
l50,53-56
mg,57-59
bid,60-63	DrugDDI.d559.s26.e1
on,64-66
the,67-70
pharmacokinetics,71-87
of,88-90
a,91-92
single,93-99
dose,100-104
of,105-107
Theophylline,108-120	DrugDDI.d559.s26.e2
(375,121-125
mg),126-129
as,130-132
442,133-136
mg,137-139
aminophylline,140-153	DrugDDI.d559.s26.e3
was,154-157
evaluated,158-167
in,168-170
12,171-173
healthy,174-181
non-smoking,,182-194
male,195-199
volunteers.,200-211

The,0-3
clearance,4-13
of,14-16
theophylline,17-29	DrugDDI.d559.s27.e0
was,30-33
decreased,34-43
approximately,44-57
3-fold.,58-65

Therefore,,0-10
if,11-13
theophylline,14-26	DrugDDI.d559.s28.e0
is,27-29
co-administered,30-45
with,46-50
fluvoxamine,51-62	DrugDDI.d559.s28.e1
maleate,,63-71
its,72-75
dose,76-80
should,81-87
be,88-90
reduced,91-98
to,99-101
one,102-105
third,106-111
of,112-114
the,115-118
usual,119-124
daily,125-130
maintenance,131-142
dose,143-147
and,148-151
plasma,152-158
concentrations,159-173
of,174-176
theophylline,177-189	DrugDDI.d559.s28.e2
should,190-196
to,197-199
monitored.,200-210

No,0-2
dosage,3-9
adjustment,10-20
is,21-23
required,24-32
for,33-36
Fluvoxamine,37-48	DrugDDI.d559.s29.e0
Tablets.,49-57

Warfarin:,0-9	DrugDDI.d559.s30.e0
When,10-14
fluvoxamine,15-26	DrugDDI.d559.s30.e1
maleate,27-34
(50,35-38
mg,39-41
tid),42-46
was,47-50
administered,51-63
concomitantly,64-77
with,78-82
warfarin,83-91	DrugDDI.d559.s30.e2
for,92-95
two,96-99
weeks,,100-106
warfarin,107-115	DrugDDI.d559.s30.e3
plasma,116-122
concentrations,123-137
increased,138-147
by,148-150
98%,151-154
and,155-158
prothrombin,159-170
times,171-176
were,177-181
prolonged.,182-192

Thus,0-4
patients,5-13
receiving,14-23
oral,24-28	DrugDDI.d559.s31.e0
anticoagulants,29-43	DrugDDI.d559.s31.e0
and,44-47
Fluvoxamine,48-59	DrugDDI.d559.s31.e1
Tablets,60-67
should,68-74
have,75-79
their,80-85
prothrombin,86-97
time,98-102
monitored,103-112
and,113-116
their,117-122
anticoagulant,123-136	DrugDDI.d559.s31.e2
dose,137-141
adjusted,142-150
accordingly.,151-163

No,0-2
dosage,3-9
adjustment,10-20
is,21-23
required,24-32
for,33-36
Fluvoxamine,37-48	DrugDDI.d559.s32.e0
Tablets.,49-57

Medications,0-11	DrugDDI.d264.s0.e0
that,12-16
interfere,17-26
with,27-31
your,32-36
bodys,37-42
ability,43-50
to,51-53
use,54-57
folate,58-64
may,65-68
also,69-73
increase,74-82
the,83-86
need,87-91
for,92-95
this,96-100
vitamin.,101-109	DrugDDI.d264.s0.e1

Medications,0-11	DrugDDI.d264.s1.e0
can,12-15
interfere,16-25
with,26-30
folate,31-37
utilization,,38-50
including:,51-61
anticonvulsant,62-76	DrugDDI.d264.s1.e1
medications,77-88
(such,89-94
as,95-97
phenytoin,,98-108
and,109-112
primidone),113-123	DrugDDI.d264.s1.e3
metformin,124-133	DrugDDI.d264.s1.e4
(sometimes,134-144
prescribed,145-155
to,156-158
control,159-166
blood,167-172
sugar,173-178
in,179-181
type,182-186
2,187-188
diabetes),189-198
sulfasalazine,199-212	DrugDDI.d264.s1.e5
(used,213-218
to,219-221
control,222-229
inflammation,230-242
associated,243-253
with,254-258
Crohns,259-265
disease,266-273
and,274-277
ulcerative,278-288
colitis),289-297
triamterene,298-309	DrugDDI.d264.s1.e6
(a,310-312
diuretic),313-322	DrugDDI.d264.s1.e7
Methotrexate,323-335	DrugDDI.d264.s1.e8
There,336-341
has,342-345
been,346-350
concern,351-358
about,359-364
the,365-368
interaction,369-380
between,381-388
vitamin,389-396	DrugDDI.d264.s1.e9
B12,397-400	DrugDDI.d264.s1.e9
and,401-404
folic,405-410	DrugDDI.d264.s1.e10
acid.,411-416	DrugDDI.d264.s1.e10

Folic,0-5	DrugDDI.d264.s2.e0
acid,6-10	DrugDDI.d264.s2.e0
supplements,11-22
can,23-26
correct,27-34
the,35-38
anemia,39-45
associated,46-56
with,57-61
vitamin,62-69
B12,70-73
deficiency.,74-85

Unfortunately,,0-14
folic,15-20	DrugDDI.d264.s3.e0
acid,21-25	DrugDDI.d264.s3.e0
will,26-30
not,31-34
correct,35-42
changes,43-50
in,51-53
the,54-57
nervous,58-65
system,66-72
that,73-77
result,78-84
from,85-89
vitamin,90-97
B12,98-101
deficiency.,102-113

Therefore,,0-10
intake,11-17
of,18-20
supplemental,21-33
folic,34-39	DrugDDI.d264.s5.e0
acid,40-44	DrugDDI.d264.s5.e0
should,45-51
not,52-55
exceed,56-62
1000,63-67
micrograms,68-78
(?g,,79-83
sometimes,84-93
mcg),94-98
per,99-102
day,103-106
to,107-109
prevent,110-117	DrugDDI.d264.s5.e1
folic,118-123	DrugDDI.d264.s5.e2
acid,124-128	DrugDDI.d264.s5.e2
from,129-133
masking,134-141
symptoms,142-150
of,151-153
vitamin,154-161
B12,162-165
deficiency.,166-177

It,0-2
is,3-5
important,6-15
for,16-19
older,20-25
adults,26-32
to,33-35
be,36-38
aware,39-44
of,45-47
the,48-51
relationship,52-64
between,65-72
folic,73-78	DrugDDI.d264.s6.e0
acid,79-83	DrugDDI.d264.s6.e0
and,84-87
vitamin,88-95	DrugDDI.d264.s6.e1
B12,96-99	DrugDDI.d264.s6.e1
because,100-107
they,108-112
are,113-116
at,117-119
greater,120-127
risk,128-132
of,133-135
having,136-142
a,143-144
vitamin,145-152
B12,153-156
deficiency.,157-168

If,0-2
you,3-6
are,7-10
50,11-13
years,14-19
of,20-22
age,23-26
or,27-29
older,,30-36
ask,37-40	DrugDDI.d264.s7.e0
your,41-45
physician,46-55
to,56-58
check,59-64
your,65-69
B12,70-73
status,74-80
before,81-87
you,88-91
take,92-96
a,97-98
supplement,99-109
that,110-114
contains,115-123
folic,124-129	DrugDDI.d264.s7.e1
acid.,130-135	DrugDDI.d264.s7.e1

No,0-2
drug/drug,3-12	DrugDDI.d201.s0.e0
interaction,13-24
studies,25-32
have,33-37
been,38-42
performed.,43-53

Oral,0-4
doses,5-10
of,11-13
Antizol,14-21	DrugDDI.d267.s0.e0
(10-20,22-28
mg/kg),,29-36
via,37-40
alcohol,41-48	DrugDDI.d267.s0.e1
dehydrogenase,49-62	DrugDDI.d267.s0.e1
inhibition,,63-74
significantly,75-88
reduced,89-96
the,97-100
rate,101-105
of,106-108
elimination,109-120
of,121-123
ethanol,124-131	DrugDDI.d267.s0.e2
(by,132-135
approximately,136-149
40%),150-154
given,155-160
to,161-163
healthy,164-171
volunteers,172-182
in,183-185
moderate,186-194
doses.,195-201

Similarly,,0-10
ethanol,11-18	DrugDDI.d267.s1.e0
decreased,19-28
the,29-32
rate,33-37
of,38-40
elimination,41-52
of,53-55
Antizol,56-63	DrugDDI.d267.s1.e1
(by,64-67
approximately,68-81
50%),82-86
by,87-89
the,90-93
same,94-98
mechanism.,99-109

Reciprocal,0-10
interactions,11-23
may,24-27
occur,28-33
with,34-38
concomitant,39-50
use,51-54
of,55-57
Antizol,58-65	DrugDDI.d267.s2.e0
and,66-69
drugs,70-75	DrugDDI.d267.s2.e1
that,76-80
increase,81-89
or,90-92
inhibit,93-100
the,101-104
cytochrome,105-115	DrugDDI.d267.s2.e2
P450,116-120	DrugDDI.d267.s2.e2
system,121-127
(e.g.,,128-134
phenytoin,,135-145
carbamazepine,,146-160
cimetidine,,161-172
ketoconazole),,173-187
though,188-194
this,195-199
has,200-203
not,204-207
been,208-212
studied,213-220

In,0-2
clinical,3-11
studies,12-19
performed,20-29
with,30-34
Fondaparinux,,35-48
the,49-52
concomitant,53-64
use,65-68
of,69-71
oral,72-76	DrugDDI.d484.s0.e1
anticoagulants,77-91	DrugDDI.d484.s0.e1
(warfarin),,92-103
platelet,104-112	DrugDDI.d484.s0.e3
inhibitors,113-123	DrugDDI.d484.s0.e3
(acetylsalicylic,124-140
acid),,141-147
NSAIDs,148-154	DrugDDI.d484.s0.e5
(piroxicam),,155-167
and,168-171
digoxin,172-179	DrugDDI.d484.s0.e7
did,180-183
not,184-187
significantly,188-201
affect,202-208
the,209-212
pharmacokinetics/pharmacodynamics,213-246
of,247-249
fondaparinux,250-262	DrugDDI.d484.s0.e8
sodium.,263-270	DrugDDI.d484.s0.e8

In,0-2
addition,,3-12
Fondaparinux,13-25	DrugDDI.d484.s1.e0
neither,26-33
influenced,34-44
the,45-48
pharmacodynamics,49-65
of,66-68
warfarin,,69-78
acetylsalicylic,79-94	DrugDDI.d484.s1.e2
acid,,95-100	DrugDDI.d484.s1.e2
piroxicam,,101-111
and,112-115
digoxin,,116-124
nor,125-128
the,129-132
pharmacokinetics,133-149
of,150-152
digoxin,153-160	DrugDDI.d484.s1.e5
at,161-163
steady,164-170
state.,171-177

Agents,0-6
that,7-11
may,12-15
enhance,16-23
the,24-27
risk,28-32
of,33-35
hemorrhage,36-46
should,47-53
be,54-56
discontinued,57-69
prior,70-75
to,76-78
initiation,79-89
of,90-92
Fondaparinux,93-105	DrugDDI.d484.s2.e0
therapy.,106-114

In,0-2
an,3-5
in,6-8
vitro,9-14
study,15-20
in,21-23
human,24-29
liver,30-35
microsomes,,36-47
inhibition,48-58
of,59-61
CYP2A6,62-68	DrugDDI.d484.s4.e0
hydroxylation,69-82
of,83-85
coumarin,86-94	DrugDDI.d484.s4.e1
by,95-97
fondaparinux,98-110	DrugDDI.d484.s4.e2
(200,111-115
m,116-117
m,118-119
M,120-121
i.e.,,122-127
350,128-131
mg/L),132-137
was,138-141
17-28%.,142-149

Inhibition,0-10
of,11-13
the,14-17
other,18-23
isozymes,24-32	DrugDDI.d484.s5.e0
evaluated,33-42
(CYPs,43-48
2A1,,49-53
2C9,,54-58
2C19,,59-64
2D6,,65-69
3A4,,70-74
and,75-78
3E1),79-83
was,84-87
0-16%.,88-94

Since,0-5
fondaparinux,6-18	DrugDDI.d484.s6.e0
does,19-23
not,24-27
markedly,28-36
inhibit,37-44
CYP450s,45-52
(CYP1A2,,53-61
CYP2A6,,62-69
CYP2C9,,70-77
CYP2C19,,78-86
CYP2D6,,87-94
CYP2E1,,95-102
or,103-105
CYP3A4),106-113	DrugDDI.d484.s6.e7
in,114-116
vitro,,117-123
fondaparinux,124-136	DrugDDI.d484.s6.e8
sodium,137-143	DrugDDI.d484.s6.e8
is,144-146
not,147-150
expected,151-159
to,160-162
significantly,163-176
interact,177-185
with,186-190
other,191-196
drugs,197-202	DrugDDI.d484.s6.e9
in,203-205
vivo,206-210
by,211-213
inhibition,214-224
of,225-227
metabolism,228-238
mediated,239-247
by,248-250
these,251-256
isozymes.,257-266	DrugDDI.d484.s6.e10

Since,0-5
fondaparinux,6-18	DrugDDI.d484.s7.e0
sodium,19-25	DrugDDI.d484.s7.e0
does,26-30
not,31-34
bind,35-39
significantly,40-53
to,54-56
plasma,57-63	DrugDDI.d484.s7.e1
proteins,64-72	DrugDDI.d484.s7.e1
other,73-78
than,79-83
ATIII,,84-90
no,91-93
drug,94-98
interactions,99-111
by,112-114
protein-binding,115-130
displacement,131-143
are,144-147
expected.,148-157

Short-Acting,0-12
?2-agonists:,13-25
Aerosol,26-33
bronchodilators,34-49	DrugDDI.d90.s0.e1
of,50-52
the,53-56
short-acting,57-69
adrenergic,70-80
stimulant,81-90	DrugDDI.d90.s0.e2
type,91-95
may,96-99
be,100-102
used,103-107
for,108-111
relief,112-118
of,119-121
breakthrough,122-134
symptoms,135-143
while,144-149
using,150-155
formoterol.,156-167	DrugDDI.d90.s0.e3

Concomitant,0-11
administration,12-26
of,27-29
other,30-35
sympathomimetic,36-51	DrugDDI.d90.s2.e0
agents,52-58	DrugDDI.d90.s2.e0
may,59-62
potentiate,63-73
the,74-77
undesirable,78-89
effects,90-97
of,98-100
FORADIL.,101-109	DrugDDI.d90.s2.e1

Monoamine,0-9	DrugDDI.d90.s3.e0
Oxidase,10-17	DrugDDI.d90.s3.e0
Inhibitors,18-28	DrugDDI.d90.s3.e0
and,29-32
Tricyclic,33-42	DrugDDI.d90.s3.e1
Antidepressants:,43-59	DrugDDI.d90.s3.e1
FORADIL,60-67	DrugDDI.d90.s3.e2
should,68-74
be,75-77
administered,78-90
with,91-95
extreme,96-103
caution,104-111
in,112-114
patients,115-123
being,124-129
treated,130-137
with,138-142
monoamine,143-152	DrugDDI.d90.s3.e3
oxidase,153-160	DrugDDI.d90.s3.e3
inhibitors,161-171	DrugDDI.d90.s3.e3
or,172-174
tricyclic,175-184	DrugDDI.d90.s3.e4
antidepressants,185-200	DrugDDI.d90.s3.e4
because,201-208
the,209-212
action,213-219
of,220-222
formoterol,223-233	DrugDDI.d90.s3.e5
on,234-236
the,237-240
cardiovascular,241-255
system,256-262
may,263-266
be,267-269
potentiated,270-281
by,282-284
these,285-290
agents.,291-298

Corticosteroids,,0-16
Methylxanthines,17-32	DrugDDI.d90.s4.e1
and,33-36
Diuretics:,37-47	DrugDDI.d90.s4.e2
Concomitant,48-59
treatment,60-69
with,70-74
xanthine,75-83	DrugDDI.d90.s4.e3
derivatives,,84-96
steroids,,97-106
or,107-109
diuretics,110-119	DrugDDI.d90.s4.e4
may,120-123
potentiate,124-134
a,135-136
possible,137-145
hypokalemic,146-157
effect,158-164
of,165-167
?2-agonists.,168-180

Hypokalemia,0-11
may,12-15
increase,16-24
susceptibility,25-39
to,40-42
cardiac,43-50
arrhythmias,51-62
in,63-65
patients,66-74
treated,75-82
with,83-87
digitalis.,88-98	DrugDDI.d90.s5.e0

?-adrenergic,0-12
Blockers:,13-22
?-adrenergic,23-35
blockers,36-44
may,45-48
weaken,49-55
or,56-58
antagonise,59-69
the,70-73
effect,74-80
of,81-83
FORADIL.,84-92	DrugDDI.d90.s6.e2

Therefore,0-9
FORADIL,10-17	DrugDDI.d90.s7.e0
should,18-24
not,25-28
be,29-31
given,32-37
together,38-46
with,47-51
?-adrenergic,52-64
blockers,65-73
(including,74-84
eye,85-88
drops),89-95
unless,96-102
there,103-108
are,109-112
compelling,113-123
reasons,124-131
for,132-135
their,136-141
use.,142-146

Other,0-5
Drugs:Drugs,6-17	DrugDDI.d90.s8.e0
such,18-22
as,23-25
quinidine,,26-36
disopyramide,,37-50
procainamide,,51-64
phenothiazines,,65-80
antihistamines,,81-96
and,97-100
tricyclic,101-110	DrugDDI.d90.s8.e7
antidepressants,111-126	DrugDDI.d90.s8.e7
may,127-130
be,131-133
associated,134-144
with,145-149
QT-interval,150-161
prolongation,162-174
and,175-178
an,179-181
increased,182-191
risk,192-196
of,197-199
ventricular,200-211
arrhythmia.,212-223

It,0-2
is,3-5
important,6-15
that,16-20
patients,21-29
understand,30-40
how,41-44
to,45-47
use,48-51
FORADIL?,52-60
(formoterol,61-72
fumarate),73-82
capsules,83-91
with,92-96
the,97-100
supplied,101-109
AerolizerTM,110-121
inhalation,122-132
device,133-139
and,140-143
how,144-147
it,148-150
should,151-157
be,158-160
used,161-165
in,166-168
relation,169-177
to,178-180
other,181-186
asthma,187-193
or,194-196
COPD,197-201
medications,202-213	DrugDDI.d90.s10.e1
they,214-218
are,219-222
taking.,223-230

FORADIL,0-7	DrugDDI.d90.s14.e0
is,8-10
not,11-14
meant,15-20
to,21-23
relieve,24-31
acute,32-37
asthma,38-44
or,45-47
COPD,48-52
symptoms,53-61
and,62-65
extra,66-71
doses,72-77
should,78-84
not,85-88
be,89-91
used,92-96
for,97-100
that,101-105
purpose.,106-114

Acute,0-5
symptoms,6-14
should,15-21
be,22-24
treated,25-32
with,33-37
a,38-39
short-acting,,40-53
inhaled,54-61
?2,62-64
-agonist,65-73
such,74-78
as,79-81
salbutamol,82-92	DrugDDI.d90.s15.e1
(the,93-97
physician,98-107
should,108-114
provide,115-122
the,123-126
patient,127-134
with,135-139
such,140-144
medication,145-155	DrugDDI.d90.s15.e2
and,156-159
instruct,160-168
the,169-172
patient,173-180
in,181-183
how,184-187
it,188-190
should,191-197
be,198-200
used).,201-207

The,0-3
physician,4-13
should,14-20
be,21-23
notified,24-32
immediately,33-44
if,45-47
any,48-51
of,52-54
the,55-58
following,59-68
situations,69-79
occur,,80-86
which,87-92
may,93-96
be,97-99
a,100-101
sign,102-106
of,107-109
seriously,110-119
worsening,120-129
asthma:,130-137
?,138-139
Decreased,140-149
effectiveness,150-163
of,164-166
short-acting,,167-180
inhaled,181-188
?2-,189-192
agonists;,193-202	DrugDDI.d90.s17.e0

?,0-1
Need,2-6
for,7-10
more,11-15
inhalations,16-27	DrugDDI.d90.s18.e0
than,28-32
usual,33-38
of,39-41
short-acting,,42-55
inhaled,56-63
?2,64-66
-agonists.,67-77

FORADIL,0-7	DrugDDI.d90.s20.e0
should,8-14
not,15-18
be,19-21
used,22-26
as,27-29
a,30-31
substitute,32-42
for,43-46
oral,47-51
or,52-54
inhaled,55-62
corticosteroids.,63-79	DrugDDI.d90.s20.e1

The,0-3
dosage,4-10
of,11-13
these,14-19
medications,20-31	DrugDDI.d90.s21.e0
should,32-38
not,39-42
be,43-45
changed,46-53
and,54-57
they,58-62
should,63-69
not,70-73
be,74-76
stopped,77-84
without,85-92
consulting,93-103
the,104-107
physician,,108-118
even,119-123
if,124-126
the,127-130
patient,131-138
feels,139-144
better,145-151
after,152-157
initiating,158-168
treatment,169-178
with,179-183
FORADIL.,184-192	DrugDDI.d90.s21.e1

In,0-2
patients,3-11
receiving,12-21
FORADIL,,22-30
other,31-36
inhaled,37-44	DrugDDI.d90.s24.e1
medications,45-56	DrugDDI.d90.s24.e1
should,57-63
be,64-66
used,67-71
only,72-76
as,77-79
directed,80-88
by,89-91
the,92-95
physician.,96-106

Guardians,0-9
of,10-12
children,13-21
who,22-25
have,26-30
been,31-35
prescribed,36-46
FORADIL,47-54	DrugDDI.d90.s26.e0
should,55-61
be,62-64
alerted,65-72
to,73-75
the,76-79
general,80-87
concern,88-95
regarding,96-105
asthma,106-112
therapy,113-120
compliance,,121-132
especially,133-143
neglect,144-151
of,152-154
anti-inflammatory,155-172
therapy,173-180
and,181-184
overuse,185-192
of,193-195
short-acting,196-208
?2-agonists.,209-221

A,0-1
possible,2-10
drug,11-15
interaction,16-27
of,28-30
FOSCAVIR,31-39	DrugDDI.d581.s0.e0
and,40-43
intravenous,44-55
pentamidine,56-67	DrugDDI.d581.s0.e1
has,68-71
been,72-76
described.,77-87

Concomitant,0-11
treatment,12-21
of,22-24
four,25-29
patients,30-38
in,39-41
the,42-45
United,46-52
Kingdom,53-60
with,61-65
FOSCAVIR,66-74	DrugDDI.d581.s1.e0
and,75-78
intravenous,79-90
pentamidine,91-102	DrugDDI.d581.s1.e1
may,103-106
have,107-111
caused,112-118
hypocalcemia;,119-132

Toxicity,0-8
associated,9-19
with,20-24
concomitant,25-36
use,37-40
of,41-43
aerosolized,44-55
pentamidine,56-67	DrugDDI.d581.s3.e0
has,68-71
not,72-75
been,76-80
reported.,81-90

Because,0-7
of,8-10
foscarnets,11-21	DrugDDI.d581.s4.e0
tendency,22-30
to,31-33
cause,34-39
renal,40-45
impairment,,46-57
the,58-61
use,62-65
of,66-68
FOSCAVIR,69-77	DrugDDI.d581.s4.e1
should,78-84
be,85-87
avoided,88-95
in,96-98
combination,99-110
with,111-115
potentially,116-127
nephrotoxic,128-139
drugs,140-145	DrugDDI.d581.s4.e2
such,146-150
as,151-153
aminoglycosides,,154-170
amphotericin,171-183	DrugDDI.d581.s4.e4
B,184-185	DrugDDI.d581.s4.e4
and,186-189
intravenous,190-201
pentamidine,202-213	DrugDDI.d581.s4.e5
unless,214-220
the,221-224
potential,225-234
benefits,235-243
outweigh,244-252
the,253-256
risks,257-262
to,263-265
the,266-269
patient.,270-278

Abnormal,0-8
renal,9-14
function,15-23
has,24-27
been,28-32
observed,33-41
in,42-44
clinical,45-53
practice,54-62
during,63-69
the,70-73
use,74-77
of,78-80
FASCAVIR,81-89
and,90-93
ritonavir,,94-104
or,105-107
FOSCAVIR,,108-117
ritonavir,,118-128
and,129-132
saquinavir.,133-144	DrugDDI.d581.s5.e3

Since,0-5
FOSCAVIR,6-14	DrugDDI.d581.s6.e0
decreases,15-24
serum,25-30
concentrations,31-45
of,46-48
ionized,49-56	DrugDDI.d581.s6.e1
calcium,,57-65	DrugDDI.d581.s6.e1
concurrent,66-76
treatment,77-86
with,87-91
other,92-97
drugs,98-103	DrugDDI.d581.s6.e2
known,104-109
to,110-112
influence,113-122
serum,123-128
calcium,129-136
concentrations,137-151
should,152-158
be,159-161
used,162-166
with,167-171
particular,172-182
caution.,183-191

Ganciclovir,0-11	DrugDDI.d581.s7.e0
The,12-15
pharmacokinetics,16-32
of,33-35
foscarnet,36-45	DrugDDI.d581.s7.e1
and,46-49
ganciclovir,50-61	DrugDDI.d581.s7.e2
were,62-66
not,67-70
altered,71-78
in,79-81
13,82-84
patients,85-93
receiving,94-103
either,104-110
concomitant,111-122
therapy,123-130
or,131-133
daily,134-139
alternating,140-151
therapy,152-159
for,160-163
maintenance,164-175
of,176-178
CMV,179-182
disease.,183-191

Metoclopramide:,0-15	DrugDDI.d261.s0.e0
When,16-20
coadministered,21-35
with,36-40
MONUROL,,41-49
metoclopramide,,50-65
a,66-67
drug,68-72	DrugDDI.d261.s0.e3
which,73-78
increases,79-88
gastrointestinal,89-105
motility,,106-115
lowers,116-122
the,123-126
serum,127-132
concentration,133-146
and,147-150
urinary,151-158
excretion,159-168
of,169-171
fosfomycin.,172-183	DrugDDI.d261.s0.e4

Other,0-5
drugs,6-11	DrugDDI.d261.s1.e0
that,12-16
increase,17-25
gastrointestinal,26-42
motility,43-51
may,52-55
produce,56-63
similar,64-71
effects.,72-80

Cimetidine:,0-11	DrugDDI.d261.s2.e0
Cimetidine,12-22	DrugDDI.d261.s2.e1
does,23-27
not,28-31
affect,32-38
the,39-42
pharmacokinetics,43-59
of,60-62
fosfomycin,63-73	DrugDDI.d261.s2.e2
when,74-78
coadministered,79-93
with,94-98
MONUROL.,99-107	DrugDDI.d261.s2.e3

Diuretics:,0-10	DrugDDI.d36.s0.e0
Patients,11-19
on,20-22
diuretics,,23-33
especially,34-44
those,45-50
with,51-55
intravascular,56-69
volume,70-76
depletion,,77-87
may,88-91
occasionally,92-104
experience,105-115
an,116-118
excessive,119-128
reduction,129-138
of,139-141
blood,142-147
pressure,148-156
after,157-162
initiation,163-173
of,174-176
therapy,177-184
with,185-189
fosinopril,190-200	DrugDDI.d36.s0.e2
sodium.,201-208	DrugDDI.d36.s0.e2

The,0-3
possibility,4-15
of,16-18
hypotensive,19-30
effects,31-38
can,39-42
be,43-45
minimized,46-55
by,56-58
either,59-65
discontinuing,66-79
the,80-83
diuretic,84-92	DrugDDI.d36.s1.e0
or,93-95
increasing,96-106
salt,107-111
intake,112-118
prior,119-124
to,125-127
initiation,128-138
of,139-141
treatment,142-151
with,152-156
fosinopril,157-167	DrugDDI.d36.s1.e1
sodium.,168-175	DrugDDI.d36.s1.e1

Potassium,0-9	DrugDDI.d36.s3.e0
Supplements,10-21	DrugDDI.d36.s3.e0
and,22-25
Potassium-Sparing,26-43	DrugDDI.d36.s3.e1
Diuretics:,44-54	DrugDDI.d36.s3.e1
Fosinopril,55-65	DrugDDI.d36.s3.e2
sodium,66-72	DrugDDI.d36.s3.e2
can,73-76
attenuate,77-86
potassium,87-96	DrugDDI.d36.s3.e3
loss,97-101
caused,102-108
by,109-111
thiazide,112-120	DrugDDI.d36.s3.e4
diuretics.,121-131	DrugDDI.d36.s3.e4

Potassium-sparing,0-17	DrugDDI.d36.s4.e0
diuretics,18-27	DrugDDI.d36.s4.e0
(spironolactone,,28-44
amiloride,triamterene,,45-67
and,68-71
others),72-79
or,80-82
potassium,83-92	DrugDDI.d36.s4.e4
supplements,93-104	DrugDDI.d36.s4.e4
can,105-108
increase,109-117
the,118-121
risk,122-126
of,127-129
hyperkalemia.,130-143

Lithium:,0-8	DrugDDI.d36.s6.e0
Increased,9-18
serum,19-24
lithium,25-32
levels,33-39
and,40-43
symptoms,44-52
of,53-55
lithium,56-63
toxicity,64-72
have,73-77
been,78-82
reported,83-91
in,92-94
patients,95-103
receiving,104-113
ACE,114-117	DrugDDI.d36.s6.e1
inhibitors,118-128	DrugDDI.d36.s6.e1
during,129-135
therapy,136-143
with,144-148
lithium.,149-157	DrugDDI.d36.s6.e2

These,0-5
drugs,6-11	DrugDDI.d36.s7.e0
should,12-18
be,19-21
coadministered,22-36
with,37-41
caution,,42-50
and,51-54
frequent,55-63
monitoring,64-74
of,75-77
serum,78-83
lithium,84-91
levels,92-98
is,99-101
recommended.,102-114

If,0-2
a,3-4
diuretic,5-13	DrugDDI.d36.s8.e0
is,14-16
also,17-21
used,,22-27
the,28-31
risk,32-36
of,37-39
lithium,40-47
toxicity,48-56
may,57-60
be,61-63
increased.,64-74

Antacids:,0-9	DrugDDI.d36.s9.e0
In,10-12
a,13-14
clinical,15-23
pharmacology,24-36
study,,37-43
coadministration,44-60
of,61-63
an,64-66
antacid,67-74	DrugDDI.d36.s9.e1
(aluminum,75-84
hydroxide,,85-95
magnesium,96-105	DrugDDI.d36.s9.e3
hydroxide,,106-116	DrugDDI.d36.s9.e3
and,117-120
simethicone),121-133	DrugDDI.d36.s9.e4
with,134-138
fosinopril,139-149	DrugDDI.d36.s9.e5
reduced,150-157
serum,158-163
levels,164-170
and,171-174
urinary,175-182
excretion,183-192
of,193-195
fosinoprilat,196-208	DrugDDI.d36.s9.e6
as,209-211
compared,212-220
with,221-225
fosinopril,226-236	DrugDDI.d36.s9.e7
administered,237-249
alone,,250-256
suggesting,257-267
that,268-272
antacids,273-281	DrugDDI.d36.s9.e8
may,282-285
impair,286-292
absorption,293-303
of,304-306
fosinopril.,307-318	DrugDDI.d36.s9.e9

Other:,0-6
Neither,7-14
fosinopril,15-25	DrugDDI.d36.s11.e0
sodium,26-32	DrugDDI.d36.s11.e0
nor,33-36
its,37-40
metabolites,41-52	DrugDDI.d36.s11.e1
have,53-57
been,58-62
found,63-68
to,69-71
interact,72-80
with,81-85
food.,86-91

In,0-2
separate,3-11
single,12-18
or,19-21
multiple,22-30
dose,31-35
pharmacokinetic,36-51
interaction,52-63
studies,64-71
with,72-76
chlorthalidone,,77-92
nifedipine,,93-104
propanolol,,105-116
hydrochlorothiazide,,117-137
cimetidine,,138-149
metoclopramide,,150-165
propantheline,,166-180
digoxin,,181-189
and,190-193
warfarin,,194-203
the,204-207
bioavailability,208-223
of,224-226
fosinoprilat,227-239	DrugDDI.d36.s12.e9
was,240-243
not,244-247
altered,248-255
by,256-258
coadministration,259-275
of,276-278
fosinopril,279-289	DrugDDI.d36.s12.e10
with,290-294
any,295-298
one,299-302
of,303-305
these,306-311
drugs.,312-318	DrugDDI.d36.s12.e11

In,0-2
a,3-4
study,5-10
with,11-15
concomitant,16-27
administration,28-42
of,43-45
aspirin,46-53	DrugDDI.d36.s13.e0
and,54-57
fosinopril,58-68	DrugDDI.d36.s13.e1
sodium,,69-76	DrugDDI.d36.s13.e1
the,77-80
bioavailability,81-96
of,97-99
unbound,100-107
fosinoprilat,108-120	DrugDDI.d36.s13.e2
was,121-124
not,125-128
altered.,129-137

In,0-2
a,3-4
pharmacokinetic,5-20
interaction,21-32
study,33-38
with,39-43
warfarin,,44-53
bioavailability,54-69
parameters,,70-81
the,82-85
degree,86-92
of,93-95
protein,96-103
binding,,104-112
and,113-116
the,117-120
anticoagulant,121-134
effect,135-141
(measured,142-151
by,152-154
prothrombin,155-166
time),167-172
of,173-175
warfarin,176-184	DrugDDI.d36.s14.e1
were,185-189
not,190-193
significantly,194-207
changed.,208-216

Drug/Laboratory,0-15	DrugDDI.d36.s15.e0
Test,16-20
Interaction,21-32
Fosinopril,33-43	DrugDDI.d36.s15.e1
may,44-47
cause,48-53
a,54-55
false,56-61
low,62-65
measurement,66-77
of,78-80
serum,81-86
digoxin,87-94
levels,95-101
with,102-106
the,107-110
Digi-,111-116
Tab?,117-121
RIA,122-125
Kit,126-129
for,130-133
Digoxin.,134-142	DrugDDI.d36.s15.e2

No,0-2
drugs,3-8	DrugDDI.d380.s0.e0
are,9-12
known,13-18
to,19-21
interfere,22-31
with,32-36
the,37-40
conversion,41-51
of,52-54
fosphenytoin,55-67	DrugDDI.d380.s0.e1
to,68-70
phenytoin.,71-81	DrugDDI.d380.s0.e2

Conversion,0-10
could,11-16
be,17-19
affected,20-28
by,29-31
alterations,32-43
in,44-46
the,47-50
level,51-56
of,57-59
phosphatase,60-71
activity,,72-81
but,82-85
given,86-91
the,92-95
abundance,96-105
and,106-109
wide,110-114
distribution,115-127
of,128-130
phosphatases,131-143	DrugDDI.d380.s1.e0
in,144-146
the,147-150
body,151-155
it,156-158
is,159-161
unlikely,162-170
that,171-175
drugs,176-181	DrugDDI.d380.s1.e1
would,182-187
affect,188-194
this,195-199
activity,200-208
enough,209-215
to,216-218
affect,219-225
conversion,226-236
of,237-239
fosphenytoin,240-252	DrugDDI.d380.s1.e2
to,253-255
phenytoin.,256-266	DrugDDI.d380.s1.e3

Drugs,0-5	DrugDDI.d380.s2.e0
highly,6-12
bound,13-18
to,19-21
albumin,22-29	DrugDDI.d380.s2.e1
could,30-35
increase,36-44
the,45-48
unbound,49-56
fraction,57-65
of,66-68
fosphenytoin.,69-82	DrugDDI.d380.s2.e2

Although,,0-9
it,10-12
is,13-15
unknown,16-23
whether,24-31
this,32-36
could,37-42
result,43-49
in,50-52
clinically,53-63
significant,64-75
effects,,76-84
caution,85-92
is,93-95
advised,96-103
when,104-108
administering,109-122
Cerebyx,123-130	DrugDDI.d380.s3.e0
with,131-135
other,136-141
drugs,142-147	DrugDDI.d380.s3.e1
that,148-152
significantly,153-166
bind,167-171
to,172-174
serum,175-180	DrugDDI.d380.s3.e2
albumin.,181-189	DrugDDI.d380.s3.e2

The,0-3
pharmacokinetics,4-20
and,21-24
protein,25-32
binding,33-40
of,41-43
fosphenytoin,,44-57
phenytoin,,58-68
and,69-72
diazepam,73-81	DrugDDI.d380.s4.e2
were,82-86
not,87-90
altered,91-98
when,99-103
diazepam,104-112	DrugDDI.d380.s4.e3
and,113-116
Cerebyx,117-124	DrugDDI.d380.s4.e4
were,125-129
concurrently,130-142
administered,143-155
in,156-158
single,159-165
submaximal,166-176
doses.,177-183

The,0-3
most,4-8
significant,9-20
drug,21-25
interactions,26-38
following,39-48
administration,49-63
of,64-66
Cerebyx,67-74	DrugDDI.d380.s5.e0
are,75-78
expected,79-87
to,88-90
occur,91-96
with,97-101
drugs,102-107	DrugDDI.d380.s5.e1
that,108-112
interact,113-121
with,122-126
phenytoin.,127-137	DrugDDI.d380.s5.e2

Phenytoin,0-9	DrugDDI.d380.s6.e0
is,10-12
extensively,13-24
bound,25-30
to,31-33
serum,34-39
plasma,40-46
proteins,47-55	DrugDDI.d380.s6.e1
and,56-59
is,60-62
prone,63-68
to,69-71
competitive,72-83
displacement.,84-97

Phenytoin,0-9	DrugDDI.d380.s7.e0
is,10-12
metabolized,13-24
by,25-27
hepatic,28-35	DrugDDI.d380.s7.e1
cytochrome,36-46	DrugDDI.d380.s7.e1
P450,47-51	DrugDDI.d380.s7.e1
enzymes,52-59	DrugDDI.d380.s7.e1
and,60-63
is,64-66
particularly,67-79
susceptible,80-91
to,92-94
inhibitory,95-105
drug,106-110
interactions,111-123
because,124-131
it,132-134
is,135-137
subject,138-145
to,146-148
saturable,149-158
metabolism.,159-170

Inhibition,0-10
of,11-13
metabolism,14-24
may,25-28
produce,29-36
significant,37-48
increases,49-58
in,59-61
circulating,62-73
phenytoin,74-83	DrugDDI.d380.s8.e0
concentrations,84-98
and,99-102
enhance,103-110
the,111-114
risk,115-119
of,120-122
drug,123-127
toxicity.,128-137

Phenytoin,0-9	DrugDDI.d380.s9.e0
is,10-12
a,13-14
potent,15-21
inducer,22-29
of,30-32
hepatic,33-40
drug-metabolizing,41-58
enzymes.,59-67

The,0-3
most,4-8
commonly,9-17
occurring,18-27
drug,28-32
interactions,33-45
are,46-49
listed,50-56
below:,57-63
-,64-65
Drugs,66-71	DrugDDI.d380.s10.e0
that,72-76
may,77-80
increase,81-89
plasma,90-96
phenytoin,97-106	DrugDDI.d380.s10.e1
concentrations,107-121
include:,122-130
acute,131-136
alcohol,137-144
intake,,145-152
amiodarone,,153-164
chboramphenicol,,165-181
chlordiazepoxide,,182-199
cimetidine,,200-211
diazepam,,212-221
dicumarol,,222-232
disulfiram,,233-244
estrogens,,245-255
ethosuximide,,256-269
fluoxetine,,270-281
H2-antagonists,,282-297
halothane,,298-308
isoniazid,,309-319
methylphenidate,,320-336
phenothiazines,,337-352
phenylbutazone,,353-368
salicylates,,369-381
succinimides,,382-395
sulfonamides,,396-409
tolbutamide,,410-422
trazodone,423-432	DrugDDI.d380.s10.e20

-,0-1
Drugs,2-7	DrugDDI.d380.s12.e0
that,8-12
may,13-16
decrease,17-25
plasma,26-32
phenytoin,33-42	DrugDDI.d380.s12.e1
concentrations,43-57
include:,58-66
carbamazepine,,67-81
chronic,82-89
alcohol,90-97
abuse,,98-104
reserpine,105-114	DrugDDI.d380.s12.e3

-,0-1
Drugs,2-7	DrugDDI.d380.s14.e0
that,8-12
may,13-16
either,17-23
increase,24-32
or,33-35
decrease,36-44
plasma,45-51
phenytoin,52-61	DrugDDI.d380.s14.e1
concentrations,62-76
include:,77-85
phenobarbital,,86-100
vaiproic,101-109
acid,,110-115
and,116-119
sodium,120-126	DrugDDI.d380.s14.e3
valproate.,127-137	DrugDDI.d380.s14.e3

Similarly,,0-10
the,11-14
effects,15-22
of,23-25
phenytoin,26-35	DrugDDI.d380.s15.e0
on,36-38
phenobarbital,,39-53
valproic,54-62	DrugDDI.d380.s15.e2
acid,63-67	DrugDDI.d380.s15.e2
and,68-71
sodium,72-78
plasma,79-85
valproate,86-95	DrugDDI.d380.s15.e3
concentrations,96-110
are,111-114
unpredictable,115-128

-,0-1
Although,2-10
not,11-14
a,15-16
true,17-21
drug,22-26
interaction,,27-39
tricyclic,40-49	DrugDDI.d380.s17.e0
antidepressants,50-65	DrugDDI.d380.s17.e0
may,66-69
precipitate,70-81
seizures,82-90
in,91-93
susceptible,94-105
patients,106-114
and,115-118
Cerebyx,119-126	DrugDDI.d380.s17.e1
dosage,127-133
may,134-137
need,138-142
to,143-145
be,146-148
adjusted,149-157

-,0-1
Drugs,2-7	DrugDDI.d380.s19.e0
whose,8-13
efficacy,14-22
is,23-25
impaired,26-34
by,35-37
phenytoin,38-47	DrugDDI.d380.s19.e1
include:,48-56
anticoagulants,,57-72
corticosteroids,,73-89
coumarin,,90-99
digitoxin,,100-110
doxycycline,,111-123
estrogens,,124-134
furosemide,,135-146
oral,147-151	DrugDDI.d380.s19.e9
contraceptives,,152-167	DrugDDI.d380.s19.e9
rifampin,,168-177
quinidine,,178-188
theophylline,,189-202
vitamin,203-210	DrugDDI.d380.s19.e13
D.,211-213	DrugDDI.d380.s19.e13

Monitoring,0-10
of,11-13
plasma,14-20
phenytoin,21-30	DrugDDI.d380.s20.e0
concentrations,31-45
may,46-49
be,50-52
helpful,53-60
when,61-65
possible,66-74
drug,75-79
interactions,80-92
are,93-96
suspected.,97-107

Drug/Laboratory,0-15	DrugDDI.d380.s21.e0
Test,16-20
Interactions,21-33
Phenytoin,34-43	DrugDDI.d380.s21.e1
may,44-47
decrease,48-56
serum,57-62
concentrations,63-77
of,78-80
14.,81-84

It,0-2
may,3-6
also,7-11
produce,12-19
artifactually,20-33
low,34-37
results,38-45
in,46-48
dexamethasone,49-62	DrugDDI.d380.s22.e0
or,63-65
metyrapone,66-76
tests.,77-83

Phenytoin,0-9	DrugDDI.d380.s23.e0
may,10-13
also,14-18
cause,19-24
increased,25-34
serum,35-40
concentrations,41-55
of,56-58
glucose,,59-67
alkaline,68-76	DrugDDI.d380.s23.e2
phosphatase,,77-89	DrugDDI.d380.s23.e2
and,90-93
gamma,94-99	DrugDDI.d380.s23.e3
glutamyl,100-108	DrugDDI.d380.s23.e3
transpeptidase,109-123	DrugDDI.d380.s23.e3
(GGT).,124-130

Care,0-4
should,5-11
be,12-14
taken,15-20
when,21-25
using,26-31
immunoanalytical,32-48
methods,49-56
to,57-59
measure,60-67
plasma,68-74
phenytoin,75-84	DrugDDI.d380.s24.e0
concentrations,85-99
following,100-109
Cerebyx,110-117	DrugDDI.d380.s24.e1
administration.,118-133

Ergot-containing,0-16
drugs,17-22	DrugDDI.d118.s0.e0
have,23-27
been,28-32
reported,33-41
to,42-44
cause,45-50
prolonged,51-60
vasospastic,61-72
reactions.,73-83

Due,0-3
to,4-6
a,7-8
theoretical,9-20
risk,21-25
of,26-28
a,29-30
pharmacodynamic,31-46
interaction,,47-59
use,60-63
of,64-66
ergotamine-containing,67-88	DrugDDI.d118.s1.e0
or,89-91
ergot-type,92-102
medications,103-114	DrugDDI.d118.s1.e1
(like,115-120
dihydroergotamine,121-138	DrugDDI.d118.s1.e2
or,139-141
methysergide),142-155	DrugDDI.d118.s1.e3
and,156-159
FROVA,160-165	DrugDDI.d118.s1.e4
within,166-172
24,173-175
hours,176-181
of,182-184
each,185-189
other,190-195
should,196-202
be,203-205
avoided,206-213
(see,214-218
,219-219
a,220-221
href=,222-227
frova_od.htm#CI,228-243	DrugDDI.d118.s1.e5
CONTRAINDICATIONS).,244-263

Concomitant,0-11
use,12-15
of,16-18
other,19-24
5-HT1B/1D,25-34
agonists,35-43	DrugDDI.d118.s2.e0
within,44-50
24,51-53
hours,54-59
of,60-62
FROVA,63-68	DrugDDI.d118.s2.e1
treatment,69-78
is,79-81
not,82-85
recommended.,86-98

Selective,0-9
serotonin,10-19	DrugDDI.d118.s3.e0
reuptake,20-28	DrugDDI.d118.s3.e0
inhibitors,29-39	DrugDDI.d118.s3.e0
(SSRIs),40-47
(e.g.,,48-54
fluoxetine,,55-66
fluvoxamine,,67-79
paroxetine,,80-91
sertraline),92-103	DrugDDI.d118.s3.e4
have,104-108
been,109-113
reported,,114-123
rarely,,124-131
to,132-134
cause,135-140
weakness,,141-150
hyperreflexia,,151-165
and,166-169
incoordination,170-184
when,185-189
coadministered,190-204
with,205-209
5-HT1,210-215
agonists.,216-225	DrugDDI.d118.s3.e5

If,0-2
concomitant,3-14
treatment,15-24
with,25-29
frovatriptan,30-42	DrugDDI.d118.s4.e0
and,43-46
an,47-49
SSRI,50-54
is,55-57
clinically,58-68
warranted,,69-79
appropriate,80-91
observation,92-103
of,104-106
the,107-110
patient,111-118
is,119-121
advised.,122-130

Drug/Laboratory,0-15	DrugDDI.d118.s5.e0
Test,16-20
Interactions,21-33
FROVA,34-39	DrugDDI.d118.s5.e1
is,40-42
not,43-46
known,47-52
to,53-55
interfere,56-65
with,66-70
commonly,71-79
employed,80-88
clinical,89-97
laboratory,98-108
tests.,109-115

Fulvestrant,0-11	DrugDDI.d88.s0.e0
is,12-14
metabolized,15-26
by,27-29
CYP,30-33	DrugDDI.d88.s0.e1
3A4,34-37
in,38-40
vitro.,41-47

Clinical,0-8
studies,9-16
of,17-19
the,20-23
effect,24-30
of,31-33
strong,34-40
CYP,41-44
3A4,45-48
inhibitors,49-59
on,60-62
the,63-66
pharmacokinetics,67-83
of,84-86
fulvestrant,87-98	DrugDDI.d88.s1.e0
have,99-103
not,104-107
been,108-112
performed.,113-123

Induction,0-9
of,10-12
such,13-17
tumors,18-24
is,25-27
consistent,28-38
with,39-43
the,44-47
pharmacology-related,48-68
endocrine,69-78
feedback,79-87
alterations,88-99
in,100-102
gonadotropin,103-115
levels,116-122
caused,123-129
by,130-132
an,133-135
antiestrogen.,136-149	DrugDDI.d88.s5.e0

Fulvestrant,0-11	DrugDDI.d88.s6.e0
was,12-15
not,16-19
mutagenic,20-29
or,30-32
clastogenic,33-44
in,45-47
multiple,48-56
in,57-59
vitro,60-65
tests,66-71
with,72-76
and,77-80
without,81-88
the,89-92
addition,93-101
of,102-104
a,105-106
mammalian,107-116
liver,117-122	DrugDDI.d88.s6.e1
metabolic,123-132
activation,133-143
factor,144-150
(bacterial,151-161
mutation,162-170
assay,171-176
in,177-179
strains,180-187
of,188-190
Salmonella,191-201
typhimurium,202-213
and,214-217
Escherichia,218-229
coli,,230-235
in,236-238
vitro,239-244
cytogenetics,245-257
study,258-263
in,264-266
human,267-272
lymphocytes,,273-285
mammalian,286-295
cell,296-300
mutation,301-309
assay,310-315
in,316-318
mouse,319-324
lymphoma,325-333
cells,334-339
and,340-343
in,344-346
vivo,347-351
micronucleus,352-364
test,365-369
in,370-372
rat.,373-377

In,0-2
female,3-9
rats,,10-15
fulvestrant,16-27	DrugDDI.d88.s7.e0
administered,28-40
at,41-43
doses,44-49
,50-50
,51-51
0.01,52-56
mg/kg/day,57-66
(approximately,67-81
one-hundredth,82-95
of,96-98
the,99-102
human,103-108
recommended,109-120
dose,121-125
based,126-131
on,132-134
body,135-139
surface,140-147
area,148-152
[BSA],,153-159
for,160-163
2,164-165
weeks,166-171
prior,172-177
to,178-180
and,181-184
for,185-188
1,189-190
week,191-195
following,196-205
mating,,206-213
caused,214-220
a,221-222
reduction,223-232
in,233-235
fertility,236-245
and,246-249
embryonic,250-259
survival.,260-269

No,0-2
adverse,3-10
effects,11-18
on,19-21
female,22-28
fertility,29-38
and,39-42
embryonic,43-52
survival,53-61
were,62-66
evident,67-74
in,75-77
female,78-84
animals,85-92
dosed,93-98
at,99-101
0.001,102-107
mg/kg/day,108-117
(approximately,118-132
one-thousandth,133-147
of,148-150
the,151-154
human,155-160
dose,161-165
based,166-171
on,172-174
BSA).,175-180	DrugDDI.d88.s8.e0

Restoration,0-11
of,12-14
female,15-21
fertility,22-31
to,32-34
values,35-41
similar,42-49
to,50-52
controls,53-61
was,62-65
evident,66-73
following,74-83
a,84-85
29-day,86-92
withdrawal,93-103
period,104-110
after,111-116
dosing,117-123
at,124-126
2,127-128
mg/kg/day,129-138
(twice,139-145
the,146-149
human,150-155
dose,156-160
based,161-166
on,167-169
BSA).,170-175	DrugDDI.d88.s9.e0

The,0-3
effects,4-11
of,12-14
fulvestrant,15-26	DrugDDI.d88.s10.e0
on,27-29
the,30-33
fertility,34-43
of,44-46
female,47-53
rats,54-58
appear,59-65
to,66-68
be,69-71
consistent,72-82
with,83-87
its,88-91
anti-estrogenic,92-107	DrugDDI.d88.s10.e1
activity.,108-117

The,0-3
potential,4-13
effects,14-21
of,22-24
fulvestrant,25-36	DrugDDI.d88.s11.e0
on,37-39
the,40-43
fertility,44-53
of,54-56
male,57-61
animals,62-69
were,70-74
not,75-78
studied,79-86
but,87-90
in,91-93
a,94-95
6-month,96-103
toxicology,104-114
study,,115-121
male,122-126
rats,127-131
treated,132-139
with,140-144
intramuscular,145-158
doses,159-164
of,165-167
15,168-170
mg/kg/30,171-179
days,,180-185
10,186-188
mg/rat/30,189-198
days,,199-204
or,205-207
10,208-210
mg/rat/15,211-220
days,221-225
fulvestrant,226-237	DrugDDI.d88.s11.e1
showed,238-244
a,245-246
loss,247-251
of,252-254
spermatozoa,255-266
from,267-271
the,272-275
seminiferous,276-288
tubules,,289-297
seminiferous,298-310
tubular,311-318
atrophy,,319-327
and,328-331
degenerative,332-344
changes,345-352
in,353-355
the,356-359
epididymides.,360-373

These,0-5
fulvestrant,6-17	DrugDDI.d88.s13.e0
doses,18-23
correspond,24-34
to,35-37
approximately,38-51
2-,,52-55
3-,,56-59
and,60-63
3-fold,64-70
the,71-74
systemic,75-83
exposure,84-92
[AUC0-30,93-101
days],102-107
achieved,108-116
in,117-119
women.,120-126

approximately,0-13
one-hundredth,14-27
of,28-30
the,31-34
human,35-40
recommended,41-52
dose,53-57
based,58-63
on,64-66
body,67-71
surface,72-79
area,80-84
[BSA]),,85-92
fulvestrant,93-104	DrugDDI.d88.s16.e1
caused,105-111
a,112-113
reversible,114-124
reduction,125-134
in,135-137
female,138-144
fertility,,145-155
as,156-158
well,159-163
as,164-166
effects,167-174
on,175-177
embryo/fetal,178-190
development,191-202
consistent,203-213
with,214-218
its,219-222
anti-estrogenic,223-238	DrugDDI.d88.s16.e2
activity.,239-248

Fulvestrant,0-11	DrugDDI.d88.s17.e0
caused,12-18
an,19-21
increased,22-31
incidence,32-41
of,42-44
fetal,45-50
abnormalities,51-64
in,65-67
rats,68-72
(tarsal,73-80
flexure,81-88
of,89-91
the,92-95
hind,96-100
paw,101-104
at,105-107
2,108-109
mg/kg/day,110-119
IM;,120-123

twice,0-5
the,6-9
human,10-15
dose,16-20
on,21-23
BSA),24-28	DrugDDI.d88.s18.e0
and,29-32
non-ossification,33-49
of,50-52
the,53-56
odontoid,57-65
and,66-69
ventral,70-77
tubercle,78-86
of,87-89
the,90-93
first,94-99
cervical,100-108
vertebra,109-117
at,118-120
doses,121-126
,127-127
,128-128
0.1,129-132
mg/kg/day,133-142
IM,143-145
(approximately,146-160
one-tenth,161-170
of,171-173
the,174-177
human,178-183
dose,184-188
on,189-191
BSA),192-196	DrugDDI.d88.s18.e1
when,197-201
administered,202-214
during,215-221
the,222-225
period,226-232
of,233-235
organogenesis.,236-250

Rabbits,0-7
failed,8-14
to,15-17
maintain,18-26
pregnancy,27-36
when,37-41
dosed,42-47
with,48-52
1,53-54
mg/kg/day,55-64
fulvestrant,65-76	DrugDDI.d88.s19.e0
IM,77-79
(twice,80-86
the,87-90
human,91-96
dose,97-101
on,102-104
BSA),105-109	DrugDDI.d88.s19.e1
during,110-116
the,117-120
period,121-127
of,128-130
organogenesis.,131-145

Further,,0-8
in,9-11
rabbits,12-19
dosed,20-25
at,26-28
0.25,29-33
mg/kg/day,34-43
(about,44-50
one-half,51-59
the,60-63
human,64-69
dose,70-74
on,75-77
BSA),,78-83
increases,84-93
in,94-96
placental,97-106
weight,107-113
and,114-117
post-implantation,118-135
loss,136-140
were,141-145
observed,146-154
but,,155-159
there,160-165
were,166-170
no,171-173
observed,174-182
effects,183-190
on,191-193
fetal,194-199
development.,200-212

Fulvestrant,0-11	DrugDDI.d88.s21.e0
was,12-15
associated,16-26
with,27-31
an,32-34
increased,35-44
incidence,45-54
of,55-57
fetal,58-63
variations,64-74
in,75-77
rabbits,78-85
(backwards,86-96
displacement,97-109
of,110-112
the,113-116
pelvic,117-123
girdle,,124-131
and,132-135
27,136-138
pre-sacral,139-149
vertebrae,150-159
at,160-162
0.25,163-167
mg/kg/day,168-177
IM;,178-181

one-half,0-8
the,9-12
human,13-18
dose,19-23
on,24-26
BSA),27-31	DrugDDI.d88.s22.e0
when,32-36
administered,37-49
during,50-56
the,57-60
period,61-67
of,68-70
organogenesis.,71-85

Because,0-7
pregnancy,8-17
could,18-23
not,24-27
be,28-30
maintained,31-41
in,42-44
the,45-48
rabbit,49-55
following,56-65
doses,66-71
of,72-74
fulvestrant,75-86	DrugDDI.d88.s23.e0
of,87-89
1,90-91
mg/kg/day,92-101
and,102-105
above,,106-112
this,113-117
study,118-123
was,124-127
inadequate,128-138
to,139-141
fully,142-147
define,148-154
the,155-158
possible,159-167
adverse,168-175
effects,176-183
on,184-186
fetal,187-192
development,193-204
at,205-207
clinically,208-218
relevant,219-227
exposures.,228-238

Nursing,0-7
Mothers,8-15
Fulvestrant,16-27	DrugDDI.d88.s24.e0
is,28-30
found,31-36
in,37-39
rat,40-43
milk,44-48
at,49-51
levels,52-58
significantly,59-72
higher,73-79
(approximately,80-94
12-fold),95-103
than,104-108
plasma,109-115
after,116-121
administration,122-136
of,137-139
2,140-141
mg/kg.,142-148

Drug,0-4
exposure,5-13
in,14-16
rodent,17-23
pups,24-28
from,29-33
fulvestrant-treated,34-53	DrugDDI.d88.s25.e0
lactating,54-63
dams,64-68
was,69-72
estimated,73-82
as,83-85
10%,86-89
of,90-92
the,93-96
administered,97-109
dose.,110-115

It,0-2
is,3-5
not,6-9
known,10-15
if,16-18
fulvestrant,19-30	DrugDDI.d88.s26.e0
is,31-33
excreted,34-42
in,43-45
human,46-51
milk.,52-57

Because,0-7
many,8-12
drugs,13-18	DrugDDI.d88.s27.e0
are,19-22
excreted,23-31
in,32-34
human,35-40
milk,,41-46
and,47-50
because,51-58
of,59-61
the,62-65
potential,66-75
for,76-79
serious,80-87
adverse,88-95
reactions,96-105
from,106-110
FASLODEX,111-119	DrugDDI.d88.s27.e1
in,120-122
nursing,123-130
infants,,131-139
a,140-141
decision,142-150
should,151-157
be,158-160
made,161-165
whether,166-173
to,174-176
discontinue,177-188
nursing,189-196
or,197-199
to,200-202
discontinue,203-214
the,215-218
drug,219-223	DrugDDI.d88.s27.e2
taking,224-230
into,231-235
account,236-243
the,244-247
importance,248-258
of,259-261
the,262-265
drug,266-270	DrugDDI.d88.s27.e3
to,271-273
the,274-277
mother.,278-285

Pediatric,0-9	DrugDDI.d88.s28.e0
Use,10-13
The,14-17
safety,18-24
and,25-28
efficacy,29-37
of,38-40
FASLODEX,41-49	DrugDDI.d88.s28.e1
in,50-52
pediatric,53-62
patients,63-71
have,72-76
not,77-80
been,81-85
established.,86-98

Geriatric,0-9
Use,10-13
When,14-18
tumor,19-24
response,25-33
was,34-37
considered,38-48
by,49-51
age,,52-56
objective,57-66
responses,67-76
were,77-81
seen,82-86
in,87-89
24%,90-93
and,94-97
22%,98-101
of,102-104
patients,105-113
under,114-119
65,120-122
years,123-128
of,129-131
age,132-135
and,136-139
in,140-142
16%,143-146
and,147-150
11%,151-154
of,155-157
patients,158-166
65,167-169
years,170-175
of,176-178
age,179-182
and,183-186
older,,187-193
who,194-197
were,198-202
treated,203-210
with,211-215
FASLODEX,216-224	DrugDDI.d88.s29.e0
in,225-227
the,228-231
European,232-240
and,241-244
North,245-250
American,251-259
trials,,260-267
respectively.,268-281

Furosemide,0-10	DrugDDI.d231.s0.e0
may,11-14
increase,15-23
the,24-27
ototoxic,28-36
potential,37-46
of,47-49
aminoglycoside,50-64	DrugDDI.d231.s0.e1
antibiotics,,65-77	DrugDDI.d231.s0.e1
especially,78-88
in,89-91
the,92-95
presence,96-104
of,105-107
impaired,108-116
renal,117-122
function.,123-132

Furosemide,0-10	DrugDDI.d231.s2.e0
should,11-17
not,18-21
be,22-24
used,25-29
concomitantly,30-43
with,44-48
ethacrynic,49-59	DrugDDI.d231.s2.e1
acid,60-64	DrugDDI.d231.s2.e1
because,65-72
of,73-75
the,76-79
possibility,80-91
of,92-94
ototoxicity.,95-107

Patients,0-8
receiving,9-18
high,19-23
doses,24-29
of,30-32
salicylates,33-44	DrugDDI.d231.s3.e0
concomitantly,45-58
with,59-63
furosemide,,64-75
as,76-78
in,79-81
rheumatic,82-91
disease,,92-100
may,101-104
experience,105-115
salicylate,116-126
toxicity,127-135
at,136-138
lower,139-144
doses,145-150
because,151-158
of,159-161
competitive,162-173
renal,174-179
excretory,180-189
sites.,190-196

Furosemide,0-10	DrugDDI.d231.s4.e0
has,11-14
a,15-16
tendency,17-25
to,26-28
antagonize,29-39
the,40-43
skeletal,44-52
muscle,53-59
relaxing,60-68
effect,69-75
of,76-78
tubocurarine,79-91	DrugDDI.d231.s4.e1
and,92-95
may,96-99
potentiate,100-110
the,111-114
action,115-121
of,122-124
succinylcholine.,125-141	DrugDDI.d231.s4.e2

Lithium,0-7	DrugDDI.d231.s5.e0
generally,8-17
should,18-24
not,25-28
be,29-31
given,32-37
with,38-42
diuretics,43-52	DrugDDI.d231.s5.e1
because,53-60
they,61-65
reduce,66-72
lithiums,73-81	DrugDDI.d231.s5.e2
renal,82-87
clearance,88-97
and,98-101
add,102-105
a,106-107
high,108-112
risk,113-117
of,118-120
lithium,121-128
toxicity.,129-138

Furosemide,0-10	DrugDDI.d231.s6.e0
may,11-14
add,15-18
to,19-21
or,22-24
potentiate,25-35
the,36-39
therapeutic,40-51
effect,52-58
of,59-61
other,62-67
antihypertensive,68-84	DrugDDI.d231.s6.e1
drugs.,85-91	DrugDDI.d231.s6.e1

Potentiation,0-12
occurs,13-19
with,20-24
ganglionic,25-35
or,36-38
peripheral,39-49
adrenergic,50-60	DrugDDI.d231.s7.e0
blocking,61-69	DrugDDI.d231.s7.e0
drugs.,70-76	DrugDDI.d231.s7.e0

Furosemide,0-10	DrugDDI.d231.s8.e0
may,11-14
decrease,15-23
arterial,24-32
responsiveness,33-47
to,48-50
norepinephrine.,51-66	DrugDDI.d231.s8.e1

However,,0-8
norepinephrine,9-23	DrugDDI.d231.s9.e0
may,24-27
still,28-33
be,34-36
used,37-41
effectively.,42-54

Tablets,0-7
Simultaneous,8-20
administration,21-35
of,36-38
sucralfate,39-49	DrugDDI.d231.s10.e0
and,50-53
furosemide,54-64	DrugDDI.d231.s10.e1
tablets,65-72	DrugDDI.d231.s10.e1
may,73-76
reduce,77-83
the,84-87
natriuretic,88-99	DrugDDI.d231.s10.e2
and,100-103
antihypertensive,104-120	DrugDDI.d231.s10.e3
effects,121-128
of,129-131
furosemide.,132-143	DrugDDI.d231.s10.e4

Patients,0-8
receiving,9-18
both,19-23
drugs,24-29	DrugDDI.d231.s11.e0
should,30-36
be,37-39
observed,40-48
closely,49-56
to,57-59
determine,60-69
if,70-72
the,73-76
desired,77-84
diuretic,85-93	DrugDDI.d231.s11.e1
and/or,94-100
antihypertensive,101-117	DrugDDI.d231.s11.e2
effect,118-124
of,125-127
furosemide,128-138	DrugDDI.d231.s11.e3
is,139-141
achieved.,142-151

The,0-3
intake,4-10
of,11-13
furosemide,14-24	DrugDDI.d231.s12.e0
and,25-28
sucralfate,29-39	DrugDDI.d231.s12.e1
should,40-46
be,47-49
separated,50-59
by,60-62
at,63-65
least,66-71
two,72-75
hours.,76-82

Tablets,,0-8
Injection,,9-19
and,20-23
Oral,24-28
Solution,29-37
One,38-41
study,42-47
in,48-50
six,51-54
subjects,55-63
demonstrated,64-76
that,77-81
the,82-85
combination,86-97
of,98-100
furosemide,101-111	DrugDDI.d231.s13.e0
and,112-115
acetylsalicylic,116-131	DrugDDI.d231.s13.e1
acid,132-136	DrugDDI.d231.s13.e1
temporarily,137-148
reduced,149-156
creatinine,157-167
clearance,168-177
in,178-180
patients,181-189
with,190-194
chronic,195-202
renal,203-208
insufficiency.,209-223

There,0-5
are,6-9
case,10-14
reports,15-22
of,23-25
patients,26-34
who,35-38
developed,39-48
increased,49-58
BUN,,59-63
serum,64-69
creatinine,70-80
and,81-84
serum,85-90
potassium,91-100
levels,,101-108
and,109-112
weight,113-119
gain,120-124
when,125-129
furosemide,130-140	DrugDDI.d231.s14.e0
was,141-144
used,145-149
in,150-152
conjunction,153-164
with,165-169
NSAIDs.,170-177	DrugDDI.d231.s14.e1

Literature,0-10
reports,11-18
indicate,19-27
that,28-32
coadministration,33-49
of,50-52
indomethacin,53-65	DrugDDI.d231.s15.e0
may,66-69
reduce,70-76
the,77-80
natriuretic,81-92	DrugDDI.d231.s15.e1
and,93-96
antihypertensive,97-113	DrugDDI.d231.s15.e2
effects,114-121
of,122-124
furosemide,125-135	DrugDDI.d231.s15.e3
in,136-138
some,139-143
patients,144-152
by,153-155
inhibiting,156-166
prostaglandin,167-180	DrugDDI.d231.s15.e4
synthesis.,181-191

Indomethacin,0-12	DrugDDI.d231.s16.e0
may,13-16
also,17-21
affect,22-28
plasma,29-35
renin,36-41
levels,,42-49
aldosterone,50-61	DrugDDI.d231.s16.e1
excretion,,62-72
and,73-76
renin,77-82	DrugDDI.d231.s16.e2
profile,83-90
evaluation.,91-102

Patients,0-8
receiving,9-18
both,19-23
indomethacin,24-36	DrugDDI.d231.s17.e0
and,37-40
furosemide,41-51	DrugDDI.d231.s17.e1
should,52-58
be,59-61
observed,62-70
closely,71-78
to,79-81
determine,82-91
if,92-94
the,95-98
desired,99-106
diuretic,107-115	DrugDDI.d231.s17.e2
and/or,116-122
antihypertensive,123-139	DrugDDI.d231.s17.e3
effect,140-146
of,147-149
furosemide,150-160	DrugDDI.d231.s17.e4
is,161-163
achieved.,164-173

In,0-2
vitro,3-8
studies,9-16
were,17-21
conducted,22-31
to,32-34
investigate,35-46
the,47-50
potential,51-60
of,61-63
gabapentin,64-74	DrugDDI.d536.s0.e0
to,75-77
inhibit,78-85
the,86-89
major,90-95
cytochrome,96-106	DrugDDI.d536.s0.e1
P450,107-111	DrugDDI.d536.s0.e1
enzymes,112-119
(CYP1A2,,120-128
CYP2A6,,129-136
CYP2C9,,137-144
CYP2C19,,145-153
CYP2D6,,154-161
CYP2E1,,162-169
and,170-173
CYP3A4),174-181	DrugDDI.d536.s0.e8
that,182-186
mediate,187-194
drug,195-199	DrugDDI.d536.s0.e9
and,200-203
xenobiotic,204-214
metabolism,215-225
using,226-231
isoform,232-239	DrugDDI.d536.s0.e10
selective,240-249
marker,250-256
substrates,257-267
and,268-271
human,272-277
liver,278-283
microsomal,284-294	DrugDDI.d536.s0.e11
preparations.,295-308	DrugDDI.d536.s0.e11

1,0-1
mM),2-5
was,6-9
a,10-11
slight,12-18
degree,19-25
of,26-28
inhibition,29-39
(14%-30%),40-49
of,50-52
isoform,53-60	DrugDDI.d536.s3.e0
CYP2A6,61-67	DrugDDI.d536.s3.e0
observed.,68-77

No,0-2
inhibition,3-13
of,14-16
any,17-20
of,21-23
the,24-27
other,28-33
isoforms,34-42	DrugDDI.d536.s4.e0
tested,43-49
was,50-53
observed,54-62
at,63-65
gabapentin,66-76	DrugDDI.d536.s4.e1
concentrations,77-91
up,92-94
to,95-97
171,98-101
mg/mL,102-107
(approximately,108-122
15,123-125
times,126-131
the,132-135
Cmax,136-140
at,141-143
3600,144-148
mg/day).,149-157

Gabapentin,0-10	DrugDDI.d536.s5.e0
is,11-13
not,14-17
appreciably,18-29
metabolized,30-41
nor,42-45
does,46-50
it,51-53
interfere,54-63
with,64-68
the,69-72
metabolism,73-83
of,84-86
commonly,87-95
coadministered,96-110
antiepileptic,111-124	DrugDDI.d536.s5.e1
drugs.,125-131	DrugDDI.d536.s5.e1

Phenytoin:,0-10	DrugDDI.d536.s7.e0
In,11-13
a,14-15
single,16-22
(400,23-27
mg),28-31
and,32-35
multiple,36-44
dose,45-49
(400,50-54
mg,55-57
TID),58-62
study,63-68
of,69-71
Neurontin,72-81
span,82-86
class=,87-93
c11,94-97
?,98-99
in,100-102
epileptic,103-112
patients,113-121
(N=8),122-127
maintained,128-138
on,139-141
phenytoin,142-151	DrugDDI.d536.s7.e1
monotherapy,152-163
for,164-167
at,168-170
least,171-176
2,177-178
months,,179-186
gabapentin,187-197	DrugDDI.d536.s7.e2
had,198-201
no,202-204
effect,205-211
on,212-214
the,215-218
steady-state,219-231
trough,232-238
plasma,239-245
concentrations,246-260
of,261-263
phenytoin,264-273	DrugDDI.d536.s7.e3
and,274-277
phenytoin,278-287	DrugDDI.d536.s7.e4
had,288-291
no,292-294
effect,295-301
on,302-304
gabapentin,305-315	DrugDDI.d536.s7.e5
pharmacokinetics.,316-333

Carbamazepine:,0-14	DrugDDI.d536.s8.e0
Steady-state,15-27
trough,28-34
plasma,35-41
carbamazepine,42-55	DrugDDI.d536.s8.e1
and,56-59
carbamazepine,60-73	DrugDDI.d536.s8.e2
10,,74-77
11,78-80
epoxide,81-88
concentrations,89-103
were,104-108
not,109-112
affected,113-121
by,122-124
concomitant,125-136
gabapentin,137-147	DrugDDI.d536.s8.e3
(400,148-152
mg,153-155
TID;,156-160

Likewise,,0-9
gabapentin,10-20	DrugDDI.d536.s10.e0
pharmacokinetics,21-37
were,38-42
unaltered,43-52
by,53-55
carbamazepine,56-69	DrugDDI.d536.s10.e1
administration.,70-85

Valproic,0-8	DrugDDI.d536.s11.e0
Acid:,9-14	DrugDDI.d536.s11.e0
The,15-18
mean,19-23
steady-state,24-36
trough,37-43
serum,44-49
valproic,50-58	DrugDDI.d536.s11.e1
acid,59-63	DrugDDI.d536.s11.e1
concentrations,64-78
prior,79-84
to,85-87
and,88-91
during,92-98
concomitant,99-110
gabapentin,111-121	DrugDDI.d536.s11.e2
administration,122-136
(400,137-141
mg,142-144
TID;,145-149

N=17),0-5
were,6-10
not,11-14
different,15-24
and,25-28
neither,29-36
were,37-41
gabapentin,42-52	DrugDDI.d536.s12.e0
pharmacokinetic,53-68
parameters,69-79
affected,80-88
by,89-91
valproic,92-100	DrugDDI.d536.s12.e1
acid.,101-106	DrugDDI.d536.s12.e1

Phenobarbital:,0-14	DrugDDI.d536.s13.e0
Estimates,15-24
of,25-27
steady-state,28-40
pharmacokinetic,41-56
parameters,57-67
for,68-71
phenobarbital,72-85	DrugDDI.d536.s13.e1
or,86-88
gabapentin,89-99	DrugDDI.d536.s13.e2
(300,100-104
mg,105-107
TID;,108-112

N=12),0-5
are,6-9
identical,10-19
whether,20-27
the,28-31
drugs,32-37	DrugDDI.d536.s14.e0
are,38-41
administered,42-54
alone,55-60
or,61-63
together.,64-73

Naproxen:,0-9	DrugDDI.d536.s15.e0
Coadministration,10-26
(N=18),27-33
of,34-36
naproxen,37-45	DrugDDI.d536.s15.e1
sodium,46-52	DrugDDI.d536.s15.e1
capsules,53-61
(250,62-66
mg),67-70
with,71-75
Neurontin,76-85
span,86-90
class=,91-97
c11,98-101
?,102-103
(125,104-108
mg),109-112
appears,113-120
to,121-123
increase,124-132
the,133-136
amount,137-143
of,144-146
gabapentin,147-157	DrugDDI.d536.s15.e2
absorbed,158-166
by,167-169
12%,170-173
to,174-176
15%.,177-181

Gabapentin,0-10	DrugDDI.d536.s16.e0
had,11-14
no,15-17
effect,18-24
on,25-27
naproxen,28-36	DrugDDI.d536.s16.e1
pharmacokinetic,37-52
parameters.,53-64

These,0-5
doses,6-11
are,12-15
lower,16-21
than,22-26
the,27-30
therapeutic,31-42
doses,43-48
for,49-52
both,53-57
drugs.,58-64	DrugDDI.d536.s17.e0

The,0-3
magnitude,4-13
of,14-16
interaction,17-28
within,29-35
the,36-39
recommended,40-51
dose,52-56
ranges,57-63
of,64-66
either,67-73
drug,74-78	DrugDDI.d536.s18.e0
is,79-81
not,82-85
known.,86-92

Hydrocodone:,0-12	DrugDDI.d536.s19.e0
Coadministration,13-29
of,30-32
Neurontin?,33-43
(125,44-48
to,49-51
500,52-55
mg;,56-59

N=48),0-5
decreases,6-15
hydrocodone,16-27	DrugDDI.d536.s20.e0
(10,28-31
mg;,32-35

N=50),0-5
Cmax,6-10
and,11-14
AUC,15-18
values,19-25
in,26-28
a,29-30
dose-dependent,31-45
manner,46-52
relative,53-61
to,62-64
administration,65-79
of,80-82
hydrocodone,83-94	DrugDDI.d536.s21.e0
alone;,95-101

Hydrocodone,0-11	DrugDDI.d536.s24.e0
increases,12-21
gabapentin,22-32	DrugDDI.d536.s24.e1
AUC,33-36
values,37-43
by,44-46
14%.,47-51

Morphine:,0-9	DrugDDI.d536.s26.e0
A,10-11
literature,12-22
article,23-30
reported,31-39
that,40-44
when,45-49
a,50-51
60-mg,52-57
controlled-release,58-76
morphine,77-85	DrugDDI.d536.s26.e1
capsule,86-93	DrugDDI.d536.s26.e1
was,94-97
administered,98-110
2,111-112
hours,113-118
prior,119-124
to,125-127
a,128-129
600-mg,130-136
Neurontin?,137-147
capsule,148-155
(N=12),,156-163
mean,164-168
gabapentin,169-179	DrugDDI.d536.s26.e2
AUC,180-183
increased,184-193
by,194-196
44%,197-200
compared,201-209
to,210-212
gabapentin,213-223	DrugDDI.d536.s26.e3
administered,224-236
without,237-244
morphine.,245-254	DrugDDI.d536.s26.e4

Morphine,0-8	DrugDDI.d536.s27.e0
pharmacokinetic,9-24
parameter,25-34
values,35-41
were,42-46
not,47-50
affected,51-59
by,60-62
administration,63-77
of,78-80
Neurontin?,81-91
2,92-93
hours,94-99
after,100-105
morphine.,106-115	DrugDDI.d536.s27.e1

Cimetidine:,0-11	DrugDDI.d536.s29.e0
In,12-14
the,15-18
presence,19-27
of,28-30
cimetidine,31-41	DrugDDI.d536.s29.e1
at,42-44
300,45-48
mg,49-51
QID,52-55
(N=12),56-62
the,63-66
mean,67-71
apparent,72-80
oral,81-85
clearance,86-95
of,96-98
gabapentin,99-109	DrugDDI.d536.s29.e2
fell,110-114
by,115-117
14%,118-121
and,122-125
creatinine,126-136
clearance,137-146
fell,147-151
by,152-154
10%.,155-159

Thus,0-4
cimetidine,5-15	DrugDDI.d536.s30.e0
appeared,16-24
to,25-27
alter,28-33
the,34-37
renal,38-43
excretion,44-53
of,54-56
both,57-61
gabapentin,62-72	DrugDDI.d536.s30.e1
and,73-76
creatinine,,77-88
an,89-91
endogenous,92-102
marker,103-109
of,110-112
renal,113-118
function.,119-128

This,0-4
small,5-10
decrease,11-19
in,20-22
excretion,23-32
of,33-35
gabapentin,36-46	DrugDDI.d536.s31.e0
by,47-49
cimetidine,50-60	DrugDDI.d536.s31.e1
is,61-63
not,64-67
expected,68-76
to,77-79
be,80-82
of,83-85
clinical,86-94
importance.,95-106

The,0-3
effect,4-10
of,11-13
gabapentin,14-24	DrugDDI.d536.s32.e0
on,25-27
cimetidine,28-38	DrugDDI.d536.s32.e1
was,39-42
not,43-46
evaluated.,47-57

Oral,0-4	DrugDDI.d536.s33.e0
Contraceptive:,5-19	DrugDDI.d536.s33.e0
Based,20-25
on,26-28
AUC,29-32
and,33-36
half-life,,37-47
multiple-dose,48-61
pharmacokinetic,62-77
profiles,78-86
of,87-89
norethindrone,90-103	DrugDDI.d536.s33.e1
and,104-107
ethinyl,108-115	DrugDDI.d536.s33.e2
estradiol,116-125	DrugDDI.d536.s33.e2
following,126-135
administration,136-150
of,151-153
tablets,154-161
containing,162-172
2.5,173-176
mg,177-179
of,180-182
norethindrone,183-196	DrugDDI.d536.s33.e3
acetate,197-204	DrugDDI.d536.s33.e3
and,205-208
50,209-211
mcg,212-215
of,216-218
ethinyl,219-226	DrugDDI.d536.s33.e4
estradiol,227-236	DrugDDI.d536.s33.e4
were,237-241
similar,242-249
with,250-254
and,255-258
without,259-266
coadministration,267-283
of,284-286
gabapentin,287-297	DrugDDI.d536.s33.e5
(400,298-302
mg,303-305
TID;,306-310

The,0-3
Cmax,4-8
of,9-11
norethindrone,12-25	DrugDDI.d536.s35.e0
was,26-29
13%,30-33
higher,34-40
when,41-45
it,46-48
was,49-52
coadministered,53-67
with,68-72
gabapentin;,73-84	DrugDDI.d536.s35.e1

Antacid,0-7	DrugDDI.d536.s37.e0
(Maalox?):,8-18
Maalox,19-25
reduced,26-33
the,34-37
bioavailability,38-53
of,54-56
gabapentin,57-67	DrugDDI.d536.s37.e2
(N=16),68-74
by,75-77
about,78-83
20%.,84-88

This,0-4
decrease,5-13
in,14-16
bioavailability,17-32
was,33-36
about,37-42
5%,43-45
when,46-50
gabapentin,51-61	DrugDDI.d536.s38.e0
was,62-65
administered,66-78
2,79-80
hours,81-86
after,87-92
Maalox.,93-100	DrugDDI.d536.s38.e1

It,0-2
is,3-5
recommended,6-17
that,18-22
gabapentin,23-33	DrugDDI.d536.s39.e0
be,34-36
taken,37-42
at,43-45
least,46-51
2,52-53
hours,54-59
following,60-69
Maalox,70-76	DrugDDI.d536.s39.e1
administration.,77-92

Effect,0-6
of,7-9
Probenecid:,10-21	DrugDDI.d536.s40.e0
Probenecid,22-32	DrugDDI.d536.s40.e1
is,33-35
a,36-37
blocker,38-45
of,46-48
renal,49-54
tubular,55-62
secretion.,63-73

Gabapentin,0-10	DrugDDI.d536.s41.e0
pharmacokinetic,11-26
parameters,27-37
without,38-45
and,46-49
with,50-54
probenecid,55-65	DrugDDI.d536.s41.e1
were,66-70
comparable.,71-82

This,0-4
indicates,5-14
that,15-19
gabapentin,20-30	DrugDDI.d536.s42.e0
does,31-35
not,36-39
undergo,40-47
renal,48-53
tubular,54-61
secretion,62-71
by,72-74
the,75-78
pathway,79-86
that,87-91
is,92-94
blocked,95-102
by,103-105
probenecid.,106-117	DrugDDI.d536.s42.e1

Drug/Laboratory,0-15	DrugDDI.d536.s43.e0
Tests,16-21
Interactions,22-34
Because,35-42
false,43-48
positive,49-57
readings,58-66
were,67-71
reported,72-80
with,81-85
the,86-89
Ames,90-94	DrugDDI.d536.s43.e1
N-Multistix,95-106
SG,107-109
span,110-114
class=,115-121
c11,122-125
?,126-127
dipstick,128-136
test,137-141
for,142-145
urinary,146-153
protein,154-161
when,162-166
gabapentin,167-177	DrugDDI.d536.s43.e2
was,178-181
added,182-187
to,188-190
other,191-196
antiepileptic,197-210	DrugDDI.d536.s43.e3
drugs,,211-217	DrugDDI.d536.s43.e3
the,218-221
more,222-226
specific,227-235
sulfosalicylic,236-250
acid,251-255
precipitation,256-269
procedure,270-279
is,280-282
recommended,283-294
to,295-297
determine,298-307
the,308-311
presence,312-320
of,321-323
urine,324-329	DrugDDI.d536.s43.e4
protein,330-337	DrugDDI.d536.s43.e4

No,0-2
drug,3-7
interactions,8-20
have,21-25
been,26-30
observed,31-39
with,40-44
the,45-48
Vitrasert,49-58	DrugDDI.d78.s0.e0
Implant.,59-67

There,0-5
is,6-8
limited,9-16
experience,17-27
with,28-32
use,33-36
of,37-39
retinal,40-47
tamponades,48-58
in,59-61
conjunction,62-73
with,74-78
the,79-82
Vitrasert,83-92	DrugDDI.d78.s1.e0
Implant.,93-101

Substances,0-10
that,11-15
are,16-19
inducers,20-28
of,29-31
CYP3A4,32-38	DrugDDI.d248.s0.e0
activity,39-47
increase,48-56
the,57-60
metabolism,61-71
of,72-74
gefitinib,75-84	DrugDDI.d248.s0.e1
and,85-88
decrease,89-97
its,98-101
plasma,102-108
concentrations.,109-124

In,0-2
patients,3-11
receiving,12-21
a,22-23
potent,24-30
CYP3A4,31-37	DrugDDI.d248.s1.e0
inducer,38-45
such,46-50
as,51-53
rifampicin,54-64	DrugDDI.d248.s1.e1
or,65-67
phenytoin,,68-78
a,79-80
dose,81-85
increase,86-94
to,95-97
500,98-101
mg,102-104
daily,105-110
should,111-117
be,118-120
considered,121-131
in,132-134
the,135-138
absence,139-146
of,147-149
severe,150-156
adverse,157-164
drug,165-169
reaction,,170-179
and,180-183
clinical,184-192
response,193-201
and,202-205
adverse,206-213
events,214-220
should,221-227
be,228-230
carefully,231-240
monitored,241-250
(see,251-255
CLINICAL,256-264
PHARMACOLOGY-Pharmacokinetics-Drug-Drug,265-304
Interactions,305-317
and,318-321
DOSAGE,322-328
AND,329-332
ADMINISTRATION-Dosage,333-354
Adjustment,355-365
sections).,366-376

International,0-13
Normalized,14-24
Ratio,25-30
(INR),31-36
elevations,37-47
and/or,48-54
bleeding,55-63
events,64-70
have,71-75
been,76-80
reported,81-89
in,90-92
some,93-97
patients,98-106
taking,107-113
warfarin,114-122	DrugDDI.d248.s2.e0
while,123-128
on,129-131
IRESSA,132-138	DrugDDI.d248.s2.e1
therapy.,139-147

Patients,0-8
taking,9-15
warfarin,16-24	DrugDDI.d248.s3.e0
should,25-31
be,32-34
monitored,35-44
regularly,45-54
for,55-58
changes,59-66
in,67-69
prothrombin,70-81
time,82-86
or,87-89
INR.,90-94

Substances,0-10
that,11-15
are,16-19
potent,20-26
inhibitors,27-37
of,38-40
CYP3A4,41-47	DrugDDI.d248.s4.e0
activity,48-56
(eg,,57-61
ketoconazole,62-74	DrugDDI.d248.s4.e1
and,75-78
itraconazole),79-92	DrugDDI.d248.s4.e2
decrease,93-101
gefitinib,102-111	DrugDDI.d248.s4.e3
metabolism,112-122
and,123-126
increase,127-135
gefitinib,136-145	DrugDDI.d248.s4.e4
plasma,146-152
concentrations.,153-168

therefore,,0-10
caution,11-18
should,19-25
be,26-28
used,29-33
when,34-38
administering,39-52
CYP3A4,53-59	DrugDDI.d248.s6.e0
inhibitors,60-70
with,71-75
IRESSA.,76-83	DrugDDI.d248.s6.e1

Drugs,0-5	DrugDDI.d248.s7.e0
that,6-10
cause,11-16
significant,17-28
sustained,29-38
elevation,39-48
in,49-51
gastric,52-59
pH,60-62
(histamine,63-73
H2-receptor,74-85
antagonists,86-97
such,98-102
as,103-105
ranitidine,106-116	DrugDDI.d248.s7.e2
or,117-119
cimetidine),120-131	DrugDDI.d248.s7.e3
may,132-135
reduce,136-142
plasma,143-149
concentrations,150-164
of,165-167
IRESSA,168-174	DrugDDI.d248.s7.e4
and,175-178
therefore,179-188
potentially,189-200
may,201-204
reduce,205-211
efficacy.,212-221

Phase,0-5
II,6-8
clinical,9-17
trial,18-23
data,,24-29
where,30-35
IRESSA,36-42	DrugDDI.d248.s8.e0
and,43-46
vinorelbine,47-58	DrugDDI.d248.s8.e1
have,59-63
been,64-68
used,69-73
concomitantly,,74-88
indicate,89-97
that,98-102
IRESSA,103-109	DrugDDI.d248.s8.e2
may,110-113
exacerbate,114-124
the,125-128
neutropenic,129-140
effect,141-147
of,148-150
vinorelbine.,151-163	DrugDDI.d248.s8.e3

For,0-3
information,4-15
on,16-18
the,19-22
pharmacokinetics,23-39
of,40-42
Gemzar,43-49	DrugDDI.d224.s1.e0
and,50-53
cisplatin,54-63	DrugDDI.d224.s1.e1
in,64-66
combination,,67-79
see,80-83
Drug,84-88
Interactions,89-101
under,102-107
CLINICAL,108-116
PHARMACOLOGY,117-129
section.,130-138

increased,0-9
creatine,10-18	DrugDDI.d567.s4.e0

phosphokinase,0-13	DrugDDI.d567.s7.e0

antibody,0-8	DrugDDI.d567.s8.e0

increased,0-9
bilirubin,10-19	DrugDDI.d567.s10.e0

increased,0-9
liver,10-15	DrugDDI.d567.s13.e0

transaminases,0-13	DrugDDI.d567.s16.e0
(AST,14-18

Administration,0-14
of,15-17
repeat,18-24
doses,25-30
of,31-33
FACTIVE,34-41	DrugDDI.d341.s0.e0
had,42-45
no,46-48
effect,49-55
on,56-58
the,59-62
repeat,63-69
dose,70-74
pharmacokinetics,75-91
of,92-94
theophylline,,95-108
digoxin,109-116	DrugDDI.d341.s0.e2
or,117-119
an,120-122
ethinylestradiol/levonorgestrol,123-154	DrugDDI.d341.s0.e3
oral,155-159	DrugDDI.d341.s0.e4
contraceptive,160-173	DrugDDI.d341.s0.e4
product,174-181
in,182-184
healthy,185-192
subjects.,193-202

Concomitant,0-11
administration,12-26
of,27-29
FACTIVE,30-37	DrugDDI.d341.s1.e0
and,38-41
calcium,42-49	DrugDDI.d341.s1.e1
carbonate,,50-60	DrugDDI.d341.s1.e1
cimetidine,,61-72
omeprazole,,73-84
or,85-87
an,88-90
estrogen/progesterone,91-112	DrugDDI.d341.s1.e4
oral,113-117
contraceptive,118-131
produced,132-140
minor,141-146
changes,147-154
in,155-157
the,158-161
pharmacokinetics,162-178
of,179-181
gemifloxacin,,182-195
which,196-201
were,202-206
considered,207-217
to,218-220
be,221-223
without,224-231
clinical,232-240
significance.,241-254

Concomitant,0-11
administration,12-26
of,27-29
FACTIVE,30-37	DrugDDI.d341.s2.e0
with,38-42
probenecid,43-53	DrugDDI.d341.s2.e1
resulted,54-62
in,63-65
a,66-67
45%,68-71
increase,72-80
in,81-83
systemic,84-92
exposure,93-101
to,102-104
gemifloxacin.,105-118	DrugDDI.d341.s2.e2

FACTIVE,0-7	DrugDDI.d341.s3.e0
had,8-11
no,12-14
significant,15-26
effect,27-33
on,34-36
the,37-40
anticoagulant,41-54
effect,55-61
of,62-64
warfarin,65-73	DrugDDI.d341.s3.e1
in,74-76
healthy,77-84
subjects,85-93
on,94-96
stable,97-103
warfarin,104-112	DrugDDI.d341.s3.e2
therapy.,113-121

However,,0-8
because,9-16
some,17-21
quinolones,22-32	DrugDDI.d341.s4.e0
have,33-37
been,38-42
reported,43-51
to,52-54
enhance,55-62
the,63-66
anticoagulant,67-80
effects,81-88
of,89-91
warfarin,92-100	DrugDDI.d341.s4.e1
or,101-103
its,104-107
derivatives,108-119	DrugDDI.d341.s4.e2
in,120-122
patients,,123-132
the,133-136
prothrombin,137-148
time,149-153
or,154-156
other,157-162
suitable,163-171
coagulation,172-183
test,184-188
should,189-195
be,196-198
closely,199-206
monitored,207-216
if,217-219
a,220-221
quinolone,222-231	DrugDDI.d341.s4.e3
antimicrobial,232-245	DrugDDI.d341.s4.e3
is,246-248
administered,249-261
concomitantly,262-275
with,276-280
warfarin,281-289	DrugDDI.d341.s4.e4
or,290-292
its,293-296
derivatives.,297-309	DrugDDI.d341.s4.e5

Quinolones,0-10	DrugDDI.d341.s5.e0
form,11-15
chelates,16-24
with,25-29
alkaline,30-38
earth,39-44
and,45-48
transition,49-59
metals.,60-67

The,0-3
absorption,4-14
of,15-17
oral,18-22
gemifloxacin,23-35	DrugDDI.d341.s6.e0
is,36-38
significantly,39-52
reduced,53-60
by,61-63
the,64-67
concomitant,68-79
administration,80-94
of,95-97
an,98-100
antacid,101-108	DrugDDI.d341.s6.e1
containing,109-119
aluminum,120-128
and,129-132
magnesium.,133-143	DrugDDI.d341.s6.e2

Magnesium-,0-10	DrugDDI.d341.s7.e0
and/or,11-17
aluminum-containing,18-37	DrugDDI.d341.s7.e1
antacids,,38-47	DrugDDI.d341.s7.e1
products,48-56
containing,57-67
ferrous,68-75	DrugDDI.d341.s7.e2
sulfate,76-83	DrugDDI.d341.s7.e2
(iron),,84-91
multivitamin,92-104	DrugDDI.d341.s7.e4
preparations,105-117	DrugDDI.d341.s7.e4
containing,118-128
zinc,129-133	DrugDDI.d341.s7.e5
or,134-136
other,137-142
metal,143-148
cations,,149-157
or,158-160
Videx,161-166	DrugDDI.d341.s7.e7
(didanosine),167-179
chewable/buffered,180-197
tablets,198-205
or,206-208
the,209-212
pediatric,213-222	DrugDDI.d341.s7.e10
powder,223-229
for,230-233
oral,234-238
solution,239-247
should,248-254
not,255-258
be,259-261
taken,262-267
within,268-274
3,275-276
hours,277-282
before,283-289
or,290-292
2,293-294
hours,295-300
after,301-306
FACTIVE.,307-315	DrugDDI.d341.s7.e11

Sucralfate,0-10	DrugDDI.d341.s8.e0
should,11-17
not,18-21
be,22-24
taken,25-30
within,31-37
2,38-39
hours,40-45
of,46-48
FACTIVE.,49-57	DrugDDI.d341.s8.e1

There,0-5
have,6-10
been,11-15
no,16-18
formal,19-25
drug-interaction,26-42
studies,43-50
performed,51-60
with,61-65
Mylotarg.,66-75	DrugDDI.d238.s0.e0

The,0-3
potential,4-13
for,14-17
drug-drug,18-27
interaction,28-39
with,40-44
drugs,45-50	DrugDDI.d238.s1.e0
affected,51-59
by,60-62
cytochrome,63-73	DrugDDI.d238.s1.e1
P450,74-78	DrugDDI.d238.s1.e1
enzymes,79-86
may,87-90
not,91-94
be,95-97
ruled,98-103
out.,104-108

Mylotarg,0-8	DrugDDI.d238.s3.e0
is,9-11
not,12-15
known,16-21
to,22-24
interfere,25-34
with,35-39
any,40-43
routine,44-51
diagnostic,52-62
tests.,63-69

Interactions,0-12
between,13-20
COPAXONE?,21-30
and,31-34
other,35-40
drugs,41-46	DrugDDI.d84.s0.e0
have,47-51
not,52-55
been,56-60
fully,61-66
evaluated.,67-77

Results,0-7
from,8-12
existing,13-21
clinical,22-30
trials,31-37
suggest,38-45
no,46-48
significant,49-60
interactions,61-73
between,74-81
COPAXONE?,82-91
and,92-95
other,96-101
therapies,102-111
commonly,112-120
used,121-125
in,126-128
MS,129-131
patients,,132-141
including,142-151
the,152-155
concurrent,156-166
use,167-170
of,171-173
corticosteroids,174-189	DrugDDI.d84.s1.e0
for,190-193
up,194-196
to,197-199
28,200-202
days.,203-208

COPAXONE?,0-9
has,10-13
not,14-17
been,18-22
formally,23-31
evaluated,32-41
in,42-44
combination,45-56
with,57-61
Interferon,62-72	DrugDDI.d84.s2.e0
beta.,73-78	DrugDDI.d84.s2.e0

However,,0-8
10,9-11
patients,12-20
who,21-24
switched,25-33
from,34-38
therapy,39-46
with,47-51
Interferon,52-62	DrugDDI.d84.s3.e0
beta,63-67	DrugDDI.d84.s3.e0
to,68-70
COPAXONE?,71-80
did,81-84
not,85-88
report,89-95
any,96-99
serious,100-107
and,108-111
unexpected,112-122
adverse,123-130
reactions,131-140
thought,141-148
to,149-151
be,152-154
related,155-162
to,163-165
treatment.,166-176

The,0-3
hypoglycemic,4-16	DrugDDI.d415.s0.e0
action,17-23	DrugDDI.d415.s0.e0
of,24-26
sulfonylureas,27-40	DrugDDI.d415.s0.e1
may,41-44
be,45-47
potentiated,48-59
by,60-62
certain,63-70
drugs,71-76	DrugDDI.d415.s0.e2
including,77-86
nonsteroidal,87-99	DrugDDI.d415.s0.e3
anti-inflammatory,100-117	DrugDDI.d415.s0.e3
agents,118-124	DrugDDI.d415.s0.e3
and,125-128
other,129-134
drugs,135-140	DrugDDI.d415.s0.e4
that,141-145
are,146-149
highly,150-156
protein,157-164	DrugDDI.d415.s0.e5
bound,,165-171
salicylates,,172-184
sulfonamides,,185-198
chloramphenicol,,199-215
probenecid,,216-227
coumarins,,228-238
monoamine,239-248	DrugDDI.d415.s0.e11
oxidase,249-256	DrugDDI.d415.s0.e11
inhibitors,,257-268	DrugDDI.d415.s0.e11
and,269-272
beta,273-277	DrugDDI.d415.s0.e12
adrenergic,278-288	DrugDDI.d415.s0.e12
blocking,289-297	DrugDDI.d415.s0.e12
agents.,298-305	DrugDDI.d415.s0.e12

When,0-4
such,5-9
drugs,10-15	DrugDDI.d415.s1.e0
are,16-19
administered,20-32
to,33-35
a,36-37
patient,38-45
receiving,46-55
MICRONASE,,56-66
the,67-70
patient,71-78
should,79-85
be,86-88
observed,89-97
closely,98-105
for,106-109
hypoglycemia.,110-123

When,0-4
such,5-9
drugs,10-15	DrugDDI.d415.s2.e0
are,16-19
withdrawn,20-29
from,30-34
a,35-36
patient,37-44
receiving,45-54
MICRONASE,,55-65
the,66-69
patient,70-77
should,78-84
be,85-87
observed,88-96
closely,97-104
for,105-108
loss,109-113
of,114-116
control.,117-125

Certain,0-7
drugs,8-13	DrugDDI.d415.s3.e0
tend,14-18
to,19-21
produce,22-29
hyperglycemia,30-43
and,44-47
may,48-51
lead,52-56
to,57-59
loss,60-64
of,65-67
control.,68-76

These,0-5
drugs,6-11	DrugDDI.d415.s4.e0
include,12-19
the,20-23
thiazides,24-33	DrugDDI.d415.s4.e1
and,34-37
other,38-43
diuretics,,44-54
corticosteroids,,55-71
phe-nothiazines,,72-88
thyroid,89-96	DrugDDI.d415.s4.e5
products,,97-106
estrogens,,107-117
oral,118-122	DrugDDI.d415.s4.e7
contraceptives,,123-138	DrugDDI.d415.s4.e7
phenytoin,,139-149
nicotinic,150-159	DrugDDI.d415.s4.e9
acid,,160-165	DrugDDI.d415.s4.e9
sympathomimet-ics,,166-184
calcium,185-192	DrugDDI.d415.s4.e10
channel,193-200	DrugDDI.d415.s4.e10
blocking,201-209	DrugDDI.d415.s4.e10
drugs,,210-216	DrugDDI.d415.s4.e10
and,217-220
isoniazid.,221-231	DrugDDI.d415.s4.e11

When,0-4
such,5-9
drugs,10-15	DrugDDI.d415.s5.e0
are,16-19
administered,20-32
to,33-35
a,36-37
patient,38-45
receiving,46-55
MICRONASE,,56-66
the,67-70
patient,71-78
should,79-85
be,86-88
closely,89-96
observed,97-105
for,106-109
loss,110-114
of,115-117
control.,118-126

When,0-4
such,5-9
drugs,10-15	DrugDDI.d415.s6.e0
are,16-19
withdrawn,20-29
from,30-34
a,35-36
patient,37-44
receiving,45-54
MICRONASE,,55-65
the,66-69
patient,70-77
should,78-84
be,85-87
observed,88-96
closely,97-104
for,105-108
hypoglycemia.,109-122

A,0-1
possible,2-10
interaction,11-22
between,23-30
glyburide,31-40	DrugDDI.d415.s7.e0
and,41-44
ciprofloxacin,,45-59
a,60-61
fluoroquinolone,62-77	DrugDDI.d415.s7.e2
antibiotic,,78-89	DrugDDI.d415.s7.e2
has,90-93
been,94-98
reported,,99-108
resulting,109-118
in,119-121
a,122-123
potentiation,124-136
of,137-139
the,140-143
hypoglycemic,144-156	DrugDDI.d415.s7.e3
action,157-163	DrugDDI.d415.s7.e3
of,164-166
glyburide.,167-177	DrugDDI.d415.s7.e4

A,0-1
potential,2-11
interaction,12-23
between,24-31
oral,32-36	DrugDDI.d415.s9.e0
miconazole,37-47	DrugDDI.d415.s9.e0
and,48-51
oral,52-56
hypoglycemic,57-69	DrugDDI.d415.s9.e1
agents,70-76	DrugDDI.d415.s9.e1
leading,77-84
to,85-87
severe,88-94
hypoglycemia,95-107
has,108-111
been,112-116
reported.,117-126

Whether,0-7
this,8-12
interaction,13-24
also,25-29
occurs,30-36
with,37-41
the,42-45
intravenous,,46-58
topical,59-66
or,67-69
vaginal,70-77
preparations,78-90
of,91-93
miconazole,94-104	DrugDDI.d415.s10.e0
is,105-107
not,108-111
known.,112-118

Metformin:,0-10	DrugDDI.d415.s11.e0
In,11-13
a,14-15
single-dose,16-27
interaction,28-39
study,40-45
in,46-48
NIDDM,49-54
subjects,,55-64
decreases,65-74
in,75-77
glyburide,78-87	DrugDDI.d415.s11.e1
AUC,88-91
and,92-95
Cmax,96-100
were,101-105
observed,,106-115
but,116-119
were,120-124
highly,125-131
variable.,132-141

The,0-3
single-dose,4-15
nature,16-22
of,23-25
this,26-30
study,31-36
and,37-40
the,41-44
lack,45-49
of,50-52
correlation,53-64
between,65-72
glyburide,73-82	DrugDDI.d415.s12.e0
blood,83-88
levels,89-95
and,96-99
pharmaco-dynamic,100-116
effects,,117-125
makes,126-131
the,132-135
clinical,136-144
significance,145-157
of,158-160
this,161-165
interaction,166-177
uncertain.,178-188

Coadministration,0-16
of,17-19
gly-buride,20-30	DrugDDI.d415.s13.e0
and,31-34
metformin,35-44	DrugDDI.d415.s13.e1
did,45-48
not,49-52
result,53-59
in,60-62
any,63-66
changes,67-74
in,75-77
either,78-84
metformin,85-94	DrugDDI.d415.s13.e2
pharmacokinetics,95-111
or,112-114
pharmaco-dynamics.,115-133

Many,0-4
other,5-10
medicines,11-20	DrugDDI.d176.s0.e0
may,21-24
increase,25-33
or,34-36
decrease,37-45
the,46-49
effects,50-57
of,58-60
glimepiride,61-72	DrugDDI.d176.s0.e1
or,73-75
affect,76-82
your,83-87
condition.,88-98

Before,0-6
taking,7-13
glimepiride,,14-26
tell,27-31
your,32-36
doctor,37-43
if,44-46
you,47-50
are,51-54
taking,55-61
any,62-65
of,66-68
the,69-72
following,73-82
medicines:,83-93	DrugDDI.d176.s1.e1
-,94-95
aspirin,96-103	DrugDDI.d176.s1.e2
or,104-106
another,107-114
salicylate,115-125	DrugDDI.d176.s1.e3
such,126-130
as,131-133
magnesium/choline,134-151	DrugDDI.d176.s1.e4
salicylate,152-162
(Trilisate),,163-175
salsalate,176-185	DrugDDI.d176.s1.e7
(Disalcid,,186-196
others),,197-205
choline,206-213	DrugDDI.d176.s1.e9
salicylate,214-224	DrugDDI.d176.s1.e9
(Arthropan),,225-237
magnesium,238-247	DrugDDI.d176.s1.e11
salicylate,248-258	DrugDDI.d176.s1.e11
(Magan),,259-267
or,268-270
bismuth,271-278	DrugDDI.d176.s1.e13
subsalicylate,279-292	DrugDDI.d176.s1.e13
(Pepto-Bismol);,293-308

-,0-1
a,2-3
nonsteroidal,4-16	DrugDDI.d176.s2.e0
anti-inflammatory,17-34	DrugDDI.d176.s2.e0
drug,35-39	DrugDDI.d176.s2.e0
(NSAID),40-47
such,48-52
as,53-55
ibuprofen,56-65	DrugDDI.d176.s2.e2
(Motrin,,66-74
Advil,,75-81
Nuprin,,82-89
others),,90-98
ketoprofen,99-109	DrugDDI.d176.s2.e6
(Orudis,,110-118
Orudis,119-125	DrugDDI.d176.s2.e8
KT,,126-129	DrugDDI.d176.s2.e8
Oruvail),,130-139
diclofenac,140-150	DrugDDI.d176.s2.e10
(Voltaren,,151-161
Cataflam),,162-172
etodolac,173-181	DrugDDI.d176.s2.e13
(Lodine),,182-191
indomethacin,192-204	DrugDDI.d176.s2.e15
(Indocin),,205-215
nabumetone,216-226	DrugDDI.d176.s2.e17
(Relafen),,227-237
oxaprozin,238-247	DrugDDI.d176.s2.e19
(Daypro),,248-257
and,258-261
naproxen,262-270	DrugDDI.d176.s2.e21
(Anaprox,,271-280
Naprosyn,,281-290
Aleve);,291-298	DrugDDI.d176.s2.e24

-,0-1
a,2-3
sulfa-based,4-15	DrugDDI.d176.s3.e0
drug,16-20	DrugDDI.d176.s3.e0
such,21-25
as,26-28
sulfamethoxazole-trimethoprim,29-58	DrugDDI.d176.s3.e1
(Bactrim,,59-68
Septra),,69-77
sulfisoxazole,78-91	DrugDDI.d176.s3.e4
(Gantrisin),,92-104
or,105-107
sulfasalazine,108-121	DrugDDI.d176.s3.e6
(Azulfidine);,122-135

-,0-1
a,2-3
monoamine,4-13	DrugDDI.d176.s4.e0
oxidase,14-21	DrugDDI.d176.s4.e0
inhibitor,22-31	DrugDDI.d176.s4.e0
(MAOI),32-38
such,39-43
as,44-46
isocarboxazid,47-60	DrugDDI.d176.s4.e1
(Marplan),,61-71
tranylcypromine,72-87	DrugDDI.d176.s4.e3
(Parnate),,88-98
or,99-101
phenelzine,102-112	DrugDDI.d176.s4.e5
(Nardil);,113-122

-,0-1
a,2-3
beta-blocker,4-16	DrugDDI.d176.s5.e0
such,17-21
as,22-24
propranolol,25-36	DrugDDI.d176.s5.e1
(Inderal),,37-47
atenolol,48-56	DrugDDI.d176.s5.e3
(Tenormin),,57-68
acebutolol,69-79	DrugDDI.d176.s5.e5
(Sectral),,80-90
metoprolol,91-101	DrugDDI.d176.s5.e7
(Lopressor),,102-114
and,115-118
others;,119-126

-,0-1
a,2-3
diuretic,4-12	DrugDDI.d176.s6.e0
(water,13-19
pill),20-25
such,26-30
as,31-33
hydrochlorothiazide,34-53	DrugDDI.d176.s6.e2
(HCTZ,,54-60
Hydrodiuril),,61-74
chlorothiazide,75-89	DrugDDI.d176.s6.e5
(Diuril),,90-99
and,100-103
others;,104-111

-,0-1
a,2-3
steroid,4-11	DrugDDI.d176.s7.e0
medicine,12-20	DrugDDI.d176.s7.e0
such,21-25
as,26-28
prednisone,29-39	DrugDDI.d176.s7.e1
(Deltasone,,40-51
Orasone,,52-60
others),,61-69
methylprednisolone,70-88	DrugDDI.d176.s7.e4
(Medrol,,89-97
others),,98-106
prednisolone,107-119	DrugDDI.d176.s7.e6
(Prelone,,120-129
Pediapred,,130-140
others),,141-149
and,150-153
others;,154-161

-,0-1
a,2-3
phenothiazine,4-17	DrugDDI.d176.s8.e0
such,18-22
as,23-25
chlorpromazine,26-40	DrugDDI.d176.s8.e1
(Thorazine),,41-53
fluphenazine,54-66	DrugDDI.d176.s8.e3
(Prolixin,,67-77
Permitil),,78-88
prochlorperazine,89-105	DrugDDI.d176.s8.e6
(Compazine),,106-118
promethazine,119-131	DrugDDI.d176.s8.e8
(Phenergan),,132-144
and,145-148
others;,149-156

-,0-1
phenytoin,2-11	DrugDDI.d176.s9.e0
(Dilantin);,12-23

-,0-1
isoniazid,2-11	DrugDDI.d176.s10.e0
(Nydrazid);,12-23

-,0-1
rifampin,2-10	DrugDDI.d176.s11.e0
(Rifadin,,11-20
Rifamate);,21-31	DrugDDI.d176.s11.e2

or,0-2
-,3-4
over-the-counter,5-21
cough,,22-28
cold,,29-34
allergy,,35-43
or,44-46
weight,47-53
loss,54-58
medications.,59-71	DrugDDI.d176.s12.e0

You,0-3
may,4-7
require,8-15
a,16-17
dosage,18-24
adjustment,25-35
or,36-38
special,39-46
monitoring,47-57
if,58-60
you,61-64
are,65-68
taking,69-75
any,76-79
of,80-82
the,83-86
medicines,87-96	DrugDDI.d176.s13.e0
listed,97-103
above.,104-110

Drugs,0-5	DrugDDI.d176.s14.e0
other,6-11
than,12-16
those,17-22
listed,23-29
here,30-34
may,35-38
also,39-43
interact,44-52
with,53-57
glimepiride,58-69	DrugDDI.d176.s14.e1
or,70-72
affect,73-79
your,80-84
condition.,85-95

Talk,0-4
to,5-7
your,8-12
doctor,13-19
and,20-23
pharmacist,24-34
before,35-41
taking,42-48
any,49-52
prescription,53-65
or,66-68
over-the-counter,69-85	DrugDDI.d176.s15.e0
medicines,,86-96	DrugDDI.d176.s15.e0
including,97-106
herbal,107-113
products.,114-123

Immediate,0-9
and,10-13
Extended,14-22	DrugDDI.d3.s0.e0
Release,23-30	DrugDDI.d3.s0.e0
Tablets,31-38	DrugDDI.d3.s0.e0
The,39-42
hypoglycemic,43-55
action,56-62
of,63-65
sulfonylureas,66-79	DrugDDI.d3.s0.e1
may,80-83
be,84-86
potentiated,87-98
by,99-101
certain,102-109
drugs,110-115	DrugDDI.d3.s0.e2
including,116-125
nonsteroidal,126-138	DrugDDI.d3.s0.e3
anti-inflammatory,139-156	DrugDDI.d3.s0.e3
agents,,157-164	DrugDDI.d3.s0.e3
some,165-169
azoles,170-176
and,177-180
other,181-186
drugs,187-192	DrugDDI.d3.s0.e4
that,193-197
are,198-201
highly,202-208
protein,209-216	DrugDDI.d3.s0.e5
bound,,217-223
salicylates,,224-236
sulfonamides,,237-250
chloramphenicol,,251-267
probenecid,,268-279
coumarins,,280-290
monoamine,291-300	DrugDDI.d3.s0.e11
oxidase,301-308	DrugDDI.d3.s0.e11
inhibitors,,309-320	DrugDDI.d3.s0.e11
and,321-324
beta,325-329	DrugDDI.d3.s0.e12
adrenergic,330-340	DrugDDI.d3.s0.e12
blocking,341-349	DrugDDI.d3.s0.e12
agents.,350-357	DrugDDI.d3.s0.e12

When,0-4
such,5-9
drugs,10-15	DrugDDI.d3.s1.e0
are,16-19
administered,20-32
to,33-35
a,36-37
patient,38-45
receiving,46-55
glipizide,,56-66
the,67-70
patient,71-78
should,79-85
be,86-88
observed,89-97
closely,98-105
for,106-109
hypoglycemia.,110-123

When,0-4
such,5-9
drugs,10-15	DrugDDI.d3.s2.e0
are,16-19
withdrawn,20-29
from,30-34
a,35-36
patient,37-44
receiving,45-54
glipizide,,55-65
the,66-69
patient,70-77
should,78-84
be,85-87
observed,88-96
closely,97-104
for,105-108
loss,109-113
of,114-116
control.,117-125

In,0-2
vitro,3-8
binding,9-16
studies,17-24
with,25-29
human,30-35
serum,36-41	DrugDDI.d3.s3.e0
proteins,42-50	DrugDDI.d3.s3.e0
indicate,51-59
that,60-64
glipizide,65-74	DrugDDI.d3.s3.e1
binds,75-80
differently,81-92
than,93-97
tolbutamide,98-109	DrugDDI.d3.s3.e2
and,110-113
does,114-118
not,119-122
interact,123-131
with,132-136
salicylate,137-147	DrugDDI.d3.s3.e3
or,148-150
dicumarol.,151-161	DrugDDI.d3.s3.e4

However,,0-8
caution,9-16
must,17-21
be,22-24
exercised,25-34
in,35-37
extrapolating,38-51
these,52-57
findings,58-66
to,67-69
the,70-73
clinical,74-82
situation,83-92
and,93-96
in,97-99
the,100-103
use,104-107
of,108-110
glipizide,111-120	DrugDDI.d3.s4.e0
with,121-125
these,126-131
drugs.,132-138	DrugDDI.d3.s4.e1

Certain,0-7
drugs,8-13	DrugDDI.d3.s5.e0
tend,14-18
to,19-21
produce,22-29
hyperglycemia,30-43
and,44-47
may,48-51
lead,52-56
to,57-59
loss,60-64
of,65-67
control.,68-76

These,0-5
drugs,6-11	DrugDDI.d3.s6.e0
include,12-19
the,20-23
thiazides,24-33	DrugDDI.d3.s6.e1
and,34-37
other,38-43
diuretics,,44-54
corticosteroids,,55-71
phenothiazines,,72-87
thyroid,88-95	DrugDDI.d3.s6.e5
products,,96-105
estrogens,,106-116
oral,117-121	DrugDDI.d3.s6.e7
contraceptives,,122-137	DrugDDI.d3.s6.e7
phenytoin,,138-148
nicotinic,149-158	DrugDDI.d3.s6.e9
acid,,159-164	DrugDDI.d3.s6.e9
sympathomimetics,,165-182
calcium,183-190	DrugDDI.d3.s6.e11
channel,191-198	DrugDDI.d3.s6.e11
blocking,199-207	DrugDDI.d3.s6.e11
drugs,,208-214	DrugDDI.d3.s6.e11
and,215-218
isoniazid.,219-229	DrugDDI.d3.s6.e12

When,0-4
such,5-9
drugs,10-15	DrugDDI.d3.s7.e0
are,16-19
administered,20-32
to,33-35
a,36-37
patient,38-45
receiving,46-55
glipizide,,56-66
the,67-70
patient,71-78
should,79-85
be,86-88
closely,89-96
observed,97-105
for,106-109
loss,110-114
of,115-117
control.,118-126

When,0-4
such,5-9
drugs,10-15	DrugDDI.d3.s8.e0
are,16-19
withdrawn,20-29
from,30-34
a,35-36
patient,37-44
receiving,45-54
glipizide,,55-65
the,66-69
patient,70-77
should,78-84
be,85-87
observed,88-96
closely,97-104
for,105-108
hypoglycemia.,109-122

A,0-1
potential,2-11
interaction,12-23
between,24-31
oral,32-36	DrugDDI.d3.s9.e0
miconazole,37-47	DrugDDI.d3.s9.e0
and,48-51
oral,52-56
hypoglycemic,57-69	DrugDDI.d3.s9.e1
agents,70-76	DrugDDI.d3.s9.e1
leading,77-84
to,85-87
severe,88-94
hypoglycemia,95-107
has,108-111
been,112-116
reported.,117-126

Whether,0-7
this,8-12
interaction,13-24
also,25-29
occurs,30-36
with,37-41
the,42-45
intravenous,,46-58
topical,,59-67
or,68-70
vaginal,71-78
preparations,79-91
of,92-94
miconazole,95-105	DrugDDI.d3.s10.e0
is,106-108
not,109-112
known.,113-119

The,0-3
effect,4-10
of,11-13
concomitant,14-25
administration,26-40
of,41-43
fluconazole,44-55	DrugDDI.d3.s11.e0
and,56-59
glipizide,60-69	DrugDDI.d3.s11.e1
has,70-73
been,74-78
demonstrated,79-91
in,92-94
a,95-96
placebo-controlled,97-115
crossover,116-125
study,126-131
in,132-134
normal,135-141
volunteers.,142-153

All,0-3
subjects,4-12
received,13-21
glipizide,22-31	DrugDDI.d3.s12.e0
alone,32-37
and,38-41
following,42-51
treatment,52-61
with,62-66
100,67-70
mg,71-73
of,74-76
fluconazole,77-88	DrugDDI.d3.s12.e1
as,89-91
a,92-93
single,94-100
daily,101-106
oral,107-111
dose,112-116
for,117-120
seven,121-126
days.,127-132

The,0-3
mean,4-8
percentage,9-19
increase,20-28
in,29-31
the,32-35
glipizide,36-45	DrugDDI.d3.s13.e0
AUC,46-49
after,50-55
fluconazole,56-67	DrugDDI.d3.s13.e1
administration,68-82
was,83-86
56.9%,87-92
(range:,93-100
35,101-103
to,104-106
81).,107-111

The,0-3
concurrent,4-14
use,15-18
of,19-21
Robinul,22-29	DrugDDI.d517.s0.e0
Injection,30-39
with,40-44
other,45-50
anticholinergics,51-67	DrugDDI.d517.s0.e1
or,68-70
medications,71-82	DrugDDI.d517.s0.e2
with,83-87
anticholinergic,88-103	DrugDDI.d517.s0.e3
activity,,104-113
such,114-118
as,119-121
phenothiazines,,122-137
antiparkinson,138-151	DrugDDI.d517.s0.e5
drugs,,152-158	DrugDDI.d517.s0.e5
or,159-161
tricyclic,162-171	DrugDDI.d517.s0.e6
antidepressants,,172-188	DrugDDI.d517.s0.e6
may,189-192
intensify,193-202
the,203-206
antimuscarinic,207-221	DrugDDI.d517.s0.e7
effects,222-229
and,230-233
may,234-237
result,238-244
in,245-247
an,248-250
increase,251-259
in,260-262
anticholinergic,263-278	DrugDDI.d517.s0.e8
side,279-283
effects.,284-292

Concomitant,0-11
administration,12-26
of,27-29
Robinul,30-37	DrugDDI.d517.s1.e0
Injection,38-47
and,48-51
potassium,52-61	DrugDDI.d517.s1.e1
chloride,62-70	DrugDDI.d517.s1.e1
in,71-73
a,74-75
wax,76-79	DrugDDI.d517.s1.e2
matrix,80-86
may,87-90
increase,91-99
the,100-103
severity,104-112
of,113-115
potassium,116-125	DrugDDI.d517.s1.e3
chloride-induced,126-142	DrugDDI.d517.s1.e3
gastrointestinal,143-159
lesions,160-167
as,168-170
a,171-172
result,173-179
of,180-182
a,183-184
slower,185-191
gastrointestinal,192-208
transit,209-216
time.,217-222

The,0-3
Factrel,4-11	DrugDDI.d226.s0.e0
test,12-16
should,17-23
be,24-26
conducted,27-36
in,37-39
the,40-43
absence,44-51
of,52-54
other,55-60
drugs,61-66	DrugDDI.d226.s0.e1
which,67-72
directly,73-81
affect,82-88
the,89-92
pituitary,93-102	DrugDDI.d226.s0.e2
secretion,103-112
of,113-115
the,116-119
gonadotropins.,120-134	DrugDDI.d226.s0.e3

These,0-5
would,6-11
include,12-19
a,20-21
variety,22-29
of,30-32
preparations,33-45
which,46-51
contain,52-59
androgens,,60-70
estrogens,,71-81
progestins,,82-93
or,94-96
glucocorticoids.,97-113

The,0-3
gonadotropin,4-16
levels,17-23
may,24-27
be,28-30
transiently,31-42
elevated,43-51
by,52-54
spironolactone,,55-70
minimally,71-80
elevated,81-89
by,90-92
levodopa,,93-102
and,103-106
suppressed,107-117
by,118-120
oral,121-125	DrugDDI.d226.s2.e2
contraceptives,126-140	DrugDDI.d226.s2.e2
and,141-144
digoxin.,145-153	DrugDDI.d226.s2.e3

The,0-3
response,4-12
to,13-15
Factrel,16-23	DrugDDI.d226.s3.e0
may,24-27
be,28-30
blunted,31-38
by,39-41
phenothiazines,42-56	DrugDDI.d226.s3.e1
and,57-60
dopamine,61-69	DrugDDI.d226.s3.e2
antagonists,70-81	DrugDDI.d226.s3.e2
which,82-87
cause,88-93
a,94-95
rise,96-100
in,101-103
prolactin.,104-114	DrugDDI.d226.s3.e3

No,0-2
confirmed,3-12
interactions,13-25
have,26-30
been,31-35
reported,36-44
between,45-52
ZOLADEX,53-60	DrugDDI.d254.s1.e0
and,61-64
other,65-70
drugs,71-76	DrugDDI.d254.s1.e1

Antacids,,0-9
Sucralfate,,10-21
Metal,22-27
Cations,,28-36
Multivitamins,37-50	DrugDDI.d425.s0.e3
Quinolones,51-61
form,62-66
chelates,67-75
with,76-80
alkaline,81-89
earth,90-95
and,96-99
transition,100-110
metal,111-116
cations.,117-125	DrugDDI.d425.s0.e4

Administration,0-14
of,15-17
quinolones,18-28	DrugDDI.d425.s1.e0
with,29-33
antacids,34-42	DrugDDI.d425.s1.e1
containing,43-53
aluminum,,54-63
magnesium,,64-74
or,75-77
calcium,,78-86
with,87-91
sucralfate,,92-103
with,104-108
metal,109-114
cations,115-122	DrugDDI.d425.s1.e5
such,123-127
as,128-130
iron,,131-136
or,137-139
with,140-144
multivitamins,145-158	DrugDDI.d425.s1.e7
containing,159-169
iron,170-174	DrugDDI.d425.s1.e8
or,175-177
zinc,,178-183
or,184-186
with,187-191
formulations,192-204
containing,205-215
divalent,216-224
and,225-228
trivalent,229-238
cations,239-246	DrugDDI.d425.s1.e10
such,247-251
as,252-254
VIDEX,255-260	DrugDDI.d425.s1.e11
(didanosine),261-273
chewable/buffered,274-291
tablets,292-299
or,300-302
the,303-306
pediatric,307-316	DrugDDI.d425.s1.e14
powder,317-323
for,324-327
oral,328-332
solution,,333-342
may,343-346
substantially,347-360
interfere,361-370
with,371-375
the,376-379
absorption,380-390
of,391-393
quinolones,,394-405
resulting,406-415
in,416-418
systemic,419-427
concentrations,428-442
considerably,443-455
lower,456-461
than,462-466
desired.,467-475

These,0-5
agents,6-12
should,13-19
not,20-23
be,24-26
taken,27-32
within,33-39
4,40-41
hours,42-47
before,48-54
or,55-57
4,58-59
hours,60-65
after,66-71
grepafloxacin,72-85	DrugDDI.d425.s2.e0
administration.,86-101

Caffeine,0-8	DrugDDI.d425.s3.e0
Theobromine,9-20
Grepafloxacin,,21-35
like,36-40
other,41-46
quinolones,,47-58
may,59-62
inhibit,63-70
the,71-74
metabolism,75-85
of,86-88
caffeine,89-97	DrugDDI.d425.s3.e2
and,98-101
theobromine.,102-114	DrugDDI.d425.s3.e3

These,0-5
stimulants,6-16	DrugDDI.d425.s4.e0
are,17-20
commonly,21-29
found,30-35
in,36-38
coffee,39-45
and,46-49
tea,,50-54
respectively.,55-68

In,0-2
some,3-7
patients,,8-17
this,18-22
may,23-26
lead,27-31
to,32-34
reduced,35-42
clearance,,43-53
prolongation,54-66
of,67-69
plasma,70-76
half-life,,77-87
and,88-91
enhanced,92-100
effects,101-108
of,109-111
caffeine,112-120	DrugDDI.d425.s5.e0
and,121-124
theobromine.,125-137	DrugDDI.d425.s5.e1

Theophylline,0-12	DrugDDI.d425.s6.e0
Grepafloxacin,13-26
is,27-29
a,30-31
competitive,32-43
inhibitor,44-53
of,54-56
the,57-60
metabolism,61-71
of,72-74
theophylline.,75-88	DrugDDI.d425.s6.e1

Serum,0-5
theophylline,6-18	DrugDDI.d425.s7.e0
concentrations,19-33
increase,34-42
when,43-47
grepafloxacin,48-61	DrugDDI.d425.s7.e1
is,62-64
initiated,65-74
in,75-77
a,78-79
patient,80-87
maintained,88-98
on,99-101
theophylline.,102-115	DrugDDI.d425.s7.e2

When,0-4
initiating,5-15
a,16-17
multi-day,18-27	DrugDDI.d425.s8.e0
course,28-34
of,35-37
grepafloxacin,38-51	DrugDDI.d425.s8.e1
in,52-54
a,55-56
patient,57-64
maintained,65-75
on,76-78
theophylline,,79-92
the,93-96
theophylline,97-109
maintenance,110-121
dose,122-126
should,127-133
be,134-136
halved,137-143
for,144-147
the,148-151
period,152-158
of,159-161
concurrent,162-172
use,173-176
of,177-179
grepafloxacin,180-193	DrugDDI.d425.s8.e3
and,194-197
monitoring,198-208
of,209-211
serum,212-217
theophylline,218-230	DrugDDI.d425.s8.e4
concentrations,231-245
should,246-252
be,253-255
initiated,256-265
as,266-268
a,269-270
guide,271-276
to,277-279
further,280-287
dosage,288-294
adjustments.,295-307

Warfarin,0-8	DrugDDI.d425.s9.e0
In,9-11
subjects,12-20
receiving,21-30
warfarin,,31-40
no,41-43
significant,44-55
change,56-62
in,63-65
clotting,66-74
time,75-79
was,80-83
observed,84-92
when,93-97
grepafloxacin,98-111	DrugDDI.d425.s9.e2
was,112-115
coadministered.,116-131

However,,0-8
because,9-16
some,17-21
quinolones,22-32	DrugDDI.d425.s10.e0
have,33-37
been,38-42
reported,43-51
to,52-54
enhance,55-62
the,63-66
effects,67-74
of,75-77
warfarin,78-86	DrugDDI.d425.s10.e1
or,87-89
its,90-93
derivatives,,94-106
prothrombin,107-118
time,119-123
or,124-126
other,127-132
suitable,133-141
anticoagulation,142-157
test,158-162
should,163-169
be,170-172
monitored,173-182
closely,183-190
if,191-193
a,194-195
quinolone,196-205	DrugDDI.d425.s10.e3
antimicrobial,206-219	DrugDDI.d425.s10.e3
is,220-222
administered,223-235
with,236-240
warfarin,241-249	DrugDDI.d425.s10.e4
or,250-252
its,253-256
derivatives.,257-269	DrugDDI.d425.s10.e5

Drugs,0-5	DrugDDI.d425.s11.e0
Metabolized,6-17
by,18-20
Cytochrome,21-31	DrugDDI.d425.s11.e1
P450,32-36	DrugDDI.d425.s11.e1
Enzymes,37-44
The,45-48
drug,49-53
interaction,54-65
study,66-71
evaluating,72-82
the,83-86
effect,87-93
of,94-96
grepafloxacin,97-110	DrugDDI.d425.s11.e2
on,111-113
theophylline,114-126	DrugDDI.d425.s11.e3
indicates,127-136
that,137-141
grepafloxacin,142-155	DrugDDI.d425.s11.e4
inhibits,156-164
theophylline,165-177	DrugDDI.d425.s11.e5
metabolism,,178-189
which,190-195
is,196-198
mediated,199-207
by,208-210
CYP1A2.,211-218	DrugDDI.d425.s11.e6

While,0-5
no,6-8
clinical,9-17
studies,18-25
have,26-30
been,31-35
conducted,36-45
to,46-48
evaluate,49-57
the,58-61
effect,62-68
of,69-71
grepafloxacin,72-85	DrugDDI.d425.s12.e0
on,86-88
the,89-92
metabolism,93-103
of,104-106
C.P.A.,107-113

substrates,,0-11
in,12-14
vitro,15-20
data,21-25
suggest,26-33
similar,34-41
effects,42-49
of,50-52
grepafloxacin,53-66	DrugDDI.d425.s13.e0
in,67-69
CYP3A4,70-76	DrugDDI.d425.s13.e1
mediated,77-85
metabolism,86-96
and,97-100
theophylline,101-113	DrugDDI.d425.s13.e2
metabolism.,114-125

In,0-2
addition,,3-12
other,13-18
quinolones,19-29	DrugDDI.d425.s14.e0
have,30-34
been,35-39
reported,40-48
to,49-51
decrease,52-60
the,61-64
CYP3A4-mediated,65-80	DrugDDI.d425.s14.e1
metabolism,81-91
of,92-94
cyclosporine.,95-108	DrugDDI.d425.s14.e2

Other,0-5
drugs,6-11	DrugDDI.d425.s15.e0
metabolized,12-23
by,24-26
C.P.A.,27-33

include,0-7
terfenadine,,8-20
astemizole,,21-32
cisapride,,33-43
midazolam,,44-54
and,55-58
triazolam.,59-69	DrugDDI.d425.s16.e4

The,0-3
clinical,4-12
relevance,13-22
of,23-25
the,26-29
potential,30-39
effect,40-46
of,47-49
grepafloxacin,50-63	DrugDDI.d425.s17.e0
on,64-66
the,67-70
metabolism,71-81
of,82-84
C.P.A.,85-91
substrates,92-102
is,103-105
not,106-109
known.,110-116

Patients,0-8
receiving,9-18
concurrent,19-29
administration,30-44
of,45-47
substrates,48-58
of,59-61
C.P.A.,62-68
were,69-73
not,74-77
excluded,78-86
from,87-91
clinical,92-100
trials,101-107
of,108-110
grepafloxacin.,111-125	DrugDDI.d425.s18.e0

Nonsteroidal,0-12	DrugDDI.d425.s19.e0
Anti-inflammatory,13-30	DrugDDI.d425.s19.e0
Drugs,31-36	DrugDDI.d425.s19.e0
(NSAIDs),37-45
The,46-49
concomitant,50-61
administration,62-76
of,77-79
a,80-81
nonsteroidal,82-94	DrugDDI.d425.s19.e2
anti,95-99	DrugDDI.d425.s19.e2
inflammatory,100-112	DrugDDI.d425.s19.e2
drug,113-117	DrugDDI.d425.s19.e2
with,118-122
a,123-124
quinolone,125-134	DrugDDI.d425.s19.e3
may,135-138
increase,139-147
the,148-151
risks,152-157
of,158-160
CNS,161-164
stimulation,165-176
and,177-180
convulsions.,181-193

Antidiabetic,0-12	DrugDDI.d425.s20.e0
Agents,13-19	DrugDDI.d425.s20.e0
Disturbances,20-32
of,33-35
blood,36-41
glucose,,42-50
including,51-60
hyperglycemia,61-74
and,75-78
hypoglycemia,,79-92
have,93-97
been,98-102
reported,103-111
in,112-114
patients,115-123
treated,124-131
concomitantly,132-145
with,146-150
quinolones,151-161	DrugDDI.d425.s20.e1
and,162-165
an,166-168
antidiabetic,169-181	DrugDDI.d425.s20.e2
agent.,182-188	DrugDDI.d425.s20.e2

Patients,0-8
on,9-11
warfarin-type,12-25	DrugDDI.d295.s0.e0
anticoagulant,26-39
therapy,40-47
may,48-51
require,52-59
dosage,60-66
adjustment,67-77
of,78-80
the,81-84
anticoagulant,85-98	DrugDDI.d295.s0.e1
during,99-105
and,106-109
after,110-115
griseofulvin,116-128	DrugDDI.d295.s0.e2
therapy.,129-137

Concomitant,0-11
use,12-15
of,16-18
barbiturates,19-31	DrugDDI.d295.s1.e0
usually,32-39
depresses,40-49
griseofulvin,50-62	DrugDDI.d295.s1.e1
activity,63-71
and,72-75
may,76-79
necessitate,80-91
raising,92-99
the,100-103
dosage.,104-111

The,0-3
concomitant,4-15
administration,16-30
of,31-33
griseofulvin,34-46	DrugDDI.d295.s2.e0
has,47-50
been,51-55
reported,56-64
to,65-67
reduce,68-74
the,75-78
efficacy,79-87
of,88-90
oral,91-95	DrugDDI.d295.s2.e1
contraceptives,96-110	DrugDDI.d295.s2.e1
and,111-114
to,115-117
increase,118-126
the,127-130
incidence,131-140
of,141-143
breakthrough,144-156
bleeding.,157-166

The,0-3
use,4-7
of,8-10
codeine,11-18	DrugDDI.d182.s0.e0
may,19-22
result,23-29
in,30-32
additive,33-41
CNS,42-45	DrugDDI.d182.s0.e1
depressant,46-56	DrugDDI.d182.s0.e1
effects,57-64
when,65-69
coadministered,70-84
with,85-89
alcohol,,90-98
antihistamines,,99-114
psychotropics,115-128
or,129-131
other,132-137
drugs,138-143	DrugDDI.d182.s0.e4
that,144-148
produce,149-156
CNS,157-160
depression.,161-172

Serious,0-7
toxicity,8-16
may,17-20
result,21-27
if,28-30
dextromethorphan,31-47	DrugDDI.d182.s1.e0
is,48-50
coadministered,51-65
with,66-70
monoamine,71-80	DrugDDI.d182.s1.e1
oxidase,81-88	DrugDDI.d182.s1.e1
inhibitors,89-99	DrugDDI.d182.s1.e1
(MAOIs).,100-108

The,0-3
use,4-7
of,8-10
dextromethorphan,11-27	DrugDDI.d182.s2.e0
hydrobromide,28-40	DrugDDI.d182.s2.e0
may,41-44
result,45-51
in,52-54
additive,55-63
CNS,64-67	DrugDDI.d182.s2.e1
depressant,68-78	DrugDDI.d182.s2.e1
effects,79-86
when,87-91
coadministered,92-106
with,107-111
alcohol,,112-120
antihistamines,,121-136
psychotropics,137-150
or,151-153
other,154-159
drugs,160-165	DrugDDI.d182.s2.e4
that,166-170
produce,171-178
CNS,179-182
depression.,183-194

The,0-3
potential,4-13
for,14-17
increased,18-27
sedation,28-36
when,37-41
guanfacine,42-52	DrugDDI.d434.s0.e0
is,53-55
given,56-61
with,62-66
other,67-72
CNS-depressant,73-87	DrugDDI.d434.s0.e1
drug,88-92	DrugDDI.d434.s0.e1
should,93-99
be,100-102
appreciated.,103-115

The,0-3
administration,4-18
of,19-21
guanfacine,22-32	DrugDDI.d434.s1.e0
concomitantly,33-46
with,47-51
known,52-57
microsomal,58-68	DrugDDI.d434.s1.e1
enzyme,69-75	DrugDDI.d434.s1.e1
inducer,76-83
(phenobarbital,84-98
or,99-101
phenytoin),102-112	DrugDDI.d434.s1.e3
to,113-115
two,116-119
patients,120-128
with,129-133
renal,134-139
impairment,140-150
reportedly,151-161
resulted,162-170
in,171-173
significant,174-185
reductions,186-196
in,197-199
elimination,200-211
half-life,212-221
and,222-225
plasma,226-232
concentration.,233-247

Further,,0-8
if,9-11
guanfacine,12-22	DrugDDI.d434.s3.e0
is,23-25
to,26-28
be,29-31
discontinued,32-44
in,45-47
such,48-52
patients,,53-62
careful,63-70
tapering,71-79
of,80-82
the,83-86
dosage,87-93
may,94-97
be,98-100
necessary,101-110
in,111-113
order,114-119
to,120-122
avoid,123-128
rebound,129-136
phenomena.,137-147

TCAs,0-4
decrease,5-13
the,14-17
hypotensive,18-29
effect,30-36
of,37-39
guanfacine.,40-51	DrugDDI.d434.s4.e0

Noncardioselective,0-18	DrugDDI.d434.s5.e0
beta-blockers,19-32	DrugDDI.d434.s5.e0
(nadolol,porpranolol,timolol),33-62
may,63-66
exacerbate,67-77
rebound,78-85
hypertension,86-98
when,99-103
guanfacine,104-114	DrugDDI.d434.s5.e3
is,115-117
withdrawn.,118-128

The,0-3
beta-blocker,4-16	DrugDDI.d434.s6.e0
should,17-23
be,24-26
withdrawn,27-36
first.,37-43

The,0-3
gradual,4-11
withdrawal,12-22
of,23-25
guafacine,26-35
or,36-38
a,39-40
cardioselective,41-56	DrugDDI.d434.s7.e0
beta-blocker,57-69	DrugDDI.d434.s7.e0
could,70-75
be,76-78
substituted.,79-91

Anticoagulants,0-14	DrugDDI.d434.s8.e0
Ten,15-18
patients,19-27
who,28-31
were,32-36
stabilized,37-47
on,48-50
oral,51-55	DrugDDI.d434.s8.e1
anticoagulants,56-70	DrugDDI.d434.s8.e1
were,71-75
given,76-81
guanfacine,,82-93
1-2,94-97
mg/day,,98-105
for,106-109
4,110-111
weeks.,112-118

In,0-2
several,3-10
well-controlled,11-26
studies,,27-35
guanfacine,36-46	DrugDDI.d434.s10.e0
was,47-50
administered,51-63
together,64-72
with,73-77
diuretics,78-87	DrugDDI.d434.s10.e1
with,88-92
no,93-95
drug,96-100
interactions,101-113
reported.,114-123

In,0-2
the,3-6
long-term,7-16
safety,17-23
studies,,24-32
guanfacine,33-43	DrugDDI.d434.s11.e0
was,44-47
given,48-53
concomitantly,54-67
with,68-72
many,73-77
drugs,78-83	DrugDDI.d434.s11.e1
without,84-91
evidence,92-100
of,101-103
any,104-107
interactions.,108-121

The,0-3
principal,4-13
drugs,14-19	DrugDDI.d434.s12.e0
given,20-25
(number,26-33
of,34-36
patients,37-45
in,46-48
parentheses),49-61
were:,62-67
cardiac,68-75	DrugDDI.d434.s12.e1
glycosides,76-86	DrugDDI.d434.s12.e1
(115),,87-93
sedatives,94-103	DrugDDI.d434.s12.e2
and,104-107
hypnotics,108-117	DrugDDI.d434.s12.e3
(103),,118-124
coronary,125-133	DrugDDI.d434.s12.e4
vasodilators,134-146	DrugDDI.d434.s12.e4
(52),,147-152
oral,153-157	DrugDDI.d434.s12.e5
hypoglycemics,158-171	DrugDDI.d434.s12.e5
(45),,172-177
cough,178-183
and,184-187
cold,188-192
preparations,193-205
(45),,206-211
NSAIDs,212-218	DrugDDI.d434.s12.e6
(38),,219-224
antihyperlipidemics,225-244	DrugDDI.d434.s12.e7
(29),,245-250
antigout,251-259
drugs,260-265	DrugDDI.d434.s12.e8
(24),,266-271
oral,272-276	DrugDDI.d434.s12.e9
contraceptives,277-291	DrugDDI.d434.s12.e9
(18),,292-297
bronchodilators,298-313	DrugDDI.d434.s12.e10
(13),,314-319
insulin,320-327	DrugDDI.d434.s12.e11
(10),,328-333
and,334-337
beta,338-342	DrugDDI.d434.s12.e12
blockers,343-351	DrugDDI.d434.s12.e12
(10).,352-357

Laboratory,0-10
Test,11-15
In,16-18
clinical,19-27
trials,,28-35
no,36-38
clinically,39-49
relevant,50-58
laboratory,59-69
test,70-74
abnormalities,75-88
were,89-93
identified,94-104
as,105-107
causally,108-116
related,117-124
to,125-127
drug,128-132	DrugDDI.d434.s13.e0
during,133-139
short-term,140-150
treatment,151-160
with,161-165
guanfacine.,166-177	DrugDDI.d434.s13.e1

Drug/Laboratory,0-15	DrugDDI.d434.s14.e0
Test,16-20
Interactions,21-33
No,34-36
laboratory,37-47
test,48-52
abnormalities,53-66
related,67-74
to,75-77
the,78-81
use,82-85
of,86-88
guanfacine,89-99	DrugDDI.d434.s14.e1
have,100-104
been,105-109
identified.,110-121

An,0-2
encephalopathic,3-18
syndrome,19-27
(characterized,28-42
by,43-45
weakness,,46-55
lethargy,,56-65
fever,,66-72
tremulousness,73-86
and,87-90
confusion,,91-101
extrapyramidal,102-116
symptoms,,117-126
leukocytosis,,127-140
elevated,141-149
serum,150-155
enzymes,,156-164
BUN,,165-169
and,170-173
FBS),174-178
followed,179-187
by,188-190
irreversible,191-203
brain,204-209
damage,210-216
has,217-220
occurred,221-229
in,230-232
a,233-234
few,235-238
patients,239-247
treated,248-255
with,256-260
lithium,261-268	DrugDDI.d403.s0.e0
plus,269-273
HALDOL.,274-281	DrugDDI.d403.s0.e1

A,0-1
causal,2-8
relationship,9-21
between,22-29
these,30-35
events,36-42
and,43-46
the,47-50
concomitant,51-62
administration,63-77
of,78-80
lithium,81-88	DrugDDI.d403.s1.e0
and,89-92
HALDOL,93-99	DrugDDI.d403.s1.e1
has,100-103
not,104-107
been,108-112
established;,113-125

As,0-2
with,3-7
other,8-13
antipsychotic,14-27	DrugDDI.d403.s3.e0
agents,,28-35	DrugDDI.d403.s3.e0
it,36-38
should,39-45
be,46-48
noted,49-54
that,55-59
HALDOL,60-66	DrugDDI.d403.s3.e1
may,67-70
be,71-73
capable,74-81
of,82-84
potentiating,85-97
CNS,98-101	DrugDDI.d403.s3.e2
depressants,102-113	DrugDDI.d403.s3.e2
such,114-118
as,119-121
anesthetics,,122-134
opiates,,135-143
and,144-147
alcohol.,148-156	DrugDDI.d403.s3.e5

In,0-2
a,3-4
study,5-10
of,11-13
12,14-16
schizophrenic,17-30
patients,31-39
coadministered,40-54
oral,55-59	DrugDDI.d403.s4.e0
haloperidol,60-71	DrugDDI.d403.s4.e0
and,72-75
rifampin,,76-85
plasma,86-92
haloperidol,93-104	DrugDDI.d403.s4.e2
levels,105-111
were,112-116
decreased,117-126
by,127-129
a,130-131
mean,132-136
of,137-139
70%,140-143
and,144-147
mean,148-152
scores,153-159
on,160-162
the,163-166
Brief,167-172
Psychiatric,173-184
Rating,185-191
Scale,192-197
were,198-202
increased,203-212
from,213-217
baseline.,218-227

In,0-2
5,3-4
other,5-10
schizophrenic,11-24
patients,25-33
treated,34-41
with,42-46
oral,47-51	DrugDDI.d403.s5.e0
haloperidol,52-63	DrugDDI.d403.s5.e0
and,64-67
rifampin,,68-77
discontinuation,78-93
of,94-96
rifampin,97-105	DrugDDI.d403.s5.e2
produced,106-114
a,115-116
mean,117-121
3.3-fold,122-130
increase,131-139
in,140-142
haloperidol,143-154	DrugDDI.d403.s5.e3
concentrations.,155-170

Thus,,0-5
careful,6-13
monitoring,14-24
of,25-27
clinical,28-36
status,37-43
is,44-46
warranted,47-56
when,57-61
rifampin,62-70	DrugDDI.d403.s6.e0
is,71-73
administered,74-86
or,87-89
discontinued,90-102
in,103-105
haloperidol-treated,106-125	DrugDDI.d403.s6.e1
patients.,126-135

FLUOTHANE,0-9	DrugDDI.d197.s0.e0
augments,10-18
the,19-22
action,23-29
of,30-32
non-depolarising,33-49	DrugDDI.d197.s0.e1
muscle,50-56	DrugDDI.d197.s0.e1
relaxants,57-66	DrugDDI.d197.s0.e1
and,67-70
the,71-74
muscle,75-81	DrugDDI.d197.s0.e2
relaxant,82-90	DrugDDI.d197.s0.e2
effects,91-98
of,99-101
aminoglycosides.,102-118	DrugDDI.d197.s0.e3

FLUOTHANE,0-9	DrugDDI.d197.s1.e0
may,10-13
augment,14-21
the,22-25
hypotension,26-37
caused,38-44
by,45-47
the,48-51
ganglionic-blocking,52-71
effect,72-78
of,79-81
tubocurarine.,82-95	DrugDDI.d197.s1.e1

Caution,0-7
should,8-14
be,15-17
exercised,18-27
during,28-34
the,35-38
administration,39-53
of,54-56
adrenaline,57-67	DrugDDI.d197.s2.e0
to,68-70
patients,71-79
anaesthetised,80-93
with,94-98
FLUOTHANE,99-108	DrugDDI.d197.s2.e1
as,109-111
arrhythmias,112-123
may,124-127
be,128-130
precipitated.,131-144

For,0-3
this,4-8
reason,9-15
the,16-19
dose,20-24
of,25-27
adrenaline,28-38	DrugDDI.d197.s3.e0
should,39-45
be,46-48
restricted,49-59
and,60-63
an,64-66
antiarrhythmic,67-81	DrugDDI.d197.s3.e1
agent,82-87	DrugDDI.d197.s3.e1
administered,88-100
as,101-103
appropriate.,104-116

Caution,0-7
should,8-14
also,15-19
be,20-22
applied,23-30
for,31-34
other,35-40
sympathomimetics,,41-58
and,59-62
for,63-66
aminophylline,67-80	DrugDDI.d197.s4.e1
and,81-84
theophylline,85-97	DrugDDI.d197.s4.e2
and,98-101
tricyclic,102-111	DrugDDI.d197.s4.e3
antidepressants,,112-128	DrugDDI.d197.s4.e3
which,129-134
may,135-138
also,139-143
precipitate,144-155
arrhythmias.,156-168

Drug,0-4
Interactions:,5-18
a.,19-21
Drugs,22-27	DrugDDI.d339.s0.e0
Enhancing,28-37
Heparin,38-45	DrugDDI.d339.s0.e1
Effect:,46-53
Oral,54-58	DrugDDI.d339.s0.e2
anticoagulants:,59-74	DrugDDI.d339.s0.e2
Heparin,75-82	DrugDDI.d339.s0.e3
sodium,83-89	DrugDDI.d339.s0.e3
may,90-93
prolong,94-101
the,102-105
one-stage,106-115
prothrombin,116-127
time.,128-133

Therefore,,0-10
when,11-15
heparin,16-23	DrugDDI.d339.s1.e0
sodium,24-30	DrugDDI.d339.s1.e0
is,31-33
given,34-39
with,40-44
dicumarol,45-54	DrugDDI.d339.s1.e1
or,55-57
warfarin,58-66	DrugDDI.d339.s1.e2
sodium,,67-74	DrugDDI.d339.s1.e2
a,75-76
period,77-83
of,84-86
at,87-89
least,90-95
5,96-97
hours,98-103
after,104-109
the,110-113
last,114-118
intravenous,119-130
dose,131-135
or,136-138
24,139-141
hours,142-147
after,148-153
the,154-157
last,158-162
subcutaneous,163-175
dose,176-180
should,181-187
elapse,188-194
before,195-201
blood,202-207
is,208-210
drawn,211-216
if,217-219
a,220-221
valid,222-227
prothrombin,228-239
time,240-244
is,245-247
to,248-250
be,251-253
obtained.,254-263

Platelet,0-8	DrugDDI.d339.s2.e0
inhibitors:,9-20	DrugDDI.d339.s2.e0
Drugs,21-26	DrugDDI.d339.s2.e1
such,27-31
as,32-34
acetylsalicylic,35-50	DrugDDI.d339.s2.e2
acid,,51-56	DrugDDI.d339.s2.e2
dextran,,57-65
phenylbutazone,,66-81
ibuprofen,,82-92
indomethacin,,93-106
dipyridamole,,107-120
hydroxychloroquine,121-139	DrugDDI.d339.s2.e8
and,140-143
others,144-150
that,151-155
interfere,156-165
with,166-170
platelet-aggregation,171-191
reactions,192-201
(the,202-206
main,207-211
hemostatic,212-222	DrugDDI.d339.s2.e9
defense,223-230
of,231-233
heparinized,234-245
patients),246-255
may,256-259
induce,260-266
bleeding,267-275
and,276-279
should,280-286
be,287-289
used,290-294
with,295-299
caution,300-307
in,308-310
patients,311-319
receiving,320-329
heparin,330-337	DrugDDI.d339.s2.e10
sodium.,338-345	DrugDDI.d339.s2.e10

The,0-3
anticoagulant,4-17
effect,18-24
of,25-27
heparin,28-35	DrugDDI.d339.s3.e0
is,36-38
enhanced,39-47
by,48-50
concurrent,51-61
treatment,62-71
with,72-76
antithrombin,77-89	DrugDDI.d339.s3.e1
III,90-93	DrugDDI.d339.s3.e1
(human),94-101
in,102-104
patients,105-113
with,114-118
hereditary,119-129
antithrombin,130-142
III,143-146
deficiency.,147-158

Thus,0-4
in,5-7
order,8-13
to,14-16
avoid,17-22
bleeding,,23-32
reduced,33-40
dosage,41-47
of,48-50
heparin,51-58	DrugDDI.d339.s4.e0
is,59-61
recommended,62-73
during,74-80
treatment,81-90
with,91-95
antithrombin,96-108	DrugDDI.d339.s4.e1
III,109-112	DrugDDI.d339.s4.e1
(human).,113-121

Drugs,0-5	DrugDDI.d339.s6.e0
Decreasing,6-16
Heparin,17-24	DrugDDI.d339.s6.e1
Effect:,25-32
Digitalis,,33-43
tetracyclines,,44-58
nicotine,,59-68
or,69-71
antihistamines,72-86	DrugDDI.d339.s6.e5
may,87-90
partially,91-100
counteract,101-111
the,112-115
anticoagulant,116-129	DrugDDI.d339.s6.e6
action,130-136
of,137-139
heparin,140-147	DrugDDI.d339.s6.e7
sodium.,148-155	DrugDDI.d339.s6.e7

Heparin,0-7	DrugDDI.d339.s7.e0
Sodium,8-14	DrugDDI.d339.s7.e0
Injection,15-24
should,25-31
not,32-35
be,36-38
mixed,39-44
with,45-49
doxorubicin,,50-62
droperidol,,63-74
ciprofloxacin,,75-89
or,90-92
mitoxantrone,,93-106
since,107-112
it,113-115
has,116-119
been,120-124
reported,125-133
that,134-138
these,139-144
drugs,145-150	DrugDDI.d339.s7.e5
are,151-154
incompatible,155-167
with,168-172
heparin,173-180	DrugDDI.d339.s7.e6
and,181-184
a,185-186
precipitate,187-198
may,199-202
form.,203-208

Drug/,0-5	DrugDDI.d339.s8.e0
Laboratory,6-16
Tests,17-22
Interactions,23-35
Hyperaminotransferasemia:,36-61
Significant,62-73
elevations,74-84
of,85-87
aminotransferase,88-104	DrugDDI.d339.s8.e1
(SGOT,105-110
[S-AST],111-118
and,119-122
SGPT,123-127	DrugDDI.d339.s8.e3
[S-ALT]),128-136	DrugDDI.d339.s8.e3
levels,137-143
have,144-148
occurred,149-157
in,158-160
a,161-162
high,163-167
percentage,168-178
of,179-181
patients,182-190
(and,191-195
healthy,196-203
subjects),204-213
who,214-217
have,218-222
received,223-231
heparin,232-239	DrugDDI.d339.s8.e4
sodium.,240-247	DrugDDI.d339.s8.e4

Since,0-5
aminotransferase,6-22	DrugDDI.d339.s9.e0
determinations,23-37
are,38-41
important,42-51
in,52-54
the,55-58
differential,59-71
diagnosis,72-81
of,82-84
myocardial,85-95
infarction,,96-107
liver,108-113
disease,114-121
and,122-125
pulmonary,126-135
emboli,,136-143
rises,144-149	DrugDDI.d339.s9.e1
that,150-154
might,155-160
be,161-163
caused,164-170
by,171-173
drugs,174-179	DrugDDI.d339.s9.e2
(heparin,180-188
sodium),189-196
should,197-203
be,204-206
interpreted,207-218
with,219-223
caution.,224-232

Opioids,0-7	DrugDDI.d69.s0.e0
are,8-11
strong,12-18
central,19-26	DrugDDI.d69.s0.e1
nervous,27-34	DrugDDI.d69.s0.e1
system,35-41	DrugDDI.d69.s0.e1
depressants,,42-54	DrugDDI.d69.s0.e1
but,55-58
regular,59-66
users,67-72
develop,73-80
physiological,81-94
tolerance,95-104
allowing,105-113
gradually,114-123
increased,124-133
dosages.,134-142

In,0-2
combination,3-14
with,15-19
other,20-25
central,26-33	DrugDDI.d69.s1.e0
nervous,34-41	DrugDDI.d69.s1.e0
system,42-48	DrugDDI.d69.s1.e0
depressants,,49-61	DrugDDI.d69.s1.e0
heroin,62-68	DrugDDI.d69.s1.e1
may,69-72
still,73-78
kill,79-83
even,84-88
experienced,89-100
users,,101-107
particularly,108-120
if,121-123
their,124-129
tolerance,130-139
to,140-142
the,143-146
drug,147-151	DrugDDI.d69.s1.e2
has,152-155
reduced,156-163
or,164-166
the,167-170
strength,171-179
of,180-182
their,183-188
usual,189-194
dose,195-199
has,200-203
increased.,204-214

Toxicology,0-10
studies,11-18
of,19-21
heroin-related,22-36	DrugDDI.d69.s2.e0
deaths,37-43
reveal,44-50
frequent,51-59
involvement,60-71
of,72-74
other,75-80
central,81-88	DrugDDI.d69.s2.e1
nervous,89-96	DrugDDI.d69.s2.e1
system,97-103	DrugDDI.d69.s2.e1
depressants,,104-116	DrugDDI.d69.s2.e1
including,117-126
alcohol,,127-135
benzodiazepines,136-151	DrugDDI.d69.s2.e3
such,152-156
as,157-159
diazepam,160-168	DrugDDI.d69.s2.e4
(Valium),,169-178
and,,179-183
to,184-186
a,187-188
rising,189-195
degree,,196-203
methadone.,204-214	DrugDDI.d69.s2.e6

Ironically,,0-11
benzodiazepines,12-27	DrugDDI.d69.s3.e0
are,28-31
often,32-37
used,38-42
in,43-45
the,46-49
treatment,50-59
of,60-62
heroin,63-69
addiction,70-79
while,80-85
they,86-90
cause,91-96
much,97-101
more,102-106
severe,107-113
withdrawal,114-124
symptoms.,125-134

Cocaine,0-7	DrugDDI.d69.s4.e0
sometimes,8-17
proves,18-24	DrugDDI.d69.s4.e1
to,25-27
be,28-30
fatal,31-36
when,37-41
used,42-46
in,47-49
combination,50-61
with,62-66
heroin.,67-74	DrugDDI.d69.s4.e2

Barbiturates,0-12	DrugDDI.d550.s0.e0
may,13-16
decrease,17-25
the,26-29
effectiveness,30-43
of,44-46
oral,47-51	DrugDDI.d550.s0.e1
contraceptives,,52-67	DrugDDI.d550.s0.e1
certain,68-75
antibiotics,,76-88
quinidine,,89-99
theophylline,,100-113
corticosteroids,,114-130
anticoagulants,,131-146
and,147-150
beta,151-155	DrugDDI.d550.s0.e7
blockers.,156-165	DrugDDI.d550.s0.e7

MAO,0-3	DrugDDI.d100.s0.e0
inhibitors,4-14	DrugDDI.d100.s0.e0
should,15-21
be,22-24
used,25-29
with,30-34
caution,35-42
in,43-45
patients,46-54
receiving,55-64
hydralazine.,65-77	DrugDDI.d100.s0.e1

When,0-4
other,5-10
potent,11-17
parental,18-26
antihypertensive,27-43	DrugDDI.d100.s1.e0
drugs,,44-50	DrugDDI.d100.s1.e0
such,51-55
as,56-58
diazoxide,,59-69
are,70-73
used,74-78
in,79-81
combination,82-93
with,94-98
hydralazine,,99-111
patients,112-120
should,121-127
be,128-130
continuously,131-143
observed,144-152
for,153-156
several,157-164
hours,165-170
for,171-174
any,175-178
excessive,179-188
fall,189-193
in,194-196
blood,197-202
pressure.,203-212

Profound,0-8
hypotensive,9-20
episodes,21-29
may,30-33
occur,34-39
when,40-44
diazoxide,45-54	DrugDDI.d100.s2.e0
infection,55-64
and,65-68
hydralazine,69-80	DrugDDI.d100.s2.e1
are,81-84
used,85-89
concomitantly.,90-104

Beta-blockers,0-13	DrugDDI.d100.s3.e0
(metoprolol,,14-26
propranolol),27-39	DrugDDI.d100.s3.e2
serum,40-45
concentrations,46-60
and,61-64
pharmacologic,65-78
effects,79-86
may,87-90
be,91-93
increased.,94-104

Propranolol,0-11	DrugDDI.d100.s5.e0
increases,12-21
hydralazines,22-34	DrugDDI.d100.s5.e1
serum,35-40
concentrations.,41-56

Acebutolol,,0-11
atenolol,,12-21
and,22-25
nadolol,26-33	DrugDDI.d100.s6.e2
(low,34-38
hepatic,39-46
clearance,47-56
or,57-59
no,60-62
first-pass,63-73
metabolism),74-85
are,86-89
unlikely,90-98
to,99-101
be,102-104
affected.,105-114

NSAIDs,0-6	DrugDDI.d100.s7.e0
may,7-10
decrease,11-19
the,20-23
hemodynamic,24-35
effects,36-43
of,44-46
hydralazine;,47-59	DrugDDI.d100.s7.e1

When,0-4
given,5-10
concurrently,11-23
the,24-27
following,28-37
drugs,38-43	DrugDDI.d308.s0.e0
may,44-47
interact,48-56
with,57-61
thiazide,62-70	DrugDDI.d308.s0.e1
diuretics.,71-81	DrugDDI.d308.s0.e1

Alcohol,,0-8
barbiturates,,9-22
or,23-25
narcotics:,26-36	DrugDDI.d308.s1.e2
potentiation,37-49
of,50-52
orthostatic,53-64
hypotension,65-76
may,77-80
occur.,81-87

Antidiabetic,0-12	DrugDDI.d308.s2.e0
drugs:,13-19	DrugDDI.d308.s2.e0
(oral,20-25
agents,26-32
and,33-36
insulin),37-45	DrugDDI.d308.s2.e1
-,46-47
dosage,48-54
adjustment,55-65
of,66-68
the,69-72
antidiabetic,73-85	DrugDDI.d308.s2.e2
drug,86-90	DrugDDI.d308.s2.e2
may,91-94
be,95-97
required.,98-107

Other,0-5
antihypertensive,6-22	DrugDDI.d308.s3.e0
drugs:,23-29	DrugDDI.d308.s3.e0
additive,30-38
effect,39-45
or,46-48
potentiation.,49-62

Cholestyramine,0-14	DrugDDI.d308.s4.e0
and,15-18
colestipol,19-29	DrugDDI.d308.s4.e1
resins:,30-37
Absorption,38-48
of,49-51
hydrochlorothiazide,52-71	DrugDDI.d308.s4.e2
is,72-74
impaired,75-83
in,84-86
the,87-90
presence,91-99
of,100-102
anionic,103-110	DrugDDI.d308.s4.e3
exchange,111-119	DrugDDI.d308.s4.e3
resins.,120-127	DrugDDI.d308.s4.e3

Single,0-6
doses,7-12
of,13-15
either,16-22
cholestyramine,23-37	DrugDDI.d308.s5.e0
or,38-40
colestipol,41-51	DrugDDI.d308.s5.e1
resins,52-58
bind,59-63
the,64-67
hydrochlorothiazide,68-87	DrugDDI.d308.s5.e2
and,88-91
reduce,92-98
its,99-102
absorption,103-113
from,114-118
the,119-122
gastrointestinal,123-139
tract,140-145
by,146-148
up,149-151
to,152-154
85,155-157
and,158-161
43,162-164
percent,,165-173
respectively.,174-187

Corticosteroids,,0-16
ACTH:,17-22	DrugDDI.d308.s6.e1
intensified,23-34
electrolyte,35-46
depletion,,47-57
particularly,58-70
hypokalemia.,71-83

Pressor,0-7	DrugDDI.d308.s7.e0
amines,8-14	DrugDDI.d308.s7.e0
(e.g.,,15-21
norepinephrine):,22-38	DrugDDI.d308.s7.e1
possible,39-47
decreased,48-57
response,58-66
to,67-69
pressor,70-77	DrugDDI.d308.s7.e2
amines,78-84	DrugDDI.d308.s7.e2
but,85-88
not,89-92
sufficient,93-103
to,104-106
preclude,107-115
their,116-121
use.,122-126

Skeletal,0-8	DrugDDI.d308.s8.e0
muscle,9-15	DrugDDI.d308.s8.e0
relaxants,,16-26	DrugDDI.d308.s8.e0
nondepolarizing,27-42
(e.g.,,43-49
tubocurarine):,50-64	DrugDDI.d308.s8.e1
possible,65-73
increased,74-83
responsiveness,84-98
to,99-101
the,102-105
muscle,106-112	DrugDDI.d308.s8.e2
relaxant.,113-122	DrugDDI.d308.s8.e2

Lithium:,0-8	DrugDDI.d308.s9.e0
generally,9-18
should,19-25
not,26-29
be,30-32
given,33-38
with,39-43
diuretics.,44-54	DrugDDI.d308.s9.e1

Diuretic,0-8	DrugDDI.d308.s10.e0
agents,9-15
reduce,16-22
the,23-26
renal,27-32
clearance,33-42
of,43-45
lithium,46-53	DrugDDI.d308.s10.e1
and,54-57
add,58-61
a,62-63
high,64-68
risk,69-73
of,74-76
lithium,77-84
toxicity.,85-94

Refer,0-5
to,6-8
the,9-12
package,13-20
insert,21-27
for,28-31
lithium,32-39	DrugDDI.d308.s11.e0
preparations,40-52	DrugDDI.d308.s11.e0
before,53-59
use,60-63
of,64-66
such,67-71
preparations,72-84
with,85-89
Hydrochlorothiazide.,90-110	DrugDDI.d308.s11.e1

Non-steroidal,0-13	DrugDDI.d308.s12.e0
Anti-inflammatory,14-31	DrugDDI.d308.s12.e0
Drugs:,32-38	DrugDDI.d308.s12.e0
In,39-41
some,42-46
patients,,47-56
the,57-60
administration,61-75
of,76-78
a,79-80
non-steroidal,81-94	DrugDDI.d308.s12.e1
anti-inflammatory,95-112	DrugDDI.d308.s12.e1
agent,113-118	DrugDDI.d308.s12.e1
can,119-122
reduce,123-129
the,130-133
diuretic,,134-143
natriuretic,,144-156
and,157-160
antihypertensive,161-177	DrugDDI.d308.s12.e3
effects,178-185
of,186-188
loop,,189-194
potassium-sparing,195-212	DrugDDI.d308.s12.e4
and,213-216
thiazide,217-225	DrugDDI.d308.s12.e5
diuretics.,226-236	DrugDDI.d308.s12.e5

Therefore,,0-10
when,11-15
Hydrochlorothiazide,16-35	DrugDDI.d308.s13.e0
and,36-39
non-steroidal,40-53	DrugDDI.d308.s13.e1
anti-inflammatory,54-71	DrugDDI.d308.s13.e1
agents,72-78	DrugDDI.d308.s13.e1
are,79-82
used,83-87
concomitantly,,88-102
the,103-106
patient,107-114
should,115-121
be,122-124
observed,125-133
closely,134-141
to,142-144
determine,145-154
if,155-157
the,158-161
desired,162-169
effect,170-176
of,177-179
the,180-183
diuretic,184-192	DrugDDI.d308.s13.e2
is,193-195
obtained.,196-205

Patients,0-8
receiving,9-18
other,19-24	DrugDDI.d74.s0.e0
narcotic,25-33	DrugDDI.d74.s0.e0
analgesics,,34-45	DrugDDI.d74.s0.e0
antipsychotics,,46-61
antianxiety,62-73	DrugDDI.d74.s0.e2
agents,,74-81	DrugDDI.d74.s0.e2
or,82-84
other,85-90
CNS,91-94	DrugDDI.d74.s0.e3
depressants,95-106	DrugDDI.d74.s0.e3
(including,107-117
alcohol),118-126	DrugDDI.d74.s0.e4
concomitantly,127-140
with,141-145
hydrocodone,146-157	DrugDDI.d74.s0.e5
and,158-161
acetaminophen,162-175	DrugDDI.d74.s0.e6
tablets,176-183	DrugDDI.d74.s0.e6
may,184-187
exhibit,188-195
an,196-198
additive,199-207
CNS,208-211
depression.,212-223

The,0-3
use,4-7
of,8-10
MAO,11-14	DrugDDI.d74.s2.e0
inhibitors,15-25	DrugDDI.d74.s2.e0
or,26-28
tricyclic,29-38	DrugDDI.d74.s2.e1
antidepressants,39-54	DrugDDI.d74.s2.e1
with,55-59
hydrocodone,60-71	DrugDDI.d74.s2.e2
preparations,72-84	DrugDDI.d74.s2.e2
may,85-88
increase,89-97
the,98-101
effect,102-108
of,109-111
either,112-118
the,119-122
antidepressant,123-137	DrugDDI.d74.s2.e3
or,138-140
hydrocodone.,141-153	DrugDDI.d74.s2.e4

The,0-3
concurrent,4-14
use,15-18
of,19-21
anticholinergics,22-38	DrugDDI.d74.s3.e0
with,39-43
hydrocodone,44-55	DrugDDI.d74.s3.e1
may,56-59
produce,60-67
paralytic,68-77
ileus.,78-84

Anticoagulants,,0-15
oral,16-20

(Effects,0-8
may,9-12
be,13-15
decreased,16-25
when,26-30
used,31-35
concurrently,36-48
with,49-53
thiazide,54-62	DrugDDI.d573.s1.e0
diuretics;,63-73	DrugDDI.d573.s1.e0

Antigout,0-8
medications,9-20	DrugDDI.d573.s3.e0

(Thiazide,0-9
diuretics,10-19
may,20-23
raise,24-29
the,30-33
level,34-39
of,40-42
blood,43-48
uric,49-53
acid;,54-59

dosage,0-6
adjustment,7-17
of,18-20
antigout,21-29
medications,30-41	DrugDDI.d573.s5.e0
may,42-45
be,46-48
necessary,49-58
to,59-61
control,62-69
hyperuricemia,70-83
and,84-87
gout.),88-94

Antihypertensive,0-16	DrugDDI.d573.s6.e0
medications,,17-29
other,,30-36
especially,37-47
diazoxide,,48-58
or,59-61
preanesthetic,62-75
and,76-79
anesthetic,80-90	DrugDDI.d573.s6.e2
agents,91-97	DrugDDI.d573.s6.e2
used,98-102
in,103-105
surgery,106-113
or,114-116
skeletal-muscle,117-132	DrugDDI.d573.s6.e3
relaxants,,133-143	DrugDDI.d573.s6.e3
nondepolarizing,,144-160
used,161-165
in,166-168
surgery,169-176

(Effects,0-8
may,9-12
be,13-15
potentiated,16-27
when,28-32
used,33-37
concurrently,38-50
with,51-55
thiazide,56-64	DrugDDI.d573.s7.e0
diuretics;,65-75	DrugDDI.d573.s7.e0

Amphotericin,0-12	DrugDDI.d573.s9.e0
B,13-14	DrugDDI.d573.s9.e0
or,15-17
Corticosteroids,18-33	DrugDDI.d573.s9.e1
or,34-36
Corticotropin,37-50	DrugDDI.d573.s9.e2
(ACTH),51-57

(Concurrent,0-11
use,12-15
with,16-20
thiazide,21-29	DrugDDI.d573.s10.e0
diuretics,30-39	DrugDDI.d573.s10.e0
may,40-43
intensify,44-53
electrolyte,54-65
imbalance,,66-76
particularly,77-89
hypokalemia.),90-103

Cardiac,0-7	DrugDDI.d573.s11.e0
glycosides,8-18	DrugDDI.d573.s11.e0

(Concurrent,0-11
use,12-15
with,16-20
thiazide,21-29	DrugDDI.d573.s12.e0
diuretics,30-39	DrugDDI.d573.s12.e0
may,40-43
enhance,44-51
the,52-55
possibility,56-67
of,68-70
digitalis,71-80
toxicity,81-89
associated,90-100
with,101-105
hypokalemia.),106-119

Colestipol,0-10	DrugDDI.d573.s13.e0

(May,0-4
inhibit,5-12
gastrointestinal,13-29
absorption,30-40
of,41-43
the,44-47
thiazide,48-56	DrugDDI.d573.s14.e0
diuretics;,57-67	DrugDDI.d573.s14.e0

administration,0-14
1,15-16
hour,17-21
before,22-28
or,29-31
4,32-33
hours,34-39
after,40-45
colestipol,46-56	DrugDDI.d573.s15.e0
is,57-59
recommended.),60-73

Hypoglycemics,0-13	DrugDDI.d573.s16.e0

(Thiazide,0-9
diuretics,10-19
may,20-23
raise,24-29
blood,30-35
glucose,36-43
levels;,44-51

for,0-3
adult-onset,4-15
diabetics,,16-26
dosage,27-33
adjustment,34-44
of,45-47
hypoglycemic,48-60	DrugDDI.d573.s18.e0
medications,61-72	DrugDDI.d573.s18.e0
may,73-76
be,77-79
necessary,80-89
during,90-96
and,97-100
after,101-106
thiazide,107-115	DrugDDI.d573.s18.e1
diuretic,116-124	DrugDDI.d573.s18.e1
therapy;,125-133

insulin,0-7	DrugDDI.d573.s19.e0
requirements,8-20
may,21-24
be,25-27
increased,,28-38
decreased,,39-49
or,50-52
unchanged.),53-64

Lithium,0-7	DrugDDI.d573.s20.e0
salts,8-13	DrugDDI.d573.s20.e0

(Concurrent,0-11
use,12-15
with,16-20
thiazide,21-29	DrugDDI.d573.s21.e0
diuretics,30-39	DrugDDI.d573.s21.e0
is,40-42
not,43-46
recommended,,47-59
as,60-62
they,63-67
may,68-71
provoke,72-79
lithium,80-87
toxicity,88-96
because,97-104
of,105-107
reduced,108-115
renal,116-121
clearance.),122-133

Methenamine,0-11	DrugDDI.d573.s22.e0

(Effectiveness,0-14
may,15-18
be,19-21
decreased,22-31
when,32-36
used,37-41
concurrently,42-54
with,55-59
thiazide,60-68	DrugDDI.d573.s23.e0
diuretics,69-78	DrugDDI.d573.s23.e0
because,79-86
of,87-89
alkalinization,90-104
of,105-107
the,108-111
urine.),112-119

Nonsteroidal,0-12	DrugDDI.d573.s24.e0
anti-inflammatory,13-30	DrugDDI.d573.s24.e0
agents,31-37	DrugDDI.d573.s24.e0

(In,0-3
some,4-8
patients,,9-18
the,19-22
steroidal,23-32	DrugDDI.d573.s25.e0
anti-inflammatory,33-50	DrugDDI.d573.s25.e0
agent,51-56	DrugDDI.d573.s25.e0
can,57-60
reduce,61-67
the,68-71
diuretic,,72-81
natriuretic,,82-94
and,95-98
antihypertensive,99-115	DrugDDI.d573.s25.e2
effects,116-123
of,124-126
loop,,127-132
potassium,133-142	DrugDDI.d573.s25.e3
sparing,,143-151
and,152-155
thiazide,156-164	DrugDDI.d573.s25.e4
diuretics.,165-175	DrugDDI.d573.s25.e4

Therefore,,0-10
when,11-15
hydroflumethiazide,16-34	DrugDDI.d573.s26.e0
and,35-38
nonsteroidal,39-51	DrugDDI.d573.s26.e1
anti-inflammatory,52-69	DrugDDI.d573.s26.e1
agents,70-76	DrugDDI.d573.s26.e1
are,77-80
used,81-85
concomitantly,,86-100
the,101-104
patient,105-112
should,113-119
be,120-122
observed,123-131
closely,132-139
to,140-142
determine,143-152
if,153-155
the,156-159
desired,160-167
effect,168-174
of,175-177
the,178-181
diuretic,182-190	DrugDDI.d573.s26.e2
is,191-193
obtained.),194-204

Norepinephrine,0-14	DrugDDI.d573.s27.e0

(Thiazides,0-10
may,11-14
decrease,15-23
arterial,24-32
responsiveness,33-47
to,48-50
norepinephrine.,51-66	DrugDDI.d573.s28.e1

This,0-4
diminution,5-15
is,16-18
not,19-22
sufficient,23-33
to,34-36
preclude,37-45
effectiveness,46-59
of,60-62
the,63-66
pressor,67-74	DrugDDI.d573.s29.e0
agent,75-80	DrugDDI.d573.s29.e0
for,81-84
therapeutic,85-96
use.),97-102

Tubocurarine,0-12	DrugDDI.d573.s30.e0

(Thiazide,0-9
drugs,10-15
may,16-19
increase,20-28
the,29-32
responsiveness,33-47
to,48-50
tubocurarine.),51-65	DrugDDI.d573.s31.e1

DIAGNOSTIC,0-10
INTERFERENCE,11-23
With,24-28
expected,29-37
physiologic,38-49
effects:,50-58
Blood,59-64
and,65-68
urine,69-74
glucose,75-82	DrugDDI.d573.s32.e0
levels,83-89
(usually,90-98
only,99-103
in,104-106
patients,107-115
with,116-120
a,121-122
predisposition,123-137
for,138-141
glucose,142-149
intolerance),150-162
and,163-166
Serum,167-172
bilirubin,173-182
levels,183-189
(by,190-193
displacement,194-206
from,207-211
albumin,212-219	DrugDDI.d573.s32.e1
binding),220-228
and,229-232
Serum,233-238
calcium,239-246
levels,247-253
(thiazide,254-263
diuretics,264-273
should,274-280
be,281-283
discontinued,284-296
before,297-303
parathyroid-function,304-324	DrugDDI.d573.s32.e3
tests,325-330
are,331-334
carried,335-342
out),343-347
and,348-351
Serum,352-357
uric,358-362
acid,363-367
levels,368-374
(may,375-379
be,380-382
increased),383-393
Serum,394-399
magnesium,,400-410
potassium,,411-421
and,422-425
sodium,426-432
levels,433-439
(may,440-444
be,445-447
decreased;,448-458

serum,0-5
magnesium,6-15
levels,16-22
may,23-26
increase,27-35
in,36-38
uremic,39-45
patients),46-55
Serum,56-61
protein-bound,62-75	DrugDDI.d573.s33.e0
iodine,76-82	DrugDDI.d573.s33.e0
(PBI),83-88
levels,89-95
(may,96-100
be,101-103
decreased),104-114
Thiazides,115-124	DrugDDI.d573.s33.e1
should,125-131
be,132-134
discontinued,135-147
before,148-154
carrying,155-163
out,164-167
tests,168-173
for,174-177
parathyroid,178-189	DrugDDI.d573.s33.e2
function.,190-199

Patients,0-8
receiving,9-18
other,19-24	DrugDDI.d154.s0.e0
narcotic,25-33	DrugDDI.d154.s0.e0
analgesics,,34-45	DrugDDI.d154.s0.e0
general,46-53	DrugDDI.d154.s0.e1
anesthetics,,54-66	DrugDDI.d154.s0.e1
phenothiazines,,67-82
tranquilizers,,83-97
sedative-hypnotics,,98-117
tricyclic,118-127	DrugDDI.d154.s0.e5
antidepressants,128-143	DrugDDI.d154.s0.e5
or,144-146
other,147-152
CNS,153-156	DrugDDI.d154.s0.e6
depressants,157-168	DrugDDI.d154.s0.e6
(including,169-179
alcohol),180-188	DrugDDI.d154.s0.e7
concomitantly,189-202
with,203-207
DILAUDID,208-216	DrugDDI.d154.s0.e8
may,217-220
exhibit,221-228
an,229-231
additive,232-240
CNS,241-244
depression.,245-256

Prospective,0-11
studies,12-19
on,20-22
the,23-26
potential,27-36
for,37-40
hydroxyurea,41-52	DrugDDI.d565.s0.e0
to,53-55
interact,56-64
with,65-69
other,70-75
drugs,76-81	DrugDDI.d565.s0.e1
have,82-86
not,87-90
been,91-95
performed.,96-106

Concurrent,0-10
use,11-14
of,15-17
hydroxyurea,18-29	DrugDDI.d565.s1.e0
and,30-33
other,34-39
myelosuppressive,40-56
agents,57-63
or,64-66
radiation,67-76
therapy,77-84
may,85-88
increase,89-97
the,98-101
likelihood,102-112
of,113-115
bone,116-120
marrow,121-127
depression,128-138
or,139-141
other,142-147
adverse,148-155
events.,156-163

Since,0-5
hydroxyurea,6-17	DrugDDI.d565.s2.e0
may,18-21
raise,22-27
the,28-31
serum,32-37
uric,38-42
acid,43-47
level,,48-54
dosage,55-61
adjustment,62-72
of,73-75
uricosuric,76-86	DrugDDI.d565.s2.e1
medication,87-97	DrugDDI.d565.s2.e1
may,98-101
be,102-104
necessary,105-114

THE,0-3
POTENTIATING,4-16
ACTION,17-23
OF,24-26
HYDROXYZINE,27-38	DrugDDI.d442.s0.e0
MUST,39-43
BE,44-46
CONSIDERED,47-57
WHEN,58-62
THE,63-66
DRUG,67-71	DrugDDI.d442.s0.e1
IS,72-74
USED,75-79
IN,80-82
CONJUNCTION,83-94
WITH,95-99
CENTRAL,100-107	DrugDDI.d442.s0.e2
NERVOUS,108-115	DrugDDI.d442.s0.e2
SYSTEM,116-122	DrugDDI.d442.s0.e2
DEPRESSANTS,123-134	DrugDDI.d442.s0.e2
SUCH,135-139
AS,140-142
NARCOTICS,,143-153
NON-NARCOTIC,154-166	DrugDDI.d442.s0.e4
ANALGESICS,167-177	DrugDDI.d442.s0.e4
AND,178-181
BARBITURATES.,182-195	DrugDDI.d442.s0.e5

Therefore,0-9
when,10-14
central,15-22	DrugDDI.d442.s1.e0
nervous,23-30	DrugDDI.d442.s1.e0
system,31-37	DrugDDI.d442.s1.e0
depressants,38-49	DrugDDI.d442.s1.e0
are,50-53
administered,54-66
concomitantly,67-80
with,81-85
hydroxyzine,86-97	DrugDDI.d442.s1.e1
their,98-103
dosage,104-110
should,111-117
be,118-120
reduced.,121-129

Since,0-5
drowsiness,6-16
may,17-20
occur,21-26
with,27-31
use,32-35
of,36-38
this,39-43
drug,,44-49
patients,50-58
should,59-65
be,66-68
warned,69-75
of,76-78
this,79-83
possibility,84-95
and,96-99
cautioned,100-109
against,110-117
driving,118-125
a,126-127
car,128-131
or,132-134
operating,135-144
dangerous,145-154
machinery,155-164
while,165-170
taking,171-177
Atarax.,178-185	DrugDDI.d442.s2.e1

Patients,0-8
should,9-15
be,16-18
advised,19-26
against,27-34
the,35-38
simultaneous,39-51
use,52-55
of,56-58
other,59-64
CNS,65-68	DrugDDI.d442.s3.e0
depressant,69-79	DrugDDI.d442.s3.e0
drugs,,80-86	DrugDDI.d442.s3.e0
and,87-90
cautioned,91-100
that,101-105
the,106-109
effect,110-116
of,117-119
alcohol,120-127	DrugDDI.d442.s3.e1
may,128-131
be,132-134
increased.,135-145

Additive,0-8
adverse,9-16
effects,17-24
resulting,25-34
from,35-39
cholinergic,40-51
blockade,52-60
may,61-64
occur,65-70
when,71-75
LEVSIN,76-82	DrugDDI.d239.s0.e0
is,83-85
administered,86-98
concomitantly,99-112
with,113-117
other,118-123
antimuscarinics,,124-140
amantadine,,141-152
haloperidol,,153-165
phenothiazines,,166-181
monoamine,182-191	DrugDDI.d239.s0.e5
oxidase,192-199	DrugDDI.d239.s0.e5
(MAO),200-205
inhibitors,,206-217
tricyclic,218-227	DrugDDI.d239.s0.e6
antidepressants,228-243	DrugDDI.d239.s0.e6
or,244-246
some,247-251
antihistamines.,252-267	DrugDDI.d239.s0.e7

Antacids,0-8	DrugDDI.d239.s1.e0
may,9-12
interfere,13-22
with,23-27
the,28-31
absorption,32-42
of,43-45
LEVSIN.,46-53	DrugDDI.d239.s1.e1

Administer,0-10
LEVSIN,11-17	DrugDDI.d239.s2.e0
before,18-24
meals;,25-31

antacids,0-8	DrugDDI.d239.s3.e0
after,9-14
meals.,15-21

Calcium,0-7	DrugDDI.d139.s0.e0
Supplements/Antacids,8-28

Products,0-8
containing,9-19
calcium,20-27	DrugDDI.d139.s1.e0
and,28-31
other,32-37
multivalent,38-49
cations,50-57	DrugDDI.d139.s1.e1
(such,58-63
as,64-66
aluminum,,67-76
magnesium,,77-87
iron),88-93	DrugDDI.d139.s1.e3
are,94-97
likely,98-104
to,105-107
interfere,108-117
with,118-122
absorption,123-133
of,134-136
Ibandronate.,137-149	DrugDDI.d139.s1.e4

Ibandronate,0-11	DrugDDI.d139.s2.e0
should,12-18
be,19-21
taken,22-27
at,28-30
least,31-36
60,37-39
minutes,40-47
before,48-54
any,55-58
oral,59-63
medications,64-75
containing,76-86
multivalent,87-98
cations,99-106	DrugDDI.d139.s2.e1
(including,107-117
antacids,,118-127
supplements,128-139
or,140-142
vitamins).,143-153	DrugDDI.d139.s2.e3

H2,0-2	DrugDDI.d139.s3.e0
Blockers,3-11	DrugDDI.d139.s3.e0
and,12-15
Proton,16-22	DrugDDI.d139.s3.e1
Pump,23-27	DrugDDI.d139.s3.e1
Inhibitors,28-38	DrugDDI.d139.s3.e1
(PPIs),39-45

Of,0-2
over,3-7
3500,8-12
patients,13-21
enrolled,22-30
in,31-33
the,34-37
Ibandronate,38-49	DrugDDI.d139.s4.e0
osteoporosis,50-62
Treatment,63-72
and,73-76
Prevention,77-87
Studies,,88-96
15%,97-100
used,101-105
anti-peptic,106-117	DrugDDI.d139.s4.e1
agents,118-124	DrugDDI.d139.s4.e1
(primarily,125-135
H2,136-138	DrugDDI.d139.s4.e2
blockers,139-147	DrugDDI.d139.s4.e2
and,148-151
PPIs).,152-158

Among,0-5
these,6-11
patients,,12-21
the,22-25
incidence,26-35
of,36-38
upper,39-44
gastrointestinal,45-61
adverse,62-69
experiences,70-81
in,82-84
the,85-88
patients,89-97
treated,98-105
with,106-110
Ibandronate,111-122	DrugDDI.d139.s5.e0
was,123-126
similar,127-134
to,135-137
that,138-142
in,143-145
placebo-treated,146-161
patients.,162-171

Similarly,,0-10
of,11-13
over,14-18
1600,19-23
patients,24-32
enrolled,33-41
in,42-44
a,45-46
study,47-52
comparing,53-62
once-monthly,63-75
with,76-80
daily,81-86
dosing,87-93
regimens,94-102
of,103-105
ibandronate,,106-118
14%,119-122
of,123-125
patients,126-134
used,135-139
anti-peptic,140-151	DrugDDI.d139.s6.e1
agents.,152-159	DrugDDI.d139.s6.e1

Among,0-5
these,6-11
patients,,12-21
the,22-25
incidence,26-35
of,36-38
upper,39-44
gastrointestinal,45-61
adverse,62-69
experiences,70-81
in,82-84
the,85-88
patients,89-97
treated,98-105
with,106-110
Ibandronate,111-122	DrugDDI.d139.s7.e0
150,123-126	DrugDDI.d139.s7.e0
mg,127-129	DrugDDI.d139.s7.e0
once,130-134
monthly,135-142
was,143-146
similar,147-154
to,155-157
that,158-162
in,163-165
patients,166-174
treated,175-182
with,183-187
Ibandronate,188-199	DrugDDI.d139.s7.e1
2.5,200-203	DrugDDI.d139.s7.e1
mg,204-206	DrugDDI.d139.s7.e1
once,207-211
daily.,212-218

Aspirin/Nonsteroidal,0-20	DrugDDI.d139.s8.e0
Antiinflammatory,21-37
Drugs,38-43
(NSAIDs),44-52

In,0-2
the,3-6
large,,7-13
placebo-controlled,14-32
osteoporosis,33-45
Treatment,46-55
Study,,56-62
aspirin,63-70	DrugDDI.d139.s9.e0
and,71-74
nonsteroidal,75-87	DrugDDI.d139.s9.e1
anti-inflammatory,88-105	DrugDDI.d139.s9.e1
drugs,106-111	DrugDDI.d139.s9.e1
were,112-116
taken,117-122
by,123-125
62%,126-129
of,130-132
the,133-136
2946,137-141
patients.,142-151

Among,0-5
aspirin,6-13	DrugDDI.d139.s10.e0
or,14-16
NSAID,17-22	DrugDDI.d139.s10.e1
users,,23-29
the,30-33
incidence,34-43
of,44-46
upper,47-52
gastrointestinal,53-69
adverse,70-77
events,78-84
in,85-87
patients,88-96
treated,97-104
with,105-109
ibandronate,110-121	DrugDDI.d139.s10.e2
2.5,122-125	DrugDDI.d139.s10.e2
mg,126-128	DrugDDI.d139.s10.e2
daily,129-134
(28.9%),135-142
was,143-146
similar,147-154
to,155-157
that,158-162
in,163-165
placebo-treated,166-181
patients,182-190
(30.7%).,191-199

Similarly,,0-10
in,11-13
the,14-17
1-year,18-24
monthly,25-32
comparison,33-43
study,,44-50
aspirin,51-58	DrugDDI.d139.s11.e0
and,59-62
nonsteroidal,63-75	DrugDDI.d139.s11.e1
anti-inflammatory,76-93	DrugDDI.d139.s11.e1
drugs,94-99	DrugDDI.d139.s11.e1
were,100-104
taken,105-110
by,111-113
39%,114-117
of,118-120
the,121-124
1602,125-129
patients.,130-139

The,0-3
incidence,4-13
of,14-16
upper,17-22
gastrointestinal,23-39
events,40-46
in,47-49
patients,50-58
concomitantly,59-72
taking,73-79
aspirin,80-87	DrugDDI.d139.s12.e0
or,88-90
NSAIDs,91-97	DrugDDI.d139.s12.e1
was,98-101
similar,102-109
in,110-112
patients,113-121
taking,122-128
ibandronate,129-140	DrugDDI.d139.s12.e2
2.5,141-144	DrugDDI.d139.s12.e2
mg,145-147	DrugDDI.d139.s12.e2
daily,148-153
(21.7%),154-161
and,162-165
150,166-169
mg,170-172
once,173-177
monthly,178-185
(22.0%).,186-194

However,,0-8
since,9-14
aspirin,,15-23
NSAIDs,,24-31
and,32-35
bisphosphonates,36-51	DrugDDI.d139.s13.e2
are,52-55
all,56-59
associated,60-70
with,71-75
gastrointestinal,76-92
irritation,,93-104
caution,105-112
should,113-119
be,120-122
exercised,123-132
in,133-135
the,136-139
concomitant,140-151
use,152-155
of,156-158
aspirin,159-166	DrugDDI.d139.s13.e3
or,167-169
NSAIDs,170-176	DrugDDI.d139.s13.e4
with,177-181
Ibandronate.,182-194	DrugDDI.d139.s13.e5

Drug/Laboratory,0-15	DrugDDI.d139.s14.e0
Test,16-20
Interactions,21-33

Bisphosphonates,0-15	DrugDDI.d139.s15.e0
are,16-19
known,20-25
to,26-28
interfere,29-38
with,39-43
the,44-47
use,48-51
of,52-54
bone-imaging,55-67
agents.,68-75

Specific,0-8
studies,9-16
with,17-21
ibandronate,22-33	DrugDDI.d139.s16.e0
have,34-38
not,39-42
been,43-47
performed.,48-58

No,0-2
formal,3-9
drug,10-14
interaction,15-26
studies,27-34
have,35-39
been,40-44
performed,45-54
with,55-59
ZEVALIN.,60-68	DrugDDI.d20.s0.e0

Due,0-3
to,4-6
the,7-10
frequent,11-19
occurrence,20-30
of,31-33
severe,34-40
and,41-44
prolonged,45-54
thrombocytopenia,,55-72
the,73-76
potential,77-86
benefits,87-95
of,96-98
medications,99-110	DrugDDI.d20.s1.e0
which,111-116
interfere,117-126
with,127-131
platelet,132-140
function,141-149
and/or,150-156
anticoagulation,157-172
should,173-179
be,180-182
weighed,183-190
against,191-198
the,199-202
potential,203-212
increased,213-222
risks,223-228
of,229-231
bleeding,232-240
and,241-244
hemorrhage.,245-256

Patients,0-8
receiving,9-18
medications,19-30	DrugDDI.d20.s2.e0
that,31-35
interfere,36-45
with,46-50
platelet,51-59
function,60-68
or,69-71
coagulation,72-83
should,84-90
have,91-95
more,96-100
frequent,101-109
laboratory,110-120
monitoring,121-131
for,132-135
thrombocytopenia.,136-153

Patients,0-8
in,9-11
clinical,12-20
studies,21-28
were,29-33
prohibited,34-44	DrugDDI.d20.s4.e0
from,45-49
receiving,50-59
growth,60-66	DrugDDI.d20.s4.e1
factor,67-73	DrugDDI.d20.s4.e1
treatment,74-83
for,84-87
2,88-89
weeks,90-95
prior,96-101
to,102-104
the,105-108
ZEVALIN,109-116	DrugDDI.d20.s4.e2
therapeutic,117-128
regimen,129-136
as,137-139
well,140-144
as,145-147
for,148-151
2,152-153
weeks,154-159
following,160-169
completion,170-180
of,181-183
the,184-187
regimen.,188-196

Coumarin-Type,0-13	DrugDDI.d364.s0.e0
Anticoagulants:,14-29	DrugDDI.d364.s0.e0
Several,30-37
short-term,38-48
controlled,49-59
studies,60-67
failed,68-74
to,75-77
wshow,78-83
that,84-88
ibuprofen,89-98	DrugDDI.d364.s0.e1
significantly,99-112
affected,113-121
prothrombin,122-133
times,134-139
or,140-142
a,143-144
variety,145-152
of,153-155
other,156-161
clotting,162-170	DrugDDI.d364.s0.e2
factors,171-178	DrugDDI.d364.s0.e2
when,179-183
administered,184-196
to,197-199
individuals,200-211
on,212-214
coumarin-type,215-228	DrugDDI.d364.s0.e3
anticoagulants.,229-244	DrugDDI.d364.s0.e3

However,,0-8
because,9-16
bleeding,17-25
has,26-29
been,30-34
reported,35-43
when,44-48
ibuprofen,49-58	DrugDDI.d364.s1.e0
and,59-62
other,63-68
nonsteroidal,69-81	DrugDDI.d364.s1.e1
anti-inflammatory,82-99	DrugDDI.d364.s1.e1
agents,100-106	DrugDDI.d364.s1.e1
have,107-111
been,112-116
administered,117-129
to,130-132
patients,133-141
on,142-144
coumarin-type,145-158	DrugDDI.d364.s1.e2
anticoagulants,,159-174	DrugDDI.d364.s1.e2
the,175-178
physician,179-188
should,189-195
be,196-198
cautious,199-207
when,208-212
administering,213-226
ibuprofen,227-236	DrugDDI.d364.s1.e3
to,237-239
patients,240-248
on,249-251
anticoagulants.,252-267	DrugDDI.d364.s1.e4

Aspirin:,0-8	DrugDDI.d364.s2.e0
Animal,9-15
studies,16-23
wshow,24-29
that,30-34
aspirin,35-42	DrugDDI.d364.s2.e1
given,43-48
with,49-53
nonsteroidal,54-66	DrugDDI.d364.s2.e2
anti-inflammatory,67-84	DrugDDI.d364.s2.e2
agents,,85-92	DrugDDI.d364.s2.e2
including,93-102
ibuprofen,,103-113
yields,114-120
a,121-122
net,123-126	DrugDDI.d364.s2.e4
decrease,127-135
in,136-138
anti-inflammatory,139-156
activity,157-165
with,166-170
lowered,171-178
blood,179-184
levels,185-191
of,192-194
the,195-198
non-aspirin,199-210	DrugDDI.d364.s2.e5
drug.,211-216

Single,0-6
dose,7-11
bioavailability,12-27
studies,28-35
in,36-38
normal,39-45
volunteers,46-56
have,57-61
failed,62-68
to,69-71
wshow,72-77
an,78-80
effect,81-87
of,88-90
aspirin,91-98	DrugDDI.d364.s3.e0
on,99-101
ibuprofen,102-111	DrugDDI.d364.s3.e1
blood,112-117
levels.,118-125

Methotrexate:,0-13	DrugDDI.d364.s5.e0
Ibuprofen,,14-24
as,25-27
well,28-32
as,33-35
other,36-41
nonsteroidal,42-54	DrugDDI.d364.s5.e2
anti-inflammatory,55-72	DrugDDI.d364.s5.e2
drugs,,73-79	DrugDDI.d364.s5.e2
probably,80-88
reduces,89-96
the,97-100
tubular,101-108
secretion,109-118
of,119-121
methotrexate,122-134	DrugDDI.d364.s5.e3
based,135-140
on,141-143
in,144-146
vitro,147-152
studies,153-160
in,161-163
rabbit,164-170
kidney,171-177
slices.,178-185

This,0-4
may,5-8
indicate,9-17
that,18-22
ibuprofen,23-32	DrugDDI.d364.s6.e0
could,33-38
enhance,39-46
the,47-50
toxicity,51-59
of,60-62
methotrexate.,63-76	DrugDDI.d364.s6.e1

Caution,0-7
should,8-14
be,15-17
used,18-22
if,23-25
ibuprofen,26-35	DrugDDI.d364.s7.e0
is,36-38
administered,39-51
concomitantly,52-65
with,66-70
methotrexate.,71-84	DrugDDI.d364.s7.e1

H-2,0-3
Antagonists:,4-16
In,17-19
studies,20-27
with,28-32
human,33-38
volunteers,,39-50
co-administration,51-68
of,69-71
cimetidine,72-82	DrugDDI.d364.s8.e0
or,83-85
ranitidine,86-96	DrugDDI.d364.s8.e1
with,97-101
ibuprofen,102-111	DrugDDI.d364.s8.e2
had,112-115
no,116-118
substantive,119-130
effect,131-137
on,138-140
ibuprofen,141-150	DrugDDI.d364.s8.e3
serum,151-156
concentrations.,157-172

Furosemide:,0-11	DrugDDI.d364.s9.e0
Clinical,12-20
studies,,21-29
as,30-32
well,33-37
as,38-40
random,41-47
observations,,48-61
have,62-66
shown,67-72
that,73-77
ibuprofen,78-87	DrugDDI.d364.s9.e1
can,88-91
reduce,92-98
the,99-102
natriuretic,103-114	DrugDDI.d364.s9.e2
effect,115-121
of,122-124
furosemide,125-135	DrugDDI.d364.s9.e3
and,136-139
thiazides,140-149	DrugDDI.d364.s9.e4
in,150-152
some,153-157
patients.,158-167

This,0-4
response,5-13
has,14-17
been,18-22
attributed,23-33
to,34-36
inhibition,37-47
of,48-50
renal,51-56
prostaglandin,57-70	DrugDDI.d364.s10.e0
synthesis.,71-81

During,0-6
concomitant,7-18
therapy,19-26
with,27-31
ibuprofen,,32-42
the,43-46
patient,47-54
should,55-61
be,62-64
observed,65-73
closely,74-81
for,82-85
signs,86-91
of,92-94
renal,95-100
failure,,101-109
as,110-112
well,113-117
as,118-120
to,121-123
assure,124-130
diuretic,131-139	DrugDDI.d364.s11.e1
efficacy.,140-149

Lithium:,0-8	DrugDDI.d364.s12.e0
Ibuprofen,9-18	DrugDDI.d364.s12.e1
produced,19-27
an,28-30
elevation,31-40
of,41-43
plasma,44-50
lithium,51-58
levels,59-65
and,66-69
a,70-71
reduction,72-81
in,82-84
renal,85-90
lithium,91-98	DrugDDI.d364.s12.e2
clearance,99-108
in,109-111
a,112-113
study,114-119
of,120-122
eleven,123-129
normal,130-136
volunteers.,137-148

The,0-3
mean,4-8
minimum,9-16
lithium,17-24	DrugDDI.d364.s13.e0
concentration,25-38
increased,39-48
15%,49-52
and,53-56
the,57-60
renal,61-66
clearance,67-76
of,77-79
lithium,80-87	DrugDDI.d364.s13.e1
was,88-91
decreased,92-101
by,102-104
19%,105-108
during,109-115
this,116-120
period,121-127
of,128-130
concomitant,131-142
drug,143-147
administration.,148-163

This,0-4
effect,5-11
has,12-15
been,16-20
attributed,21-31
to,32-34
inhibition,35-45
of,46-48
renal,49-54
prostaglandin,55-68	DrugDDI.d364.s14.e0
synthesis,69-78
by,79-81
ibuprofen.,82-92	DrugDDI.d364.s14.e1

Thus,,0-5
when,6-10
ibuprofen,11-20	DrugDDI.d364.s15.e0
and,21-24
lithium,25-32	DrugDDI.d364.s15.e1
are,33-36
administered,37-49
concurrently,,50-63
subjects,64-72
should,73-79
be,80-82
observed,83-91
carefully,92-101
for,102-105
signs,106-111
of,112-114
lithium,115-122
toxicity.,123-132

(Read,0-5
circulars,6-15
for,16-19
lithium,20-27	DrugDDI.d364.s16.e0
preparation,28-39	DrugDDI.d364.s16.e0
before,40-46
use,47-50
of,51-53
such,54-58
concurrent,59-69
therapy).,70-79

Digoxin:,0-8	DrugDDI.d283.s1.e0
Supraventricular,9-25
arrhythmias,26-37
may,38-41
mask,42-46
the,47-50
cardiotoxicity,51-65
associated,66-76
with,77-81
excessive,82-91
digoxin,92-99
levels.,100-107

Coadministration,0-16
of,17-19
digoxin,20-27	DrugDDI.d283.s3.e0
did,28-31
not,32-35
have,36-40
effects,41-48
on,49-51
either,52-58
the,59-62
safety,63-69
or,70-72
efficacy,73-81
of,82-84
ibutilide,85-94	DrugDDI.d283.s3.e1
in,95-97
the,98-101
clinical,102-110
trials.,111-118

Calcium,0-7	DrugDDI.d283.s4.e0
channel,8-15	DrugDDI.d283.s4.e0
blocking,16-24	DrugDDI.d283.s4.e0
agents:,25-32	DrugDDI.d283.s4.e0
Coadministration,33-49
of,50-52
calcium,53-60	DrugDDI.d283.s4.e1
channel,61-68	DrugDDI.d283.s4.e1
blockers,69-77	DrugDDI.d283.s4.e1
did,78-81
not,82-85
have,86-90
any,91-94
effect,95-101
on,102-104
either,105-111
the,112-115
safety,116-122
or,123-125
efficacy,126-134
of,135-137
ibutilide,138-147	DrugDDI.d283.s4.e2
in,148-150
the,151-154
clinical,155-163
trials.,164-171

Beta-adrenergic,0-15	DrugDDI.d283.s5.e0
blocking,16-24	DrugDDI.d283.s5.e0
agents:,25-32	DrugDDI.d283.s5.e0
Coadministration,33-49
of,50-52
beta-adrenergic,53-68	DrugDDI.d283.s5.e1
blocking,69-77	DrugDDI.d283.s5.e1
agents,78-84	DrugDDI.d283.s5.e1
did,85-88
not,89-92
have,93-97
any,98-101
effect,102-108
on,109-111
either,112-118
the,119-122
safety,123-129
or,130-132
efficacy,133-141
of,142-144
ibutilide,145-154	DrugDDI.d283.s5.e2
in,155-157
the,158-161
clinical,162-170
trials.,171-178

No,0-2
evaluation,3-13
of,14-16
EXTRANEALs,17-27	DrugDDI.d177.s1.e0
effects,28-35
on,36-38
the,39-42
cytochrome,43-53	DrugDDI.d177.s1.e1
P450,54-58	DrugDDI.d177.s1.e1
system,59-65
was,66-69
conducted.,70-80

As,0-2
with,3-7
other,8-13
dialysis,14-22	DrugDDI.d177.s2.e0
solutions,,23-33	DrugDDI.d177.s2.e0
blood,34-39
concentrations,40-54
of,55-57
dialyzable,58-68
drugs,69-74	DrugDDI.d177.s2.e1
may,75-78
be,79-81
reduced,82-89
by,90-92
dialysis.,93-102

Dosage,0-6
adjustment,7-17
of,18-20
concomitant,21-32
medications,33-44	DrugDDI.d177.s3.e0
may,45-48
be,49-51
necessary.,52-62

In,0-2
patients,3-11
using,12-17
cardiac,18-25	DrugDDI.d177.s4.e0
glycosides,26-36	DrugDDI.d177.s4.e0
(digoxin,37-45
and,46-49
others),,50-58
plasma,59-65
levels,66-72
of,73-75
calcium,,76-84
potassium,85-94	DrugDDI.d177.s4.e3
and,95-98
magnesium,99-108	DrugDDI.d177.s4.e4
must,109-113
be,114-116
carefully,117-126
monitored.,127-137

Insulin,0-7	DrugDDI.d177.s5.e0
A,8-9
clinical,10-18
study,19-24
in,25-27
6,28-29
insulin-dependent,30-47
diabetic,48-56
patients,57-65
demonstrated,66-78
no,79-81
effect,82-88
of,89-91
EXTRANEAL,92-101	DrugDDI.d177.s5.e1
on,102-104
insulin,105-112	DrugDDI.d177.s5.e2
absorption,113-123
from,124-128
the,129-132
peritoneal,133-143
cavity,144-150
or,151-153
on,154-156
insulins,157-165	DrugDDI.d177.s5.e3
ability,166-173
to,174-176
control,177-184
blood,185-190
glucose,191-198
when,199-203
insulin,204-211	DrugDDI.d177.s5.e4
was,212-215
administered,216-228
intraperitoneally,229-246
with,247-251
EXTRANEAL.,252-262	DrugDDI.d177.s5.e5

However,,0-8
appropriate,9-20
monitoring,21-31
of,32-34
blood,35-40
glucose,41-48
should,49-55
be,56-58
performed,59-68
when,69-73
initiating,74-84
EXTRANEAL,85-94	DrugDDI.d177.s6.e0
in,95-97
diabetic,98-106
patients,107-115
and,116-119
insulin,120-127	DrugDDI.d177.s6.e1
dosage,128-134
should,135-141
be,142-144
adjusted,145-153
if,154-156
needed.,157-164

Heparin,0-7	DrugDDI.d177.s7.e0
No,8-10
human,11-16
drug,17-21
interaction,22-33
studies,34-41
with,42-46
heparin,47-54	DrugDDI.d177.s7.e1
were,55-59
conducted.,60-70

In,0-2
vitro,3-8
studies,9-16
demonstrated,17-29
no,30-32
evidence,33-41
of,42-44
incompatibility,45-60
of,61-63
heparin,64-71	DrugDDI.d177.s8.e0
with,72-76
EXTRANEAL.,77-87	DrugDDI.d177.s8.e1

Antibiotics,0-11	DrugDDI.d177.s9.e0
No,12-14
human,15-20
drug,21-25
interaction,26-37
studies,38-45
with,46-50
antibiotics,51-62	DrugDDI.d177.s9.e1
were,63-67
conducted.,68-78

In,0-2
vitro,3-8
studies,9-16
evaluating,17-27
the,28-31
minimum,32-39
inhibitory,40-50
concentration,51-64
(MIC),65-70
of,71-73
vancomycin,,74-85
cefazolin,,86-96
ampicillin,,97-108
ampicillin/flucoxacillin,,109-134
ceftazidime,,135-147
gentamicin,,148-159
and,160-163
amphotericin,164-176	DrugDDI.d177.s10.e6
demonstrated,177-189
no,190-192
evidence,193-201
of,202-204
incompatibility,205-220
of,221-223
these,224-229
antibiotics,230-241	DrugDDI.d177.s10.e7
with,242-246
EXTRANEAL.,247-257	DrugDDI.d177.s10.e8

Drug/Laboratory,0-15	DrugDDI.d177.s11.e0
Test,16-20
Interactions,21-33
Blood,34-39
Glucose,40-47
Blood,48-53
glucose,54-61
measurement,62-73
must,74-78
be,79-81
done,82-86
with,87-91
a,92-93
glucose-specific,94-110	DrugDDI.d177.s11.e1
method,111-117
to,118-120
prevent,121-128	DrugDDI.d177.s11.e2
maltose,129-136	DrugDDI.d177.s11.e3
interference,137-149
with,150-154
test,155-159
results.,160-168

Since,0-5
falsely,6-13
elevated,14-22
glucose,23-30
levels,31-37
have,38-42
been,43-47
observed,48-56
with,57-61
blood,62-67
glucose,68-75
monitoring,76-86
devices,87-94
and,95-98
test,99-103
strips,104-110
that,111-115
use,116-119
glucose,120-127	DrugDDI.d177.s12.e0
dehydrogenase,128-141	DrugDDI.d177.s12.e0
pyrroloquinolinequinone,142-165
(GDH,166-170
PQQ)-based,171-181
methods,,182-190
GDH,191-194	DrugDDI.d177.s12.e2
PQQ-based,195-204
methods,205-212
should,213-219
not,220-223
be,224-226
used,227-231
to,232-234
measure,235-242
glucose,243-250
levels,251-257
in,258-260
patients,261-269
administered,270-282
EXTRANEAL..,283-294	DrugDDI.d177.s12.e3

Serum,0-5
Amylase,6-13
An,14-16
apparent,17-25
decrease,26-34
in,35-37
serum,38-43
amylase,44-51
activity,52-60
has,61-64
been,65-69
observed,70-78
in,79-81
patients,82-90
administered,91-103
EXTRANEAL.,104-114	DrugDDI.d177.s13.e0

Preliminary,0-11
investigations,12-26
indicate,27-35
that,36-40
icodextrin,41-51	DrugDDI.d177.s14.e0
and,52-55
its,56-59
metabolites,60-71	DrugDDI.d177.s14.e1
interfere,72-81
with,82-86
enzymatic-based,87-102
amylase,103-110	DrugDDI.d177.s14.e2
assays,,111-118
resulting,119-128
in,129-131
inaccurately,132-144
low,145-148
values.,149-156

This,0-4
should,5-11
be,12-14
taken,15-20
into,21-25
account,26-33
when,34-38
evaluating,39-49
serum,50-55
amylase,56-63
levels,64-70
for,71-74
diagnosis,75-84
or,85-87
monitoring,88-98
of,99-101
pancreatitis,102-114
in,115-117
patients,118-126
using,127-132
EXTRANEAL.,133-143	DrugDDI.d177.s15.e0

Interactions,0-12
may,13-16
occur,17-22
between,23-30
EPA,31-34	DrugDDI.d522.s0.e0
supplements,35-46
and,47-50
aspirin,51-58	DrugDDI.d522.s0.e1
and,59-62
other,63-68
non-steroidal,69-82	DrugDDI.d522.s0.e2
anti-inflammatory,83-100	DrugDDI.d522.s0.e2
drugs,101-106	DrugDDI.d522.s0.e2
and,107-110
herbs,111-116
such,117-121
as,122-124
garlic,125-131	DrugDDI.d522.s0.e3
(Allium,132-139
sativum),140-148
and,149-152
ginkgo,153-159	DrugDDI.d522.s0.e5
(Ginkgo,160-167
biloba).,168-176

Most,0-4
who,5-8
take,9-13
EPA,14-17	DrugDDI.d522.s2.e0
supplements,18-29
and,30-33
the,34-37
above,38-43
drugs,44-49	DrugDDI.d522.s2.e1
or,50-52
herbs,53-58
do,59-61
not,62-65
suffer,66-72
from,73-77
these,78-83
problems,84-92
and,93-96
if,97-99
they,100-104
occur,,105-111
they,112-116
are,117-120
rare.,121-126

If,0-2
they,3-7
do,8-10
occur,,11-17
the,18-21
EPA,22-25	DrugDDI.d522.s3.e0
dose,26-30
should,31-37
be,38-40
lowered,41-48
or,49-51
discontinued.,52-65

Conflicting,0-11
results,12-19
have,20-24
been,25-29
reported,30-38
regarding,39-48
the,49-52
effects,53-60
of,61-63
EPA,64-67	DrugDDI.d522.s4.e0
supplements,68-79
on,80-82
glycemic,83-91
control,92-99
in,100-102
non-diabetics,103-116
with,117-121
glucose,122-129
intolerance,,130-142
and,143-146
those,147-152
with,153-157
type,158-162
2,163-164
diabetes.,165-174

Some,0-4
early,5-10
studies,11-18
indicated,19-28
that,29-33
EPA,34-37	DrugDDI.d522.s5.e0
supplements,38-49
might,50-55
have,56-60
detrimental,61-72
effects,73-80
in,81-83
those,84-89
groups.,90-97

There,0-5
is,6-8
no,9-11
evidence,12-20
that,21-25
EPA,26-29	DrugDDI.d522.s7.e0
supplements,30-41
have,42-46
detrimental,47-58
effects,59-66
on,67-69
glucose,70-77
tolerance,,78-88
insulin,89-96
secretion,97-106
or,107-109
insulin,110-117
resistance,118-128
in,129-131
non-diabetic,132-144
subjects.,145-154

Diabetics,0-9
who,10-13
take,14-18
EPA,19-22	DrugDDI.d522.s9.e0
supplements,23-34
should,35-41
be,42-44
monitored,45-54
by,55-57
their,58-63
physicians.,64-75

Other,0-5
medicines,6-15	DrugDDI.d142.s0.e0
-,16-17
Although,18-26
certain,27-34
medicines,35-44	DrugDDI.d142.s0.e1
should,45-51
not,52-55
be,56-58
used,59-63
together,64-72
at,73-75
all,,76-80
in,81-83
other,84-89
cases,90-95
two,96-99
different,100-109
medicines,110-119	DrugDDI.d142.s0.e2
may,120-123
be,124-126
used,127-131
together,132-140
even,141-145
if,146-148
an,149-151
interaction,152-163
might,164-169
occur.,170-176

When,0-4
you,5-8
are,9-12
using,13-18
idoxuridine,,19-31
it,32-34
is,35-37
especially,38-48
important,49-58
that,59-63
your,64-68
health,69-75
care,76-80
professional,81-93
know,94-98
if,99-101
you,102-105
are,106-109
using,110-115
the,116-119
following:,120-130
Eye,131-134
product,135-142
containing,143-153
boric,154-159	DrugDDI.d142.s2.e1
acid.,160-165	DrugDDI.d142.s2.e1

Boric,0-5	DrugDDI.d142.s3.e0
acid,6-10	DrugDDI.d142.s3.e0
may,11-14
interact,15-23
with,24-28
the,29-32
idoxuridine,33-44	DrugDDI.d142.s3.e1
preparation,45-56	DrugDDI.d142.s3.e1
causing,57-64
a,65-66
gritty,67-73
substance,74-83
to,84-86
form,87-91
or,92-94
may,95-98
interact,99-107
with,108-112
the,113-116
preservative,117-129
in,130-132
the,133-136
idoxuridine,137-148	DrugDDI.d142.s3.e2
preparation,149-160	DrugDDI.d142.s3.e2
causing,161-168
a,169-170
toxic,171-176
effect,177-183
in,184-186
the,187-190
eye.,191-195

The,0-3
physician,4-13
should,14-20
be,21-23
alert,24-29
for,30-33
possible,34-42
combined,43-51
drug,52-56
actions,,57-65
desirable,66-75
or,76-78
undesirable,,79-91
involving,92-101
ifosfamide,102-112	DrugDDI.d515.s0.e0
even,113-117
though,118-124
ifosfamide,125-135	DrugDDI.d515.s0.e1
has,136-139
been,140-144
used,145-149
successfully,150-162
concurrently,163-175
with,176-180
other,181-186
drugs,,187-193
including,194-203
other,204-209	DrugDDI.d515.s0.e3
cytotoxic,210-219	DrugDDI.d515.s0.e3
drugs.,220-226	DrugDDI.d515.s0.e3

In,0-2
studies,3-10
in,11-13
normal,14-20
volunteers,,21-32
there,33-38
was,39-42
no,43-45
pharmacodynamic,46-61
interaction,62-73
between,74-81
intravenous,82-93
iloprost,94-102	DrugDDI.d211.s0.e0
and,103-106
either,107-113
nifedipine,,114-125
diltiazem,,126-136
or,137-139
captopril.,140-150	DrugDDI.d211.s0.e3

However,,0-8
iloprost,9-17	DrugDDI.d211.s1.e0
has,18-21
the,22-25
potential,26-35
to,36-38
increase,39-47
the,48-51
hypotensive,52-63
effect,64-70
of,71-73
vasodilators,74-86	DrugDDI.d211.s1.e1
and,87-90
antihypertensive,91-107	DrugDDI.d211.s1.e2
agents.,108-115	DrugDDI.d211.s1.e2

Since,0-5
iloprost,6-14	DrugDDI.d211.s2.e0
inhibits,15-23
platelet,24-32
function,,33-42
there,43-48
is,49-51
a,52-53
potential,54-63
for,64-67
increased,68-77
risk,78-82
of,83-85
bleeding,,86-95
particularly,96-108
in,109-111
patients,112-120
maintained,121-131
on,132-134
anticoagulants.,135-150	DrugDDI.d211.s2.e1

During,0-6
clinical,7-15
trials,,16-23
iloprost,24-32	DrugDDI.d211.s3.e0
was,33-36
used,37-41
concurrently,42-54
with,55-59
anticoagulants,,60-75
diuretics,,76-86
cardiac,87-94	DrugDDI.d211.s3.e3
glycosides,,95-106	DrugDDI.d211.s3.e3
calcium,107-114	DrugDDI.d211.s3.e4
channel,115-122	DrugDDI.d211.s3.e4
blockers,,123-132	DrugDDI.d211.s3.e4
analgesics,,133-144
antipyretics,,145-158
nonsteroidal,159-171
antiinflammatories,,172-191
corticosteroids,,192-208
and,209-212
other,213-218	DrugDDI.d211.s3.e9
medications.,219-231	DrugDDI.d211.s3.e9

Intravenous,0-11
infusion,12-20
of,21-23
iloprost,24-32	DrugDDI.d211.s4.e0
had,33-36
no,37-39
effect,40-46
on,47-49
the,50-53
pharmacokinetics,54-70
of,71-73
digoxin.,74-82	DrugDDI.d211.s4.e1

Acetylsalicylic,0-15	DrugDDI.d211.s5.e0
acid,16-20	DrugDDI.d211.s5.e0
did,21-24
not,25-28
alter,29-34
the,35-38
clearance,39-48
(pharmacokinetics),49-67
of,68-70
iloprost.,71-80	DrugDDI.d211.s5.e1

Although,0-8
clinical,9-17
studies,18-25
have,26-30
not,31-34
been,35-39
conducted,,40-50
in,51-53
vitro,54-59
studies,60-67
of,68-70
iloprost,71-79	DrugDDI.d211.s6.e0
indicate,80-88
that,89-93
no,94-96
relevant,97-105
inhibition,106-116
of,117-119
cytochrome,120-130	DrugDDI.d211.s6.e1
P450,131-135	DrugDDI.d211.s6.e1
drug,136-140
metabolism,141-151
would,152-157
be,158-160
expected.,161-170

Drugs,0-5	DrugDDI.d561.s0.e0
that,6-10
may,11-14
alter,15-20
imatinib,21-29	DrugDDI.d561.s0.e1
plasma,30-36
concentrations,37-51
Drugs,52-57
that,58-62
may,63-66
increase,67-75
imatinib,76-84	DrugDDI.d561.s0.e2
plasma,85-91
concentrations:,92-107
Caution,108-115
is,116-118
recommended,119-130
when,131-135
administering,136-149
Gleevec,150-157	DrugDDI.d561.s0.e3
with,158-162
inhibitors,163-173
of,174-176
the,177-180
CYP3A4,181-187	DrugDDI.d561.s0.e4
family,188-194
(e.g.,,195-201
ketoconazole,,202-215
itraconazole,,216-229
erythromycin,,230-243
clarithromycin).,244-260	DrugDDI.d561.s0.e8

Substances,0-10
that,11-15
inhibit,16-23
the,24-27
cytochrome,28-38	DrugDDI.d561.s1.e0
P450,39-43	DrugDDI.d561.s1.e0
isoenzyme,44-53
(CYP3A4),54-62
activity,63-71
may,72-75
decrease,76-84
metabolism,85-95
and,96-99
increase,100-108
imatinib,109-117	DrugDDI.d561.s1.e2
concentrations.,118-133

There,0-5
is,6-8
a,9-10
significant,11-22
increase,23-31
in,32-34
exposure,35-43
to,44-46
imatinib,47-55	DrugDDI.d561.s2.e0
when,56-60
Gleevec,61-68	DrugDDI.d561.s2.e1
is,69-71
coadministered,72-86
with,87-91
ketoconazole,92-104	DrugDDI.d561.s2.e2
(CYP3A4,105-112
inhibitor).,113-124

Drugs,0-5	DrugDDI.d561.s3.e0
that,6-10
may,11-14
decrease,15-23
imatinib,24-32	DrugDDI.d561.s3.e1
plasma,33-39
concentrations:,40-55
Substances,56-66
that,67-71
are,72-75
inducers,76-84
of,85-87
CYP3A4,88-94	DrugDDI.d561.s3.e2
activity,95-103
may,104-107
increase,108-116
metabolism,117-127
and,128-131
decrease,132-140
imatinib,141-149	DrugDDI.d561.s3.e3
plasma,150-156
concentrations.,157-172

Co-medications,0-14
that,15-19
induce,20-26
CYP3A4,27-33	DrugDDI.d561.s4.e1
(e.g.,,34-40
dexamethasone,,41-55
phenytoin,,56-66
carbamazepine,,67-81
rifampin,,82-91
phenobarbital,92-105	DrugDDI.d561.s4.e6
or,106-108
St.,109-112

Johns,0-5
Wort),6-11
may,12-15
significantly,16-29
reduce,30-36
exposure,37-45
to,46-48
Gleevec.,49-57	DrugDDI.d561.s5.e0

Pretreatment,0-12
of,13-15
healthy,16-23
volunteers,24-34
with,35-39
multiple,40-48
doses,49-54
of,55-57
rifampin,58-66	DrugDDI.d561.s6.e0
followed,67-75
by,76-78
a,79-80
single,81-87
dose,88-92
of,93-95
Gleevec,,96-104
increased,105-114
Gleevec,115-122	DrugDDI.d561.s6.e2
oral-dose,123-132
clearance,133-142
by,143-145
3.8-fold,,146-155
which,156-161
significantly,162-175
(p,176-178
0.05),179-184
decreased,185-194
mean,195-199
cmax,200-204
and,205-208
AUC(0-8).,209-218

In,0-2
patients,3-11
where,12-17
rifampin,18-26	DrugDDI.d561.s7.e0
or,27-29
other,30-35
CYP3A4,36-42	DrugDDI.d561.s7.e1
inducers,43-51
are,52-55
indicated,,56-66
alternative,67-78
therapeutic,79-90	DrugDDI.d561.s7.e2
agents,91-97	DrugDDI.d561.s7.e2
with,98-102
less,103-107
enzyme,108-114
induction,115-124
potential,125-134
should,135-141
be,142-144
considered.,145-156

Drugs,0-5	DrugDDI.d561.s8.e0
that,6-10
may,11-14
have,15-19
their,20-25
plasma,26-32
concentration,33-46
altered,47-54
by,55-57
Gleevec,58-65	DrugDDI.d561.s8.e1
Gleevec,66-73
increases,74-83
the,84-87
mean,88-92
cmax,93-97
and,98-101
AUC,102-105
of,106-108
simvastatin,109-120	DrugDDI.d561.s8.e2
(CYP3A4,121-128
substrate),129-139
2-,140-142
and,143-146
3.5-fold,,147-156
respectively,,157-170
suggesting,171-181
an,182-184
inhibition,185-195
of,196-198
the,199-202
CYP3A4,203-209	DrugDDI.d561.s8.e4
by,210-212
Gleevec.,213-221	DrugDDI.d561.s8.e5

Particular,0-10
caution,11-18
is,19-21
recommended,22-33
when,34-38
administering,39-52
Gleevec,53-60	DrugDDI.d561.s9.e0
with,61-65
CYP3A4,66-72	DrugDDI.d561.s9.e1
substrates,73-83
that,84-88
have,89-93
a,94-95
narrow,96-102
therapeutic,103-114
window,115-121
(e.g.,,122-128
cyclosporine,129-141	DrugDDI.d561.s9.e2
or,142-144
pimozide).,145-155	DrugDDI.d561.s9.e3

Gleevec,0-7	DrugDDI.d561.s10.e0
will,8-12
increase,13-21
plasmaconcentration,22-41
of,42-44
other,45-50
CYP3A4,51-57
metabolized,58-69
drugs,70-75	DrugDDI.d561.s10.e1
(e.g.,,76-82
triazolo-benzodiazepines,,83-108
dihydropyridine,109-124
calcium,125-132	DrugDDI.d561.s10.e3
channel,133-140	DrugDDI.d561.s10.e3
blockers,,141-150	DrugDDI.d561.s10.e3
certain,151-158
HMG-CoA,159-166	DrugDDI.d561.s10.e4
reductase,167-176	DrugDDI.d561.s10.e4
inhibitors,,177-188	DrugDDI.d561.s10.e4
etc.).,189-195

Because,0-7
warfarin,8-16	DrugDDI.d561.s11.e0
is,17-19
metabolized,20-31
by,32-34
CYP2C9,35-41	DrugDDI.d561.s11.e1
and,42-45
CYP3A4,,46-53
patients,54-62
who,63-66
require,67-74
anticoagulation,75-90
should,91-97
receive,98-105
low-molecular,106-119
weight,120-126
or,127-129
standard,130-138
heparin.,139-147	DrugDDI.d561.s11.e3

in,0-2
vitro,,3-9
Gleevec,10-17	DrugDDI.d561.s12.e0
inhibits,18-26
the,27-30
cytochrome,31-41	DrugDDI.d561.s12.e1
P450,42-46	DrugDDI.d561.s12.e1
isoenzyme,47-56	DrugDDI.d561.s12.e1
CYP2D6,57-63	DrugDDI.d561.s12.e1
activity,64-72
at,73-75
similar,76-83
concentrations,84-98
that,99-103
affect,104-110
CYP3A4,111-117	DrugDDI.d561.s12.e2
activity.,118-127

Systemic,0-8
exposure,9-17
to,18-20
substrates,21-31
of,32-34
CYP2D6,35-41	DrugDDI.d561.s13.e0
is,42-44
expected,45-53
to,54-56
be,57-59
increased,60-69
when,70-74
coadministered,75-89
with,90-94
Gleevec.,95-103	DrugDDI.d561.s13.e1

in,0-2
vitro,,3-9
Gleevec,10-17	DrugDDI.d561.s15.e0
inhibits,18-26
acetaminophen,27-40	DrugDDI.d561.s15.e1
O-glucuronidation,41-58
(Ki,59-62
value,63-68
of,69-71
58.5,72-76
?M),77-80
at,81-83
therapeutic,84-95
levels.,96-103

Systemic,0-8
exposure,9-17
to,18-20
acetaminophen,21-34	DrugDDI.d561.s16.e0
is,35-37
expected,38-46
to,47-49
be,50-52
increased,53-62
when,63-67
coadministered,68-82
with,83-87
Gleevec.,88-96	DrugDDI.d561.s16.e1

In,0-2
occasional,3-13
susceptible,14-25
patients,26-34
or,35-37
in,38-40
those,41-46
receiving,47-56
anticholinergic,57-72	DrugDDI.d367.s0.e0
drugs,73-78	DrugDDI.d367.s0.e0
(including,79-89
antiparkinsonism,90-106
agents),107-114
in,115-117
addition,,118-127
the,128-131
atropine-like,132-145	DrugDDI.d367.s0.e1
effects,146-153
may,154-157
become,158-164
more,165-169
pronounced,170-180
(e.g.,,181-187
paralytic,188-197
ileus).,198-205

Close,0-5
supervision,6-17
and,18-21
careful,22-29
adjustment,30-40
of,41-43
dosage,44-50
is,51-53
required,54-62
when,63-67
this,68-72
drug,73-77	DrugDDI.d367.s1.e0
is,78-80
administered,81-93
concomitantly,94-107
with,108-112
anticholinergic,113-128	DrugDDI.d367.s1.e1
drugs.,129-135	DrugDDI.d367.s1.e1

Avoid,0-5
the,6-9
use,10-13
of,14-16
preparations,17-29
such,30-34
as,35-37
decongestants,38-51	DrugDDI.d367.s2.e0
and,52-55
local,56-61	DrugDDI.d367.s2.e1
anesthetics,62-73	DrugDDI.d367.s2.e1
which,74-79
contain,80-87
any,88-91
sympathomimetic,92-107	DrugDDI.d367.s2.e2
amine,108-113	DrugDDI.d367.s2.e2
(e.g.,,114-120
epinephrine,,121-133
norepinephrine),,134-150
since,151-156
it,157-159
has,160-163
been,164-168
reported,169-177
that,178-182
tricyclic,183-192	DrugDDI.d367.s2.e5
antidepressants,193-208	DrugDDI.d367.s2.e5
can,209-212
potentiate,213-223
the,224-227
effects,228-235
of,236-238
catecholamines.,239-254

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
imipramine,33-43	DrugDDI.d367.s3.e0
hydrochloride,44-57	DrugDDI.d367.s3.e0
is,58-60
used,61-65
with,66-70
agents,71-77
that,78-82
lower,83-88
blood,89-94
pressure.,95-104

Imipramine,0-10	DrugDDI.d367.s4.e0
hydrochloride,11-24	DrugDDI.d367.s4.e0
may,25-28
potentiate,29-39
the,40-43
effects,44-51
of,52-54
CNS,55-58	DrugDDI.d367.s4.e1
depressant,59-69	DrugDDI.d367.s4.e1
drugs.,70-76	DrugDDI.d367.s4.e1

The,0-3
plasma,4-10
concentration,11-24
of,25-27
imipramine,28-38	DrugDDI.d367.s5.e0
may,39-42
increase,43-51
when,52-56
the,57-60
drug,61-65	DrugDDI.d367.s5.e1
is,66-68
given,69-74
concomitantly,75-88
with,89-93
hepatic,94-101
enzyme,102-108	DrugDDI.d367.s5.e2
inhibitors,109-119	DrugDDI.d367.s5.e2
(e.g.,,120-126
cimetidine,,127-138
fluoxetine),139-150	DrugDDI.d367.s5.e4
and,151-154
decrease,155-163
by,164-166
concomitant,167-178
administration,179-193
of,194-196
hepatic,197-204
enzyme,205-211
inducers,212-220
(e.g.,,221-227
barbiturates,,228-241
phenytoin),,242-253
and,254-257
adjustment,258-268
of,269-271
the,272-275
dosage,276-282
of,283-285
imipramine,286-296	DrugDDI.d367.s5.e7
may,297-300
therefore,301-310
be,311-313
necessary.,314-324

Drugs,0-5	DrugDDI.d367.s6.e0
Metabolized,6-17
by,18-20
P450,21-25	DrugDDI.d367.s6.e1
2D6,26-29	DrugDDI.d367.s6.e1
The,30-33
biochemical,34-45
activity,46-54
of,55-57
the,58-61
drug,62-66	DrugDDI.d367.s6.e2
metabolizing,67-79
isozyme,80-87
cytochrome,88-98
P450,99-103
2D6,104-107
(debrisoquin,108-120
hydroxylase),121-133
is,134-136
reduced,137-144
in,145-147
a,148-149
subset,150-156
of,157-159
the,160-163
caucasian,164-173
population,174-184
(about,185-191
7,192-193
to,194-196
10%,197-200
of,201-203
caucasians,204-214
are,215-218
so,219-221
called,222-228
poor,229-233
metabolizers);,234-248

reliable,0-8
estimates,9-18
of,19-21
the,22-25
prevalence,26-36
of,37-39
reduced,40-47
P450,48-52	DrugDDI.d367.s7.e0
2D6,53-56	DrugDDI.d367.s7.e0
isozyme,57-64	DrugDDI.d367.s7.e0
activity,65-73
among,74-79
Asian,,80-86
African,87-94
and,95-98
other,99-104
populations,105-116
are,117-120
not,121-124
yet,125-128
available.,129-139

Poor,0-4
metabolizers,5-17
have,18-22
higher,23-29
than,30-34
expected,35-43
plasma,44-50
concentrations,51-65
of,66-68
tricyclic,69-78	DrugDDI.d367.s8.e0
antidepressants,79-94	DrugDDI.d367.s8.e0
(TCAs),95-101
when,102-106
given,107-112
usual,113-118
doses.,119-125

Depending,0-9
on,10-12
the,13-16
fraction,17-25
of,26-28
drug,29-33	DrugDDI.d367.s9.e0
metabolized,34-45
by,46-48
P450,49-53	DrugDDI.d367.s9.e1
2D6,,54-58	DrugDDI.d367.s9.e1
the,59-62
increase,63-71
in,72-74
plasma,75-81
concentration,82-95
may,96-99
be,100-102
small,,103-109
or,110-112
quite,113-118
large,119-124
(8-fold,125-132
increase,133-141
in,142-144
plasma,145-151
AUC,152-155
of,156-158
the,159-162
TCA).,163-168

In,0-2
addition,,3-12
certain,13-20
drugs,21-26	DrugDDI.d367.s10.e0
inhibit,27-34
the,35-38
activity,39-47
of,48-50
this,51-55
isozyme,56-63	DrugDDI.d367.s10.e1
and,64-67
make,68-72
normal,73-79
metabolizers,80-92
resemble,93-101
p.o.,102-106

An,0-2
individual,3-13
who,14-17
is,18-20
stable,21-27
on,28-30
a,31-32
given,33-38
dose,39-43
of,44-46
TCA,47-50
may,51-54
become,55-61
abruptly,62-70
toxic,71-76
when,77-81
given,82-87
one,88-91
of,92-94
these,95-100
inhibiting,101-111
drugs,112-117	DrugDDI.d367.s12.e0
as,118-120
concomitant,121-132
therapy.,133-141

The,0-3
drugs,4-9	DrugDDI.d367.s13.e0
that,10-14
inhibit,15-22
cytochrome,23-33	DrugDDI.d367.s13.e1
P450,34-38	DrugDDI.d367.s13.e1
2D6,39-42	DrugDDI.d367.s13.e1
include,43-50
some,51-55
that,56-60
are,61-64
not,65-68
metabolized,69-80
by,81-83
the,84-87
enzyme,88-94
(quinidine;,95-106

cimetidine),0-11	DrugDDI.d367.s14.e0
and,12-15
many,16-20
that,21-25
are,26-29
substrates,30-40
for,41-44
P450,45-49	DrugDDI.d367.s14.e1
2D6,50-53	DrugDDI.d367.s14.e1
(many,54-59
other,60-65
antidepressants,,66-82
phenothiazines,,83-98
and,99-102
the,103-106
Type,107-111
1C,112-114
antiarrhythmics,115-130
propafenone,131-142	DrugDDI.d367.s14.e4
and,143-146
flecainide).,147-159	DrugDDI.d367.s14.e5

While,0-5
all,6-9
the,10-13
selective,14-23
serotonin,24-33	DrugDDI.d367.s15.e0
reuptake,34-42	DrugDDI.d367.s15.e0
inhibitors,43-53	DrugDDI.d367.s15.e0
(SSRIs),,54-62
e.,63-65
g.,,66-69
fluoxetine,,70-81
sertraline,,82-93
and,94-97
paroxetine,,98-109
inhibit,110-117
P450,118-122	DrugDDI.d367.s15.e4
2D6,,123-127	DrugDDI.d367.s15.e4
they,128-132
may,133-136
vary,137-141
in,142-144
the,145-148
extent,149-155
of,156-158
inhibition.,159-170

Of,0-2
particular,3-13
importance,,14-25
sufficient,26-36
time,37-41
must,42-46
elapse,47-53
before,54-60
initiating,61-71
TCA,72-75
treatment,76-85
in,86-88
a,89-90
patient,91-98
being,99-104
withdrawn,105-114
from,115-119
fluoxetine,,120-131
given,132-137
the,138-141
long,142-146
half-life,147-156
of,157-159
the,160-163
parent,164-170
and,171-174
active,175-181	DrugDDI.d367.s18.e1
metabolite,182-192	DrugDDI.d367.s18.e1
(at,193-196
least,197-202
5,203-204
weeks,205-210
may,211-214
be,215-217
necessary).,218-229

Concomitant,0-11
use,12-15
of,16-18
tricyclic,19-28	DrugDDI.d367.s19.e0
antidepressants,29-44	DrugDDI.d367.s19.e0
with,45-49
drugs,50-55	DrugDDI.d367.s19.e1
that,56-60
can,61-64
inhibit,65-72
cytochrome,73-83	DrugDDI.d367.s19.e2
P450,84-88	DrugDDI.d367.s19.e2
2D6,89-92	DrugDDI.d367.s19.e2
may,93-96
require,97-104
lower,105-110
doses,111-116
than,117-121
usually,122-129
prescribed,130-140
for,141-144
either,145-151
the,152-155
tricyclic,156-165	DrugDDI.d367.s19.e3
antidepressant,166-180	DrugDDI.d367.s19.e3
or,181-183
the,184-187
other,188-193
drug.,194-199	DrugDDI.d367.s19.e4

Furthermore,,0-12
whenever,13-21
one,22-25
of,26-28
these,29-34
other,35-40
drugs,41-46	DrugDDI.d367.s20.e0
is,47-49
withdrawn,50-59
from,60-64
cotherapy,,65-75
an,76-78
increased,79-88
dose,89-93
of,94-96
tricyclic,97-106	DrugDDI.d367.s20.e1
antidepressant,107-121	DrugDDI.d367.s20.e1
may,122-125
be,126-128
required.,129-138

It,0-2
is,3-5
desirable,6-15
to,16-18
monitor,19-26
TCA,27-30
plasma,31-37
levels,38-44
whenever,45-53
a,54-55
TCA,56-59
is,60-62
going,63-68
to,69-71
be,72-74
co-administered,75-90
with,91-95
another,96-103
drug,104-108	DrugDDI.d367.s21.e0
known,109-114
to,115-117
be,118-120
an,121-123
inhibitor,124-133
of,134-136
P450,137-141	DrugDDI.d367.s21.e1
2D6.,142-146	DrugDDI.d367.s21.e1

Indinavir,0-9	DrugDDI.d402.s0.e0
is,10-12
an,13-15
inhibitor,16-25
of,26-28
the,29-32
cytochrome,33-43	DrugDDI.d402.s0.e1
P450,44-48	DrugDDI.d402.s0.e1
isoform,49-56
CYP3A4.,57-64

Coadministration,0-16
of,17-19
CRIXIVAN,20-28	DrugDDI.d402.s1.e0
and,29-32
drugs,33-38	DrugDDI.d402.s1.e1
primarily,39-48
metabolized,49-60
by,61-63
CYP3A4,64-70	DrugDDI.d402.s1.e2
may,71-74
result,75-81
in,82-84
increased,85-94
plasma,95-101
concentrations,102-116
of,117-119
the,120-123
other,124-129
drug,,130-135
which,136-141
could,142-147
increase,148-156
or,157-159
prolong,160-167
its,168-171
therapeutic,172-183
and,184-187
adverse,188-195
effects.,196-204

Indinavir,0-9	DrugDDI.d402.s2.e0
is,10-12
metabolized,13-24
by,25-27
CYP3A4.,28-35	DrugDDI.d402.s2.e1

Drugs,0-5	DrugDDI.d402.s3.e0
that,6-10
induce,11-17
CYP3A4,18-24	DrugDDI.d402.s3.e1
activity,25-33
would,34-39
be,40-42
expected,43-51
to,52-54
increase,55-63
the,64-67
clearance,68-77
of,78-80
indinavir,,81-91
resulting,92-101
in,102-104
lowered,105-112
plasma,113-119
concentrations,120-134
of,135-137
indinavir.,138-148	DrugDDI.d402.s3.e3

Coadministration,0-16
of,17-19
CRIXIVAN,20-28	DrugDDI.d402.s4.e0
and,29-32
other,33-38
drugs,39-44	DrugDDI.d402.s4.e1
that,45-49
inhibit,50-57
CYP3A4,58-64	DrugDDI.d402.s4.e2
may,65-68
decrease,69-77
the,78-81
clearance,82-91
of,92-94
indinavir,95-104	DrugDDI.d402.s4.e3
and,105-108
may,109-112
result,113-119
in,120-122
increased,123-132
plasma,133-139
concentrations,140-154
of,155-157
indinavir.,158-168	DrugDDI.d402.s4.e4

Drugs,0-5	DrugDDI.d402.s6.e0
That,6-10
Should,11-17
Not,18-21
Be,22-24
Coadministered,25-39
with,40-44
CRIXIVAN,45-53	DrugDDI.d402.s6.e1

Drug,0-4	DrugDDI.d402.s7.e0
Class:,5-11
Drug,12-16	DrugDDI.d402.s7.e1
Name,17-21
Clinical,22-30
Comment,31-38

Antiarrhythmics:,0-16	DrugDDI.d402.s8.e0
amiodarone,17-27	DrugDDI.d402.s8.e1

Ergot,0-5	DrugDDI.d402.s10.e0
derivatives:,6-18	DrugDDI.d402.s10.e0
dihydroergotamine,,19-37
ergonovine,,38-49
ergotamine,,50-61
methylergonovine,62-78	DrugDDI.d402.s10.e4

CONTRAINDICATED,0-15
due,16-19
to,20-22
potential,23-32
for,33-36
serious,37-44
and/or,45-51
life-threatening,52-68
reactions,69-78
such,79-83
as,84-86
acute,87-92
ergot,93-98	DrugDDI.d402.s11.e0
toxicity,99-107
characterized,108-121
by,122-124
peripheral,125-135
vasospasm,136-145
and,146-149
ischemia,150-158
of,159-161
the,162-165
extremities,166-177
and,178-181
other,182-187
tissues.,188-196

Sedative/hypnotics:,0-19	DrugDDI.d402.s12.e0
midazolam,,20-30
triazolam,31-40	DrugDDI.d402.s12.e3

GI,0-2
motility,3-11
agents:,12-19
cisapride,20-29	DrugDDI.d402.s14.e0

Neuroleptic:,0-12	DrugDDI.d402.s16.e0
pimozide,13-21	DrugDDI.d402.s16.e1

Herbal,0-6
products:,7-16
St.,17-20
John?s,21-27
wort,28-32
(Hypericum,33-43
perforatum),44-55

May,0-3
lead,4-8
to,9-11
loss,12-16
of,17-19
virologic,20-29
response,30-38
and,39-42
possible,43-51
resistance,52-62
to,63-65
CRIXIVAN,66-74	DrugDDI.d402.s19.e0
or,75-77
to,78-80
the,81-84
class,85-90
of,91-93
protease,94-102	DrugDDI.d402.s19.e1
inhibitors.,103-114	DrugDDI.d402.s19.e1

Antimycobacterial:,0-18
rifampin,19-27	DrugDDI.d402.s20.e0

May,0-3
lead,4-8
to,9-11
loss,12-16
of,17-19
virologic,20-29
response,30-38
and,39-42
possible,43-51
resistance,52-62
to,63-65
CRIXIVAN,66-74	DrugDDI.d402.s21.e0
or,75-77
to,78-80
the,81-84
class,85-90
of,91-93
protease,94-102	DrugDDI.d402.s21.e1
inhibitors,103-113	DrugDDI.d402.s21.e1
or,114-116
other,117-122
coadministered,123-137
antiretroviral,138-152	DrugDDI.d402.s21.e2
agents.,153-160	DrugDDI.d402.s21.e2

HMG-CoA,0-7	DrugDDI.d402.s22.e0
Reductase,8-17	DrugDDI.d402.s22.e0
inhibitors:,18-29	DrugDDI.d402.s22.e0
lovastatin,,30-41
simvastatin,42-53	DrugDDI.d402.s22.e2

Protease,0-8	DrugDDI.d402.s24.e0
inhibitor:,9-19	DrugDDI.d402.s24.e0
atazanavir,20-30	DrugDDI.d402.s24.e1

Both,0-4
CRIXIVAN,5-13	DrugDDI.d402.s25.e0
and,14-17
atazanavir,18-28	DrugDDI.d402.s25.e1
are,29-32
associated,33-43
with,44-48
indirect,49-57
(unconjugated),58-72
hyperbilirubinemia.,73-92

Combinations,0-12
of,13-15
these,16-21
drugs,22-27	DrugDDI.d402.s26.e0
have,28-32
not,33-36
been,37-41
studied,42-49
and,50-53
coadministration,54-70
of,71-73
CRIXIVAN,74-82	DrugDDI.d402.s26.e1
and,83-86
atazanavir,87-97	DrugDDI.d402.s26.e2
is,98-100
not,101-104
recommended.,105-117

Drug,0-4	DrugDDI.d402.s29.e0
Name,5-9

HIV,0-3
Antiviral,4-13	DrugDDI.d402.s32.e0
Agents,14-20	DrugDDI.d402.s32.e0

Delavirdine,0-11	DrugDDI.d402.s33.e0

?,0-1
indinavir,2-11	DrugDDI.d402.s34.e0
concentration,12-25

Dose,0-4
reduction,5-14
of,15-17
CRIXIVAN,18-26	DrugDDI.d402.s35.e0
to,27-29
600,30-33
mg,34-36
every,37-42
8,43-44
hours,45-50
should,51-57
be,58-60
considered,61-71
when,72-76
taking,77-83
delavirdine,84-95	DrugDDI.d402.s35.e1
400,96-99
mg,100-102
three,103-108
times,109-114
a,115-116
day.,117-121

Didanosine,0-10	DrugDDI.d402.s36.e0

Indinavir,0-9	DrugDDI.d402.s37.e0
and,10-13
didanosine,14-24	DrugDDI.d402.s37.e1
formulations,25-37
containing,38-48
buffer,49-55	DrugDDI.d402.s37.e2
should,56-62
be,63-65
administered,66-78
at,79-81
least,82-87
one,88-91
hour,92-96
apart,97-102
on,103-105
an,106-108
empty,109-114
stomach.,115-123

Efavirenz,0-9	DrugDDI.d402.s38.e0

The,0-3
optimal,4-11
dose,12-16
of,17-19
indinavir,,20-30
when,31-35
given,36-41
in,42-44
combination,45-56
with,57-61
efavirenz,,62-72
is,73-75
not,76-79
known.,80-86

Increasing,0-10
the,11-14
indinavir,15-24	DrugDDI.d402.s41.e0
dose,25-29
to,30-32
1000,33-37
mg,38-40
every,41-46
8,47-48
hours,49-54
does,55-59
not,60-63
compensate,64-74
for,75-78
the,79-82
increased,83-92
indinavir,93-102	DrugDDI.d402.s41.e1
metabolism,103-113
due,114-117
to,118-120
efavirenz.,121-131	DrugDDI.d402.s41.e2

Nelfinavir,0-10	DrugDDI.d402.s42.e0

?,0-1
indinavir,2-11	DrugDDI.d402.s43.e0
concentration,12-25

Nevirapine,0-10	DrugDDI.d402.s45.e0

?,0-1
indinavir,2-11	DrugDDI.d402.s46.e0
concentration,12-25

Indinavir,0-9	DrugDDI.d402.s47.e0
concentrations,10-24
may,25-28
be,29-31
decreased,32-41
in,42-44
the,45-48
presence,49-57
of,58-60
nevirapine.,61-72	DrugDDI.d402.s47.e1

Ritonavir,0-9	DrugDDI.d402.s49.e0

?,0-1
indinavir,2-11	DrugDDI.d402.s50.e0
concentration,12-25
?,26-27
ritonavir,28-37	DrugDDI.d402.s50.e1
concentration,38-51

Preliminary,0-11
clinical,12-20
data,21-25
suggest,26-33
that,34-38
the,39-42
incidence,43-52
of,53-55
nephrolithiasis,56-71
is,72-74
higher,75-81
in,82-84
patients,85-93
receiving,94-103
indinavir,104-113	DrugDDI.d402.s52.e0
in,114-116
combination,117-128
with,129-133
ritonavir,134-143	DrugDDI.d402.s52.e1
than,144-148
those,149-154
receiving,155-164
CRIXIVAN,165-173	DrugDDI.d402.s52.e2
800,174-177
mg,178-180
q8h.,181-185

Saquinavir,0-10	DrugDDI.d402.s53.e0

?,0-1
saquinavir,2-12	DrugDDI.d402.s54.e0
concentration,13-26

Antiarrhythmics:,0-16	DrugDDI.d402.s57.e0
bepridil,,17-26
lidocaine,27-36	DrugDDI.d402.s57.e2
(systemic),37-47
and,48-51
quinidine,52-61	DrugDDI.d402.s57.e3

?,0-1
antiarrhythmic,2-16	DrugDDI.d402.s58.e0
agents,17-23	DrugDDI.d402.s58.e0
concentration,24-37

Caution,0-7
is,8-10
warranted,11-20
and,21-24
therapeutic,25-36
concentration,37-50
monitoring,51-61
is,62-64
recommended,65-76
for,77-80
antiarrhythmics,81-96	DrugDDI.d402.s59.e0
when,97-101
coadministered,102-116
with,117-121
CRIXIVAN.,122-131	DrugDDI.d402.s59.e1

Anticonvulsants:,0-16	DrugDDI.d402.s60.e0
carbamazepine,,17-31
phenobarbital,,32-46
phenytoin,47-56	DrugDDI.d402.s60.e3

?,0-1
indinavir,2-11	DrugDDI.d402.s61.e0
concentration,12-25

CRIXIVAN,0-8	DrugDDI.d402.s63.e0
may,9-12
not,13-16
be,17-19
effective,20-29
due,30-33
to,34-36
decreased,37-46
indinavir,47-56	DrugDDI.d402.s63.e1
concentrations,57-71
in,72-74
patients,75-83
taking,84-90
these,91-96
agents,97-103
concomitantly.,104-118

Calcium,0-7	DrugDDI.d402.s64.e0
Channel,8-15	DrugDDI.d402.s64.e0
Blockers,,16-25	DrugDDI.d402.s64.e0
Dihydropyridine:,26-42	DrugDDI.d402.s64.e1
e.g.,,43-48
felodipine,,49-60
nifedipine,,61-72
nicardipine,73-84	DrugDDI.d402.s64.e4

?,0-1
dihydropyridine,2-17
calcium,18-25	DrugDDI.d402.s65.e0
channel,26-33	DrugDDI.d402.s65.e0
blockers,34-42	DrugDDI.d402.s65.e0
concentration,43-56

Clarithromycin,0-14	DrugDDI.d402.s67.e0

?,0-1
clarithromycin,2-16	DrugDDI.d402.s68.e0
concentration,17-30
?,31-32
indinavir,33-42	DrugDDI.d402.s68.e1
concentration,43-56

HMG-CoA,0-7	DrugDDI.d402.s70.e0
Reductase,8-17	DrugDDI.d402.s70.e0
Inhibitor:,18-28	DrugDDI.d402.s70.e0
atorvastatin,29-41	DrugDDI.d402.s70.e1

?,0-1
atorvastatin,2-14	DrugDDI.d402.s71.e0
concentration,15-28

Use,0-3
lowest,4-10
possible,11-19
dose,20-24
of,25-27
atorvastatin,28-40	DrugDDI.d402.s72.e0
with,41-45
careful,46-53
monitoring,,54-65
or,66-68
consider,69-77
HMG-CoA,78-85	DrugDDI.d402.s72.e1
reductase,86-95	DrugDDI.d402.s72.e1
inhibitors,96-106	DrugDDI.d402.s72.e1
that,107-111
are,112-115
not,116-119
primarily,120-129
metabolized,130-141
by,142-144
CYP3A4,,145-152
such,153-157
as,158-160
pravastatin,,161-173
fluvastatin,,174-186
or,187-189
rosuvastatin,190-202	DrugDDI.d402.s72.e5
in,203-205
combination,206-217
with,218-222
CRIXIVAN.,223-232	DrugDDI.d402.s72.e6

Immunosuppressants:,0-19	DrugDDI.d402.s73.e0
cyclosporine,,20-33
tacrolimus,,34-45
sirolimus,46-55	DrugDDI.d402.s73.e3

?,0-1
immunosuppressant,2-19	DrugDDI.d402.s74.e0
agents,20-26	DrugDDI.d402.s74.e0
concentration,27-40

Plasma,0-6
concentrations,7-21
may,22-25
be,26-28
increased,29-38
by,39-41
CRIXIVAN.,42-51	DrugDDI.d402.s75.e0

Itraconazole,0-12	DrugDDI.d402.s76.e0

?,0-1
indinavir,2-11	DrugDDI.d402.s77.e0
concentration,12-25

Dose,0-4
reduction,5-14
of,15-17
CRIXIVAN,18-26	DrugDDI.d402.s78.e0
to,27-29
600,30-33
mg,34-36
every,37-42
8,43-44
hours,45-50
is,51-53
recommended,54-65
when,66-70
administering,71-84
itraconazole,85-97	DrugDDI.d402.s78.e1
concurrently.,98-111

Ketoconazole,0-12	DrugDDI.d402.s79.e0

?,0-1
indinavir,2-11	DrugDDI.d402.s80.e0
concentration,12-25

Dose,0-4
reduction,5-14
of,15-17
CRIXIVAN,18-26	DrugDDI.d402.s81.e0
to,27-29
600,30-33
mg,34-36
every,37-42
8,43-44
hours,45-50
should,51-57
be,58-60
considered.,61-72

Rifabutin,0-9	DrugDDI.d402.s82.e0

?,0-1
indinavir,2-11	DrugDDI.d402.s83.e0
concentration,12-25
?,26-27
rifabutin,28-37	DrugDDI.d402.s83.e1
concentration,38-51

Dose,0-4
reduction,5-14
of,15-17
rifabutin,18-27	DrugDDI.d402.s84.e0
to,28-30
half,31-35
the,36-39
standard,40-48
dose,49-53
and,54-57
a,58-59
dose,60-64
increase,65-73
of,74-76
CRIXIVAN,77-85	DrugDDI.d402.s84.e1
to,86-88
1000,89-93
mg,94-96
(three,97-103
333-mg,104-110
capsules),111-120
every,121-126
8,127-128
hours,129-134
are,135-138
recommended,139-150
when,151-155
rifabutin,156-165	DrugDDI.d402.s84.e2
and,166-169
CRIXIVAN,170-178	DrugDDI.d402.s84.e3
are,179-182
coadministered.,183-198

Sildenafil,0-10	DrugDDI.d402.s85.e0

?,0-1
sildenafil,2-12	DrugDDI.d402.s86.e0
concentration,13-26

Sildenafil,0-10	DrugDDI.d402.s87.e0
dose,11-15
should,16-22
not,23-26
exceed,27-33
a,34-35
maximum,36-43
of,44-46
25,47-49
mg,50-52
in,53-55
a,56-57
48-,58-61
hour,62-66
period,67-73
in,74-76
patients,77-85
receiving,86-95
concomitant,96-107
indinavir,108-117	DrugDDI.d402.s87.e1
therapy.,118-126

Tadalafil,0-9	DrugDDI.d402.s88.e0

?,0-1
tadalafil,2-11	DrugDDI.d402.s89.e0
concentration,12-25

Tadalafil,0-9	DrugDDI.d402.s90.e0
dose,10-14
should,15-21
not,22-25
exceed,26-32
a,33-34
maximum,35-42
of,43-45
10,46-48
mg,49-51
in,52-54
a,55-56
72-,57-60
hour,61-65
period,66-72
in,73-75
patients,76-84
receiving,85-94
concomitant,95-106
indinavir,107-116	DrugDDI.d402.s90.e1
therapy.,117-125

Vardenafil,0-10	DrugDDI.d402.s91.e0

?,0-1
vardenafil,2-12	DrugDDI.d402.s92.e0
concentration,13-26

Vardenafil,0-10	DrugDDI.d402.s93.e0
dose,11-15
should,16-22
not,23-26
exceed,27-33
a,34-35
maximum,36-43
of,44-46
2.5,47-50
mg,51-53
in,54-56
a,57-58
24-hour,59-66
period,67-73
in,74-76
patients,77-85
receiving,86-95
concomitant,96-107
indinavir,108-117	DrugDDI.d402.s93.e1
therapy.,118-126

In,0-2
normal,3-9
volunteers,10-20
receiving,21-30
indomethacin,,31-44
the,45-48
administration,49-63
of,64-66
diflunisal,67-77	DrugDDI.d577.s0.e1
decreased,78-87
the,88-91
renal,92-97
clearance,98-107
and,108-111
significantly,112-125
increased,126-135
the,136-139
plasma,140-146
levels,147-153
of,154-156
indomethacin.,157-170	DrugDDI.d577.s0.e2

In,0-2
some,3-7
patients,,8-17
combined,18-26
use,27-30
of,31-33
INDOCIN,34-41	DrugDDI.d577.s1.e0
and,42-45
diflunisal,46-56	DrugDDI.d577.s1.e1
has,57-60
been,61-65
associated,66-76
with,77-81
fatal,82-87
gastrointestinal,88-104
hemorrhage.,105-116

Therefore,,0-10
diflunisal,11-21	DrugDDI.d577.s2.e0
and,22-25
INDOCIN,26-33	DrugDDI.d577.s2.e1
should,34-40
not,41-44
be,45-47
used,48-52
concomitantly.,53-67

In,0-2
a,3-4
study,5-10
in,11-13
normal,14-20
volunteers,,21-32
it,33-35
was,36-39
found,40-45
that,46-50
chronic,51-58
concurrent,59-69
administration,70-84
of,85-87
3.6,88-91
g,92-93
of,94-96
aspirin,97-104	DrugDDI.d577.s3.e0
per,105-108
day,109-112
decreases,113-122
indomethacin,123-135	DrugDDI.d577.s3.e1
blood,136-141
levels,142-148
approximately,149-162
20%.,163-167

The,0-3
concomitant,4-15
use,16-19
of,20-22
INDOCIN,23-30	DrugDDI.d577.s4.e0
with,31-35
other,36-41
NSAIDs,42-48	DrugDDI.d577.s4.e1
is,49-51
not,52-55
recommended,56-67
due,68-71
to,72-74
the,75-78
increased,79-88
possibility,89-100
of,101-103
gastrointestinal,104-120
toxicity,,121-130
with,131-135
little,136-142
or,143-145
no,146-148
increase,149-157
in,158-160
efficacy.,161-170

Clinical,0-8
studies,9-16
have,17-21
shown,22-27
that,28-32
INDOCIN,33-40	DrugDDI.d577.s5.e0
does,41-45
not,46-49
influence,50-59
the,60-63
hypoprothrombinemia,64-83
produced,84-92
by,93-95
anticoagulants.,96-111	DrugDDI.d577.s5.e1

However,,0-8
when,9-13
any,14-17
additional,18-28
drug,,29-34
including,35-44
INDOCIN,,45-53
is,54-56
added,57-62
to,63-65
the,66-69
treatment,70-79
of,80-82
patients,83-91
on,92-94
anticoagulant,95-108
therapy,,109-117
the,118-121
patients,122-130
should,131-137
be,138-140
observed,141-149
for,150-153
alterations,154-165
of,166-168
the,169-172
prothrombin,173-184
time.,185-190

In,0-2
post-marketing,3-17
experience,,18-29
bleeding,30-38
has,39-42
been,43-47
reported,48-56
in,57-59
patients,60-68
on,69-71
concomitant,72-83
treatment,84-93
with,94-98
anticoagulants,99-113	DrugDDI.d577.s7.e0
and,114-117
INDOCIN.,118-126	DrugDDI.d577.s7.e1

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
INDOCIN,33-40	DrugDDI.d577.s8.e0
and,41-44
anticoagulants,45-59	DrugDDI.d577.s8.e1
are,60-63
administered,64-76
concomitantly.,77-91

When,0-4
INDOCIN,5-12	DrugDDI.d577.s9.e0
is,13-15
given,16-21
to,22-24
patients,25-33
receiving,34-43
probenecid,,44-55
the,56-59
plasma,60-66
levels,67-73
of,74-76
indomethacin,77-89	DrugDDI.d577.s9.e2
are,90-93
likely,94-100
to,101-103
be,104-106
increased.,107-117

Therefore,,0-10
a,11-12
lower,13-18
total,19-24
daily,25-30
dosage,31-37
of,38-40
INDOCIN,41-48	DrugDDI.d577.s10.e0
may,49-52
produce,53-60
a,61-62
satisfactory,63-75
therapeutic,76-87
effect.,88-95

When,0-4
increases,5-14
in,15-17
the,18-21
dose,22-26
of,27-29
INDOCIN,30-37	DrugDDI.d577.s11.e0
are,38-41
made,,42-47
they,48-52
should,53-59
be,60-62
made,63-67
carefully,68-77
and,78-81
in,82-84
small,85-90
increments.,91-102

Caution,0-7
should,8-14
be,15-17
used,18-22
if,23-25
INDOCIN,26-33	DrugDDI.d577.s12.e0
is,34-36
administered,37-49
simultaneously,50-64
with,65-69
methotrexate.,70-83	DrugDDI.d577.s12.e1

INDOCIN,0-7	DrugDDI.d577.s13.e0
has,8-11
been,12-16
reported,17-25
to,26-28
decrease,29-37
the,38-41
tubular,42-49
secretion,50-59
of,60-62
methotrexate,63-75	DrugDDI.d577.s13.e1
and,76-79
to,80-82
potentiate,83-93
its,94-97
toxicity.,98-107

Administration,0-14
of,15-17
non-steroidal,18-31	DrugDDI.d577.s14.e0
anti-inflammatory,32-49	DrugDDI.d577.s14.e0
drugs,50-55	DrugDDI.d577.s14.e0
concomitantly,56-69
with,70-74
cyclosporine,75-87	DrugDDI.d577.s14.e1
has,88-91
been,92-96
associated,97-107
with,108-112
an,113-115
increase,116-124
in,125-127
cyclosporine-induced,128-148
toxicity,,149-158
possibly,159-167
due,168-171
to,172-174
decreased,175-184
synthesis,185-194
of,195-197
renal,198-203
prostacyclin.,204-217	DrugDDI.d577.s14.e2

NSAIDs,0-6	DrugDDI.d577.s15.e0
should,7-13
be,14-16
used,17-21
with,22-26
caution,27-34
in,35-37
patients,38-46
taking,47-53
cyclosporine,,54-67
and,68-71
renal,72-77
function,78-86
should,87-93
be,94-96
carefully,97-106
monitored.,107-117

Capsules,0-8
INDOCIN,9-16
50,17-19
mg,20-22
t.i.d.,23-29
produced,30-38
a,39-40
clinically,41-51
relevant,52-60
elevation,61-70
of,71-73
plasma,74-80
lithium,81-88	DrugDDI.d577.s16.e0
and,89-92
reduction,93-102
in,103-105
renal,106-111
lithium,112-119	DrugDDI.d577.s16.e1
clearance,120-129
in,130-132
psychiatric,133-144
patients,145-153
and,154-157
normal,158-164
subjects,165-173
with,174-178
steady,179-185
state,186-191
plasma,192-198
lithium,199-206	DrugDDI.d577.s16.e2
concentrations.,207-222

This,0-4
effect,5-11
has,12-15
been,16-20
attributed,21-31
to,32-34
inhibition,35-45
of,46-48
prostaglandin,49-62	DrugDDI.d577.s17.e0
synthesis.,63-73

As,0-2
a,3-4
consequence,,5-17
when,18-22
INDOCIN,23-30	DrugDDI.d577.s18.e0
and,31-34
lithium,35-42	DrugDDI.d577.s18.e1
are,43-46
given,47-52
concomitantly,,53-67
the,68-71
patient,72-79
should,80-86
be,87-89
carefully,90-99
observed,100-108
for,109-112
signs,113-118
of,119-121
lithium,122-129
toxicity.,130-139

(Read,0-5
circulars,6-15
for,16-19
lithium,20-27	DrugDDI.d577.s19.e0
preparations,28-40	DrugDDI.d577.s19.e0
before,41-47
use,48-51
of,52-54
such,55-59
concomitant,60-71
therapy.),72-81

In,0-2
addition,,3-12
the,13-16
frequency,17-26
of,27-29
monitoring,30-40
serum,41-46
lithium,47-54	DrugDDI.d577.s20.e0
concentration,55-68
should,69-75
be,76-78
increased,79-88
at,89-91
the,92-95
outset,96-102
of,103-105
such,106-110
combination,111-122
drug,123-127	DrugDDI.d577.s20.e1
treatment.,128-138

INDOCIN,0-7	DrugDDI.d577.s21.e0
given,8-13
concomitantly,14-27
with,28-32
digoxin,33-40	DrugDDI.d577.s21.e1
has,41-44
been,45-49
reported,50-58
to,59-61
increase,62-70
the,71-74
serum,75-80
concentration,81-94
and,95-98
prolong,99-106
the,107-110
half-life,111-120
of,121-123
digoxin.,124-132	DrugDDI.d577.s21.e2

Therefore,,0-10
when,11-15
INDOCIN,16-23	DrugDDI.d577.s22.e0
and,24-27
digoxin,28-35	DrugDDI.d577.s22.e1
are,36-39
used,40-44
concomitantly,,45-59
serum,60-65
digoxin,66-73
levels,74-80
should,81-87
be,88-90
closely,91-98
monitored.,99-109

In,0-2
some,3-7
patients,,8-17
the,18-21
administration,22-36
of,37-39
INDOCIN,40-47	DrugDDI.d577.s23.e0
can,48-51
reduce,52-58
the,59-62
diuretic,,63-72
natriuretic,,73-85
and,86-89
antihypertensive,90-106	DrugDDI.d577.s23.e2
effects,107-114
of,115-117
loop,,118-123
potassium-sparing,,124-142
and,143-146
thiazide,147-155	DrugDDI.d577.s23.e4
diuretics.,156-166	DrugDDI.d577.s23.e4

Therefore,,0-10
when,11-15
INDOCIN,16-23	DrugDDI.d577.s24.e0
and,24-27
INDOCIN.,28-36	DrugDDI.d577.s24.e1

(Indomethacin),0-14
diuretics,15-24	DrugDDI.d577.s25.e1
are,25-28
used,29-33
concomitantly,,34-48
the,49-52
patient,53-60
should,61-67
be,68-70
observed,71-79
closely,80-87
to,88-90
determine,91-100
if,101-103
the,104-107
desired,108-115
effect,116-122
of,123-125
the,126-129
diuretic,130-138	DrugDDI.d577.s25.e2
is,139-141
obtained.,142-151

INDOCIN,0-7	DrugDDI.d577.s26.e0
reduces,8-15
basal,16-21
plasma,22-28
renin,29-34
activity,35-43
(PRA),,44-50
as,51-53
well,54-58
as,59-61
those,62-67
elevations,68-78
of,79-81
PRA,82-85
induced,86-93
by,94-96
furosemide,97-107	DrugDDI.d577.s26.e1
administration,,108-123
or,124-126
salt,127-131	DrugDDI.d577.s26.e2
or,132-134
volume,135-141
depletion.,142-152

It,0-2
has,3-6
been,7-11
reported,12-20
that,21-25
the,26-29
addition,30-38
of,39-41
triamterene,42-53	DrugDDI.d577.s28.e0
to,54-56
a,57-58
maintenance,59-70
schedule,71-79
of,80-82
INDOCIN,83-90	DrugDDI.d577.s28.e1
resulted,91-99
in,100-102
reversible,103-113
acute,114-119
renal,120-125
failure,126-133
in,134-136
two,137-140
of,141-143
four,144-148
healthy,149-156
volunteers.,157-168

INDOCIN,0-7	DrugDDI.d577.s29.e0
and,8-11
triamterene,12-23	DrugDDI.d577.s29.e1
should,24-30
not,31-34
be,35-37
administered,38-50
together.,51-60

INDOCIN,0-7	DrugDDI.d577.s30.e0
and,8-11
potassium-sparing,12-29	DrugDDI.d577.s30.e1
diuretics,30-39	DrugDDI.d577.s30.e1
each,40-44
may,45-48
be,49-51
associated,52-62
with,63-67
increased,68-77
serum,78-83
potassium,84-93
levels.,94-101

The,0-3
potential,4-13
effects,14-21
of,22-24
INDOCIN,25-32	DrugDDI.d577.s31.e0
and,33-36
potassium-sparing,37-54	DrugDDI.d577.s31.e1
diuretics,55-64	DrugDDI.d577.s31.e1
on,65-67
potassium,68-77	DrugDDI.d577.s31.e2
kinetics,78-86
and,87-90
renal,91-96
function,97-105
should,106-112
be,113-115
considered,116-126
when,127-131
these,132-137
agents,138-144
are,145-148
administered,149-161
concurrently.,162-175

Most,0-4
of,5-7
the,8-11
above,12-17
effects,18-25
concerning,26-36
diuretics,37-46	DrugDDI.d577.s32.e0
have,47-51
been,52-56
attributed,,57-68
at,69-71
least,72-77
in,78-80
part,,81-86
to,87-89
mechanisms,90-100
involving,101-110
inhibition,111-121
of,122-124
prostaglandin,125-138	DrugDDI.d577.s32.e1
synthesis,139-148
by,149-151
INDOCIN.,152-160	DrugDDI.d577.s32.e2

Blunting,0-8
of,9-11
the,12-15
antihypertensive,16-32	DrugDDI.d577.s33.e0
effect,33-39
of,40-42
beta-adrenoceptor,43-60	DrugDDI.d577.s33.e1
blocking,61-69	DrugDDI.d577.s33.e1
agents,70-76	DrugDDI.d577.s33.e1
by,77-79
non-steroidal,80-93	DrugDDI.d577.s33.e2
antiinflammatory,94-110	DrugDDI.d577.s33.e2
drugs,111-116	DrugDDI.d577.s33.e2
including,117-126
INDOCIN,127-134	DrugDDI.d577.s33.e3
has,135-138
been,139-143
reported.,144-153

INDOCIN,0-7	DrugDDI.d577.s35.e0
can,8-11
reduce,12-18
the,19-22
antihypertensive,23-39	DrugDDI.d577.s35.e1
effects,40-47
of,48-50
captopril,51-60	DrugDDI.d577.s35.e2
and,61-64
losartan.,65-74	DrugDDI.d577.s35.e3

False-negative,0-14
results,15-22
in,23-25
the,26-29
dexamethasone,30-43
suppression,44-55
test,56-60
(DST),61-66
in,67-69
patients,70-78
being,79-84
treated,85-92
with,93-97
INDOCIN,98-105	DrugDDI.d577.s36.e0
have,106-110
been,111-115
reported.,116-125

Concurrent,0-10
administration,11-25
of,26-28
etanercept,29-39	DrugDDI.d164.s0.e0
(another,40-48
TNF?-blocking,49-62
agent),63-69
and,70-73
anakinra,74-82	DrugDDI.d164.s0.e1
(an,83-86
interleukin-1,87-100	DrugDDI.d164.s0.e2
antagonist),101-112	DrugDDI.d164.s0.e2
has,113-116
been,117-121
associated,122-132
with,133-137
an,138-140
increased,141-150
risk,151-155
of,156-158
serious,159-166
infections,,167-178
and,179-182
increased,183-192
risk,193-197
of,198-200
neutropenia,201-212
and,213-216
no,217-219
additional,220-230
benefit,231-238
compared,239-247
to,248-250
these,251-256
medicinal,257-266	DrugDDI.d164.s0.e3
products,267-275	DrugDDI.d164.s0.e3
alone.,276-282

Other,0-5
TNFa-blocking,6-19	DrugDDI.d164.s1.e0
agents,20-26
(including,27-37
REMICADE),38-47	DrugDDI.d164.s1.e1
used,48-52
in,53-55
combination,56-67
with,68-72
anakinra,73-81	DrugDDI.d164.s1.e2
may,82-85
also,86-90
result,91-97
in,98-100
similar,101-108
toxicities.,109-120

Specific,0-8
drug,9-13
interaction,14-25
studies,,26-34
including,35-44
interactions,45-57
with,58-62
MTX,,63-67
have,68-72
not,73-76
been,77-81
conducted.,82-92

The,0-3
majority,4-12
of,13-15
patients,16-24
in,25-27
rheumatoid,28-38
arthritis,39-48
or,49-51
Crohn?s,52-59
disease,60-67
clinical,68-76
studies,77-84
received,85-93
one,94-97
or,98-100
more,101-105
concomitant,106-117
medications.,118-130	DrugDDI.d164.s3.e0

In,0-2
rheumatoid,3-13
arthritis,,14-24
concomitant,25-36
medications,37-48	DrugDDI.d164.s4.e0
besides,49-56
MTX,57-60	DrugDDI.d164.s4.e1
were,61-65
nonsteroidal,66-78	DrugDDI.d164.s4.e2
anti-inflammatory,79-96	DrugDDI.d164.s4.e2
agents,,97-104	DrugDDI.d164.s4.e2
folic,105-110	DrugDDI.d164.s4.e3
acid,,111-116	DrugDDI.d164.s4.e3
corticosteroids,117-132	DrugDDI.d164.s4.e4
and/or,133-139
narcotics.,140-150	DrugDDI.d164.s4.e5

Concomitant,0-11
Crohn?s,12-19
disease,20-27
medications,28-39	DrugDDI.d164.s5.e0
were,40-44
antibiotics,,45-57
antivirals,,58-69
corticosteroids,,70-86
6-MP/AZA,87-95	DrugDDI.d164.s5.e4
and,96-99
aminosalicylates.,100-117	DrugDDI.d164.s5.e5

In,0-2
psoriatic,3-12
arthritis,13-22
clinical,23-31
trials,,32-39
concomitant,40-51
medications,52-63	DrugDDI.d164.s6.e0
included,64-72
MTX,73-76	DrugDDI.d164.s6.e1
in,77-79
approximately,80-93
half,94-98
of,99-101
the,102-105
patients,106-114
as,115-117
well,118-122
as,123-125
nonsteroidal,126-138	DrugDDI.d164.s6.e2
anti-inflammatory,139-156	DrugDDI.d164.s6.e2
agents,,157-164	DrugDDI.d164.s6.e2
folic,165-170	DrugDDI.d164.s6.e3
acid,171-175	DrugDDI.d164.s6.e3
and,176-179
corticosteroids.,180-196	DrugDDI.d164.s6.e4

Patients,0-8
with,9-13
Crohn?s,14-21
disease,22-29
who,30-33
received,34-42
immunosuppressants,43-61	DrugDDI.d164.s7.e0
tended,62-68
to,69-71
experience,72-82
fewer,83-88
infusion,89-97
reactions,98-107
compared,108-116
to,117-119
patients,120-128
on,129-131
no,132-134
immunosuppressants.,135-154	DrugDDI.d164.s7.e1

Serum,0-5
infliximab,6-16	DrugDDI.d164.s8.e0
concentrations,17-31
appeared,32-40
to,41-43
be,44-46
unaffected,47-57
by,58-60
baseline,61-69
use,70-73
of,74-76
medications,77-88	DrugDDI.d164.s8.e1
for,89-92
the,93-96
treatment,97-106
of,107-109
Crohn?s,110-117
disease,118-125
including,126-135
corticosteroids,,136-152
antibiotics,153-164	DrugDDI.d164.s8.e3
(metronidazole,165-179
or,180-182
ciprofloxacin),183-197	DrugDDI.d164.s8.e5
and,198-201
aminosalicylates.,202-219	DrugDDI.d164.s8.e6

A,0-1
number,2-8
of,9-11
substances,12-22
affect,23-29
glucose,30-37
metabolism,38-48
and,49-52
may,53-56
require,57-64
insulin,65-72	DrugDDI.d315.s0.e0
dose,73-77
adjustment,78-88
and,89-92
particularly,93-105
close,106-111
monitoring.,112-123

The,0-3
following,4-13
are,14-17
examples,18-26
of,27-29
substances,30-40
that,41-45
may,46-49
increase,50-58
the,59-62
blood-glucose-lowering,63-85
effect,86-92
and,93-96
susceptibility,97-111
to,112-114
hypoglycemia:,115-128
oral,129-133
antidiabetes,134-146
products,,147-156
ACE,157-160	DrugDDI.d315.s1.e0
inhibitors,,161-172	DrugDDI.d315.s1.e0
disopyramide,,173-186
fibrates,,187-196
fluoxetine,,197-208
MAO,209-212	DrugDDI.d315.s1.e4
inhibitors,,213-224	DrugDDI.d315.s1.e4
propoxyphene,,225-238
salicylates,,239-251
somatostatin,252-264	DrugDDI.d315.s1.e7
analog,265-271	DrugDDI.d315.s1.e7
(e.g.,,272-278
octreotide),,279-291
sulfonamide,292-303	DrugDDI.d315.s1.e9
antibiotics.,304-316

The,0-3
following,4-13
are,14-17
examples,18-26
of,27-29
substances,30-40
that,41-45
may,46-49
reduce,50-56
the,57-60
blood-glucose-lowering,61-83
effect,84-90
of,91-93
insulin:,94-102	DrugDDI.d315.s2.e0
corticosteroids,,103-119
danazol,,120-128
diuretics,,129-139
sympathomimetic,140-155	DrugDDI.d315.s2.e4
agents,156-162	DrugDDI.d315.s2.e4
(e.g.,,163-169
epinephrine,,170-182
albuterol,,183-193
terbutaline),,194-207
isoniazid,,208-218
phenothiazine,219-232	DrugDDI.d315.s2.e9
derivatives,,233-245	DrugDDI.d315.s2.e9
somatropin,,246-257
thyroid,258-265	DrugDDI.d315.s2.e11
hormones,,266-275	DrugDDI.d315.s2.e11
estrogens,,276-286
progestogens,287-299	DrugDDI.d315.s2.e13
(e.g.,,300-306
in,307-309
oral,310-314	DrugDDI.d315.s2.e14
contraceptives).,315-331	DrugDDI.d315.s2.e14

Beta-blockers,,0-14
clonidine,,15-25
lithium,26-33	DrugDDI.d315.s3.e2
salts,,34-40	DrugDDI.d315.s3.e2
and,41-44
alcohol,45-52	DrugDDI.d315.s3.e3
may,53-56
either,57-63
potentiate,64-74
or,75-77
weaken,78-84
the,85-88
blood-glucose-lowering,89-111
effect,112-118
of,119-121
insulin.,122-130	DrugDDI.d315.s3.e4

Pentamidine,0-11	DrugDDI.d315.s4.e0
may,12-15
cause,16-21
hypoglycemia,,22-35
which,36-41
may,42-45
sometimes,46-55
be,56-58
followed,59-67
by,68-70
hyperglycemia.,71-85

In,0-2
addition,,3-12
under,13-18
the,19-22
influence,23-32
of,33-35
sympatholytic,36-49	DrugDDI.d315.s5.e0
medicinal,50-59
products,60-68
such,69-73
as,74-76
beta-blockers,,77-91
clonidine,,92-102
guanethidine,,103-116
and,117-120
reserpine,,121-131
the,132-135
signs,136-141
of,142-144
hypoglycemia,145-157
may,158-161
be,162-164
reduced,165-172
or,173-175
absent.,176-183

A,0-1
number,2-8
of,9-11
substances,12-22
affect,23-29
glucose,30-37
metabolism,38-48
and,49-52
may,53-56
require,57-64
insulin,65-72	DrugDDI.d70.s0.e0
dose,73-77
adjustment,78-88
and,89-92
particularly,93-105
close,106-111
monitoring.,112-123

??,0-2
?,3-4
The,5-8
following,9-18
are,19-22
examples,23-31
of,32-34
substances,35-45
that,46-50
may,51-54
increase,55-63
the,64-67
blood-glucose-lowering,68-90
effect,91-97
and,98-101
susceptibility,102-116
to,117-119
hypoglycemia:,120-133
oral,134-138
antidiabetic,139-151	DrugDDI.d70.s1.e0
products,,152-161
ACE,162-165	DrugDDI.d70.s1.e1
inhibitors,,166-177	DrugDDI.d70.s1.e1
disopyramide,,178-191
fibrates,,192-201
fluoxetine,,202-213
monoamine,214-223	DrugDDI.d70.s1.e5
oxidase,224-231	DrugDDI.d70.s1.e5
(MAO),232-237
inhibitors,,238-249
propoxyphene,,250-263
salicylates,,264-276
somatostatin,277-289	DrugDDI.d70.s1.e8
analog,290-296	DrugDDI.d70.s1.e8
(e.g.,,297-303
octreotide),,304-316
sulfonamide,317-328	DrugDDI.d70.s1.e10
antibiotics.,329-341

??,0-2
?,3-4
The,5-8
following,9-18
are,19-22
examples,23-31
of,32-34
substances,35-45
that,46-50
may,51-54
reduce,55-61
the,62-65
blood-glucose-lowering,66-88
effect:,89-96
corticosteroids,,97-113
niacin,,114-121
danazol,,122-130
diuretics,,131-141
sympathomimetic,142-157	DrugDDI.d70.s2.e4
agents,158-164	DrugDDI.d70.s2.e4
(e.g.,,165-171
epinephrine,,172-184
salbutamol,,185-196
terbutaline),,197-210
isoniazid,,211-221
phenothiazine,222-235	DrugDDI.d70.s2.e9
derivatives,,236-248	DrugDDI.d70.s2.e9
somatropin,,249-260
thyroid,261-268	DrugDDI.d70.s2.e11
hormones,,269-278	DrugDDI.d70.s2.e11
estrogens,,279-289
progestogens,290-302	DrugDDI.d70.s2.e13
(e.g.,,303-309
in,310-312
oral,313-317	DrugDDI.d70.s2.e14
contraceptives).,318-334	DrugDDI.d70.s2.e14

??,0-2	DrugDDI.d70.s3.e0
?,3-4	DrugDDI.d70.s3.e0
Beta-blockers,,5-19	DrugDDI.d70.s3.e0
clonidine,,20-30
lithium,31-38	DrugDDI.d70.s3.e2
salts,,39-45	DrugDDI.d70.s3.e2
and,46-49
alcohol,50-57	DrugDDI.d70.s3.e3
may,58-61
either,62-68
potentiate,69-79
or,80-82
weaken,83-89
the,90-93
blood-glucose-lowering,94-116
effect,117-123
of,124-126
insulin.,127-135	DrugDDI.d70.s3.e4

Pentamidine,0-11	DrugDDI.d70.s4.e0
may,12-15
cause,16-21
hypoglycemia,,22-35
which,36-41
may,42-45
sometimes,46-55
be,56-58
followed,59-67
by,68-70
hyperglycemia.,71-85

??,0-2
?,3-4
In,5-7
addition,,8-17
under,18-23
the,24-27
influence,28-37
of,38-40
sympatholytic,41-54	DrugDDI.d70.s5.e0
medicinal,55-64
products,65-73
such,74-78
as,79-81
beta-blockers,,82-96
clonidine,,97-107
guanethidine,,108-121
and,122-125
reserpine,,126-136
the,137-140
signs,141-146
of,147-149
hypoglycemia,150-162
may,163-166
be,167-169
reduced,170-177
or,178-180
absent.,181-188

Mixing,0-6
of,7-9
Insulins,10-18	DrugDDI.d70.s6.e0

??,0-2
?,3-4
A,5-6
clinical,7-15
study,16-21
in,22-24
healthy,25-32
male,33-37
volunteers,38-48
(n=24),49-55
demonstrated,56-68
that,69-73
mixing,74-80
NovoLog,81-88	DrugDDI.d70.s7.e0
with,89-93
NPH,94-97
human,98-103	DrugDDI.d70.s7.e1
insulin,104-111	DrugDDI.d70.s7.e1
immediately,112-123
before,124-130
injection,131-140
produced,141-149
some,150-154
attenuation,155-166
in,167-169
the,170-173
peak,174-178
concentration,179-192
of,193-195
NovoLog,,196-204
but,205-208
that,209-213
the,214-217
time,218-222
to,223-225
peak,226-230
and,231-234
the,235-238
total,239-244
bioavailability,245-260
of,261-263
NovoLog,264-271	DrugDDI.d70.s7.e3
were,272-276
not,277-280
significantly,281-294
affected.,295-304

If,0-2
NovoLog,3-10	DrugDDI.d70.s8.e0
is,11-13
mixed,14-19
with,20-24
NPH,25-28
human,29-34	DrugDDI.d70.s8.e1
insulin,,35-43	DrugDDI.d70.s8.e1
NovoLog,44-51	DrugDDI.d70.s8.e2
should,52-58
be,59-61
drawn,62-67
into,68-72
the,73-76
syringe,77-84
first.,85-91

Because,0-7
there,8-13
are,14-17
no,18-20
data,21-25
on,26-28
the,29-32
compatibility,33-46
of,47-49
NovoLog,50-57	DrugDDI.d70.s10.e0
and,58-61
crystalline,62-73	DrugDDI.d70.s10.e1
zinc,74-78	DrugDDI.d70.s10.e1
insulin,79-86	DrugDDI.d70.s10.e1
preparations,,87-100	DrugDDI.d70.s10.e1
NovoLog,101-108	DrugDDI.d70.s10.e2
should,109-115
not,116-119
be,120-122
mixed,123-128
with,129-133
these,134-139
preparations.,140-153

??,0-2
?,3-4
The,5-8
effects,9-16
of,17-19
mixing,20-26
NovoLog,27-34	DrugDDI.d70.s11.e0
with,35-39
insulins,40-48	DrugDDI.d70.s11.e1
of,49-51
animal,52-58
source,59-65
or,66-68
insulin,69-76	DrugDDI.d70.s11.e2
preparations,77-89	DrugDDI.d70.s11.e2
produced,90-98
by,99-101
other,102-107
manufacturers,108-121
have,122-126
not,127-130
been,131-135
studied,136-143
.,144-145

??,0-2
?,3-4
When,5-9
used,10-14
in,15-17
external,18-26
subcutaneous,27-39
infusion,40-48
pumps,49-54
for,55-58
insulin,,59-67
NovoLog,68-75	DrugDDI.d70.s13.e1
should,76-82
not,83-86
be,87-89
mixed,90-95
with,96-100
any,101-104
other,105-110
insulins,111-119	DrugDDI.d70.s13.e2
or,120-122
diluent.,123-131

Interactions,0-12
between,13-20
Betaseron,21-30	DrugDDI.d195.s0.e0
and,31-34
other,35-40
drugs,41-46	DrugDDI.d195.s0.e1
have,47-51
not,52-55
been,56-60
fully,61-66
evaluated.,67-77

Although,0-8
studies,9-16
designed,17-25
to,26-28
examine,29-36
drug,37-41
interactions,42-54
have,55-59
not,60-63
been,64-68
done,,69-74
it,75-77
was,78-81
noted,82-87
that,88-92
corticosteroid,93-107	DrugDDI.d195.s1.e0
or,108-110
ACTH,111-115	DrugDDI.d195.s1.e1
treatment,116-125
of,126-128
relapses,129-137
for,138-141
periods,142-149
of,150-152
up,153-155
to,156-158
28,159-161
days,162-166
has,167-170
been,171-175
administered,176-188
to,189-191
patients,192-200
(N=180),201-208
receiving,209-218
Betaseron.,219-229	DrugDDI.d195.s1.e2

Betaseron,0-9	DrugDDI.d195.s2.e0
administration,10-24
to,25-27
three,28-33
cancer,34-40
patients,41-49
over,50-54
a,55-56
dose,57-61
range,62-67
of,68-70
0.025,71-76
mg,77-79
to,80-82
2.2,83-86
mg,87-89
led,90-93
to,94-96
a,97-98
dose-dependent,99-113
inhibition,114-124
of,125-127
antipyrine,128-138	DrugDDI.d195.s2.e1
elimination.14,139-153
The,154-157
effect,158-164
of,165-167
alternate-day,168-181
administration,182-196
of,197-199
0.25,200-204
mg,205-207
of,208-210
Betaseron,211-220	DrugDDI.d195.s2.e2
on,221-223
drug,224-228
metabolism,229-239
in,240-242
MS,243-245
patients,246-254
is,255-257
unknown.,258-266

ATROVENT,0-8	DrugDDI.d348.s0.e0
Inhalation,9-19	DrugDDI.d348.s0.e0
Aerosol,20-27	DrugDDI.d348.s0.e0
has,28-31
been,32-36
used,37-41
concomitantly,42-55
with,56-60
other,61-66
drugs,,67-73
including,74-83
sympathomimetic,84-99	DrugDDI.d348.s0.e2
bronchodilators,,100-116	DrugDDI.d348.s0.e2
methylxanthines,,117-133
and,134-137
steroids,,138-147
commonly,148-156
used,157-161
in,162-164
the,165-168
treatment,169-178
of,179-181
chronic,182-189
obstructive,190-201
pulmonary,202-211
disease.,212-220

With,0-4
the,5-8
exception,9-18
of,19-21
albuterol,,22-32
there,33-38
are,39-42
no,43-45
formal,46-52
studies,53-60
fully,61-66
evaluating,67-77
the,78-81
interaction,82-93
effects,94-101
of,102-104
ATROVENT,105-113	DrugDDI.d348.s1.e1
Inhalation,114-124	DrugDDI.d348.s1.e1
Aerosol,125-132	DrugDDI.d348.s1.e1
and,133-136
these,137-142
drugs,143-148	DrugDDI.d348.s1.e2
with,149-153
respect,154-161
to,162-164
effectiveness.,165-179

Anticholinergic,0-15	DrugDDI.d348.s2.e0
agents:,16-23	DrugDDI.d348.s2.e0
Although,24-32
ipratropium,33-44	DrugDDI.d348.s2.e1
bromide,45-52	DrugDDI.d348.s2.e1
is,53-55
minimally,56-65
absorbed,66-74
into,75-79
the,80-83
systemic,84-92
circulation,,93-105
there,106-111
is,112-114
some,115-119
potential,120-129
for,130-133
an,134-136
additive,137-145
interaction,146-157
with,158-162
concomitantly,163-176
used,177-181
anticholinergic,182-197	DrugDDI.d348.s2.e2
medications.,198-210

Caution,0-7
is,8-10
therefore,11-20
advised,21-28
in,29-31
the,32-35
coadministration,36-52
of,53-55
ATROVENT,56-64	DrugDDI.d348.s3.e0
Inhalation,65-75	DrugDDI.d348.s3.e0
Aerosol,76-83	DrugDDI.d348.s3.e0
with,84-88
other,89-94
anticholinergic-containing,95-121	DrugDDI.d348.s3.e1
drugs.,122-128	DrugDDI.d348.s3.e1

No,0-2
significant,3-14
drug-drug,15-24	DrugDDI.d246.s0.e0
pharmacokinetic,25-40
(or,41-44
pharmacodynamic),45-61
interactions,62-74
have,75-79
been,80-84
found,85-90
in,91-93
interaction,94-105
studies,106-113
with,114-118
hydrochlorothiazide,,119-139
digoxin,,140-148
warfarin,,149-158
and,159-162
nifedipine.,163-174	DrugDDI.d246.s0.e4

In,0-2
vitro,3-8
studies,9-16
show,17-21
significant,22-33
inhibition,34-44
of,45-47
the,48-51
formation,52-61
of,62-64
oxidized,65-73
irbesartan,74-84	DrugDDI.d246.s1.e0
metabolites,85-96
with,97-101
the,102-105
known,106-111
cytochrome,112-122
CYP,123-126	DrugDDI.d246.s1.e1
2C9,127-130	DrugDDI.d246.s1.e1
substrates/inhibitors,131-152
sulphenazole,,153-166
tolbutamide,167-178	DrugDDI.d246.s1.e2
and,179-182
nifedipine.,183-194	DrugDDI.d246.s1.e3

However,,0-8
in,9-11
clinical,12-20
studies,21-28
the,29-32
consequences,33-45
of,46-48
concomitant,49-60
irbesartan,61-71	DrugDDI.d246.s2.e0
on,72-74
the,75-78
pharmacodynamics,79-95
of,96-98
warfarin,99-107	DrugDDI.d246.s2.e1
were,108-112
negligible.,113-124

Based,0-5
on,6-8
in,9-11
vitro,12-17
data,,18-23
no,24-26
interaction,27-38
would,39-44
be,45-47
expected,48-56
with,57-61
drugs,62-67	DrugDDI.d246.s3.e0
whose,68-73
metabolism,74-84
is,85-87
dependent,88-97
upon,98-102
cytochrome,103-113	DrugDDI.d246.s3.e1
P450,114-118	DrugDDI.d246.s3.e1
isozymes,119-127	DrugDDI.d246.s3.e1
1A1,,128-132	DrugDDI.d246.s3.e1
1A2,2A6,2B6,2D6,2E1,or,133-155
3A4.,156-160

In,0-2
separate,3-11
studies,12-19
of,20-22
patients,23-31
receiving,32-41
maintenance,42-53
doses,54-59
of,60-62
warfarin,,63-72
hydrochlorothiazide,,73-93
or,94-96
digoxin,,97-105
irbesartan,106-116	DrugDDI.d246.s4.e3
administration,117-131
for,132-135
7,136-137
days,138-142
had,143-146
no,147-149
effect,150-156
on,157-159
the,160-163
pharmacodynamics,164-180
of,181-183
warfarin,184-192	DrugDDI.d246.s4.e4
(prothrombin,193-205
time),206-211
or,212-214
pharmacokinetics,215-231
of,232-234
digoxin.,235-243	DrugDDI.d246.s4.e5

The,0-3
pharmacokinetics,4-20
of,21-23
irbesartan,24-34	DrugDDI.d246.s5.e0
were,35-39
not,40-43
affected,44-52
by,53-55
coadministration,56-72
of,73-75
nifedipine,76-86	DrugDDI.d246.s5.e1
or,87-89
hydrochlorothiazide,90-109	DrugDDI.d246.s5.e2

The,0-3
adverse,4-11
effects,12-19
of,20-22
CAMPTOSAR,,23-33
such,34-38
as,39-41
myelosuppression,42-58
and,59-62
diarrhea,,63-72
would,73-78
be,79-81
expected,82-90
to,91-93
be,94-96
exacerbated,97-108
by,109-111
other,112-117	DrugDDI.d14.s0.e1
antineoplastic,118-132	DrugDDI.d14.s0.e1
agents,133-139	DrugDDI.d14.s0.e1
having,140-146
similar,147-154
adverse,155-162
effects.,163-171

Patients,0-8
who,9-12
have,13-17
previously,18-28
received,29-37
pelvic/,38-45
abdominal,46-55
irradiation,56-67
are,68-71
at,72-74
increased,75-84
risk,85-89
of,90-92
severe,93-99
myelosuppression,100-116
following,117-126
the,127-130
administration,131-145
of,146-148
CAMPTOSAR.,149-159	DrugDDI.d14.s1.e0

The,0-3
concurrent,4-14
administration,15-29
of,30-32
CAMPTOSAR,33-42	DrugDDI.d14.s2.e0
with,43-47
irradiation,48-59
has,60-63
not,64-67
been,68-72
adequately,73-83
studied,84-91
and,92-95
is,96-98
not,99-102
recommended.,103-115

Lymphocytopenia,0-15
has,16-19
been,20-24
reported,25-33
in,34-36
patients,37-45
receiving,46-55
CAMPTOSAR,,56-66
and,67-70
it,71-73
is,74-76
possible,77-85
that,86-90
the,91-94
administration,95-109
of,110-112
dexamethasone,113-126	DrugDDI.d14.s3.e1
as,127-129
antiemetic,130-140	DrugDDI.d14.s3.e2
prophylaxis,141-152
may,153-156
have,157-161
enhanced,162-170
the,171-174
likelihood,175-185
of,186-188
this,189-193
effect.,194-201

Hyperglycemia,0-13
has,14-17
also,18-22
been,23-27
reported,28-36
in,37-39
patients,40-48
receiving,49-58
CAMPTOSAR.,59-69	DrugDDI.d14.s5.e0

Usually,,0-8
this,9-13
has,14-17
been,18-22
observed,23-31
in,32-34
patients,35-43
with,44-48
a,49-50
history,51-58
of,59-61
diabetes,62-70
mellitus,71-79
or,80-82
evidence,83-91
of,92-94
glucose,95-102
intolerance,103-114
prior,115-120
to,121-123
administration,124-138
of,139-141
CAMPTOSAR.,142-152	DrugDDI.d14.s6.e0

It,0-2
is,3-5
probable,6-14
that,15-19
dexamethasone,,20-34
given,35-40
as,41-43
antiemetic,44-54	DrugDDI.d14.s7.e1
prophylaxis,,55-67
contributed,68-79
to,80-82
hyperglycemia,83-96
in,97-99
some,100-104
patients.,105-114

The,0-3
incidence,4-13
of,14-16
akathisia,17-26
in,27-29
clinical,30-38
trials,39-45
of,46-48
the,49-52
weekly,53-59
dosage,60-66
schedule,67-75
was,76-79
greater,80-87
(8.5%,,88-94
4/47,95-99
patients),100-109
when,110-114
prochlorperazine,115-131	DrugDDI.d14.s8.e0
was,132-135
administered,136-148
on,149-151
the,152-155
same,156-160
day,161-164
as,165-167
CAMPTOSAR,168-177	DrugDDI.d14.s8.e1
than,178-182
when,183-187
these,188-193
drugs,194-199	DrugDDI.d14.s8.e2
were,200-204
given,205-210
on,211-213
separate,214-222
days,223-227
(1.3%,,228-234
1/80,235-239
patients).,240-250

The,0-3
8.5%,4-8
incidence,9-18
of,19-21
akathisia,,22-32
however,,33-41
is,42-44
within,45-51
the,52-55
range,56-61
reported,62-70
for,71-74
use,75-78
of,79-81
prochlorperazine,82-98	DrugDDI.d14.s9.e0
when,99-103
given,104-109
as,110-112
a,113-114
premedication,115-128
for,129-132
other,133-138
chemotherapies.,139-154

It,0-2
would,3-8
be,9-11
expected,12-20
that,21-25
laxative,26-34	DrugDDI.d14.s10.e0
use,35-38
during,39-45
therapy,46-53
with,54-58
CAMPTOSAR,59-68	DrugDDI.d14.s10.e1
would,69-74
worsen,75-81
the,82-85
incidence,86-95
or,96-98
severity,99-107
of,108-110
diarrhea,,111-120
but,121-124
this,125-129
has,130-133
not,134-137
been,138-142
studied.,143-151

In,0-2
view,3-7
of,8-10
the,11-14
potential,15-24
risk,25-29
of,30-32
dehydration,33-44
secondary,45-54
to,55-57
vomiting,58-66
and/or,67-73
diarrhea,74-82
induced,83-90
by,91-93
CAMPTOSAR,,94-104
the,105-108
physician,109-118
may,119-122
wish,123-127
to,128-130
withhold,131-139
diuretics,140-149	DrugDDI.d14.s11.e1
during,150-156
dosing,157-163
with,164-168
CAMPTOSAR,169-178	DrugDDI.d14.s11.e2
and,,179-183
certainly,,184-194
during,195-201
periods,202-209
of,210-212
active,213-219
vomiting,220-228
or,229-231
diarrhea.,232-241

Drug-Laboratory,0-15
Test,16-20
Interactions,21-33
There,34-39
are,40-43
no,44-46
known,47-52
interactions,53-65
between,66-73
CAMPTOSAR,74-83	DrugDDI.d14.s12.e0
and,84-87
laboratory,88-98
tests.,99-105

Isocarboxazid,0-13	DrugDDI.d97.s0.e0
should,14-20
be,21-23
administered,24-36
with,37-41
caution,42-49
to,50-52
patients,53-61
receiving,62-71
Antabuse,72-80	DrugDDI.d97.s0.e1
(disulfiram,,81-93
Wyeth-Ayerst,94-106
Laboratories).,107-121

In,0-2
a,3-4
single,5-11
study,,12-18
rats,19-23
given,24-29
high,30-34
intraperitoneal,35-50
doses,51-56
of,57-59
an,60-62
MAO,63-66	DrugDDI.d97.s1.e0
inhibitor,67-76	DrugDDI.d97.s1.e0
plus,77-81
disulfiram,82-92	DrugDDI.d97.s1.e1
experienced,93-104
severe,105-111
toxicity,,112-121
including,122-131
convulsions,132-143
and,144-147
death.,148-154

Concomitant,0-11
use,12-15
of,16-18
Isocarboxazid,19-32	DrugDDI.d97.s2.e0
and,33-36
other,37-42
psychotropic,43-55	DrugDDI.d97.s2.e1
agents,56-62	DrugDDI.d97.s2.e1
is,63-65
generally,66-75
not,76-79
recommended,80-91
because,92-99
of,100-102
possible,103-111
potentiating,112-124
effects.,125-133

This,0-4
is,5-7
especially,8-18
true,19-23
in,24-26
patients,27-35
who,36-39
may,40-43
subject,44-51
themselves,52-62
to,63-65
an,66-68
overdosage,69-79
of,80-82
drugs.,83-89	DrugDDI.d97.s3.e0

The,0-3
monoamine,4-13	DrugDDI.d97.s5.e0
oxidase,14-21	DrugDDI.d97.s5.e0
inhibitory,22-32	DrugDDI.d97.s5.e0
effects,33-40
of,41-43
Isocarboxazid,44-57	DrugDDI.d97.s5.e1
may,58-61
persist,62-69
for,70-73
a,74-75
substantial,76-87
period,88-94
after,95-100
discontinuation,101-116
of,117-119
the,120-123
drug,,124-129
and,130-133
this,134-138
should,139-145
be,146-148
borne,149-154
in,155-157
mind,158-162
when,163-167
another,168-175
drug,176-180	DrugDDI.d97.s5.e3
is,181-183
prescribed,184-194
following,195-204
Isocarboxazid.,205-219	DrugDDI.d97.s5.e4

To,0-2
avoid,3-8
potentiation,,9-22
the,23-26
physician,27-36
wishing,37-44
to,45-47
terminate,48-57
treatment,58-67
with,68-72
Isocarboxazid,73-86	DrugDDI.d97.s6.e0
and,87-90
begin,91-96
therapy,97-104
with,105-109
another,110-117
agent,118-123
should,124-130
allow,131-136
for,137-140
an,141-143
interval,144-152
of,153-155
10,156-158
days.,159-164

May,0-3
interact,4-12
with,13-17
the,18-21
following:,22-32
beta-adrenergic,33-48	DrugDDI.d286.s0.e0
blocking,49-57	DrugDDI.d286.s0.e0
agents,58-64	DrugDDI.d286.s0.e0
(these,65-71
medicines,72-81	DrugDDI.d286.s0.e1
may,82-85
make,86-90
your,91-95
condition,96-105
worse,106-111
and,112-115
prevent,116-123	DrugDDI.d286.s0.e2
the,124-127
adrenergic,128-138
bronchodilators,139-154	DrugDDI.d286.s0.e3
from,155-159
working,160-167
properly),168-177
and,178-181
disopyramide,,182-195
quinidine,,196-206
phenothiazines,,207-222
and,223-226
procainamide,227-239	DrugDDI.d286.s0.e7
(these,240-246
medicines,247-256	DrugDDI.d286.s0.e8
may,257-260
increase,261-269
the,270-273
risk,274-278
of,279-281
heart,282-287
problems).,288-298

Isoflurane,0-10	DrugDDI.d333.s0.e0
potentiates,11-22
the,23-26
muscle,27-33	DrugDDI.d333.s0.e1
relaxant,34-42	DrugDDI.d333.s0.e1
effect,43-49
of,50-52
all,53-56
muscle,57-63	DrugDDI.d333.s0.e2
relaxants,,64-74	DrugDDI.d333.s0.e2
most,75-79
notably,80-87
nondepolarizing,88-103
muscle,104-110	DrugDDI.d333.s0.e3
relaxants,,111-121	DrugDDI.d333.s0.e3
and,122-125
MAC,126-129
(minimum,130-138
alveolar,139-147
concentration),148-162
is,163-165
reduced,166-173
by,174-176
concomitant,177-188
administration,189-203
of,204-206
N,207-208
span,209-213
class=,214-220
c13,221-224
2O.,225-228

Food:,0-5
Isoniazid,6-15	DrugDDI.d169.s0.e0
should,16-22
not,23-26
be,27-29
administered,30-42
with,43-47
food.,48-53

Studies,0-7
have,8-12
shown,13-18
that,19-23
the,24-27
bioavailability,28-43
of,44-46
isoniazid,47-56	DrugDDI.d169.s1.e0
is,57-59
reduced,60-67
significantly,68-81
when,82-86
administered,87-99
with,100-104
food.,105-110

Acetaminophen:,0-14	DrugDDI.d169.s2.e0
A,15-16
report,17-23
of,24-26
severe,27-33
acetaminophen,34-47
toxicity,48-56
was,57-60
reported,61-69
in,70-72
a,73-74
patient,75-82
receiving,83-92
Isoniazid.,93-103	DrugDDI.d169.s2.e1

It,0-2
is,3-5
believed,6-14
that,15-19
the,20-23
toxicity,24-32
may,33-36
have,37-41
resulted,42-50
from,51-55
a,56-57
previously,58-68
unrecognized,69-81
interaction,82-93
between,94-101
isoniazid,102-111	DrugDDI.d169.s3.e0
and,112-115
acetaminophen,116-129	DrugDDI.d169.s3.e1
and,130-133
a,134-135
molecular,136-145
basis,146-151
for,152-155
this,156-160
interaction,161-172
has,173-176
been,177-181
proposed.,182-191

However,,0-8
current,9-16
evidence,17-25
suggests,26-34
that,35-39
isoniazid,40-49	DrugDDI.d169.s4.e0
does,50-54
induce,55-61
P-450IIE1,,62-72
a,73-74
mixed-function,75-89	DrugDDI.d169.s4.e1
oxidase,90-97	DrugDDI.d169.s4.e1
enzyme,98-104	DrugDDI.d169.s4.e1
that,105-109
appears,110-117
to,118-120
generate,121-129
the,130-133
toxic,134-139
metabolites,,140-152
in,153-155
the,156-159
liver.,160-166	DrugDDI.d169.s4.e3

Furthermore,0-11
it,12-14
has,15-18
been,19-23
proposed,24-32
that,33-37
isoniazid,38-47	DrugDDI.d169.s5.e0
resulted,48-56
In,57-59
induction,60-69
of,70-72
P-450IIE1,73-82
in,83-85
the,86-89
patients,90-98
liver,99-104	DrugDDI.d169.s5.e1
which,,105-111
in,112-114
turn,,115-120
resulted,121-129
in,130-132
a,133-134
greater,135-142
proportion,143-153
of,154-156
the,157-160
ingested,161-169
acetaminophen,170-183	DrugDDI.d169.s5.e2
being,184-189
converted,190-199
to,200-202
the,203-206
toxic,207-212
metabolites.,213-225	DrugDDI.d169.s5.e3

Studies,0-7
have,8-12
demonstrated,13-25
that,26-30
pretreatment,31-43
with,44-48
isoniazid,49-58	DrugDDI.d169.s6.e0
potentiates,59-70
a,71-72
cetaminophen,73-85
hepatoxicity,86-98
in,99-101
rats.,102-107

Carbamazepine:,0-14	DrugDDI.d169.s7.e0
Isoniazid,15-24	DrugDDI.d169.s7.e1
is,25-27
known,28-33
to,34-36
slow,37-41
the,42-45
metabolism,46-56
of,57-59
carbamazepine,60-73	DrugDDI.d169.s7.e2
and,74-77
increase,78-86
its,87-90
serum,91-96
levels,97-103
Carbamazepine,104-117	DrugDDI.d169.s7.e3
levels,118-124
should,125-131
be,132-134
determined,135-145
prior,146-151
to,152-154
concurrent,155-165
administration,166-180
with,181-185
isoniazid,,186-196
signs,197-202
and,203-206
symptoms,207-215
of,216-218
carbamazepine,219-232
toxicity,233-241
should,242-248
be,249-251
monitored,252-261
closely,,262-270
and,271-274
appropriate,275-286
dosage,287-293
adjustment,294-304
of,305-307
the,308-311
anticonvulsant,312-326	DrugDDI.d169.s7.e5
should,327-333
be,334-336
made.,337-342

Ketoconazole:,0-13	DrugDDI.d169.s8.e0
Potential,14-23
interaction,24-35
of,36-38
Ketoconazole,39-51	DrugDDI.d169.s8.e1
and,52-55
Isoniazid,56-65	DrugDDI.d169.s8.e2
may,66-69
exist.,70-76

When,0-4
Ketoconazole,5-17	DrugDDI.d169.s9.e0
is,18-20
given,21-26
in,27-29
combination,30-41
with,42-46
isoniazid,47-56	DrugDDI.d169.s9.e1
and,57-60
rifampin,61-69	DrugDDI.d169.s9.e2
the,70-73
AUC,74-77
of,78-80
ketoconazole,81-93	DrugDDI.d169.s9.e3
is,94-96
decreased,97-106
by,107-109
as,110-112
much,113-117
as,118-120
88%,121-124
after,125-130
5,131-132
months,133-139
of,140-142
concurrent,143-153
Isoniazid,154-163	DrugDDI.d169.s9.e4
and,164-167
Rifampin,168-176	DrugDDI.d169.s9.e5
therapy.,177-185

Phenytoin:,0-10	DrugDDI.d169.s10.e0
Isoniazid,11-20	DrugDDI.d169.s10.e1
may,21-24
increase,25-33
serum,34-39
levels,40-46
of,47-49
phenytoin.,50-60	DrugDDI.d169.s10.e2

To,0-2
avoid,3-8
phenytoin,9-18
intoxication,,19-32
appropriate,33-44
adjustment,45-55
of,56-58
the,59-62
anticonvulsant,63-77	DrugDDI.d169.s11.e0
should,78-84
be,85-87
made.,88-93

Therophylline:,0-14
A,15-16
recent,17-23
study,24-29
has,30-33
shown,34-39
that,40-44
concomitan,45-55
administration,56-70
of,71-73
isoniazid,74-83	DrugDDI.d169.s12.e0
and,84-87
theophylline,88-100	DrugDDI.d169.s12.e1
may,101-104
cause,105-110
elevated,111-119
plasma,120-126
levels,127-133
of,134-136
theophylline,,137-150
and,151-154
in,155-157
some,158-162
instances,163-172
a,173-174
slight,175-181
decrease,182-190
in,191-193
the,194-197
elimination,198-209
of,210-212
isoniazid.,213-223	DrugDDI.d169.s12.e3

Since,0-5
the,6-9
therapeutic,10-21
range,22-27
of,28-30
theophylline,31-43	DrugDDI.d169.s13.e0
is,44-46
narrow,47-53
theophylline,54-66
serum,67-72
levels,73-79
should,80-86
be,87-89
monitored,90-99
closely,,100-108
and,109-112
appropriate,113-124
dosage,125-131
adjustments,132-143
of,144-146
theophylline,147-159	DrugDDI.d169.s13.e1
should,160-166
be,167-169
made.,170-175

Valproate:,0-10	DrugDDI.d169.s14.e0
A,11-12
recent,13-19
case,20-24
study,25-30
has,31-34
shown,35-40
a,41-42
possible,43-51
increase,52-60
in,61-63
the,64-67
plasma,68-74
level,75-80
of,81-83
valproate,84-93	DrugDDI.d169.s14.e1
when,94-98
co,99-101
administered,102-114
with,115-119
isoniazid.,120-130	DrugDDI.d169.s14.e2

Plasma,0-6
valproate,7-16	DrugDDI.d169.s15.e0
concentration,17-30
should,31-37
be,38-40
monitored,41-50
when,51-55
isoniazid,56-65	DrugDDI.d169.s15.e1
and,66-69
valproate,70-79	DrugDDI.d169.s15.e2
are,80-83
co,84-86
administered,,87-100
and,101-104
appropriate,105-116
dosage,117-123
adjustments,124-135
of,136-138
valproate,139-148	DrugDDI.d169.s15.e3
should,149-155
be,156-158
made.,159-164

Isoproterenol,0-13	DrugDDI.d243.s0.e0
hydrochloride,14-27	DrugDDI.d243.s0.e0
injection,28-37
and,38-41
epinephrine,42-53	DrugDDI.d243.s0.e1
should,54-60
not,61-64
be,65-67
administered,68-80
simultaneously,81-95
because,96-103
both,104-108
drugs,109-114	DrugDDI.d243.s0.e2
are,115-118
direct,119-125
cardiac,126-133	DrugDDI.d243.s0.e3
stimulants,134-144	DrugDDI.d243.s0.e3
and,145-148
their,149-154
combined,155-163
effects,164-171
may,172-175
induce,176-182
serious,183-190
arrhythmias.,191-203

The,0-3
drugs,4-9	DrugDDI.d243.s1.e0
may,,10-14
however,,15-23
be,24-26
administered,27-39
alternately,40-51
provided,52-60
a,61-62
proper,63-69
interval,70-78
has,79-82
elapsed,83-90
between,91-98
doses.,99-105

ISUPREL,0-7	DrugDDI.d243.s2.e0
should,8-14
be,15-17
used,18-22
with,23-27
caution,,28-36
if,37-39
at,40-42
all,,43-47
when,48-52
potent,53-59
inhalational,60-72	DrugDDI.d243.s2.e1
anesthetics,73-84	DrugDDI.d243.s2.e1
such,85-89
as,90-92
halothane,93-102	DrugDDI.d243.s2.e2
are,103-106
employed,107-115
because,116-123
of,124-126
potential,127-136
to,137-139
sensitize,140-149
the,150-153
myocardium,154-164
to,165-167
effects,168-175
of,176-178
sympathomimetic,179-194	DrugDDI.d243.s2.e3
amines.,195-202	DrugDDI.d243.s2.e3

The,0-3
vasodilating,4-16
effects,17-24
of,25-27
isosorbide,28-38	DrugDDI.d569.s0.e0
dinitrate,39-48	DrugDDI.d569.s0.e0
may,49-52
be,53-55
additive,56-64
with,65-69
those,70-75
of,76-78
other,79-84
vasodilators.,85-98	DrugDDI.d569.s0.e1

Alcohol,,0-8
in,9-11
particular,,12-23
has,24-27
been,28-32
found,33-38
to,39-41
exhibit,42-49
additive,50-58
effects,59-66
of,67-69
this,70-74
variety.,75-83

The,0-3
vasodilating,4-16
effects,17-24
of,25-27
isosorbide,28-38	DrugDDI.d459.s0.e0
mononitrate,39-50	DrugDDI.d459.s0.e0
may,51-54
be,55-57
additive,58-66
with,67-71
those,72-77
of,78-80
other,81-86
vasodilators.,87-100	DrugDDI.d459.s0.e1

Alcohol,,0-8
in,9-11
particular,,12-23
has,24-27
been,28-32
found,33-38
to,39-41
exhibit,42-49
additive,50-58
effects,59-66
of,67-69
this,70-74
variety.,75-83

Marked,0-6
symptomatic,7-18
orthostatic,19-30
hypotension,31-42
has,43-46
been,47-51
reported,52-60
when,61-65
calcium,66-73	DrugDDI.d459.s2.e0
channel,74-81	DrugDDI.d459.s2.e0
blockers,82-90	DrugDDI.d459.s2.e0
and,91-94
organic,95-102
nitrates,103-111	DrugDDI.d459.s2.e1
were,112-116
used,117-121
in,122-124
combination.,125-137

?,0-1
Vitamin,2-9	DrugDDI.d423.s0.e0
A:,10-12	DrugDDI.d423.s0.e0
Because,13-20
of,21-23
the,24-27
relationship,28-40
of,41-43
Accutane,44-52	DrugDDI.d423.s0.e1
to,53-55
vitamin,56-63	DrugDDI.d423.s0.e2
A,,64-66	DrugDDI.d423.s0.e2
patients,67-75
should,76-82
be,83-85
advised,86-93
against,94-101
taking,102-108
vitamin,109-116
supplements,117-128
containing,129-139
vitamin,140-147	DrugDDI.d423.s0.e3
A,148-149	DrugDDI.d423.s0.e3
to,150-152
avoid,153-158
additive,159-167
toxic,168-173
effects,174-181

?,0-1
Tetracyclines:,2-16	DrugDDI.d423.s2.e0
Concomitant,17-28
treatment,29-38
with,39-43
Accutane,44-52	DrugDDI.d423.s2.e1
and,53-56
tetracyclines,57-70	DrugDDI.d423.s2.e2
should,71-77
be,78-80
avoided,81-88
because,89-96
Accutane,97-105	DrugDDI.d423.s2.e3
use,106-109
has,110-113
been,114-118
associated,119-129
with,130-134
a,135-136
number,137-143
of,144-146
cases,147-152
of,153-155
pseudotumor,156-167
cerebri,168-175
(benign,176-183
intracranial,184-196
hypertension),,197-211
some,212-216
of,217-219
which,220-225
involved,226-234
concomitant,235-246
use,247-250
of,251-253
tetracyclines,254-267	DrugDDI.d423.s2.e4

?,0-1
Micro-dosed,2-13
Progesterone,14-26	DrugDDI.d423.s4.e0
Preparations:,27-40	DrugDDI.d423.s4.e0
Micro-dosed,41-52
progesterone,53-65	DrugDDI.d423.s4.e1
preparations,66-78	DrugDDI.d423.s4.e1
(minipills,79-89
that,90-94
do,95-97
not,98-101
contain,102-109
an,110-112
estrogen),113-122	DrugDDI.d423.s4.e2
may,123-126
be,127-129
an,130-132
inadequate,133-143
method,144-150
of,151-153
contraception,154-167
during,168-174
Accutane,175-183	DrugDDI.d423.s4.e3
therapy.,184-192

Although,0-8
other,9-14
hormonal,15-23
contraceptives,24-38	DrugDDI.d423.s5.e0
are,39-42
highly,43-49
effective,,50-60
there,61-66
have,67-71
been,72-76
reports,77-84
of,85-87
pregnancy,88-97
from,98-102
women,103-108
who,109-112
have,113-117
used,118-122
combined,123-131
oral,132-136	DrugDDI.d423.s5.e1
contraceptives,,137-152	DrugDDI.d423.s5.e1
as,153-155
well,156-160
as,161-163
topical/injectable/implantable/insertable,164-205
hormonal,206-214
birth,215-220	DrugDDI.d423.s5.e2
control,221-228	DrugDDI.d423.s5.e2
products.,229-238

It,0-2
is,3-5
not,6-9
known,10-15
if,16-18
hormonal,19-27
contraceptives,28-42	DrugDDI.d423.s7.e0
differ,43-49
in,50-52
their,53-58
effectiveness,59-72
when,73-77
used,78-82
with,83-87
Accutane.,88-97	DrugDDI.d423.s7.e1

Therefore,,0-10
it,11-13
is,14-16
critically,17-27
important,28-37
for,38-41
women,42-47
of,48-50
childbearing,51-63
potential,64-73
to,74-76
select,77-83
and,84-87
commit,88-94	DrugDDI.d423.s8.e0
to,95-97
use,98-101
2,102-103
forms,104-109
of,110-112
effective,113-122
contraception,123-136
simultaneously,,137-152
at,153-155
least,156-161
1,162-163
of,164-166
which,167-172
must,173-177
be,178-180
a,181-182
primary,183-190
form,,191-196
unless,197-203
absolute,204-212
abstinence,213-223
is,224-226
the,227-230
chosen,231-237
method,,238-245
or,246-248
the,249-252
patient,253-260
has,261-264
undergone,265-274
a,275-276
hysterectomy,277-289

?,0-1
Phenytoin:,2-12	DrugDDI.d423.s10.e0
Accutane,13-21	DrugDDI.d423.s10.e1
has,22-25
not,26-29
been,30-34
shown,35-40
to,41-43
alter,44-49
the,50-53
pharmacokinetics,54-70
of,71-73
phenytoin,74-83	DrugDDI.d423.s10.e2
in,84-86
a,87-88
study,89-94
in,95-97
seven,98-103
healthy,104-111
volunteers.,112-123

These,0-5
results,6-13
are,14-17
consistent,18-28
with,29-33
the,34-37
in,38-40
vitro,41-46
finding,47-54
that,55-59
neither,60-67
isotretinoin,68-80	DrugDDI.d423.s11.e0
nor,81-84
its,85-88
metabolites,89-100	DrugDDI.d423.s11.e1
induce,101-107
or,108-110
inhibit,111-118
the,119-122
activity,123-131
of,132-134
the,135-138
CYP,139-142	DrugDDI.d423.s11.e2
2C9,143-146	DrugDDI.d423.s11.e2
human,147-152
hepatic,153-160
P450,161-165
enzyme.,166-173

Phenytoin,0-9	DrugDDI.d423.s12.e0
is,10-12
known,13-18
to,19-21
cause,22-27
osteomalacia.,28-41

No,0-2
formal,3-9
clinical,10-18
studies,19-26
have,27-31
been,32-36
conducted,37-46
to,47-49
assess,50-56
if,57-59
there,60-65
is,66-68
an,69-71
interactive,72-83
effect,84-90
on,91-93
bone,94-98
loss,99-103
between,104-111
phenytoin,112-121	DrugDDI.d423.s13.e0
and,122-125
Accutane.,126-135	DrugDDI.d423.s13.e1

Therefore,,0-10
caution,11-18
should,19-25
be,26-28
exercised,29-38
when,39-43
using,44-49
these,50-55
drugs,56-61	DrugDDI.d423.s14.e0
together,62-70

?,0-1
Systemic,2-10
Corticosteroids:,11-27	DrugDDI.d423.s16.e0
Systemic,28-36
corticosteroids,37-52	DrugDDI.d423.s16.e1
are,53-56
known,57-62
to,63-65
cause,66-71
osteoporosis.,72-85

No,0-2
formal,3-9
clinical,10-18
studies,19-26
have,27-31
been,32-36
conducted,37-46
to,47-49
assess,50-56
if,57-59
there,60-65
is,66-68
an,69-71
interactive,72-83
effect,84-90
on,91-93
bone,94-98
loss,99-103
between,104-111
systemic,112-120
corticosteroids,121-136	DrugDDI.d423.s17.e0
and,137-140
Accutane.,141-150	DrugDDI.d423.s17.e1

Therefore,,0-10
caution,11-18
should,19-25
be,26-28
exercised,29-38
when,39-43
using,44-49
these,50-55
drugs,56-61	DrugDDI.d423.s18.e0
together.,62-71

Prescribers,0-11
are,12-15
advised,16-23
to,24-26
consult,27-34
the,35-38
package,39-46
insert,47-53
of,54-56
medication,57-67	DrugDDI.d423.s19.e0
administered,68-80
concomitantly,81-94
with,95-99
hormonal,100-108
contraceptives,,109-124
since,125-130
some,131-135
medications,136-147	DrugDDI.d423.s19.e2
may,148-151
decrease,152-160
the,161-164
effectiveness,165-178
of,179-181
these,182-187
birth,188-193	DrugDDI.d423.s19.e3
control,194-201	DrugDDI.d423.s19.e3
products.,202-211

Accutane,0-8	DrugDDI.d423.s20.e0
use,9-12
is,13-15
associated,16-26
with,27-31
depression,32-42
in,43-45
some,46-50
patients.,51-60

Patients,0-8
should,9-15
be,16-18
prospectively,19-32
cautioned,33-42
not,43-46
to,47-49
self-medicate,50-63
with,64-68
the,69-72
herbal,73-79
supplement,80-90
St.,91-94
John?s,95-101
Wort,102-106
because,107-114
a,115-116
possible,117-125
interaction,126-137
has,138-141
been,142-146
suggested,147-156
with,157-161
hormonal,162-170
contraceptives,171-185	DrugDDI.d423.s21.e0
based,186-191
on,192-194
reports,195-202
of,203-205
breakthrough,206-218
bleeding,219-227
on,228-230
oral,231-235	DrugDDI.d423.s21.e1
contraceptives,236-250	DrugDDI.d423.s21.e1
shortly,251-258
after,259-264
starting,265-273
St.,274-277	DrugDDI.d423.s21.e2
Johns,278-283	DrugDDI.d423.s21.e2
Wort.,284-289	DrugDDI.d423.s21.e2

Pregnancies,0-11
have,12-16
been,17-21
reported,22-30
by,31-33
users,34-39
of,40-42
combined,43-51
hormonal,52-60
contraceptives,61-75	DrugDDI.d423.s22.e0
who,76-79
also,80-84
used,85-89
some,90-94
form,95-99
of,100-102
St.,103-106	DrugDDI.d423.s22.e1
Johns,107-112	DrugDDI.d423.s22.e1
Wort.,113-118	DrugDDI.d423.s22.e1

Laboratory,0-10
Tests,11-16
Pregnancy,17-26
Test,27-31
Female,32-38
patients,39-47
of,48-50
childbearing,51-63
potential,64-73
must,74-78
have,79-83
negative,84-92
results,93-100
from,101-105
2,106-107
urine,108-113
or,114-116
serum,117-122
pregnancy,123-132
tests,133-138
with,139-143
a,144-145
sensitivity,146-157
of,158-160
at,161-163
least,164-169
25,170-172
mIU/mL,173-179
before,180-186
receiving,187-196
the,197-200
initial,201-208
Accutane,209-217	DrugDDI.d423.s23.e0
prescription.,218-231

The,0-3
first,4-9
test,10-14
is,15-17
obtained,18-26
by,27-29
the,30-33
prescriber,34-44
when,45-49
the,50-53
decision,54-62
is,63-65
made,66-70
to,71-73
pursue,74-80
qualification,81-94
of,95-97
the,98-101
patient,102-109
for,110-113
Accutane,114-122	DrugDDI.d423.s24.e0
(a,123-125
screening,126-135
test).,136-142

The,0-3
second,4-10
pregnancy,11-20
test,21-25
(a,26-28
confirmation,29-41
test),42-47
should,48-54
be,55-57
done,58-62
during,63-69
the,70-73
first,74-79
5,80-81
days,82-86
of,87-89
the,90-93
menstrual,94-103
period,104-110
immediately,111-122
preceding,123-132
the,133-136
beginning,137-146
of,147-149
Accutane,150-158	DrugDDI.d423.s25.e0
therapy.,159-167

After,0-5
consumption,6-17
of,18-20
alcohol,,21-29
at,30-32
least,33-38
36,39-41
hours,42-47
should,48-54
elapse,55-61
before,62-68
these,69-74
determinations,75-89
are,90-93
made.,94-99

It,0-2
is,3-5
recommended,6-17
that,18-22
these,23-28
tests,29-34
be,35-37
performed,38-47
at,48-50
weekly,51-57
or,58-60
biweekly,61-69
intervals,70-79
until,80-85
the,86-89
lipid,90-95
response,96-104
to,105-107
Accutane,108-116	DrugDDI.d423.s32.e0
is,117-119
established.,120-132

The,0-3
incidence,4-13
of,14-16
hypertriglyceridemia,17-37
is,38-40
1,41-42
patient,43-50
in,51-53
4,54-55
on,56-58
Accutane,59-67	DrugDDI.d423.s33.e0
therapy,68-75

?,0-1
Liver,2-7
Function,8-16
Tests:,17-23
Since,24-29
elevations,30-40
of,41-43
liver,44-49	DrugDDI.d423.s35.e0
enzymes,50-57	DrugDDI.d423.s35.e0
have,58-62
been,63-67
observed,68-76
during,77-83
clinical,84-92
trials,,93-100
and,101-104
hepatitis,105-114
has,115-118
been,119-123
reported,,124-133
pretreatment,134-146
and,147-150
follow-up,151-160
liver,161-166
function,167-175
tests,176-181
should,182-188
be,189-191
performed,192-201
at,202-204
weekly,205-211
or,212-214
biweekly,215-223
intervals,224-233
until,234-239
the,240-243
response,244-252
to,253-255
Accutane,256-264	DrugDDI.d423.s35.e1
has,265-268
been,269-273
established,274-285

?,0-1
Glucose:,2-10	DrugDDI.d423.s37.e0
Some,11-15
patients,16-24
receiving,25-34
Accutane,35-43	DrugDDI.d423.s37.e1
have,44-48
experienced,49-60
problems,61-69
in,70-72
the,73-76
control,77-84
of,85-87
their,88-93
blood,94-99
sugar.,100-106

In,0-2
addition,,3-12
new,13-16
cases,17-22
of,23-25
diabetes,26-34
have,35-39
been,40-44
diagnosed,45-54
during,55-61
Accutane,62-70	DrugDDI.d423.s38.e0
therapy,,71-79
although,80-88
no,89-91
causal,92-98
relationship,99-111
has,112-115
been,116-120
established,121-132

?,0-1
CPK:,2-6
Some,7-11
patients,12-20
undergoing,21-31
vigorous,32-40
physical,41-49
activity,50-58
while,59-64
on,65-67
Accutane,68-76	DrugDDI.d423.s40.e0
therapy,77-84
have,85-89
experienced,90-101
elevated,102-110
CPK,111-114
levels;,115-122

In,0-2
a,3-4
clinical,5-13
trial,14-19
of,20-22
217,23-26
pediatric,27-36	DrugDDI.d423.s43.e0
patients,37-45
(12,46-49
to,50-52
17,53-55
years),56-62
with,63-67
severe,68-74
recalcitrant,75-87
nodular,88-95
acne,,96-101
transient,102-111
elevations,112-122
in,123-125
CPK,126-129
were,130-134
observed,135-143
in,144-146
12%,147-150
of,151-153
patients,,154-163
including,164-173
those,174-179
undergoing,180-190
strenuous,191-200
physical,201-209
activity,210-218
in,219-221
association,222-233
with,234-238
reported,239-247
musculoskeletal,248-263
adverse,264-271
events,272-278
such,279-283
as,284-286
back,287-291
pain,,292-297
arthralgia,,298-309
limb,310-314
injury,,315-322
or,323-325
muscle,326-332
sprain.,333-340

Nitroglycerin:,0-14	DrugDDI.d217.s0.e0
DynaCirc?,15-24
(isradipine),25-37
has,38-41
been,42-46
safely,47-53
coadministered,54-68
with,69-73
nitroglycerin.,74-88	DrugDDI.d217.s0.e2

Hydrochlorothiazide:,0-20	DrugDDI.d217.s1.e0
A,21-22
study,23-28
in,29-31
normal,32-38
healthy,39-46
volunteers,47-57
has,58-61
shown,62-67
that,68-72
concomitant,73-84
administration,85-99
of,100-102
DynaCirc?,103-112
(isradipine),113-125
and,126-129
hydrochlorothiazide,130-149	DrugDDI.d217.s1.e2
does,150-154
not,155-158
result,159-165
in,166-168
altered,169-176
pharmacoktnetics,177-193
of,194-196
either,197-203
drug.,204-209	DrugDDI.d217.s1.e3

In,0-2
a,3-4
study,5-10
in,11-13
hypertensive,14-26
patients,,27-36
addition,37-45
of,46-48
isradipine,49-59	DrugDDI.d217.s2.e0
to,60-62
existing,63-71
hydrochlorothiazide,72-91	DrugDDI.d217.s2.e1
therapy,92-99
did,100-103
not,104-107
result,108-114
in,115-117
any,118-121
unexpected,122-132
adverse,133-140
effects,,141-149
and,150-153
isradipine,154-164	DrugDDI.d217.s2.e2
had,165-168
an,169-171
additional,172-182
antihypertensive,183-199	DrugDDI.d217.s2.e3
effect.,200-207

Propranolol:,0-12	DrugDDI.d217.s3.e0
In,13-15
a,16-17
single,18-24
dose,25-29
study,30-35
in,36-38
normal,39-45
volunteers,,46-57
coadministration,58-74
of,75-77
propranolol,78-89	DrugDDI.d217.s3.e1
had,90-93
a,94-95
small,96-101
effect,102-108
on,109-111
the,112-115
rate,116-120
but,121-124
no,125-127
effect,128-134
on,135-137
the,138-141
extent,142-148
of,149-151
isradipine,152-162	DrugDDI.d217.s3.e2
bioavailability.,163-179

Significant,0-11
increases,12-21
In,22-24
AUC,25-28
(27%),29-34
and,35-38
Cmax,39-43
(58%),44-49
and,50-53
decreases,54-63
in,64-66
tmax,67-71
(23%),72-77
of,78-80
propranolol,81-92	DrugDDI.d217.s4.e0
were,93-97
noted,98-103
in,104-106
this,107-111
study.,112-118

However,,0-8
concomitant,9-20
administration,21-35
of,36-38
5,39-40
mg,41-43
b.i.d.,44-50
isradipine,51-61	DrugDDI.d217.s5.e0
and,62-65
40,66-68
mg,69-71
b.i.d.,72-78

propranolol,0-11	DrugDDI.d217.s6.e0
to,12-14
healthy,15-22
volunteers,23-33
under,34-39
steady-state,40-52
conditions,53-63
had,64-67
no,68-70
relevant,71-79
effect,80-86
on,87-89
either,90-96
drug?s,97-103
bioavailability,,104-120
AUC,121-124
and,125-128
Cmax,,129-134
differences,135-146
were,147-151
,152-152
20%,153-156
between,157-164
isradipine,165-175	DrugDDI.d217.s6.e1
given,176-181
singly,182-188
and,189-192
in,193-195
combination,196-207
with,208-212
propranolol,,213-225
and,226-229
between,230-237
propranolol,238-249	DrugDDI.d217.s6.e3
given,250-255
singly,256-262
and,263-266
in,267-269
combination,270-281
with,282-286
isradipine.,287-298	DrugDDI.d217.s6.e4

Cimetidine:,0-11	DrugDDI.d217.s7.e0
In,12-14
a,15-16
study,17-22
in,23-25
healthy,26-33
volunteers,,34-45
a,46-47
one-week,48-56
course,57-63
of,64-66
cimetidine,67-77	DrugDDI.d217.s7.e1
at,78-80
400,81-84
mg,85-87
b.i.d.,88-94
with,95-99
a,100-101
single,102-108
5,109-110
mg,111-113
dose,114-118
of,119-121
isradipine,122-132	DrugDDI.d217.s7.e2
on,133-135
the,136-139
sixth,140-145
day,146-149
showed,150-156
an,157-159
increase,160-168
in,169-171
isradipine,172-182	DrugDDI.d217.s7.e3
mean,183-187
peak,188-192
plasma,193-199
concentrations,200-214
(36%),215-220
and,221-224
significant,225-236
increase,237-245
in,246-248
area,249-253
under,254-259
the,260-263
curve,264-269
(50%).,270-276

If,0-2
isradipine,3-13	DrugDDI.d217.s8.e0
therapy,14-21
is,22-24
initiated,25-34
in,35-37
a,38-39
patient,40-47
currently,48-57
receiving,58-67
cimetidine,68-78	DrugDDI.d217.s8.e1
careful,79-86
monitoring,87-97
for,98-101
adverse,102-109
reactions,110-119
is,120-122
advised,123-130
and,131-134
downward,135-143
dose,144-148
adjustment,149-159
may,160-163
be,164-166
required.,167-176

Rifampicin:,0-11	DrugDDI.d217.s9.e0
In,12-14
a,15-16
study,17-22
in,23-25
healthy,26-33
volunteers,,34-45
a,46-47
six-day,48-55
course,56-62
of,63-65
rifampicin,66-76	DrugDDI.d217.s9.e1
at,77-79
600,80-83
mg/day,84-90
followed,91-99
by,100-102
a,103-104
single,105-111
5,112-113
mg,114-116
dose,117-121
of,122-124
isradipine,125-135	DrugDDI.d217.s9.e2
resulted,136-144
in,145-147
a,148-149
reduction,150-159
in,160-162
isradipine,163-173	DrugDDI.d217.s9.e3
levels,174-180
to,181-183
below,184-189
detectable,190-200
limits.,201-208

If,0-2
rifampicin,3-13	DrugDDI.d217.s10.e0
therapy,14-21
is,22-24
required,,25-34
isradipine,35-45	DrugDDI.d217.s10.e1
concentrations,46-60
and,61-64
therapeutic,65-76
effects,77-84
are,85-88
likely,89-95
to,96-98
be,99-101
markedly,102-110
reduced,111-118
or,119-121
abolished,122-131
as,132-134
a,135-136
consequence,137-148
of,149-151
increased,152-161
metabolism,162-172
and,173-176
higher,177-183
clearance,184-193
of,194-196
isradipine.,197-208	DrugDDI.d217.s10.e2

Warfarin:,0-9	DrugDDI.d217.s11.e0
In,10-12
a,13-14
study,15-20
in,21-23
healthy,24-31
volunteers,,32-43
no,44-46
clinically,47-57
relevant,58-66
pharmacokinetic,67-82
or,83-85
pharmacodynamic,86-101
interaction,102-113
between,114-121
isradipine,122-132	DrugDDI.d217.s11.e1
and,133-136
racemic,137-144
warfarin,145-153	DrugDDI.d217.s11.e2
was,154-157
seen,158-162
when,163-167
two,168-171
single,172-178
oral,179-183
doses,184-189
of,190-192
warfarin,193-201	DrugDDI.d217.s11.e3
(0.7,202-206
mg/kg,207-212
body,213-217
weight),218-225
were,226-230
administered,231-243
during,244-250
11,251-253
days,254-258
of,259-261
multipledose,262-274
treatment,275-284
with,285-289
5,290-291
mg,292-294
b.i.d.,295-301
isradipine.,302-313	DrugDDI.d217.s11.e4

Neither,0-7
racemic,8-15
warfarin,16-24	DrugDDI.d217.s12.e0
nor,25-28
isradipine,29-39	DrugDDI.d217.s12.e1
binding,40-47
to,48-50
plasma,51-57	DrugDDI.d217.s12.e2
proteins,58-66	DrugDDI.d217.s12.e2
in,67-69
vitro,70-75
was,76-79
altered,80-87
by,88-90
the,91-94
addition,95-103
of,104-106
the,107-110
other,111-116
drug.,117-122	DrugDDI.d217.s12.e3

Digoxin:,0-8	DrugDDI.d217.s13.e0
The,9-12
concomitant,13-24
administration,25-39
of,40-42
DynaCirc?,43-52
(isradipine),53-65
and,66-69
digoxin,70-77	DrugDDI.d217.s13.e2
in,78-80
a,81-82
single-dose,83-94
pharmacokinetic,95-110
study,111-116
did,117-120
not,121-124
affect,125-131
renal,,132-138
nonrenal,139-147
and,148-151
total,152-157
body,158-162
clearance,163-172
of,173-175
digoxin.,176-184	DrugDDI.d217.s13.e3

Fentanyl,0-8	DrugDDI.d217.s14.e0
Anesthesia:,9-20
Severe,21-27
hypotension,28-39
has,40-43
been,44-48
reported,49-57
during,58-64
fentanyl,65-73	DrugDDI.d217.s14.e1
anesthesia,74-84
with,85-89
concomitant,90-101
use,102-105
of,106-108
a,109-110
beta,111-115	DrugDDI.d217.s14.e2
blocker,116-123	DrugDDI.d217.s14.e2
and,124-127
a,128-129
calcium,130-137	DrugDDI.d217.s14.e3
channel,138-145	DrugDDI.d217.s14.e3
blocker.,146-154	DrugDDI.d217.s14.e3

Even,0-4
though,5-11
such,12-16
interactions,17-29
have,30-34
not,35-38
been,39-43
seen,44-48
in,49-51
clinical,52-60
studies,61-68
with,69-73
DynaCirc?,74-83
(isradipine),,84-97
an,98-100
increased,101-110
volume,111-117
of,118-120
circulating,121-132
fluids,133-139
might,140-145
be,146-148
required,149-157
if,158-160
such,161-165
an,166-168
interaction,169-180
were,181-185
to,186-188
occur.,189-195

Both,0-4
itraconazole,5-17	DrugDDI.d462.s0.e0
and,18-21
its,22-25
major,26-31
metabolite,,32-43
hydroxyitraconazole,,44-64
are,65-68
inhibitors,69-79
of,80-82
the,83-86
cytochrome,87-97	DrugDDI.d462.s0.e3
P450,98-102	DrugDDI.d462.s0.e3
3A4,103-106	DrugDDI.d462.s0.e3
enzyme,107-113
system.,114-121

Coadministration,0-16
of,17-19
Itraconazole,20-32	DrugDDI.d462.s1.e0
and,33-36
drugs,37-42	DrugDDI.d462.s1.e1
primarily,43-52
metabolized,53-64
by,65-67
the,68-71
cytochrome,72-82	DrugDDI.d462.s1.e2
P450,83-87	DrugDDI.d462.s1.e2
3A4,88-91	DrugDDI.d462.s1.e2
enzyme,92-98
system,99-105
may,106-109
result,110-116
in,117-119
increased,120-129
plasma,130-136
concentrations,137-151
of,152-154
the,155-158
drugs,159-164	DrugDDI.d462.s1.e3
that,165-169
could,170-175
increase,176-184
or,185-187
prolong,188-195
both,196-200
therapeutic,201-212
and,213-216
adverse,217-224
effects.,225-233

Coadministration,0-16
of,17-19
terfenadine,20-31	DrugDDI.d462.s3.e0
with,32-36
Itraconazole,37-49	DrugDDI.d462.s3.e1
has,50-53
led,54-57
to,58-60
elevated,61-69
plasma,70-76
concentrations,77-91
of,92-94
terfenadine,,95-107
resulting,108-117
in,118-120
rare,121-125
instances,126-135
of,136-138
life-,139-144
threatening,145-156
cardiac,157-164
dysrhythmias,165-177
and,178-181
one,182-185
death.,186-192

Another,0-7
oral,8-12
azole,13-18	DrugDDI.d462.s4.e0
antifungal,,19-30	DrugDDI.d462.s4.e0
ketoconazole,,31-44
inhibits,45-53
the,54-57
metabolism,58-68
of,69-71
astemizole,,72-83
resulting,84-93
in,94-96
elevated,97-105
plasma,106-112
concentrations,113-127
of,128-130
astemizole,131-141	DrugDDI.d462.s4.e2
and,142-145
its,146-149
active,150-156	DrugDDI.d462.s4.e3
metabolite,157-167	DrugDDI.d462.s4.e3
desmethylastermizole,168-188
which,189-194
may,195-198
prolong,199-206
QT,207-209
intervals.,210-220

In,0-2
vitro,3-8
data,9-13
suggest,14-21
that,22-26
itraconazole,,27-40
when,41-45
compared,46-54
to,55-57
ketoconazole,,58-71
has,72-75
a,76-77
less,78-82
pronounced,83-93
effect,94-100
on,101-103
the,104-107
biotransformation,108-125
system,126-132
responsible,133-144
for,145-148
the,149-152
metabolism,153-163
of,164-166
astemizole.,167-178	DrugDDI.d462.s5.e2

Based,0-5
on,6-8
the,9-12
chemical,13-21
resemblance,22-33
of,34-36
itraconazole,37-49	DrugDDI.d462.s6.e0
and,50-53
ketoconazole,,54-67
coadministration,68-84
of,85-87
astemizole,88-98	DrugDDI.d462.s6.e2
with,99-103
itraconazole,104-116	DrugDDI.d462.s6.e3
is,117-119
contraindicated.,120-136

Human,0-5
pharmacokinetics,6-22
data,23-27
indicate,28-36
that,37-41
oral,42-46
ketoconazole,47-59	DrugDDI.d462.s7.e0
potently,60-68
inhibits,69-77
the,78-81
metabolism,82-92
of,93-95
cisapride,96-105	DrugDDI.d462.s7.e1
resulting,106-115
in,116-118
an,119-121
eight-fold,122-132
increase,133-141
in,142-144
the,145-148
mean,149-153
AUC,154-157
of,158-160
cisapride.,161-171	DrugDDI.d462.s7.e2

Data,0-4
suggest,5-12
that,13-17
coadministration,18-34
of,35-37
oral,38-42
ketoconazole,43-55	DrugDDI.d462.s8.e0
and,56-59
cisapride,60-69	DrugDDI.d462.s8.e1
can,70-73
result,74-80
in,81-83
prolongation,84-96
of,97-99
the,100-103
QT,104-106
interval,107-115
on,116-118
the,119-122
ECG.,123-127

In,0-2
vitro,3-8
data,9-13
suggest,14-21
that,22-26
itraconazole,27-39	DrugDDI.d462.s9.e0
also,40-44
markedly,45-53
inhibits,54-62
the,63-66
biotransformation,67-84
system,85-91
mainly,92-98
responsible,99-110
for,111-114
the,115-118
metabolism,119-129
of,130-132
cisapride;,133-143	DrugDDI.d462.s9.e1

therefore,0-9
concomitant,10-21
administration,22-36
of,37-39
Itraconazole,40-52	DrugDDI.d462.s10.e0
with,53-57
cisapride,58-67	DrugDDI.d462.s10.e1
is,68-70
contraindicated.,71-87

Coadministration,0-16
of,17-19
Itraconazole,20-32	DrugDDI.d462.s11.e0
with,33-37
oral,38-42
midazolam,43-52	DrugDDI.d462.s11.e1
or,53-55
triazolam,56-65	DrugDDI.d462.s11.e2
has,66-69
resulted,70-78
in,79-81
elevated,82-90
plasma,91-97
concentrations,98-112
of,113-115
the,116-119
latter,120-126
two,127-130
drugs.,131-137	DrugDDI.d462.s11.e3

This,0-4
may,5-8
potentiate,9-19
and,20-23
prolong,24-31
hypnotic,32-40	DrugDDI.d462.s12.e0
and,41-44
sedative,45-53	DrugDDI.d462.s12.e1
effects.,54-62

These,0-5
agents,6-12
should,13-19
not,20-23
be,24-26
used,27-31
in,32-34
patients,35-43
treated,44-51
with,52-56
Itraconazole.,57-70	DrugDDI.d462.s13.e0

If,0-2
midazolam,3-12	DrugDDI.d462.s14.e0
is,13-15
administered,16-28
parenterally,,29-42
special,43-50
precaution,51-61
is,62-64
required,65-73
since,74-79
the,80-83
sedative,84-92	DrugDDI.d462.s14.e1
effect,93-99
may,100-103
be,104-106
prolonged.,107-117

Coadministration,0-16
of,17-19
Itraconazole,20-32	DrugDDI.d462.s15.e0
and,33-36
cyclosporine,,37-50
tacrolimus,51-61	DrugDDI.d462.s15.e2
or,62-64
digoxin,65-72	DrugDDI.d462.s15.e3
has,73-76
led,77-80
to,81-83
increased,84-93
plasma,94-100
concentrations,101-115
of,116-118
the,119-122
latter,123-129
three,130-135
drugs.,136-142	DrugDDI.d462.s15.e4

Cyclosporine,,0-13
tacrolimus,14-24	DrugDDI.d462.s16.e1
and,25-28
digoxin,29-36	DrugDDI.d462.s16.e2
concentrations,37-51
should,52-58
be,59-61
monitored,62-71
at,72-74
the,75-78
initiation,79-89
of,90-92
Itraconazole,93-105	DrugDDI.d462.s16.e3
therapy,106-113
and,114-117
frequently,118-128
thereafter,,129-140
and,141-144
the,145-148
dose,149-153
of,154-156
these,157-162
three,163-168
drug,169-173	DrugDDI.d462.s16.e4
products,174-182	DrugDDI.d462.s16.e4
adjusted,183-191
appropriately.,192-206

There,0-5
have,6-10
been,11-15
rare,16-20
reports,21-28
of,29-31
rhabdomyolysis,32-46
involving,47-56
renal,57-62
transplant,63-73
patients,74-82
receiving,83-92
the,93-96
combination,97-108
of,109-111
Itraconazole,,112-125
cyclosporine,,126-139
and,140-143
the,144-147
HMG-CoA,148-155	DrugDDI.d462.s17.e2
reductase,156-165	DrugDDI.d462.s17.e2
inhibitors,166-176	DrugDDI.d462.s17.e2
lovastatin,177-187
or,188-190
simvastatin.,191-203	DrugDDI.d462.s17.e3

Rhabdomyolysis,0-14
has,15-18
been,19-23
observed,24-32
in,33-35
patients,36-44
receiving,45-54
HMG-CoA,55-62	DrugDDI.d462.s18.e0
reductase,63-72	DrugDDI.d462.s18.e0
inhibitors,73-83	DrugDDI.d462.s18.e0
administered,84-96
alone,97-102
(at,103-106
recommended,107-118
dosages),119-127
or,128-130
concomitantly,131-144
with,145-149
immunosuppressive,150-167	DrugDDI.d462.s18.e1
drugs,168-173
including,174-183
cyclosporine.,184-197	DrugDDI.d462.s18.e2

When,0-4
Itraconazole,5-17	DrugDDI.d462.s19.e0
was,18-21
coadministered,22-36
with,37-41
phenytoin,,42-52
rifampin,,53-62
or,63-65
H2antagonists,,66-80
reduced,81-88
plasma,89-95
concentrations,96-110
of,111-113
itraconazole,114-126	DrugDDI.d462.s19.e3
were,127-131
reported.,132-141

The,0-3
physician,4-13
is,14-16
advised,17-24
to,25-27
monitor,28-35
the,36-39
plasma,40-46
concentrations,47-61
of,62-64
itraconazole,65-77	DrugDDI.d462.s20.e0
when,78-82
any,83-86
of,87-89
these,90-95
drugs,96-101	DrugDDI.d462.s20.e1
is,102-104
taken,105-110
concurrently,,111-124
and,125-128
to,129-131
increase,132-140
the,141-144
dose,145-149
of,150-152
Itraconazole,153-165	DrugDDI.d462.s20.e2
if,166-168
necessary.,169-179

Although,0-8
no,9-11
studies,12-19
have,20-24
been,25-29
conducted,,30-40
concomitant,41-52
administration,53-67
of,68-70
Itraconazole,71-83	DrugDDI.d462.s21.e0
and,84-87
phenytoin,88-97	DrugDDI.d462.s21.e1
may,98-101
alter,102-107
the,108-111
metabolism,112-122
of,123-125
phenytoin;,126-136	DrugDDI.d462.s21.e2

therefore,,0-10
plasma,11-17
concentrations,18-32
of,33-35
phenytoin,36-45	DrugDDI.d462.s22.e0
should,46-52
also,53-57
be,58-60
monitored,61-70
when,71-75
it,76-78
is,79-81
given,82-87
concurrently,88-100
with,101-105
Itraconazole.,106-119	DrugDDI.d462.s22.e1

It,0-2
has,3-6
been,7-11
reported,12-20
that,21-25
Itraconazole,26-38	DrugDDI.d462.s23.e0
enhances,39-47
the,48-51
anticoagulant,52-65
effect,66-72
of,73-75
coumarin-like,76-89	DrugDDI.d462.s23.e1
drugs.,90-96	DrugDDI.d462.s23.e2

Therefore,,0-10
prothrombin,11-22
time,23-27
should,28-34
be,35-37
carefully,38-47
monitored,48-57
in,58-60
patients,61-69
receiving,70-79
Itraconazole,80-92	DrugDDI.d462.s24.e0
and,93-96
coumarin-like,97-110	DrugDDI.d462.s24.e1
drugs,111-116	DrugDDI.d462.s24.e2
simultaneously.,117-132

Plasma,0-6
concentrations,7-21
of,22-24
azole,25-30
antifungal,31-41	DrugDDI.d462.s25.e0
agents,42-48	DrugDDI.d462.s25.e0
are,49-52
reduced,53-60
when,61-65
given,66-71
concurrently,72-84
with,85-89
isoniazid.,90-100	DrugDDI.d462.s25.e1

Itraconazole,0-12	DrugDDI.d462.s26.e0
plasma,13-19
concentrations,20-34
should,35-41
be,42-44
monitored,45-54
when,55-59
Itraconazole,60-72	DrugDDI.d462.s26.e1
and,73-76
isoniazid,77-86	DrugDDI.d462.s26.e2
are,87-90
coadministered.,91-106

Severe,0-6
hypoglycemia,7-19
has,20-23
been,24-28
reported,29-37
in,38-40
patients,41-49
concomitantly,50-63
receiving,64-73
azole,74-79
antifungal,80-90	DrugDDI.d462.s27.e0
agents,91-97	DrugDDI.d462.s27.e0
and,98-101
oral,102-106
hypoglycemic,107-119	DrugDDI.d462.s27.e1
agents.,120-127	DrugDDI.d462.s27.e1

Blood,0-5
glucose,6-13
concentrations,14-28
should,29-35
be,36-38
carefully,39-48
monitored,49-58
when,59-63
Itraconazole,64-76	DrugDDI.d462.s28.e0
and,77-80
oral,81-85
hypoglycemic,86-98	DrugDDI.d462.s28.e1
agents,99-105	DrugDDI.d462.s28.e1
are,106-109
coadministered.,110-125

Tinnitus,0-8
and,9-12
decreased,13-22
hearing,23-30
have,31-35
been,36-40
reported,41-49
in,50-52
patients,53-61
concomitantly,62-75
receiving,76-85
Itraconazole,86-98	DrugDDI.d462.s29.e0
and,99-102
quinidine.,103-113	DrugDDI.d462.s29.e1

Edema,0-5
has,6-9
been,10-14
reported,15-23
in,24-26
patients,27-35
concomitantly,36-49
receiving,50-59
Itraconazole,60-72	DrugDDI.d462.s30.e0
and,73-76
dihydropyridine,77-92
calcium,93-100	DrugDDI.d462.s30.e1
channel,101-108	DrugDDI.d462.s30.e1
blockers.,109-118	DrugDDI.d462.s30.e1

The,0-3
results,4-11
from,12-16
a,17-18
study,19-24
in,25-27
which,28-33
eight,34-39
HIV-infected,40-52
individuals,53-64
were,65-69
treated,70-77
with,78-82
zidovudine,,83-94
8,95-96
+/-,97-100
0.4,101-104
mg/kg/day,,105-115
showed,116-122
that,123-127
the,128-131
pharmacokinetics,132-148
of,149-151
zidovudine,152-162	DrugDDI.d462.s32.e1
were,163-167
not,168-171
affected,172-180
during,181-187
concomitant,188-199
administration,200-214
of,215-217
Itraconazole,,218-231
100,232-235
mg,236-238
b.i.d.,239-245

In,0-2
vitro,3-8
mixing,9-15
of,16-18
an,19-21
aminoglycoside,22-36	DrugDDI.d436.s0.e0
with,37-41
beta-lactamtype,42-57
antibiotics,58-69	DrugDDI.d436.s0.e1
(penicillins,70-82
or,83-85
cephalosporins),86-101	DrugDDI.d436.s0.e3
may,102-105
result,106-112
in,113-115
a,116-117
significant,118-129
mutual,130-136
inactivation.,137-150

Even,0-4
when,5-9
an,10-12
aminoglycoside,13-27	DrugDDI.d436.s1.e0
and,28-31
a,32-33
penicillin-type,34-49	DrugDDI.d436.s1.e1
drug,50-54
are,55-58
administered,59-71
separately,72-82
by,83-85
different,86-95
routes,,96-103
a,104-105
reduction,106-115
in,116-118
aminoglycoside,119-133	DrugDDI.d436.s1.e2
serum,134-139
half-life,140-149
or,150-152
serum,153-158
levels,159-165
has,166-169
been,170-174
reported,175-183
in,184-186
patients,187-195
with,196-200
impaired,201-209
renal,210-215
function,216-224
and,225-228
in,229-231
some,232-236
patients,237-245
with,246-250
normal,251-257
renal,258-263
function.,264-273

Usually,,0-8
such,9-13
inactivation,14-26
of,27-29
the,30-33
aminoglycoside,34-48	DrugDDI.d436.s2.e0
is,49-51
clinically,52-62
significant,63-74
only,75-79
in,80-82
patients,83-91
with,92-96
severely,97-105
impaired,106-114
renal,115-120
function..,121-131

Prolonged,0-9
recovery,10-18
time,19-23
may,24-27
occur,28-33
if,34-36
barbiturates,37-49	DrugDDI.d247.s0.e0
and/or,50-56
narcotics,57-66	DrugDDI.d247.s0.e1
are,67-70
used,71-75
concurrently,76-88
with,89-93
ketamine.,94-103	DrugDDI.d247.s0.e2

Ketamine,0-8	DrugDDI.d247.s1.e0
is,9-11
clinically,12-22
compatible,23-33
with,34-38
the,39-42
commonly,43-51
used,52-56
general,57-64
and,65-68
local,69-74
anesthetic,75-85	DrugDDI.d247.s1.e1
agents,86-92	DrugDDI.d247.s1.e1
when,93-97
an,98-100
adequate,101-109
respiratory,110-121
exchange,122-130
is,131-133
maintained.,134-145

Ketoconazole,0-12	DrugDDI.d162.s0.e0
is,13-15
a,16-17
potent,18-24
inhibitor,25-34
of,35-37
the,38-41
cytochrome,42-52	DrugDDI.d162.s0.e1
P450,53-57	DrugDDI.d162.s0.e1
3A4,58-61	DrugDDI.d162.s0.e1
enzyme,62-68
system.,69-76

Coadministration,0-16
of,17-19
NIZORAL?,20-28
Tablets,29-36
and,37-40
drugs,41-46	DrugDDI.d162.s1.e0
primarily,47-56
metabolized,57-68
by,69-71
the,72-75
cytochrome,76-86	DrugDDI.d162.s1.e1
P450,87-91	DrugDDI.d162.s1.e1
3A4,92-95	DrugDDI.d162.s1.e1
enzyme,96-102
system,103-109
may,110-113
result,114-120
in,121-123
increased,124-133
plasma,134-140
concentrations,141-155
of,156-158
the,159-162
drugs,163-168	DrugDDI.d162.s1.e2
that,169-173
could,174-179
increase,180-188
or,189-191
prolong,192-199
both,200-204
therapeutic,205-216
and,217-220
adverse,221-228
effects.,229-237

The,0-3
following,4-13
drug,14-18
interactions,19-31
have,32-36
been,37-41
identified,42-52
involving,53-62
NIZORAL,63-70
span,71-75
class=,76-82
c97,83-86
?,87-88
Tablets,89-96
and,97-100
other,101-106
drugs,107-112	DrugDDI.d162.s3.e0
metabolized,113-124
by,125-127
the,128-131
cytochrome,132-142	DrugDDI.d162.s3.e1
P450,143-147	DrugDDI.d162.s3.e1
3A4,148-151	DrugDDI.d162.s3.e1
enzyme,152-158
system:,159-166
Ketoconazole,167-179	DrugDDI.d162.s3.e2
tablets,180-187
inhibit,188-195
the,196-199
metabolism,200-210
of,211-213
terfenadine,,214-226
resulting,227-236
in,237-239
an,240-242
increased,243-252
plasma,253-259
concentration,260-273
of,274-276
terfenadine,277-288	DrugDDI.d162.s3.e4
and,289-292
a,293-294
delay,295-300
in,301-303
the,304-307
elimination,308-319
of,320-322
its,323-326
acid,327-331	DrugDDI.d162.s3.e5
metabolite.,332-343	DrugDDI.d162.s3.e5

The,0-3
increased,4-13
plasma,14-20
concentration,21-34
of,35-37
terfenadine,38-49	DrugDDI.d162.s4.e0
or,50-52
its,53-56
metabolite,57-67	DrugDDI.d162.s4.e1
may,68-71
result,72-78
in,79-81
prolonged,82-91
QT,92-94
intervals.,95-105

Pharmacokinetic,0-15
data,16-20
indicate,21-29
that,30-34
oral,35-39
ketoconazole,40-52	DrugDDI.d162.s5.e0
inhibits,53-61
the,62-65
metabolism,66-76
of,77-79
astemizole,,80-91
resulting,92-101
in,102-104
elevated,105-113
plasma,114-120
levels,121-127
of,128-130
astemizole,131-141	DrugDDI.d162.s5.e2
and,142-145
its,146-149
active,150-156	DrugDDI.d162.s5.e3
metabolite,157-167	DrugDDI.d162.s5.e3
desmethylastemizole,168-187
which,188-193
may,194-197
prolong,198-205
QT,206-208
intervals.,209-219

Coadministration,0-16
of,17-19
astemizole,20-30	DrugDDI.d162.s6.e0
with,31-35
ketoconazole,36-48	DrugDDI.d162.s6.e1
tablets,49-56
is,57-59
therefore,60-69
contraindicated.,70-86

Human,0-5
pharmacokinetics,6-22
data,23-27
indicate,28-36
that,37-41
oral,42-46
ketoconazole,47-59	DrugDDI.d162.s7.e0
potently,60-68
inhibits,69-77
the,78-81
metabolism,82-92
of,93-95
cisapride,96-105	DrugDDI.d162.s7.e1
resulting,106-115
in,116-118
a,119-120
mean,121-125
eight-fold,126-136
increase,137-145
in,146-148
AUC,149-152
of,153-155
cisapride.,156-166	DrugDDI.d162.s7.e2

Data,0-4
suggest,5-12
that,13-17
coadministration,18-34
of,35-37
oral,38-42
ketoconazole,43-55	DrugDDI.d162.s8.e0
and,56-59
cisapride,60-69	DrugDDI.d162.s8.e1
can,70-73
result,74-80
in,81-83
prolongation,84-96
of,97-99
the,100-103
QT,104-106
interval,107-115
on,116-118
the,119-122
ECG.,123-127

Therefore,0-9
concomitant,10-21
administration,22-36
of,37-39
ketoconazole,40-52	DrugDDI.d162.s9.e0
tablets,53-60
with,61-65
cisapride,66-75	DrugDDI.d162.s9.e1
is,76-78
contraindicated.,79-95

Ketoconazole,0-12	DrugDDI.d162.s10.e0
tablets,13-20
may,21-24
alter,25-30
the,31-34
metabolism,35-45
of,46-48
cyclosporine,,49-62
tacrolimus,,63-74
and,75-78
methylprednisolone,,79-98
resulting,99-108
in,109-111
elevated,112-120
plasma,121-127
concentrations,128-142
of,143-145
the,146-149
latter,150-156
drugs.,157-163	DrugDDI.d162.s10.e4

Dosage,0-6
adjustment,7-17
may,18-21
be,22-24
required,25-33
if,34-36
cyclosporine,,37-50
tacrolimus,,51-62
or,63-65
methylprednisolone,66-84	DrugDDI.d162.s11.e2
are,85-88
given,89-94
concomitantly,95-108
with,109-113
NIZORAL?,114-122
Tablets.,123-131

Coadministration,0-16
of,17-19
NIZORAL?,20-28
Tablets,29-36
with,37-41
midazolam,42-51	DrugDDI.d162.s12.e0
or,52-54
triazolam,55-64	DrugDDI.d162.s12.e1
has,65-68
resulted,69-77
in,78-80
elevated,81-89
plasma,90-96
concentrations,97-111
of,112-114
the,115-118
latter,119-125
two,126-129
drugs.,130-136	DrugDDI.d162.s12.e2

This,0-4
may,5-8
potentiate,9-19
and,20-23
prolong,24-31
hypnotic,32-40	DrugDDI.d162.s13.e0
and,41-44
sedative,45-53	DrugDDI.d162.s13.e1
effects,,54-62
especially,63-73
with,74-78
repeated,79-87
dosing,88-94
or,95-97
chronic,98-105
administration,106-120
of,121-123
these,124-129
agents.,130-137

If,0-2
midazolam,3-12	DrugDDI.d162.s15.e0
is,13-15
administered,16-28
parenterally,,29-42
special,43-50
precaution,51-61
is,62-64
required,65-73
since,74-79
the,80-83
sedative,84-92	DrugDDI.d162.s15.e1
effect,93-99
may,100-103
be,104-106
prolonged.,107-117

Rare,0-4
cases,5-10
of,11-13
elevated,14-22
plasma,23-29
concentrations,30-44
of,45-47
digoxin,48-55	DrugDDI.d162.s16.e0
have,56-60
been,61-65
reported.,66-75

It,0-2
is,,3-6
therefore,,7-17
advisable,18-27
to,28-30
monitor,31-38
digoxin,39-46	DrugDDI.d162.s18.e0
concentrations,47-61
in,62-64
patients,65-73
receiving,74-83
ketoconazole.,84-97	DrugDDI.d162.s18.e1

When,0-4
taken,5-10
orally,11-17
,,18-19
imidazole,20-29	DrugDDI.d162.s19.e0
compounds,30-39
like,40-44
ketoconazole,45-57	DrugDDI.d162.s19.e1
may,58-61
enhance,62-69
the,70-73
anticoagulant,74-87
effect,88-94
of,95-97
coumarin-like,98-111	DrugDDI.d162.s19.e2
drugs.,112-118	DrugDDI.d162.s19.e3

In,0-2
simultaneous,3-15
treatment,16-25
with,26-30
imidazole,31-40	DrugDDI.d162.s20.e0
drugs,41-46
and,47-50
coumarin,51-59	DrugDDI.d162.s20.e1
drugs,,60-66
the,67-70
anticoagulant,71-84
effect,85-91
should,92-98
be,99-101
carefully,102-111
titrated,112-120
and,121-124
monitored.,125-135

Because,0-7
severe,8-14
hypoglycemia,15-27
has,28-31
been,32-36
reported,37-45
in,46-48
patients,49-57
concomitantly,58-71
receiving,72-81
oral,82-86	DrugDDI.d162.s21.e0
miconazole,87-97	DrugDDI.d162.s21.e0
(an,98-101
imidazole),102-112	DrugDDI.d162.s21.e1
and,113-116
oral,117-121
hypoglycemic,122-134	DrugDDI.d162.s21.e2
agents,,135-142	DrugDDI.d162.s21.e2
such,143-147
a,148-149
potential,150-159
interaction,160-171
involving,172-181
the,182-185
latter,186-192
agents,193-199
when,200-204
used,205-209
concomitantly,210-223
with,224-228
ketoconazole,229-241	DrugDDI.d162.s21.e3
tablets,242-249
(an,250-253
imidazole),254-264	DrugDDI.d162.s21.e4
can,265-268
not,269-272
be,273-275
ruled,276-281
out.,282-286

Concomitant,0-11
administration,12-26
of,27-29
ketoconazole,30-42	DrugDDI.d162.s22.e0
tablets,43-50
with,51-55
phenytoin,56-65	DrugDDI.d162.s22.e1
may,66-69
alter,70-75
the,76-79
metabolism,80-90
of,91-93
one,94-97
or,98-100
both,101-105
of,106-108
the,109-112
drugs.,113-119	DrugDDI.d162.s22.e2

It,0-2
is,3-5
suggested,6-15
to,16-18
monitor,19-26
both,27-31
ketoconazole,32-44	DrugDDI.d162.s23.e0
and,45-48
phenytoin.,49-59	DrugDDI.d162.s23.e1

Concomitant,0-11
administration,12-26
of,27-29
rifampin,30-38	DrugDDI.d162.s24.e0
with,39-43
ketoconazole,44-56	DrugDDI.d162.s24.e1
tablets,57-64
reduces,65-72
the,73-76
blood,77-82
levels,83-89
of,90-92
the,93-96
latter.,97-104

INH,0-3	DrugDDI.d162.s25.e0
(Isoniazid),4-15
is,16-18
also,19-23
reported,24-32
to,33-35
affect,36-42
ketoconazole,43-55	DrugDDI.d162.s25.e2
concentrations,56-70
adversely.,71-81

These,0-5
drugs,6-11	DrugDDI.d162.s26.e0
should,12-18
not,19-22
be,23-25
given,26-31
concomitantly.,32-46

After,0-5
the,6-9
coadministration,10-26
of,27-29
200,30-33
mg,34-36
oral,37-41
ketoconazole,42-54
twice,55-60
daily,61-66
and,67-70
one,71-74
20,75-77
mg,78-80
dose,81-85
of,86-88
loratadine,89-99	DrugDDI.d162.s27.e0
to,100-102
11,103-105
subjects,,106-115
the,116-119
AUC,120-123
and,124-127
Cmax,128-132
of,133-135
loratadine,136-146	DrugDDI.d162.s27.e1
averaged,147-155
302%,156-160
(?,161-163
142,164-167
S.D.),168-173
and,174-177
251%,178-182
(?,183-185
68,186-188
S.D.),,189-195
respectively,,196-209
of,210-212
those,213-218
obtained,219-227
after,228-233
co-treatment,234-246
with,247-251
placebo.,252-260

The,0-3
AUC,4-7
and,8-11
Cmax,12-16
of,17-19
descarboethoxyloratadine,,20-45
an,46-48
active,49-55	DrugDDI.d162.s28.e0
metabolite,,56-67	DrugDDI.d162.s28.e0
averaged,68-76
155%,77-81
(?,82-84
27,85-87
S.D.),88-93
and,94-97
141%,98-102
(?,103-105
35,106-108
S.D.),,109-115
respectively.,116-129

Also,,0-5
there,6-11
were,12-16
no,17-19
clinically,20-30
significant,31-42
differences,43-54
in,55-57
adverse,58-65
events,66-72
when,73-77
loratadine,78-88	DrugDDI.d162.s30.e0
was,89-92
administered,93-105
with,106-110
or,111-113
without,114-121
ketoconazole.,122-135	DrugDDI.d162.s30.e1

Rare,0-4
cases,5-10
of,11-13
a,14-15
disulfiram-like,16-31	DrugDDI.d162.s31.e0
reaction,32-40
to,41-43
alcohol,44-51	DrugDDI.d162.s31.e1
have,52-56
been,57-61
reported.,62-71

The,0-3
following,4-13
drug,14-18
interactions,19-31
were,32-36
studied,37-44
with,45-49
ketoprofen,50-60	DrugDDI.d212.s0.e0
doses,61-66
of,67-69
200,70-73
mg/day.,74-81

The,0-3
possibility,4-15
of,16-18
increased,19-28
interaction,29-40
should,41-47
be,48-50
kept,51-55
in,56-58
mind,59-63
when,64-68
Orudis,69-75	DrugDDI.d212.s1.e0
doses,76-81
greater,82-89
than,90-94
50,95-97
mg,98-100
as,101-103
a,104-105
single,106-112
dose,113-117
or,118-120
200,121-124
mg,125-127
of,128-130
ketoprofen,131-141	DrugDDI.d212.s1.e1
per,142-145
day,146-149
are,150-153
used,154-158
concomitantly,159-172
with,173-177
highly,178-184
bound,185-190
drugs.,191-197

Antacids:,0-9	DrugDDI.d212.s3.e0
Concomitant,10-21
administration,22-36
of,37-39
magnesium,40-49	DrugDDI.d212.s3.e1
hydroxide,50-59	DrugDDI.d212.s3.e1
and,60-63
aluminum,64-72	DrugDDI.d212.s3.e2
hydroxide,73-82	DrugDDI.d212.s3.e2
does,83-87
not,88-91
interfere,92-101
with,102-106
the,107-110
rate,111-115
or,116-118
extent,119-125
of,126-128
the,129-132
absorption,133-143
of,144-146
ketoprofen,147-157	DrugDDI.d212.s3.e3
administered,158-170
as,171-173
Orudis.,174-181	DrugDDI.d212.s3.e4

Aspirin:,0-8	DrugDDI.d212.s5.e0
Ketoprofen,9-19	DrugDDI.d212.s5.e1
does,20-24
not,25-28
alter,29-34
aspirin,35-42	DrugDDI.d212.s5.e2
absorption;,43-54

however,,0-8
in,9-11
a,12-13
study,14-19
of,20-22
12,23-25
normal,26-32
subjects,,33-42
concurrent,43-53
administration,54-68
of,69-71
aspirin,72-79	DrugDDI.d212.s6.e0
decreased,80-89
ketoprofen,90-100	DrugDDI.d212.s6.e1
protein,101-108
binding,109-116
and,117-120
increased,121-130
ketoprofen,131-141	DrugDDI.d212.s6.e2
plasma,142-148
clearance,149-158
from,159-163
0.07,164-168
L/kg/h,169-175
without,176-183
aspirin,184-191	DrugDDI.d212.s6.e3
to,192-194
0.11,195-199
L/kg/h,200-206
with,207-211
aspirin.,212-220	DrugDDI.d212.s6.e4

Therefore,,0-10
concurrent,11-21
use,22-25
of,26-28
aspirin,29-36	DrugDDI.d212.s8.e0
and,37-40
ketoprofen,41-51	DrugDDI.d212.s8.e1
is,52-54
not,55-58
recommended.,59-71

Diuretic:,0-9	DrugDDI.d212.s10.e0
Hydrochlorothiazide,,10-30
given,31-36
concomitantly,37-50
with,51-55
ketoprofen,,56-67
produces,68-76
a,77-78
reduction,79-88
in,89-91
urinary,92-99
potassium,100-109
and,110-113
chloride,114-122
excretion,123-132
compared,133-141
to,142-144
hydrochlorothiazide,145-164	DrugDDI.d212.s10.e3
alone.,165-171

Patients,0-8
taking,9-15
diuretics,16-25	DrugDDI.d212.s11.e0
are,26-29
at,30-32
a,33-34
greater,35-42
risk,43-47
of,48-50
developing,51-61
renal,62-67
failure,68-75
secondary,76-85
to,86-88
a,89-90
decrease,91-99
in,100-102
renal,103-108
blood,109-114
flow,115-119
caused,120-126
by,127-129
prostaglandin,130-143
inhibition.,144-155

Digoxin:,0-8	DrugDDI.d212.s13.e0
In,9-11
a,12-13
study,14-19
in,20-22
12,23-25
patients,26-34
with,35-39
congestive,40-50
heart,51-56
failure,57-64
where,65-70
ketoprofen,71-81	DrugDDI.d212.s13.e1
and,82-85
digoxin,86-93	DrugDDI.d212.s13.e2
were,94-98
concomitantly,99-112
administered,,113-126
ketoprofen,127-137	DrugDDI.d212.s13.e3
did,138-141
not,142-145
alter,146-151
the,152-155
serum,156-161
levels,162-168
of,169-171
digoxin.,172-180	DrugDDI.d212.s13.e4

Warfarin:,0-9	DrugDDI.d212.s15.e0
In,10-12
a,13-14
short-term,15-25
controlled,26-36
study,37-42
in,43-45
14,46-48
normal,49-55
volunteers,,56-67
ketoprofen,68-78	DrugDDI.d212.s15.e1
did,79-82
not,83-86
significantly,87-100
interfere,101-110
with,111-115
the,116-119
effect,120-126
of,127-129
warfarin,130-138	DrugDDI.d212.s15.e2
on,139-141
prothrombin,142-153
time.,154-159

Bleeding,0-8
from,9-13
a,14-15
number,16-22
of,23-25
sites,26-31
may,32-35
be,36-38
a,39-40
complication,41-53
of,54-56
warfarin,57-65
treatment,66-75
and,76-79
GI,80-82
bleeding,83-91
a,92-93
complication,94-106
of,107-109
ketoprofen,110-120	DrugDDI.d212.s16.e0
treatment.,121-131

Because,0-7
prostaglandina,8-22
play,23-27
an,28-30
important,31-40
role,41-45
in,46-48
hemostasis,49-59
and,60-63
ketoprofen,64-74	DrugDDI.d212.s17.e0
has,75-78
an,79-81
effect,82-88
on,89-91
platelet,92-100
function,101-109
as,110-112
well,,113-118
concurent,119-128
therapy,129-136
with,137-141
ketoprofen,142-152	DrugDDI.d212.s17.e1
and,153-156
warfarin,157-165	DrugDDI.d212.s17.e2
requires,166-174
close,175-180
monitoring,181-191
of,192-194
patients,195-203
on,204-206
both,207-211
drugs.,212-218	DrugDDI.d212.s17.e3

Probenecid:,0-11	DrugDDI.d212.s19.e0
Probenecid,12-22	DrugDDI.d212.s19.e1
increases,23-32
both,33-37
free,38-42
and,43-46
bound,47-52
ketoprofen,53-63	DrugDDI.d212.s19.e2
by,64-66
reducing,67-75
the,76-79
plasma,80-86
clearance,87-96
of,97-99
ketoprofen,100-110	DrugDDI.d212.s19.e3
to,111-113
about,114-119
one-third,,120-130
as,131-133
well,134-138
as,139-141
decreasing,142-152
its,153-156
protein,157-164
binding.,165-173

Therefore,,0-10
the,11-14
combination,15-26
of,27-29
ketoprofen,30-40	DrugDDI.d212.s20.e0
and,41-44
probenecid,45-55	DrugDDI.d212.s20.e1
is,56-58
not,59-62
recommended.,63-75

Methotrexate:,0-13	DrugDDI.d212.s22.e0
Ketoprofen,,14-25
like,26-30
other,31-36
NSAIDs,,37-44
may,45-48
cause,49-54
changes,55-62
in,63-65
the,66-69
elimination,70-81
of,82-84
methotrexate,85-97	DrugDDI.d212.s22.e3
leading,98-105
to,106-108
elevated,109-117
serum,118-123
levels,124-130
of,131-133
the,134-137
drug,138-142	DrugDDI.d212.s22.e4
and,143-146
increased,147-156
toxicity.,157-166

Lithium:,0-8	DrugDDI.d212.s24.e0
Nonsteroidal,9-21	DrugDDI.d212.s24.e1
anti-inflammatory,22-39	DrugDDI.d212.s24.e1
agents,40-46	DrugDDI.d212.s24.e1
have,47-51
been,52-56
reported,57-65
to,66-68
increase,69-77
steadystate,78-89
plasma,90-96
lithium,97-104
levels.,105-112

It,0-2
is,3-5
recommended,6-17
that,18-22
plasma,23-29
lithium,30-37
levels,38-44
be,45-47
monitored,48-57
when,58-62
ketoprofen,63-73	DrugDDI.d212.s25.e0
is,74-76
coadministered,77-91
with,92-96
lithium.,97-105	DrugDDI.d212.s25.e1

DRUG/LABORATORY,0-15	DrugDDI.d212.s26.e0
TEST,16-20
INTERACTIONS:,21-34
EFFECT,35-41
ON,42-44
BLOOD,45-50
COAGULATION,51-62
Ketoprofen,63-73	DrugDDI.d212.s26.e1
decreases,74-83
platelet,84-92
adhesion,93-101
and,102-105
aggregation.,106-118

Ketorolac,0-9	DrugDDI.d21.s0.e0
is,10-12
highly,13-19
bound,20-25
to,26-28
human,29-34
plasma,35-41	DrugDDI.d21.s0.e1
protein,42-49	DrugDDI.d21.s0.e1
(mean,50-55
99.2%).,56-63

Warfarin,,0-9
Digoxin,,10-18
Salicylate,,19-30
and,31-34
Heparin,35-42
The,43-46
in,47-49
vitro,50-55
binding,56-63
of,64-66
warfarin,67-75	DrugDDI.d21.s1.e3
to,76-78
plasma,79-85	DrugDDI.d21.s1.e4
proteins,86-94	DrugDDI.d21.s1.e4
is,95-97
only,98-102
slightly,103-111
reduced,112-119
by,120-122
ketorolac,123-132	DrugDDI.d21.s1.e5
tromethamine,133-145	DrugDDI.d21.s1.e5
(99.5%,146-152
control,153-160
vs,161-163
99.3%),164-170
when,171-175
ketorolac,176-185	DrugDDI.d21.s1.e6
plasma,186-192
concentrations,193-207
reach,208-213
5,214-215	DrugDDI.d21.s1.e7
to10,216-220	DrugDDI.d21.s1.e7
m,221-222
g/mL.,223-228

Ketorolac,0-9	DrugDDI.d21.s2.e0
does,10-14
not,15-18
alter,19-24
digoxin,25-32	DrugDDI.d21.s2.e1
protein,33-40
binding.,41-49

In,0-2
vitro,3-8
studies,9-16
indicate,17-25
that,,26-31
at,32-34
therapeutic,35-46
concentrations,47-61
of,62-64
salicylate,65-75	DrugDDI.d21.s3.e0
(300,76-80
m,81-82
g/mL),,83-89
the,90-93
binding,94-101
of,102-104
ketorolac,105-114	DrugDDI.d21.s3.e1
was,115-118
reduced,119-126
from,127-131
approximately,132-145
99.2%,146-151
to,152-154
97.5%,,155-161
representing,162-174
a,175-176
potential,177-186
twofold,187-194
increase,195-203
in,204-206
unbound,207-214
ketorolac,215-224	DrugDDI.d21.s3.e2
plasma,225-231
levels.,232-239

Therapeutic,0-11
concentrations,12-26
of,27-29
digoxin,,30-38
warfarin,,39-48
ibuprofen,,49-59
naproxen,,60-69
piroxicam,,70-80
acetaminophen,,81-95
phenytoin,96-105	DrugDDI.d21.s4.e6
andtolbutamide,106-120
did,121-124
not,125-128
alter,129-134
ketorolac,135-144	DrugDDI.d21.s4.e7
tromethamine,145-157	DrugDDI.d21.s4.e7
protein,158-165
binding.,166-174

In,0-2
a,3-4
study,5-10
involving,11-20
12,21-23
adult,24-29
volunteers,,30-41
TORADOLORAL,42-53
was,54-57
coadministered,58-72
with,73-77
a,78-79
single,80-86
dose,87-91
of,92-94
25,95-97
mg,98-100
warfarin,,101-110
causing,111-118
no,119-121
significant,122-133
changes,134-141
in,142-144
pharmacokinetics,145-161
or,162-164
pharmacodynamics,165-181
of,182-184
warfarin.,185-194	DrugDDI.d21.s5.e1

In,0-2
another,3-10
study,,11-17
TORADOLIV/IM,18-30
was,31-34
given,35-40
with,41-45
two,46-49
doses,50-55
of,56-58
5000,59-63
U,64-65
of,66-68
heparin,69-76	DrugDDI.d21.s6.e0
to,77-79
11,80-82
healthy,83-90
volunteers,,91-102
resulting,103-112
in,113-115
a,116-117
mean,118-122
template,123-131
bleeding,132-140
time,141-145
of,146-148
6.4,149-152
minutes,153-160
(3.2,161-165
to,166-168
11.4,169-173
min),174-178
compared,179-187
to,188-190
a,191-192
mean,193-197
of,198-200
6.0,201-204
minutes,205-212
(3.4,213-217
to,218-220
7.5,221-224
min),225-229
for,230-233
heparin,234-241	DrugDDI.d21.s6.e1
alone,242-247
and,248-251
5.1,252-255
minutes,256-263
(3.5,264-268
to,269-271
8.5,272-275
min),276-280
for,281-284
placebo.,285-293

Although,0-8
these,9-14
results,15-22
do,23-25
not,26-29
indicate,30-38
a,39-40
significant,41-52
interaction,53-64
between,65-72
TORADOL,73-80	DrugDDI.d21.s7.e0
and,81-84
warfarin,85-93	DrugDDI.d21.s7.e1
or,94-96
heparin,,97-105
the,106-109
administration,110-124
of,125-127
TORADOL,128-135	DrugDDI.d21.s7.e3
to,136-138
patients,139-147
taking,148-154
anticoagulants,155-169	DrugDDI.d21.s7.e4
should,170-176
be,177-179
done,180-184
extremely,185-194
cautiously,,195-206
and,207-210
patients,211-219
should,220-226
be,227-229
closely,230-237
monitored.,238-248

Furosemide,0-10	DrugDDI.d21.s8.e0
TORADOLIV/IM,11-23	DrugDDI.d21.s8.e0
reduced,24-31
the,32-35
diuretic,36-44	DrugDDI.d21.s8.e1
response,45-53
to,54-56
furosemide,57-67	DrugDDI.d21.s8.e2
in,68-70
normovolemic,71-83
healthy,84-91
subjects,92-100
by,101-103
approximately,104-117
20%,118-121
(mean,122-127
sodium,128-134	DrugDDI.d21.s8.e3
and,135-138
urinary,139-146
output,147-153
decreased,154-163
17%).,164-169

Probenecid,0-10	DrugDDI.d21.s9.e0
Concomitant,11-22
administration,23-37
of,38-40
TORADOLORAL,41-52
and,53-56
probenecid,57-67	DrugDDI.d21.s9.e1
resulted,68-76
in,77-79
decreased,80-89
clearance,90-99
of,100-102
ketorolac,103-112	DrugDDI.d21.s9.e2
and,113-116
significant,117-128
increases,129-138
in,139-141
ketorolac,142-151	DrugDDI.d21.s9.e3
plasma,152-158
levels,159-165
(total,166-172
AUC,173-176
increased,177-186
approximately,187-200
threefold,201-210
from,211-215
5.4,216-219
to,220-222
17.8,223-227
m,228-229
g/h/mL),230-237
and,238-241
terminal,242-250
half-life,251-260
increased,261-270
approximately,271-284
twofold,285-292
from,293-297
6.6,298-301
to,302-304
15.1,305-309
hours.,310-316

Therefore,,0-10
concomitant,11-22
use,23-26
of,27-29
TORADOL,30-37	DrugDDI.d21.s10.e0
and,38-41
probenecid,42-52	DrugDDI.d21.s10.e1
is,53-55
contraindicated.,56-72

Lithium,0-7	DrugDDI.d21.s11.e0
Inhibition,8-18
of,19-21
renal,22-27
lithium,28-35	DrugDDI.d21.s11.e1
clearance,,36-46
leading,47-54
to,55-57
an,58-60
increase,61-69
in,70-72
plasma,73-79
lithium,80-87	DrugDDI.d21.s11.e2
concentration,,88-102
has,103-106
been,107-111
reported,112-120
with,121-125
some,126-130
prostaglandin,131-144	DrugDDI.d21.s11.e3
synthesis-inhibiting,145-165
drugs.,166-172	DrugDDI.d21.s11.e4

The,0-3
effect,4-10
of,11-13
TORADOL,14-21	DrugDDI.d21.s12.e0
on,22-24
plasma,25-31
lithium,32-39	DrugDDI.d21.s12.e1
has,40-43
not,44-47
been,48-52
studied,,53-61
but,62-65
cases,66-71
of,72-74
increased,75-84
lithium,85-92
plasma,93-99
levels,100-106
during,107-113
TORADOL,114-121	DrugDDI.d21.s12.e2
therapy,122-129
have,130-134
been,135-139
reported.,140-149

Methotrexate,0-12	DrugDDI.d21.s13.e0
Concomitant,13-24
administration,25-39
of,40-42
methotrexate,43-55	DrugDDI.d21.s13.e1
and,56-59
some,60-64
NSAIDs,65-71	DrugDDI.d21.s13.e2
has,72-75
been,76-80
reported,81-89
to,90-92
reduce,93-99
the,100-103
clearance,104-113
of,114-116
methotrexate,,117-130
enhancing,131-140
the,141-144
toxicity,145-153
of,154-156
methotrexate.,157-170	DrugDDI.d21.s13.e4

The,0-3
effect,4-10
of,11-13
TORADOL,14-21	DrugDDI.d21.s14.e0
on,22-24
methotrexate,25-37	DrugDDI.d21.s14.e1
clearance,38-47
has,48-51
not,52-55
been,56-60
studied.,61-69

Nondepolarizing,0-15
Muscle,16-22	DrugDDI.d21.s15.e0
Relaxants,23-32	DrugDDI.d21.s15.e0
In,33-35
postmarketing,36-49
experience,50-60
there,61-66
have,67-71
been,72-76
reports,77-84
of,85-87
a,88-89
possible,90-98
interaction,99-110
between,111-118
TORADOLIV/IM,119-131
and,132-135
nondepolarizing,136-151
muscle,152-158	DrugDDI.d21.s15.e1
relaxants,159-168	DrugDDI.d21.s15.e1
that,169-173
resulted,174-182
in,183-185
apnea.,186-192

The,0-3
concurrent,4-14
use,15-18
of,19-21
TORADOL,22-29	DrugDDI.d21.s16.e0
with,30-34
muscle,35-41	DrugDDI.d21.s16.e1
relaxants,42-51	DrugDDI.d21.s16.e1
has,52-55
not,56-59
been,60-64
formally,65-73
studied.,74-82

ACE,0-3	DrugDDI.d21.s17.e0
Inhibitors,4-14	DrugDDI.d21.s17.e0
Concomitant,15-26
use,27-30
of,31-33
ACE,34-37	DrugDDI.d21.s17.e1
inhibitors,38-48	DrugDDI.d21.s17.e1
may,49-52
increase,53-61
the,62-65
risk,66-70
of,71-73
renal,74-79
impairment,,80-91
particularly,92-104
in,105-107
volume-depleted,108-123
patients.,124-133

Antiepileptic,0-13	DrugDDI.d21.s18.e0
Drugs,14-19	DrugDDI.d21.s18.e0
Sporadic,20-28
cases,29-34
of,35-37
seizures,38-46
have,47-51
been,52-56
reported,57-65
during,66-72
concomitant,73-84
use,85-88
of,89-91
TORADOL,92-99	DrugDDI.d21.s18.e1
and,100-103
antiepileptic,104-117	DrugDDI.d21.s18.e2
drugs,118-123	DrugDDI.d21.s18.e2
(phenytoin,,124-135
carbamazepine).,136-151	DrugDDI.d21.s18.e4

Psychoactive,0-12	DrugDDI.d21.s19.e0
Drugs,13-18	DrugDDI.d21.s19.e0
Hallucinations,19-33
have,34-38
been,39-43
reported,44-52
when,53-57
TORADOL,58-65	DrugDDI.d21.s19.e1
was,66-69
used,70-74
in,75-77
patients,78-86
taking,87-93
psychoactive,94-106	DrugDDI.d21.s19.e2
drugs,107-112	DrugDDI.d21.s19.e2
(fluoxetine,,113-125
thiothixene,,126-138
alprazolam).,139-151	DrugDDI.d21.s19.e5

Morphine,0-8	DrugDDI.d21.s20.e0
TORADOLIV/IM,9-21
has,22-25
been,26-30
administered,31-43
concurrently,44-56
with,57-61
morphine,62-70	DrugDDI.d21.s20.e1
in,71-73
several,74-81
clinical,82-90
trials,91-97
of,98-100
postoperative,101-114
pain,115-119
without,120-127
evidence,128-136
of,137-139
adverse,140-147
interactions.,148-161

Do,0-2
not,3-6
mix,7-10
TORADOL,11-18	DrugDDI.d21.s21.e0
and,19-22
morphine,23-31	DrugDDI.d21.s21.e1
in,32-34
the,35-38
same,39-43
syringe.,44-52

There,0-5
is,6-8
no,9-11
evidence,12-20
in,21-23
animal,24-30
or,31-33
human,34-39
studies,40-47
that,48-52
TORADOL,53-60	DrugDDI.d21.s22.e0
induces,61-68
or,69-71
inhibits,72-80
hepatic,81-88
enzymes,89-96
capable,97-104
of,105-107
metabolizing,108-120
itself,121-127
or,128-130
other,131-136
drugs,137-142	DrugDDI.d21.s22.e1

Cyclosporine,0-12	DrugDDI.d144.s0.e0
-,13-14
L-arginine,15-25
may,26-29
counteract,30-40
the,41-44
antinaturetic,45-58
effect,59-65
of,66-68
cyclosporin.,69-81	DrugDDI.d144.s0.e1

Ibuprofen,0-9	DrugDDI.d144.s1.e0
-,10-11	DrugDDI.d144.s1.e0
L-arginine,12-22	DrugDDI.d144.s1.e0
may,23-26
increase,27-35
the,36-39
absorption,40-50
of,51-53
ibuprofen,54-63	DrugDDI.d144.s1.e1
if,64-66
taken,67-72
concomitantly.,73-87

Organic,0-7
nitrates,8-16	DrugDDI.d144.s2.e0
-,17-18
L-arginine,19-29
supplements,30-41
theoretically,42-55
may,56-59
potentiate,60-70
the,71-74
effects,75-82
of,83-85
organic,86-93
nitrates,94-102	DrugDDI.d144.s2.e1
if,103-105
taken,106-111
concomitantly.,112-126

Sildenafil,0-10	DrugDDI.d144.s3.e0
citrate,11-18	DrugDDI.d144.s3.e0
-,19-20
Theoretically,,21-35
L-arginine,36-46
supplements,47-58
taken,59-64
concomitantly,65-78
with,79-83
sildenafil,84-94	DrugDDI.d144.s3.e2
citrate,,95-103	DrugDDI.d144.s3.e2
may,104-107
potentiate,108-118
the,119-122
effects,123-130
of,131-133
the,134-137
drug.,138-143	DrugDDI.d144.s3.e3

No,0-2
drug,,3-8
nutritional,9-20
supplement,,21-32
food,33-37
or,38-40
herb,41-45
interactions,46-58
are,59-62
known.,63-69

Interacts,0-9
with,10-14
valproic,15-23	DrugDDI.d346.s0.e0
acid,24-28	DrugDDI.d346.s0.e0

No,0-2
well-known,3-13
drug,14-18
interactions,19-31
with,32-36
glutamic,37-45	DrugDDI.d255.s0.e0
acid,46-50	DrugDDI.d255.s0.e0

Human,0-5	DrugDDI.d347.s0.e0
growth,6-12	DrugDDI.d347.s0.e0
hormone,13-20	DrugDDI.d347.s0.e0
-,21-22
Concomitant,23-34
use,35-38
of,39-41
L-glutamine,42-53
and,54-57
human,58-63	DrugDDI.d347.s0.e2
growth,64-70	DrugDDI.d347.s0.e2
hormone,71-78	DrugDDI.d347.s0.e2
may,79-82
enhance,83-90
nutrient,91-99
absorption,100-110
in,111-113
those,114-119
with,120-124
severe,125-131
short,132-137
bowel,138-143
syndrome.,144-153

L-glutamine,0-11	DrugDDI.d347.s1.e0
has,12-15
orphan,16-22	DrugDDI.d347.s1.e1
drug,23-27	DrugDDI.d347.s1.e1
status,28-34
for,35-38
this,39-43
indication.,44-55

Indomethacin,0-12	DrugDDI.d347.s2.e0
-,13-14
Concomitant,15-26
use,27-30
of,31-33
L-glutamine,34-45
and,46-49
indomethacin,50-62	DrugDDI.d347.s2.e2
may,63-66
ameliorate,67-77
increased,78-87
intestinal,88-98
permeability,99-111
caused,112-118
by,119-121
indomethacin.,122-135	DrugDDI.d347.s2.e3

The,0-3
reported,4-12
dose,13-17
used,18-22
for,23-26
L-glutamine,27-38
was,39-42
21,43-45
grams,46-51
daily,52-57
taken,58-63
in,64-66
divided,67-74
doses,75-80
three,81-86
times,87-92
a,93-94
day.,95-99

Further,,0-8
misoprostol,9-20	DrugDDI.d347.s4.e0
is,21-23
reported,24-32
to,33-35
have,36-40
a,41-42
synergistic,43-54
effect,55-61
with,62-66
this,67-71
combination,72-83
in,84-86
ameliorating,87-99
intestinal,100-110
permeability.,111-124

Methotrexate,0-12	DrugDDI.d347.s5.e0
-,13-14
There,15-20
is,21-23
one,24-27
report,28-34
that,35-39
methotrexate,40-52	DrugDDI.d347.s5.e1
may,53-56
decrease,57-65
the,66-69
possible,70-78
effectiveness,79-92
of,93-95
supplemental,96-108
L-glutamine,109-120
for,121-124
chemotherapy-induced,125-145
mucositis.,146-156

In,0-2
another,3-10
report,,11-18
nine,19-23
patients,24-32
with,33-37
breast,38-44
cancer,45-51
were,52-56
reported,57-65
to,66-68
have,69-73
decreased,74-83
symptoms,84-92
of,93-95
methotrexate-related,96-116
toxicity,117-125
when,126-130
given,131-136
supplemental,137-149
L-glutamine,150-161
at,162-164
a,165-166
dose,167-171
of,172-174
0.5,175-178
gram/kilogram/day.,179-197

Paclitaxel,0-10	DrugDDI.d347.s7.e0
-,11-12
In,13-15
one,16-19
report,,20-27
L-glutamine,28-39	DrugDDI.d347.s7.e1
at,40-42
a,43-44
dose,45-49
of,50-52
10,53-55
grams,56-61
three,62-67
times,68-73
daily,,74-80
given,81-86
24,87-89
hours,90-95
after,96-101
receiving,102-111
paclitaxel,,112-123
appeared,124-132
to,133-135
prevent,136-143	DrugDDI.d347.s7.e3
the,144-147
development,148-159
of,160-162
myalgia,163-170
and,171-174
arthralgia,,175-186
adverse,187-194
reactions,195-204
of,205-207
paclitaxel.,208-219	DrugDDI.d347.s7.e4

Medroxyprogesterone,0-19	DrugDDI.d62.s0.e0
Acetate,20-27	DrugDDI.d62.s0.e0
-,28-29
L-histidine,30-41
was,42-45
observed,46-54
to,55-57
enhance,58-65
(in,66-69
tissue,70-76
culture),77-85
the,86-89
effect,90-96
of,97-99
medroxyprogesterone,100-119	DrugDDI.d62.s0.e1
acetate,120-127	DrugDDI.d62.s0.e1
in,128-130
reducing,131-139
the,140-143
number,144-150
of,151-153
human,154-159
breast,160-166
cancer,167-173
cells,174-179
that,180-184
were,185-189
in,190-192
the,193-196
S,197-198
phase.,199-205

H1,0-2
and,3-6
H2,7-9	DrugDDI.d62.s1.e0
Blockers,10-18	DrugDDI.d62.s1.e0
-,19-20
Although,21-29
not,30-33
reported,,34-43
L-histidine,,44-56
via,57-60
its,61-64
metabolism,65-75
to,76-78
histamine,,79-89
might,90-95
decrease,96-104
the,105-108
efficacy,109-117
of,118-120
H1,121-123
and,124-127
H2,128-130	DrugDDI.d62.s1.e2
blockers.,131-140	DrugDDI.d62.s1.e2

Concomitant,0-11
use,12-15
of,16-18
calcium,19-26	DrugDDI.d102.s0.e0
supplements,27-38
and,39-42
L-lysine,43-51	DrugDDI.d102.s0.e1
may,52-55
increase,56-64
calcium,65-72	DrugDDI.d102.s0.e2
absorption,73-83

Acetaminophen,0-13	DrugDDI.d25.s0.e0
and,14-17
methotrexate,18-30	DrugDDI.d25.s0.e1
-,31-32
L-methionine,33-45
may,46-49
decrease,50-58
hepatic,59-66
toxicity,67-75
in,76-78
those,79-84
with,85-89
acetaminophen,90-103	DrugDDI.d25.s0.e2
overdosage,104-114
or,115-117
in,118-120
those,121-126
taking,127-133
methotrexate.,134-147	DrugDDI.d25.s0.e3

Theoretically,,0-14
it,15-17
may,18-21
decrease,22-30
hepatic,31-38
toxicity,39-47
in,48-50
the,51-54
case,55-59
of,60-62
other,63-68
potential,69-78
hepatotoxic,79-90
drugs,,91-97
as,98-100
well.,101-106

Gentamicin,0-10	DrugDDI.d25.s2.e0
-,11-12
Methionine,13-23
may,24-27
protect,28-35
against,36-43
the,44-47
ototoxic,48-56
effects,57-64
of,65-67
gentamicin.,68-79	DrugDDI.d25.s2.e1

Non-selective,0-13
monoamine,14-23	DrugDDI.d184.s0.e0
oxidase,24-31	DrugDDI.d184.s0.e0
(MAO),32-37
inhibitors,38-48
-,49-50
including,51-60
phenelzine,61-71	DrugDDI.d184.s0.e1
sulfate,,72-80	DrugDDI.d184.s0.e1
tranylcypromine,81-96	DrugDDI.d184.s0.e2
sulfate,97-104	DrugDDI.d184.s0.e2
and,105-108
pargyline,109-118	DrugDDI.d184.s0.e3
HC1.,119-123

Concomitant,0-11
use,12-15
of,16-18
L-phenylalanine,19-34
and,35-38
non-selective,39-52
MAO,53-56	DrugDDI.d184.s1.e1
inhibitors,57-67	DrugDDI.d184.s1.e1
may,68-71
cause,72-77
hypertension.,78-91

Selegiline,0-10	DrugDDI.d184.s2.e0
-,11-12
L-phenylalanine,13-28
and,29-32
the,33-36
selective,37-46
MAO,47-50	DrugDDI.d184.s2.e1
inhibitor,51-60	DrugDDI.d184.s2.e1
selegiline,61-71
may,72-75
have,76-80
synergistic,81-92
antidepressant,93-107	DrugDDI.d184.s2.e2
activity,108-116
if,117-119
used,120-124
concomitantly.,125-139

Neuroleptic,0-11	DrugDDI.d184.s3.e0
Drugs,12-17	DrugDDI.d184.s3.e0
-,18-19
L-phenylalanine,20-35
may,36-39
potentiate,40-50
the,51-54
tardive,55-62
dyskinesia,63-73
side,74-78
reactions,79-88
of,89-91
neuroleptic,92-103	DrugDDI.d184.s3.e1
drugs,104-109	DrugDDI.d184.s3.e1
if,110-112
used,113-117
concomitantly,118-131
with,132-136
them.,137-142

Monoamine,0-9	DrugDDI.d383.s0.e0
oxidase,10-17	DrugDDI.d383.s0.e0
(MAO),18-23
inhibitors,24-34
such,35-39
as,40-42
isocarboxazid,43-56	DrugDDI.d383.s0.e1
(e.g.,,57-63
Marplan),,64-73
phenelzine,74-84	DrugDDI.d383.s0.e3
(e.g.,,85-91
Nardil),,92-100
procarbazine,101-113	DrugDDI.d383.s0.e5
(e.g.,,114-120
Matulane),,121-131
selegiline,132-142	DrugDDI.d383.s0.e7
(e.g.,,143-149
Eldepryl),,150-160
and,161-164
tranylcypromine,165-180	DrugDDI.d383.s0.e9
(e.g.,,181-187
Parnate):,188-197	DrugDDI.d383.s0.e10
Using,198-203
these,204-209
medicines,210-219	DrugDDI.d383.s0.e11
with,220-224
L-tryptophan,225-237
may,238-241
increase,242-250
the,251-254
chance,255-261
of,262-264
side,265-269
effects.,270-278

Non-selective,0-13
MAO,14-17	DrugDDI.d358.s0.e0
inhibitors,18-28	DrugDDI.d358.s0.e0
including,29-38
tranylcypromine,39-54	DrugDDI.d358.s0.e1
sulfate,,55-63	DrugDDI.d358.s0.e1
phenelzine,64-74	DrugDDI.d358.s0.e2
sulfate,,75-83	DrugDDI.d358.s0.e2
and,84-87
pargyline,88-97	DrugDDI.d358.s0.e3
HC1:,98-102
Concomitant,103-114
use,115-118
of,119-121
L-tyrosine,122-132
and,133-136
non-selective,137-150
MAO,151-154	DrugDDI.d358.s0.e5
inhibitors,155-165	DrugDDI.d358.s0.e5
may,166-169
cause,170-175
hypertension.,176-189

In,0-2
one,3-6
survey,,7-14
2.3%,15-19
of,20-22
patients,23-31
taking,32-38
labetalol,39-48	DrugDDI.d210.s0.e0
HCl,49-52	DrugDDI.d210.s0.e0
in,53-55
combination,56-67
with,68-72
tricyclic,73-82	DrugDDI.d210.s0.e1
antidepressants,83-98	DrugDDI.d210.s0.e1
experienced,99-110
tremor,,111-118
as,119-121
compared,122-130
to,131-133
0.7%,134-138
reported,139-147
to,148-150
occur,151-156
with,157-161
labetalol,162-171	DrugDDI.d210.s0.e2
HCl,172-175	DrugDDI.d210.s0.e2
alone.,176-182

Drugs,0-5	DrugDDI.d210.s2.e0
possessing,6-16
beta-blocking,17-30
properties,31-41
can,42-45
blunt,46-51
the,52-55
bronchodilator,56-70	DrugDDI.d210.s2.e1
effect,71-77
of,78-80
beta-receptor,81-94
agonist,95-102	DrugDDI.d210.s2.e2
drugs,103-108	DrugDDI.d210.s2.e2
in,109-111
patients,112-120
with,121-125
bronchospasm;,126-139

therefore,,0-10
doses,11-16
greater,17-24
than,25-29
the,30-33
normal,34-40
antiasthmatic,41-54
dose,55-59
of,60-62
beta-agonist,63-75	DrugDDI.d210.s3.e0
bronchodilator,76-90	DrugDDI.d210.s3.e0
drugs,91-96	DrugDDI.d210.s3.e0
may,97-100
be,101-103
required.,104-113

Cimetidine,0-10	DrugDDI.d210.s4.e0
has,11-14
been,15-19
shown,20-25
to,26-28
increase,29-37
the,38-41
bioavailability,42-57
of,58-60
labetalol,61-70	DrugDDI.d210.s4.e1
HCl.,71-75	DrugDDI.d210.s4.e1

Since,0-5
this,6-10
could,11-16
be,17-19
explained,20-29
either,30-36
by,37-39
enhanced,40-48
absorption,49-59
or,60-62
by,63-65
an,66-68
alteration,69-79
of,80-82
hepatic,83-90
metabolism,91-101
of,102-104
labetalol,105-114	DrugDDI.d210.s5.e0
HCl,,115-119	DrugDDI.d210.s5.e0
special,120-127
care,128-132
should,133-139
be,140-142
used,143-147
in,148-150
establishing,151-163
the,164-167
dose,168-172
required,173-181
for,182-185
blood,186-191
pressure,192-200
control,201-208
in,209-211
such,212-216
patients.,217-226

Synergism,0-9
has,10-13
been,14-18
shown,19-24
between,25-32
halothane,33-42	DrugDDI.d210.s6.e0
anesthesia,43-53
and,54-57
intravenously,58-71
administered,72-84
labetalol,85-94	DrugDDI.d210.s6.e1
HCl.,95-99	DrugDDI.d210.s6.e1

During,0-6
controlled,7-17
hypotensive,18-29
anesthesia,30-40
using,41-46
labetalol,47-56	DrugDDI.d210.s7.e0
HCl,57-60	DrugDDI.d210.s7.e0
in,61-63
association,64-75
with,76-80
halothane,,81-91
high,92-96
concentrations,97-111
(3%,112-115
or,116-118
above),119-125
of,126-128
halothane,129-138	DrugDDI.d210.s7.e2
should,139-145
not,146-149
be,150-152
used,153-157
because,158-165
the,166-169
degree,170-176
of,177-179
hypotension,180-191
will,192-196
be,197-199
increased,200-209
and,210-213
because,214-221
of,222-224
the,225-228
possibility,229-240
of,241-243
a,244-245
large,246-251
reduction,252-261
in,262-264
cardiac,265-272
output,273-279
and,280-283
an,284-286
increase,287-295
in,296-298
central,299-306
venous,307-313
pressure.,314-323

The,0-3
anesthesiologist,4-20
should,21-27
be,28-30
informed,31-39
when,40-44
a,45-46
patient,47-54
is,55-57
receiving,58-67
labetalol,68-77	DrugDDI.d210.s8.e0
HCl.,78-82	DrugDDI.d210.s8.e0

Labetalol,0-9	DrugDDI.d210.s9.e0
HCl,10-13	DrugDDI.d210.s9.e0
blunts,14-20
the,21-24
reflex,25-31
tachycardia,32-43
produced,44-52
by,53-55
nitroglycerin,56-69	DrugDDI.d210.s9.e1
without,70-77
preventing,78-88	DrugDDI.d210.s9.e2
its,89-92
hypotensive,93-104
effect.,105-112

If,0-2
labetalol,3-12	DrugDDI.d210.s10.e0
HCl,13-16	DrugDDI.d210.s10.e0
is,17-19
used,20-24
with,25-29
nitroglycerin,30-43	DrugDDI.d210.s10.e1
in,44-46
patients,47-55
with,56-60
angina,61-67
pectoris,,68-77
additional,78-88
antihypertensive,89-105	DrugDDI.d210.s10.e2
effects,106-113
may,114-117
occur.,118-124

Care,0-4
should,5-11
be,12-14
taken,15-20
if,21-23
labetalol,24-33	DrugDDI.d210.s11.e0
is,34-36
used,37-41
concomitantly,42-55
with,56-60
calcium,61-68	DrugDDI.d210.s11.e1
antagonists,69-80	DrugDDI.d210.s11.e1
of,81-83
the,84-87
verapamil,88-97	DrugDDI.d210.s11.e2
type.,98-103

Risk,0-4
of,5-7
Anaphylactic,8-20
Reaction,21-29
While,30-35
taking,36-42
beta-blockers,,43-57
patients,58-66
with,67-71
a,72-73
history,74-81
of,82-84
severe,85-91
anaphylactic,92-104
reaction,105-113
to,114-116
a,117-118
variety,119-126
of,127-129
allergens,130-139
may,140-143
be,144-146
more,147-151
reactive,152-160
to,161-163
repeated,164-172
challenge,,173-183
either,184-190
accidental,,191-202
diagnostic,,203-214
or,215-217
therapeutic.,218-230

Such,0-4
patients,5-13
may,14-17
be,18-20
unresponsive,21-33
to,34-36
the,37-40
usual,41-46
doses,47-52
of,53-55
epinephrine,56-67	DrugDDI.d210.s13.e0
used,68-72
to,73-75
treat,76-81
allergic,82-90
reaction.,91-100

Drug/Laboratory,0-15	DrugDDI.d210.s14.e0
Test,16-20
Interactions,21-33
The,34-37
presence,38-46
of,47-49
labetalol,50-59	DrugDDI.d210.s14.e1
metabolites,60-71
in,72-74
the,75-78
urine,79-84
may,85-88
result,89-95
in,96-98
falsely,99-106
elevated,107-115
levels,116-122
of,123-125
urinary,126-133
catecholamines,,134-149
metanephrine,,150-163
normetanephrine,164-179
and,180-183
vanillylmandelic,184-200	DrugDDI.d210.s14.e2
acid,201-205	DrugDDI.d210.s14.e2
when,206-210
measured,211-219
by,220-222
fluorimetric,223-235
or,236-238
photometric,239-250
methods.,251-259

In,0-2
screening,3-12
patients,13-21
suspected,22-31
of,32-34
having,35-41
a,42-43
pheochromocytoma,44-60
and,61-64
being,65-70
treated,71-78
with,79-83
labetalol,84-93	DrugDDI.d210.s15.e0
HCl,,94-98	DrugDDI.d210.s15.e0
a,99-100
specific,101-109
method,,110-117
such,118-122
as,123-125
a,126-127
high,128-132
performance,133-144
liquid,145-151
chromatographic,152-167
assay,168-173
with,174-178
solid,179-184
phase,185-190
extraction,191-201
(e.g.,,202-208
J,209-210
Chromatogr,211-221
385:241,1987),222-235
should,236-242
be,243-245
employed,246-254
in,255-257
determining,258-269
levels,270-276
of,277-279
catecholamines.,280-295

Labetalol,0-9	DrugDDI.d210.s16.e0
HCl,10-13	DrugDDI.d210.s16.e0
has,14-17
also,18-22
been,23-27
reported,28-36
to,37-39
produce,40-47
a,48-49
false,50-55
positive,56-64
test,65-69
for,70-73
amphetamine,74-85	DrugDDI.d210.s16.e1
when,86-90
screening,91-100
urine,101-106
for,107-110
the,111-114
presence,115-123
of,124-126
drugs,127-132	DrugDDI.d210.s16.e2
using,133-138
the,139-142
commercially,143-155
available,156-165
assay,166-171
methods,172-179
Toxi-Lab,180-188
A?,189-191
(thin-layer,192-203
chromatographic,204-219
assay),220-226
and,227-230
Emit-d.a.u.?,231-243
(radioenzymatic,244-259
assay).,260-267

When,0-4
patients,5-13
being,14-19
treated,20-27
with,28-32
labetalol,33-42	DrugDDI.d210.s17.e0
have,43-47
a,48-49
positive,50-58
urine,59-64
test,65-69
for,70-73
amphetamine,74-85	DrugDDI.d210.s17.e1
using,86-91
these,92-97
techniques,98-108
confirmation,109-121
should,122-128
be,129-131
made,132-136
by,137-139
using,140-145
more,146-150
specific,151-159
methods,160-167
such,168-172
as,173-175
a,176-177
gas,178-181
chromatographic-mass,182-202
spectrometer,203-215
technique.,216-226

Results,0-7
of,8-10
preliminary,11-22
studies,23-30
in,31-33
humans,34-40
and,41-44
rats,45-49
suggest,50-57
that,58-62
nonabsorbable,63-76
antacids,77-85	DrugDDI.d222.s0.e0
given,86-91
concurrently,92-104
with,105-109
lactulose,110-119	DrugDDI.d222.s0.e1
may,120-123
inhibit,124-131
the,132-135
desired,136-143
lactulose-induced,144-161	DrugDDI.d222.s0.e2
drop,162-166
in,167-169
colonic,170-177
pH.,178-181

Therefore,,0-10
a,11-12
possible,13-21
lack,22-26
of,27-29
desired,30-37
effect,38-44
of,45-47
treatment,48-57
should,58-64
be,65-67
taken,68-73
into,74-78
consideration,79-92
before,93-99
such,100-104
drugs,105-110	DrugDDI.d222.s1.e0
are,111-114
given,115-120
concomitantly,121-134
with,135-139
lactulose.,140-150	DrugDDI.d222.s1.e1

Lamivudine,0-10	DrugDDI.d498.s0.e0
is,11-13
predominantly,14-27
eliminated,28-38
in,39-41
the,42-45
urine,46-51
by,52-54
active,55-61
organic,62-69
cationic,70-78	DrugDDI.d498.s0.e1
secretion.,79-89

The,0-3
possibility,4-15
of,16-18
interactions,19-31
with,32-36
other,37-42
drugs,43-48	DrugDDI.d498.s1.e0
administered,49-61
concurrently,62-74
should,75-81
be,82-84
considered,,85-96
particularly,97-109
when,110-114
their,115-120
main,121-125
route,126-131
of,132-134
elimination,135-146
is,147-149
active,150-156
renal,157-162
secretion,163-172
via,173-176
the,177-180
organic,181-188
cationic,189-197
transport,198-207
system,208-214
(e.g.,,215-221
trimethoprim).,222-236	DrugDDI.d498.s1.e1

TMP,0-3	DrugDDI.d498.s2.e0
160,4-7
mg/SMX,8-14
800,15-18
mg,19-21
once,22-26
daily,27-32
has,33-36
been,37-41
shown,42-47
to,48-50
increase,51-59
lamivudine,60-70	DrugDDI.d498.s2.e1
exposure,71-79
(AUC),80-85
by,86-88
44%.,89-93

No,0-2
change,3-9
in,10-12
dose,13-17
of,18-20
either,21-27
drug,28-32	DrugDDI.d498.s3.e0
is,33-35
recommended.,36-48

There,0-5
is,6-8
no,9-11
information,12-23
regarding,24-33
the,34-37
effect,38-44
on,45-47
lamivudine,48-58	DrugDDI.d498.s4.e0
pharmacokinetics,59-75
of,76-78
higher,79-85
doses,86-91
of,92-94
TMP/SMX,95-102	DrugDDI.d498.s4.e1
such,103-107
as,108-110
those,111-116
used,117-121
to,122-124
treat,125-130
Pneumocystis,131-143
carinii,144-151
pneumonia.,152-162

No,0-2
data,3-7
are,8-11
available,12-21
regarding,22-31
interactions,32-44
with,45-49
other,50-55
drugs,56-61	DrugDDI.d498.s5.e0
that,62-66
have,67-71
renal,72-77
clearance,78-87
mechanisms,88-98
similar,99-106
to,107-109
that,110-114
of,115-117
lamivudine.,118-129	DrugDDI.d498.s5.e1

Lamivudine,0-10	DrugDDI.d498.s6.e0
and,11-14
zalcitabine,15-26	DrugDDI.d498.s6.e1
may,27-30
inhibit,31-38
the,39-42
intracellular,43-56
phosphorylation,57-72
of,73-75
one,76-79
another.,80-88

Therefore,,0-10
use,11-14
of,15-17
lamivudine,18-28	DrugDDI.d498.s7.e0
in,29-31
combination,32-43
with,44-48
zalcitabine,49-60	DrugDDI.d498.s7.e1
is,61-63
not,64-67
recommended,68-79

Lansoprazole,0-12	DrugDDI.d504.s0.e0
is,13-15
metabolized,16-27
through,28-35
the,36-39
cytochrome,40-50	DrugDDI.d504.s0.e1
P450,51-55	DrugDDI.d504.s0.e1
system,,56-63
specifically,64-76
through,77-84
the,85-88
CYP3A,89-94	DrugDDI.d504.s0.e2
and,95-98
CYP2C19,99-106
isozymes.,107-116	DrugDDI.d504.s0.e3

Studies,0-7
have,8-12
shown,13-18
that,19-23
lansoprazole,24-36	DrugDDI.d504.s1.e0
does,37-41
not,42-45
have,46-50
clinically,51-61
significant,62-73
interactions,74-86
with,87-91
other,92-97
drugs,98-103	DrugDDI.d504.s1.e1
metabolized,104-115
by,116-118
the,119-122
cytochrome,123-133	DrugDDI.d504.s1.e2
P450,134-138	DrugDDI.d504.s1.e2
system,,139-146
such,147-151
as,152-154
warfarin,,155-164
antipyrine,,165-176
indomethacin,,177-190
ibuprofen,,191-201
phenytoin,,202-212
propranolol,,213-225
prednisone,,226-237
diazepam,,238-247
clarithromycin,,248-263
or,264-266
terfenadine,267-278	DrugDDI.d504.s1.e12
in,279-281
healthy,282-289
subjects.,290-299

These,0-5
compounds,6-15
are,16-19
metabolized,20-31
through,32-39
various,40-47
cytochrome,48-58	DrugDDI.d504.s2.e0
P450,59-63	DrugDDI.d504.s2.e0
isozymes,64-72
including,73-82
CYP1A2,,83-90
CYP2C9,,91-98
CYP2C19,,99-107
CYP2D6,,108-115
and,116-119
CYP3A.,120-126	DrugDDI.d504.s2.e5

When,0-4
lansoprazole,5-17	DrugDDI.d504.s3.e0
was,18-21
administered,22-34
concomitantly,35-48
with,49-53
theophylline,54-66	DrugDDI.d504.s3.e1
(CYP1A2,,67-75
CYP3A),,76-83
a,84-85
minor,86-91
increase,92-100
(10%),101-106
in,107-109
the,110-113
clearance,114-123
of,124-126
theophylline,127-139	DrugDDI.d504.s3.e4
was,140-143
seen.,144-149

Because,0-7
the,8-11
small,12-17
magnitude,18-27
and,28-31
the,32-35
direction,36-45
of,46-48
the,49-52
effect,53-59
on,60-62
theophylline,63-75	DrugDDI.d504.s4.e0
clearance,,76-86
this,87-91
interaction,92-103
is,104-106
unlikely,107-115
to,116-118
be,119-121
clinical,122-130
concern.,131-139

Nonetheless,,0-12
individual,13-23
patients,24-32
may,33-36
require,37-44
additional,45-55
titration,56-65
of,66-68
their,69-74
theophylline,75-87	DrugDDI.d504.s5.e0
dosage,88-94
when,95-99
lansoprazole,100-112	DrugDDI.d504.s5.e1
is,113-115
started,116-123
or,124-126
stopped,127-134
to,135-137
ensure,138-144
clinically,145-155
effective,156-165
blood,166-171
levels.,172-179

Lansoprazole,0-12	DrugDDI.d504.s6.e0
has,13-16
also,17-21
been,22-26
shown,27-32
to,33-35
have,36-40
no,41-43
clinically,44-54
significant,55-66
interaction,67-78
with,79-83
amoxicillin.,84-96	DrugDDI.d504.s6.e1

In,0-2
a,3-4
single-dose,5-16
crossover,17-26
study,27-32
examining,33-42
lansoprazole,43-55	DrugDDI.d504.s7.e0
30,56-58	DrugDDI.d504.s7.e0
mg,59-61	DrugDDI.d504.s7.e0
and,62-65
omeprazole,66-76	DrugDDI.d504.s7.e1
20,77-79	DrugDDI.d504.s7.e1
mg,80-82	DrugDDI.d504.s7.e1
each,83-87
administered,88-100
alone,101-106
and,107-110
concomitantly,111-124
with,125-129
sucralfate,130-140	DrugDDI.d504.s7.e2
1,141-142
gram,,143-148
absorption,149-159
of,160-162
the,163-166
proton,167-173	DrugDDI.d504.s7.e3
pump,174-178	DrugDDI.d504.s7.e3
inhibitors,179-189	DrugDDI.d504.s7.e3
was,190-193
delayed,194-201
and,202-205
their,206-211
bioavailability,212-227
was,228-231
reduced,232-239
by,240-242
17%,243-246
and,247-250
16%,,251-255
respectively,,256-269
when,270-274
administered,275-287
concomitantly,288-301
with,302-306
sucralfate.,307-318	DrugDDI.d504.s7.e4

Therefore,,0-10
proton,11-17	DrugDDI.d504.s8.e0
pump,18-22	DrugDDI.d504.s8.e0
inhibitors,23-33	DrugDDI.d504.s8.e0
should,34-40
be,41-43
taken,44-49
at,50-52
least,53-58
30,59-61
minutes,62-69
prior,70-75
to,76-78
sucralfate.,79-90	DrugDDI.d504.s8.e1

In,0-2
clinical,3-11
trials,,12-19
antacids,20-28	DrugDDI.d504.s9.e0
were,29-33
administered,34-46
concomitantly,47-60
with,61-65
lansoprazole,66-78	DrugDDI.d504.s9.e1
delayed-release,79-94
capsules;,95-104

Lansoprazole,0-12	DrugDDI.d504.s11.e0
causes,13-19
a,20-21
profound,22-30
and,31-34
long,35-39
lasting,40-47
inhibition,48-58
of,59-61
gastric,62-69
acid,70-74
secretion;,75-85

therefore,,0-10
it,11-13
is,14-16
theoretically,17-30
possible,31-39
that,40-44
lansoprazole,45-57	DrugDDI.d504.s12.e0
may,58-61
interfere,62-71
with,72-76
the,77-80
absorption,81-91
of,92-94
drugs,95-100	DrugDDI.d504.s12.e1
where,101-106
gastric,107-114
pH,115-117
is,118-120
an,121-123
important,124-133
determinant,134-145
of,146-148
bioavailability,149-164
(e.g.,165-170
ketoconazole,,171-184
ampicillin,185-195	DrugDDI.d504.s12.e3
esters,,196-203
iron,204-208
salts,,209-215
digoxin).,216-225	DrugDDI.d504.s12.e4

Effects,0-7
of,8-10
Lapatinib,11-20	DrugDDI.d430.s0.e0
on,21-23
Drug,24-28	DrugDDI.d430.s0.e1
Metabolizing,29-41
Enzymes,42-49
and,50-53
Drug,54-58
Transport,59-68
Systems,69-76
Lapatinib,77-86	DrugDDI.d430.s0.e2
inhibits,87-95
CYP3A4,96-102	DrugDDI.d430.s0.e3
and,103-106
CYP2C8,107-113	DrugDDI.d430.s0.e4
in,114-116
vitro,117-122
at,123-125
clinically,126-136
relevant,137-145
concentrations.,146-161

Caution,0-7
should,8-14
be,15-17
exercised,18-27
and,28-31
dose,32-36
reduction,37-46
of,47-49
the,50-53
concomitant,54-65
substrate,66-75
drug,76-80	DrugDDI.d430.s1.e0
should,81-87
be,88-90
considered,91-101
when,102-106
dosing,107-113
lapatinib,114-123	DrugDDI.d430.s1.e1
concurrently,124-136
with,137-141
medications,142-153	DrugDDI.d430.s1.e2
with,154-158
narrow,159-165
therapeutic,166-177
windows,178-185
that,186-190
are,191-194
substrates,195-205
of,206-208
CYP3A4,209-215	DrugDDI.d430.s1.e3
or,216-218
CYP2C8.,219-226	DrugDDI.d430.s1.e4

Lapatinib,0-9	DrugDDI.d430.s2.e0
did,10-13
not,14-17
significantly,18-31
inhibit,32-39
the,40-43
following,44-53
enzymes,54-61
in,62-64
human,65-70
liver,71-76
microsomes:,77-88
CYP1A2,,89-96
CYP2C9,,97-104
CYP2C19,,105-113
and,114-117
CYP2D6,118-124	DrugDDI.d430.s2.e4
or,125-127
UGT,128-131
enzymes,132-139
in,140-142
vitro,,143-149
however,,150-158
the,159-162
clinical,163-171
significance,172-184
is,185-187
unknown.,188-196

Lapatinib,0-9	DrugDDI.d430.s3.e0
inhibits,10-18
human,19-24
P-glycoprotein.,25-40

If,0-2
TYKERB,3-9
is,10-12
administered,13-25
with,26-30
drugs,31-36	DrugDDI.d430.s4.e0
that,37-41
are,42-45
substrates,46-56
of,57-59
Pgp,,60-64
increased,65-74
concentrations,75-89
of,90-92
the,93-96
substrate,97-106
drug,107-111	DrugDDI.d430.s4.e1
are,112-115
likely,,116-123
and,124-127
caution,128-135
should,136-142
be,143-145
exercised.,146-156

Drugs,0-5	DrugDDI.d430.s5.e0
that,6-10
Inhibit,11-18
or,19-21
Induce,22-28
Cytochrome,29-39	DrugDDI.d430.s5.e1
P450,40-44	DrugDDI.d430.s5.e1
3A4,45-48	DrugDDI.d430.s5.e1
Enzymes,49-56
Lapatinib,57-66
undergoes,67-76
extensive,77-86
metabolism,87-97
by,98-100
CYP3A4,,101-108
and,109-112
concomitant,113-124
administration,125-139
of,140-142
strong,143-149
inhibitors,150-160
or,161-163
inducers,164-172
of,173-175
CYP3A4,176-182	DrugDDI.d430.s5.e3
alter,183-188
lapatinib,189-198	DrugDDI.d430.s5.e4
concentrations,199-213
significantly.,214-228

Dose,0-4
adjustment,5-15
of,16-18
lapatinib,19-28	DrugDDI.d430.s6.e0
should,29-35
be,36-38
considered,39-49
for,50-53
patients,54-62
who,63-66
must,67-71
receive,72-79
concomitant,80-91
strong,92-98
inhibitors,99-109
or,110-112
concomitant,113-124
strong,125-131
inducers,132-140
of,141-143
CYP3A4,144-150	DrugDDI.d430.s6.e1
enzymes.,151-159

Ketoconazole:,0-13	DrugDDI.d430.s7.e0
In,14-16
healthy,17-24
subjects,25-33
receiving,34-43
ketoconazole,,44-57
a,58-59
CYP3A4,60-66	DrugDDI.d430.s7.e2
inhibitor,,67-77
at,78-80
200,81-84
mg,85-87
twice,88-93
daily,94-99
for,100-103
7,104-105
days,,106-111
systemic,112-120
exposure,121-129
(AUC),130-135
to,136-138
lapatinib,139-148	DrugDDI.d430.s7.e3
was,149-152
increased,153-162
to,163-165
approximately,166-179
3.6-fold,180-188
of,189-191
control,192-199
and,200-203
half-life,204-213
increased,214-223
to,224-226
1.7-fold,227-235
of,236-238
control.,239-247

Carbamazepine:,0-14	DrugDDI.d430.s8.e0
In,15-17
healthy,18-25
subjects,26-34
receiving,35-44
the,45-48
CYP3A4,49-55	DrugDDI.d430.s8.e1
inducer,,56-64
carbamazepine,,65-79
at,80-82
100,83-86
mg,87-89
twice,90-95
daily,96-101
for,102-105
3,106-107
days,108-112
and,113-116
200,117-120
mg,121-123
twice,124-129
daily,130-135
for,136-139
17,140-142
days,,143-148
systemic,149-157
exposure,158-166
(AUC),167-172
to,173-175
lapatinib,176-185	DrugDDI.d430.s8.e3
was,186-189
decreased,190-199
approximately,200-213
72%.,214-218

Drugs,0-5	DrugDDI.d430.s9.e0
that,6-10
Inhibit,11-18
Drug,19-23
Transport,24-33
Systems,34-41
Lapatinib,42-51	DrugDDI.d430.s9.e1
is,52-54
a,55-56
substrate,57-66
of,67-69
the,70-73
efflux,74-80
transporter,81-92	DrugDDI.d430.s9.e2
P-glycoprotein,93-107
(Pgp,,108-113
ABCB1).,114-121	DrugDDI.d430.s9.e3

If,0-2
TYKERB,3-9
is,10-12
administered,13-25
with,26-30
drugs,31-36	DrugDDI.d430.s10.e0
that,37-41
inhibit,42-49
Pgp,,50-54
increased,55-64
concentrations,65-79
of,80-82
lapatinib,83-92	DrugDDI.d430.s10.e1
are,93-96
likely,,97-104
and,105-108
caution,109-116
should,117-123
be,124-126
exercised.,127-137

Other,0-5
Chemotherapy,6-18
Agents,19-25
In,26-28
a,29-30
separate,31-39
study,,40-46
concomitant,47-58
administration,59-73
of,74-76
lapatinib,77-86	DrugDDI.d430.s11.e0
with,87-91
capecitabine,92-104	DrugDDI.d430.s11.e1
did,105-108
not,109-112
meaningfully,113-125
alter,126-131
the,132-135
pharmacokinetics,136-152
of,153-155
either,156-162
agent,163-168
(or,169-172
the,173-176
metabolites,177-188	DrugDDI.d430.s11.e2
of,189-191
capecitabine).,192-206	DrugDDI.d430.s11.e3

In,0-2
vitro,3-8
studies,9-16
have,17-21
shown,22-27
that,28-32
precipitation,33-46
occurs,47-53
when,54-58
eye,59-62
drops,63-68
containing,69-79
thimerosal,80-90	DrugDDI.d215.s0.e0
are,91-94
mixed,95-100
with,101-105
latanoprost.,106-118	DrugDDI.d215.s0.e1

If,0-2
such,3-7
drugs,8-13	DrugDDI.d215.s1.e0
are,14-17
used,18-22
they,23-27
should,28-34
be,35-37
administered,38-50
with,51-55
an,56-58
interval,59-67
of,68-70
at,71-73
least,74-79
5,80-81
minutes,82-89
between,90-97
applications.,98-111

Cholestyramine,0-14	DrugDDI.d237.s0.e0
and,15-18
Charcoal,19-27	DrugDDI.d237.s0.e1
Administration,28-42
of,43-45
cholestyramine,46-60	DrugDDI.d237.s0.e2
or,61-63
activated,64-73	DrugDDI.d237.s0.e3
charcoal,74-82	DrugDDI.d237.s0.e3
in,83-85
patients,86-94
(n=13),95-101
and,102-105
volunteers,106-116
(n=96),117-123
resulted,124-132
in,133-135
a,136-137
rapid,138-143
and,144-147
significant,148-159
decrease,160-168
in,169-171
plasma,172-178
M1,179-181
(the,182-186
active,187-193	DrugDDI.d237.s0.e4
metabolite,194-204	DrugDDI.d237.s0.e4
of,205-207
leflunomide),208-220	DrugDDI.d237.s0.e5
concentration,221-234
.,235-236

Hepatotoxic,0-11
Drugs,12-17	DrugDDI.d237.s1.e0
Increased,18-27
side,28-32
effects,33-40
may,41-44
occur,45-50
when,51-55
leflunomide,56-67	DrugDDI.d237.s1.e1
is,68-70
given,71-76
concomitantly,77-90
with,91-95
hepatotoxic,96-107
substances.,108-119

This,0-4
is,5-7
also,8-12
to,13-15
be,16-18
considered,19-29
when,30-34
leflunomide,35-46	DrugDDI.d237.s2.e0
treatment,47-56
is,57-59
followed,60-68
by,69-71
such,72-76
drugs,77-82	DrugDDI.d237.s2.e1
without,83-90
a,91-92
drug,93-97
elimination,98-109
procedure.,110-120

In,0-2
a,3-4
small,5-10
(n=30),11-17
combination,18-29
study,30-35
of,36-38
ARAVA,39-44	DrugDDI.d237.s3.e0
with,45-49
methotrexate,,50-63
a,64-65
2-,66-68
to,69-71
3-fold,72-78
elevation,79-88
in,89-91
liver,92-97	DrugDDI.d237.s3.e2
enzymes,98-105	DrugDDI.d237.s3.e2
was,106-109
seen,110-114
in,115-117
5,118-119
of,120-122
30,123-125
patients.,126-135

All,0-3
elevations,4-14
resolved,,15-24
2,25-26
with,27-31
continuation,32-44
of,45-47
both,48-52
drugs,53-58	DrugDDI.d237.s4.e0
and,59-62
3,63-64
after,65-70
discontinuation,71-86
of,87-89
leflunomide.,90-102	DrugDDI.d237.s4.e1

All,0-3
of,4-6
these,7-12
also,13-17
resolved,,18-27
2,28-29
with,30-34
continuation,35-47
of,48-50
both,51-55
drugs,56-61	DrugDDI.d237.s6.e0
and,62-65
3,66-67
after,68-73
discontinuation,74-89
of,90-92
leflunomide.,93-105	DrugDDI.d237.s6.e1

Three,0-5
patients,6-14
met,15-18	DrugDDI.d237.s7.e0
ACR,19-22
criteria,23-31
for,32-35
liver,36-41
biopsy,42-48
(1:,49-52
Roegnik,53-60
Grade,61-66
I,,67-69
2:,70-72
Roegnik,73-80
Grade,81-86
IIIa).,87-93

NSAIDs,0-6	DrugDDI.d237.s9.e0
In,7-9
in,10-12
vitro,13-18
studies,,19-27
M1,28-30
was,31-34
shown,35-40
to,41-43
cause,44-49
increases,50-59
ranging,60-67
from,68-72
13,73-75
-,76-77
50%,78-81
in,82-84
the,85-88
free,89-93
fraction,94-102
of,103-105
diclofenac,106-116	DrugDDI.d237.s9.e1
and,117-120
ibuprofen,121-130	DrugDDI.d237.s9.e2
at,131-133
concentrations,134-148
in,149-151
the,152-155
clinical,156-164
range.,165-171

however,,0-8
there,9-14
was,15-18
extensive,19-28
concomitant,29-40
use,41-44
of,45-47
NSAIDs,48-54	DrugDDI.d237.s11.e0
in,55-57
clinical,58-66
studies,67-74
and,75-78
no,79-81
differential,82-94
effect,95-101
was,102-105
observed.,106-115

Tolbutamide,0-11	DrugDDI.d237.s12.e0
In,12-14
in,15-17
vitro,18-23
studies,,24-32
M1,33-35
was,36-39
shown,40-45
to,46-48
cause,49-54
increases,55-64
ranging,65-72
from,73-77
13,78-80
-,81-82
50%,83-86
in,87-89
the,90-93
free,94-98
fraction,99-107
of,108-110
tolbutamide,111-122	DrugDDI.d237.s12.e1
at,123-125
concentrations,126-140
in,141-143
the,144-147
clinical,148-156
range.,157-163

Rifampin,0-8	DrugDDI.d237.s14.e0
Following,9-18
concomitant,19-30
administration,31-45
of,46-48
a,49-50
single,51-57
dose,58-62
of,63-65
ARAVA,66-71	DrugDDI.d237.s14.e1
to,72-74
subjects,75-83
receiving,84-93
multiple,94-102
doses,103-108
of,109-111
rifampin,,112-121
M1,122-124
peak,125-129
levels,130-136
were,137-141
increased,142-151
(~40%),152-158
over,159-163
those,164-169
seen,170-174
when,175-179
ARAVA,180-185	DrugDDI.d237.s14.e3
was,186-189
given,190-195
alone.,196-202

Because,0-7
of,8-10
the,11-14
potential,15-24
for,25-28
ARAVA,29-34	DrugDDI.d237.s15.e0
levels,35-41
to,42-44
continue,45-53
to,54-56
increase,57-65
with,66-70
multiple,71-79
dosing,,80-87
caution,88-95
should,96-102
be,103-105
used,106-110
if,111-113
patients,114-122
are,123-126
to,127-129
be,130-132
receiving,133-142
both,143-147
ARAVA,148-153	DrugDDI.d237.s15.e1
and,154-157
rifampin.,158-167	DrugDDI.d237.s15.e2

Warfarin,0-8	DrugDDI.d237.s16.e0
Increased,9-18
INR,19-22
(International,23-37
Normalized,38-48
Ratio),49-55
when,56-60
ARAVA,61-66	DrugDDI.d237.s16.e1
and,67-70
warfarin,71-79	DrugDDI.d237.s16.e2
were,80-84
co-administered,85-100
has,101-104
been,105-109
rarely,110-116
reported.,117-126

Results,0-7
from,8-12
human,13-18
in,19-21
vitro,22-27
metabolism,28-38
studies,39-46
and,47-50
nonclinical,51-62
studies,63-70
show,71-75
that,76-80
REVLIMID?,81-90
(lenalidomide),91-105
is,106-108
neither,109-116
metabolized,117-128
by,129-131
nor,132-135
inhibits,136-144
or,145-147
induces,148-155
the,156-159
cytochrome,160-170	DrugDDI.d448.s0.e1
P450,171-175	DrugDDI.d448.s0.e1
pathway,176-183
suggesting,184-194
that,195-199
lenalidomide,200-212	DrugDDI.d448.s0.e2
is,213-215
not,216-219
likely,220-226
to,227-229
cause,230-235
or,236-238
be,239-241
subject,242-249
to,250-252
P450-based,253-263	DrugDDI.d448.s0.e3
metabolic,264-273
drug,274-278
interactions,279-291
in,292-294
man.,295-299

Co-administration,0-17
of,18-20
multiple,21-29
doses,30-35
of,36-38
10,39-41
mg,42-44
of,45-47
lenalidomide,48-60	DrugDDI.d448.s1.e0
had,61-64
no,65-67
effect,68-74
on,75-77
the,78-81
single,82-88
dose,89-93
pharmacokinetics,94-110
of,111-113
R-,114-116
and,117-120
S-,121-123
warfarin.,124-133	DrugDDI.d448.s1.e1

Co-administration,0-17
of,18-20
single,21-27
25-mg,28-33
dose,34-38
warfarin,39-47	DrugDDI.d448.s2.e0
had,48-51
no,52-54
effect,55-61
on,62-64
the,65-68
pharmacokinetics,69-85
of,86-88
total,89-94
lenalidomide.,95-108	DrugDDI.d448.s2.e1

Expected,0-8
changes,9-16
in,17-19
laboratory,20-30
assessments,31-42
of,43-45
PT,46-48
and,49-52
INR,53-56
were,57-61
observed,62-70
after,71-76
warfarin,77-85	DrugDDI.d448.s3.e0
administration,,86-101
but,102-105
these,106-111
changes,112-119
were,120-124
not,125-128
affected,129-137
by,138-140
concomitant,141-152
lenalidomide,153-165	DrugDDI.d448.s3.e1
administration.,166-181

Concomitant,0-11
treatment,12-21
with,22-26
thrombolytics,27-40	DrugDDI.d123.s0.e0
(eg,,41-45
rt-PA,46-51	DrugDDI.d123.s0.e1
or,52-54
streptokinase),55-69	DrugDDI.d123.s0.e2
may:,70-74
-,75-76
increase,77-85
the,86-89
risk,90-94
of,95-97
bleeding,98-106
complications,107-120
-,121-122
considerably,123-135
enhance,136-143
the,144-147
effect,148-154
of,155-157
REFLUDAN,158-166	DrugDDI.d123.s0.e3
on,167-169
aPTT,170-174
prolongation,175-187

Concomitant,0-11
treatment,12-21
with,22-26
coumarin,27-35	DrugDDI.d123.s1.e0
derivatives,36-47
(vitamin,48-56
K,57-58
antagonists),59-71
and,72-75
drugs,76-81	DrugDDI.d123.s1.e1
that,82-86
affect,87-93
platelet,94-102
function,103-111
may,112-115
also,116-120
increase,121-129
the,130-133
risk,134-138
of,139-141
bleeding.,142-151

Clinical,0-8
interaction,9-20
studies,21-28
with,29-33
cimetidine,34-44	DrugDDI.d116.s0.e0
and,45-48
warfarin,49-57	DrugDDI.d116.s0.e1
indicated,58-67
that,68-72
the,73-76
coadministration,77-93
of,94-96
Femara,97-103	DrugDDI.d116.s0.e2
with,104-108
these,109-114
drugs,115-120	DrugDDI.d116.s0.e3
does,121-125
not,126-129
result,130-136
in,137-139
clinically-,140-151
significant,152-163
drug,164-168
interactions.,169-182

(See,0-4
CLINICAL,5-13
PHARMACOLOGY),14-27
Coadministration,28-44
of,45-47
Femara,48-54	DrugDDI.d116.s1.e0
and,55-58
tamoxifen,59-68	DrugDDI.d116.s1.e1
20,69-71	DrugDDI.d116.s1.e1
mg,72-74	DrugDDI.d116.s1.e1
daily,75-80
resulted,81-89
in,90-92
a,93-94
reduction,95-104
of,105-107
letrozole,108-117	DrugDDI.d116.s1.e2
plasma,118-124
levels,125-131
by,132-134
38%,135-138
on,139-141
average.,142-150

There,0-5
is,6-8
no,9-11
clinical,12-20
experience,21-31
to,32-34
date,35-39
on,40-42
the,43-46
use,47-50
of,51-53
Femara,54-60	DrugDDI.d116.s2.e0
in,61-63
combination,64-75
with,76-80
other,81-86
anticancer,87-97
agents.,98-105

Drug/Laboratory,0-15	DrugDDI.d116.s3.e0
Test-Interactions,16-33
None,34-38
observed.,39-48

Folic,0-5	DrugDDI.d32.s0.e0
acid,6-10	DrugDDI.d32.s0.e0
in,11-13
large,14-19
amounts,20-27
may,28-31
counteract,32-42
the,43-46
antiepileptic,47-60	DrugDDI.d32.s0.e1
effect,61-67
of,68-70
phenobarbital,,71-85
phenytoin,86-95	DrugDDI.d32.s0.e3
and,96-99
primidone,,100-110
and,111-114
increase,115-123
the,124-127
frequency,128-137
of,138-140
seizures,141-149
in,150-152
susceptible,153-164
pediatric,165-174	DrugDDI.d32.s0.e5
patients.,175-184

Preliminary,0-11
animal,12-18
and,19-22
human,23-28
studies,29-36
have,37-41
shown,42-47
that,48-52
small,53-58
quantities,59-69
of,70-72
systemically,73-85
administered,86-98
leucovorin,99-109	DrugDDI.d32.s1.e0
enter,110-115
the,116-119
CSF,120-123
primarily,124-133
as,134-136
5-methyltetrahydro-folate,137-162
and,,163-167
in,168-170
humans,,171-178
remain,179-185
1,186-187
to,188-190
3,191-192
orders,193-199
of,200-202
magnitude,203-212
lower,213-218
than,219-223
the,224-227
usual,228-233
methotrexate,234-246	DrugDDI.d32.s1.e1
concentrations,247-261
following,262-271
intrathecal,272-283
administration.,284-299

However,,0-8
high,9-13
doses,14-19
of,20-22
leucovorin,23-33	DrugDDI.d32.s2.e0
may,34-37
reduce,38-44
the,45-48
efficacy,49-57
of,58-60
intrathecally,61-74
administered,75-87
methotrexate.,88-101	DrugDDI.d32.s2.e1

Leucovorin,0-10	DrugDDI.d32.s3.e0
may,11-14
enhance,15-22
the,23-26
toxicity,27-35
of,36-38
5-fluorouracil.,39-54

ERGAMISOL?,0-10
(levamisole,11-22
hydrochloride),23-37
has,38-41
been,42-46
reported,47-55
to,56-58
produce,59-66
ANTABUSE-like,67-80	DrugDDI.d537.s0.e1
side,81-85
effects,86-93
when,94-98
given,99-104
concomitantly,105-118
with,119-123
alcohol.,124-132	DrugDDI.d537.s0.e2

Concomitant,0-11
administration,12-26
of,27-29
phenytoin,30-39	DrugDDI.d537.s1.e0
and,40-43
ERGAMISOL?,44-54
plus,55-59
fluorouracil,60-72	DrugDDI.d537.s1.e1
has,73-76
lead,77-81
to,82-84
increased,85-94
plasma,95-101
levels,102-108
of,109-111
phenytoin.,112-122	DrugDDI.d537.s1.e2

The,0-3
physician,4-13
is,14-16
advised,17-24
to,25-27
monitor,28-35
plasma,36-42
levels,43-49
of,50-52
phenytoin,53-62	DrugDDI.d537.s2.e0
and,63-66
to,67-69
decrease,70-78
the,79-82
dose,83-87
if,88-90
necessary.,91-101

Because,0-7
of,8-10
reports,11-18
of,19-21
prolongation,22-34
of,35-37
the,38-41
prothrombin,42-53
time,54-58
beyond,59-65
the,66-69
therapeutic,70-81
range,82-87
in,88-90
patients,91-99
taking,100-106
concurrent,107-117
levamisole,118-128	DrugDDI.d537.s3.e0
and,129-132
warfarin,133-141	DrugDDI.d537.s3.e1
sodium,,142-149	DrugDDI.d537.s3.e1
it,150-152
is,153-155
suggested,156-165
that,166-170
the,171-174
prothrombin,175-186
time,187-191
be,192-194
monitored,195-204
carefully,,205-215
and,216-219
the,220-223
dose,224-228
of,229-231
warfarin,232-240	DrugDDI.d537.s3.e2
sodium,241-247	DrugDDI.d537.s3.e2
or,248-250
other,251-256
coumarin-like,257-270	DrugDDI.d537.s3.e3
drugs,271-276	DrugDDI.d537.s3.e4
should,277-283
be,284-286
adjusted,287-295
accordingly,,296-308
in,309-311
patients,312-320
taking,321-327
both,328-332
drugs.,333-339	DrugDDI.d537.s3.e5

Levetiracetam,0-13	DrugDDI.d369.s1.e0
and,14-17
its,18-21
major,22-27
metabolite,,28-39
at,40-42
concentrations,43-57
well,58-62
above,63-68
cmax,69-73
levels,74-80
achieved,81-89
within,90-96
the,97-100
therapeutic,101-112
dose,113-117
range,,118-124
are,125-128
neither,129-136
inhibitors,137-147
of,148-150
nor,151-154
high,155-159
affinity,160-168
substrates,169-179
for,180-183
human,184-189
liver,190-195
cytochrome,196-206	DrugDDI.d369.s1.e2
P450,207-211	DrugDDI.d369.s1.e2
isoforms,,212-221
epoxide,222-229	DrugDDI.d369.s1.e3
hydrolase,230-239	DrugDDI.d369.s1.e3
or,240-242
UDP-glucuronidation,243-262	DrugDDI.d369.s1.e4
enzymes.,263-271

In,0-2
addition,,3-12
levetiracetam,13-26	DrugDDI.d369.s2.e0
does,27-31
not,32-35
affect,36-42
the,43-46
in,47-49
vitro,50-55
glucuronidation,56-71
of,72-74
valproic,75-83	DrugDDI.d369.s2.e1
acid.,84-89	DrugDDI.d369.s2.e1

Levetiracetam,0-13	DrugDDI.d369.s3.e0
circulates,14-24
largely,25-32
unbound,33-40
(,41-42
10%,43-46
bound),47-53
to,54-56
plasma,57-63	DrugDDI.d369.s3.e1
proteins;,64-73	DrugDDI.d369.s3.e1

clinically,0-10
significant,11-22
interactions,23-35
with,36-40
other,41-46
drugs,47-52	DrugDDI.d369.s4.e0
through,53-60
competition,61-72
for,73-76
protein,77-84	DrugDDI.d369.s4.e1
binding,85-92
sites,93-98
are,99-102
therefore,103-112
unlikely.,113-122

Potential,0-9
pharmacokinetic,10-25
interactions,26-38
were,39-43
assessed,44-52
in,53-55
clinical,56-64
pharmacokinetic,65-80
studies,81-88
(phenytoin,,89-100
valproate,,101-111
oral,112-116	DrugDDI.d369.s5.e2
contraceptive,,117-131	DrugDDI.d369.s5.e2
digoxin,,132-140
warfarin,,141-150
probenecid),151-162	DrugDDI.d369.s5.e5
and,163-166
through,167-174
pharmacokinetic,175-190
screening,191-200
in,201-203
the,204-207
placebo-controlled,208-226
clinical,227-235
studies,236-243
in,244-246
epilepsy,247-255
patients.,256-265

Drug-Drug,0-9
Interactions,10-22
Between,23-30
Keppra?,31-38
And,39-42
Other,43-48
Antiepileptic,49-62	DrugDDI.d369.s6.e0
Drugs,63-68	DrugDDI.d369.s6.e0
(AEDs),69-75
Phenytoin,76-85	DrugDDI.d369.s6.e1
Keppra?,86-93
(3000,94-99
mg,100-102
daily),103-109
had,110-113
no,114-116
effect,117-123
on,124-126
the,127-130
pharmacokinetic,131-146
disposition,147-158
of,159-161
phenytoin,162-171	DrugDDI.d369.s6.e2
in,172-174
patients,175-183
with,184-188
refractory,189-199
epilepsy.,200-209

Pharmacokinetics,0-16
of,17-19
levetiracetam,20-33	DrugDDI.d369.s7.e0
were,34-38
also,39-43
not,44-47
affected,48-56
by,57-59
phenytoin.,60-70	DrugDDI.d369.s7.e1

Valproate,0-9	DrugDDI.d369.s8.e0
Keppra?,10-17
(1500,18-23
mg,24-26
twice,27-32
daily),33-39
did,40-43
not,44-47
alter,48-53
the,54-57
pharmacokinetics,58-74
of,75-77
valproate,78-87	DrugDDI.d369.s8.e1
in,88-90
healthy,91-98
volunteers.,99-110

Valproate,0-9	DrugDDI.d369.s9.e0
500,10-13
mg,14-16
twice,17-22
daily,23-28
did,29-32
not,33-36
modify,37-43
the,44-47
rate,48-52
or,53-55
extent,56-62
of,63-65
levetiracetam,66-79	DrugDDI.d369.s9.e1
absorption,80-90
or,91-93
its,94-97
plasma,98-104
clearance,105-114
or,115-117
urinary,118-125
excretion.,126-136

There,0-5
also,6-10
was,11-14
no,15-17
effect,18-24
on,25-27
exposure,28-36
to,37-39
and,40-43
the,44-47
excretion,48-57
of,58-60
the,61-64
primary,65-72
metabolite,,73-84
ucb,85-88
L057.,89-94

Potential,0-9
drug,10-14
interactions,15-27
between,28-35
Keppra?,36-43
and,44-47
other,48-53
AEDs,54-58
(carbamazepine,,59-74
gabapentin,,75-86
lamotrigine,,87-99
phenobarbital,,100-114
phenytoin,,115-125
primidone,126-135	DrugDDI.d369.s11.e5
and,136-139
valproate),140-150	DrugDDI.d369.s11.e6
were,151-155
also,156-160
assessed,161-169
by,170-172
evaluating,173-183
the,184-187
serum,188-193
concentrations,194-208
of,209-211
levetiracetam,212-225	DrugDDI.d369.s11.e7
and,226-229
these,230-235
AEDs,236-240
during,241-247
placebo-controlled,248-266
clinical,267-275
studies.,276-284

These,0-5
data,6-10
indicate,11-19
that,20-24
levetiracetam,25-38	DrugDDI.d369.s12.e0
does,39-43
not,44-47
influence,48-57
the,58-61
plasma,62-68
concentration,69-82
of,83-85
other,86-91
AEDs,92-96
and,97-100
that,101-105
these,106-111
AEDs,112-116
do,117-119
not,120-123
influence,124-133
the,134-137
pharmacokinetics,138-154
of,155-157
levetiracetam.,158-172	DrugDDI.d369.s12.e1

Effect,0-6
of,7-9
AEDs,10-14
in,15-17
Pediatric,18-27	DrugDDI.d369.s13.e0
Patients,28-36
There,37-42
was,43-46
about,47-52
a,53-54
22%,55-58
increase,59-67
of,68-70
apparent,71-79
total,80-85
body,86-90
clearance,91-100
of,101-103
levetiracetam,104-117	DrugDDI.d369.s13.e1
when,118-122
it,123-125
was,126-129
co-administered,130-145
with,146-150
enzyme-inducing,151-166
AEDs.,167-172

Dose,0-4
adjustment,5-15
is,16-18
not,19-22
recommended.Levetiracetam,23-48
had,49-52
no,53-55
effect,56-62
on,63-65
plasma,66-72
concentrations,73-87
of,88-90
carbamazepine,,91-105
valproate,,106-116
topiramate,,117-128
or,129-131
lamotrigine.,132-144	DrugDDI.d369.s14.e4

Other,0-5
Drug,6-10	DrugDDI.d369.s15.e0
Interactions,11-23
Oral,24-28
Contraceptives,29-43
Keppra?,44-51
(500,52-56
mg,57-59
twice,60-65
daily),66-72
did,73-76
not,77-80
influence,81-90
the,91-94
pharmacokinetics,95-111
of,112-114
an,115-117
oral,118-122	DrugDDI.d369.s15.e1
contraceptive,123-136	DrugDDI.d369.s15.e1
containing,137-147
0.03,148-152
mg,153-155
ethinyl,156-163	DrugDDI.d369.s15.e2
estradiol,164-173	DrugDDI.d369.s15.e2
and,174-177
0.15,178-182
mg,183-185
levonorgestrel,,186-201
or,202-204
of,205-207
the,208-211
luteinizing,212-223	DrugDDI.d369.s15.e4
hormone,224-231
and,232-235
progesterone,236-248
levels,,249-256
indicating,257-267
that,268-272
impairment,273-283
of,284-286
contraceptive,287-300	DrugDDI.d369.s15.e5
efficacy,301-309
is,310-312
unlikely.,313-322

Coadministration,0-16
of,17-19
this,20-24
oral,25-29	DrugDDI.d369.s16.e0
contraceptive,30-43	DrugDDI.d369.s16.e0
did,44-47
not,48-51
influence,52-61
the,62-65
pharmacokinetics,66-82
of,83-85
levetiracetam.,86-100	DrugDDI.d369.s16.e1

Digoxin,0-7	DrugDDI.d369.s17.e0
Keppra?,8-15
(1000,16-21
mg,22-24
twice,25-30
daily),31-37
did,38-41
not,42-45
influence,46-55
the,56-59
pharmacokinetics,60-76
and,77-80
pharmacodynamics,81-97
(ECG),98-103
of,104-106
digoxin,107-114	DrugDDI.d369.s17.e1
given,115-120
as,121-123
a,124-125
0.25,126-130
mg,131-133
dose,134-138
every,139-144
day.,145-149

Coadministration,0-16
of,17-19
digoxin,20-27	DrugDDI.d369.s18.e0
did,28-31
not,32-35
influence,36-45
the,46-49
pharmacokinetics,50-66
of,67-69
levetiracetam.,70-84	DrugDDI.d369.s18.e1

Warfarin,0-8	DrugDDI.d369.s19.e0
Keppra?,9-16
(1000,17-22
mg,23-25
twice,26-31
daily),32-38
did,39-42
not,43-46
influence,47-56
the,57-60
pharmacokinetics,61-77
of,78-80
R,81-82
and,83-86
S,87-88
warfarin.,89-98	DrugDDI.d369.s19.e1

Prothrombin,0-11
time,12-16
was,17-20
not,21-24
affected,25-33
by,34-36
levetiracetam.,37-51	DrugDDI.d369.s20.e0

Coadministration,0-16
of,17-19
warfarin,20-28	DrugDDI.d369.s21.e0
did,29-32
not,33-36
affect,37-43
the,44-47
pharmacokinetics,48-64
of,65-67
levetiracetam.,68-82	DrugDDI.d369.s21.e1

Probenecid,0-10	DrugDDI.d369.s22.e0
Probenecid,,11-22
a,23-24
renal,25-30
tubular,31-38	DrugDDI.d369.s22.e1
secretion,39-48	DrugDDI.d369.s22.e1
blocking,49-57	DrugDDI.d369.s22.e1
agent,,58-64	DrugDDI.d369.s22.e1
administered,65-77
at,78-80
a,81-82
dose,83-87
of,88-90
500,91-94
mg,95-97
four,98-102
times,103-108
a,109-110
day,,111-115
did,116-119
not,120-123
change,124-130
the,131-134
pharmacokinetics,135-151
of,152-154
levetiracetam,155-168	DrugDDI.d369.s22.e2
1000,169-173	DrugDDI.d369.s22.e2
mg,174-176	DrugDDI.d369.s22.e2
twice,177-182
daily.,183-189

Cssmax,0-6
of,7-9
the,10-13
metabolite,,14-25
ucb,26-29
L057,,30-35
was,36-39
approximately,40-53
doubled,54-61
in,62-64
the,65-68
presence,69-77
of,78-80
probenecid,81-91	DrugDDI.d369.s23.e1
while,92-97
the,98-101
fraction,102-110
of,111-113
drug,114-118	DrugDDI.d369.s23.e2
excreted,119-127
unchanged,128-137
in,138-140
the,141-144
urine,145-150
remained,151-159
the,160-163
same.,164-169

Renal,0-5
clearance,6-15
of,16-18
ucb,19-22
L057,23-27
in,28-30
the,31-34
presence,35-43
of,44-46
probenecid,47-57	DrugDDI.d369.s24.e0
decreased,58-67
60%,,68-72
probably,73-81
related,82-89
to,90-92
competitive,93-104
inhibition,105-115
of,116-118
tubular,119-126
secretion,127-136
of,137-139
ucb,140-143
L057.,144-149

The,0-3
effect,4-10
of,11-13
Keppra?,14-21
on,22-24
probenecid,25-35	DrugDDI.d369.s25.e0
was,36-39
not,40-43
studied.,44-52

Although,0-8
BETAGAN,9-16	DrugDDI.d495.s0.e0
used,17-21
alone,22-27
has,28-31
little,32-38
or,39-41
no,42-44
effect,45-51
on,52-54
pupil,55-60
size,,61-66
mydriasis,67-76
resulting,77-86
from,87-91
concomitant,92-103
therapy,104-111
with,112-116
BETAGAN,117-124	DrugDDI.d495.s0.e1
and,125-128
epinephrine,129-140	DrugDDI.d495.s0.e2
may,141-144
occur.,145-151

Close,0-5
observation,6-17
of,18-20
the,21-24
patient,25-32
is,33-35
recommended,36-47
when,48-52
a,53-54
beta-blocker,55-67	DrugDDI.d495.s1.e0
is,68-70
administered,71-83
to,84-86
patients,87-95
receiving,96-105
catecholamine-depleting,106-129
drugs,130-135	DrugDDI.d495.s1.e1
such,136-140
as,141-143
reserpine,,144-154
because,155-162
of,163-165
possible,166-174
additive,175-183
effects,184-191
and,192-195
the,196-199
production,200-210
of,211-213
hypotension,214-225
and/or,226-232
marked,233-239
bradycardia,,240-252
which,253-258
may,259-262
produce,263-270
vertigo,,271-279
syncope,280-287
or,288-290
postural,291-299
hypotension.,300-312

Patients,0-8
receiving,9-18
beta-adrenergic,19-34	DrugDDI.d495.s2.e0
blocking,35-43	DrugDDI.d495.s2.e0
agents,44-50	DrugDDI.d495.s2.e0
along,51-56
with,57-61
either,62-68
oral,69-73
or,74-76
intravenous,77-88
calcium,89-96	DrugDDI.d495.s2.e1
antagonists,97-108	DrugDDI.d495.s2.e1
should,109-115
be,116-118
monitored,119-128
for,129-132
possible,133-141
atrioventricular,142-158
conduction,159-169
disturbances,,170-183
left,184-188
ventricular,189-200
failure,201-208
and,209-212
hypotension.,213-225

The,0-3
concomitant,4-15
use,16-19
of,20-22
beta-adrenergic,23-38	DrugDDI.d495.s4.e0
blocking,39-47	DrugDDI.d495.s4.e0
agents,48-54	DrugDDI.d495.s4.e0
with,55-59
digitalis,60-69	DrugDDI.d495.s4.e1
and,70-73
calcium,74-81	DrugDDI.d495.s4.e2
antagonists,82-93	DrugDDI.d495.s4.e2
may,94-97
have,98-102
additive,103-111
effects,112-119
on,120-122
prolonging,123-133
atrioventricular,134-150
conduction,151-161
time.,162-167

Phenothiazine-related,0-21	DrugDDI.d495.s5.e0
compounds,22-31
and,32-35
beta-adrenergic,36-51	DrugDDI.d495.s5.e1
blocking,52-60	DrugDDI.d495.s5.e1
agents,61-67	DrugDDI.d495.s5.e1
may,68-71
have,72-76
additive,77-85
hypotensite,86-97
effects,98-105
due,106-109
to,110-112
the,113-116
inhibition,117-127
of,128-130
each,131-135
other?s,136-143
metabolism.,144-155

Chirocaine,0-10	DrugDDI.d513.s0.e0
?,11-12
should,13-19
be,20-22
used,23-27
with,28-32
caution,33-40
in,41-43
patients,44-52
receiving,53-62
other,63-68
local,69-74	DrugDDI.d513.s0.e1
anesthetics,75-86	DrugDDI.d513.s0.e1
or,87-89
agents,90-96
structurally,97-109
related,110-117
to,118-120
amide-type,121-131	DrugDDI.d513.s0.e2
local,132-137	DrugDDI.d513.s0.e2
anesthetics,138-149	DrugDDI.d513.s0.e2
since,150-155
the,156-159
toxic,160-165
effects,166-173
of,174-176
these,177-182
drugs,183-188	DrugDDI.d513.s0.e3
could,189-194
be,195-197
additive.,198-207

In,0-2
vitro,3-8
studies,9-16
indicate,17-25
CYP3A4,26-32	DrugDDI.d513.s1.e0
isoform,33-40	DrugDDI.d513.s1.e0
and,41-44
CYP1A2,45-51	DrugDDI.d513.s1.e1
isoform,52-59	DrugDDI.d513.s1.e1
mediate,60-67
the,68-71
metabolism,72-82
of,83-85
levobupivacaine,86-101	DrugDDI.d513.s1.e2
to,102-104
desbutyl,105-113
levobupivacaine,114-129	DrugDDI.d513.s1.e3
and,130-133
3-hydroxy,134-143
levobupivacaine,,144-160
respectively.,161-174

Thus,0-4
agents,5-11
likely,12-18	DrugDDI.d513.s2.e0
to,19-21
be,22-24
concomitantly,25-38
administered,39-51
with,52-56
Chirocaine,57-67	DrugDDI.d513.s2.e1
that,68-72
are,73-76
metabolized,77-88
by,89-91
this,92-96
isoenzyme,97-106	DrugDDI.d513.s2.e2
family,107-113	DrugDDI.d513.s2.e2
may,114-117
potentially,118-129
interact,130-138
with,139-143
Chirocaine.,144-155	DrugDDI.d513.s2.e3

Although,0-8
no,9-11
clinical,12-20
studies,21-28
have,29-33
been,34-38
conducted,,39-49
it,50-52
is,53-55
likely,56-62
that,63-67
the,68-71
metabolism,72-82
of,83-85
levobupivacaine,86-101	DrugDDI.d513.s3.e0
may,102-105
be,106-108
affected,109-117
by,118-120
the,121-124
known,125-130
CYP3A4,131-137	DrugDDI.d513.s3.e1
inducers,138-146
(such,147-152
as,153-155
phenytoin,,156-166
phenobarbital,,167-181
rifampin),,182-192
CYP3A4,193-199	DrugDDI.d513.s3.e5
inhibitors,200-210
(azole,211-217
antimycotics,218-230
e.g.,,231-236
ketoconazole;,237-250	DrugDDI.d513.s3.e6

certain,0-7
protease,8-16	DrugDDI.d513.s4.e0
inhibitors,17-27	DrugDDI.d513.s4.e0
e.g.,,28-33
ritanovir;,34-44

macrolide,0-9	DrugDDI.d513.s5.e0
antibiotics,10-21	DrugDDI.d513.s5.e0
e.g.,,22-27
erythromycin;,28-41	DrugDDI.d513.s5.e1

and,0-3
calcium,4-11	DrugDDI.d513.s6.e0
channel,12-19	DrugDDI.d513.s6.e0
antagonists,20-31
e.g.,,32-37
verapamil),,38-49
CYP1A2,50-56	DrugDDI.d513.s6.e2
inducers,57-65
(omeprazole),66-78
and,79-82
CYP1A2,83-89	DrugDDI.d513.s6.e4
inhibitors,90-100
(furafylline,101-113
and,114-117
clarithromycin).,118-134	DrugDDI.d513.s6.e6

Dosage,0-6
adjustment,7-17
may,18-21
be,22-24
warranted,25-34
when,35-39
levobupivacaine,40-55	DrugDDI.d513.s7.e0
is,56-58
concurrently,59-71
administered,72-84
with,85-89
CYP3A4,90-96	DrugDDI.d513.s7.e1
inhibitors,97-107
and,108-111
CYP1A2,112-118	DrugDDI.d513.s7.e2
inhibitors,119-129
as,130-132
systemic,133-141
levobupivacaine,142-157	DrugDDI.d513.s7.e3
levels,158-164
may,165-168
rise,169-173
resulting,174-183
in,184-186
toxicity.,187-196

Specific,0-8
drug,9-13
interaction,14-25
studies,26-33
have,34-38
not,39-42
been,43-47
conducted,48-57
with,58-62
Levofloxacin.,63-76	DrugDDI.d344.s0.e0

However,,0-8
the,9-12
systemic,13-21
administration,22-36
of,37-39
some,40-44
quinolones,45-55	DrugDDI.d344.s1.e0
has,56-59
been,60-64
shown,65-70
to,71-73
elevate,74-81
plasma,82-88
concentrations,89-103
of,104-106
theophylline,,107-120
interfere,121-130
with,131-135
the,136-139
metabolism,140-150
of,151-153
caffeine,,154-163
and,164-167
enhance,168-175
the,176-179
effects,180-187
of,188-190
the,191-194
oral,195-199	DrugDDI.d344.s1.e3
anticoagulant,200-213	DrugDDI.d344.s1.e3
warfarin,214-222	DrugDDI.d344.s1.e3
and,223-226
its,227-230
derivatives,,231-243
and,244-247
has,248-251
been,252-256
associated,257-267
with,268-272
transient,273-282
elevations,283-293
in,294-296
serum,297-302
creatinine,303-313
in,314-316
patients,317-325
receiving,326-335
systemic,336-344
cyclosporine,345-357	DrugDDI.d344.s1.e5
concomitantly.,358-372

Interactions,0-12
with,13-17
Other,18-23
CNS,24-27	DrugDDI.d332.s0.e0
Agents:,28-35	DrugDDI.d332.s0.e0
Concurrent,36-46
use,47-50
of,51-53
Levo-Dromoran,54-67	DrugDDI.d332.s0.e1
with,68-72
all,73-76
central,77-84	DrugDDI.d332.s0.e2
nervous,85-92	DrugDDI.d332.s0.e2
system,93-99	DrugDDI.d332.s0.e2
depressants,100-111	DrugDDI.d332.s0.e2
(eg,,112-116
alcohol,,117-125
sedatives,,126-136
hypnotics,,137-147
other,148-153
opioids,,154-162
general,163-170	DrugDDI.d332.s0.e7
anesthetics,,171-183	DrugDDI.d332.s0.e7
barbiturates,,184-197
tricyclic,198-207	DrugDDI.d332.s0.e9
antidepressants,,208-224	DrugDDI.d332.s0.e9
phenothiazines,,225-240
tranquilizers,,241-255
skeletal,256-264	DrugDDI.d332.s0.e12
muscle,265-271	DrugDDI.d332.s0.e12
relaxants,272-281	DrugDDI.d332.s0.e12
and,282-285
antihistamines),286-301	DrugDDI.d332.s0.e13
may,302-305
result,306-312
in,313-315
additive,316-324
central,325-332	DrugDDI.d332.s0.e14
nervous,333-340	DrugDDI.d332.s0.e14
system,341-347	DrugDDI.d332.s0.e14
depressant,348-358	DrugDDI.d332.s0.e14
effects.,359-367

Although,0-8
no,9-11
interaction,12-23
between,24-31
MAO,32-35	DrugDDI.d332.s3.e0
inhibitors,36-46	DrugDDI.d332.s3.e0
and,47-50
Levo-Dromoran,51-64	DrugDDI.d332.s3.e1
has,65-68
been,69-73
observed,,74-83
it,84-86
is,87-89
not,90-93
recommended,94-105
for,106-109
use,110-113
with,114-118
MAO,119-122	DrugDDI.d332.s3.e2
inhibitors.,123-134	DrugDDI.d332.s3.e2

Most,0-4
cases,5-10
of,11-13
serious,14-21
or,22-24
fatal,25-30
adverse,31-38
events,39-45
involving,46-55
Levo-Dromoran,56-69	DrugDDI.d332.s4.e0
reported,70-78
to,79-81
the,82-85
manufacturer,86-98
or,99-101
the,102-105
FDA,106-109
have,110-114
involved,115-123
either,124-130
the,131-134
administration,135-149
of,150-152
large,153-158
initial,159-166
doses,167-172
or,173-175
too,176-179
frequent,180-188
doses,189-194
of,195-197
the,198-201
drug,202-206	DrugDDI.d332.s4.e1
to,207-209
nonopioid,210-219	DrugDDI.d332.s4.e2
tolerant,220-228
patients,,229-238
or,239-241
the,242-245
simultaneous,246-258
administration,259-273
of,274-276
levorphanol,277-288	DrugDDI.d332.s4.e3
with,289-293
other,294-299
drugs,300-305	DrugDDI.d332.s4.e4
affecting,306-315
respiration.,316-328

The,0-3
initial,4-11
dose,12-16
of,17-19
levorphanol,20-31	DrugDDI.d332.s5.e0
should,32-38
be,39-41
reduced,42-49
by,50-52
approximately,53-66
50%,67-70
or,71-73
more,74-78
when,79-83
it,84-86
is,87-89
given,90-95
to,96-98
patients,99-107
along,108-113
with,114-118
another,119-126
drug,127-131	DrugDDI.d332.s5.e1
affecting,132-141
respiration.,142-154

Interactions,0-12
with,13-17
Mixed,18-23
Agonist/Antagonist,24-42	DrugDDI.d332.s6.e0
Opioid,43-49
Analgesics:,50-61
Agonist/antagonist,62-80	DrugDDI.d332.s6.e2
analgesics,81-91	DrugDDI.d332.s6.e3
(eg,,92-96
pentazocine,,97-109
nalbuphine,,110-121
butorphanol,,122-134
dezocine,135-143	DrugDDI.d332.s6.e7
and,144-147
buprenorphine),148-162	DrugDDI.d332.s6.e8
should,163-169
NOT,170-173
be,174-176
administered,177-189
to,190-192
a,193-194
patient,195-202
who,203-206
has,207-210
received,211-219
or,220-222
is,223-225
receiving,226-235
a,236-237
course,238-244
of,245-247
therapy,248-255
with,256-260
a,261-262
pure,263-267
agonist,268-275	DrugDDI.d332.s6.e9
opioid,276-282
analgesic,283-292
such,293-297
as,298-300
Levo-Dromoran.,301-315	DrugDDI.d332.s6.e10

In,0-2
opioid-dependent,3-19	DrugDDI.d332.s7.e0
patients,,20-29
mixed,30-35
agonist/antagonist,36-54	DrugDDI.d332.s7.e1
analgesics,55-65	DrugDDI.d332.s7.e2
may,66-69
precipitate,70-81
withdrawal,82-92
symptoms.,93-102

No,0-2
Important,3-12
Interactions,13-25
To,26-28
Date,29-33
Levosimendan,34-46	DrugDDI.d388.s0.e0
does,47-51
not,52-55
have,56-60
clinically,61-71
important,72-81
pharmacokinetic,82-97
interactions,98-110
with,111-115
captopril,,116-126
beta-blockers,,127-141
felodipine,,142-153
digoxin,,154-162
warfarin,,163-172
isosorbide,173-183	DrugDDI.d388.s0.e6
mononitrate,,184-196	DrugDDI.d388.s0.e6
carvedilol,,197-208
ethanol,209-216	DrugDDI.d388.s0.e8
or,217-219
itraconazole.,220-233	DrugDDI.d388.s0.e9

The,0-3
magnitude,4-13
and,14-17
relative,18-26
importance,27-37
of,38-40
the,41-44
effects,45-52
noted,53-58
below,59-64
are,65-68
likely,69-75
to,76-78
be,79-81
patient,82-89
specific,90-98
and,99-102
may,103-106
vary,107-111
by,112-114
such,115-119
factors,120-127
as,128-130
age,,131-135
gender,,136-143
race,,144-149
intercurrent,150-162
illnesses,,163-173
dose,174-178
of,179-181
either,182-188
agent,,189-195
additional,196-206
concomitant,207-218
medications,,219-231
and,232-235
timing,236-242
of,243-245
drug,246-250
administration.,251-266

Any,0-3
agent,4-9
that,10-14
alters,15-21
thyroid,22-29	DrugDDI.d354.s1.e0
hormone,30-37	DrugDDI.d354.s1.e0
synthesis,,38-48
secretion,,49-59
distribution,,60-73
effect,74-80
on,81-83
target,84-90
tissues,,91-99
metabolism,,100-111
or,112-114
elimination,115-126
may,127-130
alter,131-136
the,137-140
optimal,141-148
therapeutic,149-160
dose,161-165
of,166-168
levothyroxine,169-182	DrugDDI.d354.s1.e1
sodium.,183-190

Levothyroxine,0-13	DrugDDI.d354.s2.e0
Sodium,14-20
Absorption:,21-32
The,33-36
following,37-46
agents,47-53
may,54-57
bind,58-62
and,63-66
decrease,67-75
absorption,76-86
of,87-89
levothyroxine,90-103	DrugDDI.d354.s2.e1
sodium,104-110
from,111-115
the,116-119
gastrointestinal,120-136
tract:,137-143
aluminum,144-152
hydoxide,,153-162
cholestyramine,163-177	DrugDDI.d354.s2.e2
resin,,178-184
colestipol,185-195	DrugDDI.d354.s2.e3
hydrochloride,,196-210	DrugDDI.d354.s2.e3
ferrous,211-218	DrugDDI.d354.s2.e4
sulfate,,219-227	DrugDDI.d354.s2.e4
sodium,228-234	DrugDDI.d354.s2.e5
polystyrene,235-246	DrugDDI.d354.s2.e5
sulfonate,,247-257	DrugDDI.d354.s2.e5
soybean,258-265	DrugDDI.d354.s2.e6
flour,266-271
(e.g.,,272-278
infant,279-285
formula),,286-295
sucralfate.,296-307	DrugDDI.d354.s2.e7

Binding,0-7
to,8-10
Serum,11-16	DrugDDI.d354.s3.e0
Proteins:,17-26	DrugDDI.d354.s3.e0
The,27-30
following,31-40
agents,41-47
may,48-51
either,52-58
inhibit,59-66
levothyroxine,67-80	DrugDDI.d354.s3.e1
sodium,81-87
binding,88-95
to,96-98
serum,99-104	DrugDDI.d354.s3.e2
proteins,105-113	DrugDDI.d354.s3.e2
or,114-116
alter,117-122
the,123-126
concentrations,127-141
of,142-144
serum,145-150
binding,151-158	DrugDDI.d354.s3.e3
proteins:,159-168	DrugDDI.d354.s3.e3
androgens,169-178	DrugDDI.d354.s3.e4
and,179-182
related,183-190
anabolic,191-199
hormones,,200-209
asparaginase,,210-223
clofibrate,,224-235
estrogens,236-245	DrugDDI.d354.s3.e7
and,246-249
estrogen-containing,250-269	DrugDDI.d354.s3.e8
compounds,,270-280	DrugDDI.d354.s3.e8
5-fluorouracil,,281-296
furosemide,,297-308
glucocorticoids,,309-325
meclofenamic,326-338	DrugDDI.d354.s3.e11
acid,,339-344	DrugDDI.d354.s3.e11
mefenamic,345-354	DrugDDI.d354.s3.e12
acid,,355-360	DrugDDI.d354.s3.e12
methadone,,361-371
perphenazine,,372-385
phenylbutazone,,386-401
phenytoin,,402-412
salicylates,,413-425
tamoxifen.,426-436	DrugDDI.d354.s3.e18

Thyroid,0-7	DrugDDI.d354.s4.e0
Physiology:,8-19
The,20-23
following,24-33
agents,34-40
may,41-44
alter,45-50
thyroid,51-58	DrugDDI.d354.s4.e1
hormone,59-66	DrugDDI.d354.s4.e1
or,67-69
TSH,70-73
levels,,74-81
generally,82-91
by,92-94
effects,95-102
on,103-105
thyroid,106-113	DrugDDI.d354.s4.e2
hormone,114-121	DrugDDI.d354.s4.e2
synthesis,,122-132
secretion,,133-143
distribution,,144-157
metabolism,,158-169
hormone,170-177
action,,178-185
or,186-188
elimination,,189-201
or,202-204
altered,205-212
TSH,213-216
secretion:,217-227
aminoglutethimide,,228-246
p-aminosalicylic,247-263	DrugDDI.d354.s4.e4
acid,,264-269	DrugDDI.d354.s4.e4
amiodarone,,270-281
androgens,282-291	DrugDDI.d354.s4.e6
and,292-295
related,296-303
anabolic,304-312
hormones,,313-322
complex,323-330
anions,331-337
(thiocyanate,,338-351
perchlorate,,352-364
pertechnetate),,365-380
antithyroid,381-392	DrugDDI.d354.s4.e8
drugs,,393-399	DrugDDI.d354.s4.e8
b-adrenergic,400-412	DrugDDI.d354.s4.e9
blocking,413-421	DrugDDI.d354.s4.e9
agents,,422-429	DrugDDI.d354.s4.e9
carbamazepine,,430-444
chloral,445-452	DrugDDI.d354.s4.e11
hydrate,,453-461	DrugDDI.d354.s4.e11
diazepam,,462-471
dopamine,472-480	DrugDDI.d354.s4.e13
and,481-484
dopamine,485-493	DrugDDI.d354.s4.e14
agonists,,494-503	DrugDDI.d354.s4.e14
ethionamide,,504-516
glucocorticoids,,517-533
heparin,,534-542
hepatic,543-550
enzyme,551-557
inducers,,558-567
insulin,,568-576
iodinated,577-586
cholestographic,587-602
agents,,603-610
iodine-,611-618
containing,619-629
compounds,,630-640
levodopa,,641-650
lovastatin,,651-662
lithium,,663-671
6-mercaptopurine,,672-689
metoclopramide,,690-705
mitotane,,706-715
nitroprusside,,716-730
phenobarbital,,731-745
phenytoin,,746-756
resorcinol,,757-768
rifampin,,769-778
somatostatin,779-791	DrugDDI.d354.s4.e29
analogs,,792-800	DrugDDI.d354.s4.e29
sulfonamides,,801-814
sulfonylureas,,815-829
thiazide,830-838	DrugDDI.d354.s4.e32
diuretics.,839-849	DrugDDI.d354.s4.e32

Adrenocorticoids:,0-17
Metabolic,18-27
clearance,28-37
of,38-40
adrenocorticoids,41-57
is,58-60
decreased,61-70
in,71-73
hypothyroid,74-85
patients,86-94
and,95-98
increased,99-108
in,109-111
hyperthyroid,112-124
patients,,125-134
and,135-138
may,139-142
therefore,143-152
change,153-159
with,160-164
changing,165-173
thyroid,174-181	DrugDDI.d354.s5.e0
status.,182-189

Amiodarone:,0-11	DrugDDI.d354.s6.e0
Amiodarone,12-22	DrugDDI.d354.s6.e1
therapy,23-30
alone,31-36
can,37-40
cause,41-46
hypothyroidism,47-61
or,62-64
hyperthyroidism.,65-81

Anticoagulants,0-14	DrugDDI.d354.s7.e0
(Oral):,15-22
The,23-26
hypoprothrombinemic,27-46
effect,47-53
of,54-56
anticoagulants,57-71	DrugDDI.d354.s7.e1
may,72-75
be,76-78
potentiated,,79-91
apparently,92-102
by,103-105
increased,106-115
catabloism,116-126
of,127-129
vitamin,130-137	DrugDDI.d354.s7.e2
K-dependent,138-149	DrugDDI.d354.s7.e2
clotting,150-158
factors.,159-167

Antidiabetic,0-12	DrugDDI.d354.s8.e0
Agents,13-19	DrugDDI.d354.s8.e0
(Insulin,,20-29
Sulfonylureas):,30-45	DrugDDI.d354.s8.e2
Requirements,46-58
for,59-62
insulin,63-70	DrugDDI.d354.s8.e3
or,71-73
oral,74-78
antidiabetic,79-91	DrugDDI.d354.s8.e4
agents,92-98	DrugDDI.d354.s8.e4
may,99-102
be,103-105
reduced,106-113
in,114-116
hypothyroid,117-128
patients,129-137
with,138-142
diabetes,143-151
mellitus,152-160
and,161-164
may,165-168
subsequently,169-181
increase,182-190
with,191-195
the,196-199
initiation,200-210
of,211-213
thyroid,214-221	DrugDDI.d354.s8.e5
hormone,222-229
replacement,230-241
therapy.,242-250

b-Adrenergic,0-12	DrugDDI.d354.s9.e0
Blocking,13-21	DrugDDI.d354.s9.e0
Agents:,22-29	DrugDDI.d354.s9.e0
Actions,30-37
of,38-40
some,41-45
of,46-48
beta-blocking,49-62	DrugDDI.d354.s9.e1
agents,63-69	DrugDDI.d354.s9.e1
may,70-73
be,74-76
impaired,77-85
when,86-90
hypothyroid,91-102
patients,103-111
become,112-118
euthyroid.,119-129

Cytokines,0-9	DrugDDI.d354.s10.e0
(interferon,,10-22
interleukin):,23-36	DrugDDI.d354.s10.e2
Cytokines,37-46	DrugDDI.d354.s10.e3
have,47-51
been,52-56
reported,57-65
to,66-68
induce,69-75
both,76-80
hyperthyroidism,81-96
and,97-100
hypothyroidism.,101-116

Digitalis,0-9	DrugDDI.d354.s11.e0
Glycosides:,10-21	DrugDDI.d354.s11.e0
Therapeutic,22-33
effects,34-41
of,42-44
digitalis,45-54	DrugDDI.d354.s11.e1
glycosides,55-65	DrugDDI.d354.s11.e1
may,66-69
be,70-72
reduced.,73-81

Ketamine:,0-9	DrugDDI.d354.s13.e0
Marked,10-16
hypertension,17-29
and,30-33
tachycardia,34-45
have,46-50
been,51-55
reported,56-64
in,65-67
association,68-79
with,80-84
concomitant,85-96
administration,97-111
of,112-114
levothyroxine,115-128	DrugDDI.d354.s13.e1
sodium,129-135
and,136-139
ketamine.,140-149	DrugDDI.d354.s13.e2

Maprotiline:,0-12	DrugDDI.d354.s14.e0
Risk,13-17
of,18-20
cardiac,21-28
arrhythmias,29-40
may,41-44
increase.,45-54

Sodium,0-6	DrugDDI.d354.s15.e0
Iodide,7-13	DrugDDI.d354.s15.e0
(123I,14-19
and,20-23
131I),,24-30
Sodium,31-37
Pertechnetate,38-51
Tc99m:,52-58
Uptake,59-65
of,66-68
radiolabeled,69-81
ions,82-86
may,87-90
be,91-93
decreased.,94-104

Somatrem/Somatropin:,0-20	DrugDDI.d354.s16.e0
Excessive,21-30
concurrent,31-41
use,42-45
of,46-48
thyroid,49-56	DrugDDI.d354.s16.e2
hormone,57-64	DrugDDI.d354.s16.e2
may,65-68
accelerate,69-79
epiphyseal,80-90
closure.,91-99

Untreated,0-9
hypothyroidism,10-24
may,25-28
interfere,29-38
with,39-43
the,44-47
growth,48-54
response,55-63
to,64-66
somatrem,67-75	DrugDDI.d354.s17.e0
or,76-78
somatropin.,79-90	DrugDDI.d354.s17.e1

Theophylline:,0-13	DrugDDI.d354.s18.e0
Theophylline,14-26	DrugDDI.d354.s18.e1
clearance,27-36
may,37-40
decrease,41-49
in,50-52
hypothyroid,53-64
patients,65-73
and,74-77
return,78-84
toward,85-91
normal,92-98
when,99-103
a,104-105
euthyroid,106-115
state,116-121
is,122-124
achieved.,125-134

Tricyclic,0-9	DrugDDI.d354.s19.e0
Antidepressants:,10-26	DrugDDI.d354.s19.e0
Concurrent,27-37
use,38-41
may,42-45
increase,46-54
the,55-58
therapeutic,59-70
and,71-74
toxic,75-80
effects,81-88
of,89-91
both,92-96
drugs,,97-103
possibly,104-112
due,113-116
to,117-119
increased,120-129
catecholamine,130-143
sensitivity.,144-156

Onset,0-5
of,6-8
action,9-15
of,16-18
tricyclics,19-29	DrugDDI.d354.s20.e0
may,30-33
be,34-36
accelerated.,37-49

Sympathomimetic,0-15	DrugDDI.d354.s21.e0
Agents:,16-23	DrugDDI.d354.s21.e0
Possible,24-32
increased,33-42
risk,43-47
of,48-50
coronary,51-59
insufficiency,60-73
in,74-76
patients,77-85
with,86-90
coronary,91-99
artery,100-106
disease.,107-115

The,0-3
administration,4-18
of,19-21
local,22-27	DrugDDI.d196.s0.e0
anesthetic,28-38	DrugDDI.d196.s0.e0
solutions,39-48
containing,49-59
epinephrine,60-71	DrugDDI.d196.s0.e1
or,72-74
norepinephrine,75-89	DrugDDI.d196.s0.e2
to,90-92
patients,93-101
receiving,102-111
monoamine,112-121	DrugDDI.d196.s0.e3
oxidase,122-129	DrugDDI.d196.s0.e3
inhibitors,130-140	DrugDDI.d196.s0.e3
or,141-143
tricyclic,144-153	DrugDDI.d196.s0.e4
antidepressants,154-169	DrugDDI.d196.s0.e4
may,170-173
produce,174-181
severe,,182-189
prolonged,190-199
hypertension.,200-213

Phenothiazines,0-14	DrugDDI.d196.s1.e0
and,15-18
butyrophenones,19-33	DrugDDI.d196.s1.e1
may,34-37
reduce,38-44
or,45-47
reverse,48-55
the,56-59
pressor,60-67	DrugDDI.d196.s1.e2
effect,68-74	DrugDDI.d196.s1.e2
of,75-77
epinephrine.,78-90	DrugDDI.d196.s1.e3

Concurrent,0-10
administration,11-25
of,26-28
vasopressor,29-40	DrugDDI.d196.s4.e0
drugs,41-46	DrugDDI.d196.s4.e0
(for,47-51
the,52-55
treatment,56-65
of,66-68
hypotension,69-80
related,81-88
to,89-91
obstetric,92-101
blocks),102-109
and,110-113
ergot-type,114-124
oxytocic,125-133	DrugDDI.d196.s4.e1
drugs,134-139	DrugDDI.d196.s4.e1
may,140-143
cause,144-149
severe,,150-157
persistent,158-168
hypertension,169-181
or,182-184
cerebrovascular,185-200
accidents.,201-211

Lincomycin,0-10	DrugDDI.d478.s0.e0
has,11-14
been,15-19
shown,20-25
to,26-28
have,29-33
neuromuscular,34-47
blocking,48-56
properties,57-67
that,68-72
may,73-76
enhance,77-84
the,85-88
action,89-95
of,96-98
other,99-104
neuromuscular,105-118	DrugDDI.d478.s0.e1
blocking,119-127	DrugDDI.d478.s0.e1
agents.,128-135	DrugDDI.d478.s0.e1

Antagonism,0-10
between,11-18
lincomycin,19-29	DrugDDI.d478.s2.e0
and,30-33
erythromycin,34-46	DrugDDI.d478.s2.e1
in,47-49
vitro,50-55
has,56-59
been,60-64
demonstrated.,65-78

Because,0-7
of,8-10
possible,11-19
clinical,20-28
significance,,29-42
the,43-46
two,47-50
drugs,51-56	DrugDDI.d478.s3.e0
should,57-63
not,64-67
be,68-70
administered,71-83
concurrently.,84-97

Monoamine,0-9	DrugDDI.d15.s0.e0
Oxidase,10-17	DrugDDI.d15.s0.e0
Inhibition:,18-29
Linezolid,30-39	DrugDDI.d15.s0.e1
is,40-42
a,43-44
reversible,,45-56
nonselective,57-69
inhibitor,70-79
of,80-82
monoamine,83-92	DrugDDI.d15.s0.e2
oxidase.,93-101	DrugDDI.d15.s0.e2

Therefore,,0-10
linezolid,11-20	DrugDDI.d15.s1.e0
has,21-24
the,25-28
potential,29-38
for,39-42
interaction,43-54
with,55-59
adrenergic,60-70
and,71-74
serotonergic,75-87	DrugDDI.d15.s1.e1
agents.,88-95	DrugDDI.d15.s1.e1

Adrenergic,0-10	DrugDDI.d15.s2.e0
Agents:Some,11-22	DrugDDI.d15.s2.e0
individuals,23-34
receiving,35-44
ZYVOX,45-50	DrugDDI.d15.s2.e1
may,51-54
experience,55-65
a,66-67
reversible,68-78
enhancement,79-90
of,91-93
the,94-97
pressor,98-105	DrugDDI.d15.s2.e2
response,106-114
to,115-117
indirect-acting,118-133
sympathomimetic,134-149	DrugDDI.d15.s2.e3
agents,,150-157	DrugDDI.d15.s2.e3
vasopressor,158-169	DrugDDI.d15.s2.e4
or,170-172
dopaminergic,173-185	DrugDDI.d15.s2.e5
agents.,186-193	DrugDDI.d15.s2.e5

Commonly,0-8
used,9-13
drugs,14-19	DrugDDI.d15.s3.e0
such,20-24
as,25-27
phenylpropanolamine,28-47	DrugDDI.d15.s3.e1
and,48-51
pseudoephedrine,52-67	DrugDDI.d15.s3.e2
have,68-72
been,73-77
specifically,78-90
studied.,91-99

Initial,0-7
doses,8-13
of,14-16
adrenergic,17-27	DrugDDI.d15.s4.e0
agents,,28-35	DrugDDI.d15.s4.e0
such,36-40
as,41-43
dopamine,44-52	DrugDDI.d15.s4.e1
or,53-55
epinephrine,,56-68
should,69-75
be,76-78
reduced,79-86
and,87-90
titrated,91-99
to,100-102
achieve,103-110
the,111-114
desired,115-122
response.,123-132

Serotonergic,0-12	DrugDDI.d15.s5.e0
Agents:,13-20	DrugDDI.d15.s5.e0
Co-administration,21-38
of,39-41
linezolid,42-51	DrugDDI.d15.s5.e1
and,52-55
serotonergic,56-68	DrugDDI.d15.s5.e2
agents,69-75	DrugDDI.d15.s5.e2
was,76-79
not,80-83
associated,84-94
with,95-99
serotonin,100-109
syndrome,110-118
in,119-121
Phase,122-127
1,,128-130
2,131-132
or,133-135
3,136-137
studies.,138-146

Spontaneous,0-11
reports,12-19
of,20-22
serotonin,23-32
syndrome,33-41
associated,42-52
with,53-57
co-administration,58-75
of,76-78
ZYVOX,79-84	DrugDDI.d15.s6.e0
and,85-88
serotonergic,89-101	DrugDDI.d15.s6.e1
agents,,102-109	DrugDDI.d15.s6.e1
including,110-119
antidepressants,120-135	DrugDDI.d15.s6.e2
such,136-140
as,141-143
selective,144-153
serotonin,154-163	DrugDDI.d15.s6.e3
reuptake,164-172	DrugDDI.d15.s6.e3
inhibitors,173-183	DrugDDI.d15.s6.e3
(SSRIs),,184-192
have,193-197
been,198-202
reported.,203-212

Patients,0-8
who,9-12
are,13-16
treated,17-24
with,25-29
ZYVOX,30-35	DrugDDI.d15.s7.e0
and,36-39
concomitant,40-51
serotonergic,52-64	DrugDDI.d15.s7.e1
agents,65-71	DrugDDI.d15.s7.e1
should,72-78
be,79-81
closely,82-89
observed,90-98
for,99-102
signs,103-108
and,109-112
symptoms,113-121
of,122-124
serotonin,125-134
syndrome,135-143
(e.g.,,144-150
cognitive,151-160
dysfunction,,161-173
hyperpyrexia,,174-187
hyperreflexia,,188-202
incoordination).,203-219

If,0-2
any,3-6
signs,7-12
or,13-15
symptoms,16-24
occur,25-30
physicians,31-41
should,42-48
consider,49-57
discontinuation,58-73
of,74-76
either,77-83
one,84-87
or,88-90
both,91-95
agents,96-102
(ZYVOX,103-109
or,110-112
concomitant,113-124
serotonergic,125-137	DrugDDI.d15.s8.e1
agents).,138-146	DrugDDI.d15.s8.e1

Oral,0-4	DrugDDI.d165.s0.e0
Anticoagulants:,5-20	DrugDDI.d165.s0.e0
Thyroid,21-28	DrugDDI.d165.s0.e1
hormones,29-37	DrugDDI.d165.s0.e1
appear,38-44
to,45-47
increase,48-56
catabolism,57-67
of,68-70
vitamin,71-78	DrugDDI.d165.s0.e2
K-dependent,79-90	DrugDDI.d165.s0.e2
clotting,91-99
factors.,100-108

If,0-2
oral,3-7	DrugDDI.d165.s1.e0
anticoagulants,8-22	DrugDDI.d165.s1.e0
are,23-26
also,27-31
being,32-37
given,,38-44
compensatory,45-57
increases,58-67
in,68-70
clotting,71-79	DrugDDI.d165.s1.e1
factor,80-86	DrugDDI.d165.s1.e1
synthesis,87-96
are,97-100
impaired.,101-110

Patients,0-8
stabilized,9-19
on,20-22
oral,23-27	DrugDDI.d165.s2.e0
anticoagulants,28-42	DrugDDI.d165.s2.e0
who,43-46
are,47-50
found,51-56
to,57-59
require,60-67
thyroid,68-75	DrugDDI.d165.s2.e1
replacement,76-87
therapy,88-95
should,96-102
be,103-105
watched,106-113
very,114-118
closely,119-126
when,127-131
thyroid,132-139	DrugDDI.d165.s2.e2
is,140-142
started.,143-151

If,0-2
a,3-4
patient,5-12
is,13-15
truly,16-21
hypothyroid,,22-34
it,35-37
is,38-40
likely,41-47
that,48-52
a,53-54
reduction,55-64
in,65-67
anticoagulant,68-81	DrugDDI.d165.s3.e0
dosage,82-88
will,89-93
be,94-96
required.,97-106

No,0-2
special,3-10
precautions,11-22
appear,23-29
to,30-32
be,33-35
necessary,36-45
when,46-50
oral,51-55
anticoagulant,56-69
therapy,70-77
is,78-80
begun,81-86
in,87-89
a,90-91
patient,92-99
already,100-107
stabilized,108-118
on,119-121
maintenance,122-133
thyroid,134-141	DrugDDI.d165.s4.e0
replacement,142-153
therapy.,154-162

Insulin,0-7	DrugDDI.d165.s5.e0
or,8-10
Oral,11-15	DrugDDI.d165.s5.e1
Hypoglycemics:,16-30	DrugDDI.d165.s5.e1
Initiating,31-41
thyroid,42-49	DrugDDI.d165.s5.e2
replacement,50-61
therapy,62-69
may,70-73
cause,74-79
increases,80-89
in,90-92
insulin,93-100	DrugDDI.d165.s5.e3
or,101-103
oral,104-108	DrugDDI.d165.s5.e4
hypoglycemic,109-121
requirements.,122-135

The,0-3
effects,4-11
seen,12-16
are,17-20
poorly,21-27
understood,28-38
and,39-42
depend,43-49
upon,50-54
a,55-56
variety,57-64
of,65-67
factors,68-75
such,76-80
as,81-83
dose,84-88
and,89-92
type,93-97
of,98-100
thyroid,101-108	DrugDDI.d165.s6.e0
preparations,109-121	DrugDDI.d165.s6.e0
and,122-125
endocrine,126-135
status,136-142
of,143-145
the,146-149
patient.,150-158

Patients,0-8
receiving,9-18
insulin,19-26	DrugDDI.d165.s7.e0
or,27-29
oral,30-34	DrugDDI.d165.s7.e1
hypoglycemics,35-48	DrugDDI.d165.s7.e1
should,49-55
be,56-58
closely,59-66
watched,67-74
during,75-81
initiation,82-92
of,93-95
thyroid,96-103	DrugDDI.d165.s7.e2
replacement,104-115
therapy.,116-124

Cholestyramine:,0-15	DrugDDI.d165.s8.e0
Cholestyramine,16-30	DrugDDI.d165.s8.e1
binds,31-36
both,37-41
T4,42-44	DrugDDI.d165.s8.e2
and,45-48
T3,49-51	DrugDDI.d165.s8.e3
in,52-54
the,55-58
intestine,,59-69
thus,70-74
impairing,75-84
absorption,85-95
of,96-98
these,99-104
thyroid,105-112	DrugDDI.d165.s8.e4
hormones.,113-122	DrugDDI.d165.s8.e4

Therefore,,0-10
4,11-12
to,13-15
5,16-17
hours,18-23
should,24-30
elapse,31-37
between,38-45
administration,46-60
of,61-63
cholestyramine,64-78	DrugDDI.d165.s10.e0
and,79-82
thyroid,83-90	DrugDDI.d165.s10.e1
hormones.,91-100	DrugDDI.d165.s10.e1

Estrogen,,0-9
Oral,10-14	DrugDDI.d165.s11.e1
Contraceptives:,15-30	DrugDDI.d165.s11.e1
Estrogens,31-40	DrugDDI.d165.s11.e2
tend,41-45
to,46-48
increase,49-57
serum,58-63
thyroxine-binding,64-81	DrugDDI.d165.s11.e3
globulin,82-90	DrugDDI.d165.s11.e3
(TBg).,91-97

In,0-2
a,3-4
patient,5-12
with,13-17
a,18-19
nonfunctioning,20-34
thyroid,35-42
gland,43-48
who,49-52
is,53-55
receiving,56-65
thyroid,66-73	DrugDDI.d165.s12.e0
replacement,74-85
therapy,,86-94
free,95-99
levothyroxine,100-113	DrugDDI.d165.s12.e1
may,114-117
be,118-120
decreased,121-130
when,131-135
estrogens,136-145	DrugDDI.d165.s12.e2
are,146-149
started,150-157
thus,158-162
increasing,163-173
thyroid,174-181	DrugDDI.d165.s12.e3
requirements.,182-195

However,,0-8
if,9-11
the,12-15
patients,16-24
thyroid,25-32
gland,33-38
has,39-42
sufficient,43-53
function,,54-63
the,64-67
decreased,68-77
free,78-82	DrugDDI.d165.s13.e0
thyroxine,83-92	DrugDDI.d165.s13.e0
will,93-97
result,98-104
in,105-107
a,108-109
compensatory,110-122
increase,123-131
in,132-134
thyroxine,135-144	DrugDDI.d165.s13.e1
output,145-151
by,152-154
the,155-158
thyroid.,159-167	DrugDDI.d165.s13.e2

Therefore,,0-10
patients,11-19
without,20-27
a,28-29
functioning,30-41
thyroid,42-49
gland,50-55
who,56-59
are,60-63
on,64-66
thyroid,67-74	DrugDDI.d165.s14.e0
replacement,75-86
therapy,87-94
may,95-98
need,99-103
to,104-106
increase,107-115
their,116-121
thyroid,122-129	DrugDDI.d165.s14.e1
dose,130-134
if,135-137
estrogens,138-147	DrugDDI.d165.s14.e2
or,148-150
estrogen-containing,151-170	DrugDDI.d165.s14.e3
oral,171-175	DrugDDI.d165.s14.e4
contraceptives,176-190	DrugDDI.d165.s14.e4
are,191-194
given.,195-201

Tricyclic,0-9	DrugDDI.d165.s15.e0
Antidepressants:,10-26	DrugDDI.d165.s15.e0
Use,27-30
of,31-33
thyroid,34-41	DrugDDI.d165.s15.e1
products,42-50
with,51-55
imipramine,56-66	DrugDDI.d165.s15.e2
and,67-70
other,71-76
tricyclic,77-86	DrugDDI.d165.s15.e3
antidepressants,87-102	DrugDDI.d165.s15.e3
may,103-106
increase,107-115
receptor,116-124
sensitivity,125-136
and,137-140
enhance,141-148
antidepressant,149-163	DrugDDI.d165.s15.e4
activity,164-172
transient,173-182
cardiac,183-190
arrhythmias,191-202
have,203-207
been,208-212
observed.,213-222

Thyroid,0-7	DrugDDI.d165.s16.e0
hormone,8-15	DrugDDI.d165.s16.e0
activity,16-24
may,25-28
also,29-33
be,34-36
enhanced.,37-46

Digitalis:,0-10	DrugDDI.d165.s17.e0
Thyroid,11-18	DrugDDI.d165.s17.e1
preparations,19-31	DrugDDI.d165.s17.e1
may,32-35
potentiate,36-46
the,47-50
toxic,51-56
effects,57-64
of,65-67
digitalis.,68-78	DrugDDI.d165.s17.e2

Thyroid,0-7	DrugDDI.d165.s18.e0
hormonal,8-16	DrugDDI.d165.s18.e0
replacement,17-28
increases,29-38
metabolic,39-48
rate,,49-54
which,55-60
requires,61-69
an,70-72
increase,73-81
in,82-84
digitalis,85-94	DrugDDI.d165.s18.e1
dosage.,95-102

Ketamine:,0-9	DrugDDI.d165.s19.e0
When,10-14
administered,15-27
to,28-30
patients,31-39
on,40-42
a,43-44
thyroid,45-52	DrugDDI.d165.s19.e1
preparation,,53-65	DrugDDI.d165.s19.e1
this,66-70
parenteral,71-81	DrugDDI.d165.s19.e2
anesthetic,82-92	DrugDDI.d165.s19.e2
may,93-96
cause,97-102
hypertension,103-115
and,116-119
tachycardia.,120-132

Vasopressors:,0-13	DrugDDI.d165.s21.e0
Thyroxine,14-23	DrugDDI.d165.s21.e1
increases,24-33
the,34-37
adrenergic,38-48
effect,49-55
of,56-58
catecholamines,59-73
such,74-78
as,79-81
epinephrine,82-93	DrugDDI.d165.s21.e2
and,94-97
norepinephrine.,98-113	DrugDDI.d165.s21.e3

Therefore,,0-10
injection,11-20
of,21-23
these,24-29
agents,30-36
into,37-41
patients,42-50
receiving,51-60
thyroid,61-68	DrugDDI.d165.s22.e0
preparations,69-81	DrugDDI.d165.s22.e0
increases,82-91
the,92-95
risk,96-100
of,101-103
precipitating,104-117
coronary,118-126
insufficiency,127-140
especially,141-151
in,152-154
patients,155-163
with,164-168
coronary,169-177
artery,178-184
disease.,185-193

Drug/Laboratory,0-15	DrugDDI.d165.s24.e0
Test,16-20
Interactions,21-33
The,34-37
following,38-47
drugs,48-53	DrugDDI.d165.s24.e1
or,54-56
moieties,57-65
are,66-69
known,70-75
to,76-78
interfere,79-88
with,89-93
laboratory,94-104
tests,105-110
performed,111-120
in,121-123
patients,124-132
on,133-135
thyroid,136-143	DrugDDI.d165.s24.e2
hormone,144-151	DrugDDI.d165.s24.e2
therapy:,152-160
androgens,,161-171
corticosteroids,,172-188
estrogens,,189-199
oral,200-204	DrugDDI.d165.s24.e6
contraceptives,205-219	DrugDDI.d165.s24.e6
containing,220-230
estrogens,,231-241
iodine-containing,242-259	DrugDDI.d165.s24.e8
preparations,260-272	DrugDDI.d165.s24.e8
and,273-276
the,277-280
numerous,281-289
preparations,290-302
containing,303-313
salicylates.,314-326	DrugDDI.d165.s24.e9

-,0-1
Changes,2-9
in,10-12
TBg,13-16
concentration,17-30
should,31-37
be,38-40
taken,41-46
into,47-51
consideration,52-65
in,66-68
the,69-72
interpretation,73-87
of,88-90
T4,91-93	DrugDDI.d165.s25.e0
and,94-97
T3,98-100	DrugDDI.d165.s25.e1
values.,101-108

Pregnancy,0-9
estrogens,10-19	DrugDDI.d165.s27.e0
and,20-23
estrogen-containing,24-43	DrugDDI.d165.s27.e1
oral,44-48	DrugDDI.d165.s27.e2
contraceptives,49-63	DrugDDI.d165.s27.e2
increase,64-72
TBg,73-76
concentrations.,77-92

Decreases,0-9
in,10-12
TBg,13-16
concentrations,17-31
are,32-35
observed,36-44
in,45-47
nephrosis,,48-58
acromegaly,59-69
and,70-73
after,74-79
androgen,80-88	DrugDDI.d165.s29.e0
or,89-91
corticosteroid,92-106
therapy.,107-115

Familial,0-8
hyper-,9-15
or,16-18
hypo-thyroxine-binding-globulinemias,19-55
have,56-60
been,61-65
described.,66-76

The,0-3
binding,4-11
of,12-14
thyroxine,15-24	DrugDDI.d165.s32.e0
by,25-27
thyroxine-binding,28-45	DrugDDI.d165.s32.e1
prealbumin,46-56	DrugDDI.d165.s32.e1
(TBPA),57-63
is,64-66
inhibited,67-76
by,77-79
salicylates,80-91	DrugDDI.d165.s32.e2

-,0-1
Medicinal,2-11
or,12-14
dietary,15-22
iodine,23-29	DrugDDI.d165.s34.e0
interferes,30-40
with,41-45
all,46-49
in,50-52
vivo,53-57
tests,58-63
of,64-66
radio-iodine,67-79
uptake,80-86
producing,87-96
low,97-100
uptakes,101-108
which,109-114
may,115-118
not,119-122
be,123-125
reflective,126-136
of,137-139
a,140-141
true,142-146
decrease,147-155
in,156-158
hormone,159-166
synthesis,167-176

Intracellular,0-13
resistance,14-24
to,25-27
thyroid,28-35	DrugDDI.d165.s37.e0
hormone,36-43	DrugDDI.d165.s37.e0
is,44-46
quite,47-52
rare.,53-58

Urinary,0-7
acidifying,8-18
agents?These,19-31
agents,32-38
(ammonium,39-48
chloride,,49-58
sodium,59-65	DrugDDI.d146.s0.e1
acid,66-70	DrugDDI.d146.s0.e1
phosphate,,71-81	DrugDDI.d146.s0.e1
etc.),82-87
increase,88-96
the,97-100
concentration,101-114
of,115-117
the,118-121
ionized,122-129
species,130-137
of,138-140
the,141-144
amphetamine,145-156	DrugDDI.d146.s0.e2
molecule,,157-166
thereby,167-174
increasing,175-185
urinary,186-193
excretion.,194-204

Both,0-4
groups,5-11
of,12-14
agents,15-21
lower,22-27
blood,28-33
levels,34-40
and,41-44
efficacy,45-53
of,54-56
amphetamines.,57-70	DrugDDI.d146.s1.e0

Adrenergic,0-10	DrugDDI.d146.s2.e0
blockers?Adrenergic,11-30	DrugDDI.d146.s2.e0
blockers,31-39
are,40-43
inhibited,44-53
by,54-56
amphetamines.,57-70	DrugDDI.d146.s2.e1

Antidepressants,,0-16
tricyclic?Amphetamines,17-39
may,40-43
enhance,44-51
the,52-55
activity,56-64
of,65-67
tricyclic,68-77	DrugDDI.d146.s3.e1
antidepressants,78-93	DrugDDI.d146.s3.e1
or,94-96
sympathomimetic,97-112	DrugDDI.d146.s3.e2
agents;,113-120	DrugDDI.d146.s3.e2

d-amphetamine,0-13	DrugDDI.d146.s4.e0
with,14-18
desipramine,19-30	DrugDDI.d146.s4.e1
or,31-33
protriptyline,34-47	DrugDDI.d146.s4.e2
and,48-51
possibly,52-60
other,61-66
tricyclics,67-77	DrugDDI.d146.s4.e3
cause,78-83
striking,84-92
and,93-96
sustained,97-106
increases,107-116
in,117-119
the,120-123
concentration,124-137
of,138-140
d-amphetamine,141-154	DrugDDI.d146.s4.e4
in,155-157
the,158-161
brain;,162-168

MAO,0-3
inhibitors?MAOI,4-19
antidepressants,,20-36
as,37-39
well,40-44
as,45-47
a,48-49
metabolite,50-60	DrugDDI.d146.s6.e1
of,61-63
furazolidone,,64-77
slow,78-82
amphetamine,83-94	DrugDDI.d146.s6.e3
metabolism.,95-106

This,0-4
slowing,5-12
potentiates,13-24
amphetamines,,25-38
increasing,39-49
their,50-55
effect,56-62
on,63-65
the,66-69
release,70-77
of,78-80
norepinephrine,81-95	DrugDDI.d146.s7.e1
and,96-99
other,100-105
monoamines,106-116
from,117-121
adrenergic,122-132
nerve,133-138
endings;,139-147

Antihistamines?Amphetamines,0-27
may,28-31
counteract,32-42
the,43-46
sedative,47-55	DrugDDI.d146.s10.e0
effect,56-62
of,63-65
antihistamines.,66-81	DrugDDI.d146.s10.e1

Antihypertensives?Amphetamines,0-30
may,31-34
antagonize,35-45
the,46-49
hypotensive,50-61
effects,62-69
of,70-72
antihypertensives.,73-91	DrugDDI.d146.s11.e0

Chlorpromazine?Chlorpromazine,0-29
blocks,30-36
dopamine,37-45	DrugDDI.d146.s12.e0
and,46-49
norepinephrine,50-64	DrugDDI.d146.s12.e1
receptors,,65-75	DrugDDI.d146.s12.e1
thus,76-80
inhibiting,81-91
the,92-95
central,96-103	DrugDDI.d146.s12.e2
stimulant,104-113	DrugDDI.d146.s12.e2
effects,114-121
of,122-124
amphetamines,125-137	DrugDDI.d146.s12.e3
and,138-141
can,142-145
be,146-148
used,149-153
to,154-156
treat,157-162
amphetamine,163-174
poisoning.,175-185

Ethosuximide?Amphetamines,0-25
may,26-29
delay,30-35
intestinal,36-46
absorption,47-57
of,58-60
ethosuximide.,61-74	DrugDDI.d146.s13.e0

Haloperidol?Haloperidol,0-23
blocks,24-30
dopamine,31-39	DrugDDI.d146.s14.e0
receptors,,40-50	DrugDDI.d146.s14.e0
thus,51-55
inhibiting,56-66
the,67-70
central,71-78	DrugDDI.d146.s14.e1
stimulant,79-88	DrugDDI.d146.s14.e1
effects,89-96
of,97-99
amphetamines.,100-113	DrugDDI.d146.s14.e2

Lithium,0-7	DrugDDI.d146.s15.e0
carbonate?The,8-21
anorectic,22-31
and,32-35
stimulatory,36-47
effects,48-55
of,56-58
amphetamines,59-71	DrugDDI.d146.s15.e1
may,72-75
be,76-78
inhibited,79-88
by,89-91
lithium,92-99	DrugDDI.d146.s15.e2
carbonate.,100-110	DrugDDI.d146.s15.e2

Meperidine?Amphetamines,0-23
potentiate,24-34
the,35-38
analgesic,39-48
effect,49-55
of,56-58
meperidine.,59-70	DrugDDI.d146.s16.e0

Methenamine,0-11	DrugDDI.d146.s17.e0
therapy?Urinary,12-27
excretion,28-37
of,38-40
amphetamines,41-53	DrugDDI.d146.s17.e1
is,54-56
increased,,57-67
and,68-71
efficacy,72-80
is,81-83
reduced,84-91
by,92-94
acidifying,95-105
agents,106-112
used,113-117
in,118-120
methenamine,121-132	DrugDDI.d146.s17.e2
therapy.,133-141

Norepinephrine?Amphetamines,0-27
enhance,28-35
the,36-39
adrenergic,40-50
effect,51-57
of,58-60
norepinephrine.,61-76	DrugDDI.d146.s18.e0

Phenobarbital?Amphetamines,0-26
may,27-30
delay,31-36
intestinal,37-47
absorption,48-58
of,59-61
phenobarbital;,62-76	DrugDDI.d146.s19.e0

co-administration,0-17
of,18-20
phenobarbital,21-34	DrugDDI.d146.s20.e0
may,35-38
produce,39-46
a,47-48
synergistic,49-60
anticonvulsant,61-75	DrugDDI.d146.s20.e1
action.,76-83

Phenytoin?Amphetamines,0-22
may,23-26
delay,27-32
intestinal,33-43
absorption,44-54
of,55-57
phenytoin;,58-68	DrugDDI.d146.s21.e0

co-administration,0-17
of,18-20
phenytoin,21-30	DrugDDI.d146.s22.e0
may,31-34
produce,35-42
a,43-44
synergistic,45-56
anticonvulsant,57-71	DrugDDI.d146.s22.e1
action.,72-79

Propoxyphene?In,0-15
cases,16-21
of,22-24
propoxyphene,25-37	DrugDDI.d146.s23.e0
overdosage,,38-49
amphetamine,50-61	DrugDDI.d146.s23.e1
CNS,62-65	DrugDDI.d146.s23.e1
stimulation,66-77
is,78-80
potentiated,81-92
and,93-96
fatal,97-102
convulsions,103-114
can,115-118
occur.,119-125

Veratrum,0-8
alkaloids?Amphetamines,9-31
inhibit,32-39
the,40-43
hypotensive,44-55
effect,56-62
of,63-65
veratrum,66-74	DrugDDI.d146.s24.e0
alkaloids.,75-85	DrugDDI.d146.s24.e0

Drug/Laboratory,0-15	DrugDDI.d146.s25.e0
Test,16-20
Interactions:,21-34
Amphetamines,35-47	DrugDDI.d146.s25.e1
can,48-51
cause,52-57
a,58-59
significant,60-71
elevation,72-81
in,82-84
plasma,85-91
corticosteroid,92-106	DrugDDI.d146.s25.e2
levels.,107-114

Amphetamines,0-12	DrugDDI.d146.s27.e0
may,13-16
interfere,17-26
with,27-31
urinary,32-39
steroid,40-47
determinations.,48-63

Hypotension,0-11
-,12-13
Patients,14-22
on,23-25
Diuretic,26-34
Therapy:,35-43
Patients,44-52
on,53-55
diuretics,,56-66
and,67-70
especially,71-81
those,82-87
in,88-90
whom,91-95
diuretic,96-104
therapy,105-112
was,113-116
recently,117-125
instituted,,126-137
may,138-141
occasionally,142-154
experience,155-165
an,166-168
excessive,169-178
reduction,179-188
of,189-191
blood,192-197
pressure,198-206
after,207-212
initiation,213-223
of,224-226
therapy,227-234
with,235-239
PRINIVIL.,240-249	DrugDDI.d188.s0.e1

The,0-3
possibility,4-15
of,16-18
hypotensive,19-30
effects,31-38
with,39-43
PRINIVIL,44-52	DrugDDI.d188.s1.e0
can,53-56
be,57-59
minimized,60-69
by,70-72
either,73-79
discontinuing,80-93
the,94-97
diuretic,98-106	DrugDDI.d188.s1.e1
or,107-109
increasing,110-120
the,121-124
salt,125-129
intake,130-136
prior,137-142
to,143-145
initiation,146-156
of,157-159
treatment,160-169
with,170-174
PRINIVIL.,175-184	DrugDDI.d188.s1.e2

If,0-2
it,3-5
is,6-8
necessary,9-18
to,19-21
continue,22-30
the,31-34
diuretic,,35-44
initiate,45-53
therapy,54-61
with,62-66
PRINIVIL,67-75	DrugDDI.d188.s2.e1
at,76-78
a,79-80
dose,81-85
of,86-88
5,89-90
mg,91-93
daily,,94-100
and,101-104
provide,105-112
close,113-118
medical,119-126
supervision,127-138
after,139-144
the,145-148
initial,149-156
dose,157-161
until,162-167
blood,168-173
pressure,174-182
has,183-186
stabilized.,187-198

When,0-4
a,5-6
diuretic,7-15	DrugDDI.d188.s3.e0
is,16-18
added,19-24
to,25-27
the,28-31
therapy,32-39
of,40-42
a,43-44
patient,45-52
receiving,53-62
PRINIVIL,,63-72
an,73-75
additional,76-86
antihypertensive,87-103	DrugDDI.d188.s3.e2
effect,104-110
is,111-113
usually,114-121
observed.,122-131

Studies,0-7
with,8-12
ACE,13-16	DrugDDI.d188.s4.e0
inhibitors,17-27	DrugDDI.d188.s4.e0
in,28-30
combination,31-42
with,43-47
diuretics,48-57	DrugDDI.d188.s4.e1
indicate,58-66
that,67-71
the,72-75
dose,76-80
of,81-83
the,84-87
ACE,88-91	DrugDDI.d188.s4.e2
inhibitor,92-101	DrugDDI.d188.s4.e2
can,102-105
be,106-108
reduced,109-116
when,117-121
it,122-124
is,125-127
given,128-133
with,134-138
a,139-140
diuretic.,141-150	DrugDDI.d188.s4.e3

Non-steroidal,0-13	DrugDDI.d188.s5.e0
Anti-inflammatory,14-31	DrugDDI.d188.s5.e0
Agents:,32-39	DrugDDI.d188.s5.e0
In,40-42
some,43-47
patients,48-56
with,57-61
compromised,62-73
renal,74-79
function,80-88
who,89-92
are,93-96
being,97-102
treated,103-110
with,111-115
non-steroidal,116-129	DrugDDI.d188.s5.e1
anti-inflammatory,130-147	DrugDDI.d188.s5.e1
drugs,,148-154	DrugDDI.d188.s5.e1
the,155-158
co-administration,159-176
of,177-179
lisinopril,180-190	DrugDDI.d188.s5.e2
may,191-194
result,195-201
in,202-204
a,205-206
further,207-214
deterioration,215-228
of,229-231
renal,232-237
function.,238-247

Reports,0-7
suggest,8-15
that,16-20
NSAIDs,21-27	DrugDDI.d188.s7.e0
may,28-31
diminish,32-40
the,41-44
antihypertensive,45-61	DrugDDI.d188.s7.e1
effect,62-68
of,69-71
ACE,72-75	DrugDDI.d188.s7.e2
inhibitors,,76-87	DrugDDI.d188.s7.e2
including,88-97
lisinopril.,98-109	DrugDDI.d188.s7.e3

This,0-4
interaction,5-16
should,17-23
be,24-26
given,27-32
consideration,33-46
in,47-49
patients,50-58
taking,59-65
NSAIDs,66-72	DrugDDI.d188.s8.e0
concomitantly,73-86
with,87-91
ACE,92-95	DrugDDI.d188.s8.e1
inhibitors.,96-107	DrugDDI.d188.s8.e1

In,0-2
a,3-4
study,5-10
in,11-13
36,14-16
patients,17-25
with,26-30
mild,31-35
to,36-38
moderate,39-47
hypertension,48-60
where,61-66
the,67-70
antihypertensive,71-87	DrugDDI.d188.s9.e0
effects,88-95
of,96-98
PRINIVIL,99-107	DrugDDI.d188.s9.e1
alone,108-113
were,114-118
compared,119-127
to,128-130
PRINIVIL,131-139	DrugDDI.d188.s9.e2
given,140-145
concomitantly,146-159
with,160-164
indomethacin,,165-178
the,179-182
use,183-186
of,187-189
indomethacin,190-202	DrugDDI.d188.s9.e4
was,203-206
associated,207-217
with,218-222
a,223-224
reduced,225-232
antihypertensive,233-249	DrugDDI.d188.s9.e5
effect,,250-257
although,258-266
the,267-270
difference,271-281
between,282-289
the,290-293
two,294-297
regimens,298-306
was,307-310
not,311-314
significant.,315-327

Other,0-5
Agents:,6-13
PRINIVIL,14-22	DrugDDI.d188.s10.e0
has,23-26
been,27-31
used,32-36
concomitantly,37-50
with,51-55
nitrates,56-64	DrugDDI.d188.s10.e1
and/or,65-71
digoxin,72-79	DrugDDI.d188.s10.e2
without,80-87
evidence,88-96
of,97-99
clinically,100-110
significant,111-122
adverse,123-130
interactions.,131-144

This,0-4
included,5-13
post,14-18
myocardial,19-29
infarction,30-40
patients,41-49
who,50-53
were,54-58
receiving,59-68
intravenous,69-80
or,81-83
transdermal,84-95	DrugDDI.d188.s11.e0
nitroglycerin.,96-110	DrugDDI.d188.s11.e0

No,0-2
clinically,3-13
important,14-23
pharmacokinetic,24-39
interactions,40-52
occurred,53-61
when,62-66
PRINIVIL,67-75	DrugDDI.d188.s12.e0
was,76-79
used,80-84
concomitantly,85-98
with,99-103
propranolol,104-115	DrugDDI.d188.s12.e1
or,116-118
hydrochlorothiazide.,119-139	DrugDDI.d188.s12.e2

The,0-3
presence,4-12
of,13-15
food,16-20
in,21-23
the,24-27
stomach,28-35
does,36-40
not,41-44
alter,45-50
the,51-54
bioavailability,55-70
of,71-73
PRINIVIL.,74-83	DrugDDI.d188.s13.e0

Agents,0-6
Increasing,7-17
Serum,18-23
Potassium:,24-34
PRINIVIL,35-43	DrugDDI.d188.s14.e0
attenuates,44-54
potassium,55-64	DrugDDI.d188.s14.e1
loss,65-69
caused,70-76
by,77-79
thiazide-type,80-93	DrugDDI.d188.s14.e2
diuretics.,94-104	DrugDDI.d188.s14.e2

Use,0-3
of,4-6
PRINIVIL,7-15	DrugDDI.d188.s15.e0
with,16-20
potassium-sparing,21-38	DrugDDI.d188.s15.e1
diuretics,39-48	DrugDDI.d188.s15.e1
(e.g.,,49-55
spironolactone,,56-71
triamterene,,72-84
or,85-87
amiloride),,88-99
potassium,100-109	DrugDDI.d188.s15.e5
supplements,,110-122	DrugDDI.d188.s15.e5
or,123-125
potassium-containing,126-146	DrugDDI.d188.s15.e6
salt,147-151	DrugDDI.d188.s15.e6
substitutes,152-163	DrugDDI.d188.s15.e6
may,164-167
lead,168-172
to,173-175
significant,176-187
increases,188-197
in,198-200
serum,201-206
potassium.,207-217

Potassium,0-9	DrugDDI.d188.s17.e0
sparing,10-17
agents,18-24
should,25-31
generally,32-41
not,42-45
be,46-48
used,49-53
in,54-56
patients,57-65
with,66-70
heart,71-76
failure,77-84
who,85-88
are,89-92
receiving,93-102
PRINIVIL.,103-112	DrugDDI.d188.s17.e1

Lithium:,0-8	DrugDDI.d188.s18.e0
Lithium,9-16
toxicity,17-25
has,26-29
been,30-34
reported,35-43
in,44-46
patients,47-55
receiving,56-65
lithium,66-73	DrugDDI.d188.s18.e1
concomitantly,74-87
with,88-92
drugs,93-98	DrugDDI.d188.s18.e2
which,99-104
cause,105-110
elimination,111-122
of,123-125
sodium,,126-133
including,134-143
ACE,144-147	DrugDDI.d188.s18.e4
inhibitors.,148-159	DrugDDI.d188.s18.e4

Lithium,0-7
toxicity,8-16
was,17-20
usually,21-28
reversible,29-39
upon,40-44
discontinuation,45-60
of,61-63
lithium,64-71	DrugDDI.d188.s19.e0
and,72-75
the,76-79
ACE,80-83	DrugDDI.d188.s19.e1
inhibitor.,84-94	DrugDDI.d188.s19.e1

It,0-2
is,3-5
recommended,6-17
that,18-22
serum,23-28
lithium,29-36
levels,37-43
be,44-46
monitored,47-56
frequently,57-67
if,68-70
PRINIVIL,71-79	DrugDDI.d188.s20.e0
is,80-82
administered,83-95
concomitantly,96-109
with,110-114
lithium.,115-123	DrugDDI.d188.s20.e1

-,0-1
Lofexidine,2-12	DrugDDI.d99.s0.e0
may,13-16
enhance,17-24
the,25-28
CNS,29-32
depressive,33-43
effects,44-51
of,52-54
alcohol,,55-63
barbiturates,64-76	DrugDDI.d99.s0.e2
and,77-80
other,81-86
sedatives,87-96	DrugDDI.d99.s0.e3

-,0-1
Lofexidine,2-12	DrugDDI.d99.s2.e0
may,13-16
enhance,17-24
the,25-28
effects,29-36
of,37-39
anti-hypertensive,40-57	DrugDDI.d99.s2.e1
drug,58-62	DrugDDI.d99.s2.e1
therapy,63-70

-,0-1
Concomitant,2-13
use,14-17
of,18-20
tricyclic,21-30	DrugDDI.d99.s4.e0
antidepressants,31-46	DrugDDI.d99.s4.e0
may,47-50
reduce,51-57
the,58-61
efficacy,62-70
of,71-73
lofexidine.,74-85	DrugDDI.d99.s4.e1

Theophylline:,0-13	DrugDDI.d280.s0.e0
In,14-16
three,17-22
pharmacokinetic,23-38
studies,39-46
including,47-56
46,57-59
normal,,60-67
healthy,68-75
subjects,,76-85
theophylline,86-98	DrugDDI.d280.s0.e1
clearance,99-108
and,109-112
concentration,113-126
were,127-131
not,132-135
significantly,136-149
altered,150-157
by,158-160
the,161-164
addition,165-173
of,174-176
lomefloxacin.,177-190	DrugDDI.d280.s0.e2

In,0-2
clinical,3-11
studies,12-19
where,20-25
patients,26-34
were,35-39
on,40-42
chronic,43-50
theophylline,51-63	DrugDDI.d280.s1.e0
therapy,,64-72
lomefloxacin,73-85	DrugDDI.d280.s1.e1
had,86-89
no,90-92
measurable,93-103
effect,104-110
on,111-113
the,114-117
mean,118-122
distribution,123-135
of,136-138
theophylline,139-151	DrugDDI.d280.s1.e2
concentrations,152-166
or,167-169
the,170-173
mean,174-178
estimates,179-188
of,189-191
theophylline,192-204	DrugDDI.d280.s1.e3
clearance.,205-215

Antacids,0-8	DrugDDI.d280.s3.e0
and,9-12
sucralfate:,13-24	DrugDDI.d280.s3.e1
Sucralfate,25-35	DrugDDI.d280.s3.e2
and,36-39
antacids,40-48	DrugDDI.d280.s3.e3
containing,49-59
magnesium,60-69	DrugDDI.d280.s3.e4
or,70-72
aluminum,,73-82
as,83-85
well,86-90
as,91-93
formulations,94-106
containing,107-117
divalent,118-126
and,127-130
trivalent,131-140
cations,141-148	DrugDDI.d280.s3.e5
such,149-153
as,154-156
Videx?,157-163
(didanosine),,164-177
chewable/buffered,178-195
tablets,196-203
or,204-206
the,207-210
pediatric,211-220	DrugDDI.d280.s3.e8
powder,221-227
for,228-231
oral,232-236
solution,237-245
can,246-249
form,250-254
chelation,255-264
complexes,265-274
with,275-279
lomefloxacin,280-292	DrugDDI.d280.s3.e9
and,293-296
interfere,297-306
with,307-311
its,312-315
bioavailability.,316-332

Sucralfate,0-10	DrugDDI.d280.s4.e0
administered,11-23
2,24-25
hours,26-31
before,32-38
lomefloxacin,39-51	DrugDDI.d280.s4.e1
resulted,52-60
in,61-63
a,64-65
slower,66-72
absorption,73-83
(mean,84-89
C,90-91
max,92-95	DrugDDI.d280.s4.e2
decreased,96-105
by,106-108
30%,109-112
and,113-116
mean,117-121
T,122-123
max,124-127	DrugDDI.d280.s4.e3
increased,128-137
by,138-140
1,141-142
hour),143-148
and,149-152
a,153-154
lesser,155-161
extent,162-168
of,169-171
absorption,172-182
(mean,183-188
AUC,189-192
decreased,193-202
by,203-205
approximately,206-219
25%).,220-225

Magnesium-,0-10	DrugDDI.d280.s5.e0
and,11-14
aluminum-containing,15-34	DrugDDI.d280.s5.e1
antacids,,35-44	DrugDDI.d280.s5.e1
administered,45-57
concomitantly,58-71
with,72-76
lomefloxacin,,77-90
significantly,91-104
decreased,105-114
the,115-118
bioavailability,119-134
(48%),135-140
of,141-143
lomefloxacin.,144-157	DrugDDI.d280.s5.e3

Separating,0-10
the,11-14
doses,15-20
of,21-23
antacid,24-31	DrugDDI.d280.s6.e0
and,32-35
lomefloxacin,36-48	DrugDDI.d280.s6.e1
minimizes,49-58
this,59-63
decrease,64-72
in,73-75
bioavailability;,76-92

therefore,,0-10
administration,11-25
of,26-28
these,29-34
agents,35-41
should,42-48
precede,49-56
lomefloxacin,57-69	DrugDDI.d280.s7.e0
dosing,70-76
by,77-79
4,80-81
hours,82-87
or,88-90
follow,91-97
lomefloxacin,98-110	DrugDDI.d280.s7.e1
dosing,111-117
by,118-120
at,121-123
least,124-129
2,130-131
hours.,132-138

Caffeine:,0-9	DrugDDI.d280.s8.e0
Two,10-13
hundred,14-21
mg,22-24
of,25-27
caffeine,28-36	DrugDDI.d280.s8.e1
(equivalent,37-48
to,49-51
1,52-53
to,54-56
3,57-58
cups,59-63
of,64-66
American,67-75
coffee),76-83
was,84-87
administered,88-100
to,101-103
16,104-106
normal,,107-114
healthy,115-122
volunteers,123-133
who,134-137
had,138-141
achieved,142-150
steady-state,151-163
blood,164-169
concentrations,170-184
of,185-187
lomefloxacin,188-200	DrugDDI.d280.s8.e2
after,201-206
being,207-212
dosed,213-218
at,219-221
400,222-225
mg,226-228
qd.,229-232

This,0-4
did,5-8
not,9-12
result,13-19
in,20-22
any,23-26
statistically,27-40
or,41-43
clinically,44-54
relevant,55-63
changes,64-71
in,72-74
the,75-78
pharmacokinetic,79-94
parameters,95-105
of,106-108
either,109-115
caffeine,116-124	DrugDDI.d280.s9.e0
or,125-127
its,128-131
major,132-137
metabolite,,138-149
paraxanthine.,150-163

No,0-2
data,3-7
are,8-11
available,12-21
on,22-24
potential,25-34
interactions,35-47
in,48-50
individuals,51-62
who,63-66
consume,67-74
greater,75-82
than,83-87
200,88-91
mg,92-94
of,95-97
caffeine,98-106	DrugDDI.d280.s10.e0
per,107-110
day,111-114
or,115-117
in,118-120
those,,121-127
such,128-132
as,133-135
the,136-139
geriatric,140-149
population,,150-161
who,162-165
are,166-169
generally,170-179
believed,180-188
to,189-191
be,192-194
more,195-199
susceptible,200-211
to,212-214
the,215-218
development,219-230
of,231-233
drug-induced,234-246
CNS-related,247-258
adverse,259-266
effects.,267-275

Other,0-5
quinolones,6-16	DrugDDI.d280.s11.e0
have,17-21
demonstrated,22-34
moderate,35-43
to,44-46
marked,47-53
interference,54-66
with,67-71
the,72-75
metabolism,76-86
of,87-89
caffeine,,90-99
resulting,100-109
in,110-112
a,113-114
reduced,115-122
clearance,,123-133
a,134-135
prolongation,136-148
of,149-151
plasma,152-158
half-life,,159-169
and,170-173
an,174-176
increase,177-185
in,186-188
symptoms,189-197
that,198-202
accompany,203-212
high,213-217
levels,218-224
of,225-227
caffeine.,228-237	DrugDDI.d280.s11.e2

Cimetidine:,0-11	DrugDDI.d280.s12.e0
Cimetidine,12-22	DrugDDI.d280.s12.e1
has,23-26
been,27-31
demonstrated,32-44
to,45-47
interfere,48-57
with,58-62
the,63-66
elimination,67-78
of,79-81
other,82-87
quinolones.,88-99	DrugDDI.d280.s12.e2

The,0-3
interaction,4-15
between,16-23
lomefloxacin,24-36	DrugDDI.d280.s14.e0
and,37-40
cimetidine,41-51	DrugDDI.d280.s14.e1
has,52-55
not,56-59
been,60-64
studied.,65-73

Cyclosporine:,0-13	DrugDDI.d280.s15.e0
Elevated,14-22
serum,23-28
levels,29-35
of,36-38
cyclosporine,39-51	DrugDDI.d280.s15.e1
have,52-56
been,57-61
reported,62-70
with,71-75
concomitant,76-87
use,88-91
of,92-94
cyclosporine,95-107	DrugDDI.d280.s15.e2
with,108-112
other,113-118
members,119-126
of,127-129
the,130-133
quinolone,134-143	DrugDDI.d280.s15.e3
class.,144-150	DrugDDI.d280.s15.e3

Interaction,0-11
between,12-19
lomefloxacin,20-32	DrugDDI.d280.s16.e0
and,33-36
cyclosporine,37-49	DrugDDI.d280.s16.e1
has,50-53
not,54-57
been,58-62
studied.,63-71

Omeprazole:,0-11	DrugDDI.d280.s17.e0
No,12-14
clinically,15-25
significant,26-37
changes,38-45
in,46-48
lomefloxacin,49-61	DrugDDI.d280.s17.e1
pharmacokinetics,62-78
(AUC,,79-84
C,85-86
max,87-90	DrugDDI.d280.s17.e2
,,91-92
or,93-95
T,96-97
max,98-101	DrugDDI.d280.s17.e3
),102-103
were,104-108
observed,109-117
when,118-122
a,123-124
single,125-131
dose,132-136
of,137-139
lomefloxacin,140-152	DrugDDI.d280.s17.e4
400,153-156	DrugDDI.d280.s17.e4
mg,157-159	DrugDDI.d280.s17.e4
was,160-163
given,164-169
after,170-175
multiple,176-184
doses,185-190
of,191-193
omeprazole,194-204	DrugDDI.d280.s17.e5
(20,205-208
mg,209-211
qd),212-215
in,216-218
13,219-221
healthy,222-229
volunteers.,230-241

Changes,0-7
in,8-10
omeprazole,11-21	DrugDDI.d280.s18.e0
pharmacokinetics,22-38
were,39-43
not,44-47
studied.,48-56

Phenytoin:,0-10	DrugDDI.d280.s19.e0
No,11-13
significant,14-25
differences,26-37
were,38-42
observed,43-51
in,52-54
mean,55-59
phenytoin,60-69	DrugDDI.d280.s19.e1
AUC,,70-74
C,75-76
max,77-80	DrugDDI.d280.s19.e2
,,81-82
C,83-84
min,85-88
or,89-91
T,92-93
max,94-97	DrugDDI.d280.s19.e3
(although,98-107
C,108-109
max,110-113	DrugDDI.d280.s19.e4
increased,114-123
by,124-126
11%),127-131
when,132-136
extended,137-145	DrugDDI.d280.s19.e5
phenytoin,146-155	DrugDDI.d280.s19.e5
sodium,156-162
capsules,163-171
(100,172-176
mg,177-179
tid),180-184
were,185-189
coadministered,190-204
with,205-209
lomefloxacin,210-222	DrugDDI.d280.s19.e6
(400,223-227
mg,228-230
qd),231-234
for,235-238
five,239-243
days,244-248
in,249-251
15,252-254
healthy,255-262
males.,263-269

Lomefloxacin,0-12	DrugDDI.d280.s20.e0
is,13-15
unlikely,16-24
to,25-27
have,28-32
a,33-34
significant,35-46
effect,47-53
on,54-56
phenytoin,57-66	DrugDDI.d280.s20.e1
metabolism.,67-78

Probenecid:,0-11	DrugDDI.d280.s21.e0
Probenecid,12-22	DrugDDI.d280.s21.e1
slows,23-28
the,29-32
renal,33-38
elimination,39-50
of,51-53
lome-floxacin.,54-68

An,0-2
increase,3-11
of,12-14
63%,15-18
in,19-21
the,22-25
mean,26-30
AUC,31-34
and,35-38
increases,39-48
of,49-51
50%,52-55
and,56-59
4%,,60-63
respectively,,64-77
in,78-80
the,81-84
mean,85-89
T,90-91
max,92-95	DrugDDI.d280.s22.e0
and,96-99
mean,100-104
C,105-106
max,107-110	DrugDDI.d280.s22.e1
were,111-115
noted,116-121
in,122-124
1,125-126
study,127-132
of,133-135
6,136-137
individuals.,138-150

Terfenadine:,0-12	DrugDDI.d280.s23.e0
No,13-15
clinically,16-26
significant,27-38
changes,39-46
occurred,47-55
in,56-58
heart,59-64
rate,65-69
or,70-72
corrected,73-82
QT,83-85
intervals,,86-96
or,97-99
in,100-102
terfenadine,103-114	DrugDDI.d280.s23.e1
metabolite,115-125
or,126-128
lomefloxacin,129-141	DrugDDI.d280.s23.e2
pharmacokinetics,,142-159
during,160-166
concurrent,167-177
administration,178-192
of,193-195
lomefloxacin,196-208	DrugDDI.d280.s23.e3
and,209-212
terfenadine,213-224	DrugDDI.d280.s23.e4
at,225-227
steady-state,228-240
in,241-243
28,244-246
healthy,247-254
males.,255-261

Warfarin:,0-9	DrugDDI.d280.s24.e0
Quinolones,10-20	DrugDDI.d280.s24.e1
may,21-24
enhance,25-32
the,33-36
effects,37-44
of,45-47
the,48-51
oral,52-56	DrugDDI.d280.s24.e2
anticoagulant,,57-71	DrugDDI.d280.s24.e2
warfarin,,72-81
or,82-84
its,85-88
derivatives.,89-101	DrugDDI.d280.s24.e4

When,0-4
these,5-10
products,11-19
are,20-23
administered,24-36
concomitantly,,37-51
prothrombin,52-63	DrugDDI.d280.s25.e0
or,64-66
other,67-72
suitable,73-81
coagulation,82-93
tests,94-99
should,100-106
be,107-109
monitored,110-119
closely.,120-128

However,,0-8
no,9-11
clinically,12-22
or,23-25
statistically,26-39
significant,40-51
differences,52-63
in,64-66
prothrombin,67-78
time,79-83
ratio,84-89
or,90-92
warfarin,93-101
enantiomer,102-112	DrugDDI.d280.s26.e0
pharmacokinetics,113-129
were,130-134
observed,135-143
in,144-146
a,147-148
small,149-154
study,155-160
of,161-163
7,164-165
healthy,166-173
males,174-179
who,180-183
received,184-192
both,193-197
warfarin,198-206	DrugDDI.d280.s26.e1
and,207-210
lomefloxacin,211-223	DrugDDI.d280.s26.e2
under,224-229
steady-state,230-242
conditions.,243-254

There,0-5
was,6-9
no,10-12
evidence,13-21
in,22-24
clinical,25-33
trials,34-40
of,41-43
drug,44-48
interactions,49-61
with,62-66
concurrent,67-77
medications.,78-90	DrugDDI.d244.s0.e0

Probenecid:,0-11	DrugDDI.d107.s0.e0
As,12-14
with,15-19
other,20-25
b-lactam,26-34	DrugDDI.d107.s0.e1
antibiotics,,35-47	DrugDDI.d107.s0.e1
renal,48-53
excretion,54-63
of,64-66
loracarbef,67-77	DrugDDI.d107.s0.e2
is,78-80
inhibited,81-90
by,91-93
probenecid,94-104	DrugDDI.d107.s0.e3
and,105-108
resulted,109-117
in,118-120
an,121-123
approximate,124-135
80%,136-139
increase,140-148
in,149-151
the,152-155
AUC,156-159
for,160-163
loracarbef.,164-175	DrugDDI.d107.s0.e4

Loratadine,0-10	DrugDDI.d37.s0.e0
(10,11-14
mg,15-17
once,18-22
daily),23-29
has,30-33
been,34-38
coadministered,39-53
with,54-58
therapeutic,59-70
doses,71-76
of,77-79
erythromycin,,80-93
cimetidine,,94-105
and,106-109
ketoconazole,110-122	DrugDDI.d37.s0.e3
in,123-125
controlled,126-136
clinical,137-145
pharmacology,146-158
studies,159-166
in,167-169
adult,170-175
volunteers.,176-187

Although,0-8
increased,9-18
plasma,19-25
concentrations,26-40
(AUC,41-45
0-24,46-50
hrs),51-55
of,56-58
loratadine,59-69	DrugDDI.d37.s1.e0
and/or,70-76
descarboethoxyloratadine,77-101
were,102-106
observed,107-115
following,116-125
coadministration,126-142
of,143-145
loratadine,146-156	DrugDDI.d37.s1.e1
with,157-161
each,162-166
of,167-169
these,170-175
drugs,176-181	DrugDDI.d37.s1.e2
in,182-184
normal,185-191
volunteers,192-202
(n,203-205
=,206-207
24,208-210
in,211-213
each,214-218
study),,219-226
there,227-232
were,233-237
no,238-240
clinically,241-251
relevant,252-260
changes,261-268
in,269-271
the,272-275
safety,276-282
profile,283-290
of,291-293
loratadine,,294-305
as,306-308
assessed,309-317
by,318-320
electrocardiographic,321-341
parameters,,342-353
clinical,354-362
laboratory,363-373
tests,,374-380
vital,381-386
signs,,387-393
and,394-397
adverse,398-405
events.,406-413

No,0-2
effects,3-10
on,11-13
plasma,14-20
concentrations,21-35
of,36-38
cimetidine,39-49	DrugDDI.d37.s3.e0
or,50-52
ketoconazole,53-65	DrugDDI.d37.s3.e1
were,66-70
observed.,71-80

Plasma,0-6
concentrations,7-21
(AUC,22-26
0-24,27-31
hrs),32-36
of,37-39
erythromycin,40-52	DrugDDI.d37.s4.e0
decreased,53-62
15%,63-66
with,67-71
coadministration,72-88
of,89-91
loratadine,92-102	DrugDDI.d37.s4.e1
relative,103-111
to,112-114
that,115-119
observed,120-128
with,129-133
erythromycin,134-146	DrugDDI.d37.s4.e2
alone.,147-153

TABLE,0-5
1,6-7
Effects,8-15
on,16-18
Plasma,19-25
Concentrations,26-40
(AUC,41-45
0-24,46-50
hrs),51-55
of,56-58
Loratadine,59-69	DrugDDI.d37.s7.e0
and,70-73
Descarboethoxyloratadine,74-98
After,99-104
10,105-107
Days,108-112
of,113-115
Coadministration,116-132
(Loratadine,133-144
10,145-147
mg),148-151
in,152-154
Normal,155-161
Volunteers,162-172

?,0-1
Loratadine,2-12	DrugDDI.d37.s8.e0
Descarboethoxyloratadine,13-37

There,0-5
does,6-10
not,11-14
appear,15-21
to,22-24
be,25-27
an,28-30
increase,31-39
in,40-42
adverse,43-50
events,51-57
in,58-60
subjects,61-69
who,70-73
received,74-82
oral,83-87	DrugDDI.d37.s12.e0
contraceptives,88-102	DrugDDI.d37.s12.e0
and,103-106
loratadine.,107-118	DrugDDI.d37.s12.e1

Tablets:,0-8
The,9-12
benzodiazepines,,13-29
including,30-39
lorazepam,,40-50
produce,51-58
CNS-depressant,59-73	DrugDDI.d521.s0.e2
effects,74-81	DrugDDI.d521.s0.e2
when,82-86
administered,87-99
with,100-104
such,105-109
medications,110-121	DrugDDI.d521.s0.e3
as,122-124
barbiturates,125-137	DrugDDI.d521.s0.e4
or,138-140
alcohol.,141-149	DrugDDI.d521.s0.e5

Injection:,0-10
Lorazepam,11-20	DrugDDI.d521.s1.e0
injection,,21-31
like,32-36
other,37-42
injectable,43-53
benzodiazepines,,54-70
produces,71-79
depression,80-90
of,91-93
the,94-97
central,98-105
nervous,106-113
system,114-120
when,121-125
administered,126-138
with,139-143
ethyl,144-149	DrugDDI.d521.s1.e2
alcohol,,150-158	DrugDDI.d521.s1.e2
phenothiazines,,159-174
barbiturates,,175-188
MAO,189-192	DrugDDI.d521.s1.e5
inhibitors,,193-204	DrugDDI.d521.s1.e5
and,205-208
other,209-214
antidepressants.When,215-235	DrugDDI.d521.s1.e6
scopolamine,236-247	DrugDDI.d521.s1.e7
is,248-250
used,251-255
concomitantly,256-269
with,270-274
injectable,275-285
lorazepam,,286-296
an,297-299
increased,300-309
incidence,310-319
of,320-322
sedation,,323-332
hallucinations,,333-348
and,349-352
irrational,353-363
behavior,364-372
has,373-376
been,377-381
observed.,382-391

No,0-2
significant,3-14
drug-drug,15-24
pharmacokinetic,25-40
interactions,41-53
have,54-58
been,59-63
found,64-69
in,70-72
interaction,73-84
studies,85-92
with,93-97
hydrochlorothiazide,,98-118
digoxin,,119-127
warfarin,,128-137
cimetidine,138-148	DrugDDI.d481.s0.e3
and,149-152
phenobarbital.,153-167	DrugDDI.d481.s0.e4

Rifampin,,0-9
an,10-12
inducer,13-20
of,21-23
drug,24-28
metabolism,,29-40
decreased,41-50
the,51-54
concentrations,55-69
of,70-72
losartan,73-81	DrugDDI.d481.s1.e1
and,82-85
its,86-89
active,90-96	DrugDDI.d481.s1.e2
metabolite.,97-108	DrugDDI.d481.s1.e2

In,0-2
humans,,3-10
two,11-14
inhibitors,15-25
of,26-28
P450,29-33	DrugDDI.d481.s2.e0
3A4,34-37	DrugDDI.d481.s2.e0
have,38-42
been,43-47
studied.,48-56

Ketoconazole,0-12	DrugDDI.d481.s3.e0
did,13-16
not,17-20
affect,21-27
the,28-31
conversion,32-42
of,43-45
losartan,46-54	DrugDDI.d481.s3.e1
to,55-57
the,58-61
active,62-68	DrugDDI.d481.s3.e2
metabolite,69-79	DrugDDI.d481.s3.e2
after,80-85
intravenous,86-97
administration,98-112
of,113-115
losartan,,116-125
and,126-129
erythromycin,130-142	DrugDDI.d481.s3.e4
had,143-146
no,147-149
clinically,150-160
significant,161-172
effect,173-179
after,180-185
oral,186-190
administration.,191-206

Fluconazole,,0-12
an,13-15
inhibitor,16-25
of,26-28
P450,29-33	DrugDDI.d481.s4.e1
2C9,,34-38
decreased,39-48
active,49-55	DrugDDI.d481.s4.e2
metabolite,56-66	DrugDDI.d481.s4.e2
concentration,67-80
and,81-84
increased,85-94
losartan,95-103	DrugDDI.d481.s4.e3
concentration.,104-118

The,0-3
pharmacodynamic,4-19
consequences,20-32
of,33-35
concomitant,36-47
use,48-51
of,52-54
losartan,55-63	DrugDDI.d481.s5.e0
and,64-67
inhibitors,68-78
of,79-81
P450,82-86	DrugDDI.d481.s5.e1
2C9,87-90
have,91-95
not,96-99
been,100-104
examined.,105-114

Subjects,0-8
who,9-12
do,13-15
not,16-19
metabolize,20-30
losartan,31-39	DrugDDI.d481.s6.e0
to,40-42
active,43-49	DrugDDI.d481.s6.e1
metabolite,50-60	DrugDDI.d481.s6.e1
have,61-65
been,66-70
shown,71-76
to,77-79
have,80-84
a,85-86
specific,,87-96
rare,97-101
defect,102-108
in,109-111
cytochrome,112-122	DrugDDI.d481.s6.e2
P450,123-127	DrugDDI.d481.s6.e2
2C9.,128-132	DrugDDI.d481.s6.e2

These,0-5
data,6-10
suggest,11-18
that,19-23
the,24-27
conversion,28-38
of,39-41
losartan,42-50	DrugDDI.d481.s7.e0
to,51-53
its,54-57
active,58-64	DrugDDI.d481.s7.e1
metabolite,65-75	DrugDDI.d481.s7.e1
is,76-78
mediated,79-87
primarily,88-97
by,98-100
P450,101-105	DrugDDI.d481.s7.e2
2C9,106-109
and,110-113
not,114-117
P450,118-122	DrugDDI.d481.s7.e3
3A4.,123-127	DrugDDI.d481.s7.e3

As,0-2
with,3-7
other,8-13
drugs,14-19	DrugDDI.d481.s8.e0
that,20-24
block,25-30
angiotensin,31-42	DrugDDI.d481.s8.e1
II,43-45	DrugDDI.d481.s8.e1
or,46-48
its,49-52
effects,,53-61
concomitant,62-73
use,74-77
of,78-80
potassium-sparing,81-98	DrugDDI.d481.s8.e2
diuretics,99-108	DrugDDI.d481.s8.e2
(e.g.,,109-115
spironolactone,,116-131
triamterene,,132-144
amiloride),,145-156
potassium,157-166	DrugDDI.d481.s8.e6
supplements,,167-179	DrugDDI.d481.s8.e6
or,180-182
salt,183-187	DrugDDI.d481.s8.e7
substitutes,188-199
containing,200-210
potassium,211-220	DrugDDI.d481.s8.e8
may,221-224
lead,225-229
to,230-232
increases,233-242
in,243-245
serum,246-251
potassium.,252-262

As,0-2
with,3-7
other,8-13
antihypertensive,14-30	DrugDDI.d481.s9.e0
agents,,31-38	DrugDDI.d481.s9.e0
the,39-42
antihypertensive,43-59	DrugDDI.d481.s9.e1
effect,60-66
of,67-69
losartan,70-78	DrugDDI.d481.s9.e2
may,79-82
be,83-85
blunted,86-93
by,94-96
the,97-100
non-steroidal,101-114	DrugDDI.d481.s9.e3
anti-inflammatory,115-132	DrugDDI.d481.s9.e3
drug,133-137	DrugDDI.d481.s9.e3
indomethacin,138-150

CYP3A4,0-6	DrugDDI.d278.s0.e0
Interactions,7-19

Lovastatin,0-10	DrugDDI.d278.s1.e0
is,11-13
metabolized,14-25
by,26-28
CYP3A4,29-35	DrugDDI.d278.s1.e1
but,36-39
has,40-43
no,44-46
CYP3A4,47-53	DrugDDI.d278.s1.e2
inhibitory,54-64
activity;,65-74

therefore,0-9
it,10-12
is,13-15
not,16-19
expected,20-28
to,29-31
affect,32-38
the,39-42
plasma,43-49
concentrations,50-64
of,65-67
other,68-73
drugs,74-79	DrugDDI.d278.s2.e0
metabolized,80-91
by,92-94
CYP3A4.,95-102	DrugDDI.d278.s2.e1

Potent,0-6
inhibitors,7-17
of,18-20
CYP3A4,21-27	DrugDDI.d278.s3.e0
(below),28-35
increase,36-44
the,45-48
risk,49-53
of,54-56
myopathy,57-65
by,66-68
reducing,69-77
the,78-81
elimination,82-93
of,94-96
lovastatin.,97-108	DrugDDI.d278.s3.e1

Itraconazole,0-12	DrugDDI.d278.s5.e0
Ketoconazole,13-25
Erythromycin,26-38
Clarithromycin,39-53
Telithromycin,54-67
HIV,68-71
protease,72-80
inhibitors,81-91
Nefazodone,92-102
Cyclosporine,103-115
Large,116-121
quantities,122-132
of,133-135
grapefruit,136-146
juice,147-152
(,153-154
1,155-156
quart,157-162
daily),163-169

Interactions,0-12
with,13-17
lipid-lowering,18-32	DrugDDI.d278.s6.e0
drugs,33-38	DrugDDI.d278.s6.e0
that,39-43
can,44-47
cause,48-53
myopathy,54-62
when,63-67
given,68-73
alone.,74-80

The,0-3
risk,4-8
of,9-11
myopathy,12-20
is,21-23
also,24-28
increased,29-38
by,39-41
the,42-45
following,46-55
lipid-lowering,56-70	DrugDDI.d278.s7.e0
drugs,71-76	DrugDDI.d278.s7.e0
that,77-81
are,82-85
not,86-89
potent,90-96
CYP3A4,97-103	DrugDDI.d278.s7.e1
inhibitors,,104-115
but,116-119
which,120-125
can,126-129
cause,130-135
myopathy,136-144
when,145-149
given,150-155
alone.,156-162

Gemfibrozil,0-11	DrugDDI.d278.s9.e0
Other,12-17
fibrates,18-26
Niacin,27-33
(nicotinic,34-44
acid),45-50
(=1,51-54
g/day),55-61

Danazol:,0-8	DrugDDI.d278.s11.e0
The,9-12
risk,13-17
of,18-20
myopathy/rhabdomyolysis,21-44
is,45-47
increased,48-57
by,58-60
concomitant,61-72
administration,73-87
of,88-90
danazol,91-98	DrugDDI.d278.s11.e1
particularly,99-111
with,112-116
higher,117-123
doses,124-129
of,130-132
lovastatin,133-143	DrugDDI.d278.s11.e2
(see,144-148
WARNINGS,,149-158
Myopathy/Rhabdomyolysis).,159-184

Amiodarone,0-10	DrugDDI.d278.s12.e0
or,11-13
Verapamil:,14-24	DrugDDI.d278.s12.e1
The,25-28
risk,29-33
of,34-36
myopathy/rhabdomyolysis,37-60
is,61-63
increased,64-73
when,74-78
either,79-85
amiodarone,86-96	DrugDDI.d278.s12.e2
or,97-99
verapamil,100-109	DrugDDI.d278.s12.e3
is,110-112
used,113-117
concomitantly,118-131
with,132-136
a,137-138
closely,139-146
related,147-154
member,155-161
of,162-164
the,165-168
HMG-CoA,169-176	DrugDDI.d278.s12.e4
reductase,177-186	DrugDDI.d278.s12.e4
inhibitor,187-196	DrugDDI.d278.s12.e4
class,197-202
(see,203-207
WARNINGS,,208-217
Myopathy/Rhabdomyolysis).,218-243

Coumarin,0-8	DrugDDI.d278.s13.e0
Anticoagulants:,9-24	DrugDDI.d278.s13.e0
In,25-27
a,28-29
small,30-35
clinical,36-44
trial,45-50
in,51-53
which,54-59
lovastatin,60-70	DrugDDI.d278.s13.e1
was,71-74
administered,75-87
to,88-90
warfarin,91-99	DrugDDI.d278.s13.e2
treated,100-107
patients,,108-117
no,118-120
effect,121-127
on,128-130
prothrombin,131-142
time,143-147
was,148-151
detected.,152-161

However,,0-8
another,9-16
HMG-CoA,17-24	DrugDDI.d278.s14.e0
reductase,25-34	DrugDDI.d278.s14.e0
inhibitor,35-44	DrugDDI.d278.s14.e0
has,45-48
been,49-53
found,54-59
to,60-62
produce,63-70
a,71-72
less,73-77
than,78-82
two-second,83-93
increase,94-102
in,103-105
prothrombin,106-117
time,118-122
in,123-125
healthy,126-133
volunteers,134-144
receiving,145-154
low,155-158
doses,159-164
of,165-167
warfarin.,168-177	DrugDDI.d278.s14.e1

Also,,0-5
bleeding,6-14
and/or,15-21
increased,22-31
prothrombin,32-43
time,44-48
have,49-53
been,54-58
reported,59-67
in,68-70
a,71-72
few,73-76
patients,77-85
taking,86-92
coumarin,93-101	DrugDDI.d278.s15.e0
anticoagulants,102-116	DrugDDI.d278.s15.e0
concomitantly,117-130
with,131-135
lovastatin.,136-147	DrugDDI.d278.s15.e1

It,0-2
is,3-5
recommended,6-17
that,18-22
in,23-25
patients,26-34
taking,35-41
anticoagulants,,42-57
prothrombin,58-69
time,70-74
be,75-77
determined,78-88
before,89-95
starting,96-104
lovastatin,105-115	DrugDDI.d278.s16.e1
and,116-119
frequently,120-130
enough,131-137
during,138-144
early,145-150
therapy,151-158
to,159-161
insure,162-168
that,169-173
no,174-176
significant,177-188
alteration,189-199
of,200-202
prothrombin,203-214
time,215-219
occurs.,220-227

Once,0-4
a,5-6
stable,7-13
prothrombin,14-25
time,26-30
has,31-34
been,35-39
documented,,40-51
prothrombin,52-63
times,64-69
can,70-73
be,74-76
monitored,77-86
at,87-89
the,90-93
intervals,94-103
usually,104-111
recommended,112-123
for,124-127
patients,128-136
on,137-139
coumarin,140-148	DrugDDI.d278.s17.e0
anticoagulants.,149-164	DrugDDI.d278.s17.e0

If,0-2
the,3-6
dose,7-11
of,12-14
lovastatin,15-25	DrugDDI.d278.s18.e0
is,26-28
changed,,29-37
the,38-41
same,42-46
procedure,47-56
should,57-63
be,64-66
repeated.,67-76

Lovastatin,0-10	DrugDDI.d278.s19.e0
therapy,11-18
has,19-22
not,23-26
been,27-31
associated,32-42
with,43-47
bleeding,48-56
or,57-59
with,60-64
changes,65-72
in,73-75
prothrombin,76-87
time,88-92
in,93-95
patients,96-104
not,105-108
taking,109-115
anticoagulants.,116-131	DrugDDI.d278.s19.e1

Propranolol:,0-12	DrugDDI.d278.s20.e0
In,13-15
normal,16-22
volunteers,,23-34
there,35-40
was,41-44
no,45-47
clinically,48-58
significant,59-70
pharmacokinetic,71-86
or,87-89
pharmacodynamic,90-105
interaction,106-117
with,118-122
concomitant,123-134
administration,135-149
of,150-152
single,153-159
doses,160-165
of,166-168
lovastatin,169-179	DrugDDI.d278.s20.e1
and,180-183
propranolol.,184-196	DrugDDI.d278.s20.e2

Digoxin:,0-8	DrugDDI.d278.s21.e0
In,9-11
patients,12-20
with,21-25
hypercholesterolemia,,26-47
concomitant,48-59
administration,60-74
of,75-77
lovastatin,78-88	DrugDDI.d278.s21.e1
and,89-92
digoxin,93-100	DrugDDI.d278.s21.e2
resulted,101-109
in,110-112
no,113-115
effect,116-122
on,123-125
digoxin,126-133	DrugDDI.d278.s21.e3
plasma,134-140
concentrations.,141-156

Oral,0-4
Hypoglycemic,5-17	DrugDDI.d278.s22.e0
Agents:,18-25	DrugDDI.d278.s22.e0
In,26-28
pharmacokinetic,29-44
studies,45-52
of,53-55
MEVACOR,56-63	DrugDDI.d278.s22.e1
in,64-66
hypercholesterolemic,67-87
noninsulin,88-98
dependent,99-108
diabetic,109-117
patients,,118-127
there,128-133
was,134-137
no,138-140
drug,141-145
interaction,146-157
with,158-162
glipizide,163-172	DrugDDI.d278.s22.e2
or,173-175
with,176-180
chlorpropamide,181-195	DrugDDI.d278.s22.e3

There,0-5
have,6-10
been,11-15
rare,16-20
reports,21-28
of,29-31
significant,32-43
respiratory,44-55
depression,,56-67
stupor,68-74
and/or,75-81
hypotension,82-93
with,94-98
the,99-102
concomitant,103-114
use,115-118
of,119-121
loxapine,122-130	DrugDDI.d253.s0.e0
and,131-134
lorazepam.,135-145	DrugDDI.d253.s0.e1

The,0-3
risk,4-8
of,9-11
using,12-17
loxapine,18-26	DrugDDI.d253.s1.e0
in,27-29
combination,30-41
with,42-46
CNS-active,47-57	DrugDDI.d253.s1.e1
drugs,58-63	DrugDDI.d253.s1.e1
has,64-67
not,68-71
been,72-76
systematically,77-91
evaluated.,92-102

Therefore,,0-10
caution,11-18
is,19-21
advised,22-29
if,30-32
the,33-36
concomitant,37-48
administration,49-63
of,64-66
loxapine,67-75	DrugDDI.d253.s2.e0
and,76-79
CNS-active,80-90	DrugDDI.d253.s2.e1
drugs,91-96	DrugDDI.d253.s2.e1
is,97-99
required.,100-109

The,0-3
absorption,4-14
of,15-17
lymecycline,18-29	DrugDDI.d276.s0.e0
may,30-33
be,34-36
affected,37-45
by,46-48
the,49-52
simultaneous,53-65
administration,66-80
of,81-83
indigestion,84-95
remedies,,96-105
iron,106-110	DrugDDI.d276.s0.e2
or,111-113
zinc,114-118	DrugDDI.d276.s0.e3
supplements.,119-131	DrugDDI.d276.s0.e3

Oral,0-4	DrugDDI.d276.s1.e0
contraceptives,5-19	DrugDDI.d276.s1.e0
may,20-23
be,24-26
less,27-31
effective,32-41
while,42-47
you,48-51
are,52-55
taking,56-62
lymecycline.,63-75	DrugDDI.d276.s1.e1

Warfarin,0-8
Meclofenamate,9-22	DrugDDI.d460.s0.e0
sodium,23-29	DrugDDI.d460.s0.e0
enhances,30-38
the,39-42
effect,43-49
of,50-52
warfarin.,53-62	DrugDDI.d460.s0.e1

Therefore,,0-10
when,11-15
meclofenamate,16-29	DrugDDI.d460.s1.e0
sodium,30-36	DrugDDI.d460.s1.e0
is,37-39
given,40-45
to,46-48
a,49-50
patient,51-58
receiving,59-68
warfarin,,69-78
the,79-82
dosage,83-89
of,90-92
warfarin,93-101	DrugDDI.d460.s1.e2
should,102-108
be,109-111
reduced,112-119
to,120-122
prevent,123-130	DrugDDI.d460.s1.e3
excessive,131-140
prolongation,141-153
of,154-156
the,157-160
prothrombin,161-172
time.,173-178

Aspirin,0-7	DrugDDI.d460.s2.e0
Concurrent,8-18
administration,19-33
of,34-36
aspirin,37-44	DrugDDI.d460.s2.e1
may,45-48
lower,49-54
meclofenamate,55-68	DrugDDI.d460.s2.e2
sodium,69-75	DrugDDI.d460.s2.e2
plasma,76-82
levels,,83-90
possibly,91-99
by,100-102
competing,103-112
for,113-116
protein-binding,117-132	DrugDDI.d460.s2.e3
sites.,133-139

The,0-3
urinary,4-11
excretion,12-21
of,22-24
meclofenamate,25-38	DrugDDI.d460.s3.e0
sodium,39-45	DrugDDI.d460.s3.e0
is,46-48
unaffected,49-59
by,60-62
aspirin,,63-71
indicating,72-82
no,83-85
change,86-92
in,93-95
meclofenamate,96-109	DrugDDI.d460.s3.e2
sodium,110-116	DrugDDI.d460.s3.e2
absorption.,117-128

Meclofenamate,0-13	DrugDDI.d460.s4.e0
sodium,14-20	DrugDDI.d460.s4.e0
does,21-25
not,26-29
affect,30-36
serum,37-42
salicylate,43-53
levels.,54-61

Greater,0-7
fecal,8-13
blood,14-19
loss,20-24
results,25-32
from,33-37
concomitant,38-49
administration,50-64
of,65-67
both,68-72
drugs,73-78	DrugDDI.d460.s5.e0
than,79-83
from,84-88
either,89-95
drug,96-100	DrugDDI.d460.s5.e1
alone.,101-107

Propoxyphene,0-12	DrugDDI.d460.s6.e0
The,13-16
concurrent,17-27
administration,28-42
of,43-45
propoxyphene,46-58	DrugDDI.d460.s6.e1
hydrochloride,59-72	DrugDDI.d460.s6.e1
does,73-77
not,78-81
affect,82-88
the,89-92
bioavailability,93-108
of,109-111
meclofenamate,112-125	DrugDDI.d460.s6.e2
sodium.,126-133	DrugDDI.d460.s6.e2

Antacids,0-8	DrugDDI.d460.s7.e0
Concomitant,9-20
administration,21-35
of,36-38
aluminum,39-47
and,48-51
magnesium,52-61	DrugDDI.d460.s7.e1
hydroxides,62-72	DrugDDI.d460.s7.e1
does,73-77
not,78-81
interfere,82-91
with,92-96
absorption,97-107
of,108-110
meclofenamate,111-124	DrugDDI.d460.s7.e2
sodium.,125-132	DrugDDI.d460.s7.e2

Aspirin:,0-8	DrugDDI.d240.s0.e0
As,9-11
with,12-16
other,17-22
NSAIDs,,23-30
concomitant,31-42
administration,43-57
of,58-60
Ponstel,61-68	DrugDDI.d240.s0.e2
and,69-72
aspirin,73-80	DrugDDI.d240.s0.e3
is,81-83
not,84-87
generally,88-97
recommended,98-109
because,110-117
of,118-120
the,121-124
potential,125-134
of,135-137
increased,138-147
adverse,148-155
effects.,156-164

Methotrexate:,0-13	DrugDDI.d240.s1.e0
NSAIDs,14-20	DrugDDI.d240.s1.e1
have,21-25
been,26-30
reported,31-39
to,40-42
competitively,43-56
inhibit,57-64
methotrexate,65-77	DrugDDI.d240.s1.e2
accumulation,78-90
in,91-93
rabbit,94-100
kidney,101-107
slices.,108-115

This,0-4
may,5-8
indicate,9-17
that,18-22
they,23-27
could,28-33
enhance,34-41
the,42-45
toxicity,46-54
of,55-57
methotrexate.,58-71	DrugDDI.d240.s2.e0

Caution,0-7
should,8-14
be,15-17
used,18-22
when,23-27
NSAIDs,28-34	DrugDDI.d240.s3.e0
are,35-38
administered,39-51
concomitantly,52-65
with,66-70
methotrexate.,71-84	DrugDDI.d240.s3.e1

ACE,0-3	DrugDDI.d240.s4.e0
inhibitors:,4-15	DrugDDI.d240.s4.e0
Reports,16-23
suggest,24-31
that,32-36
NSAIDs,37-43	DrugDDI.d240.s4.e1
may,44-47
diminish,48-56
the,57-60
antihypertensive,61-77	DrugDDI.d240.s4.e2
effect,78-84
of,85-87
ACE,88-91	DrugDDI.d240.s4.e3
inhibitors.,92-103	DrugDDI.d240.s4.e3

This,0-4
interaction,5-16
should,17-23
be,24-26
given,27-32
consideration,33-46
in,47-49
patients,50-58
taking,59-65
NSAIDs,66-72	DrugDDI.d240.s5.e0
concomitantly,73-86
with,87-91
ACE,92-95	DrugDDI.d240.s5.e1
inhibitors.,96-107	DrugDDI.d240.s5.e1

Furosemide:,0-11	DrugDDI.d240.s6.e0
Clinical,12-20
studies,,21-29
as,30-32
well,33-37
as,38-40
post-marketing,41-55
observations,,56-69
have,70-74
shown,75-80
that,81-85
NSAIDs,86-92	DrugDDI.d240.s6.e1
can,93-96
reduce,97-103
the,104-107
natriuretic,108-119	DrugDDI.d240.s6.e2
effect,120-126
of,127-129
furosemide,130-140	DrugDDI.d240.s6.e3
and,141-144
thiazides,145-154	DrugDDI.d240.s6.e4
in,155-157
some,158-162
patients.,163-172

This,0-4
response,5-13
has,14-17
been,18-22
attributed,23-33
to,34-36
inhibition,37-47
of,48-50
renal,51-56
prostaglandin,57-70	DrugDDI.d240.s7.e0
synthesis.,71-81

During,0-6
concomitant,7-18
therapy,19-26
of,27-29
Ponstel,30-37	DrugDDI.d240.s8.e0
with,38-42
furosemide,,43-54
the,55-58
patient,59-66
should,67-73
be,74-76
observed,77-85
closely,86-93
for,94-97
signs,98-103
of,104-106
renal,107-112
failure,,113-121
as,122-124
well,125-129
as,130-132
to,133-135
assure,136-142
diuretic,143-151	DrugDDI.d240.s8.e2
efficacy.,152-161

Lithium:,0-8	DrugDDI.d240.s9.e0
NSAIDs,9-15	DrugDDI.d240.s9.e1
have,16-20
produced,21-29
an,30-32
elevation,33-42
of,43-45
plasma,46-52
lithium,53-60
levels,61-67
and,68-71
a,72-73
reduction,74-83
in,84-86
renal,87-92
lithium,93-100	DrugDDI.d240.s9.e2
clearance.,101-111

The,0-3
mean,4-8
minimum,9-16
lithium,17-24	DrugDDI.d240.s10.e0
concentration,25-38
increased,39-48
15%,49-52
and,53-56
the,57-60
renal,61-66
clearance,67-76
was,77-80
decreased,81-90
by,91-93
approximately,94-107
20%.,108-112

These,0-5
effects,6-13
have,14-18
been,19-23
attributed,24-34
to,35-37
inhibition,38-48
of,49-51
renal,52-57
prostaglandin,58-71	DrugDDI.d240.s11.e0
synthesis,72-81
by,82-84
the,85-88
NSAID.,89-95	DrugDDI.d240.s11.e1

Thus,,0-5
when,6-10
NSAIDs,11-17	DrugDDI.d240.s12.e0
and,18-21
lithium,22-29	DrugDDI.d240.s12.e1
are,30-33
administered,34-46
concurrently,,47-60
subjects,61-69
should,70-76
be,77-79
observed,80-88
carefully,89-98
for,99-102
signs,103-108
of,109-111
lithium,112-119
toxicity.,120-129

Warfarin:,0-9	DrugDDI.d240.s13.e0
The,10-13
effects,14-21
of,22-24
warfarin,25-33	DrugDDI.d240.s13.e1
and,34-37
NSAIDs,38-44	DrugDDI.d240.s13.e2
on,45-47
GI,48-50
bleeding,51-59
are,60-63
synergistic,,64-76
such,77-81
that,82-86
users,87-92
of,93-95
both,96-100
drugs,101-106	DrugDDI.d240.s13.e3
together,107-115
have,116-120
a,121-122
risk,123-127
of,128-130
serious,131-138
GI,139-141
bleeding,142-150
higher,151-157
than,158-162
users,163-168
of,169-171
either,172-178
drug,179-183	DrugDDI.d240.s13.e4
alone.,184-190

Antacids:,0-9	DrugDDI.d240.s14.e0
In,10-12
a,13-14
single,15-21
dose,22-26
study,27-32
(n=6),,33-39
ingestion,40-49
of,50-52
an,53-55
antacid,56-63	DrugDDI.d240.s14.e1
containing,64-74
1.7-gram,75-83
of,84-86
magnesium,87-96	DrugDDI.d240.s14.e2
hydroxide,97-106	DrugDDI.d240.s14.e2
with,107-111
500-mg,112-118
of,119-121
mefenamic,122-131	DrugDDI.d240.s14.e3
acid,132-136	DrugDDI.d240.s14.e3
increased,137-146
the,147-150
Cmax,151-155
and,156-159
AUC,160-163
of,164-166
mefenamic,167-176	DrugDDI.d240.s14.e4
acid,177-181	DrugDDI.d240.s14.e4
by,182-184
125%,185-189
and,190-193
36%,,194-198
respectively.?,199-213
A,214-215
number,216-222
of,223-225
compounds,226-235
are,236-239
inhibitors,240-250
of,251-253
CYP2C9,254-260	DrugDDI.d240.s14.e5
including,261-270
fluconazole,,271-283
lovastatin,284-294	DrugDDI.d240.s14.e7
and,295-298
trimethoprim.,299-312	DrugDDI.d240.s14.e8

Drug,0-4
interaction,5-16
studies,17-24
of,25-27
mefenamic,28-37	DrugDDI.d240.s15.e0
acid,38-42	DrugDDI.d240.s15.e0
and,43-46
these,47-52
compounds,53-62
have,63-67
not,68-71
been,72-76
conducted.,77-87

The,0-3
possibility,4-15
of,16-18
altered,19-26
safety,27-33
and,34-37
efficacy,38-46
should,47-53
be,54-56
considered,57-67
when,68-72
Ponstel,73-80	DrugDDI.d240.s16.e0
is,81-83
used,84-88
concomitantly,89-102
with,103-107
these,108-113
drugs.,114-120	DrugDDI.d240.s16.e1

Drug-drug,0-9
interactions,10-22
with,23-27
Mefloquine,28-38	DrugDDI.d437.s0.e0
have,39-43
not,44-47
been,48-52
explored,53-61
in,62-64
detail.,65-72

There,0-5
is,6-8
one,9-12
report,13-19
of,20-22
cardiopulmonary,23-38
arrest,,39-46
with,47-51
full,52-56
recovery,,57-66
in,67-69
a,70-71
patient,72-79
who,80-83
was,84-87
taking,88-94
a,95-96
beta,97-101	DrugDDI.d437.s1.e0
blocker,102-109	DrugDDI.d437.s1.e0
(propranolol).,110-124

The,0-3
benefits,4-12
of,13-15
Mefloquine,16-26	DrugDDI.d437.s3.e0
therapy,27-34
should,35-41
be,42-44
weighed,45-52
against,53-60
the,61-64
possibility,65-76
of,77-79
adverse,80-87
effects,88-95
in,96-98
patients,99-107
with,108-112
cardiac,113-120
disease.,121-129

Because,0-7
of,8-10
the,11-14
danger,15-21
of,22-24
a,25-26
potentially,27-38
fatal,39-44
prolongation,45-57
of,58-60
the,61-64
QTc,65-68
interval,,69-78
halofantrine,79-91	DrugDDI.d437.s4.e0
must,92-96
not,97-100
be,101-103
given,104-109
simultaneously,110-124
with,125-129
or,130-132
subsequent,133-143
to,144-146
Mefloquine.,147-158	DrugDDI.d437.s4.e1

Concomitant,0-11
administration,12-26
of,27-29
Mefloquine,30-40	DrugDDI.d437.s5.e0
and,41-44
other,45-50
related,51-58	DrugDDI.d437.s5.e1
compounds,59-68	DrugDDI.d437.s5.e1
(eg,,69-73
quinine,,74-82
quinidine,83-92	DrugDDI.d437.s5.e3
and,93-96
chloroquine),97-109	DrugDDI.d437.s5.e4
may,110-113
produce,114-121
electrocardiographic,122-142
abnormalities,143-156
and,157-160
increase,161-169
the,170-173
risk,174-178
of,179-181
convulsions.,182-194

If,0-2
these,3-8
drugs,9-14	DrugDDI.d437.s6.e0
are,15-18
to,19-21
be,22-24
used,25-29
in,30-32
the,33-36
initial,37-44
treatment,45-54
of,55-57
severe,58-64
malaria,,65-73
Mefloquine,74-84	DrugDDI.d437.s6.e2
administration,85-99
should,100-106
be,107-109
delayed,110-117
at,118-120
least,121-126
12,127-129
hours,130-135
after,136-141
the,142-145
last,146-150
dose.,151-156

There,0-5
is,6-8
evidence,9-17
that,18-22
the,23-26
use,27-30
of,31-33
halofantrine,34-46	DrugDDI.d437.s7.e0
after,47-52
Mefloquineuine,53-67
causes,68-74
a,75-76
significant,77-88
lengthening,89-100
of,101-103
the,104-107
QTc,108-111
interval.,112-121

This,0-4
appears,5-12
to,13-15
be,16-18
the,19-22
only,23-27
clinically,28-38
relevant,39-47
interaction,48-59
of,60-62
this,63-67
kind,68-72
with,73-77
Mefloquine,,78-89
although,90-98
theoretically,,99-113
coadministration,114-130
of,131-133
other,134-139
drugs,140-145	DrugDDI.d437.s9.e1
known,146-151
to,152-154
alter,155-160
cardiac,161-168
conduction,169-179
(eg,,180-184
anti-arrhythmic,185-200	DrugDDI.d437.s9.e2
or,201-203
beta-adrenergic,204-219	DrugDDI.d437.s9.e3
blocking,220-228	DrugDDI.d437.s9.e3
agents,,229-236	DrugDDI.d437.s9.e3
calcium,237-244	DrugDDI.d437.s9.e4
channel,245-252	DrugDDI.d437.s9.e4
blockers,,253-262	DrugDDI.d437.s9.e4
antihistamines,263-277	DrugDDI.d437.s9.e5
or,278-280
H1-blocking,281-292
agents,,293-300
tricyclic,301-310	DrugDDI.d437.s9.e6
antidepressants,311-326	DrugDDI.d437.s9.e6
and,327-330
phenothiazines),331-346	DrugDDI.d437.s9.e7
might,347-352
also,353-357
contribute,358-368
to,369-371
a,372-373
prolongation,374-386
of,387-389
the,390-393
QTc,394-397
interval.,398-407

In,0-2
patients,3-11
taking,12-18
an,19-21
anticonvulsant,22-36	DrugDDI.d437.s11.e0
(eg,,37-41
valproic,42-50	DrugDDI.d437.s11.e1
acid,,51-56	DrugDDI.d437.s11.e1
carbamazepine,,57-71
phenobarbital,72-85	DrugDDI.d437.s11.e3
or,86-88
phenytoin),,89-100
the,101-104
concomitant,105-116
use,117-120
of,121-123
Mefloquine,124-134	DrugDDI.d437.s11.e5
may,135-138
reduce,139-145
seizure,146-153
control,154-161
by,162-164
lowering,165-173
the,174-177
plasma,178-184
levels,185-191
of,192-194
the,195-198
anticonvulsant.,199-214	DrugDDI.d437.s11.e6

Therefore,,0-10
patients,11-19
concurrently,20-32
taking,33-39
antiseizure,40-51	DrugDDI.d437.s12.e0
medication,52-62	DrugDDI.d437.s12.e0
and,63-66
Mefloquine,67-77	DrugDDI.d437.s12.e1
should,78-84
have,85-89
the,90-93
blood,94-99
level,100-105
of,106-108
their,109-114
antiseizure,115-126	DrugDDI.d437.s12.e2
medication,127-137	DrugDDI.d437.s12.e2
monitored,138-147
and,148-151
the,152-155
dosage,156-162
adjusted,163-171
appropriately.,172-186

When,0-4
Mefloquine,5-15	DrugDDI.d437.s13.e0
is,16-18
taken,19-24
concurrently,25-37
with,38-42
oral,43-47	DrugDDI.d437.s13.e1
live,48-52	DrugDDI.d437.s13.e1
typhoid,53-60	DrugDDI.d437.s13.e1
vaccines,,61-70	DrugDDI.d437.s13.e1
attenuation,71-82
of,83-85
immunization,86-98
cannot,99-105
be,106-108
excluded.,109-118

Vaccinations,0-12
with,13-17
attenuated,18-28
live,29-33
bacteria,34-42
should,43-49
therefore,50-59
be,60-62
completed,63-72
at,73-75
least,76-81
3,82-83
days,84-88
before,89-95
the,96-99
first,100-105
dose,106-110
of,111-113
Mefloquine.,114-125	DrugDDI.d437.s14.e0

Nevertheless,,0-13
the,14-17
effects,18-25
of,26-28
Mefloquine,29-39	DrugDDI.d437.s16.e0
on,40-42
travelers,43-52
receiving,53-62
comedication,,63-76
particularly,77-89
diabetics,90-99
or,100-102
patients,103-111
using,112-117
anticoagulants,,118-133
should,134-140
be,141-143
checked,144-151
before,152-158
departure.,159-169

In,0-2
clinical,3-11
trials,,12-19
the,20-23
concomitant,24-35
administration,36-50
of,51-53
sulfadoxine,54-65	DrugDDI.d437.s17.e0
and,66-69
pyrimethamine,70-83	DrugDDI.d437.s17.e1
did,84-87
not,88-91
alter,92-97
the,98-101
adverse,102-109
reaction,110-118
profile.,119-127

Broad-Spectrum,0-14
Antibiotics-Broad-spectrum,15-41
antibiotics,42-53
may,54-57
sterilize,58-67
the,68-71
bowel,72-77
and,78-81
decrease,82-90
the,91-94
vitamin,95-102	DrugDDI.d441.s0.e0
K,103-104	DrugDDI.d441.s0.e0
contribution,105-117
to,118-120
the,121-124
body,125-129
by,130-132
the,133-136
intestinal,137-147
microflora.,148-159

Cephalosporins-Cephalosporins,0-29	DrugDDI.d441.s1.e0
containing,30-40
side,41-45
chains,46-52
of,53-55
N-methylthiotetrazole,56-77
(cefmenoxime,,78-91
cefoperazone,,92-105
cefotetan,,106-116
cefamandole,,117-129
latamoxef),130-140	DrugDDI.d441.s1.e5
or,141-143
methylthiadiazole,144-161
(cefazolin),162-173
can,174-177
cause,178-183
vitamin,184-191
K,192-193
deficiency,194-204
and,205-208
hypoprothrombinemia.,209-229

These,0-5
cephalosporins,6-20	DrugDDI.d441.s2.e0
are,21-24
inhibitors,25-35
of,36-38
hepatic,39-46
vitamin,47-54	DrugDDI.d441.s2.e1
K,55-56	DrugDDI.d441.s2.e1
epoxide,57-64	DrugDDI.d441.s2.e1
reductase.,65-75	DrugDDI.d441.s2.e1

Cholestyramine-Concomitant,0-26	DrugDDI.d441.s3.e0
intake,27-33
of,34-36
cholestyramine,37-51	DrugDDI.d441.s3.e1
and,52-55
vitamin,56-63	DrugDDI.d441.s3.e2
K,64-65	DrugDDI.d441.s3.e2
may,66-69
reduce,70-76
the,77-80
absorption,81-91
of,92-94
vitamin,95-102	DrugDDI.d441.s3.e3
K.,103-105	DrugDDI.d441.s3.e3

Colestipol-Concomitant,0-22	DrugDDI.d441.s4.e0
intake,23-29
of,30-32
colestipol,33-43	DrugDDI.d441.s4.e1
and,44-47
vitamin,48-55	DrugDDI.d441.s4.e2
K,56-57	DrugDDI.d441.s4.e2
may,58-61
reduce,62-68
the,69-72
absorption,73-83
of,84-86
vitamin,87-94	DrugDDI.d441.s4.e3
K.,95-97	DrugDDI.d441.s4.e3

Mineral,0-7	DrugDDI.d441.s5.e0
Oil-Concomitant,8-23	DrugDDI.d441.s5.e0
intake,24-30
of,31-33
mineral,34-41	DrugDDI.d441.s5.e1
oil,42-45	DrugDDI.d441.s5.e1
and,46-49
vitamin,50-57	DrugDDI.d441.s5.e2
K,58-59	DrugDDI.d441.s5.e2
may,60-63
reduce,64-70
the,71-74
absorption,75-85
of,86-88
vitamin,89-96	DrugDDI.d441.s5.e3
K.,97-99	DrugDDI.d441.s5.e3

Orlistat-Orlistat,0-17	DrugDDI.d441.s6.e0
may,18-21
decrease,22-30
the,31-34
absorption,35-45
of,46-48
vitamin,49-56	DrugDDI.d441.s6.e1
K.,57-59	DrugDDI.d441.s6.e1

Salicylates-Salicylates,0-23	DrugDDI.d441.s7.e0
in,24-26
large,27-32
doses,33-38
may,39-42
inhibit,43-50
vitamin,51-58	DrugDDI.d441.s7.e1
K,59-60	DrugDDI.d441.s7.e1
epoxide,61-68	DrugDDI.d441.s7.e1
reductase,69-78	DrugDDI.d441.s7.e1
resulting,79-88
in,89-91
vitamin,92-99
K,100-101
deficiency.,102-113

Warfarin-Vitamin,0-16
K,17-18
can,19-22
antagonize,23-33
the,34-37
effect,38-44
of,45-47
warfarin,48-56	DrugDDI.d441.s8.e1

Nabilone,0-8	DrugDDI.d292.s0.e0
should,9-15
be,16-18
administered,19-31
with,32-36
caution,37-44
to,45-47
patients,48-56
who,57-60
are,61-64
taking,65-71
other,72-77
psychoactive,78-90	DrugDDI.d292.s0.e1
drugs,91-96	DrugDDI.d292.s0.e1
or,97-99
CNS,100-103	DrugDDI.d292.s0.e2
depressants,,104-116	DrugDDI.d292.s0.e2
including,117-126
alcohol,,127-135
barbiturates,136-148	DrugDDI.d292.s0.e4
and,149-152
narcotic,153-161	DrugDDI.d292.s0.e5
analgesics,,162-173	DrugDDI.d292.s0.e5
or,174-176
to,177-179
those,180-185
with,186-190
a,191-192
history,193-200
of,201-203
psychiatric,204-215
disorder,216-224
(including,225-235
manic-depressive,236-252
illness,253-260
and,261-264
schizophrenia).,265-280

Nabilone,0-8	DrugDDI.d292.s1.e0
has,9-12
been,13-17
shown,18-23
to,24-26
have,27-31
an,32-34
additive,35-43
CNS,44-47	DrugDDI.d292.s1.e1
depressant,48-58	DrugDDI.d292.s1.e1
effect,59-65
when,66-70
given,71-76
with,77-81
either,82-88
diazepam,,89-98
secobarbitone,99-112
sodium,,113-120
alcohol,121-128	DrugDDI.d292.s1.e4
or,129-131
codeine.,132-140	DrugDDI.d292.s1.e5

In,0-2
vitro,3-8
studies,9-16
have,17-21
shown,22-27
that,,28-33
because,34-41
of,42-44
its,45-48
affinity,49-57
for,58-61
protein,,62-70
6MNA,71-75	DrugDDI.d491.s0.e1
may,76-79
displace,80-88
other,89-94
protein-bound,95-108	DrugDDI.d491.s0.e2
drugs,109-114
from,115-119
their,120-125
binding,126-133
site.,134-139

Caution,0-7
should,8-14
be,15-17
exercised,18-27
when,28-32
administering,33-46
nabumetone,47-57	DrugDDI.d491.s1.e0
with,58-62
warfarin,63-71	DrugDDI.d491.s1.e1
since,72-77
interactions,78-90
have,91-95
been,96-100
seen,101-105
with,106-110
other,111-116
NSAIDs.,117-124	DrugDDI.d491.s1.e2

Concomitant,0-11
administration,12-26
of,27-29
an,30-32
aluminum-containing,33-52	DrugDDI.d491.s2.e0
antacid,53-60	DrugDDI.d491.s2.e0
had,61-64
no,65-67
significant,68-79
effect,80-86
in,87-89
the,90-93
bioavailability,94-109
of,110-112
6MNA.,113-118	DrugDDI.d491.s2.e1

however,,0-8
the,9-12
total,13-18
amount,19-25
of,26-28
6MNA,29-33	DrugDDI.d491.s4.e0
in,34-36
the,37-40
plasma,41-47
is,48-50
unchanged,51-60
.,61-62

When,0-4
administered,5-17
concurrently,,18-31
the,32-35
following,36-45
drugs,46-51	DrugDDI.d24.s0.e0
may,52-55
interact,56-64
with,65-69
beta-adrenergic,70-85	DrugDDI.d24.s0.e1
receptor,86-94	DrugDDI.d24.s0.e1
blocking,95-103	DrugDDI.d24.s0.e1
agents:,104-111	DrugDDI.d24.s0.e1
Anesthetics,,112-124
general:,125-133
exaggeration,134-146
of,147-149
the,150-153
hypotension,154-165
induced,166-173
by,174-176
general,177-184	DrugDDI.d24.s0.e3
anesthetics.,185-197	DrugDDI.d24.s0.e3

Antidiabetic,0-12	DrugDDI.d24.s1.e0
drugs,13-18	DrugDDI.d24.s1.e0
(oral,19-24
agents,25-31
and,32-35
insulin):,36-45	DrugDDI.d24.s1.e1
hypoglycemia,46-58
or,59-61
hyperglycemia;,62-76

adjust,0-6
dosage,7-13
of,14-16
antidiabetic,17-29	DrugDDI.d24.s2.e0
drug,30-34	DrugDDI.d24.s2.e0
accordingly.,35-47

Catecholamine-depleting,0-23
drugs,24-29	DrugDDI.d24.s3.e0
(e.g.,,30-36
reserpine):,37-48	DrugDDI.d24.s3.e1
additive,49-57
effect;,58-65

Response,0-8
to,9-11
Treatment,12-21
for,22-25
Anaphylactic,26-38
Reaction:,39-48
While,49-54
taking,55-61
beta-blockers,,62-76
patients,77-85
with,86-90
a,91-92
history,93-100
of,101-103
severe,104-110
anaphylactic,111-123
reaction,124-132
to,133-135
a,136-137
variety,138-145
of,146-148
allergens,149-158
may,159-162
be,163-165
more,166-170
reactive,171-179
to,180-182
repeated,183-191
challenge,,192-202
either,203-209
accidental,,210-221
diagnostic,,222-233
or,234-236
therapeutic.,237-249

Such,0-4
patients,5-13
may,14-17
be,18-20
unresponsive,21-33
to,34-36
the,37-40
usual,41-46
doses,47-52
of,53-55
epinephrine,56-67	DrugDDI.d24.s6.e0
used,68-72
to,73-75
treat,76-81
allergic,82-90
reaction.,91-100

No,0-2
pharmacokinetic-based,3-24
drug-drug,25-34
interaction,35-46
studies,47-54
have,55-59
been,60-64
conducted,65-74
with,75-79
SYNAREL.,80-88	DrugDDI.d16.s0.e0

However,,0-8
because,9-16
nafarelin,17-26	DrugDDI.d16.s1.e0
acetate,27-34	DrugDDI.d16.s1.e0
is,35-37
a,38-39
peptide,40-47	DrugDDI.d16.s1.e1
that,48-52
is,53-55
primarily,56-65
degraded,66-74
by,75-77
peptidase,78-87	DrugDDI.d16.s1.e2
and,88-91
not,92-95
by,96-98
cytochrome,99-109	DrugDDI.d16.s1.e3
P-450,110-115	DrugDDI.d16.s1.e3
enzymes,,116-124
and,125-128
the,129-132
drug,133-137	DrugDDI.d16.s1.e4
is,138-140
only,141-145
about,146-151
80%,152-155
bound,156-161
to,162-164
plasma,165-171	DrugDDI.d16.s1.e5
proteins,172-180	DrugDDI.d16.s1.e5
at,181-183
4?C,,184-188
drug,189-193
interactions,194-206
would,207-212
not,213-216
be,217-219
expected,220-228
to,229-231
occur.,232-238

Tetracycline,,0-13
a,14-15
bacteriostatic,16-30	DrugDDI.d129.s0.e1
antibiotic,,31-42
may,43-46
antagonize,47-57
the,58-61
bactericidal,62-74
effect,75-81
of,82-84
penicillin,85-95	DrugDDI.d129.s0.e2
and,96-99
concurrent,100-110
use,111-114
of,115-117
these,118-123
drugs,124-129	DrugDDI.d129.s0.e3
should,130-136
be,137-139
avoided.,140-148

Elevated,0-8
plasma,9-15
levels,16-22
of,23-25
theophylline,26-38	DrugDDI.d275.s0.e0
have,39-43
been,44-48
reported,49-57
with,58-62
concomitant,63-74
quinolone,75-84	DrugDDI.d275.s0.e1
use.,85-89

There,0-5
have,6-10
been,11-15
reports,16-23
of,24-26
theophylline-related,27-47	DrugDDI.d275.s1.e0
side,48-52
effects,53-60
in,61-63
patients,64-72
on,73-75
concomitant,76-87
therapy,88-95
with,96-100
quinolones,101-111	DrugDDI.d275.s1.e1
and,112-115
theophylline.,116-129	DrugDDI.d275.s1.e2

Therefore,,0-10
monitoring,11-21
of,22-24
theophylline,25-37	DrugDDI.d275.s2.e0
plasma,38-44
levels,45-51
should,52-58
be,59-61
considered,62-72
and,73-76
dosage,77-83
of,84-86
theophylline,87-99
adjusted,,100-109
as,110-112
required.,113-122

Quinolones,0-10	DrugDDI.d275.s3.e0
have,11-15
been,16-20
shown,21-26
to,27-29
interfere,30-39
with,40-44
the,45-48
metabolism,49-59
of,60-62
caffeine.,63-72	DrugDDI.d275.s3.e1

This,0-4
may,5-8
lead,9-13
to,14-16
reduced,17-24
clearance,25-34
of,35-37
caffeine,38-46	DrugDDI.d275.s4.e0
and,47-50
the,51-54
prolongation,55-67
of,68-70
its,71-74
plasma,75-81
half-life.,82-92

Quinolones,,0-11
including,12-21
nalidixic,22-31	DrugDDI.d275.s5.e1
acid,,32-37	DrugDDI.d275.s5.e1
may,38-41
enhance,42-49
the,50-53
effects,54-61
of,62-64
the,65-68
oral,69-73	DrugDDI.d275.s5.e2
anticoagulant,74-87	DrugDDI.d275.s5.e2
warfarin,88-96	DrugDDI.d275.s5.e2
or,97-99
its,100-103
derivatives.,104-116	DrugDDI.d275.s5.e3

Nitrofurantoin,0-14	DrugDDI.d275.s7.e0
interferes,15-25
with,26-30
the,31-34
therapeutic,35-46
action,47-53
of,54-56
nalidixic,57-66	DrugDDI.d275.s7.e1
acid.,67-72	DrugDDI.d275.s7.e1

Antacids,0-8	DrugDDI.d275.s8.e0
containing,9-19
magnesium,,20-30
aluminum,,31-40
or,41-43
calcium;,44-52	DrugDDI.d275.s8.e2

sucralfate,0-10	DrugDDI.d275.s9.e0
or,11-13
divalent,14-22
or,23-25
trivalent,26-35
cations,36-43	DrugDDI.d275.s9.e1
such,44-48
as,49-51
iron;,52-57	DrugDDI.d275.s9.e2

multivitamins,0-13	DrugDDI.d275.s10.e0
containing,14-24
zinc;,25-30	DrugDDI.d275.s10.e1

and,0-3
Videx?,,4-11
(Didanosine),,12-25
chewable/buffered,26-43
tablets,44-51
or,52-54
the,55-58
pediatric,59-68	DrugDDI.d275.s11.e2
powder,69-75
for,76-79
oral,80-84
solution,85-93
may,94-97
substantially,98-111
interfere,112-121
with,122-126
the,127-130
absorption,131-141
of,142-144
quinolones,,145-156
resulting,157-166
in,167-169
systemic,170-178
levels,179-185
considerably,186-198
lower,199-204
than,205-209
desired.,210-218

These,0-5
agents,6-12
should,13-19
not,20-23
be,24-26
taken,27-32
within,33-39
the,40-43
two,44-47
hour,48-52
period,53-59
before,60-66
or,67-69
within,70-76
the,77-80
two-hour,81-89
period,90-96
after,97-102
nalidixic,103-112	DrugDDI.d275.s12.e0
acid,113-117	DrugDDI.d275.s12.e0
administration.,118-133

Elevated,0-8
serum,9-14
levels,15-21
of,22-24
cyclosporine,25-37	DrugDDI.d275.s13.e0
have,38-42
been,43-47
reported,48-56
with,57-61
the,62-65
concomitant,66-77
use,78-81
of,82-84
some,85-89
quinolones,90-100	DrugDDI.d275.s13.e1
and,101-104
cyclosporine.,105-118	DrugDDI.d275.s13.e2

Therefore,,0-10
cyclosporine,11-23	DrugDDI.d275.s14.e0
serum,24-29
levels,30-36
should,37-43
be,44-46
monitored,47-56
and,57-60
appropriate,61-72
cyclosporine,73-85	DrugDDI.d275.s14.e1
dosage,86-92
adjustments,93-104
made,105-109
when,110-114
these,115-120
drugs,121-126	DrugDDI.d275.s14.e2
are,127-130
used,131-135
concomitantly.,136-150

Studies,0-7
to,8-10
evaluate,11-19
possible,20-28
interactions,29-41
between,42-49
REVIA,50-55	DrugDDI.d179.s0.e0
and,56-59
drugs,60-65	DrugDDI.d179.s0.e1
other,66-71
than,72-76
opiates,77-84	DrugDDI.d179.s0.e2
have,85-89
not,90-93
been,94-98
performed.,99-109

Consequently,,0-13
caution,14-21
is,22-24
advised,25-32
if,33-35
the,36-39
concomitant,40-51
administration,52-66
of,67-69
REVIA,70-75	DrugDDI.d179.s1.e0
and,76-79
other,80-85
drugs,86-91	DrugDDI.d179.s1.e1
is,92-94
required.,95-104

The,0-3
safety,4-10
and,11-14
efficacy,15-23
of,24-26
concomitant,27-38
use,39-42
of,43-45
REVIA,46-51	DrugDDI.d179.s2.e0
and,52-55
disulfiram,56-66	DrugDDI.d179.s2.e1
is,67-69
unknown,,70-78
and,79-82
the,83-86
concomitant,87-98
use,99-102
of,103-105
two,106-109
potentially,110-121
hepatotoxic,122-133
medications,134-145	DrugDDI.d179.s2.e2
is,146-148
not,149-152
ordinarily,153-163
recommended,164-175
unless,176-182
the,183-186
probable,187-195
benefits,196-204
outweigh,205-213
the,214-217
known,218-223
risks.,224-230

Lethargy,0-8
and,9-12
somnolence,13-23
have,24-28
been,29-33
reported,34-42
following,43-52
doses,53-58
of,59-61
REVIA,62-67	DrugDDI.d179.s3.e0
and,68-71
thioridazine.,72-85	DrugDDI.d179.s3.e1

Patients,0-8
taking,9-15
REVIA,16-21	DrugDDI.d179.s4.e0
may,22-25
not,26-29
benefit,30-37
from,38-42
opioid,43-49	DrugDDI.d179.s4.e1
containing,50-60
medicines,,61-71
such,72-76
as,77-79
cough,80-85
and,86-89
cold,90-94
preparations,,95-108
antidiarrheal,109-122
preparations,,123-136
and,137-140
opioid,141-147	DrugDDI.d179.s4.e2
analgesics.,148-159	DrugDDI.d179.s4.e2

In,0-2
an,3-5
emergency,6-15
situation,16-25
when,26-30
opioid,31-37	DrugDDI.d179.s5.e0
analgesia,38-47
must,48-52
be,53-55
administered,56-68
to,69-71
a,72-73
patient,74-81
receiving,82-91
REVIA,,92-98
the,99-102
amount,103-109
of,110-112
opioid,113-119	DrugDDI.d179.s5.e2
required,120-128
may,129-132
be,133-135
greater,136-143
than,144-148
usual,,149-155
and,156-159
the,160-163
resulting,164-173
respiratory,174-185
depression,186-196
may,197-200
be,201-203
deeper,204-210
and,211-214
more,215-219
prolonged.,220-230

The,0-3
use,4-7
of,8-10
NSAIDs,11-17	DrugDDI.d159.s0.e0
in,18-20
patients,21-29
who,30-33
are,34-37
receiving,38-47
ACE,48-51	DrugDDI.d159.s0.e1
inhibitors,52-62	DrugDDI.d159.s0.e1
may,63-66
potentiate,67-77
renal,78-83
disease,84-91
states.,92-99

In,0-2
vitro,3-8
studies,9-16
have,17-21
shown,22-27
that,28-32
naproxen,33-41	DrugDDI.d159.s1.e0
anion,,42-48
because,49-56
of,57-59
its,60-63
affinity,64-72
for,73-76
protein,,77-85
may,86-89
displace,90-98
from,99-103
their,104-109
binding,110-117
sites,118-123
other,124-129
drugs,130-135	DrugDDI.d159.s1.e2
which,136-141
are,142-145
also,146-150
albumin-bound,151-164	DrugDDI.d159.s1.e3
.,165-166

Theoretically,,0-14
the,15-18
naproxen,19-27	DrugDDI.d159.s2.e0
anion,28-33
itself,34-40
could,41-46
likewise,47-55
be,56-58
displaced.,59-69

Short-term,0-10
controlled,11-21
studies,22-29
failed,30-36
to,37-39
show,40-44
that,45-49
taking,50-56
the,57-60
drug,61-65	DrugDDI.d159.s3.e0
significantly,66-79
affects,80-87
prothrombin,88-99
times,100-105
when,106-110
administered,111-123
to,124-126
individuals,127-138
on,139-141
coumarin-type,142-155	DrugDDI.d159.s3.e1
anticoagulants.,156-171	DrugDDI.d159.s3.e1

Similarly,,0-10
patients,11-19
receiving,20-29
the,30-33
drug,34-38	DrugDDI.d159.s5.e0
and,39-42
a,43-44
hydantoin,,45-55
sulfonamide,56-67	DrugDDI.d159.s5.e2
or,68-70
sulfonylurea,71-83	DrugDDI.d159.s5.e3
should,84-90
be,91-93
observed,94-102
for,103-106
signs,107-112
of,113-115
toxicity,116-124
to,125-127
these,128-133
drugs.,134-140	DrugDDI.d159.s5.e4

Concomitant,0-11
administration,12-26
of,27-29
naproxen,30-38	DrugDDI.d159.s6.e0
and,39-42
aspirin,43-50	DrugDDI.d159.s6.e1
is,51-53
not,54-57
recommended,58-69
because,70-77
naproxen,78-86	DrugDDI.d159.s6.e2
is,87-89
displaced,90-99
from,100-104
its,105-108
binding,109-116
sites,117-122
during,123-129
the,130-133
concomitant,134-145
administration,146-160
of,161-163
aspirin,,164-172
resulting,173-182
in,183-185
lower,186-191
plasma,192-198
concentrations,199-213
and,214-217
peak,218-222
plasma,223-229
levels.,230-237

The,0-3
natriuretic,4-15	DrugDDI.d159.s7.e0
effect,16-22
of,23-25
furosemide,26-36	DrugDDI.d159.s7.e1
has,37-40
been,41-45
reported,46-54
to,55-57
be,58-60
inhibited,61-70
by,71-73
some,74-78
drugs,79-84	DrugDDI.d159.s7.e2
of,85-87
this,88-92
class.,93-99

Inhibition,0-10
of,11-13
renal,14-19
lithium,20-27	DrugDDI.d159.s8.e0
clearance,28-37
leading,38-45
to,46-48
increases,49-58
in,59-61
plasma,62-68
lithium,69-76	DrugDDI.d159.s8.e1
concentrations,77-91
has,92-95
also,96-100
been,101-105
reported.,106-115

Naproxen,0-8	DrugDDI.d159.s9.e0
and,9-12
other,13-18
NSAIDs,19-25	DrugDDI.d159.s9.e1
can,26-29
reduce,30-36
the,37-40
antihypertensive,41-57	DrugDDI.d159.s9.e2
effect,58-64
of,65-67
propranolol,68-79	DrugDDI.d159.s9.e3
and,80-83
other,84-89
beta-blockers.,90-104	DrugDDI.d159.s9.e4

Probenecid,0-10	DrugDDI.d159.s10.e0
given,11-16
concurrently,17-29
increases,30-39
naproxen,40-48	DrugDDI.d159.s10.e1
anion,49-54
plasma,55-61
levels,62-68
and,69-72
extends,73-80
its,81-84
plasma,85-91
half-life,92-101
significantly.,102-116

Caution,0-7
should,8-14
be,15-17
used,18-22
if,23-25
naproxen,26-34	DrugDDI.d159.s11.e0
is,35-37
administered,38-50
concomitantly,51-64
with,65-69
methotrexate.,70-83	DrugDDI.d159.s11.e1

Naproxen,,0-9
naproxen,10-18	DrugDDI.d159.s12.e1
sodium,19-25	DrugDDI.d159.s12.e1
and,26-29
other,30-35
NSAIDs,36-42	DrugDDI.d159.s12.e2
have,43-47
been,48-52
reported,53-61
to,62-64
reduce,65-71
the,72-75
tubular,76-83
secretion,84-93
of,94-96
methotrexate,97-109	DrugDDI.d159.s12.e3
in,110-112
an,113-115
animal,116-122
model,,123-129
possibly,130-138
increasing,139-149
the,150-153
toxicity,154-162
of,163-165
methotrexate.,166-179	DrugDDI.d159.s12.e4

Drug/Laboratory,0-15	DrugDDI.d159.s13.e0
Test,16-20
Interactions,21-33
Naproxen,34-42	DrugDDI.d159.s13.e1
may,43-46
decrease,47-55
platelet,56-64
aggregation,65-76
and,77-80
prolong,81-88
bleeding,89-97
time.,98-103

The,0-3
administration,4-18
of,19-21
naproxen,22-30	DrugDDI.d159.s15.e0
may,31-34
result,35-41
in,42-44
increased,45-54
urinary,55-62
values,63-69
for,70-73
17-ketogenic,74-86
steroids,87-95
because,96-103
of,104-106
an,107-109
interaction,110-121
between,122-129
the,130-133
drug,134-138	DrugDDI.d159.s15.e1
and/or,139-145
its,146-149
metabolites,150-161	DrugDDI.d159.s15.e2
with,162-166
m-dinitrobenzene,167-183
used,184-188
in,189-191
this,192-196
assay.,197-203

Although,0-8
17-hydroxy-corticosteroid,9-34
measurements,35-47
(Porter-Silber,48-62
test),63-68
do,69-71
not,72-75
appear,76-82
to,83-85
be,86-88
artifactually,89-102
altered,,103-111
it,112-114
is,115-117
suggested,118-127
that,128-132
therapy,133-140
with,141-145
naproxen,146-154	DrugDDI.d159.s16.e1
be,155-157
temporarily,158-169
discontinued,170-182
72,183-185
hours,186-191
before,192-198
adrenal,199-206	DrugDDI.d159.s16.e2
function,207-215
tests,216-221
are,222-225
performed,226-235
if,236-238
the,239-242
Porter-Silber,243-256
test,257-261
is,262-264
to,265-267
be,268-270
used.,271-276

Naproxen,0-8	DrugDDI.d159.s17.e0
may,9-12
interfere,13-22
with,23-27
some,28-32
urinary,33-40
assays,41-47
of,48-50
5-hydroxy,51-60
indoleacetic,61-73
acid,74-78
(5HIAA).,79-87

Ergot-containing,0-16
drugs,17-22	DrugDDI.d134.s0.e0
have,23-27
been,28-32
reported,33-41
to,42-44
cause,45-50
prolonged,51-60
vasospastic,61-72
reactions.,73-83

Because,0-7
there,8-13
is,14-16
a,17-18
theoretical,19-30
basis,31-36
that,37-41
these,42-47
effects,48-55
may,56-59
be,60-62
additive,,63-72
use,73-76
of,77-79
ergotamine-containing,80-101	DrugDDI.d134.s1.e0
or,102-104
ergot-type,105-115
medications,116-127	DrugDDI.d134.s1.e1
(like,128-133
dihydroergotamine,134-151	DrugDDI.d134.s1.e2
or,152-154
methysergide),155-168	DrugDDI.d134.s1.e3
and,169-172
naratriptan,173-184	DrugDDI.d134.s1.e4
within,185-191
24,192-194
hours,195-200
is,201-203
contraindicated.,204-220

The,0-3
administration,4-18
of,19-21
naratriptan,22-33	DrugDDI.d134.s2.e0
with,34-38
other,39-44
5-HT1,45-50
agonists,51-59	DrugDDI.d134.s2.e1
has,60-63
not,64-67
been,68-72
evaluated,73-82
in,83-85
migraine,86-94
patients.,95-104

Because,0-7
their,8-13
vasospastic,14-25
effects,26-33
may,34-37
be,38-40
additive,,41-50
coadministration,51-67
of,68-70
naratriptan,71-82	DrugDDI.d134.s3.e0
and,83-86
other,87-92
5-HT1,93-98
agonists,99-107	DrugDDI.d134.s3.e1
within,108-114
24,115-117
hours,118-123
of,124-126
each,127-131
other,132-137
is,138-140
not,141-144
recommended.,145-157

Selective,0-9
serotonin,10-19	DrugDDI.d134.s4.e0
reuptake,20-28	DrugDDI.d134.s4.e0
inhibitors,29-39	DrugDDI.d134.s4.e0
(SSRIs),40-47
(e.g.,,48-54
fluoxetine,,55-66
fluvoxamine,,67-79
paroxetine,,80-91
sertraline),92-103	DrugDDI.d134.s4.e4
have,104-108
been,109-113
reported,,114-123
rarely,,124-131
to,132-134
cause,135-140
weakness,,141-150
hyperreflexia,,151-165
and,166-169
incoordination,170-184
when,185-189
coadministered,190-204
with,205-209
5-HTv,210-215
agonists.,216-225	DrugDDI.d134.s4.e5

If,0-2
concomitant,3-14
treatment,15-24
with,25-29
naratriptan,30-41	DrugDDI.d134.s5.e0
and,42-45
an,46-48
SSRI,49-53
is,54-56
clinically,57-67
warranted,,68-78
appropriate,79-90
observation,91-102
of,103-105
the,106-109
patient,110-117
is,118-120
advised.,121-129

Drug/,0-5	DrugDDI.d134.s6.e0
Laboratory,6-16
Test,17-21
Interactions,22-34
AMERGE,35-41	DrugDDI.d134.s6.e1
Tablets,42-49
are,50-53
not,54-57
known,58-63
to,64-66
interfere,67-76
with,77-81
commonly,82-90
employed,91-99
clinical,100-108
laboratory,109-119
tests.,120-126

After,0-5
multiple,6-14
dosing,,15-22
interferon,23-33	DrugDDI.d301.s0.e0
beta-1a,34-41	DrugDDI.d301.s0.e0
(AVONEX?,42-50
30,51-53
mcg,54-57
IM,58-60
once,61-65
weekly),66-73
reduced,74-81
TYSABRI?,82-90
clearance,91-100
by,101-103
approximately,104-117
30%.,118-122

Results,0-7
of,8-10
studies,11-18
in,19-21
multiple,22-30
sclerosis,31-40
patients,41-49
taking,50-56
TYSABRI?,57-65
and,66-69
concomitant,70-81
interferon,82-92	DrugDDI.d301.s2.e0
beta-1a,93-100	DrugDDI.d301.s2.e0
(AVONEX?,101-109
30,110-112
mcg,113-116
IM,117-119
once,120-124
weekly),125-132
or,133-135
glatiramer,136-146	DrugDDI.d301.s2.e1
acetate,147-154	DrugDDI.d301.s2.e1
were,155-159
inconclusive,160-172
with,173-177
regard,178-184
to,185-187
the,188-191
need,192-196
for,197-200
dose,201-205
adjustment,206-216
of,217-219
the,220-223
beta-interferon,224-239	DrugDDI.d301.s2.e2
or,240-242
glatiramer,243-253	DrugDDI.d301.s2.e3
acetate.,254-262	DrugDDI.d301.s2.e3

In,0-2
vitro,3-8
drug,9-13
metabolism,14-24
studies,25-32
indicate,33-41
that,42-46
Starlix,47-54	DrugDDI.d400.s0.e0
is,55-57
predominantly,58-71
metabolized,72-83
by,84-86
the,87-90
cytochrome,91-101	DrugDDI.d400.s0.e1
P450,102-106	DrugDDI.d400.s0.e1
isozyme,107-114
CYP2C9,115-121
(70%),122-127
and,128-131
to,132-134
a,135-136
lesser,137-143
extent,144-150
CYP3A4,151-157	DrugDDI.d400.s0.e2
(30%).,158-164

Starlix,0-7	DrugDDI.d400.s1.e0
is,8-10
a,11-12
potential,13-22
inhibitor,23-32
of,33-35
the,36-39
CYP2C9,40-46	DrugDDI.d400.s1.e1
isoenzyme,47-56	DrugDDI.d400.s1.e1
in,57-59
vivo,60-64
as,65-67
indicated,68-77
by,78-80
its,81-84
ability,85-92
to,93-95
inhibit,96-103
the,104-107
in,108-110
vitro,111-116
metabolism,117-127
of,128-130
tolbutamide.,131-143	DrugDDI.d400.s1.e2

Inhibition,0-10
of,11-13
CYP3A4,14-20	DrugDDI.d400.s2.e0
metabolic,21-30
reactions,31-40
was,41-44
not,45-48
detected,49-57
in,58-60
in,61-63
vitro,64-69
experiments.,70-82

Glyburide:,0-10	DrugDDI.d400.s3.e0
In,11-13
a,14-15
randomized,,16-27
multiple-dose,28-41
crossover,42-51
study,,52-58
patients,59-67
with,68-72
Type,73-77
2,78-79
diabetes,80-88
were,89-93
administered,94-106
120,107-110
mg,111-113
Starlix,114-121	DrugDDI.d400.s3.e1
three,122-127
times,128-133
a,134-135
day,136-139
before,140-146
meals,147-152
for,153-156
1,157-158
day,159-162
in,163-165
combination,166-177
with,178-182
glyburide,183-192	DrugDDI.d400.s3.e2
10,193-195
mg,196-198
daily.,199-205

Metformin:,0-10	DrugDDI.d400.s5.e0
When,11-15
Starlix,16-23	DrugDDI.d400.s5.e1
120,24-27
mg,28-30
three,31-36
times,37-42
daily,43-48
before,49-55
meals,56-61
was,62-65
administered,66-78
in,79-81
combination,82-93
with,94-98
metformin,99-108	DrugDDI.d400.s5.e2
500,109-112	DrugDDI.d400.s5.e2
mg,113-115	DrugDDI.d400.s5.e2
three,116-121
times,122-127
daily,128-133
to,134-136
patients,137-145
with,146-150
Type,151-155
2,156-157
diabetes,,158-167
there,168-173
were,174-178
no,179-181
clinically,182-192
relevant,193-201
changes,202-209
in,210-212
the,213-216
pharmacokinetics,217-233
of,234-236
either,237-243
agent.,244-250

Digoxin:,0-8	DrugDDI.d400.s6.e0
When,9-13
Starlix,14-21	DrugDDI.d400.s6.e1
120,22-25
mg,26-28
before,29-35
meals,36-41
was,42-45
administered,46-58
in,59-61
combination,62-73
with,74-78
a,79-80
single,81-87
1-mg,88-92
dose,93-97
of,98-100
digoxin,101-108	DrugDDI.d400.s6.e2
to,109-111
healthy,112-119
volunteers,,120-131
there,132-137
were,138-142
no,143-145
clinically,146-156
relevant,157-165
changes,166-173
in,174-176
the,177-180
pharmacokinetics,181-197
of,198-200
either,201-207
agent.,208-214

Warfarin:,0-9	DrugDDI.d400.s7.e0
When,10-14
healthy,15-22
subjects,23-31
were,32-36
administered,37-49
Starlix,50-57	DrugDDI.d400.s7.e1
120,58-61
mg,62-64
three,65-70
times,71-76
daily,77-82
before,83-89
meals,90-95
for,96-99
four,100-104
days,105-109
in,110-112
combination,113-124
with,125-129
a,130-131
single,132-138
dose,139-143
of,144-146
warfarin,147-155	DrugDDI.d400.s7.e2
30,156-158
mg,159-161
on,162-164
day,165-168
2,,169-171
there,172-177
were,178-182
no,183-185
alterations,186-197
in,198-200
the,201-204
pharmacokinetics,205-221
of,222-224
either,225-231
agent.,232-238

Diclofenac:,0-11	DrugDDI.d400.s9.e0
Administration,12-26
of,27-29
morning,30-37
and,38-41
lunch,42-47
doses,48-53
of,54-56
Starlix,57-64	DrugDDI.d400.s9.e1
120,65-68
mg,69-71
in,72-74
combination,75-86
with,87-91
a,92-93
single,94-100
75-mg,101-106
dose,107-111
of,112-114
diclofenac,115-125	DrugDDI.d400.s9.e2
in,126-128
healthy,129-136
volunteers,137-147
resulted,148-156
in,157-159
no,160-162
significant,163-174
changes,175-182
to,183-185
the,186-189
pharmacokinetics,190-206
of,207-209
either,210-216
agent.,217-223

Nateglinide,0-11	DrugDDI.d400.s10.e0
is,12-14
highly,15-21
bound,22-27
to,28-30
plasma,31-37	DrugDDI.d400.s10.e1
proteins,38-46	DrugDDI.d400.s10.e1
(98%),,47-53
mainly,54-60
albumin.,61-69	DrugDDI.d400.s10.e2

In,0-2
vitro,3-8
displacement,9-21
studies,22-29
with,30-34
highly,35-41
protein-bound,42-55	DrugDDI.d400.s11.e0
drugs,56-61
such,62-66
as,67-69
furosemide,,70-81
propranolol,,82-94
captopril,,95-105
nicardipine,,106-118
pravastatin,,119-131
glyburide,,132-142
warfarin,,143-152
phenytoin,,153-163
acetylsalicylic,164-179	DrugDDI.d400.s11.e9
acid,,180-185	DrugDDI.d400.s11.e9
tolbutamide,,186-198
and,199-202
metformin,203-212	DrugDDI.d400.s11.e11
showed,213-219
no,220-222
influence,223-232
on,233-235
the,236-239
extent,240-246
of,247-249
nateglinide,250-261	DrugDDI.d400.s11.e12
protein,262-269
binding.,270-278

Similarly,,0-10
nateglinide,11-22	DrugDDI.d400.s12.e0
had,23-26
no,27-29
influence,30-39
on,40-42
the,43-46
serum,47-52
protein,53-60	DrugDDI.d400.s12.e1
binding,61-68	DrugDDI.d400.s12.e1
of,69-71
propranolol,,72-84
glyburide,,85-95
nicardipine,,96-108
warfarin,,109-118
phenytoin,,119-129
acetylsalicylic,130-145	DrugDDI.d400.s12.e7
acid,,146-151	DrugDDI.d400.s12.e7
and,152-155
tolbutamide,156-167	DrugDDI.d400.s12.e8
in,168-170
vitro,171-176
.,177-178

Certain,0-7
drugs,,8-14
including,15-24
nonsteroidal,25-37	DrugDDI.d400.s14.e1
anti-inflammatory,38-55	DrugDDI.d400.s14.e1
agents,56-62	DrugDDI.d400.s14.e1
(NSAIDs),,63-72
salicylates,,73-85
monoamine,86-95	DrugDDI.d400.s14.e4
oxidase,96-103	DrugDDI.d400.s14.e4
inhibitors,,104-115	DrugDDI.d400.s14.e4
and,116-119
non-selective,120-133	DrugDDI.d400.s14.e5
beta-adrenergic-blocking,134-158	DrugDDI.d400.s14.e5
agents,159-165	DrugDDI.d400.s14.e5
may,166-169
potentiate,170-180
the,181-184
hypoglycemic,185-197	DrugDDI.d400.s14.e6
action,198-204	DrugDDI.d400.s14.e6
of,205-207
Starlix,208-215	DrugDDI.d400.s14.e7
and,216-219
other,220-225
oral,226-230
antidiabetic,231-243	DrugDDI.d400.s14.e8
drugs.,244-250	DrugDDI.d400.s14.e8

Certain,0-7
drugs,8-13	DrugDDI.d400.s15.e0
including,14-23
thiazides,,24-34
corticosteroids,,35-51
thyroid,52-59	DrugDDI.d400.s15.e3
products,,60-69
and,70-73
sympathomimetics,74-90	DrugDDI.d400.s15.e4
may,91-94
reduce,95-101
the,102-105
hypoglycemic,106-118	DrugDDI.d400.s15.e5
action,119-125	DrugDDI.d400.s15.e5
of,126-128
Starlix,129-136	DrugDDI.d400.s15.e6
and,137-140
other,141-146
oral,147-151
antidiabetic,152-164	DrugDDI.d400.s15.e7
drugs.,165-171	DrugDDI.d400.s15.e7

When,0-4
these,5-10
drugs,11-16	DrugDDI.d400.s16.e0
are,17-20
administered,21-33
to,34-36
or,37-39
withdrawn,40-49
from,50-54
patients,55-63
receiving,64-73
Starlix,,74-82
the,83-86
patient,87-94
should,95-101
be,102-104
observed,105-113
closely,114-121
for,122-125
changes,126-133
in,134-136
glycemic,137-145
control.,146-154

In,0-2
clinical,3-11
studies,,12-20
Tilade,21-27	DrugDDI.d193.s0.e0
has,28-31
been,32-36
co-administered,37-52
with,53-57
other,58-63
anti-asthma,64-75	DrugDDI.d193.s0.e1
medications,,76-88	DrugDDI.d193.s0.e1
including,89-98
inhaled,99-106
and,107-110
oral,111-115
bronchodilators,,116-132
and,133-136
inhaled,137-144
corticosteroids,,145-161
with,162-166
no,167-169
evidence,170-178
of,179-181
increased,182-191
frequency,192-201
of,202-204
adverse,205-212
events,213-219
or,220-222
laboratory,223-233
abnormalities.,234-248

Nelfinavir,0-10	DrugDDI.d401.s0.e0
is,11-13
an,14-16
inhibitor,17-26
of,27-29
CYP3A,30-35	DrugDDI.d401.s0.e1
(cytochrome,36-47
P450,48-52
3A).,53-57

Coadministration,0-16
of,17-19
VIRACEPT,20-28	DrugDDI.d401.s1.e0
and,29-32
drugs,33-38	DrugDDI.d401.s1.e1
primarily,39-48
metabolized,49-60
by,61-63
CYP3A,64-69	DrugDDI.d401.s1.e2
(e.g.,,70-76
dihydropyridine,77-92
calcium,93-100	DrugDDI.d401.s1.e3
channel,101-108	DrugDDI.d401.s1.e3
blockers),109-118	DrugDDI.d401.s1.e3
may,119-122
result,123-129
in,130-132
increased,133-142
plasma,143-149
concentrations,150-164
of,165-167
the,168-171
other,172-177
drug,178-182	DrugDDI.d401.s1.e4
that,183-187
could,188-193
increase,194-202
or,203-205
prolong,206-213
both,214-218
its,219-222
therapeutic,223-234
and,235-238
adverse,239-246
effects.,247-255

Nelfinavir,0-10	DrugDDI.d401.s2.e0
is,11-13
metabolized,14-25
in,26-28
proof,29-34
by,35-37
C.P.A.,38-44

Coadministration,0-16
of,17-19
VIRACEPT,20-28	DrugDDI.d401.s3.e0
and,29-32
drugs,33-38	DrugDDI.d401.s3.e1
that,39-43
induce,44-50
CYP3A,51-56	DrugDDI.d401.s3.e2
may,57-60
decrease,61-69
nelfinavir,70-80	DrugDDI.d401.s3.e3
plasma,81-87
concentrations,88-102
and,103-106
reduce,107-113
its,114-117
therapeutic,118-129
effect.,130-137

Coadministration,0-16
of,17-19
VIRACEPT,20-28	DrugDDI.d401.s4.e0
and,29-32
drugs,33-38	DrugDDI.d401.s4.e1
that,39-43
inhibit,44-51
CYP3A,52-57	DrugDDI.d401.s4.e2
may,58-61
increase,62-70
nelfinavir,71-81	DrugDDI.d401.s4.e3
plasma,82-88
concentrations.,89-104

Based,0-5
on,6-8
known,9-14
metabolic,15-24
profiles,,25-34
clinically,35-45
significant,46-57
drug,58-62
interactions,63-75
are,76-79
not,80-83
expected,84-92
between,93-100
VIRACEPT,101-109	DrugDDI.d401.s5.e0
and,110-113
dapsone,,114-122
trimethoprim/sulfamethoxazole,,123-153
clarithromycin,,154-169
erythromycin,,170-183
itraconazole,184-196	DrugDDI.d401.s5.e6
or,197-199
fluconazole.,200-212	DrugDDI.d401.s5.e7

Drugs,0-5	DrugDDI.d401.s6.e0
That,6-10
Should,11-17
Not,18-21
Be,22-24
Coadministered,25-39
With,40-44
VIRACEPT,45-53	DrugDDI.d401.s6.e1
Antiarrhythmics:,54-70
amiodarone,,71-82
quinidine,83-92	DrugDDI.d401.s6.e3
Antihistamines:,93-108
astemizole,,109-120
terfenadine,121-132	DrugDDI.d401.s6.e5
Antimigraine:,133-146
ergot,147-152	DrugDDI.d401.s6.e6
derivatives,153-164	DrugDDI.d401.s6.e6
Antimycobacterial,165-182
agents:,183-190
rifampin,191-199	DrugDDI.d401.s6.e7
Benzodiazepines,200-215
midazolam,,216-226
triazolam,227-236	DrugDDI.d401.s6.e8
GI,237-239
motility,240-248
agents:,249-256
cisapride,257-266	DrugDDI.d401.s6.e9

Drugs,0-5	DrugDDI.d401.s7.e0
Which,6-11
Require,12-19
a,20-21
Dose,22-26
Reduction,27-36
When,37-41
Coadminstered,42-55
With,56-60
VIRACEPT,61-69	DrugDDI.d401.s7.e1
Antimycobacterial,70-87
agents:,88-95
rifabutin,96-105	DrugDDI.d401.s7.e2

Other,0-5
Potentially,6-17
Clinically,18-28
Significant,29-40
Drug,41-45
Interactions,46-58
With,59-63
VIRACEPT*,64-73	DrugDDI.d401.s8.e0
Anticonvulsants:,74-90
carbamazepine,,91-105
phenobarbital,,106-120
phenytoin,121-130	DrugDDI.d401.s8.e3
May,131-134
decrease,135-143
nelfinavir,144-154	DrugDDI.d401.s8.e4
plasma,155-161
concentrations**,162-178
Anti-HIV,179-187
protease,188-196
inhibitors:,197-208
indinavir,,209-219
ritonavir,220-229	DrugDDI.d401.s8.e6
May,230-233
increase,234-242
nelfinavir,243-253	DrugDDI.d401.s8.e7
plasma,254-260
concentrations,261-275
Oral,276-280
contraceptives:,281-296
ethinyl,297-304	DrugDDI.d401.s8.e8
estradiol,,305-315	DrugDDI.d401.s8.e8
norethindrone,316-329	DrugDDI.d401.s8.e9
Plasma,330-336
concentrations,337-351
may,352-355
be,356-358
decreased,359-368
by,369-371
VIRACEPT,372-380	DrugDDI.d401.s8.e10

*,0-1
This,2-6
table,7-12
is,13-15
not,16-19
all,20-23
inclusive,24-33
**,34-36
VIRACEPT,37-45	DrugDDI.d401.s9.e0
may,46-49
not,50-53
be,54-56
effective,57-66
due,67-70
to,71-73
decreased,74-83
nelfinavir,84-94	DrugDDI.d401.s9.e1
plasma,95-101
concentrations,102-116
in,117-119
patients,120-128
taking,129-135
these,136-141
agents,142-148
concomitantly,149-162

Antihistamines,0-14	DrugDDI.d401.s10.e0

Terfenadine:,0-12	DrugDDI.d401.s11.e0
Administration,13-27
of,28-30
terfenadine,31-42	DrugDDI.d401.s11.e1
with,43-47
VIRACEPT,48-56	DrugDDI.d401.s11.e2
resulted,57-65
in,66-68
the,69-72
appearance,73-83
of,84-86
unchanged,87-96
terfenadine,97-108	DrugDDI.d401.s11.e3
in,109-111
plasma;,112-119

therefore,,0-10
VIRACEPT,11-19	DrugDDI.d401.s12.e0
should,20-26
not,27-30
be,31-33
administered,34-46
concurrently,47-59
with,60-64
terfenadine,65-76	DrugDDI.d401.s12.e1
because,77-84
of,85-87
the,88-91
potential,92-101
for,102-105
serious,106-113
and/or,114-120
life-threatening,121-137
cardiac,138-145
arrhythmias.,146-158

Because,0-7
a,8-9
similar,10-17
interaction,18-29
is,30-32
likely,,33-40
VIRACEPT,41-49	DrugDDI.d401.s13.e0
should,50-56
also,57-61
not,62-65
be,66-68
administered,69-81
concurrently,82-94
with,95-99
astemizole.,100-111	DrugDDI.d401.s13.e1

Anti-HIV,0-8	DrugDDI.d401.s14.e0
Protease,9-17	DrugDDI.d401.s14.e0
Inhibitors,18-28	DrugDDI.d401.s14.e0

Indinavir:,0-10	DrugDDI.d401.s15.e0
Coadministration,11-27
of,28-30
indinavir,31-40	DrugDDI.d401.s15.e1
with,41-45
VIRACEPT,46-54	DrugDDI.d401.s15.e2
resulted,55-63
in,64-66
an,67-69
83%,70-73
increase,74-82
in,83-85
nelfinavir,86-96	DrugDDI.d401.s15.e3
plasma,97-103
AUC,104-107
and,108-111
a,112-113
51%,114-117
increase,118-126
in,127-129
indinavir,130-139	DrugDDI.d401.s15.e4
plasma,140-146
A.C.,147-151

Ritonavir:,0-10	DrugDDI.d401.s17.e0
Coadministration,11-27
of,28-30
ritonavir,31-40	DrugDDI.d401.s17.e1
with,41-45
VIRACEPT,46-54	DrugDDI.d401.s17.e2
resulted,55-63
in,64-66
a,67-68
152%,69-73
increase,74-82
in,83-85
nelfinavir,86-96	DrugDDI.d401.s17.e3
plasma,97-103
AUC,104-107
and,108-111
very,112-116
little,117-123
change,124-130
in,131-133
ritonavir,134-143	DrugDDI.d401.s17.e4
plasma,144-150
A.C.,151-155

Saquinavir:,0-11	DrugDDI.d401.s19.e0
Coadministration,12-28
of,29-31
saquinavir,32-42	DrugDDI.d401.s19.e1
(using,43-49
an,50-52
experimental,53-65
soft-gelatin,66-78
capsule,79-86
formulation,87-98
of,99-101
saquinavir,102-112	DrugDDI.d401.s19.e3
1200mg),113-120
with,121-125
VIRACEPT,126-134	DrugDDI.d401.s19.e4
resulted,135-143
in,144-146
an,147-149
18%,150-153
increase,154-162
in,163-165
nelfinavir,166-176	DrugDDI.d401.s19.e5
plasma,177-183
AUC,184-187
and,188-191
a,192-193
4-fold,194-200
increase,201-209
in,210-212
saquinavir,213-223	DrugDDI.d401.s19.e6
plasma,224-230
A.C.,231-235

If,0-2
used,3-7
in,8-10
combination,11-22
with,23-27
saquinavir,28-38	DrugDDI.d401.s20.e0
hard,39-43
gelatin,44-51
capsules,52-60
at,61-63
the,64-67
recommended,68-79
dose,80-84
of,85-87
600,88-91
mg,92-94
tid,,95-99
no,100-102
dose,103-107
adjustments,108-119
are,120-123
needed.,124-131

Antifungal,0-10	DrugDDI.d401.s22.e0
Agents,11-17	DrugDDI.d401.s22.e0

Ketoconazole:,0-13	DrugDDI.d401.s23.e0
Coadministration,14-30
of,31-33
ketoconazole,34-46	DrugDDI.d401.s23.e1
with,47-51
VIRACEPT,52-60	DrugDDI.d401.s23.e2
resulted,61-69
in,70-72
a,73-74
35%,75-78
increase,79-87
in,88-90
nelfinavir,91-101	DrugDDI.d401.s23.e3
plasma,102-108
A.C.,109-113

This,0-4
change,5-11
was,12-15
not,16-19
considered,20-30
clinically,31-41
significant,42-53
and,54-57
no,58-60
dose,61-65
adjustment,66-76
is,77-79
needed,80-86
when,87-91
ketoconazole,92-104	DrugDDI.d401.s24.e0
and,105-108
VIRACEPT,109-117	DrugDDI.d401.s24.e1
are,118-121
coadministered.,122-137

Anti-HIV,0-8	DrugDDI.d401.s25.e0
Reverse,9-16	DrugDDI.d401.s25.e0
Transcriptase,17-30	DrugDDI.d401.s25.e0
Inhibitors,31-41	DrugDDI.d401.s25.e0

Didanosine:,0-11	DrugDDI.d401.s26.e0
It,12-14
is,15-17
recommended,18-29
that,30-34
didanosine,35-45	DrugDDI.d401.s26.e1
be,46-48
administered,49-61
on,62-64
an,65-67
empty,68-73
stomach;,74-82

therefore,,0-10
nelfinavir,11-21	DrugDDI.d401.s27.e0
should,22-28
be,29-31
administered,32-44
(with,45-50
food),51-56
one,57-60
hour,61-65
after,66-71
or,72-74
more,75-79
than,80-84
two,85-88
hours,89-94
before,95-101
didanosine.,102-113	DrugDDI.d401.s27.e1

Zidovudine:,0-11	DrugDDI.d401.s28.e0
Coadministration,12-28
of,29-31
zidovudine,32-42	DrugDDI.d401.s28.e1
and,43-46
lamivudine,47-57	DrugDDI.d401.s28.e2
with,58-62
VIRACEPT,63-71	DrugDDI.d401.s28.e3
resulted,72-80
in,81-83
a,84-85
35%,86-89
decrease,90-98
in,99-101
zidovudine,102-112	DrugDDI.d401.s28.e4
plasma,113-119
A.C.,120-124

A,0-1
dose,2-6
adjustment,7-17
is,18-20
not,21-24
needed,25-31
when,32-36
zidovudine,37-47	DrugDDI.d401.s29.e0
is,48-50
administered,51-63
with,64-68
VIRACEPT.,69-78	DrugDDI.d401.s29.e1

Little,0-6
or,7-9
no,10-12
change,13-19
in,20-22
the,23-26
pharmacokinetics,27-43
of,44-46
either,47-53
drug,54-58	DrugDDI.d401.s30.e0
was,59-62
observed,63-71
when,72-76
VIRACEPT,77-85	DrugDDI.d401.s30.e1
was,86-89
coadministered,90-104
with,105-109
lamivudine,110-120	DrugDDI.d401.s30.e2
or,121-123
stavudine.,124-134	DrugDDI.d401.s30.e3

Antimycobacterial,0-17	DrugDDI.d401.s31.e0
Agents,18-24	DrugDDI.d401.s31.e0

Rifabutin:,0-10	DrugDDI.d401.s32.e0
Coadministration,11-27
of,28-30
rifabutin,31-40	DrugDDI.d401.s32.e1
and,41-44
VIRACEPT,45-53	DrugDDI.d401.s32.e2
resulted,54-62
in,63-65
a,66-67
32%,68-71
decrease,72-80
in,81-83
nelfinavir,84-94	DrugDDI.d401.s32.e3
plasma,95-101
AUC,102-105
and,106-109
a,110-111
207%,112-116
increase,117-125
in,126-128
rifabutin,129-138	DrugDDI.d401.s32.e4
plasma,139-145
A.C.,146-150

It,0-2
is,3-5
recommended,6-17
that,18-22
the,23-26
dose,27-31
of,32-34
rifabutin,35-44	DrugDDI.d401.s33.e0
be,45-47
reduced,48-55
to,56-58
one-half,59-67
the,68-71
usual,72-77
dose,78-82
when,83-87
administered,88-100
with,101-105
VIRACEPT.,106-115	DrugDDI.d401.s33.e1

Rifampin:,0-9	DrugDDI.d401.s34.e0
Coadministration,10-26
of,27-29
rifampin,30-38	DrugDDI.d401.s34.e1
and,39-42
VIRACEPT,43-51	DrugDDI.d401.s34.e2
resulted,52-60
in,61-63
an,64-66
82%,67-70
decrease,71-79
in,80-82
nelfinavir,83-93	DrugDDI.d401.s34.e3
plasma,94-100
A.C.,101-105

VIRACEPT,0-8	DrugDDI.d401.s35.e0
and,9-12
rifampin,13-21	DrugDDI.d401.s35.e1
should,22-28
not,29-32
be,33-35
coadministered.,36-51

Oral,0-4	DrugDDI.d401.s36.e0
Contraceptives,5-19	DrugDDI.d401.s36.e0

Ethinyl,0-7	DrugDDI.d401.s37.e0
Estradiol,8-17	DrugDDI.d401.s37.e0
and,18-21
Norethindrone:,22-36	DrugDDI.d401.s37.e1
Coadministration,37-53
of,54-56
VIRACEPT,57-65	DrugDDI.d401.s37.e2
with,66-70
OVCON-35,71-79	DrugDDI.d401.s37.e3
resulted,80-88
in,89-91
a,92-93
47%,94-97
decrease,98-106
in,107-109
ethinyl,110-117	DrugDDI.d401.s37.e4
estradiol,118-127	DrugDDI.d401.s37.e4
and,128-131
an,132-134
18%,135-138
decrease,139-147
in,148-150
norethindrone,151-164	DrugDDI.d401.s37.e5
plasma,165-171
concentrations.,172-187

Alternate,0-9
or,10-12
additional,13-23
contraceptive,24-37	DrugDDI.d401.s38.e0
measures,38-46
should,47-53
be,54-56
used,57-61
during,62-68
therapy,69-76
with,77-81
VIRACEPT,82-90	DrugDDI.d401.s38.e1

Caution,0-7
should,8-14
be,15-17
taken,18-23
in,24-26
concurrent,27-37
or,38-40
serial,41-47
use,48-51
of,52-54
other,55-60
neurotoxic,61-71
and/,72-76
or,77-79
nephrotoxic,80-91
drugs,92-97	DrugDDI.d9.s0.e0
because,98-105
of,106-108
possible,109-117
enhancement,118-129
of,130-132
the,133-136
nephrotoxicity,137-151
and/or,152-158
ototoxicity,159-170
of,171-173
neomycin.,174-183	DrugDDI.d9.s0.e1

Caution,0-7
should,8-14
also,15-19
be,20-22
taken,23-28
in,29-31
concurrent,32-42
or,43-45
serial,46-52
use,53-56
of,57-59
other,60-65
aminoglycosides,66-81	DrugDDI.d9.s1.e0
and,82-85
polymyxins,86-96	DrugDDI.d9.s1.e1
because,97-104
they,105-109
may,110-113
enhance,114-121
neomycin?s,122-132
nephrotoxicity,133-147
and/or,148-154
ototoxicity,155-166
and,167-170
potentiate,171-181
neomycin,182-190	DrugDDI.d9.s1.e2
sulfate?s,191-200
neuromuscular,201-214
blocking,215-223
effects.,224-232

Oral,0-4	DrugDDI.d9.s2.e0
neomycin,5-13	DrugDDI.d9.s2.e0
inhibits,14-22
the,23-26
gastrointestinal,27-43
absorption,44-54
of,55-57
penicillin,58-68	DrugDDI.d9.s2.e1
V,,69-71	DrugDDI.d9.s2.e1
oral,72-76	DrugDDI.d9.s2.e2
vitamin,77-84	DrugDDI.d9.s2.e2
B-12,,85-90	DrugDDI.d9.s2.e2
methotrexate,91-103	DrugDDI.d9.s2.e3
and,104-107
5-fluorouracil.,108-123	DrugDDI.d9.s2.e4

The,0-3
gastrointestinal,4-20
absorption,21-31
of,32-34
digoxin,35-42	DrugDDI.d9.s3.e0
also,43-47
appears,48-55
to,56-58
be,59-61
inhibited.,62-72

Oral,0-4	DrugDDI.d9.s5.e0
neomycin,5-13	DrugDDI.d9.s5.e0
sulfate,14-21
may,22-25
enhance,26-33
the,34-37
effect,38-44
of,45-47
coumarin,48-56	DrugDDI.d9.s5.e1
in,57-59
anticoagulants,60-74	DrugDDI.d9.s5.e2
by,75-77
decreasing,78-88
vitamin,89-96
K,97-98
availability.,99-112

Certain,0-7
antibiotics,,8-20
especially,21-31
neomycin,,32-41
streptomycin,42-54	DrugDDI.d281.s0.e2
and,55-58
kanamycin,,59-69
have,70-74
a,75-76
mild,77-81
but,82-85
definite,86-94
nondepolarizing,95-110
blocking,111-119
action,120-126
which,127-132
may,133-136
accentuate,137-147
neuromuscular,148-161
block.,162-168

These,0-5
antibiotics,6-17	DrugDDI.d281.s1.e0
should,18-24
be,25-27
used,28-32
in,33-35
the,36-39
myasthenic,40-50
patient,51-58
only,59-63
where,64-69
definitely,70-80
indicated,,81-91
and,92-95
then,96-100
careful,101-108
adjustment,109-119
should,120-126
be,127-129
made,130-134
of,135-137
adjunctive,138-148
anticholinesterase,149-167	DrugDDI.d281.s1.e1
dosage.,168-175

Local,0-5
and,6-9
some,10-14
general,15-22	DrugDDI.d281.s2.e0
anesthetics,,23-35	DrugDDI.d281.s2.e0
antiarrhythmic,36-50	DrugDDI.d281.s2.e1
agents,51-57	DrugDDI.d281.s2.e1
and,58-61
other,62-67
drugs,68-73	DrugDDI.d281.s2.e2
that,74-78
interfere,79-88
with,89-93
neuromuscular,94-107
transmission,108-120
should,121-127
be,128-130
used,131-135
cautiously,,136-147
if,148-150
at,151-153
all,,154-158
in,159-161
patients,162-170
with,171-175
myasthenia,176-186
gravis;,187-194

the,0-3
dose,4-8
of,9-11
Prostigmin,12-22	DrugDDI.d281.s3.e0
may,23-26
have,27-31
to,32-34
be,35-37
increased,38-47
accordingly.,48-60

No,0-2
trials,3-9
specifically,10-22
examining,23-32
potential,33-42
drug,43-47
interactions,48-60
with,61-65
Natrecor,66-74	DrugDDI.d41.s0.e0
were,75-79
conducted,,80-90
although,91-99
many,100-104
concomitant,105-116
drugs,117-122	DrugDDI.d41.s0.e1
were,123-127
used,128-132
in,133-135
clinical,136-144
trials.,145-152

No,0-2
drug,3-7
interactions,8-20
were,21-25
detected,26-34
except,35-41
for,42-45
an,46-48
increase,49-57
in,58-60
symptomatic,61-72
hypotension,73-84
in,85-87
patients,88-96
receiving,97-106
oral,107-111
ACE,112-115	DrugDDI.d41.s1.e0
inhibitors.,116-127	DrugDDI.d41.s1.e0

The,0-3
co-administration,4-21
of,22-24
Natrecor,25-33	DrugDDI.d41.s2.e0
with,34-38
IV,39-41
vasodilators,42-54	DrugDDI.d41.s2.e1
such,55-59
as,60-62
nitroglycerin,,63-77
nitroprusside,,78-92
milrinone,,93-103
or,104-106
IV,107-109
ACE,110-113	DrugDDI.d41.s2.e5
inhibitors,114-124	DrugDDI.d41.s2.e5
has,125-128
not,129-132
been,133-137
evaluated,138-147
(these,148-154
drugs,155-160	DrugDDI.d41.s2.e6
were,161-165
not,166-169
co-administered,170-185
with,186-190
Natrecor,191-199	DrugDDI.d41.s2.e7
in,200-202
clinical,203-211
trials).,212-220

Netilmicin,0-10	DrugDDI.d540.s0.e0
should,11-17
not,18-21
be,22-24
administered,25-37
concomitantly,38-51
with,52-56
potent,57-63
loop,64-68	DrugDDI.d540.s0.e1
diuretics,69-78	DrugDDI.d540.s0.e1
such,79-83
as,84-86
furosemide,87-97	DrugDDI.d540.s0.e2
and,98-101
ethacrynic,102-112	DrugDDI.d540.s0.e3
acid,113-117	DrugDDI.d540.s0.e3
as,118-120
the,121-124
potential,125-134
for,135-138
ototoxicity,139-150
is,151-153
enhanced,154-162
by,163-165
the,166-169
combination.,170-182

Nevirapine,0-10	DrugDDI.d492.s0.e0
is,11-13
principally,14-25
metabolized,26-37
by,38-40
the,41-44
liver,45-50	DrugDDI.d492.s0.e1
via,51-54
the,55-58
cytochrome,59-69	DrugDDI.d492.s0.e2
P450,70-74	DrugDDI.d492.s0.e2
isoenzymes,,75-86
3A4,87-90
and,91-94
2B6.,95-99

Nevirapine,0-10	DrugDDI.d492.s1.e0
is,11-13
known,14-19
to,20-22
be,23-25
an,26-28
inducer,29-36
of,37-39
these,40-45
enzymes.,46-54

As,0-2
a,3-4
result,,5-12
drugs,13-18	DrugDDI.d492.s2.e0
that,19-23
are,24-27
metabolized,28-39
by,40-42
these,43-48
enzyme,49-55
systems,56-63
may,64-67
have,68-72
lower,73-78
than,79-83
expected,84-92
plasma,93-99
levels,100-106
when,107-111
coadministered,112-126
with,127-131
nevirapine.,132-143	DrugDDI.d492.s2.e1

The,0-3
specific,4-12
pharmacokinetic,13-28
changes,29-36
that,37-41
occur,42-47
with,48-52
co-administration,53-70
of,71-73
nevirapine,74-84	DrugDDI.d492.s3.e0
and,85-88
other,89-94
drugs,95-100	DrugDDI.d492.s3.e1
are,101-104
listed,105-111
in,112-114
CLINICAL,115-123
PHARMACOLOGY,,124-137
Table,138-143
1.,144-146

In,0-2
addition,3-11
to,12-14
established,15-26
drug,27-31
interactions,,32-45
there,46-51
may,52-55
be,56-58
potential,59-68
pharmacokinetic,69-84
interactions,85-97
between,98-105
nevirapine,106-116	DrugDDI.d492.s6.e0
and,117-120
other,121-126
drug,127-131	DrugDDI.d492.s6.e1
classes,132-139
that,140-144
are,145-148
metabolized,149-160
by,161-163
the,164-167
cytochrome,168-178	DrugDDI.d492.s6.e2
P450,179-183	DrugDDI.d492.s6.e2
system.,184-191

Although,0-8
specific,9-17
drug,18-22
interaction,23-34
studies,35-42
in,43-45
HIV-1,46-51
seropositive,52-64
subjects,65-73
have,74-78
not,79-82
been,83-87
conducted,88-97
for,98-101
the,102-105
classes,106-113
of,114-116
drugs,117-122	DrugDDI.d492.s8.e0
listed,123-129
in,130-132
Table,133-138
4,,139-141
additional,142-152
clinical,153-161
monitoring,162-172
may,173-176
be,177-179
warranted,180-189
when,190-194
co-administering,195-211
these,212-217
drugs.,218-224	DrugDDI.d492.s8.e1

The,0-3
in,4-6
vitro,7-12
interaction,13-24
between,25-32
nevirapine,33-43	DrugDDI.d492.s9.e0
and,44-47
the,48-51
antithrombotic,52-66	DrugDDI.d492.s9.e1
agent,67-72	DrugDDI.d492.s9.e1
warfarin,73-81
is,82-84
complex.,85-93

As,0-2
a,3-4
result,,5-12
when,13-17
giving,18-24
these,25-30
drugs,31-36	DrugDDI.d492.s10.e0
concomitantly,,37-51
plasma,52-58
warfarin,59-67	DrugDDI.d492.s10.e1
levels,68-74
may,75-78
change,79-85
with,86-90
the,91-94
potential,95-104
for,105-108
increases,109-118
in,119-121
coagulation,122-133
time.,134-139

When,0-4
warfarin,5-13	DrugDDI.d492.s11.e0
is,14-16
co-administered,17-32
with,33-37
nevirapine,,38-49
anticoagulation,50-65
levels,66-72
should,73-79
be,80-82
monitored,83-92
frequently.,93-104

Drug,0-4	DrugDDI.d492.s13.e0
Name,5-9

Effect,0-6
on,7-9
Concentration,10-23
of,24-26
Nevirapine,27-37	DrugDDI.d492.s14.e0
or,38-40
Concomitant,41-52
Drug,53-57	DrugDDI.d492.s14.e1

Clarithromycin,0-14	DrugDDI.d492.s16.e0

?,0-1
Clarithromycin,2-16	DrugDDI.d492.s17.e0
?14OH-,17-23
clarithromycin,24-38

Clarithromycin,0-14	DrugDDI.d492.s18.e0
exposure,15-23
was,24-27
significantly,28-41
decreased,42-51
by,52-54
nevirapine;,55-66	DrugDDI.d492.s18.e1

however,,0-8
14-OH,9-14
metabolite,15-25
concentrations,26-40
were,41-45
increased.Because,46-63
clarithromycin,64-78	DrugDDI.d492.s19.e0
active,79-85
metabolite,86-96
has,97-100
reduced,101-108
activity,109-117
against,118-125
Mycobacteriumavium-intracellulare,126-159
complex,,160-168
overallactivity,169-184
against,185-192
this,193-197
pathogen,198-206
may,207-210
bealtered.,211-221

Alternatives,0-12
to,13-15
clarithromycin,such,16-35
as,36-38
azithromycin,,39-52
should,53-59
be,60-62
considered.,63-74

Efavirenz,0-9	DrugDDI.d492.s21.e0

?,0-1
Efavirenz,2-11	DrugDDI.d492.s22.e0

Ethinyl,0-7	DrugDDI.d492.s24.e0
estradiol,8-17	DrugDDI.d492.s24.e0
and,18-21
Norethindrone,22-35	DrugDDI.d492.s24.e1

?,0-1
Ethinyl,2-9	DrugDDI.d492.s25.e0
estradiol,10-19	DrugDDI.d492.s25.e0
,20-20
span,21-25
class=,26-32
c272,33-37
?Norethindrone,38-52

Oral,0-4	DrugDDI.d492.s26.e0
contraceptives,5-19	DrugDDI.d492.s26.e0
and,20-23
other,24-29
hormonalmethods,30-45
of,46-48
birth,49-54	DrugDDI.d492.s26.e1
control,55-62	DrugDDI.d492.s26.e1
should,63-69
not,70-73
be,74-76
usedas,77-83
the,84-87
sole,88-92
method,93-99
of,100-102
contraception,103-116
inwomen,117-124
taking,125-131
nevirapine,,132-143
since,144-149
nevirapinemay,150-163
lower,164-169
the,170-173
plasma,174-180
levels,181-187
of,188-190
thesemedications.,191-208

Fluconazole,0-11	DrugDDI.d492.s28.e0

?,0-1
Nevirapine,2-12	DrugDDI.d492.s29.e0

Because,0-7
of,8-10
the,11-14
risk,15-19
of,20-22
increased,23-32
exposure,33-41
tonevirapine,,42-55
caution,56-63
should,64-70
be,71-73
used,74-78
inconcomitant,79-92
administration,,93-108
and,109-112
patients,113-121
should,122-128
be,129-131
monitored,132-141
closely,142-149
for,150-153
nevirapine-associated,154-175	DrugDDI.d492.s30.e0
adverse,176-183
events.,184-191

Indinavir,0-9	DrugDDI.d492.s31.e0

?,0-1
Indinavir,2-11	DrugDDI.d492.s32.e0

Appropriate,0-11
doses,12-17
for,18-21
this,22-26
combination,27-38
arenot,39-45
established,,46-58
but,59-62
an,63-65
increase,66-74
in,75-77
thedosage,78-87
of,88-90
indinavir,91-100	DrugDDI.d492.s33.e0
may,101-104
be,105-107
required.,108-117

Ketoconazole,0-12	DrugDDI.d492.s34.e0

?,0-1
Ketoconazole,2-14	DrugDDI.d492.s35.e0

Nevirapine,0-10	DrugDDI.d492.s36.e0
and,11-14
ketoconazole,15-27	DrugDDI.d492.s36.e1
should,28-34
not,35-38
beadministered,39-53
concomitantly,54-67
becausedecreases,68-84
in,85-87
ketoconazole,88-100	DrugDDI.d492.s36.e2
plasmaconcentrations,101-121
may,122-125
reduce,126-132
the,133-136
efficacy,137-145
of,146-148
the,149-152
drug.,153-158	DrugDDI.d492.s36.e3

Lopinavir/Ritonavir,0-19	DrugDDI.d492.s37.e0

?,0-1
Lopinavir,2-11	DrugDDI.d492.s38.e0

A,0-1
dose,2-6
increase,7-15
of,16-18
lopinavir/ritonavir,19-38	DrugDDI.d492.s39.e0
to,39-41
533/133,42-49
mg,50-52
twice,53-58
daily,59-64
with,65-69
food,70-74
isrecommended,75-88
in,89-91
combination,92-103
with,104-108
nevirapine.,109-120	DrugDDI.d492.s39.e2

Methadone,0-9	DrugDDI.d492.s40.e0

Methadone,0-9	DrugDDI.d492.s42.e0
levels,10-16
may,17-20
be,21-23
decreased;increased,24-43
dosages,44-51
may,52-55
be,56-58
required,59-67
toprevent,68-77
symptoms,78-86
of,87-89
opiate,90-96	DrugDDI.d492.s42.e1
withdrawal.Methadone,97-117
maintained,118-128
patients,129-137
beginningnevirapine,138-157
therapy,158-165
should,166-172
be,173-175
monitored,176-185
forevidence,186-197
of,198-200
withdrawal,201-211
and,212-215
methadone,216-225
dose,226-230
should,231-237
be,238-240
adjusted,241-249
accordingly.,250-262

Nelfinavir,0-10	DrugDDI.d492.s43.e0

?,0-1
Nelfinavir,2-12	DrugDDI.d492.s44.e0
M8,13-15	DrugDDI.d492.s44.e0
Metabolite,16-26
,27-27
span,28-32
class=,33-39
c272,40-44
?NelfinavirCmin,45-60
?,61-62

The,0-3
appropriate,4-15
dose,16-20
for,21-24
nelfinavir,25-35	DrugDDI.d492.s45.e0
incombination,36-49
with,50-54
nevirapine,,55-66
with,67-71
respectto,72-81
safety,82-88
and,89-92
efficacy,,93-102
has,103-106
not,107-110
been,111-115
established.,116-128

Rifabutin,0-9	DrugDDI.d492.s46.e0

Rifabutin,0-9	DrugDDI.d492.s48.e0
and,10-13
its,14-17
metabolite,18-28	DrugDDI.d492.s48.e1
concentrationswere,29-47
moderately,48-58
increased.,59-69

Rifampin,0-8	DrugDDI.d492.s51.e0

?,0-1
Nevirapine,2-12	DrugDDI.d492.s52.e0

Nevirapine,0-10	DrugDDI.d492.s53.e0
and,11-14
rifampin,15-23	DrugDDI.d492.s53.e1
should,24-30
not,31-34
beadministered,35-49
concomitantly,50-63
becausedecreases,64-80
in,81-83
nevirapine,84-94	DrugDDI.d492.s53.e2
plasmaconcentrations,95-115
may,116-119
reduce,120-126
the,127-130
efficacy,131-139
ofthe,140-145
drug.,146-151	DrugDDI.d492.s53.e3

Physicians,0-10
needing,11-18
to,19-21
treatpatients,22-35
co-infected,36-47
with,48-52
tuberculosis,53-65
andusing,66-74
a,75-76
nevirapine,77-87	DrugDDI.d492.s54.e0
containing,88-98
regimen,99-106
mayuse,107-113
rifabutin,114-123
instead.,124-132

Saquinavir,0-10	DrugDDI.d492.s55.e0

Appropriate,0-11
doses,12-17
for,18-21
this,22-26
combination,27-38
arenot,39-45
established,,46-58
but,59-62
an,63-65
increase,66-74
in,75-77
thedosage,78-87
of,88-90
saquinavir,91-101	DrugDDI.d492.s57.e0
may,102-105
be,106-108
required.,109-118

aBased,0-6
on,7-9
reports,10-17
of,18-20
narcotic,21-29	DrugDDI.d492.s58.e0
withdrawal,30-40
syndrome,41-49
in,50-52
patients,53-61
treated,62-69
with,70-74
nevirapine,75-85	DrugDDI.d492.s58.e1
and,86-89
methadone,90-99	DrugDDI.d492.s58.e2
concurrently,,100-113
and,114-117
evidence,118-126
of,127-129
decreased,130-139
plasma,140-146
concentrations,147-161
of,162-164
methadone.,165-175	DrugDDI.d492.s58.e3

Table,0-5
4,6-7
???????Potential,8-24
Drug,25-29	DrugDDI.d492.s59.e0
Interactions:Use,30-46
With,47-51
Caution,,52-60
Dose,61-65
Adjustment,66-76
of,77-79
Co-administered,80-95
Drug,96-100
May,101-104
Be,105-107
Needed,108-114
due,115-118
to,119-121
Possible,122-130
Decrease,131-139
in,140-142
Clinical,143-151
Effect,152-158

Examples,0-8
of,9-11
Drugs,12-17	DrugDDI.d492.s60.e0
in,18-20
Which,21-26
Plasma,27-33
Concentrations,34-48
May,49-52
Be,53-55
Decreased,56-65
By,66-68
Co-administration,69-86
With,87-91
Nevirapine,92-102	DrugDDI.d492.s60.e1

Drug,0-4	DrugDDI.d492.s61.e0
Class,5-10
Examples,11-19
of,20-22
Drugs,23-28	DrugDDI.d492.s61.e1

Antiarrhythmics,0-15	DrugDDI.d492.s62.e0

Amiodarone,,0-11
disopyramide,,12-25
lidocaine,26-35	DrugDDI.d492.s63.e2

Anticonvulsants,0-15	DrugDDI.d492.s64.e0

Carbamazepine,,0-14
clonazepam,,15-26
ethosuximide,27-39	DrugDDI.d492.s65.e2

Antifungals,0-11	DrugDDI.d492.s66.e0

Itraconazole,0-12	DrugDDI.d492.s67.e0

Calcium,0-7	DrugDDI.d492.s68.e0
channel,8-15	DrugDDI.d492.s68.e0
blockers,16-24	DrugDDI.d492.s68.e0

Diltiazem,,0-10
nifedipine,,11-22
verapamil,23-32	DrugDDI.d492.s69.e2

Cyclophosphamide,0-16	DrugDDI.d492.s71.e0

Ergot,0-5	DrugDDI.d492.s72.e0
alkaloids,6-15	DrugDDI.d492.s72.e0

Ergotamine,0-10	DrugDDI.d492.s73.e0

Immunosuppressants,0-18	DrugDDI.d492.s74.e0

Cyclosporin,,0-12
tacrolimus,,13-24
sirolimus,25-34	DrugDDI.d492.s75.e2

Cisapride,0-9	DrugDDI.d492.s77.e0

Opiate,0-6	DrugDDI.d492.s78.e0
agonists,7-15	DrugDDI.d492.s78.e0

Fentanyl,0-8	DrugDDI.d492.s79.e0

Examples,0-8
of,9-11
Drugs,12-17	DrugDDI.d492.s80.e0
in,18-20
Which,21-26
Plasma,27-33
Concentrations,34-48
May,49-52
Be,53-55
Increased,56-65
By,66-68
Co-administration,69-86
With,87-91
Nevirapine,92-102	DrugDDI.d492.s80.e1

Warfarin,0-8	DrugDDI.d492.s82.e0

Interactions,0-12
for,13-16
Vitamin,17-24	DrugDDI.d38.s0.e0
B3,25-27	DrugDDI.d38.s0.e0
(Niacin):,28-37
Antihypertensive,38-54
Therapy:,55-63
Nicotinic,64-73	DrugDDI.d38.s0.e2
acid,74-78	DrugDDI.d38.s0.e2
may,79-82
potentiate,83-93
the,94-97
effects,98-105
of,106-108
ganglionic,109-119	DrugDDI.d38.s0.e3
blocking,120-128	DrugDDI.d38.s0.e3
agents,129-135	DrugDDI.d38.s0.e3
and,136-139
vasoactive,140-150
drugs,151-156	DrugDDI.d38.s0.e4
resulting,157-166
in,167-169
postural,170-178
hypotension.,179-191

Aspirin:,0-8	DrugDDI.d38.s1.e0
Concomitant,9-20
aspirin,21-28	DrugDDI.d38.s1.e1
may,29-32
decrease,33-41
the,42-45
metabolic,46-55
clearance,56-65
of,66-68
nicotinic,69-78	DrugDDI.d38.s1.e2
acid.,79-84	DrugDDI.d38.s1.e2

Other:,0-6
Concomitant,7-18
alcohol,19-26	DrugDDI.d38.s3.e0
or,27-29
hot,30-33
drinks,34-40
may,41-44
increase,45-53
the,54-57
side,58-62
effects,63-70
of,71-73
flushing,74-82
and,83-86
pruritus,87-95
and,96-99
should,100-106
be,107-109
avoided,110-117
at,118-120
the,121-124
time,125-129
of,130-132
drug,133-137
ingestion.,138-148

Beta-Blockers,0-13	DrugDDI.d10.s0.e0
In,14-16
controlled,17-27
clinical,28-36
studies,,37-45
adrenergic,46-56	DrugDDI.d10.s0.e1
beta-receptor,57-70	DrugDDI.d10.s0.e1
blockers,71-79	DrugDDI.d10.s0.e1
have,80-84
been,85-89
frequently,90-100
administered,101-113
concomitantly,114-127
with,128-132
nicardipine,133-144	DrugDDI.d10.s0.e2
HCl.,145-149	DrugDDI.d10.s0.e2

Cimetidine,0-10	DrugDDI.d10.s2.e0
Cimetidine,11-21
increases,22-31
nicardipine,32-43	DrugDDI.d10.s2.e1
HCl,44-47	DrugDDI.d10.s2.e1
plasma,48-54
levels.,55-62

Patients,0-8
receiving,9-18
the,19-22
two,23-26
drugs,27-32	DrugDDI.d10.s3.e0
concomitantly,33-46
should,47-53
be,54-56
carefully,57-66
monitored.,67-77

Digoxin,0-7	DrugDDI.d10.s4.e0
Some,8-12
calcium,13-20
blockers,21-29
may,30-33
increase,34-42
the,43-46
concentration,47-60
of,61-63
digitalis,64-73	DrugDDI.d10.s4.e1
preparations,74-86	DrugDDI.d10.s4.e1
in,87-89
the,90-93
blood.,94-100

Nicardipine,0-11	DrugDDI.d10.s5.e0
HCl,12-15	DrugDDI.d10.s5.e0
usually,16-23
does,24-28
not,29-32
alter,33-38
the,39-42
plasma,43-49
levels,50-56
of,57-59
digoxin,,60-68
however,,69-77
serum,78-83
digoxin,84-91
levels,92-98
should,99-105
be,106-108
evaluated,109-118
after,119-124
concomitant,125-136
therapy,137-144
with,145-149
nicardipine,150-161	DrugDDI.d10.s5.e2
HCl,162-165	DrugDDI.d10.s5.e2
is,166-168
initiated.,169-179

Maalox?*,0-8
Coadministration,9-25
of,26-28
Maalox,29-35	DrugDDI.d10.s6.e0
TC,36-38	DrugDDI.d10.s6.e0
had,39-42
no,43-45
effect,46-52
on,53-55
nicardipine,56-67	DrugDDI.d10.s6.e1
HCl,68-71	DrugDDI.d10.s6.e1
absorption.,72-83

Fentanyl,0-8	DrugDDI.d10.s7.e0
Anesthesia,9-19
Severe,20-26
hypotension,27-38
has,39-42
been,43-47
reported,48-56
during,57-63
fentanyl,64-72	DrugDDI.d10.s7.e1
anesthesia,73-83
with,84-88
concomitant,89-100
use,101-104
of,105-107
a,108-109
beta-blocker,110-122	DrugDDI.d10.s7.e2
and,123-126
a,127-128
calcium,129-136	DrugDDI.d10.s7.e3
channel,137-144	DrugDDI.d10.s7.e3
blocker.,145-153	DrugDDI.d10.s7.e3

Even,0-4
though,5-11
such,12-16
interactions,17-29
were,30-34
not,35-38
seen,39-43
during,44-50
clinical,51-59
studies,60-67
with,68-72
nicardipine,73-84	DrugDDI.d10.s8.e0
HCl,,85-89	DrugDDI.d10.s8.e0
an,90-92
increased,93-102
volume,103-109
of,110-112
circulating,113-124
fluids,125-131
might,132-137
be,138-140
required,141-149
if,150-152
such,153-157
an,158-160
interaction,161-172
were,173-177
to,178-180
occur.,181-187

Cyclosporine,0-12	DrugDDI.d10.s9.e0
Concomitant,13-24
administration,25-39
of,40-42
nicardipine,43-54	DrugDDI.d10.s9.e1
and,55-58
cyclosporine,59-71	DrugDDI.d10.s9.e2
levels.,72-79

Plasma,0-6
concentrations,7-21
of,22-24
cyclosporine,25-37	DrugDDI.d10.s10.e0
should,38-44
therefore,45-54
be,55-57
closely,58-65
monitored,,66-76
and,77-80
its,81-84
dosage,85-91
reduced,92-99
accordingly,,100-112
in,113-115
patients,116-124
treated,125-132
with,133-137
nicardipine.,138-150	DrugDDI.d10.s10.e1

When,0-4
therapeutic,5-16
concentrations,17-31
of,32-34
furosemide,,35-46
propranolol,,47-59
dipyridamole,,60-73
warfarin,,74-83
quinidine,,84-94
or,95-97
naproxen,98-106	DrugDDI.d10.s11.e5
were,107-111
added,112-117
to,118-120
human,121-126	DrugDDI.d10.s11.e6
plasma,127-133	DrugDDI.d10.s11.e6
(in,134-137
vitro),,138-145
the,146-149
plasma,150-156	DrugDDI.d10.s11.e7
protein,157-164	DrugDDI.d10.s11.e7
binding,165-172
of,173-175
nicardipine,176-187	DrugDDI.d10.s11.e8
HCl,188-191	DrugDDI.d10.s11.e8
was,192-195
not,196-199
altered.,200-208

Physiological,0-13
changes,14-21
resulting,22-31
from,32-36
smoking,37-44
cessation,,45-55
with,56-60
or,61-63
without,64-71
nicotine,72-80
replacement,,81-93
may,94-97
alter,98-103
the,104-107
pharmacokinetics,108-124
of,125-127
certain,128-135
concomitant,136-147
medications,,148-160
such,161-165
as,166-168
tricyclic,169-178	DrugDDI.d208.s0.e1
antidepressants,179-194	DrugDDI.d208.s0.e1
and,195-198
theophylline.,199-212	DrugDDI.d208.s0.e2

Doses,0-5
of,6-8
these,9-14
and,15-18
perhaps,19-26
other,27-32	DrugDDI.d208.s1.e0
medications,33-44	DrugDDI.d208.s1.e0
may,45-48
need,49-53
to,54-56
be,57-59
adjusted,60-68
in,69-71
patients,72-80
who,81-84
successfully,85-97
quit,98-102
smoking.,103-111

Beta-adrenergic,0-15	DrugDDI.d120.s0.e0
Blocking,16-24	DrugDDI.d120.s0.e0
Agents:,25-32	DrugDDI.d120.s0.e0
Experience,33-43
in,44-46
over,47-51
1400,52-56
patients,57-65
in,66-68
a,69-70
non-comparative,71-86
clinical,87-95
trial,96-101
has,102-105
shown,106-111
that,112-116
concomitant,117-128
administration,129-143
of,144-146
nifedipine,147-157	DrugDDI.d120.s0.e1
and,158-161
beta-blocking,162-175	DrugDDI.d120.s0.e2
agents,176-182	DrugDDI.d120.s0.e2
is,183-185
usually,186-193
well,194-198
tolerated,,199-209
but,210-213
there,214-219
have,220-224
been,225-229
occasional,230-240
literature,241-251
reports,252-259
suggesting,260-270
that,271-275
the,276-279
combination,280-291
may,292-295
increase,296-304
the,305-308
likelihood,309-319
of,320-322
congestive,323-333
heart,334-339
failure,,340-348
severe,349-355
hypotension,356-367
or,368-370
exacerbation,371-383
of,384-386
angina.,387-394

Long,0-4
Acting,5-11
Nitrates:,12-21	DrugDDI.d120.s1.e0
Nifedipine,22-32	DrugDDI.d120.s1.e1
may,33-36
be,37-39
safely,40-46
co-administered,47-62
with,63-67
nitrates,,68-77
but,78-81
there,82-87
have,88-92
been,93-97
no,98-100
controlled,101-111
studies,112-119
to,120-122
evaluate,123-131
the,132-135
antianginal,136-147
effectiveness,148-161
of,162-164
this,165-169
combination.,170-182

Digitalis:,0-10	DrugDDI.d120.s2.e0
Immediate,11-20
Release,21-28
Capsules:,29-38
Since,39-44
there,45-50
have,51-55
been,56-60
isolated,61-69
reports,70-77
of,78-80
patients,81-89
with,90-94
elevated,95-103
digoxin,104-111
levels,,112-119
and,120-123
there,124-129
is,130-132
a,133-134
possible,135-143
interaction,144-155
between,156-163
digoxin,164-171	DrugDDI.d120.s2.e1
and,172-175
nifedipine,,176-187
it,188-190
is,191-193
recommended,194-205
that,206-210
digoxin,211-218
levels,219-225
be,226-228
monitored,229-238
when,239-243
initiating,,244-255
adjusting,,256-266
and,267-270
discontinuing,271-284
nifedipine,285-295	DrugDDI.d120.s2.e3
to,296-298
avoid,299-304
possible,305-313
over-,314-319
or,320-322
under-digitalization.,323-344

Extended,0-8
Release,9-16
Tablets:,17-25
Administration,26-40
of,41-43
nifedipine,44-54	DrugDDI.d120.s3.e0
with,55-59
digoxin,60-67	DrugDDI.d120.s3.e1
increased,68-77
digoxin,78-85
levels,86-92
in,93-95
9,96-97
of,98-100
12,101-103
normal,104-110
volunteers.,111-122

Since,0-5
there,6-11
have,12-16
been,17-21
isolated,22-30
reports,31-38
of,39-41
patients,42-50
with,51-55
elevated,56-64
digoxin,65-72
levels,,73-80
it,81-83
is,84-86
recommended,87-98
that,99-103
digoxin,104-111
levels,112-118
be,119-121
monitored,122-131
when,132-136
initiating,,137-148
adjusting,,149-159
and,160-163
discontinuing,164-177
nifedipine,178-188	DrugDDI.d120.s7.e0
to,189-191
avoid,192-197
possible,198-206
over-,207-212
or,213-215
under-digitalization.,216-237

Quinidine:,0-10	DrugDDI.d120.s8.e0
Immediate,11-20
Release,21-28
Capsules:,29-38
There,39-44
have,45-49
been,50-54
rare,55-59
reports,60-67
of,68-70
an,71-73
interaction,74-85
between,86-93
quinidine,94-103	DrugDDI.d120.s8.e1
and,104-107
nifedipine,108-118	DrugDDI.d120.s8.e2
(with,119-124
a,125-126
decreased,127-136
plasma,137-143
level,144-149
of,150-152
quinidine).,153-164	DrugDDI.d120.s8.e3

Coumarin,0-8	DrugDDI.d120.s9.e0
Anticoagulants:,9-24	DrugDDI.d120.s9.e0
There,25-30
have,31-35
been,36-40
rare,41-45
reports,46-53
of,54-56
increased,57-66
prothrombin,67-78
time,79-83
in,84-86
patients,87-95
taking,96-102
coumarin,103-111	DrugDDI.d120.s9.e1
anticoagulants,112-126	DrugDDI.d120.s9.e1
to,127-129
whom,130-134
nifedipine,135-145	DrugDDI.d120.s9.e2
was,146-149
administered.,150-163

However,,0-8
the,9-12
relationship,13-25
to,26-28
nifedipine,29-39	DrugDDI.d120.s10.e0
therapy,40-47
is,48-50
uncertain.,51-61

Cimetidine:,0-11	DrugDDI.d120.s11.e0
A,12-13
study,14-19
in,20-22
6,23-24
healthy,25-32
volunteers,33-43
has,44-47
shown,48-53
a,54-55
significant,56-67
increase,68-76
in,77-79
peak,80-84
nifedipine,85-95	DrugDDI.d120.s11.e1
plasma,96-102
levels,103-109
(80%),110-115
and,116-119
area-under-the-curve,120-140
(74%),141-146
after,147-152
a,153-154
1,155-156
week,157-161
course,162-168
of,169-171
cimetidine,172-182	DrugDDI.d120.s11.e2
at,183-185
1000,186-190
mg,191-193
per,194-197
day,198-201
and,202-205
nifedipine,206-216	DrugDDI.d120.s11.e3
at,217-219
40,220-222
mg,223-225
per,226-229
day.,230-234

Ranitidine,0-10	DrugDDI.d120.s12.e0
produced,11-19
smaller,,20-28
non-significant,29-44
increases.,45-55

The,0-3
effect,4-10
may,11-14
be,15-17
mediated,18-26
by,27-29
the,30-33
known,34-39
inhibition,40-50
of,51-53
cimetidine,54-64	DrugDDI.d120.s13.e0
on,65-67
hepatic,68-75
cytochrome,76-86	DrugDDI.d120.s13.e1
P-450,,87-93	DrugDDI.d120.s13.e1
the,94-97
enzyme,98-104
system,105-111
probably,112-120
responsible,121-132
for,133-136
the,137-140
first-pass,141-151
metabolism,152-162
of,163-165
nifedipine.,166-177	DrugDDI.d120.s13.e2

If,0-2
nifedipine,3-13	DrugDDI.d120.s14.e0
therapy,14-21
is,22-24
initiated,25-34
in,35-37
a,38-39
patient,40-47
currently,48-57
receiving,58-67
cimetidine,,68-79
cautious,80-88
titration,89-98
is,99-101
advised.,102-110

In,0-2
vitro,,3-9
nilutamide,10-20	DrugDDI.d214.s0.e0
has,21-24
been,25-29
shown,30-35
to,36-38
inhibit,39-46
the,47-50
activity,51-59
of,60-62
liver,63-68
cytochrome,69-79	DrugDDI.d214.s0.e1
P-450,80-85	DrugDDI.d214.s0.e1
isoenzymes,86-96
and,97-100
therefore,,101-111
may,112-115
reduce,116-122
the,123-126
metabolism,127-137
of,138-140
compounds,141-150
requiring,151-160
these,161-166
systems.,167-175

Consequently,,0-13
drugs,14-19	DrugDDI.d214.s1.e0
with,20-24
a,25-26
low,27-30
therapeutic,31-42
margin,,43-50
such,51-55
as,56-58
vitamin,59-66
K,67-68
antagonists,,69-81
phenytoin,,82-92
and,93-96
theophylline,,97-110
could,111-116
have,117-121
a,122-123
delayed,124-131
elimination,132-143
and,144-147
increases,148-157
in,158-160
their,161-166
serum,167-172
half-life,173-182
leading,183-190
to,191-193
a,194-195
toxic,196-201
level.,202-208

The,0-3
dosage,4-10
of,11-13
these,14-19
drugs,20-25	DrugDDI.d214.s2.e0
or,26-28
others,29-35
with,36-40
a,41-42
similar,43-50
metabolism,51-61
may,62-65
need,66-70
to,71-73
be,74-76
modified,77-85
if,86-88
they,89-93
are,94-97
administered,98-110
concomitantly,111-124
with,125-129
nilutamide.,130-141	DrugDDI.d214.s2.e1

For,0-3
example,,4-12
when,13-17
vitamin,18-25
K,26-27
antagonists,28-39
are,40-43
administered,44-56
concomitantly,57-70
with,71-75
nilutamide,,76-87
prothrombin,88-99
time,100-104
should,105-111
be,112-114
carefully,115-124
monitored,125-134
and,135-138
if,139-141
necessary,,142-152
the,153-156
dosage,157-163
of,164-166
vitamin,167-174
K,175-176
antagonists,177-188
should,189-195
be,196-198
reduced.,199-207

It,0-2
is,3-5
possible,6-14
that,15-19
the,20-23
cardiovascular,24-38
action,39-45
of,46-48
other,49-54
calcium,55-62	DrugDDI.d406.s0.e0
channel,63-70	DrugDDI.d406.s0.e0
blockers,71-79	DrugDDI.d406.s0.e0
could,80-85
be,86-88
enhanced,89-97
by,98-100
the,101-104
addition,105-113
of,114-116
Nimotop?.,117-126

In,0-2
Europe,,3-10
Nimotop?,11-19
was,20-23
observed,24-32
to,33-35
occasionally,36-48
intensify,49-58
the,59-62
effect,63-69
of,70-72
antihypertensive,73-89	DrugDDI.d406.s1.e0
compounds,90-99
taken,100-105
concomitantly,106-119
by,120-122
patients,123-131
suffering,132-141
from,142-146
hypertension;,147-160

A,0-1
study,2-7
in,8-10
eight,11-16
healthy,17-24
volunteers,25-35
has,36-39
shown,40-45
a,46-47
50%,48-51
increase,52-60
in,61-63
mean,64-68
peak,69-73
nimodipine,74-84	DrugDDI.d406.s3.e0
plasma,85-91
concentrations,92-106
and,107-110
a,111-112
90%,113-116
increase,117-125
in,126-128
mean,129-133
area,134-138
under,139-144
the,145-148
curve,,149-155
after,156-161
a,162-163
one,164-167
week,168-172
course,173-179
of,180-182
cimetidine,183-193	DrugDDI.d406.s3.e1
at,194-196
1,000,197-202
mg/day,203-209
and,210-213
nimodipine,214-224	DrugDDI.d406.s3.e2
at,225-227
90,228-230
mg/day.,231-238

This,0-4
effect,5-11
may,12-15
be,16-18
mediated,19-27
by,28-30
the,31-34
known,35-40
inhibition,41-51
of,52-54
hepatic,55-62	DrugDDI.d406.s4.e0
cytochrome,63-73	DrugDDI.d406.s4.e0
P-,74-76	DrugDDI.d406.s4.e0
450,77-80	DrugDDI.d406.s4.e0
by,81-83
cimetidine,,84-95
which,96-101
could,102-107
decrease,108-116
first,117-122
pass,123-127
metabolism,128-138
of,139-141
nimodipine.,142-153	DrugDDI.d406.s4.e2

A,0-1
30,2-4
to,5-7
45%,8-11
increase,12-20
in,21-23
AUC,24-27
and,28-31
Cmax,32-36
of,37-39
nisoldipine,40-51	DrugDDI.d439.s0.e0
was,52-55
observed,56-64
with,65-69
concomitant,70-81
administration,82-96
of,97-99
cimetidine,100-110	DrugDDI.d439.s0.e1
400,111-114	DrugDDI.d439.s0.e1
mg,115-117	DrugDDI.d439.s0.e1
twice,118-123
daily.,124-130

Ranitidine,0-10	DrugDDI.d439.s1.e0
150,11-14	DrugDDI.d439.s1.e0
mg,15-17	DrugDDI.d439.s1.e0
twice,18-23
daily,24-29
did,30-33
not,34-37
interact,38-46
significantly,47-60
with,61-65
nisoldipine,66-77	DrugDDI.d439.s1.e1
(AUC,78-82
was,83-86
decreased,87-96
by,97-99
15-20,100-105
%).,106-109

No,0-2
pharmacodynamic,3-18
effects,19-26
of,27-29
either,30-36
histamine,37-46	DrugDDI.d439.s2.e0
H2,47-49	DrugDDI.d439.s2.e0
receptor,50-58	DrugDDI.d439.s2.e0
antagonist,59-69	DrugDDI.d439.s2.e0
were,70-74
observed.,75-84

Coadministration,0-16
of,17-19
phenytoin,20-29	DrugDDI.d439.s3.e0
with,30-34
40,35-37
mg,38-40
SULAR,41-46	DrugDDI.d439.s3.e1
tablets,47-54
in,55-57
epileptic,58-67
patients,68-76
lowered,77-84
the,85-88
nisoldipine,89-100	DrugDDI.d439.s3.e2
plasma,101-107
concentrations,108-122
to,123-125
undetectable,126-138
levels.,139-146

Coadministration,0-16
of,17-19
SULAR,20-25	DrugDDI.d439.s4.e0
with,26-30
phenytoin,31-40	DrugDDI.d439.s4.e1
or,41-43
any,44-47
known,48-53
CYP3A4,54-60	DrugDDI.d439.s4.e2
inducer,61-68
should,69-75
be,76-78
avoided,79-86
and,87-90
alternative,91-102
antihypertensive,103-119	DrugDDI.d439.s4.e3
therapy,120-127
should,128-134
be,135-137
considered.,138-149

Pharmacokinetic,0-15
interactions,16-28
between,29-36
nisoldipine,37-48	DrugDDI.d439.s5.e0
and,49-52
beta-blockers,53-66	DrugDDI.d439.s5.e1
(atenolol,,67-77
propranolol),78-90	DrugDDI.d439.s5.e3
were,91-95
variable,96-104
and,105-108
not,109-112
significant.,113-125

Propranolol,0-11	DrugDDI.d439.s6.e0
attenuated,12-22
the,23-26
heart,27-32
rate,33-37
increase,38-46
following,47-56
administration,57-71
of,72-74
immediate,75-84
release,85-92
nisoldipine.,93-105	DrugDDI.d439.s6.e1

The,0-3
blood,4-9
pressure,10-18
effect,19-25
of,26-28
SULAR,29-34	DrugDDI.d439.s7.e0
tended,35-41
to,42-44
be,45-47
greater,48-55
in,56-58
patients,59-67
on,68-70
atenolol,71-79	DrugDDI.d439.s7.e1
than,80-84
in,85-87
patients,88-96
on,97-99
no,100-102
other,103-108
antihypertensive,109-125	DrugDDI.d439.s7.e2
therapy.,126-134

Quinidine,0-9	DrugDDI.d439.s8.e0
at,10-12
648,13-16
mg,17-19
bid,20-23	DrugDDI.d439.s8.e1
decreased,24-33
the,34-37
bioavailability,38-53
(AUC),54-59
of,60-62
nisoldipine,63-74	DrugDDI.d439.s8.e2
by,75-77
26%,,78-82
but,83-86
not,87-90
the,91-94
peak,95-99
concentration.,100-114

The,0-3
immediate,4-13
release,,14-22
but,23-26
not,27-30
the,31-34
coat-core,35-44
formulation,45-56
of,57-59
nisoldipine,60-71	DrugDDI.d439.s9.e0
increased,72-81
plasma,82-88
quinidine,89-98
concentrations,99-113
by,114-116
about,117-122
20%.,123-127

No,0-2
significant,3-14
interactions,15-27
were,28-32
found,33-38
between,39-46
nisoldipine,47-58	DrugDDI.d439.s11.e0
and,59-62
warfarin,63-71	DrugDDI.d439.s11.e1
or,72-74
digoxin.,75-83	DrugDDI.d439.s11.e2

Tizoxanide,0-10	DrugDDI.d272.s0.e0
is,11-13
highly,14-20
bound,21-26
to,27-29
plasma,30-36	DrugDDI.d272.s0.e1
protein,37-44	DrugDDI.d272.s0.e1
(,45-46
99.9%).,47-54

Therefore,,0-10
caution,11-18
should,19-25
be,26-28
used,29-33
when,34-38
administering,39-52
nitazoxanide,53-65	DrugDDI.d272.s1.e0
concurrently,66-78
with,79-83
other,84-89
highly,90-96
plasma,97-103
protein-bound,104-117
drugs,118-123
with,124-128
narrow,129-135
therapeutic,136-147
indices,,148-156
as,157-159
competition,160-171
for,172-175
binding,176-183
sites,184-189
may,190-193
occur,194-199
(e.g.,,200-206
warfarin).,207-217	DrugDDI.d272.s1.e1

In,0-2
vitro,3-8
metabolism,9-19
studies,20-27
have,28-32
demonstrated,33-45
that,46-50
tizoxanide,51-61	DrugDDI.d272.s2.e0
has,62-65
no,66-68
significant,69-80
inhibitory,81-91
effect,92-98
on,99-101
cytochrome,102-112	DrugDDI.d272.s2.e1
P450,113-117	DrugDDI.d272.s2.e1
enzymes.,118-126

Although,0-8
no,9-11
drug-drug,12-21
interaction,22-33
studies,34-41
have,42-46
been,47-51
conducted,52-61
in,62-64
vivo,,65-70
it,71-73
is,74-76
expected,77-85
that,86-90
no,91-93
significant,94-105
interaction,106-117
would,118-123
occur,124-129
when,130-134
nitazoxanide,135-147	DrugDDI.d272.s3.e0
is,148-150
co-administered,151-166
with,167-171
drugs,172-177	DrugDDI.d272.s3.e1
that,178-182
either,183-189
are,190-193
metabolized,194-205
by,206-208
or,209-211
inhibit,212-219
cytochrome,220-230	DrugDDI.d272.s3.e2
P450,231-235	DrugDDI.d272.s3.e2
enzymes.,236-244

No,0-2
formal,3-9
drug-interaction,10-26
studies,27-34
have,35-39
been,40-44
performed,,45-55
and,56-59
a,60-61
clinically,62-72
significant,73-84
interaction,85-96
with,97-101
other,102-107	DrugDDI.d474.s0.e0
medications,108-119	DrugDDI.d474.s0.e0
used,120-124
in,125-127
the,128-131
treatment,132-141
of,142-144
hypoxic,145-152
respiratory,153-164
failure,165-172
cannot,173-179
be,180-182
excluded,183-191
based,192-197
on,198-200
the,201-204
available,205-214
data.,215-220

INOmax,0-6	DrugDDI.d474.s1.e0
has,7-10
been,11-15
administered,16-28
with,29-33
tolazoline,,34-45
dopamine,,46-55
dobutamine,,56-67
steroids,,68-77
surfactant,,78-89
and,90-93
high-frequency,94-108
ventilation.,109-121

Although,0-8
there,9-14
are,15-18
no,19-21
study,22-27
data,28-32
to,33-35
evaluate,36-44
the,45-48
possibility,,49-61
nitric,62-68	DrugDDI.d474.s2.e0
oxide,69-74	DrugDDI.d474.s2.e0
donor,75-80	DrugDDI.d474.s2.e0
compounds,,81-91	DrugDDI.d474.s2.e0
including,92-101
sodium,102-108	DrugDDI.d474.s2.e1
nitroprusside,109-122	DrugDDI.d474.s2.e1
and,123-126
nitroglycerin,,127-141
may,142-145
have,146-150
an,151-153
additive,154-162
effect,163-169
with,170-174
INOmax,175-181	DrugDDI.d474.s2.e3
on,182-184
the,185-188
risk,189-193
of,194-196
developing,197-207
methemoglobinemia.,208-226

An,0-2
association,3-14
between,15-22
prilocaine,23-33	DrugDDI.d474.s3.e0
and,34-37
an,38-40
increased,41-50
risk,51-55
of,56-58
methaemoglobinaemia,,59-79
particularly,80-92
in,93-95
infants,,96-104
has,105-108
specifically,109-121
been,122-126
described,127-136
in,137-139
a,140-141
literature,142-152
case,153-157
report.,158-165

This,0-4
risk,5-9
is,10-12
present,13-20
whether,21-28
the,29-32
drugs,33-38	DrugDDI.d474.s4.e0
are,39-42
administered,43-55
as,56-58
oral,,59-64
parenteral,,65-76
or,77-79
topical,80-87
formulations.,88-101

Antacids,0-8	DrugDDI.d405.s0.e0
containing,9-19
magnesium,20-29	DrugDDI.d405.s0.e1
trisilicate,,30-42	DrugDDI.d405.s0.e1
when,43-47
administered,48-60
concomitantly,61-74
with,75-79
nitrofurantoin,,80-95
reduce,96-102
both,103-107
the,108-111
rate,112-116
and,117-120
extent,121-127
of,128-130
absorption.,131-142

The,0-3
mechanism,4-13
for,14-17
this,18-22
interaction,23-34
probably,35-43
is,44-46
adsorption,47-57
of,58-60
nitrofurantoin,61-75	DrugDDI.d405.s1.e0
onto,76-80
the,81-84
surface,85-92
of,93-95
magnesium,96-105	DrugDDI.d405.s1.e1
trisilicate.,106-118	DrugDDI.d405.s1.e1

Uricosuric,0-10
drugs,,11-17
such,18-22
as,23-25
probenecid,26-36	DrugDDI.d405.s2.e1
and,37-40
sulfinpyrazone,,41-56
can,57-60
inhibit,61-68
renal,69-74
tubular,75-82
secretion,83-92
of,93-95
nitrofurantoin.,96-111	DrugDDI.d405.s2.e3

The,0-3
resulting,4-13
increase,14-22
in,23-25
nitrofurantoin,26-40	DrugDDI.d405.s3.e0
serum,41-46
levels,47-53
may,54-57
increase,58-66
toxicity,,67-76
and,77-80
the,81-84
decreased,85-94
urinary,95-102
levels,103-109
could,110-115
lessen,116-122
its,123-126
efficacy,127-135
as,136-138
a,139-140
urinary,141-148
tract,149-154
antibacterial.,155-169	DrugDDI.d405.s3.e1

Drug/Laboratory,0-15	DrugDDI.d405.s4.e0
Test,16-20
Interactions,21-33
As,34-36
a,37-38
result,39-45
of,46-48
the,49-52
presence,53-61
of,62-64
nitrofurantoin,,65-80
a,81-82
false-positive,83-97
reaction,98-106
for,107-110
glucose,111-118	DrugDDI.d405.s4.e2
in,119-121
the,122-125
urine,126-131
may,132-135
occur.,136-142

This,0-4
has,5-8
been,9-13
observed,14-22
with,23-27
Benedict?s,28-38
and,39-42
Fehling?s,43-52
solutions,53-62
but,63-66
not,67-70
with,71-75
the,76-79
glucose,80-87	DrugDDI.d405.s5.e0
enzymatic,88-97
test.,98-103

The,0-3
vasodilating,4-16
effects,17-24
of,25-27
nitroglycerin,28-41	DrugDDI.d511.s0.e0
may,42-45
be,46-48
additive,49-57
with,58-62
those,63-68
of,69-71
other,72-77
vasodilators.,78-91	DrugDDI.d511.s0.e1

Alcohol,,0-8
in,9-11
particular,,12-23
has,24-27
been,28-32
found,33-38
to,39-41
exhibit,42-49
additive,50-58
effects,59-66
of,67-69
this,70-74
variety.,75-83

Marked,0-6
symptomatic,7-18
orthostatic,19-30
hypotension,31-42
has,43-46
been,47-51
reported,52-60
when,61-65
calcium,66-73	DrugDDI.d511.s2.e0
channel,74-81	DrugDDI.d511.s2.e0
blockers,82-90	DrugDDI.d511.s2.e0
and,91-94
organic,95-102
nitrates,103-111	DrugDDI.d511.s2.e1
were,112-116
used,117-121
in,122-124
combination.,125-137

The,0-3
hypotensive,4-15
effect,16-22
of,23-25
sodium,26-32	DrugDDI.d57.s0.e0
nitroprusside,33-46	DrugDDI.d57.s0.e0
is,47-49
augmented,50-59
by,60-62
that,63-67
of,68-70
most,71-75
other,76-81
hypotensive,82-93	DrugDDI.d57.s0.e1
drugs,,94-100	DrugDDI.d57.s0.e1
including,101-110
ganglionic,111-121	DrugDDI.d57.s0.e2
blocking,122-130	DrugDDI.d57.s0.e2
agents,,131-138	DrugDDI.d57.s0.e2
negative,139-147
inotropic,148-157	DrugDDI.d57.s0.e3
agents,,158-165	DrugDDI.d57.s0.e3
and,166-169
inhaled,170-177	DrugDDI.d57.s0.e4
anesthetics.,178-190	DrugDDI.d57.s0.e4

No,0-2
interactions,3-15
have,16-20
been,21-25
observed,26-34
between,35-42
nizatidine,43-53	DrugDDI.d538.s0.e0
and,54-57
theophylline,,58-71
chlordiazepoxide,,72-89
lorazepam,,90-100
lidocaine,,101-111
phenytoin,,112-122
and,123-126
warfarin.,127-136	DrugDDI.d538.s0.e6

Nizatidine,0-10	DrugDDI.d538.s1.e0
does,11-15
not,16-19
inhibit,20-27
the,28-31
cytochrome,32-42	DrugDDI.d538.s1.e1
P-450-linked,43-55	DrugDDI.d538.s1.e1
drug-metabolizing,56-73	DrugDDI.d538.s1.e1
enzyme,74-80
system;,81-88

In,0-2
patients,3-11
given,12-17
very,18-22
high,23-27
doses,28-33
(3900,34-39
mg),40-43
of,44-46
aspirin,47-54	DrugDDI.d538.s3.e0
daily,,55-61
increases,62-71
in,72-74
serum,75-80
salicylate,81-91
levels,92-98
were,99-103
seen,104-108
when,109-113
nizatidine,,114-125
150,126-129
mg,130-132
b.i.d.,,133-140
was,141-144
administered,145-157
concurrently.,158-171

The,0-3
effectiveness,4-17
of,18-20
progestin-only,21-35	DrugDDI.d51.s0.e0
pills,36-41
is,42-44
reduced,45-52
by,53-55
hepatic,56-63
enzyme-inducing,64-79
drugs,80-85	DrugDDI.d51.s0.e1
such,86-90
as,91-93
the,94-97
anticonvulsants,98-113	DrugDDI.d51.s0.e2
phenytoin,,114-124
carbamazepine,,125-139
and,140-143
barbiturates,,144-157
and,158-161
the,162-165
antituberculosis,166-182	DrugDDI.d51.s0.e5
drug,183-187
rifampin.,188-197

Elevated,0-8
plasma,9-15
levels,16-22
of,23-25
theophylline,26-38	DrugDDI.d19.s0.e0
have,39-43
been,44-48
reported,49-57
with,58-62
concomitant,63-74
quinolone,75-84	DrugDDI.d19.s0.e1
use.,85-89

There,0-5
have,6-10
been,11-15
reports,16-23
of,24-26
theophylline-related,27-47	DrugDDI.d19.s1.e0
side,48-52
effects,53-60
in,61-63
patients,64-72
on,73-75
concomitant,76-87
therapy,88-95
with,96-100
norfloxacin,101-112	DrugDDI.d19.s1.e1
and,113-116
theophylline.,117-130	DrugDDI.d19.s1.e2

Therefore,,0-10
monitoring,11-21
of,22-24
theophylline,25-37	DrugDDI.d19.s2.e0
plasma,38-44
levels,45-51
should,52-58
be,59-61
considered,62-72
and,73-76
dosage,77-83
of,84-86
theophylline,87-99
adjusted,100-108
as,109-111
required.,112-121

Elevated,0-8
serum,9-14
levels,15-21
of,22-24
cyclosporine,25-37	DrugDDI.d19.s3.e0
have,38-42
been,43-47
reported,48-56
with,57-61
concomitant,62-73
use,74-77
of,78-80
cyclosporine,81-93	DrugDDI.d19.s3.e1
with,94-98
norfloxacin.,99-111	DrugDDI.d19.s3.e2

Therefore,,0-10
cyclosporine,11-23	DrugDDI.d19.s4.e0
serum,24-29
levels,30-36
should,37-43
be,44-46
monitored,47-56
and,57-60
appropriate,61-72
cyclosporine,73-85	DrugDDI.d19.s4.e1
dosage,86-92
adjustments,93-104
made,105-109
when,110-114
these,115-120
drugs,121-126	DrugDDI.d19.s4.e2
are,127-130
used,131-135
concomitantly.,136-150

Quinolones,,0-11
including,12-21
norfloxacin,,22-34
may,35-38
enhance,39-46
the,47-50
effects,51-58
of,59-61
oral,62-66	DrugDDI.d19.s5.e2
anticoagulants,,67-82	DrugDDI.d19.s5.e2
including,83-92
warfarin,93-101	DrugDDI.d19.s5.e3
or,102-104
its,105-108
derivatives,109-120	DrugDDI.d19.s5.e4
or,121-123
similar,124-131
agents.,132-139

The,0-3
concomitant,4-15
administration,16-30
of,31-33
quinolones,34-44	DrugDDI.d19.s7.e0
including,45-54
norfloxacin,55-66	DrugDDI.d19.s7.e1
with,67-71
glyburide,72-81	DrugDDI.d19.s7.e2
(a,82-84
sulfonylurea,85-97	DrugDDI.d19.s7.e3
agent),98-104
has,,105-109
on,110-112
rare,113-117
occasions,,118-128
resulted,129-137
in,138-140
severe,141-147
hypoglycemia.,148-161

Diminished,0-10
urinary,11-18
excretion,19-28
of,29-31
norfloxacin,32-43	DrugDDI.d19.s9.e0
has,44-47
been,48-52
reported,53-61
during,62-68
the,69-72
concomitant,73-84
administration,85-99
of,100-102
probenecid,103-113	DrugDDI.d19.s9.e1
and,114-117
norfloxacin.,118-130	DrugDDI.d19.s9.e2

The,0-3
concomitant,4-15
use,16-19
of,20-22
nitrofurantoin,23-37	DrugDDI.d19.s10.e0
is,38-40
not,41-44
recommended,45-56
since,57-62
nitrofurantoin,63-77	DrugDDI.d19.s10.e1
may,78-81
antagonize,82-92
the,93-96
antibacterial,97-110	DrugDDI.d19.s10.e2
effect,111-117
of,118-120
Norfloxacin,121-132	DrugDDI.d19.s10.e3
in,133-135
the,136-139
urinary,140-147
tract.,148-154

Multivitamins,,0-14
or,15-17
other,18-23
products,24-32
containing,33-43
iron,44-48	DrugDDI.d19.s11.e1
or,49-51
zinc,,52-57
antacids,58-66	DrugDDI.d19.s11.e3
or,67-69
sucralfate,70-80	DrugDDI.d19.s11.e4
should,81-87
not,88-91
be,92-94
administered,95-107
concomitantly,108-121
with,,122-127
or,128-130
within,131-137
2,138-139
hours,140-145
of,,146-149
the,150-153
administration,154-168
of,169-171
norfloxacin,,172-184
because,185-192
they,193-197
may,198-201
interfere,202-211
with,212-216
absorption,217-227
resulting,228-237
in,238-240
lower,241-246
serum,247-252
and,253-256
urine,257-262
levels,263-269
of,270-272
norfloxacin.,273-285	DrugDDI.d19.s11.e6

Videx,0-5	DrugDDI.d19.s12.e0
(Didanosine),6-18
chewable/buffered,19-36
tablets,37-44
or,45-47
the,48-51
pediatric,52-61	DrugDDI.d19.s12.e3
powder,62-68
for,69-72
oral,73-77
solution,78-86
should,87-93
not,94-97
be,98-100
administered,101-113
concomitantly,114-127
with,,128-133
or,134-136
within,137-143
2,144-145
hours,146-151
of,,152-155
the,156-159
administration,160-174
of,175-177
norfloxacin,,178-190
because,191-198
these,199-204
products,205-213
may,214-217
interfere,218-227
with,228-232
absorption,233-243
resulting,244-253
in,254-256
lower,257-262
serum,263-268
and,269-272
urine,273-278
levels,279-285
of,286-288
norfloxacin.,289-301	DrugDDI.d19.s12.e5

Some,0-4
quinolones,5-15	DrugDDI.d19.s13.e0
have,16-20
also,21-25
been,26-30
shown,31-36
to,37-39
interfere,40-49
with,50-54
the,55-58
metabolism,59-69
of,70-72
caffeine.,73-82	DrugDDI.d19.s13.e1

This,0-4
may,5-8
lead,9-13
to,14-16
reduced,17-24
clearance,25-34
of,35-37
caffeine,38-46	DrugDDI.d19.s14.e0
and,47-50
a,51-52
prolongation,53-65
of,66-68
its,69-72
plasma,73-79
half-life.,80-90

Reduced,0-7
efficacy,8-16
and,17-20
increased,21-30
incidence,31-40
of,41-43
breakthrough,44-56
bleeding,57-65
and,66-69
menstrual,70-79
irregularities,80-94
have,95-99
been,100-104
associated,105-115
with,116-120
concomitant,121-132
use,133-136
of,137-139
rifampin.,140-149	DrugDDI.d432.s0.e0

A,0-1
similar,2-9
association,,10-22
though,23-29
less,30-34
marked,,35-42
has,43-46
been,47-51
suggested,52-61
with,62-66
barbiturates,,67-80
phenylbutazone,,81-96
phenytoin,97-106	DrugDDI.d432.s1.e2
sodium,,107-114	DrugDDI.d432.s1.e2
carbamazepine,,115-129
griseofulvin,,130-143
topiramate,,144-155
and,156-159
possibly,160-168
with,169-173
ampicillin,174-184	DrugDDI.d432.s1.e6
and,185-188
tetracyclines,189-202	DrugDDI.d432.s1.e7
72.,203-206

A,0-1
possible,2-10
interaction,11-22
has,23-26
been,27-31
suggested,32-41
with,42-46
hormonal,47-55
contraceptives,56-70	DrugDDI.d432.s2.e0
and,71-74
the,75-78
herbal,79-85
supplement,86-96
St.,97-100	DrugDDI.d432.s2.e1
Johns,101-106	DrugDDI.d432.s2.e1
Wort,107-111	DrugDDI.d432.s2.e1
based,112-117
on,118-120
some,121-125
reports,126-133
of,134-136
oral,137-141	DrugDDI.d432.s2.e2
contraceptive,142-155	DrugDDI.d432.s2.e2
users,156-161
experiencing,162-174
breakthrough,175-187
bleeding,188-196
shortly,197-204
after,205-210
starting,211-219
St.,220-223	DrugDDI.d432.s2.e3
Johns,224-229	DrugDDI.d432.s2.e3
Wort.,230-235	DrugDDI.d432.s2.e3

Pregnancies,0-11
have,12-16
been,17-21
reported,22-30
by,31-33
users,34-39
of,40-42
combined,43-51
hormonal,52-60
contraceptives,61-75	DrugDDI.d432.s3.e0
who,76-79
also,80-84
used,85-89
some,90-94
form,95-99
of,100-102
St.,103-106	DrugDDI.d432.s3.e1
Johns,107-112	DrugDDI.d432.s3.e1
Wort.,113-118	DrugDDI.d432.s3.e1

Healthcare,0-10
prescribers,11-22
are,23-26
advised,27-34
to,35-37
consult,38-45
the,46-49
package,50-57
inserts,58-65
of,66-68
medication,69-79	DrugDDI.d432.s4.e0
administered,80-92
concomitantly,93-106
with,107-111
oral,112-116	DrugDDI.d432.s4.e1
contraceptives.,117-132	DrugDDI.d432.s4.e1

Steady-state,0-12
serum,13-18
concentrations,19-33
of,34-36
tricyclic,37-46	DrugDDI.d124.s0.e0
antidepressants,47-62	DrugDDI.d124.s0.e0
are,63-66
reported,67-75
to,76-78
fluctuate,79-88
significantly,89-102
when,103-107
cimetidine,108-118	DrugDDI.d124.s0.e1
is,119-121
either,122-128
added,129-134
or,135-137
deleted,138-145
from,146-150
the,151-154
drug,155-159	DrugDDI.d124.s0.e2
regimen.,160-168

Serious,0-7
anticholinergic,8-23	DrugDDI.d124.s1.e0
symptoms,24-32
(severe,33-40
dry,41-44
mouth,,45-51
urinary,52-59
retention,,60-70
blurred,71-78
vision),79-86
have,87-91
been,92-96
associated,97-107
with,108-112
elevations,113-123
in,124-126
the,127-130
serum,131-136
levels,137-143
of,144-146
tricyclic,147-156	DrugDDI.d124.s1.e1
antidepressants,157-172	DrugDDI.d124.s1.e1
when,173-177
cimetidine,178-188	DrugDDI.d124.s1.e2
is,189-191
added,192-197
to,198-200
the,201-204
drug,205-209	DrugDDI.d124.s1.e3
regimen.,210-218

In,0-2
addition,,3-12
higher-than,13-24
expected,25-33
steady-state,34-46
serum,47-52
concentrations,53-67
of,68-70
tricyclic,71-80	DrugDDI.d124.s2.e0
antidepressants,81-96	DrugDDI.d124.s2.e0
have,97-101
been,102-106
observed,107-115
when,116-120
therapy,121-128
is,129-131
initiated,132-141
in,142-144
patients,145-153
already,154-161
taking,162-168
cimetidine.,169-180	DrugDDI.d124.s2.e1

In,0-2
well-controlled,3-18
patients,19-27
undergoing,28-38
concurrent,39-49
therapy,50-57
with,58-62
cimetidine,,63-74
a,75-76
decrease,77-85
in,86-88
the,89-92
steady-state,93-105
serum,106-111
concentrations,112-126
of,127-129
tricyclic,130-139	DrugDDI.d124.s3.e1
antidepressants,140-155	DrugDDI.d124.s3.e1
may,156-159
occur,160-165
when,166-170
cime-tidine,171-182
therapy,183-190
is,191-193
discontinued.,194-207

The,0-3
therapeutic,4-15
efficacy,16-24
of,25-27
tricyclic,28-37	DrugDDI.d124.s4.e0
antidepressants,38-53	DrugDDI.d124.s4.e0
may,54-57
be,58-60
compromised,61-72
in,73-75
these,76-81
patients,82-90
when,91-95
cimetidine,96-106	DrugDDI.d124.s4.e1
is,107-109
discontinued.,110-123

Several,0-7
of,8-10
the,11-14
tricyclic,15-24	DrugDDI.d124.s5.e0
antidepressants,25-40	DrugDDI.d124.s5.e0
have,41-45
been,46-50
cited,51-56
in,57-59
these,60-65
reports.,66-74

There,0-5
have,6-10
been,11-15
greater,16-23
than,24-28
2-fold,29-35
increases,36-45
in,46-48
previously,49-59
stable,60-66
plasma,67-73
levels,74-80
of,81-83
other,84-89
antidepressants,,90-106
including,107-116
nortriptyline,,117-131
when,132-136
fluoxetine,137-147	DrugDDI.d124.s6.e2
hydrochloride,148-161	DrugDDI.d124.s6.e2
has,162-165
been,166-170
administered,171-183
in,184-186
combination,187-198
with,199-203
these,204-209
agents.,210-217

Fluoxetine,0-10	DrugDDI.d124.s7.e0
and,11-14
its,15-18
active,19-25	DrugDDI.d124.s7.e1
metabolite,,26-37	DrugDDI.d124.s7.e1
norfluoxe-tine,,38-53
have,54-58
long,59-63
half-lives,64-74
(4,75-77
to,78-80
16,81-83
days,84-88
for,89-92
norfluoxetine),,93-108
that,109-113
may,114-117
affect,118-124
strategies,125-135
during,136-142
conversion,143-153
from,154-158
one,159-162
drug,163-167	DrugDDI.d124.s7.e3
to,168-170
the,171-174
other.,175-181

Administration,0-14
of,15-17
reserpine,18-27	DrugDDI.d124.s8.e0
during,28-34
therapy,35-42
with,43-47
a,48-49
tricyclic,50-59	DrugDDI.d124.s8.e1
antidepressant,60-74	DrugDDI.d124.s8.e1
has,75-78
been,79-83
shown,84-89
to,90-92
produce,93-100
a,101-102
?stimulating?,103-116
effect,117-123
in,124-126
some,127-131
depressed,132-141
patients.,142-151

Close,0-5
supervision,6-17
and,18-21
careful,22-29
adjustment,30-40
of,41-43
the,44-47
dosage,48-54
are,55-58
required,59-67
when,68-72
nortriptyline,73-86	DrugDDI.d124.s9.e0
hydrochloride,87-100	DrugDDI.d124.s9.e0
is,101-103
used,104-108
with,109-113
other,114-119
anticholinergic,120-135	DrugDDI.d124.s9.e1
drugs,136-141	DrugDDI.d124.s9.e1
or,142-144
sympathomimetic,145-160	DrugDDI.d124.s9.e2
drugs.,161-167	DrugDDI.d124.s9.e2

The,0-3
patient,4-11
should,12-18
be,19-21
informed,22-30
that,31-35
the,36-39
response,40-48
to,49-51
alcohol,52-59	DrugDDI.d124.s10.e0
may,60-63
be,64-66
exaggerated.,67-79

Drugs,0-5	DrugDDI.d124.s11.e0
Metabolized,6-17
by,18-20
P450IID6,21-29
?A,30-32
subset,33-39
(3%,40-43
to,44-46
10%),47-51
of,52-54
the,55-58
population,59-69
has,70-73
reduced,74-81
activity,82-90
of,91-93
certain,94-101
drug,102-106	DrugDDI.d124.s11.e1
metabolizing,107-119
enzymes,120-127
such,128-132
as,133-135
the,136-139
cytochrome,140-150	DrugDDI.d124.s11.e2
P450,151-155	DrugDDI.d124.s11.e2
isoenzyme,156-165
P450IID6.,166-175

Such,0-4
individuals,5-16
are,17-20
referred,21-29
to,30-32
as,33-35
?poor,36-41
metabolizers?,42-55
of,56-58
drugs,59-64	DrugDDI.d124.s12.e0
such,65-69
as,70-72
debrisoquin,,73-85
dextromethorphan,,86-103
and,104-107
the,108-111
tricyclic,112-121	DrugDDI.d124.s12.e3
antidepressants.,122-138	DrugDDI.d124.s12.e3

These,0-5
individuals,6-17
may,18-21
have,22-26
higher,27-33
than,34-38
expected,39-47
plasma,48-54
concentrations,55-69
of,70-72
tricyclic,73-82	DrugDDI.d124.s13.e0
antidepressants,83-98	DrugDDI.d124.s13.e0
when,99-103
given,104-109
usual,110-115
doses.,116-122

In,0-2
addition,,3-12
certain,13-20
drugs,21-26	DrugDDI.d124.s14.e0
that,27-31
are,32-35
metabolized,36-47
by,48-50
this,51-55
isoenzyme,,56-66
including,67-76
many,77-81
antidepressants,82-97	DrugDDI.d124.s14.e2
(tricyclic,98-108
antidepressants,,109-125
selective,126-135
serotonin,136-145	DrugDDI.d124.s14.e4
reuptake,146-154	DrugDDI.d124.s14.e4
inhibitors,,155-166	DrugDDI.d124.s14.e4
and,167-170
others),,171-179
may,180-183
inhibit,184-191
the,192-195
activity,196-204
of,205-207
this,208-212
isoenzyme,,213-223
and,224-227
thus,228-232
may,233-236
make,237-241
normal,242-248
metab-olizers,249-262
resemble,263-271
poor,272-276
metabolizers,277-289
with,290-294
regard,295-301
to,302-304
concomitant,305-316
therapy,317-324
with,325-329
other,330-335
drugs,336-341	DrugDDI.d124.s14.e6
metabolized,342-353
by,354-356
this,357-361
enzyme,362-368
system,,369-376
leading,377-384
to,385-387
drug,388-392
interactions.,393-406

Concomitant,0-11
use,12-15
of,16-18
tricyclic,19-28	DrugDDI.d124.s15.e0
antidepressants,29-44	DrugDDI.d124.s15.e0
with,45-49
other,50-55
drugs,56-61	DrugDDI.d124.s15.e1
metabolized,62-73
by,74-76
cytochrome,77-87	DrugDDI.d124.s15.e2
P450IID6,88-96
may,97-100
require,101-108
lower,109-114
doses,115-120
than,121-125
usually,126-133
prescribed,134-144
for,145-148
either,149-155
the,156-159
tricyclic,160-169	DrugDDI.d124.s15.e3
antidepressant,170-184	DrugDDI.d124.s15.e3
or,185-187
the,188-191
other,192-197
drug.,198-203	DrugDDI.d124.s15.e4

Therefore,,0-10
co-administration,11-28
of,29-31
tricyclic,32-41	DrugDDI.d124.s16.e0
antidepressants,42-57	DrugDDI.d124.s16.e0
with,58-62
other,63-68
drugs,69-74	DrugDDI.d124.s16.e1
that,75-79
are,80-83
metabolized,84-95
by,96-98
this,99-103
isoenzyme,,104-114
including,115-124
other,125-130
antidepressants,,131-147
phenothiazines,,148-163
carbamazepine,,164-178
and,179-182
Type,183-187
1C,188-190
antiarrhythmics,191-206	DrugDDI.d124.s16.e6
(eg,,207-211
propafenone,,212-224
flecainide,,225-236
and,237-240
encainide),,241-252
or,253-255
that,256-260
inhibit,261-268
this,269-273
enzyme,274-280
(eg,,281-285
quinidine),,286-297
should,298-304
be,305-307
approached,308-318
with,319-323
caution.,324-332

Oxcarbazepine,0-13	DrugDDI.d168.s0.e0
can,14-17
inhibit,18-25
CYP2C19,26-33	DrugDDI.d168.s0.e1
and,34-37
induce,38-44
CYP3A4/5,45-53	DrugDDI.d168.s0.e2
with,54-58
potentially,59-70
important,71-80
effects,81-88
on,89-91
plasma,92-98
concentrations,99-113
of,114-116
other,117-122
drugs.,123-129	DrugDDI.d168.s0.e3

In,0-2
addition,,3-12
several,13-20
AED?s,21-26
that,27-31
are,32-35
cytochrome,36-46	DrugDDI.d168.s1.e0
P450,47-51	DrugDDI.d168.s1.e0
inducers,52-60
can,61-64
decrease,65-73
plasma,74-80
concentrations,81-95
of,96-98
oxcarbazepine,99-112	DrugDDI.d168.s1.e1
and,113-116
MHD.,117-121

Oxcarbazepine,0-13	DrugDDI.d168.s2.e0
was,14-17
evaluated,18-27
in,28-30
human,31-36
liver,37-42
microsomes,43-53
to,54-56
determine,57-66
its,67-70
capacity,71-79
to,80-82
inhibit,83-90
the,91-94
major,95-100
cytochrome,101-111	DrugDDI.d168.s2.e1
P450,112-116	DrugDDI.d168.s2.e1
enzymes,117-124
responsible,125-136
for,137-140
the,141-144
metabolism,145-155
of,156-158
other,159-164
drugs.,165-171	DrugDDI.d168.s2.e2

Results,0-7
demonstrate,8-19
that,20-24
oxcarbazepine,25-38	DrugDDI.d168.s3.e0
and,39-42
its,43-46
pharmacologically,47-64
active,65-71	DrugDDI.d168.s3.e1
10-monohydroxy,72-86	DrugDDI.d168.s3.e1
metabolite,87-97	DrugDDI.d168.s3.e1
(MHD),98-103
have,104-108
little,109-115
or,116-118
no,119-121
capacity,122-130
to,131-133
function,134-142
as,143-145
inhibitors,146-156
for,157-160
most,161-165
of,166-168
the,169-172
human,173-178
cytochrome,179-189	DrugDDI.d168.s3.e2
P450,190-194	DrugDDI.d168.s3.e2
enzymes,195-202
evaluated,203-212
(CYP1A2,,213-221
CYP2A6,,222-229
CYP2C9,,230-237
CYP2D6,,238-245
CYP2E1,,246-253
CYP4A9,254-260
and,261-264
CYP4A11),265-273	DrugDDI.d168.s3.e8
with,274-278
the,279-282
exception,283-292
of,293-295
CYP2C19,296-303	DrugDDI.d168.s3.e9
and,304-307
CYP3A4/5.,308-317	DrugDDI.d168.s3.e10

Although,0-8
inhibition,9-19
of,20-22
CYP,23-26	DrugDDI.d168.s4.e0
3A4/5,27-32
by,33-35
OXC,36-39
and,40-43
MHD,44-47
did,48-51
occur,52-57
at,58-60
high,61-65
concentrations,,66-81
it,82-84
is,85-87
not,88-91
likely,92-98
to,99-101
be,102-104
of,105-107
clinical,108-116
significance.,117-130

The,0-3
inhibition,4-14
of,15-17
CYP-2C19,18-26	DrugDDI.d168.s5.e0
by,27-29
OXC,30-33
and,34-37
MHD,,38-42
however,,43-51
is,52-54
clinically,55-65
relevant.,66-75

In,0-2
vitro,,3-9
the,10-13
UDP-glucuronyl,14-28	DrugDDI.d168.s6.e0
transferase,29-40	DrugDDI.d168.s6.e0
level,41-46
was,47-50
increased,,51-61
indicating,62-72
induction,73-82
of,83-85
this,86-90
enzyme.,91-98

Increases,0-9
of,10-12
22%,13-16
with,17-21
MHD,22-25
and,26-29
47%,30-33
with,34-38
oxcarbazepine,39-52	DrugDDI.d168.s7.e0
were,53-57
observed.,58-67

As,0-2
MHD,,3-7
the,8-11
predominant,12-23
plasma,24-30
substrate,,31-41
is,42-44
only,45-49
a,50-51
weak,52-56
inducer,57-64
of,65-67
UDP-glucuronyl,68-82	DrugDDI.d168.s8.e0
transferase,,83-95	DrugDDI.d168.s8.e0
it,96-98
is,99-101
unlikely,102-110
to,111-113
have,114-118
an,119-121
effect,122-128
on,129-131
drugs,132-137	DrugDDI.d168.s8.e1
that,138-142
are,143-146
mainly,147-153
eliminated,154-164
by,165-167
conjugation,168-179
through,180-187
UDP-glucuronyl,188-202	DrugDDI.d168.s8.e2
transferase,203-214	DrugDDI.d168.s8.e2
(e.g.,,215-221
valproic,222-230	DrugDDI.d168.s8.e3
acid,,231-236	DrugDDI.d168.s8.e3
lamotrigine).,237-250	DrugDDI.d168.s8.e4

In,0-2
addition,,3-12
oxcarbazepine,13-26	DrugDDI.d168.s9.e0
and,27-30
MHD,31-34
induce,35-41
a,42-43
subgroup,44-52
of,53-55
the,56-59
cytochrome,60-70	DrugDDI.d168.s9.e1
P450,71-75	DrugDDI.d168.s9.e1
3A,76-78	DrugDDI.d168.s9.e1
family,79-85
(CYP3A4,86-93
and,94-97
CYP3A5),98-105	DrugDDI.d168.s9.e3
responsible,106-117
for,118-121
the,122-125
metabolism,126-136
of,137-139
dihydropyridine,140-155
calcium,156-163	DrugDDI.d168.s9.e4
antagonists,164-175	DrugDDI.d168.s9.e4
and,176-179
oral,180-184	DrugDDI.d168.s9.e5
contraceptives,,185-200	DrugDDI.d168.s9.e5
resulting,201-210
in,211-213
a,214-215
lower,216-221
plasma,222-228
concentration,229-242
of,243-245
these,246-251
drugs.,252-258	DrugDDI.d168.s9.e6

As,0-2
binding,3-10
of,11-13
MHD,14-17
to,18-20
plasma,21-27	DrugDDI.d168.s10.e0
proteins,28-36	DrugDDI.d168.s10.e0
is,37-39
low,40-43
(40%),,44-50
clinically,51-61
significant,62-73
interactions,74-86
with,87-91
other,92-97
drugs,98-103	DrugDDI.d168.s10.e1
through,104-111
competition,112-123
for,124-127
protein,128-135	DrugDDI.d168.s10.e2
binding,136-143
sites,144-149
are,150-153
unlikely.,154-163

Antiepileptic,0-13	DrugDDI.d168.s11.e0
drugs,14-19	DrugDDI.d168.s11.e0
Potential,20-29
interactions,30-42
between,43-50
Trileptal,51-60	DrugDDI.d168.s11.e1
and,61-64
other,65-70
AEDs,71-75
were,76-80
assessed,81-89
in,90-92
clinical,93-101
studies.,102-110

The,0-3
effect,4-10
of,11-13
these,14-19
interactions,20-32
on,33-35
mean,36-40
AUCs,41-45
and,46-49
Cmin,50-54
are,55-58
summarized,59-69
in,70-72
Table,73-78
2:,79-81
Table,82-87
2:,88-90
Summary,91-98
of,99-101
AED,102-105
interactions,106-118
with,119-123
Trileptal,124-133	DrugDDI.d168.s12.e0

Trileptal,0-9	DrugDDI.d168.s15.e0
dose,10-14
(mg/day),15-23

Influence,0-9
of,10-12
Trileptal,13-22	DrugDDI.d168.s16.e0
on,23-25
AED,26-29
Concentration,30-43
(Mean,44-49
change,,50-57
90%,58-61
Confidence,62-72
Interval),73-82

Carbamazepine,0-13	DrugDDI.d168.s18.e0

Phenobarbital,0-13	DrugDDI.d168.s22.e0

Phenytoin,0-9	DrugDDI.d168.s26.e0

Valproic,0-8	DrugDDI.d168.s31.e0
acid,9-13	DrugDDI.d168.s31.e0

1-,0-2
nc,3-5
denotes,6-13
a,14-15
mean,16-20
change,21-27
of,28-30
less,31-35
than,36-40
10%,41-44
2-,45-47
Pediatrics,48-58
3-,59-61
Mean,62-66
increase,67-75
in,76-78
adults,79-85
at,86-88
high,89-93
Trileptal,94-103	DrugDDI.d168.s35.e0
doses,104-109
In,110-112
vivo,,113-118
the,119-122
plasma,123-129
levels,130-136
of,137-139
phenytoin,140-149	DrugDDI.d168.s35.e1
increased,150-159
by,160-162
up,163-165
to,166-168
40%,,169-173
when,174-178
Trileptal,179-188	DrugDDI.d168.s35.e2
was,189-192
given,193-198
at,199-201
doses,202-207
above,208-213
1200,214-218
mg/day.,219-226

Therefore,,0-10
when,11-15
using,16-21
doses,22-27
of,28-30
Trileptal,31-40	DrugDDI.d168.s36.e0
greater,41-48
than,49-53
1200,54-58
mg/day,59-65
during,66-72
adjunctive,73-83
therapy,,84-92
a,93-94
decrease,95-103
in,104-106
the,107-110
dose,111-115
of,116-118
phenytoin,119-128	DrugDDI.d168.s36.e1
may,129-132
be,133-135
required.,136-145

The,0-3
increase,4-12
of,13-15
phenobarbital,16-29
level,,30-36
however,,37-45
is,46-48
small,49-54
(15%),55-60
when,61-65
given,66-71
with,72-76
Trileptal.,77-87	DrugDDI.d168.s37.e0

Strong,0-6
inducers,7-15
of,16-18
cytochrome,19-29	DrugDDI.d168.s38.e0
P450,30-34	DrugDDI.d168.s38.e0
enzymes,35-42
(i.e.,43-48
carbamazepine,,49-63
phenytoin,64-73	DrugDDI.d168.s38.e2
and,74-77
phenobarbital),78-92	DrugDDI.d168.s38.e3
have,93-97
been,98-102
shown,103-108
to,109-111
decrease,112-120
the,121-124
plasma,125-131
levels,132-138
of,139-141
MHD,142-145
(29-40%).,146-155

No,0-2
autoinduction,3-16
has,17-20
been,21-25
observed,26-34
with,35-39
Trileptal.,40-50	DrugDDI.d168.s39.e0

Hormonal,0-8
contraceptives,9-23
Co-administration,24-41
of,42-44
Trileptal,45-54	DrugDDI.d168.s40.e0
with,55-59
an,60-62
oral,63-67	DrugDDI.d168.s40.e1
contraceptive,68-81	DrugDDI.d168.s40.e1
has,82-85
been,86-90
shown,91-96
to,97-99
influence,100-109
the,110-113
plasma,114-120
concentrations,121-135
of,136-138
the,139-142
two,143-146
hormonal,147-155
components,,156-167
ethinylestradiol,168-184	DrugDDI.d168.s40.e2
(EE),185-189
and,190-193
levonorgestrel,194-208	DrugDDI.d168.s40.e3
(LNG).,209-215

Therefore,,0-10
concurrent,11-21
use,22-25
of,26-28
Trileptal,29-38	DrugDDI.d168.s43.e0
with,39-43
hormonal,44-52
contraceptives,53-67	DrugDDI.d168.s43.e1
may,68-71
render,72-78
these,79-84
contraceptives,85-99	DrugDDI.d168.s43.e2
less,100-104
effective.,105-115

Studies,0-7
with,8-12
other,13-18
oral,19-23
or,24-26
implant,27-34
contraceptives,35-49	DrugDDI.d168.s44.e0
have,50-54
not,55-58
been,59-63
conducted.,64-74

Calcium,0-7	DrugDDI.d168.s45.e0
Antagonists,8-19	DrugDDI.d168.s45.e0
After,20-25
repeated,26-34
co-administration,35-52
of,53-55
Trileptal,,56-66
the,67-70
AUC,71-74
of,75-77
felodipine,78-88	DrugDDI.d168.s45.e2
was,89-92
lowered,93-100
by,101-103
28%,104-107
[90%,108-112
CI:,113-116
20-33].,117-124

Verapamil,0-9	DrugDDI.d168.s46.e0
produced,10-18
a,19-20
decrease,21-29
of,30-32
20%,33-36
[90%,37-41
CI:,42-45
18-27],46-52
of,53-55
the,56-59
plasma,60-66
levels,67-73
of,74-76
MHD.,77-81

Other,0-5
drug,6-10
interactions,11-23
Cimetidine,,24-35
erythromycin,36-48	DrugDDI.d168.s47.e1
and,49-52
dextropropoxyphene,53-71	DrugDDI.d168.s47.e2
had,72-75
no,76-78
effect,79-85
on,86-88
the,89-92
pharmacokinetics,93-109
of,110-112
MHD.,113-117

Results,0-7
with,8-12
warfarin,13-21	DrugDDI.d168.s48.e0
wshow,22-27
no,28-30
evidence,31-39
of,40-42
interaction,43-54
with,55-59
either,60-66
single,67-73
or,74-76
repeated,77-85
doses,86-91
of,92-94
Trileptal.,95-105	DrugDDI.d168.s48.e1

In,0-2
a,3-4
Phase,5-10
I,11-12
trial,13-18
using,19-24
escalating,25-35
doses,36-41
of,42-44
TAXOL,45-50	DrugDDI.d125.s0.e0
(110-200,51-59
mg/m2),60-66
and,67-70
cisplatin,71-80	DrugDDI.d125.s0.e1
(50,81-84
or,85-87
75,88-90
mg/m2),91-97
given,98-103
as,104-106
sequential,107-117
infusions,,118-128
myelosuppression,129-145
was,146-149
more,150-154
profound,155-163
when,164-168
TAXOL,169-174	DrugDDI.d125.s0.e2
was,175-178
given,179-184
after,185-190
cisplatin,191-200	DrugDDI.d125.s0.e3
than,201-205
with,206-210
the,211-214
alternate,215-224
sequence,225-233
(ie,,234-238
TAXOL,239-244	DrugDDI.d125.s0.e4
before,245-251
cisplatin).,252-263	DrugDDI.d125.s0.e5

Pharmacokinetic,0-15
data,16-20
from,21-25
these,26-31
patients,32-40
demonstrated,41-53
a,54-55
decrease,56-64
in,65-67
paclitaxel,68-78	DrugDDI.d125.s1.e0
clearance,79-88
of,89-91
approximately,92-105
33%,106-109
when,110-114
TAXOL,115-120	DrugDDI.d125.s1.e1
was,121-124
administered,125-137
following,138-147
cisplatin.,148-158	DrugDDI.d125.s1.e2

The,0-3
metabolism,4-14
of,15-17
TAXOL,18-23	DrugDDI.d125.s2.e0
is,24-26
catalyzed,27-36
by,37-39
cytochrome,40-50	DrugDDI.d125.s2.e1
P450,51-55	DrugDDI.d125.s2.e1
isoen-zymes,56-67
CYP2C8,68-74
and,75-78
CYP3A4.,79-86	DrugDDI.d125.s2.e2

In,0-2
the,3-6
absence,7-14
of,15-17
formal,18-24
clinical,25-33
drug,34-38
interaction,39-50
studies,,51-59
caution,60-67
should,68-74
be,75-77
exercised,78-87
when,88-92
administering,93-106
TAXOL,107-112	DrugDDI.d125.s3.e0
concomitantly,113-126
with,127-131
known,132-137
substrates,138-148
or,149-151
inhibitors,152-162
of,163-165
the,166-169
cytochrome,170-180	DrugDDI.d125.s3.e1
P450,181-185	DrugDDI.d125.s3.e1
isoenzymes,186-196
CYP2C8,197-203
and,204-207
CYP3A4.,208-215	DrugDDI.d125.s3.e2

Potential,0-9
interactions,10-22
between,23-30
TAXOL,,31-37
a,38-39
substrate,40-49
of,50-52
CYP3A4,,53-60
and,61-64
protease,65-73	DrugDDI.d125.s4.e2
inhibitors,74-84	DrugDDI.d125.s4.e2
(ritonavir,,85-96
saquinavir,,97-108
indinavir,,109-119
and,120-123
nelfinavir),,124-136
which,137-142
are,143-146
substrates,147-157
and/or,158-164
inhibitors,165-175
of,176-178
CYP3A4,,179-186
have,187-191
not,192-195
been,196-200
evaluated,201-210
in,211-213
clinical,214-222
trials.,223-230

Reports,0-7
in,8-10
the,11-14
literature,15-25
suggest,26-33
that,34-38
plasma,39-45
levels,46-52
of,53-55
doxorubicin,56-67	DrugDDI.d125.s5.e0
(and,68-72
its,73-76
active,77-83	DrugDDI.d125.s5.e1
metabolite,84-94	DrugDDI.d125.s5.e1
doxorubicinol),95-109
may,110-113
be,114-116
increased,117-126
when,127-131
paclitaxel,132-142	DrugDDI.d125.s5.e2
and,143-146
doxorubicin,147-158	DrugDDI.d125.s5.e3
are,159-162
used,163-167
in,168-170
combination.,171-183

Hematology:,0-11
TAXOL,12-17	DrugDDI.d125.s6.e0
therapy,18-25
should,26-32
not,33-36
be,37-39
administered,40-52
to,53-55
patients,56-64
with,65-69
baseline,70-78
neutrophil,79-89
counts,90-96
of,97-99
less,100-104
than,105-109
1,500,110-115
cells/mm3.,116-126

In,0-2
order,3-8
to,9-11
monitor,12-19
the,20-23
occurrence,24-34
of,35-37
myelotoxicity,,38-52
it,53-55
is,56-58
recommended,59-70
that,71-75
frequent,76-84
peripheral,85-95
blood,96-101
cell,102-106
counts,107-113
be,114-116
performed,117-126
on,127-129
all,130-133
patients,134-142
receiving,143-152
TAXOL.,153-159	DrugDDI.d125.s7.e0

Patients,0-8
should,9-15
not,16-19
be,20-22
re-treated,23-33
with,34-38
subsequent,39-49
cycles,50-56
of,57-59
TAXOL,60-65	DrugDDI.d125.s8.e0
until,66-71
neutrophils,72-83
recover,84-91
to,92-94
a,95-96
level,97-102
,103-103
1500,104-108
cells/mm3,109-118
and,119-122
platelets,123-132
recover,133-140
to,141-143
a,144-145
level,146-151
,152-152
100,000,153-160
cells/mm3.,161-171

In,0-2
the,3-6
case,7-11
of,12-14
severe,15-21
neutropenia,22-33
(,34-35
500,36-39
cells/mm3,40-49
for,50-53
seven,54-59
days,60-64
or,65-67
more),68-73
during,74-80
a,81-82
course,83-89
of,90-92
TAXOL,93-98	DrugDDI.d125.s9.e0
therapy,,99-107
a,108-109
20%,110-113
reduction,114-123
in,124-126
dose,127-131
for,132-135
subsequent,136-146
courses,147-154
of,155-157
therapy,158-165
is,166-168
recommended.,169-181

For,0-3
patients,4-12
with,13-17
advanced,18-26
HIV,27-30	DrugDDI.d125.s10.e0
disease,31-38
and,39-42
poor-risk,43-52
AIDS-related,53-65
Kaposi?s,66-74
sarcoma,,75-83
TAXOL,,84-90
at,91-93
the,94-97
recommended,98-109
dose,110-114
for,115-118
this,119-123
disease,,124-132
can,133-136
be,137-139
initiated,140-149
and,150-153
repeated,154-162
if,163-165
the,166-169
neutrophil,170-180
count,181-186
is,187-189
at,190-192
least,193-198
1000,199-203
cells/mm3.,204-214

Hypersensitivity,0-16
Reactions:,17-27
Patients,28-36
with,37-41
a,42-43
history,44-51
of,52-54
severe,55-61
hypersensitivity,62-78
reactions,79-88
to,89-91
products,92-100
containing,101-111
Cremophor?,112-122
EL,123-125
(eg,,126-130
cyclosporin,131-142	DrugDDI.d125.s11.e0
for,143-146
injection,147-156
concentrate,157-168
and,169-172
teniposide,173-183	DrugDDI.d125.s11.e1
for,184-187
injection,188-197
concentrate),198-210
should,211-217
not,218-221
be,222-224
treated,225-232
with,233-237
TAXOL.,238-244	DrugDDI.d125.s11.e2

In,0-2
order,3-8
to,9-11
avoid,12-17
the,18-21
occurrence,22-32
of,33-35
severe,36-42
hypersensitivity,43-59
reactions,,60-70
all,71-74
patients,75-83
treated,84-91
with,92-96
TAXOL,97-102	DrugDDI.d125.s12.e0
should,103-109
be,110-112
premedicated,113-125
with,126-130
corticosteroids,131-146	DrugDDI.d125.s12.e1
(such,147-152
as,153-155
dexamethasone),,156-171
diphen-hydramine,172-188	DrugDDI.d125.s12.e3
and,189-192
H2,193-195
antagonists,196-207
(such,208-213
as,214-216
cimetidine,217-227	DrugDDI.d125.s12.e4
or,228-230
ranitidine).,231-243	DrugDDI.d125.s12.e5

However,,0-8
severe,9-15
reactions,,16-26
such,27-31
as,32-34
hypotension,35-46
requiring,47-56
treatment,,57-67
dyspnea,68-75
requiring,76-85
bronchodilators,,86-102
angioedema,,103-114
or,115-117
generalized,118-129
urticaria,130-139
require,140-147
immediate,148-157
discontinuation,158-173
of,174-176
TAXOL,177-182	DrugDDI.d125.s14.e1
and,183-186
aggressive,187-197
symptomatic,198-209
therapy.,210-218

Patients,0-8
who,9-12
have,13-17
developed,18-27
severe,28-34
hypersensitivity,35-51
reactions,52-61
should,62-68
not,69-72
be,73-75
rechallenged,76-88
with,89-93
TAXOL.,94-100	DrugDDI.d125.s15.e0

Cardiovascular:,0-15
Hypotension,,16-28
bradycardia,,29-41
and,42-45
hypertension,46-58
have,59-63
been,64-68
observed,69-77
during,78-84
administration,85-99
of,100-102
TAXOL,,103-109
but,110-113
generally,114-123
do,124-126
not,127-130
require,131-138
treatment.,139-149

Occasionally,0-12
TAXOL,13-18	DrugDDI.d125.s17.e0
infusions,19-28
must,29-33
be,34-36
interrupted,37-48
or,49-51
discontinued,52-64
because,65-72
of,73-75
initial,76-83
or,84-86
recurrent,87-96
hypertension.,97-110

Frequent,0-8
vital,9-14
sign,15-19
monitoring,,20-31
particularly,32-44
during,45-51
the,52-55
first,56-61
hour,62-66
of,67-69
TAXOL,70-75	DrugDDI.d125.s18.e0
infusion,,76-85
is,86-88
recommended.,89-101

Nervous,0-7
System:,8-15
Although,16-24
the,25-28
occurrence,29-39
of,40-42
peripheral,43-53
neuropathy,54-64
is,65-67
frequent,,68-77
the,78-81
development,82-93
of,94-96
severe,97-103
symptomatology,104-118
is,119-121
unusual,122-129
and,130-133
requires,134-142
a,143-144
dose,145-149
reduction,150-159
of,160-162
20%,163-166
for,167-170
all,171-174
subsequentcourses,175-192
of,193-195
TAXOL.,196-202	DrugDDI.d125.s20.e0

TAXOL,0-5	DrugDDI.d125.s21.e0
contains,6-14
dehydrated,15-25	DrugDDI.d125.s21.e1
alcohol,26-33	DrugDDI.d125.s21.e1
USP,,34-38	DrugDDI.d125.s21.e1
396,39-42
mg/mL;,43-49

consideration,0-13
should,14-20
be,21-23
given,24-29
to,30-32
possible,33-41
CNS,42-45
and,46-49
other,50-55
effects,56-63
of,64-66
alcohol.,67-75	DrugDDI.d125.s22.e0

Hepatic:,0-8
There,9-14
is,15-17
limited,18-25
evidence,26-34
that,35-39
the,40-43
myelotoxicity,44-57
of,58-60
TAXOL,61-66	DrugDDI.d125.s23.e0
may,67-70
be,71-73
exacerbated,74-85
in,86-88
patients,89-97
with,98-102
serum,103-108
total,109-114
bilirubin,115-124
,125-125
2,126-127
times,128-133
ULN.,134-138

Extreme,0-7
caution,8-15
should,16-22
be,23-25
exercised,26-35
when,36-40
administering,41-54
TAXOL,55-60	DrugDDI.d125.s24.e0
to,61-63
such,64-68
patients,,69-78
with,79-83
dose,84-88
reduction,89-98
as,99-101
recommended,102-113
in,114-116
DOSAGE,117-123
AND,124-127
ADMINISTRATION,,128-143
Table,144-149
17.,150-153

Recurrence,0-10
of,11-13
skin,14-18
reactions,19-28
at,29-31
a,32-33
site,34-38
of,39-41
previous,42-50
extravasation,51-64
following,65-74
administration,75-89
of,90-92
TAXOL,93-98	DrugDDI.d125.s27.e0
at,99-101
a,102-103
different,104-113
site,,114-119
ie,,120-123
recall,,124-131
has,132-135
been,136-140
reported,141-149
rarely.,150-157

Rare,0-4
reports,5-12
of,13-15
more,16-20
severe,21-27
events,28-34
such,35-39
as,40-42
phlebitis,,43-53
cellulitis,,54-65
induration,,66-77
skin,78-82
exfoliation,,83-95
necrosis,,96-105
and,106-109
fibrosis,110-118
have,119-123
been,124-128
received,129-137
as,138-140
part,141-145
of,146-148
the,149-152
continuing,153-163
surveillance,164-176
of,177-179
TAXOL,180-185	DrugDDI.d125.s28.e0
safety.,186-193

Treatment,0-9
with,10-14
PEGASYS,15-22	DrugDDI.d527.s0.e0
once,23-27
weekly,28-34
for,35-38
4,39-40
weeks,41-46
in,47-49
healthy,50-57
subjects,58-66
was,67-70
associated,71-81
with,82-86
an,87-89
inhibition,90-100
of,101-103
P450,104-108	DrugDDI.d527.s0.e1
1A2,109-112
and,113-116
a,117-118
25%,119-122
increase,123-131
in,132-134
theophylline,135-147	DrugDDI.d527.s0.e2
AUC.,148-152

Theophylline,0-12
serum,13-18
levels,19-25
should,26-32
be,33-35
monitored,36-45
and,46-49
appropriate,50-61
dose,62-66
adjustments,67-78
considered,79-89
for,90-93
patients,94-102
given,103-108
both,109-113
theophylline,114-126	DrugDDI.d527.s1.e0
and,127-130
PEGASYS.,131-139	DrugDDI.d527.s1.e1

There,0-5
was,6-9
no,10-12
effect,13-19
on,20-22
the,23-26
pharmacokinetics,27-43
of,44-46
representative,47-61
drugs,62-67	DrugDDI.d527.s2.e0
metabolized,68-79
by,80-82
CYP,83-86	DrugDDI.d527.s2.e1
2C9,,87-91	DrugDDI.d527.s2.e1
CYP,92-95	DrugDDI.d527.s2.e2
2C19,,96-101	DrugDDI.d527.s2.e2
CYP,102-105	DrugDDI.d527.s2.e3
2D6,106-109	DrugDDI.d527.s2.e3
or,110-112
CYP,113-116	DrugDDI.d527.s2.e4
3A4.,117-121

In,0-2
patients,3-11
with,12-16
chronic,17-24
hepatitis,25-34
C,35-36
treated,37-44
with,45-49
PEGASYS,50-57	DrugDDI.d527.s3.e0
in,58-60
combination,61-72
with,73-77
COPEGUS,,78-86
PEGASYS,87-94	DrugDDI.d527.s3.e2
treatment,95-104
did,105-108
not,109-112
affect,113-119
ribavirin,120-129	DrugDDI.d527.s3.e3
distribution,130-142
or,143-145
clearance.,146-156

Nucleoside,0-10	DrugDDI.d527.s4.e0
Analogues,11-20	DrugDDI.d527.s4.e0
Didanosine,21-31	DrugDDI.d527.s4.e0
Co-administration,32-49
of,50-52
COPEGUS,53-60	DrugDDI.d527.s4.e1
and,61-64
didanosine,65-75	DrugDDI.d527.s4.e2
is,76-78
not,79-82
recommended.,83-95

Stavudine,0-9	DrugDDI.d527.s6.e0
and,10-13
Zidovudine,14-24	DrugDDI.d527.s6.e1
Ribavirin,25-34
can,35-38
antagonize,39-49
the,50-53
in,54-56
vitro,57-62
antiviral,63-72	DrugDDI.d527.s6.e2
activity,73-81
of,82-84
stavudine,85-94	DrugDDI.d527.s6.e3
and,95-98
zidovudine,99-109	DrugDDI.d527.s6.e4
against,110-117
HIV.,118-122	DrugDDI.d527.s6.e5

Therefore,,0-10
concomitant,11-22
use,23-26
of,27-29
ribavirin,30-39	DrugDDI.d527.s7.e0
with,40-44
either,45-51
of,52-54
these,55-60
drugs,61-66	DrugDDI.d527.s7.e1
should,67-73
be,74-76
avoided.,77-85

Carcinogenesis,,0-15
Mutagenesis,,16-28
Impairment,29-39
of,40-42
Fertility,43-52
Carcinogenesis,53-67
PEGASYS,68-75	DrugDDI.d527.s8.e0
has,76-79
not,80-83
been,84-88
tested,89-95
for,96-99
its,100-103
carcinogenic,104-116
potential.,117-127

Mutagenesis,0-11
PEGASYS,12-19	DrugDDI.d527.s9.e0
did,20-23
not,24-27
cause,28-33
DNA,34-37
damage,38-44
when,45-49
tested,50-56
in,57-59
the,60-63
Ames,64-68	DrugDDI.d527.s9.e1
bacterial,69-78
mutagenicity,79-91
assay,92-97
and,98-101
in,102-104
the,105-108
in,109-111
vitro,112-117
chromosomal,118-129
aberration,130-140
assay,141-146
in,147-149
human,150-155
lymphocytes,,156-168
either,169-175
in,176-178
the,179-182
presence,183-191
or,192-194
absence,195-202
of,203-205
metabolic,206-215
activation.,216-227

Use,0-3
With,4-8
Ribavirin,9-18	DrugDDI.d527.s10.e0
Ribavirin,19-28
is,29-31
genotoxic,32-41
and,42-45
mutagenic.,46-56

The,0-3
carcinogenic,4-16
potential,17-26
of,27-29
ribavirin,30-39	DrugDDI.d527.s11.e0
has,40-43
not,44-47
been,48-52
fully,53-58
determined.,59-70

In,0-2
a,3-4
p53,5-8	DrugDDI.d527.s12.e0
(+/-),9-14
mouse,15-20
carcinogenicity,21-36
study,37-42
at,43-45
doses,46-51
up,52-54
to,55-57
the,58-61
maximum,62-69
tolerated,70-79
dose,80-84
of,85-87
100,88-91
mg/kg/day,92-101
ribavirin,102-111	DrugDDI.d527.s12.e1
was,112-115
not,116-119
oncogenic.,120-130

However,,0-8
on,9-11
a,12-13
body,14-18
surface,19-26
area,27-31
basis,,32-38
this,39-43
dose,44-48
was,49-52
0.5,53-56
times,57-62
maximum,63-70
recommended,71-82
human,83-88
24-hour,89-96
dose,97-101
of,102-104
ribavirin.,105-115	DrugDDI.d527.s13.e0

A,0-1
study,2-7
in,8-10
rats,11-15
to,16-18
assess,19-25
the,26-29
carcinogenic,30-42
potential,43-52
of,53-55
ribavirin,56-65	DrugDDI.d527.s14.e0
is,66-68
ongoing.,69-77

Mutagenesis,0-11
Impairment,12-22
of,23-25
Fertility,26-35
PEGASYS,36-43	DrugDDI.d527.s15.e0
may,44-47
impair,48-54
fertility,55-64
in,65-67
women.,68-74

Prolonged,0-9
menstrual,10-19
cycles,20-26
and/or,27-33
amenorrhea,34-44
were,45-49
observed,50-58
in,59-61
female,62-68
cynomolgus,69-79
monkeys,80-87
given,88-93
sc,94-96
injections,97-107
of,108-110
600,111-114
m,115-116
g/kg/dose,117-126
(7200,127-132
m,133-134
g/m2/dose),135-145
of,146-148
PEGASYS,149-156	DrugDDI.d527.s16.e0
every,157-162
other,163-168
day,169-172
for,173-176
one,177-180
month,,181-187
at,188-190
approximately,191-204
180,205-208
times,209-214
the,215-218
recommended,219-230
weekly,231-237
human,238-243
dose,244-248
for,249-252
a,253-254
60,255-257
kg,258-260
person,261-267
(based,268-274
on,275-277
body,278-282
surface,283-290
area).,291-297

Menstrual,0-9
cycle,10-15
irregularities,16-30
were,31-35
accompanied,36-47
by,48-50
both,51-55
a,56-57
decrease,58-66
and,67-70
delay,71-76
in,77-79
the,80-83
peak,84-88
17b,89-92
-estradiol,93-103
and,104-107
progesterone,108-120
levels,121-127
following,128-137
administration,138-152
of,153-155
PEGASYS,156-163	DrugDDI.d527.s17.e1
to,164-166
female,167-173
monkeys.,174-182

Every,0-5
other,6-11
day,12-15
dosing,16-22
with,23-27
100m,28-32
g/kg,33-37
(1200m,38-44
g/m2),45-50
PEGASYS,51-58	DrugDDI.d527.s19.e0
(equivalent,59-70
to,71-73
approximately,74-87
30,88-90
times,91-96
the,97-100
recommended,101-112
human,113-118
dose),119-124
had,125-128
no,129-131
effects,132-139
on,140-142
cycle,143-148
duration,149-157
or,158-160
reproductive,161-173
hormone,174-181
status.,182-189

The,0-3
effects,4-11
of,12-14
PEGASYS,15-22	DrugDDI.d527.s20.e0
on,23-25
male,26-30
fertility,31-40
have,41-45
not,46-49
been,50-54
studied.,55-63

However,,0-8
no,9-11
adverse,12-19
effects,20-27
on,28-30
fertility,31-40
were,41-45
observed,46-54
in,55-57
male,58-62
Rhesus,63-69
monkeys,70-77
treated,78-85
with,86-90
non-pegylated,91-104
interferon,105-115
alfa-2a,116-123
for,124-127
5,128-129
months,130-136
at,137-139
doses,140-145
up,146-148
to,149-151
25,152-154
x,155-156
106,157-160
IU/kg/day.,161-171

Pregnancy,0-9
Pregnancy:,10-20
Category,21-29
C,30-31
PEGASYS,32-39	DrugDDI.d527.s22.e0
has,40-43
not,44-47
been,48-52
studied,53-60
for,61-64
its,65-68
teratogenic,69-80
effect.,81-88

Non-pegylated,0-13
interferon,14-24
alfa-2a,25-32
treatment,33-42
of,43-45
pregnant,46-54
Rhesus,55-61
monkeys,62-69
at,70-72
approximately,73-86
20,87-89
to,90-92
500,93-96
times,97-102
the,103-106
human,107-112
weekly,113-119
dose,120-124
resulted,125-133
in,134-136
a,137-138
statistically,139-152
significant,153-164
increase,165-173
in,174-176
abortions.,177-187

No,0-2
teratogenic,3-14
effects,15-22
were,23-27
seen,28-32
in,33-35
the,36-39
offspring,40-49
delivered,50-59	DrugDDI.d527.s24.e0
at,60-62
term.,63-68

PEGASYS,0-7	DrugDDI.d527.s25.e0
should,8-14
be,15-17
assumed,18-25
to,26-28
have,29-33
abortifacient,34-47	DrugDDI.d527.s25.e1
potential.,48-58

There,0-5
are,6-9
no,10-12
adequate,13-21
and,22-25
well-controlled,26-41
studies,42-49
of,50-52
PEGASYS,53-60	DrugDDI.d527.s26.e0
in,61-63
pregnant,64-72
women.,73-79

PEGASYS,0-7	DrugDDI.d527.s27.e0
is,8-10
to,11-13
be,14-16
used,17-21
during,22-28
pregnancy,29-38
only,39-43
if,44-46
the,47-50
potential,51-60
benefit,61-68
justifies,69-78
the,79-82
potential,83-92
risk,93-97
to,98-100
the,101-104
fetus.,105-111

PEGASYS,0-7	DrugDDI.d527.s28.e0
is,8-10
recommended,11-22
for,23-26
use,27-30
in,31-33
women,34-39
of,40-42
childbearing,43-55
potential,56-65
only,66-70
when,71-75
they,76-80
are,81-84
using,85-90
effective,91-100
contraception,101-114
during,115-121
therapy.,122-130

Pregnancy:,0-10
Category,11-19
X:,20-22
Use,23-26
With,27-31
Ribavirin,32-41	DrugDDI.d527.s29.e0
(see,42-46
CONTRAINDICATIONS),47-65
Significant,66-77
teratogenic,78-89
and/or,90-96
embryocidal,97-108
effects,109-116
have,117-121
been,122-126
demonstrated,127-139
in,140-142
all,143-146
animal,147-153
species,154-161
exposed,162-169
to,170-172
ribavirin.,173-183	DrugDDI.d527.s29.e1

COPEGUS,0-7	DrugDDI.d527.s30.e0
therapy,8-15
is,16-18
contraindicated,19-34
in,35-37
women,38-43
who,44-47
are,48-51
pregnant,52-60
and,61-64
in,65-67
the,68-71
male,72-76
partners,77-85
of,86-88
women,89-94
who,95-98
are,99-102
pregnant,103-111
.,112-113

If,0-2
pregnancy,3-12
occurs,13-19
in,20-22
a,23-24
patient,25-32
or,33-35
partner,36-43
of,44-46
a,47-48
patient,49-56
during,57-63
treatment,64-73
or,74-76
during,77-83
the,84-87
6,88-89
months,90-96
after,97-102
treatment,103-112
cessation,,113-123
such,124-128
cases,129-134
should,135-141
be,142-144
reported,145-153
to,154-156
the,157-160
COPEGUS,161-168	DrugDDI.d527.s31.e0
Pregnancy,169-178
Registry,179-187
at,188-190
1-800-526-6367.,191-206

Nursing,0-7
Mothers,8-15
It,16-18
is,19-21
not,22-25
known,26-31
whether,32-39
peginterferon,40-53	DrugDDI.d527.s32.e0
or,54-56
ribavirin,57-66	DrugDDI.d527.s32.e1
or,67-69
its,70-73
components,74-84
are,85-88
excreted,89-97
in,98-100
human,101-106
milk.,107-112

The,0-3
effect,4-10
of,11-13
orally,14-20
ingested,21-29
peginterferon,30-43	DrugDDI.d527.s33.e0
or,44-46
ribavirin,47-56	DrugDDI.d527.s33.e1
from,57-61
breast,62-68
milk,69-73
on,74-76
the,77-80
nursing,81-88
infant,89-95
has,96-99
not,100-103
been,104-108
evaluated.,109-119

Because,0-7
of,8-10
the,11-14
potential,15-24
for,25-28
adverse,29-36
reactions,37-46
from,47-51
the,52-55
drugs,56-61	DrugDDI.d527.s34.e0
in,62-64
nursing,65-72
infants,,73-81
a,82-83
decision,84-92
must,93-97
be,98-100
made,101-105
whether,106-113
to,114-116
discontinue,117-128
nursing,129-136
or,137-139
discontinue,140-151
PEGASYS,152-159	DrugDDI.d527.s34.e1
and,160-163
COPEGUS,164-171	DrugDDI.d527.s34.e2
treatment.,172-182

Pediatric,0-9	DrugDDI.d527.s35.e0
Use,10-13
The,14-17
safety,18-24
and,25-28
effectiveness,29-42
of,43-45
PEGASYS,,46-54
alone,55-60
or,61-63
in,64-66
combination,67-78
with,79-83
COPEGUS,84-91	DrugDDI.d527.s35.e2
in,92-94
patients,95-103
below,104-109
the,110-113
age,114-117
of,118-120
18,121-123
years,124-129
have,130-134
not,135-138
been,139-143
established.,144-156

PEGASYS,0-7	DrugDDI.d527.s36.e0
contains,8-16
benzyl,17-23	DrugDDI.d527.s36.e1
alcohol.,24-32	DrugDDI.d527.s36.e1

Benzyl,0-6	DrugDDI.d527.s37.e0
alcohol,7-14	DrugDDI.d527.s37.e0
has,15-18
been,19-23
reported,24-32
to,33-35
be,36-38
associated,39-49
with,50-54
an,55-57
increased,58-67
incidence,68-77
of,78-80
neurological,81-93
and,94-97
other,98-103
complications,104-117
in,118-120
neonates,121-129
and,130-133
infants,,134-142
which,143-148
are,149-152
sometimes,153-162
fatal.,163-169

Clinical,0-8
studies,9-16
of,17-19
PEGASYS,20-27	DrugDDI.d527.s39.e0
alone,28-33
or,34-36
in,37-39
combination,40-51
with,52-56
COPEGUS,57-64	DrugDDI.d527.s39.e1
did,65-68
not,69-72
include,73-80
sufficient,81-91
numbers,92-99
of,100-102
subjects,103-111
aged,112-116
65,117-119
or,120-122
over,123-127
to,128-130
determine,131-140
whether,141-148
they,149-153
respond,154-161
differently,162-173
from,174-178
younger,179-186
subjects.,187-196

Adverse,0-7
reactions,8-17
related,18-25
to,26-28
alpha,29-34	DrugDDI.d527.s40.e0
interferons,,35-47	DrugDDI.d527.s40.e0
such,48-52
as,53-55
CNS,,56-60
cardiac,,61-69
and,70-73
systemic,74-82
(eg,,83-87
flu-like),88-97
effects,98-105
may,106-109
be,110-112
more,113-117
severe,118-124
in,125-127
the,128-131
elderly,132-139
and,140-143
caution,144-151
should,152-158
be,159-161
exercised,162-171
in,172-174
the,175-178
use,179-182
of,183-185
PEGASYS,186-193	DrugDDI.d527.s40.e1
in,194-196
this,197-201
population.,202-213

PEGASYS,0-7	DrugDDI.d527.s41.e0
and,8-11
COPEGUS,12-19	DrugDDI.d527.s41.e1
are,20-23
excreted,24-32
by,33-35
the,36-39
kidney,,40-47
and,48-51
the,52-55
risk,56-60
of,61-63
toxic,64-69
reactions,70-79
to,80-82
this,83-87
therapy,88-95
may,96-99
be,100-102
greater,103-110
in,111-113
patients,114-122
with,123-127
impaired,128-136
renal,137-142
function.,143-152

PEGASYS,0-7	DrugDDI.d527.s43.e0
should,8-14
be,15-17
used,18-22
with,23-27
caution,28-35
in,36-38
patients,39-47
with,48-52
creatinine,53-63
clearance,64-73
,74-74
50,75-77
mL/min,78-84
and,85-88
COPEGUS,89-96	DrugDDI.d527.s43.e1
should,97-103
not,104-107
be,108-110
administered,111-123
to,124-126
patients,127-135
with,136-140
creatinine,141-151
clearance,152-161
,162-162
50,163-165
mL/min,166-172

Aminoglycosides,0-15	DrugDDI.d376.s0.e0
The,16-19
mixing,20-26
of,27-29
piperacillin,30-42	DrugDDI.d376.s0.e1
with,43-47
an,48-50
aminoglycoside,51-65	DrugDDI.d376.s0.e2
in,66-68
vitro,69-74
can,75-78
result,79-85
in,86-88
substantial,89-100
inactivation,101-113
of,114-116
the,117-120
aminoglycoside.,121-136	DrugDDI.d376.s0.e3

Vecuronium,0-10	DrugDDI.d376.s1.e0
When,11-15
used,16-20
in,21-23
the,24-27
perioperative,28-41
period,,42-49
piperacillin,50-62	DrugDDI.d376.s1.e1
has,63-66
been,67-71
implicated,72-82
in,83-85
the,86-89
prolongation,90-102
of,103-105
the,106-109
neuromuscular,110-123
blockade,124-132
of,133-135
vecuronium.,136-147	DrugDDI.d376.s1.e2

Caution,0-7
is,8-10
indicated,11-20
when,21-25
piperacillin,26-38	DrugDDI.d376.s2.e0
is,39-41
used,42-46
perioperatively.,47-63

In,0-2
one,3-6
controlled,7-17
clinical,18-26
study,,27-33
the,34-37
ureidopenicillins,,38-56
including,57-66
piperacillin,,67-80
were,81-85
reported,86-94
to,95-97
prolong,98-105
the,106-109
action,110-116
of,117-119
vecuronium.,120-131	DrugDDI.d376.s3.e1

Due,0-3
to,4-6
their,7-12
similar,13-20
mechanism,21-30
of,31-33
action,,34-41
it,42-44
is,45-47
expected,48-56
that,57-61
the,62-65
neuromuscular,66-79
blockade,80-88
produced,89-97
by,98-100
any,101-104
of,105-107
the,108-111
non-depolarizing,112-128	DrugDDI.d376.s4.e0
muscle,129-135	DrugDDI.d376.s4.e0
relaxants,136-145	DrugDDI.d376.s4.e0
could,146-151
be,152-154
prolonged,155-164
in,165-167
the,168-171
presence,172-180
of,181-183
piperacillin.,184-197	DrugDDI.d376.s4.e1

Probenecid,0-10	DrugDDI.d376.s5.e0
The,11-14
oral,15-19
combination,20-31
of,32-34
probenecid,35-45	DrugDDI.d376.s5.e1
before,46-52
intramuscular,53-66
injection,67-76
of,77-79
PIPRACIL,80-88	DrugDDI.d376.s5.e2
produces,89-97
an,98-100
increase,101-109
in,110-112
piperacillin,113-125	DrugDDI.d376.s5.e3
peak,126-130
serum,131-136
level,137-142
of,143-145
about,146-151
30%.,152-156

Anticoagulants,0-14	DrugDDI.d376.s6.e0
Coagulation,15-26
parameters,27-37
should,38-44
be,45-47
tested,48-54
more,55-59
frequently,60-70
and,71-74
monitored,75-84
regularly,85-94
during,95-101
simultaneous,102-114
administration,115-129
of,130-132
high,133-137
doses,138-143
of,144-146
heparin,,147-155
oral,156-160	DrugDDI.d376.s6.e2
anticoagulants,,161-176	DrugDDI.d376.s6.e2
or,177-179
other,180-185
drugs,186-191	DrugDDI.d376.s6.e3
that,192-196
may,197-200
affect,201-207
the,208-211
blood,212-217
coagulation,218-229
system,230-236
or,237-239
the,240-243
thrombocyte,244-255
function.,256-265

Methotrexate,0-12	DrugDDI.d376.s7.e0
Piperacillin,13-25	DrugDDI.d376.s7.e0
sodium,26-32
may,33-36
reduce,37-43
the,44-47
excretion,48-57
of,58-60
methotrexate.,61-74	DrugDDI.d376.s7.e1

Therefore,,0-10
serum,11-16
levels,17-23
of,24-26
methotrexate,27-39	DrugDDI.d376.s8.e0
should,40-46
be,47-49
monitored,50-59
in,60-62
patients,63-71
to,72-74
avoid,75-80
drug,81-85
toxicity.,86-95

Drug/Laboratory,0-15	DrugDDI.d376.s9.e0
Test,16-20
Interactions,21-33
As,34-36
with,37-41
other,42-47	DrugDDI.d376.s9.e1
penicillins,,48-60	DrugDDI.d376.s9.e1
the,61-64
administration,65-79
of,80-82
PIPRACIL,83-91	DrugDDI.d376.s9.e2
may,92-95
result,96-102
in,103-105
a,106-107
false-positive,108-122
reaction,123-131
for,132-135
glucose,136-143	DrugDDI.d376.s9.e3
in,144-146
the,147-150
urine,151-156
using,157-162
a,163-164
copper-reduction,165-181	DrugDDI.d376.s9.e4
method.,182-189

It,0-2
is,3-5
recommended,6-17
that,18-22
glucose,23-30
tests,31-36
based,37-42
on,43-45
enzymatic,46-55
glucose,56-63	DrugDDI.d376.s10.e0
oxidase,64-71	DrugDDI.d376.s10.e0
reactions,72-81
be,82-84
used.,85-90

There,0-5
have,6-10
been,11-15
reports,16-23
of,24-26
positive,27-35
test,36-40
results,41-48
using,49-54
the,55-58
Bio-Rad,59-66
Laboratories,67-79
Platelia,80-88
Aspergillus,89-100
EIA,101-104
test,105-109
in,110-112
patients,113-121
receiving,122-131
piperacillin/tazobactam,132-155	DrugDDI.d376.s11.e0
injection,156-165
who,166-169
were,170-174
subsequently,175-187
found,188-193
to,194-196
be,197-199
free,200-204
of,205-207
Aspergillus,208-219
infection.,220-230

Cross-reactions,0-15
with,16-20
non-Aspergillus,21-36
polysaccharides,37-52	DrugDDI.d376.s12.e0
and,53-56
polyfuranoses,57-70
with,71-75
the,76-79
Bio-Rad,80-87
Laboratories,88-100
Platelia,101-109
Aspergillus,110-121
EIA,122-125
test,126-130
have,131-135
been,136-140
reported.,141-150

Therefore,,0-10
positive,11-19
test,20-24
results,25-32
in,33-35
patients,36-44
receiving,45-54
piperacillin,55-67	DrugDDI.d376.s13.e0
should,68-74
be,75-77
interpreted,78-89
cautiously,90-100
and,101-104
confirmed,105-114
by,115-117
other,118-123
diagnostic,124-134
methods.,135-143

Phenothiazines,0-14	DrugDDI.d252.s0.e0
-,15-16
Taking,17-23
piperazine,24-34
and,35-38
a,39-40
phenothiazine,41-54	DrugDDI.d252.s0.e1
together,55-63
may,64-67
increase,68-76
the,77-80
risk,81-85
of,86-88
convulsions,89-100
(seizures).,101-112

Pyrantel,0-8	DrugDDI.d252.s1.e0
(e.g.,,9-15
Antiminth),16-26	DrugDDI.d252.s1.e1
-,27-28
Taking,29-35
piperazine,36-46	DrugDDI.d252.s1.e2
and,47-50
pyrantel,51-59	DrugDDI.d252.s1.e3
together,60-68
may,69-72
decrease,73-81
the,82-85
effects,86-93
of,94-96
piperazine.,97-108	DrugDDI.d252.s1.e4

ACE,0-3	DrugDDI.d531.s0.e0
inhibitors:,4-15	DrugDDI.d531.s0.e0
Reports,16-23
suggest,24-31
that,32-36
NSAIDs,37-43	DrugDDI.d531.s0.e1
may,44-47
diminish,48-56
the,57-60
antihypertensive,61-77	DrugDDI.d531.s0.e2
effect,78-84
of,85-87
Angiotensin,88-99	DrugDDI.d531.s0.e3
Converting,100-110	DrugDDI.d531.s0.e3
Enzyme,111-117	DrugDDI.d531.s0.e3
(ACE),118-123
inhibitors.,124-135

In,0-2
patients,3-11
with,12-16
mild,17-21
to,22-24
moderate,25-33
hypertension,,34-47
administration,48-62
of,63-65
25,66-68
mg,69-71
daily,72-77
of,78-80
VIOXX,81-86	DrugDDI.d531.s1.e0
with,87-91
the,92-95
ACE,96-99
inhibitor,100-109
benazepril,,110-121
10,122-124
to,125-127
40,128-130
mg,131-133
for,134-137
4,138-139
weeks,,140-146
was,147-150
associated,151-161
with,162-166
an,167-169
average,170-177
increase,178-186
in,187-189
mean,190-194
arterial,195-203
pressure,204-212
of,213-215
about,216-221
3,222-223
mm,224-226
Hg,227-229
compared,230-238
to,239-241
ACE,242-245	DrugDDI.d531.s1.e2
inhibitor,246-255	DrugDDI.d531.s1.e2
alone.,256-262

This,0-4
interaction,5-16
should,17-23
be,24-26
given,27-32
consideration,33-46
in,47-49
patients,50-58
taking,59-65
VIOXX,66-71	DrugDDI.d531.s2.e0
concomitantly,72-85
with,86-90
ACE,91-94	DrugDDI.d531.s2.e1
inhibitors.,95-106	DrugDDI.d531.s2.e1

Aspirin,0-7	DrugDDI.d531.s3.e0
Concomitant,8-19
administration,20-34
of,35-37
low-dose,38-46
aspirin,47-54	DrugDDI.d531.s3.e1
with,55-59
VIOXX,60-65	DrugDDI.d531.s3.e2
may,66-69
result,70-76
in,77-79
an,80-82
increased,83-92
rate,93-97
of,98-100
GI,101-103
ulceration,104-114
or,115-117
other,118-123
complications,,124-138
compared,139-147
to,148-150
use,151-154
of,155-157
VIOXX,158-163	DrugDDI.d531.s3.e3
alone.,164-170

In,0-2
a,3-4
12-week,5-12
endoscopy,13-22
study,23-28
conducted,29-38
in,39-41
OA,42-44
patients,45-53
there,54-59
was,60-63
no,64-66
difference,67-77
in,78-80
the,81-84
cumulative,85-95
incidence,96-105
of,106-108
endoscopic,109-119
gastroduodenal,120-134
ulcers,135-141
in,142-144
patients,145-153
taking,154-160
low-dose,161-169
(81,170-173
mg),174-177
enteric,178-185
coated,186-192	DrugDDI.d531.s4.e0
aspirin,193-200	DrugDDI.d531.s4.e0
plus,201-205
VIOXX,206-211	DrugDDI.d531.s4.e1
25,212-214
mg,215-217
daily,,218-224
as,225-227
compared,228-236
to,237-239
those,240-245
taking,246-252
ibuprofen,253-262	DrugDDI.d531.s4.e2
2400,263-267
mg,268-270
daily,271-276
alone.,277-283

Patients,0-8
taking,9-15
low-dose,16-24
aspirin,25-32	DrugDDI.d531.s5.e0
plus,33-37
ibuprofen,38-47	DrugDDI.d531.s5.e1
were,48-52
not,53-56
studied.,57-65

At,0-2
steady,3-9
state,,10-16
VIOXX,17-22	DrugDDI.d531.s6.e0
50,23-25
mg,26-28
once,29-33
daily,34-39
had,40-43
no,44-46
effect,47-53
on,54-56
the,57-60
anti-platelet,61-74
activity,75-83
of,84-86
low-dose,87-95
(81,96-99
mg,100-102
once,103-107
daily),108-114
aspirin,,115-123
as,124-126
assessed,127-135
by,136-138
ex,139-141
vivo,142-146
platelet,147-155
aggregation,156-167
and,168-171
serum,172-177
TXB2,178-182
generation,183-193
in,194-196
clotting,197-205
blood.,206-212

Because,0-7
of,8-10
its,11-14
lack,15-19
of,20-22
platelet,23-31
effects,,32-40
VIOXX,41-46	DrugDDI.d531.s7.e0
is,47-49
not,50-53
a,54-55
substitute,56-66
for,67-70
aspirin,71-78	DrugDDI.d531.s7.e1
for,79-82
cardiovascular,83-97
prophylaxis.,98-110

Therefore,,0-10
in,11-13
patients,14-22
taking,23-29
VIOXX,,30-36
antiplatelet,37-49
therapies,50-59
should,60-66
not,67-70
be,71-73
discontinued,74-86
and,87-90
should,91-97
be,98-100
considered,101-111
in,112-114
patients,115-123
with,124-128
an,129-131
indication,132-142
for,143-146
cardiovascular,147-161
prophylaxis.,162-174

Prospective,,0-12
long-term,13-22
studies,23-30
on,31-33
concomitant,34-45
administration,46-60
of,61-63
VIOXX,64-69	DrugDDI.d531.s9.e0
and,70-73
aspirin,74-81	DrugDDI.d531.s9.e1
have,82-86
not,87-90
been,91-95
conducted.,96-106

Cimetidine,0-10	DrugDDI.d531.s10.e0
Co-administration,11-28
with,29-33
high,34-38
doses,39-44
of,45-47
cimetidine,48-58	DrugDDI.d531.s10.e1
[800,59-63	DrugDDI.d531.s10.e1
mg,64-66
twice,67-72
daily],73-79
increased,80-89
the,90-93
Cmax,94-98
of,99-101
rofecoxib,102-111	DrugDDI.d531.s10.e2
by,112-114
21%,,115-119
the,120-123
AUC0-120hr,124-134
by,135-137
23%,138-141
and,142-145
the,146-149
t1/2,150-154	DrugDDI.d531.s10.e3
by,155-157
15%.,158-162

Digoxin,0-7	DrugDDI.d531.s12.e0
Rofecoxib,8-17
75,18-20
mg,21-23
once,24-28
daily,29-34
for,35-38
11,39-41
days,42-46
does,47-51
not,52-55
alter,56-61
the,62-65
plasma,66-72
concentration,73-86
profile,87-94
or,95-97
renal,98-103
elimination,104-115
of,116-118
digoxin,119-126	DrugDDI.d531.s12.e1
after,127-132
a,133-134
single,135-141
0.5,142-145
mg,146-148
oral,149-153
dose.,154-159

Furosemide,0-10	DrugDDI.d531.s13.e0
Clinical,11-19
studies,,20-28
as,29-31
well,32-36
as,37-39
post-marketing,40-54
observations,,55-68
have,69-73
shown,74-79
that,80-84
NSAIDs,85-91	DrugDDI.d531.s13.e1
can,92-95
reduce,96-102
the,103-106
natriuretic,107-118	DrugDDI.d531.s13.e2
effect,119-125
of,126-128
furosemide,129-139	DrugDDI.d531.s13.e3
and,140-143
thiazides,144-153	DrugDDI.d531.s13.e4
in,154-156
some,157-161
patients.,162-171

This,0-4
response,5-13
has,14-17
been,18-22
attributed,23-33
to,34-36
inhibition,37-47
of,48-50
renal,51-56
prostaglandin,57-70	DrugDDI.d531.s14.e0
synthesis.,71-81

Ketoconazole,0-12	DrugDDI.d531.s15.e0
Ketoconazole,13-25
400,26-29
mg,30-32
daily,33-38
did,39-42
not,43-46
have,47-51
any,52-55
clinically,56-66
important,67-76
effect,77-83
on,84-86
the,87-90
pharmacokinetics,91-107
of,108-110
rofecoxib.,111-121	DrugDDI.d531.s15.e1

Lithium,0-7	DrugDDI.d531.s16.e0
NSAIDs,8-14
have,15-19
produced,20-28
an,29-31
elevation,32-41
of,42-44
plasma,45-51
lithium,52-59
levels,60-66
and,67-70
a,71-72
reduction,73-82
in,83-85
renal,86-91
lithium,92-99	DrugDDI.d531.s16.e1
clearance.,100-110

Thus,,0-5
when,6-10
VIOXX,11-16	DrugDDI.d531.s18.e0
and,17-20
lithium,21-28	DrugDDI.d531.s18.e1
are,29-32
administered,33-45
concurrently,,46-59
subjects,60-68
should,69-75
be,76-78
observed,79-87
carefully,88-97
for,98-101
signs,102-107
of,108-110
lithium,111-118
toxicity.,119-128

Methotrexate,0-12	DrugDDI.d531.s19.e0
VIOXX,13-18
12.5,,19-24
25,,25-28
and,29-32
50,33-35
mg,,36-39
each,40-44
dose,45-49
administered,50-62
once,63-67
daily,68-73
for,74-77
7,78-79
days,,80-85
had,86-89
no,90-92
effect,93-99
on,100-102
the,103-106
plasma,107-113
concentration,114-127
of,128-130
methotrexate,131-143	DrugDDI.d531.s19.e1
as,144-146
measured,147-155
by,156-158
AUC0-24hr,159-168
in,169-171
patients,172-180
receiving,181-190
single,191-197
weekly,198-204
methotrexate,205-217	DrugDDI.d531.s19.e2
doses,218-223
of,224-226
7.5,227-230
to,231-233
20,234-236
mg,237-239
for,240-243
rheumatoid,244-254
arthritis.,255-265

At,0-2
higher,3-9
than,10-14
recommended,15-26
doses,,27-33
VIOXX,34-39	DrugDDI.d531.s20.e0
75,40-42
mg,43-45
administered,46-58
once,59-63
daily,64-69
for,70-73
10,74-76
days,77-81
increased,82-91
plasma,92-98
concentrations,99-113
by,114-116
23%,117-120
as,121-123
measured,124-132
by,133-135
AUC0-24hr,136-145
in,146-148
patients,149-157
receiving,158-167
methotrexate,168-180	DrugDDI.d531.s20.e1
7.5,181-184
to,185-187
15,188-190
mg/week,191-198
for,199-202
rheumatoid,203-213
arthritis.,214-224

At,0-2
24,3-5
hours,6-11
postdose,,12-21
a,22-23
similar,24-31
proportion,32-42
of,43-45
patients,46-54
treated,55-62
with,63-67
methotrexate,68-80	DrugDDI.d531.s21.e0
alone,81-86
(94%),87-92
and,93-96
subsequently,97-109
treated,110-117
with,118-122
methotrexate,123-135	DrugDDI.d531.s21.e1
co-administered,136-151
with,152-156
75,157-159
mg,160-162
of,163-165
rofecoxib,166-175	DrugDDI.d531.s21.e2
(88%),176-181
had,182-185
methotrexate,186-198	DrugDDI.d531.s21.e3
plasma,199-205
concentrations,206-220
below,221-226
the,227-230
measurable,231-241
limit,242-247
(5,248-250
ng/mL).,251-258

Standard,0-8
monitoring,9-19
of,20-22
methotrexate-related,23-43
toxicity,44-52
should,53-59
be,60-62
continued,63-72
if,73-75
VIOXX,76-81	DrugDDI.d531.s22.e0
and,82-85
methotrexate,86-98	DrugDDI.d531.s22.e1
are,99-102
administered,103-115
concomitantly.,116-130

Oral,0-4	DrugDDI.d531.s23.e0
Contraceptives,5-19	DrugDDI.d531.s23.e0
Rofecoxib,20-29
did,30-33
not,34-37
have,38-42
any,43-46
clinically,47-57
important,58-67
effect,68-74
on,75-77
the,78-81
pharmacokinetics,82-98
of,99-101
ethinyl,102-109	DrugDDI.d531.s23.e1
estradiol,110-119	DrugDDI.d531.s23.e1
and,120-123
norethindrone.,124-138	DrugDDI.d531.s23.e2

Prednisone/prednisolone,0-23	DrugDDI.d531.s24.e0
Rofecoxib,24-33
did,34-37
not,38-41
have,42-46
any,47-50
clinically,51-61
important,62-71
effect,72-78
on,79-81
the,82-85
pharmacokinetics,86-102
of,103-105
prednisolone,106-118	DrugDDI.d531.s24.e2
or,119-121
prednisone.,122-133	DrugDDI.d531.s24.e3

Rifampin,0-8	DrugDDI.d531.s25.e0
Co-administration,9-26
of,27-29
VIOXX,30-35	DrugDDI.d531.s25.e1
with,36-40
rifampin,41-49	DrugDDI.d531.s25.e2
600,50-53	DrugDDI.d531.s25.e2
mg,54-56	DrugDDI.d531.s25.e2
daily,,57-63
a,64-65
potent,66-72
inducer,73-80
of,81-83
hepatic,84-91
metabolism,,92-103
produced,104-112
an,113-115
approximate,116-127
50%,128-131
decrease,132-140
in,141-143
rofecoxib,144-153	DrugDDI.d531.s25.e3
plasma,154-160
concentrations.,161-176

Therefore,,0-10
a,11-12
starting,13-21
daily,22-27
dose,28-32
of,33-35
25,36-38
mg,39-41
of,42-44
VIOXX,45-50	DrugDDI.d531.s26.e0
should,51-57
be,58-60
considered,61-71
for,72-75
the,76-79
treatment,80-89
of,90-92
osteoarthritis,93-107
when,108-112
VIOXX,113-118	DrugDDI.d531.s26.e1
is,119-121
co-administered,122-137
with,138-142
potent,143-149
inducers,150-158
of,159-161
hepatic,162-169
metabolism.,170-181

Theophylline,0-12	DrugDDI.d531.s27.e0
VIOXX,13-18
12.5,,19-24
25,,25-28
and,29-32
50,33-35
mg,36-38
administered,39-51
once,52-56
daily,57-62
for,63-66
7,67-68
days,69-73
increased,74-83
plasma,84-90
theophylline,91-103	DrugDDI.d531.s27.e1
concentrations,104-118
(AUC(0-?)),119-129
by,130-132
38,133-135
to,136-138
60%,139-142
in,143-145
healthy,146-153
subjects,154-162
administered,163-175
a,176-177
single,178-184
300-mg,185-191
dose,192-196
of,197-199
theophylline.,200-213	DrugDDI.d531.s27.e2

Adequate,0-8
monitoring,9-19
of,20-22
theophylline,23-35	DrugDDI.d531.s28.e0
plasma,36-42
concentrations,43-57
should,58-64
be,65-67
considered,68-78
when,79-83
therapy,84-91
with,92-96
VIOXX,97-102	DrugDDI.d531.s28.e1
is,103-105
initiated,106-115
or,116-118
changed,119-126
in,127-129
patients,130-138
receiving,139-148
theophylline.,149-162	DrugDDI.d531.s28.e2

These,0-5
data,6-10
suggest,11-18
that,19-23
rofecoxib,24-33	DrugDDI.d531.s29.e0
may,34-37
produce,38-45
a,46-47
modest,48-54
inhibition,55-65
of,66-68
cytochrome,69-79	DrugDDI.d531.s29.e1
P450,80-84	DrugDDI.d531.s29.e1
(CYP),85-90
1A2.,91-95

Therefore,,0-10
there,11-16
is,17-19
a,20-21
potential,22-31
for,32-35
an,36-38
interaction,39-50
with,51-55
other,56-61
drugs,62-67	DrugDDI.d531.s30.e0
that,68-72
are,73-76
metabolized,77-88
by,89-91
CYP,92-95	DrugDDI.d531.s30.e1
1A2,96-99	DrugDDI.d531.s30.e1
(e.g.,,100-106
amitriptyline,,107-121
tacrine,,122-130
and,131-134
zileuton).,135-145	DrugDDI.d531.s30.e4

Warfarin,0-8	DrugDDI.d531.s31.e0
Anticoagulant,9-22
activity,23-31
should,32-38
be,39-41
monitored,,42-52
particularly,53-65
in,66-68
the,69-72
first,73-78
few,79-82
days,83-87
after,88-93
initiating,94-104
or,105-107
changing,108-116
VIOXX,117-122	DrugDDI.d531.s31.e1
therapy,123-130
in,131-133
patients,134-142
receiving,143-152
warfarin,153-161	DrugDDI.d531.s31.e2
or,162-164
similar,165-172
agents,,173-180
since,181-186
these,187-192
patients,193-201
are,202-205
at,206-208
an,209-211
increased,212-221
risk,222-226
of,227-229
bleeding,230-238
complications.,239-253

In,0-2
single,3-9
and,10-13
multiple,14-22
dose,23-27
studies,28-35
in,36-38
healthy,39-46
subjects,47-55
receiving,56-65
both,66-70
warfarin,71-79	DrugDDI.d531.s32.e0
and,80-83
rofecoxib,,84-94
prothrombin,95-106
time,107-111
(measured,112-121
as,122-124
INR),125-129
was,130-133
increased,134-143
by,144-146
approximately,147-160
8%,161-163
to,164-166
11%.,167-171

In,0-2
post-marketing,3-17
experience,,18-29
bleeding,30-38
events,39-45
have,46-50
been,51-55
reported,,56-65
predominantly,66-79
in,80-82
the,83-86
elderly,,87-95
in,96-98
association,99-110
with,111-115
increases,116-125
in,126-128
prothrombin,129-140
time,141-145
in,146-148
patients,149-157
receiving,158-167
VIOXX,168-173	DrugDDI.d531.s33.e0
concurrently,174-186
with,187-191
warfarin.,192-201	DrugDDI.d531.s33.e1

Several,0-7
drug,8-12
interaction,13-24
studies,25-32
have,33-37
been,38-42
completed,43-52
with,53-57
both,58-62
INVIRASE,63-71	DrugDDI.d455.s1.e0
and,72-75
FORTOVASE.,76-86	DrugDDI.d455.s1.e1

Observations,0-12
from,13-17
drug,18-22
interaction,23-34
studies,35-42
with,43-47
FORTOVASE,48-57	DrugDDI.d455.s2.e0
may,58-61
not,62-65
be,66-68
predictive,69-79
for,80-83
INVIRASE.,84-93	DrugDDI.d455.s2.e1

Because,0-7
ritonavir,8-17	DrugDDI.d455.s3.e0
is,18-20
coadministered,,21-36
prescribers,37-48
should,49-55
also,56-60
refer,61-66
to,67-69
the,70-73
prescribing,74-85
information,86-97
for,98-101
ritonavir,102-111	DrugDDI.d455.s3.e1
regarding,112-121
drug,122-126
interactions,127-139
associated,140-150
with,151-155
this,156-160
agent.,161-167

The,0-3
metabolism,4-14
of,15-17
saquinavir,18-28	DrugDDI.d455.s4.e0
is,29-31
mediated,32-40
by,41-43
cytochrome,44-54	DrugDDI.d455.s4.e1
P450,,55-60	DrugDDI.d455.s4.e1
with,61-65
the,66-69
specific,70-78
isoenzyme,79-88	DrugDDI.d455.s4.e2
CYP3A4,89-95	DrugDDI.d455.s4.e2
responsible,96-107
for,108-111
90%,112-115
of,116-118
the,119-122
hepatic,123-130
metabolism.,131-142

Additionally,,0-13
saquinavir,14-24	DrugDDI.d455.s5.e0
is,25-27
a,28-29
substrate,30-39
for,40-43
P-Glycoprotein,44-58
(Pgp).,59-65

Therefore,,0-10
drugs,11-16	DrugDDI.d455.s6.e0
that,17-21
affect,22-28
CYP3A4,29-35	DrugDDI.d455.s6.e1
and/or,36-42
Pgp,,43-47
may,48-51
modify,52-58
the,59-62
pharmacokinetics,63-79
of,80-82
saquinavir.,83-94	DrugDDI.d455.s6.e2

Similarly,,0-10
saquinavir,11-21	DrugDDI.d455.s7.e0
might,22-27
also,28-32
modify,33-39
the,40-43
pharmacokinetics,44-60
of,61-63
other,64-69
drugs,70-75	DrugDDI.d455.s7.e1
that,76-80
are,81-84
substrates,85-95
for,96-99
CYP3A4,100-106	DrugDDI.d455.s7.e2
or,107-109
Pgp.,110-114

Drugs,0-5	DrugDDI.d455.s8.e0
that,6-10
are,11-14
contraindicated,15-30
specifically,31-43
due,44-47
to,48-50
the,51-54
expected,55-63
magnitude,64-73
of,74-76
interaction,77-88
and,89-92
potential,93-102
for,103-106
serious,107-114
adverse,115-122
events,123-129
are,130-133
listed,134-140
CONTRAINDICATIONS.,141-159

Additional,0-10
drugs,11-16	DrugDDI.d455.s9.e0
that,17-21
are,22-25
not,26-29
recommended,30-41
for,42-45
coadministration,46-62
with,63-67
INVIRASE,68-76	DrugDDI.d455.s9.e1
and,77-80
ritonavir,81-90	DrugDDI.d455.s9.e2
are,91-94
included,95-103
below.,104-110

When,0-4
coadministering,5-20
INVIRASE/ritonavir,21-39	DrugDDI.d455.s11.e0
with,40-44
any,45-48
agent,49-54
having,55-61
a,62-63
narrow,64-70
therapeutic,71-82
margin,,83-90
such,91-95
as,96-98
anticoagulants,,99-114
anticonvulsants,,115-131
and,132-135
antiarrhythmics,,136-152
special,153-160
attention,161-170
is,171-173
warranted.,174-184

Drugs,0-5	DrugDDI.d455.s13.e0
That,6-10
Should,11-17
Not,18-21
Be,22-24
Coadministered,25-39
With,40-44
INVIRASE/Ritonavir,45-63	DrugDDI.d455.s13.e1

Drug,0-4	DrugDDI.d455.s14.e0
Class:,5-11
Drug,12-16	DrugDDI.d455.s14.e1
Name,17-21
Clinical,22-30
Comment,31-38

Antiarrhythmics:,0-16	DrugDDI.d455.s15.e0
Amiodarone,,17-28
bepridil,,29-38
flecainide,,39-50
propafenone,,51-63
quinidine,64-73	DrugDDI.d455.s15.e5
CONTRAINDICATED,74-89
due,90-93
to,94-96
potential,97-106
for,107-110
serious,111-118
and/or,119-125
life-threatening,126-142
reactions.,143-153

Antihistamines:,0-15	DrugDDI.d455.s16.e0
astemizole*,,16-28
terfenadine*,29-41	DrugDDI.d455.s16.e2
CONTRAINDICATED,42-57
due,58-61
to,62-64
potential,65-74
for,75-78
serious,79-86
and/or,87-93
life-threatening,94-110
cardiac,111-118
arrhythmias.,119-131

Ergot,0-5	DrugDDI.d455.s17.e0
Derivatives:,6-18	DrugDDI.d455.s17.e0
Dihydroergotamine,,19-37
ergonovine,,38-49
ergotamine,,50-61
methylergonovine,62-78	DrugDDI.d455.s17.e4
CONTRAINDICATED,79-94
due,95-98
to,99-101
potential,102-111
for,112-115
serious,116-123
and,124-127
life-threatening,128-144
reactions,145-154
such,155-159
as,160-162
acute,163-168
ergot,169-174	DrugDDI.d455.s17.e5
toxicity,175-183
characterized,184-197
by,198-200
peripheral,201-211
vasospasm,212-221
and,222-225
ischemia,226-234
of,235-237
the,238-241
extremities,242-253
and,254-257
other,258-263
tissues.,264-272

Antimycobacterial,0-17	DrugDDI.d455.s18.e0
Agents:,18-25	DrugDDI.d455.s18.e0
rifampin,26-34	DrugDDI.d455.s18.e1
CONTRAINDICATED,35-50
since,51-56
the,57-60
coadministration,61-77
of,78-80
this,81-85
product,86-93
with,94-98
saquinavir,99-109	DrugDDI.d455.s18.e2
in,110-112
an,113-115
antiretroviral,116-130
regimen,131-138
reduces,139-146
the,147-150
plasma,151-157
concentrations,158-172
of,173-175
saquinavir.,176-187	DrugDDI.d455.s18.e3

Garlic,0-6	DrugDDI.d455.s19.e0
Capsules,7-15	DrugDDI.d455.s19.e0
Garlic,16-22
capsules,23-31
should,32-38
not,39-42
be,43-45
used,46-50
while,51-56
taking,57-63
saquinavir,64-74	DrugDDI.d455.s19.e1
(FORTOVASE),75-86
as,87-89
the,90-93
sole,94-98
protease,99-107	DrugDDI.d455.s19.e3
inhibitor,108-117	DrugDDI.d455.s19.e3
due,118-121
to,122-124
the,125-128
risk,129-133
of,134-136
decreased,137-146
saquinavir,147-157	DrugDDI.d455.s19.e4
plasma,158-164
concentrations.,165-180

No,0-2
data,3-7
are,8-11
available,12-21
for,22-25
the,26-29
coadministration,30-46
of,47-49
INVIRASE/ritonavir,50-68	DrugDDI.d455.s20.e0
or,69-71
FORTOVASE/ritonavir,72-91	DrugDDI.d455.s20.e2
and,92-95
garlic,96-102	DrugDDI.d455.s20.e4
capsules.,103-112

GI,0-2
Motility,3-11
Agent:,12-18
cisapride*,19-29	DrugDDI.d455.s21.e0
CONTRAINDICATED,30-45
due,46-49
to,50-52
potential,53-62
for,63-66
serious,67-74
and/or,75-81
life-threatening,82-98
reactions,99-108
such,109-113
as,114-116
cardiac,117-124
arrhythmias.,125-137

Herbal,0-6
Products:,7-16
St.,17-20
John?s,21-27
wort,28-32
(hypericum,33-43
perforatum),44-55
WARNING,56-63
coadministration,64-80
may,81-84
lead,85-89
to,90-92
loss,93-97
of,98-100
virologic,101-110
response,111-119
and,120-123
possible,124-132
resistance,133-143
to,144-146
INVIRASE,147-155	DrugDDI.d455.s22.e1
or,156-158
to,159-161
the,162-165
class,166-171
of,172-174
protease,175-183	DrugDDI.d455.s22.e2
inhibitors.,184-195	DrugDDI.d455.s22.e2

HMG-CoA,0-7	DrugDDI.d455.s23.e0
Reductase,8-17	DrugDDI.d455.s23.e0
Inhibitors:,18-29	DrugDDI.d455.s23.e0
lovastatin,,30-41
simvastatin,42-53	DrugDDI.d455.s23.e2
WARNING,54-61
potential,62-71
for,72-75
serious,76-83
reactions,84-93
such,94-98
as,99-101
risk,102-106
of,107-109
myopathy,110-118
including,119-128
rhabdomyolysis.,129-144

Sedatives/Hypnotics:,0-20	DrugDDI.d455.s24.e0
triazolam,,21-31
midazolam,32-41	DrugDDI.d455.s24.e3
CONTRAINDICATED,42-57
due,58-61
to,62-64
potential,65-74
for,75-78
serious,79-86
and/or,87-93
life-threatening,94-110
reactions,111-120
such,121-125
as,126-128
prolonged,129-138
or,139-141
increased,142-151
sedation,152-160
or,161-163
respiratory,164-175
depression.,176-187

Drugs,0-5	DrugDDI.d455.s26.e0
That,6-10
Are,11-14
Mainly,15-21
Metabolized,22-33
by,34-36
CYP3A4,37-43	DrugDDI.d455.s26.e1

Although,0-8
specific,9-17
studies,18-25
have,26-30
not,31-34
been,35-39
performed,,40-50
coadministration,51-67
with,68-72
drugs,73-78	DrugDDI.d455.s27.e0
that,79-83
are,84-87
mainly,88-94
metabolized,95-106
by,107-109
CYP3A4,110-116	DrugDDI.d455.s27.e1
(eg,,117-121
calcium,122-129	DrugDDI.d455.s27.e2
channel,130-137	DrugDDI.d455.s27.e2
blockers,,138-147	DrugDDI.d455.s27.e2
dapsone,,148-156
disopyramide,,157-170
quinine,,171-179
amiodarone,,180-191
quinidine,,192-202
warfarin,,203-212
tacrolimus,,213-224
cyclosporine,,225-238
ergot,239-244	DrugDDI.d455.s27.e11
derivatives,,245-257	DrugDDI.d455.s27.e11
pimozide,,258-267
carbamazepine,,268-282
fentanyl,,283-292
alfentanyl,,293-304
alprazolam,,305-316
and,317-320
triazolam),321-331	DrugDDI.d455.s27.e17
may,332-335
have,336-340
elevated,341-349
plasma,350-356
concentrations,357-371
when,372-376
coadministered,377-391
with,392-396
saquinavir;,397-408	DrugDDI.d455.s27.e18

Since,0-5
INVIRASE,6-14	DrugDDI.d455.s29.e0
is,15-17
coadministered,18-32
with,33-37
ritonavir,,38-48
the,49-52
ritonavir,53-62	DrugDDI.d455.s29.e2
label,63-68
should,69-75
be,76-78
reviewed,79-87
for,88-91
additional,92-102
drugs,103-108	DrugDDI.d455.s29.e3
that,109-113
should,114-120
not,121-124
be,125-127
coadministered.,128-143

Inducers,0-8
of,9-11
CYP3A4,12-18	DrugDDI.d455.s30.e0

Coadministration,0-16
with,17-21
compounds,22-31
that,32-36
are,37-40
potent,41-47
inducers,48-56
of,57-59
CYP3A4,60-66	DrugDDI.d455.s31.e0
(eg,,67-71
phenobarbital,,72-86
phenytoin,,87-97
dexamethasone,,98-112
carbamazepine),113-127	DrugDDI.d455.s31.e4
may,128-131
result,132-138
in,139-141
decreased,142-151
plasma,152-158
levels,159-165
of,166-168
saquinavir.,169-180	DrugDDI.d455.s31.e5

Sulfacetamide,0-13	DrugDDI.d232.s0.e0
preparations,14-26	DrugDDI.d232.s0.e0
are,27-30
incompatible,31-43
with,44-48
silver,49-55	DrugDDI.d232.s0.e1
preparations.,56-69	DrugDDI.d232.s0.e1

Sulfapyridine,0-13	DrugDDI.d525.s1.e0
may,14-17
interact,18-26
with,27-31
any,32-35
of,36-38
the,39-42
following:,43-53
-,54-55
Acetaminophen,56-69	DrugDDI.d525.s1.e1
(e.g.,,70-76
Tylenol),77-85	DrugDDI.d525.s1.e2
(with,86-91
long-term,,92-102
high-dose,103-112
use),113-117
or,118-120

-,0-1
Amiodarone,2-12	DrugDDI.d525.s2.e0
(e.g.,,13-19
Cordarone),20-30	DrugDDI.d525.s2.e1
or,31-33

-,0-1
Anabolic,2-10	DrugDDI.d525.s3.e0
steroids,11-19	DrugDDI.d525.s3.e0
(nandrolone,20-31
[e.g.,,32-38
Anabolin],,39-49
oxandrolone,50-61	DrugDDI.d525.s3.e2
[e.g.,,62-68
Anavar],,69-77
oxymetholone,78-90	DrugDDI.d525.s3.e4
[e.g.,,91-97
Anadrol],,98-107
stanozolol,108-118	DrugDDI.d525.s3.e6
[e.g.,,119-125
Winstrol]),126-136	DrugDDI.d525.s3.e7
or,137-139

-,0-1
Androgens,2-11	DrugDDI.d525.s4.e0
(male,12-17
hormones),18-27
or,28-30

-,0-1
Antithyroid,2-13	DrugDDI.d525.s5.e0
agents,14-20	DrugDDI.d525.s5.e0
(medicine,21-30
for,31-34
overactive,35-45
thyroid),46-54
or,55-57

-,0-1
Carbamazepine,2-15	DrugDDI.d525.s6.e0
(e.g.,,16-22
Tegretol),23-32	DrugDDI.d525.s6.e1
or,33-35

-,0-1
Carmustine,2-12	DrugDDI.d525.s7.e0
(e.g.,,13-19
BiCNU),20-26	DrugDDI.d525.s7.e1
or,27-29

-,0-1
Chloroquine,2-13	DrugDDI.d525.s8.e0
(e.g.,,14-20
Aralen),21-28	DrugDDI.d525.s8.e1
or,29-31

-,0-1
Dantrolene,2-12	DrugDDI.d525.s9.e0
(e.g.,,13-19
Dantrium),20-29	DrugDDI.d525.s9.e1
or,30-32

-,0-1
Daunorubicin,2-14	DrugDDI.d525.s10.e0
(e.g.,,15-21
Cerubidine),22-33	DrugDDI.d525.s10.e1
or,34-36

-,0-1
Disulfiram,2-12	DrugDDI.d525.s11.e0
(e.g.,,13-19
Antabuse),20-29	DrugDDI.d525.s11.e1
or,30-32

-,0-1
Divalproex,2-12	DrugDDI.d525.s12.e0
(e.g.,,13-19
Depakote),20-29	DrugDDI.d525.s12.e1
or,30-32

-,0-1
Estrogens,2-11	DrugDDI.d525.s13.e0
(female,12-19
hormones),20-29
or,30-32

-,0-1
Etretinate,2-12	DrugDDI.d525.s14.e0
(e.g.,,13-19
Tegison),20-28	DrugDDI.d525.s14.e1
or,29-31

-,0-1
Gold,2-6	DrugDDI.d525.s15.e0
salts,7-12	DrugDDI.d525.s15.e0
(medicine,13-22
for,23-26
arthritis),27-37
or,38-40

-,0-1
Hydroxychloroquine,2-20	DrugDDI.d525.s16.e0
(e.g.,,21-27
Plaquenil),28-38	DrugDDI.d525.s16.e1
or,39-41

-,0-1
Mercaptopurine,2-16	DrugDDI.d525.s17.e0
(e.g.,,17-23
Purinethol),24-35	DrugDDI.d525.s17.e1
or,36-38

-,0-1
Naltrexone,2-12	DrugDDI.d525.s18.e0
(e.g.,,13-19
Trexan),20-27	DrugDDI.d525.s18.e1
(with,28-33
long-term,,34-44
high-dose,45-54
use),55-59
or,60-62

-,0-1
Oral,2-6	DrugDDI.d525.s19.e0
contraceptives,7-21	DrugDDI.d525.s19.e0
(birth,22-28
control,29-36
pills),37-43
containing,44-54
estrogen,55-63	DrugDDI.d525.s19.e2
or,64-66

-,0-1
Other,2-7
anti-infectives,8-23	DrugDDI.d525.s20.e0
by,24-26
mouth,27-32
or,33-35
by,36-38
injection,39-48
(medicine,49-58
for,59-62
infection),63-73
or,74-76

-,0-1
Phenothiazines,2-16	DrugDDI.d525.s21.e0
(acetophenazine,17-32
[e.g.,,33-39
Tindal],,40-48
chlorpromazine,49-63	DrugDDI.d525.s21.e2
[e.g.,,64-70
Thorazine],,71-82
fluphenazine,83-95	DrugDDI.d525.s21.e4
[e.g.,,96-102
Prolixin],,103-113
mesoridazine,114-126	DrugDDI.d525.s21.e6
[e.g.,,127-133
Serentil],,134-144
perphenazine,145-157	DrugDDI.d525.s21.e8
[e.g.,,158-164
Trilafon],,165-175
prochlorperazine,176-192	DrugDDI.d525.s21.e10
[e.g.,,193-199
Compazine],,200-211
promazine,212-221	DrugDDI.d525.s21.e12
[e.g.,,222-228
Sparine],,229-238
promethazine,239-251	DrugDDI.d525.s21.e14
[e.g.,,252-258
Phenergan],,259-270
thioridazine,271-283	DrugDDI.d525.s21.e16
[e.g.,,284-290
Mellaril],,291-301
trifluoperazine,302-317	DrugDDI.d525.s21.e18
[e.g.,,318-324
Stelazine],,325-336
triflupromazine,337-352	DrugDDI.d525.s21.e20
[e.g.,,353-359
Vesprin],,360-369
trimeprazine,370-382	DrugDDI.d525.s21.e22
[e.g.,,383-389
Temaril]),390-399	DrugDDI.d525.s21.e23
or,400-402

-,0-1
Plicamycin,2-12	DrugDDI.d525.s22.e0
(e.g.,,13-19
Mithracin),20-30	DrugDDI.d525.s22.e1
or,31-33

-,0-1
Valproic,2-10	DrugDDI.d525.s23.e0
acid,11-15	DrugDDI.d525.s23.e0
(e.g.,,16-22
Depakene)?Use,23-36	DrugDDI.d525.s23.e1
of,37-39
sulfapyridine,40-53	DrugDDI.d525.s23.e2
with,54-58
these,59-64
medicines,65-74	DrugDDI.d525.s23.e3
may,75-78
increase,79-87
the,88-91
chance,92-98
of,99-101
side,102-106
effects,107-114
affecting,115-124
the,125-128
liver,129-134	DrugDDI.d525.s23.e4

-,0-1
Acetohydroxamic,2-17	DrugDDI.d525.s24.e0
acid,18-22	DrugDDI.d525.s24.e0
(e.g.,,23-29
Lithostat),30-40	DrugDDI.d525.s24.e1
or,41-43

-,0-1
Dapsone,2-9	DrugDDI.d525.s25.e0
or,10-12

-,0-1
Furazolidone,2-14	DrugDDI.d525.s26.e0
(e.g.,,15-21
Furoxone),22-31	DrugDDI.d525.s26.e1
or,32-34

-,0-1
Nitrofurantoin,2-16	DrugDDI.d525.s27.e0
(e.g.,,17-23
Furadantin),24-35	DrugDDI.d525.s27.e1
or,36-38

-,0-1
Primaquine,2-12	DrugDDI.d525.s28.e0
or,13-15

-,0-1
Procainamide,2-14	DrugDDI.d525.s29.e0
(e.g.,,15-21
Pronestyl),22-32	DrugDDI.d525.s29.e1
or,33-35

-,0-1
Quinidine,2-11	DrugDDI.d525.s30.e0
(e.g.,,12-18
Quinidex),19-28	DrugDDI.d525.s30.e1
or,29-31

-,0-1
Quinine,2-9	DrugDDI.d525.s31.e0
(e.g.,,10-16
Quinamm),17-25	DrugDDI.d525.s31.e1
or,26-28

-,0-1
Sulfoxone,2-11	DrugDDI.d525.s32.e0
(e.g.,,12-18
Diasone),19-27	DrugDDI.d525.s32.e1
or,28-30

-,0-1
Vitamin,2-9	DrugDDI.d525.s33.e0
K,10-11	DrugDDI.d525.s33.e0
(e.g.,,12-18
AquaMEPHYTON,,19-32
Synkayvite)?Use,33-48
of,49-51
sulfapyridine,52-65	DrugDDI.d525.s33.e2
with,66-70
these,71-76
medicines,77-86	DrugDDI.d525.s33.e3
may,87-90
increase,91-99
the,100-103
chance,104-110
of,111-113
side,114-118
effects,119-126
affecting,127-136
the,137-140
blood,141-146

-,0-1
Anticoagulants,2-16	DrugDDI.d525.s34.e0
(blood,17-23
thinners),24-33
or,34-36

-,0-1
Ethotoin,2-10	DrugDDI.d525.s35.e0
(e.g.,,11-17
Peganone),18-27	DrugDDI.d525.s35.e1
or,28-30

-,0-1
Mephenytoin,2-13	DrugDDI.d525.s36.e0
(e.g.,,14-20
Mesantoin)?Use,21-35	DrugDDI.d525.s36.e1
of,36-38
sulfapyridine,39-52	DrugDDI.d525.s36.e2
with,53-57
these,58-63
medicines,64-73	DrugDDI.d525.s36.e3
may,74-77
increase,78-86
the,87-90
chance,91-97
of,98-100
side,101-105
effects,106-113
of,114-116
these,117-122
medicines,123-132	DrugDDI.d525.s36.e4

-,0-1
Antidiabetics,,2-16
oral,17-21
(diabetes,22-31
medicine,32-40
you,41-44
take,45-49
by,50-52
mouth)?Use,53-63
of,64-66
oral,67-71
antidiabetics,72-85	DrugDDI.d525.s37.e1
with,86-90
sulfapyridine,91-104	DrugDDI.d525.s37.e2
may,105-108
increase,109-117
the,118-121
chance,122-128
of,129-131
side,132-136
effects,137-144
affecting,145-154
the,155-158
blood,159-164
and/or,165-171
the,172-175
side,176-180
effects,181-188
or,189-191
oral,192-196
antidiabetics,197-210	DrugDDI.d525.s37.e3

-,0-1
Methotrexate,2-14	DrugDDI.d525.s38.e0
(e.g.,,15-21
Mexate)?Use,22-33	DrugDDI.d525.s38.e1
of,34-36
methotrexate,37-49	DrugDDI.d525.s38.e2
with,50-54
sulfapyridine,55-68	DrugDDI.d525.s38.e3
may,69-72
increase,73-81
the,82-85
chance,86-92
of,93-95
side,96-100
effects,101-108
affecting,109-118
the,119-122
liver,123-128	DrugDDI.d525.s38.e4
and/or,129-135
the,136-139
side,140-144
effects,145-152
of,153-155
methotrexate,156-168	DrugDDI.d525.s38.e5

-,0-1
Methyldopa,2-12	DrugDDI.d525.s39.e0
(e.g.,,13-19
Aldomet)?Use,20-32	DrugDDI.d525.s39.e1
of,33-35
methyldopa,36-46	DrugDDI.d525.s39.e2
with,47-51
sulfapyridine,52-65	DrugDDI.d525.s39.e3
may,66-69
increase,70-78
the,79-82
chance,83-89
of,90-92
side,93-97
effects,98-105
affecting,106-115
the,116-119
liver,120-125	DrugDDI.d525.s39.e4
and/or,126-132
the,133-136
blood,137-142

-,0-1
Phenytoin,2-11	DrugDDI.d525.s40.e0
(e.g.,,12-18
Dilantin)?Use,19-32	DrugDDI.d525.s40.e1
of,33-35
phenytoin,36-45	DrugDDI.d525.s40.e2
with,46-50
sulfapyridine,51-64	DrugDDI.d525.s40.e3
may,65-68
increase,69-77
the,78-81
chance,82-88
of,89-91
side,92-96
effects,97-104
affecting,105-114
the,115-118
liver,119-124	DrugDDI.d525.s40.e4
and/or,125-131
the,132-135
side,136-140
effects,141-148
of,149-151
phenytoin,152-161	DrugDDI.d525.s40.e5

In,0-2
evaluating,3-13
the,14-17
potential,18-27
for,28-31
interactions,32-44
among,45-50
co-administered,51-66
antiepilepsy,67-79
drugs,80-85	DrugDDI.d579.s0.e0
(AEDs),,86-93
whether,94-101
or,102-104
not,105-108
an,109-111
AED,112-115
induces,116-123
or,124-126
does,127-131
not,132-135
induce,136-142
metabolic,143-152
enzymes,153-160
is,161-163
an,164-166
important,167-176
consideration.,177-191

Phenytoin,,0-10
phenobarbital,11-24	DrugDDI.d579.s1.e1
and,25-28
carbamazepine,29-42	DrugDDI.d579.s1.e2
are,43-46
ge,47-49
nerally,50-57
classified,58-68
as,69-71
enzyme,72-78
inducers;,79-88

valproate,0-9	DrugDDI.d579.s2.e0
and,10-13
gabapentin,14-24	DrugDDI.d579.s2.e1
are,25-28
not.,29-33

GABITRIL,0-8	DrugDDI.d579.s3.e0
is,9-11
considered,12-22
to,23-25
be,26-28
a,29-30
non-enzyme,31-41
inducing,42-50
AED.,51-55

Effects,0-7
of,8-10
GABITRIL,11-19	DrugDDI.d579.s5.e0
on,20-22
other,23-28
Antiepilepsy,29-41
Drugs,42-47	DrugDDI.d579.s5.e1
(AEDs),48-54
:,55-56
Phenytoin:,57-67	DrugDDI.d579.s5.e2
Tiagabine,68-77	DrugDDI.d579.s5.e3
had,78-81
no,82-84
effect,85-91
on,92-94
the,95-98
steady-state,99-111
plasma,112-118
concentrations,119-133
of,134-136
phenytoin,137-146	DrugDDI.d579.s5.e4
in,147-149
patients,150-158
with,159-163
epilepsy.,164-173

Carbamazepine:,0-14	DrugDDI.d579.s6.e0
Tiagabine,15-24	DrugDDI.d579.s6.e1
had,25-28
no,29-31
effect,32-38
on,39-41
the,42-45
steady-state,46-58
plasma,59-65
concentrations,66-80
of,81-83
carbamazepine,84-97	DrugDDI.d579.s6.e2
or,98-100
its,101-104
epoxide,105-112	DrugDDI.d579.s6.e3
metabolite,113-123	DrugDDI.d579.s6.e3
in,124-126
patients,127-135
with,136-140
epilepsy.,141-150

Valproate:,0-10	DrugDDI.d579.s7.e0
Tiagabine,11-20	DrugDDI.d579.s7.e1
causes,21-27
a,28-29
slight,30-36
decrease,37-45
(about,46-52
10%),53-57
in,58-60
steady-state,61-73
valproate,74-83	DrugDDI.d579.s7.e2
concentrations.,84-99

Phenobarbital,0-13	DrugDDI.d579.s8.e0
or,14-16
Primidone,17-26	DrugDDI.d579.s8.e1
:,27-28
No,29-31
formal,32-38
pharmacokinetic,39-54
studies,55-62
have,63-67
been,68-72
performed,73-82
examining,83-92
the,93-96
addition,97-105
of,106-108
tiagabine,109-118	DrugDDI.d579.s8.e2
to,119-121
regimens,122-130
containing,131-141
phenobarbital,142-155	DrugDDI.d579.s8.e3
or,156-158
primidone.,159-169	DrugDDI.d579.s8.e4

The,0-3
addition,4-12
of,13-15
tiagabine,16-25	DrugDDI.d579.s9.e0
in,26-28
a,29-30
limited,31-38
number,39-45
of,46-48
patients,49-57
in,58-60
three,61-66
well-controlled,67-82
studies,83-90
caused,91-97
no,98-100
systematic,101-111
changes,112-119
in,120-122
phenobarbital,123-136	DrugDDI.d579.s9.e1
or,137-139
primidone,140-149	DrugDDI.d579.s9.e2
concentrations,150-164
when,165-169
compared,170-178
to,179-181
placebo.,182-190

Effects,0-7
of,8-10
other,11-16
Antiepilepsy,17-29
Drugs,30-35	DrugDDI.d579.s10.e0
(AEDs),36-42
on,43-45
GABITRIL,46-54	DrugDDI.d579.s10.e1
:,55-56
Carbamazepine:,57-71	DrugDDI.d579.s10.e2
Population,72-82
pharmacokinetic,83-98
analyses,99-107
indicate,108-116
that,117-121
tiagabine,122-131	DrugDDI.d579.s10.e3
clearance,132-141
is,142-144
60%,145-148
greater,149-156
in,157-159
patients,160-168
taking,169-175
carbamazepine,176-189	DrugDDI.d579.s10.e4
with,190-194
or,195-197
without,198-205
other,206-211
enzyme-,212-219
inducing,220-228
AEDs.,229-234

Phenytoin:,0-10	DrugDDI.d579.s11.e0
Population,11-21
pharmacokinetic,22-37
analyses,38-46
indicate,47-55
that,56-60
tiagabine,61-70	DrugDDI.d579.s11.e1
clearance,71-80
is,81-83
60%,84-87
greater,88-95
in,96-98
patients,99-107
taking,108-114
phenytoin,115-124	DrugDDI.d579.s11.e2
with,125-129
or,130-132
without,133-140
other,141-146
enzyme-,147-154
inducing,155-163
AEDs.,164-169

Phenobarbital,0-13	DrugDDI.d579.s12.e0
(Primidone):,14-26
Population,27-37
pharmacokinetic,38-53
analyses,54-62
indicate,63-71
that,72-76
tiagabine,77-86	DrugDDI.d579.s12.e2
clearance,87-96
is,97-99
60%,100-103
greater,104-111
in,112-114
patients,115-123
taking,124-130
phenobarbital,131-144	DrugDDI.d579.s12.e3
(primidone),145-156
with,157-161
or,162-164
without,165-172
other,173-178
enzyme-inducing,179-194
AEDs.,195-200

Valproate:,0-10	DrugDDI.d579.s13.e0
The,11-14
addition,15-23
of,24-26
tiagabine,27-36	DrugDDI.d579.s13.e1
to,37-39
patients,40-48
taking,49-55
valproate,56-65	DrugDDI.d579.s13.e2
chronically,66-77
had,78-81
no,82-84
effect,85-91
on,92-94
tiagabine,95-104	DrugDDI.d579.s13.e3
pharmacokinetics,,105-122
but,123-126
valproate,127-136	DrugDDI.d579.s13.e4
significantly,137-150
decreased,151-160
tiagabine,161-170
binding,171-178
in,179-181
vitro,182-187
from,188-192
96.3,193-197
to,198-200
94.8%,,201-207
which,208-213
resulted,214-222
in,223-225
an,226-228
increase,229-237
of,238-240
approximately,241-254
40%,255-258
in,259-261
the,262-265
free,266-270
tiagabine,271-280	DrugDDI.d579.s13.e5
concentration.,281-295

Interaction,0-11
of,12-14
GABITRIL,15-23	DrugDDI.d579.s15.e0
with,24-28
Other,29-34
Drugs,35-40	DrugDDI.d579.s15.e1
:,41-42
Cimetidine,43-53	DrugDDI.d579.s15.e2
:,54-55
Co-administration,56-73
of,74-76
cimetidine,77-87	DrugDDI.d579.s15.e3
(800,88-92
mg/day),93-100
to,101-103
patients,104-112
taking,113-119
tiagabine,120-129	DrugDDI.d579.s15.e4
chronically,130-141
had,142-145
no,146-148
effect,149-155
on,156-158
tiagabine,159-168	DrugDDI.d579.s15.e5
pharmacokinetics.,169-186

Theophylline:,0-13	DrugDDI.d579.s16.e0
A,14-15
single,16-22
10,23-25
mg,26-28
dose,29-33
of,34-36
tiagabine,37-46	DrugDDI.d579.s16.e1
did,47-50
not,51-54
affect,55-61
the,62-65
pharmacokinetics,66-82
of,83-85
theophylline,86-98	DrugDDI.d579.s16.e2
at,99-101
steady,102-108
state.,109-115

Warfarin:,0-9	DrugDDI.d579.s17.e0
No,10-12
significant,13-24
differences,25-36
were,37-41
observed,42-50
in,51-53
the,54-57
steady-state,58-70
pharmacokinetics,71-87
of,88-90
R-warfarin,91-101
or,102-104
S-warfarin,105-115
with,116-120
the,121-124
addition,125-133
of,134-136
tiagabine,137-146	DrugDDI.d579.s17.e3
given,147-152
as,153-155
a,156-157
single,158-164
dose.,165-170

Prothrombin,0-11
times,12-17
were,18-22
not,23-26
affected,27-35
by,36-38
tiagabine.,39-49	DrugDDI.d579.s18.e0

Digoxin:,0-8	DrugDDI.d579.s19.e0
Concomitant,9-20
administration,21-35
of,36-38
tiagabine,39-48	DrugDDI.d579.s19.e1
did,49-52
not,53-56
affect,57-63
the,64-67
steady-state,68-80
pharmacokinetics,81-97
of,98-100
digoxin,101-108	DrugDDI.d579.s19.e2
or,109-111
the,112-115
mean,116-120
daily,121-126
trough,127-133
serum,134-139
level,140-145
of,146-148
digoxin.,149-157	DrugDDI.d579.s19.e3

Ethanol,0-7	DrugDDI.d579.s20.e0
or,8-10
Triazolam:,11-21	DrugDDI.d579.s20.e1
No,22-24
significant,25-36
differences,37-48
were,49-53
observed,54-62
in,63-65
the,66-69
pharmacokinetics,70-86
of,87-89
triazolam,90-99	DrugDDI.d579.s20.e2
(0.125,100-106
mg),107-110
and,111-114
tiagabine,115-124	DrugDDI.d579.s20.e3
(10,125-128
mg),129-132
when,133-137
given,138-143
together,144-152
as,153-155
a,156-157
single,158-164
dose.,165-170

The,0-3
pharmacokinetics,4-20
of,21-23
ethanol,24-31	DrugDDI.d579.s21.e0
were,32-36
not,37-40
affected,41-49
by,50-52
multiple-dose,53-66
administration,67-81
of,82-84
tiagabine.,85-95	DrugDDI.d579.s21.e1

Tiagabine,0-9	DrugDDI.d579.s22.e0
has,10-13
shown,14-19
no,20-22
clinically,23-33
important,34-43
potentiation,44-56
of,57-59
the,60-63
pharmacodynamic,64-79
effects,80-87
of,88-90
triazo,91-97
lam,98-101
or,102-104
alcohol.,105-113	DrugDDI.d579.s22.e1

Because,0-7
of,8-10
the,11-14
possible,15-23
additive,24-32
effects,33-40
of,41-43
drugs,44-49	DrugDDI.d579.s23.e0
that,50-54
may,55-58
depress,59-66
the,67-70
nervous,71-78
system,,79-86
ethanol,87-94	DrugDDI.d579.s23.e1
or,95-97
triazolam,98-107	DrugDDI.d579.s23.e2
should,108-114
be,115-117
used,118-122
cautiously,123-133
in,134-136
combination,137-148
with,149-153
tiagabine.,154-164	DrugDDI.d579.s23.e3

Oral,0-4	DrugDDI.d579.s24.e0
Contraceptives:,5-20	DrugDDI.d579.s24.e0
Multiple,21-29
dose,30-34
administration,35-49
of,50-52
tiagabine,53-62	DrugDDI.d579.s24.e1
(8,63-65
mg/day,66-72
monotherapy),73-85
did,86-89
not,90-93
alter,94-99
the,100-103
pharmacokinetics,104-120
of,121-123
oral,124-128	DrugDDI.d579.s24.e2
contraceptives,129-143	DrugDDI.d579.s24.e2
in,144-146
healthy,147-154
women,155-160
of,161-163
childbearing,164-176
age.,177-181

Antipyrine,0-10	DrugDDI.d579.s25.e0
:,11-12
Antipyrine,13-23	DrugDDI.d579.s25.e1
pharmacokinetics,24-40
were,41-45
not,46-49
significantly,50-63
different,64-73
before,74-80
and,81-84
after,85-90
tiagabine,91-100	DrugDDI.d579.s25.e2
multiple-dose,101-114
regimens.,115-124

This,0-4
indicates,5-14
that,15-19
tiagabine,20-29	DrugDDI.d579.s26.e0
does,30-34
not,35-38
cause,39-44
induction,45-54
or,55-57
inhibition,58-68
of,69-71
the,72-75
hepatic,76-83
microsomal,84-94	DrugDDI.d579.s26.e1
enzyme,95-101	DrugDDI.d579.s26.e1
systems,102-109
responsible,110-121
for,122-125
the,126-129
metabolism,130-140
of,141-143
antipyrine.,144-155	DrugDDI.d579.s26.e2

Interaction,0-11
of,12-14
GABITRIL,15-23	DrugDDI.d579.s27.e0
with,24-28
Highly,29-35
Protein,36-43	DrugDDI.d579.s27.e1
Bound,44-49
Drugs:,50-56
In,57-59
vitro,60-65
data,66-70
showed,71-77
that,78-82
tiagabine,83-92	DrugDDI.d579.s27.e2
is,93-95
96%,96-99
bound,100-105
to,106-108
human,109-114
plasma,115-121	DrugDDI.d579.s27.e3
protein,122-129	DrugDDI.d579.s27.e3
and,130-133
therefore,134-143
has,144-147
the,148-151
potential,152-161
to,162-164
interact,165-173
with,174-178
other,179-184
highly,185-191
protein,192-199
bound,200-205
compounds.,206-216

Such,0-4
an,5-7
interaction,8-19
can,20-23
potentially,24-35
lead,36-40
to,41-43
higher,44-50
free,51-55
fractions,56-65
of,66-68
either,69-75
tiagabine,76-85	DrugDDI.d579.s28.e0
or,86-88
the,89-92
competing,93-102
drug.,103-108	DrugDDI.d579.s28.e1

The,0-3
drug,4-8
interaction,9-20
studies,21-28
with,29-33
valdecoxib,34-44	DrugDDI.d54.s0.e0
were,45-49
performed,50-59
both,60-64
with,65-69
valdecoxib,70-80	DrugDDI.d54.s0.e1
and,81-84
a,85-86
rapidly,87-94
hydrolyzed,95-105
intravenous,106-117
prodrug,118-125
form.,126-131

The,0-3
results,4-11
from,12-16
trials,17-23
using,24-29
the,30-33
intravenous,34-45
prodrug,46-53
are,54-57
reported,58-66
in,67-69
this,70-74
section,75-82
as,83-85
they,86-90
relate,91-97
to,98-100
the,101-104
role,105-109
of,110-112
valdecoxib,113-123	DrugDDI.d54.s1.e0
in,124-126
drug,127-131
interactions.,132-145

General:,0-8
In,9-11
humans,,12-19
valdecoxib,20-30	DrugDDI.d54.s2.e0
metabolism,31-41
is,42-44
predominantly,45-58
mediated,59-67
via,68-71
CYP,72-75	DrugDDI.d54.s2.e1
3A4,76-79
and,80-83
2C9,84-87	DrugDDI.d54.s2.e2
with,88-92
glucuronidation,93-108
being,109-114
a,115-116
further,117-124
(20%),125-130
route,131-136
of,137-139
metabolism.,140-151

In,0-2
vitro,3-8
studies,9-16
indicate,17-25
that,26-30
valdecoxib,31-41	DrugDDI.d54.s3.e0
is,42-44
a,45-46
moderate,47-55
inhibitor,56-65
of,66-68
CYP,69-72	DrugDDI.d54.s3.e1
2C19,73-77	DrugDDI.d54.s3.e1
(IC50,78-83
=,84-85
6,86-87
?g/mL,88-93
or,94-96
19,97-99
?M),100-103
and,104-107
2C9,108-111
(IC50,112-117
=,118-119
13,120-122
?g/mL,123-128
or,129-131
41,132-134
?M),,135-139
and,140-143
a,144-145
weak,146-150
inhibitor,151-160
of,161-163
CYP,164-167	DrugDDI.d54.s3.e2
2D6,168-171	DrugDDI.d54.s3.e2
(IC50,172-177
=,178-179
31,180-182
?g/mL,183-188
or,189-191
100,192-195
?M),196-199
and,200-203
3A4,204-207
(IC50,208-213
=,214-215
44,216-218
?g/mL,219-224
or,225-227
141,228-231
?M,232-234
)..,235-238

Aspirin:,0-8	DrugDDI.d54.s4.e0
Concomitant,9-20
administration,21-35
of,36-38
aspirin,39-46	DrugDDI.d54.s4.e1
with,47-51
valdecoxib,52-62	DrugDDI.d54.s4.e2
may,63-66
result,67-73
in,74-76
an,77-79
increased,80-89
risk,90-94
of,95-97
GI,98-100
ulceration,101-111
and,112-115
complications,116-129
compared,130-138
to,139-141
valdecoxib,142-152	DrugDDI.d54.s4.e3
alone.,153-159

Because,0-7
of,8-10
its,11-14
lack,15-19
of,20-22
anti-platelet,23-36
effect,37-43
valdecoxib,44-54	DrugDDI.d54.s5.e0
is,55-57
not,58-61
a,62-63
substitute,64-74
for,75-78
aspirin,79-86	DrugDDI.d54.s5.e1
for,87-90
cardiovascular,91-105
prophylaxis.,106-118

In,0-2
a,3-4
parallel,5-13
group,14-19
drug,20-24
interaction,25-36
study,37-42
comparing,43-52
the,53-56
intravenous,57-68
prodrug,69-76
form,77-81
of,82-84
valdecoxib,85-95	DrugDDI.d54.s6.e0
at,96-98
40,99-101
mg,102-104
BID,105-108
(n=10),109-115
vs,116-118
placebo,119-126
(n=9),,127-133
valdecoxib,134-144	DrugDDI.d54.s6.e1
had,145-148
no,149-151
effect,152-158
on,159-161
in,162-164
vitro,165-170
aspirin-mediated,171-187	DrugDDI.d54.s6.e2
inhibition,188-198
of,199-201
arachidonate-,202-215	DrugDDI.d54.s6.e3
or,216-218
collagen-stimulated,219-238	DrugDDI.d54.s6.e4
platelet,239-247
aggregation.,248-260

Methotrexate:,0-13	DrugDDI.d54.s7.e0
Valdecoxib,14-24	DrugDDI.d54.s7.e1
10,25-27	DrugDDI.d54.s7.e1
mg,28-30	DrugDDI.d54.s7.e1
BID,31-34
did,35-38
not,39-42
show,43-47
a,48-49
significant,50-61
effect,62-68
on,69-71
the,72-75
plasma,76-82
exposure,83-91
or,92-94
renal,95-100
clearance,101-110
of,111-113
methotrexate.,114-127	DrugDDI.d54.s7.e2

ACE-inhibitors:Reports,0-22	DrugDDI.d54.s8.e0
suggest,23-30
that,31-35
NSAIDs,36-42	DrugDDI.d54.s8.e1
may,43-46
diminish,47-55
the,56-59
antihypertensive,60-76	DrugDDI.d54.s8.e2
effect,77-83
of,84-86
ACE-inhibitors.,87-102	DrugDDI.d54.s8.e3

This,0-4
interaction,5-16
should,17-23
be,24-26
given,27-32
consideration,33-46
in,47-49
patients,50-58
taking,59-65
BEXTRA,66-72	DrugDDI.d54.s9.e0
concomitantly,73-86
with,87-91
ACE-inhibitors.,92-107	DrugDDI.d54.s9.e1

Furosemide:,0-11	DrugDDI.d54.s10.e0
Clinical,12-20
studies,,21-29
as,30-32
well,33-37
as,38-40
post-marketing,41-55
observations,,56-69
have,70-74
shown,75-80
that,81-85
NSAIDs,86-92	DrugDDI.d54.s10.e1
can,93-96
reduce,97-103
the,104-107
natriuretic,108-119	DrugDDI.d54.s10.e2
effect,120-126
of,127-129
furosemide,130-140	DrugDDI.d54.s10.e3
and,141-144
thiazides,145-154	DrugDDI.d54.s10.e4
in,155-157
some,158-162
patients.,163-172

This,0-4
response,5-13
has,14-17
been,18-22
attributed,23-33
to,34-36
inhibition,37-47
of,48-50
renal,51-56
prostaglandin,57-70	DrugDDI.d54.s11.e0
synthesis.,71-81

Anticonvulsants,0-15	DrugDDI.d54.s12.e0
(Phenytoin):,16-28
Steady,29-35
state,36-41
plasma,42-48
exposure,49-57
(AUC),58-63
of,64-66
valdecoxib,67-77	DrugDDI.d54.s12.e2
(40,78-81
mg,82-84
BID,85-88	DrugDDI.d54.s12.e3
for,89-92
12,93-95
days),96-101
was,102-105
decreased,106-115
by,116-118
27%,119-122
when,123-127
co-administered,128-143
with,144-148
multiple,149-157
doses,158-163
(300,164-168
mg,169-171
QD,172-174
for,175-178
12,179-181
days),182-187
of,188-190
phenytoin,191-200	DrugDDI.d54.s12.e4
(a,201-203
CYP,204-207	DrugDDI.d54.s12.e5
3A4,208-211
inducer).,212-221

Patients,0-8
already,9-16
stabilized,17-27
on,28-30
valdecoxib,31-41	DrugDDI.d54.s13.e0
should,42-48
be,49-51
closely,52-59
monitored,60-69
for,70-73
loss,74-78
of,79-81
symptom,82-89
control,90-97
with,98-102
phenytoin,103-112	DrugDDI.d54.s13.e1
coadministration.,113-130

Valdecoxib,0-10	DrugDDI.d54.s14.e0
did,11-14
not,15-18
have,19-23
a,24-25
statistically,26-39
significant,40-51
effect,52-58
on,59-61
the,62-65
pharmacokinetics,66-82
of,83-85
phenytoin,86-95	DrugDDI.d54.s14.e1
(a,96-98
CYP,99-102	DrugDDI.d54.s14.e2
2C9,103-106	DrugDDI.d54.s14.e2
and,107-110
CYP,111-114	DrugDDI.d54.s14.e3
2C19,115-119	DrugDDI.d54.s14.e3
substrate).,120-131

Drug,0-4
interaction,5-16
studies,17-24
with,25-29
other,30-35
anticonvulsants,36-51	DrugDDI.d54.s15.e0
have,52-56
not,57-60
been,61-65
conducted.,66-76

Routine,0-7
monitoring,8-18
should,19-25
be,26-28
performed,29-38
when,39-43
therapy,44-51
with,52-56
BEXTRA,57-63	DrugDDI.d54.s16.e0
is,64-66
either,67-73
initiated,74-83
or,84-86
discontinued,87-99
in,100-102
patients,103-111
on,112-114
anticonvulsant,115-129
therapy.,130-138

Dextromethorphan:,0-17	DrugDDI.d54.s17.e0
Dextromethorphan,18-34	DrugDDI.d54.s17.e1
is,35-37
primarily,38-47
metabolized,48-59
by,60-62
CYP,63-66	DrugDDI.d54.s17.e2
2D6,67-70	DrugDDI.d54.s17.e2
and,71-74
to,75-77
a,78-79
lesser,80-86
extent,87-93
by,94-96
3A4.,97-101

Coadministration,0-16
with,17-21
valdecoxib,22-32	DrugDDI.d54.s18.e0
(40,33-36
mg,37-39
BID,40-43	DrugDDI.d54.s18.e1
for,44-47
7,48-49
days),50-55
resulted,56-64
in,65-67
a,68-69
significant,70-81
increase,82-90
in,91-93
dextromethorphan,94-110	DrugDDI.d54.s18.e2
plasma,111-117
levels,118-124
suggesting,125-135
that,,136-141
at,142-144
these,145-150
doses,,151-157
valdecoxib,158-168	DrugDDI.d54.s18.e3
is,169-171
a,172-173
weak,174-178
inhibitor,179-188
of,189-191
2D6.,192-196

Even,0-4
so,5-7
dextromethorphan,8-24	DrugDDI.d54.s19.e0
plasma,25-31
concentrations,32-46
in,47-49
the,50-53
presence,54-62
of,63-65
high,66-70
doses,71-76
of,77-79
valdecoxib,80-90	DrugDDI.d54.s19.e1
were,91-95
almost,96-102
5-fold,103-109
lower,110-115
than,116-120
those,121-126
seen,127-131
in,132-134
CYP,135-138	DrugDDI.d54.s19.e2
2D6,139-142	DrugDDI.d54.s19.e2
poor,143-147
metabolizers,148-160
suggesting,161-171
that,172-176
dose,177-181
adjustment,182-192
is,193-195
not,196-199
necessary.,200-210

Lithium:,0-8	DrugDDI.d54.s20.e0
Valdecoxib,9-19	DrugDDI.d54.s20.e1
40,20-22	DrugDDI.d54.s20.e1
mg,23-25	DrugDDI.d54.s20.e1
BID,26-29
for,30-33
7,34-35
days,36-40
produced,41-49
significant,50-61
decreases,62-71
in,72-74
lithium,75-82	DrugDDI.d54.s20.e2
serum,83-88
clearance,89-98
(25%),99-104
and,105-108
renal,109-114
clearance,115-124
(30%),125-130
with,131-135
a,136-137
34%,138-141
higher,142-148
serum,149-154
exposure,155-163
compared,164-172
to,173-175
lithium,176-183	DrugDDI.d54.s20.e3
alone.,184-190

Lithium,0-7	DrugDDI.d54.s21.e0
serum,8-13
concentrations,14-28
should,29-35
be,36-38
monitored,39-48
closely,49-56
when,57-61
initiating,62-72
or,73-75
changing,76-84
therapy,85-92
with,93-97
BEXTRA,98-104	DrugDDI.d54.s21.e1
in,105-107
patients,108-116
receiving,117-126
lithium.,127-135	DrugDDI.d54.s21.e2

Lithium,0-7	DrugDDI.d54.s22.e0
carbonate,8-17	DrugDDI.d54.s22.e0
(450,18-22
mg,23-25
BID,26-29	DrugDDI.d54.s22.e1
for,30-33
7,34-35
days),36-41
had,42-45
no,46-48
effect,49-55
on,56-58
valdecoxib,59-69	DrugDDI.d54.s22.e2
pharmacokinetics.,70-87

Warfarin:,0-9	DrugDDI.d54.s23.e0
The,10-13
effect,14-20
of,21-23
valdecoxib,24-34	DrugDDI.d54.s23.e1
on,35-37
the,38-41
anticoagulant,42-55
effect,56-62
of,63-65
warfarin,66-74	DrugDDI.d54.s23.e2
(1,75-77
-,78-79
8,80-81
mg/day),82-89
was,90-93
studied,94-101
in,102-104
healthy,105-112
subjects,113-121
by,122-124
coadministration,125-141
of,142-144
BEXTRA,145-151	DrugDDI.d54.s23.e3
40,152-154
mg,155-157
BID,158-161
for,162-165
7,166-167
days.,168-173

Valdecoxib,0-10	DrugDDI.d54.s24.e0
caused,11-17
a,18-19
statistically,20-33
significant,34-45
increase,46-54
in,55-57
plasma,58-64
exposures,65-74
of,75-77
R-warfarin,78-88
and,89-92
S-warfarin,93-103
(12%,104-108
and,109-112
15%,,113-117
respectively),,118-132
and,133-136
in,137-139
the,140-143
pharmacodynamic,144-159
effects,160-167
(prothrombin,168-180
time,,181-186
measured,187-195
as,196-198
INR),199-203
of,204-206
warfarin.,207-216	DrugDDI.d54.s24.e3

While,0-5
mean,6-10
INR,11-14
values,15-21
were,22-26
only,27-31
slightly,32-40
increased,41-50
with,51-55
coadministration,56-72
of,73-75
valdecoxib,,76-87
the,88-91
day-to-day,92-102
variability,103-114
in,115-117
individual,118-128
INR,129-132
values,133-139
was,140-143
increased.,144-154

Anticoagulant,0-13
therapy,14-21
should,22-28
be,29-31
monitored,,32-42
particularly,43-55
during,56-62
the,63-66
first,67-72
few,73-76
weeks,,77-83
after,84-89
initiating,90-100
therapy,101-108
with,109-113
BEXTRA,114-120	DrugDDI.d54.s26.e0
in,121-123
patients,124-132
receiving,133-142
warfarin,143-151	DrugDDI.d54.s26.e1
or,152-154
similar,155-162
agents.,163-170

Fluconazole,0-11	DrugDDI.d54.s27.e0
and,12-15
Ketoconazole:,16-29	DrugDDI.d54.s27.e1
Ketoconazole,30-42	DrugDDI.d54.s27.e2
and,43-46
fluconazole,47-58	DrugDDI.d54.s27.e3
are,59-62
predominantly,63-76
CYP,77-80	DrugDDI.d54.s27.e4
3A4,81-84
and,85-88
2C9,89-92
inhibitors,,93-104
respectively.,105-118

Concomitant,0-11
single,12-18
dose,19-23
administration,24-38
of,39-41
valdecoxib,42-52	DrugDDI.d54.s28.e0
20,53-55	DrugDDI.d54.s28.e0
mg,56-58	DrugDDI.d54.s28.e0
with,59-63
multiple,64-72
doses,73-78
of,79-81
ketoconazole,82-94	DrugDDI.d54.s28.e1
and,95-98
fluconazole,99-110	DrugDDI.d54.s28.e2
produced,111-119
a,120-121
significant,122-133
increase,134-142
in,143-145
exposure,146-154
of,155-157
valdecoxib.,158-169	DrugDDI.d54.s28.e3

Plasma,0-6
exposure,7-15
(AUC),16-21
to,22-24
valdecoxib,25-35	DrugDDI.d54.s29.e0
was,36-39
increased,40-49
62%,50-53
when,54-58
coadministered,59-73
with,74-78
fluconazole,79-90	DrugDDI.d54.s29.e1
and,91-94
38%,95-98
when,99-103
coadministered,104-118
with,119-123
ketoconazole.,124-137	DrugDDI.d54.s29.e2

Glyburide:,0-10	DrugDDI.d54.s30.e0
Glyburide,11-20	DrugDDI.d54.s30.e1
is,21-23
a,24-25
CYP,26-29	DrugDDI.d54.s30.e2
2C9,30-33	DrugDDI.d54.s30.e2
substrate.,34-44

Coadministration,0-16
of,17-19
valdecoxib,20-30	DrugDDI.d54.s31.e0
(10,31-34
mg,35-37
BID,38-41	DrugDDI.d54.s31.e1
for,42-45
7,46-47
days),48-53
with,54-58
glyburide,59-68	DrugDDI.d54.s31.e2
(5,69-71
mg,72-74
QD,75-77
or,78-80
10,81-83
mg,84-86
BID),87-91	DrugDDI.d54.s31.e3
did,92-95
not,96-99
affect,100-106
the,107-110
pharmacokinetics,111-127
(exposure),128-138
of,139-141
glyburide.,142-152	DrugDDI.d54.s31.e4

Coadministration,0-16
of,17-19
valdecoxib,20-30	DrugDDI.d54.s32.e0
(40,31-34
mg,35-37
BID,38-41	DrugDDI.d54.s32.e1
(day,42-46
1),47-49
and,50-53
40,54-56
mg,57-59
QD,60-62
(days,63-68
2-7)),69-74
with,75-79
glyburide,80-89	DrugDDI.d54.s32.e2
(5,90-92
mg,93-95
QD),96-99
did,100-103
not,104-107
affect,108-114
either,115-121
the,122-125
pharmacokinetics,126-142
(exposure),143-153
or,154-156
the,157-160
pharmacodynamics,161-177
(blood,178-184
glucose,185-192
and,193-196
insulin,197-204
levels),205-212
of,213-215
glyburide.,216-226	DrugDDI.d54.s32.e3

Coadministration,0-16
of,17-19
valdecoxib,20-30	DrugDDI.d54.s33.e0
(40,31-34
mg,35-37
BID,38-41	DrugDDI.d54.s33.e1
(day,42-46
1),47-49
and,50-53
40,54-56
mg,57-59
QD,60-62
(days,63-68
2-7)),69-74
with,75-79
glyburide,80-89	DrugDDI.d54.s33.e2
(10,90-93
mg,94-96
glyburide,97-106	DrugDDI.d54.s33.e3
BID),107-111
resulted,112-120
in,121-123
21%,124-127
increase,128-136
in,137-139
glyburide,140-149	DrugDDI.d54.s33.e4
AUC0-12,150-157
and,158-161
a,162-163
16%,164-167
increase,168-176
in,177-179
glyburide,180-189	DrugDDI.d54.s33.e5
Cmax,190-194
leading,195-202
to,203-205
a,206-207
16%,208-211
decrease,212-220
in,221-223
glucose,224-231	DrugDDI.d54.s33.e6
AUC0-24.,232-240

Insulin,0-7	DrugDDI.d54.s34.e0
parameters,8-18
were,19-23
not,24-27
affected.,28-37

Because,0-7
changes,8-15
in,16-18
glucose,19-26
concentrations,27-41
with,42-46
valdecoxib,47-57	DrugDDI.d54.s35.e0
coadministration,58-74
were,75-79
within,80-86
the,87-90
normal,91-97
variability,98-109
and,110-113
individual,114-124
glucose,125-132
concentrations,133-147
were,148-152
above,153-158
or,159-161
near,162-166
70,167-169
mg/dL,,170-176
dose,177-181
adjustment,182-192
for,193-196
glyburide,197-206	DrugDDI.d54.s35.e1
(5,207-209
mg,210-212
QD,213-215
and,216-219
10,220-222
mg,223-225
BID),226-230	DrugDDI.d54.s35.e2
with,231-235
valdecoxib,236-246	DrugDDI.d54.s35.e3
coadministration,247-263
(up,264-267
to,268-270
40,271-273
mg,274-276
QD),277-280
is,281-283
not,284-287
indicated.,288-298

Coadministration,0-16
of,17-19
glyburide,20-29	DrugDDI.d54.s36.e0
with,30-34
doses,35-40
higher,41-47
than,48-52
40,53-55
mg,56-58
valdecoxib,59-69	DrugDDI.d54.s36.e1
(e.g.,,70-76
40,77-79
mg,80-82
BID),83-87	DrugDDI.d54.s36.e2
have,88-92
not,93-96
been,97-101
studied.,102-110

Omeprazole:,0-11	DrugDDI.d54.s37.e0
Omeprazole,12-22	DrugDDI.d54.s37.e1
is,23-25
a,26-27
CYP,28-31	DrugDDI.d54.s37.e2
3A4,32-35
substrate,36-45
and,46-49
CYP,50-53	DrugDDI.d54.s37.e3
2C19,54-58	DrugDDI.d54.s37.e3
substrate,59-68
and,69-72
inhibitor.,73-83

Valdecoxib,0-10	DrugDDI.d54.s38.e0
steady,11-17
state,18-23
plasma,24-30
concentrations,31-45
(40,46-49
mg,50-52
BID),53-57	DrugDDI.d54.s38.e1
were,58-62
not,63-66
affected,67-75
significantly,76-89
with,90-94
multiple,95-103
doses,104-109
of,110-112
omeprazole,113-123	DrugDDI.d54.s38.e2
(40,124-127
mg,128-130
QD).,131-135

Coadministration,0-16
with,17-21
valdecoxib,22-32	DrugDDI.d54.s39.e0
increased,33-42
exposure,43-51
of,52-54
omeprazole,55-65	DrugDDI.d54.s39.e1
(AUC),66-71
by,72-74
46%.,75-79

Drugs,0-5	DrugDDI.d54.s40.e0
whose,6-11
absorption,12-22
is,23-25
sensitive,26-35
to,36-38
pH,39-41
may,42-45
be,46-48
negatively,49-59
impacted,60-68
by,69-71
concomitant,72-83
administration,84-98
of,99-101
omeprazole,102-112	DrugDDI.d54.s40.e1
and,113-116
valdecoxib.,117-128	DrugDDI.d54.s40.e2

However,,0-8
because,9-16
higher,17-23
doses,24-29
(up,30-33
to,34-36
360,37-40
mg,41-43
QD),44-47
of,48-50
omeprazole,51-61	DrugDDI.d54.s41.e0
are,62-65
tolerated,66-75
in,76-78
Zollinger-Ellison,79-96
(ZE),97-101
patients,,102-111
no,112-114
dose,115-119
adjustment,120-130
for,131-134
omeprazole,135-145	DrugDDI.d54.s41.e1
is,146-148
recommended,149-160
at,161-163
current,164-171
doses.,172-178

Coadministration,0-16
of,17-19
valdecoxib,20-30	DrugDDI.d54.s42.e0
with,31-35
doses,36-41
higher,42-48
than,49-53
40,54-56
mg,57-59
QD,60-62
omeprazole,63-73	DrugDDI.d54.s42.e1
has,74-77
not,78-81
been,82-86
studied.,87-95

Oral,0-4	DrugDDI.d54.s43.e0
Contraceptives:,5-20	DrugDDI.d54.s43.e0
Valdecoxib,21-31	DrugDDI.d54.s43.e1
(40,32-35
mg,36-38
BID),39-43	DrugDDI.d54.s43.e2
did,44-47
not,48-51
induce,52-58
the,59-62
metabolism,63-73
of,74-76
the,77-80
combination,81-92
oral,93-97	DrugDDI.d54.s43.e3
contraceptive,98-111	DrugDDI.d54.s43.e3
norethindrone/ethinyl,112-133
estradiol,134-143
(1,144-146
mg,147-149
/35,150-153
mcg,154-157
combination,,158-170
Ortho-Novum,171-182	DrugDDI.d54.s43.e5
1/35?).,183-190	DrugDDI.d54.s43.e5

Coadministration,0-16
of,17-19
valdecoxib,20-30	DrugDDI.d54.s44.e0
and,31-34
Ortho-Novum,35-46	DrugDDI.d54.s44.e1
1/35?,47-52	DrugDDI.d54.s44.e1
increased,53-62
the,63-66
exposure,67-75
of,76-78
norethindrone,79-92	DrugDDI.d54.s44.e2
and,93-96
ethinyl,97-104	DrugDDI.d54.s44.e3
estradiol,105-114	DrugDDI.d54.s44.e3
by,115-117
20%,118-121
and,122-125
34%,,126-130
respectively.,131-144

Although,0-8
there,9-14
is,15-17
little,18-24
risk,25-29
for,30-33
loss,34-38
of,39-41
contraceptive,42-55	DrugDDI.d54.s45.e0
efficacy,,56-65
the,66-69
clinical,70-78
significance,79-91
of,92-94
these,95-100
increased,101-110
exposures,111-120
in,121-123
terms,124-129
of,130-132
safety,133-139
is,140-142
not,143-146
known.,147-153

These,0-5
increased,6-15
exposures,16-25
of,26-28
norethindrone,29-42	DrugDDI.d54.s46.e0
and,43-46
ethinyl,47-54	DrugDDI.d54.s46.e1
estradiol,55-64	DrugDDI.d54.s46.e1
should,65-71
be,72-74
taken,75-80
into,81-85
consideration,86-99
when,100-104
selecting,105-114
an,115-117
oral,118-122	DrugDDI.d54.s46.e2
contraceptive,123-136	DrugDDI.d54.s46.e2
for,137-140
women,141-146
taking,147-153
valdecoxib.,154-165	DrugDDI.d54.s46.e3

Diazepam:,0-9	DrugDDI.d54.s47.e0
Diazepam,10-18	DrugDDI.d54.s47.e1
(Valium),19-27
is,28-30
a,31-32
CYP,33-36	DrugDDI.d54.s47.e3
3A4,37-40
and,41-44
CYP,45-48	DrugDDI.d54.s47.e4
2C19,49-53	DrugDDI.d54.s47.e4
substrate.,54-64

Plasma,0-6
exposure,7-15
of,16-18
diazepam,19-27	DrugDDI.d54.s48.e0
(10,28-31
mg,32-34
BID),35-39	DrugDDI.d54.s48.e1
was,40-43
increased,44-53
by,54-56
28%,57-60
following,61-70
administration,71-85
of,86-88
valdecoxib,89-99	DrugDDI.d54.s48.e2
(40,100-103
mg,104-106
BID),107-111	DrugDDI.d54.s48.e3
for,112-115
12,116-118
days,,119-124
while,125-130
plasma,131-137
exposure,138-146
of,147-149
valdecoxib,150-160	DrugDDI.d54.s48.e4
(40,161-164
mg,165-167
BID),168-172	DrugDDI.d54.s48.e5
was,173-176
not,177-180
substantially,181-194
increased,195-204
following,205-214
administration,215-229
of,230-232
diazepam,233-241	DrugDDI.d54.s48.e6
(10,242-245
mg,246-248
BID),249-253	DrugDDI.d54.s48.e7
for,254-257
12,258-260
days.,261-266

Although,0-8
the,9-12
magnitude,13-22
of,23-25
changes,26-33
in,34-36
diazepam,37-45	DrugDDI.d54.s49.e0
plasma,46-52
exposure,53-61
when,62-66
coadministered,67-81
with,82-86
valdecoxib,87-97	DrugDDI.d54.s49.e1
were,98-102
not,103-106
sufficient,107-117
to,118-120
warrant,121-128
dosage,129-135
adjustments,,136-148
patients,149-157
may,158-161
experience,162-172
enhanced,173-181
sedative,182-190	DrugDDI.d54.s49.e2
side,191-195
effects,196-203
caused,204-210
by,211-213
increased,214-223
exposure,224-232
of,233-235
diazepam,236-244	DrugDDI.d54.s49.e3
under,245-250
this,251-255
circumstance.,256-269

Effect,0-6
of,7-9
other,10-15
drugs,16-21	DrugDDI.d269.s0.e0
on,22-24
Vardenafil,25-35	DrugDDI.d269.s0.e1

In,0-2
vitro,3-8
studies:,9-17
Studies,18-25
in,26-28
human,29-34
liver,35-40
microsomes,41-51
showed,52-58
that,59-63
vardenafil,64-74	DrugDDI.d269.s1.e0
is,75-77
metabolized,78-89
primarily,90-99
by,100-102
cytochrome,103-113	DrugDDI.d269.s1.e1
P450,114-118	DrugDDI.d269.s1.e1
(CYP),119-124
isoforms,125-133	DrugDDI.d269.s1.e3
3A4/5,,134-140
and,141-144
to,145-147
a,148-149
lesser,150-156
degree,157-163
by,164-166
CYP2C9.,167-174	DrugDDI.d269.s1.e4

Therefore,,0-10
inhibitors,11-21
of,22-24
these,25-30
enzymes,31-38
are,39-42
expected,43-51
to,52-54
reduce,55-61
vardenafil,62-72	DrugDDI.d269.s2.e0
clearance.,73-83

In,0-2
vivo,3-7
studies:,8-16
Cytochrome,17-27	DrugDDI.d269.s3.e0
P450,28-32	DrugDDI.d269.s3.e0
Inhibitors,33-43

Cimetidine,0-10	DrugDDI.d269.s4.e0
(400,11-15
mg,16-18
b.i.d.),19-26
had,27-30
no,31-33
effect,34-40
on,41-43
vardenafil,44-54	DrugDDI.d269.s4.e1
bioavailability,55-70
(AUC),71-76
and,77-80
maximum,81-88
concentration,89-102
(Cmax),103-109
of,110-112
vardenafil,113-123	DrugDDI.d269.s4.e2
when,124-128
co-administered,129-144
with,145-149
20,150-152
mg,153-155
Vardenafil,156-166	DrugDDI.d269.s4.e3
in,167-169
healthy,170-177
volunteers.,178-189

Erythromycin,0-12	DrugDDI.d269.s5.e0
(500,13-17
mg,18-20
t.i.d),21-27
produced,28-36
a,37-38
4-fold,39-45
increase,46-54
in,55-57
vardenafil,58-68	DrugDDI.d269.s5.e2
AUC,69-72
and,73-76
a,77-78
3-fold,79-85
increase,86-94
in,95-97
Cmax,98-102
when,103-107
co-administered,108-123
with,124-128
Vardenafil,129-139	DrugDDI.d269.s5.e3
5,140-141	DrugDDI.d269.s5.e3
mg,142-144	DrugDDI.d269.s5.e3
in,145-147
healthy,148-155
volunteers.,156-167

It,0-2
is,3-5
recommended,6-17
not,18-21
to,22-24
exceed,25-31
a,32-33
single,34-40
5,41-42
mg,43-45
dose,46-50
of,51-53
Vardenafil,54-64	DrugDDI.d269.s6.e0
in,65-67
a,68-69
24-hour,70-77
period,78-84
when,85-89
used,90-94
in,95-97
combination,98-109
with,110-114
erythromycin.,115-128	DrugDDI.d269.s6.e1

Ketoconazole,0-12	DrugDDI.d269.s7.e0
(200,13-17
mg,18-20
once,21-25
daily),26-32
produced,33-41
a,42-43
10-fold,44-51
increase,52-60
in,61-63
vardenafil,64-74	DrugDDI.d269.s7.e1
AUC,75-78
and,79-82
a,83-84
4-fold,85-91
increase,92-100
in,101-103
Cmax,104-108
when,109-113
co-administered,114-129
with,130-134
Vardenafil,135-145	DrugDDI.d269.s7.e2
(5,146-148
mg),149-152
in,153-155
healthy,156-163
volunteers.,164-175

A,0-1
5-mg,2-6
Vardenafil,7-17	DrugDDI.d269.s8.e0
dose,18-22
should,23-29
not,30-33
be,34-36
exceeded,37-45
when,46-50
used,51-55
in,56-58
combination,59-70
with,71-75
200,76-79
mg,80-82
once,83-87
daily,88-93
ketoconazole.,94-107	DrugDDI.d269.s8.e1

Since,0-5
higher,6-12
doses,13-18
of,19-21
ketoconazole,22-34	DrugDDI.d269.s9.e0
(400,35-39
mg,40-42
daily),43-49
may,50-53
result,54-60
in,61-63
higher,64-70
increases,71-80
in,81-83
Cmax,84-88
and,89-92
AUC,,93-97
a,98-99
single,100-106
2.5,107-110
mg,111-113
dose,114-118
of,119-121
Vardenafil,122-132	DrugDDI.d269.s9.e1
should,133-139
not,140-143
be,144-146
exceeded,147-155
in,156-158
a,159-160
24-hour,161-168
period,169-175
when,176-180
used,181-185
in,186-188
combination,189-200
with,201-205
ketoconazole,206-218	DrugDDI.d269.s9.e2
400,219-222	DrugDDI.d269.s9.e2
mg,223-225	DrugDDI.d269.s9.e2
daily.,226-232

HIV,0-3	DrugDDI.d269.s10.e0
Protease,4-12	DrugDDI.d269.s10.e0
Inhibitors:,13-24	DrugDDI.d269.s10.e0
Indinavir,25-34	DrugDDI.d269.s10.e1
(800,35-39
mg,40-42
t.i.d.),43-50
co-administered,51-66
with,67-71
Vardenafil,72-82	DrugDDI.d269.s10.e3
10,83-85	DrugDDI.d269.s10.e3
mg,86-88	DrugDDI.d269.s10.e3
resulted,89-97
in,98-100
a,101-102
16-fold,103-110
increase,111-119
in,120-122
vardenafil,123-133	DrugDDI.d269.s10.e4
AUC,,134-138
a,139-140
7-fold,141-147
increase,148-156
in,157-159
vardenafil,160-170	DrugDDI.d269.s10.e5
Cmax,171-175
and,176-179
a,180-181
2-fold,182-188
increase,189-197
in,198-200
vardenafil,201-211	DrugDDI.d269.s10.e6
half-life.,212-222

It,0-2
is,3-5
recommended,6-17
not,18-21
to,22-24
exceed,25-31
a,32-33
single,34-40
2.5,41-44
mg,45-47
Vardenafil,48-58
dose,59-63
in,64-66
a,67-68
24-hour,69-76
period,77-83
when,84-88
used,89-93
in,94-96
combination,97-108
with,109-113
indinavir.,114-124	DrugDDI.d269.s11.e0

Ritonavir,0-9	DrugDDI.d269.s12.e0
(600,10-14
mg,15-17
b.i.d.),18-25
co-administered,26-41
with,42-46
Vardenafil,47-57	DrugDDI.d269.s12.e1
5,58-59	DrugDDI.d269.s12.e1
mg,60-62	DrugDDI.d269.s12.e1
resulted,63-71
in,72-74
a,75-76
49-fold,77-84
increase,85-93
in,94-96
vardenafil,97-107	DrugDDI.d269.s12.e2
AUC,108-111
and,112-115
a,116-117
13-fold,118-125
increase,126-134
in,135-137
vardenafil,138-148	DrugDDI.d269.s12.e3
Cmax.,149-154

The,0-3
interaction,4-15
is,16-18
a,19-20
consequence,21-32
of,33-35
blocking,36-44
hepatic,45-52
metabolism,53-63
of,64-66
vardenafil,67-77	DrugDDI.d269.s13.e0
by,78-80
ritonavir,,81-91
a,92-93
highly,94-100
potent,101-107
CYP3A4,108-114	DrugDDI.d269.s13.e2
inhibitor,,115-125
which,126-131
also,132-136
inhibits,137-145
CYP2C9.,146-153	DrugDDI.d269.s13.e3

Ritonavir,0-9	DrugDDI.d269.s14.e0
significantly,10-23
prolonged,24-33
the,34-37
half-life,38-47
of,48-50
vardenafil,51-61	DrugDDI.d269.s14.e1
to,62-64
26,65-67
hours.,68-74

Consequently,,0-13
it,14-16
is,17-19
recommended,20-31
not,32-35
to,36-38
exceed,39-45
a,46-47
single,48-54
2.5,55-58
mg,59-61
Vardenafil,62-72
dose,73-77
in,78-80
a,81-82
72-hour,83-90
period,91-97
when,98-102
used,103-107
in,108-110
combination,111-122
with,123-127
ritonavir.,128-138	DrugDDI.d269.s15.e0

Other,0-5
Drug,6-10
Interactions:,11-24
No,25-27
pharmacokinetic,28-43
interactions,44-56
were,57-61
observed,62-70
between,71-78
vardenafil,79-89	DrugDDI.d269.s16.e0
and,90-93
the,94-97
following,98-107
drugs:,108-114	DrugDDI.d269.s16.e1
glyburide,,115-125
warfarin,,126-135
digoxin,,136-144
Maalox,,145-152
and,153-156
ranitidine.,157-168	DrugDDI.d269.s16.e6

In,0-2
the,3-6
warfarin,7-15	DrugDDI.d269.s17.e0
study,,16-22
vardenafil,23-33	DrugDDI.d269.s17.e1
had,34-37
no,38-40
effect,41-47
on,48-50
the,51-54
prothrombin,55-66
time,67-71
or,72-74
other,75-80
pharmacodynamic,81-96
parameters.,97-108

Effects,0-7
of,8-10
Vardenafil,11-21	DrugDDI.d269.s18.e0
on,22-24
other,25-30
drugs,31-36	DrugDDI.d269.s18.e1

In,0-2
vitro,3-8
studies:,9-17
Vardenafil,18-28	DrugDDI.d269.s19.e0
and,29-32
its,33-36
metabolites,37-48	DrugDDI.d269.s19.e1
had,49-52
no,53-55
effect,56-62
on,63-65
CYP1A2,,66-73
2A6,,74-78
and,79-82
2E1,83-86
(Ki,87-90
,91-91
,92-92
100uM).,93-100

Weak,0-4
inhibitory,5-15
effects,16-23
toward,24-30
other,31-36
isoforms,37-45	DrugDDI.d269.s20.e0
(CYP2C8,,46-54
2C9,,55-59
2C19,,60-65
2D6,,66-70
3A4),71-75
were,76-80
found,,81-87
but,88-91
Ki,92-94
values,95-101
were,102-106
in,107-109
excess,110-116
of,117-119
plasma,120-126
concentrations,127-141
achieved,142-150
following,151-160
dosing.,161-168

The,0-3
most,4-8
potent,9-15
inhibitory,16-26
activity,27-35
was,36-39
observed,40-48
for,49-52
vardenafil,53-63	DrugDDI.d269.s21.e0
metabolite,64-74
M1,,75-78
which,79-84
had,85-88
a,89-90
Ki,91-93
of,94-96
1.4,97-100
uM,101-103
toward,104-110
CYP3A4,,111-118
which,119-124
is,125-127
about,128-133
20,134-136
times,137-142
higher,143-149
than,150-154
the,155-158
M1,159-161
Cmax,162-166
values,167-173
after,174-179
an,180-182
80,183-185
mg,186-188
Vardenafil,189-199	DrugDDI.d269.s21.e2
dose.,200-205

In,0-2
vivo,3-7
studies:,8-16
Nitrates:,17-26	DrugDDI.d269.s22.e0
The,27-30
blood,31-36
pressure,37-45
lowering,46-54
effects,55-62
of,63-65
sublingual,66-76
nitrates,77-85	DrugDDI.d269.s22.e1
(0.4,86-90
mg),91-94
taken,95-100
1,101-102
and,103-106
4,107-108
hours,109-114
after,115-120
vardenafil,121-131	DrugDDI.d269.s22.e2
and,132-135
increases,136-145
in,146-148
heart,149-154
rate,155-159
when,160-164
taken,165-170
at,171-173
1,,174-176
4,177-178
and,179-182
8,183-184
hours,185-190
were,191-195
potentiated,196-207
by,208-210
a,211-212
20,213-215
mg,216-218
dose,219-223
of,224-226
Vardenafil,227-237	DrugDDI.d269.s22.e3
in,238-240
healthy,241-248
middle-aged,249-260
subjects.,261-270

These,0-5
effects,6-13
were,14-18
not,19-22
observed,23-31
when,32-36
Vardenafil,37-47	DrugDDI.d269.s23.e0
20,48-50	DrugDDI.d269.s23.e0
mg,51-53	DrugDDI.d269.s23.e0
was,54-57
taken,58-63
24,64-66
hours,67-72
before,73-79
the,80-83
NTG.,84-88

Potentiation,0-12
of,13-15
the,16-19
hypotensive,20-31
effects,32-39
of,40-42
nitrates,43-51	DrugDDI.d269.s24.e0
for,52-55
patients,56-64
with,65-69
ischemic,70-78
heart,79-84
disease,85-92
has,93-96
not,97-100
been,101-105
evaluated,,106-116
and,117-120
concomitant,121-132
use,133-136
of,137-139
Vardenafil,140-150	DrugDDI.d269.s24.e1
and,151-154
nitrates,155-163	DrugDDI.d269.s24.e2
is,164-166
contraindicated.,167-183

Nifedipine:,0-11	DrugDDI.d269.s25.e0
Vardenafil,12-22	DrugDDI.d269.s25.e1
20,23-25	DrugDDI.d269.s25.e1
mg,,26-29	DrugDDI.d269.s25.e1
when,30-34
co-administered,35-50
with,51-55
slow-release,56-68
nifedipine,69-79	DrugDDI.d269.s25.e2
30,80-82	DrugDDI.d269.s25.e2
mg,83-85	DrugDDI.d269.s25.e2
or,86-88
60,89-91
mg,92-94
once,95-99
daily,,100-106
did,107-110
not,111-114
affect,115-121
the,122-125
relative,126-134
bioavailability,135-150
(AUC),151-156
or,157-159
maximum,160-167
concentration,168-181
(Cmax),182-188
of,189-191
nifedipine,,192-203
a,204-205
drug,206-210	DrugDDI.d269.s25.e4
that,211-215
is,216-218
metabolized,219-230
via,231-234
CYP3A4.,235-242	DrugDDI.d269.s25.e5

Nifedipine,0-10	DrugDDI.d269.s26.e0
did,11-14
not,15-18
alter,19-24
the,25-28
plasma,29-35
levels,36-42
of,43-45
Vardenafil,46-56	DrugDDI.d269.s26.e1
when,57-61
taken,62-67
in,68-70
combination.,71-83

In,0-2
these,3-8
patients,9-17
whose,18-23
hypertension,24-36
was,37-40
controlled,41-51
with,52-56
nifedipine,,57-68
Vardenafil,69-79	DrugDDI.d269.s27.e1
20,80-82	DrugDDI.d269.s27.e1
mg,83-85	DrugDDI.d269.s27.e1
produced,86-94
mean,95-99
additional,100-110
supine,111-117
systolic/diastolic,118-136
blood,137-142
pressure,143-151
reductions,152-162
of,163-165
6/5,166-169
mm,170-172
Hg,173-175
compared,176-184
to,185-187
placebo.,188-196

Alpha-blockers:,0-15
When,16-20
Vardenafil,21-31	DrugDDI.d269.s28.e0
10,32-34
or,35-37
20,38-40
mg,41-43
was,44-47
given,48-53
to,54-56
healthy,57-64
volunteers,65-75
either,76-82
simultaneously,83-97
or,98-100
6,101-102
hours,103-108
after,109-114
a,115-116
10,117-119
mg,120-122
dose,123-127
of,128-130
terazosin,,131-141
significant,142-153
hypotension,154-165
developed,166-175
in,176-178
a,179-180
substantial,181-192
number,193-199
of,200-202
subjects.,203-212

With,0-4
simultaneous,5-17
dosing,18-24
of,25-27
Vardenafil,28-38	DrugDDI.d269.s29.e0
10,39-41	DrugDDI.d269.s29.e0
mg,42-44	DrugDDI.d269.s29.e0
and,45-48
terazosin,49-58	DrugDDI.d269.s29.e1
10,59-61	DrugDDI.d269.s29.e1
mg,,62-65
6,66-67
of,68-70
8,71-72
subjects,73-81
experienced,82-93
a,94-95
standing,96-104
systolic,105-113
blood,114-119
pressure,120-128
of,129-131
less,132-136
than,137-141
85,142-144
mm,145-147
Hg.,148-151

With,0-4
simultaneous,5-17
dosing,18-24
of,25-27
Vardenafil,28-38	DrugDDI.d269.s30.e0
20,39-41	DrugDDI.d269.s30.e0
mg,42-44	DrugDDI.d269.s30.e0
and,45-48
terazosin,49-58	DrugDDI.d269.s30.e1
10,59-61	DrugDDI.d269.s30.e1
mg,,62-65
2,66-67
of,68-70
9,71-72
subjects,73-81
experienced,82-93
a,94-95
standing,96-104
systolic,105-113
blood,114-119
pressure,120-128
of,129-131
less,132-136
than,137-141
85,142-144
mm,145-147
Hg.,148-151

When,0-4
Vardenafil,5-15	DrugDDI.d269.s31.e0
dosing,16-22
was,23-26
separated,27-36
from,37-41
terazosin,42-51	DrugDDI.d269.s31.e1
10,52-54	DrugDDI.d269.s31.e1
mg,55-57
by,58-60
6,61-62
hours,,63-69
7,70-71
of,72-74
28,75-77
subjects,78-86
who,87-90
received,91-99
20,100-102
mg,103-105
of,106-108
Vardenafil,109-119	DrugDDI.d269.s31.e2
experienced,120-131
a,132-133
decrease,134-142
in,143-145
standing,146-154
systolic,155-163
blood,164-169
pressure,170-178
below,179-184
85,185-187
mm,188-190
Hg.,191-194

In,0-2
a,3-4
similar,5-12
study,13-18
with,19-23
tamsulosin,24-34	DrugDDI.d269.s32.e0
in,35-37
healthy,38-45
volunteers,,46-57
1,58-59
of,60-62
24,63-65
subjects,66-74
dosed,75-80
with,81-85
Vardenafil,86-96	DrugDDI.d269.s32.e1
20,97-99	DrugDDI.d269.s32.e1
mg,100-102	DrugDDI.d269.s32.e1
and,103-106
tamsulosin,107-117	DrugDDI.d269.s32.e2
0.4,118-121	DrugDDI.d269.s32.e2
mg,122-124	DrugDDI.d269.s32.e2
separated,125-134
by,135-137
6,138-139
hours,140-145
experienced,146-157
a,158-159
standing,160-168
systolic,169-177
blood,178-183
pressure,184-192
below,193-198
85,199-201
mm,202-204
Hg.,205-208

Two,0-3
of,4-6
16,7-9
subjects,10-18
dosed,19-24
simultaneously,25-39
with,40-44
Vardenafil,45-55	DrugDDI.d269.s33.e0
10,56-58	DrugDDI.d269.s33.e0
mg,59-61	DrugDDI.d269.s33.e0
and,62-65
tamsulosin,66-76	DrugDDI.d269.s33.e1
0.4,77-80	DrugDDI.d269.s33.e1
mg,81-83	DrugDDI.d269.s33.e1
experienced,84-95
a,96-97
standing,98-106
systolic,107-115
blood,116-121
pressure,122-130
below,131-136
85,137-139
mm,140-142
Hg.,143-146

The,0-3
administration,4-18
of,19-21
lower,22-27
doses,28-33
of,34-36
Vardenafil,37-47	DrugDDI.d269.s34.e0
with,48-52
alpha-blockers,53-67
has,68-71
not,72-75
been,76-80
completely,81-91
evaluated,92-101
to,102-104
determine,105-114
if,115-117
they,118-122
can,123-126
be,127-129
safely,130-136
administered,137-149
together.,150-159

Based,0-5
on,6-8
these,9-14
data,,15-20
Vardenafil,21-31	DrugDDI.d269.s35.e0
should,32-38
not,39-42
be,43-45
used,46-50
in,51-53
patients,54-62
on,63-65
alpha-blocker,66-79	DrugDDI.d269.s35.e1
therapy.,80-88

Ritonavir,0-9	DrugDDI.d269.s36.e0
and,10-13
indinavir:,14-24	DrugDDI.d269.s36.e1
Upon,25-29
concomitant,30-41
administration,42-56
of,57-59
5,60-61
mg,62-64
of,65-67
Vardenafil,68-78	DrugDDI.d269.s36.e2
with,79-83
600,84-87
mg,88-90
BID,91-94
ritonavir,,95-105
the,106-109
Cmax,110-114
and,115-118
AUC,119-122
of,123-125
ritonavir,126-135	DrugDDI.d269.s36.e4
were,136-140
reduced,141-148
by,149-151
approximately,152-165
20%.,166-170

Upon,0-4
administration,5-19
of,20-22
10,23-25
mg,26-28
of,29-31
Vardenafil,32-42	DrugDDI.d269.s37.e0
with,43-47
800,48-51
mg,52-54
TID,55-58
indinavir,,59-69
the,70-73
Cmax,74-78
and,79-82
AUC,83-86
of,87-89
indinavir,90-99	DrugDDI.d269.s37.e2
were,100-104
reduced,105-112
by,113-115
40%,116-119
and,120-123
30%,,124-128
respectively.,129-142

Alcohol:,0-8	DrugDDI.d269.s38.e0
Alcohol,9-16	DrugDDI.d269.s38.e1
(0.5,17-21
g/kg,22-26
body,27-31
weight:,32-39
approximately,40-53
40,54-56
mL,57-59
of,60-62
absolute,63-71
alcohol,72-79
in,80-82
a,83-84
70,85-87
kg,88-90
person),91-98
and,99-102
vardenafil,103-113	DrugDDI.d269.s38.e2
plasma,114-120
levels,121-127
were,128-132
not,133-136
altered,137-144
when,145-149
dosed,150-155
simultaneously.,156-171

Vardenafil,0-10	DrugDDI.d269.s39.e0
(20,11-14
mg),15-18
did,19-22
not,23-26
potentiate,27-37
the,38-41
hypotensive,42-53
effects,54-61
of,62-64
alcohol,65-72	DrugDDI.d269.s39.e1
during,73-79
the,80-83
4-hour,84-90
observation,91-102
period,103-109
in,110-112
healthy,113-120
volunteers,121-131
when,132-136
administered,137-149
with,150-154
alcohol,155-162	DrugDDI.d269.s39.e2
(0.5,163-167
g/kg,168-172
body,173-177
weight).,178-186

Aspirin:,0-8	DrugDDI.d269.s40.e0
Vardenafil,9-19	DrugDDI.d269.s40.e1
(10,20-23
mg,24-26
and,27-30
20,31-33
mg),34-37
did,38-41
not,42-45
potentiate,46-56
the,57-60
increase,61-69
in,70-72
bleeding,73-81
time,82-86
caused,87-93
by,94-96
aspirin,97-104	DrugDDI.d269.s40.e2
(two,105-109
81,110-112
mg,113-115
tablets).,116-125

Other,0-5
interactions:,6-19
Vardenafil,20-30	DrugDDI.d269.s41.e0
had,31-34
no,35-37
effect,38-44
on,45-47
the,48-51
pharmacodynamics,52-68
of,69-71
glyburide,72-81	DrugDDI.d269.s41.e1
(glucose,82-90
and,91-94
insulin,95-102	DrugDDI.d269.s41.e3
concentrations),103-118
and,119-122
warfarin,123-131	DrugDDI.d269.s41.e4
(prothrombin,132-144
time,145-149
or,150-152
other,153-158
pharmacodynamic,159-174
parameters).,175-187

Zidovudine:,0-11	DrugDDI.d291.s0.e0
There,12-17
is,18-20
no,21-23
significant,24-35
pharmacokinetic,36-51
interaction,52-63
between,64-71
ZDV,72-75	DrugDDI.d291.s0.e1
and,76-79
zalcitabine,80-91	DrugDDI.d291.s0.e2
which,92-97
has,98-101
been,102-106
confirmed,107-116
clinically.,117-128

Zalcitabine,0-11	DrugDDI.d291.s1.e0
also,12-16
has,17-20
no,21-23
significant,24-35
effect,36-42
on,43-45
the,46-49
intracellular,50-63
phosphorylation,64-79
of,80-82
ZDV,,83-87
as,88-90
shown,91-96
in,97-99
vitro,100-105
in,106-108
peripheral,109-119
blood,120-125
mononuclear,126-137
cells,138-143
or,144-146
in,147-149
two,150-153
other,154-159
cell,160-164
lines,165-170
(U937,171-176
and,177-180
Molt-4).,181-189

In,0-2
the,3-6
same,7-11
study,12-17
it,18-20
was,21-24
shown,25-30
that,31-35
didanosine,36-46	DrugDDI.d291.s2.e0
and,47-50
stavudine,51-60	DrugDDI.d291.s2.e1
had,61-64
no,65-67
significant,68-79
effect,80-86
on,87-89
the,90-93
intracellular,94-107
phosphorylation,108-123
of,124-126
zalcitabine,127-138	DrugDDI.d291.s2.e2
in,139-141
peripheral,142-152
blood,153-158
mononuclear,159-170
cells.,171-177

Lamivudine:,0-11	DrugDDI.d291.s3.e0
In,12-14
vitro,15-20
studies,21-28
in,29-31
peripheral,32-42
blood,43-48
mononuclear,49-60
cells,,61-67
U937,68-72
and,73-76
Molt-4,77-83
cells,84-89
revealed,90-98
that,99-103
lamivudine,104-114	DrugDDI.d291.s3.e1
significantly,115-128
inhibited,129-138
zalcitabine,139-150	DrugDDI.d291.s3.e2
phosphorylation,151-166
in,167-169
a,170-171
dose,172-176
dependent,177-186
manner.,187-194

Effects,0-7
were,8-12
already,13-20
seen,21-25
with,26-30
doses,31-36
corresponding,37-50
to,51-53
relevant,54-62
plasma,63-69
levels,70-76
in,77-79
humans,,80-87
and,88-91
the,92-95
intracellular,96-109
phosphorylation,110-125
of,126-128
zalcitabine,129-140	DrugDDI.d291.s4.e0
to,141-143
its,144-147
three,148-153
metabolites,154-165	DrugDDI.d291.s4.e1
(including,166-176
the,177-180
active,181-187
zalcitabine,188-199	DrugDDI.d291.s4.e2
triphosphate,200-212
metabolite),213-224
was,225-228
significantly,229-242
inhibited.,243-253

Zalcitabine,0-11	DrugDDI.d291.s5.e0
inhibited,12-21
lamivudine,22-32	DrugDDI.d291.s5.e1
phosphorylation,33-48
at,49-51
high,52-56
concentration,57-70
ratios,71-77
(10,78-81
and,82-85
100);,86-91

however,,0-8
it,9-11
is,12-14
considered,15-25
to,26-28
be,29-31
unlikely,32-40
that,41-45
this,46-50
decrease,51-59
of,60-62
phosphorylated,63-77
lamivudine,78-88	DrugDDI.d291.s6.e0
concentration,89-102
is,103-105
of,106-108
clinical,109-117
significance,,118-131
as,132-134
lamivudine,135-145	DrugDDI.d291.s6.e1
is,146-148
a,149-150
more,151-155
efficient,156-165
substrate,166-175
for,176-179
deoxycytidine,180-193	DrugDDI.d291.s6.e2
kinase,194-200	DrugDDI.d291.s6.e2
than,201-205
zalcitabine.,206-218	DrugDDI.d291.s6.e3

These,0-5
in,6-8
vitro,9-14
studies,15-22
suggest,23-30
that,31-35
concomitant,36-47
administration,48-62
of,63-65
zalcitabine,66-77	DrugDDI.d291.s7.e0
and,78-81
lamivudine,82-92	DrugDDI.d291.s7.e1
in,93-95
humans,96-102
may,103-106
result,107-113
in,114-116
sub-therapeutic,117-132
concentrations,133-147
of,148-150
active,151-157
phosphorylated,158-172
zalcitabine,,173-185
which,186-191
may,192-195
lead,196-200
to,201-203
a,204-205
decreased,206-215
antiretroviral,216-230
effect,231-237
of,238-240
zalcitabine.,241-253	DrugDDI.d291.s7.e3

Concomitant,0-11
use,12-15
of,16-18
zalcitabine,19-30	DrugDDI.d291.s9.e0
and,31-34
lamivudine,35-45	DrugDDI.d291.s9.e1
is,46-48
not,49-52
recommended.,53-65

Saquinavir:,0-11	DrugDDI.d291.s10.e0
The,12-15
combination,16-27
of,28-30
HIVID,,31-37
saquinavir,,38-49
and,50-53
ZDV,54-57	DrugDDI.d291.s10.e3
has,58-61
been,62-66
studied,67-74
(as,75-78
triple,79-85
combination),86-98
in,99-101
adults.,102-109

Pharmacokinetic,0-15
data,16-20
suggest,21-28
that,29-33
absorption,,34-45
metabolism,,46-57
and,58-61
elimination,62-73
of,74-76
each,77-81
of,82-84
these,85-90
drugs,91-96	DrugDDI.d291.s11.e0
are,97-100
unchanged,101-110
when,111-115
they,116-120
are,121-124
used,125-129
together.,130-139

Drugs,0-5	DrugDDI.d291.s12.e0
Associated,6-16
With,17-21
Peripheral,22-32
Neuropathy:,33-44
The,45-48
concomitant,49-60
use,61-64
of,65-67
HIVID,68-73	DrugDDI.d291.s12.e1
with,74-78
drugs,79-84	DrugDDI.d291.s12.e2
that,85-89
have,90-94
the,95-98
potential,99-108
to,109-111
cause,112-117
peripheral,118-128
neuropathy,129-139
should,140-146
be,147-149
avoided,150-157
where,158-163
possible.,164-173

Drugs,0-5	DrugDDI.d291.s13.e0
that,6-10
have,11-15
been,16-20
associated,21-31
with,32-36
peripheral,37-47
neuropathy,48-58
include,59-66
antiretroviral,67-81	DrugDDI.d291.s13.e1
nucleoside,82-92	DrugDDI.d291.s13.e1
analogues,,93-103	DrugDDI.d291.s13.e1
chloramphenicol,,104-120
cisplatin,,121-131
dapsone,,132-140
disulfiram,,141-152
ethionamide,,153-165
glutethimide,,166-179
gold,,180-185
hydralazine,,186-198
iodoquinol,,199-210
isoniazid,,211-221
metronidazole,,222-236
nitrofurantoin,,237-252
phenytoin,,253-263
ribavirin,,264-274
and,275-278
vincristine.,279-291	DrugDDI.d291.s13.e16

Concomitant,0-11
use,12-15
of,16-18
HIVID,19-24	DrugDDI.d291.s14.e0
with,25-29
didanosine,30-40	DrugDDI.d291.s14.e1
is,41-43
not,44-47
recommended.,48-60

Intravenous,0-11
Pentamidine:,12-24	DrugDDI.d291.s15.e0
Treatment,25-34
with,35-39
HIVID,40-45	DrugDDI.d291.s15.e1
should,46-52
be,53-55
interrupted,56-67
when,68-72
the,73-76
use,77-80
of,81-83
a,84-85
drug,86-90	DrugDDI.d291.s15.e2
that,91-95
has,96-99
the,100-103
potential,104-113
to,114-116
cause,117-122
pancreatitis,123-135
is,136-138
required.,139-148

Death,0-5
due,6-9
to,10-12
fulminant,13-22
pancreatitis,23-35
possibly,36-44
related,45-52
to,53-55
intravenous,56-67
pentamidine,68-79	DrugDDI.d291.s16.e0
and,80-83
HIVID,84-89	DrugDDI.d291.s16.e1
has,90-93
been,94-98
reported.,99-108

If,0-2
intravenous,3-14
pentamidine,15-26	DrugDDI.d291.s17.e0
is,27-29
required,30-38
to,39-41
treat,42-47
Pneumocystis,48-60
carinii,61-68
pneumonia,,69-79
treatment,80-89
with,90-94
HIVID,95-100	DrugDDI.d291.s17.e1
should,101-107
be,108-110
interrupted.,111-123

Amphotericin,,0-13
Foscarnet,,14-24
and,25-28
Aminoglycosides:,29-45	DrugDDI.d291.s18.e2
Drugs,46-51	DrugDDI.d291.s18.e3
such,52-56
as,57-59
amphotericin,,60-73
foscarnet,,74-84
and,85-88
aminoglycosides,89-104	DrugDDI.d291.s18.e6
may,105-108
increase,109-117
the,118-121
risk,122-126
of,127-129
developing,130-140
peripheral,141-151
neuropathy,152-162
or,163-165
other,166-171
HIVID-associated,172-188	DrugDDI.d291.s18.e7
adverse,189-196
events,197-203
by,204-206
interfering,207-218
with,219-223
the,224-227
renal,228-233
clearance,234-243
of,244-246
zalcitabine,247-258	DrugDDI.d291.s18.e8
(thereby,259-267
raising,268-275
systemic,276-284
exposure).,285-295

Patients,0-8
who,9-12
require,13-20
the,21-24
use,25-28
of,29-31
one,32-35
of,36-38
these,39-44
drugs,45-50	DrugDDI.d291.s19.e0
with,51-55
HIVID,56-61	DrugDDI.d291.s19.e1
should,62-68
have,69-73
frequent,74-82
clinical,83-91
and,92-95
laboratory,96-106
monitoring,107-117
with,118-122
dosage,123-129
adjustment,130-140
for,141-144
any,145-148
significant,149-160
change,161-167
in,168-170
renal,171-176
function.,177-186

Probenecid,0-10	DrugDDI.d291.s20.e0
or,11-13
Cimetidine:,14-25	DrugDDI.d291.s20.e1
Concomitant,26-37
administration,38-52
of,53-55
probenecid,56-66	DrugDDI.d291.s20.e2
or,67-69
cimetidine,70-80	DrugDDI.d291.s20.e3
decreases,81-90
the,91-94
elimination,95-106
of,107-109
zalcitabine,,110-122
most,123-127
likely,128-134
by,135-137
inhibition,138-148
of,149-151
renal,152-157
tubular,158-165
secretion,166-175
of,176-178
zalcitabine.,179-191	DrugDDI.d291.s20.e5

Patients,0-8
receiving,9-18
these,19-24
drugs,25-30	DrugDDI.d291.s21.e0
in,31-33
combination,34-45
with,46-50
zalcitabine,51-62	DrugDDI.d291.s21.e1
should,63-69
be,70-72
monitored,73-82
for,83-86
signs,87-92
of,93-95
toxicity,96-104
and,105-108
the,109-112
dose,113-117
of,118-120
zalcitabine,121-132	DrugDDI.d291.s21.e2
reduced,133-140
if,141-143
warranted.,144-154

Magnesium/Aluminum-containing,0-29	DrugDDI.d291.s22.e0
Antacid,30-37
Products:,38-47
Absorption,48-58
of,59-61
zalcitabine,62-73	DrugDDI.d291.s22.e2
is,74-76
moderately,77-87
reduced,88-95
(approximately,96-110
25%),111-115
when,116-120
coadministered,121-135
with,136-140
magnesium/aluminum-containing,141-170	DrugDDI.d291.s22.e3
antacid,171-178
products.,179-188

The,0-3
clinical,4-12
significance,13-25
of,26-28
this,29-33
reduction,34-43
is,44-46
not,47-50
known,,51-57
hence,58-63
zalcitabine,64-75	DrugDDI.d291.s23.e0
is,76-78
not,79-82
recommended,83-94
to,95-97
be,98-100
ingested,101-109
simultaneously,110-124
with,125-129
magnesium/aluminum-containing,130-159	DrugDDI.d291.s23.e1
antacids.,160-169

Metoclopramide:,0-15	DrugDDI.d291.s24.e0
Bioavailability,16-31
is,32-34
mildly,35-41
reduced,42-49
(approximately,50-64
10%),65-69
when,70-74
zalcitabine,75-86	DrugDDI.d291.s24.e1
and,87-90
metoclopramide,91-105	DrugDDI.d291.s24.e2
are,106-109
coadministered.,110-125

Doxorubicin:,0-12	DrugDDI.d291.s25.e0
Doxorubicin,13-24	DrugDDI.d291.s25.e1
caused,25-31
a,32-33
decrease,34-42
in,43-45
zalcitabine,46-57	DrugDDI.d291.s25.e2
phosphorylation,58-73
(,74-75
50%,76-79
inhibition,80-90
of,91-93
total,94-99
phosphate,100-109
formation),110-120
in,121-123
U937/Molt,124-133
4,134-135
cells.,136-142

Although,0-8
there,9-14
may,15-18
be,19-21
decreased,22-31
zalcitabine,32-43	DrugDDI.d291.s26.e0
activity,44-52
because,53-60
of,61-63
lessened,64-72
active,73-79	DrugDDI.d291.s26.e1
metabolite,80-90	DrugDDI.d291.s26.e1
formation,,91-101
the,102-105
clinical,106-114
relevance,115-124
of,125-127
these,128-133
in,134-136
vitro,137-142
results,143-150
are,151-154
not,155-158
known.,159-165

As,0-2
with,3-7
all,8-11
drugs,,12-18
the,19-22
potential,23-32
exists,33-39
for,40-43
interaction,44-55
with,56-60
other,61-66
drugs,67-72	DrugDDI.d385.s0.e1
by,73-75
a,76-77
variety,78-85
of,86-88
mechanisms.,89-100

CNS-Active,0-10	DrugDDI.d385.s1.e0
Drugs,11-16	DrugDDI.d385.s1.e0
Ethanol:,17-25
Sonata,26-32	DrugDDI.d385.s1.e1
10,33-35
mg,36-38
potentiated,39-50
the,51-54
CNS-impairing,55-68
effects,69-76
of,77-79
ethanol,80-87	DrugDDI.d385.s1.e2
0.75,88-92
g/kg,93-97
on,98-100
balance,101-108
testing,109-116
and,117-120
reaction,121-129
time,130-134
for,135-138
1,139-140
hour,141-145
after,146-151
ethanol,152-159	DrugDDI.d385.s1.e3
administration,160-174
and,175-178
on,179-181
the,182-185
digit,186-191
symbol,192-198
substitution,199-211
test,212-216
(DSST),,217-224
symbol,225-231
copying,232-239
test,,240-245
and,246-249
the,250-253
variability,254-265
component,266-275
of,276-278
the,279-282
divided,283-290
attention,291-300
test,301-305
for,306-309
2.5,310-313
hours,314-319
after,320-325
ethanol,326-333	DrugDDI.d385.s1.e4
administration.,334-349

zaleplon,0-8	DrugDDI.d385.s3.e0
did,9-12
not,13-16
affect,17-23
the,24-27
pharmacokinetics,28-44
of,45-47
ethanol.,48-56	DrugDDI.d385.s3.e1

Imipramine:,0-11	DrugDDI.d385.s4.e0
Coadministration,12-28
of,29-31
single,32-38
doses,39-44
of,45-47
Sonata,48-54	DrugDDI.d385.s4.e1
20,55-57
mg,58-60
and,61-64
imipramine,65-75	DrugDDI.d385.s4.e2
75,76-78	DrugDDI.d385.s4.e2
mg,79-81	DrugDDI.d385.s4.e2
produced,82-90
additive,91-99
effects,100-107
on,108-110
decreased,111-120
alertness,121-130
and,131-134
impaired,135-143
psychomotor,144-155
performance,156-167
for,168-171
2,172-173
to,174-176
4,177-178
hours,179-184
after,185-190
administration.,191-206

The,0-3
interaction,4-15
was,16-19
pharmacodynamic,20-35
with,36-40
no,41-43
alteration,44-54
of,55-57
the,58-61
pharmacokinetics,62-78
of,79-81
either,82-88
drug.,89-94	DrugDDI.d385.s5.e0

Paroxetine:,0-11	DrugDDI.d385.s6.e0
Coadministration,12-28
of,29-31
a,32-33
single,34-40
dose,41-45
of,46-48
Sonata,49-55	DrugDDI.d385.s6.e1
20,56-58
mg,59-61
and,62-65
paroxetine,66-76	DrugDDI.d385.s6.e2
20,77-79	DrugDDI.d385.s6.e2
mg,80-82	DrugDDI.d385.s6.e2
daily,83-88
for,89-92
7,93-94
days,95-99
did,100-103
not,104-107
produce,108-115
any,116-119
interaction,120-131
on,132-134
psychomotor,135-146
performance.,147-159

Additionally,,0-13
paroxetine,14-24	DrugDDI.d385.s7.e0
did,25-28
not,29-32
alter,33-38
the,39-42
pharmacokinetics,43-59
of,60-62
Sonata,,63-70
reflecting,71-81
the,82-85
absence,86-93
of,94-96
a,97-98
role,99-103
of,104-106
CYP2D6,107-113	DrugDDI.d385.s7.e2
in,114-116
zaleplon?s,117-127
metabolism.,128-139

Thioridazine:,0-13	DrugDDI.d385.s8.e0
Coadministration,14-30
of,31-33
single,34-40
doses,41-46
of,47-49
Sonata,50-56	DrugDDI.d385.s8.e1
20,57-59
mg,60-62
and,63-66
thioridazine,67-79	DrugDDI.d385.s8.e2
50,80-82	DrugDDI.d385.s8.e2
mg,83-85	DrugDDI.d385.s8.e2
produced,86-94
additive,95-103
effects,104-111
on,112-114
decreased,115-124
alertness,125-134
and,135-138
impaired,139-147
psychomotor,148-159
performance,160-171
for,172-175
2,176-177
to,178-180
4,181-182
hours,183-188
after,189-194
administration.,195-210

The,0-3
interaction,4-15
was,16-19
pharmacodynamic,20-35
with,36-40
no,41-43
alteration,44-54
of,55-57
the,58-61
pharmacokinetics,62-78
of,79-81
either,82-88
drug.,89-94	DrugDDI.d385.s9.e0

Venlafaxine:,0-12	DrugDDI.d385.s10.e0
Coadministration,13-29
of,30-32
a,33-34
single,35-41
dose,42-46
of,47-49
zaleplon,50-58	DrugDDI.d385.s10.e1
10,59-61	DrugDDI.d385.s10.e1
mg,62-64	DrugDDI.d385.s10.e1
and,65-68
multiple,69-77
doses,78-83
of,84-86
venlafaxine,87-98	DrugDDI.d385.s10.e2
ER,99-101
(extended,102-111
release),112-120
150,121-124
mg,125-127
did,128-131
not,132-135
result,136-142
in,143-145
any,146-149
significant,150-161
changes,162-169
in,170-172
the,173-176
pharmacokinetics,177-193
of,194-196
either,197-203
zaleplon,204-212	DrugDDI.d385.s10.e3
or,213-215
venlafaxine.,216-228	DrugDDI.d385.s10.e4

In,0-2
addition,,3-12
there,13-18
was,19-22
no,23-25
pharmacodynamic,26-41
interaction,42-53
as,54-56
a,57-58
result,59-65
of,66-68
coadministration,69-85
of,86-88
zaleplon,89-97	DrugDDI.d385.s11.e0
and,98-101
venlafaxine,102-113	DrugDDI.d385.s11.e1
ER.,114-117

Promethazine:,0-13	DrugDDI.d385.s12.e0
Coadministration,14-30
of,31-33
a,34-35
single,36-42
dose,43-47
of,48-50
zaleplon,51-59	DrugDDI.d385.s12.e1
and,60-63
promethazine,64-76	DrugDDI.d385.s12.e2
(10,77-80
and,81-84
25,85-87
mg,,88-91
respectively),92-105
resulted,106-114
in,115-117
a,118-119
15%,120-123
decrease,124-132
in,133-135
maximal,136-143
plasma,144-150
concentrations,151-165
of,166-168
zaleplon,,169-178
but,179-182
no,183-185
change,186-192
in,193-195
the,196-199
area,200-204
under,205-210
the,211-214
plasma,215-221
concentration-time,222-240
curve.,241-247

However,,0-8
the,9-12
pharmacodynamics,13-29
of,30-32
coadministration,33-49
of,50-52
zaleplon,53-61	DrugDDI.d385.s13.e0
and,62-65
promethazine,66-78	DrugDDI.d385.s13.e1
have,79-83
not,84-87
been,88-92
evaluated.,93-103

Drugs,0-5	DrugDDI.d385.s15.e0
That,6-10
Induce,11-17
CYP3A4,18-24
Rifampin:,25-34	DrugDDI.d385.s15.e1
CYP3A4,35-41	DrugDDI.d385.s15.e2
is,42-44
ordinarily,45-55
a,56-57
minor,58-63
metabolizing,64-76
enzyme,77-83
of,84-86
zaleplon.,87-96	DrugDDI.d385.s15.e3

Multiple-dose,0-13
administration,14-28
of,29-31
the,32-35
potent,36-42
CYP3A4,43-49
inducer,50-57
rifampin,58-66	DrugDDI.d385.s16.e0
(600,67-71
mg,72-74
every,75-80
24,81-83
hours,,84-90
q24h,,91-96
for,97-100
14,101-103
days),,104-110
however,,111-119
reduced,120-127
zaleplon,128-136	DrugDDI.d385.s16.e1
Cmax,137-141
and,142-145
AUC,146-149
by,150-152
approximately,153-166
80%.,167-171

The,0-3
coadministration,4-20
of,21-23
a,24-25
potent,26-32
CYP3A4,33-39	DrugDDI.d385.s17.e0
enzyme,40-46
inducer,,47-55
although,56-64
not,65-68
posing,69-75
a,76-77
safety,78-84
concern,,85-93
thus,94-98
could,99-104
lead,105-109
to,110-112
ineffectiveness,113-128
of,129-131
zaleplon.,132-141	DrugDDI.d385.s17.e1

An,0-2
alternative,3-14
non-CYP3A4,15-25
substrate,26-35
hypnotic,36-44	DrugDDI.d385.s18.e0
agent,45-50	DrugDDI.d385.s18.e0
may,51-54
be,55-57
considered,58-68
in,69-71
patients,72-80
taking,81-87
CYP3A4,88-94	DrugDDI.d385.s18.e1
inducers,95-103
such,104-108
as,109-111
rifampin,,112-121
phenytoin,,122-132
carbamazepine,,133-147
and,148-151
phenobarbital.,152-166	DrugDDI.d385.s18.e5

Drugs,0-5	DrugDDI.d385.s19.e0
That,6-10
Inhibit,11-18
CYP3A4,19-25	DrugDDI.d385.s19.e1
CYP3A4,26-32
is,33-35
a,36-37
minor,38-43
metabolic,44-53
pathway,54-61
for,62-65
the,66-69
elimination,70-81
of,82-84
zaleplon,85-93	DrugDDI.d385.s19.e2
because,94-101
the,102-105
sum,106-109
of,110-112
desethylzaleplon,113-129
(formed,130-137
via,138-141
CYP3A4,142-148	DrugDDI.d385.s19.e3
in,149-151
vitro),152-158
and,159-162
its,163-166
metabolites,,167-179
5-oxo-desethylzaleplon,180-202
and,203-206
5-oxo-desethylzaleplon,207-229
glucuronide,,230-242
account,243-250
for,251-254
only,255-259
9%,260-262
of,263-265
the,266-269
urinary,270-277
recovery,278-286
of,287-289
a,290-291
zaleplon,292-300	DrugDDI.d385.s19.e5
dose.,301-306

Coadministration,0-16
of,17-19
single,,20-27
oral,28-32
doses,33-38
of,39-41
zaleplon,42-50	DrugDDI.d385.s20.e0
with,51-55
erythromycin,56-68	DrugDDI.d385.s20.e1
(10,69-72
mg,73-75
and,76-79
800,80-83
mg,,84-87
respectively),,88-102
a,103-104
strong,,105-112
selective,113-122
CYP3A4,123-129
inhibitor,130-139
produced,140-148
a,149-150
34%,151-154
increase,155-163
in,164-166
zaleplons,167-176	DrugDDI.d385.s20.e2
maximal,177-184
plasma,185-191
concentrations,192-206
and,207-210
a,211-212
20%,213-216
increase,217-225
in,226-228
the,229-232
area,233-237
under,238-243
the,244-247
plasma,248-254
concentration-time,255-273
curve.,274-280

The,0-3
magnitude,4-13
of,14-16
interaction,17-28
with,29-33
multiple,34-42
doses,43-48
of,49-51
erythromycin,52-64	DrugDDI.d385.s21.e0
is,65-67
unknown.,68-76

Other,0-5
strong,6-12
selective,13-22
CYP3A4,23-29
inhibitors,30-40
such,41-45
as,46-48
ketoconazole,49-61	DrugDDI.d385.s22.e0
can,62-65
also,66-70
be,71-73
expected,74-82
to,83-85
increase,86-94
the,95-98
exposure,99-107
of,108-110
zaleplon.,111-120	DrugDDI.d385.s22.e1

A,0-1
routine,2-9
dosage,10-16
adjustment,17-27
of,28-30
zaleplon,31-39	DrugDDI.d385.s23.e0
is,40-42
not,43-46
considered,47-57
necessary.,58-68

Drugs,0-5	DrugDDI.d385.s24.e0
That,6-10
Inhibit,11-18
Aldehyde,19-27	DrugDDI.d385.s24.e1
Oxidase,28-35	DrugDDI.d385.s24.e1
The,36-39
aldehyde,40-48
oxidase,49-56
enzyme,57-63
system,64-70
is,71-73
less,74-78
well,79-83
studied,84-91
than,92-96
the,97-100
cytochrome,101-111	DrugDDI.d385.s24.e2
P450,112-116	DrugDDI.d385.s24.e2
enzyme,117-123
system.,124-131

Diphenhydramine:,0-16	DrugDDI.d385.s25.e0
Diphenhydramine,17-32	DrugDDI.d385.s25.e1
is,33-35
reported,36-44
to,45-47
be,48-50
a,51-52
weak,53-57
inhibitor,58-67
of,68-70
aldehyde,71-79	DrugDDI.d385.s25.e2
oxidase,80-87	DrugDDI.d385.s25.e2
in,88-90
rat,91-94
liver,,95-101
but,102-105
its,106-109
inhibitory,110-120
effects,121-128
in,129-131
human,132-137
liver,138-143	DrugDDI.d385.s25.e4
are,144-147
not,148-151
known.,152-158

There,0-5
is,6-8
no,9-11
pharmacokinetic,12-27
interaction,28-39
between,40-47
zaleplon,48-56	DrugDDI.d385.s26.e0
and,57-60
diphenhydramine,61-76	DrugDDI.d385.s26.e1
following,77-86
the,87-90
administration,91-105
of,106-108
a,109-110
single,111-117
dose,118-122
(10,123-126
mg,127-129
and,130-133
50,134-136
mg,,137-140
respectively),141-154
of,155-157
each,158-162
drug.,163-168	DrugDDI.d385.s26.e2

Drugs,0-5	DrugDDI.d385.s28.e0
That,6-10
Inhibit,11-18
Both,19-23
Aldehyde,24-32	DrugDDI.d385.s28.e1
Oxidase,33-40	DrugDDI.d385.s28.e1
and,41-44
CYP3A4,45-51
Cimetidine:,52-63	DrugDDI.d385.s28.e2
Cimetidine,64-74	DrugDDI.d385.s28.e3
inhibits,75-83
both,84-88
aldehyde,89-97	DrugDDI.d385.s28.e4
oxidase,98-105	DrugDDI.d385.s28.e4
(in,106-109
vitro),110-116
and,117-120
CYP3A4,121-127	DrugDDI.d385.s28.e5
(in,128-131
vitro,132-137
and,138-141
in,142-144
vivo),,145-151
the,152-155
primary,156-163
and,164-167
secondary,168-177
enzymes,,178-186
respectively,,187-200
responsible,201-212
for,213-216
zaleplon,217-225	DrugDDI.d385.s28.e6
metabolism.,226-237

Concomitant,0-11
administration,12-26
of,27-29
Sonata,30-36	DrugDDI.d385.s29.e0
(10,37-40
mg),41-44
and,45-48
cimetidine,49-59	DrugDDI.d385.s29.e1
(800,60-64
mg),65-68
produced,69-77
an,78-80
85%,81-84
increase,85-93
in,94-96
the,97-100
mean,101-105
Cmax,106-110
and,111-114
AUC,115-118
of,119-121
zaleplon.,122-131	DrugDDI.d385.s29.e2

An,0-2
initial,3-10
dose,11-15
of,16-18
5,19-20
mg,21-23
should,24-30
be,31-33
given,34-39
to,40-42
patients,43-51
who,52-55
are,56-59
concomitantly,60-73
being,74-79
treated,80-87
with,88-92
cimetidine.,93-104	DrugDDI.d385.s30.e0

Drugs,0-5	DrugDDI.d385.s31.e0
Highly,6-12
Bound,13-18
to,19-21
Plasma,22-28	DrugDDI.d385.s31.e1
Protein,29-36	DrugDDI.d385.s31.e1
Zaleplon,37-45
is,46-48
not,49-52
highly,53-59
bound,60-65
to,66-68
plasma,69-75	DrugDDI.d385.s31.e2
proteins,76-84	DrugDDI.d385.s31.e2
(fraction,85-94
bound,95-100
60%,101-104
span,105-109
class=,110-116
c104,117-121
?15%);,122-128

therefore,,0-10
the,11-14
disposition,15-26
of,27-29
zaleplon,30-38	DrugDDI.d385.s32.e0
is,39-41
not,42-45
expected,46-54
to,55-57
be,58-60
sensitive,61-70
to,71-73
alterations,74-85
in,86-88
protein,89-96
binding.,97-105

In,0-2
addition,,3-12
administration,13-27
of,28-30
Sonata,31-37	DrugDDI.d385.s33.e0
to,38-40
a,41-42
patient,43-50
taking,51-57
another,58-65
drug,66-70	DrugDDI.d385.s33.e1
that,71-75
is,76-78
highly,79-85
protein,86-93	DrugDDI.d385.s33.e2
bound,94-99
should,100-106
not,107-110
cause,111-116
transient,117-126
increase,127-135
in,136-138
free,139-143
concentrations,144-158
of,159-161
the,162-165
other,166-171
drug.,172-177	DrugDDI.d385.s33.e3

Drugs,0-5	DrugDDI.d385.s34.e0
with,6-10
a,11-12
Narrow,13-19
Therapeutic,20-31
Index,32-37
Digoxin:,38-46	DrugDDI.d385.s34.e1
Sonata,47-53	DrugDDI.d385.s34.e2
(10,54-57
mg),58-61
did,62-65
not,66-69
affect,70-76
the,77-80
pharmacokinetic,81-96
or,97-99
pharmacodynamic,100-115
profile,116-123
of,124-126
digoxin,127-134	DrugDDI.d385.s34.e3
(0.375,135-141
mg,142-144
q24h,145-149
for,150-153
8,154-155
days).,156-162

Warfarin:,0-9	DrugDDI.d385.s35.e0
Multiple,10-18
oral,19-23
doses,24-29
of,30-32
Sonata,33-39	DrugDDI.d385.s35.e1
(20,40-43
mg,44-46
q24h,47-51
for,52-55
13,56-58
days),59-64
did,65-68
not,69-72
affect,73-79
the,80-83
pharmacokinetics,84-100
of,101-103
warfarin,104-112	DrugDDI.d385.s35.e2
(R+)-,113-118
or,119-121
(S-)-enantiomers,122-138
or,139-141
the,142-145
pharmacodynamics,146-162
(prothrombin,163-175
time),176-181
following,182-191
a,192-193
single,194-200
25-mg,201-206
oral,207-211
dose,212-216
of,217-219
warfarin.,220-229	DrugDDI.d385.s35.e4

Drugs,0-5	DrugDDI.d385.s36.e0
That,6-10
Alter,11-16
Renal,17-22
Excretion,23-32
Ibuprofen:,33-43	DrugDDI.d385.s36.e1
Ibuprofen,44-53	DrugDDI.d385.s36.e2
is,54-56
known,57-62
to,63-65
affect,66-72
renal,73-78
function,79-87
and,,88-92
consequently,,93-106
alter,107-112
the,113-116
renal,117-122
excretion,123-132
of,133-135
other,136-141
drugs.,142-148	DrugDDI.d385.s36.e3

There,0-5
was,6-9
no,10-12
apparent,13-21
pharmacokinetic,22-37
interaction,38-49
between,50-57
zaleplon,58-66	DrugDDI.d385.s37.e0
and,67-70
ibuprofen,71-80	DrugDDI.d385.s37.e1
following,81-90
single,91-97
dose,98-102
administration,103-117
(10,118-121
mg,122-124
and,125-128
600,129-132
mg,,133-136
respectively),137-150
of,151-153
each,154-158
drug.,159-164	DrugDDI.d385.s37.e2

This,0-4
was,5-8
expected,9-17
because,18-25
zaleplon,26-34	DrugDDI.d385.s38.e0
is,35-37
primarily,38-47
metabolized,48-59
and,60-63
renal,64-69
excretion,70-79
of,80-82
unchanged,83-92
zaleplon,93-101	DrugDDI.d385.s38.e1
accounts,102-110
for,111-114
less,115-119
than,120-124
1%,125-127
of,128-130
the,131-134
administered,135-147
dose.,148-153

